PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Perez-Alea, M; McGrail, K; Sanchez-Redondo, S; Ferrer, B; Fournet, G; Cortes, J; Munoz, E; Hernandez-Losa, J; Tenbaum, S; Martin, G; Costello, R; Ceylan, I; Garcia-Patos, V; Recio, JA				Perez-Alea, M.; McGrail, K.; Sanchez-Redondo, S.; Ferrer, B.; Fournet, G.; Cortes, J.; Munoz, E.; Hernandez-Losa, J.; Tenbaum, S.; Martin, G.; Costello, R.; Ceylan, I.; Garcia-Patos, V.; Recio, J. A.			ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment	ONCOGENE			English	Article							ALDEHYDE DEHYDROGENASE-ACTIVITY; STEM-CELLS; LIPID-PEROXIDATION; HUMAN PROSTATE; HL-60 CELLS; CANCER; INHIBITORS; METASTASIS; MARKER; GROWTH	Despite the promising targeted and immune-based interventions in melanoma treatment, long-lasting responses are limited. Melanoma cells present an aberrant redox state that leads to the production of toxic aldehydes that must be converted into less reactive molecules. Targeting the detoxification machinery constitutes a novel therapeutic avenue for melanoma. Here, using 56 cell lines representing nine different tumor types, we demonstrate that melanoma cells exhibit a strong correlation between reactive oxygen species amounts and aldehyde dehydrogenase 1 (ALDH1) activity. We found that ALDH1A3 is upregulated by epigenetic mechanisms in melanoma cells compared with normal melanocytes. Furthermore, it is highly expressed in a large percentage of human nevi and melanomas during melanocyte transformation, which is consistent with the data from the TCGA, CCLE and protein atlas databases. Melanoma treatment with the novel irreversible isoform-specific ALDH1 inhibitor [4-dimethylamino-4-methyl-pent-2-ynthioic acid-S methylester] di-methyl-ampal-thio-ester (DIMATE) or depletion of ALDH1A1 and/or ALDH1A3, promoted the accumulation of apoptogenic aldehydes leading to apoptosis and tumor growth inhibition in immunocompetent, immunosuppressed and patient-derived xenograft mouse models. Interestingly, DIMATE also targeted the slow cycling label-retaining tumor cell population containing the tumorigenic and chemoresistant cells. Our findings suggest that aldehyde detoxification is relevant metabolic mechanism in melanoma cells, which can be used as a novel approach for melanoma treatment.	[Perez-Alea, M.; McGrail, K.; Sanchez-Redondo, S.; Ferrer, B.; Garcia-Patos, V.; Recio, J. A.] Barcelona UAB, VHIR Vall dHebron Hosp, Vall dHebron Res Inst, Biomed Res Melanoma Anim Models, Barcelona, Spain; [Perez-Alea, M.; McGrail, K.; Sanchez-Redondo, S.; Ferrer, B.; Garcia-Patos, V.; Recio, J. A.] Barcelona UAB, VHIR Vall dHebron Hosp, Vall dHebron Res Inst, Canc Lab,Oncol Program, Barcelona, Spain; [Ferrer, B.; Hernandez-Losa, J.] Barcelona UAB, Vall dHebron Hosp, Anat Pathol Dept, Barcelona, Spain; [Fournet, G.] Univ Claude Bernard Lyon1, UMR CNRS 5246, Inst Chim & Biochim Mol & Supramol, Villeurbanne, France; [Cortes, J.] Ramon y Cajal Univ Hosp, Madrid, Spain; [Cortes, J.; Munoz, E.] Barcelona UAB, Vall dHebron Hosp, Vall dHebron Inst Oncol VHIO, Clin Oncol Program, Barcelona, Spain; [Tenbaum, S.] Vall dHebron Inst Oncol, Stem Cells & Canc Lab, Barcelona, Spain; [Martin, G.; Ceylan, I.] Adv BioDesign, Parc Technol Lyon,Woodstock Batiment Cedre 1, St Priest, France; [Costello, R.] Ctr Hosp Univ La Conception, Serv Hematol & Therapie Cellulaire, Marseille, France; [Garcia-Patos, V.] Barcelona UAB, Vall dHebron Hosp, Dermatol Dept, Barcelona, Spain; [Sanchez-Redondo, S.] CNIO, Microenvironm & Metastasis Grp, Madrid 28029, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Hospital Universitario Ramon y Cajal; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Vall d'Hebron Institut d'Oncologia (VHIO); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Hospital Universitari Vall d'Hebron; Centro Nacional de Investigaciones Oncologicas (CNIO)	Recio, JA (corresponding author), Inst Recerca Vall dHebron VHIR, Biomed Res Melanoma Anim Models & Canc Lab, Lab 203 Ed Collserola, Barcelona 08035, Spain.	juan.recio@vhir.org	Varela, Pedro Fuentes/AAD-4607-2020; Javier, Hernandez Losa/C-1173-2008; Miquel, Josep Maria/AAG-3508-2019	Varela, Pedro Fuentes/0000-0001-8471-0197; Javier, Hernandez Losa/0000-0003-1526-3201; Garcia-Patos Briones, Vicente/0000-0003-1654-6035; Recio, Juan Angel/0000-0002-7320-3832; Mc Grail Fernandez, Kimberley/0000-0001-7227-7306; Cortes, Javier/0000-0001-7623-1583; PEREZ, Mileidys/0000-0002-8739-8087	Advanced BioDesign; Spanish Health Ministry (Fondo de Investigaciones Sanitarias-FIS) [PI1400375-Fondos FEDER, AECC-GCB15152978SOEN]; Marie Curie Actions [IEF_METABOSET-627869]	Advanced BioDesign; Spanish Health Ministry (Fondo de Investigaciones Sanitarias-FIS); Marie Curie Actions(European Commission)	Dr G Quash is gratefully acknowledged for critical reading of the manuscript and his contributions. We also thank Dr HG Palmer for his generous contribution. This work was supported by funds from Advanced BioDesign (MPA), the Spanish Health Ministry (Fondo de Investigaciones Sanitarias-FIS) PI1400375-Fondos FEDER, AECC-GCB15152978SOEN, Marie Curie Actions (IEF_METABOSET-627869) supported MPA.	Alnouti Y, 2008, TOXICOL SCI, V101, P51, DOI 10.1093/toxsci/kfm280; Andreu-Perez P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-265; BARRERA G, 1991, EXP CELL RES, V197, P148, DOI 10.1016/0014-4827(91)90416-R; BLACKWELL LF, 1983, BIOCHEMISTRY-US, V22, P3784, DOI 10.1021/bi00285a011; Boonyaratanakornkit JB, 2010, J INVEST DERMATOL, V130, P2799, DOI 10.1038/jid.2010.237; Burger PE, 2009, STEM CELLS, V27, P2220, DOI 10.1002/stem.135; Charafe-Jauffret E, 2013, CANCER RES, V73, P7290, DOI 10.1158/0008-5472.CAN-12-4704; Chen Y, 2009, OCUL SURF, V7, P176, DOI 10.1016/S1542-0124(12)70185-4; Cheung AMS, 2007, LEUKEMIA, V21, P1423, DOI 10.1038/sj.leu.2404721; Dalleau S, 2013, CELL DEATH DIFFER, V20, P1615, DOI 10.1038/cdd.2013.138; Delyon J, 2013, ANN ONCOL, V24, P1697, DOI 10.1093/annonc/mdt027; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; ESTERBAUER H, 1990, MUTAT RES, V238, P223, DOI 10.1016/0165-1110(90)90014-3; Estey T, 2007, J BIOL CHEM, V282, P4382, DOI 10.1074/jbc.M607546200; Fournet G, 2013, CURR MED CHEM, V20, P527; Grammatico P, 1998, EXP DERMATOL, V7, P205, DOI 10.1111/j.1600-0625.1998.tb00325.x; Hill BG, 2009, CIRC RES, V105, P1044, DOI 10.1161/CIRCRESAHA.109.209791; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Jackson Brian, 2011, Human Genomics, V5, P283; Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P669, DOI 10.1016/j.biopha.2013.04.005; Koppaka V, 2012, PHARMACOL REV, V64, P520, DOI 10.1124/pr.111.005538; Li X, 2012, J THORAC ONCOL, V7, P1235, DOI 10.1097/JTO.0b013e318257cc6d; Lopez-Fauqued M, 2010, INT J CANCER, V126, P1549, DOI 10.1002/ijc.24926; Luo YC, 2012, STEM CELLS, V30, P2100, DOI 10.1002/stem.1193; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; Marcato P, 2015, MOL ONCOL, V9, P17, DOI 10.1016/j.molonc.2014.07.010; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI [10.1517/17425255.4.6.697, 10.1517/17425255.4.6.697 ]; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Monneuse O, 2005, J GASTROINTEST SURG, V9, P769, DOI 10.1016/j.gassur.2005.02.006; Moore N, 2012, STEM CELLS DEV, V21, P1822, DOI 10.1089/scd.2011.0477; Moore N, 2011, J ONCOL, V2011, DOI 10.1155/2011/396076; Moreb JS, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-87; Pizzimenti S, 2002, FREE RADICAL BIO MED, V32, P233, DOI 10.1016/S0891-5849(01)00798-5; Pizzimenti S, 1999, FREE RADICAL BIO MED, V26, P1578, DOI 10.1016/S0891-5849(99)00022-2; Prasmickaite L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010731; Quash G, 2002, BIOCHEM PHARMACOL, V64, P1279, DOI 10.1016/S0006-2952(02)01294-7; Quash G, 2008, EUR J MED CHEM, V43, P906, DOI 10.1016/j.ejmech.2007.06.004; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Roch AM, 1996, BIOCHEM J, V313, P973, DOI 10.1042/bj3130973; Rodriguez-Torres M, 2016, CLIN EXP METASTAS, V33, P97, DOI 10.1007/s10585-015-9755-9; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sovic A, 2001, ANTICANCER RES, V21, P1997; SUMMERFIELD FW, 1984, CHEM-BIOL INTERACT, V50, P87, DOI 10.1016/0009-2797(84)90134-0; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Townsend AJ, 2001, CHEM-BIOL INTERACT, V130, P261, DOI 10.1016/S0009-2797(00)00270-2; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; Vasiliou V, 2000, CHEM-BIOL INTERACT, V129, P1, DOI 10.1016/S0009-2797(00)00211-8; Vasiliou Vasilis, 2005, Human Genomics, V2, P138; Venza M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/481782; Wittgen HGM, 2007, MELANOMA RES, V17, P400, DOI 10.1097/CMR.0b013e3282f1d312; Wonisch W, 1998, FREE RADICAL BIO MED, V25, P682, DOI 10.1016/S0891-5849(98)00110-5; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; Yue LL, 2015, MELANOMA RES, V25, P138, DOI 10.1097/CMR.0000000000000144	57	30	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5695	5708		10.1038/onc.2017.160	http://dx.doi.org/10.1038/onc.2017.160			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581514				2022-12-17	WOS:000412843900004
J	Liu-Chittenden, Y; Jain, M; Gaskins, K; Wang, S; Merino, MJ; Kotian, S; Gara, SK; Davis, S; Zhang, L; Kebebew, E				Liu-Chittenden, Y.; Jain, M.; Gaskins, K.; Wang, S.; Merino, M. J.; Kotian, S.; Gara, S. Kumar; Davis, S.; Zhang, L.; Kebebew, E.			RARRES2 functions as a tumor suppressor by promoting beta-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma	ONCOGENE			English	Article							DENDRITIC CELLS; CANCER-THERAPY; HUMAN BLOOD; CHEMERIN; EXPRESSION; ACTIVATION; PATHWAY; CLASSIFICATION; INFLAMMATION; METABOLISM	Tumor suppressor genes and the immune system are critical players in inhibiting cancer initiation and/or progression. However, little is known about whether a tumor suppressor gene can function through both immune-dependent and - independent mechanisms. Retinoic acid receptor responder 2 (RARRES2) is transcriptionally downregulated in multiple cancer types. Previous studies suggested that it can serve as an immune-dependent tumor suppressor by acting as a chemoattractant to recruit anticancer immune cells expressing its receptor, the chemerin chemokine receptor 1 (CMKLR1), to sites of tumor. In this study, we investigated the role of RARRES2 in adrenocortical carcinoma (ACC), a rare lethal malignancy in which aberrant Wnt/beta-catenin signaling is frequently detected. We show that RARRES2 expression is downregulated in ACC as compared with normal and benign adrenocortical tissues, which is a result of CpG hypermethylation. Despite minimal CMKLR1 expression and lack of phenotypic tumor-suppressive effect with exogenous RARRES2 treatment, RARRES2 overexpression in ACC cell lines not only reduced cell proliferation, cell invasion and tumorigenicity in vitro, but also inhibited tumor growth in vivo in two immunodeficient mouse xenograft models. Mechanistically, RARRES2 overexpression in ACC cells inhibited Wnt/beta-catenin pathway activity by promoting beta-catenin phosphorylation and degradation, it also inhibited the phosphorylation of p38 mitogen-activated protein kinase. Thus our study identifies RARRES2 as a novel tumor suppressor for ACC, which can function through an immune-independent mechanism.	[Liu-Chittenden, Y.; Jain, M.; Gaskins, K.; Wang, S.; Kotian, S.; Gara, S. Kumar; Zhang, L.; Kebebew, E.] NCI, NIH, Endocrine Oncol Branch, 10 Ctr Dr,Room 4-5952, Bethesda, MD 20892 USA; [Merino, M. J.] NCI, NIH, Pathol Lab, Bethesda, MD 20892 USA; [Davis, S.] NIH, Ctr Canc Res, Canc Genet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kebebew, E (corresponding author), NCI, NIH, Endocrine Oncol Branch, 10 Ctr Dr,Room 4-5952, Bethesda, MD 20892 USA.	kebebewe@mail.nih.gov	Kotian, Shweta/GMX-3418-2022; Davis, Sean/AAD-1801-2021; Gara, Sudheer Kumar/E-8084-2016	Davis, Sean/0000-0002-8991-6458; Liu, Yi/0000-0001-6357-5360	intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health [1ZIABC01127506]; NATIONAL CANCER INSTITUTE [ZIABC011275] Funding Source: NIH RePORTER	intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health (1ZIABC01127506). Supported by the intramural research program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health (1ZIABC01127506).	Barnea G, 2008, P NATL ACAD SCI USA, V105, P64, DOI 10.1073/pnas.0710487105; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bilimoria KY, 2008, CANCER, V113, P3130, DOI 10.1002/cncr.23886; Bondue B, 2011, CYTOKINE GROWTH F R, V22, P331, DOI 10.1016/j.cytogfr.2011.11.004; Bozaoglu K, 2007, ENDOCRINOLOGY, V148, P4687, DOI 10.1210/en.2007-0175; Chiacchiera F, 2012, CANCER LETT, V324, P98, DOI 10.1016/j.canlet.2012.05.006; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Ernst MC, 2010, TRENDS ENDOCRIN MET, V21, P660, DOI 10.1016/j.tem.2010.08.001; Fassnacht M, 2013, J CLIN ENDOCR METAB, V98, P4551, DOI 10.1210/jc.2013-3020; Fassnacht M, 2009, BEST PRACT RES CL EN, V23, P273, DOI 10.1016/j.beem.2008.10.008; Fernandez-Ranvier GG, 2008, ARCH SURG-CHICAGO, V143, P841, DOI 10.1001/archsurg.143.9.841; Finn OJ, 2012, ANN ONCOL, V23, P6, DOI 10.1093/annonc/mds256; Gaujoux S, 2011, CLIN CANCER RES, V17, P328, DOI 10.1158/1078-0432.CCR-10-2006; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; Goralski KB, 2007, J BIOL CHEM, V282, P28175, DOI 10.1074/jbc.M700793200; Grossi V, 2014, WORLD J GASTROENTERO, V20, P9744, DOI 10.3748/wjg.v20.i29.9744; Igea A, 2015, CANCER RES, V75, P3997, DOI 10.1158/0008-5472.CAN-15-0173; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Kerkhofs TMA, 2013, EUR J CANCER, V49, P2579, DOI 10.1016/j.ejca.2013.02.034; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Lin W, 2011, CLIN LAB, V57, P879; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Pachynski RK, 2012, J EXP MED, V209, P1427, DOI 10.1084/jem.20112124; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Rechache NS, 2012, J CLIN ENDOCR METAB, V97, pE1004, DOI 10.1210/jc.2011-3298; Salomon A, 2015, ONCOTARGET, V6, P11421, DOI 10.18632/oncotarget.3222; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; Velazquez-Fernandez D, 2005, SURGERY, V138, P1087, DOI 10.1016/j.surg.2005.09.031; Vermi W, 2005, J EXP MED, V201, P509, DOI 10.1084/jem.20041310; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wittamer V, 2005, J IMMUNOL, V175, P487, DOI 10.4049/jimmunol.175.1.487; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Zabel BA, 2005, J IMMUNOL, V174, P244, DOI 10.4049/jimmunol.174.1.244; Zabel BA, 2008, J EXP MED, V205, P2207, DOI 10.1084/jem.20080300; Zheng Y, 2008, EUR J DERMATOL, V18, P638, DOI 10.1684/ejd.2008.0511	38	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3541	3552		10.1038/onc.2016.497	http://dx.doi.org/10.1038/onc.2016.497			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28114280	Green Accepted			2022-12-17	WOS:000403878600004
J	Ma, X; Huang, J; Tian, Y; Chen, Y; Yang, Y; Zhang, X; Zhang, F; Xue, L				Ma, X.; Huang, J.; Tian, Y.; Chen, Y.; Yang, Y.; Zhang, X.; Zhang, F.; Xue, L.			Myc suppresses tumor invasion and cell migration by inhibiting JNK signaling	ONCOGENE			English	Article							ONCOGENIC RAS; DNA-BINDING; DROSOPHILA; DEATH; EXPRESSION; APOPTOSIS; METASTASIS; ACTIVATION; GROWTH; MAX	Tumor metastasis, but not primary overgrowth, is the leading cause of mortality for cancer patients. During the past decade, Drosophila melanogaster has been well-accepted as an excellent model to address the intrinsic mechanism of different aspects of cancer progression, ranging from tumor initiation to metastasis. In a genetic screen performed in Drosophila, aiming to find novel modulators of tumor invasion, we identified the oncoprotein Myc as a negative regulator. While expression of Myc dramatically blocks tumor invasion and cell migration, loss of Myc promotes cell migration in vivo. The activity of Myc is further enhanced by the co-expression of its transcription partner Max. Mechanistically, we found Myc/Max directly upregulates the transcription of puc, which encodes an inhibitor of JNK signaling crucial for tumor invasion and cell migration. Furthermore, we demonstrated that human cMyc potently suppresses JNK-dependent cell invasion and migration in both Drosophila and lung adenocarcinoma cell lines. These findings provide novel molecular insights into Myc-mediated cancer progression and raise the noteworthy problem in therapeutic strategies as inhibiting Myc might conversely accelerate tumor metastasis.	[Ma, X.; Huang, J.; Chen, Y.; Zhang, X.; Xue, L.] Tongji Univ, Shanghai Peoples Hosp 10, Inst Intervent Vessel, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, Shanghai, Peoples R China; [Tian, Y.; Yang, Y.; Zhang, F.] Tongji Univ, Shanghai Pulm Hosp, Sch Life Sci & Technol, Clin Translat Res Ctr, Shanghai, Peoples R China; [Ma, X.] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 333 Cedar St, New Haven, CT 06519 USA	Tongji University; Tongji University; Howard Hughes Medical Institute; Yale University	Zhang, X; Zhang, F; Xue, L (corresponding author), Tongji Univ, Sch Life Sci & Technol, 1239 Siping Rd, Shanghai 200092, Peoples R China.	zxpkxy@126.com; fzhang@tongji.edu.cn; lei.xue@tongji.edu.cn		Ma, Xianjue/0000-0003-4360-3947; Zhang, Fan/0000-0003-4068-3726	National Basic Research Program of China (973 Program) [2011CB943903]; National Natural Sciences Foundation of China [31171413, 31371490]; Ministry of Education of China [20120072110023]; Shanghai Committee of Science and Technology [09DZ2260100, 14JC1406000]; Shanghai Pulmonary Hospital and Tongji University [129212]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); Shanghai Pulmonary Hospital and Tongji University	We thank Dr Peter Gallant, Bloomington, VDRC and NIG stock centers for fly stocks and reagents. This work was supported by the National Basic Research Program of China (973 Program) (2011CB943903), National Natural Sciences Foundation of China (31171413 and 31371490), the PhD Programs Foundation of Ministry of Education of China (20120072110023), and Shanghai Committee of Science and Technology (09DZ2260100 and 14JC1406000) to LX, and the research start-up funds from Shanghai Pulmonary Hospital and Tongji University (No. 129212) to FZ.	ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Benassayag C, 2005, MOL CELL BIOL, V25, P9897, DOI 10.1128/MCB.25.22.9897-9909.2005; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chen YH, 2008, EXPERT REV ANTICANC, V8, P1689, DOI 10.1586/14737140.8.10.1689; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 1999, MOL CELL BIOL, V19, P1; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Liu H, 2012, NAT CELL BIOL, V14, P567, DOI 10.1038/ncb2491; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Ma X, 2016, ONCOGENE, V35, P846, DOI 10.1038/onc.2015.137; Ma X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.111; Ma X, 2014, CELL DEATH DIFFER, V21, P407, DOI 10.1038/cdd.2013.154; Ma X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.392; Ma XJ, 2013, DEV BIOL, V380, P211, DOI 10.1016/j.ydbio.2013.05.013; Ma XJ, 2012, CELL RES, V22, P425, DOI 10.1038/cr.2011.135; McEwen DG, 2005, DEVELOPMENT, V132, P3935, DOI 10.1242/dev.01949; Miles WO, 2011, DIS MODEL MECH, V4, P753, DOI 10.1242/dmm.006908; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pastor-Pareja JC, 2013, ANNU REV GENET, V47, P51, DOI 10.1146/annurev-genet-110711-155414; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Willoughby LF, 2013, DIS MODEL MECH, V6, P521, DOI 10.1242/dmm.009985; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Xue L, 2007, DEV CELL, V13, P446, DOI 10.1016/j.devcel.2007.07.012; Zeitlinger J, 1999, DEVELOPMENT, V126, P3947	46	30	33	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3159	3167		10.1038/onc.2016.463	http://dx.doi.org/10.1038/onc.2016.463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068320				2022-12-17	WOS:000402617900008
J	Swidnicka-Siergiejko, AK; Gomez-Chou, SB; Cruz-Monserrate, Z; Deng, D; Liu, Y; Huang, H; Ji, B; Azizian, N; Daniluk, J; Lu, W; Wang, H; Maitra, A; Logsdon, CD				Swidnicka-Siergiejko, A. K.; Gomez-Chou, S. B.; Cruz-Monserrate, Z.; Deng, D.; Liu, Y.; Huang, H.; Ji, B.; Azizian, N.; Daniluk, J.; Lu, W.; Wang, H.; Maitra, A.; Logsdon, C. D.			Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53	ONCOGENE			English	Article							FACTOR-KAPPA-B; ACINAR DIFFERENTIATION; DUCTAL ADENOCARCINOMAS; MICE; OVEREXPRESSION; CELLS; ACTIVATION; EXPRESSION; INDUCTION; NEOPLASMS	Chronic inflammation (CI) is a risk factor for pancreatic cancer (PC) including the most common type, ductal adenocarcinoma (PDAC), but its role and the mechanisms involved are unclear. To investigate the role of CI in PC, we generated genetic mouse models with pancreatic specific CI in the presence or absence of TP53. Mice were engineered to express either cyclooxygenase-2 (COX-2) or I kappa B kinase-2 (IKK2), and TP53(+/+) or TP53(f/f) specifically in adult pancreatic acinar cells by using a full-length pancreatic elastase promoter-driven Cre. Animals were followed for > 80 weeks and pancreatic lesions were evaluated histologically and immunohistochemically. The presence of K-ras mutations was assessed by direct sequencing, locked nuclei acid (LNA)-based PCR, and immunohistochemistry. We observed that sustained COX-2/IKK2 expression caused histological abnormalities of pancreas, including increased immune cell infiltration, proliferation rate and DNA damage. A minority of animals with CI developed pre-neoplastic lesions, but cancer was not observed in any TP53(+/+) animals within 84 weeks. In contrast, all animals with CI-lacking TP53 developed various subtypes of PC, including acinar cell carcinoma, ductal adenocarcinoma, sarcomatoid carcinoma and neuroendocrine tumors, and all died within 65 weeks. No evidence of K-ras mutations was observed. Variations in the activity of the Hippo, pERK and c-Myc pathways were found in the diverse cancer subtypes. In summary, chronic inflammation is extremely inefficient at inducing PC in the presence of TP53. However, in the absence of TP53, CI leads to the development of several rare K-ras-independent forms of PC, with infrequent PDAC. This may help explain the rarity of PDAC in persons with chronic inflammatory conditions.	[Swidnicka-Siergiejko, A. K.; Gomez-Chou, S. B.; Deng, D.; Liu, Y.; Huang, H.; Ji, B.; Azizian, N.; Daniluk, J.; Logsdon, C. D.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 1906,1515 Holcombe Blvd, Houston, TX 77030 USA; [Swidnicka-Siergiejko, A. K.; Daniluk, J.] Univ Bialystok, Dept Gastroenterol & Internal Med, Bialystok, Poland; [Cruz-Monserrate, Z.] Ohio State Univ, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Wexner Med Ctr, Columbus, OH 43210 USA; [Huang, H.] Second Mil Med Univ, Shanghai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Ji, B.] Mayo Clin, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA; [Lu, W.; Logsdon, C. D.] Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA; [Wang, H.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Maitra, A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Bialystok; University System of Ohio; Ohio State University; Naval Medical University; Mayo Clinic; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Logsdon, CD (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 1906,1515 Holcombe Blvd, Houston, TX 77030 USA.	clogsdon@mdanderson.org	Daniluk, Jaroslaw/T-3437-2018	Daniluk, Jaroslaw/0000-0002-0787-1461; , Agnieszka/0000-0001-6577-5796; Cruz-Monserrate, Zobeida/0000-0003-0849-655X; azizian, nancy/0000-0002-1158-0608	Lockton Endowment;  [NIH-DK05206];  [AA020822]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA020822] Funding Source: NIH RePORTER	Lockton Endowment; ; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank Dr Bogdan Czerniak, Dr Tadeusz Majewski and Jolanta Bondaruk from Department of Pathology and Todd Moore from Department of Surgery, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA for technical support. Grant support: NIH-DK05206, AA020822 and The Lockton Endowment (to CDL).	Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Cho CH, 2012, ADV DIAGNOSIS THERAP; Colby JK, 2008, NEOPLASIA, V10, P782, DOI 10.1593/neo.08330; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Daniluk J, 2012, J CLIN INVEST, V122, P1519, DOI 10.1172/JCI59743; Feldmann G, 2011, CANCER BIOL THER, V11, P959, DOI 10.4161/cbt.11.11.15534; Grippo PJ, 2012, INT J CANCER, V131, P1243, DOI 10.1002/ijc.27322; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hill R, 2010, CANCER RES, V70, P7114, DOI 10.1158/0008-5472.CAN-10-1649; Holmes C, 2007, STEM CELLS, V25, P1339, DOI 10.1634/stemcells.2006-0644; Hu Y, 2009, MUTAT RES-GEN TOX EN, V677, P27, DOI 10.1016/j.mrgentox.2009.05.003; Huang H, 2014, ONCOGENE, V33, P532, DOI 10.1038/onc.2012.619; Huang HJ, 2013, GASTROENTEROLOGY, V144, P202, DOI 10.1053/j.gastro.2012.09.059; Ji BA, 2008, GENESIS, V46, P390, DOI 10.1002/dvg.20411; Jiao YC, 2014, J PATHOL, V232, P428, DOI 10.1002/path.4310; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kamei K, 2006, GENESIS, V44, P177, DOI 10.1002/dvg.20199; Kwon MJ, 2015, PANCREAS, V44, P484, DOI 10.1097/MPA.0000000000000280; La Rosa S, 2016, VIRCHOWS ARCH, V468, P289, DOI 10.1007/s00428-015-1882-9; La Rosa S, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00041; Ling SB, 2014, ONCOL LETT, V7, P1747, DOI 10.3892/ol.2014.2003; Liu B, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0260-7; Marrache F, 2008, GASTROENTEROLOGY, V135, P1277, DOI 10.1053/j.gastro.2008.06.078; Morton JP, 2008, AM J PATHOL, V172, P1081, DOI 10.2353/ajpath.2008.070778; Morvaridi S, 2015, SCI REP-UK, V5, DOI 10.1038/srep16759; Murata M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/623019; Myant K, 2015, CELL REP, V12, P1019, DOI 10.1016/j.celrep.2015.07.003; Phesse TJ, 2014, CELL DEATH DIFFER, V21, P956, DOI 10.1038/cdd.2014.15; Philip B, 2013, GASTROENTEROLOGY, V145, P1449, DOI 10.1053/j.gastro.2013.08.018; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Rowley M, 2011, GASTROENTEROLOGY, V140, P1303, DOI 10.1053/j.gastro.2010.12.039; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; URBAN T, 1993, J NATL CANCER I, V85, P2008, DOI 10.1093/jnci/85.24.2008; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wood LD, 2014, SEMIN DIAGN PATHOL, V31, P491, DOI 10.1053/j.semdp.2014.08.003	38	30	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3149	3158		10.1038/onc.2016.461	http://dx.doi.org/10.1038/onc.2016.461			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	27991926	hybrid, Green Published			2022-12-17	WOS:000402617900007
J	Kerr, C; Szmacinski, H; Fisher, ML; Nance, B; Lakowicz, JR; Akbar, A; Keillor, JW; Wong, TL; Godoy-Ruiz, R; Toth, EA; Weber, DJ; Eckert, RL				Kerr, C.; Szmacinski, H.; Fisher, M. L.; Nance, B.; Lakowicz, J. R.; Akbar, A.; Keillor, J. W.; Wong, T. Lok; Godoy-Ruiz, R.; Toth, E. A.; Weber, D. J.; Eckert, R. L.			Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival	ONCOGENE			English	Article							TISSUE TRANSGLUTAMINASE; MESENCHYMAL TRANSITION; INHIBITORS; LOCALIZATION; POTENT; FRET; DIFFERENTIATION; EXPRESSION; MECHANISM; DOMAIN	Type 2 transglutaminase (TG2) is an important cancer stem cell survival protein that exists in open and closed conformations. The major intracellular form is the closed conformation that functions as a GTP-binding GTPase and is required for cancer stem cell survival. However, at a finite rate, TG2 transitions to an open conformation that exposes the transamidase catalytic site involved in protein-protein crosslinking. The activities are mutually exclusive, as the closed conformation has GTP binding/GTPase activity, and the open conformation transamidase activity. We recently showed that GTP binding, but not transamidase activity, is required for TG2-dependent cancer stem cell invasion, migration and tumour formation. However, we were surprised that transamidase sites-specific inhibitors reduce cancer stem cell survival. We now show that compounds NC9, VA4 and VA5, which react exclusively at the TG2 transamidase site, inhibit both transamidase and GTP-binding activities. Transamidase activity is inhibited by direct inhibitor binding at the transamidase site, and GTP binding is blocked because inhibitor interaction at the transamidase site locks the protein in the extended/open conformation to disorganize/inactivate the GTP binding/GTPase site. These findings suggest that transamidase site-specific inhibitors can inhibit GTP binding/signalling by driving a conformation change that disorganizes the TG2 GTP binding to reduce TG2-dependent signalling, and that drugs designed to target this site may be potent anti-cancer agents.	[Kerr, C.; Szmacinski, H.; Fisher, M. L.; Nance, B.; Lakowicz, J. R.; Toth, E. A.; Weber, D. J.; Eckert, R. L.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108N Greene St, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA; [Eckert, R. L.] Univ Maryland, Sch Med, Dept Reprod Biol, Baltimore, MD 21201 USA; [Toth, E. A.; Weber, D. J.; Eckert, R. L.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Wong, T. Lok; Toth, E. A.; Weber, D. J.] Inst Biosci & Biotechnol Res, Rockville, MD USA; [Wong, T. Lok; Toth, E. A.; Weber, D. J.] Ctr Biomol Therapeut, Rockville, MD USA; [Akbar, A.; Keillor, J. W.] Univ Ottawa, Dept Chem & Biomol Sci, Ottawa, ON, Canada	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Ottawa	Eckert, RL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108N Greene St, Baltimore, MD 21201 USA.	reckert@umaryland.edu	Godoy Ruiz, Raquel/GOH-1617-2022	GODOY-RUIZ, RAQUEL/0000-0003-4569-0781; Nance, Bailey/0000-0002-2617-651X	National Institutes of Health [R01-CA184027, R01-CA131074]; NATIONAL CANCER INSTITUTE [R01CA184027, R01CA131074] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health grants R01-CA184027 and R01-CA131074 to Richard Eckert.	Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; Agnihotri N, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3371; Badarau E, 2013, AMINO ACIDS, V44, P119, DOI 10.1007/s00726-011-1188-4; Begg GE, 2006, J BIOL CHEM, V281, P12603, DOI 10.1074/jbc.M600146200; Begg GE, 2006, P NATL ACAD SCI USA, V103, P19683, DOI 10.1073/pnas.0609283103; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cao L, 2012, ONCOGENE, V31, P2521, DOI 10.1038/onc.2011.429; Cariati M, 2008, HISTOPATHOLOGY, V52, P99, DOI 10.1111/j.1365-2559.2007.02895.x; Caron NS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044159; Chen Y, 2003, DIFFERENTIATION, V71, P528, DOI 10.1111/j.1432-0436.2003.07109007.x; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Clouthier CM, 2012, ANGEW CHEM INT EDIT, V51, P12464, DOI 10.1002/anie.201205575; Eckert RL, 2015, MOL CARCINOGEN, V54, P947, DOI 10.1002/mc.22375; Eckert RL, 2014, PHYSIOL REV, V94, P383, DOI 10.1152/physrev.00019.2013; Eckert RL, 2009, AMINO ACIDS, V36, P739, DOI 10.1007/s00726-008-0123-9; Fisher ML, 2015, ONCOTARGET, V6, P20525, DOI 10.18632/oncotarget.3890; Fisher ML, 2015, MOL CANCER RES, V13, P1083, DOI 10.1158/1541-7786.MCR-14-0685-T; Fu J, 2013, NEURO-ONCOLOGY, V15, P1353, DOI 10.1093/neuonc/not079; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Griffin M, 2008, BIOORG MED CHEM LETT, V18, P5559, DOI 10.1016/j.bmcl.2008.09.006; Gundemir S, 2012, BBA-MOL CELL RES, V1823, P406, DOI 10.1016/j.bbamcr.2011.09.012; Gundemir S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006123; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324; Jang TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107005; Jans R, 2008, J INVEST DERMATOL, V128, P517, DOI 10.1038/sj.jid.5701035; Keillor JW, 2008, CAN J CHEM, V86, P271, DOI 10.1139/V08-024; Keillor JW, 2015, TRENDS PHARMACOL SCI, V36, P32, DOI 10.1016/j.tips.2014.10.014; Keillor JW, 2014, BIOORG CHEM, V57, P186, DOI 10.1016/j.bioorg.2014.06.003; Keillor Jeffrey W, 2011, Adv Enzymol Relat Areas Mol Biol, V78, P415; Kiraly R, 2009, FEBS J, V276, P7083, DOI 10.1111/j.1742-4658.2009.07420.x; Kumar A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3085; Kumar A, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0018759, 10.1371/journal.pone.0020701, 10.1371/journal.pone.0026520]; Kumar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013390; LAKOWICZ JR, 1992, ANAL BIOCHEM, V202, P316, DOI 10.1016/0003-2697(92)90112-K; LAKOWICZ JR, 1992, P NATL ACAD SCI USA, V89, P1271, DOI 10.1073/pnas.89.4.1271; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Mehta K, 2009, AMINO ACIDS, V36, P709, DOI 10.1007/s00726-008-0128-4; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Pardin C, 2008, CHEM BIOL DRUG DES, V72, P189, DOI 10.1111/j.1747-0285.2008.00696.x; Pardin C, 2009, BIOCHEMISTRY-US, V48, P3346, DOI 10.1021/bi802021c; Pavlyukov MS, 2012, BIOCHEM BIOPH RES CO, V421, P773, DOI 10.1016/j.bbrc.2012.04.082; Pinkas DM, 2007, PLOS BIOL, V5, P2788, DOI 10.1371/journal.pbio.0050327; Prime ME, 2012, J MED CHEM, V55, P1021, DOI 10.1021/jm201310y; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Rizzo MA, 2006, MICROSC MICROANAL, V12, P238, DOI 10.1017/S1431927606060235; Siegel M, 2007, PHARMACOL THERAPEUT, V115, P232, DOI 10.1016/j.pharmthera.2007.05.003; Stamnaes J, 2010, J BIOL CHEM, V285, P25402, DOI 10.1074/jbc.M109.097162; Sturniolo MT, 2005, ONCOGENE, V24, P2963, DOI 10.1038/sj.onc.1208392; Sturniolo MT, 2003, J BIOL CHEM, V278, P48066, DOI 10.1074/jbc.M307215200; Wallrabe H, 2005, CURR OPIN BIOTECH, V16, P19, DOI 10.1016/j.copbio.2004.12.002; Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048	55	30	30	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2981	2990		10.1038/onc.2016.452	http://dx.doi.org/10.1038/onc.2016.452			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27941875	Green Accepted			2022-12-17	WOS:000402000400006
J	Yang, J; Lu, C; Wei, J; Guo, Y; Liu, W; Luo, L; Fisch, G; Li, X				Yang, J.; Lu, C.; Wei, J.; Guo, Y.; Liu, W.; Luo, L.; Fisch, G.; Li, X.			Inhibition of KPNA4 attenuates prostate cancer metastasis	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TNF-ALPHA; ANDROGEN RECEPTOR; BREAST-CANCER; IMPORTIN ALPHA-3; MACROPHAGES; EXPRESSION; CELLS; ACTIVATION	Prostate cancer (PCa) is a common cancer in men. Although current treatments effectively palliate symptoms and prolong life, the metastatic PCa remains incurable. It is important to find biomarkers and targets to improve metastatic PCa diagnosis and treatment. Here we report a novel correlation between karyopherin alpha 4 (KPNA4) and PCa pathological stages. KPNA4 mediates the cytoplasm-to- nucleus translocation of transcription factors, including nuclear factor kappa B, although its role in PCa was largely unknown. We find that knockdown of KPNA4 reduces cell migration in multiple PCa cell lines, suggesting a role of KPNA4 in PCa progression. Indeed, stable knockdown of KPNA4 significantly reduces PCa invasion and distant metastasis in mouse models. Functionally, KPNA4 alters tumor microenvironment in terms of macrophage polarization and osteoclastogenesis by modulating tumor necrosis factor (TNF)-alpha and -beta. Further, KPNA4 is proved as a direct target of miR-708, a tumor-suppressive microRNA. We disclose the role of miR-708-KPNA4-TNF axes in PCa metastasis and KPNA4's potential as a novel biomarker for PCa metastasis.	[Yang, J.; Lu, C.; Guo, Y.; Liu, W.; Luo, L.; Li, X.] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, Room 901D,345 East 24th St, New York, NY 10010 USA; [Wei, J.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Obstet & Gynaecol, Tongji Hosp, Wuhan, Peoples R China; [Fisch, G.] CUNY, Baruch Coll, Dept Stat & Comp Informat Syst, New York, NY 10021 USA; [Li, X.] NYU, Langone Med Ctr, Dept Urol, New York, NY USA	New York University; Huazhong University of Science & Technology; City University of New York (CUNY) System; Baruch College (CUNY); New York University; NYU Langone Medical Center	Li, X (corresponding author), NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, Room 901D,345 East 24th St, New York, NY 10010 USA.	xl15@nyu.edu	Yang, Jian/E-1051-2015	Li, Xin/0000-0002-7414-5734	NIH [R01CA180277, R03CA172894]; NYU CTSA [1UL1TR001445, 1KL2TR001446, 1TL1TR001447]; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health; NATIONAL CANCER INSTITUTE [R01CA180277, R03CA172894] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001445] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NYU CTSA; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by NIH grants R01CA180277 and R03CA172894 to Xin Li, and in part by the NYU CTSA grant numbers 1UL1TR001445, 1KL2TR001446 and 1TL1TR001447 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health. We thank Dr Deepak Saxena (New York University, New York, NY, USA) for the proofreading.	Abravanel DL, 2015, J CLIN INVEST, V125, P2484, DOI 10.1172/JCI74883; Adams DL, 2014, P NATL ACAD SCI USA, V111, P3514, DOI 10.1073/pnas.1320198111; Agrawal T, 2012, J CLIN IMMUNOL, V32, P1093, DOI 10.1007/s10875-012-9696-x; Ahluwalia A, 2014, AM J PHYSIOL-GASTR L, V306, pG338, DOI 10.1152/ajpgi.00382.2013; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bertrand F, 2015, CANCER RES, V75, P2619, DOI 10.1158/0008-5472.CAN-14-2524; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Brenner D, 2015, NAT REV IMMUNOL, V15, P362, DOI 10.1038/nri3834; Chen PC, 2014, ONCOTARGET, V5, P1595, DOI 10.18632/oncotarget.1570; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; Fang LY, 2013, CANCER RES, V73, P5633, DOI 10.1158/0008-5472.CAN-12-3228; Feng FY, 2016, P NATL ACAD SCI USA, V113, P473, DOI 10.1073/pnas.1522938113; Finisguerra V, 2015, NATURE, V522, P349, DOI 10.1038/nature14407; Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009; Gartrell BA, 2014, NAT REV CLIN ONCOL, V11, P335, DOI 10.1038/nrclinonc.2014.70; Gerondalds S, 2014, NAT IMMUNOL, V15, P15, DOI 10.1038/ni.2785; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y; Hagemann T, 2004, CARCINOGENESIS, V25, P1543, DOI 10.1093/carcin/bgh146; Hagemann T, 2006, J IMMUNOL, V176, P5023, DOI 10.4049/jimmunol.176.8.5023; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Hu X, 2014, J IMMUNOL, V192, P1320, DOI 10.4049/jimmunol.1203195; Ikenberg K, 2014, J PATHOL, V234, P239, DOI 10.1002/path.4390; Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116; Jin R, 2015, ONCOGENE, V34, P3700, DOI 10.1038/onc.2014.302; Jin RJ, 2014, CANCER RES, V74, P2763, DOI 10.1158/0008-5472.CAN-13-2543; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Ke G, 2013, ONCOGENE, V32, P3019, DOI 10.1038/onc.2012.323; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lamb LE, 2011, CANCER RES, V71, P2739, DOI 10.1158/0008-5472.CAN-10-2745; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Li X, 2009, CANCER RES, V69, P1685, DOI 10.1158/0008-5472.CAN-08-2164; Liang JQ, 2015, AM J CANCER RES, V5, P1124; Lin KT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6917; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Mak P, 2015, ONCOTARGET, V6, P40247, DOI 10.18632/oncotarget.5377; Mortezavi A, 2011, CLIN CANCER RES, V17, P1111, DOI 10.1158/1078-0432.CCR-10-0081; Nadiminty N, 2010, CANCER RES, V70, P3309, DOI 10.1158/0008-5472.CAN-09-3703; Ostuni R, 2015, TRENDS IMMUNOL, V36, P229, DOI 10.1016/j.it.2015.02.004; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Rachidi Saleh M, 2013, PLoS One, V8, pe57911, DOI 10.1371/journal.pone.0057911; Ryu S, 2013, CANCER CELL, V23, P63, DOI 10.1016/j.ccr.2012.11.019; Sachan N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068247; Saini S, 2012, CANCER RES, V72, P3618, DOI 10.1158/0008-5472.CAN-12-0540; Sakai M, 2010, ANTICANCER RES, V30, P851; Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004-1211; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stathopoulos GT, 2007, CANCER RES, V67, P9825, DOI 10.1158/0008-5472.CAN-07-1064; Theiss AL, 2009, MOL BIOL CELL, V20, P4412, DOI 10.1091/mbc.E09-05-0361; Wang HQ, 2015, CELL BIOSCI, V5, DOI 10.1186/2045-3701-5-4; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Xu AX, 2015, ONCOL LETT, V10, P1402, DOI 10.3892/ol.2015.3472; Yang J, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.18; Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078-0432.CCR-14-2808; Zadran S, 2013, P NATL ACAD SCI USA, V110, P19160, DOI 10.1073/pnas.1316991110; Zhang XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065896; Zins K, 2007, CANCER RES, V67, P1038, DOI 10.1158/0008-5472.CAN-06-2295; Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224	66	30	31	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2868	2878		10.1038/onc.2016.440	http://dx.doi.org/10.1038/onc.2016.440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27941876	Green Accepted			2022-12-17	WOS:000401697800009
J	Goreczny, GJ; Ouderkirk-Pecone, JL; Olson, EC; Krendel, M; Turner, CE				Goreczny, G. J.; Ouderkirk-Pecone, J. L.; Olson, E. C.; Krendel, M.; Turner, C. E.			Hic-5 remodeling of the stromal matrix promotes breast tumor progression	ONCOGENE			English	Article							CANCER-ASSOCIATED FIBROBLASTS; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; TGF-BETA; MESENCHYMAL TRANSITION; COLLECTIVE INVASION; GENE-EXPRESSION; CELL-MIGRATION; MYOFIBROBLAST; PAXILLIN	The remodeling of the stromal extracellular matrix (ECM) has a crucial, but incompletely understood role during tumor progression and metastasis. Hic-5, a focal adhesion scaffold protein, has previously been implicated in tumor cell invasion, proliferation and metastasis. To investigate the role of Hic-5 in breast tumor progression in vivo, Hic-(5-/-) mice were generated and crossed with the Mouse Mammary Tumor Virus-Polyoma Middle T-Antigen mouse. Tumors from the Hic-5(-/-) ;PyMT mice exhibited increased latency and reduced growth, with fewer lung metastases, as compared with Hic-5(+/-); PyMT mice. Immunohistochemical analysis showed that Hic-5 is primarily expressed in the cancer-associated fibroblasts (CAFs). Further analysis revealed that the Hic-5(-/-); PyMT tumor stroma contains fewer CAFs and exhibits reduced ECM deposition. The remodeling of the stromal matrix by CAFs has been shown to increase tumor rigidity to indirectly regulate FAK Y397 phosphorylation in tumor cells to promote their growth and invasion. Accordingly, the Hic-5(-/-) ;PyMT tumor cells exhibited a reduction in FAK Y397 phosphorylation. Isolated Hic-5(-/-); PyMT CAFs were defective in stress fiber organization and exhibited reduced contractility. These cells also failed to efficiently deposit and organize the ECM in two and three dimensions. This, in turn, impacted three-dimensional MDA-MB-231 tumor cell migration behavior. Thus, using a new knockout mouse model, we have identified Hic-5 expression in CAFs as a key requirement for deposition and remodeling of the stromal ECM to promote non-cell autonomous breast tumor progression.	[Goreczny, G. J.; Ouderkirk-Pecone, J. L.; Krendel, M.; Turner, C. E.] SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 East Adams St, Syracuse, NY 13210 USA; [Olson, E. C.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 East Adams St, Syracuse, NY 13210 USA.	turnerce@upstate.edu			National Institutes of Health [R01 CA163296, R01 GM047607, R01 NS066071, R01 DK083345]; Carol M Baldwin Breast Cancer Research Fund of CNY; NATIONAL CANCER INSTITUTE [R01CA163296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS066071] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Carol M Baldwin Breast Cancer Research Fund of CNY; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank members of the Turner lab for critical reading of this manuscript and for insightful discussions. We are grateful to Ian Forsythe for the mouse genotyping and additional technical assistance. We also thank Nicholas Deakin for his assistance in isolating CTCs. This work was supported by the National Institutes of Health Grant R01 CA163296 and R01 GM047607 to CET R01 NS066071 to ECO and CET, R01 DK083345 to MK and the Carol M Baldwin Breast Cancer Research Fund of CNY awards to CET and MK.	Amatangelo MD, 2005, AM J PATHOL, V167, P475, DOI 10.1016/S0002-9440(10)62991-4; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Boyd NF, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2942; Burridge K, 2016, EXP CELL RES, V343, P14, DOI 10.1016/j.yexcr.2015.10.029; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cirri P, 2011, AM J CANCER RES, V1, P482; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Dabiri G, 2008, J INVEST DERMATOL, V128, P2518, DOI 10.1038/jid.2008.90; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; Deakin NO, 2011, MOL BIOL CELL, V22, P327, DOI 10.1091/mbc.E10-09-0790; Deakin NO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037990; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Hinz B, 2012, AM J PATHOL, V180, P1340, DOI 10.1016/j.ajpath.2012.02.004; Humphrey JD, 2014, NAT REV MOL CELL BIO, V15, P802, DOI 10.1038/nrm3896; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Kuo JC, 2013, J CELL MOL MED, V17, P704, DOI 10.1111/jcmm.12054; Kutys ML, 2013, EXP CELL RES, V319, P2434, DOI 10.1016/j.yexcr.2013.05.030; Lei XF, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000747; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Nguyen-Ngoc KV, 2015, METHODS MOL BIOL, V1189, P135, DOI 10.1007/978-1-4939-1164-6_10; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ouderkirk-Pecone JL, 2016, ONCOTARGET, DOI 10.18632/oncotarget.10139; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Plante Isabelle, 2011, J Vis Exp, DOI 10.3791/2828; Provenzano PP, 2009, ONCOGENE, V28, P4326, DOI 10.1038/onc.2009.299; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Rezakhaniha R, 2012, BIOMECH MODEL MECHAN, V11, P461, DOI 10.1007/s10237-011-0325-z; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Shola DTN, 2012, ONCOGENE, V31, P2480, DOI 10.1038/onc.2011.422; Tchou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-39; Thomas SM, 1999, J CELL SCI, V112, P181; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; Varney SD, 2016, J CELL SCI, V129, P774, DOI 10.1242/jcs.170589; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5	52	30	31	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2693	2703		10.1038/onc.2016.422	http://dx.doi.org/10.1038/onc.2016.422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893716	Green Accepted			2022-12-17	WOS:000401120900007
J	Schrock, MS; Batar, B; Lee, J; Druck, T; Ferguson, B; Cho, JH; Akakpo, K; Hagrass, H; Heerema, NA; Xia, F; Parvin, JD; Aldaz, CM; Huebner, K				Schrock, M. S.; Batar, B.; Lee, J.; Druck, T.; Ferguson, B.; Cho, J. H.; Akakpo, K.; Hagrass, H.; Heerema, N. A.; Xia, F.; Parvin, J. D.; Aldaz, C. M.; Huebner, K.			Wwox-Brca1 interaction: role in DNA repair pathway choice	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; HOMOLOGOUS RECOMBINATION; WWOX; BRCA1; ASSOCIATION; INHIBITION; DAMAGE; ATM	In this study, loss of expression of the fragile site-encoded Wwox protein was found to contribute to radiation and cisplatin resistance of cells, responses that could be associated with cancer recurrence and poor outcome. WWOX gene deletions occur in a variety of human cancer types, and reduced Wwox protein expression can be detected early during cancer development. We found that Wwox loss is followed by mild chromosome instability in genomes of mouse embryo fibroblast cells from Wwox-knockout mice. Human and mouse cells deficient for Wwox also exhibit significantly enhanced survival of ionizing radiation and bleomycin treatment, agents that induce double-strand breaks (DSBs). Cancer cells that survive radiation recur more rapidly in a xenograft model of irradiated breast cancer cells; Wwox-deficient cells exhibited significantly shorter tumor latencies vs Wwox-expressing cells. This Wwox effect has important consequences in human disease: in a cohort of cancer patients treated with radiation, Wwox deficiency significantly correlated with shorter overall survival times. In examining mechanisms underlying Wwox-dependent survival differences, we found that Wwox-deficient cells exhibit enhanced homology directed repair (HDR) and decreased nonhomologous end-joining (NHEJ) repair, suggesting that Wwox contributes to DNA DSB repair pathway choice. Upon silencing of Rad51, a protein critical for HDR, Wwox-deficient cells were resensitized to radiation. We also demonstrated interaction of Wwox with Brca1, a driver of HDR, and show via immunofluorescent detection of repair proteins at ionizing radiation-induced DNA damage foci that Wwox expression suppresses DSB repair at the end-resection step of HDR. We propose a genome caretaker function for WWOX, in which Brca1-Wwox interaction supports NHEJ as the dominant DSB repair pathway in Wwox-sufficient cells. Taken together, the experimental results suggest that reduced Wwox expression, a common occurrence in cancers, dysregulates DSB repair, enhancing efficiency of likely mutagenic repair, and enabling radiation and cisplatin treatment resistance.	[Schrock, M. S.; Batar, B.; Druck, T.; Akakpo, K.; Hagrass, H.; Huebner, K.] Ohio State Univ, Wexner Med Ctr, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Schrock, M. S.; Batar, B.; Druck, T.; Cho, J. H.; Akakpo, K.; Hagrass, H.; Heerema, N. A.; Xia, F.; Parvin, J. D.; Huebner, K.] Ohio State Univ, Wexner Med Ctr, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Lee, J.; Ferguson, B.; Aldaz, C. M.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Sci Pk,1808 Pk Rd 1C, Smithville, TX 78957 USA; [Cho, J. H.; Xia, F.] Ohio State Univ, Wexner Med Ctr, Dept Radiat Oncol, Columbus, OH 43210 USA; [Heerema, N. A.] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH 43210 USA; [Parvin, J. D.] Ohio State Univ, Wexner Med Ctr, Dept Biomed Informat, Div Computat Biol & Bioinformat, Columbus, OH 43210 USA; [Hagrass, H.] Zagazig Univ, Zagazig, Egypt; [Xia, F.] Univ Arkansas Med Sci, Dept Radiat Oncol, Little Rock, AR 72205 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Egyptian Knowledge Bank (EKB); Zagazig University; University of Arkansas System; University of Arkansas Medical Sciences	Aldaz, CM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Sci Pk,1808 Pk Rd 1C, Smithville, TX 78957 USA.; Huebner, K (corresponding author), Ohio State Univ, Wexner Med Ctr, Dept Canc Biol & Genet, Ctr Comprehens Canc, Biomed Res Tower,Room 916,460 W 12th Ave, Columbus, OH 43210 USA.	maaldaz@mdanderson.org; kay.huebner@osumc.edu	Aldaz, C. Marcelo/E-7868-2011; Parvin, Jeffrey D/C-8955-2009; Batar, Bahadir/F-4724-2018	Aldaz, C. Marcelo/0000-0002-2453-2939; Akakpo, Kenneth/0000-0003-4720-7626	Pelotonia [9T32OD010429, CA154200, R01CA120516]; NIH/NCI [R01 CA102444, CA198228]; Scientific and Technological Research Council of Turkey (TUBITAK); Egyptian Cultural and Educational Bureau; breast cancer support foundations; Stefanie Spielman Fund of the OSUCCC; Anne M Wolfe Foundation; NATIONAL CANCER INSTITUTE [R01CA102444, P30CA016672, U01CA154200, R01CA120516, P30CA016058, R21CA198228] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [T32OD010429] Funding Source: NIH RePORTER	Pelotonia; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Scientific and Technological Research Council of Turkey (TUBITAK)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Egyptian Cultural and Educational Bureau(Egyptian Cultural & Educational Bureau); breast cancer support foundations; Stefanie Spielman Fund of the OSUCCC; Anne M Wolfe Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by Pelotonia Graduate and Post-Doctoral Fellowships (to MS, BB), 9T32OD010429 (to MS), CA154200 (to KH), R01CA120516 (to KH), NIH/NCI R01 CA102444 (to CMA), CA198228 (to JP), a fellowship from the Scientific and Technological Research Council of Turkey (TUBITAK to BB) and a graduate research scholarship from the Egyptian Cultural and Educational Bureau (to HH). We thank the OSU CMIF shared Facility for confocal microscopy and the Genome Quebec company for assistance with CNA experiments. We also thank Matthew Guggenbiller (OSUMC) for help with the analysis of the brain cancer cohort and Megan Lowery and Richard D Wood (The University of Texas MD Anderson Cancer Center, Smithville, TX, USA) for providing the data in Figure 1d and Jenna Karras and T Banerjee for helpful discussions. We are especially appreciative of the additional funding by the breast cancer support foundations, the Stefanie Spielman Fund of the OSUCCC and the Anne M Wolfe Foundation (Anne's Army).	Abdeen SK, 2011, ONCOGENE, V30, P3900, DOI 10.1038/onc.2011.115; Abu-Odeh M, 2014, P NATL ACAD SCI USA, V111, pE4716, DOI 10.1073/pnas.1409252111; Aldaz CM, 2014, BBA-REV CANCER, V1846, P188, DOI 10.1016/j.bbcan.2014.06.001; Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Aqeilan RI, 2009, ENDOCRINOLOGY, V150, P1530, DOI 10.1210/en.2008-1087; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Bednarek AK, 2000, CANCER RES, V60, P2140; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Choo A, 2015, GENE CHROMOSOME CANC, V54, P745, DOI 10.1002/gcc.22286; Christou Charita M, 2013, Biology (Basel), V2, P40, DOI 10.3390/biology2010040; Ferguson BW, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-593; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; Hartmann C, 1999, INT J ONCOL, V15, P975; Hu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084638; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038; Letessier A, 2011, NATURE, V470, P120, DOI 10.1038/nature09745; Li YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039588; Lim YC, 2014, MOL ONCOL, V8, P1603, DOI 10.1016/j.molonc.2014.06.012; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Ludes-Meyers JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007775; Miuma S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080730; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Ransburgh DJR, 2010, CANCER RES, V70, P988, DOI 10.1158/0008-5472.CAN-09-2850; Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053; Salah Z, 2010, FUTURE ONCOL, V6, P249, DOI [10.2217/fon.09.152, 10.2217/FON.09.152]; Saldivar JC, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003077; Sankaran S, 2006, CANCER RES, V66, P4100, DOI 10.1158/0008-5472.CAN-05-4430; Scarpace L, 2015, CANC IMAG ARCH; Schrock MS, 2015, EXP BIOL MED, V240, P296, DOI 10.1177/1535370214561590; Towler WI, 2013, HUM MUTAT, V34, P439, DOI 10.1002/humu.22251; Veronese A, 2011, P NATL ACAD SCI USA, V108, P4840, DOI 10.1073/pnas.1101734108; You FL, 2004, ONCOGENE, V23, P5792, DOI 10.1038/sj.onc.1207739; Zimmerman M, 2014, TRENDS CELL BIOL, V24, P108, DOI 10.1016/j.tcb.2013.09.003	41	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2215	2227		10.1038/onc.2016.389	http://dx.doi.org/10.1038/onc.2016.389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27869163	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000399782700003
J	Liao, PH; Hsu, HH; Chen, TS; Chen, MC; Day, CH; Tu, CC; Lin, YM; Tsai, FJ; Kuo, WW; Huang, CY				Liao, P-H; Hsu, H-H; Chen, T-S; Chen, M-C; Day, C-H; Tu, C-C; Lin, Y-M; Tsai, F-J; Kuo, W-W; Huang, C-Y			Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injury	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; SIGNALING PATHWAY; PROSTATE-CANCER; MAMMARY-TUMORS; OVARIAN-CANCER; IN-VITRO; APICIDIN; TRANSLOCATION; ACTIVATION; EXPRESSION	Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Despite the availability of several treatment strategies, resistance to chemotherapeutic agents, which limits the effectiveness of anticancer drugs, is a major problem in cancer therapy. In this study, we used a histone deacetylases inhibitor (HDACi) to establish drug-resistant HCC cells and further analyzed the molecular mechanisms underlying the development of resistance in HCC cells. Compared with the parental cells, HDACi-resistant cells showed high metastatic and pro-survival abilities. Two-dimensional electrophoresis data showed that the cofilin-1 (CFL-1) protein was altered in HDACi-resistant cells and was highly expressed in resistant cells compared with parental cells. The molecular function of CFL-1 is actin depolymerization, and it is involved in tumor metastasis. In this study, we showed that CFL-1 inhibition decreased cell migration and increased cell apoptosis in HDACi-resistant cells. We observed that HDACi induced ROS accumulation in cells and apoptosis via promotion of the CFL-1 interaction with Bax and CFL-1 translocation to the mitochondria, resulting in cytochrome C release. Importantly, phosphorylation of CFL-1 by activated extracellular signal-regulated kinases 1 and 2 (ERK1/2) confers strong protection against HDAC inhibitor-induced cell injury. p-CFL-1 shows a loss of affinity with Bax and will not translocate to mitochondria, stably remaining in the cytoplasm. These results indicate that phosphorylation to inactivate CFL-1 decreased the chemosensitivity to HDAC inhibitors and resulting in drug resistance of HCC cells.	[Liao, P-H; Huang, C-Y] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Hsu, H-H] Mackay Mem Hosp, Div Colorectal Surg, Taipei, Taiwan; [Hsu, H-H] Nursing & Management Coll, Dept Mackay Med, Taipei, Taiwan; [Chen, T-S] China Med Univ Hosp, Biomat Translat Res Ctr, Taichung, Taiwan; [Chen, M-C] Taichung Vet Gen Hosp, Div Colorectal Surg, Taichung, Taiwan; [Day, C-H] Mei Ho Univ, Dept Nursing, Pingtung, Taiwan; [Tu, C-C] Armed Force Taichung Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan; [Lin, Y-M] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan; [Tsai, F-J; Huang, C-Y] China Med Univ, Grad Inst Chinese Med Sci, 91 Hsueh Shih Rd, Taichung 404, Taiwan; [Kuo, W-W] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan; [Huang, C-Y] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan	China Medical University Taiwan; Mackay Memorial Hospital; Mackay Junior College of Medicine, Nursing & Management; China Medical University Taiwan; China Medical University Hospital - Taiwan; Taichung Veterans General Hospital; Changhua Christian Hospital; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan	Huang, CY (corresponding author), China Med Univ, Grad Inst Chinese Med Sci, 91 Hsueh Shih Rd, Taichung 404, Taiwan.	cyhuang@mail.cmu.edu.tw	Chen, Tung-Sheng/U-4788-2019; Chen, Tung-Sheng/GPK-0411-2022	Chen, Tung-Sheng/0000-0002-4400-3428	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW105-TDU-B-212-133019]	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019).	Baylin SB, 2011, NAT MED, V17, P288, DOI 10.1038/nm0311-288; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Collazo J, 2014, CANCER RES, V74, P2362, DOI 10.1158/0008-5472.CAN-13-3058; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; Ding YM, 2008, MOL CELL BIOL, V28, P3742, DOI 10.1128/MCB.01832-07; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Hsieh CH, 2013, BIOSCI BIOTECH BIOCH, V77, P2397, DOI 10.1271/bbb.130503; Hsieh YC, 2010, CHEM RES TOXICOL, V23, P1256, DOI 10.1021/tx100116a; Hsu HH, 2014, TUMOR BIOL, V35, P303, DOI 10.1007/s13277-013-1041-3; Huang X, 2013, J BIOL CHEM, V288, P36418, DOI 10.1074/jbc.M113.495713; Kim MS, 2000, CANCER LETT, V157, P23, DOI 10.1016/S0304-3835(00)00465-1; Klamt F, 2009, NAT CELL BIOL, V11, P1241, DOI 10.1038/ncb1968; Kotiadis VN, 2012, J CELL SCI, V125, P2288, DOI 10.1242/jcs.099390; Lai JP, 2009, J HEPATOL, V50, P1112, DOI 10.1016/j.jhep.2008.12.031; Li GB, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-50; Li M, 2013, ONCOL REP, V29, P58, DOI 10.3892/or.2012.2078; Lu L, 2015, ONCOL LETT, V9, P2757, DOI 10.3892/ol.2015.3133; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Posadas I, 2012, J NEUROCHEM, V120, P515, DOI 10.1111/j.1471-4159.2011.07599.x; Serezani CH, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002448; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659; Stresing V, 2013, ONCOGENE, V32, P724, DOI 10.1038/onc.2012.93; Tahtamouni LH, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-45; Tang WW, 2011, DEV CELL, V21, P1038, DOI 10.1016/j.devcel.2011.10.023; Tu CC, 2013, CHINESE J PHYSIOL, V56, P326, DOI 10.4077/CJP.2013.BAB158; Wabnitz GH, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.36; Wang WG, 2007, CANCER RES, V67, P3505, DOI 10.1158/0008-5472.CAN-06-3714; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Wang ZQ, 2010, J CELL PHYSIOL, V224, P559, DOI 10.1002/jcp.22160; Weiller M, 2011, EXP TOXICOL PATHOL, V63, P511, DOI 10.1016/j.etp.2010.04.001; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Zhang HH, 2015, MOL ENDOCRINOL, V29, P434, DOI 10.1210/me.2014-1297; Zhou JW, 2012, ONCOL LETT, V4, P1187, DOI 10.3892/ol.2012.897; Zhou Y, 2013, ONCOL REP, V29, P394, DOI 10.3892/or.2012.2115	34	30	31	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1978	1990		10.1038/onc.2016.357	http://dx.doi.org/10.1038/onc.2016.357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27748761				2022-12-17	WOS:000398898500008
J	Wijetunga, NA; Pascual, M; Tozour, J; Delahaye, F; Alani, M; Adeyeye, M; Wolkoff, AW; Verma, A; Greally, JM				Wijetunga, N. A.; Pascual, M.; Tozour, J.; Delahaye, F.; Alani, M.; Adeyeye, M.; Wolkoff, A. W.; Verma, A.; Greally, J. M.			A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets	ONCOGENE			English	Article							HEPATITIS-C VIRUS; ENDOPLASMIC-RETICULUM STRESS; TUMOR-SUPPRESSOR GENES; SMALL MAF PROTEINS; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; HUMAN GENOME; MESENCHYMAL TRANSITION; ABERRANT METHYLATION; MOLECULAR SIGNATURE	The predisposition of patients with Hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) involves components of viral infection, inflammation and time. The development of multifocal, genetically distinct tumours is suggestive of a field defect affecting the entire liver. The molecular susceptibility mediating such a field defect is not understood. One potential mediator of long-term cellular reprogramming is heritable (epigenetic) regulation of transcription, exemplified by DNA methylation. We studied epigenetic and transcriptional changes in HCV-infected livers in comparison with control, uninfected livers and HCC, allowing us to identify pre-neoplastic epigenetic and transcriptional events. We find the HCV-infected liver to have a pattern of acquisition of DNA methylation targeted to candidate enhancers active in liver cells, enriched for the binding sites of the FOXA1, FOXA2 and HNF4A transcription factors. These enhancers can be subdivided into those proximal to genes implicated in liver cancer or to genes involved in stem cell development, the latter distinguished by increased CG dinucleotide density and polycomb-mediated repression, manifested by the additional acquisition of histone H3 lysine 27 trimethylation (H3K27me3). Transcriptional studies on our samples showed that the increased DNA methylation at enhancers was associated with decreased local gene expression, results validated in independent samples from The Cancer Genome Atlas. Pharmacological depletion of H3K27me3 using the EZH2 inhibitor GSK343 in HepG2 cells suppressed cell growth and also revealed that local acquired DNA methylation was not dependent upon the presence of polycomb-mediated repression. The results support a model of HCV infection influencing the binding of transcription factors to cognate sites in the genome, with consequent local acquisition of DNA methylation, and the added repressive influence of polycomb at a subset of CG-dense cis-regulatory sequences. These epigenetic events occur before neoplastic transformation, resulting in what may be a pharmacologically reversible epigenetic field defect in HCV-infected liver.	[Wijetunga, N. A.; Pascual, M.; Tozour, J.; Adeyeye, M.; Greally, J. M.] Dept Genet, Bronx, NY USA; [Wijetunga, N. A.; Pascual, M.; Tozour, J.; Adeyeye, M.; Greally, J. M.] Ctr Epigen, Bronx, NY USA; [Pascual, M.] IDISNA, Oncohematol Dept, CIMA, Pamplona, Spain; [Delahaye, F.] Dept Obstet Gynecol & Womens Hlth, Bronx, NY USA; [Alani, M.; Wolkoff, A. W.] Dept Med, Div Gastroenterol & Liver Dis, Bronx, NY USA; [Alani, M.; Wolkoff, A. W.] Marion Bessin Liver Res Ctr, Bronx, NY USA; [Verma, A.] Albert Einstein Coll Med, Dept Med Oncol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Greally, JM (corresponding author), Albert Einstein Coll Med, 1301 Morris Pk Ave, Bronx, NY 10461 USA.	john.greally@einstein.yu.edu	Greally, John/AAF-9540-2019; Pascual, Marién/F-6661-2013	Greally, John/0000-0001-6069-7960; Pascual, Marién/0000-0002-1678-1054; Delahaye, Fabien/0000-0002-9921-8653; Adeyeye, Mary/0000-0003-4900-2237	NIH [30 DK041296]; MSTP program at Albert Einstein College of Medicine [NIH T32 GM007288]; Sara Borrell fellowship [CD12/00540]; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK098408, P30DK041296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MSTP program at Albert Einstein College of Medicine; Sara Borrell fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the assistance in sample procurement from Ms. Estella Forbes, Dr Steven Libutti, Dr Jonathan Schwartz, Dr Milan Kinkhabwala, Dr Sarah Bellemare and Dr Harmit Kalia at the Montefiore-Einstein Center for Cancer Care. Support for work: Support for this work was in part from NIH P30 DK041296 (Marion Bessin Liver Research Center (JM Greally, AW Wolkoff), and the MSTP program at Albert Einstein College of Medicine (Einstein) (NA Wijetunga, J Tozour, NIH T32 GM007288). M Pascual is supported by a Sara Borrell fellowship CD12/00540. This manuscript was published in partial fulfillment of the requirements for a PhD in Biomedical Sciences at Einstein (NA Wijetunga).	ALAM T, 1992, J BIOL CHEM, V267, P5021; Alder O, 2014, CELL REP, V9, P261, DOI 10.1016/j.celrep.2014.08.046; Alvarez H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001356; Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21; Aran D, 2013, CELL, V154, P11, DOI 10.1016/j.cell.2013.06.018; Archer KJ, 2010, MOL GENET GENOMICS, V283, P341, DOI 10.1007/s00438-010-0522-y; Arensdorf AM, 2013, J CELL SCI, V126, P4026, DOI 10.1242/jcs.130757; Banerjee A, 2010, J VIROL, V84, P5936, DOI 10.1128/JVI.02344-09; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bochkis IM, 2008, NAT MED, V14, P828, DOI 10.1038/nm.1853; Bockmuhl Y, 2015, EPIGENETICS-US, V10, P247, DOI 10.1080/15592294.2015.1017199; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Choy MK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-519; Colletti M, 2009, GASTROENTEROLOGY, V137, P660, DOI 10.1053/j.gastro.2009.05.038; Colombo M, 2015, DIGEST LIVER DIS, V47, P727, DOI 10.1016/j.dld.2015.04.003; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Couvert P, 2008, WORLD J GASTROENTERO, V14, P5419, DOI 10.3748/wjg.14.5419; Dammacco F, 2000, SEMIN LIVER DIS, V20, P143, DOI 10.1055/s-2000-9613; DeLaForest A, 2011, DEVELOPMENT, V138, P4143, DOI 10.1242/dev.062547; Delahaye F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6187; Domcke S, 2015, NATURE, V528, P575, DOI 10.1038/nature16462; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eads CA, 2000, CANCER RES, V60, P5021; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feldmann A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003994; Feo F, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2014.12.08; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gebhard C, 2010, CANCER RES, V70, P1398, DOI 10.1158/0008-5472.CAN-09-3406; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749; Heuck CJ, 2013, J IMMUNOL, V190, P2966, DOI 10.4049/jimmunol.1202493; Hodges E, 2011, MOL CELL, V44, P17, DOI 10.1016/j.molcel.2011.08.026; Hogart A, 2012, GENOME RES, V22, P1407, DOI 10.1101/gr.132878.111; Hon GC, 2013, NAT GENET, V45, P1198, DOI 10.1038/ng.2746; Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Hu CY, 2014, CLIN CANCER RES, V20, P4349, DOI 10.1158/1078-0432.CCR-14-0494; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jelic S, 2010, ANN ONCOL, V21, pv59, DOI 10.1093/annonc/mdq166; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kaposi-Novak P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; Katsurano M, 2012, ONCOGENE, V31, P342, DOI 10.1038/onc.2011.241; Kim JW, 2004, HEPATOLOGY, V39, P518, DOI 10.1002/hep.20053; Koike K, 2014, RECENT RESULTS CANC, V193, P97, DOI 10.1007/978-3-642-38965-8_6; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Lister R, 2013, SCIENCE, V341, P629, DOI 10.1126/science.1237905; Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014; Lu CY, 2009, GENE CHROMOSOME CANC, V48, P1057, DOI 10.1002/gcc.20708; Machida K, 2004, J VIROL, V78, P8835, DOI 10.1128/JVI.78.16.8835-8843.2004; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Machida K, 2010, J IMMUNOL, V185, P6985, DOI 10.4049/jimmunol.1000618; Meir O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009516; Minguez B, 2011, J HEPATOL, V55, P1325, DOI 10.1016/j.jhep.2011.02.034; Moriya K, 2001, CANCER RES, V61, P4365; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110; Ohguchi H, 2008, MOL CELL BIOL, V28, P3917, DOI 10.1128/MCB.02154-07; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Palomer X, 2013, INT J CARDIOL, V168, P3160, DOI 10.1016/j.ijcard.2013.07.150; Ptashne M, 2007, CURR BIOL, V17, pR233, DOI 10.1016/j.cub.2007.02.030; Ptashne M, 2013, FASEB J, V27, P1, DOI 10.1096/fj.13-0101ufm; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474; Rush Margaret, 2009, Epigenetics, V4, P404; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Schubeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192; Schwartz Myron E, 2013, Recent Results Cancer Res, V190, P85, DOI 10.1007/978-3-642-16037-0_6; Shen J, 2013, EPIGENETICS-US, V8, P34, DOI 10.4161/epi.23062; Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569; Signolet J, 2015, FEBS J, V282, P1692, DOI 10.1111/febs.13132; Song MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055761; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111; Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Suzuki M, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-4-r36; Taberlay PC, 2014, GENOME RES, V24, P1421, DOI 10.1101/gr.163485.113; Tanigawa S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.448; Tao Y, 2011, P NATL ACAD SCI USA, V108, P12042, DOI 10.1073/pnas.1108715108; Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382; Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Umer M, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-117; Verma SK, 2012, ACS MED CHEM LETT, V3, P1091, DOI 10.1021/ml3003346; Villacorte M, 2013, ONCOGENE, V32, P3477, DOI 10.1038/onc.2012.376; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wijetunga NA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6195; Won KJ, 2013, NUCLEIC ACIDS RES, V41, P4423, DOI 10.1093/nar/gkt143; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yagi K, 2012, AM J PATHOL, V180, P616, DOI 10.1016/j.ajpath.2011.10.010; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Yamazaki H, 2012, MOL CELL BIOL, V32, P808, DOI 10.1128/MCB.06543-11; Yang M, 2013, J CELL SCI, V126, P5692, DOI 10.1242/jcs.135053; Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang YJ, 2007, CLIN CANCER RES, V13, P2378, DOI 10.1158/1078-0432.CCR-06-1900; Zhao Hongtao, 2013, Hepatobiliary Surg Nutr, V2, P78, DOI 10.3978/j.issn.2304-3881.2012.12.12; Zhao W, 2006, INT J ONCOL, V28, P1081; Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433; Zimmerman TL, 2006, J BIOL CHEM, V281, P15434, DOI 10.1074/jbc.M508277200; Zogopoulos George, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P1434	128	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					2030	2044		10.1038/onc.2016.340	http://dx.doi.org/10.1038/onc.2016.340			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27721404	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000398898500013
J	Qi, DL; Cobrinik, D				Qi, D-L; Cobrinik, D.			MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation	ONCOGENE			English	Article							TUMOR SUPPRESSION; GENE-EXPRESSION; P53 ACTIVATION; CANCER-THERAPY; DNA-DAMAGE; RB; P14(ARF); NEUROBLASTOMA; PATHWAYS; MICE	Retinoblastomas can arise from cone photoreceptor precursors in response to the loss of pRB function. Cone precursor-specific circuitry cooperates with pRB loss to initiate this process and subsequently contributes to the malignancy. Intrinsic high-level MDM2 expression is a key component of the cone precursor circuitry and is thought to inactivate p53-mediated tumor surveillance, which could otherwise be induced in response to pRB loss. However, the MDM2-related MDM4 has also been proposed to abrogate p53-mediated tumor surveillance in the absence of detectable MDM2 in retinoblastoma cells, bringing into question the importance of high-level MDM2 versus MDM4 expression. Here we report that high-level MDM2 but not MDM4 has a consistent critical role in retinoblastoma cell proliferation in vitro, as well as in orthotopic xenografts. Reduction of either MDM2 or MDM4 weakly induced p53, yet reduction of MDM2 but not MDM4 severely impaired proliferation and survival through a p53-independent mechanism. Specifically, MDM2 upregulated the mRNA expression and translation of another component of the cone circuitry, MYCN, in retinoblastoma cells. Moreover, MYCN was essential to retinoblastoma cell growth and tumor formation, and ectopic MYCN partially reversed the effects of MDM2 depletion, indicating that MYCN is an important MDM2 target. These findings indicate that high-level MDM2 expression is needed in order to perform a critical p53-independent function and may obviate the need for genomic alterations to the p53 pathway during retinoblastoma tumorigenesis.	[Qi, D-L; Cobrinik, D.] Childrens Hosp Los Angeles, Dept Surg, Div Ophthalmol, Vis Ctr, Los Angeles, CA 90027 USA; [Qi, D-L; Cobrinik, D.] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA; [Cobrinik, D.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA USA; [Cobrinik, D.] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA USA; [Cobrinik, D.] Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Cobrinik, D.] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA	Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Cobrinik, D (corresponding author), Childrens Hosp Los Angeles, 4650 Sunset Blvd,MS 163, Los Angeles, CA 90027 USA.	dcobrinik@chla.usc.edu			NIH [1R01CA137124, P30CA014089]; Saban Research Institute Research Career Development Fellowship; Research to Prevent Blindness (New York, New York); Larry & Celia Moh Foundation; NATIONAL CANCER INSTITUTE [P30CA014089, R01CA137124] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Saban Research Institute Research Career Development Fellowship; Research to Prevent Blindness (New York, New York)(Research to Prevent Blindness (RPB)); Larry & Celia Moh Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	D-L Qi and D Cobrinik designed the study. D-L Qi conducted all the experiments. D-L Qi and D Cobrinik wrote the manuscript. We thank Xiaoliang Leon Xu for early passage retinoblastoma cell preparations, Narine Harutyunyan and Jennifer Aparicio for CHLAVC-RB43, Pat Reynolds and A Linn Murphree for CHLA-RB215 cells, and the Saban Research Institute Research Imaging Core for assistance. This study was supported by NIH grants 1R01CA137124 and P30CA014089, by a Saban Research Institute Research Career Development Fellowship to D-L Qi, by Research to Prevent Blindness (New York, New York), by the Larry & Celia Moh Foundation and by the charitable support of the Nautica Malibu Triathlon event produced by MESP, Inc.	Ajioka I, 2007, CELL, V131, P378, DOI 10.1016/j.cell.2007.09.036; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brennan RC, 2011, CANCER RES, V71, P4205, DOI 10.1158/0008-5472.CAN-11-0058; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Carr-Wilkinson J, 2010, CLIN CANCER RES, V16, P1108, DOI 10.1158/1078-0432.CCR-09-1865; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cobrinik D, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-72; Cobrinik D, 2015, EBIOMEDICINE, V2, P623, DOI 10.1016/j.ebiom.2015.07.023; Cobrinik D, 2013, GENE CHROMOSOME CANC, V52, P1150, DOI 10.1002/gcc.22110; Dieterich DC, 2006, P NATL ACAD SCI USA, V103, P9482, DOI 10.1073/pnas.0601637103; DIMARAS H, 2015, NAT REV DIS PRIMERS, V1, P1, DOI DOI 10.1038/NRDP.2015.21.ACCESSED; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Elison JR, 2006, ARCH OPHTHALMOL-CHIC, V124, P1269, DOI 10.1001/archopht.124.9.1269; Embade N, 2012, HEPATOLOGY, V55, P1237, DOI 10.1002/hep.24795; Evans L, 2015, CANCER LETT, V363, P37, DOI 10.1016/j.canlet.2015.03.044; Gratias S, 2005, INT J CANCER, V116, P555, DOI 10.1002/ijc.21051; Gu L, 2012, ONCOGENE, V31, P1342, DOI 10.1038/onc.2011.343; Guo Y, 2008, BIOCHEM BIOPH RES CO, V375, P1, DOI 10.1016/j.bbrc.2008.07.055; Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Kato MV, 1996, CANCER LETT, V106, P75, DOI 10.1016/0304-3835(96)04305-4; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komori H, 2005, EMBO J, V24, P3724, DOI 10.1038/sj.emboj.7600836; Kooi IE, 2015, EBIOMEDICINE, V2, P660, DOI 10.1016/j.ebiom.2015.06.022; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee TC, 2006, INVEST OPHTH VIS SCI, V47, P5590, DOI 10.1167/iovs.06-0063; Li Q, 2013, CLIN CANCER RES, V19, P34, DOI 10.1158/1078-0432.CCR-12-0053; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; McEvoy J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042739; McEvoy J, 2011, CANCER CELL, V20, P260, DOI 10.1016/j.ccr.2011.07.005; Miles WO, 2014, EMBO J, V33, P2201, DOI 10.15252/embj.201488057; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Rushlow DE, 2013, LANCET ONCOL, V14, P327, DOI 10.1016/S1470-2045(13)70045-7; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sohn D, 2009, CELL DEATH DIFFER, V16, P869, DOI 10.1038/cdd.2009.17; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Theriault BL, 2014, CLIN EXP OPHTHALMOL, V42, P33, DOI 10.1111/ceo.12132; To KH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-69; Viatour P, 2011, DIS MODEL MECH, V4, P581, DOI 10.1242/dmm.008060; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Xu XLL, 2014, NATURE, V514, P385, DOI 10.1038/nature13813; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051	53	30	30	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1760	1769		10.1038/onc.2016.350	http://dx.doi.org/10.1038/onc.2016.350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27748758	Green Accepted			2022-12-17	WOS:000398128900002
J	Tsai, CT; So, CWE				Tsai, C. T.; So, C. W. E.			Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; MLL-REARRANGED LEUKEMIA; MIXED-LINEAGE LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; HEMATOPOIETIC STEM-CELLS; MYELODYSPLASTIC SYNDROME; MLL-AF9-MEDIATED LEUKEMOGENESIS; H3K79 METHYLTRANSFERASE; MLL-AF9 LEUKEMIA; FUSION LEUKEMIA	While the current epigenetic drug development is still largely restricted to target DNA methylome, emerging evidence indicates that histone methylome is indeed another major epigenetic determinant for gene expression and frequently deregulated in acute myeloid leukaemia (AML). The recent advances in dissecting the molecular regulation and targeting histone methylome in AML together with the success in developing lead compounds specific to key histone methylation-modifying enzymes have revealed new opportunities for effective leukaemia treatment. In this article, we will review the emerging functions of histone methyltransferases and histone demethylases in AML, especially MLL-rearranged leukaemia. We will also examine recent preclinical and clinical studies that show significant promises of targeting these histone methylation-modifying enzymes for AML treatment.	[Tsai, C. T.; So, C. W. E.] Kings Coll London, Leukaemia & Stem Cell Biol Grp, Div Canc Studies, Dept Haematol Med,Rayne Inst, Denmark Hill Campus,123 Coldharbour Lane, London SE5 9NU, England	University of London; King's College London	So, CWE (corresponding author), Kings Coll London, Leukaemia & Stem Cell Biol Grp, Div Canc Studies, Dept Haematol Med,Rayne Inst, Denmark Hill Campus,123 Coldharbour Lane, London SE5 9NU, England.	eric.so@kcl.ac.uk	Tsai, Chiou-Tsun/AAO-6782-2021		Bloodwise; Cancer Research UK; Cancer Research UK [16753] Funding Source: researchfish; Medical Research Council [G0800892] Funding Source: researchfish; MRC [G0800892] Funding Source: UKRI	Bloodwise; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We wish to thank Drs Bernd Zeisig and Ngai Cheung in the lab for their useful inputs. This work is supported by Bloodwise and Cancer Research UK.	Abdel-Wahab O, 2013, J EXP MED, V210, P2641, DOI 10.1084/jem.20131141; Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032; Agger K, 2016, GENE DEV, V30, P1278, DOI 10.1101/gad.280495.116; Nguyen AT, 2011, BLOOD, V117, P6912, DOI 10.1182/blood-2011-02-334359; Arteaga MF, 2013, CANCER CELL, V23, P376, DOI 10.1016/j.ccr.2013.02.014; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Cao F, 2014, MOL CELL, V53, P247, DOI 10.1016/j.molcel.2013.12.001; Chang MJ, 2010, CANCER RES, V70, P10234, DOI 10.1158/0008-5472.CAN-10-3294; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; Chen M, 2015, GENE DEV, V29, P2123, DOI 10.1101/gad.267278.115; Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642; Cheung N, 2016, CANCER CELL, V29, P32, DOI 10.1016/j.ccell.2015.12.007; Cheung N, 2011, FEBS LETT, V585, P2100, DOI 10.1016/j.febslet.2011.03.068; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Danis E, 2015, EXP HEMATOL, V43, P930, DOI 10.1016/j.exphem.2015.06.005; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Deshpande AJ, 2013, BLOOD, V121, P2533, DOI 10.1182/blood-2012-11-465120; Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711; Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Ferrara F, 2013, LANCET, V381, P484, DOI 10.1016/S0140-6736(12)61727-9; Fiskus W, 2014, LEUKEMIA, V28, P2155, DOI 10.1038/leu.2014.119; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Fung TK, 2013, ONCOTARGET, V4, P1128, DOI 10.18632/oncotarget.1244; Gahr M, 2013, EUR NEUROPSYCHOPHARM, V23, P1364, DOI 10.1016/j.euroneuro.2013.05.009; Garcia-Manero G, 2012, J CLIN ONCOL, V30, P2204, DOI 10.1200/JCO.2011.38.3265; Greenblatt SM, 2014, LEUKEMIA, V28, P1396, DOI 10.1038/leu.2014.94; Guenther MG, 2008, GENE DEV, V22, P3403, DOI 10.1101/gad.1741408; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; He J, 2011, BLOOD, V117, P3869, DOI 10.1182/blood-2010-10-312736; Hou HA, 2012, BLOOD, V119, P559, DOI 10.1182/blood-2011-07-369934; Huls G, 2015, BLOOD, V126, P283, DOI 10.1182/blood-2015-06-648071; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kirschbaum M, 2014, BRIT J HAEMATOL, V167, P185, DOI 10.1111/bjh.13016; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Kronke J, 2013, BLOOD, V122, P100, DOI 10.1182/blood-2013-01-479188; Labbe RM, 2014, AM J TRANSL RES, V6, P1; Lau PNI, 2016, TRANSL EPIGENET SER, P63, DOI 10.1016/B978-0-12-799958-6.00004-4; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Meyer C, 2013, LEUKEMIA, V27, P2165, DOI 10.1038/leu.2013.135; Mochizuki-Kashio M, 2015, BLOOD, V126, P1172, DOI 10.1182/blood-2015-03-634428; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Navada SC, 2014, J CLIN INVEST, V124, P40, DOI 10.1172/JCI69739; Neff T, 2012, P NATL ACAD SCI USA, V109, P5028, DOI 10.1073/pnas.1202258109; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Pratcorona M, 2012, HAEMATOL-HEMATOL J, V97, P388, DOI 10.3324/haematol.2011.051532; Puda A, 2012, AM J HEMATOL, V87, P245, DOI 10.1002/ajh.22257; Quintas-Cardama A, 2011, LEUKEMIA, V25, P226, DOI 10.1038/leu.2010.276; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Ruthenburg AJ, 2006, NAT STRUCT MOL BIOL, V13, P704, DOI 10.1038/nsmb1119; Sahtoe DD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10292; Sashida G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5177; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Sroczynska P, 2014, BLOOD, V123, P1870, DOI 10.1182/blood-2013-08-522094; Wong SHK, 2015, CANCER CELL, V28, P198, DOI 10.1016/j.ccell.2015.06.003; Wouters BJ, 2016, BLOOD, V127, P42, DOI 10.1182/blood-2015-07-604512; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Xu BW, 2015, BLOOD, V125, P346, DOI 10.1182/blood-2014-06-581082; Zeisig BB, 2016, CHROMOSOMAL TRANSLOC, P223; Zeisig BB, 2008, CANCER CELL, V14, P345, DOI 10.1016/j.ccr.2008.10.008; Zeisig Bernd B, 2012, Cancer Cell, V22, P698, DOI 10.1016/j.ccr.2012.10.017; Zhou JB, 2011, BLOOD, V118, P2830, DOI 10.1182/blood-2010-07-294827; Zhu N, 2016, J CLIN INVEST, V126, P997, DOI 10.1172/JCI82978; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	74	30	32	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1753	1759		10.1038/onc.2016.315	http://dx.doi.org/10.1038/onc.2016.315			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27593928	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000398128900001
J	Ramadoss, S; Sen, S; Ramachandran, I; Roy, S; Chaudhuri, G; Farias-Eisner, R				Ramadoss, S.; Sen, S.; Ramachandran, I.; Roy, S.; Chaudhuri, G.; Farias-Eisner, R.			Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance	ONCOGENE			English	Article							GENE-EXPRESSION; HISTONE; P53; CELLS; INHIBITION; RESISTANCE; CHROMATIN; MARKERS; JHDM2A	Ovarian cancer is the leading cause of death among all gynecological malignancies due to the development of acquired chemoresistance and disease relapse. Although the role of cancer stem cells (CSCs), a subset of tumor cells with the self-renewal and differentiation capabilities, in therapeutic resistance is beginning to be better understood, the significance of epigenetic regulatory mechanisms responsible for integrating the stemness with drug resistance remain poorly understood. Here we identified that lysine demethylase KDM3A as a critical regulator of ovarian cancer stemness and cisplatin resistance by inducing the expressions of pluripotent molecules Sox2 and Nanog and anti-apoptotic B-cell lymphoma 2 (Bcl-2), respectively. In addition, KDM3A induces ovarian cancer growth while antagonizing cellular senescence by repressing the expression of cyclin-dependent kinase inhibitor, p21(Waf1/Cip1). The underlying mechanism of the noted biological processes include KDM3A-mediatedstimulation of Sox2 expression, and demethylating p53 protein and consequently, modulating its target genes such as Bcl-2 and p(21Waf1/Cip1) expression. Consistently, KDM3A depletion inhibited the growth of subcutaneously implanted cisplatin-resistant human ovarian cancer cells in athymic nude mice. Moreover, KDM3A is abundantly expressed and positively correlated with Sox2 expression in human ovarian cancer tissues. In brief, our findings reveal a novel mechanism by which KDM3A promotes ovarian CSCs, proliferation and chemoresistance and thus, highlights the significance of KDM3A as a novel therapeutic target for resistant ovarian cancer.	[Ramadoss, S.; Sen, S.; Roy, S.; Chaudhuri, G.; Farias-Eisner, R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; [Ramachandran, I.] Univ Madras, Dr ALM PG Inst Basic Med Sci, Dept Endocrinol, Taramani Campus, Madras 600113, Tamil Nadu, India; [Chaudhuri, G.] Univ Calif Los Angeles, David Geffen Sch Med, Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Madras; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ramadoss, S; Farias-Eisner, R (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.	ramasiva@ucla.edu; rfeisner@mednet.ucla.edu			The Roberta Deutsch Foundation	The Roberta Deutsch Foundation	We acknowledge The Roberta Deutsch Foundation and Kelly Day for their financial support. We thank Professor Oliver Dorigo, Stanford University Medical Center, for the generous gift of cisplatin-resistant ovarian cancer cell lines. We thank Dr Xiangming Ding, UCLA Clinical Microarray Core for the statistical assistance.	Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Chen K, 2013, ACTA PHARMACOL SIN, V34, P732, DOI 10.1038/aps.2013.27; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Cioffi M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10357; Cohen Joshua G, 2014, World J Biol Chem, V5, P286, DOI 10.4331/wjbc.v5.i3.286; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Fraser M, 2008, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086; Huang L, 2010, J CANCER RES CLIN, V136, P447, DOI 10.1007/s00432-009-0675-4; Jelovac D, 2011, CA-CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113; Kong Yahui, 2011, J Aging Res, V2011, P963172, DOI 10.4061/2011/963172; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Liang DM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-201; Liu T, 2015, TUMOR BIOL, V36, P1881, DOI 10.1007/s13277-014-2790-3; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; McEvoy LM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1539-8; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Nair SS, 2012, MOL ONCOL, V6, P611, DOI 10.1016/j.molonc.2012.09.005; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Ramadoss S, 2017, ONCOGENE, V36, P47, DOI 10.1038/onc.2016.174; Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903; Ramadoss S, 2011, MOL CELL BIOL, V31, P924, DOI 10.1128/MCB.00576-10; Rasheed ZA, 2011, STEM CELLS, V29, P883, DOI 10.1002/stem.648; Semenza GL, 2011, NEW ENGL J MED, V365, P537, DOI [10.1056/NEJMra1011165, 10.1056/NEJMc1110602]; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tapia N, 2010, J EXP MED, V207, P2045, DOI 10.1084/jem.20101866; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Zhang XM, 2013, CELL REP, V5, P445, DOI 10.1016/j.celrep.2013.09.018	36	30	32	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1537	1545		10.1038/onc.2016.320	http://dx.doi.org/10.1038/onc.2016.320			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27694900	Green Published, hybrid			2022-12-17	WOS:000397458100008
J	Hu, Y; Su, H; Liu, C; Wang, Z; Huang, L; Wang, Q; Liu, S; Chen, S; Zhou, J; Li, P; Chen, Z; Liu, H; Qing, G				Hu, Y.; Su, H.; Liu, C.; Wang, Z.; Huang, L.; Wang, Q.; Liu, S.; Chen, S.; Zhou, J.; Li, P.; Chen, Z.; Liu, H.; Qing, G.			DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GAMMA-SECRETASE INHIBITORS; MULTIPLE-MYELOMA; BETA-TRCP; INCREASES CHEMOSENSITIVITY; GLUCOCORTICOID RESISTANCE; UBIQUITIN LIGASE; MTOR INHIBITOR; ACTIVATION; EXPRESSION	Aberrant activation of NOTCH1 signaling plays a vital role in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL). Yet the molecular events downstream of NOTCH1 that drive T-cell leukemogenesis remain incompletely understood. Starting from genome-wide gene-expression profiling to seek important NOTCH1 transcriptional targets, we identified DEP-domain containing mTOR-interacting protein (DEPTOR), which was previously shown to be important in multiple myeloma but remains functionally unclear in other hematological malignancies. Mechanistically, we demonstrated NOTCH1 directly bound to and activated the human DEPTOR promoter in T-ALL cells. DEPTOR depletion abolished cellular proliferation, attenuated glycolytic metabolism and enhanced cell death, while ectopically expressed DEPTOR significantly promoted cell growth and glycolysis. We further showed that DEPTOR depletion inhibited while its overexpression enhanced AKT activation in T-ALL cells. Importantly, AKT inhibition completely abrogated DEPTOR-mediated cell growth advantages. Moreover, DEPTOR depletion in a human T-ALL xenograft model significantly delayed T-ALL onset and caused a substantial decrease of AKT activation in leukemic blasts. We thus reveal a novel mechanism involved in NOTCH1-driven leukemogenesis, identifying the transcriptional control of DEPTOR and its regulation of AKT as additional key elements of the leukemogenic program activated by NOTCH1.	[Hu, Y.; Liu, C.; Wang, Z.] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan, Peoples R China; [Su, H.; Chen, Z.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China; [Huang, L.; Zhou, J.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China; [Wang, Q.; Chen, S.] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostasis,Minist Hlth, Suzhou, Peoples R China; [Liu, S.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat Hematol, Wuhan, Peoples R China; [Li, P.] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, South China Inst Stem Cell Biol & Regenerat Med, Key Lab Regenerat Biol, Guangzhou, Guangdong, Peoples R China; [Liu, H.; Qing, G.] Wuhan Univ, Inst Med Res, 185 Donghu Rd, Wuhan 430071, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Soochow University - China; Huazhong University of Science & Technology; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; Wuhan University	Liu, H; Qing, G (corresponding author), Wuhan Univ, Inst Med Res, 185 Donghu Rd, Wuhan 430071, Peoples R China.	hudanliu@whu.edu.cn; qingguoliang@whu.edu.cn	Li, Peng/AER-7520-2022; Huang, Liang/I-3299-2019; Huang, Liang/L-6106-2013	Huang, Liang/0000-0002-8370-3232; Huang, Liang/0000-0002-8370-3232; Li, Peng/0000-0003-4530-2400	National Natural Science Foundation of China [81470332, 81272211, 81372205]; New Investigator Foundation, State Education Ministry of China [20120142120097]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); New Investigator Foundation, State Education Ministry of China	We thank Drs Warren Pear (University of Pennsylvania, Philadelphia, PA, US), Hongbing Shu and Zan Huang (Wuhan University, Wuhan, People's Republic of China), Yi Sun (Zhejiang University, Hangzhou, People's Republic of China) for sharing reagents. This work was supported by grants from the National Natural Science Foundation of China, 81470332 and 81272211 to HL, and 81372205 to GQ and New Investigator Foundation, State Education Ministry of China 20120142120097 to HL.	Bruneau S, 2013, BLOOD, V122, P1833, DOI 10.1182/blood-2013-03-488486; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dohda T, 2007, EXP CELL RES, V313, P3141, DOI 10.1016/j.yexcr.2007.04.027; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Hu YF, 2015, MOL CANCER THER, V14, P289, DOI 10.1158/1535-7163.MCT-14-0501; Khwaja SS, 2010, J CLIN INVEST, V120, P2537, DOI 10.1172/JCI41277; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Laplante M, 2012, CELL METAB, V16, P202, DOI 10.1016/j.cmet.2012.07.008; Liu HD, 2010, GENE DEV, V24, P2395, DOI 10.1101/gad.1975210; Lu B, 2015, CELL MOL LIFE SCI, V72, P821, DOI 10.1007/s00018-014-1704-2; Margolin AA, 2009, P NATL ACAD SCI USA, V106, P244, DOI 10.1073/pnas.0806445106; Medyouf H, 2011, J EXP MED, V208, P1809, DOI 10.1084/jem.20110121; Mendes RD, 2014, BLOOD, V124, P567, DOI 10.1182/blood-2014-03-562751; Meng ZX, 2013, NAT MED, V19, P640, DOI 10.1038/nm.3144; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Paganin M, 2011, BLOOD REV, V25, P83, DOI 10.1016/j.blre.2010.09.004; Palomero T, 2008, CLIN CANCER RES, V14, P5314, DOI 10.1158/1078-0432.CCR-07-4864; Palomero T, 2008, CELL CYCLE, V7, P965, DOI 10.4161/cc.7.8.5753; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; Proud CG, 2009, J MOL CELL BIOL, V1, P61, DOI 10.1093/jmcb/mjp012; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Qing GL, 2006, CELL RES, V16, P895, DOI 10.1038/sj.cr.7310109; Real PJ, 2009, NAT MED, V15, P50, DOI 10.1038/nm.1900; Ren P, 2015, J PATHOL, V235, P90, DOI 10.1002/path.4429; Roti G, 2013, CANCER CELL, V23, P390, DOI 10.1016/j.ccr.2013.01.015; Schnell SA, 2015, BLOOD, V125, P2806, DOI 10.1182/blood-2014-10-608448; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; van Stralen E, 2009, EXP HEMATOL, V37, P78, DOI 10.1016/j.exphem.2008.08.006; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Wang HF, 2014, P NATL ACAD SCI USA, V111, P705, DOI 10.1073/pnas.1315023111; Wang HF, 2011, P NATL ACAD SCI USA, V108, P14908, DOI 10.1073/pnas.1109023108; Wang ZW, 2012, NEOPLASIA, V14, P368, DOI 10.1593/neo.12542; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Xiao YR, 2015, HAEMATOLOGICA, V100, P585, DOI 10.3324/haematol.2014.118612; Ye W, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0156-y; Zhang HR, 2013, J INT MED RES, V41, P584, DOI 10.1177/0300060513480920; Zhang HR, 2013, INT J MOL MED, V31, P1127, DOI 10.3892/ijmm.2013.1299; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029	46	30	32	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1038	1047		10.1038/onc.2016.275	http://dx.doi.org/10.1038/onc.2016.275			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27593934				2022-12-17	WOS:000395371500002
J	Ma, Y; Yu, C; Mohamed, EM; Shao, H; Wang, L; Sundaresan, G; Zweit, J; Idowu, M; Fang, X				Ma, Y.; Yu, C.; Mohamed, E. M.; Shao, H.; Wang, L.; Sundaresan, G.; Zweit, J.; Idowu, M.; Fang, X.			A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR 1-ALPHA; EML4-ALK FUSION GENE; GLUCOSE CATABOLISM; RESPONSE ELEMENTS; EXPRESSION; METABOLISM; TARGET; IDENTIFICATION	A high rate of aerobic glycolysis is a hallmark of malignant transformation. Accumulating evidence suggests that diverse regulatory mechanisms mediate this cancer-associated metabolic change seen in a wide spectrum of cancer. The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein is found in approximately 3-7% of non-small cell lung carcinomas (NSCLC). Molecular evidence and therapeutic effectiveness of FDA-approved ALK inhibitors indicated that EML4-ALK is a driving factor of lung tumorigenesis. A recent clinical study showed that NSCLC harboring EML4-ALK rearrangements displayed higher glucose metabolism compared with EML4-ALK-negative NSCLC. In the current work, we presented evidence that EML4-ALK is coupled to overexpression of hexokinase II (HK2), one of the rate-limiting enzymes of the glycolytic pathway. The link from EML4-ALK to HK2 upregulation is essential for a high rate of glycolysis and proliferation of EML4-ALK-rearranged NSCLC cells. We identified hypoxia-inducible factor 1a (HIF1a) as a key transcription factor to drive HK2 gene expression in normoxia in these cells. EML4-ALK induced hypoxia-independent but glucose-dependent accumulation of HIF1a protein via both transcriptional activation of HIF1a mRNA and the phosphatidylinositol 3 kinase-AKT pathway to enhance HIF1a protein synthesis. The EML4ALK- mediated upregulation of HIF1a, HK2 and glycolytic metabolism was also highly active in vivo as demonstrated by fluorodeoxyglucose-positron emission tomography imaging of xenografts grown from EML4-ALK-positive NSCLC cells. Our data reveal a novel EML4-ALK-HIF1a-HK2 cascade to enhance glucose metabolism in EML4-ALK-positive NSCLC.	[Ma, Y.; Mohamed, E. M.; Shao, H.; Fang, X.] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Sanger Hall 2-016,1101 East Marshall St, Richmond, VA 23298 USA; [Yu, C.] Wuhan Univ, Coll Life Sci, Wuhan, Hunan, Peoples R China; [Wang, L.; Sundaresan, G.; Zweit, J.] Virginia Commonwealth Univ, Sch Med, Dept Radiol, Richmond, VA USA; [Idowu, M.] Virginia Commonwealth Univ, Sch Med, Dept Pathol, Richmond, VA USA	Virginia Commonwealth University; Wuhan University; Virginia Commonwealth University; Virginia Commonwealth University	Fang, X (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Sanger Hall 2-016,1101 East Marshall St, Richmond, VA 23298 USA.	xfang@vcu.edu	Ma, Yibao/H-3849-2016	Ma, Yibao/0000-0002-3270-8893	Astar Biotech research award; Jeffress Memorial Fund award; NIH [P30 CA16059]; NATIONAL CANCER INSTITUTE [P30CA016059] Funding Source: NIH RePORTER	Astar Biotech research award; Jeffress Memorial Fund award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported in part by Astar Biotech research award (XF), the Jeffress Memorial Fund award (XF) and the NIH grant P30 CA16059 to Massey Cancer Center of VCU School of Medicine.	Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Choi H, 2013, LUNG CANCER, V79, P242, DOI 10.1016/j.lungcan.2012.11.021; Choi YL, 2008, CANCER RES, V68, P4971, DOI 10.1158/0008-5472.CAN-07-6158; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Fang R, 2012, J BIOL CHEM, V287, P23227, DOI 10.1074/jbc.M112.373084; Ferreira JV, 2013, AUTOPHAGY, V9, P1349, DOI 10.4161/auto.25190; Friboulet L, 2014, CANCER DISCOV, V4, P662, DOI 10.1158/2159-8290.CD-13-0846; Ganapathy-Kanniappan S, 2010, CURR PHARM BIOTECHNO, V11, P510, DOI 10.2174/138920110791591427; Gershon TR, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-2; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Horn L, 2009, J CLIN ONCOL, V27, P4232, DOI 10.1200/JCO.2009.23.6661; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hubbi ME, 2013, J BIOL CHEM, V288, P10703, DOI 10.1074/jbc.M112.414771; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Koivunen JP, 2008, CLIN CANCER RES, V14, P4275, DOI 10.1158/1078-0432.CCR-08-0168; Kuo AH, 2007, ONCOGENE, V26, P859, DOI 10.1038/sj.onc.1209840; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Mano H, 2015, P JPN ACAD B-PHYS, V91, P193, DOI 10.2183/pjab.91.193; Martinengo C, 2014, CANCER RES, V74, P6094, DOI 10.1158/0008-5472.CAN-14-0268; Marzec M, 2011, ONCOGENE, V30, P1372, DOI 10.1038/onc.2010.505; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; McDonnell SRP, 2013, BLOOD, V122, P958, DOI 10.1182/blood-2013-01-482026; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Mukherjee A, 2015, NEOPLASIA, V17, P723, DOI 10.1016/j.neo.2015.09.003; Nishino M, 2012, MODERN PATHOL, V25, P1462, DOI 10.1038/modpathol.2012.109; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Rempel A, 1996, CANCER RES, V56, P2468; Ren H, 2012, CANCER RES, V72, P3312, DOI 10.1158/0008-5472.CAN-11-3931; Riddle SR, 2000, AM J PHYSIOL-LUNG C, V278, pL407, DOI 10.1152/ajplung.2000.278.2.L407; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Sasaki T, 2010, EUR J CANCER, V46, P1773, DOI 10.1016/j.ejca.2010.04.002; SATO S, 1969, CANCER RES, V29, P1437; Schonherr C, 2011, TRANSL ONCOL, V4, P248, DOI 10.1593/tlo.11139; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shaw AT, 2014, NEW ENGL J MED, V370, P1189, DOI [10.1056/NEJMoa1311107, 10.1056/NEJMc1404894]; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Soda M, 2012, CLIN CANCER RES, V18, P5682, DOI 10.1158/1078-0432.CCR-11-2947; Wang L, 2014, CELL REP, V8, P1461, DOI 10.1016/j.celrep.2014.07.053; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Wu J, 2013, ONCOGENE, V32, P3198, DOI 10.1038/onc.2012.325; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yoshida A, 2011, AM J SURG PATHOL, V35, P1226, DOI 10.1097/PAS.0b013e3182233e06; Younes M, 1997, CANCER-AM CANCER SOC, V80, P1046, DOI 10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7	59	30	30	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6132	6142		10.1038/onc.2016.150	http://dx.doi.org/10.1038/onc.2016.150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27132509	Green Accepted			2022-12-17	WOS:000388509800009
J	Stalin, J; Nollet, M; Garigue, P; Fernandez, S; Vivancos, L; Essaadi, A; Muller, A; Bachelier, R; Foucault-Bertaud, A; Fugazza, L; Leroyer, AS; Bardin, N; Guillet, B; Dignat-George, F; Blot-Chabaud, M				Stalin, J.; Nollet, M.; Garigue, P.; Fernandez, S.; Vivancos, L.; Essaadi, A.; Muller, A.; Bachelier, R.; Foucault-Bertaud, A.; Fugazza, L.; Leroyer, A. S.; Bardin, N.; Guillet, B.; Dignat-George, F.; Blot-Chabaud, M.			Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors	ONCOGENE			English	Article							ENDOTHELIAL PROGENITOR CELLS; HUMAN BREAST-CANCER; HUMAN-MELANOMA; ADHESION MOLECULE; PROSTATE-CANCER; C-MYC; EXPRESSION; THERAPY; ANGIOGENESIS; ANGIOMOTIN	CD146 (MUC-18, MCAM) expression on cancer cells correlates with cancer progression and a bad prognosis in several tumors, including melanoma and pancreatic tumors. Deciphering the mechanism mediating the CD146 role in cancer is essential for generating new therapeutic strategies. We found that CD146 expression in cancer cells is associated with a secretion of soluble CD146 (sCD146) that constitutes an active player in tumor development. Indeed, sCD146 induces the overexpression of its binding protein, angiomotin, on both endothelial and cancer cells and promotes both paracrine effects on angiogenesis and autocrine effects on cancer cells proliferation and survival. These last effects are mediated in part through the induction and phosphorylation of c-myc in cancer cells. In mice models xenografted with human CD146-positive melanoma or pancreatic cancer cells, administration of a novel monoclonal antibody specifically targeting sCD146, but not its membrane form, successfully suppresses tumor vascularization and growth. Our findings demonstrate that sCD146 secreted by CD146-positive tumors mediates important pro-angiogenic and pro-tumoral effects. Targeting sCD146 with a novel neutralizing antibody could thus constitute an innovative therapeutic strategy for the treatment of CD146-positive tumors.	[Stalin, J.; Nollet, M.; Garigue, P.; Vivancos, L.; Essaadi, A.; Muller, A.; Bachelier, R.; Foucault-Bertaud, A.; Leroyer, A. S.; Bardin, N.; Guillet, B.; Dignat-George, F.; Blot-Chabaud, M.] Aix Marseille Univ, UFR Pharm, INSERM, UMR S 1076, 27 Bd J Moulin, F-13005 Marseille, France; [Garigue, P.; Fernandez, S.; Guillet, B.] Aix Marseille Univ, CERIMED European Ctr Res Med Imaging, Marseille, France; [Fugazza, L.] Adv Accelerator Applicat SRL, Colleretto Giacosa, TO, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Blot-Chabaud, M (corresponding author), Aix Marseille Univ, UFR Pharm, INSERM, UMR S 1076, 27 Bd J Moulin, F-13005 Marseille, France.	marcel.blot-chabaud@laposte.net	Bardin, Nathalie/AAL-3663-2020; Blot-Chabaud, Marcel/D-4064-2017; Leroyer, Aurelie S./M-4400-2016; NOLLET, MARIE/M-2752-2017; DIGNAT-GEORGE, Françoise/R-1129-2016	Bardin, Nathalie/0000-0003-3680-082X; Leroyer, Aurelie S./0000-0002-8079-7122; NOLLET, MARIE/0000-0002-9667-8216; DIGNAT-GEORGE, Françoise/0000-0001-7006-4462; Stalin, Jimmy/0000-0001-8092-7057	Inserm, Aix-Marseille University; Region Provence-Alpes-Cote d'Azur; Martine Midy Fundation; FRM; ANR	Inserm, Aix-Marseille University; Region Provence-Alpes-Cote d'Azur(Region Provence-Alpes-Cote d'Azur); Martine Midy Fundation; FRM(Fondation pour la Recherche Medicale); ANR(French National Research Agency (ANR))	We thank Biocytex company (Marseille, France) for rsCD146, CD146 Elisa and S-Endo-1 antibody. We thank E Mas, G Pommier, N Alfaidy and D Lombardo for providing us with several cell lines. This study was financed by grants from Inserm, Aix-Marseille University and ANR. Jimmy Stalin was financed by grants from Region Provence-Alpes-Cote d'Azur, FRM and Martine Midy Fundation.	Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Anfosso F, 2001, J BIOL CHEM, V276, P1564, DOI 10.1074/jbc.M007065200; Aulakh GK, 2014, CELL TISSUE RES, V355, P375, DOI 10.1007/s00441-013-1753-0; Bardin N, 2003, THROMB HAEMOSTASIS, V90, P915, DOI 10.1160/TH02-11-0285; Bardin N, 1998, FEBS LETT, V421, P12, DOI 10.1016/S0014-5793(97)01455-5; Bardin N, 2001, BLOOD, V98, P3677, DOI 10.1182/blood.V98.13.3677; Bardin N, 2009, ARTERIOSCL THROM VAS, V29, P746, DOI 10.1161/ATVBAHA.108.183251; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94; Dagur PK, 2014, CLIN IMMUNOL, V152, P36, DOI 10.1016/j.clim.2014.01.009; Dorrell MI, 2007, P NATL ACAD SCI USA, V104, P967, DOI 10.1073/pnas.0607542104; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Feng G, 2012, INT UROL NEPHROL, V44, P1663, DOI 10.1007/s11255-012-0255-4; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Gerber HP, 2005, CANCER RES, V65, P671; Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008; Harhouri K, 2010, BLOOD, V115, P3843, DOI 10.1182/blood-2009-06-229591; Ilie M, 2014, BRIT J CANCER, V110, P1236, DOI 10.1038/bjc.2014.11; Imbert AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043752; Jiang WG, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-16; Kebir A, 2010, CIRC RES, V107, P66, DOI 10.1161/CIRCRESAHA.109.213827; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Liu JW, 2008, PROSTATE, V68, P418, DOI 10.1002/pros.20709; Liu WF, 2012, INT J MOL SCI, V13, P6399, DOI 10.3390/ijms13056399; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Ma WW, 2009, CA-CANCER J CLIN, V59, P111, DOI 10.3322/caac.20003; Maitra A, 2003, CLIN CANCER RES, V9, P5988; Mao BB, 2011, INT J BIOCHEM CELL B, V43, P1573, DOI 10.1016/j.biocel.2011.07.006; Mills L, 2002, CANCER RES, V62, P5106; Mizukami Y, 2006, J BIOL CHEM, V281, P13957, DOI 10.1074/jbc.M511763200; Oka S, 2012, ANTICANCER RES, V32, P861; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Roudier E, 2009, J PHYSIOL-LONDON, V587, P4105, DOI 10.1113/jphysiol.2009.175554; Salgaller ML, 2003, CURR OPIN MOL THER, V5, P657; Satchi-Fainaro R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044395; SENGER DR, 1986, CANCER RES, V46, P5629; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shojaei F, 2007, CANCER J, V13, P345, DOI 10.1097/PPO.0b013e31815a7b69; Shojaei F, 2007, LAB INVEST, V87, P227, DOI 10.1038/labinvest.3700526; Stalin J, 2013, J BIOL CHEM, V288, P8991, DOI 10.1074/jbc.M112.446518; Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445; Wu GJ, 2005, J UROLOGY, V173, P1778, DOI 10.1097/01.ju.0000154643.30048.2c; Wu GJ, 2001, PROSTATE, V48, P305, DOI 10.1002/pros.1111; Yan XY, 2003, BLOOD, V102, P184, DOI 10.1182/blood-2002-04-1004; Zabouo G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2215; Zeng GF, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-113; Zeng QQ, 2012, P NATL ACAD SCI USA, V109, P1127, DOI 10.1073/pnas.1111053108; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111	50	30	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5489	5500		10.1038/onc.2016.83	http://dx.doi.org/10.1038/onc.2016.83			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27065325				2022-12-17	WOS:000386998200004
J	Tandon, M; Chen, Z; Othman, AH; Pratap, J				Tandon, M.; Chen, Z.; Othman, A. H.; Pratap, J.			Role of Runx2 in IGF-1R beta/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR RUNX2; MAMMARY EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; SIGNALING PATHWAYS; ECTOPIC EXPRESSION; PROSTATE-CANCER; DNA-DAMAGE; PROGRESSION; INVASION	The mechanisms underlying reprogramming of growth factor signaling and metabolic pathways during bone metastasis of breast cancer are not clear. The Runt-related transcription factor (Runx2) regulates cell signaling during mammary epithelial morphogenesis and promotes invasion; therefore, we investigated its role in cell growth and metabolic signaling in bone-seeking breast cancer cells. We performed systemic inoculation of control or Runx2 knockdown invasive MDA-MB-231 cells in NOD/SCID mice, and compared parental and bone-derived variants for phenotypic and molecular alterations. The Runx2 knockdown showed early (0-2 weeks) inhibition of metastatic spread but late (4-6 weeks) outgrowth, suggesting Runx2-dependent bi-phasic response and reprogramming of metastatic cells. The late-stage tumor outgrowth of bone-derived Runx2 knockdown cells was associated with increased insulin-like growth factor-1R beta (IGF-1R beta) levels. Interestingly, glucose uptake and glycolysis were reduced in the bone-derived Runx2 knockdown cells that could be further reduced by extracellular-regulated protein kinase (Erk1/2) inhibition. Furthermore, the Runx2 knockdown cells displayed activation of AMP-activated protein kinase (AMPK alpha), the sensor of cellular metabolism. Importantly, the Runx2 knockdown in bone-derived cells resulted in increased sensitivity to both Erk1/2 inhibition and AMPK alpha activation by PD184161 and metformin, respectively, despite increased IGF-1R beta and AMPK alpha levels. Our results reveal that Runx2 promotes metastatic spread of mammary tumor cells. The growth of late-stage tumor cells can be targeted by Runx2 knockdown in combination with Mek-Erk1/2 inhibition and metformin treatment.	[Tandon, M.; Chen, Z.; Othman, A. H.; Pratap, J.] Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL 60612 USA	Rush University	Pratap, J (corresponding author), Rush Univ, Med Ctr, Armour Acad Ctr, Dept Anat & Cell Biol, 600 South Paulina St,Suite 507, Chicago, IL 60612 USA.	jitesh_pratap@rush.edu		Othman, Ahmad/0000-0001-9995-1233	Bears Care Foundation	Bears Care Foundation	We thank Rush University Medical Center investigators; Dr Rick Sumner and his lab members, Dr Ryan Ross and Maleeha Mashiatulla for assistance with mu CT data acquisition and analysis; Dr Amarjit Virdi for help with the ex vivo bone tumor co-culture model. We thank Dr Carl Maki and members of his lab, Dr Lei Duan and Ricardo Perez for helpful discussions throughout this study; Dr Elena Dedkova and Dr Lothar Blatter for assistance with sea horse data acquisition and analysis. This study was supported by the grant from Bears Care Foundation.	Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609; Ali SA, 2012, J CELL SCI, V125, P2732, DOI 10.1242/jcs.100909; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Boumah CE, 2009, MOL ENDOCRINOL, V23, P1255, DOI 10.1210/me.2008-0217; Campbell JP, 2012, JOVE-J VIS EXP, DOI 10.3791/4260; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13; Dowling RJO, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-33; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Dunn SE, 1998, CANCER RES, V58, P3353; Foley John, 2010, Semin Cell Dev Biol, V21, P951, DOI 10.1016/j.semcdb.2010.08.009; Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747; Ge C, 2016, ONCOGENE, V35, P366, DOI 10.1038/onc.2015.91; Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046; Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980; Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Hatoum D, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/548436; Henkels KM, 2015, FASEB J, V29, P1299, DOI 10.1096/fj.14-260992; Hiraga T, 2012, CANCER RES, V72, P4238, DOI 10.1158/0008-5472.CAN-11-3061; Ibrahim T, 2013, ONCOL LETT, V6, P306, DOI 10.3892/ol.2013.1372; Inman CK, 2005, MOL CELL BIOL, V25, P3182, DOI 10.1128/MCB.25.8.3182-3193.2005; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kovacs JJ, 2009, DEV CELL, V17, P443, DOI 10.1016/j.devcel.2009.09.011; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Leong DT, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2762; Lian JB, 2003, CONNECT TISSUE RES, V44, P141, DOI 10.1080/03008200390152232; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579; Lucero CMJ, 2013, J CELL PHYSIOL, V228, P714, DOI 10.1002/jcp.24218; Martin TJ, 2001, TRENDS ENDOCRIN MET, V12, P2, DOI 10.1016/S1043-2760(00)00351-9; McDonald L, 2014, DIS MODEL MECH, V7, P525, DOI 10.1242/dmm.015040; Monami G, 2008, J CELL PHYSIOL, V216, P426, DOI 10.1002/jcp.21405; Morales DR, 2015, ANNU REV MED, V66, P17, DOI 10.1146/annurev-med-062613-093128; MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756-3282(91)90057-P; Oakley RH, 2012, P NATL ACAD SCI USA, V109, P17591, DOI 10.1073/pnas.1209411109; Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj.neo.7900229; Onodera Y, 2010, CANCER SCI, V101, P2670, DOI 10.1111/j.1349-7006.2010.01742.x; Ozaki T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.127; Pande S, 2013, J CELL PHYSIOL, V228, P1784, DOI 10.1002/jcp.24339; Park HU, 2009, MOL CANCER THER, V8, P733, DOI 10.1158/1535-7163.MCT-08-0631; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Pratap J, 2003, CANCER RES, V63, P5357; Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008-5472.CAN-08-1078; Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008-5472.CAN-09-1471; Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280; Robey IF, 2008, NEOPLASIA, V10, P745, DOI 10.1593/neo.07724; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Ross RD, 2014, J BONE MINER RES, V29, P1597, DOI 10.1002/jbmr.2188; Sachdev D, 2010, ONCOGENE, V29, P251, DOI 10.1038/onc.2009.316; Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227; Taipaleenmaki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008-5472.CAN-14-1026; Taliaferro-Smith L, 2009, ONCOGENE, V28, P2621, DOI 10.1038/onc.2009.129; Tandon M, 2014, J CELL BIOCHEM, V115, P2208, DOI 10.1002/jcb.24939; Tandon M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3611; Tandon M, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-27; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Westendorf JJ, 2006, J CELL BIOCHEM, V98, P54, DOI 10.1002/jcb.20805; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r52; Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18; Zhuang YX, 2011, MOL CANCER RES, V9, P603, DOI 10.1158/1541-7786.MCR-10-0343; Zordoky BNM, 2014, BBA-GEN SUBJECTS, V1840, P1943, DOI 10.1016/j.bbagen.2014.01.023	79	30	32	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4730	4740		10.1038/onc.2015.518	http://dx.doi.org/10.1038/onc.2015.518			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26804175				2022-12-17	WOS:000383324700006
J	Chen, X; Kamranvar, SA; Masucci, MG				Chen, X.; Kamranvar, S. A.; Masucci, M. G.			Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors	ONCOGENE			English	Article							MEMBRANE-PROTEIN 1; SIGNAL-BINDING-PROTEIN; NF-KAPPA-B; DNA-DAMAGE; NUCLEAR ANTIGEN; GENOMIC INSTABILITY; TYROSINE KINASES; ACTIVATION; EXPRESSION; INDUCTION	Infection of human B lymphocytes by Epstein-Barr virus (EBV) leads to the establishment of immortalized lymphoblastoid cell lines (LCLs) that are widely used as a model of viral oncogenesis. An early consequence of infection is the induction of DNA damage and activation of the DNA damage response, which limits the efficiency of growth transformation. The cause of the DNA damage remains poorly understood. We have addressed this question by comparing the response of B lymphocytes infected with EBV or stimulated with a potent B-cell mitogen. We found that although the two stimuli induce comparable proliferation during the first 10 days of culture, the EBV-infected blasts showed significantly higher levels of DNA damage, which correlated with stronger and sustained accumulation of reactive oxygen species (ROS). Treatment with ROS scavengers decreased DNA damage in both mitogen-stimulated and EBV-infected cells. However, while mitogen-induced proliferation was slightly improved, the proliferation of EBV-infected cells and the establishment of LCLs were severely impaired. Quenching of ROS did not affect the kinetics and magnitude of viral gene expression but was associated with selective downregulation of the viral LMP1 and phosphorylated cellular transcription factor STAT3 that have key roles in transformation. Analysis of the mechanism by which high levels of ROS support LMP1 expression revealed selective inhibition of viral microRNAs that target the LMP1 transcript. Our study provides novel insights into the role of EBV-induced oxidative stress in promoting B-cell immortalization and malignant transformation.	[Chen, X.; Kamranvar, S. A.; Masucci, M. G.] Karolinska Inst, Dept Cell & Mol Biol, Berzelius Vag 35, S-17177 Stockholm, Sweden; [Kamranvar, S. A.] Uppsala Univ, Biomed Ctr BMC, Med Biochem & Microbiol IMBIM, Uppsala, Sweden	Karolinska Institutet; Uppsala University	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Berzelius Vag 35, S-17177 Stockholm, Sweden.	maria.masucci@ki.se	Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809; Chen, Xinsong/0000-0002-3214-9075	Swedish Cancer Society; Swedish Medical Research Council; Karolinska Institutet, Stockholm, Sweden; China Scholarship Council	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Karolinska Institutet, Stockholm, Sweden; China Scholarship Council(China Scholarship Council)	This study was supported by grants awarded by the Swedish Cancer Society, the Swedish Medical Research Council and the Karolinska Institutet, Stockholm, Sweden. XC was partly supported by a fellowship awarded by the China Scholarship Council. We are grateful to Dr Glenn Goldstein (David Pharmaceuticals, NY, USA), Dr Svante Norgren (Karolinska University Hospital, Stockholm, Sweden) and Dr Jaap Middeldorp (Vrije Universiteit, Amsterdam, The Netherlands) for providing chemicals and antibodies. The contribution of the master student Iris Valent is gratefully acknowledged.	Altmann M, 2006, P NATL ACAD SCI USA, V103, P14188, DOI 10.1073/pnas.0605985103; Ates B, 2008, FREE RADICAL RES, V42, P372, DOI 10.1080/10715760801998638; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bottero V, 2013, J VIROL, V87, P1733, DOI 10.1128/JVI.02958-12; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Dando I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/425708; Davy C, 2007, VIROLOGY, V368, P219, DOI 10.1016/j.virol.2007.05.043; DIEHL V, 1968, J VIROL, V2, P663, DOI 10.1128/JVI.2.7.663-669.1968; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Gargouri B, 2011, BIOL TRACE ELEM RES, V144, P1449, DOI 10.1007/s12011-011-9135-5; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Grand RJA, 1998, VIROLOGY, V244, P330, DOI 10.1006/viro.1998.9102; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; Gruhne B, 2009, ONCOGENE, V28, P3997, DOI 10.1038/onc.2009.258; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HU LF, 1993, ONCOGENE, V8, P1575; HUEN DS, 1995, ONCOGENE, V10, P549; Ingham RJ, 2005, J BIOL CHEM, V280, P34133, DOI 10.1074/jbc.M507831200; Jochum S, 2012, P NATL ACAD SCI USA, V109, pE1396, DOI 10.1073/pnas.1115906109; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; Kinjo T, 2010, J VIROL, V84, P5431, DOI 10.1128/JVI.02460-09; Knight JS, 2003, J VIROL, V77, P4261, DOI 10.1128/JVI.77.7.4261-4272.2003; Koganti S, 2014, P NATL ACAD SCI USA, V111, P4946, DOI 10.1073/pnas.1400683111; Koganti S, 2014, J VIROL, V88, P516, DOI 10.1128/JVI.02601-13; Koopal S, 2007, PLOS PATHOG, V3, P1348, DOI 10.1371/journal.ppat.0030140; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Le Clorennec C, 2008, J VIROL, V82, P6721, DOI 10.1128/JVI.02250-07; Lee YJ, 2007, AM J PHYSIOL-RENAL, V293, pF1036, DOI 10.1152/ajprenal.00034.2007; LEIBOLD W, 1975, J NATL CANCER I, V54, P65, DOI 10.1093/jnci/54.1.65; Liu TS, 2004, J BIOL CHEM, V279, P2461, DOI 10.1074/jbc.M307251200; Lo AKF, 2007, P NATL ACAD SCI USA, V104, P16164, DOI 10.1073/pnas.0702896104; Ma Q, 2013, ANTIOXID REDOX SIGN, V18, P80, DOI 10.1089/ars.2012.4584; Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NALESNIK MA, 1988, AM J PATHOL, V133, P173; Nikitin PA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087299; Nikitin PA, 2010, CELL HOST MICROBE, V8, P510, DOI 10.1016/j.chom.2010.11.004; Portal D, 2013, P NATL ACAD SCI USA, V110, P18537, DOI 10.1073/pnas.1317608110; Price AM, 2014, ADV VIRUS RES, V88, P279, DOI 10.1016/B978-0-12-800098-4.00006-4; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; Rickinson A, 2002, VIRUS RES, V82, P109; Rickinson AB, 1996, VIROLOGY, P2397; Riley KJ, 2012, EMBO J, V31, P2207, DOI 10.1038/emboj.2012.63; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; Skalsky RL, 2014, J VIROL, V88, P1617, DOI 10.1128/JVI.02071-13; Skalsky RL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002484; Sompallae R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012052; Souza V, 2009, TOXICOL LETT, V187, P180, DOI 10.1016/j.toxlet.2009.02.021; Sunitha K, 2013, FREE RADICAL RES, V47, P357, DOI 10.3109/10715762.2013.781595; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Weitzman MD, 2014, CELL HOST MICROBE, V15, P283, DOI 10.1016/j.chom.2014.02.010; White RE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013979; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; Zhao B, 2011, P NATL ACAD SCI USA, V108, P14902, DOI 10.1073/pnas.1108892108	61	30	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3807	3816		10.1038/onc.2015.450	http://dx.doi.org/10.1038/onc.2015.450			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26592445	Bronze			2022-12-17	WOS:000380753200006
J	Macari, F; El-houfi, Y; Boldina, G; Xu, H; Khoury-Hanna, S; Ollier, J; Yazdani, L; Zheng, G; Bieche, I; Legrand, N; Paulet, D; Durrieu, S; Bystrom, A; Delbecq, S; Lapeyre, B; Bauchet, L; Pannequin, J; Hollande, F; Pan, T; Teichmann, M; Vagner, S; David, A; Choquet, A; Joubert, D				Macari, F.; El-houfi, Y.; Boldina, G.; Xu, H.; Khoury-Hanna, S.; Ollier, J.; Yazdani, L.; Zheng, G.; Bieche, I.; Legrand, N.; Paulet, D.; Durrieu, S.; Bystrom, A.; Delbecq, S.; Lapeyre, B.; Bauchet, L.; Pannequin, J.; Hollande, F.; Pan, T.; Teichmann, M.; Vagner, S.; David, A.; Choquet, A.; Joubert, D.			TRM6/61 connects PKC alpha with translational control through tRNA(i)(Met) stabilization: impact on tumorigenesis	ONCOGENE			English	Article							PROTEIN-KINASE-C; MULTIDRUG-RESISTANCE; INITIATOR TRNA(MET); GENE-EXPRESSION; CELL-LINES; CANCER; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION; ACTIVATION	Accumulating evidence suggests that changes of the protein synthesis machinery alter translation of specific mRNAs and participate in malignant transformation. Here we show that protein kinase C alpha (PKC alpha) interacts with TRM61, the catalytic subunit of the TRM6/61 tRNA methyltransferase. The TRM6/61 complex is known to methylate the adenosine 58 of the initiator methionine tRNA (tRNA(i)(Met)), a nuclear post-transcriptional modification associated with the stabilization of this crucial component of the translation-initiation process. Depletion of TRM6/61 reduced proliferation and increased death of C6 glioma cells, effects that can be partially rescued by overexpression of tRNA(i)(Met). In contrast, elevated TRM6/61 expression regulated the translation of a subset of mRNAs encoding proteins involved in the tumorigenic process and increased the ability of C6 cells to form colonies in soft agar or spheres when grown in suspension. In TRM6/61/tRNA(i)(Met)-overexpressing cells, PKC alpha overexpression decreased tRNA(i)(Met) expression and both colony-and sphere-forming potentials. A concomitant increase in TRM6/TRM61 mRNA and tRNA(i)(Met) expression with decreased expression of PKC alpha mRNA was detected in highly aggressive glioblastoma multiforme as compared with Grade II/III glioblastomas, highlighting the clinical relevance of our findings. Altogether, we suggest that PKC alpha tightly controls TRM6/61 activity to prevent translation deregulation that would favor neoplastic development.	[Macari, F.; El-houfi, Y.; Khoury-Hanna, S.; Ollier, J.; Yazdani, L.; Legrand, N.; Pannequin, J.; Hollande, F.; David, A.; Choquet, A.; Joubert, D.] CNRS, UMR 5203, Dept Oncol, Inst Genom Fonct, 141 Rue Cardonille, F-34094 Montpellier, France; [Macari, F.; El-houfi, Y.; Khoury-Hanna, S.; Ollier, J.; Yazdani, L.; Legrand, N.; Pannequin, J.; Hollande, F.; David, A.; Choquet, A.; Joubert, D.] INSERM, U1191, Montpellier, France; [Macari, F.; El-houfi, Y.; Khoury-Hanna, S.; Ollier, J.; Yazdani, L.; Legrand, N.; Pannequin, J.; Hollande, F.; David, A.; Choquet, A.; Joubert, D.] Univ Montpellier, Montpellier, France; [Boldina, G.; Vagner, S.] Inst Curie, Ctr Rech, F-91405 Orsay, France; [Boldina, G.; Vagner, S.] CNRS, UMR3348, F-91405 Orsay, France; [Boldina, G.; Vagner, S.] Univ Paris 11, Orsay, France; [Boldina, G.; Vagner, S.] PSL Res Univ, Paris, France; [Xu, H.; Bystrom, A.] Umea Univ, Dept Mol Biol, Umea, Sweden; [Zheng, G.; Pan, T.] Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA; [Bieche, I.] Hop Rene Huguenin, Inst Curie, Lab Oncogenet, St Cloud, France; [Paulet, D.] Lab Informat Robot & Microelect Montpellier, Montpellier, France; [Durrieu, S.; Teichmann, M.] Univ Bordeaux, Inst Europeen Chim & Biol, ARNA Lab, Pessac, France; [Delbecq, S.] Univ Montpellier I, Lab Biol Cellulaire & Mol, Montpellier, France; [Lapeyre, B.] CNRS UPHE UPVD, CRIOBE, USR 3278, Moorea, France; [Lapeyre, B.] CNRS, UMR5237, Ctr Rech Biochim Macromol, F-34094 Montpellier, France; [Bauchet, L.] Hop Gui de Chauliac, Dept Neurosurg, Montpellier, France; [Hollande, F.] Univ Melbourne, Dept Pathol, Mol Mech Tumor Progress Lab, Melbourne, Vic, Australia	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Umea University; University of Chicago; Rene Huguenin Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Montpellier; UDICE-French Research Universities; Universite de Bordeaux; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; University of Melbourne	David, A; Choquet, A (corresponding author), CNRS, UMR 5203, Dept Oncol, Inst Genom Fonct, 141 Rue Cardonille, F-34094 Montpellier, France.	alexandre.david@igf.cnrs.fr; armelle.choquet@igf.cnrs.fr	Bièche, Ivan/O-7399-2017; macari, francoise/E-9941-2014; Wegglin, Reto/AAV-4341-2021; Hollande, Frederic/GLS-4120-2022; Vagner, Stephan/G-3664-2013; David, Alexandre/B-2447-2013; David, Alexandre/AAL-2758-2021; Teichmann, Martin/M-7407-2014	Bièche, Ivan/0000-0002-2430-5429; macari, francoise/0000-0001-8942-1845; Hollande, Frederic/0000-0002-7046-8392; David, Alexandre/0000-0003-3365-1339; David, Alexandre/0000-0003-3365-1339; vagner, stephan/0000-0003-1452-7164; Teichmann, Martin/0000-0002-5257-0510; Bystrom, Anders/0000-0003-1281-3888; Delbecq, Stephane/0000-0002-2813-1219; pannequin, julie/0000-0002-9956-373X; Choquet, armelle/0000-0002-6959-9387	Swedish Cancer Foundation [13 0301]; Swedish Research Council [621-2012-3576]; Karin and Harald Silvanders Foundation [223-2808-12]; Institut National du Cancer (INCa); Fondation ARC	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Karin and Harald Silvanders Foundation; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation ARC	This work was generously supported by the Institut National du Cancer (INCa) and the Fondation ARC. We thank Martial Seveno, Serge Urbach and Edith Demettre from the 'Plate-forme de Proteomique Fonctionnelle' (FPP) for their work on proteomic analysis of cell samples. We thank the Gustave Roussy Genomic Core Facility (Noemie Pata-Merci) and the Gustave Roussy Bioinformatic Core Facility (Guillaume Meurice). ASB is supported by grants from the Swedish Cancer Foundation (13 0301), Swedish Research Council (621-2012-3576) and Karin and Harald Silvanders Foundation (223-2808-12).	AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Andaya A, 2011, J PROTEOME RES, V10, P4613, DOI 10.1021/pr200429y; Anderson J, 2000, P NATL ACAD SCI USA, V97, P5173, DOI 10.1073/pnas.090102597; Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; BENZIL DL, 1992, CANCER RES, V52, P2951; Bjork GR, 2001, EMBO J, V20, P231, DOI 10.1093/emboj/20.1.231; Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572; Budworth J, 1997, BRIT J CANCER, V75, P1330, DOI 10.1038/bjc.1997.225; Cameron AJ, 2008, INT J CANCER, V123, P769, DOI 10.1002/ijc.23560; Chen CC, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002258; Collazos A, 2006, MOL CELL BIOL, V26, P2247, DOI 10.1128/MCB.26.6.2247-2261.2006; David A, 2012, J CELL BIOL, V197, P45, DOI 10.1083/jcb.201112145; David A, 2011, J BIOL CHEM, V286, P20688, DOI 10.1074/jbc.M110.209452; Diouf B, 2009, J BIOL CHEM, V284, P18808, DOI 10.1074/jbc.M109.004614; Torres AG, 2014, TRENDS MOL MED, V20, P306, DOI 10.1016/j.molmed.2014.01.008; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V48, P375, DOI 10.1016/0006-2952(94)90110-4; GRUBER JR, 1995, EXP CELL RES, V221, P377, DOI 10.1006/excr.1995.1388; Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200; Hou JQ, 2012, ONCOTARGET, V3, P118; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804; Koromilas A.-E., 2014, BIOCH BIOPHYS ACTA B, V1849, P871, DOI DOI 10.1016/J.BBAGRM.2014.12.007; Lee SK, 2012, MOL CELLS, V34, P61, DOI 10.1007/s10059-012-0087-1; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Mandil R, 2001, CANCER RES, V61, P4612; Marques JM, 2013, J NEUROSCI, V33, P18298, DOI 10.1523/JNEUROSCI.3136-13.2013; MISRAPRESS A, 1992, GLIA, V6, P188, DOI 10.1002/glia.440060306; Ozanick S, 2005, RNA, V11, P1281, DOI 10.1261/rna.5040605; Ozanick SG, 2009, NUCLEIC ACIDS RES, V37, P298, DOI 10.1093/nar/gkn925; Pavon-Eternod M, 2013, RNA, V19, P461, DOI 10.1261/rna.037507.112; Pavon-Eternod M, 2009, NUCLEIC ACIDS RES, V37, P7268, DOI 10.1093/nar/gkp787; Quittau-Prevostel C, 2004, J CELL SCI, V117, P63, DOI 10.1242/jcs.00832; Reme T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066574; Ron D, 2007, ELF2ALPHA PHOSPHORYL; Roovers M, 2004, NUCLEIC ACIDS RES, V32, P465, DOI 10.1093/nar/gkh191; Rosse C, 2010, NAT REV MOL CELL BIO, V11, P103, DOI 10.1038/nrm2847; Saikia M, 2010, RNA, V16, P1317, DOI 10.1261/rna.2057810; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Thakor N, 2012, NUCLEIC ACIDS RES, V40, P541, DOI 10.1093/nar/gkr701; Towns WL, 2012, DNA CELL BIOL, V31, P434, DOI 10.1089/dna.2011.1437; WELSH GI, 1994, BIOCHEM BIOPH RES CO, V201, P1279, DOI 10.1006/bbrc.1994.1843; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831; XIAO HG, 1994, J NEUROSURG, V81, P734, DOI 10.3171/jns.1994.81.5.0734; Zellner A, 1998, CLIN CANCER RES, V4, P1797; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420	49	30	31	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1785	1796		10.1038/onc.2015.244	http://dx.doi.org/10.1038/onc.2015.244			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26234676				2022-12-17	WOS:000373610400005
J	Tervonen, TA; Belitskin, D; Pant, SM; Englund, JI; Marques, E; Ala-Hongisto, H; Nevalaita, L; Sihto, H; Heikkila, P; Leidenius, M; Hewitson, K; Ramachandra, M; Moilanen, A; Joensuu, H; Kovanen, PE; Poso, A; Klefstrom, J				Tervonen, T. A.; Belitskin, D.; Pant, S. M.; Englund, J. I.; Marques, E.; Ala-Hongisto, H.; Nevalaita, L.; Sihto, H.; Heikkila, P.; Leidenius, M.; Hewitson, K.; Ramachandra, M.; Moilanen, A.; Joensuu, H.; Kovanen, P. E.; Poso, A.; Klefstrom, J.			Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR ACTIVATOR INHIBITOR-1; BREAST-CANCER; MATRIPTASE ACTIVATION; IN-VITRO; PROSTATE; IDENTIFICATION; PROGRESSION; SUBSTRATE; CELLS	Hepsin belongs to a family of cell-surface serine proteases, which have sparked interest as therapeutic targets because of the accessibility of extracellular protease domain for inhibitors. Hepsin is frequently amplified and/or overexpressed in epithelial cancers, but it is not clear how enhanced hepsin expression confers a potential for oncogenicity. We show that hepsin is consistently overexpressed in more than 40% of examined breast cancers, including all major biological subtypes. The effects of doxycycline-induced hepsin overexpression were examined in mammary epithelial organoids, and we found that induced hepsin acutely downmodulates its cognate inhibitor, hepatocyte growth factor (HGF) activator inhibitor type 1 (HAI-1). Hepsin-induced depletion of cellular HAI-1 led to a sharp increase in pericellular serine protease activity. The derepressed hepsin proteolytically activated downstream serine proteases, augmented HGF/MET signalling and caused deterioration of desmosomes and hemidesmosomes; structures important for cell cohesion and cell-basement membrane interaction. Moreover, chronic induction of hepsin considerably shortened the latency of Myc-dependent tumourigenesis in the mouse mammary gland. The serine protease and uPA system inhibitor WX-UK1, identified as a micromolar range hepsin inhibitor, prevented hepsin from augmenting HGF/MET signalling and disrupting desmosomes and hemidesmosomes. The findings suggest that the oncogenic activity of hepsin arises not only from elevated expression level but also from depletion of HAI-1, events which together trigger gain-of-function activity impacting HGF/MET signalling and epithelial cohesion. Thus, hepsin overexpression is a major oncogenic conferrer to a serine protease activity involved in breast cancer dissemination.	[Tervonen, T. A.; Belitskin, D.; Pant, S. M.; Englund, J. I.; Marques, E.; Ala-Hongisto, H.; Nevalaita, L.; Klefstrom, J.] Univ Helsinki, Translat Canc Biol & Inst Biomed, Res Programs Unit, Canc Cell Circuitry Lab, FIN-00014 Helsinki, Finland; [Sihto, H.; Joensuu, H.] Univ Helsinki, Dept Oncol, FIN-00014 Helsinki, Finland; [Sihto, H.; Joensuu, H.] Helsinki Univ Cent Hosp, Helsinki, Finland; [Heikkila, P.; Kovanen, P. E.] Helsinki Univ Cent Hosp, HUSLAB, Dept Pathol, Helsinki, Finland; [Heikkila, P.; Kovanen, P. E.] Helsinki Univ Cent Hosp, Haartman Inst, Helsinki, Finland; [Heikkila, P.; Kovanen, P. E.] Univ Helsinki, FIN-00014 Helsinki, Finland; [Leidenius, M.] Helsinki Univ Cent Hosp, Breast Surg Unit, Helsinki, Finland; [Hewitson, K.] Helsinki Innovat Serv Ltd, Tukholmankatu 8A, Helsinki 00290, Finland; [Ramachandra, M.] Aurigene Discovery Technol Ltd, 39-40 KIADB Ind Area,Elect City Phase 2, Bangalore, Karnataka, India; [Moilanen, A.] Orion Pharma, Orion Corp, Turku, Finland; [Poso, A.] Univ Eastern Finland, Sch Pharm, Kuopio, Finland; [Poso, A.] Finnish Inst Mol Med, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aurigene Discovery Technologies Limited; Orion Corporation; University of Eastern Finland	Klefstrom, J (corresponding author), Univ Helsinki, Canc Cell Circuitry Lab, Translat Canc Biol Res Program, Haartmaninkatu 8,Room B507,POB 63, FIN-00014 Helsinki, Finland.	Juha.Klefstrom@helsinki.fi	Sihto, Harri J/B-3432-2015; Englund, Johanna/GYJ-7086-2022; Englund, Johanna/ABG-6420-2021	Sihto, Harri J/0000-0001-5265-5509; Englund, Johanna/0000-0001-9637-6843; Joensuu, Heikki/0000-0003-0281-2507; Ramachandra, Murali/0000-0003-4039-1491; Belitskin, Denis/0000-0002-0032-2769; Poso, Antti/0000-0003-4196-4204	Academy of Finland; Sigrid Juselius Foundation; Finnish Cancer Society; Research Funds of the Helsinki University Central Hospital; Jane and Aatos Erkko Foundation; Helsinki Graduate Program in Biotechnology and Molecular Biology and Innovative Medicines Initiative Joint Undertaking [115188]	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Society; Research Funds of the Helsinki University Central Hospital; Jane and Aatos Erkko Foundation; Helsinki Graduate Program in Biotechnology and Molecular Biology and Innovative Medicines Initiative Joint Undertaking	We thank all the members of Klefstrom laboratory for discussions and critical comments on the manuscript. T Raatikainen and T Valimaki are thanked for technical assistance. Biomedicum Imaging Unit and Biomedicum Functional Genomics Unit are acknowledged for core services and technical support. This study was funded by the Academy of Finland, Sigrid Juselius Foundation, the Finnish Cancer Society, the Research Funds of the Helsinki University Central Hospital, Jane and Aatos Erkko Foundation, and Helsinki Graduate Program in Biotechnology and Molecular Biology and Innovative Medicines Initiative Joint Undertaking under grant agreement no 115188.	Antalis TM, 2010, BIOCHEM J, V428, P325, DOI 10.1042/BJ20100046; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Buzza MS, 2013, J BIOL CHEM, V288, P10328, DOI 10.1074/jbc.M112.443432; Chen MQ, 2010, MOL CELL BIOCHEM, V337, P259, DOI 10.1007/s11010-009-0307-y; Chen YW, 2010, J BIOL CHEM, V285, P31755, DOI 10.1074/jbc.M110.150367; Chevillet JR, 2008, MOL CANCER THER, V7, P3343, DOI 10.1158/1535-7163.MCT-08-0446; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Domoto T, 2012, CANCER SCI, V103, P448, DOI 10.1111/j.1349-7006.2011.02162.x; Fan B, 2005, J BIOL CHEM, V280, P34513, DOI 10.1074/jbc.M502119200; Friis S, 2013, J BIOL CHEM, V288, P19028, DOI 10.1074/jbc.M113.469932; Ganesan R, 2012, PROTEIN ENG DES SEL, V25, P127, DOI 10.1093/protein/gzr067; Ganesan R, 2011, MOL CANCER RES, V9, P1175, DOI 10.1158/1541-7786.MCR-11-0004; Gastaldi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2617; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Godiksen S, 2008, BIOCHEM J, V413, P251, DOI 10.1042/BJ20071496; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Goswami R, 2013, ACS MED CHEM LETT, V4, P1152, DOI 10.1021/ml400213v; Guerin-Dubiard C, 2006, J AGR FOOD CHEM, V54, P3901, DOI 10.1021/jf0529969; Heinemann V, 2013, BRIT J CANCER, V108, P766, DOI 10.1038/bjc.2013.62; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Kaipparettu BA, 2008, BIOTECHNIQUES, V45, P165, DOI 10.2144/000112883; Kiyomiya KI, 2006, AM J PHYSIOL-CELL PH, V291, pC40, DOI 10.1152/ajpcell.00351.2005; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Koschubs T, 2012, BIOCHEM J, V442, P483, DOI 10.1042/BJ20111317; Li W, 2009, CANCER RES, V69, P8395, DOI 10.1158/0008-5472.CAN-09-1995; Li Y, 2005, BBA-GENE STRUCT EXPR, V1681, P157, DOI 10.1016/j.bbaexp.2004.11.003; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Miao JY, 2008, INT J CANCER, V123, P2041, DOI 10.1002/ijc.23726; Moran P, 2006, J BIOL CHEM, V281, P30439, DOI 10.1074/jbc.M605440200; Nandana S, 2010, PROSTATE, V70, P591, DOI 10.1002/pros.21093; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Partanen JI, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0111; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Peters DE, 2014, J BIOL CHEM, V289, P14740, DOI 10.1074/jbc.M113.541318; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Szabo R, 2008, INT J BIOCHEM CELL B, V40, P1297, DOI 10.1016/j.biocel.2007.11.013; Tang X, 2014, ONCOTARGET, V5, P1352, DOI 10.18632/oncotarget.1817; Tripathi M, 2008, J BIOL CHEM, V283, P30576, DOI 10.1074/jbc.M802312200; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Xing P, 2011, J INVEST MED, V59, P803, DOI 10.2310/JIM.0b013e31821451a1; Xuan JA, 2006, CANCER RES, V66, P3611, DOI 10.1158/0008-5472.CAN-05-2983; Yue J, 2012, CANCER MICROENVIRON, V5, P275, DOI 10.1007/s12307-012-0101-3	46	30	30	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1832	1846		10.1038/onc.2015.248	http://dx.doi.org/10.1038/onc.2015.248			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26165838				2022-12-17	WOS:000373610400009
J	Ahn, BY; Saldanha-Gama, RFG; Rahn, JJ; Hao, X; Zhang, J; Dang, NH; Alshehri, M; Robbins, SM; Senger, DL				Ahn, B. Y.; Saldanha-Gama, R. F. G.; Rahn, J. J.; Hao, X.; Zhang, J.; Dang, N-H; Alshehri, M.; Robbins, S. M.; Senger, D. L.			Glioma invasion mediated by the p75 neurotrophin receptor (p75(NTR)/CD271) requires regulated interaction with PDLIM1	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; LIM-DOMAIN PROTEIN; NF-KAPPA-B; PDZ-DOMAIN; GENE AMPLIFICATION; MALIGNANT GLIOMAS; ALPHA-ACTININ; CELL; BINDING; MELANOMA	The invasive nature of glioblastoma renders them incurable by current therapeutic interventions. Using a novel invasive human glioma model, we previously identified the neurotrophin receptor p75(NTR) (aka CD271) as a mediator of glioma invasion. Herein, we provide evidence that preventing phosphorylation of p75(NTR) on S303 by pharmacological inhibition of PKA, or by a mutational strategy (S303G), cripples p75(NTR)-mediated glioma invasion resulting in serine phosphorylation within the C-terminal PDZ-binding motif (SPV) of p75(NTR). Consistent with this, deletion (Delta SPV) or mutation (SPM) of the PDZ motif results in abrogation of p75(NTR)-mediated invasion. Using a peptide-based strategy, we identified PDLIM1 as a novel signaling adaptor for p75(NTR) and provide the first evidence for a regulated interaction via S425 phosphorylation. Importantly, PDLIM1 was shown to interact with p75(NTR) in highly invasive patient-derived glioma stem cells/tumor-initiating cells and shRNA knockdown of PDLIM1 in vitro and in vivo results in complete ablation of p75(NTR)-mediated invasion. Collectively, these data demonstrate a requirement for a regulated interaction of p75(NTR) with PDLIM1 and suggest that targeting either the PDZ domain interactions and/or the phosphorylation of p75(NTR) by PKA could provide therapeutic strategies for patients with glioblastoma.	[Ahn, B. Y.; Saldanha-Gama, R. F. G.; Rahn, J. J.; Hao, X.; Zhang, J.; Dang, N-H; Alshehri, M.; Robbins, S. M.; Senger, D. L.] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada; [Ahn, B. Y.; Rahn, J. J.; Hao, X.; Robbins, S. M.; Senger, D. L.] Univ Calgary, Hughes Childhood Canc Program, Calgary, AB, Canada; [Ahn, B. Y.; Saldanha-Gama, R. F. G.; Rahn, J. J.; Hao, X.; Dang, N-H; Alshehri, M.; Robbins, S. M.; Senger, D. L.] Univ Calgary, Dept Oncol, Room 362,Heritage Med Res Bldg,Hosp Dr NW, Calgary, AB T2N 4N1, Canada; [Saldanha-Gama, R. F. G.; Zhang, J.; Dang, N-H; Alshehri, M.; Robbins, S. M.; Senger, D. L.] Univ Calgary, Clark H Smith Brain Tumour Ctr, Calgary, AB, Canada; [Saldanha-Gama, R. F. G.] Univ Estado Rio de Janeiro, Dept Biol Celular, Rua Sao Francisco Xavier 524,PHLC Sala 500, BR-20550013 Rio De Janeiro, Brazil	University of Calgary; University of Calgary; University of Calgary; University of Calgary; Universidade do Estado do Rio de Janeiro	Senger, DL (corresponding author), Univ Calgary, Dept Oncol, Room 362,Heritage Med Res Bldg,Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	senger@ucalgary.ca		Robbins, Stephen/0000-0001-7475-1665; Alshehri, Mana/0000-0001-9587-2693; Senger, Donna/0000-0003-2403-3395	Hotchkiss Brain Institute; Alberta Cancer Foundation; Terry Fox Research Institute; Clark H. Smith Family; Southern Alberta Mass Spectrometry (SAMS) Centre; Alberta Children's Hospital Foundation; Alberta Innovates Health Solutions; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Ministerio da Educacao - Brasil; Alberta Innovates [201201242] Funding Source: researchfish	Hotchkiss Brain Institute; Alberta Cancer Foundation; Terry Fox Research Institute; Clark H. Smith Family; Southern Alberta Mass Spectrometry (SAMS) Centre; Alberta Children's Hospital Foundation; Alberta Innovates Health Solutions; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Ministerio da Educacao - Brasil; Alberta Innovates	We would like to thank the Brain Tumor Stem Cell Core supported by funds from the Hotchkiss Brain Institute, the Alberta Cancer Foundation and the Terry Fox Research Institute. We also thank the Calgary Brain Tumour and Tissue Bank generously supported by funds from the Clark H. Smith Family and the Southern Alberta Mass Spectrometry (SAMS) Centre. This work was supported by grants to SMR and DLS from the Alberta Children's Hospital Foundation, the Alberta Cancer Foundation and Alberta Innovates Health Solutions. RSG acknowledges fellowship support from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Ministerio da Educacao - Brasil.	ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Babault N, 2011, STRUCTURE, V19, P1518, DOI 10.1016/j.str.2011.07.007; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001; Bashirova AA, 1998, GENE, V210, P239, DOI 10.1016/S0378-1119(98)00080-8; Bauer K, 2000, BLOOD, V96, P4236; Bentley CA, 2000, J NEUROSCI, V20, P7706; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Blazer LL, 2009, NEUROPSYCHOPHARMACOL, V34, P126, DOI 10.1038/npp.2008.151; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Chan JR, 2006, SCIENCE, V314, P832, DOI 10.1126/science.1134069; Collin GB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037925; Cragnolini AB, 2008, TRENDS NEUROSCI, V31, P99, DOI 10.1016/j.tins.2007.11.005; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Eli Lilly and Company, 2010, LILL HALTS DEV SEM A; Elkins JM, 2007, PROTEIN SCI, V16, P683, DOI 10.1110/ps.062657507; Ensign SPF, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00241; Essmann CL, 2008, NAT NEUROSCI, V11, P1035, DOI 10.1038/nn.2171; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Fujitani M, 2005, J NEUROCHEM, V94, P15, DOI 10.1111/j.1471-4159.2005.03121.x; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gauthier LR, 2003, LIFE SCI, V74, P207, DOI 10.1016/j.lfs.2003.09.029; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gil C, 2007, FEBS LETT, V581, P1851, DOI 10.1016/j.febslet.2007.03.080; Gold MG, 2013, J CELL SCI, V126, P4537, DOI 10.1242/jcs.133751; Gritsenko PG, 2012, J PATHOL, V226, P185, DOI 10.1002/path.3031; Hasegawa T, 2010, NEUROSCI LETT, V476, P53, DOI 10.1016/j.neulet.2010.03.081; HERRMANN JL, 1993, MOL BIOL CELL, V4, P1205, DOI 10.1091/mbc.4.11.1205; Higuchi H, 2003, EMBO J, V22, P1790, DOI 10.1093/emboj/cdg177; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Hopkins CR, 2011, ACS CHEM NEUROSCI, V2, P279, DOI 10.1021/cn2000469; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Hupalowska A, 2012, TRAFFIC, V13, P9, DOI 10.1111/j.1600-0854.2011.01249.x; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; Ivarsson Y, 2012, FEBS LETT, V586, P2638, DOI 10.1016/j.febslet.2012.04.015; Johnston ALM, 2007, PLOS BIOL, V5, P1723, DOI 10.1371/journal.pbio.0050212; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; Kaplan DR, 2004, NATURE, V427, P798, DOI 10.1038/427798a; Kegelman TP, 2014, NEURO-ONCOLOGY, V16, P50, DOI 10.1093/neuonc/not157; Kelly JJP, 2009, STEM CELLS, V27, P1722, DOI 10.1002/stem.98; KERBEL RS, 1984, INVAS METAST, V4, P31; KERBEL RS, 1984, J NATL CANCER I, V72, P93, DOI 10.1093/jnci/72.1.93; Kikuchi S, 2008, CLIN CANCER RES, V14, P5348, DOI 10.1158/1078-0432.CCR-08-0075; Klaavuniemi T, 2006, EXP CELL RES, V312, P1299, DOI 10.1016/j.yexcr.2005.12.036; Kotaka M, 2000, J CELL BIOCHEM, V78, P558, DOI 10.1002/1097-4644(20000915)78:4<558::AID-JCB5>3.0.CO;2-I; Kotaka M, 1999, J CELL BIOCHEM, V72, P279, DOI 10.1002/(SICI)1097-4644(19990201)72:2<279::AID-JCB12>3.0.CO;2-7; Kraemer B R, 2014, Handb Exp Pharmacol, V220, P121, DOI 10.1007/978-3-642-45106-5_6; Kwiatkowska A, 2013, ADV EXP MED BIOL, V986, P121, DOI 10.1007/978-94-007-4719-7_7; Le Moan N, 2011, MOL CELL, V44, P476, DOI 10.1016/j.molcel.2011.08.033; Li A, 2009, CANCER RES, V69, P2091, DOI 10.1158/0008-5472.CAN-08-2100; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; LIU Z, 2014, ONCOGENE, V0034, P01300, DOI DOI 10.1038/ONC.2014.64; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Mariani L, 2001, CANCER RES, V61, P4190; MENTER DG, 1994, INVAS METAST, V14, P372; Nakada M, 2007, CELL MOL LIFE SCI, V64, P458, DOI 10.1007/s00018-007-6342-5; Nakagawa N, 2000, BIOCHEM BIOPH RES CO, V272, P505, DOI 10.1006/bbrc.2000.2787; Ohno K, 2009, J NEUROCHEM, V111, P790, DOI 10.1111/j.1471-4159.2009.06370.x; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Quick Q, 2010, EXP CELL RES, V316, P1137, DOI 10.1016/j.yexcr.2010.02.011; Redmer T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092596; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Robbins SM, 2013, NEUROMETHODS, P275; Sarkar S, 2015, NEUROONCOL; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Shonukan T, 2003, ONCOGENE, V22, P3616, DOI 10.1038/sj.onc.1206561; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Skeldal S, 2011, BIOESSAYS, V33, P614, DOI 10.1002/bies.201100036; Smith MA, 2014, TRENDS CELL BIOL, V24, P575, DOI [10.1016/j.tcb.2014.04.009, 10.1016/J.tcb.2014.04.009]; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Teodorczyk M, 2010, J CELL PHYSIOL, V222, P1, DOI 10.1002/jcp.21901; Teyra J, 2012, FEBS LETT, V586, P2631, DOI 10.1016/j.febslet.2012.05.043; Torrado M, 2004, INVEST OPHTH VIS SCI, V45, P3955, DOI 10.1167/iovs.04-0721; Underwood CK, 2008, MOL CELL NEUROSCI, V37, P346, DOI 10.1016/j.mcn.2007.10.005; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; Verbeke S, 2013, FEBS LETT, V587, P2591, DOI 10.1016/j.febslet.2013.06.039; Verbeke S, 2010, CELL SIGNAL, V22, P1864, DOI 10.1016/j.cellsig.2010.07.014; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; von Nandelstadh P, 2009, MOL CELL BIOL, V29, P822, DOI 10.1128/MCB.01454-08; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; Wang LM, 2008, PLOS BIOL, V6, P2496, DOI 10.1371/journal.pbio.0060289; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Yamamoto S, 2009, MODERN PATHOL, V22, P499, DOI 10.1038/modpathol.2008.234; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	98	30	31	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1411	1422		10.1038/onc.2015.199	http://dx.doi.org/10.1038/onc.2015.199			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26119933	Green Published, hybrid			2022-12-17	WOS:000372196400007
J	Peyser, ND; Freilino, M; Wang, L; Zeng, Y; Li, H; Johnson, DE; Grandis, JR				Peyser, N. D.; Freilino, M.; Wang, L.; Zeng, Y.; Li, H.; Johnson, D. E.; Grandis, J. R.			Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer	ONCOGENE			English	Article							TARGETING STAT3	Signal transducer and activator of transcription 3 (STAT3) overactivation is a common event in many cancers, including head and neck squamous cell carcinoma (HNSCC), where STAT3 represents a promising therapeutic target. HNSCC is not characterized by frequent kinase mutations, in contrast to some malignancies where mutational activation of kinases upstream of STAT3 is common. Instead, STAT3 may be activated by loss-of-function of negative regulators of STAT3, including by promoter hypermethylation of PTPRT. Here we first analyzed The Cancer Genome Atlas data and determined that the PTPRT promoter is frequently hypermethylated in several cancers, including HNSCC (60.1% of tumors analyzed) in association with downregulation of PTPRT mRNA expression and upregulation of pSTAT3 expression. These findings were confirmed in an independent cohort of HNSCC tumors by methylation-specific PCR and immunohistochemistry. We demonstrate that PTPRT promoter methylation and gene silencing is reversible in HNSCC cells, leading to PTPRT-specific downregulation of pSTAT3 expression. We further show that PTPRT promoter methylation is significantly associated with sensitivity to STAT3 inhibition in HNSCC cells, suggesting that PTPRT promoter methylation may serve as a predictive biomarker for responsiveness to STAT3 inhibitors in clinical development.	[Peyser, N. D.; Johnson, D. E.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Peyser, N. D.; Freilino, M.; Wang, L.; Zeng, Y.; Li, H.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; [Johnson, D. E.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Grandis, J. R.] Univ Calif San Francisco, Dept Otolaryngol, 550 16th St,6th Floor, San Francisco, CA 94143 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco	Grandis, JR (corresponding author), Univ Calif San Francisco, Otolaryngol, 550 16th St,6th Floor, San Francisco, CA 94143 USA.	Jennifer.Grandis@ucsf.edu		Peyser, Noah/0000-0003-4529-8325	National Cancer Institute at the National Institutes of Health [P50 CA097190, R01 CA077308]; National Institute for Dental and Craniofacial Research at the National Institutes of Health [F31 DE024007]; NATIONAL CANCER INSTITUTE [R01CA077308, P50CA097190] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [F31DE024007] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute for Dental and Craniofacial Research at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers P50 CA097190 and R01 CA077308 to JRG); and by the National Institute for Dental and Craniofacial Research at the National Institutes of Health (grant number F31 DE024007 to NDP). The authors wish to thank Mark H Gage for technical assistance.	Benson E, 2014, ORAL ONCOL, V50, P565, DOI 10.1016/j.oraloncology.2013.09.008; Gao W, 2008, CARCINOGENESIS, V29, P1901, DOI 10.1093/carcin/bgn170; Ji T, 2013, CANCER LETT, V341, P231, DOI 10.1016/j.canlet.2013.08.022; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Laczmanska I, 2013, J HUM GENET, V58, P11, DOI 10.1038/jhg.2012.119; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Licitra L, 2011, ANN ONCOL, V22, P1078, DOI 10.1093/annonc/mdq588; Lui VWY, 2014, P NATL ACAD SCI USA, V111, P1114, DOI 10.1073/pnas.1319551111; Peyser ND, 2013, ONCOTARGETS THER, V6, P999, DOI 10.2147/OTT.S47903; Sen M, 2012, CLIN CANCER RES, V18, P4986, DOI 10.1158/1078-0432.CCR-12-0792; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104	13	30	31	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1163	1169		10.1038/onc.2015.171	http://dx.doi.org/10.1038/onc.2015.171			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982282	Green Submitted, Green Accepted			2022-12-17	WOS:000371351700010
J	Prahallad, A; Bernards, R				Prahallad, A.; Bernards, R.			Opportunities and challenges provided by crosstalk between signalling pathways in cancer	ONCOGENE			English	Review							HISTONE DEACETYLASE INHIBITOR; SYNTHETIC LETHAL INTERACTION; KRAS-MUTANT LUNG; MEK INHIBITION; RAF INHIBITORS; COMBINED BRAF; BRAF(V600E) INHIBITION; TUMOR MICROENVIRONMENT; COLON-CANCER; RESISTANCE	During evolution, connections between the major signalling pathways were established to provide cells with an ability to deal with perturbations of homeostasis. However, these feedback and crosstalk mechanisms can become a liability in the treatment of cancer, as the inhibition of one cancer-relevant signalling pathway can lead to the activation of a secondary survival pathway that interferes with cancer drug efficacy. In this review, we discuss connections between signalling pathways in relation to cancer therapy and we evaluate the use of genetic approaches to identify pathway crosstalk. We also discuss how insight into connections between signalling pathways can be exploited to design powerful synthetic lethal drug combination therapies for the treatment of cancer.	[Prahallad, A.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherlands, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherlands, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl		Bernards, Rene/0000-0001-8677-3423	EU FP7 grant 'COLTHERES'; Cancer Genomics Netherlands consortium	EU FP7 grant 'COLTHERES'; Cancer Genomics Netherlands consortium	This work was funded by the EU FP7 grant 'COLTHERES' and by the Cancer Genomics Netherlands consortium.	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Alifrangis CC, 2014, MOL ONCOL, V8, P1112, DOI 10.1016/j.molonc.2014.05.014; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Azad NS, 2008, J CLIN ONCOL, V26, P3709, DOI 10.1200/JCO.2007.10.8332; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Bertino EM, 2011, EXPERT OPIN INV DRUG, V20, P1151, DOI 10.1517/13543784.2011.594437; Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847; Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862; Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Dancey JE, 2006, NAT REV DRUG DISCOV, V5, P649, DOI 10.1038/nrd2089; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Garralda E, 2014, CLIN CANCER RES, V20, P2476, DOI 10.1158/1078-0432.CCR-13-3047; Geel R.V., 2014, J CLIN ONCOL, V32, P5; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Groenendijk FH, 2014, MOL ONCOL, V8, P1067, DOI 10.1016/j.molonc.2014.05.004; Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Janne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Julien S, 2012, CLIN CANCER RES, V18, P5314, DOI 10.1158/1078-0432.CCR-12-0372; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Kopetz S., 2010, J CLIN ONCOL, V28; Kuczynski EA, 2013, NAT REV CLIN ONCOL, V10, P571, DOI 10.1038/nrclinonc.2013.158; Kummar S, 2010, NAT REV DRUG DISCOV, V9, P843, DOI 10.1038/nrd3216; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Lee EQ, 2012, NEURO-ONCOLOGY, V14, P1511, DOI 10.1093/neuonc/nos264; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nebbioso A, 2012, MOL ONCOL, V6, P657, DOI 10.1016/j.molonc.2012.09.004; Packer LM, 2011, CANCER CELL, V20, P715, DOI 10.1016/j.ccr.2011.11.004; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sosman JA, 2008, EXPERT REV ANTICANC, V8, P481, DOI 10.1586/14737140.8.3.481; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI [10.2217/fon.11.2, 10.2217/FON.11.2]; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Valachis A, 2010, BREAST CANCER RES TR, V122, P1, DOI 10.1007/s10549-009-0727-0; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249	73	30	32	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1073	1079		10.1038/onc.2015.151	http://dx.doi.org/10.1038/onc.2015.151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982281				2022-12-17	WOS:000371351700001
J	Mancini, F; Pieroni, L; Monteleone, V; Luca, R; Fici, L; Luca, E; Urbani, A; Xiong, S; Soddu, S; Masetti, R; Lozano, G; Pontecorvi, A; Moretti, F				Mancini, F.; Pieroni, L.; Monteleone, V.; Luca, R.; Fici, L.; Luca, E.; Urbani, A.; Xiong, S.; Soddu, S.; Masetti, R.; Lozano, G.; Pontecorvi, A.; Moretti, F.			MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response	ONCOGENE			English	Article							CELL-CYCLE ARREST; MDM4 MDMX; GROWTH ARREST; P53 ACTIVITY; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL PROGRAM; DOWN-REGULATION; PROTEIN; PHOSPHORYLATION; HIPK2	The p53 inhibitor, MDM4 (MDMX) is a cytoplasmic protein with p53-activating function under DNA damage conditions. Particularly, MDM4 promotes phosphorylation of p53 at Ser46, a modification that precedes different p53 activities. We investigated the mechanism by which MDM4 promotes this p53 modification and its consequences in untransformed mammary epithelial cells and tissues. In response to severe DNA damage, MDM4 stimulates p53Ser46P by binding and stabilizing serine-threonine kinase HIPK2. Under these conditions, the p53-inhibitory complex, MDM4/MDM2, dissociates and this allows MDM4 to promote p53/HIPK2 functional interaction. Comparative proteomic analysis of DNA damage-treated cells versus - untreated cells evidenced a diffuse downregulation of proteins with anti-apoptotic activity, some of which were targets of p53Ser46P/HIPK2 repressive activity. Importantly, MDM4 depletion abolishes the downregulation of these proteins indicating the requirement of MDM4 to promote p53-mediated transcriptional repression. Consistently, MDM4-mediated HIPK2/p53 activation precedes HIPK2/p53 nuclear translocation and activity. Noteworthy, repression of these proteins was evident also in mammary glands of mice subjected to.-irradiation and was significantly enhanced in transgenic mice overexpressing MDM4. This study evidences the flexibility of MDM2/MDM4 heterodimer, which allows the development of a positive activity of cytoplasmic MDM4 towards p53-mediated transcriptional function. Noteworthy, this activity uncovers coordinated repression of molecules with shared anti-apoptotic function which precedes active cell apoptosis and that are frequently overexpressed and/or markers of tumour phenotype in human cancer.	[Mancini, F.; Monteleone, V.; Luca, R.; Fici, L.; Luca, E.; Moretti, F.] Natl Res Council Italy CNR, Inst Cell Biol & Neurobiol, I-00143 Rome, Italy; [Mancini, F.; Luca, E.; Pontecorvi, A.] Univ Cattolica Sacro Cuore, Dept Endocrinol & Metab, Rome, Italy; [Pieroni, L.; Urbani, A.] Fdn Santa Lucia, Prote & Metabol Lab, Rome, Italy; [Pieroni, L.; Urbani, A.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy; [Fici, L.; Masetti, R.] Univ Cattolica Sacro Cuore, Dept Obstet & Gynaecol, Rome, Italy; [Xiong, S.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Soddu, S.] Regina Elena Inst Canc Res, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Santa Lucia; University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Texas System; UTMD Anderson Cancer Center; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Mancini, F (corresponding author), Natl Res Council Italy CNR, Inst Cell Biol & Neurobiol, I-00143 Rome, Italy.	francesca.mancini@ibcn.cnr.it; fabiola.moretti@cnr.it	Luca, Emilia/K-6983-2019; Lucà, Rossella/J-5921-2018; Pieroni, Luisa/Q-6315-2019; Urbani, Andrea/AAD-1675-2022; mancini, francesca/K-6062-2016; Urbani, Andrea/B-2953-2012; Soddu, Silvia/K-2467-2018; Pieroni, Luisa/J-8651-2018; Soddu, Silvia/ABH-6774-2020; Xiong, Shunbin/AAR-5823-2021; Mancini, Francesca/AAZ-1672-2021; Moretti, Fabiola/I-5647-2013	Lucà, Rossella/0000-0003-2495-7803; Pieroni, Luisa/0000-0001-7141-1817; mancini, francesca/0000-0002-2459-8815; Soddu, Silvia/0000-0001-8526-0044; Pieroni, Luisa/0000-0001-7141-1817; Soddu, Silvia/0000-0001-8526-0044; Mancini, Francesca/0000-0002-2459-8815; Moretti, Fabiola/0000-0002-2691-1254; Luca, Emilia/0000-0002-8279-067X; MASETTI, Riccardo/0000-0002-7520-9111	Associazione Italiana Ricerca sul Cancro (AIRC) [IG-8825, IG-12767]; Italian Ministry of Economy and Finance; FIRB [RBAP1153LS_007, RBAP11WCRZ_003]; Susan Komen Italia Fellowship; NATIONAL CANCER INSTITUTE [R01CA047296] Funding Source: NIH RePORTER	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Economy and Finance; FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Susan Komen Italia Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported by research grants from Associazione Italiana Ricerca sul Cancro (AIRC; IG-8825, IG-12767) and from the Italian Ministry of Economy and Finance to the CNR for the Project 'FaReBio di Qualita' to FM; by FIRB RBAP1153LS_007 to AP; by FIRB: RBAP11WCRZ_003 to AU. LP and LF were supported by Susan Komen Italia Fellowship. We are grateful to Dr JC Marine for Mdm4<SUP>-/--</SUP>p53<SUP>-/-</SUP> MEFs and lentiviral vectors, Dr L Schmith for polyclonal aHIPK2 antibody and Dr Cinzia Rinaldo for pSuper.retro-ip53 plasmid.	Barboza JA, 2008, MOL CANCER RES, V6, P947, DOI 10.1158/1541-7786.MCR-07-2079; Biderman Lynn, 2012, Genes Cancer, V3, P264, DOI 10.1177/1947601912455331; Bon G, 2009, CANCER RES, V69, P5978, DOI 10.1158/0008-5472.CAN-09-0244; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Cecchinelli B, 2006, MOL CELL BIOL, V26, P4746, DOI 10.1128/MCB.00959-05; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Chiu CG, 2010, AM J PATHOL, V176, P2067, DOI 10.2353/ajpath.2010.090353; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Conza G, 2012, CELL CYCLE, V11, P749, DOI 10.4161/cc.11.4.19208; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Giglio S, 2010, ONCOGENE, V29, P5935, DOI 10.1038/onc.2010.324; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Iacovelli S, 2009, CELL PROLIFERAT, V42, P373, DOI 10.1111/j.1365-2184.2009.00601.x; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kracikova M, 2013, CELL DEATH DIFFER, V20, P576, DOI 10.1038/cdd.2012.155; Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Lecona E, 2008, MOL CELL BIOL, V28, P4665, DOI 10.1128/MCB.00650-07; Lenos K, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-111; Leventaki V, 2012, BRIT J HAEMATOL, V158, P763, DOI 10.1111/j.1365-2141.2012.09243.x; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Lipscomb EA, 2005, CANCER RES, V65, P10970, DOI 10.1158/0008-5472.CAN-05-2327; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mancini F, 2004, J BIOL CHEM, V279, P8169, DOI 10.1074/jbc.M311793200; Mancini F, 2010, INT J BIOCHEM CELL B, V42, P1080, DOI 10.1016/j.biocel.2010.04.010; Mancini F, 2009, CELL CYCLE, V8, P3854, DOI 10.4161/cc.8.23.10089; Mancini F, 2009, EMBO J, V28, P1926, DOI 10.1038/emboj.2009.154; Marchenko ND, 2010, CELL DEATH DIFFER, V17, P255, DOI 10.1038/cdd.2009.173; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Moller A, 2003, CANCER RES, V63, P4310; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Nardinocchi L, 2011, AGING-US, V3, P33, DOI 10.18632/aging.100254; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pieroni L, 2011, MOL BIOSYST, V7, P630, DOI 10.1039/c0mb00135j; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rinaldo C, 2012, MOL CELL, V47, P87, DOI 10.1016/j.molcel.2012.04.029; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Silva JC, 2005, ANAL CHEM, V77, P2187, DOI 10.1021/ac048455k; Sorrentino G, 2013, CELL DEATH DIFFER, V20, P198, DOI 10.1038/cdd.2012.112; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Tsvetkov P, 2009, J BIOL CHEM, V284, P26234, DOI 10.1074/jbc.M109.040493; Wang CL, 2014, CARCINOGENESIS, V35, P1500, DOI 10.1093/carcin/bgu015; Wang XJ, 2011, J BIOL CHEM, V286, P23725, DOI 10.1074/jbc.M110.213868; Werner ME, 2007, J BIOL CHEM, V282, P5560, DOI 10.1074/jbc.M603669200; Xiong SB, 2010, CANCER RES, V70, P7148, DOI 10.1158/0008-5472.CAN-10-1457; Zhu Y, 2013, GENE DEV, V27, P1739, DOI 10.1101/gad.212258.112	65	30	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					228	240		10.1038/onc.2015.76	http://dx.doi.org/10.1038/onc.2015.76			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25961923	Green Published, hybrid			2022-12-17	WOS:000368193900009
J	Warnier, M; Roudbaraki, M; Derouiche, S; Delcourt, P; Bokhobza, A; Prevarskaya, N; Mariot, P				Warnier, M.; Roudbaraki, M.; Derouiche, S.; Delcourt, P.; Bokhobza, A.; Prevarskaya, N.; Mariot, P.			CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; GATED CALCIUM-CHANNELS; TUMOR-SUPPRESSOR; ION CHANNELS; GENE; ALPHA(2)DELTA; SUBUNITS; METHYLATION; PROGRESSION; TRAFFICKING	In the present study, we have assessed whether a putative calcium channel alpha 2 delta 2 auxiliary subunit (CACNA2D2 gene) could be involved in prostate cancer (PCA) progression. We therefore carried out experiments to determine whether this protein is expressed in PCA LNCaP cells and in PCA tissues, and whether its expression may be altered during cancer development. In addition, we evaluated the influence on cell proliferation of overexpressing or downregulating this subunit. In vitro experiments show that alpha 2 delta 2 subunit overexpression is associated with increased cell proliferation, alterations of calcium homeostasis and the recruitment of a nuclear factor of activated T-cells pathway. Furthermore, we carried out in vivo experiments on immuno-deficient nude mice in order to evaluate the tumorigenic potency of the alpha 2 delta 2 subunit. We show that alpha 2 delta 2-overexpressing PCA LNCaP cells are more tumorigenic than control LNCaP cells when injected into nude mice. In addition, gabapentin, a ligand of alpha 2 delta 2, reduces tumor development in LNCaP xenografts. Finally, we show that the action of alpha 2 delta 2 on tumor development occurs not only through a stimulation of proliferation, but also through a stimulation of angiogenesis, via an increased secretion of vascular endothelial growth factor in cells overexpressing alpha 2 delta 2.	[Warnier, M.; Roudbaraki, M.; Derouiche, S.; Delcourt, P.; Bokhobza, A.; Prevarskaya, N.; Mariot, P.] INSERM, Lab Phys Cellulaire, U1003, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Mariot, P (corresponding author), Univ Lille 1, Lab Physiol Cellulaire, INSERM, U1003, Batiment SN3, F-59655 Villeneuve Dascq, France.	Pascal.Mariot@univ-lille1.fr		Prevarskaya, natacha/0000-0003-0316-197X; bokhobza, Alexandre/0000-0001-7953-4328; Morad, Roudbaraki/0000-0001-5751-3323; Mariot, Pascal/0000-0001-7226-9162	INSERM; University of Lille1; Region Nord-Pas de Calais	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University of Lille1; Region Nord-Pas de Calais(Region Hauts-de-FranceEuropean Commission)	We thank the members of the imaging platform BICEL, E Richard and C Slommiany for their helpful contribution. This work was supported by INSERM, the University of Lille1 and the Region Nord-Pas de Calais. This work was supported by INSERM, the University of Lille1 and the Region Nord-Pas de Calais.	Bennett ES, 2004, PFLUG ARCH EUR J PHY, V447, P908, DOI 10.1007/s00424-003-1205-x; Bidaud I, 2006, BBA-MOL CELL RES, V1763, P1169, DOI 10.1016/j.bbamcr.2006.08.049; Bornstein P, 2009, J CELL COMMUN SIGNAL, V3, P189, DOI 10.1007/s12079-009-0060-8; Canti C, 2005, P NATL ACAD SCI USA, V102, P11230, DOI 10.1073/pnas.0504183102; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Davies A, 2007, TRENDS PHARMACOL SCI, V28, P220, DOI 10.1016/j.tips.2007.03.005; Dolphin AC, 1999, J PHYSIOL-LONDON, V519, P35, DOI 10.1111/j.1469-7793.1999.0035o.x; Dolphin AC, 2012, NAT REV NEUROSCI, V13, P542, DOI 10.1038/nrn3311; Dooley DJ, 2007, TRENDS PHARMACOL SCI, V28, P75, DOI 10.1016/j.tips.2006.12.006; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Fiske JL, 2006, CANCER METAST REV, V25, P493, DOI 10.1007/s10555-006-9017-z; Gackiere F, 2006, CELL CALCIUM, V39, P357, DOI 10.1016/j.ceca.2005.12.003; Gackiere F, 2008, J BIOL CHEM, V283, P10162, DOI 10.1074/jbc.M707159200; Gackiere F, 2013, BIOL OPEN, V2, P941, DOI 10.1242/bio.20135215; Garcia K, 2008, J PHYSIOL-LONDON, V586, P727, DOI 10.1113/jphysiol.2007.147959; Ghosh S, 2008, INT J CANCER, V123, P2594, DOI 10.1002/ijc.23834; Halatsch ME, 2009, J NEUROSURG, V111, P211, DOI 10.3171/2008.9.JNS08551; Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x; Katsogiannou M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007068; Kondratska K., 2014, ONCOGENE, V1843, P2263; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Lee JM, 2011, AM J PHYSIOL-CELL PH, V301, pC969, DOI 10.1152/ajpcell.00136.2011; Li Z, 2011, EUR J PHARMACOL, V667, P80, DOI 10.1016/j.ejphar.2011.05.054; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; LIU CM, 1978, J BIOL CHEM, V253, P5892; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Negrini S, 2013, TRENDS CELL BIOL, V23, P289, DOI 10.1016/j.tcb.2013.01.006; Oh C, 2013, SCI REP-UK, V3, DOI 10.1038/srep02623; Pelosi G, 2010, ANTICANCER RES, V30, P4269; Prando ED, 2011, EPIGENETICS-US, V6, P1413, DOI 10.4161/epi.6.12.18271; Spitzner M, 2007, FASEB J, V21, P35, DOI 10.1096/fj.06-6200com; Starborg M, 1996, J CELL SCI, V109, P143; Toyota M, 1999, CANCER RES, V59, P4535; Wanajo A, 2008, GASTROENTEROLOGY, V135, P580, DOI 10.1053/j.gastro.2008.05.041; Wang XT, 2000, AM J PATHOL, V157, P1549, DOI 10.1016/S0002-9440(10)64792-X; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Zhao W, 2013, CANCER CELL, V23, P541, DOI 10.1016/j.ccr.2013.02.025; ZOUR E, 1992, PHARMACEUT RES, V9, P595, DOI 10.1023/A:1015833622943	41	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5383	5394		10.1038/onc.2014.467	http://dx.doi.org/10.1038/onc.2014.467			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25619833				2022-12-17	WOS:000363479200008
J	Xu, HG; Zhai, YX; Chen, J; Lu, Y; Wang, JW; Quan, CS; Zhao, RX; Xiao, X; He, Q; Werle, KD; Kim, HG; Lopez, R; Cui, R; Liang, J; Li, YL; Xu, ZX				Xu, H-G; Zhai, Y-X; Chen, J.; Lu, Y.; Wang, J-W; Quan, C-S; Zhao, R-X; Xiao, X.; He, Q.; Werle, K. D.; Kim, H-G; Lopez, R.; Cui, R.; Liang, J.; Li, Y-L; Xu, Z-X			LKB1 reduces ROS-mediated cell damage via activation of p38	ONCOGENE			English	Article							PROTEIN-KINASE; LUNG-CANCER; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; MAP KINASE; OXYGEN; GROWTH; METABOLISM; CDC42; AMPK	Liver kinase B1 (LKB1, also known as serine/threonine kinase 11, STK11) is a tumor suppressor mutated in Peutz-Jeghers syndrome and in a variety of sporadic cancers. Herein, we demonstrate that LKB1 controls the levels of intracellular reactive oxygen species (ROS) and protects the genome from oxidative damage. Cells lacking LKB1 exhibit markedly increased intracellular ROS levels, excessive oxidation of DNA, increased mutation rates and accumulation of DNA damage, which are effectively prevented by ectopic expression of LKB1 and by incubation with antioxidant N-acetylcysteine. The role of LKB1 in suppressing ROS is independent of AMP-activated protein kinase, a canonical substrate of LKB1. Instead, under the elevated ROS, LKB1 binds to and maintains the activity of the cdc42-PAK1 (p21-activated kinase 1) complex, which triggers the activation of p38 and its downstream signaling targets, such as ATF-2, thereby enhancing the activity of superoxide dismutase-2 and catalase, two antioxidant enzymes that protect the cells from ROS accumulation, DNA damage and loss of viability. Our results provide a new paradigm for a non-canonical tumor suppressor function of LKB1 and highlight the importance of targeting ROS signaling as a potential therapeutic strategy for cancer cells lacking LKB1.	[Xu, H-G; Chen, J.; Zhao, R-X; Xiao, X.; He, Q.; Werle, K. D.; Kim, H-G; Lopez, R.; Xu, Z-X] Univ Alabama Birmingham, Dept Med, Ctr Comprehens Canc, Div Hematol & Oncol, Birmingham, AL 35294 USA; [Zhai, Y-X; Wang, J-W; Quan, C-S; Li, Y-L; Xu, Z-X] Jilin Univ, Minist Educ, Norman Bethune Coll Med, Key Lab Pathobiol,Dept Pathol, Changchun 35294, Jilin, Peoples R China; [Lu, Y.] Nanjing Med Univ, Affiliated Hosp 2, Dept Endocrinol, Nanjing, Peoples R China; [Cui, R.] Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02215 USA; [Liang, J.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA	University of Alabama System; University of Alabama Birmingham; Jilin University; Nanjing Medical University; Boston University; University of Texas System; UTMD Anderson Cancer Center	Xu, ZX (corresponding author), Jilin Univ, Minist Educ, Norman Bethune Coll Med, Key Lab Pathobiol,Dept Pathol, 126 Xin Min Ave, Changchun 35294, Jilin, Peoples R China.	ylli@jlu.edu.cn; zhixiangxu08@gmail.com			National Cancer Institute [R01CA133053]; National 863 Program [2004AA205020]; National Natural Science Foundation of China [30700872]; NATIONAL CANCER INSTITUTE [R01CA133053] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National 863 Program(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Mousseau at University of Saskatchewan for providing p38-WT, CA and DN constructs; Dr Laderoute at SRI International for providing WT and AMPK-null MEFs; Dr Frazier at University of Texas MD Cancer Center for providing the LKB1-null cells; Dr Lizhong Wang from University of Alabama at Birmingham for providing WT and LKB1<SUP>fl/fl</SUP> MEFs. This work was supported by grants from National Cancer Institute R01CA133053 (ZXX) and the National 863 Program #2004AA205020 and the National Natural Science Foundation of China #30700872 (YLL).	Adams DJ, 2012, P NATL ACAD SCI USA, V109, P15115, DOI 10.1073/pnas.1212802109; Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Archer Herbert, 2002, Methods Mol Biol, V189, P67; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Cao X, 2009, J NEUROCHEM, V111, P101, DOI 10.1111/j.1471-4159.2009.06300.x; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Gutierrez-Uzquiza A, 2012, J BIOL CHEM, V287, P2632, DOI 10.1074/jbc.M111.323709; Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hsieh CC, 2010, AGING-US, V2, P582, DOI 10.18632/aging.100194; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jian WG, 2014, ANTI-CANCER DRUG, V25, P878, DOI 10.1097/CAD.0000000000000114; Jimenez AI, 2003, CANCER RES, V63, P1382; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Li XN, 2009, DIABETES, V58, P2246, DOI 10.2337/db08-1512; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Madesh M, 1998, INDIAN J BIOCHEM BIO, V35, P184; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Montero J, 2013, CELL DEATH DIFFER, V20, P1465, DOI 10.1038/cdd.2013.52; Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571; Pan JX, 2005, CANCER RES, V65, P3671, DOI 10.1158/0008-5472.CAN-04-2744; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Sen P, 2005, FEBS LETT, V579, P4402, DOI 10.1016/j.febslet.2005.06.081; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Slaughter MR, 2000, CLIN BIOCHEM, V33, P525, DOI 10.1016/S0009-9120(00)00158-2; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Ui A, 2014, ONCOGENE, V33, P1640, DOI 10.1038/onc.2013.125; Wang Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.358; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xiao XX, 2012, GYNECOL ONCOL, V127, P249, DOI 10.1016/j.ygyno.2012.06.032; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhang SM, 2008, CANCER RES, V68, P740, DOI 10.1158/0008-5472.CAN-07-2989; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao RX, 2014, CURR DRUG TARGETS, V15, P32, DOI 10.2174/1389450114666140106095811	56	30	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3848	3859		10.1038/onc.2014.315	http://dx.doi.org/10.1038/onc.2014.315			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263448	Green Accepted			2022-12-17	WOS:000358001600010
J	Shin, YJ; Kumarasamy, V; Camacho, D; Sun, D				Shin, Y-J; Kumarasamy, V.; Camacho, D.; Sun, D.			Involvement of G-quadruplex structures in regulation of human RET gene expression by small molecules in human medullary thyroid carcinoma TT cells	ONCOGENE			English	Article							PROXIMAL PROMOTER REGION; POLYPYRIMIDINE/POLYPURINE TRACT; DNA; PROTOONCOGENE; TRANSCRIPTION; TRANSITION; ONCOGENE; PATHWAY; PROTEIN; SYSTEM	The RET (rearranged during transfection) proto-oncogene encodes a receptor tyrosine kinase for members of the glial cell line-derived neurotrophic factor family of extracellular signaling molecules. The activating germline point mutations in the RET, which are known to induce oncogenic activation of RET tyrosine kinase, are associated with the development of medullary thyroid carcinoma (MTC) and pathogenesis of multiple endocrine neoplasia type 2 (MEN2). The polypurine/ polypyrimidine tract in the proximal promoter region of the human RET gene (similar to 51 to similar to 33 relative to transcription start site) is essential for basal transcriptional activity of this gene. This tract consists of a guanine-rich sequence containing five runs of at least three contiguous guanines separated by one or more bases, conforming to a general motif capable of forming an intramolecular G-quadruplex. Here, we show that specific G-quadruplex structures formed in the RET promoter region act to repress the transcription of this gene, and transcription of this gene can be controlled by ligand-mediated G-quadruplex stabilization. In this study, NSC194598, a derivative of indeno[1,2,3-de] quinazoline, was found to be a novel G-quadruplex interactive agent that interfered with transcriptional activation of mutated RET gene in human medullary thyroid carcinoma TT cells. This compound significantly reduced endogenous RET protein levels and increased apoptosis in these cells. Our results provide further support for the idea that G-quadruplex structures may have a critical role in transcriptional regulation of the RET gene in vivo, providing insight into a novel strategy for transcriptional repression of this gene by small molecules.	[Shin, Y-J; Kumarasamy, V.; Camacho, D.; Sun, D.] Univ Arizona, Dept Pharmacol & Toxicol, Coll Pharm, Tucson, AZ 85721 USA; [Sun, D.] BIO5 Inst, Tucson, AZ USA; [Sun, D.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA	University of Arizona; Arizona Center Cancer Care; University of Arizona	Sun, D (corresponding author), Univ Arizona, Dept Pharmacol & Toxicol, Coll Pharm, 1657 E Helen St, Tucson, AZ 85721 USA.	sun@pharmacy.arizona.edu			American Cancer Society [RSGM-12-046-01-CDD]	American Cancer Society(American Cancer Society)	We thank the American Cancer Society for support of this work (RSGM-12-046-01-CDD).	Andrew SD, 2000, GENE, V256, P283, DOI 10.1016/S0378-1119(00)00302-4; Andrew SD, 2002, GENE, V298, P9, DOI 10.1016/S0378-1119(02)00919-8; Bachetti T, 2005, GENE EXPRESSION, V12, P137, DOI 10.3727/000000005783992106; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/NCHEM.1548, 10.1038/nchem.1548]; Carter MT, 2001, CYTOGENET CELL GENET, V95, P169, DOI 10.1159/000059341; Dai JX, 2006, J AM CHEM SOC, V128, P1096, DOI 10.1021/ja055636a; de Groot JWB, 2006, ENDOCR REV, V27, P535, DOI 10.1210/er.2006-0017; EVANS T, 1986, J BIOL CHEM, V261, P4771; Gray DM, 2002, ENANTIOMER, V7, P49, DOI 10.1080/10242430212192; Guo K, 2007, J AM CHEM SOC, V129, P10220, DOI 10.1021/ja072185g; Han HY, 1999, NUCLEIC ACIDS RES, V27, P537, DOI 10.1093/nar/27.2.537; Lam EYN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2792; Lodish MB, 2008, EXPERT REV ANTICANC, V8, P625, DOI 10.1586/14737140.8.4.625; Massoll N, 2004, CLIN LAB MED, V24, P49, DOI 10.1016/j.cll.2004.01.006; MCCARTHY JG, 1987, NUCLEIC ACIDS RES, V15, P8069, DOI 10.1093/nar/15.19.8069; Nair RR, 2008, MOL PHARMACOL, V73, P919, DOI 10.1124/mol.107.042606; Niccoli-Sire P, 2007, ANN ENDOCRINOL-PARIS, V68, P317, DOI 10.1016/j.ando.2007.04.005; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Phan AT, 2004, J AM CHEM SOC, V126, P8710, DOI 10.1021/ja048805k; Plaza-Menacho I, 2006, TRENDS GENET, V22, P627, DOI 10.1016/j.tig.2006.09.005; Rahman KM, 2012, BIOORG MED CHEM LETT, V22, P3006, DOI 10.1016/j.bmcl.2012.02.020; Runeberg-Roos P, 2007, ANN MED, V39, P572, DOI 10.1080/07853890701646256; Rustighi A, 2002, BIOCHEMISTRY-US, V41, P1229, DOI 10.1021/bi011666o; Sassano Maria Florencia, 2012, Open Med Chem J, V6, P20, DOI 10.2174/1874104501206010020; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Simonsson T, 2001, BIOL CHEM, V382, P621, DOI 10.1515/BC.2001.073; Sun DK, 2011, NUCLEIC ACIDS RES, V39, P1256, DOI 10.1093/nar/gkq926; Sun DY, 2005, NUCLEIC ACIDS RES, V33, P6070, DOI 10.1093/nar/gki917; Todd AK, 2008, NUCLEIC ACIDS RES, V36, P2700, DOI 10.1093/nar/gkn078; Wells SA, 2009, CLIN CANCER RES, V15, P7119, DOI 10.1158/1078-0432.CCR-08-2742; Yan CH, 2004, FASEB J, V18, P540, DOI 10.1096/fj.03-0960fje	33	30	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1292	1299		10.1038/onc.2014.65	http://dx.doi.org/10.1038/onc.2014.65			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662821				2022-12-17	WOS:000350687100009
J	Wang, G; Cao, X; Lai, S; Luo, X; Feng, Y; Wu, J; Ning, Q; Xia, X; Wang, J; Gong, J; Hu, J				Wang, G.; Cao, X.; Lai, S.; Luo, X.; Feng, Y.; Wu, J.; Ning, Q.; Xia, X.; Wang, J.; Gong, J.; Hu, J.			Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MICRORNA BIOGENESIS; THERAPEUTIC TARGET; GASTRIC-CANCER; CELL; EXPRESSION; SUBUNIT; SUPPRESSOR; CARCINOMA; PIK3R3	MicroRNAs are a class of small non-coding RNAs that regulate the expressions of many genes. Previously, we found that the expression of p55PIK, an isoform of phosphatidylinosotol 3-kinase that has important roles in the regulation of cell cycle, is increased significantly in several types of cancer and contributes to the tumor growth. However, the mechanism for this increased p55PIK expression is not well understood. In this study, we show that miR-148b binds specifically to the 3'-untranslated region of p55PIK and significantly suppresses p55PIK expression. MiR-148b overexpression abolished p55PIK stimulation of cell proliferation and cell cycle progression in colorectal cancer (CRC) cell lines and decreased tumor growth in vivo. Furthermore, we demonstrated that p53 directly activates the transcription of miR-148b by binding to its promoter. In CRC cell lines and tissues, p53 expression was associated with miR-148b expression, and both were negatively associated with p55PIK expression. Our study shows that the p53/miR-148b/p55PIK axis has an important role in cell proliferation and tumor growth, and may represent a novel therapeutic target for treating cancers containing p53 mutations or losses.	[Wang, G.; Cao, X.; Lai, S.; Luo, X.; Xia, X.; Hu, J.] Huazhong Univ Sci & Technol, Tongji Hosp, Canc Res Inst, Wuhan 430030, Peoples R China; [Feng, Y.; Wu, J.; Gong, J.] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Mol Med Ctr, Wuhan 430030, Peoples R China; [Ning, Q.] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Infect Dis, Wuhan 430030, Peoples R China; [Wang, J.] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan 430030, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Gong, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Mol Med Ctr, Wuhan 430030, Peoples R China.	jpgong@tjh.tjmu.edu.cn; jbhu@tjh.tjmu.edu.cn	Wang, Guihua/AAX-3130-2021		National Natural Science Foundation [81300411, 81372662, 81072431, 81272278, 31000612]; '973' Program [2009CB521802]; Program for Changjiang Scholars and Innovative Research Team in University [PCSIRT1131]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); '973' Program(National Basic Research Program of China); Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT))	This study was supported by National Natural Science Foundation (No. 81300411, No. 81372662, No. 81072431, No. 81272278, No. 31000612), '973' Program (No. 2009CB521802) and Program for Changjiang Scholars and Innovative Research Team in University (No. PCSIRT1131).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chang H, 2012, MOL MED REP, V5, P1277, DOI 10.3892/mmr.2012.794; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; De Santa F, 2013, CURR PHARM DESIGN, V19, P745, DOI 10.2174/138161213804581846; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Hu JB, 2005, INT J ONCOL, V26, P1321; Hu JB, 2008, MOL CANCER THER, V7, P3719, DOI 10.1158/1535-7163.MCT-08-0499; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Nymark P, 2011, GENE CHROMOSOME CANC, V50, P585, DOI 10.1002/gcc.20880; PONS S, 1995, MOL CELL BIOL, V15, P4453; Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471; Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1; Song YX, 2012, INT J CANCER, V131, P1042, DOI 10.1002/ijc.26485; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang G, 2012, CELL DEATH DIFFER, V19, P1870, DOI 10.1038/cdd.2012.70; Wang GH, 2013, ANGIOGENESIS, V16, P561, DOI 10.1007/s10456-013-9336-y; Xia XM, 2003, MOL CELL BIOL, V23, P1717, DOI 10.1128/MCB.23.5.1717-1725.2003; Zhang L, 2007, CLIN CANCER RES, V13, P5314, DOI 10.1158/1078-0432.CCR-06-2660; Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T; Zhou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-34	29	30	31	4	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					912	921		10.1038/onc.2014.30	http://dx.doi.org/10.1038/onc.2014.30			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24632606				2022-12-17	WOS:000349472000011
J	Kim, J; Wu, L; Zhao, JC; Jin, HJ; Yu, J				Kim, J.; Wu, L.; Zhao, J. C.; Jin, H-J; Yu, J.			TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c	ONCOGENE			English	Article						TMPRSS2-ERG; miR-200c; EMT; prostate cancer	TO-MESENCHYMAL TRANSITION; CANCER-CELLS; ANDROGEN RECEPTOR; DNA METHYLATION; EXPRESSION; POLYCOMB; ERG; FAMILY; TRANSFORMATION; SIGNATURE	Chromosomal translocations that juxtapose the androgen-sensitive transmembrane protease, serine 2 (TMPRSS2) gene promoter to the oncogenic ETS-family transcription factor ERG result in excessive ERG overexpression in approximately 50% of prostate cancer (PCa) patients. Although numerous studies have investigated ERG-downstream genes, such studies have not attempted to examine miRNAs, which however are emerging to be important regulators of cancer. Through bioinformatics analysis of ChIP-Seq ERG data and miRNA expression profiling data we nominated miR-200c as a direct target of ERG. Experimentation of PCa cells with ERG overexpression or knockdown demonstrated that ERG directly repressed miR-200c expression by physically binding to the erythroblast transformation-specific (ETS) motif within its promoter. Consequently, miR-200c was downregulated in ERG-positive PCa, and miR-200c target gene expression was restored. In addition, the expression pattern of miR-200c target genes predicted ERG status in clinical PCa specimens. Furthermore, miR-200c was found to be important in modulating ZEB1 upregulation by ERG. Most importantly, miR-200c reconstitution fully reversed ERG-induced epithelial-to-mesenchymal transition (EMT), cell migration and invasion. Therefore, our study report miR-200c as the first miRNA target of ERG and a critical inhibitor of PCa cell motility. Therapeutic delivery of miR-200c may provide personalized treatment for patients with the molecular subtype of PCa that harbors TMPRSS2-ERG gene fusions.	[Kim, J.; Wu, L.; Zhao, J. C.; Jin, H-J; Yu, J.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA; [Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med, Lurie 5-117,303 E Super St, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	Kim, Jung/Q-7801-2016	Kim, Jung/0000-0001-6274-2841; Jin, Hongjian/0000-0003-3833-7170	NIH [R01CA172384, R00CA129565]; Research Scholar Award [RSG-12-085-01]; American Cancer Society; NRSA pre-doctoral fellowship [T32 CA080621]; NATIONAL CANCER INSTITUTE [R00CA129565, T32CA080621, R01CA172384] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Scholar Award; American Cancer Society(American Cancer Society); NRSA pre-doctoral fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jianjun Yu for helpful discussions. This work was supported by funding from the NIH R01CA172384 (to JY), NIH R00CA129565 (to JY) the Research Scholar Award RSG-12-085-01 (to JY) from the American Cancer Society and the NRSA pre-doctoral fellowship T32 CA080621 (to JK).	Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Becker-Santos DD, 2012, CARCINOGENESIS, V33, P2558, DOI 10.1093/carcin/bgs285; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Carver BS, 2009, NATURE, V457, pE1, DOI 10.1038/nature07738; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Cittelly DM, 2012, MOL CANCER THER, V11, P2556, DOI 10.1158/1535-7163.MCT-12-0463; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Fang YX, 2014, ONCOGENE, V33, P135, DOI 10.1038/onc.2013.54; Gordanpour A, 2011, ANTICANCER RES, V31, P403; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Hart M, 2013, FEBS J, V280, P2105, DOI 10.1111/febs.12236; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Hu M, 2010, NUCLEIC ACIDS RES, V38, P2154, DOI 10.1093/nar/gkp1180; Huang S, 2012, ONCOL REP, V28, P1831, DOI 10.3892/or.2012.2015; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Kopp F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050469; Kumar-Sinha C, 2008, NAT REV CANCER, V8, P497, DOI 10.1038/nrc2402; Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Peltier HJ, 2008, RNA, V14, P844, DOI 10.1261/rna.939908; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Rokavec M, 2012, MOL CELL, V45, P777, DOI 10.1016/j.molcel.2012.01.015; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Shi XB, 2008, J CELL MOL MED, V12, P1456, DOI 10.1111/j.1582-4934.2008.00420.x; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Vallejo DM, 2011, EMBO J, V30, P756, DOI 10.1038/emboj.2010.358; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wang JH, 2011, CANCER RES, V71, P1325, DOI 10.1158/0008-5472.CAN-10-2210; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yamamura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029722; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111	55	30	30	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5183	5192		10.1038/onc.2013.461	http://dx.doi.org/10.1038/onc.2013.461			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24186205	Green Accepted			2022-12-17	WOS:000343914900005
J	Erkan, EP; Strobel, T; Lewandrowski, G; Tannous, B; Madlener, S; Czech, T; Saydam, N; Saydam, O				Erkan, E. P.; Stroebel, T.; Lewandrowski, G.; Tannous, B.; Madlener, S.; Czech, T.; Saydam, N.; Saydam, O.			Depletion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth in vivo	ONCOGENE			English	Article						glioblastoma multiforme; minichromosome maintenance; MCM7; the cancer genome atlas; prognostic marker	CELL LUNG-CANCER; MCM PROTEINS; DNA-REPLICATION; PROGNOSTIC-SIGNIFICANCE; PHOSPHORYLATION; IDENTIFICATION; MARKER; FAMILY; PROLIFERATION; INITIATION	Minichromosome maintenance (MCM) proteins are key elements that function as a part of the pre-replication complex to initiate DNA replication in eukaryotes. Consistent with their roles in initiating DNA replication, overexpression of MCM family members has been observed in several malignancies. Through bioinformatic analysis of The Cancer Genome Atlas's data on glioblastoma multiforme (GBM), we found that the genomic region containing MCM7 gene was amplified in more than 80% of the present cases. To validate this finding and to identify the possible contribution of the remaining members of the MCM family to GBM progression, we used quantitative real-time PCR to analyze the gene expression profiles of all MCM family members in Grade IV (GBM) tissue samples and observed a significant upregulation in GBM samples compared with normal white matter tissues. In addition, we compared the observed gene expression profiles with those of Grade II and Grade III astrocytoma samples and determined that the observed upregulation was restricted and specific to Grade IV. MCM7 was the most upregulated gene in the gene set we analyzed, and therefore we wanted to identify the role of MCM7 in GBM progression. We determined that siRNA-mediated knockdown of MCM7 expression reduced GBM cell proliferation and also inhibited tumor growth in both xenograft and orthotopic mouse models of GBM. Taken together, our data suggest that MCM7 can be a potential prognostic marker and a novel therapeutic target in GBM therapy.	[Erkan, E. P.; Madlener, S.; Saydam, N.; Saydam, O.] Med Univ Vienna, Dept Pediat, Mol Neurooncol Res Unit, A-1090 Vienna, Austria; [Stroebel, T.] Med Univ Vienna, Inst Neurol, A-1090 Vienna, Austria; [Lewandrowski, G.; Tannous, B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Expt Therapeut & Mol Imaging Lab, Boston, MA USA; [Czech, T.] Med Univ Vienna, Dept Neurosurg, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Harvard University; Harvard Medical School; Massachusetts General Hospital; Medical University of Vienna	Saydam, O (corresponding author), Med Univ Vienna, Dept Pediat, Mol Neurooncol Res Unit, A-1090 Vienna, Austria.	okay.saydam@meduniwien.ac.at	Saydam, Okay/HDM-4999-2022; Madlener, Sibylle/AAP-2541-2020; Erkan, Erdogan Pekcan/GQR-2513-2022; Erkan, Erdogan Pekcan/ABI-6822-2020	Erkan, Erdogan Pekcan/0000-0001-9287-4773; Madlener, Sibylle/0000-0001-7099-9997	Forschungsgesellschaft for Brain Tumors; EU-FP7-PEOPLE-CIG; Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind'	Forschungsgesellschaft for Brain Tumors; EU-FP7-PEOPLE-CIG; Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind'	This work was supported, in part, by Forschungsgesellschaft for Brain Tumors (OS, NS), EU-FP7-PEOPLE-2011-CIG (OS) and Association for Conduct of Scientific Research in the Field of Neonatology and Pediatric Intensive Care: 'Unser Kind' (OS and NS).	BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bruck I, 2009, J BIOL CHEM, V284, P28823, DOI 10.1074/jbc.M109.039123; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cho WH, 2006, P NATL ACAD SCI USA, V103, P11521, DOI 10.1073/pnas.0604990103; Chuang LC, 2009, MOL CELL, V35, P206, DOI 10.1016/j.molcel.2009.06.014; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Facoetti A, 2006, ANTICANCER RES, V26, P3513; Facoetti A, 2006, ANTICANCER RES, V26, P1071; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Gambus A, 2006, NAT CELL BIOL, V8, P358, DOI 10.1038/ncb1382; Giaginis C, 2011, DIGEST DIS SCI, V56, P777, DOI 10.1007/s10620-010-1348-5; Giaginis C, 2010, HISTOL HISTOPATHOL, V25, P351, DOI 10.14670/HH-25.351; Gozuacik D, 2003, NUCLEIC ACIDS RES, V31, P570, DOI 10.1093/nar/gkg136; Gruber-Olipitz M, 2006, CANCER LETT, V238, P76, DOI 10.1016/j.canlet.2005.06.024; Guida T, 2005, J CLIN ENDOCR METAB, V90, P4703, DOI 10.1210/jc.2004-2459; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Kikuchi J, 2011, LUNG CANCER, V72, P229, DOI 10.1016/j.lungcan.2010.08.020; Lau KM, 2010, ONCOGENE, V29, P5475, DOI 10.1038/onc.2010.287; Louis DN, 2007, WHO CLASSIFICATION T; Lutzmann M, 2005, GENE, V362, P51, DOI 10.1016/j.gene.2005.07.031; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2006, CURR OPIN CELL BIOL, V18, P130, DOI 10.1016/j.ceb.2006.02.006; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Montagnoli A, 2010, CLIN CANCER RES, V16, P4503, DOI 10.1158/1078-0432.CCR-10-0185; Nishihara K, 2008, INT J ONCOL, V33, P245, DOI 10.3892/ijo_00000003; Ramnath N, 2001, J CLIN ONCOL, V19, P4259, DOI 10.1200/JCO.2001.19.22.4259; Randell JCW, 2006, MOL CELL, V21, P29, DOI 10.1016/j.molcel.2005.11.023; Saydam O, 2005, MOL THER, V12, P803, DOI 10.1016/j.ymthe.2005.07.534; Saydam O, 2011, CANCER RES, V71, P852, DOI 10.1158/0008-5472.CAN-10-1219; Saydam O, 2010, J PROTEOME RES, V9, P485, DOI 10.1021/pr900834h; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Tamura T, 2010, J ORAL PATHOL MED, V39, P328, DOI 10.1111/j.1600-0714.2009.00861.x; Toyokawa G, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-65; Tsuji T, 2006, MOL BIOL CELL, V17, P4459, DOI 10.1091/mbc.E06-03-0241; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wurdinger T, 2008, NAT METHODS, V5, P171, DOI 10.1038/NMETH.1177; Yang J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-203; Yoshida K, 2005, BIOCHEM BIOPH RES CO, V331, P669, DOI 10.1016/j.bbrc.2005.03.222	39	30	32	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4778	4785		10.1038/onc.2013.423	http://dx.doi.org/10.1038/onc.2013.423			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24166506				2022-12-17	WOS:000343239500008
J	Li, T; Lu, H; Shen, C; Lahiri, SK; Wason, MS; Mukherjee, D; Yu, L; Zhao, J				Li, T.; Lu, H.; Shen, C.; Lahiri, S. K.; Wason, M. S.; Mukherjee, D.; Yu, L.; Zhao, J.			Identification of epithelial stromal interaction 1 as a novel effector downstream of Kruppel-like factor 8 in breast cancer invasion and metastasis	ONCOGENE			English	Article						KLF8; EPSTI1; VCP; NF-kappa B; invasion and metastasis; breast cancer	FOCAL ADHESION KINASE; HUMAN SOMATIC-CELLS; MESENCHYMAL TRANSITION; KLF8 TRANSCRIPTION; CYCLIN D1; ACTIVATION; VCP/P97; TARGET; EPSTI1; GENE	Kruppel-like factor 8 (KLF8) is a transcriptional factor critical for metastatic progression of breast cancer. Epithelial stromal interaction 1 (EPSTI1), a recently identified stromal fibroblast-induced gene in non-invasive breast cancer cells is highly overexpressed in invasive breast carcinomas. The function and regulation of EPSTI1, however, remain largely unknown. In this paper, we report a novel KLF8 to EPSTI1 signaling pathway in breast cancer. Using various expression analyses, we revealed a high co-overexpression of KLF8 and EPSTI1 in invasive human breast cancer cells and patient tumors. Ectopic overexpression of KLF8 in the non-invasive MCF-10A cells induced the EPSTI1 expression, whereas KLF8 knockdown from the invasive, MDA-MB-231 cells decreased the EPSTI1 expression. Promoter activation and binding analyses indicated that KLF8 promoted the EPSTI1 expression by directly acting on the EPSTI1 gene promoter. EPSTI1 knockdown dramatically reduced the KLF8-promoted MCF-10A cell invasion, and ectopic expression of EPSTI1 in the non-invasive MCF-7 cells is sufficient to induce the cell invasion. Experiments using nude mice demonstrated that the ectopic EPSTI1 granted the MCF-7 cells capability of both invasive growth in the breasts and metastasis to the lungs. Using co-immunoprecipitation coupled with mass spectrometry, we discovered that EPSTI1 interacts with the valosin-containing protein (VCP), resulting in the degradation of I kappa B alpha and subsequent activation of NF-kappa B in the nucleus. These findings suggest a novel KLF8 to EPSTI1 to VCP to NF-kappa B signaling mechanism potentially critical for breast cancer invasion and metastasis.	[Li, T.; Lu, H.; Shen, C.; Lahiri, S. K.; Wason, M. S.; Mukherjee, D.; Yu, L.; Zhao, J.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA	State University System of Florida; University of Central Florida	Zhao, J (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	Jihe.Zhao@ucf.edu	Li, Tianshu/L-6426-2014; Lahiri, Satadru/J-3483-2019	Li, Tianshu/0000-0002-9972-4644; 	NCI [CA132977]; Susan G. Komen for the Cure breast cancer foundation [KG090444, KG080616]; NATIONAL CANCER INSTITUTE [R01CA132977] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G. Komen for the Cure breast cancer foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Dr Vladimir Ponomarev of Memorial Sloan-Kettering Cancer Center for kindly providing the trimodal imaging reporter vector SFG-nTGL and Dr Qishan Lin of UAlbany for helping with the mass spectrometry. This work was supported by grants from NCI (CA132977) and Susan G. Komen for the Cure breast cancer foundation (KG090444 and KG080616) to JZ.	Asai T, 2002, JPN J CANCER RES, V93, P296, DOI 10.1111/j.1349-7006.2002.tb02172.x; Buess M, 2009, NEOPLASIA, V11, P987, DOI 10.1593/neo.09670; Carey BW, 2009, P NATL ACAD SCI USA, V106, P157, DOI 10.1073/pnas.0811426106; de Neergaard M, 2010, AM J PATHOL, V176, P1229, DOI 10.2353/ajpath.2010.090648; Ding SZ, 2013, TOXICOL APPL PHARM, V269, P61, DOI 10.1016/j.taap.2013.03.006; Gudjonsson T, 2003, METHODS, V30, P247, DOI 10.1016/S1046-2023(03)00031-8; Hockemeyer D, 2008, CELL STEM CELL, V3, P346, DOI 10.1016/j.stem.2008.08.014; Lahiri SK, 2012, AM J TRANSL RES, V4, P357; Lu H, 2014, ONCOGENE, V33, P10, DOI 10.1038/onc.2012.545; Lu H, 2012, J BIOL CHEM, V287, P43720, DOI 10.1074/jbc.M112.418053; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; Mehta TS, 2009, CELL RES, V19, P1098, DOI 10.1038/cr.2009.64; Meyer H, 2012, NAT CELL BIOL, V14, P117, DOI 10.1038/ncb2407; Moserle L, 2008, CANCER RES, V68, P5658, DOI 10.1158/0008-5472.CAN-07-6341; Nielsen HL, 2002, GENOMICS, V79, P703, DOI 10.1006/geno.2002.6755; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Schnell O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030429; Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014; Urvalek AM, 2011, AM J TRANSL RES, V3, P121; Urvalek AM, 2010, CELL CYCLE, V9, P601, DOI 10.4161/cc.9.3.10606; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; Wang X, 2011, ONCOGENE, V30, P1901, DOI 10.1038/onc.2010.563; Wang XH, 2008, J BIOL CHEM, V283, P13934, DOI 10.1074/jbc.M709300200; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yang T, 2012, PLOS ONE, V7, P6; Zhang H, 2013, J CANCER RES CLIN, V139, P1033, DOI 10.1007/s00432-012-1363-3; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 2000, J CELL SCI, V113, P3063; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zubair A, 2013, CURR ALLERGY ASTHM R, V13, P44, DOI 10.1007/s11882-012-0300-5	35	30	31	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4746	4755		10.1038/onc.2013.415	http://dx.doi.org/10.1038/onc.2013.415			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24096480	Green Accepted			2022-12-17	WOS:000343239500005
J	Oue, N; Naito, Y; Hayashi, T; Takigahira, M; Kawano-Nagatsuma, A; Sentani, K; Sakamoto, N; Oo, HZ; Uraoka, N; Yanagihara, K; Ochiai, A; Sasaki, H; Yasui, W				Oue, N.; Naito, Y.; Hayashi, T.; Takigahira, M.; Kawano-Nagatsuma, A.; Sentani, K.; Sakamoto, N.; Oo, H. Zarni; Uraoka, N.; Yanagihara, K.; Ochiai, A.; Sasaki, H.; Yasui, W.			Signal peptidase complex 18, encoded by SEC11A, contributes to progression via TGF-alpha secretion in gastric cancer	ONCOGENE			English	Article						SPC18; SEC11A; signal peptidase complex; prognosis; gastric cancer	GROWTH-FACTOR-ALPHA; GENE-EXPRESSION PROFILES; CDNA MICROARRAY; REG-IV; PROTEIN; CARCINOGENESIS; TUMORIGENESIS; CARCINOMA; BIOMARKER; INVASION	We built an in-house oligonucleotide array on which 394 genes were selected based on our Serial Analysis of Gene Expression (SAGE) data and previously reported array data and listed several genes related to cancer progression. Among these, we focused on SEC11A, which encodes the SPC18 protein. SEC11A mRNA expression was measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in gastric cancer (GC) tissue samples. Expression and distribution of SPC18 protein were investigated by immunohistochemical analysis in two independent GC cohorts (Hiroshima cohort, n = 99 and Chiba cohort, n 989). To determine the effect of SPC18 on cell viability and invasiveness in vitro, MTT and Boyden chamber invasion assays were performed. To evaluate the influence of SPC18 on cell growth in vivo, GC cells were injected into severe combined immunodeficiency mice. Levels of TGF-alpha and EGF in media from the GC cells were measured by enzyme-linked immunosorbent assay (ELISA). Studies in human tissue revealed overexpression of SEC11A mRNA in 40% of 42 GC samples by qRT-PCR. Immunohistochemical analysis of SPC18 revealed that 26 and 20% of GC cases were SPC18-positive in the Hiroshima and Chiba cohorts, respectively. In both cohorts, the Kaplan-Meier analysis showed poorer survival in SPC18-positive GC cases than in SPC18-negative GC cases. Forced expression of SPC18 activates GC cell growth in vitro and in vivo. The levels of TGF-alpha in culture media from GC cells were reduced by knockdown of SPC18. These results indicate that SPC18 contributes to malignant progression through promotion of TGF-alpha secretion in GC.	[Oue, N.; Naito, Y.; Hayashi, T.; Sentani, K.; Sakamoto, N.; Oo, H. Zarni; Uraoka, N.; Yasui, W.] Hiroshima Univ Inst Biomed & Hlth Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; [Takigahira, M.] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Investigat Treatment Div, Kashiwa, Chiba, Japan; [Kawano-Nagatsuma, A.; Ochiai, A.] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Div Pathol, Kashiwa, Chiba, Japan; [Yanagihara, K.] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Div Translat Res, Kashiwa, Chiba, Japan; [Sasaki, H.] Natl Canc Ctr, Div Genet, Tokyo, Japan	Hiroshima University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Yasui, W (corresponding author), Hiroshima Univ Inst Biomed & Hlth Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp			Grants-in-Aid for Scientific Research [13J01171] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; de Castro NP, 2010, FUTURE ONCOL, V6, P1127, DOI 10.2217/FON.10.68; Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; Hasegawa S, 2002, CANCER RES, V62, P7012; Hippo Y, 2001, CANCER RES, V61, P889; Hippo Y, 2002, CANCER RES, V62, P233; Ii M, 2006, EXP BIOL MED, V231, P20; Inoue H, 2002, CLIN CANCER RES, V8, P3475; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; Mitani Y, 2007, ONCOGENE, V26, P4383, DOI 10.1038/sj.onc.1210215; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617; Nitadori JI, 2006, AM J CLIN PATHOL, V125, P682, DOI 10.1309/DT6BJ698LDX2NGGX; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Oue N, 2009, INT J CANCER, V125, P2383, DOI 10.1002/ijc.24624; Regalo G, 2010, LAB INVEST, V90, P1132, DOI 10.1038/labinvest.2010.79; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; Ueda Masatsugu, 1998, Invasion and Metastasis, V18, P176, DOI 10.1159/000024510; Yasui W, 1999, JPN J CANCER RES, V90, P589, DOI 10.1111/j.1349-7006.1999.tb00787.x; Yasui W, 2011, PATHOL RES PRACT, V207, P608, DOI 10.1016/j.prp.2011.09.006; Zembutsu H, 2002, CANCER RES, V62, P518	25	30	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3918	3926		10.1038/onc.2013.364	http://dx.doi.org/10.1038/onc.2013.364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	23995782				2022-12-17	WOS:000339394700004
J	Kim, ES; Cha, Y; Ham, M; Jung, J; Kim, SG; Hwang, S; Kleemann, R; Moon, A				Kim, E-S; Cha, Y.; Ham, M.; Jung, J.; Kim, S. G.; Hwang, S.; Kleemann, R.; Moon, A.			Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBP beta and potentiates breast cancer progression	ONCOGENE			English	Article						C-reactive protein; S1P; MMP-9; invasion; breast cell	PHOSPHOLIPASE C-CA2+ SYSTEM; GROWTH-FACTOR RECEPTOR; NADPH OXIDASE ACTIVITY; NF-KAPPA-B; SPHINGOSINE 1-PHOSPHATE; GENE-EXPRESSION; H-RAS; ENDOTHELIAL-CELLS; DNA-SEQUENCE; ACTIVATION	A crucial role of the inflammatory lipid sphingosine-1-phosphate (S1P) in breast cancer aggressiveness has been reported. Recent clinical studies have suggested that C-reactive protein (CRP) has a role in breast cancer development. However, limited information is available on the molecular basis for the expression of CRP and its functional significance in breast cell invasion. The present study aimed to elucidate the molecular link between S1P and CRP during the invasive process of breast epithelial cells. This is the first report showing that transcription of CRP was markedly activated by S1P in breast cells. Our data suggest that not only S1P treatment but also the endogenously produced S1P may upregulate CRP in breast carcinoma cells. Transcription factors CCAAT/enhancer-binding protein beta and c-fos were required for S1P-induced CRP expression. Coupling of S1P(3) to heterotrimeric G(alpha q) triggered the expression of CRP, utilizing signaling pathways involving reactive oxygen species (ROS), Ca2- and extracellular signal-related kinases (ERKs). S1P-induced CRP expression was crucial for the transcriptional activation of matrix metalloproteinase-9 through ERKs, ROS and c-fos, leading to breast cell invasion. Using a xenograft mice tumor model, we demonstrated that S1P induced CRP expression both in vitro and in vivo. Taken together, our findings have revealed a molecular basis for S1P-induced transcriptional activation of CRP and its functional significance in the acquisition of the invasive phenotype of human breast epithelial cells under inflammatory conditions. Our findings may provide useful information on the identification of useful therapeutic targets for inflammatory breast cancer.	[Kim, E-S; Cha, Y.; Ham, M.; Jung, J.; Moon, A.] Duksung Womens Univ, Coll Pharm, Seoul 132714, South Korea; [Kim, S. G.] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Kim, S. G.] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea; [Hwang, S.] Hanyang Univ, Coll Med, Seoul 133791, South Korea; [Kleemann, R.] TNO, Ck Leiden, Netherlands	Duksung Women's University; Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Netherlands Organization Applied Science Research	Moon, A (corresponding author), Duksung Womens Univ, Coll Pharm, 419 Ssangmun Dong, Seoul 132714, South Korea.	armoon@duksung.ac.kr			National Research Foundation of Korea (NRF) [ROA-2012-0006262, R11-2007-0056817, 2013R1A2A2A04013379]; Korea Drug Development Fund [A100030101002011]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea Drug Development Fund(Korea Drug Development Fund (KDDF))	This work was supported by the National Research Foundation of Korea (NRF) grants (no. ROA-2012-0006262, no R11-2007-0056817, and no. 2013R1A2A2A04013379) and Korea Drug Development Fund (no. A100030101002011).	Allin KH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2891; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Azuma H, 2002, CANCER RES, V62, P1410; BODMER B, 1977, J IMMUNOL, V118, P1086; Bonnaud S, 2010, CANCER RES, V70, P9905, DOI 10.1158/0008-5472.CAN-10-2043; Catarzi S, 2007, BBA-GEN SUBJECTS, V1770, P872, DOI 10.1016/j.bbagen.2007.01.008; Cha Y, 2012, BMB REP, V45, P719, DOI 10.5483/BMBRep.2012.45.12.164; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang JW, 2005, NEPHRON EXP NEPHROL, V101, pE165, DOI 10.1159/000087940; Cole SW, 2009, J CLIN ONCOL, V27, P3418, DOI 10.1200/JCO.2009.21.9782; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dai DF, 2011, J AM COLL CARDIOL, V58, P73, DOI 10.1016/j.jacc.2010.12.044; DEPRAETERE S, 1991, AGENTS ACTIONS, V34, P369, DOI 10.1007/BF01988730; Devaraj S, 2009, ATHEROSCLEROSIS, V203, P67, DOI 10.1016/j.atherosclerosis.2008.05.060; Doronzo G, 2005, J LAB CLIN MED, V146, P287, DOI 10.1016/j.lab.2005.07.010; Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772; Erlinger TP, 2004, JAMA-J AM MED ASSOC, V291, P585, DOI 10.1001/jama.291.5.585; French KJ, 2003, CANCER RES, V63, P5962; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; Goetzl EJ, 1999, CANCER RES, V59, P4732; Goldberg JE, 2010, CURR DRUG TARGETS, V11, P1133; Gong YQ, 2008, J CLIN INVEST, V118, P3012, DOI 10.1172/JCI32750; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haider DG, 2006, CLIN EXP IMMUNOL, V146, P533, DOI 10.1111/j.1365-2249.2006.03224.x; Hammad SM, 2008, PROSTAG OTH LIPID M, V85, P107, DOI 10.1016/j.prostaglandins.2007.11.002; Han CJ, 2010, ATHEROSCLEROSIS, V212, P206, DOI 10.1016/j.atherosclerosis.2010.05.020; Hojilla CV, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1980; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jongsma M, 2009, BRIT J PHARMACOL, V156, P1305, DOI 10.1111/j.1476-5381.2009.00134.x; Kaur G, 2007, J THROMB HAEMOST, V5, P1309, DOI 10.1111/j.1538-7836.2007.02527.x; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kilareski EM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-118; Kim ES, 2011, J CELL SCI, V124, P2220, DOI 10.1242/jcs.076794; Kim ES, 2010, BREAST CANCER RES TR, V124, P49, DOI 10.1007/s10549-009-0697-2; Kim MS, 2003, CANCER RES, V63, P5454; Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762; Kleemann R, 2011, ATHEROSCLEROSIS, V218, P44, DOI 10.1016/j.atherosclerosis.2011.04.023; Koide Y, 2002, J MED CHEM, V45, P4629, DOI 10.1021/jm020080c; LEI KJ, 1985, J BIOL CHEM, V260, P3377; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; Lewis CE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1679; Li J, 2012, ARCH PHARM RES, V35, P1259, DOI 10.1007/s12272-012-0717-3; Long JS, 2010, J BIOL CHEM, V285, P35957, DOI 10.1074/jbc.M110.117945; Lu JH, 2011, P NATL ACAD SCI USA, V108, P4974, DOI 10.1073/pnas.1018369108; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Masamune A, 2008, AM J PHYSIOL-GASTR L, V294, pG99, DOI 10.1152/ajpgi.00272.2007; Montero I, 2006, J AM COLL CARDIOL, V47, P1369, DOI 10.1016/j.jacc.2005.10.070; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; MOSHAGE HJ, 1988, BIOCHEM BIOPH RES CO, V155, P112, DOI 10.1016/S0006-291X(88)81056-8; Nabata A, 2008, ATHEROSCLEROSIS, V196, P129, DOI 10.1016/j.atherosclerosis.2007.03.003; Nagahashi M, 2012, CANCER RES, V72, P726, DOI 10.1158/0008-5472.CAN-11-2167; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Nishikawa T, 2008, J IMMUNOL, V180, P3492, DOI 10.4049/jimmunol.180.5.3492; Okajima F, 1997, ENDOCRINOLOGY, V138, P220, DOI 10.1210/en.138.1.220; Patel DN, 2007, J BIOL CHEM, V282, P27229, DOI 10.1074/jbc.M703250200; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pchejetski D, 2010, CANCER RES, V70, P8651, DOI 10.1158/0008-5472.CAN-10-1388; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Pierce BL, 2009, J CLIN ONCOL, V27, P3437, DOI 10.1200/JCO.2008.18.9068; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Przybylowska K, 2006, BREAST CANCER RES TR, V95, P65, DOI 10.1007/s10549-005-9042-6; Radeke HH, 2005, J IMMUNOL, V174, P2778, DOI 10.4049/jimmunol.174.5.2778; Ravishankaran P, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-18; Salmenpera P, 2003, AM J PHYSIOL-CELL PH, V284, pC1133, DOI 10.1152/ajpcell.00293.2002; Saren P, 1996, J IMMUNOL, V157, P4159; Sato K, 1999, FEBS LETT, V443, P25, DOI 10.1016/S0014-5793(98)01676-7; Schneider G, 2013, MOL CANCER RES, V11, P793, DOI 10.1158/1541-7786.MCR-12-0600; Shida D, 2008, CANCER RES, V68, P6569, DOI 10.1158/0008-5472.CAN-08-0411; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Singh P, 2007, ARTERIOSCL THROM VAS, V27, pE302, DOI 10.1161/ATVBAHA.107.148353; Smicun Y, 2006, GYNECOL ONCOL, V103, P952, DOI 10.1016/j.ygyno.2006.06.036; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; Suresh MV, 2004, J BIOL CHEM, V279, P52552, DOI 10.1074/jbc.M409054200; SWANSON SJ, 1989, J CELL BIOCHEM, V40, P121, DOI 10.1002/jcb.240400112; Tanimoto T, 2004, CIRC RES, V94, P1050, DOI 10.1161/01.RES.0000126404.41421.BE; Teoh H, 2008, ATHEROSCLEROSIS, V201, P318, DOI 10.1016/j.atherosclerosis.2008.02.034; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tobar N, 2010, BRIT J CANCER, V103, P1040, DOI 10.1038/sj.bjc.6605847; Tron K, 2008, EUR J IMMUNOL, V38, P1414, DOI 10.1002/eji.200738002; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Venugopal SK, 2005, AM J PATHOL, V166, P1265, DOI 10.1016/S0002-9440(10)62345-0; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Wilsher N, 2007, DRUG METAB DISPOS, V35, P1017, DOI 10.1124/dmd.106.014498; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; WOO P, 1985, J BIOL CHEM, V260, P3384; Wu ZS, 2008, INT J CANCER, V122, P2050, DOI 10.1002/ijc.23337; Yong HY, 2011, NEOPLASIA, V13, P98, DOI 10.1593/neo.101088; Young DP, 2008, J IMMUNOL, V181, P2420, DOI 10.4049/jimmunol.181.4.2420	92	30	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3583	3593		10.1038/onc.2013.319	http://dx.doi.org/10.1038/onc.2013.319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23955082				2022-12-17	WOS:000338941100010
J	Shan, L; Li, X; Liu, L; Ding, X; Wang, Q; Zheng, Y; Duan, Y; Xuan, C; Wang, Y; Yang, F; Shang, Y; Shi, L				Shan, L.; Li, X.; Liu, L.; Ding, X.; Wang, Q.; Zheng, Y.; Duan, Y.; Xuan, C.; Wang, Y.; Yang, F.; Shang, Y.; Shi, L.			GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation	ONCOGENE			English	Article						breast cancer; cell proliferation; gene transcription	DNA-DAMAGE RESPONSE; LUMINAL CELL FATE; BREAST-CANCER; ESTROGEN-RECEPTOR; GENE-EXPRESSION; CYCLIN D1; MAMMARY-GLAND; DIFFERENTIATION; BINDING; METASTASIS	The transcription factor GATA3 is a key regulator of mammary gland development and a definitive marker of luminal breast cancer. However, the molecular mechanisms underlying the role of GATA3 in breast carcinogenesis is still not fully understood. We report here that GATA3 promotes cell proliferation and tumorigenesis by facilitating the G(1)/S transition through its transcription regulation of the CCND1 gene in breast cancer cells. We found that GATA3 is physically associated with poly-ADP ribose polymerase-1 (PARP1), an enzyme modifying nuclear proteins by poly(ADP-ribosyl)ation. We showed that PARP1 acts as a transcription coactivator for GATA3 in breast cancer cells and demonstrated that GATA3 cooperates with PARP1 in transactivation of the CCND1 gene. We demonstrated that PARP1 competes with linker histone H1 to maintain a transcriptional competent chromatin environment for CCND1 gene. Our results unveiled a molecular basis for the coordinated regulation between GATA3 and PARP1 in transcription activation, providing a mechanism for GATA3 in breast carcinogenesis.	[Shan, L.; Li, X.; Liu, L.; Wang, Q.; Zheng, Y.; Duan, Y.; Xuan, C.; Wang, Y.; Shang, Y.; Shi, L.] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin 300070, Peoples R China; [Ding, X.; Yang, F.] Chinese Acad Sci, Inst Biophys, Lab Prote, Beijing 100080, Peoples R China	Tianjin Medical University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Shi, L (corresponding author), Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.	shilei@tmu.edu.cn	duan, yang/GZA-6440-2022		National Natural Science Foundation of China [81130048, 81272284, 91219102]; Ministry of Science and Technology of China [2011CB504204]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by grants (81130048 to YS, 81272284 and 91219102 to Lei Shi) from the National Natural Science Foundation of China and grants (973 Program: 2011CB504204 to YS) from the Ministry of Science and Technology of China.	Aguilar-Quesada R, 2007, CURR MED CHEM, V14, P1179, DOI 10.2174/092986707780597998; Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Blokzijl A, 2002, CURR BIOL, V12, P35, DOI 10.1016/S0960-9822(01)00623-6; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Ciocca V, 2009, HUM PATHOL, V40, P489, DOI 10.1016/j.humpath.2008.09.010; Cipak L, 2010, NEOPLASMA, V57, P401, DOI 10.4149/neo_2010_05_401; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; FANTL V, 1993, CANCER SURV, V18, P77; GILLETT C, 1994, CANCER RES, V54, P1812; Haffner MC, 2011, CLIN CANCER RES, V17, P3858, DOI 10.1158/1078-0432.CCR-10-2044; Ho IC, 2009, NAT REV IMMUNOL, V9, P125, DOI 10.1038/nri2476; Hoch RV, 1999, INT J CANCER, V84, P122; Hoene V, 2009, BRIT J CANCER, V101, P1481, DOI 10.1038/sj.bjc.6605276; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Hwang SS, 2010, IMMUNOLOGY, V131, P50, DOI 10.1111/j.1365-2567.2010.03271.x; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Kurokawa R, 2009, RNA BIOL, V6, P233, DOI 10.4161/rna.6.3.8329; Li RF, 2009, EMBO J, V28, P2763, DOI 10.1038/emboj.2009.211; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Ossovskaya V, 2010, GENES CANC, V1, P812, DOI 10.1177/1947601910383418; Parikh P, 2005, J AM COLL SURGEONS, V200, P705, DOI 10.1016/j.jamcollsurg.2004.12.025; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Rojo F, 2012, ANN ONCOL, V23, P1156, DOI 10.1093/annonc/mdr361; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Simsek D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002080; Taghon T, 2007, NAT IMMUNOL, V8, P845, DOI 10.1038/ni1486; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Tsarovina K, 2004, DEVELOPMENT, V131, P4775, DOI 10.1242/dev.01370; Tulin A, 2011, NAT BIOTECHNOL, V29, P1078, DOI 10.1038/nbt.2058; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wei G, 2011, IMMUNITY, V35, P299, DOI 10.1016/j.immuni.2011.08.007; Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010; Zhang C, 2007, STEM CELLS DEV, V16, P605, DOI 10.1089/scd.2006.0077; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	58	30	30	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3205	3216		10.1038/onc.2013.270	http://dx.doi.org/10.1038/onc.2013.270			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851505				2022-12-17	WOS:000338410000013
J	Foley, CJ; Fanjul-Fernandez, M; Bohm, A; Nguyen, N; Agarwal, A; Austin, K; Koukos, G; Covic, L; Lopez-Otin, C; Kuliopulos, A				Foley, C. J.; Fanjul-Fernandez, M.; Bohm, A.; Nguyen, N.; Agarwal, A.; Austin, K.; Koukos, G.; Covic, L.; Lopez-Otin, C.; Kuliopulos, A.			Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis	ONCOGENE			English	Article						angiogenesis; lung cancer; Mmp1a; MMP1; PAR1	CELL-PENETRATING PEPDUCINS; BREAST-CANCER CELLS; ACTIVATED RECEPTOR-1; 13-DEFICIENT MICE; ENDOTHELIAL-CELLS; SIGNALING SYSTEM; POOR-PROGNOSIS; OVARIAN-CANCER; EXPRESSION; GENE	Matrix metalloprotease-1 (MMP1) is an important mediator of tumorigenesis, inflammation and tissue remodeling through its ability to degrade critical matrix components. Recent studies indicate that stromal-derived MMP1 may exert direct oncogenic activity by signaling through protease-activated receptor-1 (PAR1) in carcinoma cells; however, this has not been established in vivo. We generated an Mmp1a knockout mouse to ascertain whether stromal-derived Mmp1a affects tumor growth. Mmp1a-deficient mice are grossly normal and born in Mendelian ratios; however, deficiency of Mmp1a results in significantly decreased growth and angiogenesis of lung tumors. Coimplantation of lung cancer cells with wild-type Mmp1a(+/+) fibroblasts completely restored tumor growth in Mmp1a-deficient animals, highlighting the critical role of stromal-derived Mmp1a. Silencing of PAR1 expression in the lung carcinoma cells phenocopied stromal Mmp1a-deficiency, thus validating tumor-derived PAR1 as an Mmp1a target. Mmp1a secretion is controlled by the ability of its prodomain to facilitate autocleavage, whereas human MMP1 is efficiently secreted because of stable pro-and catalytic domain interactions. Taken together, these data demonstrate that stromal Mmp1a drives in vivo tumorigenesis and provide proof of concept that targeting the MMP1-PAR1 axis may afford effective treatments of lung cancer.	[Foley, C. J.; Nguyen, N.; Agarwal, A.; Austin, K.; Koukos, G.; Covic, L.; Kuliopulos, A.] Tufts Univ, Sch Med, Tufts Med Ctr, Div Hematol Oncol,Mol Oncol Res Inst, Boston, MA 02111 USA; [Foley, C. J.; Bohm, A.; Austin, K.; Koukos, G.; Covic, L.; Kuliopulos, A.] Tufts Univ, Sch Med, Dept Biochem, Sackler Sch Grad Biomed Sci,Program Genet, Boston, MA 02111 USA; [Foley, C. J.; Bohm, A.; Austin, K.; Koukos, G.; Covic, L.; Kuliopulos, A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; [Fanjul-Fernandez, M.; Lopez-Otin, C.] Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, Oviedo, Spain	Tufts Medical Center; Tufts University; Tufts University; Tufts University; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Kuliopulos, A (corresponding author), Tufts Univ, Sch Med, Tufts Med Ctr, Div Hematol Oncol,Mol Oncol Res Inst, 75 Kneeland St, Boston, MA 02111 USA.	athan.kuliopulos@tufts.edu	López-Otín, Carlos/AAB-2106-2020; Koukos, Georgios/B-1544-2009	López-Otín, Carlos/0000-0001-6964-1904; Koukos, Georgios/0000-0002-9470-0651; Miriam, Fanjul Fernandez/0000-0002-0074-2325	NIH [F30-HL104835, CA122992, HL64701, CA104406]; NATIONAL CANCER INSTITUTE [R01CA122992, R01CA104406] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL104835, R01HL064701] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We are grateful to Sheida Sharifi for her expertise in quantifying tumor angiogenesis, and Rutika V Pradhan and Namrata Nammi for the analysis of endothelial tube formation. This work was supported, in part, by NIH grants F30-HL104835 (to CJF), CA122992, HL64701 (to AK) and CA104406 (to LC).	Agarwal A, 2008, MOL CANCER THER, V7, P2746, DOI 10.1158/1535-7163.MCT-08-0177; Agarwal A, 2010, CANCER RES, V70, P5880, DOI 10.1158/0008-5472.CAN-09-4341; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; BERTRAM JS, 1980, CANCER LETT, V11, P63, DOI 10.1016/0304-3835(80)90130-5; Blackburn JS, 2008, AM J PATHOL, V173, P1736, DOI 10.2353/ajpath.2008.080512; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; BOLON I, 1995, AM J PATHOL, V147, P1298; Bostrom P, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-348; Cisowski J, 2011, AM J PATHOL, V179, P513, DOI 10.1016/j.ajpath.2011.03.025; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Eck SM, 2009, J AUTOIMMUN, V33, P214, DOI 10.1016/j.jaut.2009.09.011; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Foley CJ, 2012, J BIOL CHEM, V287, P24330, DOI 10.1074/jbc.M112.356303; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Goerge T, 2006, CANCER RES, V66, P7766, DOI 10.1158/0008-5472.CAN-05-3897; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Hartenstein B, 2006, J INVEST DERMATOL, V126, P486, DOI 10.1038/sj.jid.5700084; Heppner KJ, 1996, AM J PATHOL, V149, P273; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Ito M, 2012, CHEST, V142, P151, DOI 10.1378/chest.11-2458; Jozic D, 2005, J BIOL CHEM, V280, P9578, DOI 10.1074/jbc.M411084200; Kanamori Y, 1999, CANCER RES, V59, P4225; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Murray GI, 1998, J PATHOL, V185, P256; Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082; Nikkola J, 2002, INT J CANCER, V97, P432, DOI 10.1002/ijc.1636; Nuttall RK, 2004, FEBS LETT, V563, P129, DOI 10.1016/S0014-5793(04)00281-9; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; Pfaffen S, 2010, EXP CELL RES, V316, P836, DOI 10.1016/j.yexcr.2009.11.004; Saarinen J, 1999, EUR J BIOCHEM, V259, P829, DOI 10.1046/j.1432-1327.1999.00105.x; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Smith Victoria, 2008, Cancer Genomics & Proteomics, V5, P263; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Tressel SL, 2011, EMBO MOL MED, V3, P370, DOI 10.1002/emmm.201100145; Vanlaere I, 2009, CLIN MICROBIOL REV, V22, P224, DOI 10.1128/CMR.00047-08; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vizoso FJ, 2007, BRIT J CANCER, V96, P903, DOI 10.1038/sj.bjc.6603666	43	30	30	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2264	2272		10.1038/onc.2013.157	http://dx.doi.org/10.1038/onc.2013.157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708660	Green Accepted			2022-12-17	WOS:000334996000012
J	Hunter, KE; Palermo, C; Kester, JC; Simpson, K; Li, JP; Tang, LH; Klimstra, DS; Vlodavsky, I; Joyce, JA				Hunter, K. E.; Palermo, C.; Kester, J. C.; Simpson, K.; Li, J-P; Tang, L. H.; Klimstra, D. S.; Vlodavsky, I.; Joyce, J. A.			Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors	ONCOGENE			English	Article						tumor microenvironment; tumor-associated macrophages; matrix-degrading enzyme; heparan sulfate proteoglycans	MOUSE MODEL; SULFATE; MICE; METASTASIS; GROWTH; CANCER; ANGIOGENESIS; MACROPHAGES; CELLS	Heparan sulfate proteoglycans are an important and abundant component of the extracellular matrix, which undergo substantial remodeling throughout tumorigenesis via the enzymatic activity of heparanase. Heparanase has been shown to be upregulated in many human cancers; however, its specific functions in human pancreatic neuroendocrine tumors (PanNETs) and spontaneous mouse models of cancer have not been evaluated. Here, we investigated the role of heparanase in PanNETs using patient samples and the RIP1-Tag2 (RT2) PanNET-transgenic mouse model. High heparanase expression significantly correlated with more advanced tumor stage, higher tumor grade and the presence of distant metastasis in PanNET patients. We genetically manipulated heparanase levels in the RT2 model using heparanase-transgenic mice, which constitutively overexpress heparanase, and heparanase-knockout mice. Heparanase was found to have a critical role in promoting tumor invasion, through both macrophage and cancer cell sources in the tumor microenvironment. In addition, elevated heparanase levels significantly increased peritumoral lymphangiogenesis in vivo and promoted the trans-differentiation of macrophages into lymphatic endothelial cell-like structures in culture. Conversely, we found that heparanase deletion led to increased angiogenesis and pericyte coverage. Together, these data identify important roles for heparanase in regulating several critical aspects of tumorigenesis, demonstrating that heparanase represents a potential therapeutic target for PanNET patients.	[Hunter, K. E.; Palermo, C.; Kester, J. C.; Simpson, K.; Joyce, J. A.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Hunter, K. E.] Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, New York, NY 10021 USA; [Li, J-P] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Tang, L. H.; Klimstra, D. S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Vlodavsky, I.] Technion Israel Inst Technol, Rappaport Fac Med, Canc & Vasc Res Ctr, IL-32000 Haifa, Israel	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Uppsala University; Memorial Sloan Kettering Cancer Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Joyce, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 372, New York, NY 10065 USA.	joycej@mskcc.org			National Cancer Institute [R01 CA125162]; Grayer Fellowship; NATIONAL CANCER INSTITUTE [R01CA125162] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grayer Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Joyce Lab; Drs Jacqueline Bromberg and Andrew Koff for discussion on this topic; and Robert Bowman, Daniela Quail, Alberto Schuhmacher and Hao- Wei Wang for reading the manuscript. We gratefully acknowledge Xiaoping Chen and Lin Song for excellent technical assistance; Marsha Quick and Karoline Dubin for project assistance; Elyn Reidel, MSKCC Epidemiology and Biostatistics Department for statistical analysis of RT2 tumor grades; Sho Fujisawa and the Molecular Cytology Core Facility for assistance with the MetaMorph lymphangiogenesis analysis; the MSKCC Flow Cytometry Core for technical assistance and advice; and Aisha Khan of the cGMP Cell Processing Facility, Cell Transplant Center, Diabetes Research Institute, University of Miami School of Medicine for providing normal islets. This research was funded by the National Cancer Institute R01 CA125162 and Cycle for Survival (JAJ). KEH was supported in part by a Grayer Fellowship.	Arvatz G, 2011, CANCER METAST REV, V30, P253, DOI 10.1007/s10555-011-9288-x; Cohen-Kaplan V, 2008, INT J CANCER, V123, P2566, DOI 10.1002/ijc.23898; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Ferrone CR, 2007, J CLIN ONCOL, V25, P5609, DOI 10.1200/JCO.2007.12.9809; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hu Wenwei, 2010, Genes Cancer, V1, P360; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Joyce JA, 2005, ONCOGENE, V24, P4037, DOI 10.1038/sj.onc.1208602; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Lindahl U, 2009, INT REV CEL MOL BIO, V276, P105, DOI 10.1016/S1937-6448(09)76003-4; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; Nolan-Stevaux Olivier, 2010, Genes Cancer, V1, P125, DOI 10.1177/1947601909358722; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Ori A, 2011, J BIOL CHEM, V286, P19892, DOI 10.1074/jbc.M111.228114; Parish CR, 1999, CANCER RES, V59, P3433; Pyonteck SM, 2012, ONCOGENE, V31, P1459, DOI 10.1038/onc.2011.337; Stenzel D, 2009, BLOOD, V114, P915, DOI 10.1182/blood-2008-10-186239; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Tuveson D, 2011, NATURE, V471, P316, DOI 10.1038/471316a; Vlodavsky I, 2012, CANCER MICROENVIRON, V5, P115, DOI 10.1007/s12307-011-0082-7; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Yao JC, 2007, ANN SURG ONCOL, V14, P3492, DOI 10.1245/s10434-007-9566-6; Zcharia E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005181; Zumsteg A, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006494; Zumsteg A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007067	30	30	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1799	1808		10.1038/onc.2013.142	http://dx.doi.org/10.1038/onc.2013.142			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23644656				2022-12-17	WOS:000334345500006
J	Laser-Azogui, A; Diamant-Levi, T; Israeli, S; Roytman, Y; Tsarfaty, I				Laser-Azogui, A.; Diamant-Levi, T.; Israeli, S.; Roytman, Y.; Tsarfaty, I.			Met-induced membrane blebbing leads to amoeboid cell motility and invasion	ONCOGENE			English	Article						Met; blebbing; amoeboid cell motility; invasion; metastasis	HEPATOCYTE GROWTH-FACTOR; FACTOR INHIBITS ANOIKIS; FC-EPSILON-RI; C-MET; PSEUDOPODIAL PROTRUSION; LUNG-CANCER; RECEPTOR; ACTIVATION; MICRODOMAINS; METASTASIS	Met tyrosine kinase has been implicated in tumorigenesis and metastasis; its overexpression and deregulation is often observed in cancer. Although Met's functions in cell motility has been studied extensively, its involvement in bleb-based, amoeboid motility is yet to be determined. The aim of this work is to study the role of Met in amoeboid cell motility and invasion. We show that aggressive breast cancer cells expressing high levels of endogenous Met, as well as HEK293T cells over expressing fluorescent Met, exhibit constitutive, ligand-independent Met activation, leading to Met-dependent membrane blebbing and amoeboid cell motility; HEK293T cells over expressing fluorescent Met were able to invade in three-dimensional matrix. Hyper-activated Met mutant significantly enhances blebbing and cell motility. Met inhibition by either a Met-specific inhibitor or by exogenous expression of a dominant-negative Met remarkably repressed membrane blebbing and invasion. Inhibition of Rho signaling pathway by a ROCK inhibitor also represses Met-induced blebbing, suggesting that Met regulates the blebbing machinery through Rho-ROCK pathway, which controls the actin-myosin contractile force. Either de-polymerization or hyper-polymerization of the actin cytoskeleton abrogates Met-induced blebbing, signifying that actin polymerization has a role in halting and retracting Met-induced mature blebs. Indeed, when blebs retract, membrane wrinkles containing high levels of Met and actin are generated, indicating localized formation of Met-signaling microdomains. We suggest that this bleb-based activity is induced by amplification of Met signaling in unique membrane domains generated by bleb retraction. Our results indicate that Met-induced blebbing has an important role in cell detachment, amoeboid motility and invasion ability, which are utilized by cancer cells for migration and metastasis.	[Laser-Azogui, A.; Diamant-Levi, T.; Israeli, S.; Roytman, Y.; Tsarfaty, I.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Tsarfaty, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel.	ilants@post.tau.ac.il		Tsarfaty, Ilan/0000-0002-5230-7093	Breast Cancer Research Foundation; United States-Israel Binational Science Foundation; Federico Foundation Grants	Breast Cancer Research Foundation; United States-Israel Binational Science Foundation(US-Israel Binational Science Foundation); Federico Foundation Grants	We thank Professor Iafa Keydar for T47D cells and Dr Joyce Taylor-Papadimitriou for HB2 cells. We also thank Dr Yifat Merbl (Harvard medical school) for her critical review of this manuscript. This work was supported by research grants from the Breast Cancer Research Foundation, the United States-Israel Binational Science Foundation and the Federico Foundation Grants.	Abella JV, 2010, J BIOL CHEM, V285, P24956, DOI 10.1074/jbc.M110.127985; Abella JV, 2010, J CELL SCI, V123, P1306, DOI 10.1242/jcs.062570; Andrews NL, 2008, NAT CELL BIOL, V10, P955, DOI 10.1038/ncb1755; Arni S, 1996, BIOCHEM BIOPH RES CO, V225, P801, DOI 10.1006/bbrc.1996.1254; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Charras GT, 2008, BIOPHYS J, V94, P1836, DOI 10.1529/biophysj.107.113605; Charras GT, 2006, J CELL BIOL, V175, P477, DOI 10.1083/jcb.200602085; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Douglass AD, 2005, CELL, V121, P937, DOI 10.1016/j.cell.2005.04.009; Firon M, 2000, ONCOGENE, V19, P2386, DOI 10.1038/sj.onc.1203557; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Holowka D, 2000, J CELL SCI, V113, P1009; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jia ZJ, 2006, BIOL CELL, V98, P337, DOI 10.1042/BC20050088; Jiang WG, 2005, CRIT REV ONCOL HEMAT, V53, P35, DOI 10.1016/j.critrevonc.2004.09.004; Jung KH, 2012, ARCH PHARM RES, V35, P595, DOI 10.1007/s12272-012-0402-6; Keller HU, 1996, CELL MOTIL CYTOSKEL, V33, P241, DOI 10.1002/(SICI)1097-0169(1996)33:4<241::AID-CM1>3.0.CO;2-C; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; Maulik G, 2002, CLIN CANCER RES, V8, P620; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Miller M, 2001, PROTEINS, V44, P32, DOI 10.1002/prot.1069; Moffatt OD, 1999, J IMMUNOL, V162, P6800; Moshitch-Moshkovitz S, 2006, NEOPLASIA, V8, P353, DOI 10.1593/neo.05634; Nguyen TN, 2000, EXP CELL RES, V258, P171, DOI 10.1006/excr.2000.4929; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; SAMBROOK A, 1989, MOL CLONING LAB MANU; Tournaviti S, 2007, J CELL SCI, V120, P3820, DOI 10.1242/jcs.011130; Vadnais J, 2002, J BIOL CHEM, V277, P48342, DOI 10.1074/jbc.M209481200; Vasiliev JM, 2004, P NATL ACAD SCI USA, V101, P12526, DOI 10.1073/pnas.0404723101; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yoshida K, 2006, J CELL SCI, V119, P3833, DOI 10.1242/jcs.03152; Zeng QH, 2002, J BIOL CHEM, V277, P50137, DOI 10.1074/jbc.M208952200; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	43	30	30	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1788	1798		10.1038/onc.2013.138	http://dx.doi.org/10.1038/onc.2013.138			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23665680				2022-12-17	WOS:000334345500005
J	Kyula, JN; Khan, AA; Mansfield, D; Karapanagiotou, EM; McLaughlin, M; Roulstone, V; Zaidi, S; Pencavel, T; Touchefeu, Y; Seth, R; Chen, NG; Yu, YA; Zhang, Q; Melcher, AA; Vile, RG; Pandha, HS; Ajaz, M; Szalay, AA; Harrington, KJ				Kyula, J. N.; Khan, A. A.; Mansfield, D.; Karapanagiotou, E. M.; McLaughlin, M.; Roulstone, V.; Zaidi, S.; Pencavel, T.; Touchefeu, Y.; Seth, R.; Chen, N. G.; Yu, Y. A.; Zhang, Q.; Melcher, A. A.; Vile, R. G.; Pandha, H. S.; Ajaz, M.; Szalay, A. A.; Harrington, K. J.			Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-alpha signaling	ONCOGENE			English	Article						oncolytic vaccinia; GLV-1h68; JNK; TNF-alpha; RT; apoptosis	NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; CELL LUNG; NUDE-MICE; VIRUS; CANCER; ACTIVATION; THERAPY; BRAF; COMBINATION	Melanoma is an aggressive skin cancer that carries an extremely poor prognosis when local invasion, nodal spread or systemic metastasis has occurred. Recent advances in melanoma biology have revealed that RAS-RAF-MEK-ERK signaling has a pivotal role in governing disease progression and treatment resistance. Proof-of-concept clinical studies have shown that direct BRAF inhibition yields impressive responses in advanced disease but these are short-lived as treatment resistance rapidly emerges. Therefore, there is a pressing need to develop new targeted strategies for BRAF mutant melanoma. As such, oncolytic viruses represent a promising cancer-specific approach with significant activity in melanoma. This study investigated interactions between genetically-modified vaccinia virus (GLV-1h68) and radiotherapy in melanoma cell lines with BRAF mutant, Ras mutant or wild-type genotype. Preclinical studies revealed that GLV-1h68 combined with radiotherapy significantly increased cytotoxicity and apoptosis relative to either single agent in (V600D)BRAF/(V600E)BRAF mutant melanoma in vitro and in vivo. The mechanism of enhanced cytotoxicity with GLV-1h68/radiation (RT) was independent of viral replication and due to attenuation of JNK, p38 and ERK MAPK phosphorylation specifically in BRAF mutant cells. Further studies showed that JNK pathway inhibition sensitized BRAF mutant cells to GLV-1h68-mediated cell death, mimicking the effect of RT. GLV-1h68 infection activated MAPK signaling in (V600D)BRAF/(V600E)BRAF mutant cell lines and this was associated with TNF-alpha secretion which, in turn, provided a prosurvival signal. Combination GLV-1h68/RT (or GLV-1h68/JNK inhibition) caused abrogation of TNF-alpha secretion. These data provide a strong rationale for combining GLV-1h68 with irradiation in (V600D/E)BRAF mutant tumors.	[Kyula, J. N.; Khan, A. A.; Mansfield, D.; Karapanagiotou, E. M.; McLaughlin, M.; Roulstone, V.; Zaidi, S.; Pencavel, T.; Touchefeu, Y.; Seth, R.; Harrington, K. J.] Inst Canc Res, Div Canc Biol, Targeted Therapy Team, London SW3 6JB, England; [Chen, N. G.; Yu, Y. A.; Zhang, Q.; Szalay, A. A.] Genelux Corp, San Diego Sci Ctr, San Diego, CA USA; [Melcher, A. A.; Vile, R. G.] Leeds Inst Mol Med, Leeds, W Yorkshire, England; [Vile, R. G.] Mayo Clin, Mol Med Program, Rochester, MN USA; [Pandha, H. S.; Ajaz, M.] Univ Surrey, Postgrad Med Sch, Guildford GU2 5XH, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Leeds; Mayo Clinic; University of Surrey	Kyula, JN (corresponding author), Inst Canc Res, Div Canc Biol, Targeted Therapy Team, 237 Fulham Rd, London SW3 6JB, England.	Joan.Kyula@icr.ac.uk	Touchefeu, Yann/M-2969-2015; Touchefeu, Yann/AGH-7655-2022; Khan, Aadil/AAB-6853-2021	Touchefeu, Yann/0000-0001-8421-3182; Khan, Aadil/0000-0003-1284-6049; Melcher, Alan/0000-0002-2042-3380; McLaughlin, Martin/0000-0002-9739-7133; Harrington, Kevin/0000-0002-6014-348X	Myfanwy Townsend Melanoma Research Fund; Cotswold Trust; Cancer Research UK [13244] Funding Source: researchfish; Rosetrees Trust [M236-CD1] Funding Source: researchfish	Myfanwy Townsend Melanoma Research Fund; Cotswold Trust; Cancer Research UK(Cancer Research UK); Rosetrees Trust(Rosetrees Trust)	We would like to thank Dr Khin Thway and Dr Michelle Wilkinson for their assistance with data acquisition and analysis. This work was supported in part by research grants from the Myfanwy Townsend Melanoma Research Fund and the Cotswold Trust.	Amaravadi RK, 2009, CLIN CANCER RES, V15, P7711, DOI 10.1158/1078-0432.CCR-09-2074; Andrade AA, 2004, BIOCHEM J, V381, P437, DOI 10.1042/BJ20031375; Ascierto ML, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-451; Beyaert R, 2002, INT REV CYTOL, V214, P225; BLISS CI, 1956, BACTERIOL REV, V20, P243, DOI 10.1128/MMBR.20.4.243-258.1956; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; Comins C, 2010, CLIN CANCER RES, V16, P5564, DOI 10.1158/1078-0432.CCR-10-1233; de Magalhaes JC, 2001, J BIOL CHEM, V276, P38353, DOI 10.1074/jbc.M100183200; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Gentschev I, 2009, CANCER GENE THER, V16, P320, DOI 10.1038/cgt.2008.87; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gray-Schopfer VC, 2007, CANCER RES, V67, P122, DOI 10.1158/0008-5472.CAN-06-1880; GRECO WR, 1995, PHARMACOL REV, V47, P331; Gutermann A, 2006, HUM GENE THER, V17, P1241, DOI 10.1089/hum.2006.17.1241; Harrington KJ, 2010, CLIN CANCER RES, V16, P3067, DOI 10.1158/1078-0432.CCR-10-0054; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Heinemann L, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-221; Kelly KJ, 2008, HUM GENE THER, V19, P774, DOI 10.1089/hum.2008.036; Khan N, 2011, INT J RADIAT ONCOL, V80, P645, DOI 10.1016/j.ijrobp.2010.12.071; King AJ, 2006, CANCER RES, V66, P11100, DOI 10.1158/0008-5472.CAN-06-2554; Lin SF, 2008, J CLIN ENDOCR METAB, V93, P4403, DOI 10.1210/jc.2008-0316; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; Mansfield D, 2013, ORAL ONCOL, V49, P108, DOI 10.1016/j.oraloncology.2012.07.019; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Pandha HS, 2009, CLIN CANCER RES, V15, P6158, DOI 10.1158/1078-0432.CCR-09-0796; Pawlik TM, 2002, CANCER-AM CANCER SOC, V95, P1171, DOI 10.1002/cncr.10776; Post DE, 2004, CLIN CANCER RES, V10, P8603, DOI 10.1158/1078-0432.CCR-04-1432; Raki M, 2005, GENE THER, V12, P1198, DOI 10.1038/sj.gt.3302517; Soares JAP, 2009, J VIROL, V83, P6883, DOI 10.1128/JVI.00245-09; Tawbi HA, 2007, SEMIN ONCOL, V34, P532, DOI 10.1053/j.seminoncol.2007.09.008; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Twigger K, 2008, CLIN CANCER RES, V14, P912, DOI 10.1158/1078-0432.CCR-07-1400; Tyminski E, 2005, CANCER RES, V65, P6850, DOI 10.1158/0008-5472.CAN-05-0154; Wang G, 2006, P NATL ACAD SCI USA, V103, P4640, DOI 10.1073/pnas.0509341103; Wullaert A, 2006, BIOCHEM PHARMACOL, V72, P1090, DOI 10.1016/j.bcp.2006.07.003; Yu YA, 2009, MOL CANCER THER, V8, P141, DOI 10.1158/1535-7163.MCT-08-0533; Yu ZJ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-45; Zhang Q, 2007, CANCER RES, V67, P10038, DOI 10.1158/0008-5472.CAN-07-0146	42	30	31	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1700	1712		10.1038/onc.2013.112	http://dx.doi.org/10.1038/onc.2013.112			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23624923	Bronze, Green Accepted			2022-12-17	WOS:000334344700010
J	Lu, R; Pal, J; Buon, L; Nanjappa, P; Shi, J; Fulciniti, M; Tai, YT; Guo, L; Yu, M; Gryaznov, S; Munshi, NC; Shammas, MA				Lu, R.; Pal, J.; Buon, L.; Nanjappa, P.; Shi, J.; Fulciniti, M.; Tai, Y-T; Guo, L.; Yu, M.; Gryaznov, S.; Munshi, N. C.; Shammas, M. A.			Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth	ONCOGENE			English	Article						homologous recombination; telomerase; telomeres; Barrett's adenocarcinoma	LASER CAPTURE MICRODISSECTION; QUADRUPLEX-INTERACTIVE AGENT; MULTIPLE-MYELOMA CELLS; DNA-DAMAGE RESPONSE; TO-END FUSIONS; LEUKEMIA-CELLS; IMMORTAL CELLS; IN-VIVO; TELOMESTATIN SOT-095; MAMMALIAN TELOMERES	Homologous recombination (HR), a mechanism to accurately repair DNA in normal cells, is deregulated in cancer. Elevated/deregulated HR is implicated in genomic instability and telomere maintenance, which are critical lifelines of cancer cells. We have previously shown that HR activity is elevated and significantly contributes to genomic instability in Barrett's esophageal adenocarcinoma (BAC). The purpose of this study was to evaluate therapeutic potential of HR inhibition, alone and in combination with telomerase inhibition, in BAC. We demonstrate that telomerase inhibition in BAC cells increases HR activity, RAD51 expression, and association of RAD51 to telomeres. Suppression of HR leads to shorter telomeres as well as markedly reduced genomic instability in BAC cells over time. Combination of HR suppression (whether transgenic or chemical) with telomerase inhibition, causes a significant increase in telomere attrition and apoptotic death in all BAC cell lines tested, relative to either treatment alone. A subset of treated cells also stain positive for beta-galactosidase, indicating senescence. The combined treatment is also associated with decline in S-phase and a strong G2/M arrest, indicating massive telomere attrition. In a subcutaneous tumor model, the combined treatment resulted in the smallest tumors, which were even smaller (P - 0.001) than those that resulted from either treatment alone. Even the tumors removed from these mice had significantly reduced telomeres and evidence of apoptosis. We therefore conclude that although telomeres are elongated by telomerase, elevated RAD51/HR assist in their maintenance/ stabilization in BAC cells. Telomerase inhibitor prevents telomere elongation but induces RAD51/HR, which contributes to telomere maintenance/ stabilization and prevention of apoptosis, reducing the efficacy of treatment. Combining HR inhibition with telomerase renders telomeres more vulnerable to degradation and significantly increases/ expedites their attrition, leading to apoptosis. We therefore demonstrate that a therapy targeting HR and telomerase has the potential to prevent both tumor growth and genomic evolution in BAC.	[Lu, R.; Pal, J.; Buon, L.; Nanjappa, P.; Shi, J.; Fulciniti, M.; Tai, Y-T; Munshi, N. C.; Shammas, M. A.] Harvard Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA USA; [Lu, R.; Pal, J.; Buon, L.; Nanjappa, P.; Shi, J.; Fulciniti, M.; Tai, Y-T; Munshi, N. C.; Shammas, M. A.] VA Hlth Care Syst, Boston, MA USA; [Lu, R.; Guo, L.; Yu, M.] Fudan Univ, Dept Clin Lab, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Lu, R.; Guo, L.; Yu, M.] Shanghai Med Sch, Shanghai, Peoples R China; [Shi, J.; Fulciniti, M.; Tai, Y-T; Munshi, N. C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Gryaznov, S.] Geron Corp, Dept Nucle Acid Chem, Menlo Pk, CA USA	Fudan University; Harvard University; Harvard Medical School; Geron Corporation	Shammas, MA (corresponding author), Harvard Dana Farber Canc Inst, Dept Adult Oncol, 1400 VFW Pkwy,Bldg 3,Room 2A111, West Roxbury, MA 02132 USA.	Masood_Shammas@DFCI.Harvard.Edu	Munshi, Nikhil/ABE-2338-2021	Shi, Jialan/0000-0001-5642-5436	National Cancer Institute [R01CA125711]; Department of Veterans Affairs Merit Review Awards; National Institutes of Health [RO1-1375555, P50-100007, PO1-78378]; NATIONAL CANCER INSTITUTE [P01CA155258, R01CA125711] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Veterans Affairs Merit Review Awards(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr David G Beer, Department of Surgery, University of Michigan, Ann Arbor, MI, USA, for providing FLO-1 cells. This work was supported in part by grants from National Cancer Institute R01CA125711 to MAS, from the Department of Veterans Affairs Merit Review Awards (to NCM) and from the National Institutes of Health Grants RO1-1375555, P50-100007 and PO1-78378 to NCM.	Abdallah P, 2009, NAT CELL BIOL, V11, P988, DOI 10.1038/ncb1911; Aggarwal S, 2000, NEOPLASIA, V2, P346, DOI 10.1038/sj.neo.7900097; Akiyama M, 2003, CANCER RES, V63, P6187; ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; Badie S, 2010, NAT STRUCT MOL BIOL, V17, P1461, DOI 10.1038/nsmb.1943; Bechter OE, 1998, CANCER RES, V58, P4918; BLACKBURN EH, 1989, GENOME, V31, P553, DOI 10.1139/g89-104; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAY JP, 1993, ENVIRON MOL MUTAGEN, V22, P245, DOI 10.1002/em.2850220411; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Engelhardt M, 1998, ONCOL REP, V5, P1043; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Ganapathipillai SS, 2008, CANCER RES, V68, P5769, DOI 10.1158/0008-5472.CAN-08-1269; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Ijpma AS, 2003, MOL BIOL CELL, V14, P987, DOI 10.1091/mbc.02-04-0057; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lord RVN, 2000, J GASTROINTEST SURG, V4, P135, DOI 10.1016/S1091-255X(00)80049-9; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Morrish TA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000357; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Ogunwobi OO, 2008, AM J GASTROENTEROL, V103, P825, DOI 10.1111/j.1572-0241.2007.01773.x; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Pal J, 2011, ONCOGENE, V30, P3585, DOI 10.1038/onc.2011.83; Pal J, 2012, CANCER GENOM PROTEOM, V9, P55; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Seimiya H, 2002, MOL CANCER THER, V1, P657; Shammas MA, 2008, LEUKEMIA, V22, P1410, DOI 10.1038/leu.2008.81; Shammas MA, 1999, ONCOGENE, V18, P6191, DOI 10.1038/sj.onc.1203069; Shammas MA, 2004, GASTROENTEROLOGY, V126, P1337, DOI 10.1053/j.gastro.2004.01.026; Shammas MA, 2004, EXP CELL RES, V295, P204, DOI 10.1016/j.yexcr.2004.01.003; Shammas MA, 2004, CLIN CANCER RES, V10, P770, DOI 10.1158/1078-0432.CCR-0793-03; Shammas MA, 2003, MOL CANCER THER, V2, P825; Shammas MA, 2008, CLIN CANCER RES, V14, P4971, DOI 10.1158/1078-0432.CCR-08-0473; Shammas MA, 2006, BLOOD, V108, P2804, DOI 10.1182/blood-2006-05-022814; Shammas MA, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-24; Shammas MA, 2011, METHODS MOL BIOL, V755, P181, DOI 10.1007/978-1-61779-163-5_14; Shammas MA, 2009, BLOOD, V113, P2290, DOI 10.1182/blood-2007-05-089193; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shi J, 2006, CYTOM PART A, V69A, P1193, DOI 10.1002/cyto.a.20345; Sumi M, 2004, INT J ONCOL, V24, P1481; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wai Lin Kah, 2004, MedGenMed, V6, P19; Wallweber G, 2003, BIOCHEMISTRY-US, V42, P589, DOI 10.1021/bi026914a	59	30	31	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1495	1505		10.1038/onc.2013.103	http://dx.doi.org/10.1038/onc.2013.103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23604115	Green Accepted, Green Submitted			2022-12-17	WOS:000333244200003
J	Xia, L; Huang, W; Tian, D; Chen, Z; Zhang, L; Li, Y; Hu, H; Liu, J; Chen, Z; Tang, G; Dou, J; Sha, S; Xu, B; Liu, C; Ma, J; Zhang, S; Li, M; Fan, D; Nie, Y; Wu, K				Xia, L.; Huang, W.; Tian, D.; Chen, Z.; Zhang, L.; Li, Y.; Hu, H.; Liu, J.; Chen, Z.; Tang, G.; Dou, J.; Sha, S.; Xu, B.; Liu, C.; Ma, J.; Zhang, S.; Li, M.; Fan, D.; Nie, Y.; Wu, K.			ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma	ONCOGENE			English	Article						Forkhead box M1; tartrate-resistant acid phosphatase 5; hepatocellular carcinoma; metastasis; transcriptional regulation	RESISTANT ACID-PHOSPHATASE; FORKHEAD BOX M1B; FOCAL-ADHESION KINASE; HUMAN BREAST-CANCER; BONE METASTASES; UP-REGULATION; SERUM MARKER; HEPATITIS-B; EXPRESSION; 5B	Tartrate-resistant acid phosphatase 5 (ACP5), which is essential for bone resorption and osteoclast differentiation, promotes cell motility through the modulation of focal adhesion kinase phosphorylation. However, whether ACP5 contributes to the metastasis and progression of hepatocellular carcinoma (HCC) remains unknown. In this paper, a complementary DNA microarray, serial deletion, site-directed mutagenesis and a chromatin immunoprecipitation assays confirmed that ACP5 is a direct transcriptional target of Forkhead box M1 (FoxM1). ACP5 expression was markedly higher in HCC tissues compared with adjacent noncancerous tissues. ACP5 overexpression was correlated with microvascular invasion, poor differentiation and higher tumor-node-metastasis stage. HCC patients with positive ACP5 expression had poorer prognoses than those with negative ACP5 expression. A multivariate analysis revealed that ACP5 expression was an independent and significant risk factor for disease recurrence and reduced-patient survival following curative resection. Transwell assays and an orthotopic metastatic model showed that the upregulation of ACP5 promoted HCC invasion and lung metastasis, whereas ACP5 knockdown inhibited these processes. The knockdown of ACP5 significantly attenuated FoxM1-enhanced invasion and lung metastasis. Immunohistochemistry revealed that ACP5 expression was positively correlated with FoxM1 expression in human HCC tissues, and their coexpression was associated with poor prognoses. In summary, ACP5 is a direct transcriptional and functional target of FoxM1. This novel FoxM1/ACP5 signaling pathway promotes HCC metastasis and may be a candidate biomarker for prognosis and a target for new therapies.	[Xia, L.; Huang, W.; Chen, Z.; Zhang, L.; Hu, H.; Liu, J.; Chen, Z.; Tang, G.; Dou, J.; Sha, S.; Xu, B.; Liu, C.; Ma, J.; Zhang, S.; Li, M.; Fan, D.; Nie, Y.; Wu, K.] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shaanxi Provinc, Peoples R China; [Tian, D.] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi Provinc, Peoples R China; [Li, Y.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastroenterol, Wuhan 430074, Hubei Province, Peoples R China; [Xia, L.; Huang, W.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Air Force Military Medical University; Air Force Military Medical University; Huazhong University of Science & Technology; University of British Columbia	Nie, Y (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shaanxi Provinc, Peoples R China.	yongznie@fmmu.edu.cn; wu_kaichun@yahoo.cn	Huang, Wenjie/G-1778-2017; meng, li/GVT-2063-2022		National Natural Science Foundation of China [81272652, 81172290, 91129723, 81090270, 81090273, 81120108005]; National Key and Basic Research Development Program of China [2010CB529302, 2010CB529306]; National Municipal Science and Technology Project [2009ZX09103-667, 2009ZX09301-009-RC06]; Chinese Postdoctoral Science Foundation [20100471776, 201104757]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key and Basic Research Development Program of China(National Basic Research Program of China); National Municipal Science and Technology Project; Chinese Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study was supported by combined grants from the National Natural Science Foundation of China (No. 81272652, No. 81172290, No. 91129723, No.81090270, No.81090273 and No.81120108005), the National Key and Basic Research Development Program of China (No. 2010CB529302 and 2010CB529306), the National Municipal Science and Technology Project (2009ZX09103-667 and 2009ZX09301-009-RC06) and the Chinese Postdoctoral Science Foundation (No. 20100471776 and No.201104757).	Adams LM, 2007, CELL BIOL INT, V31, P191, DOI 10.1016/j.cellbi.2006.09.022; Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Calvisi DF, 2009, GUT, V58, P679, DOI 10.1136/gut.2008.152652; Capeller B, 2003, ANTICANCER RES, V23, P1011; Chao TY, 2005, CLIN CANCER RES, V11, P544; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2008, GASTROENTEROLOGY, V134, P1752, DOI 10.1053/j.gastro.2008.02.090; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Halleen JM, 2001, CLIN CHEM, V47, P597; Honig A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-199; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Li Y, 2012, NAT REV GASTRO HEPAT, V9, P32, DOI 10.1038/nrgastro.2011.196; Lyubimova NV, 2004, B EXP BIOL MED+, V138, P77, DOI 10.1007/BF02694481; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Park HJ, 2011, EMBO MOL MED, V3, P21, DOI 10.1002/emmm.201000107; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Scott KL, 2011, CANCER CELL, V20, P92, DOI 10.1016/j.ccr.2011.05.025; Sun HC, 2011, CANCER LETT, V306, P214, DOI 10.1016/j.canlet.2011.03.009; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Wu YY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-158; Xia LM, 2012, CARCINOGENESIS, V33, P2250, DOI 10.1093/carcin/bgs249; Xia LM, 2012, J HEPATOL, V57, P600, DOI 10.1016/j.jhep.2012.04.020; Xia LM, 2012, J IMMUNOL, V188, P753, DOI 10.4049/jimmunol.1101652; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Zenger S, 2011, CLIN EXP METASTAS, V28, P65, DOI 10.1007/s10585-010-9358-4	33	30	31	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1395	1406		10.1038/onc.2013.90	http://dx.doi.org/10.1038/onc.2013.90			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23604121				2022-12-17	WOS:000332943500007
J	Kambach, DM; Sodi, VL; Lelkes, PI; Azizkhan-Clifford, J; Reginato, MJ				Kambach, D. M.; Sodi, V. L.; Lelkes, P. I.; Azizkhan-Clifford, J.; Reginato, M. J.			ErbB2, FoxM1 and 14-3-3 zeta prime breast cancer cells for invasion in response to ionizing radiation	ONCOGENE			English	Article						ErbB2; FoxM1; 14-3-3 zeta; invasion; reactive oxygen species	MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; CARCINOMA IN-SITU; SIGNALING NETWORK; OXIDATIVE STRESS; FREE-RADICALS; PROGRESSION; SRC; TRANSCRIPTION; RESISTANCE	ErbB2 is frequently highly expressed in premalignant breast cancers, including ductal carcinoma in situ (DCIS); however, little is known about the signals or pathways it contributes to progression into the invasive/malignant state. Radiotherapy is often used to treat early premalignant lesions regardless of ErbB2 status. Here, we show that clinically relevant doses of ionizing radiation (IR)-induce cellular invasion of ErbB2-expressing breast cancer cells, as well as MCF10A cells overexpressing ErbB2. ErbB2-negative breast cancer cells, such as MCF7 and T47D, do not invade following treatment with IR nor do MCF10A cells overexpressing epidermal growth factor receptor. ErbB2 becomes phosphorylated at tyrosine 877 in a dose- and time- dependent manner following exposure to X-rays, and activates downstream signaling cascades including PI3K/Akt. Inhibition of these pathways, as well as inhibition of reactive oxygen species (ROS) with antioxidants, prevents IR-induced invasion. Activation of ErbB2-dependent signaling results in upregulation of the forkhead family transcription factor, FoxM1, and its transcriptional targets, including matrix metalloproteinase 2 (MMP2). Inhibition of FoxM1 by RNA interference prevented induction of invasion by IR, and overexpression of FoxM1 in MCF10A cells was sufficient to promote IR-induced invasion. Moreover, we found that 14-3-3 zeta is also upregulated by IR in cancer cells in a ROS-dependent manner, is required for IR-induced invasion in ErbB2-positive breast cancer cells and together with FoxM1 is sufficient for invasion in ErbB2-negative breast cancer cells. Thus, our data show that IR-mediated activation of ErbB2 and induction of 14-3-3 zeta collaborate to regulate FoxM1 and promote invasion of breast cancer cells and furthermore, may serve as therapeutic targets to enhance radiosensitivity of breast cancers.	[Kambach, D. M.; Sodi, V. L.; Azizkhan-Clifford, J.; Reginato, M. J.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; [Lelkes, P. I.] Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19102 USA	Drexel University; Drexel University	Azizkhan-Clifford, J (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th St,NCB Rm 11117, Philadelphia, PA 19102 USA.	jane.clifford@drexelmed.edu; Mauricio.Reginato@drexelmed.edu	Lelkes, Peter I/S-1751-2019; Lelkes, Peter/HGA-2907-2022		Drexel University College of Medicine CURE grants; NATIONAL CANCER INSTITUTE [P30CA056036, R01CA155413] Funding Source: NIH RePORTER	Drexel University College of Medicine CURE grants; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Gieira Jones and Prachi Thanawala for technical support and Dr Gianluca Gallo for the PI3K activating peptide. We would also like to thank Drs Jay Reiff and Jacqueline Emrich and the Radiation Oncology Department at Hahnemann University Hospital for their assistance. This work was supported by Drexel University College of Medicine CURE grants (to MJR).	Ahmad A, 2010, BREAST CANCER RES TR, V122, P337, DOI 10.1007/s10549-009-0572-1; Andarawewa KL, 2007, CANCER RES, V67, P8662, DOI 10.1158/0008-5472.CAN-07-1294; Badache A, 2006, J MAMMARY GLAND BIOL, V11, P13, DOI 10.1007/s10911-006-9009-1; Bektas N, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-42; Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Bergamaschi A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2913; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Chabottaux V, 2007, CLIN EXP METASTAS, V24, P647, DOI 10.1007/s10585-007-9113-7; Contessa JN, 2006, BREAST CANCER RES TR, V95, P17, DOI 10.1007/s10549-005-9023-9; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; Danes CG, 2008, CANCER RES, V68, P1760, DOI 10.1158/0008-5472.CAN-07-3177; DiGiovanna MP, 2002, CANCER RES, V62, P6667; Feinendegen LE, 2002, HUM EXP TOXICOL, V21, P85, DOI 10.1191/0960327102ht216oa; Francis RE, 2009, INT J ONCOL, V35, P57, DOI 10.3892/ijo_00000313; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Gemenetzidis E, 2010, CANCER RES, V70, P9515, DOI 10.1158/0008-5472.CAN-10-2173; Giannoni E, 2010, FREE RADICAL BIO MED, V49, P516, DOI 10.1016/j.freeradbiomed.2010.04.025; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Lagadec C, 2012, STEM CELLS, V30, P833, DOI 10.1002/stem.1058; LAWRENCE TS, 2008, CANC PRINCIPLES PRAC, P307; Leach JK, 2001, CANCER RES, V61, P3894; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Littler DR, 2010, NUCLEIC ACIDS RES, V38, P4527, DOI 10.1093/nar/gkq194; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Mendes O, 2007, CLIN EXP METASTAS, V24, P341, DOI 10.1007/s10585-007-9071-0; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Neal CL, 2010, EXPERT OPIN THER TAR, V14, P1343, DOI 10.1517/14728222.2010.531011; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; O'Toole TE, 2011, J CELL PHYSIOL, V226, P2965, DOI 10.1002/jcp.22644; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Park HJ, 2009, EMBO J, V28, P2908, DOI 10.1038/emboj.2009.239; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; SATO K, 1994, BIOCHEM BIOPH RES CO, V205, P1716, DOI 10.1006/bbrc.1994.2866; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tofilon PJ, 2009, CHEM REV, V109, P2974, DOI 10.1021/cr800504x; Tzivion G, 2006, SEMIN CANCER BIOL, V16, P203, DOI 10.1016/j.semcancer.2006.03.004; Vera-Ramirez L, 2011, CRIT REV ONCOL HEMAT, V80, P347, DOI 10.1016/j.critrevonc.2011.01.004; Xiang B, 2006, METHOD ENZYMOL, V406, P692, DOI 10.1016/S0076-6879(06)06054-X; Yang X, 2012, CANCER GENE THER, V19, P153, DOI 10.1038/cgt.2011.85; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309	56	30	30	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					589	598		10.1038/onc.2012.629	http://dx.doi.org/10.1038/onc.2012.629			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318431	Green Accepted			2022-12-17	WOS:000331125100007
J	Bisikirska, BC; Adam, SJ; Alvarez, MJ; Rajbhandari, P; Cox, R; Lefebvre, C; Wang, K; Rieckhof, GE; Felsher, DW; Califano, A				Bisikirska, B. C.; Adam, S. J.; Alvarez, M. J.; Rajbhandari, P.; Cox, R.; Lefebvre, C.; Wang, K.; Rieckhof, G. E.; Felsher, D. W.; Califano, A.			STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma	ONCOGENE			English	Article						STK38; MYC post-translational modifications; protein turnover; transcriptional activity; protein-protein interaction	NDR PROTEIN-KINASE; C-MYC; TRANSCRIPTION FACTOR; TUMOR-REGRESSION; ACTIVATION; COMPLEX; BINDING; DNA; PHOSPHORYLATION; IDENTIFICATION	The MYC protooncogene is associated with the pathogenesis of most human neoplasia. Conversely, its experimental inactivation elicits oncogene addiction. Besides constituting a formidable therapeutic target, MYC also has an essential function in normal physiology, thus creating the need for context-specific targeting strategies. The analysis of post-translational MYC activity modulation yields novel targets for MYC inactivation. Specifically, following regulatory network analysis in human B-cells, we identify a novel role of the STK38 kinase as a regulator of MYC activity and a candidate target for abrogating tumorigenesis in MYC-addicted lymphoma. We found that STK38 regulates MYC protein stability and turnover in a kinase activity-dependent manner. STK38 kinase inactivation abrogates apoptosis following B-cell receptor activation, whereas its silencing significantly decreases MYC levels and increases apoptosis. Moreover, STK38 knockdown suppresses growth of MYC-addicted tumors in vivo, thus providing a novel viable target for treating these malignancies.	[Bisikirska, B. C.; Alvarez, M. J.; Rajbhandari, P.; Cox, R.; Lefebvre, C.; Rieckhof, G. E.; Califano, A.] Columbia Univ, Joint Ctr Syst Biol, New York, NY USA; [Adam, S. J.; Felsher, D. W.] Stanford Univ, Div Oncol, Dept Med, Stanford, CA 94305 USA; [Adam, S. J.; Felsher, D. W.] Stanford Univ, Div Oncol, Dept Pathol, Stanford, CA 94305 USA; [Cox, R.] Riverdale Country Sch, Bronx, NY USA; [Wang, K.; Califano, A.] Columbia Univ, Dept Biomed Informat, New York, NY USA; [Wang, K.] Pfizer Inc, San Diego, CA USA; [Califano, A.] Columbia Univ, Dept Pathol & Genet & Dev, New York, NY USA	Columbia University; Stanford University; Stanford University; Columbia University; Pfizer; Columbia University	Felsher, DW (corresponding author), Stanford Univ, Div Oncol, Dept Med, 1120 CCSR 269 Campus Dr, Stanford, CA 94305 USA.	dfelsher@stanford.edu; califano@c2b2.columbia.edu	Lefebvre, Celine/E-6290-2013	Wang, Kai/0000-0003-0567-3004; Califano, Andrea/0000-0003-4742-3679	NCI [R01CA109755]; NIAID [R01AI066116]; NCBC NIH Roadmap Initiative [U54CA121852]; Burroughs Welcome Fund Career Award; Damon Runyon Foundation; NIH [R01CA089305, R01CA105102]; National Cancer Institute's in-vivo Cellular and Molecular Imaging Center [P50CA114747]; Integrative Cancer Biology Program [1P20CA112973]; NIH/NCI [P01CA034233]; Leukemia and Lymphoma Society [R6223-07]; American Cancer Society [PF-10-237-01-TBG]; NATIONAL CANCER INSTITUTE [R01CA109755, R01CA105102, P50CA114747, R01CA170378, R01CA089305, P01CA034233, U54CA121852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008798] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCBC NIH Roadmap Initiative; Burroughs Welcome Fund Career Award(Burroughs Wellcome Fund); Damon Runyon Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute's in-vivo Cellular and Molecular Imaging Center; Integrative Cancer Biology Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Riccardo Dalla-Favera for critical review of this manuscript and Masumichi Saito for supplying MYC deletion mutant expression vectors (both from Columbia University). This work was supported by the NCI (R01CA109755), the NIAID (R01AI066116) and the NCBC NIH Roadmap Initiative (U54CA121852) (AC), Burroughs Welcome Fund Career Award, the Damon Runyon Foundation Lilly Clinical Investigator Award, NIH (R01CA089305, R01CA105102), National Cancer Institute's in-vivo Cellular and Molecular Imaging Center (P50CA114747), Integrative Cancer Biology Program (1P20CA112973), NIH/NCI (P01CA034233), the Leukemia and Lymphoma Society Translational Research grant number R6223-07 (DWF), and the American Cancer Society Fellowship PF-10-237-01-TBG (SJA).	Adeyinka A, 2002, CLIN CANCER RES, V8, P3788; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Babu MM, 2011, CURR OPIN STRUC BIOL, V21, P432, DOI 10.1016/j.sbi.2011.03.011; Bansal M, 2012, METHODS MOL BIOL, V786, P131, DOI 10.1007/978-1-61779-292-2_8; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Bhattacharya S, 2003, BIOCHEMISTRY-US, V42, P14416, DOI 10.1021/bi035089a; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BONNEFOYBERARD N, 1994, BLOOD, V83, P1051; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Cornils H, 2011, CELL CYCLE, V10, P1897, DOI 10.4161/cc.10.12.15826; Cornils H, 2011, MOL CELL BIOL, V31, P1382, DOI 10.1128/MCB.01216-10; Cui DX, 2005, WORLD J GASTROENTERO, V11, P1273, DOI 10.3748/wjg.v11.i9.1273; Devroe E, 2004, J BIOL CHEM, V279, P24444, DOI 10.1074/jbc.M401999200; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Engelberg D, 2004, SEMIN CANCER BIOL, V14, P271, DOI 10.1016/j.semcancer.2004.04.006; Enomoto A, 2008, ONCOGENE, V27, P1930, DOI 10.1038/sj.onc.1210828; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 2004, SEMIN CANCER BIOL, V14, P1, DOI 10.1016/j.semcancer.2003.11.001; Felsher DW, 2004, CURR OPIN GENET DEV, V14, P37, DOI 10.1016/j.gde.2003.12.008; Follis AV, 2008, CHEM BIOL, V15, P1149, DOI 10.1016/j.chembiol.2008.09.011; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Hergovich A, 2007, MOL CELL, V25, P625, DOI 10.1016/j.molcel.2007.01.020; Hergovich A, 2006, BIOCHEM BIOPH RES CO, V345, P50, DOI 10.1016/j.bbrc.2006.03.244; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kaptein JS, 1996, J BIOL CHEM, V271, P18875, DOI 10.1074/jbc.271.31.18875; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tamaskovic R, 2003, J BIOL CHEM, V278, P6710, DOI 10.1074/jbc.M210590200; Tran PT, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002018; Tsvetkov P, 2009, NAT CHEM BIOL, V5, P778, DOI 10.1038/nchembio.233; Tsvetkov P, 2009, J BIOL CHEM, V284, P26234, DOI 10.1074/jbc.M109.040493; Vichalkovski A, 2008, CURR BIOL, V18, P1889, DOI 10.1016/j.cub.2008.10.060; Wang K, 2009, NAT BIOTECHNOL, V27, P829, DOI 10.1038/nbt.1563; Wang K, 2009, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2009, P264; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	52	30	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5283	5291		10.1038/onc.2012.543	http://dx.doi.org/10.1038/onc.2012.543			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23178486	Green Accepted, hybrid			2022-12-17	WOS:000326922100004
J	Ballarino, M; Jobert, L; Dembele, D; de la Grange, P; Auboeuf, D; Tora, L				Ballarino, M.; Jobert, L.; Dembele, D.; de la Grange, P.; Auboeuf, D.; Tora, L.			TAF15 is important for cellular proliferation and regulates the expression of a subset of cell cycle genes through miRNAs	ONCOGENE			English	Article						FUS/EWS/TAF15 (FET) proteins; miRNAs; transcription; proliferation; neuronal differentiation; neuroblastoma	BINDING PROTEIN; EWS; MICRORNAS; NEUROBLASTOMA; RESOURCE; TARGETS; GROWTH; FUS	TAF15 (formerly TAFII68) is a member of the FET (FUS, EWS, TAF15) family of RNA-and DNA-binding proteins whose genes are frequently translocated in sarcomas. By performing global gene expression profiling, we found that TAF15 knockdown affects the expression of a large subset of genes, of which a significant percentage is involved in cell cycle and cell death. In agreement, TAF15 depletion had a growth-inhibitory effect and resulted in increased apoptosis. Among the TAF15-regulated genes, targets of microRNAs (miRNAs) generated from the onco-miR-17 locus were overrepresented, with CDKN1A/p21 being the top miRNAs-targeted gene. Interestingly, the levels of onco-miR-17 locus coded miRNAs (miR-17-5p and miR-20a) were decreased upon TAF15 depletion and shown to affect the post-transcriptional regulation of TAF15-dependent genes, such as CDKN1A/p21. Thus, our results demonstrate that TAF15 is required to regulate gene expression of cell cycle regulatory genes post-transcriptionally through a pathway involving miRNAs. The findings that high TAF15 levels are needed for rapid cellular proliferation and that endogenous TAF15 levels decrease during differentiation strongly suggest that TAF15 is a key regulator of maintaining a highly proliferative rate of cellular homeostasis.	[Ballarino, M.; Jobert, L.; Dembele, D.; Tora, L.] Univ Strasbourg, Dept Funct Genom & Canc, Inst Genet & Biol Mol & Cellulaire, INSERM,U964,CNRS,UMR 7104, F-67404 Illkirch Graffenstaden, Cu De Strasbour, France; [de la Grange, P.] Hop St Louis, GenoSplice Technol, Paris, France; [Auboeuf, D.] Ctr Leon Berard, INSERM, U1052, Canc Res Ctr Lyon, F-69373 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Tora, L (corresponding author), Univ Strasbourg, Dept Funct Genom & Canc, Inst Genet & Biol Mol & Cellulaire, INSERM,U964,CNRS,UMR 7104, BP 10142, F-67404 Illkirch Graffenstaden, Cu De Strasbour, France.	laszlo@igbmc.fr	Auboeuf, Didier/M-4610-2014; Dembélé, Doulaye/O-6513-2017; Tora, Laszlo/E-9999-2018; ballarino, monica/AAA-5065-2020	Dembélé, Doulaye/0000-0003-3879-6940; Tora, Laszlo/0000-0001-7398-2250; Auboeuf, Didier/0000-0002-3757-0002; Ballarino, Monica/0000-0002-8595-7105	CNRS; INSERM; AICR [09-0258]; Fondation Recherche Medicale; MRET; Association pour la Recherche sur le Cancer	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); AICR; Fondation Recherche Medicale; MRET; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We are very grateful to JF Caceres, VN Kim and ME Fiori for providing the Pri-17-92, Flag-DGCR8 and pGL3-p21-30UTR plasmids, respectively. We also thank N Charlet Berguerand and M Morlando for the advice in miRNA processing assay, D Devys, M Fournier, A Helmrich, P Bheda and P Laneve for critically reading the manuscript, R Contzler for the XCELLigence analysis and the IGBMC cell culture facility. This work was supported by funds from CNRS, INSERM and AICR (09-0258) grants. MB was supported by the Fondation Recherche Medicale and LJ by MRET and Association pour la Recherche sur le Cancer.	Andersson MK, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-37; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1999, ONCOGENE, V18, P8000, DOI 10.1038/sj.onc.1203207; Beveridge NJ, 2009, CELL SIGNAL, V21, P1837, DOI 10.1016/j.cellsig.2009.07.019; Blechingberg J, 2012, GENE, V493, P27, DOI 10.1016/j.gene.2011.11.038; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Chaulk SG, 2011, RNA BIOL, V8, P1105, DOI 10.4161/rna.8.6.17410; de la Grange P, 2005, NUCLEIC ACIDS RES, V33, P4276, DOI 10.1093/nar/gki738; De Vito C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023592; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; Hoell JI, 2011, NAT STRUCT MOL BIOL, V18, P1428, DOI 10.1038/nsmb.2163; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jobert L, 2009, EMBO REP, V10, P494, DOI 10.1038/embor.2009.24; Jobert L, 2009, EXP CELL RES, V315, P1273, DOI 10.1016/j.yexcr.2008.12.008; Law Warren J., 2006, Briefings in Functional Genomics & Proteomics, V5, P8, DOI 10.1093/bfgp/ell015; Le Brigand K, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl485; Lee Y, 2007, METHOD ENZYMOL, V427, P89, DOI 10.1016/S0076-6879(07)27005-3; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Pall GS, 2008, NAT PROTOC, V3, P1077, DOI 10.1038/nprot.2008.67; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768; ROSSI A, 1992, INT J DEV NEUROSCI, V10, P527, DOI 10.1016/0736-5748(92)90053-3; Sankar S, 2011, CANCER GENET-NY, V204, P351, DOI 10.1016/j.cancergen.2011.07.008; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spitzer JI, 2011, GENE CHROMOSOME CANC, V50, P338, DOI 10.1002/gcc.20858; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402	33	30	30	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4646	4655		10.1038/onc.2012.490	http://dx.doi.org/10.1038/onc.2012.490			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23128393				2022-12-17	WOS:000325072200006
J	Peng, H; Liu, J; Sun, Q; Chen, R; Wang, Y; Duan, J; Li, C; Li, B; Jing, Y; Chen, X; Mao, Q; Xu, KF; Walker, CL; Li, J; Wang, J; Zhang, H				Peng, H.; Liu, J.; Sun, Q.; Chen, R.; Wang, Y.; Duan, J.; Li, C.; Li, B.; Jing, Y.; Chen, X.; Mao, Q.; Xu, K-F; Walker, C. L.; Li, J.; Wang, J.; Zhang, H.			mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development	ONCOGENE			English	Article						TSC; mTORC1; STIM1; calcium; tumorigenesis	MAMMALIAN TARGET; TRANSCRIPTIONAL CONTROL; CELL PROLIFERATION; MOUSE MODELS; IFN-GAMMA; CANCER; RAPAMYCIN; CALCIUM; GROWTH; ACTIVATION	The protein complex of tuberous sclerosis complex (TSC) 1 and TSC2 tumor suppressors is a key negative regulator of mammalian target of rapamycin (mTOR). Hyperactive mTOR signaling due to the loss-of-function of mutations in either TSC1 or TSC2 gene causes TSC, an autosomal dominant disorder featured with benign tumors in multiple organs. As the ubiquitous second messenger calcium (Ca2+) regulates various cellular processes involved in tumorigenesis, we explored the potential role of mTOR in modulation of cellular Ca2+ homeostasis, and in turn the effect of Ca2+ signaling in TSC-related tumor development. We found that loss of Tsc2 potentiated store-operated Ca2+ entry (SOCE) in an mTOR complex 1 (mTORC1)-dependent way. The endoplasmic reticulum Ca2+ sensor, stromal interaction molecule 1 (STIM1), was upregulated in Tsc2-deficient cells, and was suppressed by mTORC1 inhibitor rapamycin. In addition, SOCE repressed AKT1 phosphorylation. Blocking SOCE either by depleting STIM1 or ectopically expressing dominant-negative Orai1 accelerated TSC-related tumor development, likely because of restored AKT1 activity and enhanced tumor angiogenesis. Our data, therefore, suggest that mTORC1 enhancement of store-operated Ca2+ signaling hinders TSC-related tumor growth through suppression of AKT1 signaling. The augmented SOCE by hyperactive mTORC1-STIM1 cascade may contribute to the benign nature of TSC-related tumors. Application of SOCE agonists could thus be a contraindication for TSC patients. In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.	[Peng, H.; Chen, R.; Wang, Y.; Duan, J.; Li, C.; Li, B.; Jing, Y.; Chen, X.; Zhang, H.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, Dept Physiol & Pathophysiol, Beijing 100005, Peoples R China; [Peng, H.; Chen, R.; Wang, Y.; Duan, J.; Li, C.; Li, B.; Jing, Y.; Chen, X.; Zhang, H.] Chinese Acad Med Sci, Sch Basic Med, Beijing 100005, Peoples R China; [Peng, H.; Chen, R.; Wang, Y.; Duan, J.; Li, C.; Li, B.; Jing, Y.; Chen, X.; Zhang, H.] Peking Union Med Coll, Beijing 100005, Peoples R China; [Liu, J.; Wang, J.] Capital Med Univ, Dept Physiol, Beijing 100069, Peoples R China; [Sun, Q.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China; [Mao, Q.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Urol, Beijing 100005, Peoples R China; [Xu, K-F] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp Med, Beijing 100005, Peoples R China; [Walker, C. L.] Texas A&M Hlth Sci Ctr, Ctr Translat Canc Res, Inst Biosci & Technol, Houston, TX USA; [Li, J.] Huazhong Univ Sci & Technol, Inst Cardiovasc Dis, Union Hosp, Tongji Med Coll,Dept Cardiol, Wuhan 430074, Peoples R China; [Zhang, H.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Capital Medical University; Tianjin Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Wang, J (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Physiol, 10 Xitoutiao, Beijing 100069, Peoples R China.	wang_jun@ccmu.edu.cn; hbzhang@ibms.pumc.edu.cn	Peng, Haiyong/S-8045-2016; Xu, Kai-Feng/AAO-2445-2020		National Basic Research Program of China 973 Program [2009CB522107, 2009CB522203]; National Natural Science Foundation of China [30971503, 81130085]; Ministry of Education of China 111 Project [B08007]; NATIONAL CANCER INSTITUTE [R01CA143811] Funding Source: NIH RePORTER	National Basic Research Program of China 973 Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China 111 Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The mouse kidney tumor tissues were kindly provided by David J Kwiatkowski, Brigham and Women's Hospital. This work was supported by the National Basic Research Program of China 973 Program Grant (2009CB522107 and 2009CB522203), the National Natural Science Foundation of China Grants (30971503 and 81130085), and the Ministry of Education of China 111 Project (B08007).	Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Chen YF, 2011, P NATL ACAD SCI USA, V108, P15225, DOI 10.1073/pnas.1103315108; Choo AY, 2009, CELL CYCLE, V8, P567, DOI 10.4161/cc.8.4.7659; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Davies DM, 2011, CLIN CANCER RES, V17, P4071, DOI 10.1158/1078-0432.CCR-11-0445; Derler I, 2012, ADV EXP MED BIOL, V740, P383, DOI 10.1007/978-94-007-2888-2_16; El Boustany C, 2008, HEPATOLOGY, V47, P2068, DOI 10.1002/hep.22263; El-Hashemite N, 2004, CANCER RES, V64, P3436, DOI 10.1158/0008-5472.CAN-03-3609; El-Hashemite N, 2003, CANCER RES, V63, P5173; Engh A, 2012, FRONT BIOSCI-LANDMRK, V17, P1613, DOI 10.2741/4007; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Feske S, 2010, CLIN IMMUNOL, V135, P169, DOI 10.1016/j.clim.2010.01.011; Feske S, 2010, PFLUG ARCH EUR J PHY, V460, P417, DOI 10.1007/s00424-009-0777-5; Flourakis M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.52; Gilio K, 2010, J BIOL CHEM, V285, P23629, DOI 10.1074/jbc.M110.108696; Gough NR, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003044; Grosse J, 2007, J CLIN INVEST, V117, P3540, DOI 10.1172/JCI32312; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HOWE SR, 1995, AM J PATHOL, V146, P1568; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Ogawa A, 2012, AM J PHYSIOL-CELL PH, V302, pC405, DOI 10.1152/ajpcell.00337.2011; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Pollizzi K, 2009, HUM MOL GENET, V18, P2378, DOI 10.1093/hmg/ddp176; Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006; Sabbioni S, 1997, CANCER RES, V57, P4493; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Suyama E, 2004, J BIOL CHEM, V279, P38083, DOI 10.1074/jbc.C400313200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984	50	30	30	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4702	4711		10.1038/onc.2012.481	http://dx.doi.org/10.1038/onc.2012.481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108404	Green Accepted			2022-12-17	WOS:000325072200012
J	Yang, Q; Liao, L; Deng, X; Chen, R; Gray, NS; Yates, JR; Lee, JD				Yang, Q.; Liao, L.; Deng, X.; Chen, R.; Gray, N. S.; Yates, J. R., III; Lee, J. D.			BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction	ONCOGENE			English	Article						BMK1; PML; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; MAMMALIAN MAP KINASE; PREMATURE SENESCENCE; SIGNAL-TRANSDUCTION; CUTANEOUS MELANOMA; CELL-PROLIFERATION; GENE-EXPRESSION; E6 ONCOPROTEIN; ONCOGENIC RAS; GROWTH-FACTOR	Promyelocytic leukemia protein (PML) modulates the p53 tumor suppressor through its interaction with p53 and MDM2. We found that activated big MAP kinase 1 (BMK1) preferentially associates with PML isoform IV and disrupts PML-MDM2 interaction. Doxorubicin, a common chemotherapeutic agent, is known to promote PML-mediated p53 activation in part by promoting PML-dependent MDM2 nucleolar sequestration. We discovered that BMK1 deactivation coupled with doxorubicin synergistically enhanced MDM2 nucleolar sequestration and, consequently, promoted PML-mediated p53 upregulation leading to tumor cell apoptosis in vitro and tumor regression in vivo. Collectively, these results not only suggest that BMK1 activity has a role in suppressing p53 by blocking the interaction between PML and MDM2, but also implicate that pharmacological BMK1 inhibitor should significantly enhance the anticancer capacity of doxorubicin-based chemotherapy.	[Yang, Q.; Chen, R.; Lee, J. D.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Liao, L.; Yates, J. R., III] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Deng, X.; Gray, N. S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Scripps Research Institute; Scripps Research Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.	jdlee@scripps.edu	Yang, Qingkai/AAK-5111-2021	Yang, Qingkai/0000-0001-6628-5393; Deng, Xianming/0000-0002-9354-5864	National Institutes of Health [CA079871, CA114059]; University of California [19XT-0084]; NATIONAL CANCER INSTITUTE [R01CA114059, R01CA079871] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California(University of California System); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Giovanni Blandino, Dr Myung Kim and Dr Pier Paolo Pandolfi for generously providing the PML null and control cell lines. This work was supported by the National Institutes of Health [CA079871 and CA114059 to JDL] and by the funds from the Tobacco-Related Disease, Research Program of the University of California [19XT-0084 to JDL].	Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Beech SJ, 2005, EXP CELL RES, V307, P109, DOI 10.1016/j.yexcr.2005.03.012; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bisht S, 2009, WIRES NANOMED NANOBI, V1, P415, DOI 10.1002/wnan.43; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Ferbeyre G, 2000, GENE DEV, V14, P2015; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Hayashi M, 2005, CANCER RES, V65, P7699, DOI 10.1158/0008-5472.CAN-04-4540; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kondoh K, 2006, MOL CELL BIOL, V26, P1679, DOI 10.1128/MCB.26.5.1679-1690.2006; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Polsky D, 2001, CANCER RES, V61, P7642; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200	37	30	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3156	3164		10.1038/onc.2012.332	http://dx.doi.org/10.1038/onc.2012.332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22869143	Green Accepted			2022-12-17	WOS:000321004600006
J	Brennan, K; McSherry, EA; Hudson, L; Kay, EW; Hill, ADK; Young, LS; Hopkins, AM				Brennan, K.; McSherry, E. A.; Hudson, L.; Kay, E. W.; Hill, A. D. K.; Young, L. S.; Hopkins, A. M.			Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling	ONCOGENE			English	Article						junctional adhesion molecule-A; breast cancer; tight junction; human epidermal growth factor receptor-2; AKT; estrogen receptor	ADJUVANT CHEMOTHERAPY; POOR-PROGNOSIS; CANCER; EXPRESSION; SURVIVAL; TRASTUZUMAB; RECEPTOR; GROWTH; MIGRATION; MOTILITY	Junctional adhesion molecule-A (JAM-A) is a membranous cell-cell adhesion protein involved in tight-junction formation in epithelial and endothelial cells. Its overexpression in breast tumors has recently been linked with increased risk of metastasis. We sought to identify if JAM-A overexpression was associated with specific subtypes of breast cancer as defined by the expression of human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor. To this end, JAM-A immunohistochemistry was performed in two breast cancer tissue microarrays. In parallel, cross-talk between JAM-A, HER2 and ER was examined in several breast cell lines, using complementary genetic and pharmacological approaches. High JAM-A expression correlated significantly with HER2 protein expression, ER negativity, lower patient age, high-grade breast cancers, and aggressive luminal B, HER2 and basal subtypes of breast cancer. JAM-A and HER2 were co-expressed at high levels in vitro in SKBR3, UACC-812, UACC-893 and MCF7-HER2 cells. Knockdown or functional antagonism of HER2 did not alter JAM-A expression in any cell line tested. Interestingly, however, JAM-A knockdown decreased HER2 and ER-alpha expression, resulting in reduced levels of phospho-(active) AKT without an effect on the extracellular signal-related kinase phosphorylation. The downstream effects of JAM-A knockdown on HER2 and phospho-AKT were partially reversed upon treatment with the proteasomal inhibitor MG132. We conclude that JAM-A is co-expressed with HER2 and associates with aggressive breast cancer phenotypes. Furthermore, we speculate that JAM-A may regulate HER2 proteasomal degradation and activity, potentially offering a promise as a therapeutic target in HER2-positive breast cancers.	[Brennan, K.; McSherry, E. A.; Hudson, L.; Hill, A. D. K.; Young, L. S.; Hopkins, A. M.] Royal Coll Surgeons Ireland, RCSI Educ & Res Ctr, Dept Surg, Dublin 2, Ireland; [Kay, E. W.] Royal Coll Surgeons Ireland, Dept Pathol, RCSI Educ & Res Ctr, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland	Hopkins, AM (corresponding author), Beaumont Hosp, Royal Coll Surg Ireland, RCSI Educ & Res Ctr, Dept Surg, Dublin 9, Ireland.	annhopkins@rcsi.ie	Hopkins, Ann/C-3400-2012; brennan, kieran/HCI-2509-2022	brennan, kieran/0000-0003-3520-6394; Hopkins, Ann/0000-0003-2836-6584; Young, Leonie/0000-0002-4904-0367	Science Foundation Ireland [2008/RFP/NSC1427]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We are grateful for funding from Science Foundation Ireland (2008/RFP/NSC1427 to AMH), to Dr Tony O'Grady and Trudi Roche for their assistance with obtaining tissue microarray clinical data, and to Dr Marie McIlroy for statistical advice. Herceptin was a kind gift from the St James' Hospital Pharmacy, Dublin, Ireland; LCC1 cells were a kind gift from Professor Robert Clarke, Georgetown University, USA; and MCF7-HER2 cells were a kind gift from Professor Dennis Slamon, University College Los Angeles, USA and Dr Norma O'Donovan, Dublin City University, Ireland.	Babinska A, 2002, THROMB HAEMOSTASIS, V87, P712, DOI 10.1055/s-0037-1613070; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bazzoni G, 2005, J CELL SCI, V118, P623, DOI 10.1242/jcs.01661; Braniste V, 2009, J PHYSIOL-LONDON, V587, P3317, DOI 10.1113/jphysiol.2009.169300; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chakraborty AK, 2008, CANCER RES, V68, P1538, DOI 10.1158/0008-5472.CAN-07-5935; Clark AS, 2002, MOL CANCER THER, V1, P707; Cooke VG, 2006, ARTERIOSCL THROM VAS, V26, P2005, DOI 10.1161/01.ATV.0000234923.79173.99; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Ferlay J, 2010, IARC CANCERBASE; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hewitt KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-186; Hoevel T, 2004, INT J CANCER, V108, P374, DOI 10.1002/ijc.11571; Jang JY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-391; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159; Liang TW, 2000, AM J PHYSIOL-CELL PH, V279, pC1733, DOI 10.1152/ajpcell.2000.279.6.C1733; Mandell KJ, 2005, J BIOL CHEM, V280, P11665, DOI 10.1074/jbc.M412650200; Martin TA, 2005, CLIN EXP MED, V5, P122, DOI 10.1007/s10238-005-0076-1; McSherry EA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2853; McSherry EA, 2009, INT J CANCER, V125, P1343, DOI 10.1002/ijc.24498; Murakami M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021242; Naik MU, 2008, CANCER RES, V68, P2194, DOI 10.1158/0008-5472.CAN-07-3057; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x; Osanai M, 2007, CANCER SCI, V98, P1027, DOI 10.1111/j.1349-7006.2007.00494.x; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Severson EA, 2009, MOL BIOL CELL, V20, P1916, DOI 10.1091/mbc.E08-10-1014; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	40	30	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2799	2804		10.1038/onc.2012.276	http://dx.doi.org/10.1038/onc.2012.276			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22751120	Green Submitted			2022-12-17	WOS:000319808000011
J	Jia, Y; Song, W; Zhang, F; Yan, J; Yang, Q				Jia, Y.; Song, W.; Zhang, F.; Yan, J.; Yang, Q.			Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway	ONCOGENE			English	Article						Brca1; PKB/Akt; Chk1; Rad51; HR	CYCLE CHECKPOINT; BRCA1; CANCER; BREAST; ACTIVATION; RAD51; CHK1	Brca1 deficiency leads to the development of breast cancer. We previously found that Brca1 deficiency activates the Akt oncogenic pathway. Reduced expression of Brca1 was highly correlated with increased activated Akt in human breast cancer samples. Furthermore, activation of Akt1 was involved in Brca1-deficiency-mediated tumorigenesis in mice. Defective homologous recombination (HR) is thought to be a major contributor to tumorigenesis in Brca1 deficiency. Here, we show that Akt1 promotes chromosome instability in Brca1-deficent cells. DNA breaks in Brca1-deficent cells are aberrantly joined into complex chromosome rearrangements by a process dependent on Akt1. Depletion of Akt1 increases HR in Brca1-mutant cells, which is rescued by expression of wild-type, but not mutant Akt1 with deletion of Brca1-binding domain. Mechanistically, activated Akt1 in Brca1-deficient cells impairs Chk1 nuclear localization and subsequently disrupts interaction of Chk1 and Rad51 leading to HR defects. Our results indicate that Brca1 deficiency might activate Akt1 contributing to tumorigenesis through regulation of the Chk1-Rad51 signaling. Oncogene (2013) 32, 1943-1949; doi:10.1038/onc.2012.211; published online 4 June 2012	[Jia, Y.; Song, W.; Zhang, F.; Yan, J.; Yang, Q.] Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO 63108 USA; [Jia, Y.] Harbin Med Univ, Affiliated Hosp 3, Colorectal Canc Surg Dept, Harbin, Peoples R China; [Yan, J.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA	Washington University (WUSTL); Harbin Medical University; University of Washington; University of Washington Seattle	Yang, Q (corresponding author), Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, 4511 Forest Pk, St Louis, MO 63108 USA.	qyang@wustl.edu			Susan G. Komen Foundation; Siteman Cancer Center Award; NIH [CA129440]; NATIONAL CANCER INSTITUTE [R01CA129440] Funding Source: NIH RePORTER	Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Siteman Cancer Center Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Chuxia Deng for providing the Brca1<SUP>WT</SUP> and Brca1<SUP>Delta 11/Delta 11</SUP> MEFs. We thank Buck Rogers and Xiaowei Wang for proof reading. This work is supported in part by grants from the Susan G. Komen Foundation (QY), Siteman Cancer Center Award (QY) and NIH CA129440 (QY).	Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2002, ENVIRON MOL MUTAGEN, V39, P171, DOI 10.1002/em.10069; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Xiang T, 2011, ONCOGENE, V30, P2443, DOI 10.1038/onc.2010.603; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang O, 2004, ONCOGENE, V23, P3749, DOI 10.1038/sj.onc.1207462; Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zeng SC, 2009, NAT CELL BIOL, V11, P616, DOI 10.1038/ncb1867	25	30	30	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1943	1949		10.1038/onc.2012.211	http://dx.doi.org/10.1038/onc.2012.211			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665067	Green Accepted			2022-12-17	WOS:000317599900008
J	Wimmer, P; Blanchette, P; Schreiner, S; Ching, W; Groitl, P; Berscheminski, J; Branton, PE; Will, H; Dobner, T				Wimmer, P.; Blanchette, P.; Schreiner, S.; Ching, W.; Groitl, P.; Berscheminski, J.; Branton, P. E.; Will, H.; Dobner, T.			Cross-talk between phosphorylation and SUMOylation regulates transforming activities of an adenoviral oncoprotein	ONCOGENE			English	Article						transformation; oncoprotein; SUMO; phosphorylation	E1B 55-KILODALTON PROTEIN; E1B-58KD TUMOR-ANTIGEN; NUCLEAR EXPORT; CELL-TRANSFORMATION; TRANSCRIPTIONAL REPRESSION; DEPENDENT DEGRADATION; SUMO-1 MODIFICATION; VIRAL INCLUSIONS; GENE-EXPRESSION; INFECTED-CELLS	Since the discovery of post-translational modification (PTM) by the small ubiquitin-related modifiers (SUMOs), a multitude of proteins have been described to be reversibly modified, resulting in the alteration of several cellular pathways. Interestingly, various pathogens gain access to this modification system, although the molecular mechanisms and functional consequences are barely understood. We show here that the adenoviral oncoprotein E1B-55K is a substrate of the SUMO conjugation system, which is directly linked to its C-terminal phosphorylation. This regulative connection is indispensable for modulation of the tumor suppressor p53/chromatin-remodeling factor Daxx by E1B-55K and, consequently, its oncogenic potential in primary mammalian cells. In virus infection, E1B-55K PTMs are necessary for localization to viral transcription/replication sites. Furthermore, we identify the E2 enzyme Ubc9 as an interaction partner of E1B-55K, providing a possible molecular explanation for SUMO-dependent modulation of cellular target proteins. In conclusion, these results for the first time provide evidence how E1B-55K PTMs are regulated and subsequently facilitate exploitation of the host cell SUMOylation machinery. Oncogene (2013) 32, 1626-1637; doi:10.1038/onc.2012.187; published online 21 May 2012	[Wimmer, P.; Schreiner, S.; Ching, W.; Groitl, P.; Berscheminski, J.; Will, H.; Dobner, T.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Mol Virol, D-20251 Hamburg, Germany; [Blanchette, P.; Branton, P. E.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Goodman Canc Ctr, Montreal, PQ, Canada	Heinrich Pette Institute; McGill University; McGill University; McGill University	Dobner, T (corresponding author), Leibniz Inst Expt Virol, Heinrich Pette Inst, Dept Mol Virol, Martinistr 52, D-20251 Hamburg, Germany.	thomas.dobner@hpi.uni-hamburg.de	Ching, Wai-Yim/B-4686-2009	Ching, Wai-Yim/0000-0001-7738-8822; Schreiner, Sabrina/0000-0002-5744-7159	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit; Wilhelm Sander-Stiftung, Munich, Germany; Canadian Institutes of Health Research	Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit; Wilhelm Sander-Stiftung, Munich, Germany; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We apologize for all the important publications and excellent reviews we could not cite/refer to due to space limitations. The Heinrich-Pette-Institute is supported by the 'Freie und Hansestadt Hamburg' and the 'Bundesministerium fur Gesundheit'. TD was supported by a grant from the Wilhelm Sander-Stiftung, Munich, Germany. PEB and PB were supported through grants from the Canadian Institutes of Health Research.	Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Berk AJ, 2007, ADENOVIRIDAE VIRUSES; Blackford AN, 2009, J VIROL, V83, P4000, DOI 10.1128/JVI.02417-08; Blanchette P, 2008, J VIROL, V82, P2642, DOI 10.1128/JVI.02309-07; Boggio R, 2006, CURR OPIN MICROBIOL, V9, P430, DOI 10.1016/j.mib.2006.06.008; Boivin D, 1999, J VIROL, V73, P1245, DOI 10.1128/JVI.73.2.1245-1253.1999; Bossis G, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-13; Ching W, 2011, J VIROL; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Escobar-Cabrera E, 2011, J BIOL CHEM, V286, P19816, DOI 10.1074/jbc.M111.231647; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gonzalez RA, 2002, J VIROL, V76, P4507, DOI 10.1128/JVI.76.9.4507-4519.2002; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Groitl P, 2005, ADENOVIRUS METHODS P; Groitl Peter, 2007, Methods Mol Med, V130, P29; Haas AL, 2007, MOL CELL, V27, P174, DOI 10.1016/j.molcel.2007.07.003; Hartl B, 2008, ONCOGENE, V27, P3673, DOI 10.1038/sj.onc.1211039; Hannoun Z, 2010, TOXICOLOGY, V278, P288, DOI 10.1016/j.tox.2010.07.013; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kindsmuller K, 2007, P NATL ACAD SCI USA, V104, P6684, DOI 10.1073/pnas.0702158104; Kindsmuller K, 2009, J VIROL, V83, P9045, DOI 10.1128/JVI.00728-09; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Latonen L, 2011, BIOESSAYS, V33, P386, DOI 10.1002/bies.201100008; Leppard KN, 1998, SEMIN VIROL, V8, P301, DOI 10.1006/smvy.1997.0132; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LEPPARD KN, 1993, J GEN VIROL, V74, P575, DOI 10.1099/0022-1317-74-4-575; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; Li X, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000781; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Logan J, 1984, CANCER CELL, V2, P527; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Mohideen F, 2009, NAT STRUCT MOL BIOL, V16, P945, DOI 10.1038/nsmb.1648; Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002; Muller S, 2008, CELL CYCLE, V7, P754, DOI 10.4161/cc.7.6.5495; Nevels M, 2006, ADENOVIRUS METHODS P, P187; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Pennella MA, 2010, J VIROL, V84, P12210, DOI 10.1128/JVI.01442-10; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rangasamy D, 2000, J BIOL CHEM, V275, P30487, DOI 10.1074/jbc.M003898200; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; Santiago A, 2009, CELL CYCLE, V8, P76, DOI 10.4161/cc.8.1.7493; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schreiner S, 2011, J VIROL, V85, P8752, DOI 10.1128/JVI.00440-11; Schreiner S, 2010, J VIROL, V84, P7029, DOI 10.1128/JVI.00074-10; Schwartz RA, 2008, J VIROL, V82, P9043, DOI 10.1128/JVI.00925-08; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Soria C, 2010, NATURE, V466, P1076, DOI 10.1038/nature09307; Souquere-Besse S, 2002, MICROSC RES TECHNIQ, V56, P465, DOI 10.1002/jemt.10060; Stehmeier P, 2009, MOL CELL, V33, P400, DOI 10.1016/j.molcel.2009.01.013; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Tan JAT, 2010, MOL CELL BIOL, V30, P2823, DOI 10.1128/MCB.01603-09; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; Ulrich Helle D., 2009, V497, P3, DOI 10.1007/978-1-59745-566-4_1; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Wilson VG, 2001, VIRUS RES, V81, P17, DOI 10.1016/S0168-1702(01)00365-3; Wimmer P, 2010, ONCOGENE, V29, P5511, DOI 10.1038/onc.2010.284; Wimmer P, 2012, J VIROL, V86, P642, DOI 10.1128/JVI.06227-11; Wojcik C, 2003, INT J BIOCHEM CELL B, V35, P579, DOI 10.1016/S1357-2725(02)00380-1; Woo JL, 2007, J VIROL, V81, P575, DOI 10.1128/JVI.01725-06; Yang SH, 2006, EMBO J, V25, P5083, DOI 10.1038/sj.emboj.7601383; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yousef AF, 2010, ONCOGENE, V29, P4693, DOI 10.1038/onc.2010.226; Zhang XD, 2008, MOL CELL, V29, P729, DOI 10.1016/j.molcel.2008.01.013; Zhu JM, 2008, J BIOL CHEM, V283, P29405, DOI 10.1074/jbc.M803632200	88	30	31	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1626	1637		10.1038/onc.2012.187	http://dx.doi.org/10.1038/onc.2012.187			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614022				2022-12-17	WOS:000316855800003
J	Ahlqvist, K; Saamarthy, K; Khaja, ASS; Bjartell, A; Massoumi, R				Ahlqvist, K.; Saamarthy, K.; Khaja, A. S. Syed; Bjartell, A.; Massoumi, R.			Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer	ONCOGENE			English	Article						Bcl-3; prostate cancer; interleukin-6; inhibitor of DNA binding (Id)	NF-KAPPA-B; PROLIFERATIVE INFLAMMATORY ATROPHY; PROMOTES CELL-SURVIVAL; BREAST-CANCER; ACTIVATION; APOPTOSIS; PATHWAY; NF-KAPPA-B2/P52; INTERLEUKIN-6; INHIBITOR	B-cell leukemia 3 (Bcl-3) is a member of the inhibitor of kappa B family, which regulates a wide range of biological processes by functioning as a transcriptional activator or as a repressor of target genes. As high levels of Bcl-3 expression and activation have been detected in different types of human cancer, Bcl-3 has been labeled a proto-oncogene. Our study uncovered a markedly upregulated Bcl-3 expression in human prostate cancer (PCa), where inflammatory cell infiltration was observed. Elevated Bcl-3 expression in PCa was dependent on the proinflammatory cytokine interleukin-6-mediated STAT3 activation. Microarray analyses, using Bcl-3 knockdown in PCa cells, identified the inhibitor of DNA-binding (Id) family of helix-loop-helix proteins as potential Bcl-3-regulated genes. Bcl-3 knockdown reduced the abundance of Id-1 and Id-2 proteins and boosted PCa cells to be more receptive to undergoing apoptosis following treatment with anticancer drug. Our data imply that inactivation of Bcl-3 may lead to sensitization of cancer cells to chemotherapeutic drug-induced apoptosis, thus suggesting a potential therapeutic strategy in PCa treatment. Oncogene (2013) 32, 1601-1608; doi:10.1038/onc.2012.175; published online 14 May 2012	[Ahlqvist, K.; Saamarthy, K.; Massoumi, R.] Lund Univ, Skane Univ Hosp, Dept Lab Med, Ctr Mol Tumor Pathol, SE-20502 Malmo, Sweden; [Khaja, A. S. Syed; Bjartell, A.] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Div Urol Canc, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Massoumi, R (corresponding author), Lund Univ, Skane Univ Hosp, Dept Lab Med, SUS, Entrance 78,2nd Floor, SE-20502 Malmo, Sweden.	Ramin.Massoumi@med.lu.se	Massoumi, Ramin/AAG-4786-2019; Syed Khaja, Azharuddin Sajid/AAF-2693-2021	Syed Khaja, Azharuddin Sajid/0000-0003-1594-1826	Swedish Society for Medical Research; Swedish Cancer Foundation; Swedish Medical Research Council; Royal Physiographic Society in Lund; U-MAS Research Foundations; European Research Council under the European Union [260460]	Swedish Society for Medical Research; Swedish Cancer Foundation; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Royal Physiographic Society in Lund; U-MAS Research Foundations; European Research Council under the European Union(European Research Council (ERC))	We thank Elise Nilsson for excellent technical assistance, Dr Zoran Culig (Innsbruck Medical University, Austria) for providing us the LNCaP-IL-6<SUP>+</SUP> cells, Dr Takashi Tokino (Cancer Research Institute, Sapporo, Japan) for human Id-2 promoter luciferase reporter construct, Dr Roland M Schmid (Technical University Munich, Munich, Germany) for FLAG-Bcl-3 expression construct, Dr David Ulmert (Lund University, Lund, Sweden) for characterization of the human PCa tissue microarray and Dr Srinivas Veerla (SCIBLU, Lund University, Lund, Sweden) for microarray analysis and gene expression profiling. This work was supported by the Swedish Society for Medical Research, Swedish Cancer Foundation, Swedish Medical Research Council, Royal Physiographic Society in Lund, U-MAS Research Foundations, and funding from the European Research Council under the European Union's seventh framework program ERC grant agreement (260460 to RM).	Brocke-Heidrich K, 2006, ONCOGENE, V25, P7297, DOI 10.1038/sj.onc.1209711; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Cai C, 2011, PATHOL ONCOL RES, V17, P873, DOI 10.1007/s12253-011-9396-5; Cheung HW, 2004, CARCINOGENESIS, V25, P881, DOI 10.1093/carcin/bgh087; Choi HJ, 2010, BIOCHEM BIOPH RES CO, V400, P396, DOI 10.1016/j.bbrc.2010.08.084; Chung TDK, 2000, PROSTATE, V42, P1; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; CORREA P, 1992, CANCER RES, V52, P6735; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Forootan SS, 2007, HUM PATHOL, V38, P1321, DOI 10.1016/j.humpath.2007.02.011; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hobisch A, 2000, J PATHOL, V191, P239, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X; Hobisch A, 2001, CLIN CANCER RES, V7, P2941; Hua H, 2007, ENDOCRINE, V32, P329, DOI 10.1007/s12020-008-9039-0; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kashatus D, 2006, GENE DEV, V20, P225, DOI 10.1101/gad.1352206; Keutgens A, 2010, MOL CELL BIOL, V30, P4006, DOI 10.1128/MCB.01600-09; Kim H, 2008, BREAST CANCER RES TR, V112, P287, DOI 10.1007/s10549-007-9871-6; Kuphal S, 2011, ONCOGENE, V30, P4523, DOI 10.1038/onc.2011.163; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; Monticelli LA, 2009, P NATL ACAD SCI USA, V106, P19461, DOI 10.1073/pnas.0908249106; Nadiminty N, 2010, CANCER RES, V70, P3309, DOI 10.1158/0008-5472.CAN-09-3703; Nadiminty N, 2008, PROSTATE, V68, P1725, DOI 10.1002/pros.20839; Paule B, 2007, WORLD J UROL, V25, P477, DOI 10.1007/s00345-007-0175-6; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Smith PC, 2001, PROSTATE, V48, P47; Sottnik JL, 2011, CANCER MICROENVIRON, V4, P283, DOI 10.1007/s12307-011-0073-8; Thornburg NJ, 2003, CANCER RES, V63, P8293; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Wong YC, 2008, ADV EXP MED BIOL, V617, P565, DOI 10.1007/978-0-387-69080-3_58; Zha S, 2001, CANCER RES, V61, P8617; Zhang HM, 2007, AM J PATHOL, V171, P1113, DOI 10.2353/ajpath.2007.070226; Zhang XM, 2007, J BIOL CHEM, V282, P33284, DOI 10.1074/jbc.M705089200; Zhang XM, 2007, CANCER SCI, V98, P308, DOI 10.1111/j.1349-7006.2007.00400.x; Zhang XM, 2006, INT J CANCER, V118, P2072, DOI 10.1002/ijc.21592; Zielinski AJ, 2010, INT J CANCER, V126, P2490, DOI 10.1002/ijc.24811	45	30	35	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1601	1608		10.1038/onc.2012.175	http://dx.doi.org/10.1038/onc.2012.175			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580608				2022-12-17	WOS:000316456000013
J	Chen, HZ; Li, L; Wang, WJ; Du, XD; Wen, Q; He, JP; Zhao, BX; Li, GD; Zhou, W; Xia, Y; Yang, QY; Hew, CL; Liou, YC; Wu, Q				Chen, H-Z; Li, L.; Wang, W-J; Du, X-D; Wen, Q.; He, J-P; Zhao, B-X; Li, G-D; Zhou, W.; Xia, Y.; Yang, Q-Y; Hew, C-L; Liou, Y-C; Wu, Q.			Prolyl isomerase Pin1 stabilizes and activates orphan nuclear receptor TR3 to promote mitogenesis	ONCOGENE			English	Article						prolyl isomerase pin1; orphan receptor TR3; phosphorylation; cell proliferation	N-TERMINAL KINASE; CANCER CELL; NEGATIVE REGULATION; GROWTH-FACTORS; NGFI-B; APOPTOSIS; PHOSPHORYLATION; SUBSTRATE; TRANSLOCATION; DOMAINS	Pin1 regulates a subset of phosphoproteins by isomerizing phospho-Ser/Thr-Pro motifs via a 'post-phosphorylation' mechanism. Here, we characterize TR3 as a novel Pin1 substrate, and the mitogenic function of TR3 depends on Pin1-induced isomerization. There are at least three phospho-Ser-Pro motifs on TR3 that bind to Pin1. The Ser95-Pro motif of TR3 is the key site through which Pin1 enhances TR3 stability by retarding its degradation. Pin1 can also catalyze TR3 through phospho-Ser431-Pro motif, which is phosphorylated by extracellular signal-regulated kinase 2 (ERK2), resulting in enhanced TR3 transactivation. Furthermore, Pin1 not only facilitates TR3 targeting to the promoter of cyclin D2, a novel downstream target of TR3, but also promotes TR3 to recruit p300, thereby inducing cell proliferation. Importantly, we found that Pin1 is indispensable for TR3 to promote tumor growth both in vitro and in vivo. Our study thus suggests that Pin1 has an important role in cell proliferation by isomerizing TR3. Oncogene (2012) 31, 2876-2887; doi:10.1038/onc.2011.463; published online 17 October 2011	[Chen, H-Z; Li, L.; Wang, W-J; Du, X-D; Wen, Q.; He, J-P; Zhao, B-X; Li, G-D; Wu, Q.] Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China; [Zhou, W.; Xia, Y.; Yang, Q-Y; Hew, C-L; Liou, Y-C] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Xiamen University; National University of Singapore	Wu, Q (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China.	dbslyc@nus.edu.sg; qiaow@xmu.edu.cn	Wu, Q/G-4646-2010; Hew, Choy Leong/I-1501-2012; Xia, Yun/K-4128-2015	Hew, Choy Leong/0000-0002-9441-0064; Xia, Yun/0000-0003-2184-4870; Li, Li/0000-0002-7720-6731	Ministry of Education, China [B06016]; Ministry of Science and Technology, China [2007CB914402]; National Natural Science Foundation of China [30810103905, 30871281, 31000620]; National Key New Drug Creation Program of China [2009ZX09103-083]; Fundamental Research Funds for the Central Universities, China [2010121096]; Science Planning program grant of Fujian Province, China [2009J1010]; Biomedical Research Council, the Agency for Science, Research and Technology, Singapore [09/1/21/19/604]	Ministry of Education, China(Ministry of Education, China); Ministry of Science and Technology, China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key New Drug Creation Program of China; Fundamental Research Funds for the Central Universities, China(Fundamental Research Funds for the Central Universities); Science Planning program grant of Fujian Province, China; Biomedical Research Council, the Agency for Science, Research and Technology, Singapore(Agency for Science Technology & Research (A*STAR))	This work was supported by grants from Ministry of Education, China (Project 111, B06016) to WQ and YCL; grants from the Ministry of Science and Technology, China (2007CB914402) to WQ; the National Natural Science Foundation of China (30810103905 and 30871281 to WQ, 31000620 to CHZ); grants from the National Key New Drug Creation Program of China (2009ZX09103-083) to WQ; grants from the Fundamental Research Funds for the Central Universities, China (2010121096) to CHZ; Science Planning program grant of Fujian Province, China (2009J1010); and the grant (09/1/21/19/604) from the Biomedical Research Council, the Agency for Science, Research and Technology, Singapore to YCL.	CHANG C, 1989, J STEROID BIOCHEM, V34, P391; Chen HZ, 2008, CARCINOGENESIS, V29, P2078, DOI 10.1093/carcin/bgn197; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Fan G, 2009, CANCER RES, V69, P4589, DOI 10.1158/0008-5472.CAN-08-4117; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992; Lei NZ, 2009, NUCLEIC ACIDS RES, V37, P832, DOI 10.1093/nar/gkn941; Li GD, 2007, NUCLEIC ACIDS RES, V35, P7348, DOI 10.1093/nar/gkm870; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Liu B, 2007, ENDOCRINOLOGY, V148, P34, DOI 10.1210/en.2006-0800; Liu JJ, 2010, CANCER RES, V70, P3628, DOI 10.1158/0008-5472.CAN-09-3160; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; Mu XM, 2003, J BIOL CHEM, V278, P42840, DOI 10.1074/jbc.M305594200; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Ryo A, 2007, J BIOL CHEM, V282, P36671, DOI 10.1074/jbc.M704145200; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Siepe D, 2009, NAT CELL BIOL, V11, P967, DOI 10.1038/ncb1908; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Yang QY, 2009, J BIOL CHEM, V284, P23980, DOI 10.1074/jbc.M109.022814; Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	42	30	32	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2876	2887		10.1038/onc.2011.463	http://dx.doi.org/10.1038/onc.2011.463			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	22002310				2022-12-17	WOS:000305277900007
J	Russell, P; Hennessy, BT; Li, J; Carey, MS; Bast, RC; Freeman, T; Venkitaraman, AR				Russell, P.; Hennessy, B. T.; Li, J.; Carey, M. S.; Bast, R. C.; Freeman, T.; Venkitaraman, A. R.			Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest	ONCOGENE			English	Article						mitotic checkpoint; cyclin G1; anti-mitotic drugs; cancer therapy	SPINDLE-ASSEMBLY CHECKPOINT; CELL-CYCLE; ANTIMITOTIC DRUGS; CANCER-CELLS; DNA-DAMAGE; TARGET; PROTEIN; P53; MICROTUBULES; BRCA2	Anti-mitotic chemotherapeutic agents such as taxanes activate the spindle assembly checkpoint (SAC) to arrest anaphase onset, but taxane-exposed cells eventually undergo slippage to exit mitosis. The therapeutic efficacy of taxanes depends on whether slippage after SAC arrest culminates in continued cell survival, or in death by apoptosis. However, the mechanisms that determine these outcomes remain unclear. Here, we identify a novel role for cyclin G1 (CCNG1), an atypical cyclin. Increased CCNG1 expression accompanies paclitaxel-induced, SAC-mediated mitotic arrest, independent of p53 integrity or signaling through the SAC component, BUBR1. CCNG1 overexpression promotes cell survival after paclitaxel exposure. Conversely, CCNG1 depletion by RNA interference delays slippage and enhances paclitaxel-induced apoptosis. Consistent with these observations, CCNG1 amplification is associated with significantly shorter post-surgical survival in patients with ovarian cancer who have received adjuvant chemotherapy with taxanes and platinum compounds. Collectively, our findings implicate CCNG1 in regulating slippage and the outcome of taxane-induced mitotic arrest, with potential implications for cancer therapy. Oncogene (2012) 31, 2450-2460; doi: 10.1038/onc.2011.431; published online 7 November 2011	[Russell, P.; Venkitaraman, A. R.] Univ Cambridge, Med Res Council Canc Cell Unit, Dept Oncol, Hutchison MRC Res Ctr, Cambridge CB2 2XZ, England; [Hennessy, B. T.; Li, J.; Carey, M. S.; Bast, R. C.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Freeman, T.] Roslin Inst, Roslin, Midlothian, Scotland	University of Cambridge; University of Texas System; UTMD Anderson Cancer Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Venkitaraman, AR (corresponding author), Univ Cambridge, Med Res Council Canc Cell Unit, Dept Oncol, Hutchison MRC Res Ctr, Hills Rd, Cambridge CB2 2XZ, England.	arv22@cam.ac.uk	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462; Hennessy, Bryan/0000-0002-7871-6477	UK Medical Research Council; MRC [G1001521, G0600332, MC_U105359877, G0700651] Funding Source: UKRI; Medical Research Council [G0700651, MC_U105359877, G1001521, G0600332] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The experiments described in this paper were conceived and performed by PR and ARV, with the exception of the results in Figure 6, which were the work of BTH, JL, MSC and RCB. TF provided advice and assistance for microarray hybridization and analysis. This work was supported in ARV's laboratory by the UK Medical Research Council.	Abkevich V, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/386870; Bates S, 1996, ONCOGENE, V13, P1103; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719; Hennessy BT, 2009, LANCET, V374, P1371, DOI 10.1016/S0140-6736(09)61338-6; Huang HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015724; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Markman M, 2008, DRUGS, V68, P771, DOI 10.2165/00003495-200868060-00004; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michalakis J, 2005, CANCER CHEMOTH PHARM, V56, P615, DOI 10.1007/s00280-005-1002-7; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Perez R, 2003, J GASTROINTEST SURG, V7, P884, DOI 10.1016/j.gassur.2003.08.001; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sena G, 1999, CYTOMETRY, V37, P113, DOI 10.1002/(SICI)1097-0320(19991001)37:2<113::AID-CYTO4>3.0.CO;2-M; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; TAMURA K, 1993, ONCOGENE, V8, P2113; van Leuken R, 2008, BBA-REV CANCER, V1786, P49, DOI 10.1016/j.bbcan.2008.05.002; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011	31	30	32	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2450	2460		10.1038/onc.2011.431	http://dx.doi.org/10.1038/onc.2011.431			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	22056875	hybrid, Green Published			2022-12-17	WOS:000303985300007
J	Charoenfuprasert, S; Yang, YY; Lee, YC; Chao, KC; Chu, PY; Lai, CR; Hsu, KF; Chang, KC; Chen, YC; Chen, LT; Chang, JY; Leu, SJ; Shih, NY				Charoenfuprasert, S.; Yang, Y-Y; Lee, Y-C; Chao, K-C; Chu, P-Y; Lai, C-R; Hsu, K-F; Chang, K-C; Chen, Y-C; Chen, L-T; Chang, J-Y; Leu, S-J; Shih, N-Y			Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer	ONCOGENE			English	Article						tumor-associated antigen; ovarian cancer; CA125; malignant ascitic fluid; phage display	RECEPTOR; GROWTH; CELLS; SIK1; LKB1; STEROIDOGENESIS; STANNIOCALCIN; ADIPOGENESIS; EXPRESSION; CREB	Existence of humoral immunity has been previously demonstrated in malignant ascitic fluids. However, only a limited number of immunogenic tumor-associated antigens (TAAs) were identified, and few of which are associated with ovarian cancer. Here, we identified salt-inducible kinase 3 (SIK3) as a TAA through screening of a random peptide library in the phage display system. Overexpression of SIK3 markedly promoted cell proliferation, attenuated p21(Waf/Cip1) and p27(Kip) expressions in low-grade OVCAR3 cells, and permitted the cells to grow in mice. Decrease in SIK3 expression in high-grade SK-OV3 cells consistently demonstrated its tumorigenic potency by modulating the protein levels of cell cycle regulators. When the expressions of SIK3 and CA125 were compared in cancer tissues, immunohistochemical (IHC) studies indicated that cytoplasm-localized SIK3 was highly expressed in 55% of the ovarian cancer samples. In contrast, it was rarely detected in adenomyosis, leiomyoma and normal ovary tissues, showing its higher specificity (97%) to CA125 (65%) in ovarian cancer. Moreover, experiments using pharmacological inhibitors to block SIK3-induced p21(Waf/Cip1) expression revealed that activation of c-Src and phosphoinositide-3-kinase were critically required for its biological activity, suggesting that they are the downstream signaling mediators of SIK3. These data were further supported by IHC studies, showing coexpression of c-Src with SIK3 in 85% of the ovarian tumor samples stained positive for SIK3. Collectively, our findings indicate that SIK3 is a novel ovarian TAA. Overexpression of SIK3 promotes G1/S cell cycle progression, bestows survival advantages to cancer cells for growth and correlates the clinicopathological conditions of patients with ovarian cancer. Oncogene (2011) 30, 3570-3584; doi:10.1038/onc.2011.77; published online 14 March 2011	[Charoenfuprasert, S.; Leu, S-J] Taipei Med Univ, Coll Med, Sch Med, Dept Microbiol & Immunol, Taipei 110, Taiwan; [Charoenfuprasert, S.; Leu, S-J] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 110, Taiwan; [Yang, Y-Y; Lee, Y-C] Taipei Med Univ, Coll Med Sci & Technol, Sch Med Lab Sci & Biotechnol, Taipei 110, Taiwan; [Chao, K-C] Taipei Vet Gen Hosp, Dept Obstet & Gynecol, Taipei, Taiwan; [Chu, P-Y] Changhua Christian Hosp, Dept Surg Pathol, Changhua, Taiwan; [Lai, C-R] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan; [Hsu, K-F] Natl Cheng Kung Univ, Dept Obstet & Gynecol, Tainan 70101, Taiwan; [Chang, K-C] Natl Cheng Kung Univ, Dept Pathol, Tainan 70101, Taiwan; [Charoenfuprasert, S.; Chen, Y-C; Chen, L-T; Chang, J-Y; Shih, N-Y] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Veterans General Hospital; Changhua Christian Hospital; Taipei Veterans General Hospital; National Cheng Kung University; National Cheng Kung University; National Health Research Institutes - Taiwan	Leu, SJ (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Microbiol & Immunol, Taipei 110, Taiwan.	cmbsycl@tmu.edu.tw; jshih@nhri.org.tw	Chen, Li-Tzong/D-2071-2010; Chang, Jang-Yang/D-2099-2010; Shih, Neng-Yao/D-2086-2010	Chu, Pei-Yi/0000-0001-7336-2465	National Health Research Institutes; Department of Health, Executive Yuan, Taiwan [DOH97-TD-G-111-022 (NYS)]; National Science Council of Taiwan [NSC 99-2320-B-400-011-MY3, NSC 96-2314-B-038-022, NSC 97-2314-B-038-004-MY3, NSC 96-2320-B-038-005/NSC 97-2320-B-038-012-MY2]	National Health Research Institutes(National Health Research Institutes, Japan); Department of Health, Executive Yuan, Taiwan; National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was partially supported by the Intramural Research Grant of the National Health Research Institutes, the National Research Program for Genomic Medicine Grant from the Department of Health, Executive Yuan, Taiwan, DOH97-TD-G-111-022 (NYS), and by the National Science Council Grants of Taiwan, NSC 99-2320-B-400-011-MY3 (NYS), NSC 96-2314-B-038-022 (SJL), NSC 97-2314-B-038-004-MY3 (SJL), as well as NSC 96-2320-B-038-005/NSC 97-2320-B-038-012-MY2 (YYY). We are also grateful to Dr Nagase from the Kazusa DNA Research Institute for kindly providing the FJ10213 plasmid to facilitate the SIK3 study, and thank National Research Program for Genomic Medicine, Taiwan (National Clinical Core, NSC-95-3112-B-001-010 and National Genotyping Core, NSC-95-3112-B-001-011) for supply of interfering small hairpin RNA plasmids.	Ahmed AA, 2010, CANCER CELL, V18, P109, DOI 10.1016/j.ccr.2010.06.018; Amin N, 2009, P NATL ACAD SCI USA, V106, P8941, DOI 10.1073/pnas.0812469106; Baron AT, 2005, CANCER EPIDEM BIOMAR, V14, P306, DOI 10.1158/1055-9965.EPI-04-0423; Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Brewer BG, 2009, EXP MOL PATHOL, V86, P192, DOI 10.1016/j.yexmp.2008.12.002; Bright NJ, 2009, ACTA PHYSIOL, V196, P15, DOI 10.1111/j.1748-1716.2009.01971.x; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang GC, 2006, CLIN CANCER RES, V12, P5746, DOI 10.1158/1078-0432.CCR-06-0324; Cheng HL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000369; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Gagnon A, 2008, CLIN CANCER RES, V14, P764, DOI 10.1158/1078-0432.CCR-07-0856; GIANCOTTI FR, 1990, GYNECOL ONCOL, V37, P24, DOI 10.1016/0090-8258(90)90301-Z; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Horike N, 2003, J BIOL CHEM, V278, P18440, DOI 10.1074/jbc.M211770200; Katoh Y, 2004, MOL CELL ENDOCRINOL, V217, P109, DOI 10.1016/j.mce.2003.10.016; Katoh Y, 2006, FEBS J, V273, P2730, DOI 10.1111/j.1742-4658.2006.05291.x; Kowanetz M, 2008, J CELL BIOL, V182, P655, DOI 10.1083/jcb.200804107; Liu GZ, 2010, JNCI-J NATL CANCER I, V102, P812, DOI 10.1093/jnci/djq127; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Mizrachy-Schwartz S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000628; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; Okamoto M, 2004, TRENDS ENDOCRIN MET, V15, P21, DOI 10.1016/j.tem.2003.11.002; Old Lloyd J, 2008, Cancer Immun, V8 Suppl 1, P1; Paciga M, 2003, J BIOL CHEM, V278, P49549, DOI 10.1074/jbc.M307302200; Reuschenbach M, 2009, CANCER IMMUNOL IMMUN, V58, P1535, DOI 10.1007/s00262-009-0733-4; Rosenthal AN, 2006, CLIN OBSTET GYNECOL, V49, P433, DOI 10.1097/00003081-200609000-00004; Ruda JM, 2006, INVEST NEW DRUG, V24, P377, DOI 10.1007/s10637-006-6271-4; Runnebaum IB, 2001, J CANCER RES CLIN, V127, P73, DOI 10.1007/s004320000153; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Serlachius M, 2002, BRIT J HAEMATOL, V119, P359, DOI 10.1046/j.1365-2141.2002.03916.x; Sjostrom M, 2007, P NATL ACAD SCI USA, V104, P16922, DOI 10.1073/pnas.0706838104; Taylor DD, 2009, GYNECOL ONCOL, V115, P112, DOI 10.1016/j.ygyno.2009.06.031	33	30	44	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	33					3570	3584		10.1038/onc.2011.77	http://dx.doi.org/10.1038/onc.2011.77			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21399663	Bronze			2022-12-17	WOS:000294005100002
J	Pal, J; Bertheau, R; Buon, L; Qazi, A; Batchu, RB; Bandyopadhyay, S; Ali-Fehmi, R; Beer, DG; Weaver, DW; Reis, RJS; Goyal, RK; Huang, Q; Munshi, NC; Shammas, MA				Pal, J.; Bertheau, R.; Buon, L.; Qazi, A.; Batchu, R. B.; Bandyopadhyay, S.; Ali-Fehmi, R.; Beer, D. G.; Weaver, D. W.; Reis, R. J. Shmookler; Goyal, R. K.; Huang, Q.; Munshi, N. C.; Shammas, M. A.			Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome	ONCOGENE			English	Article						Barrett's adenocarcinoma; recombination; evolution; alu; hsRad51	TELOMERASE INHIBITION; DNA-REPAIR; CHROMOSOMAL INSTABILITY; GENETIC-CONTROL; GROWTH ARREST; UP-REGULATION; T-ANTIGEN; APC GENE; CANCER; ESOPHAGUS	A prominent feature of most cancers including Barrett's adenocarcinoma (BAC) is genetic instability, which is associated with development and progression of disease. In this study, we investigated the role of recombinase (hsRAD51), a key component of homologous recombination (HR)/repair, in evolving genomic changes and growth of BAC cells. We show that the expression of RAD51 is elevated in BAC cell lines and tissue specimens, relative to normal cells. HR activity is also elevated and significantly correlates with RAD51 expression in BAC cells. The suppression of RAD51 expression, by short hairpin RNA (shRNA) specifically targeting this gene, significantly prevented BAC cells from acquiring genomic changes to either copy number or heterozygosity (P<0.02) in several independent experiments employing single-nucleotide polymorphism arrays. The reduction in copy-number changes, following shRNA treatment, was confirmed by Comparative Genome Hybridization analyses of the same DNA samples. Moreover, the chromosomal distributions of mutations correlated strongly with frequencies and locations of Alu interspersed repetitive elements on individual chromosomes. We conclude that the hsRAD51 protein level is systematically elevated in BAC, contributes significantly to genomic evolution during serial propagation of these cells and correlates with disease progression. Alu sequences may serve as substrates for elevated HR during cell proliferation in vitro, as they have been reported to do during the evolution of species, and thus may provide additional targets for prevention or treatment of this disease. Oncogene (2011) 30, 3585-3598; doi:10.1038/onc.2011.83; published online 21 March 2011	[Pal, J.; Bertheau, R.; Buon, L.; Munshi, N. C.; Shammas, M. A.] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; [Pal, J.; Bertheau, R.; Goyal, R. K.; Huang, Q.; Munshi, N. C.; Shammas, M. A.] VA Hlth Care Syst, Dept Med Pathol, Boston, MA USA; [Qazi, A.; Batchu, R. B.; Bandyopadhyay, S.; Ali-Fehmi, R.; Weaver, D. W.] Wayne State Univ, Dept Surg Pathol, Detroit, MI USA; [Qazi, A.; Batchu, R. B.; Bandyopadhyay, S.; Ali-Fehmi, R.; Weaver, D. W.] Karmanos Canc Inst, Detroit, MI USA; [Beer, D. G.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Reis, R. J. Shmookler] Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; [Reis, R. J. Shmookler] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; [Reis, R. J. Shmookler] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA; [Goyal, R. K.; Munshi, N. C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; University of Michigan System; University of Michigan; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; Harvard University; Harvard Medical School	Shammas, MA (corresponding author), Dana Farber Canc Inst, 1400 VFW Pkwy,Bldg 3,Room 2A111, W Roxbury, MA 02132 USA.	Masood_Shammas@DFCI.Harvard.Edu	Qazi, Aamer M/V-4249-2018; Munshi, Nikhil/ABE-2338-2021	Qazi, Aamer M/0000-0003-0425-4246; 	National Cancer Institute [R01CA125711]; Department of Veterans Affairs; National Institutes of Health [RO1-1375555, P50-100007, PO1-78378]; NATIONAL CANCER INSTITUTE [R01CA124929, R01CA125711] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Cheng Li, Department of Bioinformatics and Dr Samir Amin, Departments of Medical Oncology and Bioinformatics, Dana Farber Cancer Institute, Boston, MA, USA, for their critical review of paper and guidance in data analyses. This work was supported in part by grants from National Cancer Institute (R01CA125711 to MAS), from the Department of Veterans Affairs (Merit Review Awards to NCM and RJSR and a Research Career Scientist Award to RJSR) and from the National Institutes of Health (RO1-1375555, P50-100007 and PO1-78378 to NCM).	Abdurashitov MA, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-305; Aggarwal S, 2000, NEOPLASIA, V2, P346, DOI 10.1038/sj.neo.7900097; Akagi T, 2009, INT J CANCER, V125, P2349, DOI 10.1002/ijc.24620; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; Barlund M, 2000, CANCER RES, V60, P5340; Bastos HN, 2009, THYROID, V19, P1067, DOI 10.1089/thy.2009.0099; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Beerenwinkel N, 2007, PLOS COMPUT BIOL, V3, P2239, DOI 10.1371/journal.pcbi.0030225; Bishop AJR, 2003, EXP MOL PATHOL, V74, P94, DOI 10.1016/S0014-4800(03)00010-8; BROOKFIELD JFY, 1994, BIOESSAYS, V16, P793, DOI 10.1002/bies.950161104; BRUNNER AM, 1986, BIOCHEMISTRY-US, V25, P5028, DOI 10.1021/bi00366a009; Cai JC, 2008, WORLD J GASTROENTERO, V14, P4070, DOI 10.3748/wjg.14.4070; Cheng RZ, 1997, EXP CELL RES, V234, P300, DOI 10.1006/excr.1997.3649; Croft J, 2002, EUR J GASTROEN HEPAT, V14, P1179, DOI 10.1097/00042737-200211000-00004; ECONOMOUPACHNIS A, 1985, P NATL ACAD SCI USA, V82, P2857, DOI 10.1073/pnas.82.9.2857; ECONOMOUPACHNIS A, 1985, NUCLEIC ACIDS RES, V13, P8379, DOI 10.1093/nar/13.23.8379; FARBER E, 1984, CANCER RES, V44, P4217; Finley JC, 2006, CANCER EPIDEM BIOMAR, V15, P1451, DOI 10.1158/1055-9965.EPI-05-0837; Frank B, 2010, CARCINOGENESIS, V31, P442, DOI 10.1093/carcin/bgp293; GALLI A, 1995, MOL GEN GENET, V248, P301, DOI 10.1007/BF02191597; GEE CJ, 1979, J CELL SCI, V36, P223; Graves JAM, 2006, CELL, V124, P901, DOI 10.1016/j.cell.2006.02.024; Graves JAM, 2004, REPROD FERT DEVELOP, V16, P527, DOI 10.1071/RD03096; Hansen LT, 2003, INT J CANCER, V105, P472, DOI 10.1002/ijc.11106; HESS JF, 1983, P NATL ACAD SCI-BIOL, V80, P5970, DOI 10.1073/pnas.80.19.5970; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; HORII A, 1992, CANCER RES, V52, P3231; Jara L, 2010, BREAST CANCER RES TR, V122, P813, DOI 10.1007/s10549-009-0709-2; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kolomietz E, 2002, GENE CHROMOSOME CANC, V35, P97, DOI 10.1002/gcc.10111; Koppert LB, 2005, J SURG ONCOL, V92, P169, DOI 10.1002/jso.20359; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li HZ, 2001, GENOME BIOL, V2; Li J, 1997, MUTAT RES-DNA REPAIR, V385, P173, DOI 10.1016/S0921-8777(97)00054-2; Lynch HT, 1998, ONCOLOGY-BASEL, V55, P103, DOI 10.1159/000011843; Lynch HT, 1998, DIGESTION, V59, P481, DOI 10.1159/000007525; Maacke H, 2000, ONCOGENE, V19, P2791, DOI 10.1038/sj.onc.1203578; Maciejewski JP, 2008, BLOOD, V112, P965, DOI 10.1182/blood-2008-02-130435; MIKI H, 1991, CANCER LETT, V58, P107, DOI 10.1016/0304-3835(91)90031-C; MIKI Y, 1992, CANCER RES, V52, P643; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; NEIMAN PE, 1991, NEW BIOL, V3, P347; Ogunwobi OO, 2008, AM J GASTROENTEROL, V103, P825, DOI 10.1111/j.1572-0241.2007.01773.x; Pathak S., 1994, In Vivo (Attiki), V8, P843; Paulson TG, 2009, CLIN CANCER RES, V15, P3305, DOI 10.1158/1078-0432.CCR-08-2494; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; RADMAN M, 1982, MUTAT RES, V98, P249, DOI 10.1016/0165-1110(82)90035-5; RESNICK MA, 1989, P NATL ACAD SCI USA, V86, P2276, DOI 10.1073/pnas.86.7.2276; RODARTERAMON US, 1972, RADIAT RES, V49, P148, DOI 10.2307/3573379; Romagnoli S, 2001, LAB INVEST, V81, P241, DOI 10.1038/labinvest.3780232; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; SCHIMENTI JC, 1984, NUCLEIC ACIDS RES, V12, P1641, DOI 10.1093/nar/12.3.1641; SENGSTAG C, 1994, CRIT REV TOXICOL, V24, P323, DOI 10.3109/10408449409017922; Shammas MA, 1997, GENETICS, V146, P1417; Shammas MA, 1999, ONCOGENE, V18, P6191, DOI 10.1038/sj.onc.1203069; Shammas MA, 2004, GASTROENTEROLOGY, V126, P1337, DOI 10.1053/j.gastro.2004.01.026; Shammas MA, 2003, MOL CANCER THER, V2, P825; Shammas MA, 2008, CLIN CANCER RES, V14, P4971, DOI 10.1158/1078-0432.CCR-08-0473; Shammas MA, 2006, BLOOD, V108, P2804, DOI 10.1182/blood-2006-05-022814; Shammas MA, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-24; Shammas MA, 2009, BLOOD, V113, P2290, DOI 10.1182/blood-2007-05-089193; Silva SN, 2010, CANCER EPIDEMIOL, V34, P85, DOI 10.1016/j.canep.2009.11.002; SINGER MF, 1982, CELL, V28, P433, DOI 10.1016/0092-8674(82)90194-5; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; Steinemann S, 2005, BIOESSAYS, V27, P1076, DOI 10.1002/bies.20288; Stilgenbauer S, 2007, HAEMATOLOGICA, V92, P1242, DOI 10.3324/haematol.10720; Stoler DL, 1999, P NATL ACAD SCI USA, V96, P15121, DOI 10.1073/pnas.96.26.15121; Sturgis EM, 1999, ARCH OTOLARYNGOL, V125, P185, DOI 10.1001/archotol.125.2.185; Tal A, 2009, J MOL BIOL, V393, P1007, DOI 10.1016/j.jmb.2009.09.011; Tsancheva M, 1997, Khirurgiia (Sofiia), V50, P40; Tselepis C, 2003, GUT, V52, P174, DOI 10.1136/gut.52.2.174; van Dekken H, 2001, AM J PATHOL, V158, P1961, DOI 10.1016/S0002-9440(10)64666-4; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; YAMADA Y, 1991, CANCER RES, V51, P5800; Ye CJ, 2007, CYTOGENET GENOME RES, V118, P237, DOI 10.1159/000108306; Yoshida N, 2007, INT J MOL MED, V19, P335	79	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	33					3585	3598		10.1038/onc.2011.83	http://dx.doi.org/10.1038/onc.2011.83			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423218	Green Accepted			2022-12-17	WOS:000294005100003
J	Nazeer, FI; Devany, E; Mohammed, S; Fonseca, D; Akukwe, B; Taveras, C; Kleiman, FE				Nazeer, F. I.; Devany, E.; Mohammed, S.; Fonseca, D.; Akukwe, B.; Taveras, C.; Kleiman, F. E.			p53 inhibits mRNA 3 ' processing through its interaction with the CstF/BARD1 complex	ONCOGENE			English	Article						p53; cleavage-stimulation factor; BARD1; DNA damage; RNA processing	DNA-DAMAGE; POLYMERASE-II; POLYADENYLATION FACTOR; UNTRANSLATED REGIONS; EXPRESSION; IDENTIFICATION; APOPTOSIS; PROTEIN; CELLS; PHOSPHORYLATION	The mechanisms involved in the p53-dependent control of gene expression following DNA damage have not been completely elucidated. Here, we show that the p53 C terminus associates with factors that are required for the ultraviolet (UV)-induced inhibition of the mRNA 3' cleavage step of the polyadenylation reaction, such as the tumor suppressor BARD1 and the 3' processing factor cleavage-stimulation factor 1 (CstF1). We found that p53 can coexist in complexes with CstF and BARD1 in extracts of UV-treated cells, suggesting a role for p53 in mRNA 3' cleavage following DNA damage. Consistent with this, we found that p53 inhibits 3' cleavage in vitro and that there is a reverse correlation between the levels of p53 expression and the levels of mRNA 3' cleavage under different cellular conditions. Supporting these results, a tumor-associated mutation in p53 not only decreases the interaction with BARD1 and CstF, but also decreases the UV-induced inhibition of 3' processing, all of which is restored by wild-type-p53 expression. We also found that p53 expression levels affect the polyadenylation levels of housekeeping genes, but not of p21 and c-fos genes, which are involved in the DNA damage response (DDR). Here, we identify a novel 3' RNA processing inhibitory function of p53, adding a new level of complexity to the DDR by linking RNA processing to the p53 network. Oncogene (2011) 3', 3'73-3'83; doi: 10.1038/onc.2011.29; published online 7 March 2011	[Nazeer, F. I.; Devany, E.; Mohammed, S.; Fonseca, D.; Akukwe, B.; Taveras, C.; Kleiman, F. E.] CUNY Hunter Coll, Dept Chem, New York, NY 10065 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Kleiman, FE (corresponding author), CUNY Hunter Coll, Dept Chem, 695 Pk Ave, New York, NY 10065 USA.	fkleiman@hunter.cuny.edu		Mathmann, Carmen/0000-0002-7406-2285	National Institute of General Medical Sciences [SC1GM083806]; Minority Access to Research Careers Program (MARC); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC1GM083806] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Minority Access to Research Careers Program (MARC); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr JL Manley for anti-CstF2 antibodies, Dr B Vogelstein and Dr J Bargonetti for cell lines DLD-1 and D-A2, Dr EK Boamah for technical advice, Dr C Prives for p53 encoding plasmids, Dr R Baer for BARD1 encoding plasmids and Dr S Pinol-Roma and Dr MA Cevher for advice and discussion. This work is supported by National Institute of General Medical Sciences Grant SC1GM083806 to FEK and by Minority Access to Research Careers Program (MARC) to BA and CT.	Akeo K, 2007, TISSUE CULT RES COMM, V26, P149; CEVHER MA, 2010, CONNECTIONS 3 END PR; Cevher MA, 2010, EMBO J, V29, P1674, DOI 10.1038/emboj.2010.59; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Feki A, 2005, ONCOGENE, V24, P3726, DOI 10.1038/sj.onc.1208491; Fong S, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-23; Fox JT, 2009, J BIOL CHEM, V284, P31097, DOI 10.1074/jbc.M109.015800; Fu N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000216; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Gry M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-365; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Ji Z, 2009, P NATL ACAD SCI USA, V106, P7028, DOI 10.1073/pnas.0900028106; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(01)00270-7; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Maccoux LJ, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-62; Mandel CR, 2008, CELL MOL LIFE SCI, V65, P1099, DOI 10.1007/s00018-007-7474-3; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Mirkin N, 2008, NUCLEIC ACIDS RES, V36, P1792, DOI 10.1093/nar/gkn005; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Rozenblatt-Rosen O, 2009, P NATL ACAD SCI USA, V106, P755, DOI 10.1073/pnas.0812023106; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Sauer M, 2008, NUCLEIC ACIDS RES, V36, P1900, DOI 10.1093/nar/gkn044; Scorilas A, 2002, CRIT REV CL LAB SCI, V39, P193, DOI 10.1080/10408360290795510; Shi YS, 2009, MOL CELL, V33, P365, DOI 10.1016/j.molcel.2008.12.028; Singh P, 2009, CANCER RES, V69, P9422, DOI 10.1158/0008-5472.CAN-09-2236; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takwi A, 2009, CURR GENOMICS, V10, P194, DOI 10.2174/138920209788185270; Topalian SL, 2001, MOL CELL BIOL, V21, P5614, DOI 10.1128/MCB.21.16.5614-5623.2001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Wei QZ, 2005, J BIOL CHEM, V280, P37790, DOI 10.1074/jbc.M502974200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu ZH, 2009, ONCOGENE, V28, P41, DOI 10.1038/onc.2008.359; Zlotorynski E, 2008, CELL, V134, P208, DOI 10.1016/j.cell.2008.07.003	46	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	27					3073	3083		10.1038/onc.2011.29	http://dx.doi.org/10.1038/onc.2011.29			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21383700				2022-12-17	WOS:000292510100007
J	Terrinoni, A; Pagani, IS; Zucchi, I; Chiaravalli, AM; Serra, V; Rovera, F; Sirchia, S; Dionigi, G; Miozzo, M; Frattini, A; Ferrari, A; Capella, C; Pasquali, F; Curto, FL; Albertini, A; Melino, G; Porta, G				Terrinoni, A.; Pagani, I. S.; Zucchi, I.; Chiaravalli, A. M.; Serra, V.; Rovera, F.; Sirchia, S.; Dionigi, G.; Miozzo, M.; Frattini, A.; Ferrari, A.; Capella, C.; Pasquali, F.; Curto, F. L.; Albertini, A.; Melino, G.; Porta, G.			OTX1 expression in breast cancer is regulated by p53	ONCOGENE			English	Article						p53; OTX1; human breast cancer; cancer stem cells	HOMEOBOX GENES; MAMMARY-GLAND; STEM-CELLS; HOX GENES; DIFFERENTIATION; DIVISIONS; APOPTOSIS; FAMILY; P63	The p53 transcription factor has a critical role in cell stress response and in tumor suppression. Wild-type p53 protein is a growth modulator and its inactivation is a critical event in malignant transformation. It has been recently demonstrated that wild-type p53 has developmental and differentiation functions. Indeed an overexpression of p53 in tumor cells induces asymmetrical division avoiding self-renewal of cancer stem cells (CSCs) and instead promoting their differentiation. In this study, 28 human breast carcinomas have been analyzed for expression of wild-type p53 and of a pool of non-clustered homeobox genes. We demonstrated that orthodenticle homolog 1 gene (OTX1) is transcribed in breast cancer. We established that the p53 protein directly induces OTX1 expression by acting on its promoter. OTX1 has been described as a critical molecule for axon refinement in the developing cerebral cortex of mice, and its activity in breast cancer suggests a synergistic function with p53 in CSC differentiation. Wild-type p53 may regulate cellular differentiation by an alternative pathway controlling OTX1 signaling only in breast cancer cells and not in physiological conditions. Oncogene (2011) 30, 3096-3103; doi: 10.1038/onc.2011.31; published online 11 April 2011	[Pagani, I. S.; Pasquali, F.; Curto, F. L.; Porta, G.] Univ Insubria, Dept Expt & Clin Biomed Sci, I-21100 Varese, Italy; [Terrinoni, A.; Serra, V.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Biochem Lab, IDI IRCCS, I-00173 Rome, Italy; [Zucchi, I.; Frattini, A.; Albertini, A.] CNR, Inst Biomed Technol, Milan, Italy; [Chiaravalli, A. M.] Osped Circolo Varese, Dept Pathol, Varese, Italy; [Dionigi, G.] Univ Insubria, Dept Surg Sci, Endocrine Surg Res Ctr, I-21100 Varese, Italy; [Sirchia, S.; Miozzo, M.] Univ Milan, Dept Med Surg & Dent, Med Genet Unit, Milan, Italy; [Ferrari, A.] Fdn IRCCS Policlin San Matteo, Pavia, Italy; [Capella, C.] Univ Insubria, Osped Circolo, Ctr Insubre Biotecnol Salute Umana, Dept Human Morphol,Anat Pathol Unit, I-21100 Varese, Italy; [Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	University of Insubria; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Insubria; University of Milan; IRCCS Fondazione San Matteo; Ospedale Circolo & Fondazione Macchi; University of Insubria; University of Leicester	Porta, G (corresponding author), Univ Insubria, Dept Expt & Clin Biomed Sci, Via Dunant 5, I-21100 Varese, Italy.	giovanni.porta@uninsubria.it	Frattini, Annalisa/B-7684-2015; Miozzo, Monica Rosa/AAC-6401-2022; Chiaravalli, Anna Maria/AAC-4135-2022; Pagani, Ilaria Stefania/J-9856-2019; Sirchia, Silvia/AAB-2620-2019; CHIARAVALLI, Anna Maria/AAC-2679-2022; Dionigi, Gianlorenzo/R-4381-2017; TERRINONI, Alessandro/J-1533-2012	Frattini, Annalisa/0000-0002-1166-3091; Miozzo, Monica Rosa/0000-0002-6523-4575; Pagani, Ilaria Stefania/0000-0002-3216-2966; CHIARAVALLI, Anna Maria/0000-0002-3924-2117; Dionigi, Gianlorenzo/0000-0003-0864-6087; TERRINONI, Alessandro/0000-0002-7442-2252; Ferrari, Alberta/0000-0003-2525-3787; albertini, alberto/0000-0002-7989-649X; Sirchia, Silvia/0000-0002-6106-3721; porta, giovanni/0000-0001-5260-2415	Medical Research Council, UK; Alleanza contro il Cancro [ACC12-ACC6]; MIUR [RBIP06LCA9_0023]; AIRC [2008-2010_33-08]; Italian Human ProteomeNet [RBRN07BMCT_007]; Telethon [GGPO9133]; Ministero della Salute [RF06-RF07]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alleanza contro il Cancro; MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC(Fondazione AIRC per la ricerca sul cancro); Italian Human ProteomeNet; Telethon(Fondazione Telethon); Ministero della Salute(Ministry of Health, Italy); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Centro Grandi Strumenti University of Insubria, Fondazione Comunitaria del Varesotto-ONLUS, Ministero dell'Istruzione, dell'Universita e della Ricerca DM25591 and Banca del Monte di Lombardia, Pavia, Italy to GP. This work has also been supported by the Medical Research Council, UK; 'Alleanza contro il Cancro' (ACC12-ACC6), MIUR/PRIN (RBIP06LCA9_0023), AIRC (2008-2010_33-08), Italian Human ProteomeNet RBRN07BMCT_007 and Telethon (GGPO9133) to GM, Ministero della Salute RF06-RF07 to GM. GP thanks to AIL Varese.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760; Blackburn AC, 2002, BREAST CANCER RES, V4, P98; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; CARBONE D, 1991, ONCOGENE, V6, P1691; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; Danilova N, 2008, MECH DEVELOP, V125, P919, DOI 10.1016/j.mod.2008.09.003; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Ford HL, 1998, CELL BIOL INT, V22, P397, DOI 10.1006/cbir.1998.0329; Gonzalez C, 2007, NAT REV GENET, V8, P462, DOI 10.1038/nrg2103; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Larsen KB, 2010, J HISTOCHEM CYTOCHEM, V58, P669, DOI 10.1369/jhc.2010.955757; Levantini E, 2003, P NATL ACAD SCI USA, V100, P10299, DOI 10.1073/pnas.1734071100; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Omodei D, 2009, AM J PATHOL, V175, P2609, DOI 10.2353/ajpath.2009.090542; Papadakis E. N., 2000, Molecular Cell Biology Research Communications, V3, P389, DOI 10.1006/mcbr.2000.0241; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Zhang YA, 2002, MOL CELL NEUROSCI, V19, P430, DOI 10.1006/mcne.2001.1076; Zucchi I, 2008, P NATL ACAD SCI USA, V105, P16940, DOI 10.1073/pnas.0808978105; Zucchi I, 2007, P NATL ACAD SCI USA, V104, P10476, DOI 10.1073/pnas.0703071104	33	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3096	3103		10.1038/onc.2011.31	http://dx.doi.org/10.1038/onc.2011.31			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21478910	Green Published			2022-12-17	WOS:000292510100009
J	Hu, G; Ren, G; Shi, Y				Hu, G.; Ren, G.; Shi, Y.			The putative cannabinoid receptor GPR55 promotes cancer cell proliferation	ONCOGENE			English	Editorial Material							LYSOPHOSPHATIDYLINOSITOL; LIGAND; BINDS	Cannabinoids, the active ingredients in marijuana, have dramatic effects on various organ systems. They exert their effects through two receptor types: CB1, primarily located in the brain, and CB2, primarily located in the immune system. Vertebrates also produce their own cannabinoid-like substances called endocannabinoids, including anandamide and 2-arachidonoylglyceral. Interestingly, some effects of endocannabinoids could not be explained by the signals through either CB1 or CB2. Recently, the orphan G protein-coupled receptor 55 (GPR55) was proposed to be an atypical cannabinoid receptor. In this issue of Oncogene, two groups demonstrated that GPR55 is expressed in various cancer types in an aggressiveness-related manner, suggesting a novel cancer biomarker and a potential therapeutic target. Oncogene (2011) 30, 139-141; doi:10.1038/onc.2010.502; published online 8 November 2010	[Hu, G.; Shi, Y.] Shanghai Jiao Tong Univ, Chinese Acad Sci, Key Lab Stem Cell Biol, Shanghai Inst Biol Sci,Sch Med,Inst Hlth Sci, Shanghai 200025, Peoples R China; [Ren, G.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Shi, Y (corresponding author), Shanghai Jiao Tong Univ, Chinese Acad Sci, Key Lab Stem Cell Biol, Shanghai Inst Biol Sci,Sch Med,Inst Hlth Sci, 225 S Chongqing Rd, Shanghai 200025, Peoples R China.	yufangshi@sibs.ac.cn	Ren, Gary/F-6724-2011; Shi, Yufang/AAE-4431-2020; Ren, Guangwen/D-8895-2012; Ren, Guangwen/H-5671-2011	Shi, Yufang/0000-0001-8964-319X; 				Alexander A, 2009, CANCER LETT, V285, P6, DOI 10.1016/j.canlet.2009.04.005; Andradas C, 2011, ONCOGENE, V30, P245, DOI 10.1038/onc.2010.402; DAS SK, 1995, P NATL ACAD SCI USA, V92, P4332, DOI 10.1073/pnas.92.10.4332; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Oesch S, 2009, J PHARM PHARMACOL, V61, P839, DOI 10.1211/jpp/61.07.0002; Oka S, 2010, J BIOCHEM, V147, P671, DOI 10.1093/jb/mvp208; PINCIRO R, 2011, ONCOGENE, V30, P142; Sharir H, 2010, PHARMACOL THERAPEUT, V126, P301, DOI 10.1016/j.pharmthera.2010.02.004; Staton PC, 2008, PAIN, V139, P225, DOI 10.1016/j.pain.2008.04.006; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V229, P58, DOI 10.1006/bbrc.1996.1757; Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106	14	30	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					139	141		10.1038/onc.2010.502	http://dx.doi.org/10.1038/onc.2010.502			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	21057532				2022-12-17	WOS:000286438900002
J	Carter, CL; Lin, C; Liu, CY; Yang, L; Liu, ZR				Carter, C. L.; Lin, C.; Liu, C-Y; Yang, L.; Liu, Z-R			Phosphorylated p68 RNA helicase activates snail1 transcription by promoting HDAC1 dissociation from the snail1 promoter	ONCOGENE			English	Article						p68 RNA helicase; Snail1; transcription activation; HDAC1; Mi-2/NuRD	EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; E-CADHERIN EXPRESSION; HISTONE ACETYLATION; TUMOR PROGRESSION; BETA-CATENIN; CHROMATIN; PROTEIN; COMPLEX; CANCER	The nuclear p68 RNA helicase is a prototypical member of the DEAD-box family of RNA helicases. p68 RNA helicase has been implicated in cell proliferation and early organ development and maturation. However, the functional role of p68 RNA helicase in these biological processes at the molecular level is not well understood. We previously reported that tyrosine phosphorylation of p68 RNA helicase mediates the effects of platelet-derived growth factor (PDGF) in induction of epithelial mesenchymal transition by promoting beta-catenin nuclear translocation. Here, we report that phosphorylation of p68 RNA helicase at Y593 upregulates transcription of the Snail1 gene. The phosphorylated p68 activates transcription of the Snail1 gene by promoting histone deacetylase (HDAC) 1 dissociation from the Snail1 promoter. Our results showed that p68 interacted with the nuclear remodeling and deacetylation complex MBD3:Mi-2/NuRD. Thus, our data suggested that a DEAD-box RNA unwindase could potentially regulate gene expression by functioning as a protein 'displacer' to modulate protein-protein interactions at the chromatin-remodeling complex. Oncogene (2010) 29, 5427-5436; doi: 10.1038/onc.2010.276; published online 2 August 2010	[Carter, C. L.; Lin, C.; Liu, C-Y; Yang, L.; Liu, Z-R] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Liu, ZR (corresponding author), Georgia State Univ, Dept Biol, Univ Plaza,24 Peachtree Ctr Ave, Atlanta, GA 30303 USA.	biozrl@langate.gsu.edu	Yang, Liuqing/B-7935-2011		National Institute of Health [GM063874, CA118113]; Georgia Cancer Coalition; NATIONAL CANCER INSTITUTE [R01CA118113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063874] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Roger Bridgeman for antibody p68-rgg production. We also thank Birgit Neuhaus for assistance in confocal imaging. This paper is greatly improved by critical comments from Jenny Yang, Mike Kirberger, Julian A. Johnson and Heena Dey. This study is supported in part by Research Grants from National Institute of Health (GM063874), (CA118113) and Georgia Cancer Coalition to ZR Liu.	Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Buszczak M, 2006, GENE DEV, V20, P977, DOI 10.1101/gad.1396306; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Liu ZR, 1998, MOL CELL BIOL, V18, P6910, DOI 10.1128/MCB.18.12.6910; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miyoshi A, 2005, BRIT J CANCER, V92, P252, DOI 10.1038/sj.bjc.6602266; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; Nyormoi O, 2003, CLIN EXP METASTAS, V20, P251, DOI 10.1023/A:1022991302172; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wei Y, 2001, Yi Chuan Xue Bao, V28, P991; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, CELL SIGNAL, V17, P1495, DOI 10.1016/j.cellsig.2005.03.008; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yang LQ, 2004, PROTEIN EXPRES PURIF, V35, P327, DOI 10.1016/j.pep.2004.02.004; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	48	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5427	5436		10.1038/onc.2010.276	http://dx.doi.org/10.1038/onc.2010.276			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20676135	Green Accepted			2022-12-17	WOS:000282944500009
J	Chu, WK; Hanada, K; Kanaar, R; Hickson, ID				Chu, W. K.; Hanada, K.; Kanaar, R.; Hickson, I. D.			BLM has early and late functions in homologous recombination repair in mouse embryonic stem cells	ONCOGENE			English	Article						Rad54; gene targeting; mitomycin C; sister chromatid exchanges; DNA crosslinking agents	SISTER-CHROMATID EXCHANGES; BLOOMS-SYNDROME HELICASE; DNA-DAMAGE; RESECT DNA; D-LOOPS; RAD54; PROTEIN; PROMOTES; SGS1; DISRUPTION	BLM is a RecQ family helicase that is defective in individuals with the cancer predisposition disorder, Bloom's syndrome (BS). At the cellular level, BS is characterized by hyper-recombination manifested as excessive sister chromatid exchange and loss of heterozygosity. However, the precise function of BLM remains unclear. Multiple roles have been proposed for BLM in the homologous recombination (HR) repair pathway, including 'early' functions, such as the stimulation of resection of DNA double-strand break ends or displacement of the invading strand of DNA displacement loops, and 'late' roles, such as dissolution of double Holliday junctions. However, most of the evidence for these putative roles comes from in vitro biochemical data. In this study, we report the characterization of mouse embryonic stem cells with disruption of Blm and/or Rad54 genes. We show that Blm has roles both upstream and downstream of the Rad54 protein, a core HR factor. Disruption of Rad54 in the Blm-mutant background reduced the elevated level of gene targeting and of sister chromatid exchanges, implying that Blm primarily functions downstream of Rad54 in the HR pathway. Conversely, however, mutation of Blm in Rad54(-/-) cells rescued their mitomycin C (MMC) sensitivity, and decreased both the level of DNA damage and cell cycle perturbation induced by MMC, suggesting an early role for Blm. Our data are consistent with Blm having at least two roles in HR repair in mammalian cells. Oncogene (2010) 29, 4705-4714; doi:10.1038/onc.2010.214; published online 7 June 2010	[Chu, W. K.; Hanada, K.; Hickson, I. D.] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England; [Hanada, K.; Kanaar, R.] Erasmus MC, Dept Cell Biol & Genet, Canc Genom Ctr, Dept Radiat Oncol, Rotterdam, Netherlands; [Hickson, I. D.] Univ Copenhagen, Panum Inst, Dept Cellular & Mol Med, DK-2200 Copenhagen N, Denmark	University of Oxford; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Copenhagen	Hickson, ID (corresponding author), Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England.	hickson@imm.ox.ac.uk	Hickson, Ian/AAJ-7548-2020; Chu, Wai Kit/F-9405-2016	Chu, Wai Kit/0000-0003-2903-3247; Hanada, Katsuhiro/0000-0003-0429-1899; Hickson, Ian/0000-0002-0583-566X	Cancer Research UK; Bloom's Syndrome Foundation; Netherlands Genomic Initiative/The Netherlands Organization for Scientific Research; Anita Mui 'True Heart' Charity Foundation; K P Tin Foundation Limited; China Oxford Scholarship	Cancer Research UK(Cancer Research UK); Bloom's Syndrome Foundation; Netherlands Genomic Initiative/The Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Anita Mui 'True Heart' Charity Foundation; K P Tin Foundation Limited; China Oxford Scholarship	We thank Dr A Bradley for Blm<SUP>m3/m4</SUP> cells, and Drs H te Riele and D Adams for the targeting vectors. We also thank Drs L Wu, P McHugh and CZ Bachrati for helpful comments on the paper, Mr PS North for advice on SCE assays and Miss P White for preparing the paper. This work was supported by Cancer Research UK and by The Bloom's Syndrome Foundation (IDH), and by The Netherlands Genomic Initiative/The Netherlands Organization for Scientific Research (RK). WK Chu was supported by the Anita Mui 'True Heart' Charity Foundation, the K P Tin Foundation Limited and the China Oxford Scholarship Fund.	Amitani I, 2006, MOL CELL, V23, P143, DOI 10.1016/j.molcel.2006.05.009; Bachrati CZ, 2006, NUCLEIC ACIDS RES, V34, P2269, DOI 10.1093/nar/gkl258; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Bugreev DV, 2007, GENE DEV, V21, P3085, DOI 10.1101/gad.1609007; Bugreev DV, 2006, NATURE, V442, P590, DOI 10.1038/nature04889; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Chu WK, 2009, NAT REV CANCER, V9, P644, DOI 10.1038/nrc2682; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Hanada K, 2006, EMBO J, V25, P4921, DOI 10.1038/sj.emboj.7601344; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Li X, 2009, MOL CELL, V36, P704, DOI 10.1016/j.molcel.2009.09.036; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Mankouri HW, 2007, MOL BIOL CELL, V18, P4062, DOI 10.1091/mbc.E07-05-0490; Marple T, 2006, MUTAT RES-FUND MOL M, V602, P110, DOI 10.1016/j.mrfmmm.2006.08.005; Mazina OM, 2008, P NATL ACAD SCI USA, V105, P18249, DOI 10.1073/pnas.0807016105; Mimitou EP, 2008, NATURE, V455, P770, DOI 10.1038/nature07312; Nimonkar AV, 2008, P NATL ACAD SCI USA, V105, P16906, DOI 10.1073/pnas.0809380105; Otsuki M, 2007, J CELL BIOL, V179, P53, DOI 10.1083/jcb.200702183; Ralf C, 2006, J BIOL CHEM, V281, P22839, DOI 10.1074/jbc.M604268200; Raynard S, 2006, J BIOL CHEM, V281, P13861, DOI 10.1074/jbc.C600051200; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Singh TR, 2008, GENE DEV, V22, P2856, DOI 10.1101/gad.1725108; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 2003, DNA REPAIR, V2, P787, DOI 10.1016/S1568-7864(03)00070-3; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wesoly J, 2006, MOL CELL BIOL, V26, P976, DOI 10.1128/MCB.26.3.976-989.2006; Wu L, 2006, P NATL ACAD SCI USA, V103, P4068, DOI 10.1073/pnas.0508295103; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Xu DY, 2008, GENE DEV, V22, P2843, DOI 10.1101/gad.1708608; Zhang R, 2005, CANCER RES, V65, P2526, DOI 10.1158/0008-5472.CAN-04-2421; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037	46	30	30	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4705	4714		10.1038/onc.2010.214	http://dx.doi.org/10.1038/onc.2010.214			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531307				2022-12-17	WOS:000281127400009
J	Zipfel, PA; Brady, DC; Kashatus, DF; Ancrile, BD; Tyler, DS; Counter, CM				Zipfel, P. A.; Brady, D. C.; Kashatus, D. F.; Ancrile, B. D.; Tyler, D. S.; Counter, C. M.			Ral activation promotes melanomagenesis	ONCOGENE			English	Article						melanoma; RalA; RalB; NRas	GTPASES; CANCER; PATHWAYS; EXPRESSION; FAMILY; GROWTH; RAIA	Up to one-third of human melanomas are characterized by an oncogenic mutation in the gene encoding the small guanosine triphosphatase (GTPase) NRAS. Ras proteins activate three primary classes of effectors, namely, Rafs, phosphatidyl-inositol-3-kinases (PI3Ks) and Ral guanine exchange factors (RalGEFs). In melanomas lacking NRAS mutations, the first two effectors can still be activated through an oncogenic BRAF mutation coupled with a loss of the PI3K negative regulator PTEN. This suggests that Ras effectors promote melanoma, regardless of whether they are activated by oncogenic NRas. The only major Ras effector pathway not explored for its role in melanoma is the RalGEF-Ral pathway, in which Ras activation of RalGEFs converts the small GTPases RalA and RalB to an active guanosine triphosphate-bound state. We report that RalA is activated in several human melanoma cancer cell lines harboring an oncogenic NRAS allele, an oncogenic BRAF allele or wild-type NRAS and BRAF alleles. Furthermore, short hairpin RNA (shRNA)-mediated knockdown of RalA, and to a lesser extent of RalB, variably inhibited the tumorigenic growth of melanoma cell lines having these three genotypes. Thus, as is the case for Raf and PI3K signaling, Rals also contribute to melanoma tumorigenesis. Oncogene (2010) 29, 4859-4864; doi:10.1038/onc.2010.224; published online 21 June 2010	[Zipfel, P. A.; Tyler, D. S.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Zipfel, P. A.; Tyler, D. S.] Durham VA Med Ctr, Durham, NC USA; [Brady, D. C.; Kashatus, D. F.; Ancrile, B. D.; Counter, C. M.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Counter, C. M.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; Duke University	Tyler, DS (corresponding author), Duke Univ, Med Ctr, Dept Surg, LSRC Bldg Room C225,Res Dr, Durham, NC 27710 USA.	tyler002@mc.duke.edu; count004@mc.duke.edu	Kashatus, David F/D-8299-2012; Brady, Donita/E-3801-2012	Kashatus, David F/0000-0001-8007-0612; Counter, Christopher M/0000-0003-0748-3079	American Cancer Society; National Institutes of Health [CA94184]; Leukemia & Lymphoma Fellowship; Veterans Affairs; NATIONAL CANCER INSTITUTE [R01CA094184] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Fellowship; Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by an American Cancer Society Grant to PAZ, a Leukemia & Lymphoma Fellowship to DFK, a Veterans Affairs Merit Review Grant to DST and a National Institutes of Health grant (CA94184) to CMC. We thank Dr Hillard Siegler (Duke University Medical Center) for all melanoma cell lines except SKMel28 cells.	Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Bodempudi V, 2009, MOL CELL BIOL, V29, P3964, DOI 10.1128/MCB.01153-08; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; de Gorter DJJ, 2008, BLOOD, V111, P3364, DOI 10.1182/blood-2007-08-106583; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Falsetti SC, 2007, MOL CELL BIOL, V27, P8003, DOI 10.1128/MCB.00057-07; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Lim KH, 2010, MOL CELL BIOL, V30, P508, DOI 10.1128/MCB.00916-08; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Mishra PJ, 2010, ONCOGENE, V29, P2449, DOI 10.1038/onc.2009.521; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Sowalsky AG, 2010, ONCOGENE, V29, P45, DOI 10.1038/onc.2009.307; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07	28	30	32	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4859	4864		10.1038/onc.2010.224	http://dx.doi.org/10.1038/onc.2010.224			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20562921	Green Accepted			2022-12-17	WOS:000281326400011
J	Ji, P; Smith, SM; Wang, Y; Jiang, R; Song, SW; Li, B; Sawaya, R; Bruner, JM; Kuang, J; Yu, H; Fuller, GN; Zhang, W				Ji, P.; Smith, S. M.; Wang, Y.; Jiang, R.; Song, S. W.; Li, B.; Sawaya, R.; Bruner, J. M.; Kuang, J.; Yu, H.; Fuller, G. N.; Zhang, W.			Inhibition of gliomagenesis and attenuation of mitotic transition by MIIP	ONCOGENE			English	Article						MIIP; mitotic transition; gliomagenesis; APC/C(Cdc20); centrosome; mitotic catastrophe	ANAPHASE-PROMOTING COMPLEX; PRIMARY BRAIN-TUMORS; CELL-MIGRATION; SPINDLE CHECKPOINT; CYCLIN-B; CDC20; GLIOMA; DESTRUCTION; DEGRADATION; INVASION	The migration and invasion inhibitor protein (MIIP, also known as IIp45) was discovered as a negative regulator of cell migration and invasion in glioma. Our previous studies have shown that the MIIP protein was reduced or undetectable in some tissue samples obtained from patients with glioblastoma. The significance of MIIP in gliomagenesis is unknown. In this study, we report that MIIP has an important role in the inhibition of gliomagenesis and attenuation of mitotic transition. Increased MIIP expression levels inhibited colony formation and cell growth of glioma cell lines in vitro, whereas decreased expression by specific small interfering RNA for MIIP resulted in increased cell growth. Expression of MIIP in a glial-specific mouse model blocked glioma development and progression, thus showing that MIIP is an inhibitor of gliomagenesis. Furthermore, we show that MIIP attenuates mitotic transition and results in increased mitotic catastrophe. The biochemical mechanism of MIIP in this process is associated with its regulation of anaphase-promoting complex (APC/C) activity. MIIP interacts directly with Cdc20, and the interaction of MIIP with Cdc20 inhibits APC/C-mediated degradation of cyclin B1. Thus, MIIP attenuates mitotic transition and increases mitotic catastrophe, thereby inhibiting glioma development and progression. Oncogene (2010) 29, 3501-3508; doi:10.1038/onc.2010.114; published online 26 April 2010	[Ji, P.; Smith, S. M.; Wang, Y.; Jiang, R.; Song, S. W.; Bruner, J. M.; Fuller, G. N.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Smith, S. M.] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA; [Wang, Y.] Tianjin Med Univ, Gen Hosp, Dept Gynecol, Tianjin, Peoples R China; [Wang, Y.] Tianjin Med Univ, Gen Hosp, Dept Obstet, Tianjin, Peoples R China; [Jiang, R.] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Song, S. W.] Capital Med Univ, Beijing Shijitan Hosp, Canc Res Lab, Beijing, Peoples R China; [Li, B.; Yu, H.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Sawaya, R.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Kuang, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Capital Medical University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Unit 85, Houston, TX 77030 USA.	wzhang@mdanderson.org		Yu, Hongtao/0000-0002-8861-049X; Wang, Yingmei/0000-0001-6457-3420; Fuller, Gregory/0000-0001-9447-2647	Texas Higher Education Coordinating Board; Anthony Bullock Brain Tumor Research Fund; NIH [RO1 CA98503]; National Foundation for Cancer Research; Goldhirsh Foundation; James S McDonnell Foundation; Oreffice Foundation; American Legion Fellowship; NATIONAL CANCER INSTITUTE [R01CA098503] Funding Source: NIH RePORTER	Texas Higher Education Coordinating Board; Anthony Bullock Brain Tumor Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Foundation for Cancer Research; Goldhirsh Foundation; James S McDonnell Foundation; Oreffice Foundation; American Legion Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kanchana Natarajan-Mendes for her contribution to the cell-cycle assays in this study, and Hong Zheng for her technical assistance. We thank Drs Ying Wu, Limei Hu and Paul Chiao for critically reviewing the manuscript and providing valuable comments. We gratefully thank Dr Kate J Newberry at the Department of Scientific Publications of MD Anderson Cancer Center for editing this paper. This study was partially supported by an ARP Grant from the Texas Higher Education Coordinating Board, the Anthony Bullock Brain Tumor Research Fund and NIH grant RO1 CA98503 (to WZ and GNF). We also thank the National Foundation for Cancer Research, the Goldhirsh Foundation, the James S McDonnell Foundation and the Oreffice Foundation for their support. Sarah M Smith (formerly Sarah M Dunlap) was supported by an NIH Pharmacoinformatics Training Fellowship and an American Legion Fellowship.	Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Demuth T, 2004, J NEURO-ONCOL, V70, P217, DOI 10.1007/s11060-004-2751-6; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; Gibbs M, 1999, AM J HUM GENET, V64, P776, DOI 10.1086/302287; Hoffman S, 2006, NEURO-ONCOLOGY, V8, P27, DOI 10.1215/S1522851705000323; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Homer HA, 2005, REPRODUCTION, V130, P829, DOI 10.1530/rep.1.00856; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Munirajan AK, 2008, J BIOL CHEM, V283, P24426, DOI 10.1074/jbc.M802316200; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Song FF, 2010, CANCER RES, V70, P1024, DOI 10.1158/0008-5472.CAN-09-3742; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Song SW, 2005, CANCER RES, V65, P3562, DOI 10.1158/0008-5472.CAN-04-3392; Song SW, 2003, P NATL ACAD SCI USA, V100, P13970, DOI 10.1073/pnas.2332186100; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Wolthuis R, 2008, MOL CELL, V30, P290, DOI 10.1016/j.molcel.2008.02.027; Wu Y, 2010, J BIOL CHEM, V285, P3554, DOI 10.1074/jbc.M109.063354; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yu H, 2007, MOL CELL, V27, P3, DOI 10.1016/j.molcel.2007.06.009	30	30	35	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3501	3508		10.1038/onc.2010.114	http://dx.doi.org/10.1038/onc.2010.114			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20418911				2022-12-17	WOS:000278835400005
J	Molenaar, JJ; Ebus, ME; Koster, J; Santo, E; Geerts, D; Versteeg, R; Caron, HN				Molenaar, J. J.; Ebus, M. E.; Koster, J.; Santo, E.; Geerts, D.; Versteeg, R.; Caron, H. N.			Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells	ONCOGENE			English	Article						CCND1; ChIP; GATA3; microarray; neuroblastoma	ESTROGEN-RECEPTOR; BREAST-CANCER; AMPLIFICATION; HYDROXYLASE; EXPRESSION; FATE; GENE	Almost all neuroblastoma tumors express excess levels of Cyclin D1 (CCND1) compared to normal tissues and other tumor types. Only a small percentage of these neuroblastoma tumors have high-level amplification of the Cyclin D1 gene. The other neuroblastoma tumors have equally high Cyclin D1 expression without amplification. Silencing of Cyclin D1 expression was previously found to trigger differentiation of neuroblastoma cells. Overexpression of Cyclin D1 is therefore one of the most frequent mechanisms with a postulated function in neuroblastoma pathogenesis. The cause for the Cyclin D1 overexpression is unknown. Here we show that Cyclin D1 overexpression results from transcriptional upregulation. To identify upstream regulators, we searched in mRNA profiles of neuroblastoma tumor series for transcription factors with expression patterns correlating to Cyclin D1. GATA3 most consistently correlated to Cyclin D1 in four independent data sets. We identified a highly conserved GATA3 binding site 27 bp upstream of the Cyclin D1 transcriptional start. Chromatin immune precipitation confirmed binding of GATA3 to the Cyclin D1 promoter. Overexpression of GATA3 induced Cyclin D1 promoter activity, which decreased after site-directed mutagenesis of the GATA3 binding site in the Cyclin D1 promoter. Silencing of GATA3 resulted in reduced Cyclin D1 promoter activity and reduced Cyclin D1 mRNA and protein levels. Moreover, GATA3 silencing caused differentiation that was similar to that caused by Cyclin D1 inhibition. These finding implicate GATA3 in Cyclin D1 overexpression in neuroblastoma. Oncogene (2010) 29, 2739-2745; doi:10.1038/onc.2010.21; published online 15 February 2010	[Molenaar, J. J.; Ebus, M. E.; Koster, J.; Santo, E.; Geerts, D.; Versteeg, R.] Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; [Molenaar, J. J.; Caron, H. N.] Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, Dept Pediat Oncol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Molenaar, JJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Genet, M1-132,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.j.molenaar@amc.uva.nl	Koster, Jan/C-5934-2008; Versteeg, Rogier/AAQ-1765-2020; Geerts, Dirk/K-8260-2015	Koster, Jan/0000-0002-0890-7585; Geerts, Dirk/0000-0002-6386-8187; Versteeg, Rogier/0000-0001-7172-0388	Stichting Koningin Wilhelmina Fonds; Stichting Kindergeneeskundig Kankeronderzoek; Kinderen Kankervrij	Stichting Koningin Wilhelmina Fonds; Stichting Kindergeneeskundig Kankeronderzoek; Kinderen Kankervrij	We kindly thank Dr RG Pestell for the full-length Cyclin D1 pA3 promoter construct that we used to generate our pGL3 Cyclin D1 promoter construct. The work was supported by Stichting Koningin Wilhelmina Fonds (KWF), Stichting Kindergeneeskundig Kankeronderzoek (SKK) and Kinderen Kankervrij (KiKa).	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Caren H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-353; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoch RV, 1999, INT J CANCER, V84, P122; Hong SJ, 2008, NEUROCHEM RES, V33, P1821, DOI 10.1007/s11064-008-9639-3; Hong SJ, 2006, J NEUROCHEM, V98, P773, DOI 10.1111/j.1471-4159.2006.03924.x; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Michels E, 2007, GENE CHROMOSOME CANC, V46, P1098, DOI 10.1002/gcc.20496; Molenaar JJ, 2008, CANCER RES, V68, P2599, DOI 10.1158/0008-5472.CAN-07-5032; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; Pei XH, 2009, CANCER CELL, V15, P389, DOI 10.1016/j.ccr.2009.03.004; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tsarovina K, 2004, DEVELOPMENT, V131, P4775, DOI 10.1242/dev.01370; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Vallania F, 2009, P NATL ACAD SCI USA, V106, P5117, DOI 10.1073/pnas.0900473106; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; VANROY N, 1995, CANCER GENET CYTOGEN, V82, P151; Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49	23	30	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2739	2745		10.1038/onc.2010.21	http://dx.doi.org/10.1038/onc.2010.21			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20154722				2022-12-17	WOS:000277354600013
J	Luo, P; Yang, X; Ying, M; Chaudhry, P; Wang, A; Shimada, H; May, WA; Adams, GB; Mock, D; Triche, TJ; He, Q; Wu, L				Luo, P.; Yang, X.; Ying, M.; Chaudhry, P.; Wang, A.; Shimada, H.; May, W. A.; Adams, G. B.; Mock, D.; Triche, T. J.; He, Q.; Wu, L.			Retinoid-suppressed phosphorylation of RAR alpha mediates the differentiation pathway of osteosarcoma cells	ONCOGENE			English	Article						RA response pathways; decreased CAK phosphorylation of RAR alpha; cell-cycle G(1) exit; RA-RAR alpha-FGF8f signaling; transcriptional expression of RA target genes	KINASE-ACTIVATING KINASE; ACID RECEPTOR-ALPHA; FGF SIGNALING PATHWAYS; IN-VITRO; HUMAN OSTEOBLASTS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GROWTH-FACTOR; CYCLE CONTROL; TARGET GENES	Although retinoic acid (RA) is a potent agent that coordinates inhibition of proliferation with differentiation of many cell types, RA-mediated signaling pathways in osteosarcoma cell differentiation are uncharacterized. In this study, we show that in human U2OS osteosarcoma cells, decreased phosphorylation of RA receptor alpha (RAR alpha) by RA treatment or overexpressing a phosphorylation- defective mutant RAR alpha S77A results in the inhibition of proliferation and induction of differentiation, and that U2OS cells transduced with RAR alpha S77A suppresses tumor formation in nude mice. Moreover, using different human primary osteosarcoma cells and human mesenchymal stem cells for gene expression analysis, we found that either RA or RAR alpha S77A induces many of the same differentiation response pathways and signaling molecules involved in U2OS cell differentiation. In addition, overexpression of the fibroblast growth factor 8f (FGF8f), one of the downstream targets induced by both RA and RAR alpha S77A in U2OS cells, inhibits proliferation and induces expression of osteoblastic differentiation regulators. Hence, these data strongly suggest that RA-suppressed phosphorylation of RAR alpha induces FGF8f expression to mediate differentiation response pathway in U2OS osteosarcoma cells. Oncogene (2010) 29, 2772-2783; doi: 10.1038/onc.2010.50; published online 1 March 2010	[Wu, L.] Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med, Los Angeles, CA 90027 USA; [Luo, P.; Yang, X.; Ying, M.; Chaudhry, P.; Wang, A.; Shimada, H.; Mock, D.; Triche, T. J.; Wu, L.] Childrens Hosp Los Angeles, Dept Pathol, Saban Res Inst, Los Angeles, CA 90027 USA; [May, W. A.] Childrens Hosp Los Angeles, Dept Pediat, Saban Res Inst, Los Angeles, CA 90027 USA; [Adams, G. B.] Univ So Calif, Keck Sch Med, Ctr Stem Cell & Regenerat Med, Los Angeles, CA 90027 USA; [He, Q.] Zhejiang Univ, Inst Pharmacol & Toxicol, Sch Pharmaceut Sci, Hangzhou 310003, Zhejiang, Peoples R China	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of Southern California; Zhejiang University	Wu, L (corresponding author), Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu	Chaudhry, Parvesh/I-4417-2015; he, qiaojun/F-3198-2010		National Institutes of Health [R21 CA111440, R01 CA120512, 1 UO1 CA114757-01]; NATIONAL CANCER INSTITUTE [R01CA120512, R21CA111440, U01CA114757, R21CA137485] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Grants from the National Institutes of Health R21 CA111440 and R01 CA120512 to L Wu, and 1 UO1 CA114757-01 to TJ Triche.	Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bacci G, 2001, EUR J CANCER, V37, P32, DOI 10.1016/S0959-8049(00)00361-0; Barroga E, 1999, J VET MED A, V46, P573, DOI 10.1046/j.1439-0442.1999.00251.x; Barroga EF, 2000, VET J, V159, P186, DOI 10.1053/tvjl.1999.0441; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BEERE HM, 1993, ANTI-CANCER DRUG DES, V8, P299; BENAYAHU D, 1994, J CELL BIOCHEM, V56, P62, DOI 10.1002/jcb.240560111; Brondani V, 2000, BIOCHEM BIOPH RES CO, V272, P98, DOI 10.1006/bbrc.2000.2740; Brondani V, 2002, J MOL BIOL, V319, P715, DOI 10.1016/S0022-2836(02)00376-5; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432-007-0330-x; Crowe David L, 2002, Cancer Cell Int, V2, P15, DOI 10.1186/1475-2867-2-15; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; He QJ, 2004, FASEB J, V18, P1734, DOI 10.1096/fj.04-2182fje; Hoffman UM, 2003, J BONE JOINT SURG AM, V85A, P124, DOI 10.2106/00004623-200300002-00017; Hong SH, 2000, RES VET SCI, V68, P57, DOI 10.1053/rvsc.1999.0338; Hong SH, 2000, AM J VET RES, V61, P69, DOI 10.2460/ajvr.2000.61.69; Horowitz MC, 2005, IMMUNOL REV, V208, P141, DOI 10.1111/j.0105-2896.2005.00328.x; Jackson RA, 2006, GENE, V379, P79, DOI 10.1016/j.gene.2006.04.028; Jacobson A, 2004, BIOCHEM BIOPH RES CO, V322, P162, DOI 10.1016/j.bbrc.2004.07.092; Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; Li ZX, 2006, TRENDS BIOCHEM SCI, V31, P589, DOI 10.1016/j.tibs.2006.08.001; Liu F, 2008, CELL SIGNAL, V20, P999, DOI 10.1016/j.cellsig.2007.11.011; Luo PH, 2007, STEM CELLS, V25, P2628, DOI 10.1634/stemcells.2007-0264; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Mattila MA, 2007, CYTOKINE GROWTH F R, V18, P257, DOI 10.1016/j.cytogfr.2007.04.010; Mayack SR, 2008, BLOOD, V112, P519, DOI 10.1182/blood-2008-01-133710; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Orimo H, 2005, BONE, V36, P866, DOI 10.1016/j.bone.2005.02.010; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Rochette-Egly C, 2000, MOL ENDOCRINOL, V14, P1398, DOI 10.1210/me.14.9.1398; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; SONG LN, 1994, ONCOL RES, V6, P111; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518; TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850; TRAIANEDES K, 1993, J CELL PHYSIOL, V157, P243, DOI 10.1002/jcp.1041570206; WANG A, 2009, FASEB J; Wang JG, 2006, FASEB J, V20, P2142, DOI 10.1096/fj.06-5900fje; Wang JW, 2002, J BIOL CHEM, V277, P43369, DOI 10.1074/jbc.M206792200; Wang XD, 2005, ALCOHOL, V35, P251, DOI 10.1016/j.alcohol.2005.04.006; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; WU LT, 1994, ONCOGENE, V9, P2089; Zhang SN, 2004, CANCER RES, V64, P2977, DOI 10.1158/0008-5472.CAN-03-4018; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	57	30	32	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2772	2783		10.1038/onc.2010.50	http://dx.doi.org/10.1038/onc.2010.50			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190807				2022-12-17	WOS:000277591900003
J	Wu, J; Zhang, YC; Suo, WH; Liu, XB; Shen, WW; Tian, H; Fu, GH				Wu, J.; Zhang, Y-C; Suo, W-H; Liu, X-B; Shen, W-W; Tian, H.; Fu, G-H			Induction of anion exchanger-1 translation and its opposite roles in the carcinogenesis of gastric cancer cells and differentiation of K562 cells	ONCOGENE			English	Article						anion exchanger-1; band-3; miR-24; erythropoiesis; gastric carcinogenesis	ERYTHROID-DIFFERENTIATION; NONERYTHROID CELLS; PROGENITOR CELLS; ALPHA-SPECTRIN; BETA-SPECTRIN; KIDNEY BAND-3; PROTEIN 4.1; AE1 GENE; EXPRESSION; CLONING	Anion exchanger-1 (AE1), an erythroid-specific membrane protein, mediates the Cl(-)/HCO(3)(-) exchange across the plasma membrane and regulates intracellular pH. We have found that AE1 was unexpectedly expressed in gastric cancer cells and participated in the tumorigenesis of the cancer. Here, we focus on the induction of AE1 expression and its role in gastric carcinogenesis as well as in the differentiation of K562 cells. The results show that expression of AE1 is not related to genetic mutation or the mRNA level, but rather, that it is modulated by miR-24. miR-24 decreases the expression of AE1 through binding to the 3'UTR of AE1 mRNA. Transfection of an miR-24 into gastric cancer cells reduced the elevation of the AE1 protein, which resulted in return of AE1-sequestrated p16 to the nucleus, thereby inhibiting proliferation of the cells. Furthermore, the miR-24 inhibitor cooperated with hemin to induce the expression of AE1 in K562 cells and differentiation of the cells, which is consistent with results obtained from the cells cultured at pH 7.6 or from forced stable expression of AE1. These findings establish a novel regulation of miR-24-related AE1 expression in gastric carcinogenesis and erythropoiesis. Oncogene (2010) 29, 1987-1996; doi:10.1038/onc.2009.481; published online 11 January 2010	[Wu, J.; Zhang, Y-C; Suo, W-H; Shen, W-W; Tian, H.; Fu, G-H] Shanghai Jiao Tong Univ, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Sch Med,Inst Med Sci,Dept Pathol, Shanghai 200025, Peoples R China; [Liu, X-B] Harbin Med Coll, Oncol Affiliated Hosp 2, Radiat Dept, Harbin, Peoples R China	Shanghai Jiao Tong University; Harbin Medical University	Fu, GH (corresponding author), Shanghai Jiao Tong Univ, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Sch Med,Inst Med Sci,Dept Pathol, 280 S Chong Qing Rd, Shanghai 200025, Peoples R China.	fuguhu@263.net		Wu, Jun/0000-0003-2515-6418	National Natural Science Foundation of China [NO30570697, NO30770960]; National High Technology Research and Development Program of China [NO2008AA02Z120]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China)	This work was supported in part by the National Natural Science Foundation of China (NO30570697, NO30770960) and National High Technology Research and Development Program of China (863 Program) (NO2008AA02Z120).	ALPER SL, 1994, J CLIN INVEST, V93, P1430, DOI 10.1172/JCI117120; An XL, 2005, BIOCHEMISTRY-US, V44, P10681, DOI 10.1021/bi047331z; Durham JT, 2009, MICROVASC RES, V77, P281, DOI 10.1016/j.mvr.2008.12.003; ENDO T, 1994, LEUKEMIA RES, V18, P49, DOI 10.1016/0145-2126(94)90008-6; Friis-Hansen L, 2006, SCAND J CLIN LAB INV, V66, P607, DOI 10.1080/00365510600873894; Fu GH, 2005, FEBS LETT, V579, P2105, DOI 10.1016/j.febslet.2005.02.063; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Galluzzi L, 2001, FEBS LETT, V489, P254, DOI 10.1016/S0014-5793(00)02333-4; Gascard P, 2000, CURR OPIN HEMATOL, V7, P123, DOI 10.1097/00062752-200003000-00009; Georgantas RW, 2007, P NATL ACAD SCI USA, V104, P2750, DOI 10.1073/pnas.0610983104; Huo XF, 2006, MOL CELL BIOCHEM, V292, P155, DOI 10.1007/s11010-006-9229-0; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; Lal A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001864; Lal A, 2009, NAT STRUCT MOL BIOL, V16, P492, DOI 10.1038/nsmb.1589; LEHNERT ME, 1988, J CELL BIOL, V107, P413, DOI 10.1083/jcb.107.2.413; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; McAdams TA, 1998, BRIT J HAEMATOL, V103, P317, DOI 10.1046/j.1365-2141.1998.00975.x; McAdams TA, 1997, BRIT J HAEMATOL, V97, P889, DOI 10.1046/j.1365-2141.1997.1372951.x; Merkerova M, 2008, EUR J HAEMATOL, V81, P304, DOI 10.1111/j.1600-0609.2008.01111.x; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Richards SM, 1999, J CELL SCI, V112, P1519; Ruan K, 2009, CANCER LETT, V285, P116, DOI 10.1016/j.canlet.2009.04.031; SAHR KE, 1994, GENOMICS, V24, P491, DOI 10.1006/geno.1994.1658; SCHOFIELD AE, 1994, BLOOD, V84, P2000; Shapiro GI, 2000, CELL BIOCHEM BIOPHYS, V33, P189, DOI 10.1385/CBB:33:2:189; Shen WW, 2007, NEOPLASIA, V9, P812, DOI 10.1593/neo.07403; SHOWE L C, 1987, Genomics, V1, P71, DOI 10.1016/0888-7543(87)90107-8; Takakuwa Y, 2000, INT J HEMATOL, V72, P298; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; WANG CC, 1995, J BIOL CHEM, V270, P17892, DOI 10.1074/jbc.270.30.17892; Wang JY, 2009, J CELL PHYSIOL, V219, P617, DOI 10.1002/jcp.21711; Wang Q, 2008, BLOOD, V111, P588, DOI 10.1182/blood-2007-05-092718; Xu WQ, 2009, J CANCER RES CLIN, V135, P1323, DOI 10.1007/s00432-009-0573-9; Yang GH, 2009, J CELL BIOCHEM, V107, P548, DOI 10.1002/jcb.22156	35	30	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1987	1996		10.1038/onc.2009.481	http://dx.doi.org/10.1038/onc.2009.481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062076				2022-12-17	WOS:000276199600011
J	Yamasaki, N; Miyazaki, K; Nagamachi, A; Koller, R; Oda, H; Miyazaki, M; Sasaki, T; Honda, Z; Wolff, L; Inaba, T; Honda, H				Yamasaki, N.; Miyazaki, K.; Nagamachi, A.; Koller, R.; Oda, H.; Miyazaki, M.; Sasaki, T.; Honda, Z-i; Wolff, L.; Inaba, T.; Honda, H.			Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia	ONCOGENE			English	Article						E2A-HLF; inducible knock-in mice; retrovirus insertional mutagenesis; Zfp521/ZNF521	RETROVIRAL INSERTIONAL MUTAGENESIS; DOWNSTREAM TARGET; CELL DEVELOPMENT; BLAST CRISIS; E2A GENE; EXPRESSION; TRANSFORMATION; MYC; DIFFERENTIATION; LYMPHOMAGENESIS	E2A-hepatic leukemia factor (HLF) is a chimeric protein found B-lineage acute lymphoblastic leukemia (ALL) with t(17;19). To analyze the leukemogenic process and to create model mice for t(17;19)-positive leukemia, we generated inducible knock-in (iKI) mice for E2A-HLF. Despite the induced expression of E2A-HLF in the hematopoietic tissues, no disease was developed during the long observation period, indicating that additional gene alterations are required to develop leukemia. To elucidate this process, E2A-HLF iKI and control littermates were subjected to retroviral insertional mutagenesis. Virus infection induced acute leukemias in E2A-HLF iKI mice with higher morbidity and mortality than in control mice. Inverse PCR detected three common integration sites specific for E2A-HLF iKI leukemic mice, which induced overexpression of zinc-finger transcription factors: growth factor independent 1 (Gfi1), zinc-finger protein subfamily 1A1 isoform a (Zfp1a1, also known as Ikaros) and zinc-finger protein 521 (Zfp521). Interestingly, tumors with Zfp521 integration exclusively showed B-lineage ALL, which corresponds to the phenotype of human t(17;19)-positive leukemia. In addition, ZNF521 (human counterpart of Zfp521) was found to be over-expressed in human leukemic cell lines harboring t(17;19). Moreover, both iKI for E2A-HLF and transgenic for Zfp521 mice frequently developed B-lineage ALL. These results indicate that a set of transcription factors promote leukemic transformation of E2A-HLF-expressing hematopoietic progenitors and suggest that aberrant expression of Zfp521/ZNF521 may be clinically relevant to t(17;19)positive B-lineage ALL. Oncogene (2010) 29, 1963-1975; doi:10.1038/onc.2009.475; published online 11 January 2010	[Yamasaki, N.; Miyazaki, K.; Sasaki, T.; Honda, H.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol, Minami Ku, Hiroshima 7348553, Japan; [Nagamachi, A.; Inaba, T.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Oncol, Minami Ku, Hiroshima 7348553, Japan; [Koller, R.; Wolff, L.] NCI, Leukemogenosis Sect, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; [Oda, H.] Tokyo Womens Med Univ, Dept Pathol, Shinjuku Ku, Tokyo, Japan; [Miyazaki, M.] Hiroshima Univ, Grad Sch Biomed Sci, Dept Immunol, Minami Ku, Hiroshima 7348553, Japan; [Honda, Z-i] Univ Tokyo, Grad Sch Med, Fac Med, Dept Allergy & Rheumatol,Bunkyo Ku, Tokyo, Japan	Hiroshima University; Hiroshima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tokyo Women's Medical University; Hiroshima University; University of Tokyo	Honda, H (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	hhonda@hiroshima-u.ac.jp			Ministry of Education, Science and Culture of Japan; Ministry of Health, Labour and Welfare of Japan [13-2]; Takeda Science Foundation; Astellas Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Takeda Science Foundation(Takeda Science Foundation (TSF)); Astellas Foundation(Astellas Pharmaceuticals)	We thank Yuki Sakai, Kayoko Hashimoto, Yuko Tsukawaki and Rika Tai, for the care of the mice and technical assistance, Dr Nobuaki Yoshida for E14 ES cells, Dr Soren Warming, Dr Neal G Copeland and Dr Nancy A Jenkins for mouse Zfp521 cDNA, Dr Koichi Ikuta for mouse TCRJb probe, Dr Hirotaka Matsui for statistical analysis and Dr Takuro Nakamura for helpful discussion. This work was in part supported by a grant-in-aid from the Ministry of Education, Science and Culture of Japan, a grant-in-aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (13-2), Takeda Science Foundation, Astellas Foundation for Research on Metabolic Disorders, the Japan Leukaemia Research Fund and Tsuchiya Foundation.	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Aspland SE, 2001, ONCOGENE, V20, P5708, DOI 10.1038/sj.onc.1204592; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Bond HM, 2008, INT J BIOCHEM CELL B, V40, P848, DOI 10.1016/j.biocel.2007.04.006; Dang JJ, 2001, MOL CELL BIOL, V21, P5935, DOI 10.1128/MCB.21.17.5935-5945.2001; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Hentges KE, 2005, ONCOGENE, V24, P1220, DOI 10.1038/sj.onc.1208243; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Honda H, 1999, BLOOD, V93, P2780; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inukai T, 1997, MOL CELL BIOL, V17, P1417, DOI 10.1128/MCB.17.3.1417; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kurosawa H, 1999, BLOOD, V93, P321, DOI 10.1182/blood.V93.1.321.401k05_321_332; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Matsunaga T, 2004, BLOOD, V103, P3185, DOI 10.1182/blood-2003-09-3022; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Miyazaki K, 2009, BLOOD, V113, P4702, DOI 10.1182/blood-2007-05-088724; Mizuno T, 2008, ONCOGENE, V27, P3465, DOI 10.1038/sj.onc.1211007; Nakamura T, 2005, CANCER SCI, V96, P7, DOI 10.1111/j.1349-7006.2005.00011.x; Nakayama H, 1999, CANCER RES, V59, P3931; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Seidel MG, 2001, ONCOGENE, V20, P5718, DOI 10.1038/sj.onc.1204591; SHINTO Y, 1995, ONCOGENE, V11, P1729; Smith KS, 2002, MOL CELL BIOL, V22, P7678, DOI 10.1128/MCB.22.21.7678-7688.2002; Smith KS, 1999, MOL CELL BIOL, V19, P4443; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; Wolff L, 2003, ONCOGENE, V22, P9265, DOI 10.1038/sj.onc.1207092; Wolff L, 2003, J VIROL, V77, P4965, DOI 10.1128/JVI.77.8.4965-4971.2003; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zornig M, 1996, ONCOGENE, V12, P1789	43	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1963	1975		10.1038/onc.2009.475	http://dx.doi.org/10.1038/onc.2009.475			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062079				2022-12-17	WOS:000276199600009
J	See, WL; Miller, JP; Squatrito, M; Holland, E; Resh, MD; Koff, A				See, W. L.; Miller, J. P.; Squatrito, M.; Holland, E.; Resh, M. D.; Koff, A.			Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas	ONCOGENE			English	Article						p27; tumor suppressor; DNA repair; glioma; mouse model	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; HOMOLOGOUS RECOMBINATION; TUMOR SUPPRESSION; NUCLEAR FOCI; FACTOR-B; P27(KIP1); P27; EXPRESSION; DAMAGE	The tumor suppressive activities of the Kip-family of cyclin-dependent kinase (cdk) inhibitors often go beyond their role directly regulating the cell cycle. In this study, we show that p27 enhances Rad51 accumulation during repair of double-strand DNA breaks. Progression of platelet-derived growth factor (PDGF)-induced oligodendrogliomas was accelerated in mice lacking the cyclin-cdk binding activities of p27(kip1). To understand how p27 deficiency contributes, cell lines were developed from RCAS-PDGF infection of nestin-tv-a brain progenitor cells in culture. p27 deficiency did not affect cell proliferation in early passage cell lines; however, the absence of p27 affected chromosomal stability. In p27-deficient cells, the activation of Atm and Chk2 and the accumulation of gamma-H2AX was unaffected when compared with wild-type cells, and the number of phospho-histone H3 staining mitotic cells was decreased, consistent with G2/M checkpoint activation. However, the percentage of Rad51 foci-positive cells was decreased, and the kinase activity that targets the C-terminus of BRCA2, regulating BRCA2/Rad51 interactions, was increased in lysates derived from p27-deficient cells. Increased numbers of chromatid breaks in p27-deficient cells that adapted to the checkpoint were also observed. These findings suggest that Rad51-dependent repair of double-stranded breaks was hindered in p27-deficient cells, leading to chromosomal instability, a hallmark of cancers with poor prognosis. Oncogene (2010) 29, 1720-1731; doi:10.1038/onc.2009.465; published online 11 January 2010	[See, W. L.; Resh, M. D.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; [Miller, J. P.; Koff, A.] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; [Squatrito, M.; Holland, E.] Mem Sloan Kettering Canc Ctr, Program Canc Biol & Genet, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, RRL917C,Box 207,1275 York Ave, New York, NY 10021 USA.	m-resh@ski.mskcc.org; a-koff@ski.mskcc.org	Squatrito, Massimo/F-4149-2016	Squatrito, Massimo/0000-0002-4593-3790; Resh, Marilyn/0000-0001-6118-9466; Koff, Andrew/0000-0003-3271-3067	US National Institutes of Health [CA96582, CA89563]; Golfers Against Cancer Foundation; Institutional Core Grant; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA096582, R01CA089563] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Golfers Against Cancer Foundation; Institutional Core Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Travis Stracker, John Petrini, Yossi Shiloh, Yuhui Liu, Nancy Yeh, Daniel Ciznadija, Dolores Hambardzumyan, Oren Becher, Elena Fomchenko, and Robert Finney, Katia Manova, Lei Zhang, Kalyani Chadalavada, Margaret Leversha, Jan Hendrix and Diane Domingo. This research was supported by the US National Institutes of Health Grant CA96582 (to MR, AK and EH), CA89563 (to AK) and funds from The Golfers Against Cancer Foundation (to AK). Additional support was provided by an Institutional Core Grant to Memorial Sloan-Kettering Cancer Center.	Anantha RW, 2007, J BIOL CHEM, V282, P35910, DOI 10.1074/jbc.M704645200; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Aylon Y, 2004, EMBO J, V23, P4868, DOI 10.1038/sj.emboj.7600469; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Becher OJ, 2008, CANCER RES, V68, P2241, DOI 10.1158/0008-5472.CAN-07-6350; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Carneiro C, 2003, ONCOGENE, V22, P361, DOI 10.1038/sj.onc.1206163; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Cavalla P, 1999, ACTA NEUROPATHOL, V98, P629, DOI 10.1007/s004010051128; Chibazakura T, 2004, P NATL ACAD SCI USA, V101, P4465, DOI 10.1073/pnas.0400655101; Cipriano SC, 2001, MOL ENDOCRINOL, V15, P985, DOI 10.1210/me.15.6.985; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Di Rocco F, 1998, NEUROSURGERY, V42, P341, DOI 10.1097/00006123-199802000-00080; Doetsch F, 2002, J NEUROSCI, V22, P2255, DOI 10.1523/JNEUROSCI.22-06-02255.2002; Doetsch F, 1997, J NEUROSCI, V17, P5046; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Holland EC, 2001, CURR OPIN NEUROL, V14, P683, DOI 10.1097/00019052-200112000-00002; Huertas P, 2008, NATURE, V455, P689, DOI 10.1038/nature07215; Jin KL, 2003, EXP NEUROL, V184, P78, DOI 10.1016/S0014-4886(03)00133-X; Kamiya M, 2002, CLIN NEUROPATHOL, V21, P52; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Koff A, 2006, CANCER CELL, V9, P75, DOI 10.1016/j.ccr.2006.01.020; Korshunov A, 2002, J NEURO-ONCOL, V58, P237, DOI 10.1023/A:1016270101321; Liu Y, 2007, EMBO J, V26, P4683, DOI 10.1038/sj.emboj.7601886; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Musgrove EA, 2004, J MAMMARY GLAND BIOL, V9, P55, DOI 10.1023/B:JOMG.0000023588.55733.84; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Payne SR, 2008, MOL CELL BIOL, V28, P258, DOI 10.1128/MCB.01536-07; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Powell SN, 2009, DNA REPAIR, V8, P1153, DOI 10.1016/j.dnarep.2009.04.011; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shaffer DR, 2005, P NATL ACAD SCI USA, V102, P210, DOI 10.1073/pnas.0407362102; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Uhrbom L, 2001, J NEURO-ONCOL, V53, P297, DOI 10.1023/A:1012208314436; Uhrbom L, 1998, CANCER RES, V58, P5275; Weinstock DM, 2006, DNA REPAIR, V5, P1065, DOI 10.1016/j.dnarep.2006.05.028	52	30	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1720	1731		10.1038/onc.2009.465	http://dx.doi.org/10.1038/onc.2009.465			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062078	Bronze, Green Accepted			2022-12-17	WOS:000276022800002
J	Bonadies, N; Neururer, C; Steege, A; Vallabhapurapu, S; Pabst, T; Mueller, BU				Bonadies, N.; Neururer, Ch; Steege, A.; Vallabhapurapu, S.; Pabst, T.; Mueller, B. U.			PU.1 is regulated by NF-kappa B through a novel binding site in a 17 kb upstream enhancer element	ONCOGENE			English	Article						NF-kappa B; PU.1; Spi-1; enhancer	TRANSCRIPTION FACTOR PU.1; ACUTE MYELOID-LEUKEMIA; C/EBP-ALPHA BINDS; DNA-BINDING; GENE; EXPRESSION; NEUTROPHILS; DISRUPTION; MECHANISMS; PROMOTER	The majority of patients with acute myeloid leukemia (AML) still die of their disease, and novel therapeutic concepts are needed. Timely expression of the hematopoietic master regulator PU.1 is crucial for normal development of myeloid and lymphoid cells. Targeted disruption of an upstream regulatory element (URE) located several kb upstream in the PU.1 promoter decreases PU.1 expression thereby inducing AML in mice. In addition, suppression of PU.1 has been observed in specific subtypes of human AML. Here, we identified nuclear factor-kappa B (NF-kappa B) to activate PU.1 expression through a novel site within the URE. We found sequence variations of this particular NF-kappa B site in 4 of 120 AML patients. These variant NF-kappa B sequences failed to mediate activation of PU.1. Moreover, the synergistic activation of PU.1 together with CEBPB through these variant sequences was also lost. Finally, AML patients with such variant sequences had suppressed PU.1 mRNA expression. This study suggests that changes of a single base pair in a distal element critically affect the regulation of the tumor suppressor gene PU.1 thereby contributing to the development of AML. Oncogene (2010) 29, 1062-1072; doi:10.1038/onc.2009.371; published online 7 December 2009	[Bonadies, N.; Neururer, Ch; Steege, A.; Vallabhapurapu, S.; Mueller, B. U.] Univ Bern, Univ Hosp Bern, Dept Internal Med & Clin Res, CH-3010 Bern, Switzerland; [Pabst, T.] Univ Bern, Univ Hosp Bern, Dept Med Oncol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Mueller, BU (corresponding author), Univ Bern, Univ Hosp Bern, Dept Internal Med & Clin Res, CH-3010 Bern, Switzerland.	beatrice.mueller@insel.ch	Bonadies, Nicolas/F-2388-2017; Steege, Andreas/F-3885-2010	Bonadies, Nicolas/0000-0001-8761-2066; 	Swiss National Science Foundation [SF 310000-113761]; Swiss Cancer League [OCS 01731082005]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League	This work was supported by a grant from the Swiss National Science Foundation SF 310000-113761 (to BUM), and a grant from the Swiss Cancer League, OCS 01731082005 (to BUM).	Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Back J, 2005, EXP HEMATOL, V33, P395, DOI 10.1016/j.exphem.2004.12.010; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Cook WD, 2004, BLOOD, V104, P3437, DOI 10.1182/blood-2004-06-2234; Ebralidze AK, 2008, GENE DEV, V22, P2085, DOI 10.1101/gad.1654808; Friedman AD, 2007, BLOOD CELL MOL DIS, V39, P340, DOI 10.1016/j.bcmd.2007.06.010; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hoogenkamp M, 2007, MOL CELL BIOL, V27, P7425, DOI 10.1128/MCB.00905-07; HROMAS R, 1993, BLOOD, V82, P2998; Huang G, 2008, NAT GENET, V40, P51, DOI 10.1038/ng.2007.7; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mueller BU, 2006, BLOOD, V107, P3330, DOI 10.1182/blood-2005-07-3068; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Nijnik A, 2003, NUCLEIC ACIDS RES, V31, P1497, DOI 10.1093/nar/gkg231; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Paz-Priel I, 2005, MOL CANCER RES, V3, P585, DOI 10.1158/1541-7786.MCR-05-0111; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Steidl U, 2007, J CLIN INVEST, V117, P2611, DOI 10.1172/JCI30525; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Suraweera N, 2005, ONCOGENE, V24, P3678, DOI 10.1038/sj.onc.1208422; Tisne C, 1999, BIOCHEMISTRY-US, V38, P3883, DOI 10.1021/bi982402d; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; Yeamans C, 2007, BLOOD, V110, P3136, DOI 10.1182/blood-2007-03-080291	39	30	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1062	1072		10.1038/onc.2009.371	http://dx.doi.org/10.1038/onc.2009.371			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19966852				2022-12-17	WOS:000274604400012
J	Cowling, VH				Cowling, V. H.			Enhanced mRNA cap methylation increases Cyclin D1 expression and promotes cell transformation	ONCOGENE			English	Article						Cyclin D1; cell transformation; mRNA cap methylation; mRNA translation	C-MYC; CANCER; METHYLTRANSFERASE; TRANSLATION; RECRUITMENT; REPRESSION; APOPTOSIS; BINDING; EIF4E; GENE	Cap-dependent mRNA translation requires the methylation of the mRNA guanosine cap by RNA guanine-7-methyltransferase (RNMT). mRNA cap methylation was recently described to be rate-limiting for a subset of mRNAs, and to be enhanced by expression of c-Myc and E2F1, although the biological significance of this finding was not investigated. Here, it is reported that increased RNMT expression enhances cellular mRNA cap methyltransferase activity, promotes mammary epithelial cell transformation and cooperates with H-RasV12 or c-Myc to promote fibroblast cell transformation. Cyclin D1 is a prominent oncogene in epithelial tumours. A signi. cant fraction of Cyclin D1 mRNA was found to be unmethylated on the mRNA cap and thus dormant in mammary epithelial cells. Cyclin D1 expression was increased by enhanced mRNA cap methylation. In summary, this report shows that mRNA cap methylation is rate-limiting for expression of an oncogene and cell transformation. Oncogene (2010) 29, 930-936; doi:10.1038/onc.2009.368; published online 16 November 2009	Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee	Cowling, VH (corresponding author), Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dow St, Dundee DD1 5EH, Scotland.	v.h.cowling@dundee.ac.uk		Cowling, Victoria/0000-0001-7638-4870	MRC; Tenovus Scotland Project; MRC [G0700240] Funding Source: UKRI; Medical Research Council [G0700240] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Tenovus Scotland Project; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	I thank Mike Cole for the generous gift of the anti-m7G antibodies, Aaron Shatkin for providing the RNMT-GFP construct, Julian Downward for providing the H-RasV12 construct and James DiRenzo for providing IMEC. I also thank all of the above and the Cowling lab for advice. This work was funded by an MRC Career Development Award and a Tenovus Scotland Project Grant.	Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; Chu C, 2008, MOL CELL BIOL, V28, P5829, DOI 10.1128/MCB.00021-08; Cole MD, 2009, ONCOGENE, V28, P1169, DOI 10.1038/onc.2008.463; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; DiRenzo J, 2002, CANCER RES, V62, P89; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Goy A, 2006, CANCER CYTOPATHOL, V108, P10, DOI 10.1002/cncr.21500; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Shafer B, 2005, MOL CELL BIOL, V25, P2644, DOI 10.1128/MCB.25.7.2644-2649.2005; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Tsai YP, 2008, FEBS LETT, V582, P4083, DOI 10.1016/j.febslet.2008.11.004; Vallat LD, 2007, BLOOD, V109, P3989, DOI 10.1182/blood-2006-09-045377; Wen YX, 2000, GENE DEV, V14, P2944, DOI 10.1101/gad.848200; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; White RJ, 2008, TRENDS GENET, V24, P622, DOI 10.1016/j.tig.2008.10.003	26	30	30	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	2010	29	6					930	936		10.1038/onc.2009.368	http://dx.doi.org/10.1038/onc.2009.368			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915615	Green Accepted, Bronze			2022-12-17	WOS:000274397800015
J	Nirde, P; Derocq, D; Maynadier, M; Chambon, M; Basile, I; Gary-Bobo, M; Garcia, M				Nirde, P.; Derocq, D.; Maynadier, M.; Chambon, M.; Basile, I.; Gary-Bobo, M.; Garcia, M.			Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells	ONCOGENE			English	Article						cancer; growth inhibition; Hsc70; secretion; extracellular; cathepsin D	TRANSFECTED CATHEPSIN-D; BREAST-CANCER; TUMOR-CELLS; HSP70-LIKE PROTEIN; CRYSTAL-STRUCTURES; HEAT-SHOCK-PROTEIN-70; EXPRESSION; HSC70; RELEASE; DEGRADATION	Earlier studies indicated that density-arrested cancer cells released an unidentified growth inhibitor whose secretion was prevented by overexpression of the lysosomal protease cathepsin D (cath D). In this study, this growth inhibitor was purified by affinity chromatography and identified as the heat shock cognate 70 protein (hsc70) based on its peptide microsequencing and specific antibody recognition. Among intracellular proteins, including other heat shock proteins, only constitutive hsc70 was secreted in response to the high-cell density. Moreover, hsc70 secretion from cancer cells was generated by serum deprivation, whereas its cellular concentration did not change. Prevention of Hsc70 secretion by cath D overexpression was associated with the formation of multilayer cell cultures, thus indicating a loss of contact inhibition. In addition, we showed that supplementing the culture medium with purified hsc70 inhibited cell proliferation in the nanomolar range. Conversely, removal of this extracellular hsc70 from the medium by either retention on ADP-agarose or competition at the Hsc70 binding site restored cell proliferation. Hsc70 appears active in human breast cancer cells and hypersecreted by direct cath D inhibition. These results suggest a new role of this secreted hsc70 chaperone in cell proliferation that might account for the higher tumor growth of cancer cells overexpressing cath D.	[Garcia, M.] CRLC Val dAurelle Paul Lamarque, IRCM, F-34298 Montpellier 5, France; [Nirde, P.; Derocq, D.; Maynadier, M.; Chambon, M.; Basile, I.; Gary-Bobo, M.; Garcia, M.] INSERM, U896, Montpellier, France; [Nirde, P.; Derocq, D.; Maynadier, M.; Chambon, M.; Basile, I.; Gary-Bobo, M.; Garcia, M.] Univ Montpellier I, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Garcia, M (corresponding author), CRLC Val dAurelle Paul Lamarque, IRCM, 208 Rue Apothicaires, F-34298 Montpellier 5, France.	marcel.garcia@valdorel.fnclcc.fr			Institut National de la Sante et de la Recherche Medicale; Association pour la Recherche sur le Cancer; Ligue contre le cancer; Comite de l'Herault; CNRS	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue contre le cancer(Ligue nationale contre le cancer); Comite de l'Herault; CNRS(Centre National de la Recherche Scientifique (CNRS))	We thank Jean Derancourt, (Centre de Recherches de Biochimie Macromoleculaire du CNRS, 1919 Route de Mende, 34293 Montpellier Cedex 5, France) for peptide fragments analysis. The authors thank the Centre Regional d'Imagerie Cellulaire (Montpellier-France) for access to the scanning microscopy facilities. This work was supported by the Institut National de la Sante et de la Recherche Medicale, the Association pour la Recherche sur le Cancer, the Ligue contre le cancer, Comite de l'Herault (fellowship to MM), and CNRS.	ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1954, EXP CELL RES, V6, P293, DOI 10.1016/0014-4827(54)90176-7; Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; Anagnostopouloua A, 2006, CANCER LETT, V242, P120, DOI 10.1016/j.canlet.2005.10.047; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Barreto A, 2003, CELL IMMUNOL, V222, P97, DOI 10.1016/S0008-8749(03)00115-1; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Bossard N, 2003, BREAST CANCER RES TR, V82, P47, DOI 10.1023/B:BREA.0000003919.75055.e8; Brighty DW, 2001, J VIROL, V75, P10472, DOI 10.1128/JVI.75.21.10472-10478.2001; Brocchieri L, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-19; Chen S, 2007, J NEUROSCI RES, V85, P402, DOI 10.1002/jnr.21124; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CIOCCA DR, 1992, CANCER RES, V52, P3648; Ciocca DR, 2003, CELL STRESS CHAPERON, V8, P26, DOI 10.1379/1466-1268(2003)8<26:HAHIRT>2.0.CO;2; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Clayton A, 2005, J CELL SCI, V118, P3631, DOI 10.1242/jcs.02494; COHEN LA, 1974, IN VITRO CELL DEV B, V10, P51, DOI 10.1007/BF02615338; Dressel R, 2003, CANCER RES, V63, P8212; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; ELLEDGE RM, 1994, CANCER RES, V54, P3752; Florin L, 2004, J VIROL, V78, P5546, DOI 10.1128/JVI.78.11.5546-5553.2004; Fouchaq B, 1999, EUR J BIOCHEM, V259, P379, DOI 10.1046/j.1432-1327.1999.00053.x; GARCIA M, 1990, ONCOGENE, V5, P1809; Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642; Geminard C, 2001, J BIOL CHEM, V276, P9910, DOI 10.1074/jbc.M009641200; Glondu M, 2002, ONCOGENE, V21, P5127, DOI 10.1038/sj.onc.1205657; Goldfarb SB, 2006, P NATL ACAD SCI USA, V103, P5817, DOI 10.1073/pnas.0507903103; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; Kao RH, 2003, INT J EXP PATHOL, V84, P207, DOI 10.1111/j.1365-2613.2003.00356.x; Lazaris AC, 1997, BREAST CANCER RES TR, V43, P43, DOI 10.1023/A:1005706110275; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Marnbula SS, 2007, METHODS, V43, P168, DOI 10.1016/j.ymeth.2007.06.009; Melendez K, 2006, CELL STRESS CHAPERON, V11, P334, DOI 10.1379/CSC-187.1; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Nylandsted J, 2002, CANCER RES, V62, P7139; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; Saito K, 2005, EXP CELL RES, V310, P229, DOI 10.1016/j.yexcr.2005.07.014; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; Soulier S, 1996, GENE, V172, P285, DOI 10.1016/0378-1119(96)00169-2; Srivastava Pramod K, 2005, Curr Oncol Rep, V7, P104, DOI 10.1007/s11912-005-0035-8; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; Thanner F, 2003, ANTICANCER RES, V23, P1057; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Torronteguy C, 2006, CELL STRESS CHAPERON, V11, P34, DOI 10.1379/CSC-159R.1; Tsukahara F, 2000, MOL PHARMACOL, V58, P1257, DOI 10.1124/mol.58.6.1257; Tsukahara F, 2004, J BIOL CHEM, V279, P8867, DOI 10.1074/jbc.M308848200; Tutar Y, 2006, GENETICS, V172, P851, DOI 10.1534/genetics.105.048926; Tytell M, 2005, INT J HYPERTHER, V21, P445, DOI 10.1080/02656730500041921; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Vargas-Roig LM, 1998, INT J CANCER, V79, P468, DOI 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; Zou N, 2008, AM J PHYSIOL-HEART C, V294, pH2805, DOI 10.1152/ajpheart.00299.2008	61	30	37	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					117	127		10.1038/onc.2009.311	http://dx.doi.org/10.1038/onc.2009.311			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802014	Green Submitted, Green Accepted			2022-12-17	WOS:000273373500011
J	Hegde, S; Ni, S; He, S; Yoon, D; Feng, GS; Watowich, SS; Paulson, RF; Hankey, PA				Hegde, S.; Ni, S.; He, S.; Yoon, D.; Feng, G. S.; Watowich, S. S.; Paulson, R. F.; Hankey, P. A.			Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation	ONCOGENE			English	Article						Stk; Ron; Gab2; Stat3; Pu.1; leukemia	RECEPTOR TYROSINE KINASE; FRIEND-VIRUS; LEUKEMIA VIRUS; CELLS; MICE; ACTIVATION; GROWTH; GENE; POLYCYTHEMIA; GATA-1	Leukemogenesis requires two classes of mutations, one that promotes proliferation and one that blocks differentiation. The erythroleukemia induced by Friend virus is a multi-stage disease characterized by an early proliferative stage driven by the interaction of the viral glycoprotein, gp55, with Sf-Stk and the EpoR, and a late block to differentiation resulting from retroviral insertion in the Pu.1 locus. We demonstrate here that activation of Stat3 by Sf-Stk in the early stage of disease is essential for the progression of erythroleukemia in the presence of differentiation signals induced by the EpoR, but is dispensable in the late stages of the disease. Furthermore, we identify Pu.1 as a Stat3 target gene in the early stages of erythroleukemia development. Our results support a model whereby the activation of Stat3 in the early stage of disease plays a pivotal role in regulating differentiation through the upregulation of Pu.1, thus inhibiting differentiation and favoring the expansion of infected erythroblasts and enhancing the pool of progenitors available for the acquisition of additional mutations, including insertional activation of Pu.1, resulting in full leukemic transformation. Oncogene (2009) 28, 3349-3359; doi: 10.1038/onc.2009.202; published online 6 July 2009	[Hegde, S.; Ni, S.; He, S.; Paulson, R. F.; Hankey, P. A.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Ni, S.; Paulson, R. F.; Hankey, P. A.] Penn State Univ, Grad Program Immunol & Infect Dis, University Pk, PA 16802 USA; [He, S.; Paulson, R. F.; Hankey, P. A.] Penn State Univ, Grad Program Pathobiol, University Pk, PA 16802 USA; [Yoon, D.; Watowich, S. S.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Yoon, D.; Watowich, S. S.] Univ Texas MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX 77030 USA; [Yoon, D.; Watowich, S. S.] Grad Sch Biomed Sci, Program Immunol, Houston, TX USA; [Feng, G. S.] Burnham Inst Med Res, La Jolla, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Sanford Burnham Prebys Medical Discovery Institute	Hankey, PA (corresponding author), Penn State Univ, Dept Vet & Biomed Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu	he, shihan/N-8067-2014	he, shihan/0000-0001-5806-8583; Watowich, Stephanie/0000-0003-1969-659X	National Institutes of Health [R01 HL066571]; Leukemia and Lymphoma Society; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066571, R01HL066471] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grant R01 HL066571 from the National Institutes of Health and by a scholar award from the Leukemia and Lymphoma Society to P Hankey.	Afrikanova I, 2002, ONCOGENE, V21, P1272, DOI 10.1038/sj.onc.1205183; CHESEBRO B, 1981, VIROLOGY, V112, P131, DOI 10.1016/0042-6822(81)90619-X; Choe KS, 2003, CANCER RES, V63, P6363; Constantinescu SN, 2003, J BIOL CHEM, V278, P43755, DOI 10.1074/jbc.M302974200; Fang C, 1998, VIROLOGY, V252, P46, DOI 10.1006/viro.1998.9453; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Kosmider O, 2005, CANCER CELL, V8, P467, DOI 10.1016/j.ccr.2005.11.009; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Ney PA, 2000, BLOOD, V96, P3675, DOI 10.1182/blood.V96.12.3675.h8003675_3675_3680; Ni S, 2007, MOL CELL BIOL, V27, P3708, DOI 10.1128/MCB.01838-06; Panopoulos AD, 2002, J BIOL CHEM, V277, P19001, DOI 10.1074/jbc.M112271200; Papetti M, 2007, MOL CANCER RES, V5, P1053, DOI 10.1158/1541-7786.MCR-07-0145; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Shimizu R, 2004, MOL CELL BIOL, V24, P10814, DOI 10.1128/MCB.24.24.10814-10825.2004; TAMBOURIN PE, 1973, BRIT J HAEMATOL, V24, P511, DOI 10.1111/j.1365-2141.1973.tb01677.x; Teal HE, 2006, ONCOGENE, V25, P2433, DOI 10.1038/sj.onc.1209288; Yang J, 2005, CANCER RES, V65, P939; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang J, 2006, BLOOD, V107, P73, DOI 10.1182/blood-2005-05-1784; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200	24	30	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3349	3359		10.1038/onc.2009.202	http://dx.doi.org/10.1038/onc.2009.202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19581930	Green Accepted			2022-12-17	WOS:000270103300002
J	Morioka, S; Omori, E; Kajino, T; Kajino-Sakamoto, R; Matsumoto, K; Ninomiya-Tsuji, J				Morioka, S.; Omori, E.; Kajino, T.; Kajino-Sakamoto, R.; Matsumoto, K.; Ninomiya-Tsuji, J.			TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP	ONCOGENE			English	Article						TAK1; TRAIL; reactive oxygen species; cIAP; apoptosis	NF-KAPPA-B; APOPTOSIS-INDUCING LIGAND; HUMAN CANCER-CELLS; INDUCED DEATH; CASPASE-8 ACTIVATION; SIGNALING PATHWAYS; DECOY RECEPTORS; TARGETING DEATH; JNK ACTIVATION; UP-REGULATION	TNF-related apoptosis-inducing ligand (TRAIL) is a potent inducer of cell death in several cancer cells, but many cells are resistant to TRAIL. The mechanism that determines sensitivity to TRAIL-killing is still elusive. Here we report that deletion of TAK1 kinase greatly increased activation of caspase-3 and cell death after TRAIL stimulation in keratinocytes, fibroblasts and cancer cells. Although TAK1 kinase is involved in NF-kappa B pathway, ablation of NF-kappa B did not alter sensitivity to TRAIL. We found that TRAIL could induce accumulation of reactive oxygen species (ROS) when TAK1 was deleted. Furthermore, we found that TAK1 deletion induced TRAIL-dependent downregulation of cIAP, which enhanced activation of caspase-3. These results show that TAK1 deletion facilitates TRAIL-induced cell death by activating caspase through ROS and downregulation of cIAP. Thus, inhibition of TAK1 can be an effective approach to increase TRAIL sensitivity. Oncogene (2009) 28, 2257-2265; doi: 10.1038/onc.2009.110; published online 4 May 2009	[Morioka, S.; Omori, E.; Kajino-Sakamoto, R.; Ninomiya-Tsuji, J.] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; [Morioka, S.; Kajino, T.; Matsumoto, K.] Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648601, Japan; [Matsumoto, K.] Japan Sci & Technol Agcy, SORST, Tokyo, Japan	University of North Carolina; North Carolina State University; Nagoya University; Japan Science & Technology Agency (JST)	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu	Morioka, Sho/I-2074-2019	Morioka, Sho/0000-0002-1153-4919; Ninomiya-Tsuji, Jun/0000-0002-5584-0176	NIH [GM068812]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Akira, Karin, Ballard and Wang for materials. This work was supported by a grant ( GM068812) from NIH to JN-T.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; Choo MK, 2006, MOL CANCER THER, V5, P2970, DOI 10.1158/1535-7163.MCT-06-0379; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8; Kajino T, 2007, J BIOL CHEM, V282, P9475, DOI 10.1074/jbc.M700875200; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim JY, 2008, J BIOL CHEM, V283, P137, DOI 10.1074/jbc.M704746200; Kim SH, 2008, CANCER RES, V68, P2062, DOI 10.1158/0008-5472.CAN-07-6278; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kurbanov BM, 2007, ONCOGENE, V26, P3364, DOI 10.1038/sj.onc.1210134; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Meng XW, 2007, J BIOL CHEM, V282, P29831, DOI 10.1074/jbc.M706110200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Omori E, 2008, J BIOL CHEM, V283, P26161, DOI 10.1074/jbc.M804513200; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; Rudolph D, 2000, GENE DEV, V14, P854; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200	40	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2257	2265		10.1038/onc.2009.110	http://dx.doi.org/10.1038/onc.2009.110			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421137	Green Accepted			2022-12-17	WOS:000266886300002
J	Gray, MJ; Dallas, NA; Van Buren, G; Xia, L; Yang, AD; Somcio, RJ; Gaur, P; Mangala, LS; Vivas-Mejia, PE; Fan, F; Sanguino, AM; Gallick, GE; Lopez-Berestein, G; Sood, AK; Ellis, LM				Gray, M. J.; Dallas, N. A.; Van Buren, G.; Xia, L.; Yang, A. D.; Somcio, R. J.; Gaur, P.; Mangala, L. S.; Vivas-Mejia, P. E.; Fan, F.; Sanguino, A. M.; Gallick, G. E.; Lopez-Berestein, G.; Sood, A. K.; Ellis, L. M.			Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver	ONCOGENE			English	Article						Id2; colorectal carcinoma; Inhibitor of DNA-binding; metastasis; siRNA	LOOP-HELIX PROTEINS; RETINOBLASTOMA PROTEIN; PANCREATIC-CANCER; CELL-CYCLE; EXPRESSION; PROLIFERATION; ANGIOGENESIS; GENE; APOPTOSIS; DIFFERENTIATION	During development inhibitor of DNA-bind-2 (Id2) regulates proliferation and differentiation. Id2 expression has been detected in cancer cells, yet its cellular function and validity as a therapeutic target remains largely unknown. Immunohistochemical analysis of colorectal cancer (CRC) specimens revealed that Id2 was undetectable in normal colonic mucosa, but occurs in 40% of primary tumors and in most CRC liver metastases (P<0.0001). Additionally, Id2 was expressed in all CRC cell lines assayed. CRC cells with reduced Id2 expression demonstrated reduced proliferation. Analysis of CRC cell cycle regulatory proteins showed that reducing Id2 levels reduces cyclin D1 levels and increased p21 levels. Reduction of Id2 expression also enhanced tumor cell apoptosis, increasing levels of the pro-apoptotic protein Bim/Bod, and cleavage of caspase-7 and poly (ADP-ribose) polymerase. In vivo studies show tumors derived from cells with decreased Id2 levels formed smaller tumors with fewer metastases compared with tumors with normal levels (P<0.05). Furthermore, intraperitoneal administration of Id2 small interfering RNA (siRNA) conjugated with the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine decreased tumor burden in mice compared with control treatment (P = 0.006). We conclude that Id2 is upregulated in CRC, and is important in promoting cell survival. In vivo targeting of Id2 by siRNA establishes that it is a valid therapeutic target where its expression occurs.	[Gray, M. J.; Dallas, N. A.; Van Buren, G.; Yang, A. D.; Gaur, P.; Ellis, L. M.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Xia, L.; Somcio, R. J.; Fan, F.; Gallick, G. E.; Sood, A. K.; Ellis, L. M.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Mangala, L. S.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; [Vivas-Mejia, P. E.; Sanguino, A. M.; Lopez-Berestein, G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gray, MJ (corresponding author), OSI Pharmaceut, Dept Canc Biol, 1 Biosci Pk Dr, Farmingdale, NY 11735 USA.	mgray@osip.com; lellis@mdanderson.org	Khaitan, Puja/AAQ-6413-2020	Khaitan, Puja/0000-0001-8654-062X	Ovarian Cancer Research Fund, Inc; Zarrow Foundation; William C Liedtke, Jr Chair in Cancer Research (LME);  [NIH-5 T32 CA09599]; NATIONAL CANCER INSTITUTE [T32CA009599] Funding Source: NIH RePORTER	Ovarian Cancer Research Fund, Inc; Zarrow Foundation; William C Liedtke, Jr Chair in Cancer Research (LME); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Rita Hernandez (Department of Surgical Oncology) and Christine Wogan (Department of Scientific Publications) for manuscript editing and preparation. Supported by NIH-5 T32 CA09599 (GVB, NAD, ADY and PG), Program Project Development Grant from the Ovarian Cancer Research Fund, Inc. (AKS), the Zarrow Foundation (AKS) and William C Liedtke, Jr Chair in Cancer Research (LME).	Arumugam T, 2006, J NATL CANCER I, V98, P1806, DOI 10.1093/jnci/djj498; Asirvatharn AJ, 2007, PROSTATE, V67, P1411, DOI 10.1002/pros.20633; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Broude EV, 2007, ONCOGENE, V26, P6954, DOI 10.1038/sj.onc.1210516; Camp ER, 2006, CLIN CANCER RES, V12, P2628, DOI 10.1158/1078-0432.CCR-05-2257; Cannarile MA, 2006, NAT IMMUNOL, V7, P1317, DOI 10.1038/ni1403; Gray MJ, 2005, CANCER RES, V65, P3664, DOI 10.1158/0008-5472.CAN-04-2229; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Hughes TA, 2005, BIOCHEM BIOPH RES CO, V329, P1267, DOI 10.1016/j.bbrc.2005.02.102; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jen Y, 1996, DEV DYNAM, V207, P235; Kleeff J, 1998, CANCER RES, V58, P3769; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Langley RR, 2003, CANCER RES, V63, P2971; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pagliuca A, 2000, CANCER RES, V60, P1376; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Rothschild G, 2006, MOL CELL BIOL, V26, P4351, DOI 10.1128/MCB.01743-05; Russell RG, 2004, CANCER RES, V64, P7220, DOI 10.1158/0008-5472.CAN-04-2095; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilson JW, 2001, CANCER RES, V61, P8803; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Zhang XM, 2007, CANCER SCI, V98, P308, DOI 10.1111/j.1349-7006.2007.00400.x	35	30	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2008	27	57					7192	7200		10.1038/onc.2008.356	http://dx.doi.org/10.1038/onc.2008.356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18806828	Green Accepted			2022-12-17	WOS:000261384100006
J	Rebillard, A; Rioux-Leclercq, N; Muller, C; Bellaud, P; Jouan, F; Meurette, O; Jouan, E; Vernhet, L; Le Quement, C; Carpinteiro, A; Schenck, M; Lagadic-Gossmann, D; Gulbins, E; Dimanche-Boitrel, MT				Rebillard, A.; Rioux-Leclercq, N.; Muller, C.; Bellaud, P.; Jouan, F.; Meurette, O.; Jouan, E.; Vernhet, L.; Le Quement, C.; Carpinteiro, A.; Schenck, M.; Lagadic-Gossmann, D.; Gulbins, E.; Dimanche-Boitrel, M. T.			Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage	ONCOGENE			English	Article						acid sphingomyelinase; cisplatin; small intestine; endothelial cells; p53	RADIATION-INDUCED APOPTOSIS; COLON-CANCER CELLS; MICE; ACTIVATION; TOXICITY; CERAMIDE; ANALOGS; DRUGS	Cisplatin is one of the most effectively used chemotherapeutic agents for cancer treatment. However, in humans, important cytotoxic side effects are observed including dose-limiting renal damage and profound gastrointestinal symptomatology. The toxic responses to cisplatin in mice are similar to those in human patients. Here, we evaluated whether the acid sphingomyelinase (Asm) mediates at least some of the toxic in vivo effects of cisplatin. To this end, we determined the toxic effects of a single intraperitoneal dose of cisplatin (27 mg/kg) in wild type (Asm(+/+)) and Asm-deficient mice (Asm(-/-)). Tissue injury and apoptosis were determined histologically on hematox-ylin-eosin and TUNEL ( terminal deoxynucleotidyl transferase (TdT)-mediated nick end labeling) stainings 3, 12, 36 and 72 h after treatment. Our results revealed severe toxicity of cisplatin in Asm(+/+) mice with increased numbers of apoptotic cells in the thymus and small intestine. In marked contrast, Asm(-/-) mice were resistant to cisplatin and no apoptosis was observed in these organs after treatment. Moreover, cisplatin treatment primarily triggered apoptosis of endothelial cells in microvessels of intestine and thymus, an effect that was absent in mice lacking Asm. The data thus suggest that at least some toxic effects of cisplatin are mediated by the Asm in vivo resulting in early death of endothelial cells and consecutive organ damage.	[Rebillard, A.; Muller, C.; Meurette, O.; Jouan, E.; Vernhet, L.; Le Quement, C.; Lagadic-Gossmann, D.; Dimanche-Boitrel, M. T.] INSERM, UMR620, IFR GFAS 140, Rennes, France; [Rebillard, A.; Meurette, O.; Jouan, E.; Vernhet, L.; Le Quement, C.; Lagadic-Gossmann, D.; Dimanche-Boitrel, M. T.] Univ Rennes, UPRES EA SeRAIC, Rennes, France; [Rioux-Leclercq, N.; Bellaud, P.] Rennes Univ, Dept Pathol, Rennes, France; [Rioux-Leclercq, N.; Jouan, F.] Rennes Univ, CNRS, UMR6061, Rennes, France; [Carpinteiro, A.; Schenck, M.; Gulbins, E.] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes 1; Universite de Rennes 1; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1; University of Duisburg Essen	Dimanche-Boitrel, MT (corresponding author), Univ Rennes 1, INSERM, UMR620, Fac Pharm, 2 Av Pr Leon Bernard, F-35043 Rennes, France.	marie-therese.boitrel@rennes.inserm.fr	Gulbins, Erich/L-6989-2014; LAGADIC-GOSSMANN, Dominique/I-5079-2015; VERNHET, Laurent/K-3364-2015; Dimanche-Boitrel, Marie-Therese M/I-4642-2015	Gulbins, Erich/0000-0002-3117-1342; LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; Vernhet, Laurent/0000-0001-6476-7583; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780	Ligue Nationale Contre le Cancer; Region Bretagne [DFG-10-2238-Gu2]	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Region Bretagne(Region Bretagne)	We thank F Paris, M Le Vee and I Guenon. This study was supported by grants from the Ligue Nationale Contre le Cancer ( the Cote d'Armor, Ille et Vilaine and Loire-Atlantique Committees), Rennes Metropole, the Region Bretagne and DFG-10-2238-Gu2.	ALLAN SG, 1986, BRIT J CANCER, V53, P355, DOI 10.1038/bjc.1986.59; Bezombes C, 2004, BLOOD, V104, P1166, DOI 10.1182/blood-2004-01-0277; GRUNICKE H, 1992, PHARMACOL THERAPEUT, V55, P1, DOI 10.1016/0163-7258(92)90027-W; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Gulbins E, 2002, BBA-MOL CELL BIOL L, V1585, P139, DOI 10.1016/S1388-1981(02)00334-7; Harrison S D Jr, 1981, Fundam Appl Toxicol, V1, P382, DOI 10.1093/toxsci/1.5.382; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Pena LA, 2000, CANCER RES, V60, P321; PRESTAYKO AW, 1979, CANCER TREAT REP, V63, P1503; Rebillard A, 2007, CANCER RES, V67, P7865, DOI 10.1158/0008-5472.CAN-07-0353; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Tamaki T, 2003, J INT MED RES, V31, P6, DOI 10.1177/147323000303100102; Vasey PA, 1996, MOL PHARMACOL, V50, P1536	19	30	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6590	6595		10.1038/onc.2008.257	http://dx.doi.org/10.1038/onc.2008.257			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679423				2022-12-17	WOS:000260501700006
J	Cai, Z; Zhang, G; Zhou, Z; Bembas, K; Drebin, JA; Greene, MI; Zhang, H				Cai, Z.; Zhang, G.; Zhou, Z.; Bembas, K.; Drebin, J. A.; Greene, M. I.; Zhang, H.			Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185(her2/neu) and the EGFR-p185(her2/neu) complexes	ONCOGENE			English	Article						her2; Pertuzumab; heterodimer; 4D5	EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR; EXTRACELLULAR REGION; C-ERBB-2 ONCOGENE; BREAST; EXPRESSION; CANCER; P185NEU; PROTEIN; HER2	2C4 ( Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185(her2/neu), which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185(her2/neu) and ErbB3. In our studies of epidermal growth factor receptor ( EGFR)-p185(her2/neu) heterodimerization, we noted that 2C4 formed associations with the EGFR-p185(her2/neu) receptor complex. Our data argue against 2C4 as a universal heterodimerization blocker for p185(her2/neu), but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185(her2/neu) will emerge as the most potent targeted therapy.	[Cai, Z.; Zhang, G.; Zhou, Z.; Bembas, K.; Greene, M. I.; Zhang, H.] Univ Penn, Sch Med, Dept Pathol Lab Med, Philadelphia, PA 19104 USA; [Drebin, J. A.] Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Zhang, H (corresponding author), Univ Penn, Sch Med, Dept Pathol Lab Med, 3620 Hamilton Walk,252 John Morgan Bldg, Philadelphia, PA 19104 USA.	zhanghon@mail.med.upenn.edu		Zhang, Hongtao/0000-0001-9173-0049	NATIONAL CANCER INSTITUTE [P01CA089480] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA089480, 5P01 CA89480, P01 CA089480-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; COHEN JA, 1989, ONCOGENE, V4, P81; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KERN JA, 1990, CANCER RES, V50, P5184; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; LODATO RF, 1990, MODERN PATHOL, V3, P449; Mendoza N, 2002, CANCER RES, V62, P5485; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WADA T, 1990, ONCOGENE, V5, P489; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614	30	30	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3870	3874		10.1038/onc.2008.13	http://dx.doi.org/10.1038/onc.2008.13			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264138	Green Accepted			2022-12-17	WOS:000256904700011
J	Didier, C; Cavelier, C; Quaranta, M; Galcera, MO; Demur, C; Laurent, G; Manenti, S; Ducommun, B				Didier, C.; Cavelier, C.; Quaranta, M.; Galcera, M-O; Demur, C.; Laurent, G.; Manenti, S.; Ducommun, B.			G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress	ONCOGENE			English	Article						AML; G2/M checkpoint; chemoresistance; CDC25 phosphatase; CHK1 kinase	ACUTE MYELOID-LEUKEMIA; DNA-DAMAGE; IONIZING-RADIATION; CDC25 PHOSPHATASES; MAMMALIAN-CELLS; PROTEIN-KINASE; HUMAN CLASPIN; IN-VITRO; CHK1; RECOVERY	Acute myeloid leukemia ( AML) cells exposed to genotoxic agents arrest their cell cycle at the G2/M checkpoint and are inherently chemoresistant. To understand the mechanism of this chemoresistance, we compared the ability of immature CD34+ versus mature CD34- AML cell lines ( KG1a and U937, respectively) to recover from a DNA damage-induced cell cycle checkpoint in G2. Here, we report that KG1a cells have a more stringent G2/M checkpoint response than U937 cells. We show that in both cell types, the CDC25B phosphatase participates in the G2/M checkpoint recovery and that its expression is upregulated. Furthermore, we show that CHK1 inhibition by UCN-01 in immature KG1a cells allows checkpoint exit and induces sensitivity to genotoxic agents. Similarly, UCN-01 treatment potentializes genotoxic-induced inhibition of colony formation efficiency of primary leukemic cells from AML patients. Altogether, our results demonstrate that checkpoint stringency varies during the maturation process and indicate that targeting checkpoint mechanisms might represent an attractive therapeutic opportunity for chemoresistant immature AML cells.	[Didier, C.; Cavelier, C.; Quaranta, M.; Ducommun, B.] Univ Toulouse 3, CNRS, LBCMCP, UMR5088,IFR109,Inst Explorat Fonct Genomes, F-31062 Toulouse, France; [Galcera, M-O] Inst Henri Beaufour, IPSEN, F-91952 Les Ulis, France; [Demur, C.; Laurent, G.; Manenti, S.] CHU Purpan, Ctr Physiopathol Toulouse, INSERM, U563, Toulouse, France; [Demur, C.; Laurent, G.; Ducommun, B.] TSA, CHU Purpan, Serv Hematol, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, LBCMCP, UMR5088,IFR109,Inst Explorat Fonct Genomes, 118 Route Narbonne, F-31062 Toulouse, France.	ducommun@cict.fr	manenti, stephane/P-1518-2014; DIDIER, Christine O/P-2785-2014; DUCOMMUN, Bernard/B-3208-2008	manenti, stephane/0000-0002-4793-3196; DIDIER, Christine O/0000-0003-3979-0743; DUCOMMUN, Bernard/0000-0002-7126-8368				Amico D, 2003, BLOOD, V101, P4589, DOI 10.1182/blood-2002-07-2311; Bansal P, 2007, CANCER RES, V67, P3356, DOI 10.1158/0008-5472.CAN-06-3685; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Blagosklonny MV, 2006, LEUKEMIA, V20, P385, DOI 10.1038/sj.leu.2404075; Bouquet F, 2006, CELL CYCLE, V5, P1116, DOI 10.4161/cc.5.10.2799; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Brezak MC, 2005, MOL CANCER THER, V4, P1378, DOI 10.1158/1535-7163.MCT-05-0168; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Chini C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/sj.onc.1209447; Chini CCS, 2006, J BIOL CHEM, V281, P33276, DOI 10.1074/jbc.M604373200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Clave E, 1997, LEUKEMIA, V11, P114, DOI 10.1038/sj.leu.2400528; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Fernandez-Vidal A, 2006, CANCER RES, V66, P7128, DOI 10.1158/0008-5472.CAN-05-2552; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Humbert O, 2002, J BIOL CHEM, V277, P18061, DOI 10.1074/jbc.M103451200; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; McManus KJ, 2005, MOL BIOL CELL, V16, P5013, DOI 10.1091/mbc.E05-01-0065; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Roberge M, 1998, CANCER RES, V58, P5701; Sampath D, 2006, BLOOD, V107, P2517, DOI 10.1182/blood-2005-08-3351; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Shiloh Y, 2003, CELL CYCLE, V2, P116, DOI 10.4161/cc.2.2.342; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; van Vugt MATM, 2004, CELL CYCLE, V3, P1383, DOI 10.4161/cc.3.11.1248; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; WARTERS RL, 1995, MUTAT RES-DNA REPAIR, V336, P1, DOI 10.1016/0921-8777(94)00036-6; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002	40	30	32	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3811	3820		10.1038/sj.onc.1211041	http://dx.doi.org/10.1038/sj.onc.1211041			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18212737				2022-12-17	WOS:000256904700005
J	Eichele, K; Ramer, R; Hinz, B				Eichele, K.; Ramer, R.; Hinz, B.			Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells	ONCOGENE			English	Article						chemotherapeutics; cyclooxygenase-2; lipocalin-type prostaglandin D synthase; prostaglandins; peroxisome proliferator-activated receptor gamma; apoptosis	HUMAN NEUROGLIOMA CELLS; PHASE-II TRIAL; LUNG-CANCER; COLORECTAL-CANCER; EPITHELIAL-CELLS; UP-REGULATION; CELECOXIB; PROLIFERATION; EXPRESSION; DOCETAXEL	The role of cyclooxygenase-2 (COX-2) in cancer remains controversial. Using cervical carcinoma cells (HeLa), the present study investigates the involvement of COX-2 in apoptosis elicited by the chemotherapeutics paclitaxel, cisplatin and 5-fluorouracil. Each compound led to a profound induction of COX-2 expression and prostaglandin (PG) synthesis, accompanied by a substantial decrease of viability and enhanced apoptosis. Cells were significantly less sensitive to apoptotic death when either COX-2 expression or its activity was suppressed by smallinterfering RNA (siRNA) and by the selective COX-2 inhibitor NS-398, respectively. Experiments performed to clarify how COX-2 leads to apoptosis revealed a profound proapoptotic action of PGD2 and its dehydration product, 15-deoxy- D12,14 PGJ2 (15d-PGJ2). In line with these findings, chemotherapeutics-induced apoptosis was prevented by siRNA targeting lipocalin-type PGD synthase (L-PGDS), which catalyses the isomerization of PGH2 to PGD2. Moreover, apoptosis by chemotherapeutics, PGD2 and 15d-PGJ2 was suppressed by the peroxisome proliferator-activated receptor c (PPARc) antagonist, GW-9662 or PPARc siRNA. Finally, a COX-2-dependent apoptotic mechanism of all investigated chemotherapeutics was confirmed in human lung cancer cells (A549) as well as in another cervical carcinoma cell line (C33A). Collectively, this study suggests COX-2 induction and synthesis of L-PGDS-derived, PPARc-activating PGs as a decisive target by which several chemotherapeutics induce apoptosis. COX-2 is therefore suspected to sensitize cancer cells to apoptotic death under certain circumstances, suggesting that COX-2 inhibition during cancer therapy could diminish its efficacy.	[Eichele, K.; Ramer, R.; Hinz, B.] Univ Rostock, Inst Pharmacol & Toxicol, D-18057 Rostock, Germany	University of Rostock	Hinz, B (corresponding author), Univ Rostock, Inst Pharmacol & Toxicol, Schillingallee 70, D-18057 Rostock, Germany.	burkhard.hinz@med.uni-rostock.de						Altorki NK, 2003, J CLIN ONCOL, V21, P2645, DOI 10.1200/JCO.2003.07.127; Argiris A, 2006, INVEST NEW DRUG, V24, P203, DOI 10.1007/s10637-005-3259-4; Chen Q, 2004, ANAL BIOCHEM, V335, P253, DOI 10.1016/j.ab.2004.09.004; Chen YC, 2005, BBA-MOL CELL RES, V1743, P291, DOI 10.1016/j.bbamcr.2004.10.016; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Csiki I, 2005, CLIN CANCER RES, V11, P6634, DOI 10.1158/1078-0432.CCR-05-0436; Danesi R, 2002, BRIT J CLIN PHARMACO, V53, P508, DOI 10.1046/j.1365-2125.2002.01579.x; Denkert C, 2003, ONCOGENE, V22, P8653, DOI 10.1038/sj.onc.1206920; Dommels YEM, 2003, CARCINOGENESIS, V24, P385, DOI 10.1093/carcin/24.3.385; Eichele K, 2006, PHARM RES-DORDR, V23, P90, DOI 10.1007/s11095-005-8815-2; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Hwang Daniel H., 2002, Neoplasia (New York), V4, P91, DOI 10.1038/sj.neo.7900226; Kim J, 2005, CANCER RES, V65, P6189, DOI 10.1158/0008-5472.CAN-04-4439; Lalier L, 2007, ONCOGENE, V26, P4999, DOI 10.1038/sj.onc.1210303; Maccarrone M, 2002, BIOCHEM J, V366, P137, DOI 10.1042/BJ20020438; Na HK, 2005, FEBS LETT, V579, P6279, DOI 10.1016/j.febslet.2005.09.094; Na HK, 2003, BIOCHEM PHARMACOL, V66, P1381, DOI 10.1016/S0006-2952(03)00488-X; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Nugent FW, 2005, LUNG CANCER, V48, P267, DOI 10.1016/j.lungcan.2004.11.004; Pan CX, 2005, ONCOLOGY-BASEL, V69, P63, DOI 10.1159/000087302; Ramer R, 2003, MOL PHARMACOL, V64, P1189, DOI 10.1124/mol.64.5.1189; Shen ZN, 2005, BIOCHEM BIOPH RES CO, V328, P375, DOI 10.1016/j.bbrc.2004.12.186; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Xu Z, 2006, CANCER RES, V66, P6657, DOI 10.1158/0008-5472.CAN-05-3624; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	27	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3032	3044		10.1038/sj.onc.1210962	http://dx.doi.org/10.1038/sj.onc.1210962			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18071320				2022-12-17	WOS:000255681700010
J	Ji, Y; Shah, S; Soanes, K; Islam, MN; Hoxter, B; Biffo, S; Heslip, T; Byers, S				Ji, Y.; Shah, S.; Soanes, K.; Islam, M. N.; Hoxter, B.; Biffo, S.; Heslip, T.; Byers, S.			Eukaryotic initiation factor 6 selectively regulates Wnt signaling and beta-catenin protein synthesis	ONCOGENE			English	Article						beta-catenin; eIF6; wnt; wingless; Drosophila; APC	SACCHAROMYCES-CEREVISIAE HOMOLOG; C-MYC; TRANSLATION; APC; PHOSPHORYLATION; UBIQUITINATION; P27(BBP); ADHESION; COMPLEX; BINDING	Eukaryotic initiation factor 6 ( eIF6), an essential protein important in ribosome biosynthesis and assembly, was identified as an interacting partner of the beta-catenin C terminus in the yeast two-hybrid assay. Independent studies identified Drosophila eIF6 ( DeIF6) in a genetic screen designed to detect new genes involved in the regulation of the Wnt/Wg ( wingless) pathway. Ectopic expression of DeIF6 in wing discs results in a Wg phenotype. Expression of eIF6 in adenomatous polyposis coli ( APC)-mutant colon cancer cells, which express high levels of active beta-catenin, showed that eIF6 selectively inhibits the Wnt pathway at the level of beta-catenin protein independently of proteasomal degradation. Incorporation of radiolabeled amino acids into beta-catenin was selectively decreased in cells that overexpressed eIF6. A similar inverse relationship of the two proteins was observed in the APC(min/+) mouse intestine, in which beta-catenin levels are very high. Taken together these data reveal a link between eIF6 and Wnt signaling, perhaps at the level of ribosome recycling on beta-catenin mRNA.	[Ji, Y.; Shah, S.; Islam, M. N.; Hoxter, B.; Byers, S.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Biffo, S.] DIBIT HSR, Mol Histol Unit, Milan, Italy; [Soanes, K.; Heslip, T.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada	Georgetown University; University of Calgary	Byers, S (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, E415 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	byerss@georgetown.edu	Ji, Yun/B-7245-2009; Waldmann, Thomas/AAT-5972-2021	Ji, Yun/0000-0001-6340-7009; Waldmann, Thomas/0000-0003-4500-6660; biffo, stefano/0000-0002-3780-1050				Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Basu U, 2003, MOL CELL BIOL, V23, P6187, DOI 10.1128/MCB.23.17.6187-6199.2003; Basu U, 2001, MOL CELL BIOL, V21, P1453, DOI 10.1128/MCB.21.5.1453-1462.2001; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Biffo S, 1997, J BIOL CHEM, V272, P30314, DOI 10.1074/jbc.272.48.30314; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chendrimada TP, 2007, NATURE, V447, P823, DOI 10.1038/nature05841; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Donadini A, 2001, GENE, V266, P35, DOI 10.1016/S0378-1119(01)00370-5; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Greaves S, 1999, GENETICS, V153, P1753; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Sanvito F, 1999, J CELL BIOL, V144, P823, DOI 10.1083/jcb.144.5.823; Si K, 1999, MOL CELL BIOL, V19, P1416; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wood LC, 1999, J BIOL CHEM, V274, P11653, DOI 10.1074/jbc.274.17.11653	30	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					755	762		10.1038/sj.onc.1210667	http://dx.doi.org/10.1038/sj.onc.1210667			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17667944				2022-12-17	WOS:000252884500004
J	Gurzov, EN; Bakiri, L; Alfaro, JM; Wagner, EF; Izquierdo, M				Gurzov, E. N.; Bakiri, L.; Alfaro, J. M.; Wagner, E. F.; Izquierdo, M.			Targeting c-Jun and JunB proteins as potential anticancer cell therapy	ONCOGENE			English	Article						B16-F10 cancer cells; c-Jun; JunB; RNA interference; SP600125	APOPTOSIS-INDUCING FACTOR; N-TERMINAL KINASE; TRANSCRIPTION FACTOR AP-1; CHRONIC MYELOID-LEUKEMIA; OSTEO-SARCOMA VIRUS; DNA-BINDING; RNA INTERFERENCE; BREAST-CANCER; TUMOR-GROWTH; PROLIFERATION	The activating protein-1 transcription factor, in particular the Jun proteins play critical roles in the regulation of cell proliferation and tumor progression. To study the potential clinical relevance of interfering with JunB expression, we generated retroviruses expressing short hairpin RNA. Reduction of JunB levels causes increased proliferation and tumorigenicity in wild-type murine fibroblasts, whereas in c-Jun knockout cells p53-independent cell cycle arrest and apoptosis are induced. Using melanoma-derived B16-F10 cancer cells the combination of JunB knockdown and c-Jun/JNK inactivation leads to cell cycle arrest and apoptosis-inducing factor-dependent apoptosis. Furthermore, the combined treatment extends survival of mice inoculated with the tumor cells. These results indicate that in the absence of c-Jun, JunB can act as a tumor promoter and inactivation of both, c-Jun and JunB, could provide a valuable strategy for antitumor intervention.	[Gurzov, E. N.; Alfaro, J. M.; Izquierdo, M.] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Dept Mol Biol, E-28049 Madrid, Spain; [Bakiri, L.; Wagner, E. F.] Res Inst Mol Pathol, A-1030 Vienna, Austria	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Izquierdo, M (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Dept Mol Biol, E-28049 Madrid, Spain.	mizquierdo@cbm.uam.es	Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020	Wagner, Erwin F/0000-0001-7872-0196; bakiri, latifa/0000-0002-6300-2420; Gurzov, Esteban/0000-0003-4642-0273				Artus C, 2006, ONCOGENE, V25, P5741, DOI 10.1038/sj.onc.1209581; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWDEN GT, 1994, CANCER RES, V54, pS1882; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ennis BW, 2005, J PHARMACOL EXP THER, V313, P325, DOI 10.1124/jpet.104.078873; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Gurzov EN, 2006, GENE THER, V13, P1, DOI 10.1038/sj.gt.3302595; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Libermann TA, 2006, CURR GENE THER, V6, P17, DOI 10.2174/156652306775515501; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Marchetti P, 1996, J IMMUNOL, V157, P4830; Mariani O, 2007, CANCER CELL, V11, P361, DOI 10.1016/j.ccr.2007.02.007; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szremska AP, 2003, BLOOD, V102, P4159, DOI 10.1182/blood-2003-03-0915; Vleugel MM, 2006, HUM PATHOL, V37, P668, DOI 10.1016/j.humpath.2006.01.022; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Xia HHX, 2006, CANCER LETT, V241, P268, DOI 10.1016/j.canlet.2005.10.031; Yang MY, 2003, BLOOD, V101, P3205, DOI 10.1182/blood-2002-05-1598; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zhang WH, 2005, AM J CLIN PATHOL, V124, P11, DOI 10.1309/T1H2Y2CHWY7PD2BN	41	30	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					641	652		10.1038/sj.onc.1210690	http://dx.doi.org/10.1038/sj.onc.1210690			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667939				2022-12-17	WOS:000252674900008
J	Lackey, J; Barnett, J; Davidson, L; Batty, IH; Leslie, NR; Downes, CP				Lackey, J.; Barnett, J.; Davidson, L.; Batty, I. H.; Leslie, N. R.; Downes, C. P.			Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling	ONCOGENE			English	Article						phosphatase; signal transduction; feedback; insulin-like growth factor; phosphoinositide; tumor; suppressor	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; C-ZETA; EXPRESSION; INHIBITION; PATHWAYS; DOWNSTREAM; ACTIVATION; IRS-1	Many tumors have chronically elevated activity of PI 3-kinase-dependent signaling pathways, caused largely by oncogenic mutation of PI 3-kinase itself or loss of the opposing tumor suppressor lipid phosphatase, PTEN. Several PI 3-kinase-dependent feedback mechanisms have been identified that may affect the sensitivity of upstream receptor signaling, but the events required to initiate an inhibited state have not been addressed. We show that in a variety of cell types, loss of PTEN via experimental knockdown or in tumor cell lines correlates with a block in insulin-like growth factor 1 (IGF1)/insulin signaling, without affecting the sensitivity of platelet-derived growth factor or epidermal growth factor signaling. These effects on IGF/insulin signaling include a reduction of up to. veto tenfold in IGF-stimulated PI 3-kinase activation, a failure to activate the ERK kinases and, in some cells, reduced expression of insulin receptor substrate 1, and both IGF1 and insulin receptors. These data indicate that chronically elevated PI 3-kinase-dependent signaling to the degree seen in many tumors causes a selective loss of sensitivity in IGF1/insulin signaling that could significantly reduce the selective advantage of deregulated activation of IGF1/IGF1-R signaling in tumor development.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Coll Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Leslie, NR (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Physiol, Coll Life Sci, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk	Leslie, Nicholas/D-2699-2009	LESLIE, Nicholas/0000-0001-5131-0541	MRC [G9403619] Funding Source: UKRI; Medical Research Council [G9403619(67505), G9403619] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Batty IH, 2004, BIOCHEM J, V379, P641, DOI 10.1042/BJ20031700; Board R, 2005, DRUG RESIST UPDATE, V8, P75, DOI 10.1016/j.drup.2005.03.004; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Cutillas PR, 2006, P NATL ACAD SCI USA, V103, P8959, DOI 10.1073/pnas.0602101103; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Darragh J, 2005, BIOCHEM J, V390, P749, DOI 10.1042/BJ20050196; Fisher TL, 2004, CURR BIOL, V14, pR1005, DOI 10.1016/j.cub.2004.11.024; Foukas LC, 2006, NATURE, V441, P366, DOI 10.1038/nature04694; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hellawell GO, 2002, CANCER RES, V62, P2942; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Keeton AB, 2005, ENDOCRINOLOGY, V146, P2716, DOI 10.1210/en.2004-1662; Kiepe D, 2005, ENDOCRINOLOGY, V146, P3096, DOI 10.1210/en.2005-0324; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; LAM K, 1994, J BIOL CHEM, V269, P20648; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Mise-Omata S, 2005, BIOCHEM BIOPH RES CO, V328, P1034, DOI 10.1016/j.bbrc.2005.01.066; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Natarajan M, 2006, NAT CELL BIOL, V8, P571, DOI 10.1038/ncb1418; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shelton JG, 2005, EXPERT OPIN THER TAR, V9, P1009, DOI 10.1517/14728222.9.5.1009; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Vivekanand P, 2006, ANNU REV GENET, V40, P139, DOI 10.1146/annurev.genet.40.110405.090555; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001	40	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7132	7142		10.1038/sj.onc.1210520	http://dx.doi.org/10.1038/sj.onc.1210520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486056	Green Accepted			2022-12-17	WOS:000250715000007
J	Morrow, M; Samanta, A; Kioussis, D; Brady, HJM; Williams, O				Morrow, M.; Samanta, A.; Kioussis, D.; Brady, H. J. M.; Williams, O.			TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL	ONCOGENE			English	Article						leukemia; translocation; ETV6-RUNX1	ACUTE LYMPHOBLASTIC-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; RUNT DOMAIN; NUCLEAR-MATRIX; TRANSCRIPTIONAL REPRESSION; AML1/PEBP2-ALPHA-B GENE; ADULT HEMATOPOIESIS; MUTATION ANALYSIS; POINT MUTATIONS; FUSION PROTEIN	The t(12;21)(p13;q22) translocation generates the TEL-AML1 (TEL, translocation-Ets-leukemia; AML1, acute myeloid leukemia-1) (ETV6-RUNX1) fusion product and is the most common chromosomal abnormality in pediatric leukemia. Our previous studies using a murine fetal liver transplantation model demonstrated that TEL-AML1 promotes the self-renewal of B-cell precursors in vitro and enhances the expansion of hematopoietic stem cells (HSCs) in vivo. This is consistent with the hypothesis that TEL-AML1 induces expansion of a preleukemic clone. Several studies have described domains within TEL-AML1 involved in the transcriptional regulation of specific target genes. However, it is unclear which of these domains is important for the activity of TEL-AML1 in preleukemic hematopoiesis. In order to examine this, we have generated a panel of deletion mutants and expressed them in HSCs. These experiments demonstrate that TEL-AML1 requires multiple domains from both TEL and AML1 to alter hematopoiesis. Furthermore, mutation of a single amino-acid residue within the runt homology domain of AML1, required for DNA binding, was sufficient to abrogate TEL-AML1 activity. These data suggest that TEL-AML1 acts as an aberrant transcription factor to perturb multiple pathways during hematopoiesis.	UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; Natl Inst Med Res, Div Mol Immunol, London NW7 1AA, England	University of London; University College London; MRC National Institute for Medical Research	Williams, O (corresponding author), UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England.	owen.williams@ich.ucl.ac.uk	Williams, Owen/B-5003-2013	Williams, Owen/0000-0002-1760-6880; Brady, Hugh/0000-0002-3152-067X; Morrow, Michelle/0000-0002-4565-2008	Medical Research Council [MC_U117512796] Funding Source: Medline; MRC [MC_U117512796] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bernardin F, 2002, CANCER RES, V62, P3904; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Busson-Le Coniat M, 2001, GENE CHROMOSOME CANC, V32, P244, DOI 10.1002/gcc.1188; CAMERON ER, 2001, GENE CHROMOSOME CANC, V30, P407; Cin Paola Dal, 2001, Genes Chromosomes and Cancer, V30, P407; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischer M, 2005, ONCOGENE, V24, P7579, DOI 10.1038/sj.onc.1208931; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Guidez F, 2000, BLOOD, V96, P2557; Gunji H, 2004, BIOCHEM BIOPH RES CO, V322, P623, DOI 10.1016/j.bbrc.2004.07.169; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Javed A, 2000, J CELL SCI, V113, P2221; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Li Z, 2003, J BIOL CHEM, V278, P33088, DOI 10.1074/jbc.M303973200; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morrow M, 2004, BLOOD, V103, P3890, DOI 10.1182/blood-2003-10-3695; Niini T, 2000, HAEMATOLOGICA, V85, P362; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Quack I, 1999, AM J HUM GENET, V65, P1268, DOI 10.1086/302622; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Rho JK, 2002, BIOCHEM BIOPH RES CO, V297, P91, DOI 10.1016/S0006-291X(02)02075-2; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Tsuzuki S, 2004, P NATL ACAD SCI USA, V101, P8443, DOI 10.1073/pnas.0402063101; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Yoshida T, 2002, AM J HUM GENET, V71, P724, DOI 10.1086/342717; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	57	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4404	4414		10.1038/sj.onc.1210227	http://dx.doi.org/10.1038/sj.onc.1210227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237815				2022-12-17	WOS:000247620000008
J	Hao, N; Behar, M; Elston, TC; Dohlman, HG				Hao, N.; Behar, M.; Elston, T. C.; Dohlman, H. G.			Systems biology analysis of G protein and MAP kinase signaling in yeast	ONCOGENE			English	Review						mitogen-activated protein kinases; yeast; genetics; modeling; systems biology; desensitization	COUPLED RECEPTORS; ALPHA-SUBUNIT; RGS PROTEIN; GENETIC-ANALYSIS; GLOBAL ANALYSIS; A-FACTOR; FEEDBACK; PHOSPHORYLATION; PHEROMONE; INHIBITION	Approximately a third of all drugs act by binding directly to cell surface receptors coupled to G proteins. Other drugs act indirectly on these same pathways, for example, by inhibiting neurotransmitter reuptake or by blocking the inactivation of intracellular second messengers. The se drugs have revolutionized the treatment of human disease. However, the complexity of G protein signaling mechanisms has significantly hampered our ability to identify additional new drug targets. Moreover, today's molecular pharmacologists are accustomed to working on narrowly focused problems centered on a single protein or enzymatic process. Here we describe emerging efforts in yeast aimed at identifying proteins and processes that modulate the function of receptors, G proteins and MAP kinase effectors. The scope of these efforts is far more systematic, comprehensive and quantitative than anything attempted previously, and includes integrated approaches in genetics, proteomics and computational biology.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Phys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Elston, TC (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	telston@med.unc.edu; hdohlman@med.unc.edu	Hao, Nan/O-3462-2016	Hao, Nan/0000-0003-2857-4789; Dohlman, Henrik/0000-0003-2443-0729				Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Alon U., 2006, INTRO SYSTEMS BIOL; Apanovitch DM, 1998, J BIOL CHEM, V273, P28597, DOI 10.1074/jbc.273.44.28597; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Barnes DJ, 2003, SEMIN HEMATOL, V40, P34, DOI 10.1053/shem.2003.50002; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bornheimer SJ, 2004, P NATL ACAD SCI USA, V101, P15899, DOI 10.1073/pnas.0407009101; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chasse SA, 2006, EUKARYOT CELL, V5, P330, DOI 10.1128/EC.5.2.330-346.2006; Chasse SA, 2003, ASSAY DRUG DEV TECHN, V1, P357, DOI 10.1089/154065803764958649; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dohlman HG, 2002, NATURE, V418, P591, DOI 10.1038/418591a; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; Ferrell JE, 2001, CHAOS, V11, P227, DOI 10.1063/1.1349894; Force T, 2004, CIRCULATION, V109, P1196, DOI 10.1161/01.CIR.0000118538.21306.A9; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Gelperin DM, 2005, GENE DEV, V19, P2816, DOI 10.1101/gad.1362105; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gold SJ, 1997, J NEUROSCI, V17, P8024; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Guo M, 2003, MOL CELL, V12, P517, DOI 10.1016/S1097-2765(03)00307-1; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hao N, 2003, J BIOL CHEM, V278, P46506, DOI 10.1074/jbc.M308432200; HAO N, 2007, IN PRESS CURR BIOL; Hardcastle JL, 2000, ULTRASON SONOCHEM, V7, P7, DOI 10.1016/S1350-4177(99)00026-7; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Hornberg JJ, 2005, FEBS J, V272, P244, DOI 10.1111/j.1432-1033.2004.04404.x; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Johnson GL, 2005, CURR OPIN CHEM BIOL, V9, P325, DOI 10.1016/j.cbpa.2005.04.004; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; Klipp E, 2005, NAT BIOTECHNOL, V23, P975, DOI 10.1038/nbt1114; Kofahl B, 2004, YEAST, V21, P831, DOI 10.1002/yea.1122; Komarova NL, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100031; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin H, 2005, MOL MICROBIOL, V58, P6, DOI 10.1111/j.1365-2958.2005.04822.x; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Parnell SC, 2005, BIOCHEMISTRY-US, V44, P8159, DOI 10.1021/bi0503091; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Roman DL, 2007, MOL PHARMACOL, V71, P169, DOI 10.1124/mol.106.028670; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Schaber J, 2006, FEBS J, V273, P3520, DOI 10.1111/j.1742-4658.2006.05359.x; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Sebolt-Leopold JS, 2006, NATURE, V441, P457, DOI 10.1038/nature04874; Shao DY, 2006, BIOPHYS J, V91, P3986, DOI 10.1529/biophysj.106.081661; Shenoy S.K., 2005, SCI STKE, V2005, pcm10; Slessareva JE, 2006, CELL, V126, P191, DOI 10.1016/j.cell.2006.04.045; Somsen OJG, 2002, J THEOR BIOL, V218, P343, DOI 10.1006/jtbi.2002.3082; Spiegel AM, 2000, HORM RES, V53, P17, DOI 10.1159/000023526; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Wang X, 2006, BIOPHYS J, V90, P1961, DOI 10.1529/biophysj.105.073874; Wang YQ, 2003, J BIOL CHEM, V278, P22284, DOI 10.1074/jbc.M301272200; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yi TM, 2003, P NATL ACAD SCI USA, V100, P10764, DOI 10.1073/pnas.1834247100; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649; Zhong HL, 2003, J BIOL CHEM, V278, P7278, DOI 10.1074/jbc.M208819200	80	30	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3254	3266		10.1038/sj.onc.1210416	http://dx.doi.org/10.1038/sj.onc.1210416			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496920				2022-12-17	WOS:000246603600013
J	Man, C; Rosa, J; Lee, LTO; Lee, VHY; Chow, BKC; Lo, KW; Doxsey, S; Wu, ZG; Kwong, YL; Jin, DY; Cheung, ALM; Tsao, SW				Man, C.; Rosa, J.; Lee, L. T. O.; Lee, V. H. Y.; Chow, B. K. C.; Lo, K. W.; Doxsey, S.; Wu, Z. G.; Kwong, Y. L.; Jin, D. Y.; Cheung, A. L. M.; Tsao, S. W.			Latent membrane protein 1 suppresses RASSF1A expression, disrupts microtubule structures and induces chromosomal aberrations in human epithelial cells	ONCOGENE			English	Article						Epstein-Barr virus; LMP1; microtubules; RASSF1A; NF-kappa B; nasopharyngeal epithelial cells	EPSTEIN-BARR-VIRUS; ENCODED LATENT MEMBRANE-PROTEIN-1; PAPILLOMAVIRUS TYPE-16 E6; NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; TUMOR-SUPPRESSOR; CPG ISLAND; HONG-KONG; LARGE T; GENE	Epstein-Barr virus ( EBV) infection is closely associated with nasopharyngeal carcinoma ( NPC) and can be detected in early premalignant lesions of nasopharyngeal epithelium. The latent membrane protein 1 ( LMP1) is an oncoprotein encoded by the EBV and is believed to play a role in transforming premalignant nasopharyngeal epithelial cells into cancer cells. RASSF1A is a tumor-suppressor gene commonly inactivated in many types of human cancer including NPC. In this study, we report a novel function of LMP1, in down-regulating RASSF1A expression in human epithelial cells. Downregulation of RASSF1A expression by LMP1 is dependent on the activation of intracellular signaling of NF-kappa B involving the C-terminal activating regions ( CTARs) of LMP1. LMP1 expression also suppresses the transcriptional activity of the RASSF1A core promoter. RASSF1A stabilizes microtubules and regulates mitotic events. Aberrant mitotic spindles and chromosome aberrations are reported phenotypes in RASSF1A inactivated cells. In this study, we observed that LMP1 expression in human epithelial cells could induce aberrant mitotic spindles, disorganized interphase microtubules and aneuploidy. LMP1 expression could also suppress microtubule dynamics as exemplified by tracking movements of the growing tips of microtubules in live cells by transfecting EGFP-tagged EB1 into cells. The aberrant mitotic spindles and interphase microtubule organization induced by LMP1 could be rescued by transfecting RASSF1A expression plasmid into cells. Downregulation of RASSF1A expression by LMP1 may facilitate its role in transformation of premalignant nasopharyngeal epithelial cells into cancer cells.	Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Sci, Dept Zool, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; University of Massachusetts System; University of Massachusetts Worcester; Hong Kong University of Science & Technology	Tsao, SW (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, L01-53,Lab Block,Li Ka Shing Fac Med,21 Sassoon R, Hong Kong, Hong Kong, Peoples R China.	gswtsao@hkucc.hku.hk	Kwong, Yok Lam/C-4296-2009; Tsao, George/C-4422-2009; Lee, Tsz On/D-3095-2009; Chow, Billy/D-3064-2009; Lee, Leo T.O./AAB-1581-2021; /C-4230-2009	Chow, Billy/0000-0003-3390-0307; /0000-0003-3217-1456; Wu, Zhenguo/0000-0003-3049-8324				Balsitis S, 2005, J VIROL, V79, P11392, DOI 10.1128/JVI.79.17.11392-11402.2005; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; Cheung ST, 1998, INT J CANCER, V76, P399, DOI 10.1002/(SICI)1097-0215(19980504)76:3<399::AID-IJC18>3.0.CO;2-6; Chow LSN, 2006, ONCOGENE, V25, P310, DOI 10.1038/sj.onc.1209001; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Duensing S, 2002, CANCER RES, V62, P7075; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; HUANG DP, 1980, INT J CANCER, V26, P127, DOI 10.1002/ijc.2910260202; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Li HM, 2004, ONCOGENE, V23, P4488, DOI 10.1038/sj.onc.1207580; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; Lo AKF, 2004, INT J CANCER, V109, P919, DOI 10.1002/ijc.20051; Lo AKF, 2003, LAB INVEST, V83, P697, DOI 10.1097/01.LAB.0000067480.44925.10; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2002, SEMIN CANCER BIOL, V12, P451, DOI 10.1016/S1044579X02000883; Mathe E, 2004, NAT GENET, V36, P117, DOI 10.1038/ng0204-117; Patel D, 2004, CANCER RES, V64, P1299, DOI 10.1158/0008-5472.CAN-03-2917; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; RONG R, 2004, ONCOGENE, V23, P8126; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; VOS MD, 2004, CANCER RES, V12, P4112; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wu LM, 2006, J BIOL CHEM, V281, P2162, DOI 10.1074/jbc.M505903200; Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29; Zhang H, 2004, CANCER GENET CYTOGEN, V150, P144, DOI 10.1016/j.cancergencyto.2003.09.007	38	30	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					3069	3080		10.1038/sj.onc.1210106	http://dx.doi.org/10.1038/sj.onc.1210106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17099724				2022-12-17	WOS:000246395400012
J	Schagdarsurengin, U; Pfeifer, GP; Dammann, R				Schagdarsurengin, U.; Pfeifer, G. P.; Dammann, R.			Frequent epigenetic inactivation of cystatin M in breast carcinoma	ONCOGENE			English	Article						cystatin M; tumour suppressor gene; epigenetic inactivation; methylation; breast cancer; CST6	CYSTEINE PROTEINASE-INHIBITOR; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; PROMOTER HYPERMETHYLATION; MALIGNANT PHENOTYPE; CANCER; ASSOCIATION; PROGRESSION; EXPRESSION	Cystatin M is a potent endogenous inhibitor of lysosomal cysteine proteases. In breast carcinoma, cystatin M expression is frequently downregulated. It has been shown that cystatin M expression suppressed growth and migration of breast cancer cells. We examined the methylation status of the CpG island promoter of cystatin M in four breast cancer cell lines ( MDAMB231, ZR75-1, MCF7 and T47D), in 40 primary breast carcinoma and in corresponding normal tissue probes by combined bisulphite restriction analysis. To investigate the effects of cystatin M expression on the growth of breast carcinoma, cystatin M was transfected in T47D. The cystatin M promoter was highly methylated in all four-breast cancer cell lines. Primary breast tumours were significantly more frequently methylated compared to normal tissue samples ( 60 vs 25%; P = 0.006 Fisher's exact test). Treatment of breast cancer cells with 5-aza-2'-deoxycytidine ( 5-Aza-CdR), reactivated the transcription of cystatin M. Transfection of breast carcinoma cells with cystatin M caused a 30% decrease in colony formation compared to control transfection ( P = 0.002). Our results show that cystatin M is frequently epigenetically inactivated during breast carcinogenesis and cystatin M expression suppresses the growth of breast carcinoma. These data suggest that cystatin M may encode a novel epigenetically inactivated candidate tumour suppressor gene.	Univ Halle Wittenberg, Fac Med, Inst Human Genet, AWG Tumour Genet, D-06097 Halle, Germany; City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA USA	Martin Luther University Halle Wittenberg; City of Hope; Beckman Research Institute of City of Hope	Dammann, R (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Human Genet, AWG Tumour Genet, Magdeburger Str 2, D-06097 Halle, Germany.	reinhard.dammann@medizin.uni-halle.de	Schagdarsurengin, Undraga/AAH-4346-2020; Schagdarsurengin, Undraga/AAH-4312-2020	Schagdarsurengin, Undraga/0000-0003-0127-4938	NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CALKINS CC, 1995, BIOL CHEM H-S, V376, P71; Cheng T, 2006, J BIOL CHEM, V281, P15893, DOI 10.1074/jbc.M600694200; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Henskens YMC, 1996, BIOL CHEM H-S, V377, P71; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Krepela E, 2001, NEOPLASMA, V48, P332; Lah TT, 1998, BIOL CHEM, V379, P125; Ni J, 1997, J BIOL CHEM, V272, P10853; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340; Song J, 2006, BIOCHEM BIOPH RES CO, V340, P175, DOI 10.1016/j.bbrc.2005.11.171; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; Srivatsan ES, 2002, ONCOGENE, V21, P5631, DOI 10.1038/sj.onc.1205698; Stenman G, 1997, CYTOGENET CELL GENET, V76, P45, DOI 10.1159/000134512; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Vigneswaran N, 2003, ORAL ONCOL, V39, P559, DOI 10.1016/S1368-8375(03)00038-1; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388; Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x; Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819	31	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					3089	3094		10.1038/sj.onc.1210107	http://dx.doi.org/10.1038/sj.onc.1210107			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17099723				2022-12-17	WOS:000246395400014
J	Chang, BH; Smith, L; Huang, J; Thayer, M				Chang, B. H.; Smith, L.; Huang, J.; Thayer, M.			Chromosomes with delayed replication timing lead to checkpoint activation, delayed recruitment of Aurora B and chromosome instability	ONCOGENE			English	Article						replication checkpoint; chromosome passenger complex; genomic instability; spindle assembly checkpoint; endoreduplication; chromosome instability	DNA-DAMAGE; ARREST; TRANSLOCATIONS; ADAPTATION; SURVIVIN; CELLS; G2	Certain chromosome rearrangements display a significant delay in chromosome replication timing (DRT) that is associated with a subsequent delay in mitotic chromosome condensation (DMC). DRT/DMC chromosomes are common in tumor cells in vitro and in vivo and occur frequently in cells exposed to ionizing radiation. A hallmark for these chromosomes is the delayed phosphorylation of serine 10 of histone H3 during mitosis. The chromosome passenger complex, consisting of multiple proteins including Aurora B kinase and INCENP is thought to be responsible for H3 phosphorylation, chromosome condensation and the subsequent segregation of chromosomes. In this report, we show that chromosomes with DRT/DMC contain phosphorylated Chk1, consistent with activation of the S-M phase checkpoint. Furthermore, we show that INCENP is recruited to the DRT/DMC chromosomes during all phases of mitosis. In contrast, Aurora B kinase is absent on DRT/DMC chromosomes when these chromosomes lack serine 10 phosphorylation of H3. We also show that mitotic arrest deficient 2 (Mad2), a member of the spindle assembly checkpoint, is present on DRT/DMC chromosomes at a time when the normally condensed chromosomes show no Mad2 staining, indicating that DRT/DMC activates the spindle assembly checkpoint. Finally, cells with DRT/DMC chromosomes have centrosome amplication, abnormal spindle assembly, endoreduplication and significant chromosome instability.	Oregon Hlth & Sci Univ, Dept Biochem, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Hematol & Oncol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Thayer, M (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	thayerm@ohsu.edu		Chang, Bill/0000-0003-3783-1820; Smith, Leslie/0000-0001-6452-6624	NATIONAL CANCER INSTITUTE [R01CA097021, R01CA104693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM071176] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104693, CA 104693, R01 CA097021, CA 97021] Funding Source: Medline; NIGMS NIH HHS [F32 GM071176, F32-GM071176-01A1, F32 GM071176-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Breger KS, 2005, HUM MOL GENET, V14, P2813, DOI 10.1093/hmg/ddi314; Breger KS, 2004, CANCER RES, V64, P8231, DOI 10.1158/0008-5472.CAN-04-0879; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Liu QH, 2000, GENE DEV, V14, P1448; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Mills AD, 2000, NAT CELL BIOL, V2, P244, DOI 10.1038/35008670; Rajagopalan H, 2004, CANCER CHEMOTH PHARM, V54, pS65, DOI 10.1007/s00280-004-0889-8; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Smith A, 1998, PHARM SCI TECHNOL TO, V1, P47, DOI 10.1016/S1461-5347(98)00021-2; Smith L, 2001, P NATL ACAD SCI USA, V98, P13300, DOI 10.1073/pnas.241355098; Trask B, 1990, Methods Cell Biol, V33, P383; Yu KR, 2000, NAT CELL BIOL, V2, P609, DOI 10.1038/35023555	23	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1852	1861		10.1038/sj.onc.1209995	http://dx.doi.org/10.1038/sj.onc.1209995			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001311	Green Accepted			2022-12-17	WOS:000245117700003
J	Smith, APL; Henze, M; Lee, JA; Osborn, KG; Keck, JM; Tedesco, D; Bortner, DM; Rosenberg, MP; Reed, SI				Smith, A. P. L.; Henze, M.; Lee, J. A.; Osborn, K. G.; Keck, J. M.; Tedesco, D.; Bortner, D. M.; Rosenberg, M. P.; Reed, S. I.			Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland	ONCOGENE			English	Article						cyclin E; mammary tumorigenesis; genomic instability; p53; loss of heterozygosity	T-CELL LYMPHOMAGENESIS; WILD-TYPE P53; BREAST-CANCER; TRANSGENIC MICE; CHROMOSOMAL INSTABILITY; ENDOMETRIAL CANCER; PHASE-TRANSITION; E OVEREXPRESSION; GENE-EXPRESSION; ACTIVATION	Deregulation of cyclin E expression and/or high levels have been reported in a variety of tumors and have been used as indicators of poor prognosis. Although the role that cyclin E plays in tumorigenesis remains unclear, there is evidence that it confers genomic instability when deregulated in cultured cells. Here we show that deregulated expression of a hyperstable allele of cyclin E in mice heterozygous for p53 synergistically increases mammary tumorigenesis more than that in mice carrying either of these markers individually. Most tumors and tumor-derived cell lines demonstrated loss of p53 heterozygosity. Furthermore, this tumor susceptibility is related to the number of times the transgene is induced indicating that it is directly attributable to the expression of the cyclin E transgene. An indirect assay indicates that loss of p53 function is an early event occurring in the mammary epithelia of midlactation mammary glands in which cyclin E is deregulated long before evidence of malignancy. These data support the hypothesis that deregulated expression of cyclin E stimulates p53 loss of heterozygosity by promoting genomic instability and provides specific evidence for this in vivo. Cyclin E deregulation and p53 loss are characteristics often observed in human breast carcinoma.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Rotherham Gen Hosp, Dept Histopathol, Rotherham, S Yorkshire, England; Scripps Res Inst, Dept Anim Resources, La Jolla, CA 92037 USA; GlaxoSmithKline, Res Triangle Pk, NC USA	Scripps Research Institute; Scripps Research Institute; GlaxoSmithKline	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	sreed@scripps.edu		Smith, Adrian/0000-0001-9732-1422	NCI NIH HHS [R01-CA78343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bieche I, 2002, BRIT J CANCER, V86, P580, DOI 10.1038/sj.bjc.6600109; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Calhoun ES, 2003, AM J PATHOL, V163, P1255, DOI 10.1016/S0002-9440(10)63485-2; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Covini G, 1997, HEPATOLOGY, V25, P75; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hamilton AS, 2003, NEW ENGL J MED, V348, P2313, DOI 10.1056/NEJMoa021293; Hosokawa Y, 2001, TRANSGENIC RES, V10, P471, DOI 10.1023/A:1012064911751; Hubalek MM, 2004, ONCOGENE, V23, P4187, DOI 10.1038/sj.onc.1207560; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lindahl T, 2004, CARCINOGENESIS, V25, P375, DOI 10.1093/carcin/bgh019; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; MOON RC, 1969, INT J CANCER, V4, P312, DOI 10.1002/ijc.2910040308; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Park M, 2000, CANCER RES, V60, P542; Qiu J, 2003, LEUKEMIA, V17, P1891, DOI 10.1038/sj.leu.2403073; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SWANSON SM, 1995, CANCER LETT, V90, P171, DOI 10.1016/0304-3835(95)03712-6; THORDARSON G, 1995, CARCINOGENESIS, V16, P2847, DOI 10.1093/carcin/16.11.2847; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yin XY, 2001, CANCER RES, V61, P6487; Yu M, 2002, MOL IMMUNOL, V38, P981, DOI 10.1016/S0161-5890(02)00026-3	56	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7245	7259		10.1038/sj.onc.1209713	http://dx.doi.org/10.1038/sj.onc.1209713			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751806				2022-12-17	WOS:000242244700003
J	Glaviano, A; Nayak, V; Cabuy, E; Baird, DM; Yin, Z; Newson, R; Ladon, D; Rubio, MA; Slijepcevic, P; Lyng, F; Mothersill, C; Case, CP				Glaviano, A.; Nayak, V.; Cabuy, E.; Baird, D. M.; Yin, Z.; Newson, R.; Ladon, D.; Rubio, M. A.; Slijepcevic, P.; Lyng, F.; Mothersill, C.; Case, C. P.			Effects of hTERT on metal ion-induced genomic instability	ONCOGENE			English	Article						chromium; vanadium; hTERT; genomic instability; carcinogenesis	TELOMERE LENGTH; CHROMOSOMAL INSTABILITY; GENE-EXPRESSION; HUMAN-CELLS; IONIZING-RADIATION; CELLULAR-RESPONSE; HUMAN FIBROBLASTS; LETHAL MUTATIONS; MAMMALIAN-CELLS; ANEUPLOID CELLS	There is currently a great interest in delayed chromosomal and other damaging effects of low-dose exposure to a variety of pollutants which appear collectively to act through induction of stress-response pathways related to oxidative stress and ageing. These have been studied mostly in the radiation field but evidence is accumulating that the mechanisms can also be triggered by chemicals, especially heavy metals. Humans are exposed to metals, including chromium (Cr) (VI) and vanadium (V) (V), from the environment, industry and surgical implants. Thus, the impact of low-dose stress responses may be larger than expected from individual toxicity projections. In this study, a short (24 h) exposure of human fibroblasts to low doses of Cr (VI) and V (V) caused both acute chromosome damage and genomic instability in the progeny of exposed cells for at least 30 days after exposure. Acutely, Cr (VI) caused chromatid breaks without aneuploidy while V (V) caused aneuploidy without chromatid breaks. The longer-term genomic instability was similar but depended on hTERT positivity. In telomerase-negative hTERT - cells, Cr (VI) and V (V) caused a long lasting and transmissible induction of dicentric chromosomes, nucleoplasmic bridges, micronuclei and aneuploidy. There was also a long term and transmissible reduction of clonogenic survival, with an increased beta-galactosidase staining and apoptosis. This instability was not present in telomerase-positive hTERT+ cells. In contrast, in hTERT+ cells the metals caused a persistent induction of tetraploidy, which was not noted in hTERT - cells. The growth and survival of both metal-exposed hTERT+ and hTERT+ cells differed if they were cultured at subconfluent levels or plated out as colonies. Genomic instability is considered to be a driving force towards cancer. This study suggests that the type of genomic instability in human cells may depend critically on whether they are telomerase-positive or - negative and that their sensitivities to metals could depend on whether they are clustered or diffuse.	Univ Bristol, Bristol Implant Res Ctr, Bristol BS10 5NB, Avon, England; Dublin Inst Technol, Radiat & Environm Sci Ctr, Dublin 8, Ireland; Brunel Univ, Uxbridge UB8 3PH, Middx, England; Cardiff Univ, Dept Pathol, Sch Med, Cardiff, S Glam, Wales; Kings Coll London, Dept Publ Hlth Serv, London WC2R 2LS, England; Netherlands Canc Inst, Amsterdam, Netherlands	University of Bristol; Technological University Dublin; Brunel University; Cardiff University; University of London; King's College London; Netherlands Cancer Institute	Case, CP (corresponding author), Univ Bristol, Bristol Implant Res Ctr, Bristol BS10 5NB, Avon, England.	cpcase@hotmail.com	Lyng, Fiona/AAD-2842-2020; Baird, Duncan M/C-9671-2011	Lyng, Fiona/0000-0002-9876-963X; Baird, Duncan M/0000-0001-8408-5467				Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Bindra RS, 2005, MUTAT RES-FUND MOL M, V569, P75, DOI 10.1016/j.mrfmmm.2004.03.013; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cabuy E, 2004, CYTOM PART A, V62A, P150, DOI 10.1002/cyto.a.20096; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Cheng RYS, 2003, TOXICOL APPL PHARM, V191, P22, DOI 10.1016/S0041-008X(03)00228-X; Coen N, 2003, BRIT J CANCER, V88, P548, DOI 10.1038/sj.bjc.6600758; Coen N, 2001, J PATHOL, V195, P293; CORINNA M, 2003, CARCINOGENESIS, V24, P1183; Cui W, 2002, J BIOL CHEM, V277, P38531, DOI 10.1074/jbc.M205981200; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Ha LN, 2004, CARCINOGENESIS, V25, P2265, DOI 10.1093/carcin/bgh242; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; HARDIN J, 2001, COLLEGE STATION; Henegariu O, 2001, CYTOMETRY, V43, P101, DOI 10.1002/1097-0320(20010201)43:2<101::AID-CYTO1024>3.0.CO;2-8; IARC, 1990, MON EV CARC RISK HUM; Ivancsits S, 2002, MUTAT RES-GEN TOX EN, V519, P25, DOI 10.1016/S1383-5718(02)00138-9; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Koizumi S, 2003, J OCCUP HEALTH, V45, P331, DOI 10.1539/joh.45.331; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; Luther MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE502, DOI 10.1152/ajpendo.00424.2004; McClintock B, 1941, GENETICS, V26, P234; McIlrath J, 2001, CANCER RES, V61, P912; Mese H, 2001, CHEMOTHERAPY, V47, P136, DOI 10.1159/000048513; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2004, MUTAT RES-FUND MOL M, V568, P121, DOI 10.1016/j.mrfmmm.2004.06.050; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nijjar T, 2005, ONCOGENE, V24, P3369, DOI 10.1038/sj.onc.1208482; NIOSH (National Institute for Occupational Safety and Health), 1997, NIOSH POCK GUID CHEM; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; O'Brien TJ, 2003, MUTAT RES-FUND MOL M, V533, P3, DOI 10.1016/j.mrfmmm.2003.09.006; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Park HR, 2004, J CUTAN PATHOL, V31, P544, DOI 10.1111/j.0303-6987.2004.00228.x; Piboonniyom SO, 2003, CANCER RES, V63, P476; Pritchard DE, 2001, CELL GROWTH DIFFER, V12, P487; PUCK TT, 1956, J EXP MED, V103, P653, DOI 10.1084/jem.103.5.653; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ramirez P, 1997, MUTAT RES-REV MUTAT, V386, P291, DOI 10.1016/S1383-5742(97)00018-5; REID BJ, 1987, GASTROENTEROLOGY, V93, P1; Risques RA, 2003, CANCER RES, V63, P7206; Rubio MA, 2004, EXP CELL RES, V298, P17, DOI 10.1016/j.yexcr.2004.04.004; Rubio MA, 2002, J BIOL CHEM, V277, P28609, DOI 10.1074/jbc.M203747200; SABATIER L, 1994, INT J RADIAT BIOL, V66, P611, DOI 10.1080/09553009414551701; Sciandrello G, 2004, CARCINOGENESIS, V25, P413, DOI 10.1093/carcin/bgh029; SEONE AI, 2001, MUTAT RES, V490, P99; Seymour CB, 2003, BRIT J CANCER, V89, P1979, DOI 10.1038/sj.bjc.6601361; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; SMORGORZEWSKA A, 2002, CURR BIOL, V12, P1635; Sorensen M, 2005, CANCER EPIDEM BIOMAR, V14, P1340, DOI 10.1158/1055-9965.EPI-04-0899; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sugden Kent D., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P215; Thomas P, 2003, MUTAGENESIS, V18, P187, DOI 10.1093/mutage/18.2.187; TSUNETA Y, 1980, THORAX, V35, P294, DOI 10.1136/thx.35.4.294; Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Urushibara A, 2004, BIOCHEM BIOPH RES CO, V313, P1037, DOI 10.1016/j.bbrc.2003.12.039; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; World Health Organization (WHO), 2001, VAN PENT OTH IN VAN; Zhang Y, 2005, EUR J PHARMACOL, V516, P1, DOI 10.1016/j.ejphar.2005.04.022	76	30	30	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3424	3435		10.1038/sj.onc.1209399	http://dx.doi.org/10.1038/sj.onc.1209399			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16449970	Bronze			2022-12-17	WOS:000238448100007
J	Romano, PR; McCallus, DE; Pachuk, CJ				Romano, P. R.; McCallus, D. E.; Pachuk, C. J.			RNA interference-mediated prevention and therapy for hepatocellular carcinoma	ONCOGENE			English	Review						HCC; HBV; HCV; RNAi; shRNA; siRNA	HEPATITIS-C VIRUS; ENDOTHELIAL GROWTH-FACTOR; DOUBLE-STRANDED-RNA; B-VIRUS; GENE-EXPRESSION; NUCLEOSIDE ANALOGS; MESSENGER-RNA; HBV ACTIVITY; CELL-LINES; IN-VIVO	Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death and is on the increase worldwide. Hepatocellular carcinoma results from chronic liver disease and cirrhosis most commonly associated with chronic hepatitis B (HBV) or hepatitis C (HCV) infection. The highest incidences of HCC are found in China and Africa, where chronic HBV infection is the major risk component. In the United States, Europe and Japan, the significant increase in HCC and HCC-related deaths within the last three decades is mainly attributed to the rise in the number of HCV-infected individuals; smaller increases of HCC are associated with HBV. Given that HCV and HBV infection account for the majority of HCCs, therapeutic and prophylactic approaches to control or eliminate virus infection may prove effective in reducing the occurrence of HCC. Although anti-viral therapies exist for both HBV and HCV infections, they are ineffective for a significant number of patients. In addition, some treatments such as interferon therapy are dose limiting owing to toxic side effects. Clearly, new approaches are needed. RNA interference (RNAi)-based approaches may meet this need and have already shown promising preclinical results in cell culture and animal models. Although this paper focuses on the potential of RNAi as a prophylactic for HCC development, the potential use of RNAi-mediated approaches for HCC therapy will also be discussed.	Nucleonics, Horsham, PA 19044 USA		Pachuk, CJ (corresponding author), Nucleonics, 702 Elect Dr, Horsham, PA 19044 USA.	cpachuk@nucleonicsinc.com						Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Blanc JF, 2005, PROTEOMICS, V5, P3778, DOI 10.1002/pmic.200401194; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Cai ZH, 2005, J VIROL, V79, P13963, DOI 10.1128/JVI.79.22.13963-13973.2005; Chayama K, 1995, J HEPATOL, V23, P648, DOI 10.1016/0168-8278(95)80029-8; Chen M, 2005, J VIROL, V79, P3016, DOI 10.1128/JVI.79.5.3016-3027.2005; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Ghany MG, 2000, HEPATOLOGY, V32, p376A, DOI 10.1053/jhep.2000.17912; Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Guo Y, 2005, J VIROL, V79, P14392, DOI 10.1128/JVI.79.22.14392-14403.2005; Hamasaki K, 2003, FEBS LETT, V543, P51, DOI 10.1016/S0014-5793(03)00400-9; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hisaka T, 1999, INT J ONCOL, V14, P453; HUANG ZM, 1993, J VIROL, V67, P7032, DOI 10.1128/JVI.67.12.7032-7040.1993; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Kapadia SB, 2003, P NATL ACAD SCI USA, V100, P2014, DOI 10.1073/pnas.252783999; KAWABATA K, 1995, PHARMACEUT RES, V12, P825, DOI 10.1023/A:1016248701505; Klein C, 2003, GASTROENTEROLOGY, V125, P9, DOI 10.1016/S0016-5085(03)00720-0; Korf M, 2005, J HEPATOL, V43, P225, DOI 10.1016/j.jhep.2005.02.046; Kronke J, 2004, J VIROL, V78, P3436, DOI 10.1128/JVI.78.7.3436-3446.2004; Kruger M, 2001, MOL CELL BIOL, V21, P8357, DOI 10.1128/MCB.21.24.8357-8364.2001; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Leonard JN, 2006, GENE THER, V13, P532, DOI 10.1038/sj.gt.3302645; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 2000, J VIRAL HEPATITIS, V7, P167; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; LUI F, 1999, GENE THER, V6, P1258; Mao HJ, 2005, WORLD J GASTROENTERO, V11, P2811, DOI 10.3748/wjg.v11.i18.2811; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34; Miura H, 1997, J HEPATOL, V27, P854, DOI 10.1016/S0168-8278(97)80323-6; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; Papatheodoridis GV, 2002, AM J GASTROENTEROL, V97, P1618, DOI 10.1111/j.1572-0241.2002.05819.x; Prabhu R, 2005, J MED VIROL, V76, P511, DOI 10.1002/jmv.20391; Radhakrishnan SK, 2004, VIROLOGY, V323, P173, DOI 10.1016/j.virol.2004.02.021; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; Randall G, 2003, P NATL ACAD SCI USA, V100, P235, DOI 10.1073/pnas.0235524100; Ren GL, 2005, BIOCHEM BIOPH RES CO, V335, P1051, DOI 10.1016/j.bbrc.2005.07.170; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Shlomai A, 2003, HEPATOLOGY, V37, P764, DOI 10.1053/jhep.2003.50146; Simmonds P, 1999, J HEPATOL, V31, P54, DOI 10.1016/S0168-8278(99)80375-4; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Spangberg K, 2000, VIROLOGY, V274, P378, DOI 10.1006/viro.2000.0461; Suzuki K, 1996, CANCER RES, V56, P3004; Uprichard SL, 2005, P NATL ACAD SCI USA, V102, P773, DOI 10.1073/pnas.0409028102; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wilson JA, 2005, J VIROL, V79, P7050, DOI 10.1128/JVI.79.11.7050-7058.2005; Wilson JA, 2003, P NATL ACAD SCI USA, V100, P2783, DOI 10.1073/pnas.252758799; Wong N, 2005, CLIN CANCER RES, V11, P1319; Wu HL, 2005, GASTROENTEROLOGY, V128, P708, DOI 10.1053/j.gastro.2004.12.007; Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599; Ying CX, 2003, BIOCHEM BIOPH RES CO, V309, P482, DOI 10.1016/j.bbrc.2003.08.021; Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang G, 2004, GENE THER, V11, P675, DOI 10.1038/sj.gt.3302210; Zhang XN, 2004, WORLD J GASTROENTERO, V10, P2967; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	66	30	34	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3857	3865		10.1038/sj.onc.1209549	http://dx.doi.org/10.1038/sj.onc.1209549			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799627				2022-12-17	WOS:000238559600013
J	Luo, W; Wang, X; Kageshita, T; Wakasugi, S; Karpf, AR; Ferrone, S				Luo, W.; Wang, X.; Kageshita, T.; Wakasugi, S.; Karpf, A. R.; Ferrone, S.			Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells	ONCOGENE			English	Article						HMW-MAA expression; melanoma cell lines and lesions; promoter DNA methylation; 5-aza 2 '-deoxycytidine	CHONDROITIN SULFATE PROTEOGLYCAN; ACRAL LENTIGINOUS MELANOMA; MONOCLONAL-ANTIBODY MK2-23; CPG ISLANDS; TUMOR; 5-AZA-2'-DEOXYCYTIDINE; LESIONS; CANCER; ACTIVATION; INDUCTION	The human high molecular weight- melanoma associated antigen ( HMW- MAA) is a membrane- bound chondroitin sulfate proteoglycan that is variably expressed in a high percentage of melanoma cell lines and tumors. Since the mechanism( s) regulating HMW- MAA expression has( ve) not been defined, in this study, we have examined whether promoter DNA methylation regulates the level of HMW-MAA expression. In melanoma cell lines, the level of HMW- MAA mRNA and protein expression is coordinately regulated, implicating a transcriptional control mechanism. Consistent with a role for regulation by DNA methylation, we have found that a dense CpG island flanks the human HMW- MAA gene transcriptional start site. Methylation- specific PCR and sodium bisulfite DNA sequencing analyses indicate that the HMW- MAA promoter is heavily methylated in melanoma cell lines, melanoma lesions and normal lymphocytes that do not express HMW- MAA; in contrast, the HMW- MAA promoter is not methylated in melanoma cell lines and tumors that express this antigen. In addition, HMW-MAA expression is markedly induced in HMW- MAA-negative melanoma cell lines by incubation with the DNA methyltransferase inhibitor 5- aza- 2'- deoxycytidine. In summary, our results establish DNA methylation as a key regulator of HMW- MAA expression by human melanoma cells. This information represents a useful background to optimize immunotherapeutic strategies targeting HMW- MAA.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Kumamoto Univ, Grad Sch Med Sci, Dept Dermatol, Kumamoto, Japan	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Kumamoto University	Ferrone, S (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton St, Buffalo, NY 14263 USA.	soldano.ferrone@roswellpark.org		Karpf, Adam/0000-0002-0866-0666	NCI NIH HHS [P01 CA89480, R01 CA105500, R01 CA116674-01A1, R01 CA116674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105500, P01CA089480, R01CA116674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bestor TH, 2003, ANN NY ACAD SCI, V983, P22, DOI 10.1111/j.1749-6632.2003.tb05959.x; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Campoli MR, 2004, CRIT REV IMMUNOL, V24, P267, DOI 10.1615/CritRevImmunol.v24.i4.40; Chekenya M, 1999, INT J DEV NEUROSCI, V17, P421, DOI 10.1016/S0736-5748(99)00019-2; Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hafner C, 2005, INT J CANCER, V114, P426, DOI 10.1002/ijc.20769; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAGESHITA T, 1991, CANCER RES, V51, P1726; KAGESHITA T, 1993, CANCER RES, V53, P2830; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; KUSAMA M, 1989, J IMMUNOL, V143, P3844; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liu G, 2004, CANCER RES, V64, P4980, DOI 10.1158/0008-5472.CAN-03-3504; MITTELMAN A, 1992, P NATL ACAD SCI USA, V89, P466, DOI 10.1073/pnas.89.2.466; MITTELMAN A, 1994, CANCER RES, V54, P415; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Song F, 2005, P NATL ACAD SCI USA, V102, P3336, DOI 10.1073/pnas.0408436102; TEMPONI M, 1992, CANCER RES, V52, P2497; WEBER J, 1994, CANCER RES, V54, P1766; Yang JB, 2004, J CELL BIOL, V165, P881, DOI 10.1083/jcb.200403174	35	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2873	2884		10.1038/sj.onc.1209319	http://dx.doi.org/10.1038/sj.onc.1209319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407841				2022-12-17	WOS:000237448200005
J	Qiu, W; Schonleben, F; Thaker, HM; Goggins, M; Su, GH				Qiu, W.; Schoenleben, F.; Thaker, H. M.; Goggins, M.; Su, G. H.			A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma	ONCOGENE			English	Article						HNSCC; PJS; STK11; LKB1; genetic mutation; tumor-suppressor gene	PEUTZ-JEGHERS-SYNDROME; SYNDROME KINASE LKB1; SOMATIC MUTATIONS; LKB1/STK11 GENE; TUMORS; POLYPOSIS; EXPRESSION; CANCER; RISK; LUNG	To investigate whether genetic alteration of the STK11 ( serine/ threonine kinase 11)/ LKB1 tumor- suppressor gene is involved in the carcinogenesis of head and neck squamous cell carcinoma ( HNSCC), the entire encoding exons and flanking intronic sequences of the STK11/ LKB1 gene were analysed with direct genomic sequencing of 15 HNSCC specimens. A novel missense mutation with presumed loss of heterozygosity ( LOH) and 10 polymorphisms were identified in these samples. The novel mutation of STK11/ LKB1 at nucleotide position 613 G -> A, which causes the amino- acid substitution from alanine to threonine at residue 205 within the catalytic kinase domain, was identified in cell line RPMI 2650. To further determine whether this point mutation affects the gene function, constructs of the wild type and A205T mutant of the STK11/ LKB1 gene expression vectors were created and transfected into RPMI 2650 cells. Our results showed that the reintroduction of the wild- type but not the mutant STK11/ LKB1 construct into RPMI 2650 cells induced suppression of the cell growth. The mutation also affected the kinase activity of the Stk11/ Lkb1 protein. This led us to conclude that the A205T point mutation of the STK11/ LKB1 gene produces functionally inactive proteins. This is the first described mutation of the STK11/ LKB1 gene in HNSCC. While the mutation frequency of the STK11/ LKB1 gene in HNSCC remains to be determined in future studies, our data strongly suggests that STK11/ LKB1 is involved in the carcinogenesis of HNSCC.	Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Columbia University; Columbia University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Su, GH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, 1130 St Nicholas Ave,ICRC 10-04, New York, NY 10032 USA.	gs2157@columbia.edu	Su, Gloria/AAJ-1457-2020	Su, Gloria/0000-0002-5158-6019	NATIONAL CANCER INSTITUTE [R01CA109525, K01CA095434] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA095434, CA95434, R01 CA109525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Boudeau J, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9112; Chen RW, 1999, J MED GENET, V36, P943; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Jordanova A, 1997, HUM MUTAT, V10, P65, DOI 10.1002/(SICI)1098-1004(1997)10:1<65::AID-HUMU9>3.3.CO;2-9; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Nakau M, 2002, CANCER RES, V62, P4549; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Rowan A, 2000, J PATHOL, V192, P203; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Westerman AM, 1999, HUM MUTAT, V13, P476, DOI 10.1002/(SICI)1098-1004(1999)13:6<476::AID-HUMU7>3.3.CO;2-U; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074	34	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2937	2942		10.1038/sj.onc.1209325	http://dx.doi.org/10.1038/sj.onc.1209325			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407837	Green Accepted			2022-12-17	WOS:000237448200012
J	Hausel, P; Latado, H; Courjault-Gautier, F; Felley-Bosco, E				Hausel, P; Latado, H; Courjault-Gautier, F; Felley-Bosco, E			Src-mediated phosphorylation regulates subcellular distribution and activity of human inducible nitric oxide synthase	ONCOGENE			English	Article						inducible nitric oxide synthase; Src kinase; tyrosine phosphorylation	INTESTINAL EPITHELIAL-CELLS; ULCERATIVE-COLITIS; TYROSINE KINASES; CROHNS-DISEASE; PROTEIN-KINASE; EXPRESSION; ACTIVATION; PATHWAY; INDUCTION; CANCER	Inducible nitric oxide synthase ( iNOS) expression is regulated at both the transcriptional and post-transcriptional level in epithelial cells. The aim of this study was to characterize the effects of tyrosine phosphorylation on iNOS activity. In a human intestinal epithelial cell line stimulated with cytokines, tyrosine phosphorylation of human iNOS protein was observed after 30 min exposure to pervanadate (PV), an inhibitor of protein tyrosine phosphatases. 4-Amino-5-(4-chlorophenyl)7-(t-butyl) pyrazolo[3,4-d] pyrimidine, a specific inhibitor of Src tyrosine kinases, abolished the PV-induced iNOS tyrosine phosphorylation. Cotransfection of Src with iNOS cDNA in human embryonic kidney (HEK) 293 cells resulted in a threefold (P < 0.001) increase of iNOS protein levels and tyrosine phosphorylation of iNOS. In the presence of Src, 76% of wild-type (wt) iNOS was redistributed to detergent-insoluble domains and iNOS activity was decreased by 28% (P < 0.05) despite increased iNOS protein levels. Analysis of iNOS tyrosine mutants revealed decreased Src-induced effects in Y151F iNOS mutant. Using a GST-fusion protein containing a domain encompassing Y151, we show that Y151 is a direct substrate for active Src in vitro. These findings indicate a role for iNOS tyrosine phosphorylation in the regulation of iNOS activity and the implication of Src tyrosine kinases in this pathway.	Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland		Felley-Bosco, E (corresponding author), Dept Pharmacol & Toxicol, Rue Burgnon 27, CH-1005 Lausanne, Switzerland.	emanuela.felley-bosco@unil.ch	Felley-Bosco, Emanuela/E-7484-2017	Felley-Bosco, Emanuela/0000-0002-3408-0294				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; Ambs S, 1998, CANCER RES, V58, P334; Andre M, 2005, BIOCHEM PHARMACOL, V69, P595, DOI 10.1016/j.bcp.2004.11.007; Andre M, 2003, FEBS LETT, V546, P223, DOI 10.1016/S0014-5793(03)00576-3; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Chiu T, 2002, AM J PHYSIOL-CELL PH, V282, pC434, DOI 10.1152/ajpcell.00240.2001; COBBS CS, 1995, CANCER RES, V55, P727; Espey MG, 2000, J BIOL CHEM, V275, P11341, DOI 10.1074/jbc.275.15.11341; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; FELLEYBOSCO E, 1994, AM J RESP CELL MOL, V11, P159, DOI 10.1165/ajrcmb.11.2.7519434; Feng XS, 2002, P NATL ACAD SCI USA, V99, P14212, DOI 10.1073/pnas.212306199; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Kimura H, 1997, DIGEST DIS SCI, V42, P1047, DOI 10.1023/A:1018849405922; Kolodziejski PJ, 2002, P NATL ACAD SCI USA, V99, P12315, DOI 10.1073/pnas.192345199; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lee J, 2003, P NATL ACAD SCI USA, V100, P4843, DOI 10.1073/pnas.0735876100; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Miller MJS, 1999, AM J PHYSIOL-GASTR L, V276, pG795, DOI 10.1152/ajpgi.1999.276.4.G795; Musial A, 2001, J BIOL CHEM, V276, P24268, DOI 10.1074/jbc.M100725200; Navarro-Lerida I, 2004, J BIOL CHEM, V279, P55682, DOI 10.1074/jbc.M406621200; Paccani SR, 2005, BLOOD, V105, P2042, DOI 10.1182/blood-2004-04-1299; Pan JM, 1996, BIOCHEM J, V314, P889, DOI 10.1042/bj3140889; POSNER BI, 1994, J BIOL CHEM, V269, P4596; RACHMILEWITZ D, 1995, GUT, V36, P718, DOI 10.1136/gut.36.5.718; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Rumbo M, 2005, FEBS J, V272, P444, DOI 10.1111/j.1742-4658.2004.04484.x; Salh B, 1998, J IMMUNOL, V161, P6947; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Sondermann H, 2005, CELL, V121, P158, DOI 10.1016/j.cell.2005.04.001; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Vecchini F, 1997, CELL GROWTH DIFFER, V8, P261; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914	44	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					198	206		10.1038/sj.onc.1209030	http://dx.doi.org/10.1038/sj.onc.1209030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16116474				2022-12-17	WOS:000234583600004
J	Zhou, L; Isenberg, JS; Cao, Z; Roberts, DD				Zhou, L; Isenberg, JS; Cao, Z; Roberts, DD			Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1	ONCOGENE			English	Article						3D culture; endothelial cells; angiogenesis inhibitors; collagens	GROWTH-FACTOR-BETA; ENDOTHELIAL-CELL RESPONSES; TUMOR-GROWTH; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; CAPILLARY MORPHOGENESIS; ACTIVATION; VIVO; MECHANISMS; APOPTOSIS	Three-dimensional explant cultures of muscle tissue were used to characterize secreted proteins regulated by endogenous levels of the angiogenesis modulator thrombospondin (TSP)-1. Explants from TSP1 null mice exhibit enhanced neovascularization associated with increased endothelial outgrowth but decreased outgrowth of perivascular smooth muscle cells. The absence of endogenous TSP1 did not diminish activation of latent transforming growth factor-beta and moderately decreased matrix metal-loproteinase levels. However, significant changes in other secreted proteins were observed. Endogenous TSP1 decreased mRNA levels for collagens I alpha 1, I alpha 2, and III alpha 1 and laminin alpha 4 and increased collagen IV alpha 1 mRNA expression. Endogenous TSP1 also decreased the level of type I collagen protein produced by the vascular out-growths. Collagens Ia1, Ia2, and IIIa1 are known tumor endothelial markers, suggesting that TSP1 coordinately regulates a set of extracellular matrix genes that reverse the angiogenic switch. Suppression of collagen Ia1 or Ia2 mRNAs using antisense morpholinos inhibited outgrowth in TSP1 null explants and proliferation of TSP1 null endothelial cells, indicating that type I collagen synthesis is limiting for this neovascularization response.	NCI, Biochem Pathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, DD (corresponding author), NCI, Biochem Pathol Sect, Pathol Lab, NIH, Bldg 10,Room 2A33,10 Ctr Dr MSC 1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC009172, Z01SC009172] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelouahed M, 2000, J BIOL CHEM, V275, P17933, DOI 10.1074/jbc.275.24.17933; Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009; ALBINI A, 1987, CANCER RES, V47, P3239; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Bell SE, 2001, J CELL SCI, V114, P2755; Bogdanov A. Jr., 1999, Neoplasia (New York), V1, P438, DOI 10.1038/sj.neo.7900044; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen DH, 1999, AM J PHYSIOL-HEART C, V277, pH1100, DOI 10.1152/ajpheart.1999.277.3.H1100; CHOI ME, 1995, J BIOL CHEM, V270, P21144, DOI 10.1074/jbc.270.36.21144; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; de Fraipont F, 2004, ONCOGENE, V23, P3642, DOI 10.1038/sj.onc.1207438; DeHahn KC, 2004, EXP CELL RES, V294, P281, DOI 10.1016/j.yexcr.2003.11.006; Donnini S, 2004, LIFE SCI, V74, P2975, DOI 10.1016/j.lfs.2003.09.075; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; FOUSER L, 1991, J BIOL CHEM, V266, P18345; GONZALEZ AM, 2002, P NATL ACAD SCI USA, V26, P26; Guo NH, 1997, J PEPT RES, V50, P210; Guo NH, 1997, CANCER RES, V57, P1735; Hamano Y, 2004, CANCER RES, V64, P1570, DOI 10.1158/0008-5472.CAN-03-3126; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; Isenberg JS, 2005, MATRIX BIOL, V24, P110, DOI 10.1016/j.matbio.2005.01.002; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jimenez B, 2001, ONCOGENE, V20, P3443, DOI 10.1038/sj.onc.1204464; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kanda S, 1999, EXP CELL RES, V252, P262, DOI 10.1006/excr.1999.4622; Keezer SM, 2003, CANCER RES, V63, P6405; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; Lawler J, 2001, AM J PATHOL, V159, P1949, DOI 10.1016/S0002-9440(10)63042-8; Li ZQ, 2002, J CELL BIOL, V157, P509, DOI 10.1083/jcb.200109098; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Maeda K, 2001, ONCOL REP, V8, P763; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; Mazzanti CM, 2004, GENOME RES, V14, P1585, DOI 10.1101/gr.2552804; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Pedersen TX, 2003, ONCOGENE, V22, P3964, DOI 10.1038/sj.onc.1206614; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; St Croix B, 2000, SCIENCE, V289, P1197; Streit M, 2002, CANCER RES, V62, P2004; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Taraboletti G, 2000, FASEB J, V14, P1674; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Westphal JR, 2004, CURR OPIN MOL THER, V6, P451; Yakubenko VP, 2000, EXP CELL RES, V260, P73, DOI 10.1006/excr.2000.5002; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	66	30	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					536	545		10.1038/sj.onc.1209069	http://dx.doi.org/10.1038/sj.onc.1209069			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247480				2022-12-17	WOS:000234897400005
J	Smakman, N; Veenendaal, LM; van Diest, P; Bos, R; Offringa, R; Rinkes, IHMB; Kranenburg, O				Smakman, N; Veenendaal, LM; van Diest, P; Bos, R; Offringa, R; Rinkes, IHMB; Kranenburg, O			Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy	ONCOGENE			English	Article						Ras; interleukin-18; colorectal; immune-evasion; malignancy	KIRSTEN RAS MUTATIONS; COLORECTAL-CANCER; RNA INTERFERENCE; KI-RAS; COLON; GENE; INTERLEUKIN-18; CELLS; EXPRESSION; INDUCTION	Activating mutations in the human KRAS proto-oncogene are acquired during the earliest stages of colorectal cancer development. If mutant KRAS is to be used as a target for therapy in colorectal cancer, tumor growth should depend on its continued presence. Here, we report that stable knockdown of Kras(D12) in murine C26 colorectal cancer cells by RN A interference resulted in loss of transformed properties in vitro. The incidence of subcutaneous tumor formation was reduced by 60% and the lag time was increased sevenfold. Kras(D12)-knockdown tumors grew noninvasively and did not cause morbidity. Remarkably, some of the Kras(D12)-knockdown tumors regressed spontaneously, which rendered these mice resistant to parental C26 tumor growth. In immune-deficient hosts, the incidence of tumor formation by Kras(D12)-knockdown cells was 100%. None of these tumors regressed spontaneously. We conclude that the reduced incidence of tumor formation by Kras(D12)-knockdown cells is due to tumor cell clearance by the host immune system, but not to an intrinsic inability of these cells to grow out as tumors. Interestingly, Kras(D12) knockdown resulted in increased production of interleukin 18 (Il-18), an immune-stimulatory cytokine that has been implicated in limiting colorectal tumor formation. Thus, mutant Kras(D12) suppresses Il-18 production in colorectal tumor cells, which may contribute to evasion of the local immune system during tumor development.	Univ Utrecht, Med Ctr, Dept Surg, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands; Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Tumor Immunol Grp, NL-2333 ZA Leiden, Netherlands	Utrecht University; Utrecht University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kranenburg, O (corresponding author), Univ Utrecht, Med Ctr, Dept Surg, POB 85500, NL-3508 GA Utrecht, Netherlands.	o.kranenburg@azu.nl	Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Campbell I, 2000, CANCER GENE THER, V7, P37, DOI 10.1038/sj.cgt.7700116; Carlotti F, 2004, MOL THER, V9, P209, DOI 10.1016/j.ymthe.2003.11.021; CORBETT TH, 1975, CANCER RES, V35, P2434; FEARON ER, 1988, CANCER RES, V48, P2975; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GRISWOLD DP, 1975, CANCER, V36, P2441, DOI 10.1002/1097-0142(197512)36:6<2441::AID-CNCR2820360627>3.0.CO;2-P; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Leng JH, 2003, CHINESE MED J-PEKING, V116, P1475; Pages F, 1999, INT J CANCER, V84, P326, DOI 10.1002/(SICI)1097-0215(19990621)84:3<326::AID-IJC22>3.0.CO;2-K; Pages F, 2000, IMMUNOL LETT, V75, P9, DOI 10.1016/S0165-2478(00)00285-6; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Velde EAT, 2002, BRIT J SURG, V89, P1302, DOI 10.1046/j.1365-2168.2002.02183.x; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	20	30	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8338	8342		10.1038/sj.onc.1208995	http://dx.doi.org/10.1038/sj.onc.1208995			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091732				2022-12-17	WOS:000233956500012
J	Syed, V; Zhang, X; Lau, KM; Cheng, R; Mukherjee, K; Ho, SM				Syed, V; Zhang, X; Lau, KM; Cheng, R; Mukherjee, K; Ho, SM			Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells	ONCOGENE			English	Article						erythrocyte adducin alpha subunit clone; 5.1 RNA-binding protein S1; nuclear protein SkiP; Rap-2 plexin A3; sex gene	HORMONE REPLACEMENT THERAPY; SUPPRESSES TUMOR-FORMATION; SKI-INTERACTING PROTEIN; MESSENGER-RNA; BREAST-CANCER; IN-VITRO; INDUCED APOPTOSIS; KINASE-C; RECEPTOR; GROWTH	Estrogens regulate normal ovarian surface epithelium (OSE) cell functions but also affect epithelial ovarian cancer (OCa) development. Little is known about how estrogens play such opposing roles. Transcriptional pro. ling using a cDNA microarray containing 2400 named genes identified 155 genes whose expression was altered by estradiol-17 beta (E2) in three immortalized normal human ovarian surface epithelial (HOSE) cell lines and 315 genes whose expression was affected by the hormone in three established OCa (OVCA) cell lines. All but 19 of the genes in these two sets were different. Among the 19 overlapping genes, five were found to show discordant responses between HOSE and OVCA cell lines. The five genes are those that encode clone 5.1 RNA-binding protein (RNPS1), erythrocyte adducin a subunit (ADD1), plexin A3 (PLXNA3 or the SEX gene), nuclear protein SkiP (SKIIP), and Rap-2 (rap-2). RNPS1, ADD1, rap-2, and SKIIP were upregulated by E2 in HOSE cells but downregulated by estrogen in OVCA cells, whereas PLXNA3 showed the reverse pattern of regulation. The estrogen effects was observed within 6 18 h of treatment. In silicon analyses revealed presence of estrogen response elements in the proximal promoters of all five genes. RNPS1, ADD1, and PLXNA3 were underexpressed in OVCA cell lines compared to HOSE cell lines, while the opposite was true for rap-2 and SKIIP. Functional studies showed that RNPS1 and ADD1 exerted multiple antitumor actions in OVCA cells, while PLXNA3 only inhibited cell invasiveness. In contrast, rap-2 was found to cause significant oncogenic effects in OVCA cells, while SKIIP promotes only anchorage-independent growth. In sum, gene pro. ling data reveal that (1) E2 exerts different actions on HOSE cells than on OVCA cells by affecting two distinct transcriptomes with few overlapping genes and (2) among the overlapping genes, a set of putative oncogenes/tumor suppressors have been identified due to their differential responses to E2 between the two cell types. These findings may explain the paradoxical roles of estrogens in regulating normal and malignant OSE cell functions.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Room 504,Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	Shuk-Mei.Ho@umassmed.edu	Zhang, Xiang/D-3632-2009; Cheng, Robert/E-9799-2013	Cheng, Robert/0000-0003-0287-6439; Lau, Kin-Mang/0000-0001-5888-1937	NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NCI NIH HHS [CA94221, CA091250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AACR, 2005, STAT; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Badolato J, 1995, GENE, V166, P323, DOI 10.1016/0378-1119(95)00571-4; Bai WL, 2000, IN VITRO CELL DEV-AN, V36, P657; Bakken L, 2004, INT J CANCER, V112, P130, DOI 10.1002/ijc.20389; Bardin A, 2004, CANCER RES, V64, P5861, DOI 10.1158/0008-5472.CAN-04-0552; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Birkenmeier CS, 2004, J PATHOL, V204, P450, DOI 10.1002/path.1636; Bowen SL, 2003, J PATHOL, V201, P119, DOI 10.1002/path.1389; Callow ME, 2000, APPL ENVIRON MICROB, V66, P3249, DOI 10.1128/AEM.66.8.3249-3254.2000; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Chadwick CC, 2005, P NATL ACAD SCI USA, V102, P2543, DOI 10.1073/pnas.0405841102; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; Dahl R, 1998, ONCOGENE, V16, P1579, DOI 10.1038/sj.onc.1201687; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Folk P, 1996, GENE, V181, P229, DOI 10.1016/S0378-1119(96)00483-0; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; GALTIERDEREURE F, 1992, J CLIN ENDOCR METAB, V75, P1497, DOI 10.1210/jc.75.6.1497; Garg PP, 1998, OBSTET GYNECOL, V92, P472, DOI 10.1016/S0029-7844(98)00139-2; Ghisletti S, 2005, MOL CELL BIOL, V25, P2957, DOI 10.1128/MCB.25.8.2957-2968.2005; Gorringe KL, 2005, CARCINOGENESIS, V26, P923, DOI 10.1093/carcin/bgi032; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; HEINONEN PK, 1982, BRIT J OBSTET GYNAEC, V89, P84, DOI 10.1111/j.1471-0528.1982.tb04643.x; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Ho SM, 2003, ONCOGENE, V22, P4243, DOI 10.1038/sj.onc.1206437; Hough CD, 2001, CANCER RES, V61, P3869; JANOUEIXLEROSEY I, 1992, BIOCHEM BIOPH RES CO, V189, P455, DOI 10.1016/0006-291X(92)91580-J; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kim K, 2005, MOL ENDOCRINOL, V19, P843, DOI 10.1210/me.2004-0326; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Lancaster JM, 2004, J SOC GYNECOL INVEST, V11, P51, DOI 10.1016/j.jsgi.2003.07.004; LANGDON SP, 1990, BRIT J CANCER, V62, P213, DOI 10.1038/bjc.1990.263; LANGDON SP, 1993, INT J CANCER, V55, P459, DOI 10.1002/ijc.2910550323; LANGDON SP, 1994, EUR J CANCER, V30A, P682, DOI 10.1016/0959-8049(94)90545-2; Lassus H, 2003, GYNECOL ONCOL, V91, P504, DOI 10.1016/j.ygyno.2003.08.034; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Lau KM, 2003, LAB INVEST, V83, P743, DOI 10.1097/01.LAB.0000069519.06988.24; Lee BC, 2004, INT J ONCOL, V24, P847; Leong GM, 2004, BIOCHEM BIOPH RES CO, V315, P1070, DOI 10.1016/j.bbrc.2004.02.004; Leong GM, 2001, J BIOL CHEM, V276, P18243, DOI 10.1074/jbc.M010815200; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Mariani L, 2001, J NEURO-ONCOL, V53, P161, DOI 10.1023/A:1012253317934; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NASH JD, 1989, OBSTET GYNECOL, V73, P1009; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; Okamura H, 2003, MOL CELL ENDOCRINOL, V202, P37, DOI 10.1016/S0303-7207(03)00060-1; Pavao M, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-15; Prathapam T, 2002, NUCLEIC ACIDS RES, V30, P5261, DOI 10.1093/nar/gkf658; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Riman T, 2004, ACTA OBSTET GYN SCAN, V83, P783, DOI 10.1111/j.0001-6349.2004.00550.x; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Roche J, 2001, Clin Lung Cancer, V3, P145, DOI 10.3816/CLC.2001.n.026; RUNGE HM, 1986, EUR J CANCER CLIN ON, V22, P691, DOI 10.1016/0277-5379(86)90167-7; RUNGE HM, 1986, CANCER CHEMOTH PHARM, V16, P58; Sakamoto M, 2001, Hum Cell, V14, P305; Santin AD, 2004, BRIT J CANCER, V90, P1814, DOI 10.1038/sj.bjc.6601791; Simpson BJB, 1998, J STEROID BIOCHEM, V64, P137, DOI 10.1016/S0960-0760(97)00159-3; Sit ASY, 2002, GYNECOL ONCOL, V86, P118, DOI 10.1006/gyno.2002.6746; Song J, 2005, CANCER LETT, V220, P57, DOI 10.1016/j.canlet.2004.04.024; Stopper H, 2003, MUTAGENESIS, V18, P243, DOI 10.1093/mutage/18.3.243; Sugimura M, 2004, ONCOLOGY-BASEL, V66, P53, DOI 10.1159/000076335; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Syed V, 2003, ONCOGENE, V22, P6883, DOI 10.1038/sj.onc.1206828; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Taube M, 2002, INT J ONCOL, V20, P589; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tse C, 2002, CANCER RES, V62, P542; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Xiang RH, 2002, CANCER RES, V62, P2637; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhang C, 2001, J BIOL CHEM, V276, P40614, DOI 10.1074/jbc.M106263200; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	88	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8128	8143		10.1038/sj.onc.1208959	http://dx.doi.org/10.1038/sj.onc.1208959			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16116479				2022-12-17	WOS:000233809400005
J	Formisano, P; Perruolo, G; Libertini, S; Santopietro, S; Troncone, G; Raciti, GA; Oriente, F; Portella, G; Miele, C; Beguinot, F				Formisano, P; Perruolo, G; Libertini, S; Santopietro, S; Troncone, G; Raciti, GA; Oriente, F; Portella, G; Miele, C; Beguinot, F			Raised expression of the antiapoptotic protein ped/pea-15 increases susceptibility to chemically induced skin tumor development	ONCOGENE			English	Article						ped/pea-15; transgenic mice; chemical carcinogenesis; skin cancer; apoptosis	MAP KINASE; PEA-15; DEATH; APOPTOSIS; CELLS; MOUSE; ASTROCYTES; ACTIVATION; GROWTH; CANCER	ped/pea-15 is a cytosolic protein performing a broad antiapoptotic function. We show that, upon DMBA/TPA-induced skin carcinogenesis, transgenic mice overexpressing ped/pea-15 (Tg(ped/pea-15)) display early development of papillomas and a four-fold increase in papilloma number compared to the nontransgenic littermates (P < 0.001). The malignant conversion frequency was 24% for the Tg(ped/pea-15) mice and only 5% in controls (P < 0.01). The isolated application of TPA, but not that of DMBA, was sufficient to reversibly upregulate ped/pea-15 in both untransformed skin and cultured keratinocytes. ped/pea15 protein levels were also increased in DMBA/TPA-induced papillomas of both Tg(ped/pea-15) and control mice. Isolated TPA applications induced Caspase-3 activation and apoptosis in nontransformed mouse epidermal tissues. The induction of both Caspase-3 and apoptosis by TPA were four-fold inhibited in the skin of the Tg(ped/pea-15) compared to the nontransgenic mice, accompanied by a similarly sized reduction in TPA-induced JNK and p38 stimulation and by constitutive induction of cytoplasmic ERK activity in the transgenics. ped/pea-15 expression was stably increased in cell lines from DMBA/TPA-induced skin papillomas and carcinomas, paralleled by protection from TPA apoptosis. In the A5 spindle carcinoma cell line, antisense inhibition of ped/pea-15 expression simultaneously rescued sensitivity to TPA-induced Caspase-3 function and apoptosis. The antisense also reduced A5 cell ability to grow in semisolid media by 65% (P < 0.001) and increased by three-fold tumor latency time (P < 0.01). Thus, the expression levels of ped/pea-15 control Caspase-3 function and epidermal cell apoptosis in vivo and determine susceptibility to skin tumor development.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Sci Biomorfol & Funzionali, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II	Beguinot, F (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR, Via Sergio Pansini 5, I-80131 Naples, Italy.	beguino@unina.it	Libertini, Silvana/A-3531-2011; Portella, Giuseppe/AFU-6826-2022; giuseppe, perruolo/AAW-3869-2021; Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	Libertini, Silvana/0000-0003-2633-1564; PORTELLA, Giuseppe/0000-0001-8276-9769; Formisano, Pietro/0000-0001-7020-6870; Perruolo, Giuseppe/0000-0003-0479-8729; RACITI, GREGORYALEXANDER/0000-0003-2742-5634; ORIENTE, Francesco/0000-0003-4375-4526	Telethon [GGP04041] Funding Source: Medline	Telethon(Fondazione Telethon)		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Baldi A, 2004, EXP DERMATOL, V13, P93, DOI 10.1111/j.0906-6705.2004.00136.x; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; BURNS FJ, 1978, CARCINOGENESIS MECH; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Dong G, 2001, CANCER RES, V61, P4797; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Hao CH, 2001, CANCER RES, V61, P1162; Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kitsberg D, 1999, J NEUROSCI, V19, P8244; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Tsukamoto T, 2000, CANCER LETT, V149, P105, DOI 10.1016/S0304-3835(99)00350-X; Vaidyanathan H, 2003, J BIOL CHEM, V278, P32367, DOI 10.1074/jbc.M303988200; Vigliotta G, 2004, MOL CELL BIOL, V24, P5005, DOI 10.1128/MCB.24.11.5005-5015.2004	24	30	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7012	7021		10.1038/sj.onc.1208871	http://dx.doi.org/10.1038/sj.onc.1208871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16044159				2022-12-17	WOS:000232833200003
J	Becker, KA; Lu, SL; Dickinson, ES; Dunphy, KA; Mathews, L; Schneider, SS; Jerry, DJ				Becker, KA; Lu, SL; Dickinson, ES; Dunphy, KA; Mathews, L; Schneider, SS; Jerry, DJ			Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-beta-dependent pathways	ONCOGENE			English	Article						p53; estrogen; progesterone; TGF-beta; chemoprevention; mammary	GROWTH-FACTOR-BETA; CELL-CYCLE; BREAST-CANCER; CROSS-TALK; IN-VIVO; RECEPTOR; ASSOCIATION; ACTIVATION; PROLIFERATION; INSTABILITY	DNA damage normally induces p53 activity, but responses to ionizing radiation in the mammary epithelium vary among developmental stages. The following studies examined the hormones and growth factors that regulate radiation-responsiveness of p53 in mouse mammary epithelium. Immunoreactive p21/WAF1 and TUNEL staining were used as indicators of p53 activity following exposure to ionizing radiation. In ovariectomized mice, radiation-induced accumulation of p21/WAF1 was minimal in the mammary epithelial cells ( < 1%). Systemic injections of estrogen and progesterone (E + P) for 72 h were necessary to recover maximal expression of p21/WAF1 following ionizing radiation (55%). The effects of E + P on radiation-induced p21/WAF1 were p53-dependent as responses were absent in Trp53(-/-) mice. Though hormonal treatments stimulated increases in the proportion of cycling cells (PCNA-positive), this was not directly correlated with p53 activity. Whole organ cultures were used to determine whether E + P act directly upon the mammary gland. Treatment with E + P was sufficient to render p53 responsive to radiation, but TGF-beta-neutralizing antibodies blocked responsiveness. In the absence of E + P, TGF-beta 1 alone did not alter p53 activity. These results demonstrate that estrogen and progesterone together with TGF-beta signaling are necessary for maintenance of p53 activity in the mammary epithelium.	Univ Massachusetts, Mol & Cellular Biol Program, Amherst, MA 01003 USA; Univ Massachusetts, Dept Vet & Anim Sci, Paige Lab, Amherst, MA 01003 USA; Baystate Med Ctr, UMass Biomed Res Inst, Springfield, MA 01099 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center	Jerry, DJ (corresponding author), Univ Massachusetts, Mol & Cellular Biol Program, Amherst, MA 01003 USA.	jjerry@vasci.umass.edu		Lu, Shaolei/0000-0003-2870-5793	NATIONAL CANCER INSTITUTE [R21CA087531, R01CA095164] Funding Source: NIH RePORTER; NCI NIH HHS [CA87531, CA095164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson E, 2004, J MAMMARY GLAND BIOL, V9, P3, DOI 10.1023/B:JOMG.0000023584.01750.16; BARCELLOSHOFF MH, 2003, BREAST CANC RES S1, V5, P33; Bedford JS, 2002, RADIAT RES, V158, P251, DOI 10.1667/0033-7587(2002)158[0251:HACHIR]2.0.CO;2; Blackburn AC, 2002, BREAST CANCER RES, V4, P98; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clarke RB, 1997, BREAST CANCER RES TR, V45, P121, DOI 10.1023/A:1005805831460; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; DIBBS KI, 1995, AM J OBSTET GYNECOL, V173, P134, DOI 10.1016/0002-9378(95)90181-7; Ewan KB, 2002, CANCER RES, V62, P5627; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Iatropoulos MJ, 1996, EXP TOXICOL PATHOL, V48, P175, DOI 10.1016/S0940-2993(96)80039-X; JENG MH, 1993, ENDOCRINOLOGY, V132, P2622, DOI 10.1210/en.132.6.2622; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kuperwasser C, 2000, CANCER RES, V60, P2723; Lanari C, 2001, CANCER RES, V61, P293; Liu GZ, 2000, CANCER RES, V60, P1810; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Medina D, 2003, CANCER RES, V63, P6140; Medina D, 2003, CANCER RES, V63, P1067; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Minter LM, 2002, DEVELOPMENT, V129, P2997; Pati D, 2004, CANCER RES, V64, P5608, DOI 10.1158/0008-5472.CAN-03-0629; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; RUSSO IH, 1990, J NATL CANCER I, V82, P1286, DOI 10.1093/jnci/82.15.1286; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Stavridi ES, 2001, CANCER RES, V61, P7030; Thorstenson YR, 2003, CANCER RES, V63, P3325; THURSTON SJ, 1989, ANAL BIOCHEM, V178, P41, DOI 10.1016/0003-2697(89)90353-9; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635	46	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6345	6353		10.1038/sj.onc.1208787	http://dx.doi.org/10.1038/sj.onc.1208787			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	15940247				2022-12-17	WOS:000232038200002
J	Vanharanta, S; Wortham, NC; Laiho, P; Sjoberg, J; Aittomaki, K; Arola, J; Tomlinson, IP; Karhu, A; Arango, D; Aaltonen, LA				Vanharanta, S; Wortham, NC; Laiho, P; Sjoberg, J; Aittomaki, K; Arola, J; Tomlinson, IP; Karhu, A; Arango, D; Aaltonen, LA			7q deletion mapping and expression profiling in uterine fibroids	ONCOGENE			English	Article						fibroid; oligonucleotide microarray; gene expression; chromosome 7; loss of heterozygosity; tumour suppressor gene	GENE-EXPRESSION; MITOTIC RECOMBINATION; ADJACENT MYOMETRIUM; LEIOMYOMAS; TUMORS; HETEROZYGOSITY; CANCER; MICROARRAYS; ALLELOTYPE; ONTOLOGY	Uterine fibroids are some of the most common tumours of females, but relatively little is known about their molecular basis. Several studies have suggested that deletions on chromosome 7q could have a role in fibroid formation. We analysed 165 sporadic uterine fibroids to define a small 3.2 megabase (Mb) commonly deleted region on 7q22.3-q31.1, flanked by clones AC005070 and AC007567. We also used oligonucleotide microarrays to compare the expression profiles of 10 samples of normal myometrium and 15 fibroids, nine of which displayed 7q-deletions. Activating transcription factor 3, patched homolog ( Drosophila), homeo box A5, death-associated protein kinase 1, and retinoic acid receptor responder 3 were downregulated, and excision repair crosscomplementing 3, transcription factor AP-2 gamma and protein kinase C beta 1 were upregulated in fibroids. New pathways were discovered related to fibroid formation. The presence or absence of 7q-deletions did not dramatically affect the global expression pattern of the tumours; changes, however, were observed in genes related to vesicular transport and nucleic acid binding.	Univ Helsinki, Biomedicum, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Clin Genet, FIN-00029 Helsinki, Finland; Univ Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland	University of Helsinki; Cancer Research UK; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Aaltonen, LA (corresponding author), Univ Helsinki, Biomedicum, Haartman Inst, Dept Med Genet, Room B520A,POB 63,Haatmaninkatu 8, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Aaltonen, Lauri/A-5375-2010; Arango, Diego/M-5667-2016; Arango, Diego/AFW-0125-2022	Aaltonen, Lauri/0000-0001-6839-4286; Arango, Diego/0000-0003-2953-3284; Arango, Diego/0000-0003-2953-3284; Karhu, Auli/0000-0002-7927-0796				Ahn WS, 2003, INT J EXP PATHOL, V84, P267, DOI 10.1111/j.0959-9673.2003.00362.x; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Blackburn AC, 2004, CANCER RES, V64, P5140, DOI 10.1158/0008-5472.CAN-03-3435; CAIRNS P, 1994, CANCER RES, V54, P1422; Canzian F, 1996, CANCER RES, V56, P3331; Chegini N, 2003, J SOC GYNECOL INVEST, V10, P161, DOI 10.1016/S1071-5576(03)00004-2; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Gupta PK, 1997, CANCER RES, V57, P1188; Hall KL, 1997, GYNECOL ONCOL, V65, P330, DOI 10.1006/gyno.1997.4653; Herz DB, 2003, J UROLOGY, V170, P2072, DOI 10.1097/01.ju.0000091810.33953.13; Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297; Ishwad CS, 1997, GENE CHROMOSOME CANC, V19, P156, DOI 10.1002/(SICI)1098-2264(199707)19:3<156::AID-GCC4>3.0.CO;2-X; ISHWAD CS, 1995, GENE CHROMOSOME CANC, V14, P51, DOI 10.1002/gcc.2870140109; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kovacs KA, 2001, MOL HUM REPROD, V7, P1085, DOI 10.1093/molehr/7.11.1085; Lehtonen R, 2004, AM J PATHOL, V164, P17, DOI 10.1016/S0002-9440(10)63091-X; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Ligon AH, 2000, GENE CHROMOSOME CANC, V28, P235, DOI 10.1002/1098-2264(200007)28:3<235::AID-GCC1>3.3.CO;2-Z; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Mao X, 1999, CANCER GENET CYTOGEN, V114, P89, DOI 10.1016/S0165-4608(99)00053-9; Mori Y, 2003, CANCER RES, V63, P4577; NILBERT M, 1990, GENE CHROMOSOME CANC, V2, P3, DOI 10.1002/gcc.2870020103; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; PANDIS N, 1991, CANCER GENET CYTOGEN, V55, P11, DOI 10.1016/0165-4608(91)90229-N; Parameswaran K, 2004, EUR RESPIR J, V24, P545, DOI 10.1183/09031936.04.00113103; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; REIN MS, 1991, OBSTET GYNECOL, V77, P923; Stewart EA, 2001, LANCET, V357, P293, DOI 10.1016/S0140-6736(00)03622-9; Terashita Y, 2004, ONCOL REP, V12, P827; Tsibris JCM, 2002, FERTIL STERIL, V78, P114, DOI 10.1016/S0015-0282(02)03191-6; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van der Heijden O, 1998, MOL CARCINOGEN, V23, P243, DOI 10.1002/(SICI)1098-2744(199812)23:4<243::AID-MC7>3.0.CO;2-E; VANNI R, 1991, CANCER GENET CYTOGEN, V53, P247, DOI 10.1016/0165-4608(91)90101-Y; Wang HB, 2003, FERTIL STERIL, V80, P266, DOI 10.1016/S0015-0282(03)00730-1; Weston G, 2003, MOL HUM REPROD, V9, P541, DOI 10.1093/molehr/gag066; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	42	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6545	6554		10.1038/sj.onc.1208784	http://dx.doi.org/10.1038/sj.onc.1208784			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	15940248				2022-12-17	WOS:000232204100008
J	Yoo, E; Kim, BU; Lee, SY; Cho, CH; Chung, JH; Lee, CH				Yoo, E; Kim, BU; Lee, SY; Cho, CH; Chung, JH; Lee, CH			53BP1 is associated with replication protein A and is required for RPA2 hyperphosphorylation following DNA damage	ONCOGENE			English	Article						53BP1; replication protein A; camptothecin	DOUBLE-STRAND BREAKS; BINDING PROTEIN; ATAXIA-TELANGIECTASIA; P34 SUBUNIT; HELA-CELLS; PHOSPHORYLATION; CHECKPOINT; KINASE; CAMPTOTHECIN; SENSITIVITY	p53-binding protein 1 (53BP1) acts as an 'adaptor/mediator' for transducing DNA damage signals, especially following detection of DNA double-strand breaks. In an effort to broaden our understanding of the protein network surrounding 53BP1, we isolated possible 53BP1 binding partners by co-immunoprecipitation, and identified them via tandem mass spectrometric analysis. The 53BP1-associated proteins included RPA1 and RPA2, two components of the replication protein A (RPA) complex. The presence of RPA components in the immunoprecipitates was confirmed by immunoblotting, and we found that the association between 53BP1 and RPA2 was disrupted following DNA damage induced by treatment with camptothecin, a topoisomerase I inhibitor. To investigate the functional meaning of the 53BP1 and RPA interaction, we established U2OS osteosarcoma cell lines stably expressing dominant-negative fragments of 53BP1. We found that camptothecin-induced RPA2 phosphorylation was inhibited in these cells, and also following 53BP1 knockdown by siRNA transfection. On the cellular level, camptothecin-induced apoptosis was augmented in the dominant-negative cell lines, resulting in increased chemosensitivity to this drug. Taken together, these results suggest that 53BP1 is involved in DNA damage-induced RPA2 hyperphosphorylation, and inhibition of 53BP1 function may sensitize cancer cells to camptothecin treatment.	Natl Canc Ctr, Res Inst, Gyeonggi 411769, South Korea; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Cancer Center - Korea (NCC); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lee, CH (corresponding author), Natl Canc Ctr, Res Inst, 809 Madu Dong, Gyeonggi 411769, South Korea.	chlee@ncc.re.kr						Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; Fedier A, 2003, INT J ONCOL, V22, P1169; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SMITH PJ, 1989, INT J RADIAT BIOL, V55, P217, DOI 10.1080/09553008914550271; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang HY, 2001, CANCER RES, V61, P8554; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	35	30	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5423	5430		10.1038/sj.onc.1208710	http://dx.doi.org/10.1038/sj.onc.1208710			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15856006				2022-12-17	WOS:000231222300003
J	Greenberg, VL; Zimmer, SG				Greenberg, VL; Zimmer, SG			Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism	ONCOGENE			English	Article						translation; eIF-4E; 4E-BP1; paclitaxel; cdk1; G2/M arrest; cyclin B	CAP-BINDING PROTEIN; INDUCED CELL-DEATH; MESSENGER-RNA; OVARIAN-CANCER; FACTOR EIF-4E; DEPENDENT PHOSPHORYLATION; PHOSPHATASE 2A; (S/T)P SITES; S6 KINASE; FACTOR 4E	Initial chemotherapeutic treatment triggers a stress-related response, which can lead to an increase in the expression of survival proteins. In this study we examine whether paclitaxel (PTX) alters the expression and/ or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state. We found that PTX induced the hyperphosphorylation of 4E-BP1 in the breast cancer cell line, MDA MB 231, which reduced its association with eIF-4E, but did not alter the expression and phosphorylation of eIF-4E. The hyperphosphorylation of 4E-BP1 correlated with G2/M accumulation and with an increase in the phosphorylation of cdk1 substrates. Cotreatment with a histone deacetylase inhibitor (an indirect inhibitor of cdk activity), purvalanol A and roscovitine (direct cdk inhibitors), and the reduction of cyclin B expression using RNA interference decreased the hyperphosphorylation of 4E-BP1 in PTX treated cells. The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF- 4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells. Taken together, our data suggest that PTX-increases the functional level of eIF-4E by promoting the hyperphosphorylation and release of 4E-BP1 through a cdk1-dependent mechanism.	Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA	University of Kentucky	Zimmer, SG (corresponding author), Univ Kentucky, Dept Microbiol Immunol & Mol Genet, 800 Rose St, Lexington, KY 40536 USA.	szimm1@uky.edu			NATIONAL CANCER INSTITUTE [R01CA077614] Funding Source: NIH RePORTER; NCI NIH HHS [CA77614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Asnaghi L, 2004, PHARMACOL RES, V50, P545, DOI 10.1016/j.phrs.2004.03.007; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Chobanian NH, 2004, ANTICANCER RES, V24, P539; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; du Bois A, 2001, EUR J CANCER, V37, pS1; Ferlini C, 2003, MOL PHARMACOL, V64, P51, DOI 10.1124/mol.64.1.51; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Greenberg VL, 2001, THYROID, V11, P315, DOI 10.1089/10507250152039046; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Herbert TP, 2000, CURR BIOL, V10, P793, DOI 10.1016/S0960-9822(00)00567-4; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meric F, 2002, MOL CANCER THER, V1, P971; Minamoto T, 2001, CRIT REV ONCOL HEMAT, V40, P195, DOI 10.1016/S1040-8428(01)00098-1; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Shapiro GI, 2004, CLIN CANCER RES, V10, p4270S, DOI 10.1158/1078-0432.CCR-040020; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogel C L, 1999, Oncologist, V4, P17; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	52	30	33	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4851	4860		10.1038/sj.onc.1208624	http://dx.doi.org/10.1038/sj.onc.1208624			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897904				2022-12-17	WOS:000230477900012
J	Hemmati, PG; Normand, G; Verdoodt, B; von Haefen, C; Hasenjager, A; Guner, D; Wendt, J; Dorken, B; Daniel, PT				Hemmati, PG; Normand, G; Verdoodt, B; von Haefen, C; Hasenjager, A; Guner, D; Wendt, J; Dorken, B; Daniel, PT			Loss of p21 disrupts p14(ARF)-induced G1 cell cycle arrest but augments p14(ARF)-induced apoptosis in human carcinoma cells	ONCOGENE			English	Article						p14(ARF); p53; p21; cell cycle; apoptosis	P19(ARF) TUMOR-SUPPRESSOR; HUMAN CANCER-CELLS; P53-DEPENDENT APOPTOSIS; GROWTH ARREST; G(2) ARREST; P53; ARF; PATHWAYS; P16(INK4A); LOCUS	The human INK4a locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF) (p19(ARF) in the mouse), which are frequently inactivated in human cancer. Both the proapoptotic and cell cycle-regulatory functions of p14ARF were initially proposed to be strictly dependent on a functional p53/mdm-2 tumor suppressor pathway. However, a number of recent reports have implicated p53-independent mechanisms in the regulation of cell cycle arrest and apoptosis induction by p14ARF. Here, we show that the G1 cell cycle arrest induced by p14ARF entirely depends on both p53 and p21 in human HCT116 and DU145 carcinoma cells. In contrast, neither loss of p53 nor p21 impaired apoptosis induction by p14ARF as evidenced by nuclear DNA fragmentation, phosphatidyl serine exposure, and caspase activation, which included caspase-3/7- and caspase-9-like activities. However, lack of functional p21 resulted in the accumulation of cells in G2/Mphase of the cell cycle and markedly enhanced p14(ARF)-induced apoptosis that was, nevertheless, efficiently inhibited by the cell permeable broad-spectrum caspase inhibitor zVAD-fmk (valyl-alanyl-aspartyl( O)-methyl)-fluoromethylketone). Thus, loss of cell cycle restriction point control in the absence of p21 may interfere with p14(ARF)-induced apoptosis. Finally, these data indicate that the signaling events required for G1 cell cycle arrest and apoptosis induction by p14ARF dissociate upstream of p53.	Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Daniel, PT (corresponding author), Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Normand, Guillaume/A-1975-2010	Normand, Guillaume/0000-0003-1228-3813				Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cleveland JL, 2004, CANCER CELL, V6, P309, DOI 10.1016/j.ccr.2004.09.020; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; DURO D, 1995, ONCOGENE, V11, P21; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Groth A, 2000, J BIOL CHEM, V275, P27473; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Kuo ML, 2003, CANCER RES, V63, P1046; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; MAO L, 1995, CANCER RES, V55, P2995; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Mason SL, 2002, ONCOGENE, V21, P4220, DOI 10.1038/sj.onc.1205524; Modestou M, 2001, CANCER RES, V61, P3145; NORMAND G, 2004, J BIOL CHEM     1206; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Scholz C, 2002, GENE THER, V9, P1438, DOI 10.1038/sj.gt.3301796; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; WALDMAN T, 1995, CANCER RES, V55, P5187; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426; Zhu JH, 1998, CANCER RES, V58, P5061; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	49	30	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4114	4128		10.1038/sj.onc.1208579	http://dx.doi.org/10.1038/sj.onc.1208579			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15750619				2022-12-17	WOS:000229680300010
J	Nijjar, T; Bassett, E; Garbe, J; Takenaka, Y; Stampfer, MR; Gilley, D; Yaswen, P				Nijjar, T; Bassett, E; Garbe, J; Takenaka, Y; Stampfer, MR; Gilley, D; Yaswen, P			Accumulation and altered localization of telomere-associated protein TRF2 in immortally transformed and tumor-derived human breast cells	ONCOGENE			English	Article						telomeres; senescence; immortalization	MAMMARY EPITHELIAL-CELLS; MAMMALIAN TELOMERES; IMMORTALIZATION; SENESCENCE; EXPRESSION; P53; CONVERSION; ARREST; CANCER; LINES	We have used cultured human mammary epithelial cells (HMEC) and breast tumor-derived lines to gain information on defects that occur during breast cancer progression. HMEC immortalized by a variety of agents ( the chemical carcinogen benzo( a) pyrene, oncogenes c-myc and ZNF217, and/or dominant negative p53 genetic suppressor element GSE22) displayed marked upregulation (10-15 fold) of the telomere-binding protein, TRF2. Upregulation of TRF2 protein was apparently due to differences in post-transcriptional regulation, as mRNA levels remained comparable infinite lifespan and immortal HMEC. TRF2 protein was not upregulated by the oncogenic agents alone in the absence of immortalization, nor by expression of exogenously introduced hTERT genes. We found TRF2 levels to be at least twofold higher than in control cells in 11/15 breast tumor cell lines, suggesting that elevated TRF2 levels are a frequent occurrence during the transformation of breast tumor cells in vivo. The dispersed distribution of TRF2 throughout the nuclei in some immortalized and tumor-derived cells indicated that not all the TRF2 was associated with telomeres in these cells. The process responsible for accumulation of TRF2 in immortalized HMEC and breast tumor-derived cell lines may promote tumorigenesis by contributing to the cells' ability to maintain an indefinite lifespan.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Indiana University System; Indiana University-Purdue University Indianapolis	Gilley, D (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Bldg 70A1118,1 Cyclotron Rd, Berkeley, CA 94720 USA.	dpgilley@iupui.edu; P_Yaswen@lbl.gov			NATIONAL CANCER INSTITUTE [R37CA024844, F32CA108480, R01CA024844] Funding Source: NIH RePORTER; NCI NIH HHS [CA-108480, CA-24844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Klapper W, 2003, LEUKEMIA, V17, P2007, DOI 10.1038/sj.leu.2403086; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakagami Yoshihiro, 2002, Radiat Med, V20, P121; Nijjar T, 1999, CANCER RES, V59, P5112; Nonet GH, 2001, CANCER RES, V61, P1250; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	29	30	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 5	2005	24	20					3369	3376		10.1038/sj.onc.1208482	http://dx.doi.org/10.1038/sj.onc.1208482			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735711	Green Submitted			2022-12-17	WOS:000228881800015
J	Yan, L; Donze, JR; Liu, LL				Yan, L; Donze, JR; Liu, LL			Inactivated MGMT by O-6-benzylguanine is associated with prolonged G(2)/M arrest in cancer cells treated with BCNU	ONCOGENE			English	Article						MGMT; cell cycle checkpoint; mitosis; DNA damage	DNA-DAMAGE CHECKPOINT; TERMINAL PROLIFERATION ARREST; BRAIN-TUMOR CELLS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; DEPENDENT PROTEOLYSIS; CYCLE REGULATION; CARCINOMA-CELLS; GROWTH ARREST; COLON-CANCER; PHOSPHORYLATION	HCT116 and HCT15 cells that highly express O-6-methylguanine-DNA-methyltransferase (MGMT) displayed a transient cell cycle G2/M arrest in response to exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea ( BCNU) alone; however, 70 - 80% of cells were arrested in G2/M after treatment with O-6-benzylguanine (BG) and BCNU. Cells accumulated in G2/M showed elevated levels of an inactive form of cyclin B1/p-Cdc2 (Tyr15) complex that was not associated with activation of Chk1/p-Cdc25C and was independent of p53/p21 status. The most prominent feature of cell death was the appearance of enlarged and multinucleated cells that was related to the inhibition of mitotic entry. In contrast, BG-resistant cell lines, HCT116 BBR and HCT15 BBR cells that contain mutations K165E and K165N of MGMT, respectively, displayed a normal cell cycle progression with a slight and transient increase in G2/M arrest at 24 h after treatments with either BCNU alone or BG combined with BCNU. The differences in the ability to progress toward G2/M after treatment with BG and BCNU between cells expressing wild-type MGMT and mutated MGMT were confirmed in CHO cells transfected with human wild type and K165E mutant MGMT cDNA, respectively. Thus, our findings suggest that BG-inactivated MGMT may be linked to cell signaling events, forcing cells into a permanent G2/M arrest in response to the DNA damages induced by BCNU.	Case Western Reserve Univ, Dept Med, Div Hematol & Oncol, Cleveland, OH 44106 USA	Case Western Reserve University	Liu, LL (corresponding author), Case Western Reserve Univ, Dept Med, Div Hematol & Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	1x132@cwru.edu			NATIONAL CANCER INSTITUTE [R01CA082292] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA82292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguda BD, 1999, P NATL ACAD SCI USA, V96, P11352, DOI 10.1073/pnas.96.20.11352; Andreassen PR, 2001, CANCER RES, V61, P7660; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; FUNARI B, 1997, SCIENCE, V277, P1495; GERSON SL, 1993, BIOCHEM PHARMACOL, V45, P483, DOI 10.1016/0006-2952(93)90086-C; GIBSON NW, 1985, PHARMACOL THERAPEUT, V31, P153, DOI 10.1016/0163-7258(85)90042-7; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hirose Y, 2001, CANCER RES, V61, P5843; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Liu LL, 2002, CANCER RES, V62, P3070; Liu LL, 1996, CANCER RES, V56, P5375; Liu QH, 2000, GENE DEV, V14, P1448; LOCK RB, 1992, CANCER RES, V52, P1817; Monte M, 2003, J BIOL CHEM, V278, P30356, DOI 10.1074/jbc.M302902200; Mullapudi SRS, 2000, BIOCHEM J, V351, P393, DOI 10.1042/0264-6021:3510393; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Park JI, 2000, J CANCER RES CLIN, V126, P455, DOI 10.1007/s004320050013; PEGG AE, 1990, CANCER RES, V50, P6119; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Roninson IB, 2003, CANCER RES, V63, P2705; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Srivenugopal KS, 2000, CANCER RES, V60, P282; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; STAMATO TD, 1990, RADIAT RES, V121, P196, DOI 10.2307/3577504; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang XH, 1998, CANCER RES, V58, P5019; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	44	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2175	2183		10.1038/sj.onc.1208250	http://dx.doi.org/10.1038/sj.onc.1208250			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735757				2022-12-17	WOS:000227857900005
J	Duan, WM; Gabril, MY; Moussa, M; Chan, FL; Sakai, H; Fong, GH; Xuan, JW				Duan, WM; Gabril, MY; Moussa, M; Chan, FL; Sakai, H; Fong, GH; Xuan, JW			Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model	ONCOGENE			English	Article						prostate cancer; SV40 Tag oncogene; mouse cancer modeling; knockin mouse; tumorigenesis and progression; PSP94( beta microseminoprotein)	TISSUE-SPECIFIC EXPRESSION; ETS TRANSCRIPTION FACTOR; BETA-MICROSEMINOPROTEIN; GENE-EXPRESSION; SECRETORY PROTEIN; ORGAN SYSTEMS; ANTIGEN GENE; TUMOR-GROWTH; CANCER; MICE	Prostate cancer (CaP) is the most common cancer in adult men in North America. Since there is no naturally occurring prostate cancer in the mouse, preclinical studies stipulate for the establishment of a genetically manipulated mouse CaP model with features close to the human situation. In view of the limitations of transgenic technique-derived CaP models, herein we report the first application of knockin technology to establish a new mouse adenocarcinoma prostate model (PSP-KIMAP) by targeting of SV40 Tag to a prostate tissue-specific gene, PSP94 (prostate secretory protein of 94 amino acids). In order to demonstrate its novelty, we compared KIMAP to a PSP94 gene-directed transgenic mouse adenocarcinoma of the prostate (PSP-TGMAP) model. The CaP development of the PSP-KIMAP mice started almost immediately after puberty at 10 weeks of age from mouse prostatic intraepithelial neoplasia (mPIN) with micro-invasion to well-differentiated CaP, and demonstrated a close-to-human kinetics of prolonged tumor growth and a predominance of well and moderately differentiated tumors. The invasive nature of KIMAP model was demonstrated by multitissue metastases (lymph node, lung and liver etc) and also by immunohistochemical study of multiple invasive prostate tumor markers. PSP-KIMAP model is responsive to androgen deprivation (castration). The knockin technology in our KIMAP model demonstrates highly predictive CaP development procedures and many advantageous features, which the traditional transgenic technique-derived CaP models could not reach for both basic and clinical studies. These features include the high stability of both phenotype and genotype, highly synchronous prostate cancer development, high and precise prostate tissue targeting and with no founder line variation. The differences between the two CaP models were attributed to the introduction of a single endogenous knockin mutation, resulting in a CaP model self-regulated and controlled by a prostate gene promoter/enhancer of PSP94.	Univ Western Ontario, Dept Surg, London, ON, Canada; Univ Western Ontario, Dept Pathol, London, ON, Canada; Chinese Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 852, Japan; Univ Connecticut, Dept Physiol, Farmington, CT USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Chinese University of Hong Kong; Nagasaki University; University of Connecticut	Xuan, JW (corresponding author), London Hlth Sci Ctr, Urol Res Lab, 375 S St, London, ON N6A 4G5, Canada.	jim.xuan@lhsc.on.ca	Chan, Franky L./M-1043-2018	Chan, Franky L./0000-0003-0567-2052				Abate-Shen Cory, 2002, Trends Genet, V18, pS1, DOI 10.1016/S0168-9525(02)02683-5; ABRAHAMSSON PA, 1988, PROSTATE, V12, P39, DOI 10.1002/pros.2990120106; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; Deshmukh N, 1998, PATHOLOGY PROSTATE; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; DUBE JY, 1987, J ANDROL, V8, P182; Fernlund P, 1996, ARCH BIOCHEM BIOPHYS, V334, P73, DOI 10.1006/abbi.1996.0431; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gabril MY, 2002, GENE THER, V9, P1589, DOI 10.1038/sj.gt.3301895; GARABEDIAN EM, 1998, P NATL ACAD SCI USA, V62, P227; Gingrich JR, 1996, CANCER RES, V56, P4096; Green JE, 1998, PROSTATE, V36, P59, DOI 10.1002/(SICI)1097-0045(19980615)36:1<59::AID-PROS11>3.0.CO;2-H; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; HARA M, 1989, J LAB CLIN MED, V113, P541; Huss WJ, 2001, SEMIN CANCER BIOL, V11, P245, DOI 10.1006/scbi.2001.0373; HYAKUTAKE H, 1993, PROSTATE, V22, P347, DOI 10.1002/pros.2990220409; Imasato Y, 2000, J UROLOGY, V164, P1819, DOI 10.1016/S0022-5347(05)67113-3; Imasato Y, 2001, ENDOCRINOLOGY, V142, P2138, DOI 10.1210/en.142.5.2138; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kim MJ, 2002, CANCER RES, V62, P2999; Lazure C, 2001, PROTEIN SCI, V10, P2207, DOI 10.1110/ps.06501; LOKESHWAR BL, 1993, CANCER RES, V53, P4855; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Masumori N, 2001, CANCER RES, V61, P2239; Matsubara S, 2001, CANCER RES, V61, P6012; Matusik RJ, 2001, CONT ENDOCRINOL, P401; Miyamoto N, 1997, DEVELOPMENT, V124, P1653; Mostofi FK, 2002, HISTOLOGICAL TYPING; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; PerezStable C, 1997, CANCER RES, V57, P900; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Shibata MA, 1996, CANCER RES, V56, P4894; Shukeir N, 2003, CANCER RES, V63, P2072; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; Stege R, 2000, CLIN CANCER RES, V6, P160; THOMPSON TC, 1996, UROL ONCOL, V2, P99; Watabe T, 2002, P NATL ACAD SCI USA, V99, P401, DOI 10.1073/pnas.012574899; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Xuan JW, 1999, DNA CELL BIOL, V18, P11, DOI 10.1089/104454999315583	43	30	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1510	1524		10.1038/sj.onc.1208229	http://dx.doi.org/10.1038/sj.onc.1208229			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674347				2022-12-17	WOS:000227218200004
J	Fliegauf, M; Stock, M; Berg, T; Lubbert, M				Fliegauf, M; Stock, M; Berg, T; Lubbert, M			Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO	ONCOGENE			English	Article						chromosomal translocation (8;21); acute myeloid leukemia; transcription factor; gene regulation; representational difference analysis	ACUTE MYELOID-LEUKEMIA; REPRESENTATIONAL DIFFERENCE ANALYSIS; CORE-BINDING-FACTOR; T-CELL-RECEPTOR; PROTEIN-PROTEIN INTERACTIONS; STIMULATING FACTOR-RECEPTOR; T(8/21) FUSION PROTEIN; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTION FACTOR; DNA-BINDING	The chromosomal translocation t(8;21) fuses the AML1 (RUNX1) gene on chromosome 21 and the ETO gene on chromosome 8 in human acute myeloid leukemias (AMLs), resulting in expression of the chimeric transcription factor AML1/ETO. AML1/ETO-mediated dysregulation of target genes critical for hematopoietic differentiation and proliferation is thought to contribute to the leukemic phenotype. Several mechanisms, including recruitment of histone deacetylases (HDACs) to AML1 target genes, may be responsible for altered gene expression. We used an ecdysone-inducible expression system in the human monoblastic U-937 cell line to isolate genes that were differentially expressed upon induction of AML1/ETO expression. By representational difference analysis (cDNA-RDA), we identified 26 genes whose expression levels were significantly modulated following AML1/ETO induction for 48 h. None of these genes has previously been described as a target of AML1, ETO or AML1/ETO. One gene downregulated by AML1/ETO in vitro, Williams Beuren syndrome critical region 5 (WBSCR5), was expressed in primary t(8;21)-negative AML blasts but not in primary t(8;21)-positive AML blasts, strongly implying a role of this gene in the phenotype of t(8;21)-positive AML. Four upregulated and four downregulated genes were further studied with all-trans-retinoic acid (ATRA), an inducer of differentiation of U-937 cells, and Trichostatin A (TSA), an HDAC inhibitor. Three out of eight genes including WBSCR5 were regulated during ATRA-induced monocytic differentiation of U-937 cells, however, none of them antagonistically, upon both ATRA treatment and AML1/ETO induction. AML1/ETO-associated dysregulation of gene expression was not mediated by a TSA-sensitive mechanism. The identified genes provide a useful model to study the mechanism by which the AML1/ETO fusion protein exerts its function in transcriptional dysregulation in AML. The possible role of WBSCR5 in normal and malignant hematopoiesis warrants further study.	Univ Freiburg, Med Ctr, Div Hematol Oncol, D-79106 Freiburg, Germany; Univ Freiburg, Depb Biol 3, D-79104 Freiburg, Germany; Univ Freiburg, Depb Biol 1, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg	Lubbert, M (corresponding author), Univ Freiburg, Med Ctr, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	luebbert@mm11.ukl.uni-freiburg.de	Berg, Tobias/AAT-5094-2021; Stock, Michael/B-9829-2009	Berg, Tobias/0000-0003-2668-0449; Stock, Michael/0000-0002-3322-0961				Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Burger JA, 2000, BLOOD, V96, P2655; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Downing JR, 2001, LEUKEMIA, V15, P664, DOI 10.1038/sj.leu.2402035; Doyle JL, 2000, CYTOGENET CELL GENET, V90, P285, DOI 10.1159/000056790; ERICKSON P, 1992, BLOOD, V80, P1825; FLIEGAUF M, 2003, HEMAT BLOOD, V41, P28; Francke U, 1999, HUM MOL GENET, V8, P1947, DOI 10.1093/hmg/8.10.1947; Frank R, 1995, ONCOGENE, V11, P2667; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRIMM T, 1980, Z KARDIOL, V69, P168; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Hwang ES, 1999, FEBS LETT, V446, P86, DOI 10.1016/S0014-5793(99)00190-8; Janssen E, 2003, NAT IMMUNOL, V4, P117, DOI 10.1038/ni882; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Koonpaew S, 2004, J BIOL CHEM, V279, P11229, DOI 10.1074/jbc.M311394200; Kozu T, 1996, J CANCER RES CLIN, V122, P254, DOI 10.1007/BF01209655; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LISITSYN N, 1995, METHOD ENZYMOL, V254, P291; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MATSUSHITA H, 1995, BIOCHEM BIOPH RES CO, V215, P431, DOI 10.1006/bbrc.1995.2483; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; RICCIO ML, 1993, DNA SEQUENCE, V4, P129, DOI 10.3109/10425179309020152; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SCHUTTE M, 1995, NUCLEIC ACIDS RES, V23, P4127, DOI 10.1093/nar/23.20.4127; Shimada H, 2000, BLOOD, V96, P655; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TKACZYK C, 2004, BLOOD; Uchida H, 1997, J IMMUNOL, V158, P2251; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	71	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9070	9081		10.1038/sj.onc.1208042	http://dx.doi.org/10.1038/sj.onc.1208042			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489901				2022-12-17	WOS:000225492800008
J	Kameoka, Y; Tagawa, H; Tsuzuki, S; Karnan, S; Ota, A; Suguro, M; Suzuki, R; Yamaguchi, M; Morishima, Y; Nakamura, S; Seto, M				Kameoka, Y; Tagawa, H; Tsuzuki, S; Karnan, S; Ota, A; Suguro, M; Suzuki, R; Yamaguchi, M; Morishima, Y; Nakamura, S; Seto, M			Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma	ONCOGENE			English	Article						array CGH; diffuse large B-cell lymphoma; Fragile Histidine Triad; 3p14.2	COMPARATIVE GENOMIC HYBRIDIZATION; FHIT GENE; CHROMOSOMAL IMBALANCES; EXPRESSION; CLASSIFICATION; TRANSCRIPTS; PROTEIN; ACID; SITE	Deletions of the 3p arm have been detected in various solid tumors, but no study to date has investigated this deletion in diffuse large B-cell lymphoma (DLBCL). Recently, we demonstrated that 3p14.2 was deleted in approximately 30% of DLBCL cases by use of a genome-wide array-comparative genomic hybridization (CGH). For a more detailed examination of the genomic losses at 3p14.2, here we made use of contig BAC array for 3p14.2, and found that 12 DLBCL samples displayed losses. All of the deleted regions were located within the fragile histidine triad (FHIT) gene, and the most frequent region of loss was mapped to 0.4 Mbp of the region encompassing the introns 4 and 5 and exon 5 of the FHIT gene. Concomitant analysis of transcripts showed that the FHIT gene was aberrantly transcribed in 31% of the DLBCL samples examined and that the lost exons of the aberrant transcripts were correlated with genomic deletions. These findings indicate that (1) loss of genomic material at 3q14.2 is responsible for exon losses of the FHIT gene, and (2) genomic loss of the FHIT gene is one of the causes of the generation of aberrant transcripts.	Mie Univ, Sch Med, Dept Internal Med 2, Tsu, Mie 514, Japan; Aichi Canc Ctr, Dept Hematol & Chemotherapy, Aichi, Japan; Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Aichi, Japan; Aichi Canc Ctr, Res Inst, Div Mol Med, Aichi, Japan	Mie University; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan.	mseto@aichi-cc.jp	Nakamura, Shigeo/I-1571-2012; Ota, Akinobu/CAC-5999-2022; Ota, Akinobu/AAI-9396-2020; Ota, Akinobu/H-4510-2019	Ota, Akinobu/0000-0002-6296-2921; Suzuki, Ritsuro/0000-0002-5974-7614; Yamaguchi, Motoko/0000-0002-7094-6489; Tsuzuki, Shinobu/0000-0002-3209-3550				Albitar M, 2001, LEUKEMIA RES, V25, P859, DOI 10.1016/S0145-2126(01)00042-X; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Berglund M, 2002, MODERN PATHOL, V15, P807, DOI 10.1097/01.MP.0000024375.04135.2B; Chen PM, 2004, ONCOL REP, V11, P349; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cigudosa JC, 1999, GENE CHROMOSOME CANC, V25, P123, DOI 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4; Dave BJ, 2002, CANCER GENET CYTOGEN, V132, P125, DOI 10.1016/S0165-4608(01)00548-9; Druck T, 1997, CANCER RES, V57, P504; Ferrer M, 1999, MOL CARCINOGEN, V25, P55, DOI 10.1002/(SICI)1098-2744(199905)25:1<55::AID-MC7>3.0.CO;2-3; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Gemma A, 1997, CANCER RES, V57, P1435; Hallas C, 1999, CLIN CANCER RES, V5, P2409; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; HARRIS NL, 1994, BLOOD, V84, P1361; Hendricks DT, 1997, CANCER RES, V57, P2112; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Iwai T, 1998, CANCER RES, V58, P5182; Karnan S, 2004, GENE CHROMOSOME CANC, V39, P77, DOI 10.1002/gcc.10298; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2; Peters UR, 1999, ONCOGENE, V18, P79, DOI 10.1038/sj.onc.1202256; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Tagawa H, 2004, CANCER RES, V64, P5948, DOI 10.1158/0008-5472.CAN-03-4056; TWEEDDALE ME, 1987, BLOOD, V69, P1307; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Wessendorf S, 2003, ONCOGENE, V22, P1425, DOI 10.1038/sj.onc.1206297	33	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9148	9154		10.1038/sj.onc.1208136	http://dx.doi.org/10.1038/sj.onc.1208136			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480422				2022-12-17	WOS:000225492800017
J	Roz, L; Andriani, F; Ferreira, CG; Giaccone, G; Sozzi, G				Roz, L; Andriani, F; Ferreira, CG; Giaccone, G; Sozzi, G			The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression	ONCOGENE			English	Article						Fhit; lung cancer; apoptosis control	HISTIDINE TRIAD GENE; TUMOR-DEVELOPMENT; DEATH DOMAIN; EXPRESSION; LESIONS; TUMORIGENICITY; MITOCHONDRIA; TRANSDUCTION; CHEMOTHERAPY; INHIBITION	The expression of the tumour suppressor protein fragile histidine triad (Fhit) is often impaired in many human cancers and its restoration in Fhit-negative cancer cell lines suppresses tumorigenicity and induces apoptosis. Although the proapoptotic function of Fhit is well documented, little is known about its precise mechanism of action and further studies are needed in order to elucidate the putative therapeutic properties of this protein. To this end, we have engineered the lung cancer cell line NCI-H460 in order to express different molecules involved in the control of apoptotic pathways. Infection of these cells with an adenoviral vector transducing the Fhit gene (Ad-Fhit) revealed that complete protection from apoptosis was conferred by the inhibitor of caspases Cytokine response modifier A (CrmA) and by a dominant-negative form of the adapter protein Fas-associated death domain (FADD) and partial protection by a dominant-negative form of caspase-8, while cells over expressing mitochondrial mediators of the apoptotic response such as Bcl-2 or Bcl-x(L) that are resistant to treatment with cisplatin, remained highly susceptible to cell death triggered by Fhit gene transfer. In line to what was observed in H460 cells, Ad-Fhit efficacy was not affected by Bcl-2 overexpression also in two other lung cancer cell lines (A549 and Calu-1). Analysis of cytochrome c release also confirmed that in Bcl-2- or Bel-x(L)-expressing cells apoptosis could be detected by terminal deoxynucleotidyltransferase mediated dUTP nick-end labelling (TUNEL) assay before any evidence of mitochondrial membrane perturbation. In conclusion, our analysis indicates that the Fhit protein exerts its oncosuppressor activity through induction of an apoptotic mechanism that seems to be FADD dependent, caspase-8 mediated and independent from mitochondrial amplification.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands	Fondazione IRCCS Istituto Nazionale Tumori Milan; Vrije Universiteit Amsterdam	Roz, L (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	luca.roz@istitutotumori.mi.it	sozzi, gabriella/G-8259-2011; Ferreira, Carlos Gil/AAD-4104-2020; Giaccone, Giuseppe/E-8297-2017; Roz, Luca/AAB-3889-2019; Andriani, Francesca/D-4898-2017; Ferreira, Carlos Gil/G-4957-2013	sozzi, gabriella/0000-0001-9360-6914; Ferreira, Carlos Gil/0000-0002-7228-7018; Giaccone, Giuseppe/0000-0002-5023-7562; Roz, Luca/0000-0001-5817-7149; Andriani, Francesca/0000-0002-6178-7789; 				Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; Broker LE, 2002, CANCER RES, V62, P4081; CAVAZZONI A, 2004, ONCOGENE        0913; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Connolly DC, 2000, CLIN CANCER RES, V6, P3505; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Ferreira CG, 2000, CANCER RES, V60, P7133; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Huisman C, 2002, CLIN CANCER RES, V8, P596; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Mori M, 2000, CANCER RES, V60, P1177; Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sozzi G, 1998, CANCER RES, V58, P5032; van Heerden WFP, 1999, J ORAL PATHOL MED, V28, P433; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	29	30	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	2004	23	56					9102	9110		10.1038/sj.onc.1208142	http://dx.doi.org/10.1038/sj.onc.1208142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489891				2022-12-17	WOS:000225492800011
J	Eischen, CM; Alt, JR; Wang, P				Eischen, CM; Alt, JR; Wang, P			Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development	ONCOGENE			English	Article						Mdm2; ARF; lymphoma; apoptosis; Myc; p53	MYC-INDUCED LYMPHOMAGENESIS; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TRANSGENIC MICE; CANCER-THERAPY; MAMMARY-GLAND; FEEDBACK LOOP; IN-VIVO	The tumor suppressor p19(ARF) inhibits Mdm2, which restricts the activity of p53. Complicated feedback and control mechanisms regulate ARF, Mdm2, and p53 interactions. Here we report that ARF haploinsufficiency completely rescued the p53-dependent effects of Mdm2 haploinsufficiency on B-cell development, survival, and transformation. In contrast to Mdm2(+/-) B cells, Mdm2(+/-) B cells deficient in ARF were similar to wild-type B cells in their rates of growth and apoptosis and activation of p53. Consequently, the profoundly reduced numbers of B cells in Mdm2(+/-) Emu-myc transgenic mice were restored to normal levels in ARF(+/-)Mdm(2+/-) Emu-myc transgenics. Additionally, ARF(+/-)Mdm2(+/-) Emu-myc transgenics developed lymphomas at rates analogous to those observed for wild-type Emu-myc transgenics, demonstrating that loss of one allele of ARF rescued the protracted lymphoma latency in Mdm2(+/-) Emu-myc transgenics. Importantly, in ARF(+/-)Mdm2(+/-) Emu-myc transgenic lymphomas, p53 was inactivated at the frequency observed in lymphomas of wild-type Emu-myc transgenics. Collectively, these results support a model whereby the stoichiometry of Mdm2 and ARF controls apoptosis and tumor development, which should have significant implications in the treatment of malignancies that have inactivated ARF.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Eischen, CM (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA.	ceischen@unmc.edu			NCI NIH HHS [CA098139, T32 CA09476] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098139, T32CA009476] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Foster CJ, 2002, ONCOGENE, V21, P3525, DOI 10.1038/sj.onc.1205441; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; O'Leary KA, 2004, MOL CELL BIOL, V24, P186, DOI 10.1128/MCB.24.1.186-191.2004; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun Y, 2003, CANCER BIOL THER, V2, P623; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang H, 2001, CURR CANCER DRUG TAR, V1, P177, DOI 10.2174/1568009013334133; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	45	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	2004	23	55					8931	8940		10.1038/sj.onc.1208052	http://dx.doi.org/10.1038/sj.onc.1208052			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467748				2022-12-17	WOS:000225354600008
J	Miron, MJ; Gallouzi, IE; Lavoie, JN; Branton, PE				Miron, MJ; Gallouzi, IE; Lavoie, JN; Branton, PE			Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death	ONCOGENE			English	Article						adenovirus; E4orf4; cell death; nuclear localization signal; nucleus; nucleolus; arginine-rich motif	REV TRANS-ACTIVATOR; NUCLEOLAR-LOCALIZATION; P53-INDEPENDENT APOPTOSIS; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; TAT PROTEIN; B-ALPHA; VIRUS; HIV-1; SEQUENCE	The adenovirus E4orf4 protein induces p53-independent death of human cancer cells by a mechanism requiring interactions with the Balpha subunit of protein phosphatase 2A. When expressed alone E4orf4 localizes predominantly in the nucleus, although significant levels are also present in the cytoplasm. While tyrosine phosphorylation of E4orf4 and recruitment of Src have been linked with E4orf4 cytoplasmic cell death functions, little is known about the functions of E4orf4 in the nucleus. In this study, we identified an arginine-rich motif (E4ARM; residues 66-75) that is necessary and sufficient for nuclear and nucleolar localization. This motif, which is highly homologous to the arginine-rich nuclear and nucleolar localization motif of some lentiviral proteins, was shown to target heterologous proteins to the nucleus and to nucleoli, functions found to be dependent on the overall charge of the motif rather than on specific residues. Furthermore, mutation of arginine residues to alanines but not to lysines in E4ARM was shown to block such targeting activity and, when introduced into full-length E4orf4, to decrease induction of cell death. Finally, coexpression of the ARM motifs of E4orf4, HIV-1 Tat or Rev along with full-length E4orf4 was seen to decrease E4orf4-dependent cell killing. Thus it appears that targeting of E4orf4 to the nucleus and cell nucleoli by E4ARM is an important component of E4orf4-induced cell death.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Laval, Hotel Dieu Quebec, CHUQ, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; Laval University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Promenade Sir William Osle, Montreal, PQ H3G 1Y6, Canada.	philip.branton@mcgill.ca		Lavoie, Josee N/0000-0001-6912-1132				Afifi R, 2001, J VIROL, V75, P4444, DOI 10.1128/JVI.75.9.4444-4447.2001; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CASTIGLIA CL, 1983, MOL CELL BIOL, V3, P662, DOI 10.1128/MCB.3.4.662; Catez F, 2002, MOL CELL BIOL, V22, P1126, DOI 10.1128/MCB.22.4.1126-1139.2002; Champagne C, 2004, J BIOL CHEM, V279, P25905, DOI 10.1074/jbc.M400933200; DANG CV, 1989, J BIOL CHEM, V264, P18019; DUNDR M, 1995, J CELL SCI, V108, P2811; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Gingras MC, 2002, MOL CELL BIOL, V22, P41, DOI 10.1128/MCB.22.1.41-56.2002; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; Hiscox JA, 2002, ARCH VIROL, V147, P1077, DOI 10.1007/s00705-001-0792-0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; LEDINKO N, 1972, VIROLOGY, V49, P79, DOI 10.1016/S0042-6822(72)80008-4; Lee TWR, 2003, J GEN VIROL, V84, P3423, DOI 10.1099/vir.0.19546-0; Lee TWR, 2004, J GEN VIROL, V85, P185, DOI 10.1099/vir.0.19352-0; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lutz P, 1996, J VIROL, V70, P3449, DOI 10.1128/JVI.70.6.3449-3460.1996; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARASCO WA, 1994, ARCH VIROL, V139, P133, DOI 10.1007/BF01309460; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matthews DA, 2001, J VIROL, V75, P1031, DOI 10.1128/JVI.75.2.1031-1038.2001; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PUVIONDUTILLEUL F, 1993, EUR J CELL BIOL, V61, P168; RASKAS HJ, 1970, VIROLOGY, V40, P893, DOI 10.1016/0042-6822(70)90135-2; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Roopchand DE, 2001, ONCOGENE, V20, P5279, DOI 10.1038/sj.onc.1204693; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; RUBEN S, 1989, J VIROL, V63, P1; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Strom AC, 2001, GENOME BIOL, V2; Truant R, 1999, MOL CELL BIOL, V19, P1210; WALTON TH, 1989, J VIROL, V63, P3651, DOI 10.1128/JVI.63.9.3651-3660.1989	63	30	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7458	7468		10.1038/sj.onc.1207919	http://dx.doi.org/10.1038/sj.onc.1207919			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334069				2022-12-17	WOS:000224176500002
J	Makridakis, N; Akalu, A; Reichardt, JKV				Makridakis, N; Akalu, A; Reichardt, JKV			Identification and characterization of somatic steroid 5 alpha-reductase (SRD5A2) mutations in human prostate cancer tissue	ONCOGENE			English	Article						somatic mutations; androgen metabolism; prostate cancer; steroid 5 alpha-reductase; pharmacogenetics	ANDROGEN RECEPTOR GENE; AMPLIFICATION; SUBSTITUTION; PROGRESSION; FINASTERIDE; INHIBITOR; CARCINOMA	Prostate cancer is a very common disease in industrialized countries and it is known to be androgen-dependent. The human SRD5A2 gene encodes the prostatic ( or type II) steroid 5alpha-reductase, which catalyses the irreversible conversion of testosterone to dihydrotestosterone (DHT), the most active androgen in the prostate. We have sequenced the entire protein-coding region of this locus in 30 microdissected prostate adenocarcinomas. We identified a total of 17 de novo amino-acid substitutions in 13 of these tumors. We also identified six additional silent substitutions. In total, 18 out of 30 (60%) of the tumors examined had de novo somatic substitutions in the prostatic steroid 5alpha-reductase-coding region. We also characterized all of the SRD5A2 missense substitutions biochemically and pharmacologically, using three 5alpha-reductase inhibitors, including. nasteride. The biochemical parameters of the distinct 5alpha-reductase missense substitutions varied substantially. We note that two out of the three recurrent SRD5A2 missense substitutions increased 5alpha-reductase in vitro activity, while the third one is essentially neutral. These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients. Our pharmacologic studies also reveal substantial variability for each 5alpha-reductase inhibitor. These data, therefore, should be taken into account in both prevention as well as therapeutic trials of prostate cancer utilizing 5alpha-reductase inhibitors.	Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Reichardt, JKV (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, 2250 Alcazar St,IGM240, Los Angeles, CA 90089 USA.	reichard@usc.edu		Reichardt, Juergen/0000-0001-6458-2773				Akalu A, 1999, J UROLOGY, V161, P1355, DOI 10.1016/S0022-5347(01)61683-5; Akalu A, 1999, GENET ANAL-BIOMOL E, V15, P229, DOI 10.1016/S1050-3862(99)00050-9; BROTHMAN AR, 1990, CANCER RES, V50, P3795; Cheng Earl, 1993, P57; di Salle E, 1998, J STEROID BIOCHEM, V64, P179, DOI 10.1016/S0960-0760(97)00158-1; Frye S V, 1998, Pharm Biotechnol, V11, P393; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.3.CO;2-1; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Luo J, 2003, PROSTATE, V57, P134, DOI 10.1002/pros.10284; MACOSKA JA, 1992, J UROLOGY, V147, P1142, DOI 10.1016/S0022-5347(17)37504-3; Makridakis N, 1997, CANCER RES, V57, P1020; Makridakis NM, 2000, PHARMACOGENETICS, V10, P407, DOI 10.1097/00008571-200007000-00004; Makridakis NM, 1999, LANCET, V354, P975, DOI 10.1016/S0140-6736(98)11282-5; Nelson DL, 2000, LEHNINGER PRINCIPLES, P257; Ross RK, 1998, CANCER RES, V58, P4497; SCHRODER FH, 1992, PROSTATE, P129; Stoner E, 1996, PROSTATE, P82; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WIGLEY WC, 1994, BIOCHEMISTRY-US, V33, P1265, DOI 10.1021/bi00171a029	22	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7399	7405		10.1038/sj.onc.1207922	http://dx.doi.org/10.1038/sj.onc.1207922			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326487				2022-12-17	WOS:000224021400010
J	Miller, LD; Lee, KC; Mochly-Rosen, D; Cartwright, CA				Miller, LD; Lee, KC; Mochly-Rosen, D; Cartwright, CA			RACK1 regulates Src-mediated Sam68 and p190RhoGAP signaling	ONCOGENE			English	Article						Src; tyrosine kinase; RACK1; PKC; Sam68; p190RhoGAP	PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; BETA-SUBUNIT; ACTIVATION; GROWTH; REGION; P190; MECHANISMS; INHIBITOR; SUBSTRATE	RACK1 is the founding member of a family of receptors for activated C kinase collectively called RACKs. Upon activation of PKC, RACK1 co-localizes with the Src tyrosine kinase at the plasma membrane and functions as a substrate, binding partner and inhibitor of Src (as measured in vitro), and a growth inhibitor in NIH 3T3 cells. To further analyze the function of RACK1 in Src and PKC signaling, we utilized cell-permeable peptides that modulate the interaction of RACK1 and betaIIPKC, thereby affecting betaIIPKC translocation and function. We found that the association of betaIIPKC and RACK1 is necessary for Src phosphorylation of RACK1. Src activity is required for tyrosine phosphorylation of RACK1, and for RACK1 binding to Src, but not to betaIIPKC. Endogenous Src kinase activity, as measured by phosphorylation of Sam68 (a mitotic-specific Src substrate involved in cell cycle regulation and RNA splicing) or p190RhoGAP (a Src substrate and GTPase-activating protein involved in actin reorganization), increases with disruption of the Src-RACK1 complex, and decreases with enhanced complex formation. RACK1 inhibits Src-mediated p190RhoGAP signaling and actin cytoskeleton rearrangement. Thus, RACK1 functions as an endogenous inhibitor of the Src kinase in diverse signaling pathways that regulate distinct cellular functions. Our results demonstrate the potential for using peptide modulators of Src activity as a tool for uncovering the function of Src in cells.	Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, Sch Med, M211 Alway Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [R01 HL52141] Funding Source: Medline; NIDDK NIH HHS [DK65339, R01 DK43743] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043743] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Fincham VJ, 1999, J CELL SCI, V112, P947; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Roof RW, 2000, FEBS LETT, V472, P117, DOI 10.1016/S0014-5793(00)01439-3; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513	28	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5682	5686		10.1038/sj.onc.1207735	http://dx.doi.org/10.1038/sj.onc.1207735			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184885				2022-12-17	WOS:000222629500013
J	Al Moustafa, AE; Foulkes, WD; Wong, A; Jallal, H; Batist, G; Yu, QY; Herlyn, M; Sicinski, P; Alaoui-Jamali, MA				Al Moustafa, AE; Foulkes, WD; Wong, A; Jallal, H; Batist, G; Yu, QY; Herlyn, M; Sicinski, P; Alaoui-Jamali, MA			Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells	ONCOGENE			English	Article						cyclin D1; E6/E7 of HPV; ErbB-2; cell transformation	HUMAN-PAPILLOMAVIRUS INFECTION; GENE AMPLIFICATION; CERVICAL-CANCER; UTERINE CERVIX; GROWTH-FACTOR; IN-VIVO; EXPRESSION; CARCINOMA; P53; OVEREXPRESSION	More than 25% of head and neck squamous cell carcinomas (HNSCC) and 99% of cervical cancers (CxCa) are positive for high-risk human papillomaviruses (HPVs). Furthermore, the type I tyrosine kinase receptor ErbB-2 is overexpressed in at least 30% of HNSCC and CxCa. Recently, we demonstrated that E6/E7 of HPV type 16 cooperate with ErbB-2 to induce cell transformation of human normal oral epithelial ( NOE) cells. This is accompanied by overexpression of cyclin D1 in NOE cells. To determine the role of cyclin D1 in E6/E7/ErbB-2 cooperation, we examined the independent effects of E6/E7 and ErbB-2, and the combined effect of E6/E7 and ErbB-2 in mouse normal embryonic. broblast (NEF), wild type (wt), and knockout cyclin D1 ( D1(-/-)) cells. We report that NEF-wt cells transduced with E6/E7 alone and E6/E7/ ErbB-2 together form small and large tumors in nude mice, respectively, as well as different sized colonies in soft agar; whereas ErbB-2 alone elicits neither tumor formation in vivo nor colony formation in soft agar. More importantly, E6/E7, ErbB-2 and E6/E7/ ErbB-2 together all fail to induce neoplastic transformation of cyclin D1(-/-) cells in vivo and in vitro. Furthermore, using antisense cyclin D1 we completely inhibited tumor and colony formation of NEF-wt-E6/E7 and wt-E6/E7-ErbB-2 as well as human NOE-E6/E7-ErbB-2-transformed cells. These analyses reveal that cyclin D1 is the downstream target of the neoplastic transformation induced by E6/E7 or E6/E7/ ErbB-2 cooperation in normal cells. Our data suggest that anti-cyclin D1 therapy may be highly specific in the treatment of all human cancers expressing high-risk HPVs or HPVs/ErbB-2.	McGill Univ, Program Canc Genet, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Expt Therapeut Canc,Dept Oncol, Montreal, PQ, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Expt Therapeut Canc,Dept Med, Montreal, PQ, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Expt Therapeut Canc,Dept Pathol, Montreal, PQ, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Expt Therapeut Canc,Dept Pharmacol & Therapeu, Montreal, PQ, Canada; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; The Wistar Institute; Fox Chase Cancer Center	Al Moustafa, AE (corresponding author), McGill Univ, Program Canc Genet, 3755 Ch Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	aalmoust@ldi.jgh.mcgill.ca	Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651				Al Moustafa AE, 2004, ONCOGENE, V23, P350, DOI 10.1038/sj.onc.1207148; Almadori G, 2002, HEAD NECK-J SCI SPEC, V24, P597, DOI 10.1002/hed.10097; Carraresi L, 2001, ONCOGENE, V20, P8148, DOI 10.1038/sj.onc.1205007; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; Decker T, 2002, LEUKEMIA, V16, P327, DOI 10.1038/sj.leu.2402389; Eckert RL, 2000, INT J ONCOL, V16, P853; Gasco M, 2003, ORAL ONCOL, V39, P222, DOI 10.1016/S1368-8375(02)00163-X; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Ibrahim SO, 1999, ORAL ONCOL, V35, P302, DOI 10.1016/S1368-8375(98)00120-1; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; Lee JS, 2002, GYNECOL ONCOL, V85, P469, DOI 10.1006/gyno.2002.6648; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu SC, 2002, MOL CARCINOGEN, V34, P131, DOI 10.1002/mc.10057; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; Niv A, 2000, J LARYNGOL OTOL, V114, P41, DOI 10.1258/0022215001903870; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rousseau A, 2001, ORAL ONCOL, V37, P268, DOI 10.1016/S1368-8375(00)00114-7; Sauter ER, 2002, CANCER GENE THER, V9, P807, DOI 10.1038/sj.cgt.7700492; Sauter ER, 1999, CANCER RES, V59, P4876; Sauter ER, 2002, CANCER RES, V62, P3200; Sauter ER, 2000, CLIN CANCER RES, V6, P654; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Wilkman TSE, 1998, INT J ORAL MAX SURG, V27, P209, DOI 10.1016/S0901-5027(98)80012-X; Xia WY, 1997, CLIN CANCER RES, V3, P3; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	28	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5252	5256		10.1038/sj.onc.1207679	http://dx.doi.org/10.1038/sj.onc.1207679			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15229656				2022-12-17	WOS:000222382500014
J	Keith, WN				Keith, WN			From stem cells to cancer: balancing immortality and neoplasia	ONCOGENE			English	Editorial Material						mesenchyme; stem cell; cancer stem cell; telomerase; neoplasia; mesenchymal stem cell	TELOMERASE EXPRESSION; BRAIN-TUMORS; IDENTIFICATION	In this issue of Oncogene, Serakinci et al show that adult stem cells can be targets for neoplastic transformation. After transducing human adult mesenchymal stem cells (hMSC) with the telomerase hTERT gene, and growing them for many population doublings in culture, Serakinci et al observed that the transduced cells developed characteristics consistent with transformation including loss of contact inhibition, anchorage independence and tumour formation in mice. Underlying these changes were alterations to genes involved in cell cycle regulation and senescence as well as oncogene activation. The importance of these observations is twofold. Firstly, showing that stem cells can become tumours raises a note of caution for stem cell therapeutics. Secondly, the findings lend support to the stem cell hypothesis of cancer development, and provide an experimental system in which the tantalizing hint of new diagnostic, prognostic, and therapeutic opportunities offered by this concept can be explored further.	Univ Glasgow, Canc Res UK Beatson Labs, Ctr Oncol & Appl Pharmacol, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow	Keith, WN (corresponding author), Univ Glasgow, Canc Res UK Beatson Labs, Ctr Oncol & Appl Pharmacol, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	n.keith@beatson.gla.ac.uk	Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Marx J, 2003, SCIENCE, V301, P1308, DOI 10.1126/science.301.5638.1308; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Preston SL, 2003, J CLIN PATHOL-MOL PA, V56, P86, DOI 10.1136/mp.56.2.86; SERAKINCI N, 2004, IN PRESS ONCOGENE; Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Singh SK, 2003, CANCER RES, V63, P5821; Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614; Zimmermann S, 2003, LEUKEMIA, V17, P1146, DOI 10.1038/sj.leu.2402962	11	30	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5092	5094		10.1038/sj.onc.1207762	http://dx.doi.org/10.1038/sj.onc.1207762			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107816				2022-12-17	WOS:000222237300016
J	Cazillis, M; Bringuier, AF; Delautier, D; Buisine, M; Bernuau, D; Gespach, C; Groyer, A				Cazillis, M; Bringuier, AF; Delautier, D; Buisine, M; Bernuau, D; Gespach, C; Groyer, A			Disruption of MKK4 signaling reveals its tumor-suppressor role in embryonic stem cells	ONCOGENE			English	Article						SEK1/MKK4/JNKK; SAPK/JNK; p38; Erk-1/-2.; morphological transformation; cell proliferation and survival; apoptosis; growth in soft agar; tumor growth	GROWTH-FACTOR-BETA; PROTEIN-KINASE KINASE-4; N-TERMINAL KINASE; HUMAN T-CELLS; MAP KINASE; C-JUN; INDUCED APOPTOSIS; TRANSDUCTION PATHWAYS; MOUSE EMBRYOS; COLON-CANCER	The dual Ser/Thr kinase MKK4 and its downstream targets JNK and p38 regulate critical cellular functions during embryogenesis and development. MKK4 has been identified as a putative tumor-suppressor gene in human solid tumors of breast, prostate and pancreas. To clarify the mechanisms underlying the transforming potential of molecular defects targeting MKK4, we have generated totipotent embryonic stem (ES) cells expressing the dominant-negative mutant DN-MKK4(Ala), S257A/T261A. Stably transfected DN-MKK4-ES cells exhibit a transformed fibroblast-like morphology, reduced proliferation rate, were no more submitted to cell contact inhibition, were growing in soft agar, and were much more tumorigenic than parental ES cells in athymic nude mice. These phenotypic changes: (i) are consistent with the protection of DN-MKK4-transfected ES cells from spontaneous, cell density-dependent, and stress-induced apoptosis (DAPI staining and poly (ADP-ribose) polymerase (PARP) cleavage) and (ii) correlated with alterations in JNK, p38, and Erk-1/-2 MAPK/SAPK signaling. Taken together, our data provide a new mechanism linking the MKK4 signaling pathways to cancer progression and identify MKK4 as a tumor-suppressor gene implicated in several transforming functions.	Univ Paris 07, INSERM, U481, F-75870 Paris 18, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Groyer, A (corresponding author), Univ Paris 07, INSERM, U481, 16 Rue Henri Huchard,BP 416, F-75870 Paris 18, France.	groyer@bichat.inserm.fr						Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BRUNET A, 1994, ONCOGENE, V9, P3379; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kieran MW, 1999, ONCOGENE, V18, P6647, DOI 10.1038/sj.onc.1203057; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lee JK, 1999, MOL BRAIN RES, V66, P133, DOI 10.1016/S0169-328X(99)00035-2; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; McPherson JP, 1998, CANCER RES, V58, P4519; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Nakano T, 1995, Semin Immunol, V7, P197, DOI 10.1016/1044-5323(95)90047-0; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1999, DEVELOPMENT, V126, P505; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rao CV, 1997, CANCER RES, V57, P3717; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schultz RM, 2003, PROG DRUG RES, V60, P59; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Skov S, 1997, J CELL BIOL, V139, P1523, DOI 10.1083/jcb.139.6.1523; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Su GH, 1998, CANCER RES, V58, P2339; Teng DHF, 1997, CANCER RES, V57, P4177; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WARE LM, 1972, VIROLOGY, V50, P339, DOI 10.1016/0042-6822(72)90385-6; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; Yamada SD, 2002, CANCER RES, V62, P6717; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yoshida BA, 1999, CANCER RES, V59, P5483; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6	60	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4735	4744		10.1038/sj.onc.1207619	http://dx.doi.org/10.1038/sj.onc.1207619			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122334				2022-12-17	WOS:000221799200008
J	Guccione, E; Lethbridge, KJ; Killick, N; Leppard, KN; Banks, L				Guccione, E; Lethbridge, KJ; Killick, N; Leppard, KN; Banks, L			HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures	ONCOGENE			English	Article						HPV; E6; PML; PODs	HUMAN-PAPILLOMAVIRUS TYPE-16; ACUTE PROMYELOCYTIC LEUKEMIA; CERVICAL-CARCINOMA CELLS; NUCLEAR-BODY FORMATION; HUMAN CYTOMEGALOVIRUS; PREMATURE SENESCENCE; HUMAN KERATINOCYTES; ONCOGENIC DOMAINS; SP100 PROTEINS; CAPSID PROTEIN	Mucosal human papillomaviruses (HPVs) are the causative agents of a number of human pathologies, including benign condylomas, as well as of the majority of cervical cancers and their high-grade precursor lesions. Although the viral E6 protein is known to be essential for driving malignant progression of HPV-infected cells, there are still many uncertainties about its mode of action. In this study, we have analysed the intracellular distribution of the E6 oncoproteins from the high-risk HPV-18 and the low-risk HPV-11. We show that both E6 proteins localize within the nucleus in nuclear bodies that are confocal with the promyelocytic leukaemia (PML) protein. Using a panel of different PML isoforms, we demonstrate specific co-localization between the E6 proteins and PML isoforms I-IV, but not with PML isoforms V and VI. We also demonstrate the interaction between E6 and a subset of PML isoforms in vivo. As a consequence of this interaction, the insoluble form of PML IV is destabilized by HPV-18 E6 through a proteasome-dependent pathway. Interestingly, both HPV-11 E6 and HPV-18 E6 can readily overcome PML IV-induced cellular senescence in primary cells. These results show separable functions for different PML isoforms that are specifically targeted by the HPV E6 oncoproteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Warwick	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	guccione, ernesto/G-9874-2011; Leppard, Keith N/A-1853-2009	Leppard, Keith N/0000-0003-2155-7919				Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Becker KA, 2003, VIROLOGY, V314, P161, DOI 10.1016/S0042-6822(03)00447-1; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHEN Z, 1992, LEUKEMIA LYMPHOMA, V8, P253, DOI 10.3109/10428199209051004; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIPAOLO J A, 1986, Toxicologic Pathology, V14, P417; DOEBERITZ MV, 1992, INT J CANCER, V51, P831; Duprez E, 1999, J CELL SCI, V112, P381; DURST M, 1987, ONCOGENE, V1, P251; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Ferbeyre G, 2000, GENE DEV, V14, P2015; Florin L, 2002, VIROLOGY, V295, P97, DOI 10.1006/viro.2002.1360; Florin L, 2002, J VIROL, V76, P10009, DOI 10.1128/JVI.76.19.10009-10014.2002; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; Ishov AM, 2002, J VIROL, V76, P7705, DOI 10.1128/JVI.76.15.7705-7712.2002; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Li H, 2000, CURR OPIN CELL BIOL, V12, P641, DOI 10.1016/S0955-0674(00)00144-7; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Muller S, 1999, J VIROL, V73, P5137; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Muratani M, 2002, NAT CELL BIOL, V4, P106, DOI 10.1038/ncb740; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wiesmeijer K, 2002, J STRUCT BIOL, V140, P180, DOI 10.1016/S1047-8477(02)00529-4; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; ZUR HH, 1987, APPL PATHOL, V5, P19	61	30	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4662	4672		10.1038/sj.onc.1207631	http://dx.doi.org/10.1038/sj.onc.1207631			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107834				2022-12-17	WOS:000221799200002
J	Jackson, MW; Agarwal, MK; Agarwal, ML; Agarwal, A; Stanhope-Baker, P; Williams, BRG; Stark, GR				Jackson, MW; Agarwal, MK; Agarwal, ML; Agarwal, A; Stanhope-Baker, P; Williams, BRG; Stark, GR			Limited role of N-terminal phosphoserine residues in the activation of transcription by p53	ONCOGENE			English	Article						p14ARF; adriamycin; p21; MDM2	ARF TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; PROLYL ISOMERASE PIN1; ACID-BINDING PROTEIN; RING-FINGER DOMAIN; DNA-DAMAGE; ONCOPROTEIN MDM2; STABILIZES P53; GROWTH ARREST; MAMMARY-GLAND	The p53 tumor suppressor is phosphorylated in response to various cellular stress signals, such as DNA damage, leading to its release from MDM2 and consequent stabilization and activation as a transcription factor. In human U2OS cells, treatment with adriamycin causes p53 to be phosphorylated on all six serine residues tested, leading to the dissociation of p53 from MDM2 and transcription of the p21 and mdm2 genes. In contrast, in these cells, IPTG-dependent induction of p14ARF, which sequesters MDM2 away from p53, does not lead to detectable phosphorylation of any of the five N-terminal serine residues tested (6, 9, 15, 20, 37). Only C-terminal serine 392 is phosphorylated. However, the increase of p21 and mdm2 mRNAs was indistinguishable following treatment with adriamycin or induction of p14ARF. By using cDNA arrays to examine global p53-dependent gene expression in response to adriamycin or p14ARF, we found that most genes were regulated similarly by the two treatments. However, a subset of p53-regulated genes whose products have proliferative roles or regulate VEGF activity, newly described here, are repressed by p14ARF much more than by adriamycin. We conclude that the phosphorylation of p53 on N-terminal serine residues is not required for increased transcription of the great majority of p53-responsive genes and that the induction of p53 by p14ARF, with little phosphorylation, leads to substantial repression of genes whose products have roles in proliferation.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, NC20,9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org	Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [R01CA089279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NCI NIH HHS [CA 89279] Funding Source: Medline; NIGMS NIH HHS [GM 049345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alarcon R, 1999, CANCER RES, V59, P6046; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chehab NH, 2000, GENE DEV, V14, P278; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Foster CJ, 2002, ONCOGENE, V21, P3525, DOI 10.1038/sj.onc.1205441; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Jing C, 2000, CANCER RES, V60, P2390; Jing C, 2001, CANCER RES, V61, P4357; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kar S, 2002, J BIOL CHEM, V277, P15579, DOI 10.1074/jbc.M106915200; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mayo LD, 1997, CANCER RES, V57, P5013; McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Schlaak JF, 2002, J BIOL CHEM, V277, P49428, DOI 10.1074/jbc.M205571200; Sherr CJ, 2000, CANCER RES, V60, P3689; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Xiao G, 2000, CANCER RES, V60, P1711; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RB, 2000, GENE DEV, V14, P981; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	87	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4477	4487		10.1038/sj.onc.1207575	http://dx.doi.org/10.1038/sj.onc.1207575			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064747				2022-12-17	WOS:000221661300013
J	Yoshida, Y; Izumi, H; Torigoe, T; Ishiguchi, H; Yoshida, T; Itoh, H; Kohno, K				Yoshida, Y; Izumi, H; Torigoe, T; Ishiguchi, H; Yoshida, T; Itoh, H; Kohno, K			Binding of RNA to p53 regulates its oligomerization and DNA-binding activity	ONCOGENE			English	Article						p53; RNA; DNA binding; oligomerization; RNase	TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; IN-VIVO; PHOSPHORYLATION; DOMAIN; SITE; ACTIVATION; GROWTH; POLYPEPTIDE; COMPLEXES	The C-terminus of p53 is responsible for maintaining the latent, non-DNA-binding form of p53. However, the mechanism by which the C-terminus regulates DNA binding is not yet fully understood. We show here that p53 interacts with RNA via its C-terminal domain and that disruption of this interaction, by RNase A treatment, truncation or phosphorylation of the C-terminus, restores DNA-binding activity. Furthermore, the oligomerization of p53 is significantly enhanced by disrupting the interaction between p53 and RNA. These findings suggest that binding of RNA to p53 is involved in the mechanism of p53 latency.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Surg 1, Yahatanishi Ku, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp		Yoshida, Yoichiro/0000-0001-6583-7352				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FISCELLA M, 1994, ONCOGENE, V9, P3249; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; FUCHS B, 1995, ONCOGENE, V10, P789; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Izumi H, 2003, BIOCHEM J, V373, P713, DOI 10.1042/BJ20021902; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Marston NJ, 1998, ONCOGENE, V16, P3123, DOI 10.1038/sj.onc.1201856; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Minamoto T, 2001, ONCOGENE, V20, P3341, DOI 10.1038/sj.onc.1204458; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; Torigoe T, 2003, NUCLEIC ACIDS RES, V31, P4523, DOI 10.1093/nar/gkg487; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Yakovleva T, 2002, TRENDS BIOCHEM SCI, V27, P612, DOI 10.1016/S0968-0004(02)02209-0; Yoshida Y, 2003, CANCER RES, V63, P3729; Yoshida Y, 2002, BIOCHEM BIOPH RES CO, V295, P945, DOI 10.1016/S0006-291X(02)00757-X	43	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4371	4379		10.1038/sj.onc.1207583	http://dx.doi.org/10.1038/sj.onc.1207583			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064727				2022-12-17	WOS:000221661300003
J	Tagawa, H; Karnan, S; Kasugai, Y; Tuzuki, S; Suzuki, R; Hosokawa, Y; Seto, M				Tagawa, H; Karnan, S; Kasugai, Y; Tuzuki, S; Suzuki, R; Hosokawa, Y; Seto, M			MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8	ONCOGENE			English	Article						MASL1; lymphoma; oncogene; 8p23; translocation; amplification	NON-HODGKIN-LYMPHOMA; CHROMOSOME 8P; FREQUENT LOSS; CYCLIN D1; CANCER; GENE; LYMPHOMA/LEUKEMIA; CARCINOMA; SEQUENCES; PRAD1	Genetic amplification at chromosome 8p23.1 has been reported in some solid tumors. Translocation of 8p23.1 has also been reported in hematological malignancies and head and neck squamous cell cancer. In an attempt to clarify whether this translocation is implicated in lymphomagenesis, we performed FISH analysis of the immunoblastic B-cell lymphoma cell line OCI-LY8, which has chromosome translocation at 8p23.1, with various BAC clones. We found split signals on BAC, RP11-18L2 where the MASL1 gene is located. This translocation was found to produce a chimeric transcript of MASL1 exon 1 with a cryptic exon from the genome region at 14q21. Our study indicates that MASL1 is not only a target gene for genomic amplification but also for chromosomal translocation. Since tumorigenic activity of the MASL1 has not been proven, its in vitro transforming activity was studied and in vivo nude mice assay were performed. Although no in vitro transforming activity was detected by focus formation, the in vivo tumorigenesis assay with nude mice showed that both MASL1 and chimeric MASL1 possess tumorigenic activity. This suggests that MASL1 is an important oncogene not only for solid tumors but also for hematologic malignancies.	Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	mseto@aichi-cc.jp		Kasugai, Yumiko/0000-0003-4764-4455; Suzuki, Ritsuro/0000-0002-5974-7614				Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P328, DOI 10.1002/(SICI)1098-2264(199812)23:4<328::AID-GCC8>3.0.CO;2-M; CHANG H, 1992, J CLIN INVEST, V89, P1014, DOI 10.1172/JCI115642; EMI M, 1992, CANCER RES, V52, P5368; Gilhuis HJ, 2000, CLIN NEUROL NEUROSUR, V102, P203, DOI 10.1016/S0303-8467(00)00112-8; Jin YS, 2001, CANCER GENET CYTOGEN, V130, P111, DOI 10.1016/S0165-4608(01)00476-9; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOMATSU H, 1994, BLOOD, V84, P1226; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; Mehra S, 2002, GENE CHROMOSOME CANC, V33, P225, DOI 10.1002/gcc.10025; Nupponen NN, 2000, MICROSC RES TECHNIQ, V51, P456, DOI 10.1002/1097-0029(20001201)51:5<456::AID-JEMT8>3.0.CO;2-H; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; Sakabe T, 1999, CANCER RES, V59, P511; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; SETO M, 1992, ONCOGENE, V7, P1401; SIN C, 1979, P NATL ACAD SCI USA, V76, P5714; Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Tagawa H, 2002, GENE CHROMOSOME CANC, V34, P175, DOI 10.1002/gcc.10057; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; TWEEDDALE ME, 1987, BLOOD, V69, P1307; Wong N, 2000, HUM PATHOL, V31, P771, DOI 10.1053/hupa.2000.7625	22	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2576	2581		10.1038/sj.onc.1207352	http://dx.doi.org/10.1038/sj.onc.1207352			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14691450				2022-12-17	WOS:000220558000016
J	Wichert, A; Stege, A; Midorikawa, Y; Holm, PS; Lage, H				Wichert, A; Stege, A; Midorikawa, Y; Holm, PS; Lage, H			Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells	ONCOGENE			English	Article						drug resistance; mitoxantrone; glypicans; ribozymes; gastric carcinoma	HEPARAN-SULFATE PROTEOGLYCANS; DEVELOPMENTALLY-REGULATED TRANSCRIPT; BEHMEL OVERGROWTH SYNDROME; DNA TOPOISOMERASE-II; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; BREAST-CANCER; MELANOMA-CELLS; IN-VITRO; EXPRESSION	Elevated expression of the heparan sulphate proteoglycan glypican-3 (GPC3) was found on mRNA and protein levels in the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV, which was established by in vitro selection against mitoxantrone. In order to elucidate a putative role of GPC3 in the drug-resistant phenotype, the mitoxantrone-resistant cell line EPG85-257RNOV was transfected with an expression vector construct carrying an anti-GPC3 hammerhead ribozyme. It could be demonstrated that in anti-GPC3 ribozyme-transfected cell clones, the GPC3-specific mRNA and corresponding protein expression levels were decreased to levels that are similar to those observed in nonresistant, parental cells. The anti-GPC3 ribozyme-containing clones reduced the mitoxantrone resistance level up to 21% of the original resistance and the crossresistance against etoposide to 33% of the original value. This reversal of drug resistance was accompanied by an increased cellular mitoxantrone accumulation in the anti-GPC3 ribozyme-expressing cells. In conclusion, it was verified that GPC3 is involved in the cellular protection against mitoxantrone in the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV.	Humboldt Univ, Inst Pathol, Charite, D-10117 Berlin, Germany; Univ Tokyo, Genome Sci Div, Meguro Ku, Tokyo 1538944, Japan	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Tokyo	Lage, H (corresponding author), Humboldt Univ, Inst Pathol, Charite, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	hermann.lage@charite.de		Stege, Alexandra/0000-0001-9659-1930				AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Boyd AP, 1998, MOL MICROBIOL, V27, P425, DOI 10.1046/j.1365-2958.1998.00691.x; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DIETEL M, 1990, CANCER RES, V50, P6100; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; GORCZYCA W, 1993, CANCER RES, V53, P3186; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; Hsu HC, 1997, CANCER RES, V57, P5179; HughesBenzie RM, 1996, AM J MED GENET, V66, P227, DOI 10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U; HYAFIL F, 1993, CANCER RES, V53, P4595; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kellner U, 1997, INT J CANCER, V71, P817, DOI 10.1002/(SICI)1097-0215(19970529)71:5<817::AID-IJC20>3.0.CO;2-3; Kowalski P, 2002, CANCER GENE THER, V9, P579, DOI 10.1038/sj.cgt.7700471; Lage H, 2003, INT J ANTIMICROB AG, V22, P188, DOI 10.1016/S0924-8579(03)00203-6; Lage H, 2000, BRIT J CANCER, V82, P488, DOI 10.1054/bjoc.1999.0947; Lage H, 1997, GENE, V188, P151, DOI 10.1016/S0378-1119(96)00689-0; Lage H, 1998, INT J CLIN PHARM TH, V36, P58; Lage H, 2002, J CANCER RES CLIN, V128, P349, DOI 10.1007/s00432-002-0349-y; Lage H, 2001, FEBS LETT, V503, P179, DOI 10.1016/S0014-5793(01)02722-3; Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3; Lage H, 2000, Lancet Oncol, V1, P169, DOI 10.1016/S1470-2045(00)00032-2; Lin HC, 1999, CANCER RES, V59, P807; Midorikawa Y, 2003, INT J CANCER, V103, P455, DOI 10.1002/ijc.10856; Mulder M, 1998, HAEMOSTASIS, V28, P174; Murthy SS, 2000, ONCOGENE, V19, P410, DOI 10.1038/sj.onc.1203322; Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Saikali Z, 2000, INT J CANCER, V89, P418; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Song HH, 1997, J BIOL CHEM, V272, P7574, DOI 10.1074/jbc.272.12.7574; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; WALKER PR, 1991, CANCER RES, V51, P1078; Wells MJ, 1998, J BIOL CHEM, V273, P23440, DOI 10.1074/jbc.273.36.23440; Wichert A, 1999, CANCER GENE THER, V6, P263, DOI 10.1038/sj.cgt.7700045; Xiang YY, 2001, ONCOGENE, V20, P7408, DOI 10.1038/sj.onc.1204925	47	30	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					945	955		10.1038/sj.onc.1207237	http://dx.doi.org/10.1038/sj.onc.1207237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661052				2022-12-17	WOS:000188486600010
J	Huang, Y; Rangwala, F; Fulkerson, PC; Ling, B; Reed, E; Cox, AD; Kamholz, J; Ratner, N				Huang, Y; Rangwala, F; Fulkerson, PC; Ling, B; Reed, E; Cox, AD; Kamholz, J; Ratner, N			Role of TC/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells	ONCOGENE			English	Article						Schwann cell; TC21; neurofibromin; chemotaxis; R-Ras; Ras	FARNESYL-PROTEIN TRANSFERASE; NUCLEOTIDE EXCHANGE FACTOR; GTP-BINDING PROTEINS; R-RAS; TYPE-1 GENE; FARNESYLTRANSFERASE INHIBITORS; CYTOPLASMIC DOMAINS; TRANSGENIC MICE; N-RAS; H-RAS	The neurofibromatosis type 1 tumor suppressor protein neurofibromin, is a GTPase activating protein for H-, N-, K-, R-Ras and TC21/R-Ras2 proteins. We demonstrate that Schwann cells derived from Nf1-null mice have enhanced chemokinetic and chemotactic migration in comparison to wild-type controls. Surprisingly, this migratory phenotype is not inhibited by a farnesyltransferase inhibitor or dominant-negative (dn) (N17)H-Ras (which inhibits H-, N-, and K-Ras activation). We postulated that increased activity of R-Ras and/or TC21/R-Ras2, due to loss of Nf1, contributes to increased migration. Mouse Schwann cells (MSCs) express R-Ras and TC21/R-Ras2 and their specific guanine exchange factors, C3G and AND-34. Infection of Nf1-null MSCs with a dn(43N)R-Ras adenovirus (to inhibit both R-Ras and TC21/R-Ras2 activation) decreases migration by approximately 50%. Conversely, expression of activated (72L)TC21/R-Ras2, but not activated (38V)R-Ras, increases migration, suggesting a role of TC21/R-Ras2 activation in the migration of neurofibromin-deficient Schwann cells. TC21/R-Ras2 preferentially couples to the phosphatidylinositol 3-kinase (PI3-kinase) and MAP kinase pathways. Treatment with a PI3-kinase or MAP kinase inhibitor reduces Nf1-null Schwann cell migration, implicating these TC21 effectors in Schwann cell migration. These data reveal a key role for neurofibromin regulation of TC21/R-Ras2 in Schwann cells, a cell type critical to NF1 tumor pathogenesis.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Wayne State Univ, Dept Neurol, Detroit, MI 48201 USA	University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University	Ratner, N (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 3125 Eden Ave, Cincinnati, OH 45267 USA.	nancy.ratner@uc.edu		Cox, Adrienne D./0000-0002-4901-2454; RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS028840, NS-28840, R01 NS028840-09] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CARBONI JM, 1995, ONCOGENE, V10, P1905; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; COX AD, 1994, ONCOGENE, V9, P3281; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Graham SM, 2001, METHOD ENZYMOL, V333, P203; Guha A, 1996, ONCOGENE, V12, P507; Gutmann DH, 2001, HUM MOL GENET, V10, P3009, DOI 10.1093/hmg/10.26.3009; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Huson SM, 1994, NEUROFIBROMATOSES; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KIM HA, 1995, ONCOGENE, V11, P325; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Movilla N, 1999, ONCOGENE, V18, P5860, DOI 10.1038/sj.onc.1202968; MUIR D, 1995, CLIN EXP METASTAS, V13, P303, DOI 10.1007/BF00133486; Murphy GA, 2002, J BIOL CHEM, V277, P9966, DOI 10.1074/jbc.M109059200; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Omer CA, 2000, CANCER RES, V60, P2680; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REY I, 1994, ONCOGENE, V9, P685; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Serra E, 2001, NAT GENET, V28, P294, DOI 10.1038/90148; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; YAN N, 1995, CANCER RES, V55, P3569; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	64	30	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					368	378		10.1038/sj.onc.1207075	http://dx.doi.org/10.1038/sj.onc.1207075			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724565	Green Accepted, Green Submitted			2022-12-17	WOS:000188098300006
J	Claij, N; Riele, HT				Claij, N; Riele, HT			Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells	ONCOGENE			English	Article						mismatch repair; MSH2; cisplatin; Cre-Lox	DNA MISMATCH REPAIR; TUMOR-CELLS; MICROSATELLITE INSTABILITY; DRUG-RESISTANCE; METHYLATION TOLERANCE; REPLICATIVE BYPASS; IN-VITRO; DAMAGE; P53; CANCER	Several reports have suggested that a defect in the DNA mismatch repair (MMR) system not only causes resistance to methylating agents but also confers low-level resistance to the chemotherapeutic drug cisplatin. Here we report that in a clonogenic assay, mouse embryonic stem (ES) cells deficient for the MMR protein MSH2 respond similarly as wild-type cells to cisplatin. Furthermore, restoring MSH2 expression in a cisplatin-resistant subclone selected from an Msh2(-/-) cell population did not sensitize cells to cisplatin. To ascertain that our observations were not the result of a mutation in the Msh2(-/-) cells that obscured the contribution of a defective MMR machinery to cisplatin resistance, we made use of the Cre-lox system to create a cell line in which the Msh2 gene can be conditionally inactivated. However, while de novo inactivation of Msh2 rendered cells tolerant to the methylating drug N-methyl-N'-nitro-N-nitrosoguanidine as expected, it did not alter the sensitivity to cisplatin. In addition, we were not able to derive cisplatin-resistant subclones from this freshly generated MMR-deficient cell line. Thus, in ES cells we did not find evidence for direct involvement of MMR deficiency in cisplatin resistance.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.t.riele@nki.nl						Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; Aquilina G, 2000, CLIN CANCER RES, V6, P671; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Buermeyer AB, 1999, CANCER RES, V59, P538; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Claij N, 2002, ONCOGENE, V21, P2873, DOI 10.1038/sj.onc.1205395; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Fink D, 1998, BRIT J CANCER, V77, P703, DOI 10.1038/bjc.1998.116; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1997, CANCER RES, V57, P1841; Gong JG, 1999, NATURE, V399, P806; HAWN MT, 1995, CANCER RES, V55, P3721; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; KOI M, 1994, CANCER RES, V54, P4308; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; MAMENTA EL, 1994, CANCER RES, V54, P3500; Massey A, 2003, DNA REPAIR, V2, P73, DOI 10.1016/S1568-7864(02)00187-8; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Nehme A, 1997, CANCER RES, V57, P3253; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Samimi G, 2000, CLIN CANCER RES, V6, P1415; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Sergent C, 2002, CANCER CHEMOTH PHARM, V49, P445, DOI 10.1007/s00280-002-0450-6; Siddik ZH, 1998, CANCER RES, V58, P698; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; Vaisman A, 1998, CANCER RES, V58, P3579; Watanabe Y, 2001, BRIT J CANCER, V85, P1064, DOI 10.1054/bjoc.2001.2037; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	37	30	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					260	266		10.1038/sj.onc.1207015	http://dx.doi.org/10.1038/sj.onc.1207015			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712231				2022-12-17	WOS:000187895300027
J	Weissman, JT; Ma, JN; Essex, A; Gao, Y; Burstein, ES				Weissman, JT; Ma, JN; Essex, A; Gao, Y; Burstein, ES			G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel G alpha i regulated pathway	ONCOGENE			English	Article						Rap; Ras; G-protein; receptor; proliferation; transformation	NUCLEOTIDE-EXCHANGE FACTOR; GROWTH-FACTOR RECEPTOR; SRC-DEPENDENT PHOSPHORYLATION; BETA-GAMMA-SUBUNITS; CYCLIC-AMP; MAP KINASE; B-RAF; BETA(2)-ADRENERGIC RECEPTOR; BINDING PROTEINS; HUMAN PLATELETS	Ras proteins mediate the proliferative effects of G-protein-coupled receptors (GPCRs), but the role of Rap proteins in GPCR signaling is unclear. We have developed a novel cellular proliferation assay for examining signal transduction to Rap utilizing Ras/rap chimeras that respond selectively to Rap-specific exchange factors, but which stimulate cellular proliferation through Ras effectors. Both the D1 dopamine receptor (Gs-coupled) and the 5HT1E serotonin receptor (Gi-coupled) mediated cellular proliferation in a Ras/rap chimera-dependent manner. Responses to both receptors were PKA-independent. Both receptors activated Ras/rap and full-length Rap as measured by activation-specific probes. Pertussis toxin blocked Ras/rap-dependent responses to 5HT1E but not D1. Ras/rap-dependent responses to both receptors were insensitive to beta-gamma scavengers. Responses to 5HT1E, but not D1, were sensitive to inhibition by a dominant-negative C3G fragment, by the Src-like kinase inhibitors PP1 and PP2, and by a dominant-negative mutant of Src. Very similar data were obtained for two other Gi-coupled receptors, the D2 dopamine receptor and the alpha2C adrenergic receptor. A constitutively active mutant of Galphai2 also mediated Ras/rap-dependent responses. These data indicate that GPCRs coupled to pertussis-toxin-sensitive G-proteins activate Rap through a Galpha subunit, C3G, and Src-dependent pathway.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA		Burstein, ES (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	eburstein@acadia-pharm.com						ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1997, J NEUROCHEM, V68, P525; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao YL, 2001, J PHARMACOL EXP THER, V296, P426; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1991, J BIOL CHEM, V266, P6571; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Smit MJ, 2002, METHOD ENZYMOL, V343, P430; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tsygankova OM, 2000, ONCOGENE, V19, P3609, DOI 10.1038/sj.onc.1203680; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	51	30	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					241	249		10.1038/sj.onc.1207014	http://dx.doi.org/10.1038/sj.onc.1207014			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712229				2022-12-17	WOS:000187895300025
J	Bertholon, J; Wang, Q; Falette, N; Verny, C; Auclair, J; Chassot, C; Navarro, C; Saurin, JC; Puisieux, A				Bertholon, J; Wang, Q; Falette, N; Verny, C; Auclair, J; Chassot, C; Navarro, C; Saurin, JC; Puisieux, A			Chfr inactivation is not associated to chromosomal instability in colon cancers	ONCOGENE			English	Article						Chfr; hypermethylation; chromosome instability; breast cancer; colon cancer	COMPARATIVE GENOMIC HYBRIDIZATION; MITOTIC STRESS CHECKPOINT; CELL-LINES; BREAST-CANCER; COLORECTAL-CANCER; CPG ISLAND; CENTROSOME AMPLIFICATION; MULTIPLE MUTATIONS; LUNG-CANCER; GENES	Numerous observations suggest that chromosome instability is caused by mitotic abnormalities such as errors in the partitioning of chromosomes. Chfr was recently defined as a central component of a new mitotic checkpoint that delays chromosome condensation in response to mitotic stress. Chfr was shown to be frequently inactivated in several human neoplasms, including colon, lung and esophageal cancers. To test whether Chfr inactivation may lead or participate to chromosomal instability (CIN), we analysed the genetic and epigenetic status of the gene in a large panel of primary colon and breast cancers, as well as in colon and breast cancer cell lines displaying either a microsatellite instability or a CIN. Our results confirm that Chfr is frequently inactivated in colon cancers, through a mechanism of hypermethylation of the promoter sequences. In contrast, the loss of Chfr expression appears to be a rare event in breast cancers. Furthermore, our data demonstrate that Chfr inactivation is not associated with CIN in these frequent types of human cancers.	Ctr Leon Berard, INSERM, U590, Unite Oncol Mol, F-69373 Lyon 08, France; Fac Pharm Lyon, F-69373 Lyon, France; Hop Edouard Herriot, Federat Special Digest, F-69437 Lyon 03, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Puisieux, A (corresponding author), Ctr Leon Berard, INSERM, U590, Unite Oncol Mol, 28 Rue Laennec, F-69373 Lyon 08, France.			PUISIEUX, Alain/0000-0002-9938-3798				Ahuja N, 1997, CANCER RES, V57, P3370; Bunz F, 2002, CANCER RES, V62, P1129; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Duval A, 2002, ANN GENET-PARIS, V45, P71, DOI 10.1016/S0003-3995(02)01115-2; Forozan F, 2000, CANCER RES, V60, P4519; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; Jackson AL, 1998, SEMIN CANCER BIOL, V8, P421, DOI 10.1006/scbi.1998.0113; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kytola S, 2000, GENE CHROMOSOME CANC, V28, P308, DOI 10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4; Luker KE, 2001, CANCER RES, V61, P6540; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Tsushimi T, 2001, CANCER GENET CYTOGEN, V126, P34, DOI 10.1016/S0165-4608(00)00391-5; Wang Q, 2003, ONCOGENE, V22, P1486, DOI 10.1038/sj.onc.1206224; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	32	30	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8956	8960		10.1038/sj.onc.1207078	http://dx.doi.org/10.1038/sj.onc.1207078			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654793				2022-12-17	WOS:000186982200018
J	Kadhim, MA				Kadhim, MA			Role of genetic background in induced instability	ONCOGENE			English	Article						genetic predisposition; induced genomic instability; radiation; carcinogenesis	INDUCED GENOMIC INSTABILITY; INDUCED CHROMOSOMAL INSTABILITY; HUMAN LYMPHOBLASTOID-CELLS; HEMATOPOIETIC STEM-CELLS; BONE-MARROW CELLS; IONIZING-RADIATION; DNA-DAMAGE; LETHAL MUTATIONS; MAMMALIAN-CELLS; CANCER-PATIENTS	Genomic instability is effectively induced by ionizing radiation. Recently, evidence has accumulated supporting a relationship between genetic background and the radiation-induced genomic instability phenotype. This is possibly due to alterations in proteins responsible for maintenance of genomic integrity or altered oxidative metabolism. Studies in human cell lines, human primary cells, and mouse models have been performed predominantly using high linear energy transfer (LET) radiation, or high doses of low LET radiation. The interplay between genetics, radiation response, and genomic instability has not been fully determined at low doses of low LET radiation. However, recent studies using low doses of low LET radiation suggest that the relationship between genetic background and radiation-induced genomic instability may be more complicated than these same relationships at high LET or high doses of low LET radiation. The complexity of this relationship at low doses of low LET radiation suggests that more of the population may be at risk than previously recognized and may have implications for radiation risk assessment.	MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Berks, England		Kadhim, MA (corresponding author), MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Berks, England.	m.kadhim@har.mrc.ac.uk						Amundson SA, 1999, RADIAT RES, V152, P225, DOI 10.2307/3580321; An Mi-Young, 2002, J Vet Sci, V3, P213; Ban N, 2002, RADIAT RES, V158, P69, DOI 10.1667/0033-7587(2002)158[0069:CAORIL]2.0.CO;2; Baria K, 2002, INT J RADIAT BIOL, V78, P341, DOI 10.1080/09553000110117359; BAVERSTOCK K, 2003, UNPUB; Bouffler SD, 1996, RADIAT RES, V146, P349, DOI 10.2307/3579467; Boulton E, 2001, INT J RADIAT BIOL, V77, P21, DOI 10.1080/0955300010001880; Chang WP, 1997, LANCET, V350, P330, DOI 10.1016/S0140-6736(97)11056-X; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; *COMM BIOL EFF ION, 1990, EFF EXP LOW LEV ION; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; DiMajo V, 1996, RADIAT RES, V146, P81, DOI 10.2307/3579399; GOODHEAD DT, 1988, HEALTH PHYS, V55, P231, DOI 10.1097/00004032-198808000-00015; GORGOJO L, 1989, INT J RADIAT BIOL, V55, P619, DOI 10.1080/09553008914550661; Green LM, 2001, RADIAT RES, V155, P32, DOI 10.1667/0033-7587(2001)155[0032:ROTFCT]2.0.CO;2; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Harper K, 1997, EXP HEMATOL, V25, P263; HOLMBERG K, 1993, MUTAT RES, V286, P321, DOI 10.1016/0027-5107(93)90197-N; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; Honma M, 2000, MOL CARCINOGEN, V28, P203, DOI 10.1002/1098-2744(200008)28:4<203::AID-MC3>3.0.CO;2-1; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kadhim MA, 1998, INT J RADIAT BIOL, V73, P143, DOI 10.1080/095530098142518; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; KADHIM MA, 1994, LANCET, V344, P987, DOI 10.1016/S0140-6736(94)91643-8; Kadhim MA, 1999, BRIT J HAEMATOL, V105, P673, DOI 10.1046/j.1365-2141.1999.01428.x; Kadhim MA, 1996, INT J RADIAT BIOL, V69, P167, DOI 10.1080/095530096145995; Kang CM, 2003, RADIAT RES, V159, P312, DOI 10.1667/0033-7587(2003)159[0312:PBFIRE]2.0.CO;2; Lavin MF, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P306; Leger C, 2002, CARCINOGENESIS, V23, P1631, DOI 10.1093/carcin/23.10.1631; Limoli CL, 2000, ADV SPACE RES, V25, P2107, DOI 10.1016/S0273-1177(99)01062-5; Limoli CL, 2001, BRIT J CANCER, V84, P489, DOI 10.1054/bjoc.2000.1604; Lindholm C, 1999, INT J RADIAT BIOL, V75, P921, DOI 10.1080/095530099139683; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; LORIMORE SA, 1993, INT J RADIAT BIOL, V63, P655, DOI 10.1080/09553009314450851; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; MAJOR IR, 1979, BRIT J CANCER, V40, P903, DOI 10.1038/bjc.1979.284; MAJOR IR, 1978, NATURE, V272, P455, DOI 10.1038/272455a0; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; McIlrath J, 2003, INT J RADIAT BIOL, V79, P27, DOI 10.1080/0955300021000038635; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Mothersill CE, 1999, CARCINOGENESIS, V20, P2273, DOI 10.1093/carcin/20.12.2273; Okayasu R, 2000, CANCER RES, V60, P4342; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; Papworth R, 2001, BRIT J CANCER, V84, P776, DOI 10.1054/bjoc.2000.1692; Plumb M, 1998, INT J RADIAT BIOL, V74, P711, DOI 10.1080/095530098140989; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Rodgers BE, 2001, ENVIRON TOXICOL CHEM, V20, P2830, DOI 10.1002/etc.5620201223; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; Salomaa S, 2002, RADIAT RES, V158, P591, DOI 10.1667/0033-7587(2002)158[0591:SCAITL]2.0.CO;2; Salomaa S, 1998, INT J RADIAT BIOL, V74, P771, DOI 10.1080/095530098141050; Sankaranarayanan K, 2001, HEALTH PHYS, V80, P363, DOI 10.1097/00004032-200104000-00013; Sankaranarayanan K, 2001, RADIAT RES, V156, P648, DOI 10.1667/0033-7587(2001)156[0648:IOCPAR]2.0.CO;2; Schwartz JL, 2001, GENE CHROMOSOME CANC, V30, P236, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1085>3.3.CO;2-7; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; Smith L, 2001, P NATL ACAD SCI USA, V98, P13300, DOI 10.1073/pnas.241355098; Smith LE, 1998, MUTAGENESIS, V13, P435, DOI 10.1093/mutage/13.5.435; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; Vessey CJ, 2000, PROG NUCLEIC ACID RE, V63, P189, DOI 10.1016/S0079-6603(08)60723-0; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2001, INT J RADIAT BIOL, V77, P409, DOI 10.1080/09553000010028476; Weil MM, 2001, ONCOGENE, V20, P4409, DOI 10.1038/sj.onc.1204589; Yu YJ, 2001, CANCER RES, V61, P1820	65	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					6994	6999		10.1038/sj.onc.1206883	http://dx.doi.org/10.1038/sj.onc.1206883			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557803				2022-12-17	WOS:000185903900003
J	Karnauskas, R; Niu, Q; Talapatra, S; Plas, DR; Greene, ME; Crispino, JD; Rudin, CM				Karnauskas, R; Niu, Q; Talapatra, S; Plas, DR; Greene, ME; Crispino, JD; Rudin, CM			Bcl-X-L and Akt cooperate to promote leukemogenesis in vivo	ONCOGENE			English	Article						leukemia; Akt; Bcl-X-L; p53; interleukin-3	CHROMOSOMAL TRANSLOCATIONS; SURVIVAL; BCL-X(L); EXPRESSION; LYMPHOMA; GROWTH; CANCER; CELLS; GENE; HAPLOINSUFFICIENCY	To analyse individual factors that may contribute to leukemic transformation in vivo, we have developed a murine model of leukemogenesis based on the early hematopoietic precursor cell FL5.12. FL5.12 cells are interleukin-3 (IL-3) dependent for growth, proliferation, and survival. Relative resistance to cell death following IL-3 withdrawal can be conferred by either overexpression of the Bcl-x(L) apoptotic inhibitor, or constitutive activation of the serine/threonine kinase Akt. The ability of Bcl-x(L) or a constitutively active myristylated Akt to promote leukemic transformation of FL5.12 cells was compared in athymic nu(+)/nu(+) mice. Bcl-x(L) alone could not promote leukemic transformation, but mice injected with FL5.12 cells overexpressing Bcl-x(L), and a dominant-negative p53 construct developed leukocytosis and blastic infiltration of lymph nodes, spleen, and liver with features of a high-grade lymphoid malignancy. In contrast to the cells injected into these animals, cell lines derived from the mice were able to proliferate in the absence of IL-3, and were found to have constitutively activated Akt. This constitutive activation was associated with a variety of alterations of the signaling pathway regulating Akt activity, including alterations of PTEN mRNA and protein expression. In addition, some of these leukemic clones demonstrated concurrent constitutive upregulation of ERK activity. A constitutively active Akt construct introduced into FL5.12 cells promoted similar clonal expansion in vivo, with emergence of clonal IL-3-independent proliferation. Bcl-x(L) and Akt appeared to function cooperatively in this model, enhancing rapid clonal outgrowth in vivo relative to Akt alone. These results implicate activated Akt and growth-factor independence in leukemogenic transformation, and demonstrate the potential for in vivo analysis of genetic determinants of leukemogenesis.	Univ Chicago, Med Ctr, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; University of Pennsylvania; Pennsylvania Medicine; University of Chicago	Rudin, CM (corresponding author), Univ Chicago, Med Ctr, Hematol Oncol Sect, Dept Med, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	crudin@medicine.bsd.uchicago.edu	Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Crispino, John/0000-0002-8182-8306	NCI NIH HHS [CA81138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K23CA081138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; BELLACOSA A, 1993, ONCOGENE, V8, P745; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DellaRagione F, 1995, HAEMATOLOGICA, V80, P557; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DREXLER HG, 1995, LEUKEMIA, V9, P480; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; ISSA JP, 1997, LEUKEMIA S1, V11, P7; Klein G, 2000, BIOESSAYS, V22, P414, DOI 10.1002/(SICI)1521-1878(200005)22:5<414::AID-BIES3>3.0.CO;2-5; Komuro Hiroaki, 1999, Neoplasia (New York), V1, P253, DOI 10.1038/sj.neo.7900033; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Rowley JD, 2000, SEMIN HEMATOL, V37, P315; RUDIN CM, 2001, METABOLIC MOL BASES, P631; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Xerri L, 1998, LEUKEMIA LYMPHOMA, V28, P451, DOI 10.3109/10428199809058352	37	30	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					688	698		10.1038/sj.onc.1206159	http://dx.doi.org/10.1038/sj.onc.1206159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569361				2022-12-17	WOS:000180642100006
J	Belka, C; Gruber, C; Jendrossek, V; Wesselborg, S; Budach, W				Belka, C; Gruber, C; Jendrossek, V; Wesselborg, S; Budach, W			The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways	ONCOGENE			English	Article							RADIATION-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; IRRADIATION-INDUCED APOPTOSIS; NF-KAPPA-B; LYMPHOMA-CELLS; DIFFERENTIAL REQUIREMENT; CD95-INDUCED APOPTOSIS; IONIZING-RADIATION; CASPASE ACTIVATION; LEUKEMIA-CELLS	The induction of apoptosis requires the activation of a highly coordinated signaling network ultimately leading to the activation of caspases. In previous experiments we and others have shown that the tyrosine kinase Lck is required for adequate apoptosis induction in response to ionizing radiation, ceramide incubation and overexpression of the HIV-TAT protein. However, the position of Lck within given apoptotic signaling cascades remains unclear. We therefore aimed to define the role of Lck during radiation-induced apoptosis. Apoptosis induction in response to ionizing radiation, CD95 or TRAIL receptor stimulation was determined in Jurkat T-cells, the Lck-deficient Jurkat clone JCaM1.6- and Lck-retransfected JCaM1.6/Lck. No apoptosis, release of cytochrome c, breakdown of the mitochondrial potential were detectable during the first 48 h after irradiation of JCaM1.6 cells. In parallel, no activation of caspase-9, -8 and -3 was detectable. Since mitochondrial apoptosis pathways act within a feedback mechanism during death-receptor-mediated apoptosis, the influence of the Lck defect on CD95/Fas/Apo-1-L or TRAIL-induced apoptosis was also tested. Both stimuli induced apoptosis in Lck-deficient cells. However, the kinetics of apoptosis induction determined by caspase-8, -9 and -3 activation as well as DeltaPsi(m) breakdown was slowed. We conclude that the Lck deficiency influences early steps during radiation-induced mitochondrial alterations.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107; Wesselborg, Sebastian/0000-0002-5236-942X				Belka C, 2000, ANTICANCER RES, V20, P3243; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JIMENEZ B, 1995, ONCOGENE, V10, P811; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Pena LA, 2000, CANCER RES, V60, P321; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schlottmann KE, 1996, J LEUKOCYTE BIOL, V60, P546, DOI 10.1002/jlb.60.4.546; SCHRAVEN B, 1995, FEBS LETT, V368, P491, DOI 10.1016/0014-5793(95)00720-T; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Tomicic MT, 2002, ONCOGENE, V21, P2141, DOI 10.1038/sj.onc.1205280; Tuosto L, 2002, J IMMUNOL, V168, P6106, DOI 10.4049/jimmunol.168.12.6106; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; WADDICK KG, 1993, RADIAT RES, V136, P313, DOI 10.2307/3578542; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	50	30	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					176	185		10.1038/sj.onc.1206103	http://dx.doi.org/10.1038/sj.onc.1206103			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527887				2022-12-17	WOS:000180322400003
J	Kadakia, M; Brown, TL; McGorry, MM; Berberich, SJ				Kadakia, M; Brown, TL; McGorry, MM; Berberich, SJ			MdmX inhibits Smad transactivation	ONCOGENE			English	Article						MdmX; Mdm2; Smad; TGF-beta	GROWTH-FACTOR-BETA; P53; EXPRESSION; PROTEIN; DIFFERENTIATION; DEGRADATION; INTERACTS; PROMOTES; PATHWAY; ARREST	Mdm2 overexpression confers a growth promoting activity upon cells primarily by downregulating the p53 tumor suppressor protein. Nevertheless, Mdm2 deregulation has also been implicated in inhibiting TGF-beta growth repression in a p53 independent manner. Our goal in this study was to examine whether overexpression of Mdm2 or MdmX, a Mdm2-related protein, could affect Smad-induced transactivation. As downstream signaling elements of the TGF-beta pathway, Smads represent one potential target for Mdm2 and MdmX. Here we show that MdmX but not Mdm2 is capable of inhibiting Smad induced transactivation. Based on deletion mutant analysis, MdmX inhibition of Smad transactivation was independent of the p53 and Mdm2 interaction domains, yet required amino acid residues 128-444. Using TGF-beta sensitive HepG2 cells, MdmX overexpression was shown to inhibit TGF-beta induced Smad transactivation. Additionally, mouse embryo fibroblasts (MEFs) lacking p53 and MdmX showed enhanced Smad transactivation when compared to MEFs lacking either p53 or p53 and Mdm2. Interestingly, the inhibition of Smad transactivation by MdmX could be reversed by p300, a functional co-activator of Smads and a necessary factor for Mdm2 nuclear export and did not result from altered Smad localization. In vitro studies demonstrate that MdmX binds to p300 as well as Smad3 and Smad4. Taken together, these results suggest that inhibition of Smad-induced transactivation by MdmX occurs by altering Smad interaction with its coactivator p300.	Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA; Wright State Univ, Dept Physiol & Biophys, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton	Berberich, SJ (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA.	steven.berberich@wright.edu			NATIONAL CANCER INSTITUTE [R29CA064430, R01CA064430] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA064430, CA64430, R01 CA064430-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Blain SW, 2000, J BIOL CHEM, V275, P32066, DOI 10.1074/jbc.M006496200; Brown TL, 1998, CELL GROWTH DIFFER, V9, P869; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Finch RA, 2002, CANCER RES, V62, P3221; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; JACKSON MW, 2001, J BIOL CHEM, V10, P10; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kim RH, 2000, GENE DEV, V14, P1605; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Luna RMD, 1997, NAT GENET, V16, P336; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; TERUEL T, 1995, FEBS LETT, V364, P193, DOI 10.1016/0014-5793(95)00385-M; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yam CH, 1999, CANCER RES, V59, P5075; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	41	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8776	8785		10.1038/sj.onc.1205993	http://dx.doi.org/10.1038/sj.onc.1205993			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483531				2022-12-17	WOS:000179734400012
J	Perri, P; Longo, L; Cusano, R; McConville, CM; Rees, SA; Devoto, M; Conte, M; Ferrara, GB; Seri, M; Romeo, G; Tonini, GP				Perri, P; Longo, L; Cusano, R; McConville, CM; Rees, SA; Devoto, M; Conte, M; Ferrara, GB; Seri, M; Romeo, G; Tonini, GP			Weak linkage at 4p16 to predisposition for human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; chromosome 4p; LOH; linkage analysis; tumor suppressor genes	COMPARATIVE GENOMIC HYBRIDIZATION; TUMORS; MUTATION; DELETION; CANCER; REGION; LOCUS; MYC	The most frequent genetic alterations described in neuroblastoma (NB) are amplification of MYCN oncogene and deletion of chromosome 1p, although somatic deletions have been demonstrated at other chromosomal intervals. Since loss of heterozygosity (LOH) at distal 4p has been observed in about 20-29% of neuroblastomas, we have evaluated deletions in 41 Italian NB samples by LOH analysis at loci mapping to 4p as follows: pter-D4S2936-D4S412-D4S2957MS432-D4S3023-MS431-cen. Our analysis showed allele losses in eight out of 41 samples (19.5%) and allowed the identification of a smallest region of overlapping deletion (SRO) of 3.0 cM, delimited by D4S412 and D4S3023. Two of these tumors with 4p LOH are from patients belonging to a family with recurrent NB. Interestingly the genotyping of this family revealed an identical haplotype that includes the nonrecombinant loci D4S412, D4S2957 and D4S432 shared by all affected children and demonstrated that this haplotype is retained in the two tumors carrying somatic deletions from patients of this family. Furthermore linkage analysis was performed in two NB families and yielded an overall lod-score of 3.0 in the interval including the haplotype. This provides a confirmatory indication that the region delimited by D4S2936 and D4S3023, which also includes the new defined SRO, may harbor NB predisposing gene/s.	Natl Inst Canc Res, IST, Lab Populat Genet, I-16132 Genoa, Italy; Adv Biotechnol Ctr, Lab Neuroblastoma Res, I-16132 Genoa, Italy; Gaslini Childrens Hosp, Mol Genet Lab, I-16148 Genoa, Italy; Univ Birmingham, Dept Paediat & Child Hlth, Birmingham B15 2TT, W Midlands, England; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; AI duPont Hosp Children, Dept Res, Wilmington, DE 19899 USA; Gaslini Childrens Hosp, Dept Hematol & Oncol, I-16148 Genoa, Italy; Natl Inst Canc Res, IST, Immunogenet Lab, I-16132 Genoa, Italy; Univ Bologna, Dept Internal Med Cardioangiol & Hepatol, I-40138 Bologna, Italy	University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Birmingham; University of Genoa; Nemours Alfred I. duPont Hospital for Children; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS AOU San Martino IST; University of Bologna	Tonini, GP (corresponding author), Natl Inst Canc Res, IST, Lab Populat Genet, Lgo R Benzi 10, I-16132 Genoa, Italy.		conte, massimo/K-2049-2016; conte, massimo/AAA-8044-2019; Devoto, Marcella/AAP-7595-2021; Longo, Luca/K-6156-2018; Perri, Patrizia/I-8124-2018; Perri, Patrizia/AFV-5794-2022; Eva, Alessandra/J-8268-2016; Seri, Marco/A-4339-2014	conte, massimo/0000-0001-9405-7339; conte, massimo/0000-0001-9405-7339; Longo, Luca/0000-0002-5153-4243; Perri, Patrizia/0000-0003-2538-8278; Perri, Patrizia/0000-0003-2538-8278; Eva, Alessandra/0000-0003-2949-078X; DEVOTO, MARCELLA/0000-0002-4431-5114; Seri, Marco/0000-0003-2425-2176; Cusano, Roberto/0000-0001-5543-7881				Altura RA, 1997, GENE CHROMOSOME CANC, V19, P176, DOI 10.1002/(SICI)1098-2264(199707)19:3<176::AID-GCC7>3.0.CO;2-V; Bown N, 2001, MED PEDIATR ONCOL, V36, P14, DOI 10.1002/1096-911X(20010101)36:1<14::AID-MPO1005>3.3.CO;2-7; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Caron H, 1996, HUM GENET, V97, P834; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Lo Cunsolo C, 2000, BRIT J CANCER, V83, P1295, DOI 10.1054/bjoc.2000.1432; Luttikhuis MEMO, 2001, BRIT J CANCER, V85, P531, DOI 10.1054/bjoc.2001.1960; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Perri P, 1997, EUR J CANCER, V33, P1949, DOI 10.1016/S0959-8049(97)00286-4; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; TAKITA J, 1995, ONCOGENE, V11, P1829; Vandesompele J, 2001, MED PEDIATR ONCOL, V36, P5, DOI 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E; Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	20	30	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8356	8360		10.1038/sj.onc.1206009	http://dx.doi.org/10.1038/sj.onc.1206009			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447700				2022-12-17	WOS:000179323900015
J	Lemoine, FJ; Marriott, SJ				Lemoine, FJ; Marriott, SJ			Genomic instability driven by the human T-cell leukemia virus type I (HTLV-1) oncoprotein, Tax	ONCOGENE			English	Article						HTLV-1; tax gene amplification; genome stability; PALA; cell cycle	MAMMALIAN GENE AMPLIFICATION; 1ST 3 ENZYMES; WILD-TYPE P53; ASPARTATE-TRANSCARBAMYLASE; TRANSACTIVATION FUNCTION; CHROMOSOME BREAKAGE; CYCLE ARREST; DNA-DAMAGE; PROTEIN; LYMPHOCYTES	The importance of maintaining genomic stability is evidenced by the fact that transformed cells often contain a variety of chromosomal abnormalities such as euploidy, translocations, and inversions. Gene amplification is a well-characterized hallmark of genomic instability thought to result from recombination events following the formation of double-strand, chromosomal breaks. Therefore, gene amplification frequency serves as an indicator of genomic stability. The PALA assay is designed to measure directly the frequency with which a specific gene, CAD, is amplified within a cell's genome. We have used the PALA assay to analyse the effects of the human T-cell leukemia virus type I (HTLV-1) oncoprotein, Tax, on genomic amplification. We demonstrate that Tax-expressing cells are five-times more likely to undergo gene amplification than control cells. Additionally, we show that Tax alters the ability of cells to undergo the typical PALA-mediated G, phase cell cycle arrest, thereby allowing cells to replicate DNA in the absence of appropriate nucleotide pools. This effect is likely the mechanism by which Tax induces gene amplification. These data suggest that HTLV-1 Tax alters the genomic stability of cells, an effect that may play an important role in Tax-mediated, HTLV-1 associated cellular transformation.	Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA-09197, CA-77371] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; BENNER SE, 1991, ANTI-CANCER DRUG, V2, P11, DOI 10.1097/00001813-199102000-00002; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KAO SY, 2000, RES ADV VIROL, V1, P1; KEMPE TD, 1976, CELL, V9, P541, DOI 10.1016/0092-8674(76)90036-2; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MONDELLO C, 1995, MUTAT RES LETT, V346, P61, DOI 10.1016/0165-7992(95)90052-7; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OTTO E, 1989, J BIOL CHEM, V264, P3390; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; REID RL, 1993, ONCOGENE, V8, P3029; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WETTERGREN Y, 1994, SOMAT CELL MOLEC GEN, V20, P267, DOI 10.1007/BF02254717; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YAMAOKA S, 1992, ONCOGENE, V7, P433	39	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7230	7234		10.1038/sj.onc.1205898	http://dx.doi.org/10.1038/sj.onc.1205898			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370813				2022-12-17	WOS:000178504600011
J	Aigner, A; Renneberg, H; Bojunga, J; Apel, J; Nelson, PS; Czubayko, F				Aigner, A; Renneberg, H; Bojunga, J; Apel, J; Nelson, PS; Czubayko, F			Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo	ONCOGENE			English	Article						FGF-binding proteins; FGF-BP; prostate cancer cells; ribozyme-targeting; prostate tumorigenesis; HBp17	FIBROBLAST-GROWTH-FACTOR; GENE-EXPRESSION; STRUCTURAL CHARACTERIZATION; ANGIOGENIC SWITCH; OVER-EXPRESSION; RETINOIC ACID; TUMOR-GROWTH; RECEPTOR; STIMULATION; CARCINOMA	Prostate cancer is one of the most common malignant tumors with increasing incidence rates in the aging male. Since locally advanced or metastatic prostate tumors are essentially incurable, identification of new target molecules and treatment strategies is of critical importance. Fibroblast growth factor-2 (FGF-2) acts as potent mitogen which is upregulated in prostate cancers modulating cancer cell proliferation and development of an invasive phenotype. Normally it is tightly bound to the extracellular matrix that quenches its biological activity. The FGF-binding proteins (FGF-BP, HBp17) is a secreted protein which is able to mobilize and activate FGF-2 from the extracellular matrix. Here we show that FGF-BP is highly expressed in prostate tumor cells. To study the functional role of FGF-BP, we use a ribozymetargeting approach to selectively deplete FGF-BP in prostate cancer cells achieving a more than 50% reduction of FGF-BP mRNA and protein levels in two mass-transfected cell lines. FGF-BP depletion reduces proliferation of the cells in vitro without changes in cell cycle distribution or apoptosis. Using cDNA microarrays, Northern blotting and RT-PCR, we show a complex pattern of changes in the gene expression profiles upon FGF-BP depletion. Most strikingly, ribozyme-mediated reduction of FGF-BP levels completely abolishes the ability of the highly metastatic PC-3 prostate carcinoma cells to grow tumors in an athymic nude mouse in vivo model which is far beyond the effects of FGF-BP ribozyme targeting observed previously in cells from other tumors in the same model. Taken together, our study identifies FGF-BP as a potential rate-limiting factor for prostate cancer growth and, due to its restricted expression pattern in adults, a potentially attractive target for prostate cancer therapy.	Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, Marburg, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; JW Goethe Univ, Dept Med 1, Frankfurt, Germany	Philipps University Marburg; Fred Hutchinson Cancer Center; Goethe University Frankfurt	Aigner, A (corresponding author), Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, Marburg, Germany.		Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256				Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Aigner A, 2000, TOXICOLOGY, V144, P221, DOI 10.1016/S0300-483X(99)00210-3; Aigner A, 2002, HISTOCHEM CELL BIOL, V117, P1, DOI 10.1007/s00418-001-0360-4; Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Aumuller G, 1999, PROSTATE, V38, P261; BEGUN FP, 1995, J UROLOGY, V153, P839, DOI 10.1016/S0022-5347(01)67732-2; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; CHACKALROY M, 1989, J CLIN INVEST, V84, P43, DOI 10.1172/JCI114167; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Giri D, 1999, J CELL PHYSIOL, V180, P53, DOI 10.1002/(SICI)1097-4652(199907)180:1<53::AID-JCP6>3.0.CO;2-P; Giri D, 1999, CLIN CANCER RES, V5, P1063; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Lametsch R, 2000, J BIOL CHEM, V275, P19469, DOI 10.1074/jbc.M002550200; LAROCCA RV, 1991, J UROLOGY, V145, P393, DOI 10.1016/S0022-5347(17)38351-9; Leung HY, 1996, ONCOGENE, V12, P1833; LiaudetCoopman EDE, 1996, BIOCHEM BIOPH RES CO, V229, P930, DOI 10.1006/bbrc.1996.1904; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Lieberman R, 2001, UROLOGY, V57, P4, DOI 10.1016/S0090-4295(00)00931-6; Martin R, 2000, J HISTOCHEM CYTOCHEM, V48, P1121, DOI 10.1177/002215540004800809; Mehta PB, 2000, J UROLOGY, V164, P2151, DOI 10.1016/S0022-5347(05)66988-1; Middleman MN, 1996, CANCER TREAT REV, V22, P105, DOI 10.1016/S0305-7372(96)90030-4; MORI H, 1990, PROSTATE, V16, P71, DOI 10.1002/pros.2990160108; NAKAMOTO T, 1992, CANCER RES, V52, P571; NISHI N, 1988, PROSTATE, V13, P39, DOI 10.1002/pros.2990130105; Okamoto T, 1996, IN VITRO CELL DEV-AN, V32, P69; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Ropiquet F, 2000, CANCER RES, V60, P4245; Ropiquet F, 1999, J UROLOGY, V162, P595, DOI 10.1016/S0022-5347(05)68632-6; Shain SA, 1996, CELL GROWTH DIFFER, V7, P573; Stoppler H, 2001, ONCOGENE, V20, P7430, DOI 10.1038/sj.onc.1204957; STORY MT, 1989, PROSTATE, V15, P355, DOI 10.1002/pros.2990150408; Thomas R, 2001, INT J CANCER, V93, P47, DOI 10.1002/ijc.1291; van Bokhoven A, 2001, PROSTATE, V47, P36; Webber MM, 1997, PROSTATE, V30, P58; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; Wellstein A, 1996, BREAST CANCER RES TR, V38, P109, DOI 10.1007/BF01803789; WU DQ, 1991, J BIOL CHEM, V266, P16778; YAGODA A, 1993, CANCER-AM CANCER SOC, V71, P1098, DOI 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	49	30	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5733	5742		10.1038/sj.onc.1205560	http://dx.doi.org/10.1038/sj.onc.1205560			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173043				2022-12-17	WOS:000177463400008
J	Baudry, D; Faussillon, M; Cabanis, MO; Rigolet, M; Zucker, JM; Patte, C; Sarnacki, S; Boccon-Gibod, L; Junien, C; Jeanpierre, C				Baudry, D; Faussillon, M; Cabanis, MO; Rigolet, M; Zucker, JM; Patte, C; Sarnacki, S; Boccon-Gibod, L; Junien, C; Jeanpierre, C			Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour	ONCOGENE			English	Article						Wilms' tumour; expression profiling; WTI splicing; prognosis	ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; SUPPRESSOR WT1; FUNCTIONAL INTERACTION; TISSUE INHIBITOR; SEX; PROTOONCOGENE; METASTASIS; MUTATIONS; INDUCTION	Wilms' tumour (WT) or nephroblastoma is the most frequent kidney cancer in children. In a previous study, we reported alterations to WTI transcription in 90% of WT tested, with decreased exon 5 +/- isoform ratio being the most frequent alteration (56% of WT). We now report an approach based on cDNA profiling of tumour pools to identify genes likely to be dysregulated in association with a decreased WTI exon 5 +/- ratio. We compared the expression profiles of pools of tumours classified according to whether this isoform imbalance was present (five tumours) or not (four tumours), using Atlas Cancer cDNA expression arrays. Fourteen of 588 genes tested displayed specific up-regulation (CCND2, PCNA, N-MYC, E2F3, TOP2A, PAK1, DCC and PCDH2) or down-regulation (VEGF, IGFBP5, TIMP3, ARHB, C-FOS and CD9) in the pool of tumours with decreased exon 5 +/- ratio. These results were validated by RT-PCR analysis of four genes (CCND2, PCNA, VEGF and IGFBP5). We extended the analysis of VEGF expression to 51 tumours by real-time RTPCR and ascertained differential expression of this gene associated with WTI expression pattern. Moreover, our results suggest that the VEGF expression level may be of prognosis relevance for relapsed patients.	Univ Paris 05, Hop Necker Enfants Malad, INSERM, U383, F-75743 Paris 15, France; Inst Curie, F-75248 Paris, France; Inst Gustave Roussy, F-94805 Villejuif, France; Hop Necker Enfants Malad, Clin Chirurg Infantile, F-75743 Paris 15, France; Hop Armand Trousseau, Serv Anat Pathol, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite	Jeanpierre, C (corresponding author), Univ Paris 05, Hop Necker Enfants Malad, INSERM, U383, F-75743 Paris 15, France.	jeanpierre@necker.fr	Sarnacki, Sabine/I-2692-2017; Jeanpierre, cecile/H-3770-2017; BLUTEAU, Dominique/AAH-8113-2021	Sarnacki, Sabine/0000-0003-4304-5578; Jeanpierre, cecile/0000-0002-3463-5907; BLUTEAU, Dominique/0000-0002-6530-2363				Bachman KE, 1999, CANCER RES, V59, P798; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Baudry D, 2000, CLIN CANCER RES, V6, P3957; Celiker MY, 2001, ONCOGENE, V20, P4337, DOI 10.1038/sj.onc.1204508; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DECLERCK YA, 1992, CANCER RES, V52, P701; Englert C, 1997, CANCER RES, V57, P1429; Granzen B, 2001, ANTICANCER RES, V21, P771; Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hastie ND, 2001, CELL, V106, P391, DOI 10.1016/S0092-8674(01)00469-X; Hewitt SM, 1996, ANTICANCER RES, V16, P621; Humbert PO, 2000, GENE DEV, V14, P690; Jeanpierre C, 1998, NUCLEIC ACIDS RES, V26, P271, DOI 10.1093/nar/26.1.271; Kayton ML, 1999, J PEDIATR SURG, V34, P743, DOI 10.1016/S0022-3468(99)90367-6; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim CJ, 1996, PATHOL INT, V46, P137, DOI 10.1111/j.1440-1827.1996.tb03589.x; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Linderholm BK, 2001, CANCER RES, V61, P2256; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Menke A, 1998, KIDNEY INT, V53, P1512, DOI 10.1046/j.1523-1755.1998.00935.x; Mrowka C, 2000, J AM SOC NEPHROL, V11, pS106; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NISEN PD, 1986, CANCER RES, V46, P6217; Plisov SY, 2000, GENESIS, V27, P22, DOI 10.1002/1526-968X(200005)27:1<22::AID-GENE40>3.3.CO;2-M; Rechler MM, 1998, TRENDS ENDOCRIN MET, V9, P176, DOI 10.1016/S1043-2760(98)00047-2; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Richard DJ, 2001, GENE DEV, V15, P328, DOI 10.1101/gad.185901; Rigolet M, 2001, PEDIATR NEPHROL, V16, P1113, DOI 10.1007/s004670100040; Rowe DH, 2000, J PEDIATR SURG, V35, P30, DOI 10.1016/S0022-3468(00)80008-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STANTON BR, 1992, BRAIN PATHOL, V2, P71; Wagner KJ, 2001, BIOCHEM BIOPH RES CO, V287, P977, DOI 10.1006/bbrc.2001.5693; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; WANG ZY, 1995, ONCOGENE, V10, P1243; Yuan A, 2001, J CLIN ONCOL, V19, P432, DOI 10.1200/JCO.2001.19.2.432; Zhang XH, 1999, ANTICANCER RES, V19, P1641	40	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5566	5573		10.1038/sj.onc.1205752	http://dx.doi.org/10.1038/sj.onc.1205752			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165855				2022-12-17	WOS:000177442000006
J	Degot, S; Regnier, CH; Wendling, C; Chenard, MP; Rio, MC; Tomasetto, C				Degot, S; Regnier, CH; Wendling, C; Chenard, MP; Rio, MC; Tomasetto, C			Metastatic Lymph Node 51, a novel nucleo-cytoplasmic protein overexpressed in breast cancer	ONCOGENE			English	Article						MLN51; breast cancer; SH2; SH3; NLS; coiled-coil	SIGNALING PROTEINS; SH3 DOMAINS; MAMMALIAN-CELLS; FACTOR RECEPTOR; COILED COILS; IDENTIFICATION; CARCINOMA; DNA; LOCALIZATION; PRECURSOR	Metastatic Lymph Node 51 (MLN51) cDNA was isolated by differential screening of a human breast cancer metastasis cDNA library. MLN51 cDNA encodes a novel human protein of 703 residues that shares no significant homology to any known protein. However MLN51 is well conserved between vertebrate and invertebrate species suggesting an important biological function. The amino terminal half of the protein contains a coiled-coil domain and two potential nuclear localization signals (NLS). The carboxy terminal half contains one SH2 and four SH3 binding motifs. The coiled-coil domain promotes MLN51 oligomerization in transfected cells. When transiently expressed, the MLN51 protein is mainly found in the cytoplasm with a weak nuclear staining. However, deletion of the carboxy terminal half of the protein allows the targeting of the protein to the nucleus, demonstrating that the NLSs are functional. MLN51 is ubiquitously expressed in normal tissues. Human breast carcinomas show MLN51 overexpression in malignant epithelial cells. The uncommon association of protein-protein interaction domains often found either in nuclear or in cytoplasmic signaling proteins raises a possible nucleo-cytoplasmic function for MLN51.	Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, F-67404 Illkirch Graffenstaden, CU De Strasbour, France; CHU Hautepierre, Serv Anat Pathol Gen, F-67098 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg	Tomasetto, C (corresponding author), Univ Strasbourg 1, INSERM, U184, CNRS,UPR 6520,IGBMC, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, CU De Strasbour, France.	cat@igbmc.u-strasburg.fr	Chenard, Marie-Pierre/O-2373-2016; Tomasetto, Catherine Laure/J-2783-2014	Tomasetto, Catherine Laure/0000-0002-1811-5848; Regnier, Catherine/0000-0002-4386-1324				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Bieche I, 1996, CANCER RES, V56, P3886; Boyle P, 2000, INT J GYNECOL OBSTET, V70, P263, DOI 10.1016/S0020-7292(00)00298-8; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HOBERT O, 1994, J BIOL CHEM, V269, P20225; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Klapper LN, 2000, ADV CANCER RES, V77, P25; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Liotta LA, 2001, NATURE, V410, P24, DOI 10.1038/35065180; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mayer BJ, 2001, J CELL SCI, V114, P1253; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; SHOEMAN RL, 1993, BIOESSAYS, V15, P605, DOI 10.1002/bies.950150906; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tanaka S, 1997, CANCER RES, V57, P28; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Yan YT, 2000, MOL CELL BIOL, V20, P661, DOI 10.1128/MCB.20.2.661-671.2000; Yu DL, 2000, CHINESE PHYS LETT, V17, P19, DOI 10.1088/0256-307X/17/1/007; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	30	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4422	4434		10.1038/sj.onc.1205611	http://dx.doi.org/10.1038/sj.onc.1205611			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080473				2022-12-17	WOS:000176317100008
J	Daosukho, C; Kiningham, K; Kasarskis, EJ; Ittarat, W; Clair, DKS				Daosukho, C; Kiningham, K; Kasarskis, EJ; Ittarat, W; Clair, DKS			Tamoxifen enhancement of TNF-alpha induced MnSOD expression: modulation of NF-kappa B dimerization	ONCOGENE			English	Article						NF-kappa B; tamoxifen; tumor control; MnSOD; tumor suppressor gene	MANGANESE SUPEROXIDE-DISMUTASE; BREAST-CANCER-CELLS; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; SUBUNIT; OVEREXPRESSION; SUPPRESSION; ACTIVATION; INDUCTION; RECEPTOR	Manganese superoxide dismutase (MuSOD) has been shown to suppress the development of cancer. Tamoxifen (TAM), a nonsteroidal anti-estrogen that is widely used in chemotherapy, is known to be a modulator of antioxidant status. However, the mechanism by which TAM mediates antioxidant enzyme induction remains unclear. In this study we investigated TAM enhancement of MnSOD induction by TNF-alpha. The results show that co-treatment with TAM and TNF-alpha increases the MnSOD promoter/enhancer driven luciferase activity, MnSOD mRNA and protein levels. Interestingly, co-treatment with TAM and TNF-a drastically decreases the binding activity of the p50/p50 homodimer and increases that of the p50/p65 heterodimer compared to TNF-alpha alone. This change in DNA binding could not be attributed to a decrease in the level of p50, its precursor, p105, or its inhibitors. Furthermore, TAM did not enhance degradation of IkappaB-alpha. These results suggest that p50/p50 homodimer may act as an inhibitory complex of MnSOD expression. Modulation of the DNA binding activity in favor of the p50/p65 complex may enhance NF-kappaB mediated induction of MnSOD by TAM. These findings reveal a potential novel mechanism for the induction of the human MnSOD gene.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand	University of Kentucky; Mahidol University	Clair, DKS (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 361 Hlth Sci Res Bldg, Lexington, KY 40536 USA.	dstc100@pop.uky.edu			NCI NIH HHS [CA 59835, CA 49797] Funding Source: Medline; NHLBI NIH HHS [HL-03544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059835, R29CA049797, R01CA049797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GOLDENBERG GJ, 1982, CANCER RES, V42, P5147; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; LI JJ, 1995, ONCOGENE, V10, P1989; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; NEGRINI M, 1994, CANCER RES, V54, P1331; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; StClair DK, 1996, ONCOL REP, V3, P429; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; TAYLOR CM, 1984, CANCER RES, V44, P1409; THANGARAJU M, 1994, CANCER, V74, P78, DOI 10.1002/1097-0142(19940701)74:1<78::AID-CNCR2820740114>3.0.CO;2-L; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zhao YF, 2001, CANCER RES, V61, P6082	40	30	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3603	3610		10.1038/sj.onc.1205448	http://dx.doi.org/10.1038/sj.onc.1205448			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032862				2022-12-17	WOS:000175793700011
J	Poetsch, M; Dittberner, T; Woenckhaus, C				Poetsch, M; Dittberner, T; Woenckhaus, C			Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36	ONCOGENE			English	Article						melanoma; RIZ; frameshift mutations	MISMATCH REPAIR GENE; ZINC-FINGER GENE; MICROSATELLITE INSTABILITY; TUMOR PROGRESSION; CELL-LINES; EXPRESSION; CYTOGENETICS; CARCINOMA; PRODUCT; CANCERS	Recently, the retinoblastoma protein interacting zinc finger gene RIZ has been proposed as a candidate for the tumor suppressor locus on 1p36, because of the common loss of RIZ1 RNA in human tumors. In addition, frameshift mutations of this gene have been demonstrated in a variety of tumors with microsatellite instability. Since alterations in this region have been described in malignant melanomas, we investigated DNA of paraffin-em bedded sections from 16 typical naevi, 19 atypical naevi, 33 primary melanoma lesions and 25 metastases and DNA from four melanoma cell lines by PCR and direct sequencing analysis of RIZ. Frameshift mutations in the RIZ gene were found in 17% of melanoma samples and 8.6% of naevi, but we could not demonstrate any missense mutations in the exons of RIZ1. No LOH of the RIZ gene nor any microsatellite instability in six dinucleotide markers or in the mononucleotide repeats IGRIIR, hMSH3, and hMSH6 could be demonstrated in the samples with RIZ frameshift mutations. Although our results do not explain the high rate of deletions in 1p36 found in this tumor, they assign RIZ a potential role in the multi-step tumor forming process of malignant melanoma of the skin.	Ernst Moritz Arndt Univ Greifswald, Inst Forens Med, D-17489 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Dept Dermatol, D-17489 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Inst Pathol, D-17489 Greifswald, Germany	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald	Poetsch, M (corresponding author), Ernst Moritz Arndt Univ Greifswald, Inst Forens Med, Kuhstr 30, D-17489 Greifswald, Germany.	poetsch@mail.uni-greifswald.de						ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; Boni R, 1998, J INVEST DERMATOL, V110, P215, DOI 10.1046/j.1523-1747.1998.00109.x; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.0.CO;2-I; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.0.CO;2-K; Fleisher AS, 2000, CANCER RES, V60, P4864; He LS, 1998, CANCER RES, V58, P4238; Heim S., 1995, CANC CYTOGENETICS CH, V2nd; Hussein MR, 2001, AM J DERMATOPATH, V23, P308, DOI 10.1097/00000372-200108000-00006; Jiang GL, 2001, CANCER RES, V61, P1796; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; Korabiowska M, 1999, ONCOL REP, V6, P921; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Piao Z, 2000, CANCER RES, V60, P4701; Poetsch M, 1998, LAB INVEST, V78, P883; Poetsch M, 1999, VIRCHOWS ARCH, V435, P105, DOI 10.1007/s004280050406; Poetsch M, 2001, CANCER GENET CYTOGEN, V125, P21, DOI 10.1016/S0165-4608(00)00353-8; Richetta A, 2001, MELANOMA RES, V11, P283, DOI 10.1097/00008390-200106000-00010; Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V; SIRACKY J, 1982, NEOPLASMA, V29, P661; Talwalkar VR, 1998, CANCER GENET CYTOGEN, V104, P111, DOI 10.1016/S0165-4608(97)00452-4; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V	24	30	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3038	3042		10.1038/sj.onc.1205457	http://dx.doi.org/10.1038/sj.onc.1205457			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082534				2022-12-17	WOS:000175262700011
J	Meriane, M; Charrasse, S; Comunale, F; Mery, A; Fort, P; Roux, P; Gauthier-Rouviere, C				Meriane, M; Charrasse, S; Comunale, F; Mery, A; Fort, P; Roux, P; Gauthier-Rouviere, C			Participation of small GTPases Rac1 and Cdc42Hs in myoblast transformation	ONCOGENE			English	Article						Rho GTPases; myogenesis; transformations; rhabdomyosarcoma	SKELETAL-MUSCLE DIFFERENTIATION; KINASE PATHWAY; GROWTH-FACTOR; RAS; RHO; P38; ACTIVATION; EXPRESSION; PROLIFERATION; PROTEINS	We have previously shown that expression of active Rac1 and Cdc4Hs inhibits skeletal muscle cell differentiation. We show here, by bromodeoxyuridine incorporation and cyclin D1 expression, that the expression of active Rac1 and Cdc42Hs but not RhoA impairs cell cycle exit of L6 myoblasts cultured in differentiation medium. Furthermore, expression of activated forms of Rac1 and Cdc42Hs elicits the loss of cell contact inhibition and anchorage-dependent growth as measured by focus forming activity and growth in soft agar. RhoA was once again not found to have this effect. We found a constitutive Rac1 and Cdc42Hs activation in three human rhabdomyosarcoma-derived cell lines, one of the most common causes of solid tumours arising from muscle precursors during childhood. Finally, dominant negative forms of Rac1 and Cdc42Hs inhibit cell proliferation of the RD rhabdomyosarcoma cell line. These data suggest an important role for the small GTPases Rac1 and Cdc42Hs in the generation of skeletal muscle tumours.	CNRS, Ctr Rech Biochim Macromol, UPR 1086, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Gauthier-Rouviere, C (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier, France.	gauthier@erbm.cnrs.mop.fr	Fort, Philippe/M-9498-2015; Roux, Pierre/D-8833-2017	Fort, Philippe/0000-0001-5997-8722; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; Comunale, Franck/0000-0001-8838-2151				Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; HELLER H, 2001, J BIOL CHEM, V6, P6; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Mangues R, 1992, Semin Cancer Biol, V3, P229; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Puri PL, 2000, GENE DEV, V14, P574; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; VAN AL, 1997, GENE DEV, V11, P2295; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	36	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2901	2907		10.1038/sj.onc.1205396	http://dx.doi.org/10.1038/sj.onc.1205396			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973651				2022-12-17	WOS:000175063700016
J	Chazal, M; Marionnet, C; Michel, L; Mollier, K; Dazard, JE; Della Valle, V; Larsen, CJ; Gras, MP; Basset-Seguin, N				Chazal, M; Marionnet, C; Michel, L; Mollier, K; Dazard, JE; Della Valle, V; Larsen, CJ; Gras, MP; Basset-Seguin, N			P16(INK4A) is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation	ONCOGENE			English	Article						p16(INK4A); keratinocyte; UVB	P53 TUMOR SUPPRESSION; HUMAN CANCER-CELLS; ULTRAVIOLET-RADIATION; G(1) ARREST; HUMAN SKIN; INK4A LOCUS; DNA-DAMAGE; EXPRESSION; PROTEIN; GENE	The P16(INK4A-ARF) locus plays a crucial role in the control of cellular proliferation via both the Rb and P53 pathways. We previously demonstrated that this locus is altered in human skin carcinomas. In the present study we have studied the expression of the p16(INK4A-ARF) locus following UVB irradiation of normal human keratinocytes both at the mRNA (RT-PCR) and at the protein (Western blotting) levels. Our data confirmed that P16(INK4A) protein is induced by UVB at low (30 mJ cm(2)) and high (100 mJ cm(2)) doses and is observed after a single or repeated exposure implying that this response is involved in both the immediate and adaptative response to UVB. The apparent absence of induction p16(INK4A) mRNA suggested that P16(INK4A) protein is upregulated at the post-transcriptional level. Analysis by flow cytometry and BrdU staining indicated that the highest protein level of P16(INK4A) in the cells was associated with a G(2) cell cycle arrest. Comparative analysis of P16(INK4A) and P53 showed that they were differentially modulated in keratinocytes according to the UVB dose and regimen. Low, acute or repeated UVB exposures led to accumulation of both P16(INK4A) and p53, whereas at high UVB doses, P53 and P53-dependent genes were not induced or even downregulated and only a slight but reproducible stabilization of P16(INK4A) protein was observed. In our conditions, P14(ARF) did not seem to participate in the UV response in these cells as P14(ARF) protein did not vary. These results infer that P16(INK4A) plays a role in cell cycle regulation of keratinocytes submitted to UVB irradiation. They also reinforce our previous demonstration of the importance of inactivation of this gene in UV-induced skin carcinogenesis.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75010 Paris, France; Inst Genet Mol, CNRS, UMR 5535, F-34090 Montpellier, France; Inst Genet Mol, INSERM, U434, F-75010 Paris, France; IBMIG, Oncol Mol Lab, F-86022 Poitiers, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers	Basset-Seguin, N (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave C Vellefaux, F-75010 Paris, France.		Michel, Laurence/E-8605-2017					AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ahmed NU, 1999, J DERMATOL SCI, V19, P175, DOI 10.1016/S0923-1811(98)00068-1; BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, P102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enders GH, 1996, ONCOGENE, V12, P1239; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; HALL PA, 1993, ONCOGENE, V8, P203; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1993, CELL, V75, P805; Inohara S, 1996, BRIT J DERMATOL, V135, P717; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1993, ENVIRON HEALTH PERSP, V101, P55, DOI 10.2307/3431842; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, BRIT J DERMATOL, V139, P3; Liefer KM, 2000, CANCER RES, V60, P4016; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; MIYASHITA T, 1995, CELL, V80, P293; Nielsen GP, 1999, LAB INVEST, V79, P1137; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Parker C.A, 1968, PHOTOLUMINESCENCE SO; Pavey S, 1999, CANCER RES, V59, P4185; Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P741, DOI 10.1067/mjd.2000.103988; Reznikoff CA, 1996, CANCER RES, V56, P2886; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soufir N, 2000, J NATL CANCER I, V92, P1841, DOI 10.1093/jnci/92.22.1841; Soufir N, 1999, ONCOGENE, V18, P5477, DOI 10.1038/sj.onc.1202915; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang XQ, 1996, CANCER RES, V56, P2510; WEINBERG WC, 1994, CANCER RES, V54, P5584; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	47	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2652	2661		10.1038/sj.onc.1205349	http://dx.doi.org/10.1038/sj.onc.1205349			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965538				2022-12-17	WOS:000174996500005
J	Bhatia, N; Herter, JR; Slaga, TJ; Fuchs, SY; Spiegelman, VS				Bhatia, N; Herter, JR; Slaga, TJ; Fuchs, SY; Spiegelman, VS			Mouse homologue of HOS (mHOS) is overexpressed in skin tumors and implicated in constitutive activation of NF-kappa B	ONCOGENE			English	Article						NF-kappa B; ubiquitin ligase; skin carcinogenesis; beta TrCP; HOS; F-box	F-BOX PROTEIN; BETA-TRCP; HA-RAS; UBIQUITIN LIGASE; DEPENDENT DEGRADATION; TRANSCRIPTION FACTORS; INCREASED EXPRESSION; ELEVATED EXPRESSION; POINT MUTATION; ALPHA	NF-kappaB transcription factor is activated upon ubiquitination and subsequent proteolysis of its inhibitor IkappaB. The phosphorylation-dependent ubiquitination is mediated by SCIF E3 ubiquitin ligase. In this study, we identified a novel murine F-box/WD40 repeat-containing protein, mHOS (a homologue of HOS/betaTrCP2). mHOS efficiently binds Skp1 protein (a 'core' component of SCIF ubiquitin ligase), and phosphorylated IkappaBalpha. We found that mHOS associates with SCF-ROC1 E3 ubiquitin ligase activity. We have also observed that mHOS is overexpressed in chemically-induced mouse skin tumors, and its overexpression (but not accelerated IkappaB phosphorylation) coincides with the accelerated degradation of IkappaB in vivo. The role of mHOS in the constitutive activation of NF-kappaB in skin carcinogenesis is discussed.	AMC Canc Res Ctr, Ctr Canc Causat & Prevent, Lakewood, CO 80214 USA; Univ Penn, Dept Biol Anim, Philadelphia, PA 19104 USA	AMC Cancer Research Center; University of Pennsylvania	Spiegelman, VS (corresponding author), AMC Canc Res Ctr, Ctr Canc Causat & Prevent, 1600 Pierce St, Lakewood, CO 80214 USA.	spiegelman@amc.org		Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA 92900, CA 76262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DIGIOVANNI J, 1993, MOL CARCINOGEN, V8, P272, DOI 10.1002/mc.2940080410; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; PELLING JC, 1988, CARCINOGENESIS, V9, P665, DOI 10.1093/carcin/9.4.665; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; PELLING JC, 1986, CARCINOGENESIS, V7, P1599, DOI 10.1093/carcin/7.9.1599; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Suzuki H, 1999, FEBS LETT, V458, P343, DOI 10.1016/S0014-5793(99)01173-4; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang XY, 1997, AM J HEMATOL, V55, P205, DOI 10.1002/(SICI)1096-8652(199707)55:4<205::AID-AJH7>3.0.CO;2-W	38	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1501	1509		10.1038/sj.onc.1205311	http://dx.doi.org/10.1038/sj.onc.1205311			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896578				2022-12-17	WOS:000173956800005
J	Faivre, J; Frank-Vaillant, M; Poulhe, R; Mouly, H; Jessus, C; Brechot, C; Sobczak-Thepot, J				Faivre, J; Frank-Vaillant, M; Poulhe, R; Mouly, H; Jessus, C; Brechot, C; Sobczak-Thepot, J			Centrosome overduplication, increased ploidy and transformation in cells expressing endoplasmic reticulum-associated cyclin A2	ONCOGENE			English	Article						cell cycle; cyclins; cytoplasm; endoplasmic reticulum	HEPATITIS-B-VIRUS; TRANSMEMBRANE ORIENTATION; MALIGNANT-TRANSFORMATION; ONCOGENIC ACTIVATION; NUCLEAR-LOCALIZATION; DEPENDENT KINASES; REQUIRES E2F; G(1) CYCLIN; IN-VITRO; PROTEIN	Cyclin A2 is predominantly, but not exclusively, localized in the nucleus from G1/S transition onwards. It is degraded when cells enter mitosis after nuclear envelope breakdown. We previously showed that a fusion protein (S2A) between the hepatitis B virus (HBV) surface antigen protein and a non-degradable fragment of human cyclin A2 (Delta152) resides in the endoplasmic reticulum membranes, escapes degradation and transforms normal rat fibroblasts. The present study investigates whether cytoplasmic cyclin A2 may play a role in oncogenesis. We show that the sequestration of non-degradable cyclin A2-Delta152 by a cellular ER targeting domain (PRL-A2) leads to cell transformation when coexpressed with activated Ha-ras. REF52 cells constitutively expressing PRL-A2 are found to have a high incidence of multinucleate giant cells, polyploidy and abnormal centrosome numbers, giving rise to the nucleation of multipolar spindles. Injection of these cells into athymic nude mice causes tumors, even in the absence of a cooperating Ha-ras oncogene. These results demonstrate that, independently of any viral context, an intracellular redistribution of non-degradable cyclin A2 is capable of deregulating the normal cell cycle to the point where it promotes aneuploidy and cancer.	Inst Pasteur, INSERM, U370, Fac Med Necker, F-75015 Paris, France; Univ Paris 06, CNRS, UMR 7622, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Faivre, J (corresponding author), Inst Pasteur, INSERM, U370, Fac Med Necker, 156 Rue Vaugirard, F-75015 Paris, France.	faivre@necker.fr		Sobczak, Joelle/0000-0001-7180-2789				Aaltomaa S, 1999, PROSTATE, V38, P175; Aaltomaa S, 1999, BRIT J CANCER, V80, P2001, DOI 10.1038/sj.bjc.6690634; Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; Allan K, 2000, ARCH PATHOL LAB MED, V124, P216; BAILLY E, 1992, J CELL SCI, V101, P529; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CASTRO A, 1994, BIOCHEM BIOPH RES CO, V201, P1072, DOI 10.1006/bbrc.1994.1814; Coverley D, 2000, J CELL SCI, V113, P1929; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; Faivre J, 2001, FEBS LETT, V506, P243, DOI 10.1016/S0014-5793(01)02920-9; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Grzanka A, 2001, NEOPLASMA, V48, P112; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL FL, 1991, J BIOL CHEM, V266, P17430; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; Hildt E, 1998, RECENT RES CANCER, V154, P315; Huuhtanen RL, 1999, CANCER RES, V59, P2885; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Kaufmann H, 2001, J BIOL CHEM, V276, P29987, DOI 10.1074/jbc.M005452200; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LINGAPPA VR, 1984, P NATL ACAD SCI-BIOL, V81, P456, DOI 10.1073/pnas.81.2.456; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; LU XP, 1992, J BIOL CHEM, V267, P2841; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; MARIDOR G, 1993, J CELL SCI, V106, P535; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PRANGE R, 1995, EMBO J, V14, P247, DOI 10.1002/j.1460-2075.1995.tb06998.x; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; Sluder G, 1999, BIOL CELL, V91, P413, DOI 10.1016/S0248-4900(99)80083-5; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; THOMAS L, 1992, J BIOL CHEM, V267, P6183; Verges M, 1997, BIOCHEM BIOPH RES CO, V230, P49, DOI 10.1006/bbrc.1996.5851; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Winston N, 2000, DEV BIOL, V223, P139, DOI 10.1006/dbio.2000.9721; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; WOODMAN PG, 1993, MOL BIOL CELL, V4, P541, DOI 10.1091/mbc.4.5.541; YOST CS, 1983, CELL, V34, P759; Zhai YL, 1999, INT J CANCER, V84, P244, DOI 10.1002/(SICI)1097-0215(19990621)84:3<244::AID-IJC8>3.0.CO;2-2	54	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1493	1500		10.1038/sj.onc.1205215	http://dx.doi.org/10.1038/sj.onc.1205215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896577				2022-12-17	WOS:000173956800004
J	Vail, ME; Chaisson, ML; Thompson, J; Fausto, N				Vail, ME; Chaisson, ML; Thompson, J; Fausto, N			Bcl-2 expression delays hepatocyte cell cycle progression during liver regeneration	ONCOGENE			English	Article						liver regeneration; cell cycle; Bcl-2; transgenic mice; hepatocyte	PROLIFERATION; FAMILY; DEATH; E2F; CARCINOGENESIS; INHIBITION; APOPTOSIS; PROTEINS; P130	Bcl-2 is the prototype of a family of genes that prevent apoptosis. However, several reports indicate that Bcl-2 may also act as a cell cycle modulator. In several human tumors, Bcl-2 expression correlates with a more favorable prognosis and lower tumor proliferative activity. We have shown that Bcl-2 expression delays liver tumor development in transgenic mice even when the gene is turned on shortly before the time of tumor development. We hypothesized that Bcl-2 may delay liver tumorigenesis by interfering with hepatocyte proliferation. To test whether Bcl-2 expression may act on hepatocyte replication we studied liver regeneration in Bcl-2 transgenic mice and wild-type littermates. DNA replication was delayed by approximately 8 h in Bcl-2 transgenic mice compared to the timing of the response in wild-type littermates. Cyclin D expression showed no alterations in the regenerating liver of Bcl-2 transgenic mice. In contrast, there was a delay in the expression of p107, cyclin E and in the activity of cyclin E/cdk 2 activity. These results show that Bcl-2 expression delays cell cycle progression in hepatocytes and suggests that it acts at a step involving cyclin E and p107.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Fausto, N (corresponding author), Univ Washington, Dept Pathol, K-078 Hlth Sci Bldg,Box 357705, Seattle, WA 98195 USA.	nfausto@u.washington.edu			NCI NIH HHS [CA 09437, CA74131] Funding Source: Medline; NIGMS NIH HHS [T32 GMO7270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074131, T32CA009437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; de la Coste A, 1999, CANCER RES, V59, P5017; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; Kuwashima Y, 1997, ANTICANCER RES, V17, P3773; Lin HM, 2001, CELL DEATH DIFFER, V8, P44, DOI 10.1038/sj.cdd.4400770; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Silvestrini R, 1996, J CLIN ONCOL, V14, P1604, DOI 10.1200/JCO.1996.14.5.1604; Sinicrope FA, 1995, CLIN CANCER RES, V1, P1103; Truchet I, 2000, EXP CELL RES, V254, P241, DOI 10.1006/excr.1999.4756; Tzung SP, 1997, AM J PATHOL, V150, P1985; Vail ME, 2001, CANCER RES, V61, P594; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; WEBBER EM, 1994, AM J PATHOL, V145, P398; Winter JN, 1998, BLOOD, V91, P1391, DOI 10.1182/blood.V91.4.1391; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674	29	30	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1548	1555		10.1038/sj.onc.1205212	http://dx.doi.org/10.1038/sj.onc.1205212			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896583				2022-12-17	WOS:000173956800010
J	Boyd, M; Mairs, RJ; Mairs, SC; Wilson, L; Livingstone, A; Cunningham, SH; Brown, MM; Quigg, M; Keith, WN				Boyd, M; Mairs, RJ; Mairs, SC; Wilson, L; Livingstone, A; Cunningham, SH; Brown, MM; Quigg, M; Keith, WN			Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [I-131]MIBG and clonogenic cell kill	ONCOGENE			English	Article						gene therapy; hTR promoter; noradrenaline transporter; [I-131]MIBG; spheroids	THYMIDINE KINASE GENE; COLORECTAL-CARCINOMA; THERAPY; TUMOR; NEUROBLASTOMA; RADIOTHERAPY; CANCER; LINES	One of the most effective ways to kill cancer cells is by treatment of tumours with radiation. However, the administered dose of radiation to the tumour is limited by normal tissue toxicity. Strategies which decrease normal tissue exposure relative to tumour dose are urgently sought. One such promising scheme involves gene transfer, leading to the introduction of transporters specific for pharmaceuticals which can be labelled with radionuclides. We have previously demonstrated in vitro, that transfer of the noradrenaline transporter (NAT) gene, under viral promoter control, induces in host cells the active accumulation of the radiopharmaceutical [I-131]meta-iodobenzylguanidine ([I-131],MIBG) which results in kill of clonogens. We now report 17-fold enhancement of [I-131]MIBG uptake by UVW glioma cells transfected with the NAT gene whose expression is driven by the human telomerase RNA (hTR) promoter (70% the uptake achieved by the strong viral promoter). Multicellular spheroids composed of hTR-NAT-transfected UVW cells exhibited dose-dependent susceptibility to treatment with [I-131]MIBG. This was demonstrated by decreased survival of clonogens and complete sterilization of clonogens derived from spheroids and also failure of spheroids to regrow after administration of 7 MBq/ml [I-131]MIBG. These data suggest hTR regulated expression of NAT may be an effective gene therapy strategy.	Univ Glasgow, Dept Radiat Oncol, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Yorkhill Hosp, Dept Child Hlth, Glasgow, Lanark, Scotland; Western Infirm, Beatson Oncol Ctr, Dept Clin Phys, Glasgow, Lanark, Scotland; Gartnavel Hosp, Dept Urol, Glasgow, Lanark, Scotland; Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow; Beatson Oncology Centre; Beatson Institute; University of Glasgow	Boyd, M (corresponding author), Univ Glasgow, Dept Radiat Oncol, CRC, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Boyd, Marie/0000-0003-4120-2218				Boyd M, 2001, J GENE MED, V3, P165, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM158>3.0.CO;2-C; Boyd M, 1999, GENE THER, V6, P1147, DOI 10.1038/sj.gt.3300905; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brown JM, 1998, CANCER RES, V58, P1408; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cao G, 1999, GENE THER, V6, P83, DOI 10.1038/sj.gt.3300823; Chen J, 1998, CANCER RES, V58, P3504; Cunningham SH, 1998, BRIT J CANCER, V77, P2061, DOI 10.1038/bjc.1998.348; DEKRAKER J, 1995, EUR J CANCER, V31A, P600, DOI 10.1016/0959-8049(95)00063-O; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Gaze MN, 1996, EUR J CANCER, V32A, P93, DOI 10.1016/0959-8049(95)00511-0; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Hoefnagel CA, 2001, EUR J NUCL MED, V28, P359, DOI 10.1007/s002590000454; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Kanai F, 1996, HEPATOLOGY, V23, P1359, DOI 10.1002/hep.510230611; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lavelle F, 2000, CRIT REV ONCOL HEMAT, V34, P111, DOI 10.1016/S1040-8428(00)00057-3; Meller S, 1997, ARCH DIS CHILD, V77, P389, DOI 10.1136/adc.77.5.389; Nettelbeck DM, 1999, GENE THER, V6, P1276, DOI 10.1038/sj.gt.3300943; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458; Vandier D, 1998, CANCER RES, V58, P4577; Wheldon TE, 2000, PHYS MED BIOL, V45, pR77, DOI 10.1088/0031-9155/45/7/201; Zhao JQ, 1998, ONCOGENE, V16, P1345, DOI 10.1038/sj.onc.1201892	29	30	33	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7804	7808		10.1038/sj.onc.1204955	http://dx.doi.org/10.1038/sj.onc.1204955			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753659				2022-12-17	WOS:000172161700012
J	Zou, CP; Youssef, EM; Zou, CC; Carey, TE; Lotan, R				Zou, CP; Youssef, EM; Zou, CC; Carey, TE; Lotan, R			Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells	ONCOGENE			English	Article						chromosome 3p; retinoic acid receptor beta; retinoic acid; growth inhibition; head and neck cancer	ACID RECEPTOR-BETA; HUMAN HEAD; RESPONSIVE ELEMENT; BREAST-CANCER; GROWTH; GENE; METHYLATION; PROMOTER; OVEREXPRESSION; KERATINIZATION	Retinoids' effects on cell growth and differentiation are mediated by nuclear retinoid receptors, which are ligand-activated transcription enhancing factors. Because the expression of the retinoic acid receptor beta (RAR beta) gene, which is located on chromosome 3p24, is diminished in premalignant and malignant tissues it has been proposed that it acts as a tumor suppressor. To test the hypothesis that RAR beta loss leads to retinoid resistance, we studied several karyotyped head and neck squamous carcinoma (HNSCC) cell lines (UMSCC-17A, -17B, -22A, -22B, and -38) with deletion of one chromosome 3p arm. RAR beta mRNA was neither detected nor induced by retinoic acid in these cells, whereas it was expressed and induced by retinoic acid in two other HNSCC cell lines (1483 and 183) without 3p deletion. Methylation of the RAR beta gene promoter was detected in the 17B and 22B cells that failed to express RAR beta but no methylation was found in 183A cells that did express RAR beta mRNA. Responsiveness of HNSCC cells to several retinoids in assays of growth inhibition and colony formation, was rank ordered as: 22B > 1483 > 38 > 183 > 17B. Additionally, retinoid response elements were transactivated in 22B more efficiently than in 17B cells. These results indicate that loss of RAR beta expression does not necessarily lead to loss of growth inhibition by retinoids or to a block of retinoid signaling.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Obstet Gynecol & Reprod Sci, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Michigan, Ctr Canc, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org		Carey, Thomas/0000-0002-5202-7518	NCI NIH HHS [P01 CA52051, R25 CA57730] Funding Source: Medline; NIDCR NIH HHS [P50 DE11906] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA057730, P01CA052051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Buchhagen DL, 1996, HEAD NECK-J SCI SPEC, V18, P529; Burge-Bottenbley A, 1983, Nutr Cancer, V5, P121, DOI 10.1080/01635588309513788; CAREY TE, 1989, CANCER RES, V49, P6098; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FERRARI N, 1994, EXP CELL RES, V211, P121, DOI 10.1006/excr.1994.1067; GEBERT JF, 1991, ONCOGENE, V6, P1859; GRENMAN R, 1991, CANCER, V67, P2741, DOI 10.1002/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S; Hayashi K, 2000, CANCER LETT, V151, P199, DOI 10.1016/S0304-3835(99)00422-X; Hayashi K, 2001, JPN J CANCER RES, V92, P42, DOI 10.1111/j.1349-7006.2001.tb01046.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KRAUSE CJ, 1981, ARCH OTOLARYNGOL, V107, P703; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LATIF F, 1992, CANCER RES, V52, P1451; Le Q, 2000, ONCOGENE, V19, P1457, DOI 10.1038/sj.onc.1203436; LOTAN R, 1994, CANCER RES, V54, pS1987; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LOTAN R, 1991, METHODS ENZYMOLOGY R, P100; MAESTRO R, 1993, CANCER RES, V53, P5775; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; McGregor F, 1997, CANCER RES, V57, P3886; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; Oridate N, 1996, ONCOGENE, V12, P2019; Oridate N, 1996, IN VITRO CELL DEV-AN, V32, P192; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; SACKS PG, 1988, CANCER RES, V48, P2858; SCHWARTZ J L, 1985, Nutrition and Cancer, V7, P77; SHALINSKY DR, 1995, CANCER RES, V55, P3183; Shalinsky DR, 1997, CANCER RES, V57, P162; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sun SY, 2000, CLIN CANCER RES, V6, P1563; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDYKE DL, 1994, GENE CHROMOSOME CANC, V9, P192, DOI 10.1002/gcc.2870090308; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wan HS, 1999, CANCER RES, V59, P3518; Wan HS, 1998, J BIOL CHEM, V273, P26915, DOI 10.1074/jbc.273.41.26915; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; XU XC, 1994, CANCER RES, V54, P3580; Youssef Emile M., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P550; ZOU CP, 1994, CANCER RES, V54, P5479; Zou CP, 1999, DIFFERENTIATION, V64, P123, DOI 10.1046/j.1432-0436.1999.6420123.x	55	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6820	6827		10.1038/sj.onc.1204846	http://dx.doi.org/10.1038/sj.onc.1204846			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687961				2022-12-17	WOS:000171641000003
J	Heit, I; Wieser, RJ; Herget, T; Faust, D; Borchert-Stuhltrager, M; Oesch, F; Dietrich, C				Heit, I; Wieser, RJ; Herget, T; Faust, D; Borchert-Stuhltrager, M; Oesch, F; Dietrich, C			Involvement of protein kinase C delta in contact-dependent inhibition of growth in human and murine fibroblasts	ONCOGENE			English	Article						contact-inhibition; PKC delta; fibroblast	HUMAN-DIPLOID FIBROBLASTS; PHORBOL ESTER; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; RAT FIBROBLASTS; PKC-DELTA; EXPRESSION; CELLS; SRC; ROTTLERIN	There is evidence that protein kinase C delta (PKC delta) is a tumor suppressor, although its physiological role has not been elucidated so far. Since important anti-proliferative signals are mediated by cell-cell contacts we studied whether PKC delta is involved in contact-dependent inhibition of growth in human (FH109) and murine (NIH3T3) fibroblasts. Cell-cell contacts were imitated by the addition of glutardialdehyde-fixed cells to sparsely seeded fibroblasts. Downregulation of the PKC isoforms alpha, delta, epsilon, and mu after prolonged treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA, 0.1 mum) resulted in a significant release from contact-inhibition in FH109 cells. Bryostatin I selectively prevented TPA-induced PKC delta -downregulation and reversed TPA-induced release from contact-inhibition arguing for a role of PKC delta in contact-inhibition. In accordance, the PKC delta specific inhibitor Rottlerin (1 mum) totally abolished contact-inhibition. Interestingly, immunofluorescence revealed a rapid translocation of PKC delta to the nucleus when cultures reached confluence with a peak in early-mid G1 phase. Nuclear translocation of PKC delta in response to cell-cell contacts could also be demonstrated after subcellular fractionation by Western blotting and by measuring PKC delta -activity after immunoprecipitation. Transient transfection of NIH3T3 cells with a dominant negative mutant of PKC delta induced a transformed phenotype. We conclude that PKC delta is involved in contact-dependent inhibition of growth.	Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Dietrich, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	cdietric@mail.uni-mainz.de	Oesch, Franz/AAA-8746-2020					Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1992, J BIOL CHEM, V267, P12892; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Dietrich C, 2001, BIOCHEM BIOPH RES CO, V282, P575, DOI 10.1006/bbrc.2001.4530; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Guay J, 1997, J CELL SCI, V110, P357; Hamada K, 1996, BBA-MOL CELL RES, V1310, P149, DOI 10.1016/0167-4889(95)00148-4; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTA CAM, 1995, CARCINOGENESIS, V16, P1233; LaPorta CAM, 1997, CARCINOGENESIS, V18, P715, DOI 10.1093/carcin/18.4.715; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LI WQ, 1994, J BIOL CHEM, V269, P2349; Lorenzo PS, 1997, J BIOL CHEM, V272, P33338, DOI 10.1074/jbc.272.52.33338; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; MORETON K, 1995, FEBS LETT, V372, P33, DOI 10.1016/0014-5793(95)00941-2; OESCH F, 1988, CARCINOGENESIS, V9, P1319, DOI 10.1093/carcin/9.7.1319; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; Parmer TG, 1997, CELL GROWTH DIFFER, V8, P327; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; WIESER RJ, 1990, J CELL BIOL, V111, P2681, DOI 10.1083/jcb.111.6.2681; WIESER RJ, 1986, J CELL BIOL, V103, P361, DOI 10.1083/jcb.103.2.361; WIESER RJ, 1985, EXP CELL RES, V158, P493, DOI 10.1016/0014-4827(85)90472-0; WIESER RJ, 1990, ENVIRON HEALTH PERSP, V88, P251, DOI 10.2307/3431085; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	54	30	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2001	20	37					5143	5154		10.1038/sj.onc.1204657	http://dx.doi.org/10.1038/sj.onc.1204657			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526503				2022-12-17	WOS:000170464000008
J	Yang, HW; Chen, YZ; Takita, JK; Soeda, EC; Piao, HY; Hayashi, YS				Yang, HW; Chen, YZ; Takita, JK; Soeda, EC; Piao, HY; Hayashi, YS			Genomic structure and mutational analysis of the human KIF1B gene which is homozygously deleted in neuroblastoma at chromosome 1p36.2	ONCOGENE			English	Article						neuroblastoma; homozygous deletion; KIF1B gene; 1p36; kinesin superfamily	MOTOR PROTEIN; MOLECULAR-BIOLOGY; MONOMERIC MOTOR; KINESIN; TRANSPORT; REGION; HETEROZYGOSITY; IDENTIFICATION; CELLS; PROGRESSION	In order to clone candidate tumor suppressor genes whose loss contributes to the pathogenesis of neuroblastoma (NB), we performed polymerase chain reaction (PCR) screening using a high-density sequence tagged site-content map within a commonly deleted region (chromosome band 1p36) in 24 NB cell lines. We found a similar to 480 kb homozygously deleted region at chromosome band 1p36.2 in one of the 24 NB cell lines, NB-1, and cloned the human homologue (KIF1B-beta) of the mouse-Kif1B-beta gene in this region. The KIF1B-beta gene had at least 47 exons, all of which had a classic exon-intron boundary structure. Mouse Kif1B is a microtubule-based putative anterograde motor protein for the transport of mitochondria in neural cells. We performed mutational analysis of the KIF1B-beta gene in 23 cell lines using 46 sets of primers and also an allelic imbalance (Al) analysis of KIF1B-beta in 50 fresh NB samples. A missense mutation at codon 1554, GTG (Gly) to ATG (Met), silent mutations at codon 409 (ACG to ACA) and codon 1721 (ACC to ACT), and polymorphisms at codon 170, GAT (Asp) to GAA (Glu), and at codon 1087, TAT (Tyr), to TGT (Cys), were all identified, although their functional significances remain to be determined. The Al for KIF1B-beta was slightly higher (38%) than those for the other two markers (D1S244, D1S1350) (35 and 32%) within the commonly deleted region (1p36). Reverse transcriptase-PCR analysis of the KIF-IB-fl gene revealed obvious expression in all NB cell lines except NB-1, although decreased expression of the KIF1B-beta gene was found in a subset of early- and advanced-stage NBs. These results suggest that the KIF1B-beta gene may not be a candidate for tumor suppressor gene of NB.	Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan	University of Tokyo; RIKEN	Hayashi, YS (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Chen YZ, 2001, GENOMICS, V74, P55, DOI 10.1006/geno.2001.6511; CHEN YZ, 2001, IN PRESS GENES CHROM, V31; Conforti L, 1999, MAMM GENOME, V10, P617, DOI 10.1007/s003359901056; DEED RW, 1994, GENE, V151, P309, DOI 10.1016/0378-1119(94)90676-9; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; Furlong RA, 1996, GENOMICS, V33, P421, DOI 10.1006/geno.1996.0217; Gong TWL, 1999, GENE, V239, P117, DOI 10.1016/S0378-1119(99)00370-4; Greene MH, 1999, CANCER-AM CANCER SOC, V86, P2464, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2464::AID-CNCR3>3.0.CO;2-F; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; Hirokawa N, 1996, CELL STRUCT FUNCT, V21, P357, DOI 10.1247/csf.21.357; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; IMASHUKU S, 1973, J CLIN ENDOCR METAB, V36, P931, DOI 10.1210/jcem-36-5-931; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KOMURO H, 1993, CANCER RES, V53, P5284; Kong XT, 1997, CANCER RES, V57, P3772; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; Leek JP, 1997, CYTOGENET CELL GENET, V79, P212, DOI 10.1159/000134725; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakagawa T, 1998, MOL BIOL CELL, V9, p393A; NAKAGAWA T, 1999, GENBANK ACCESSION; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Saito M, 1997, NEUROLOGY, V49, P1630, DOI 10.1212/WNL.49.6.1630; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAPIRO DN, 1993, GENOMICS, V17, P767, DOI 10.1006/geno.1993.1404; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Takita J, 2000, EUR J CANCER, V36, P508, DOI 10.1016/S0959-8049(99)00342-1; Yang HW, 2000, INT J MOL MED, V5, P379; Yang HW, 2001, NEOPLASIA, V3, P165, DOI 10.1038/sj.neo.7900141; Yonekawa Y, 1998, J CELL BIOL, V141, P431, DOI 10.1083/jcb.141.2.431	47	30	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					5075	5083		10.1038/sj.onc.1204456	http://dx.doi.org/10.1038/sj.onc.1204456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526494				2022-12-17	WOS:000170439800019
J	Morrione, A; Navarro, M; Romano, G; Dews, M; Reiss, K; Valentinis, B; Belletti, B; Baserga, R				Morrione, A; Navarro, M; Romano, G; Dews, M; Reiss, K; Valentinis, B; Belletti, B; Baserga, R			The role of the insulin receptor substrate-1 in the differentiation of rat hippocampal neuronal cells	ONCOGENE			English	Article						IGF-IR, insulin-like growth factor-1 receptor; IGF-I, insulin-like growth factor-I; IGF-II, insulin-like growth factor-II; IRS-1, insulin receptor substrate-1; PI3K, phosphatidylinositol-3 kinase	GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; RIBOSOMAL S6 KINASE; PHOSPHOTYROSINE-DEPENDENT INTERACTION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; TYROSINE PHOSPHORYLATION; PLECKSTRIN HOMOLOGY; NPEY MOTIF; APOPTOSIS	H19-7/IGF-IR cells are rat hippocampal cells expressing a human IGF-I receptor, which differentiate to a neuronal phenotype when stimulated by IGF-I at 39 degreesC. H19-7/IGF-IR cells have low levels of expression of insulin receptor substrate-1 (IRS-1), a major substrate of the IGF-IR. IGF-I induces serine-phosphorylation and down-regulation of the endogenous IRS-1 upon differentiation of H19-7/IGF-IR cells. The profound influence of IRS-1 on differentiation of H19-7/IGF-IR cells was confirmed by transfecting these cells with a plasmid expressing mouse IRS-1. Over-expression of wild type IRS-1 in H19-7/IGF-IR cells abolishes IGF-I-induced differentiation at 39 degrees C. A mutant of IRS-1 lacking the PTB domain loses the ability to inhibit the differentiation program. H19-7/IGF-IR/IRS-1 cells at 39 degrees C show a stronger and prolonged activation of Akt, when compared to H19-7/IGF-IR cells. The role of Akt in the inhibition of the differentiation program was confirmed by using the inhibitor of Class I PI3 kinases LY29400, which restores IGF-I-induced differentiation of H19-7/IGF-IR/IRS-1 cells. H19-7/IGF-IR/IRS-1 cells show a strong reduction in MAP kinases signaling, which is related to the superactivation of Akt. This was confirmed by expressing in H19-7/IGF-IR cells a constitutively active Akt, which inhibited MAP kinases activation in these cells. These experiments confirm the importance of MAPK in the mechanism of IGF-I-mediated differentiation of H19-7/IGF-IR cells.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	r_baserga@lac.jci.tju.edu	Belletti, Barbara/J-2028-2018	Belletti, Barbara/0000-0003-2249-0285	NCI NIH HHS [CA 78890] Funding Source: Medline; NIA NIH HHS [AG 16291] Funding Source: Medline; NIDDK NIH HHS [KO1 DK 02896-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Anlar B, 1999, HORM METAB RES, V31, P120, DOI 10.1055/s-2007-978708; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Baserga R, 1999, J CELL BIOCHEM, P68; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Craparo A, 1997, J BIOL CHEM, V272, P11663; DAmbrosio C, 1997, CANCER RES, V57, P3264; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EVES EM, 1994, BRAIN RES, V656, P396, DOI 10.1016/0006-8993(94)91484-2; Eves EM, 1996, J NEUROCHEM, V67, P1908; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Guan KL, 2000, J BIOL CHEM, V275, P27354; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; LEROITH D, 1993, NEUROTROPHIC FACTORS, P391; Leventhal PS, 1999, CONT ENDOCRINOL, V17, P425; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 2000, CANCER RES, V60, P2263; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RECIOPINTO E, 1984, P NATL ACAD SCI-BIOL, V81, P2562, DOI 10.1073/pnas.81.8.2562; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	63	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4842	4852		10.1038/sj.onc.1204649	http://dx.doi.org/10.1038/sj.onc.1204649			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521195				2022-12-17	WOS:000170271800008
J	Chiu, IM; Touhalisky, K; Liu, Y; Yates, A; Frostholm, A				Chiu, IM; Touhalisky, K; Liu, Y; Yates, A; Frostholm, A			Tumorigenesis in transgenic mice in which the SV40 T antigen is driven by the brain-specific FGF1 promoter	ONCOGENE			English	Article						FGF1; brain tumor; gene expression; promoter regulation; neural stem cells	FIBROBLAST-GROWTH-FACTOR; PRIMITIVE NEUROECTODERMAL TUMORS; STEM-CELL; DIFFERENTIAL EXPRESSION; HEPARAN-SULFATE; MESSENGER-RNA; FIBROBLAST-GROWTH-FACTOR-1; ADULT; PROTEIN; IDENTIFICATION	Gene expression can be manipulated by the introduction of a hybrid gene formed by linking a highly tissue-specific regulatory element to a gene whose expression might be expected to alter cellular function. Previously, we have shown that the human FGF1 gene contains four distinct tissue-specific promoters. In an effort to perturb the programming of proliferation and differentiation in a subset of neural cells, we have produced transgenic mice bearing the brain-specific promoter of the human FGF1 gene joined to the SV40 immediate early gene, which encodes the large T antigen. The resulting mice, and offspring from four individual lines, developed brain tumors that originated in the pontine gray, just rostral to the fourth ventricle, Tumors were moderately vascularized, as demonstrated by staining with both hematoxylin and eosin and antibodies to three different endothelial cell markers, but vessels were histologically normal. Scattered tumor foci were present as early as postnatal day 26; and affected animals died between 5-8 months of age. In mature animals, tumors lacked terminal differentiation markers for astrocytes (glial fibrillary acidic protein) or neurons (synaptophysin and neuron-specific enolase). However, they expressed high levels of proliferating cell nuclear antigen and vimentin, markers for proliferating cells. This immunophenotype iis consistent with the tumor being at an early stage of differentiation. Therefore, these mice may provide a valuable tool for the study of tumorigenesis, replenishment and differentiation of neural stem cells.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.		Chiu, Ing-Ming/B-1534-2008					Alam KY, 1996, J BIOL CHEM, V271, P30263, DOI 10.1074/jbc.271.47.30263; Anderson DJ, 1999, CURR OPIN NEUROBIOL, V9, P517, DOI 10.1016/S0959-4388(99)00015-X; Barres BA, 1999, CELL, V97, P667, DOI 10.1016/S0092-8674(00)80777-1; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; CHIU IM, 1990, ONCOGENE, V5, P755; Cho JY, 2000, GENE THER, V7, P740, DOI 10.1038/sj.gt.3301170; Chotani MA, 1997, CELL GROWTH DIFFER, V8, P999; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; ECKENSTEIN FP, 1994, BIOCHEM PHARMACOL, V47, P103, DOI 10.1016/0006-2952(94)90442-1; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; FUNG KM, 1994, LAB INVEST, V70, P114; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Liu Y, 1998, J BIOL CHEM, V273, P19269, DOI 10.1074/jbc.273.30.19269; Madiai F, 1999, J BIOL CHEM, V274, P11937, DOI 10.1074/jbc.274.17.11937; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Mehta VB, 1998, J BIOL CHEM, V273, P4197, DOI 10.1074/jbc.273.7.4197; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; ORAITZ DM, 1996, J BIOL CHEM, V271, P15292; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; REIFENBERGER G, 1987, ACTA NEUROPATHOL, V74, P105, DOI 10.1007/BF00692841; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TABERPIERCE E, 1966, J COMP NEUROL, V126, P219; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; TOOZE J, 1981, MOL BIOL TUMOR VIR 2; YACHNIS AT, 1994, J NEUROPATH EXP NEUR, V53, P61, DOI 10.1097/00005072-199401000-00008	44	30	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6229	6239		10.1038/sj.onc.1204021	http://dx.doi.org/10.1038/sj.onc.1204021			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175337				2022-12-17	WOS:000166210500006
J	Periyasamy, S; Ammanamanchi, S; Tillekeratne, MPM; Brattain, M				Periyasamy, S; Ammanamanchi, S; Tillekeratne, MPM; Brattain, M			Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency	ONCOGENE			English	Article						azacytidine; transforming growth factor-beta; transforming growth factor-beta receptor type I (RI)	COLON-CARCINOMA CELLS; TGF-BETA; O-GLYCOSYLATION; CANCER CELLS; MICROSATELLITE INSTABILITY; TRANSCRIPTION FACTOR; PROTEIN-KINASE; ACTIVATION; MECHANISM; GENE	In this report, we describe the mechanism of TGF-beta receptor type I (RI) repression in the CEO human colon carcinoma cells. Treatment of GEO cells with the DNA methyltransferase inhibitor, 5 azacytidine induced RI expression and restored TGF-beta response. A stably transfected RI promoter-reporter construct (RI-Luc) expressed higher activity in the 5 aza C treated GEO cells, suggesting the activation of a transactivator for RI transcription. Gel shift analysis indicated enhanced binding of proteins from the 5 aza C treated nuclear extracts to radiolabeled Sp1 oligonucleotides specifically contained in the RT promoter, Protein stability studies after cyclohexamide treatment suggested an increase in the Spl protein stability from the 5 aza C treated GEO cells. Further, transfection of Sp1 cDNA into untreated GEO control cells increased RI promoter activity and thus induced RI expression. 5 aza C mediated Spl expression in Sp1 deficient CEO colon and MCF-7 breast cancer cells also enhanced the activity of several other Sp1 dependent promoters such as TGF-beta receptor type II (RII), Cyclin A and p21/waf1/cip1. These results indicate that restoration of Sp1 in several different types of Sp1 deficient cells leads to enhanced activation of a wide range of Sp1 dependent promoters.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA	University of Texas System; University of Texas Health San Antonio	Brattain, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL CANCER INSTITUTE [R37CA038173, R01CA072001, R01CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38173, CA 72001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones PA, 1996, CANCER RES, V56, P2463; Kim DH, 1997, J BIOL CHEM, V272, P688; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Periyasamy S, 1996, J CELL PHYSIOL, V168, P711, DOI 10.1002/(SICI)1097-4652(199609)168:3<711::AID-JCP24>3.0.CO;2-#; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; SHEN WJ, 1995, J BIOL CHEM, V270, P20525, DOI 10.1074/jbc.270.35.20525; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Yoshizumi M, 1997, J BIOL CHEM, V272, P22259, DOI 10.1074/jbc.272.35.22259	31	30	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4660	4667		10.1038/sj.onc.1203822	http://dx.doi.org/10.1038/sj.onc.1203822			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030155				2022-12-17	WOS:000089438200012
J	Banelli, B; Casciano, I; Romani, M				Banelli, B; Casciano, I; Romani, M			Methylation-independent silencing of the p73 gene in neuroblastoma	ONCOGENE			English	Article						p73; methylation; neuroblastoma; chromosome 1	DNA METHYLATION; CELL-LINES; EXPRESSION; CANCER; IDENTIFICATION; AMPLIFICATION; SEQUENCES; MUTATION; ALLELE; ASSAY	p73 is a p53 homolog that, in vitro, inhibits cell growth and induce apoptosis, In some tumors p73 is mono-allelically expressed and this raised the possibility that this gene is subjected to imprinting, Silencing of p73 in acute leukemia and in Burkitt's lymphoma occurs in association with the aberrant methylation of the first exon of the gene, We have analysed the methylation pattern of the p73 promoter and of upstream and downstream sequences in neuroblastoma, Our results demonstrate that p73 expression in this tumor is not regulated by methylation. We concluded that it is unlikely that p73 is imprinted in neuroblastoma and that the methylation-dependent silencing of this gene, thus far, is a characteristic of hematologic malignancies.	IST Genova, Lab Populat Genet, Ist Nazl Ric Canc, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST	Romani, M (corresponding author), IST Genova, Lab Populat Genet, Ist Nazl Ric Canc, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		Banelli, Barbara/Y-1151-2019	Banelli, Barbara/0000-0003-1505-7141; casciano, ida/0000-0003-1776-670X				Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Baylin SB, 1998, ADV CANCER RES, V72, P141; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Chi SG, 1999, CANCER RES, V59, P2791; Corn PG, 1999, CANCER RES, V59, P3352; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kawano S, 1999, BLOOD, V94, P1113; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lo Cunsolo C, 1998, CYTOGENET CELL GENET, V82, P199, DOI 10.1159/000015099; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Nomoto S, 1998, CANCER RES, V58, P1380; Peters UR, 1999, CANCER RES, V59, P4233; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; REESE MG, 1996, BIOC P 1996 PAC S; Romani M, 1999, ANAL BIOCHEM, V271, P204, DOI 10.1006/abio.1999.4152; Romani M, 1999, INT J CANCER, V84, P365, DOI 10.1002/(SICI)1097-0215(19990820)84:4<365::AID-IJC6>3.0.CO;2-X; Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058; Scaruffi P, 2000, LEUKEMIA, V14, P518, DOI 10.1038/sj.leu.2401698; Toyota M, 1999, CANCER RES, V59, P2307; Zaika AI, 1999, CANCER RES, V59, P3257	27	30	30	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4553	4556		10.1038/sj.onc.1203807	http://dx.doi.org/10.1038/sj.onc.1203807			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002429				2022-12-17	WOS:000089236800013
J	Blanchard, DA; Mouhamad, S; Auffredou, MT; Pesty, A; Bertoglio, J; Leca, G; Vazquez, A				Blanchard, DA; Mouhamad, S; Auffredou, MT; Pesty, A; Bertoglio, J; Leca, G; Vazquez, A			Cdk2 associates with MAP kinase in vivo and its nuclear translocation is dependent on MAP Kinase activation in IL-2-dependent Kit 225 T lymphocytes	ONCOGENE			English	Article						cell cycle; lymphocyte; IL-2; cdk2; MAP kinase; nuclear localization	CELL-CYCLE CONTROL; PROTEIN-KINASE; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; G(1)/S TRANSITION; GROWTH-FACTORS; GENE-PRODUCT; IN-VIVO; S-PHASE; PHOSPHORYLATION	Cell proliferation is controlled by cdk2 which in association with cyclin E and a regulates G1/S transition and S phase progression. cdk2 activation is dependent on its localization in the nucleus where regulatory mediators are found, We report that activation of cdk2 is associated with the formation of cdk2/MAP kinase complexes, cdk2 associates with both inactive and activated MAP Kinase. Prevention of MAP Kinase activation ba the MEK inhibitor PD98059 inhibits both activation and nuclear localization of cdk2 and S phase entry. These findings indicate that the nuclear translocation of cdk2 is associated with the formation of molecular complexes containing active MAP Kinase and is dependent on MAP Kinase activation.	IPSC, INSERM U131, F-92140 Clamart, France; Claude Bernard Res Ctr, F-92140 Clamart, France; IPSC, INSERM U355, F-92140 Clamart, France; Fac Pharm Chatenay Malabry, INSERM U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Vazquez, A (corresponding author), IPSC, INSERM U131, 32 Rue des Carnets, F-92140 Clamart, France.							ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; Fisher RP, 1997, CURR OPIN GENET DEV, V7, P32, DOI 10.1016/S0959-437X(97)80106-2; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1993, CELL, V75, P805; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; HORI T, 1987, BLOOD, V70, P1069; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Prosperi E, 1997, EUR J HISTOCHEM, V41, P161; Reed SI, 1997, CANCER SURV, V29, P7; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; Ruckdeschel K, 1997, J BIOL CHEM, V272, P15920, DOI 10.1074/jbc.272.25.15920; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAIEB J, 1995, J IMMUNOL, V155, P5623; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	54	30	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2000	19	36					4184	4189		10.1038/sj.onc.1203761	http://dx.doi.org/10.1038/sj.onc.1203761			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962581				2022-12-17	WOS:000088955100014
J	Koga, H; Deppert, W				Koga, H; Deppert, W			Identification of genomic DNA sequences bound by mutant p53 protein (Gly(245)-> Ser) in vivo	ONCOGENE			English	Article						mutant p53; CHIP; PCR-EMSA; microinjection; repetitive DNA elements	CROSS-LINKING; BINDING; TRANSCRIPTION; ELEMENTS; GENE; MUTATIONS; REGIONS; COMPLEX; MURINE	Mutant p53 proteins were shown to exert complex DNA-interactions interactions in vitro, like binding to MAR-DNA, but so far it is unknown whether such interactions also occur in vivo. Therefore we analysed the binding of mutant (mut) p53 (Gly(245)-->Ser) in Onda 11 glioma cells to cellular DNA in vivo, using p53-specific chromatin immunoprecipitation (CHIP) after in vivo cross-linking of mut p53 to genomic DNA with cisplatin, We identified genomic DNA fragments to which mut p53 (Gly(245)-->Ser) could be cross-linked in vivo. Purified recombinant mut p53 (Gly(245)-->Ser) was able to bind specifically to such elements in PCR-EMSA in vitro, supporting the idea that this mut p53 protein interacts with genomic DNA in vivo. The genomic DNA fragments identified are vastly different in sequence, but display as a common feature a high likelihood to adopt a non B-DNA conformation. Therefore we propose that structural determinants within these DNA elements are important for their interaction with mut p53 (Gly(245)-->Ser) in vivo.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Bode J, 1996, CRIT REV EUKAR GENE, V6, P115, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.20; Bode J, 1995, INT REV CYTOL, V162A, P389; Boulikas T, 1995, INT REV CYTOL, V162A, P279; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Deppert W, 1996, J CELL BIOCHEM, V62, P172, DOI 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FLOROS J, 1995, BIOCHEM J, V305, P583, DOI 10.1042/bj3050583; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hart CM, 1998, CURR OPIN GENET DEV, V8, P519, DOI 10.1016/S0959-437X(98)80005-1; HERNANDEZBOUSSA.T, 1999, IARC SCI PUBL, V146, P43; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Koga H, 1996, Noshuyo Byori, V13, P1; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Muller BF, 1996, ONCOGENE, V12, P1941; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Samuel SK, 1998, CANCER RES, V58, P3004; Shimajiri S, 1999, FEBS LETT, V455, P70, DOI 10.1016/S0014-5793(99)00863-7; TRIPATHI J, 1991, J BIOMOL STRUCT DYN, V9, P387, DOI 10.1080/07391102.1991.10507919; WEISSKER SN, 1992, ONCOGENE, V7, P1921; Will K, 1998, J CELL BIOCHEM, V69, P260, DOI 10.1002/(SICI)1097-4644(19980601)69:3<260::AID-JCB4>3.0.CO;2-P; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; Zhang SJ, 1996, JPN J CANCER RES, V87, P900, DOI 10.1111/j.1349-7006.1996.tb02118.x	31	30	30	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4178	4183		10.1038/sj.onc.1203745	http://dx.doi.org/10.1038/sj.onc.1203745			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962580	Bronze			2022-12-17	WOS:000088955100013
J	Argentini, M; Barboule, N; Wasylyk, B				Argentini, M; Barboule, N; Wasylyk, B			The contribution of the RING finger domain of MDM2 to cell cycle progression	ONCOGENE			English	Article						cell cycle regulation; RING finger domain; p53 degradation; ubiquitination	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; ONCOPROTEIN MDM2; TRANSCRIPTIONAL ACTIVATION; P53-ASSOCIATED PROTEIN; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NUCLEAR EXPORT; IN-VIVO	The MDM2 oncoprotein binds to p53 and abrogates p53-mediated G1 arrest and apoptosis, We show that MDM2 over-expression accelerates cell cycle progression of RPMI2650 cells by overcoming the negative effect of endogenous wild type p53 at the G1/S checkpoint. The interaction with p53 and transcription inhibition are necessary but not sufficient, The RING finger domain of MDM2 is also required for the positive effect of MDM2 on the cell cycle, Surprisingly, several point mutants in the zinc binding sites of the RING finger are fully competent for cell cycle stimulation even though they abolish MDM2-directed degradation of p53 and MDM2 E3-ligase activity. In contrast, alterations in and around the cryptic nucleolar localization sequence (KR motif) inhibit MDM2-mediated cell cycle progression as well as p53 degradation and MDM2 E3 ligase activity, We found that all the RING mutants decrease inhibition of both p53 dependent reporters and endogenous p21(CIP1/WAF1/SDI1). These results indicate that the RING finger of MDM2 has a role in the regulation of the cell cycle that is independent of p53 degradation and endogenous p21(CIP1/WAF1/SDI1) regulation.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hu G, 1999, MOL CELL BIOL, V19, P724; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; JUVEN T, 1993, ONCOGENE, V8, P3411; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Lai ZH, 1998, BIOCHEMISTRY-US, V37, P17005, DOI 10.1021/bi980596r; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	30	30	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3849	3857		10.1038/sj.onc.1203737	http://dx.doi.org/10.1038/sj.onc.1203737			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951578				2022-12-17	WOS:000088614300003
J	Alunni-Fabbroni, M; Littlewood, T; Deleu, L; Caldeira, S; Giarre, M; Dell'Orco, M; Tommasino, M				Alunni-Fabbroni, M; Littlewood, T; Deleu, L; Caldeira, S; Giarre, M; Dell'Orco, M; Tommasino, M			Induction of S phase and apoptosis by the human papillomavirus type 16 E7 protein are separable events in immortalized rodent fibroblasts	ONCOGENE			English	Article						human papillomaviruses; E7 protein; apoptosis; S phase; pRb destabilization	CELL-CYCLE REGULATION; ABL TYROSINE KINASE; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; ONCOPROTEIN MDM2; LENS DEVELOPMENT; ADENOVIRUS E1A; STABILIZES P53; GROWTH ARREST	The HPV16 E7 oncoprotein neutralizes several cell cycle checkpoints, favouring the entry of quiescent cells into S phase, This activity is mediated in part by association of E7 with the pocket proteins and consequent activation of E2F transcription factors. In addition, HPV16 E7 protein is able to promote apoptosis, In this study we demonstrate that the ability to induce apoptosis is a common property of E7s belonging to both benign and malignant HPV types. The E7-induced apoptosis is mediated by inactivation of pRb, whilst neutralization of the other two pRB-related proteins, p107 and 130, is not sufficient to trigger apoptosis, Moreover, we show that certain point mutations in the conserved region 1 (CRI) of HPV16 E7 abolish the induction of apoptosis without altering the ability to stimulate S phase. Thus, these two E7-mediated cellular events, apoptosis and S phase entry, can be separated in immortalized rodent fibroblasts. Our findings demonstrate that the E7-mediated pRb destabilization is not required for its ability to drive quiescent cells into S phase and to induce apoptosis, Finally, expression of E7 proteins in NIH3T3, which lack a functional p19(ARF), does not lead to p53 accumulation, indicating that the E7 impacts upon additional cellular pathways to promote apoptosis.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Imperial Canc Res Fund, London WC2A 3PX, England	Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, INF 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019	Caldeira, Sandra/0000-0002-6057-5979				ARMSTRONG DJ, 1993, BIOCHEM BIOPH RES CO, V192, P1380, DOI 10.1006/bbrc.1993.1569; BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Boyer SN, 1996, CANCER RES, V56, P4620; CICCOLINI F, 1994, ONCOGENE, V9, P2342; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HU TH, 1995, INT J ONCOL, V6, P167; Iglesias M, 1998, ONCOGENE, V17, P1195, DOI 10.1038/sj.onc.1202054; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; McCaffrey J, 1999, MOL CELL BIOL, V19, P6458; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; TOMMASINO M, 1993, ONCOGENE, V8, P195; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	58	30	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2277	2285		10.1038/sj.onc.1203570	http://dx.doi.org/10.1038/sj.onc.1203570			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822378				2022-12-17	WOS:000086974300002
J	Garcia, P; Frampton, J; Ballester, A; Cales, C				Garcia, P; Frampton, J; Ballester, A; Cales, C			Ectopic expression of cyclin E allows non-endomitotic megakaryoblastic K562 cells to establish re-replication cycles	ONCOGENE			English	Article						cyclins; cell cycle; re-replication; megakaryocytic differentiation; transcriptional regulation	DEPENDENT KINASE INHIBITOR; POLYPLOID DNA CONTENT; S-PHASE; DROSOPHILA EMBRYOGENESIS; DOWN-REGULATION; ENDOREDUPLICATION CYCLES; DEVELOPMENTAL CONTROL; MEGAKARYOCYTE PLOIDY; A GENE; TRANSITION	Megakaryocytes become polyploid by entering a truncated cell cycle, consisting of alternate S phases and abortive mitoses, We have investigated the regulation of the G1/S transition by comparing two megakaryoblastic cell lines, HEL and K562, which respectively do or do not become polyploid in response to phorbol esters, A pronounced downregulation of cyclin A, and to a lesser extent of cyclin E, occurred in K562 cells during the first 24 h after TPA treatment, in contrast with re-replicating HEL cells, in which both cyclins were present in individual G2/M cells, Transactivation experiments suggested that the absence of cyclin A in differentiated K562 cells could be due to a TPA-mediated inhibition of its transcription. To investigate the potential role of cyclin E in the establishment of re-replication cycles, we isolated K562 clones constitutively expressing cyclin E, The resulting clones, and also K562 cells transiently expressing cyclin E, entered re-replication cycles when treated with TPA, The transcriptional activity of the cyclin A promoter was not inhibited after TPA treatment, and although the Levels of cyclin A fluctuated during further re-replication cycles, they never decreased below S phase levels. We conclude that the presence of cyclin E in megakaryoblastic G2/M cells determines cyclin A expression and allows the entrance into an extra S phase.	Univ Autonoma Madrid, CSIC, Dept Bioquim, Inst Invest Biomed A Sols, E-28029 Madrid, Spain; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Oxford	Cales, C (corresponding author), Univ Autonoma Madrid, CSIC, Dept Bioquim, Inst Invest Biomed A Sols, Arturo Duperier 4, E-28029 Madrid, Spain.		Calés, Carmela/AAB-1595-2019	Cales, Carmela/0000-0002-6987-2259; Ballester Jareno, Alicia/0000-0002-6474-7248; Garcia, Paloma/0000-0001-5582-8575				CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Datta NS, 1998, CELL GROWTH DIFFER, V9, P639; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; DENARIER E, 1993, BIOCHEM BIOPH RES CO, V195, P1360, DOI 10.1006/bbrc.1993.2193; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dong XZ, 1997, GENE DEV, V11, P94, DOI 10.1101/gad.11.1.94; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Ebbe S, 1976, Prog Hemost Thromb, V3, P211; EDGAR B, 1995, CURR OPIN CELL BIOL, V7, P815, DOI 10.1016/0955-0674(95)80065-4; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Garcia P, 1996, ONCOGENE, V13, P695; GIRARD F, 1991, CELL, V67, P1; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; HEGYI E, 1991, EXP HEMATOL, V19, P87; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOFFMAN R, 1989, BLOOD, V74, P1196; HORIGUCHIYAMADA J, 1993, MOL CELL BIOCHEM, V119, P29, DOI 10.1007/BF00926850; Jallepalli PV, 1997, CURR OPIN CELL BIOL, V9, P358, DOI 10.1016/S0955-0674(97)80008-7; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KRISTENSEN SD, 1988, THROMB HAEMOSTASIS, V59, P357; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; KUTER DJ, 1990, BLOOD, V75, P74; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; MacAuley A, 1998, MOL BIOL CELL, V9, P795, DOI 10.1091/mbc.9.4.795; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SMITH AV, 1991, DEVELOPMENT, V112, P997; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; STERN B, 1993, DEVELOPMENT, V117, P219; TOMER A, 1989, BLOOD, V74, P594; VANDERLOO B, 1993, EUR J CLIN INVEST, V23, P621; VARMUZA S, 1988, DEVELOPMENT, V102, P127; Vitrat N, 1998, BLOOD, V91, P3711; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhang Y, 1996, J BIOL CHEM, V271, P4266; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	55	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1820	1833		10.1038/sj.onc.1203494	http://dx.doi.org/10.1038/sj.onc.1203494			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777216				2022-12-17	WOS:000086292500010
J	Vial, E; Castellazzi, M				Vial, E; Castellazzi, M			Down-regulation of the extracellular matrix protein SPARC in vSrc- and vJun-transformed chick embryo fibroblasts contributes to tumor formation in vivo	ONCOGENE			English	Article						vSrc; vJun; AP1; SPARC; chick embryo fibroblasts; cell transformation; tumorigenesis	ENDOTHELIAL GROWTH-FACTOR; C-JUN; CELLULAR-TRANSFORMATION; NEOPLASTIC PROGRESSION; AP-1 FUNCTION; V-JUN; EXPRESSION; CELLS; OSTEONECTIN; OVEREXPRESSION	In vitro transformation of primary cultures of chick embryo fibroblasts by the membrane-bound vSrc or the nuclear vJun oncoproteins is correlated with a downregulation of the secreted glycoprotein SPARC (also called BM-40 or osteonectin). This protein is a nonstructural component of the extracellular matrix that is thought to regulate cell-matrix interaction during development, wound repair, and carcinogenesis. Its precise function remains unclear. To estimate the contribution of SPARC down-regulation to the major aspects of the transformed phenotype, we have reexpressed this protein from a self-replicating retrovirus Rcas, designated R-SPARC, in the transformed cultures. These R-SPARC-infected cultures display the following main properties: (i) they accumulate the SPARC protein to a level identical to or only slightly higher than the level in normal chick embryo fibroblasts; (ii) they retain the main phenotypic properties characteristic of in vitro transformed cells, that is, altered morphology, capacity to grow in a reduced amount of serum, and capacity to develop colonies from single cells in agar; (iii) they display a clearly reduced capacity to develop local fibrosarcomas in vivo. Taken together, these data strongly suggest that down-regulation of SPARC contributes to the transformed phenotype triggered by vSrc and vJun in primary avian fibroblasts, by facilitating in vivo tumorigenesis.	Ecole Normale Super Lyon, INSERM U412, Inst Natl Sante & Rech Med, Unite Virol Humaine, F-69364 Lyon 07, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM U412, Inst Natl Sante & Rech Med, Unite Virol Humaine, 46 Allee Italie, F-69364 Lyon 07, France.							Akamatsu H, 1996, CANCER RES, V56, P4541; BASSUK JA, 1993, EUR J BIOCHEM, V218, P117, DOI 10.1111/j.1432-1033.1993.tb18358.x; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; COLOMBO MP, 1991, EUR J CANCER, V27, P58, DOI 10.1016/0277-5379(91)90062-I; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; EVERITT EA, 1992, EXP CELL RES, V199, P134, DOI 10.1016/0014-4827(92)90471-J; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GIVOL I, 1992, ONCOGENE, V7, P141; HONENESTER E, 1997, EMBO J, V16, P3778; HUGUES SH, 1987, J VIROL, V61, P3004; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANKATBUTTGEREI.B, 1998, FEBS LETT, V236, P352; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; MORGAN IM, 1994, ONCOGENE, V9, P2793; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; PIU F, 1993, CR ACAD SCI III-VIE, V316, P772; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Reed KL, 1996, ULTRASOUND OBST GYN, V8, P1, DOI 10.1046/j.1469-0705.1996.08010001.x; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TIMPL R, 1993, MOL CELLULAR ASPECTS, P211; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VOGT PK, 1994, FOS JUN FAMILIES TRA, P203; YOUNG MF, 1986, NUCLEIC ACIDS RES, V14, P4483, DOI 10.1093/nar/14.11.4483	46	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1772	1782		10.1038/sj.onc.1203493	http://dx.doi.org/10.1038/sj.onc.1203493			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777211				2022-12-17	WOS:000086292500005
J	Steiner, MS; Wang, Y; Zhang, Y; Zhang, XW; Lu, Y				Steiner, MS; Wang, Y; Zhang, Y; Zhang, XW; Lu, Y			p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways	ONCOGENE			English	Article						p16; pRb; senescence; demethylation; adenovirus	INHIBITS CELL-PROLIFERATION; P16 MTS1; MALIGNANT MESOTHELIOMA; REPLICATIVE SENESCENCE; RETINOBLASTOMA-PROTEIN; P16(INK4A) EXPRESSION; HOMOZYGOUS DELETIONS; GROWTH SUPPRESSION; KINASE INHIBITORS; INVITRO LIFESPAN	Tumor suppressor gene p16 is a cyclin-dependent kinase inhibitor and an important negative cell cycle regulator. The inactivation of p16 appears to be a common event in prostate cancer. Replacement of p16 inhibits prostate tumor cell growth, but the mechanism is not known. Human prostate cancer cell lines PPC-1, which has an inactivated p16, and DU145, which has a nonfunctional retinoblastoma Rb protein (pRb), were used to determine the possible mechanism of p16 mediated growth inhibition. PPC-1 cells treated with 5-aza-2'-deoxycytidine (5-aza-dC), a demethylating agent, induced p16 expression, inhibited cell growth, and induced senescence. Similarly, PPC-1 cells transduced by an adenoviral vector containing the p16 gene (AdRSVp16) produced a p16 protein that suppressed cellular proliferation and induced senescence. Go-staining of AdRSVp16-transduced PPC-1 cells by p16 immunohistochemistry and by beta-galactosidase substrate X-gal showed that the morphologically enlarged cells expressed both p16 and senescence-associated beta-galactosidase. In contrast, AdRSVp16 did not induce senescence in DU145 cells, but did inhibit its growth. However, when wild-type pRb was introduced in DU145 cells, AdRSVp16 was able to induce senescence. Thus, the mechanism by which p16 suppressed prostate cancer was dependent on the pRb functional status of cells whereby p16 caused pRb(+) cells to undergo inhibition by senescence, whereas pRb(-) cells were also inhibited, but not by senescence.	Univ Tennessee, Coll Med, Dept Urol, Urol Res Labs, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Lu, Y (corresponding author), Univ Tennessee, Coll Med, Dept Urol, Urol Res Labs, 956 Court Ave, Memphis, TN 38163 USA.							ARAP W, 1995, CANCER RES, V55, P1351; BANERJEE A, 1992, CANCER RES, V52, P6297; BATES S, 1994, ONCOGENE, V9, P71; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chen ZH, 1996, CANCER RES, V56, P1083; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FAIRWEATHER DS, 1987, EXP CELL RES, V168, P153, DOI 10.1016/0014-4827(87)90424-1; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Fueyo J, 1996, ONCOGENE, V12, P103; Geradts J, 1996, AM J PATHOL, V149, P15; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Hama S, 1997, ANTICANCER RES, V17, P1933; Hara E, 1996, MOL CELL BIOL, V16, P859; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Herman JG, 1996, CANCER RES, V56, P722; HOLLIDAY R, 1986, EXP CELL RES, V166, P543, DOI 10.1016/0014-4827(86)90499-4; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Itoh N, 1997, JPN J CANCER RES, V88, P229, DOI 10.1111/j.1349-7006.1997.tb00371.x; Jarrard DF, 1999, CANCER RES, V59, P2957; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; JEN J, 1994, CANCER RES, V54, P6353; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; Kratzke RA, 1996, CANCER RES, V56, P3415; LI YJ, 1995, ONCOGENE, V11, P597; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; LIU Q, 1995, ONCOGENE, V10, P1061; Loughran O, 1996, ONCOGENE, V13, P561; Lu Y, 1998, BIOL CHEM, V379, P1323, DOI 10.1515/bchm.1998.379.11.1323; Lu Y, 1998, DNA CELL BIOL, V17, P643, DOI 10.1089/dna.1998.17.643; Lu Y, 1999, CANCER GENE THER, V6, P64, DOI 10.1038/sj.cgt.7700011; Lu Yi, 1995, Molecular and Cellular Differentiation, V3, P175; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Mobley SR, 1998, ARCH OTOLARYNGOL, V124, P88, DOI 10.1001/archotol.124.1.88; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORLEW I, 1995, J INT CANC I, V87, P1524; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARK M, 1998, CURRENT PROTOCOLS CE, pCH8; Quesnel B, 1996, BRIT J HAEMATOL, V95, P291, DOI 10.1046/j.1365-2141.1996.d01-1913.x; Reznikoff CA, 1996, CANCER RES, V56, P2886; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Schrump DS, 1996, CANCER GENE THER, V3, P357; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shapiro GI, 1996, BBA-REV CANCER, V1242, P165, DOI 10.1016/0304-419X(95)00011-4; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITHSORENSON B, 1995, HUM MUTAT, V7, P294; Steiner MS, 1999, CANCER GENE THER, V6, P456, DOI 10.1038/sj.cgt.7700065; Steiner MS, 1998, HUM GENE THER, V9, P747, DOI 10.1089/hum.1998.9.5-747; Steiner MS, 1996, MOL CELL DIFFER, V4, P275; STEINER MS, 1999, IN PRESS CANC GENE T; Stone S, 1996, CANCER RES, V56, P3199; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; Talve L, 1997, INT J CANCER, V74, P255, DOI 10.1002/(SICI)1097-0215(19970620)74:3<255::AID-IJC4>3.0.CO;2-Y; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WASHIMI O, 1995, CANCER RES, V55, P514; WILSON VL, 1983, SCIENCE, V220, P1054; Wolf JK, 1999, GYNECOL ONCOL, V73, P27, DOI 10.1006/gyno.1998.5259; XIAO S, 1995, ONCOGENE, V11, P511; XIAO S, 1995, CANCER RES, V55, P2968; ZHANG XW, 1996, ANTI-CANCER DRUG, V10, P569; Zhang Y, 1999, TUMOR TARGET, V4, P158	74	30	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1297	1306		10.1038/sj.onc.1203428	http://dx.doi.org/10.1038/sj.onc.1203428			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713671				2022-12-17	WOS:000085743800006
J	Murphy, KL; Rosen, JM				Murphy, KL; Rosen, JM			Mutant p53 and genomic instability in a transgenic mouse model of breast cancer	ONCOGENE			English	Article						mutant p53; mammary tumorigenesis; DMBA; transgenic mice; review	MAMMARY TUMORIGENESIS; DNA-BINDING; CENTROSOME AMPLIFICATION; GENETIC INSTABILITY; SPINDLE CHECKPOINT; CELL-PROLIFERATION; MICE; MUTATIONS; PROTEIN; EXPRESSION		Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Mol & Cellular Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA 16303] Funding Source: Medline; NIGMS NIH HHS [GM08231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen JJ, 1999, CANCER RES, V59, p1752S; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gretarsdottir S, 1998, CANCER RES, V58, P859; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Liu PK, 1996, ONCOGENE, V12, P2267; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Ritland SR, 1997, CANCER RES, V57, P3520; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STEWART N, 1995, ONCOGENE, V10, P109; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; TISTY TD, 1995, MUTAT RES, V337, P1; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	54	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1045	1051		10.1038/sj.onc.1203274	http://dx.doi.org/10.1038/sj.onc.1203274			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713688				2022-12-17	WOS:000085796400010
J	Sjoblom, T; Boureux, A; Ronnstrand, L; Heldin, CH; Ghysdael, J; Ostman, A				Sjoblom, T; Boureux, A; Ronnstrand, L; Heldin, CH; Ghysdael, J; Ostman, A			Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein	ONCOGENE			English	Article						chronic myelomonocytic leukemia; chromosomal translocation; platelet-derived growth factor; TEL	ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL; TRANSFORMING PROTEIN; PHOSPHORYLATION SITE; TYROSINE KINASE; RECEPTOR-BETA; GENE FUSION; GROWTH; ETS; DOMAIN	The t(5;12) translocation, associated with chronic myelomonocytic leukemia, generates a novel gene encoding a protein, TEL-PDGF beta R, composed of the 154 amino-terminal amino acids of the transcription factor TEL and the transmembrane and intracellular part of the PDGF beta-receptor (PDGF beta R). TEL also occurs as a tumor-associated fusion partner for the tyrosine kinases c-ABL, JAK2 and TRK-C. Previous studies have demonstrated growth promoting activity of TEL-PDGF beta R and also indicated that the TEL moiety activates the tyrosine kinase of the PDGF beta R through the formation of TEL-PDGF beta R oligomers. We demonstrate that tyrosine phosphorylation of the fusion protein can be attenuated through overexpression of the TEL part of TEL-PDGF beta R, suggesting a strategy for antagonizing the signaling of TEL-PDGF beta R, and other TEL-fusion proteins containing tyrosine kinase domains. Comparison of BaF/3 cell lines expressing TEL-PDGF beta R and ligand-stimulated PDGF beta R revealed that only TEL-PDGF beta R expression conferred IL-3-independent growth, suggesting differences in signaling capacity of the two proteins. Finally, tyrosine residues 17 and 27 in TEL-PDGF beta R was identified as autophosphorylation sites in TEL-PDGF beta R.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Ctr Univ Orsay, Inst Curie, CNRS UMR 146, Sect Rech, F-91405 Orsay, France	Ludwig Institute for Cancer Research; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Ostman, A (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.		GHYSDAEL, Jacques/F-3377-2013; Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				Abe A, 1997, BLOOD, V90, P4271, DOI 10.1182/blood.V90.11.4271.4271_4271_4277; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HELDIN CH, 1986, MOL CELLULAR BIOL WO, P249; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; KOVALENKO M, 1994, CANCER RES, V54, P6106; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995	28	30	34	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7055	7062		10.1038/sj.onc.1203190	http://dx.doi.org/10.1038/sj.onc.1203190			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597306				2022-12-17	WOS:000083901900012
J	Slosberg, ED; Klein, MG; Yao, Y; Han, EKH; Schieren, I; Weinstein, IB				Slosberg, ED; Klein, MG; Yao, Y; Han, EKH; Schieren, I; Weinstein, IB			The alpha isoform of protein kinase C mediates phorbol ester-induced growth inhibition and p21(cip1) induction in HC11 mammary epithelial cells	ONCOGENE			English	Article						protein kinase C; mammary; cell cycle; TPA; HC11; p21(cip1)	CYCLIN-DEPENDENT KINASES; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; MUTANT FORM; WILD-TYPE; CANCER; OVEREXPRESSION; SUPPRESSION; INVOLVEMENT	To clarify the roles of specific isoforms of PKC in regulating growth and cell cycle progression of the HC11 mammary epithelial cell line, we investigated the effects of activating endogenous PKC isoforms,vith the phorbol ester tumor promoter TPA, and also the effects of TPA on genetically engineered cells containing increased levels of individual PKC isoforms. We found that TPA treatment of HC11 cells induced a transient cell cycle arrest in G0/G1. Western blot analyses of the TPA treated cells provided evidence that the endogenous PKC alpha present in these cells mediated these effects, Indeed, derivatives of the HC11 cell line that inducibly overexpress an exogenous PKC alpha or ectopic PKC beta(1) exhibited more marked growth inhibition by TPA than control cells. Immunohistochemical staining of cells following treatment with TPA revealed selective translocation of PKC alpha into the nucleus, whereas PKC beta(1) remained in the cytoplasm. The transient arrest of HC11 cells following treatment with TPA was associated with marked induction of both p21(cip1) mRNA and protein. This induction was exaggerated in the derivatives that overexpressed either PKC alpha or PKC beta(1). Therefore, in mouse mammary epithelial cells activation of the endogenous PKC alpha can transiently arrest cells in G0/G1 which may be due, at least in part, to induction of the transcription of p21(cip1).	Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Novartis Pharmaceut Corp, Summit, NJ 07901 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Abbott Labs, Abbott Pk, IL 60064 USA	Columbia University; Novartis; Yeshiva University; Albert Einstein College of Medicine; Abbott Laboratories	Weinstein, IB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, HHSC 1509,701 W 168th St, New York, NY 10032 USA.				NCI NIH HHS [T32CA09503, CA02656] Funding Source: Medline; NIGMS NIH HHS [T32GM07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; Alvaro V, 1997, ONCOGENE, V14, P677, DOI 10.1038/sj.onc.1200880; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BLUMBERG PM, 1994, PROG CLIN BIOL RES, V387, P3; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BORNER C, 1992, PROTEIN KINASE C CUR, P297; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; CACACE A, 1993, ONCOGENE, V8, P2094; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COPPOCK DL, 1995, EXP CELL RES, V221, P92, DOI 10.1006/excr.1995.1356; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; Fabbro D, 1992, Cancer Treat Res, V61, P229; FABBRO D, 1986, CANCER RES, V46, P2720; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; Kiley SC, 1996, J MAMMARY GLAND BIOL, V1, P177, DOI 10.1007/BF02013641; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1993, BIOCHEM SOC T, V21, P879, DOI 10.1042/bst0210879; LEACH KL, 1992, J BIOL CHEM, V267, P21816; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; LIVNEH E, 1994, SIGNAL ACTIVATED PHO, P165; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; MERLO GR, 1994, ONCOGENE, V9, P443; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OBRIAN CA, 1989, CANCER RES, V49, P3215; OBRIAN CA, 1985, CANCER RES, V45, P2462; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SAVART M, 1992, INT J CANCER, V52, P399, DOI 10.1002/ijc.2910520312; Schmalz D, 1996, J CELL SCI, V109, P2401; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TIEFENBRUN N, 1991, ONCOGENE, V6, P1001; VILCEK J, 1976, J INFECT DIS, V133, pA22, DOI 10.1093/infdis/133.Supplement_2.A22; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Weinstein I. B., 1996, ENCY CANC, V1, P256; ZHOU W, 1993, J BIOL CHEM, V268, P23041	56	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6658	6666		10.1038/sj.onc.1203083	http://dx.doi.org/10.1038/sj.onc.1203083			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597271				2022-12-17	WOS:000083792000005
J	Barnouin, K; Fredersdorf, S; Eddaoudi, A; Mittnacht, S; Pan, LX; Du, MQ; Lu, X				Barnouin, K; Fredersdorf, S; Eddaoudi, A; Mittnacht, S; Pan, LX; Du, MQ; Lu, X			Antiproliferative function of p27(kip1) is frequently inhibited in highly malignant Burkitt's lymphoma cells	ONCOGENE			English	Article						D-type cyclin; cyclin dependant kinase; p27(kip1); cell cycle; Birkitt's lymphoma	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; CDK INHIBITORS; MICE LACKING; CYCLE ARREST; TGF-BETA; INACTIVATION; EXPRESSION; GROWTH; HYPERPLASIA	Lack of detectable expression of p27(kip1) cyclin dependent kinase inhibitor has previously been correlated with high degree of malignancy in human breast, colorectal, gastric and smalt cell lung carcinomas. Here me demonstrate that an inverse correlation between p27(kip1) expression and tumour malignancy also exists in most types of human B cell lymphomas examined. A clear exception was Burkitt's lymphoma (BL), a highly malignant tumour which often expresses high levels of p27(kip1). Analysis of p27(kip1) derived from Burkitt's lymphoma cell lines expressing high levels of p27(kip1), BL40 and BL41, in a cyclin E/cdk2 kinase inhibition assay demonstrated that p27(kip1) is not permanently inactivated since heat treatment can restore the inhibitory activity of p27(kip1). However, p27(kip1) expressed in these two cell lines is largely sequestered in inactive complexes and me have no evidence that c-myc or Epstein-Barr virus are responsible for the sequestration of p27(kip1) in these two cell lines although c-myc and EBV are two oncogenic agents often associated with Burkitt's lymphomas. Interestingly, we observed that high level p27(kip1) expression often correlated,vith cyclin D3 overexpression both in vivo and in BL cell lines. The majority of p27(kip1) in BL40 cells was complexed with cyclin D3 indicating that overexpressed cyclin D3 may at least be part of the sequestering activity for the inhibitory function of p27(kip1). Furthermore, cyclinD3/cdk4 complex could sequester p27(kip1) in a cyclin E/cdk2 kinase assay in vitro. Finally, me show that cyclin D3 transfected into an inducible p27(kip1) cell line could overcome the G1 arrest mediated by p27(kip1). These results argue that in addition to down-regulation of p27(kip1) expression, some tumour cells can sequester and tolerate the antiproliferative function of p27(kip1), They also suggest a novel role for the overexpression of D-type cyclins as one pathway allowing tumour cells to overcome the antiproliferative function of p27(kip1).	St Marys Hosp, Imperial Coll, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; UCL, Sch Med, Dept Histopathol, London WC1E 6JJ, England; Inst Canc Res, London SW3 6JB, England; St Marys Hosp, Imperial Coll, Sch Med, Dept Med Microbiol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Lu, X (corresponding author), St Marys Hosp, Imperial Coll, Sch Med, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.			Lu, Xin/0000-0002-6587-1152; Du, Ming-Qing/0000-0002-1017-5045; Eddaoudi, Ayad/0000-0001-5272-6426				Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SanchezBeato M, 1997, AM J PATHOL, V151, P151; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SINCLAIR AJ, 1995, METH MOL G, V7, P89; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZerfassThome K, 1996, ONCOGENE, V13, P2323	28	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6388	6397		10.1038/sj.onc.1203162	http://dx.doi.org/10.1038/sj.onc.1203162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597239				2022-12-17	WOS:000083934100024
J	Daftari, P; Gavva, NR; Shen, CKJ				Daftari, P; Gavva, NR; Shen, CKJ			Distinction between AP1 and NF-E2 factor-binding at specific chromatin regions in mammalian cells	ONCOGENE			English	Article						chromatin immunoprecipitation; AP1; NF-E2; in vivo binding	PROTEIN-DNA INTERACTIONS; LOCUS-CONTROL REGION; GLOBIN GENE-EXPRESSION; TRANSCRIPTION FACTOR NF-E2; C-JUN PROMOTER; IN-VIVO; ALPHA-GLOBIN; INTERACTIONS INVIVO; INDUCIBLE ENHANCER; REGULATORY ELEMENT	Specific nuclear factor-DNA complexes formed within the promoters and enhancers are essential for transcriptional regulation, For eukaryotic systems, however, some DNA motif(s) are capable of binding to a family of related factors, thus making it difficult to identify the factor actually binding on the chromatic DNA in vivo and modulating the local transcription processes, To resolve this matter, we have refined a chromatin immunoprecipitation assay. Using the assay, we could directly link the regulatory functions of tao members of the AP1/NF-E2 transcription factor family and their stable binding in vivo within distinct chromatin regions, The study demonstrated the feasibility of a general scheme in the determination of the identity of specific factor(s), among a group of family members, bound at unique sequence(s) in living mammalian cells.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Acad Sinica, Inst Mol Biol, Taipei, Taiwan	University of California System; University of California Davis; Academia Sinica - Taiwan	Shen, CKJ (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK29800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FLEENOR DE, 1993, BLOOD, V81, P2781; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Gong QH, 1996, MOL CELL BIOL, V16, P6055; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; Huang BL, 1998, P NATL ACAD SCI USA, V95, P14669, DOI 10.1073/pnas.95.25.14669; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Walter J, 1996, P NATL ACAD SCI USA, V93, P2680, DOI 10.1073/pnas.93.7.2680; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	42	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5482	5486		10.1038/sj.onc.1202916	http://dx.doi.org/10.1038/sj.onc.1202916			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498903				2022-12-17	WOS:000082718600014
J	Yamashita, A; Hakura, A; Inoue, H				Yamashita, A; Hakura, A; Inoue, H			Suppression of anchorage-independent growth of human cancer cell lines by the drs gene	ONCOGENE			English	Article						drs; tumor suppressor; anchorage-independent growth; human cancer cell line; cyclin A	LINKED RETINITIS-PIGMENTOSA; RAT EMBRYO FIBROBLASTS; HUMAN-COLON CARCINOMA; V-SRC TRANSFORMATION; CYCLE PROGRESSION; BETA-CATENIN; L-SELECTIN; RETINOBLASTOMA PROTEIN; LEUKOCYTE ADHESION; DNA METHYLATION	We have previously reported that the drs gene, whose mRNA expression is downregulated by retroviral oncogenes such as v-src and v-K-ras, has the ability to suppress transformation by v-src in a rat cell line F2408, We have now isolated a human homolog of this gene (h-drs) and found that the expression of h-dfs mRNA is markedly downregulated in a variety of human cancer cell lines including those of the colon, bladder, and ovary. To investigate the function of the h-drs gene as a tumor suppressor in human cancer cells, we constructed recombinant amphotropic retrovirus containing the drs gene, introduced this virus into human cancer cell lines whose nps expression was downregulated and found that drs has the ability to suppress anchorage-independent growth of these cells without disturbing cell proliferation. Analyses with deletion mutants of the drs gene revealed that both the C-terminal region inside the transmembrane domain and three consensus repeats in the N-terminal region are essential for the suppression of anchorage-independent growth of the cells. We also found that the GI-S progression of the cell cycle and expression of cyclin A mRNA were significantly suppressed in T24 cells expressing the drs gene under non-adhesion culture conditions. In contrast, the expression of cyclin D and E and the phosphorylation of Rb protein were not affected by ectopic expression of the drs gene, suggesting that an Rb-independent downregulation of cyclin A is involved in the suppression of anchorage-independent growth by means of the drs gene.	Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Osaka 5650871, Japan	Osaka University	Inoue, H (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, 3-1 Yamadaoka, Osaka 5650871, Japan.							Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1989, CANCER RES, V49, P4682; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DRY KL, 1995, HUM MOL GENET, V4, P2347, DOI 10.1093/hmg/4.12.2347; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUANDAGNO TM, 1993, SCIENCE, V262, P1572; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; INOUE H, 1995, ONCOGENE, V11, P231; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; JUTILA MA, 1992, J EXP MED, V175, P1565, DOI 10.1084/jem.175.6.1565; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LI SH, 1994, J BIOL CHEM, V269, P4431; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEINDL A, 1995, HUM MOL GENET, V4, P2339, DOI 10.1093/hmg/4.12.2339; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIYASAKA M, 1991, J VIROL, V65, P479, DOI 10.1128/JVI.65.1.479-482.1991; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagase T, 1997, BRIT J CANCER, V76, P1001, DOI 10.1038/bjc.1997.499; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NEVINS JR, 1992, SCIENCE, V258, P424; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Pan J, 1996, FEBS LETT, V383, P21; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	73	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4777	4787		10.1038/sj.onc.1202852	http://dx.doi.org/10.1038/sj.onc.1202852			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490811				2022-12-17	WOS:000082184800002
J	Ogihara, H; Kanno, T; Morii, E; Kim, DK; Lee, YM; Sato, M; Kim, WY; Nomura, S; Ito, Y; Kitamura, Y				Ogihara, H; Kanno, T; Morii, E; Kim, DK; Lee, YM; Sato, M; Kim, WY; Nomura, S; Ito, Y; Kitamura, Y			Synergy of PEBP2/CBF with mi transcription factor (MITF) for transactivation of mouse mast cell protease 6 gene	ONCOGENE			English	Article						mast cells; mi transcription factor (MITF); PEBP2/CBF; AML1; mouse mast cell protease 6	CORE-BINDING-FACTOR; STIMULATING FACTOR-RECEPTOR; NERVE GROWTH-FACTOR; MI/MI GENOTYPE; MUTANT MICE; C-KIT; IMPAIRED EXPRESSION; DELTA-ENHANCER; LOCUS; MICROPHTHALMIA	The mi locus encodes a member of the basic-helix-loop-helix-leucine zipper (bHLH-Zip) protein family of transcription factors (hereafter called MITF), Although the bHLH-Zip family transcription factors generally recognize and bind CANNTG motifs, the expression of mouse mast cell protease 6 (MMCP-6) gene is regulated by MITF through the (G) under bar ACCTG motif in the promoter region. The GACC<(TG)under bar> motif was partly overlapped the <(TG)under bar>TGGTC sequence, which was bound by polyomavirus enhancer binding protein 2 (PEBP2), In the present study, the effect of PEBP2 on the expression of MMCP-6 gene was examined, PEBP2 that is composed of alpha and beta subunits was expressed by mast cell Lines and cultured mast cells derived from spleen, The overexpression of dominant negative PEBP2 cDNA reduced the expression of MMCP-6. Moreover, the simultaneous transfection of the plasmid containing MITF cDNA and the plasmid containing PEBP2 cDNA increased the MMCP-6 promoter activity, For the synergistic action of PEBP2 and MITF, the intact GACC<(TG)under bar> and <(TG)under bar>TGGTC motifs were prerequisite. The PEBP2 alpha B1 mutant which lacked the region downstream from the Runt domain did not bind MITF and lost the synergistic function. These results indicated that PEBP2 and MITF synergistically transactivated the MMCP-6 gene and that the region downstream from the Runt domain of PEBP2 alpha B1 was essential for the physical and functional interactions with MITF.	Osaka Univ, Sch Med, Dept Pathol, Osaka 5650871, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068397, Japan	Osaka University; Kyoto University	Morii, E (corresponding author), Osaka Univ, Sch Med, Dept Pathol, 2-2 Yamadaoka, Osaka 5650871, Japan.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAE SC, 1993, ONCOGENE, V8, P809; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; EBI Y, 1992, BLOOD, V80, P1454; EBI Y, 1990, BLOOD, V75, P1247; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GREEN MC, 1981, GENETIC VARIANTS STR, P158; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; ISOZAKI K, 1994, AM J PATHOL, V145, P827; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; JIPPO T, 1994, BLOOD, V84, P2977; Jippo T, 1997, BLOOD, V90, P2601, DOI 10.1182/blood.V90.7.2601.2601_2601_2608; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; KASUGAI T, 1993, AM J PATHOL, V143, P1337; Kim DK, 1998, BLOOD, V92, P1973, DOI 10.1182/blood.V92.6.1973.418k23_1973_1980; KIM WY, 1999, IN PRESS EMBO J; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; MORII E, 1994, BIOCHEM BIOPH RES CO, V205, P1299, DOI 10.1006/bbrc.1994.2806; Morii E, 1997, BLOOD, V90, P3057, DOI 10.1182/blood.V90.8.3057; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; STECHSCHULTE DJ, 1987, J CELL PHYSIOL, V132, P565, DOI 10.1002/jcp.1041320321; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; STEVENS J, 1982, PROC R SOC SER B-BIO, V215, P405, DOI 10.1098/rspb.1982.0050; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	45	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4632	4639		10.1038/sj.onc.1202844	http://dx.doi.org/10.1038/sj.onc.1202844			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467408				2022-12-17	WOS:000082018600013
J	Lee, TH; Chuang, LY; Hung, WC				Lee, TH; Chuang, LY; Hung, WC			Tamoxifen induces p21(WAF1) and p27(KIP1) expression in estrogen receptor-negative lung cancer cells	ONCOGENE			English	Article						tamoxifen; estrogen receptor; p21(WAF1); p27(KIP1)	DEPENDENT KINASE INHIBITOR; HIGH-DOSE TAMOXIFEN; BREAST-CANCER; CYCLE CONTROL; CHROMOSOMAL LOCALIZATION; METASTATIC MELANOMA; POTENTIAL MEDIATOR; GROWTH-INHIBITION; P53 GENE; PHASE-I	Tamoxifen (Tam), besides its action as an anti-estrogen, also inhibits cell proliferation of estrogen receptor (ER)negative cancer cells by an unknown mechanism. In this study, we used ER-negative lung cancer cells to clarify such ER-independent inhibitory effect of Tam, We found that Tam induced G1 growth arrest in these cells. However, our results indicated that the expression of G1 cyclins (including D1, 2, 3 and E) was not regulated by Tam in these lung cancer cells, Additionally, the protein levels of G1 acting cyclin-dependent kinases (CDKs), CDK2, 4 and 6, was unaltered in Tam-treated lung cancer cells with the exception of CDK2 expression in H322 cells which was attenuated by Tam in a cell line-specific manner. We next examined the effect of Tam on the expression of cyclin-dependent kinase inhibitors (CDKIs) and our results demonstrated that the expression of p21(WAF1) and p27(KIP1), but not p57(KIP2), was strongly activated by Tam in these cells. The amounts of p21(WAF1) and p27(KIP1) co-immunoprecipitated with cyclin E were obviously increased after Tam treatment and reduced activity of cyclin E-associated kinases and accumulation of hypo-phosphorylated retinoblastoma (Rb) protein mere clearly detected in Tam-incubated cells. No consentaneous induction of CDKIs was found when ER-negative lung cancer cells were incubated with cytotoxic drugs, cisplatin and etoposide, this indicates that enhancement of CDKI expression is not a non-specific effect of Tam, We also found that Tam may up-regulate p21(WAF1) expression via transcription activation. Considered together, these results suggest that Tam-induced growth inhibition in ER-negative lung cancer cells is associated with induction of p21(WAF1) and p27(KIP1).	Kaohsiung Med Coll, Sch Technol Med Sci, Kaohsiung 807, Taiwan; Kaohsiung Med Coll, Grad Inst Med, Kaohsiung 807, Taiwan; Kaohsiung Med Coll, Dept Biochem, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Coll, Sch Technol Med Sci, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.		Chuang, Lea-Yea/C-7450-2009					AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Cabot MC, 1996, FEBS LETT, V394, P129, DOI 10.1016/0014-5793(96)00942-8; Caputi M, 1998, AM J RESP CELL MOL, V18, P213, DOI 10.1165/ajrcmb.18.2.2937m; CHIBA I, 1990, ONCOGENE, V5, P1603; COULDWELL WT, 1993, NEUROSURGERY, V32, P485, DOI 10.1227/00006123-199303000-00034; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; DELPRETE SA, 1984, CANCER TREAT REP, V68, P1403; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hung WC, 1996, HUM PATHOL, V27, P1324, DOI 10.1016/S0046-8177(96)90345-7; Hung WC, 1996, BIOCHEM BIOPH RES CO, V220, P719, DOI 10.1006/bbrc.1996.0470; JORDAN VC, 1994, BREAST CANCER RES TR, V31, P41, DOI 10.1007/BF00689675; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KISS Z, 1994, FEBS LETT, V355, P173, DOI 10.1016/0014-5793(94)01200-8; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Komiya T, 1997, CLIN CANCER RES, V3, P1831; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; McClay EF, 1997, CANCER, V79, P1037, DOI 10.1002/(SICI)1097-0142(19970301)79:5<1037::AID-CNCR22>3.0.CO;2-1; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Robinson EK, 1998, ANN SURG ONCOL, V5, P342, DOI 10.1007/BF02303498; Rohlff C, 1998, PROSTATE, V37, P51, DOI 10.1002/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B; ROWLANDS MG, 1990, BIOCHEM PHARMACOL, V40, P283, DOI 10.1016/0006-2952(90)90689-I; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yatabe Y, 1998, CANCER RES, V58, P1042	50	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4269	4274		10.1038/sj.onc.1202755	http://dx.doi.org/10.1038/sj.onc.1202755			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435640				2022-12-17	WOS:000081542400011
J	Pelicano, L; Brumpt, C; Pitha, PM; Chelbi-Alix, MK				Pelicano, L; Brumpt, C; Pitha, PM; Chelbi-Alix, MK			Retinoic acid resistance in NB4 APL cells is associated with lack of interferon alpha synthesis Stat1 and p48 induction	ONCOGENE			English	Article						IRF-1; IRF-3; cAMP; Sp100; differentiation	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; IFN-ALPHA; SIGNAL TRANSDUCER; GENOMIC STRUCTURE; T(15-17); ELEMENT; GAMMA	In the t(15;17) acute promyelocytic leukaemia (APL), all trans-retinoic (RA) treatment induces maturation leading to clinically complete but not durable remission, as RA resistance develops in the treated patients as well as lit vitro. RA and interferons (IFNs) are known inhibitors of proliferation in various cells including those from APL, In this report, we show that they can act cooperatively to inhibit growth and to induce differentiation of NB4 cells but not of two RA-resistant NB4 derived cell lines, NB4-R1 and NB4-R2, However, the resistant cell lines respond to IFN, In NB4 cells, RA increases the expression of Stat1, p48 and IRF-1, three transcription factors playing a central role in the IFN response and induces the synthesis and the secretion of IFN alpha, RA-induced IFN alpha seems to play a role in inhibition of NB4 cell growth but not in their differentiation, In the resistant cells, NB4-R1 and NB4-R2, both the induction of IFN and the increase of Stat1 and p48 expression by RA are completely blocked, In contrast, IRF-1 mRNA and protein expressions are induced in the three cell lines. This suggests that increase of IRF-1 expression is not sufficient for IFN induction. Our results identify some defects linked to RA-resistance in APL and support the hypothesis that RA-induced Stat1 expression and IFN secretion may be one of the mechanisms mediating growth inhibition by RA.	Hop St Louis, CNRS, UPR 9051, F-75475 Paris 10, France; Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21231 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University; Johns Hopkins Medicine	Chelbi-Alix, MK (corresponding author), Hop St Louis, CNRS, UPR 9051, 1 Ave Vellefaux, F-75475 Paris 10, France.							ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; Demaeyer E., 1988, INTERFERONS OTHER RE; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Duprez E, 1996, ONCOGENE, V12, P2451; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; EISENHAUER EA, 1994, LEUKEMIA, V8, P1622; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Giandomenico V, 1997, CELL GROWTH DIFFER, V8, P91; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; Handa H, 1997, LEUKEMIA RES, V21, P1087, DOI 10.1016/S0145-2126(97)00090-8; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Kizaki M, 1997, LEUKEMIA LYMPHOMA, V25, P427, DOI 10.3109/10428199709039029; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KUMAR R, 1995, ANTICANCER RES, V15, P353; LANCILLOTTI F, 1995, CANCER RES, V55, P3158; LANOTTE M, 1991, BLOOD, V77, P1080; Lehtonen A, 1997, J IMMUNOL, V159, P794; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Matikainen S, 1996, BLOOD, V88, P114; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pelicano L, 1998, B CANCER, V85, P313; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; Pfeffer LM, 1998, CANCER RES, V58, P2489; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROBERTSON KA, 1992, BLOOD, V80, P1885; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Stadler M, 1995, ONCOGENE, V11, P2565; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; Yoshida H, 1996, CANCER RES, V56, P2945	62	30	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3944	3953		10.1038/sj.onc.1202802	http://dx.doi.org/10.1038/sj.onc.1202802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435617				2022-12-17	WOS:000081327800004
J	Srivastava, RK; Srivastava, AR; Cho-Chung, YS; Longo, DL				Srivastava, RK; Srivastava, AR; Cho-Chung, YS; Longo, DL			Synergistic effects of retinoic acid and 8-Cl-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells	ONCOGENE			English	Article						retinoic acid; caspase protein kinase A; cytochrome c; apoptosis	DEPENDENT PROTEIN-KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION; RECEPTOR-BETA; POLY(ADP-RIBOSE) POLYMERASE; CATALYTIC SUBUNIT; UP-REGULATION; CYTOCHROME-C; ELEMENT; SUPPRESSION; GROWTH	We investigated the intracellular mechanisms of retinoic acid (9-cis-RA, 13-cis-RA or all-trans-RA) and a cyclic AMP analog 8-Cl-cAMP on growth-inhibition and apoptosis in human ovarian cancer NIH: OVCAR-3 and OVCGR-8 cells, The cyclic AMP analog, 8-Cl-cAMP, acted synergistically with RA in inducing and activating retinoic acid receptor beta (RAR beta) which correlated with the growth inhibition, cell cycle arrest, and apoptosis in both cell types. In addition, combined treatment of cells with RA plus 8-Cl-cAMP resulted in the release of cytochrome c, loss in mitochondrial membrane potential and activation of caspase-3 followed by cleavage of anti-poly(ADP-ribose)polymerase and DNA-dependent protein kinase (catalytic subunit), Interestingly, inhibition of caspase-3 activation blocked RA plus 8-Cl-cAMP induced apoptosis, Furthermore, mutations in a CRE-related motif within the RAR beta promoter resulted in loss of both transcriptional activation of RAR beta and synergy between RA and 8-Cl-cAMP, Thus, RAR beta can mediate RA and/or cyclic AMP action in ovarian cancer cells by promoting apoptosis, Loss of RAR beta expression, therefore, may contribute to the tumorigenicity of human ovarian cancer cells, These findings suggest that RA and 8-Cl-cAMP act in a synergistic fashion in inducing apoptosis via caspase-3 activation, and may have potential for combination biotherapy for the treatment of malignant disease such as ovarian cancer.	NIA, Immunol Lab, NIH, Baltimore, MD 21224 USA; NCI, Med Branch, Bethesda, MD 20892 USA; NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Srivastava, RK (corresponding author), NIA, Immunol Lab, NIH, Box 28,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Longo, Dan L./F-6022-2011					ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Heiden MGV, 1997, CELL, V91, P627; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hong Waun Ki, 1994, P597; Hong WK, 1995, CLIN CANCER RES, V1, P677; HOULE B, 1993, EXP CELL RES, V195, P163; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Srivastava RK, 1998, BREAST CANCER RES TR, V49, P97, DOI 10.1023/A:1005905723550; Srivastava RK, 1998, CLIN CANCER RES, V4, P755; SRIVASTAVA RK, 1998, IN PRESS MOL CELL BI; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TORTORA G, 1995, CLIN CANCER RES, V1, P377; VAVSSIARE JL, 1994, P NATL ACAD SCI USA, V91, P11752; VINTERMYR OK, 1993, EXP CELL RES, V206, P157, DOI 10.1006/excr.1993.1132; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; ZHANG XK, 1994, CANCER RES, V54, P5663	45	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1755	1763		10.1038/sj.onc.1202464	http://dx.doi.org/10.1038/sj.onc.1202464			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208436				2022-12-17	WOS:000079025000010
J	Tsutsumi, M; Tsai, YC; Gonzalgo, ML; Nichols, PW; Jones, PA				Tsutsumi, M; Tsai, YC; Gonzalgo, ML; Nichols, PW; Jones, PA			Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer	ONCOGENE			English	Article						p16/p19; deletion; DNA methylation; 9p21; bladder cancer; squamous metaplasia	TUMOR-SUPPRESSOR GENE; HIGH-FREQUENCY; URINARY-BLADDER; CPG ISLAND; P15 GENES; IN-SITU; CARCINOMA; CHROMOSOME-9; METHYLATION; INACTIVATION	We looked for p16/p19 deletion and p16 promoter methylation, as well as loss of 9p21 heterozygosity in pure squamous cell carcinomas (SCC), and in transitional cell carcinomas (TCC) of the bladder with SCC components. Homozygous deletion of p16/p10 was detected in 11 of 21 (52%) cases of pure SCCs and in three of ten (30%) cases of TCC with SCC. Three cases of TCC with SCC had p16/p19 deletion, hypermethylation of the p16 promoter, or LOH on 9p21 only in the SCC components, suggesting that these molecular alterations occurred preferentially in SCC. Interestingly, homozygous deletion of p16/p19 was observed in squamous metaplasia from bladder cancer patients (five of 11, 45%), showing that this change occurred in preneoplastic cells. On the other hand, p16/p19 deletions were not found in squamous metaplasias from non cancerous patients. Hypermethylation of the p16 promoter was observed in two of 14 tumors (14%) and none of seven metaplasias examined. These data suggest that: (a) p16/p19 deletion is associated with early carcinogenesis of SCC of the bladder, and squamous metaplasia of the bladder cancer patient has already sustained genetic changes found in cancer, and (b) genetic mosaicism occurs in cases of TCC with SCC, with the SCC component showing more frequent 9p21 alterations than the TCC component.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Urol Canc Res Lab, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Jones, PA (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, 1441 Eastlake Ave,Room 815, Los Angeles, CA 90033 USA.				NATIONAL CANCER INSTITUTE [R35CA049758] Funding Source: NIH RePORTER; NCI NIH HHS [5 R35 CA49758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DURO D, 1995, ONCOGENE, V11, P21; ELMASRI WS, 1981, PARAPLEGIA, V19, P265, DOI 10.1038/sc.1981.52; Fueyo J, 1996, ONCOGENE, V13, P1615; FUJIMOTO K, 1992, CANCER RES, V52, P1393; Ghaleb AH, 1996, AM J CLIN PATHOL, V106, P234; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Herman JG, 1997, CANCER RES, V57, P837; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAUFMAN JM, 1977, J UROLOGY, V118, P967, DOI 10.1016/S0022-5347(17)58266-X; KEEN AJ, 1994, ONCOGENE, V9, P2083; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MESSING EM, 1997, CAMPBELLS UROLOGY, P2343; MIYAO N, 1993, CANCER RES, V53, P4066; Navon JD, 1997, J UROLOGY, V157, P2109, DOI 10.1016/S0022-5347(01)64687-1; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PACKENHAM JP, 1995, MOL CARCINOGEN, V14, P147, DOI 10.1002/mc.2940140303; QUELLE DE, 1995, CELL, V83, P993; Reed AL, 1996, CANCER RES, V56, P3630; ROSIN MP, 1995, CANCER RES, V55, P5213; RUPPERT JM, 1993, CANCER RES, V53, P5093; SAKAMOTO N, 1992, HISTOPATHOLOGY, V21, P135, DOI 10.1111/j.1365-2559.1992.tb00361.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Simoneau AR, 1996, CANCER RES, V56, P5039; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P687, DOI 10.1093/nar/18.3.687; SPRUCK CH, 1994, CANCER RES, V54, P784; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Tamimi Y, 1996, INT J CANCER, V68, P183, DOI 10.1002/(SICI)1097-0215(19961009)68:2<183::AID-IJC7>3.0.CO;2-U; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; Wong DJ, 1997, CANCER RES, V57, P2619; YOUNG RH, 1991, HUM PATHOL, V22, P948, DOI 10.1016/0046-8177(91)90003-8	38	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3021	3027		10.1038/sj.onc.1202228	http://dx.doi.org/10.1038/sj.onc.1202228			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881704				2022-12-17	WOS:000077427800009
J	de Jong, R; van Wijk, A; Heisterkamp, N; Groffen, J				de Jong, R; van Wijk, A; Heisterkamp, N; Groffen, J			C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells	ONCOGENE			English	Article						C3G; Crkl; integrin; Bcr/Abl p210	CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-3 DOMAIN; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; SIGNALING PATHWAYS; KINASE PATHWAY; CRK PROTEINS; R-RAS; C-ABL; P130(CAS)	The SH2-SH3 adaptor protein Crkl has been implicated in the signal transduction pathways of several membrane-bound receptors. Tyrosine phosphorylation of proteins associated with such signalling complexes can generate binding sites for the Crkl SH2-domain and can recruit proteins constitutively bound to Crkl via the Crkl SH3 domain into such complexes. In the current study we show that Crkl, but only a minor amount of the related Crk, form constitutive complexes in vivo with guanine nucleotide exchange factor C3G in 3T3 fibroblasts. Adhesion of both normal and transformed cells to fibronectin or other extracellular matrix proteins consistently induces the tyrosine-phosphorylation of C3G. Adhesion-induced tyrosine phosphorylation of C3G is dependent on an intact cytoskeleton and peaks at 5-10 min after attachment. In contrast, 3T3 cells stably transfected with Bcr/Abl P210 show a prominent reduction in the amount of C3G complexed to Crkl and do not exhibit tyrosine-phosphorylation of C3G upon spreading and attachment. These data establish that integrin-mediated cell adhesion results in Crkl-mediated tyrosine phosphorylation of C3G, a pathway which can be disrupted by Bcr/Abl.	Childrens Hosp Los Angeles, Inst Res, Dept Pathol, Sect Mol Carcinogenesis, Los Angeles, CA 90027 USA; USC, Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Groffen, J (corresponding author), Childrens Hosp Los Angeles, Inst Res, Dept Pathol, Sect Mol Carcinogenesis, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456, R01CA050248] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47456, CA 50248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1995, ONCOGENE, V10, P1465; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6476; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; NICHOLS GL, 1994, BLOOD, V84, P2912; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; TANAKA T, 1994, P NATL ACAD SCI USA, V91, P3433; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	39	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2805	2810		10.1038/sj.onc.1202207	http://dx.doi.org/10.1038/sj.onc.1202207			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840945				2022-12-17	WOS:000077146700014
J	Feng, ZW; Joos, HJ; Vallan, C; Muhlbauer, R; Altermatt, HJ; Jaggi, R				Feng, ZW; Joos, HJ; Vallan, C; Muhlbauer, R; Altermatt, HJ; Jaggi, R			Apoptosis during castration-induced regression of the prostate is Fos dependent	ONCOGENE			English	Article						apoptosis; castration; c-Fos; prostate; transcription factor AP-1	PROGRAMMED CELL-DEATH; TRANSCRIPTION FACTOR AP-1; MAMMARY-GLAND INVOLUTION; RAT VENTRAL PROSTATE; C-FOS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; ANDROGEN ABLATION; TRANSGENIC MICE; IN-VIVO	Apoptotic cell death was shown to be accompanied or preceded by an elevated expression of the c-fos protooncogene and DNA binding activity of transcription factor AP-1. We used Fos-deficient mice to study the role of c-Fos during programmed cell death in the prostate. In normal mice apoptosis is induced in the prostate within 2-4 days after castration. Histological features of reduced secretory activity and morphological signs of programmed cell death become obvious. No apparent decrease in secretory activity and no epithelial cell death were observed in Fos-deficient animals after castration. Fragmentation of nuclear DNA was measured by in situ terminal transferase reaction. DNA fragmentation was observed in the prostate epithelium of control mice after castration whereas no similar fragmentation was found in Fos-deficient animals. After castration an AP-1 complex accumulated in the prostate of Fos deficient mice which mainly consists of FosB, Fra-2 and JunD whereas in control animals the AP-1 complex in addition contained c-Fos. Our data strongly suggest that c-Fos is required for programmed cell death of prostate epithelial cells.	Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; Pathol Langgasse, CH-3012 Bern, Switzerland	University of Bern; Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Jaggi, R (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35, CH-3010 Bern, Switzerland.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; Bielke W, 1997, CELL DEATH DIFFER, V4, P114, DOI 10.1038/sj.cdd.4400220; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COLOMBEL M, 1992, CANCER RES, V52, P4313; COLOMBEL M, 1995, ONCOGENE, V10, P1269; COLOMBEL M, 1993, AM J PATHOL, V143, P390; COLOMBEL MC, 1995, METHOD CELL BIOL, V46, P369; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FREEMAN SN, 1990, BIOCHEM J, V269, P189, DOI 10.1042/bj2690189; FURUYA Y, 1995, ENDOCRINOLOGY, V136, P1898, DOI 10.1210/en.136.5.1898; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; GONZALEZMARTIN C, 1992, DEV BRAIN RES, V68, P83, DOI 10.1016/0165-3806(92)90250-Z; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kueng P, 1997, J CELL BIOL, V139, P1851, DOI 10.1083/jcb.139.7.1851; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; Lund LR, 1996, DEVELOPMENT, V122, P181; MARTI A, 1994, ONCOGENE, V9, P1213; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Preston GA, 1996, MOL CELL BIOL, V16, P211; RAFFO AJ, 1995, CANCER RES, V55, P4438; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRANGE R, 1992, DEVELOPMENT, V115, P49; Sukharev SA, 1997, CELL DEATH DIFFER, V4, P457, DOI 10.1038/sj.cdd.4400263; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	61	30	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2593	2600		10.1038/sj.onc.1202195	http://dx.doi.org/10.1038/sj.onc.1202195			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840922				2022-12-17	WOS:000077058900006
J	Spinella, MJ; Kitareewan, S; Mellado, B; Sekula, D; Khoo, KS; Dmitrovsky, E				Spinella, MJ; Kitareewan, S; Mellado, B; Sekula, D; Khoo, KS; Dmitrovsky, E			Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells	ONCOGENE			English	Article						retinoic acid; differentiation; embryonal carcinoma; teratocarcinoma; retinoid receptors	ACUTE PROMYELOCYTIC LEUKEMIA; 2ND PRIMARY TUMORS; ACID RECEPTOR; NEURONAL DIFFERENTIATION; HUMAN TERATOCARCINOMAS; SELECTIVE LIGANDS; RESPONSE ELEMENT; BINDING-PROTEIN; CO-REPRESSOR; ALPHA	This study addresses the contributions of specific retinoid receptors during all-trans-retinoic acid (RA)-mediated differentiation and growth suppression of human embryonal carcinoma cells. The pleiotropic effects of RA are mediated bg retinoic acid receptors (RARs) and retinoid, X receptors (RXRs), members of the nuclear receptor family of transcription factors, After RA-treatment the multipotent human embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1) displays limited proliferative potential, reduced tumorigenicity, and morphologic and immunophenotypic neuronal maturation. RAR gamma over-expression in NT2/D1 cells signals mesenchymal NT2/D1 terminal differentiation while RAR alpha and RAR beta do not and RAR gamma overcomes retinoid resistance in an NT2/D1 clone (NT2/D1-R1) having deregulated RAR gamma expression, Since RAR gamma transfectants do not display neuronal maturation, this study sought to identify cooperating retinoid receptors engaged in NT2/D1 differentiation. Through gain of function experiments, this report highlights RXR beta as playing an important role along with RAR gamma in signaling differentiation of NTZ/DI cells. Stable over-expression of RXR beta, but not RXR alpha or RXR gamma, was found to signal NT2/D1 growth suppression and to induce a non-neuronal morphology and immunophenotype pe. Notably, co-transfection of RAR gamma, and RXR beta resulted in marked growth suppression and for the first time, expression of typical neuronal markers of NT2/D1 differentiation. To clarify the role of RXR beta and RAR gamma in this differentiation program, a modified transient fibroblast growth factor-4 (FGF4) promoter-enhancer reporter assay that reflects effective RA-mediated differentiation of NT2/D1 cells was employed, Transfection of RAR gamma or RXR beta in NT2/D1 cells augments transcriptional repression of the FGF4 reporter and RAR gamma and RXR beta co-transfection markedly repressed reporter activity, indicating the combined role of these receptors in RA-induced NT2/D1 differentiation. Taken together, these findings reveal specific retinoid receptors must cooperate to signal terminal growth suppression and maturation of NT2/D1 cells. Since the transcriptional repression of FGF4 is coupled to the effective maturation of human embryonal carcinoma cells, the described co-transfection strategy should prove useful to identify genes with positive or negative effects on the differentiation program of these tumor cells.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mem Hosp & Mol Pharmacol & Therapeut Program, Dept Med,Lab Mol Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Spinella, MJ (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mem Hosp & Mol Pharmacol & Therapeut Program, Dept Med,Lab Mol Med, New York, NY 10021 USA.		Spinella, Michael/B-7210-2014		NCI NIH HHS [R01-CA54494-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; AHN MJ, 1995, ONCOGENE, V10, P2307; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANGULO A, 1995, J VIROL, V69, P3831, DOI 10.1128/JVI.69.6.3831-3837.1995; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Collignon J, 1996, DEVELOPMENT, V122, P509; Costa SL, 1996, EXP CELL RES, V225, P35, DOI 10.1006/excr.1996.0154; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DOLLE P, 1990, DEVELOPMENT, V110, P1133; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; Horn V, 1996, FASEB J, V10, P1071, DOI 10.1096/fasebj.10.9.8801169; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JETTEN AM, 1979, NATURE, V278, P180, DOI 10.1038/278180a0; Kastner P, 1997, DEVELOPMENT, V124, P313; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2; KURIE JM, 1993, DIFFERENTIATION, V54, P123; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; Lei W, 1997, J MOL ENDOCRINOL, V18, P167, DOI 10.1677/jme.0.0180167; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOTAN R, 1995, CANCER RES, V55, P232; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; Mills KJ, 1996, CELL GROWTH DIFFER, V7, P327; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; ONATE SA, 1995, SCIENCE, V270, P1354; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Sporn M.B., 1994, RETINOIDS BIOL CHEM; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	66	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3471	3480		10.1038/sj.onc.1201876	http://dx.doi.org/10.1038/sj.onc.1201876			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692555				2022-12-17	WOS:000074544100014
J	Wellbrock, C; Geissinger, E; Gomez, A; Fischer, P; Friedrich, K; Schartl, M				Wellbrock, C; Geissinger, E; Gomez, A; Fischer, P; Friedrich, K; Schartl, M			Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma	ONCOGENE			English	Article						receptor tyrosine kinase; melanoma; STAT5; signal transduction	EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; COLONY-STIMULATING FACTOR; GENE-EXPRESSION; BETA-CHAIN; TRANSCRIPTIONAL ACTIVATION; CELL-PROLIFERATION; ONCOSTATIN-M; ERYTHROPOIETIN; INTERLEUKIN-2	Overexpression of the mutationally activated Xmrk receptor initiates the formation of hereditary malignant melanoma in the fish Xiphophorus, In addition to transcriptional overexpression a cell-type specific signal transduction is essential for Xmrk mediated tumor formation. To elucidate the consequence of Xmrk signalling and to identify target proteins that characterize the tumor phenotype, we analysed proteins that are strongly tyrosine phosphorylated in the fish melanoma cell line PSM, One of the most prominent phosphotyrosine proteins was found to be the signal transducer and activator of transcription STAT5. In a heterologous cell system (murine pro B-cells), activation of the Xmrk kinase in a chimeric receptor induced tyrosine phosphorylation, nuclear translocation and DNA binding of STAT5. Following receptor stimulation, expression of the STAT5 specific target genes cis, osm and pim-1 was induced, In Xiphophorus PSM cells STAT5 was found to be preferentially localized in the nucleus, but treatment with tyrphostin AG555, a specific Xmrk kinase-inhibitor, blocked nuclear localization. In these cells as well as in Xiphophorus melanoma expression of pim-1 and constitutive DNA-binding activity of STATS was detectable. This constitutive activity was higher in malignant than in benign melanomas, indicating that STATS activation is correlated with the malignancy of these tumors.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, D-97074 Wurzburg, Germany; Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Phys Chem 2, D-97074 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Schartl, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, Dept Physiol Chem 1, Am Hubland, D-97074 Wurzburg, Germany.		Gómez, Ana/K-6998-2014	Gómez, Ana/0000-0003-4714-8064; Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DOMEN J, 1993, LEUKEMIA S2, V7, P108; FENDLY BM, 1990, CANCER RES, V50, P1550; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HOOVER D, 1991, J BIOL CHEM, V266, P14018; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LILLY M, 1992, ONCOGENE, V7, P727; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MALITSCHEK B, 1994, J BIOL CHEM, V14, P10423; MAUELER W, 1993, INT J CANCER, V55, P288, DOI 10.1002/ijc.2910550220; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHARTL M, 1995, TRENDS GENET, V11, P185, DOI 10.1016/S0168-9525(00)89041-1; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Shuai K, 1996, ONCOGENE, V13, P247; STEWART BE, 1995, J INVEST DERMATOL, V105, P699, DOI 10.1111/1523-1747.ep12324482; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VIELKIND U, 1976, J EXP ZOOL, V196, P197, DOI 10.1002/jez.1401960207; VIGNAIS ML, 1996, MOL CELL BIOL, V16, P17759; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WELLBROCK C, 1995, ONCOGENE, V10, P2135; WELLBROCK C, 1998, IN PRESS INT J CANC; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	61	30	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3047	3056		10.1038/sj.onc.1201844	http://dx.doi.org/10.1038/sj.onc.1201844			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662338	Bronze			2022-12-17	WOS:000074125300012
J	Jackson, P; Mastrangelo, I; Reed, M; Tegtmeyer, P; Yardley, G; Barrett, J				Jackson, P; Mastrangelo, I; Reed, M; Tegtmeyer, P; Yardley, G; Barrett, J			Synergistic transcriptional activation of the MCK promoter by p53: tetramers link separated DNA response elements by DNA looping	ONCOGENE			English	Article						p53; MCK; transcription; DNA looping	TATA-BINDING PROTEIN; GENE; IDENTIFICATION; ENHANCER; SEQUENCE; DOMAINS; MUTANT; SITES; TRANSACTIVATION; SUPPRESSION	The WAF1, Cyclin G and muscle creatine kinase (MCK) genes, all contain multiple copies of the consensus p53-binding element within their regulatory regions, We examined the role of these elements in transactivation of the muscle creatine kinase (MCK) gene by p53, The MCK promoter possesses distal (-3182 to -3133) and proximal (-177 to -81) p53-binding elements within which residues -3182 to -3151 (distal) and -176 to -149 (proximal) show homology to the consensus p53-binding site, Using promoter deletion studies, we find that both proximal and distal elements are required for high level, synergistic transcriptional activation in vivo. Electron microscopy indicates that p53-p53 interactions link proximal and distal p53-binding elements and cause looping out of intervening DNA, suggesting that this DNA sequence may be dispensable for synergy, This idea was confirmed by progressive deletion of the DNA between p53-binding elements, Synergism persisted with spacing reduced to only 150 bp, Tetramerization-deficient p53 mutants were defective for transcriptional activation but still capable of synergy, Our results provide evidence for a model by which high level transcriptional activation of promoters with multiple p53 response elements is achieved.	Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; SUNY Stony Brook, Med Ctr, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Jackson, P (corresponding author), Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia.				NCI NIH HHS [CA-18808, CA-28148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018808, R37CA018808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BURATOWSKI S, 1995, SCIENCE, V270, P1773, DOI 10.1126/science.270.5243.1773; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; JACKSON P, 1995, GENE EXPRESSION, V5, P19; JACKSON P, 1993, ONCOGENE, V8, P589; Jackson P, 1997, FEBS LETT, V406, P271, DOI 10.1016/S0014-5793(97)00283-4; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAYR GA, 1995, CANCER RES, V55, P2410; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; Reed Michael, 1993, Gene Expression, V3, P95; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YUAN JN, 1993, BIOCHEM BIOPH RES CO, V192, P662; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	47	30	30	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					283	292		10.1038/sj.onc.1201491	http://dx.doi.org/10.1038/sj.onc.1201491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464547				2022-12-17	WOS:000071427100016
J	Wagner, P; Fuchs, A; Gotz, C; Nastainczyk, W; Montenarh, M				Wagner, P; Fuchs, A; Gotz, C; Nastainczyk, W; Montenarh, M			Fine mapping and regulation of the association of p53 with p34(cdc2)	ONCOGENE			English	Article						p53; growth suppressor protein; protein kinase p34(cdc2)	CASEIN KINASE-II; CELL-CYCLE CONTROL; TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; FISSION YEAST; DNA-BINDING; TMS1 PROTEIN; PHOSPHORYLATION SITES; GROWTH ARREST; MUTANT	In vivo p53 is multiply phosphorylated by different protein kinases suggesting a central role for phosphorylation in modulating p53 function. In addition, p53 was found to be associated with two protein kinases, p34(cdc2) and protein kinase CK2. Here we report the precise mapping of the interaction sites of p53-p34(cdc2) complexes. The p34(cdc2) binding site on human p53 maps to one distinct C-terminal site LQIRGRERFE (aa 330-339) close to the corresponding phosphorylation site at serine 315. In order to test whether phosphorylation of p53 might influence the binding of p53 to p34(cdc2) phosphorylation mutants of the C-terminus of p53, which mimick permanent phosphorylation, were tested on their ability to bind to p34(cdc2) in vitro. Substitution of serine 315 (the p34(cdc2) phosphorylation site) with aspartic acid had only little effect on complex formation whereas an exchange of serine 392 (the protein kinase CK2 phosphorylation site) to aspartic acid resulted in a significant reduced relative binding affinity of p53 to p34(cdc2). The same result was obtained when the C-terminus of p53 was phosphorylated by purified protein kinase CK2 prior to examination of complex formation. In addition, the specificity of the complex formation has been checked by competition experiments with full length p53 proteins and the influence of cyclin B on complex formation was examined.	Univ Saarlandes, D-66421 Homburg, Germany	Saarland University	Wagner, P (corresponding author), Univ Saarlandes, Bldg 44, D-66421 Homburg, Germany.		Montenarh, Mathias/AAB-6689-2020					APPEL K, 1995, ONCOGENE, V11, P1971; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAMICO D, 1992, ONCOGENE, V7, P339; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARLOW E, 1981, J VIROL, V398, P61; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hecker D, 1996, ONCOGENE, V12, P953; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1993, ADV EXP MED BIOL, V339, P291; KRAISS S, 1990, ONCOGENE, V5, P845; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LIU FS, 1994, OBSTET GYNECOL, V83, P118; LORENZ A, 1992, INT J ONCOL, V1, P571; MEEK DW, 1992, BIOCHEM J, V287, P1; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NISHIDA N, 1993, CANCER RES, V53, P368; SCHNEIDER E, 1995, HYBRIDOMA, V14, P329, DOI 10.1089/hyb.1995.14.329; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; STURZBECHER HW, 1990, ONCOGENE, V5, P795; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; WAGNER P, 1991, ONCOGENE, V6, P1539; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; WAGNER P, 1994, HYBRIDOMA, V13, P527, DOI 10.1089/hyb.1994.13.527; WAGNER P, 1995, INT J ONCOL, V7, P171; WAGNER P, 1994, INT J ONCOL, V4, P987; WAGNER P, 1994, INT J ONCOL, V4, P491; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0	49	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					105	111		10.1038/sj.onc.1201510	http://dx.doi.org/10.1038/sj.onc.1201510			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467949				2022-12-17	WOS:000071236800013
J	Waltz, SE; Toms, CLV; McDowell, SA; Clay, LA; Muraoka, RS; Air, EL; Sun, WY; Thomas, MB; Degen, SJF				Waltz, SE; Toms, CLV; McDowell, SA; Clay, LA; Muraoka, RS; Air, EL; Sun, WY; Thomas, MB; Degen, SJF			Characterization of the mouse Ron/Stk receptor tyrosine kinase gene	ONCOGENE			English	Article						Ron; Stk; hepatocyte growth factor-like protein receptor	MACROPHAGE-STIMULATING PROTEIN; HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; MOLECULAR-CLONING; CONSTITUTIVE ACTIVATION; MET; EXPRESSION; RON; MSP; STK	In an effort to understand the mechanisms governing the regulation of the mouse Ron receptor gene, a mouse genomic library was screened and overlapping clones coding for the Ron gene and flanking DNA were identified, Continuous DNA sequence was obtained for approximately 16.4 kilobases, The gene, from the initiator methionine to the polyadenylation site, is contained within 13 244 basepairs and contains 19 exons, Primer extension analyses were performed to determine the transcription start site of the mouse Ron transcript, Multiple transcription start sites were found which also appear to be used in transfected reporter constructs containing Ron 5' flanking DNA, To determine the location of sites which may be critical for the function of the Ron gene promoter, a series of chimeric genes containing serial deletions of the Ron gene promoter fused to the coding sequences for the chloramphenicol acetyl-transferase gene were constructed, Transient transfection analyses of these hybrid genes into various cell lines demonstrated that two regions of the Ron gene promoter, encompassing nucleotides -585 to -465 and from -465 to -285, are important for expression of this transcript in CMT-93 cells, Further analysis of the Ron promoter utilizing gel mobility shift analyses suggests that regions encompassing nucleotides -585 to -508 and nucleotides -375 to -285 appear to bind specific proteins which may be involved in the negative and positive regulation, respectively, of the mouse Ron gene.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45221 USA; Univ Cincinnati, Grad Program Dev Biol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Degen, SJF (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45221 USA.		Toms, Christy/L-4472-2013	Toms, Christy/0000-0003-4305-6357; Waltz, Susan/0000-0003-3572-4642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009466] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07382] Funding Source: Medline; NIDDK NIH HHS [DK47003, DK09466] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERKNER KL, 1985, NUCLEIC ACIDS RES, V13, P841, DOI 10.1093/nar/13.3.841; BEZERRA JA, 1993, PROTEIN SCI, V2, P666; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORRELL PH, 1997, GENES FUNCTION, V1, P1; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; DEGEN SJF, 1992, GENOMICS, V13, P1368, DOI 10.1016/0888-7543(92)90073-2; DELGATTO F, 1995, BBA-GENE STRUCT EXPR, V1263, P93, DOI 10.1016/0167-4781(95)00082-R; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; Gambarotta G, 1996, ONCOGENE, V13, P1911; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HAN S, 1993, HEPATOCYTE GROWTH FA, P81; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QUANTIN B, 1995, DEV DYNAM, V204, P383, DOI 10.1002/aja.1002040405; RONSIN C, 1993, ONCOGENE, V8, P1195; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, J IMMUNOL, V152, P4618; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; ZHEN Z, 1994, ONCOGENE, V9, P1691	44	30	33	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					27	42		10.1038/sj.onc.1201508	http://dx.doi.org/10.1038/sj.onc.1201508			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467940				2022-12-17	WOS:000071236800004
J	Isfort, RJ; Cody, DB; Doersen, CJ; Richards, WG; Yoder, BK; Wilkinson, JE; Kier, LD; Jirtle, RL; Isenberg, JS; Klounig, JE; Woychik, RP				Isfort, RJ; Cody, DB; Doersen, CJ; Richards, WG; Yoder, BK; Wilkinson, JE; Kier, LD; Jirtle, RL; Isenberg, JS; Klounig, JE; Woychik, RP			The tetratricopeptide repeat containing Tg737 gene is a liver neoplasia tumor suppressor gene	ONCOGENE			English	Article						Tg737; tumor suppressor gene; liver neoplasia	POLYCYSTIC KIDNEY-DISEASE; STEM-CELLS; HUMAN HOMOLOG; SNAP HELIX; GROWTH; PROTEIN; DIFFERENTIATION; MUTATION; MOUSE; CARCINOGENESIS	The Tg737 gene was investigated for gross alterations in a series of rodent/human liver tumors and human tumorigenic cell lines. The Tg737 gene was found to be altered in approximately 40% of the rodent chemically-induced liver tumors, 40% of the human liver tumors, and in liver, kidney and pancreatic human tumor cell lines. Ectopic re-expression of the Tg737 gene in a Tg737 deleted mouse liver tumor cell line resulted in suppression of tumorigenic growth, without altering in vitro cell culture growth. Treatment of mice which are either homozygous normal or heterozygous deleted at the Tg737 locus with the carcinogen diethylnitrosamine resulted in an increase in preneoplastic foci formation in the Tg737 heterozygous deleted mice. Ectopic expression of the Tg737 gene results in multinucleated cells, loss of Tg737 gene expression results in the proliferation of liver stem cells (oval cells) without concomitant differentiation, and reexpression of the Tg737 gene reestablished responsiveness to external differentiation factors. We believe this is the first report demonstrating tumor suppression activity for a tetratricopeptide repeat gene family member and provides insights into the function of this family of genes in mammalian cells.	OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; UNIV TENNESSEE,SCH VET MED,KNOXVILLE,TN; MONSANTO AGR CO,ST LOUIS,MO; DUKE UNIV,MED CTR,DURHAM,NC; INDIANA UNIV,SCH MED,DEPT PHARMACOL & TOXICOL,INDIANAPOLIS,IN 46202	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Monsanto; Duke University; Indiana University System; Indiana University-Purdue University Indianapolis	Isfort, RJ (corresponding author), PROCTER & GAMBLE CO,MIAMI VALLEY LABS,POB 398707,CINCINNATI,OH 45247, USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732				ATERMAN K, 1992, J CANCER RES CLIN, V118, P87, DOI 10.1007/BF01187498; AVNER ED, 1994, LANCET, V344, P833, DOI 10.1016/S0140-6736(94)92820-7; Avner Ellis D., 1994, V5, P63; BIRCHMEIER W, 1994, BIOESSAYS, V16, P305, DOI 10.1002/bies.950160503; BRILL S, 1993, P SOC EXP BIOL MED, V204, P261; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; COLEMAN WB, 1993, AM J PATHOL, V142, P1373; FACTOR VM, 1994, AM J PATHOL, V145, P409; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HENNINGS H, 1993, P SOC EXP BIOL MED, V202, P1; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; ISFORT R, 1987, ONCOGENE RES, V2, P81; ISFORT RJ, 1994, INT J CANCER, V59, P114, DOI 10.1002/ijc.2910590121; ISFORT RJ, 1995, MOL CARCINOGEN, V14, P170, DOI 10.1002/mc.2940140306; ISFORT RJ, 1997, IN PRESS J CELL SCI; ISFORT RJ, 1997, IN PRESS MOL CARCINO; KUMADA K, 1995, J CELL SCI, V108, P895; LEBOEUF RA, 1986, CARCINOGENESIS, V7, P1431, DOI 10.1093/carcin/7.9.1431; LILLEBERG SL, 1992, PROG CLIN BIOL RES, V376, P203; LILLEBERG SL, 1992, MOL CARCINOGEN, V6, P159, DOI 10.1002/mc.2940060211; MARCEAU N, 1989, IN VITRO CELL DEV B, V25, P336; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; NICKOLOFF BJ, 1988, AM J PATHOL, V132, P543; PUGH TD, 1992, CANCER RES, V52, P280; Richards WG, 1996, AM J PATHOL, V149, P1919; RICHARDS WG, 1997, IN PRESS HEPATOLOGY; RIJKSEN G, 1993, J CELL PHYSIOL, V154, P393, DOI 10.1002/jcp.1041540223; RUBIN H, 1993, DIFFERENTIATION, V53, P123, DOI 10.1111/j.1432-0436.1993.tb00652.x; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHRICK JJ, 1995, HUM MOL GENET, V4, P559, DOI 10.1093/hmg/4.4.559; SELL S, 1993, INT J DEV BIOL, V37, P189; SELL S, 1994, LAB INVEST, V70, P6; SIKORSKI RS, 1993, MOL CELL BIOL, V13, P1212, DOI 10.1128/MCB.13.2.1212; SORIANO P, 1991, CELL, V64, P692; THORGEIRSSON SS, 1993, AM J PATHOL, V142, P1331; WILLIAMS ED, 1992, AM J PATHOL, V141, P773	40	30	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1797	1803		10.1038/sj.onc.1201535	http://dx.doi.org/10.1038/sj.onc.1201535			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362446				2022-12-17	WOS:A1997XZ72500006
J	Suzuki, J; Kaziro, Y; Koide, H				Suzuki, J; Kaziro, Y; Koide, H			An activated mutant of R-Ras inhibits cell death caused by cytokine deprivation in BaF3 cells in the presence of IGF-I	ONCOGENE			English	Article						R-Ras; apoptosis; PI3K; MAPK; IGF-I; Ras	GROWTH-FACTOR; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL-TRANSDUCTION; PROTO-ONCOGENES; H-RAS; APOPTOSIS; EXPRESSION; RECEPTOR; IDENTIFICATION	R-Ras belongs to a family of low molecular weight GTP-binding proteins and exhibits 55% amino acid identity to H-Ras. It has been demonstrated that H-Ras inhibits cell death caused by interleukin-3 (IL-3) withdrawal in BaF3 cells (Kinoshita rt al. (1995b); Terada et al. (1995)). In the present study, we examined whether R-Ras also rescues BaF3 cells from the factor-deprived cell death, To do this, several BaF3 transfectants were established, in which expression of wild-type as well as mutant R-Ras was regulated by an inducible promoter. Using these transfectants, we found that expression of an activated R-Ras mutant, R-Ras (Q87L), suppressed the death of IL-3-deprived BaF3 cells. On the other hand, expression of the wild-type and the dominant-negative mutant of R-Ras showed no inhibitory effect on cell death, indicating that R-Ras.GTP abrogated cell death caused by deprivation of IL-3, Furthermore, it was found that IGF-I in serum was required for the anti-apoptotic activity of R-Ras, Suppression of cell death by R-Ras(Q87L) was inhibited by wortmannin, LY294002 (phosphatidylinositol 3-kinase (PI3K) inhibitors), or PD98059 (inhibitor for MEK, a specific activator of mitogen-activated protein kinase (MAPK)), In addition, we have shown that, in HEK293 cells, R-Ras and IGF-I could activate MAPK synergistically. Also, PI3K activity was co-immunoprecipitated with an activated mutant of R-Ras. These results suggest that R-Ras in collaboration with IGF-I suppressed apoptotic cell death of BaF3 caused by IL-3 deprivation, presumably by modulating the activitites of MAPK and PI3K.	TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, MIDORI KU, YOKOHAMA, KANAGAWA 227, JAPAN	Tokyo Institute of Technology			Koide, Hiroshi/E-9000-2011	Koide, Hiroshi/0000-0001-5916-3179				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; Cormier F, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104811; COX AD, 1994, ONCOGENE, V9, P3281; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Minshall C, 1996, J IMMUNOL, V156, P939; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; REY I, 1994, ONCOGENE, V9, P685; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	45	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1689	1697		10.1038/sj.onc.1201333	http://dx.doi.org/10.1038/sj.onc.1201333			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349502				2022-12-17	WOS:A1997XY63100008
J	Fesquet, D; Morin, N; Doree, M; Devault, A				Fesquet, D; Morin, N; Doree, M; Devault, A			Is Cdk7 cyclin H MAT1 the genuine cdk activating kinase in cycling xenopus egg extracts?	ONCOGENE			English	Article						cdk; cdk7; CAK; phosphorylation; cell cycle; Xenopus	MATURATION-PROMOTING FACTOR; RING FINGER PROTEIN; CELL-CYCLE; DEPENDENT KINASES; DNA-REPLICATION; BUDDING YEAST; CAK; PHOSPHORYLATION; P34CDC2; CDC2	Formation of active cdk (cyclin dependent kinase)/ cyclin kinases involves phosphorylation of a conserved threonine residue in the T loop of the cdk catalytic subunit by CAK (Cdk Activating Kinase). CAK was first purified biochemically from higher eukaryotes and identified as a trimeric complex containing a cdk7 catalytic subunit, cyclin H and MAT1 (Menage a trois), a member of the RING finger family. The same trimeric complex is also part of basal transcription factor TFIIH. In budding yeast, the closest homologs of cdk7 and cyclin H, KIN28 and CCL1, respectively, also associate with TFIIH. However, the KIN28/CCL1 complex does not display CAK activity and a distinct protein kinase able to phosphorylate monomeric CDC28 and GST-cdk2 was recently identified, challenging the identification of cdk7 as the physiological CAK in higher eukaryotes. Here we demonstrate that immunodepletion of cdk7 suppresses CAK activity from cycling Xenopus egg extracts, and arrest them before M-phase. We also show that specific translation of mRNAs encoding Xenopus cdk7 and its associated subunits restores CAK activity in cdk7-immunodepleted Xenopus egg extracts. Hence, the cdk7 complex is necessary and sufficient for activation of cdk-cyclin complexes in cycling Xenopus egg extracts.	CTR RECH BIOCHIM MACROMOL,CNRS ERS 155,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Fesquet, didier/M-9750-2019; Fesquet, Didier/A-1490-2009	Fesquet, didier/0000-0001-5657-9689; Morin, Nathalie/0000-0001-8677-1401				Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KREK W, 1992, NEW BIOL, V4, P323; LOHKA MJ, 1984, DEV BIOL, V103, P434, DOI 10.1016/0012-1606(84)90331-2; MATTHEWS G, 1994, CELL BIOL LAB HDB, P131; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; POON RYC, 1995, CURR BIOL, V5, P1243; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Wagner M, 1997, EMBO J, V16, P1305, DOI 10.1093/emboj/16.6.1305	29	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1303	1307		10.1038/sj.onc.1201300	http://dx.doi.org/10.1038/sj.onc.1201300			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315098				2022-12-17	WOS:A1997XV84500008
J	Alimandi, M; Heidaran, MA; Gutkind, JS; Zhang, JC; Ellmore, N; Valius, M; Kazlauskas, A; Pierce, JH; Li, WQ				Alimandi, M; Heidaran, MA; Gutkind, JS; Zhang, JC; Ellmore, N; Valius, M; Kazlauskas, A; Pierce, JH; Li, WQ			PLC-gamma activation is required for PDGF-beta R-mediated mitogenesis and monocytic differentiation of myeloid progenitor cells	ONCOGENE			English	Article						PLC-gamma; PDGF-beta R; monocytic differentiation	PROTEIN-KINASE-C; GROWTH-FACTOR; PHOSPHOLIPASE-C; MONOCLONAL-ANTIBODY; RECEPTOR; DELTA; ALPHA; AUTOPHOSPHORYLATION; PHOSPHORYLATION; INVOLVEMENT	To investigate the molecular mechanisms mediating hematopoietic cell differentiation and mitogenesis by activation of the platelet-derived growth factor beta receptor (PDGF-beta R), the mild type PDGF-beta R (PDGF-beta RWT) and tyrosine to phenylalanine mutants of the PDGF-beta R, including F751, F966, F970, F1009, F1021 and F1009/F1021 were overexpressed in FDC-P2 myeloid progenitor cells by retroviral-mediated gene transfer. Stimulation of PDGF-beta RWT and F966, F970 and F1009 infectants with PDGF-BB led to the increased expression of monocytic differentiation markers, In contrast, activation of PDGF-beta R in the parental line or the F1021 or F1009/F1021 mutant infectants failed to induce monocytic differentiation, PDGF-BB stimulation of PDGF-beta RWT, F751, F966, F970 and F1009 infectants led to pronounced DNA synthesis, whereas F1021 and F1009/F1021 infectants did not reveal any increase in mitogenesis when compared to that of the FDC-P2 line, While PDGF stimulation of FDC-2 cells overexpressing PDGF-beta RWT led to a pronounced increase in inositol phosphate formation due to phospholipase C-gamma (PLC-gamma) activation, PDGF-BB induced phosphoinositol hydrolysis was completely abolished in the F1021 and F1009/F1021 infectants, GF 109203X, a specific inhibitor of protein kinase C (PKC) activation, fully blocked PDGF-beta R-mediated monocytic differentiation and mitogenesis, Taken together, these results suggest that stimulation of the PDGF-beta R signaling pathway can mediate monocytic differentiation when PDGF-beta R is expressed at sufficient levels and that activation of PLC-gamma and PKC plays a pivotal role in PDGF-beta R-mediated differentiation and mitogenesis in FDC-P2 cell system.	NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892; NIDR,MOL SIGNALING UNIT,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892; LITHUANIA ACAD SCI,INST BIOCHEM,LT-2600 VILNIUS,LITHUANIA; HARVARD UNIV,SCH MED,SCHEPENS EYE RES INST,BOSTON,MA 02114	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Vilnius University; Harvard University; Harvard Medical School; Schepens Eye Research Institute			Alimandi, Maurizio/AAG-9246-2019; Gutkind, J. Silvio/J-1201-2016; Valius, Mindaugas/N-1220-2019; Valius, Mindaugas/F-2734-2012; Gutkind, J. Silvio/A-1053-2009	Alimandi, Maurizio/0000-0002-1409-6803; Gutkind, J. Silvio/0000-0002-5150-4482; Valius, Mindaugas/0000-0001-8478-8517; 	NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER; NCI NIH HHS [CA55063] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Aprikian A., 1996, Blood, V88, p633A; ASHCROFT M, 1996, 1996 M TYR PHOSPH CE; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HO MK, 1982, J IMMUNOL, V128, P1221; INABA T, 1993, J BIOL CHEM, V268, P24353; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LEE SH, 1985, J EXP MED, V161, P475, DOI 10.1084/jem.161.3.475; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; MARTINYBARON G, 1993, J BIOL CHEM, V268, P1749; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UKELESS JC, 1979, J EXP MED, V150, P580; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Uren A, 1996, J BIOL CHEM, V271, P11051, DOI 10.1074/jbc.271.19.11051; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479	31	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					585	593		10.1038/sj.onc.1201221	http://dx.doi.org/10.1038/sj.onc.1201221			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247312	Bronze			2022-12-17	WOS:A1997XN25500010
J	Smith, KS; Jacobs, Y; Chang, CP; Cleary, ML				Smith, KS; Jacobs, Y; Chang, CP; Cleary, ML			Chimeric oncoprotein E2a-Pbx1 induces apoptosis of hematopoietic cells by a p53-independent mechanism that is suppressed by Bcl-2	ONCOGENE			English	Article						apoptosis; inducible oncoprotein; translocation; homeodomain	LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN PROTOONCOGENE PBX1; WILD-TYPE P53; DNA-BINDING; PRE-B; FUSION; E2A; TRANSCRIPTION; EXPRESSION	The chimeric oncoprotein E2a-Pbx1 results from fusion of the E2A and PBX1 genes following t(1;19) chromosomal translocations in B cell precursor acute leukemias. Experimentally B cell progenitors do not tolerate constitutive expression of E2a-Pbx1 which contrasts with transformation of several other cell types following its stable expression both in vitro and in vivo, To further investigate the effects of E2a-Pbx1 on the B cell progenitors, we conditionally expressed E2a-Pbx1 under control of a metal response element in hematopoietic precursor cell lines in vitro, Inducible expression of E2a-Pbx1 resulted in cell death with the morphologic and molecular features of apoptosis, A structure-function analysis demonstrated that induction of apoptosis was not a dominant-negative effect of the E2a moiety but, rather, required the DNA-binding homeodomain of Pbx1, E2a-Pbx1-induced apoptosis proceeded through a BCL2-responsive checkpoint eventuating in PARP inactivation but did require p53, Constitutive expression of E2a-Pbx1 did not induce apoptosis or continued cycling of Rat-1 fibroblasts in low serum conditions, These studies demonstrate that E2a-Pbx1 initiates programmed cell death of hematopoietic precursers by a mechanism that requires its chimeric transcriptional properties, but, unlike other nuclear oncoproteins, is independent of p53.			Smith, KS (corresponding author), STANFORD UNIV,MED CTR,DEPT PATHOL,EXPT ONCOL LAB,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42971, CA09151, CA66284] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042971, R01CA042971, F32CA066284] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHANG CP, 1997, IN RPESS MOL CELL BI; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMURA M, 1995, BLOOD, V85, P2546, DOI 10.1182/blood.V85.9.2546.bloodjournal8592546; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU QA, 1995, MOL CELL BIOL, V15, P3786; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZHOU H, 1996, SCIENCE, V272, P738	44	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2917	2926		10.1038/sj.onc.1201249	http://dx.doi.org/10.1038/sj.onc.1201249			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205098				2022-12-17	WOS:A1997XF55500005
J	Martinez, JD; Craven, MT; Joseloff, E; Milczarek, G; Bowden, GT				Martinez, JD; Craven, MT; Joseloff, E; Milczarek, G; Bowden, GT			Regulation of DNA binding and transactivation in p53 by nuclear localization and phosphorylation	ONCOGENE			English	Article						p53; DNA binding; nuclear localization; phosphorylation; transactivation	TEMPERATURE-SENSITIVE MUTANT; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; DAMAGING AGENTS; INDUCED TUMORS; 3T3 CELLS; IN-VITRO; PROTEIN	Compelling evidence indicates that p53 acts as a transcription factor and that this activity is regulated by several factors including subcellular localization and phosphorylation status of the protein. To learn more about how these two processes determine whether p53 becomes activated, we studied the temperature sensitive murine p53, p53(val135). At nonpermissive temperatures, p53(val135) remains sequestered in the cytoplasm of cells ,which express it. Electrophoretic mobility shift assays demonstrated that, under these conditions, the protein lacked DNA binding activity. However, by shifting to the permissive temperature, p53(val135) became concentrated in the nucleus, hyperphosphorylated, and had acquired the ability to bind DNA in a sequence specific manner. This was accompanied by the induction of two p53 regulated genes, mdm2 and p21(waf1), which indicated that p53(val135) had become an active transcription factor. Two dimensional gel electrophoresis and tryptic peptide mapping showed that entry into the nucleus resulted in the appearance of new phosphorylated isoforms and that the protein had become extensively phosphorylation at the N-terminus. Notably, phosphorylation at the N-terminus occurred only in the nucleus, whereas phosphorylation at the C-terminus could occur in both the cytoplasm and the nucleus. Based on these observations, we suggest that phosphorylation of p53's N-terminus is compartmentally restricted.			Martinez, JD (corresponding author), UNIV ARIZONA,DEPT RADIAT ONCOL,TUCSON,AZ 85724, USA.				NCI NIH HHS [CA23074, CA40584, R29-CA64842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064842, R01CA040584, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Boyle W J, 1991, Methods Enzymol, V201, P110; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1993, ONCOGENE, V8, P1519; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARPER JW, 1993, CELL, V75, P805; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hecker D, 1996, ONCOGENE, V12, P953; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO L, 1991, CYANOGEN BROMIDE CLE, P149; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	52	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2511	2520		10.1038/sj.onc.1201095	http://dx.doi.org/10.1038/sj.onc.1201095			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191051				2022-12-17	WOS:A1997XA94900003
J	Mao, SF; Neale, GAM; Goorha, RM				Mao, SF; Neale, GAM; Goorha, RM			T-cell oncogene rhombotin-2 interacts with retinoblastoma-binding protein 2	ONCOGENE			English	Article						oncogene; rhombotin-2; RBP2; transcription	LIM-DOMAIN PROTEINS; CYSTEINE-RICH MOTIF; LOOP-HELIX PROTEIN; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; TRANSCRIPTION FACTOR; TRANSGENIC MICE; ACUTE LEUKEMIAS; INSULIN GENE; RBTN2	The LIM domain protein rhombotin-2 (RBTN-2/TTG-2/Lmo2) has distinct functions in erythropoiesis and in T-cell leukemogenesis. Additional functions for RBTN2 are indicated by its expression in non-hematopoietic tissues. These diverse functions of RBTN2 are presumed to be accomplished through physical interaction with different protein partners that bind the LIM domains of RBTN2. To identify these proteins which may modulate the activity of RBTN2, a human cDNA library was screened using the yeast two-hybrid assay. Using the RBTN2 LIM domain region as 'bait', the retinoblastoma-binding protein 2 (RBP2) was identified as a partner for RBTN2. The interaction between RBTN2 and RBP2 was confirmed using in vitro binding assays, and by coimmunoprecipitation of the two proteins. Deletion analysis showed the second LM domain of RBTN2 was necessary and sufficient for binding to the last 69 amino acids of RBP2. The interaction between RBTN2 and RBP2 had a functional consequence: the combination of RBP2 and RBTN2 gave higher transcription in vitro, than RBTN2 alone. The interaction with RBP2 suggests tao additional functions for RBTN2: (i) RBTN2 may directly affect the activity of RBP2, and/or (ii) RBTN2 may indirectly modulate the functions of the retinoblastoma protein by binding to RBP2.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOL BIOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT PATHOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NATIONAL CANCER INSTITUTE [P30CA021765, R01CA043237] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765, CA 43237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AUSEBEL F, 1993, CURRENT PROTOCOLS MO; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FATTAEY AR, 1993, ONCOGENE, V8, P3149; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HARPER JW, 1993, CELL, V75, P805; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LARSON RC, 1995, ONCOGENE, V11, P853; LARSON RC, 1994, ONCOGENE, V9, P3676; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; NEALE GAM, 1995, CELL GROWTH DIFFER, V6, P587; NEALE GAM, 1995, BLOOD, V86, P3060; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SANCHEZGARCIA I, 1995, ONCOGENE, V10, P1301; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	47	30	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1531	1539		10.1038/sj.onc.1200988	http://dx.doi.org/10.1038/sj.onc.1200988			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129143				2022-12-17	WOS:A1997WQ54800003
J	Shridhar, V; Wang, L; Rosati, R; Paradee, W; Shridhar, R; Mullins, C; Sakr, W; Grignon, D; Miller, OJ; Sun, QC; Petros, J; Smith, DI				Shridhar, V; Wang, L; Rosati, R; Paradee, W; Shridhar, R; Mullins, C; Sakr, W; Grignon, D; Miller, OJ; Sun, QC; Petros, J; Smith, DI			Frequent breakpoints in the region surrounding FRA3B in sporadic renal cell carcinomas	ONCOGENE			English	Article						fragile site; breakpoints; renal cell carcinoma	TUMOR-SUPPRESSOR GENE; SHORT ARM; FRAGILE SITE; HETEROZYGOSITY; DELETION; IDENTIFICATION; TRANSLOCATION; CHROMOSOME-3; SEQUENCES; 3P14	The constitutive fragile site at chromosomal band 3p14.2, FRA3B, is the most active common fragile site in the human genome, We have localized aphidicolin-induced breakpoints to two distinct clusters, separated by 200 Kb, in FRA3B (Paradee et al., 1996). Sequence analysis of these regions identified two polymorphic microsatellite markers immediately adjacent to each of these breakpoint clusters. In this report we have used these two new microsatellites and 14 additional 3p microsatellites to analyse chromosome 3p breakage and loss in 94 sporadic RCC samples, including nonpapillary, papillary and oncocytomas, We have found heterozygous loss of 3p14 sequences in >60% of the RCC samples, including both clear cell and papillary renal cell carcinomas, We have found frequent breakage in the region immediately surrounding FRA3B, demonstrating that FRA3B does play a role in chromosome breakage and loss in RCC, In contrast to other reports, >50% of the papillary tumors also showed LOH of 3p markers, We also observed microsatellite instability (MIN) with most of the tested markers in seven of eight oncocytomas and one of 69 clear cell carcinomas, The MIN in some oncocytomas was of the RER + (replication error) type I phenotype, None of the five 3p14.2 markers detected any homozygous deletions in tumor samples, but 69/94 (73%) of the tumors had LOH for the region, which includes the recently identified FHIT gene.	WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,KARMANOS CANC INST,DETROIT,MI 48201; EMORY UNIV,SCH MED,DEPT HUMAN GENET,ATLANTA,GA 30322; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201; EMORY UNIV,SCH MED,DEPT UROL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,WINSHIP CANC CTR,ATLANTA,GA 30322	Barbara Ann Karmanos Cancer Institute; Wayne State University; Emory University; Wayne State University; Wayne State University; Emory University; Emory University					NCI NIH HHS [CA48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGLEY DH, 1990, COMPREHENSIVE TXB ON, P1055; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DRUCK T, 1995, CANCER RES, V55, P5348; Kastury K, 1996, CANCER RES, V56, P978; KOVACS G, 1989, AM J PATHOL, V134, P27; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MORITA R, 1991, CANCER RES, V51, P820; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; PARADEE W, 1995, GENOMICS, V27, P358, DOI 10.1006/geno.1995.1057; PRESTI JC, 1993, CANCER RES, V53, P5780; Schwerdtle RF, 1996, CANCER RES, V56, P2927; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SHUIN T, 1994, CANCER RES, V54, P2852; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; Sozzi G, 1996, CANCER RES, V56, P2472; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; STORKEL SF, 1995, BIOL RENAL CELL CARC, P1; Thiagalingam S, 1996, CANCER RES, V56, P2936; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330; WILHELM M, 1995, CANCER RES, V55, P5383; WILKE CM, 1994, GENOMICS, V22, P319, DOI 10.1006/geno.1994.1390; YAMAKAWA K, 1991, CANCER RES, V51, P4707; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	31	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1269	1277		10.1038/sj.onc.1201100	http://dx.doi.org/10.1038/sj.onc.1201100			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178887				2022-12-17	WOS:A1997WP10900002
J	Calogero, A; Cuomo, L; DOnofrio, M; deGrazia, U; Spinsanti, P; Mercola, D; Faggioni, A; Frati, L; Adamson, ED; Ragona, G				Calogero, A; Cuomo, L; DOnofrio, M; deGrazia, U; Spinsanti, P; Mercola, D; Faggioni, A; Frati, L; Adamson, ED; Ragona, G			Expression of Egr-1 correlates with the transformed phenotype and the type of viral latency in EBV genome positive lymphoid cell lines	ONCOGENE			English	Article						Egr-1; EBV; lymphoid cell lines	EPSTEIN-BARR-VIRUS; ZINC FINGER GENE; TRANSCRIPTION FACTOR; BURKITTS-LYMPHOMA; B-LYMPHOCYTES; INVITRO INFECTION; RESPONSE GENES; CROSS-LINKING; WILMS-TUMOR; LUNG-CANCER	In this paper we have investigated the role of Egr-1 in B cell growth regulation by examining the gene expression in a panel of B cell lines, including both EBV genome negative and EBV carrying cell lines. Egr-1 expression correlates with the cellular phenotype and the specific pattern of viral latency established within the individual cell lines. Thus, constitutive activation of Egr-1 gene is invariably associated with unrestricted expression of viral latent genes in all group III EBV genome carrying cell lines. In contrast, Egr-1 expression is abrogated in group I Burkitt tumor cells, irrespective of the EBV genome carrying status. Activated viral gene expression associated with phenotypic conversion of group I cell lines in to group II or III restores the Egr-1 gene expression. Several forms of EGR-1 protein are found within the different groups of cell lines, and the binding activity to DNA consensus sequences was investigated. Finally, time course analysis of Egr-1 expression during the early steps of EBV infection in vitro demonstrated that Egr-1 is upregulated within minutes from the initial interaction with the B lymphocyte.	IRCCS, IST NEUROL MEDITERRANEO, POZZILLI, ITALY; UNIV ROMA LA SAPIENZA, DIPARTIMENTO MED SPERIMENTALE & PATOL, I-00185 ROME, ITALY; SIDNEY KIMMEL CANC CTR, SAN DIEGO, CA USA; BURNHAM INST, SAN DIEGO, CA USA	IRCCS Neuromed; Sapienza University Rome			de Grazia, Ugo/K-1307-2016; Frati, Luigi/ABI-7437-2020; mercola, dan/L-4182-2013; calogero, antonella/U-5418-2019	de Grazia, Ugo/0000-0001-8648-0372; mercola, dan/0000-0002-0281-9840; calogero, antonella/0000-0002-3322-2916				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BOULTWOOD J, 1994, GENOMICS, V19, P425, DOI 10.1006/geno.1994.1090; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CIRONE M, 1995, CANCER LETT, V89, P125, DOI 10.1016/0304-3835(94)03663-4; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; EHLINHENRIKSSON B, 1987, INT J CANCER, V39, P211, DOI 10.1002/ijc.2910390215; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; GREGORY CD, 1992, REV MED VIROL, V2, P205, DOI 10.1002/rmv.1980020405; GUALANDI G, 1992, J VIROL, V66, P5677, DOI 10.1128/JVI.66.9.5677-5681.1992; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; HUANG RP, 1995, CANCER RES, V55, P5054; KLAUS SJ, 1993, MOL IMMUNOL, V30, P1553, DOI 10.1016/0161-5890(93)90463-L; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; Lenoir G M, 1985, IARC Sci Publ, P309; LEVIN WJ, 1995, ONCOGENE, V11, P1261; LEVIN WJ, 1994, CHEST, V106, pS372, DOI 10.1378/chest.106.6.372S; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MCMAHON SB, 1995, J EXP MED, V181, P417, DOI 10.1084/jem.181.1.417; MENEZES J, 1975, BIOMEDICINE, V22, P276; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Mitchell R L, 1986, Symp Fundam Cancer Res, V39, P99; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; MONROE JG, 1993, ADV MOL CELL IMMUN B, V1, P1; MURRAY RJ, 1988, J VIROL, V62, P894, DOI 10.1128/JVI.62.3.894-901.1988; Nemerow G R, 1990, Adv Cancer Res, V54, P273, DOI 10.1016/S0065-230X(08)60814-3; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RAGONA G, 1986, CELL BIOL INT REP, V10, P315, DOI 10.1016/0309-1651(86)90002-0; RAGONA G, 1991, DNA CELL BIOL, V10, P61, DOI 10.1089/dna.1991.10.61; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; ROONEY CM, 1984, INT J CANCER, V34, P339, DOI 10.1002/ijc.2910340310; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRIVEDI P, 1995, ONCOGENE, V11, P505; WILSON RE, 1993, ONCOGENE, V8, P3229; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; ZALANI S, 1995, J VIROL, V69, P3816, DOI 10.1128/JVI.69.6.3816-3823.1995	52	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2105	2112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950977				2022-12-17	WOS:A1996VV14500007
J	Karlsson, T; Welsh, M				Karlsson, T; Welsh, M			Apoptosis of NIH3T3 cells overexpressing the Src homology 2 domain protein Shb	ONCOGENE			English	Article						Shb; Src homology 2 domain; Src homology 3 domain; NIH3T3 fibroblasts; apoptosis	DNA FRAGMENTATION; TYROSINE KINASE; NUCLEAR-DNA; FIBROBLASTS; ACTIVATION; RECEPTOR; DEATH	To understand the role of the Src homology 2 (SH2) domain protein Shb in the signal transduction of tyrosine kinase receptors, NIH3T3 cells were transfected with a DNA construct expressing the Shb cDNA (NIHSHB cells), The NIHSHB cells expressed elevated levels of proteins with the estimated molecular weights of 77, 66 and 55 kDa as determined by immunoblotting, In contrast to the control cells, the NIHSHB cells failed to increase in cell number in the presence of 1% serum, This effect was largely due to apoptosis, since staining of pyknotic nuclei was observed using the terminal transferase labeling method, The NIHSHB cells displayed similar levels of c-myc mRNA and decreased contents of the p53 protein after culture in 1% serum compared with control cells, The addition of platelet-derived growth factor (PDGF-BB) restored the growth of the NIHSHB cells, whereas insulin-like growth factor-1 (IGF-1) failed to affect the proliferation of Shb overexpressing cells in 1% serum, We conclude that Shb overexpression is associated with cell degeneration under certain conditions, and that Shb could transduce apoptotic signals from tyrosine kinase receptors.	UNIV UPPSALA,BIOMEDICUM,DEPT MED CELL BIOL,S-75123 UPPSALA,SWEDEN	Uppsala University			Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755				BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; KARLSSON T, 1995, ONCOGENE, V10, P1475; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; Maniatis T, 1982, MOL CLONING LABORATO; OBERHAMMER F, 1993, J CELL SCI, V104, P317; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; WELSH M, 1994, ONCOGENE, V9, P19; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128	23	30	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					955	961						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806685				2022-12-17	WOS:A1996VG76600009
J	Murty, VVVS; Reuter, VE; Bosl, GJ; Chaganti, RSK				Murty, VVVS; Reuter, VE; Bosl, GJ; Chaganti, RSK			Deletion mapping identifies loss of heterozygosity at 5p15.1-15.2, 5q11 and 5q34-35 in human male germ cell tumors	ONCOGENE			English	Article						male germ cell tumor; chromosome 5; loss of heterozygosity; monosomy; tumor suppressor gene	HEPATOCELLULAR-CARCINOMA; GENE; CHROMOSOME-5Q	Cytogenetic and loss of heterozygosity (LOH) studies of chromosome 5 in male germ cell tumors (GCTs) previously reported suggested the presence of one or more tumor suppressor genes (TSGs) on this chromosome which may play a role in the development of these tumors, In an attempt to further characterize allelic deletions on chromosome 5, we performed a detailed deletion mapping utilizing 66 normal-tumor DNAs from male GCTs assaying 24 polymorphic markers mapped to both the short and long arms, Thirty-seven (56%) tumors exhibited LOH at one or more loci, Loss of one allele at all informative loci was found in 15 of 37 (40.5%) cases suggesting monosomy of chromosome 5, The pattern of LOH in the remaining 22 (59.5%) tumors revealed regional losses identifying three common sites of deletions at 5p15.1-15.2, 5q11, and 5q34-35, respectively, The distribution of allelic deletions was found to be similar in all histologic subtypes with predominance of monosomy in teratomas, Thus, the present study revealed 2 types of chromosome 5 abnormalities in male GCTs, genetic monosomy and regional deletion, the latter identifying three novel sites of candidate TSGs, These data suggest that loss of genetic information on chromosome 5 plays an important role in male GCT development.	MEM SLOAN KETTERING CANC CTR,PROGRAM GENET & CELL BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,SOLID TUMOR DIV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA05826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALJEHANI RMA, 1995, GENE CHROMOSOME CANC, V13, P249, DOI 10.1002/gcc.2870130404; ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; DING SF, 1993, CANCER DETECT PREV, V17, P405; DING SF, 1991, BRIT J CANCER, V64, P1083, DOI 10.1038/bjc.1991.468; GODDARD AD, 1993, ADV HUM GENET, V21, P321; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOSOE S, 1994, CANCER RES, V54, P1787; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MITRA AB, 1994, CANCER RES, V54, P4481; MURTY VVVS, 1994, CANCER RES, V54, P3983; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1994, ONCOGENE, V9, P2245; PENG HQ, 1995, CANCER RES, V55, P2871; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; Tamura G, 1996, CANCER RES, V56, P612; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772	20	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2719	2723						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700532				2022-12-17	WOS:A1996UW48700027
J	Momand, J; Zambetti, GP				Momand, J; Zambetti, GP			Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics	ONCOGENE			English	Article						cell cycle; immortalized; post-translational; tumorigenic	GENE-EXPRESSION; 3T3 CELLS; PROTEIN; DNA; PHOSPHORYLATION; TRANSFORMATION; ONCOGENE; PRODUCT; COMPLEX; FORMS	A critical parameter affecting cell growth properties is the relative levels of the p53 tumor suppressor protein and the mdm-2 oncoprotein. Because mdm-2 overexpression is observed in several types of human cancers and its physical association with p53 appears essential for down-regulating p53 activity the proportion of p53 bound to mdm-2 was examined in four types of cells with divergent growth properties: (1) Growth arrested cells (Al) expressing high levels of wild-type p53 activity; (2) Tumorigenic cells (3T3DM) expressing high levels of mdm-2; (3) Immortalized non tumorigenic cells (Swiss3T3 and Balb/c3T3); and (4) Normal murine fibroblasts. In Al cells, greater than 78% of the p53 was not bound to mdm-2, demonstrating that excess free p53 is available for cell cycle arrest. In 3T3DM cells 100% of the p53 was bound to mdm-2 and these cells were unable to support p53-mediated transactivation, a p53 function essential for cell growth inhibition, In Swiss3T3 cells 75% of the p53 was bound to mdm-2. In Balb/c3T3 cells and normal cells no detectable mdm-2 was bound to p53. Since free p53 was detected in several of these cell lines the possibility that mdm-2 is completely titrated by p53 was investigated. However, free mdm-2 was present in all these cells. Phosphorylation of p53 does not appear to control complex formation since the free and the mdm-2-bound form of p53 from Al cells had identical phosphorylation maps. These data suggest that a high proportion of p53 bound to mdm-2 is observed in some cells with a more transformed phenotype and that p53-mdm-2 complex formation is controlled by a posttranslational event other than p53 phosphorylation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	Momand, J (corresponding author), CITY HOPE NATL MED CTR, DEPT CELL & TUMOR BIOL, 1500 E DUARTE RD, DUARTE, CA 91010 USA.		Zambetti, Gerard/N-8093-2018; Momand, Jamil/F-8154-2012	Zambetti, Gerard/0000-0002-0929-5007; 	NCI NIH HHS [5 P30CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CORDONCARDO C, 1994, CANCER RES, V54, P794; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUDAS JM, 1995, CLIN CANCER RES, V1, P71; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MELTZER PS, 1994, J NATL CANCER I, V86, P1265, DOI 10.1093/jnci/86.17.1265; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTALVO EA, 1991, J VIROL, V65, P3647, DOI 10.1128/JVI.65.7.3647-3655.1991; MOSNER J, 1994, ONCOGENE, V9, P3321; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1992, ONCOGENE, V7, P1649; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; RITTLING SR, 1992, ONCOGENE, V7, P935; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	61	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2279	2289						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649767				2022-12-17	WOS:A1996UQ22000004
J	Givehchian, M; Woerner, SM; Lacroix, J; Zoller, M; Drings, P; Becker, H; Kayser, K; Ridder, R; Doeberitz, MV				Givehchian, M; Woerner, SM; Lacroix, J; Zoller, M; Drings, P; Becker, H; Kayser, K; Ridder, R; Doeberitz, MV			Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: No evidence for altered CD44 splicing in metastasis	ONCOGENE			English	Article						lung cancer; bronchial epithelium; adhesion molecules; RT-PCR; immunohistology	SMALL-CELL CARCINOMA; ADHESION MOLECULE; RECEPTOR CD44; LUNG-CANCER; ESTABLISHMENT; HYALURONATE; BEHAVIOR; PRODUCTS; LINES	Expression of alternatively spliced CD44 adhesion molecules has been implicated in metastatic spread of various rodent and human tumors. To determine whether specific CD44 splice variants contribute to metastatic spread of bronchial cancers, we compared the expression of CD44 splice variants in normal bronchial epithelium and bronchial cancers, including tumors which already spread to regional lymph nodes or distant organs. Variant CD44 expression was analysed by immunohistochemistry using variant exon-specific monoclonal antibodies. The precise composition of CD44 transcripts was delineated by exon-specific RT-PCR. The concurring data obtained by both methods revealed that high levels of standard CD44 and variants v5 and v6 as well as low levels of variants v7 and v10 are expressed both in normal bronchial epithelium and squamous cell lung cancers. No CD44 expression was observed in the highly metastatic small cell lung cancers and adenocarcinomas with the exception of bronchioalveolar cancers showing weak expression of standard CD44. These data suggest that expression of alternatively spliced CD44 molecules in the bronchial tract is related to the distinct differentiation of the respiratory epithelium. No correlation between expression of specific CD44 splice variants and metastasis of bronchial cancers was observed.	DEUTSCH KREBSFORSCHUNGSZENTRUM, FSP ANGEW TUMORVIROL 6, NEUENHEIMER FELD 242, D-69120 HEIDELBERG, GERMANY; THORAXKLIN HEIDELBERG, D-69126 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Woerner, Stefan/A-2187-2010					ABBASI AM, 1993, EUR J CANCER, V29A, P1995, DOI 10.1016/0959-8049(93)90461-N; [Anonymous], 1982, AM J CLIN PATHOL, V77, P123; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; CARNEY DN, 1985, CANCER RES, V45, P2913; COMBARET V, 1995, EUR J CANCER, V31A, P545, DOI 10.1016/0959-8049(95)00027-G; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; GAZDAR AF, 1980, CANCER RES, V40, P3502; GROSS N, 1995, EUR J CANCER, V31A, P471, DOI 10.1016/0959-8049(95)00029-I; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HARN HJ, 1991, BIOCHEM BIOPH RES CO, V178, P1127, DOI 10.1016/0006-291X(91)91009-2; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HEIDER KH, 1993, CANCER RES, V53, P4197; HOFMANN M, 1991, CANCER RES, V51, P5292; HONG RL, 1995, ONCOLOGY-BASEL, V52, P334; HONG RL, 1995, CANCER LETT, V89, P81, DOI 10.1016/0304-3835(94)03653-Z; ICHIKAWA W, 1994, PATHOBIOLOGY, V62, P172, DOI 10.1159/000163907; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; JACKSON DG, 1994, INT J CANCER, P110; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; KUGELMAN LC, 1992, J INVEST DERMATOL, V99, P886; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LINNOILA I, 1990, HEMATOL ONCOL CLIN N, V4, P1027; LIU AY, 1994, CANCER LETT, V76, P63, DOI 10.1016/0304-3835(94)90135-X; MANTENHORST E, 1995, INT J CANCER, V64, P182, DOI 10.1002/ijc.2910640307; MATSUMURA Y, 1994, BRIT MED J, V308, P619, DOI 10.1136/bmj.308.6929.619; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; OSTERLIND K, 1986, J CLIN ONCOL, V4, P1307, DOI 10.1200/JCO.1986.4.9.1307; PENNO MB, 1994, CANCER RES, V54, P1381; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; RALL CJN, 1995, CANCER RES, V55, P1831; RISTAMAKI R, 1995, J PATHOL, V176, P259, DOI 10.1002/path.1711760308; RUDY W, 1993, CANCER RES, V53, P1262; SALMI M, 1993, J CELL BIOL, V122, P431, DOI 10.1083/jcb.122.2.431; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; TAKEUCHI K, 1995, JPN J CANCER RES, V86, P292, DOI 10.1111/j.1349-7006.1995.tb03053.x; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; UNDERHILL C, 1992, J CELL SCI, V103, P293; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; WASHIMI O, 1994, JPN J CANCER RES, V85, P1112, DOI 10.1111/j.1349-7006.1994.tb02915.x; Woerner SM, 1995, CLIN CANCER RES, V1, P1125; YOKOZAKI H, 1994, CANCER LETT, V83, P229, DOI 10.1016/0304-3835(94)90324-7; ZOLLER M, 1995, J MOL MED, V73, P425	47	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1137	1144						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649806				2022-12-17	WOS:A1996UA88400023
J	Wang, YP; Becker, D				Wang, YP; Becker, D			Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system	ONCOGENE			English	Article						melanocytes; melanoma progression; cyclin-dependent kinase inhibitors; retinoblastoma gene product	RETINOBLASTOMA PROTEIN; TUMOR PROGRESSION; MELANOMA; HOMOLOGY; BINDING	To determine whether loss or inactivation of the putative tumor-suppressor gene, p16, represents an initiating or a secondary event in the progression of human melanoma, we evaluated the status of this gene in early and advanced-stage melanomas of sporadic origin. The results of this analysis revealed p16 deletions in 4/6 primary and 6/14 metastatic melanoma cell lines but not in 3/3 metastatic melanoma specimens. Surprisingly, p16 deletions were also detected in 8/8 benign compound nevi and in 1/3 normal human melanocyte isolates. To investigate whether these deletions in benign and malignant stages of the human melanocytic system were specific for p16, we analysed the same specimens and cell lines for expression of p21, another cyclin-dependent kinase inhibitor and potential tumor suppressor. In contrast to p16, expression of p21 was detected in 3/3 melanocytes, in 3/3 benign nevi, and in greater than 50% of malignant melanoma cell lines and specimens. Finally, because of the recently documented inverse relationship between expression of p16 and pRb protein in a variety of tumor cell lines, we analysed some of the p16-positive and negative melanoma cell lines for the presence of pRb protein. The results demonstrated pRb protein in each of these cell Lines. Taken together, although this study revealed deletions of the p16 gene in a significant number of sporadic primary and metastatic melanoma cell lines, they were also detected in benign nevus specimens and in some normal human melanocyte isolates. Thus, these findings cast some doubt on the role of this gene as being causal to the onset and progression of human melanoma, in particular, sporadic melanoma.	UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BECKER D, 1989, GENOMICS, V4, P97, DOI 10.1016/0888-7543(89)90320-0; BECKER D, 1992, ONCOGENE, V7, P2302; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARK WH, 1988, ARCH DERMATOL, V124, P1207, DOI 10.1001/archderm.124.8.1207; CLARK WH, 1986, HUM PATHOL, V17, P443, DOI 10.1016/S0046-8177(86)80032-6; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; CLARK WH, 1991, BRIT J CANCER, V64, P101; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDER DE, 1993, SEMIN DIAGN PATHOL, V10, P18; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HERLYN M, 1987, LAB INVEST, V56, P461; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORI T, 1994, CANCER RES, V54, P3396; NIKAJIMAIIJIMA S, 1995, P NATL ACAD SCI USA, V82, P6133; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Parmiter A., 1988, MALIGNANT MELANOMA B, P47; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; REED JA, 1995, CANCER RES, V55, P2713; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TRENT JM, 1992, CUTANEOUS MELANOMA, P1001; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0	43	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1069	1075						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649798				2022-12-17	WOS:A1996UA88400015
J	Givol, I; Givol, D; Rulong, S; Resau, J; Tsarfaty, I; Hughes, SH				Givol, I; Givol, D; Rulong, S; Resau, J; Tsarfaty, I; Hughes, SH			Overexpression of human p21(waf1/cip1) arrests the growth of chicken embryo fibroblasts transformed by individual oncogenes	ONCOGENE			English	Article						retrovirus; growth suppressor; cell cycle; waf1/cip1; p53	CYCLIN-DEPENDENT KINASES; SARCOMA VIRUS; P53; DNA; VECTORS; CELLS; EXPRESSION; INHIBITOR; PROTEIN; P21	In normal cells, cell growth and division is controlled by the interplay between proto-oncogenes and tumor genes, Cancer cells usually have both suppressor activated an suppressor gene, High level expression of a tumor suppressor, p53, can block the growth of cancer cells, waf1/cip1 is transactivated by the tumor suppressor p53 and the p21(waf1/cip1)protein is itself a suppressor of cell growth, To test the effect of growth suppression genes on the growth of cells transformed by individual oncogenes, we have used replication-competent retroviral vectors to induce high level expression of p53 and p21(waf1/cip1). Overexpression of p21(waf1/cip1) arrests chicken embryo fibroblasts (CEF) transformed by v-Src, tf-Ras, c-Mos and c-Myc. These data suggest that p21(waf1/cip1) might be a useful tool in gene therapy for human cancer.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; WEIZMANN INST SCI,DEPT MOLEC CELL BIOL,IL-76100 REHOVOT,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine				Tsarfaty, Ilan/0000-0002-5230-7093				CHEDID M, 1994, ONCOGENE, V9, P3021; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIVOL I, 1992, ONCOGENE, V7, P141; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4923; LI R, 1994, NATURE, V371, P535; LI Y, 1994, ONCOGENE, V9, P2261; LOWE SW, 1993, CELL, V74, P954; LOWE SW, 1994, SCIENCE, V266, P804; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MICHIELI P, 1994, CANCER RES, V54, P3391; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; THORNTHWAITE JT, 1980, CYTOMETRY, V1, P229, DOI 10.1002/cyto.990010309; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	41	30	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2609	2618						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545118				2022-12-17	WOS:A1995TP18800017
J	Ahn, MJ; Langenfeld, J; Moasser, MM; Rusch, V; Dmitrovsky, E				Ahn, MJ; Langenfeld, J; Moasser, MM; Rusch, V; Dmitrovsky, E			Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors	ONCOGENE			English	Article						all-trans-retinoic acid; bronchial epithelial cells; retinoid receptors	ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN LUNG-CANCER; X-RECEPTOR; THYROID-HORMONE; DIFFERENTIATION THERAPY; NUCLEAR RECEPTORS; RIBONUCLEIC-ACID; VITAMIN-A; ALPHA; BETA	The retinoids are reported to chemoprevent second aerodigestive tract cancers in patients with prior lung or head and neck cancers, Since those retinoids already examined in clinical trials do not induce major clinical responses in lung cancers, it is hypothesized that the beneficial chemoprevention activity in lung neoplasias occurs within 'fields' of carcinogen-transformed epithelial cells, To begin to investigate this retinoid action during lung carcinogenesis, the BZR-T33 ras transformed human bronchial epithelial cell line that grows in an anchorage independent manner was examined, This study reports, as compared to controls, that all-trans-retinoic acid (RA)-treatment suppresses BZR-T33 proliferation in monolayer cultures and in anchorage independent and cloning efficiency growth assays, RA induces RAR-gamma 2 > RAR gamma 1 in BZR-T33 cells but expression at the total cellular RNA level of RAR alpha and RXR alpha is not augmented by RA-treatment, RAR beta mRNA expression is repressed before and after RA-treatment and is only detected using a reverse transcription polymerase chain reaction (RT-PCR) assay, To determine directly which of these expressed retinoid receptors signals growth suppression, each receptor was individually transfected into BZR-T33 cells using episomal expression vectors, Growth inhibitory effects of these transfectants were compared to a control; episomal vector in colony efficiency assays, RAR gamma over-expression in the presence or absence of RA-treatment did not suppress BZR-T33 growth more than controls, In contrast, over-expression of the other examined retinoid receptors inhibited BZR-T33 cellular cloning efficiency prior to RA-treatment and in this decreasing order after RA-treatment: RAR alpha > RAR beta > RXR alpha, The findings reported here reveal that RA suppresses proliferation and cloning efficiency in this transformed human bronchial epithelial cell through specific retinoid receptors, Further work is needed to evaluate the role of RA or its nuclear receptors in inhibiting even earlier steps in lung carcinogenesis.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,DEPT MED,MOLEC MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,DEPT SURG,THORAC SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOLEC PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [T32CA009512, R01CA054494] Funding Source: NIH RePORTER; NCI NIH HHS [2R01-CA54494-04, T32-CA-09512] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN MJ, 1995, ONCOGENE, V10, P2307; AMSTAD P, 1988, MOL CARCINOGEN, V1, P151, DOI 10.1002/mc.2940010303; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BRAND N, 1988, NATURE, V332, P851; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; REDDEL RR, 1988, CANCER RES, V48, P1904; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	46	30	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2357	2364						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570187				2022-12-17	WOS:A1995TK70200020
J	LYMAN, SD; STOCKING, K; DAVISON, B; FLETCHER, F; JOHNSON, L; ESCOBAR, S				LYMAN, SD; STOCKING, K; DAVISON, B; FLETCHER, F; JOHNSON, L; ESCOBAR, S			STRUCTURAL-ANALYSIS OF HUMAN AND MURINE FLT3 LIGAND GENOMIC LOCI	ONCOGENE			English	Article						FLT3 LIGAND; GROWTH FACTORS; HEMATOPOIESIS; TYROSINE KINASE RECEPTORS	COLONY-STIMULATING FACTOR; MESSENGER-RNA PRECURSORS; CELL GROWTH-FACTOR; MOLECULAR-CLONING; HUMAN CSF-1; KIT-LIGAND; EXPRESSION; GENE; PROTEIN; FORMS	Both the murine and human genomic loci that encode flt3 ligand have been cloned, flt3 ligand is a hematopoietic growth factor that stimulates the proliferation of stem and progenitor cells, The portions of the murine and human flt3 ligand genomic loci encompassing the coding region of the protein are approximately 4.0 kb and 5.9 kb, respectively. The human genomic locus is larger as a result of the presence of repeated sequences within introns I, II, IV, V and VI, The transmembrane isoform of the murine and human flt3 ligand proteins are each encoded within seven exons (1-5+7 and 8), Analyses of flt3 ligand cDNA clones show that alternative splicing of a putative sixth exon results in the generation of a soluble form of the flt3 ligand protein, The sizes of each of the exons are well conserved between species, Murine and human flt3 genomic loci have a similar exon:intron structure compared to the genomic loci encoding Steel factor and colony stimulating factor 1. These proteins, which appear to be ancestrally related, are hematopoietic growth factors that stimulate cells via specific and structurally related tyrosine kinase receptors on the cell surface.			LYMAN, SD (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KAWASAKI ES, 1990, COLONY STIMULATING F, P155; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; Lyman S D, 1995, Curr Opin Hematol, V2, P177; LYMAN SD, 1995, ONCOGENE, V10, P149; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYMAN SD, 1994, BLOOD, V83, P2795, DOI 10.1182/blood.V83.10.2795.2795; LYMAN SD, 1994, STEM CELLS, V12, P99; MAJUMDAR MK, 1994, J BIOL CHEM, V269, P1237; MAKALOWSKI W, 1994, TRENDS GENET, V10, P98; MARASKOVSKY E, 1993, CELL, V75, P1157; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529	23	30	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1165	1172						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566977				2022-12-17	WOS:A1995RX18000020
J	MYERS, RL; CHEDID, M; TRONICK, SR; CHIU, IM				MYERS, RL; CHEDID, M; TRONICK, SR; CHIU, IM			DIFFERENT FIBROBLAST-GROWTH-FACTOR-1 (FGF-1) TRANSCRIPTS IN NEURAL TISSUES, GLIOBLASTOMAS AND KIDNEY CARCINOMA CELL-LINES	ONCOGENE			English	Note						AFGF; ALTERNATIVE SPLICING; GLIOBLASTOMA; RETINA; DIABETIC RETINOPATHY; ALTERNATIVE PROMOTER USAGE	FACTOR MESSENGER-RNA; SMOOTH-MUSCLE CELLS; FACTOR-I; EPITHELIAL-CELLS; GENE-EXPRESSION; HUMAN GLIOMA; ACIDIC FGF; CLONING; FAMILY; SEQUENCE	We have previously reported the tissue specific distribution of four different FGF-1 transcripts containing alternative 5' untranslated exons Spliced to the first protein coding exon. The predominant transcript in brain is FGF-1.B and in kidney FGF-1.A. Others have shown, by in situ hybridization and immunohistochemical analysis, that expression of FGF-1 in the brain is exclusively in neural cells but not in glial cells. Here we have examined the distribution of FGF-1.B and FGF-1.A transcripts in glioblastoma and retinal tissues and in kidney carcinoma cell lines. Our results show that FGF-1.B is the predominant transcript in neural derived tissues including both the diabetic retina and normal retina tissues. Surprisingly, FGF-1.B transcript is highly expressed in glioblastoma tissues. In contrast, a normal brain glial cell line, CHII, expresses very low levels of FGF-1 mRNA. These results strongly implicate the role of FGF-1 in the etiology of glioblastoma. We also examined several kidney carcinoma derived cell lines for the expression of FGF-1 mRNA. Most of these kidney cell lines do not express any FGF-1 transcripts. An interpretation by deduction is that kidney adenocarcinomas are derived from cortex but medulla has been reported as the site of FGF-I synthesis. Of the kidney derived cell lines which are positive for FGF-1 message, only one expressed FGF-1.A transcript. The data may suggest that the establishment of kidney cell lines results in a switch of promoter usage from the 1.A seen in kidney tissue. Similarly, culturing of glioma cell lines may result in a snitch from FGF-1.B seen in glioma tissues to FGF-1.D seen in most glioma cell lines. Continued studies of the FGF-1 transcripts, their functional promoters and their tissues distribution will provide insight into the potential role of FGF-1 in cell growth, tissue differentiation and malignant transformation.	OHIO STATE UNIV, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA; NCI, MOLEC & CELLULAR BIOL LAB, BETHESDA, MD 20892 USA; SANTA CRUZ BIOTECHNOL INC, SANTA CRUZ, CA 95060 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chiu, Ing-Ming/B-1534-2008		NCI NIH HHS [T32 CA09338, R01 CA45611] Funding Source: Medline; NINDS NIH HHS [P20 NS31087] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045611, T32CA009338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031087] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALTERIO J, 1990, BIOCHEM BIOPH RES CO, V166, P1205, DOI 10.1016/0006-291X(90)90994-X; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAUDOUIN C, 1990, OPHTHALMIC RES, V22, P73, DOI 10.1159/000267004; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, ANN REV BIOCH, V58, P575; CHIU IM, 1990, ONCOGENE, V5, P755; CHOTANI MA, 1995, NUCLEIC ACIDS RES, V23, P434, DOI 10.1093/nar/23.3.434; COOK PW, 1990, MOL ENDOCRINOL, V4, P1377, DOI 10.1210/mend-4-9-1377; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; ECKENSTEIN FP, 1994, BIOCHEM PHARMACOL, V47, P103, DOI 10.1016/0006-2952(94)90442-1; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FREDJREYGROBELLET D, 1991, OPHTHALMIC RES, V23, P154, DOI 10.1159/000267115; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MARICS I, 1989, ONCOGENE, V4, P335; MILNER RJ, 1983, NUCLEIC ACIDS RES, V11, P5497, DOI 10.1093/nar/11.16.5497; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; NISHIGUCHI DJ, 1985, J NEUROPATH EXP NEUR, V44, P254, DOI 10.1097/00005072-198505000-00004; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STOCK A, 1992, J NEUROSCI, V12, P4688; SULLIVAN DE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P17, DOI 10.1016/0167-4781(91)90031-G; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG WP, 1991, DNA CELL BIOL, V10, P771, DOI 10.1089/dna.1991.10.771; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHANG GH, 1993, J BIOL CHEM, V268, P11542	40	30	31	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					785	789						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7544453				2022-12-17	WOS:A1995RQ46900022
J	BAZAR, L; HARRIS, V; SUNITHA, I; HARTMANN, D; AVIGAN, M				BAZAR, L; HARRIS, V; SUNITHA, I; HARTMANN, D; AVIGAN, M			A TRANSACTIVATOR OF C-MYC IS COORDINATELY REGULATED WITH THE PROTOONCOGENE DURING CELLULAR GROWTH	ONCOGENE			English	Article						C-MYC REGULATOR; FUSE BINDING PROTEIN; GROWTH RESPONSE GENE	HEMATOPOIETIC-CELLS; LEUKEMIA-CELLS; HL60 CELLS; 3T3 CELLS; EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; ACTIVATION; RNA; GENES	A recently cloned nuclear protein, which binds a far upstream element (FUSE) of the human c-myc protooncogene, stimulates promoter driven expression in undifferentiated cells. In concert with a loss of c-myc expression, both FUSE binding protein (FBP) mRNA and protein levels disappeared in HL60 cells after PMA-induced differentiation, due to a drop in the rate of transcription that was measured by nuclear runoff. During the differentiation of these cells, the brief half-lives of FBP mRNA (3 h) and protein (1.5 h) did not change, allowing for the rapid down-regulation of nuclear protein levels, as detected by immunohistochemical staining. Like c-myc, FBP is expressed in proliferating cells from a variety of lineages, but not in quiescent cells. When T cells and fibroblasts were stimulated to transit from G0 into the cell cycle, there was a dramatic rise of both FBP mRNA and DNA sequence specific nuclear FBP binding activity, which correlated with the appearance of c-myc mRNA. In contrast to the transient expression of many other immediate early growth response genes, both FBP and c-myc expression were sustained for more than 24 h. In fibroblasts, the coordinate expression of FBP and c-myc throughout all phases of the cell cycle is consistent with FBP's role as a growth-dependent regulator of c-myc expression.	GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT MED, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University					NATIONAL CANCER INSTITUTE [R29CA054818] Funding Source: NIH RePORTER; NCI NIH HHS [CA54818] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; BECKER B, 1994, BIOTECHNIQUES, V17, P630; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DANOVA M, 1993, ANN NY ACAD SCI, V698, P174, DOI 10.1111/j.1749-6632.1993.tb17206.x; DIAMOND LW, 1980, CANCER RES, V40, P703; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1988, J BIOL CHEM, V263, P4828; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANDBERG G, 1991, ACTA ONCOL, V30, P917, DOI 10.3109/02841869109088244; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; MARCUKB, 1992, ANNU REV BIOCHEM, V61, P809; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUNITHA I, 1994, CLIN EXP METASTAS, V12, P143, DOI 10.1007/BF01753981; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	47	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2229	2238						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784068				2022-12-17	WOS:A1995RB70300019
J	MADANI, A; SOULIER, J; SCHMID, M; PLICHTOVA, R; LERME, F; GATEAUROESCH, O; GARNIER, JP; PLA, M; SIGAUX, F; STERN, MH				MADANI, A; SOULIER, J; SCHMID, M; PLICHTOVA, R; LERME, F; GATEAUROESCH, O; GARNIER, JP; PLA, M; SIGAUX, F; STERN, MH			THE 8-KD PRODUCT OF THE PUTATIVE ONCOGENE MTCP-1 IS A MITOCHONDRIAL PROTEIN	ONCOGENE			English	Note						MITOCHONDRIA; T-CELL PROLYMPHOCYTIC LEUKEMIA; (X-14) TRANSLOCATION; MTCP-1	CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; TRANSLOCATION; CHROMOSOME; GENE; ABNORMALITIES; SEQUENCE; IMPORT	An unusually small (8 kD) protein (p8(MTCP-1)) is coded by the putative oncogene MTCP-1 (also called c6.1B), involved in the translocation t(X;14)(q28;q11) associated with some mature T-cell proliferations. Here, we show by subcellular fractionation and by confocal microscopy that this protein is located in the mitochondria. This localization orientates toward a role of p8(MTCP-1) in the mitochondrial metabolism which may be relevant for the oncogenic process.	HOP ST LOUIS,HEMATOL MOLEC LAB,F-75475 PARIS,FRANCE; HOP ST LOUIS,INSERM,U93,F-75475 PARIS,FRANCE; HOP ST LOUIS,INST HEMATOL,SERV COMMUN IMAGERIE CELLULAIRE,F-75475 PARIS,FRANCE; HOP ST LOUIS,BIOCHIM LAB,F-75475 PARIS,FRANCE; FAC MED LYON SUD,INSERM,U189,F-69921 OULLINS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272				BEATTY DW, 1986, S AFR MED J, V69, P115; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; CANKI N, 1983, ZDRAV VESTN, V52, P567; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; FISCH P, 1993, ONCOGENE, V8, P3271; GASNIER F, 1993, ANAL BIOCHEM, V212, P173, DOI 10.1006/abio.1993.1309; GLICK B, 1991, ANNU REV GENET, V25, P21; GOYNS MH, 1993, LEUKEMIA, V7, P848; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; MACKAY IR, 1989, IMMUNOL TODAY, V10, P315, DOI 10.1016/0167-5699(89)90088-1; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; SOULIER J, 1994, ONCOGENE, V9, P3565; STERN MH, 1993, ONCOGENE, V8, P2475; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; THICK J, 1994, LEUKEMIA, V8, P564; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204	25	30	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2259	2262						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784073				2022-12-17	WOS:A1995RB70300024
J	TALMAGE, DA; LISTERUD, M				TALMAGE, DA; LISTERUD, M			RETINOIC ACID SUPPRESSES POLYOMA-VIRUS TRANSFORMATION BY INHIBITING TRANSCRIPTION OF THE C-FOS PROTOONCOGENE	ONCOGENE			English	Article							SERUM RESPONSE ELEMENT; MIDDLE T-ANTIGEN; TUMOR-INDUCTION; CELL-LINE; EXPRESSION; GENE; PHOSPHORYLATION; GROWTH; JUN; REPLICATION	In a previous paper, we predicted that retinoic acid suppressed polyoma virus transformation of rat F111 fibroblasts by affecting the expression of one or more genes that are involved in signalling pathways normally activated by the viral mT oncogene (Talmage and Lackey, Oncogene 7, 1837-1845, 1992). We had identified the cellular c-fos proto-oncogene as a possible candidate target for both polyoma virus mT and retinoic acid regulated expression. In this report we present the results of experiments that demonstrate that retinoic acid does indeed inhibit transcriptional transactivation of the c-fos promoter by polyoma virus, as well as by calf serum and purified serum growth factors. Further experiments demonstrate that inhibition of c-fos expression with antisense fos RNA also prevents polyoma virus induced transformation. Restoration of c-fos expression, even in the presence of retinoic acid, restored transformation, indicating that retinoic acid inhibition of c-fos expression is sufficient to explain the retinoid suppression of transformation. These results identify the c-fos protooncogene as a key nuclear target for mT-dependent transformation and show that the anticarcinogenic properties of retinoic acid can be brought about by inhibiting c-fos expression.			TALMAGE, DA (corresponding author), COLUMBIA UNIV,INST HUMAN NUTR,NEW YORK,NY 10032, USA.			Talmage, David/0000-0003-4627-3007	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026854] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26854] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENJAMIN TL, 1982, BIOCHIM BIOPHYS ACTA, V695, P69, DOI 10.1016/0304-419X(82)90018-X; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DUBENSKY TW, 1991, J VIROL, V65, P342, DOI 10.1128/JVI.65.1.342-349.1991; FREUND R, 1991, J VIROL, V65, P335, DOI 10.1128/JVI.65.1.335-341.1991; FREUND R, 1992, VIROLOGY, V191, P716, DOI 10.1016/0042-6822(92)90247-M; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GIESE NA, 1985, J NATL CANCER I, V74, P1135; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; JAFFEY P, 1992, CANCER RES, V52, P2384; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KOLCH W, 1993, ONCOGENE, V8, P361; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LOTAN R, 1977, J NATL CANCER I, V59, P1717, DOI 10.1093/jnci/59.6.1717; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SCHNEIDTMAN KH, 1991, MOL CELL BIOL, V11, P1996; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TALMAGE DA, 1992, VIROLOGY, V187, P734, DOI 10.1016/0042-6822(92)90476-6; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; TALMAGE DA, 1992, ONCOGENE, V7, P1837; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; Treisman R, 1990, Semin Cancer Biol, V1, P47; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2721; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WICK M, 1992, ONCOGENE, V7, P859; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	46	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3557	3563						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970716				2022-12-17	WOS:A1994PT39200018
J	ZHENG, DQ; VAYSSIERE, JL; PETIT, PX; LECOEUR, H; SPATZ, A; MIGNOTTE, B; FEUNTEUN, J				ZHENG, DQ; VAYSSIERE, JL; PETIT, PX; LECOEUR, H; SPATZ, A; MIGNOTTE, B; FEUNTEUN, J			APOPTOSIS IS ANTAGONIZED BY LARGE T-ANTIGENS IN THE PATHWAY TO IMMORTALIZATION BY POLYOMAVIRUSES	ONCOGENE			English	Article							WILD-TYPE P53; CELL-CYCLE CONTROL; SIMIAN VIRUS-40; EMBRYO FIBROBLASTS; HAMSTER POLYOMAVIRUS; THYMOCYTE APOPTOSIS; GROWTH ARREST; PROTEIN; TRANSFORMATION; BINDING	The viability of rat embryo cells immortalized by thermosensitive mutants of SV40 or polyoma Large T antigen is impaired at the non-permissive temperature thus demonstrating that the immortal phenotype is dominantly maintained by Large T antigens. We have observed that exposing these cells to the restrictive temperature not only induces growth arrest but also causes apoptotic cell death. We present evidence supporting the model that polyomaviruses may indeed establish immortality by antagonizing the lethal effects of tumor suppressor genes via physical interactions between their products and Large T antigens. In the case of SV40-immortalized cells REtsAF, shift-up to 39.5 degrees C dissociates Large T antigen/p53 complexes releasing wild-type p53 molecules capable of inducing apoptotic cell death. In polyomavirus-immortalized cells, apoptosis may result from an alternative pathway mediated by other unidentified negatively acting molecules.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; INST PASTEUR,UNITE ONCOL VIRALE,F-75015 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			SPATZ, ALAN/B-8645-2009; Feunteun, Jean/AAZ-1267-2020; Petit, Patrice X./A-3692-2009; Petit, patrice/AAF-6774-2020; PETIT, Patrice/A-4453-2008; Mignotte, Bernard/A-3499-2009	SPATZ, ALAN/0000-0003-3020-1420; Petit, Patrice X./0000-0002-5038-9101; Mignotte, Bernard/0000-0002-8512-8518; Feunteun, Jean/0000-0003-1212-9189				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOUTEBROZE L, 1993, ONCOGENE, V8, P685; GOUTEBROZE L, 1992, J VIROL, V66, P2495, DOI 10.1128/JVI.66.4.2495-2504.1992; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JONKER RR, 1993, NATO ASI SERIES H, V67, P355; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEREM BS, 1983, NATURE, V304, P88, DOI 10.1038/304088a0; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUHAR SG, 1991, ONCOGENE, V6, P1499; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MIGNOTTE B, 1990, ONCOGENE, V5, P1529; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRANGE R, 1992, DEVELOPMENT, V115, P49; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAYSSOERE JL, 1994, UNPUB COMMITMENT APO; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHU J, 1981, J VIROL, V65, P6872; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	44	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3345	3351						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936660				2022-12-17	WOS:A1994PM65800029
J	AOKI, K; NAKAHARA, K; IKEGAWA, C; SETO, M; TAKAHASHI, T; MINOWADA, J; STROMINGER, JL; MAZIARZ, RT; KASAI, M				AOKI, K; NAKAHARA, K; IKEGAWA, C; SETO, M; TAKAHASHI, T; MINOWADA, J; STROMINGER, JL; MAZIARZ, RT; KASAI, M			NUCLEAR PROTEINS BINDING TO A NOVEL TARGET SEQUENCE WITHIN THE RECOMBINATION HOTSPOT REGIONS OF BCL-2 AND THE IMMUNOGLOBULIN-D(H) GENE FAMILY	ONCOGENE			English	Article							T-CELL LEUKEMIA; CHROMOSOMAL BREAKPOINT; FOLLICULAR LYMPHOMA; DNA-REPLICATION; TRANSLOCATION; T(14-18); MECHANISM; CONSENSUS; NEOPLASMS; CLONING	The chromosomal breakpoints of follicular lymphomas carrying the t(14;18)(q32;q21) are known to be clustered within a 150-bp region in the major breakpoint region (mbr) of the Bc1-2 oncogene. We have demonstrated that nuclear proteins specifically bind to a novel target sequence within this 150-bp region and a region of Dxp genes, members of the immunoglobulin (Ig) diversity (D(H)) gene family. One protein, designated BCLF-1, appears to be specifically expressed in lymphoid lineage cells. Two other proteins, BCLF-2 and -3, bind only to the complementary single strand of the target sequence. The manner in which these proteins interact with the target sequence is similar to the interaction of the ReHF-1 and -2 proteins to the signal-like sequence at the chromosomal breakpoint junctions in patients with the t(8;14)(q24;q11) and t(1;14)(p32;q11) translocations. It was further suggested that the BCLF-1 is quite similar to or identical to the ReHF-1. It is therefore hypothesized that these conserved target sequences found in recombination hotspot regions may define novel sequence motifs recognized by two classes of DNA binding proteins. One class of DNA binding proteins is specifically expressed in lymphoid cells while the other class binds to the complementary single strand DNA. These binding activities may play a crucial role in chromosomal translocation in lymphoid neoplasms.	NATL INST HLTH,DEPT IMMUN,1-23-1 TOYAMA,SHINJUKU KU,TOKYO 162,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 1,BUNKYO KU,TOKYO 113,JAPAN; KYORIN UNIV,SCH MED,DEPT CLIN PATHOL,MITAKA,TOKYO 181,JAPAN; AICHI CANC CTR,CHEMOTHERAPY LAB,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,CHIYODA KU,NAGOYA,AICHI 464,JAPAN; HAYASHIBARA BIOCHEM LABS INC,FUJISAKI CELL CTR,OKAYAMA 702,JAPAN; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; OREGON HLTH SCI UNIV,DIV HEMATOL ONCOL,PORTLAND,OR 97201; VAMC,PORTLAND,OR 97207	University of Tokyo; Kyorin University; Aichi Cancer Center; Aichi Cancer Center; Hayashibara Biochemical Laboratories, Inc.; Harvard University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; JAEGER U, 1993, BLOOD, V81, P1883; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; KASAI M, 1993, UNPUB; KOBAYASHI I, 1984, COLD SPRING HARB SYM, V49, P497, DOI 10.1101/SQB.1984.049.01.056; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MAZIARZ RT, 1992, BLOOD, V79, P1523; MINOWADA J, 1988, Cancer Reviews, V10, P1; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; SETO M, 1991, JPN J CANCER RES, V82, P65, DOI 10.1111/j.1349-7006.1991.tb01747.x; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; TAYLOR AF, 1988, REC BCD ENZYME ESCHE, P231; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	28	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1109	1115						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134113				2022-12-17	WOS:A1994NC04800013
J	PASTOR, R; BERNAL, J; RODRIGUEZPENA, A				PASTOR, R; BERNAL, J; RODRIGUEZPENA, A			UNLIGANDED C-ERBA THYROID-HORMONE RECEPTOR INDUCES TRKB EXPRESSION IN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; THYROID-HORMONE; NEUROTROPHIC FACTOR; 3,5,3'-TRIIODOTHYRONINE RECEPTOR; MORPHOLOGICAL-DIFFERENTIATION; BRAIN-DEVELOPMENT; RETINOIC ACID; GENE ENCODES; PC12 CELLS	Neurotrophins are responsible for the differentiation and survival of neurons in the developing and in the adult nervous system. They bind to specific membrane receptors with tyrosine kinase activity whose prototype is the product of the trkA proto-oncogene. TrkB, a member of this family, is the receptor for the neurotrophins brain derived growth factor (BDNF) and neurotrophins-3, 4/5. In this study, we show that stable expression of the c-erbA proto-oncogene, which encodes the alpha1-isoform of the nuclear receptor for thyroid hormone (Tralpha1) induces the expression of trkB mRNA with a concomitant decrease to undetectable levels of trkA and trkC mRNAs in the mouse neuroblastoma N2a cell line. trkB induction by c-erbA is ligand independent, since addition of T3 had no effect. The induced trkB transcript encodes a functional gp145trkB protein, which is phosphorylated on tyrosine in response to BDNF. Furthermore, induction of trkB mRNA is also caused by transient expression of either TR alpha1 or beta1 isoforms. Our results are compatible with the idea that there are certain pathways which are under control of unliganded thyroid hormone receptor, and that one of these pathways results in regulation of trk expression.	UNIV AUTONOMA MADRID,FAC MED,CONSEJO SUPER INVEST CIENTIFICAS,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Bernal, Juan/J-6086-2014	Bernal, Juan/0000-0002-5867-4951; Rodriguez-Pena, Angeles/0000-0002-2515-4626				ALTIN JG, 1992, NEUROTROPHIC FACTORS, P129; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; Barbacid Mariano, 1993, P123; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERNAL J, 1984, ENDOCRINOLOGY, V114, P677, DOI 10.1210/endo-114-2-677; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clos J, 1990, GROWTH FACTORS, V3, P205, DOI 10.3109/08977199009043905; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORREST D, 1991, EMBO J, V10, P269, DOI 10.1002/j.1460-2075.1991.tb07947.x; GLOWACKA D, 1990, J NEUROSCI RES, V25, P453, DOI 10.1002/jnr.490250403; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; KAPLAN DR, 1993, NEURON, V11, P1; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MELLSTROM B, 1991, MOL ENDOCRINOL, V5, P1339, DOI 10.1210/mend-5-9-1339; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; PATTERSON PH, 1993, NEURON S, V10, P123; PEREZCASTILLO A, 1985, ENDOCRINOLOGY, V117, P2457, DOI 10.1210/endo-117-6-2457; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; Sambrook J., 1989, MOL CLONING LAB MANU; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHEA TB, 1985, DEV BRAIN RES, V21, P307, DOI 10.1016/0165-3806(85)90220-2; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	45	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1081	1089						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134111				2022-12-17	WOS:A1994NC04800010
J	HASHIMOTO, Y; MATUOKA, K; TAKENAWA, T; MUROYA, K; HATTORI, S; NAKAMURA, S				HASHIMOTO, Y; MATUOKA, K; TAKENAWA, T; MUROYA, K; HATTORI, S; NAKAMURA, S			DIFFERENT INTERACTIONS OF GRB2/ASH MOLECULE WITH THE NGF AND EGF RECEPTORS IN RAT PHEOCHROMOCYTOMA PC12 CELLS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; SH3 DOMAINS; SIGNAL TRANSDUCTION; TRK PROTOONCOGENE; PROTEIN-KINASE; SRC; ACTIVATION; ACCUMULATION; ASSOCIATION	We have previously shown that nerve growth factor (NGF) induces a rapid and relatively continuous activation of pas in rat pheochromocytoma PC12 cells while epidermal growth factor (EGF) activates Ras transiently, and that tyrosine kinase activity of the NGF receptor is essential for the activation of pas (Muroya et al., Oncogene, 7, 277-281, 1992). In order to explore the signaling mechanism from tyrosine kinase to Ras activation in more detail, interactions between two adaptor molecules, She and Grb2/Ash, which contain Src homology regions, and their interactions with the NGF and EGF receptors were examined. Both NGF and EGF induced rapid tyrosine phosphorylation of She and its association with both the receptors and with Grb2/Ash. When cells were stimulated with EGF at 4 degrees C, the activation of pas proceeded slowly and MAP kinase activation was quite low. Under such restricted conditions, tyrosine-phosphorylated She formed a complex with Grb2/Ash, suggesting that the complex formation may be one of the immediate early responses. In contrast to She, Grb2/Ash bound to EGF receptor but did not form a stable complex with the NGF receptor. These results suggest that there may be an alternative pathway for the activation of Ras in PC12 cells.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO,TOKYO 173,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO,TOKYO 108,JAPAN	National Center for Neurology & Psychiatry - Japan; Tokyo Metropolitan Institute of Gerontology; University of Tokyo								BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, IN PRESS P NATL ACAD; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; MUROYA K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P353, DOI 10.1016/0167-4889(92)90243-5; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409	39	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					869	875						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108130				2022-12-17	WOS:A1994MW55100023
J	LAVENU, A; POURNIN, S; BABINET, C; MORELLO, D				LAVENU, A; POURNIN, S; BABINET, C; MORELLO, D			THE CIS-ACTING ELEMENTS KNOWN TO REGULATE C-MYC EXPRESSION EX-VIVO ARE NOT SUFFICIENT FOR CORRECT TRANSCRIPTION IN-VIVO	ONCOGENE			English	Article							LOCUS ACTIVATION REGION; RNA POLYMERASE-II; TRANSGENIC MICE; BURKITT-LYMPHOMA; CHROMATIN STRUCTURE; MESSENGER-RNA; CHROMOSOME-TRANSLOCATION; EFFICIENT TRANSCRIPTION; MODULATE EXPRESSION; NEOPLASTIC-CELLS	Much of our knowledge about the regulation of the c-myc proto-oncogene expression has come from studies of c-myc gene expression in several well defined ex vivo systems, including differentiation systems and tumor cells. However, very few investigations have been performed to determine the factors and cis-acting sequences that regulate c-myc expression in vivo. In order to obtain information on the sequences required to regulate c-myc gene transcription from the two major P1 and P2 initiation sites in the mouse, we have generated several constructs containing human or murine c-myc genomic sequences with various 5' flanking sequences and derived corresponding transgenic mice. A sensitive S1 nuclease protection assay was performed to analyse and to compare transgene expression with that of the endogeneous c-myc mRNA, either in adult organs, or during development. None of the transgenic mice expressed the construct appropriately, although several strains exhibited unexpected expression most probably due to position effects. Our results indicate that the cis-acting elements described to regulate c-myc expression ex vivo are not sufficient to drive the correct expression of c-myc gene in vivo and strongly suggest that additional regulatory elements located upstream from -3500 (with respect to mouse P1 promoter) and downstream 1500 bp from polyadenylation sites are required.	INST PASTEUR, DEPT IMMUNOL, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ASSELIN C, 1989, ONCOGENE, V4, P549; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DUBIK D, 1992, ONCOGENE, V7, P1587; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FINVER SN, 1988, P NATL ACAD SCI USA, V85, P3052, DOI 10.1073/pnas.85.9.3052; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KUMAR S, 1991, J MOL BIOL, V222, P45, DOI 10.1016/0022-2836(91)90736-P; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MANGO SE, 1989, MOL CELL BIOL, V9, P3482, DOI 10.1128/MCB.9.8.3482; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1989, ONCOGENE RES, V4, P111; MORELLO D, 1993, ONCOGENE, V8, P1921; NISHIKURA K, 1985, MOL CELL BIOL, V5, P1434, DOI 10.1128/MCB.5.6.1434; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; ROLAND J, 1993, CELL GROWTH DIFFER, V4, P891; SACCA R, 1990, ONCOGENE, V5, P1499; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEI Y, 1990, GENE, V93, P301, DOI 10.1016/0378-1119(90)90240-R; WEISINGER G, 1988, ONCOGENE, V3, P635; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; ZOBEL A, 1991, ONCOGENE, V6, P1397	65	30	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					527	536						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290263				2022-12-17	WOS:A1994MW24800020
J	JACOBS, SM; GORSE, KM; WESTIN, EH				JACOBS, SM; GORSE, KM; WESTIN, EH			IDENTIFICATION OF A 2ND PROMOTER IN THE HUMAN C-MYB PROTOONCOGENE	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; CYCLE-RELATED GENES; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; MAMMALIAN-CELLS; V-MYB; DNA; ACTIVATION; SEQUENCES; BINDING	We have previously described an alternatively spliced cDNA clone of the human c-myb proto-oncogene which has been shown to enhance the differentiation of Friend murine erythroleukemia cells. This clone, pMbm-2, contains unique 5' sequences which replace exon 1. The human c-myb intron 1 was sequenced to determine the exact position of this unique sequence and to further characterize the role of intron 1 in the regulation of the human c-myb gene. Here we report that intron 1 of c-myb is highly conserved between human and mouse throughout the intron, while only those sequences directly adjacent to exons 1 and 2 are conserved between human and chicken. The unique sequence of pMbm-2 was located directly adjacent to exon 2, suggesting that it arose as a product of alternative transcription initiation within intron 1. RNAase protection analysis was used to map a cluster of transcription start sites at the 5' end of exon 2. Levels of messages utilizing these start sites are proportional to those arising from the primary promoter. Functional characterization of this region revealed that this region can function as a promoter. Deletion studies have revealed the presence of negative and positive regulatory elements within this region which are utilized with different efficiencies in different cell lines. These studies suggest that cis or trans factors acting in this region may serve a dual function in both attenuation and transcription initiation.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MICROBIOL IMMUNOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, DIV HEMATOL ONCOL, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University								ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BOISE LH, 1992, CELL GROWTH DIFFER, V3, P53; BOISE LH, 1992, ONCOGENE, V7, P1817; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DVORAK M, 1989, NUCLEIC ACIDS RES, V17, P5651; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HRUBY DE, 1990, BIOTECHNIQUES, V8, P170; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LI WH, 1985, MOL BIOL EVOL, V2, P150; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maniatis T, 1989, MOL CLONING; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OHYASHIKI K, 1988, CANCER GENET CYTOGEN, V33, P83, DOI 10.1016/0165-4608(88)90053-2; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; ROSSON D, 1990, VIROLOGY, V175, P562, DOI 10.1016/0042-6822(90)90441-S; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; TORELLI U, 1986, LEUKEMIA RES, V10, P1249, DOI 10.1016/0145-2126(86)90244-4; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	56	30	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					227	235						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302584				2022-12-17	WOS:A1994MW24700028
J	OZAKI, T; SAKIYAMA, S				OZAKI, T; SAKIYAMA, S			MOLECULAR-CLONING OF RAT CALPACTIN-I HEAVY-CHAIN CDNA WHOSE EXPRESSION IS INDUCED IN V-SRC-TRANSFORMED RAT CULTURE CELL-LINES	ONCOGENE			English	Note							TYROSINE KINASE SUBSTRATE; EPIDERMAL GROWTH-FACTOR; AVIAN-SARCOMA VIRUS; MESSENGER-RNA; GENE-PRODUCT; PROTEIN; FIBROBLASTS; BINDING; P36; HOMOLOGY	A cDNA clone, termed NO2, was isolated from a rat 3Y1 cDNA library using a differential screening procedure. The amount of NO2 mRNA was increased in 3Y1 cells transformed with the Schmidt-Ruppin strain of Rous sarcoma virus (SR-3Y1) compared with that in 3Y1 cells. Sequence analysis revealed that NO2 cDNA encodes a p36 calpactin I heavy chain. In addition, the amount of a p11 calpactin I light-chain mRNA was also increased in v-src-transformed rat culture cells. The expression of both p36 and p11 genes was also induced in several sets of transformed cells, including v-H-ras-, v-mos- or SV40-transformed 3Y1 cells. As the expression of p36 and p11 genes was increased in transformed cells irrespective of the nature of oncogene products, overexpression of p36 and p11 genes might be involved in the key step of cellular transformation.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,666-2 NITONA,CHUOH KU,CHIBA 260,JAPAN	Chiba Cancer Center								BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BRYAN WR, 1955, JNCI-J NATL CANCER I, V16, P317; CALABRETTA B, 1986, P NATL ACAD SCI USA, V83, P1495, DOI 10.1073/pnas.83.5.1495; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; COOPER JA, 1983, CURR TOP MICROBIOL, V107, P125; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; GAL S, 1986, J BIOL CHEM, V261, P1760; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GROUDINE M, 1975, P NATL ACAD SCI USA, V72, P4464, DOI 10.1073/pnas.72.11.4464; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KRISTENSEN T, 1986, BIOCHEMISTRY-US, V25, P4497, DOI 10.1021/bi00364a007; Maniatis T, 1989, DECONTAMINATION DILU; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1987, J BIOL CHEM, V262, P10663; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SCHMIDTRUPPIN KH, 1964, ONCOLOGIA-BASEL, V17, P247, DOI 10.1159/000224235; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; UNKELESS J, 1974, J BIOL CHEM, V249, P4295	31	30	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1707	1710						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389036				2022-12-17	WOS:A1993LE06400038
J	SCHULZ, AS; SCHLEITHOFF, L; FAUST, M; BARTRAM, CR; JANSSEN, JWG				SCHULZ, AS; SCHLEITHOFF, L; FAUST, M; BARTRAM, CR; JANSSEN, JWG			THE GENOMIC STRUCTURE OF THE HUMAN UFO RECEPTOR	ONCOGENE			English	Note							PROMOTER REGION; LEUKEMIA-CELLS; SEQUENCE; GENE; PROTEINS; CLEAVAGE; KINASE	Using a DNA transfection-tumorigenicity assay we have recently identified the UFO oncogene. It encodes a tyrosine kinase receptor characterized by the juxtaposition of two immunoglobulin-like and two fibronectin type III repeats in its extracellular domain. Here we describe the genomic organization of the human UFO locus. The UFO receptor is encoded by 20 exons that are distributed over a region of 44 kb. Different isoforms of UFO mRNA am generated by alternative splicing of exon 10 and differential usage of two imperfect polyadenylation sites resulting in the presence or absence of 1.5-kb 3' untranslated sequences. Primer extension and Sl nuclease analyses revealed multiple transcriptional initiation sites including a major site 169 bp upstream of the translation start site. The promoter region is GC rich, lacks TATA and CAAT boxes, but contains potential recognition sites for a variety of trans-acting factors, including Sp1, AP-2 and the cyclic AMP response element-binding protein. Proto-UFO and its oncogenic counterpart exhibit identical cDNA and promoter regions sequences. Possible modes of UFO activation are discussed.	UNIV ULM,DEPT PEDIAT 2,MOLEC BIOL SECT,PRITTWITZSTR 43,W-7900 ULM,GERMANY	Ulm University								ARAKI E, 1987, J BIOL CHEM, V262, P16186; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FAUST M, 1992, ONCOGENE, V7, P1287; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JANSSEN WG, 1991, ONCOGENE, V6, P2113; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SAMBROOK J, 1986, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P375	26	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					509	513						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381225				2022-12-17	WOS:A1993KN00600032
J	SZEPETOWSKI, P; COURSEAUX, A; CARLE, GF; THEILLET, C; GAUDRAY, P				SZEPETOWSKI, P; COURSEAUX, A; CARLE, GF; THEILLET, C; GAUDRAY, P			AMPLIFICATION OF 11Q13 DNA-SEQUENCES IN HUMAN BREAST-CANCER - D11S97 IDENTIFIES A REGION TIGHTLY LINKED TO BCL1 WHICH CAN BE AMPLIFIED SEPARATELY	ONCOGENE			English	Article							FREQUENT AMPLIFICATION; GENE; CHROMOSOME-11; CARCINOMAS; TUMORS; LOCUS; MAPS	In the course of our study on the amplification of 11q13 sequences in human breast cancer, we have investigated the amplification status of the anonymous DNA fragment D11S97 in a series of 125 mammary tumors. Our results indicate that, as with bladder carcinomas, D11S97 can be amplified separately from BCL1. In addition, we have shown that D11597 is physically linked to both D11S146 and BCL1, and is less than 100 kb centromeric to the D115146. These results indicate that, in addition to other 11q13 loci, sequences located approximately 500kb centromeric from BCL1 could contribute to carcinogenesis of epithelial cells in vivo.	CNRS,URA 1462,LGMCH,F-06107 NICE 2,FRANCE; INSERM,U273,CTR BIOCHIM,F-06034 NICE,FRANCE; CTR PAUL LAMARQUE,CNRS,URA 1191,F-34094 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS)			Carle, Georges/GWC-5240-2022; Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Carle, Georges/0000-0002-3901-1052				ADNANE J, 1991, ONCOGENE, V6, P659; ARMOUR JAL, 1989, NUCLEIC ACIDS RES, V17, P4925, DOI 10.1093/nar/17.13.4925; BERENSON JR, 1989, ONCOGENE, V4, P1111; BERENSON JR, 1990, ONCOGENE, V5, P1343; BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; COOKSON WOC, 1989, LANCET, P1292; HAGEMEIJER A, 1991, GENE CHROMOSOME CANC, V3, P210, DOI 10.1002/gcc.2870030307; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; LAMMIE GA, 1991, ONCOGENE, V6, P439; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P376, DOI 10.1093/nar/16.1.376; PROCTOR AJ, 1991, ONCOGENE, V6, P789; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SZEPETOWSKI P, 1991, GENOMICS, V10, P410, DOI 10.1016/0888-7543(91)90326-A; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS BP, 1988, ONCOGENE, V3, P345	21	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					751	755						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565470				2022-12-17	WOS:A1992HQ68200018
J	DESBOIS, C; PAIN, B; GUILHOT, C; BENCHAIBI, M; FFRENCH, M; GHYSDAEL, J; MADJAR, JJ; SAMARUT, J				DESBOIS, C; PAIN, B; GUILHOT, C; BENCHAIBI, M; FFRENCH, M; GHYSDAEL, J; MADJAR, JJ; SAMARUT, J			V-ERBA ONCOGENE ABROGATES GROWTH-INHIBITION OF CHICKEN-EMBRYO FIBROBLASTS INDUCED BY RETINOIC ACID	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; RESPONSIVE ELEMENT; GLUCOCORTICOID RECEPTOR; GENE-TRANSCRIPTION; BINDING DOMAIN; DNA-BINDING; VITAMIN-A; C-ERBA; JUN; CELLS	Retinoic acid inhibits chicken embryo fibroblast (CEF) proliferation by altering the G1 phase of the cell cycle with induction of a strong increase in the generation time. This growth-inhibitory response to retinoic acid is abrogated by expression of the v-erbA oncogene, suggesting an interference between retinoic acid receptors and the v-ErbA oncoprotein. Moreover, CEF expressing either the v-src, v-jun or v-fos oncogenes are also insensitive to retinoic acid treatment. In contrast, CEF expressing either the v-myc, v-myb-ets, v-mil, v-sea or v-erbB oncogenes are still sensitive to retinoic acid. These data strongly suggest functional interferences between the retinoic acid receptors and the AP-1 transcription factor complex in the control of expression of genes involved in CEF proliferation.	FAC MED GRANGE BLANCHE,CYTOL ANALYT LAB,F-69373 LYONS 08,FRANCE; CTR UNIV ORSAY,INST CURIE,BIOL SECT,LABS 110-111-112,F-91405 ORSAY,FRANCE; ECOLE NORMALE SUPER LYON,INRA,CNRS,BIOL MOLEC & CELLULAIRE LAB,UMR 49,F-69364 LYONS 07,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	DESBOIS, C (corresponding author), UNIV CLAUDE BERNARD LYON 1,FAC MED ALEXIS CARREL,CNRS,UMR 30,RUE GUILLAUME PARADIN,F-69372 LYONS 08,FRANCE.		Samarut, Jacques/AAD-2587-2019; GHYSDAEL, Jacques/F-3377-2013; Morris, Christelle/M-8168-2014; Pain, Bertrand/A-7686-2015	Morris, Christelle/0000-0003-1575-4609; Pain, Bertrand/0000-0002-1210-8444				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; CORDELL J, 1984, J HISTOCHEM CYTOCHEM, V31, P219; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIAZ JJ, 1989, ONCOL RES, V1, P163; DION LD, 1980, P SOC EXP BIOL MED, V163, P510; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HADDOX MK, 1979, CANCER RES, V39, P2476; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JANSSON M, 1987, ONCOGENE, V1, P167; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KHAZAIE K, 1991, ONCOGENE, V6, P21; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; LI RP, 1989, ONCOGENE RES, V5, P137; MAGAUD JP, 1988, J IMMUNOL METHODS, V106, P95, DOI 10.1016/0022-1759(88)90276-1; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PAIN B, 1990, New Biologist, V2, P284; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHRODER EW, 1982, P NATL ACAD SCI-BIOL, V79, P1549, DOI 10.1073/pnas.79.5.1549; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	46	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2129	2135						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1682867				2022-12-17	WOS:A1991GX11900025
J	MAGUIRE, K; SHI, XP; HORIKOSHI, N; RAPPAPORT, J; ROSENBERG, M; WEINMANN, R				MAGUIRE, K; SHI, XP; HORIKOSHI, N; RAPPAPORT, J; ROSENBERG, M; WEINMANN, R			INTERACTIONS BETWEEN ADENOVIRUS-E1A AND MEMBERS OF THE AP-1 FAMILY OF CELLULAR TRANSCRIPTION FACTORS	ONCOGENE			English	Note							RNA POLYMERASE-II; ESCHERICHIA-COLI; GENE-PRODUCT; CYCLIC-AMP; LEUCINE ZIPPER; E1A PROTEIN; BINDING; DNA; ACTIVATION; PROMOTER	We have studied interactions between bacterially produced E1A linked to Sepharose and the various DNA-binding proteins present in HeLa cell nuclear extracts (NE). DNA-binding activities and cross-reactive polypeptides recognizing the cAMP-responsive element (CRE) and the activator protein 1 (AP1) sites were bound to the E1A column, whereas nuclear factor 1 (NF1) and the activator protein 2 (AP2) DNA-binding activities were not retained by E1A. The binding activities that were retained belonged to the CRE and JUN protein family, as judged by Western blot analysis. Authentic CRE-BP1, c-Jun and c-Fos proteins produced by in-vitro translation also bound to the E1A column. However, efficient binding of in-vitro-translated CRE-BP1 and c-Fos proteins to E1A required preincubation with NE. We show here that immobilized E1A sequesters several cellular upstream transcription activators, and suggest a role for members of the AP1 family of transcription factors in E1A-mediated gene regulation.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; SMITHKLINE BEECHAM CORP,KING OF PRUSSIA,PA 19406	The Wistar Institute; GlaxoSmithKline			Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NCI NIH HHS [F32 CA08338, CA44466, CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA044466, F32CA008338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERK AJ, 1990, GENE DEV, V4, P151; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P80; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; EGAN C, 1987, VIROLOGY, V160, P292, DOI 10.1016/0042-6822(87)90077-8; FERGUSON B, 1984, SCIENCE, V224, P1343, DOI 10.1126/science.6374895; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARCIA J, 1987, NUCLEIC ACIDS RES, V15, P8367, DOI 10.1093/nar/15.20.8367; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEFF T, 1985, NUCLEIC ACIDS RES, V13, P1209, DOI 10.1093/nar/13.4.1209; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHI XP, 1986, NUCLEIC ACIDS RES, V14, P3729, DOI 10.1093/nar/14.9.3729; SIVARAMAN L, 1987, P NATL ACAD SCI USA, V84, P6112, DOI 10.1073/pnas.84.17.6112; SOPTA M, 1985, J BIOL CHEM, V260, P353; SPANGLER R, 1987, SCIENCE, V237, P1044, DOI 10.1126/science.2956686; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; WEBSTER LC, 1991, IN PRESS MOL CELL BI; WEEKS DL, 1985, NUCLEIC ACIDS RES, V13, P5389, DOI 10.1093/nar/13.14.5389; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YACIUK P, 1990, J VIROL, V64, P4421; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZOPF D, 1990, NATURE, V346, P87, DOI 10.1038/346087a0	40	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1417	1422						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1832215				2022-12-17	WOS:A1991GX27200018
J	SUBRAMANIAN, T; MALSTROM, SE; CHINNADURAI, G				SUBRAMANIAN, T; MALSTROM, SE; CHINNADURAI, G			REQUIREMENT OF THE C-TERMINAL REGION OF ADENOVIRUS-E1A FOR CELL-TRANSFORMATION IN COOPERATION WITH E1B	ONCOGENE			English	Note							GROWTH-FACTOR; PROTEINS; ONCOGENE; IMMORTALIZATION; INDUCTION; GENES; POLYPEPTIDES; ASSOCIATION; ANTIGEN; DOMAINS	We have previously reported that adenovirus E1a mutants lacking the C-terminal 61 or 67 amino acids were severely defective in immortalization, but cooperated more efficiently (than wt E1a) with activated T24 ras oncogene in transformation of primary rat kidney (BRK) cells (Subramanian et al., 1989; Oncogene, 4:415-420). Here, we show that in contrast to these previous results, transformation of BRK cells in cooperation with the Ad2 E1b region is dependent on the C-terminal region of E1a. Mutational analysis of the C-terminal region has revealed that a region located between residues 266 and 276 may be important for E1a/E1b cooperative transformation. Like E1a/T24 ras cooperative transformation, E1a/E1b cooperative transformation also requires two essential domains involved in the binding of two cellular proteins (300K and 105K) within the N-terminal half of E1a. E1a/E1b cooperative transformation therefore requires an additional E1a activity encoded within the C-terminal region of E1a.	ST LOUIS UNIV,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110	Saint Louis University	CHINNADURAI, G (corresponding author), ST LOUIS UNIV,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110, USA.				NCI NIH HHS [CA-31719, CA-33616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031719, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BRUSCA JS, 1981, J VIROL, V39, P300, DOI 10.1128/JVI.39.1.300-305.1981; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	20	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1171	1173						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1830644				2022-12-17	WOS:A1991GV26000011
J	DRIVAS, GT; SHIH, A; COUTAVAS, EE; DEUSTACHIO, P; RUSH, MG				DRIVAS, GT; SHIH, A; COUTAVAS, EE; DEUSTACHIO, P; RUSH, MG			IDENTIFICATION AND CHARACTERIZATION OF A HUMAN HOMOLOG OF THE SCHIZOSACCHAROMYCES-POMBE RAS-LIKE GENE YPT-3	ONCOGENE			English	Article							ADENYLATE-CYCLASE; CODING SEQUENCES; CELL-LINE; YEAST; PROTEINS; SECRETION; CDNAS; ACTIVATION; ONCOGENE; PRODUCTS	The Polymerase Chain Reaction was used to amplify ras and ras-like sequences from two human cDNA libraries. Members corresponding to each of the three major ras-subfamilies (ras, rho, and rab/YPT) were identified. The one homologous to rab/YPT, referred to here as YL8, appears to be the human homolog of the recently reported Schizosaccharomyces pombe YPT3 gene. The YL8 gene could encode a guanine nucleotide binding protein of 216 amino acids with about 70% amino acid sequence identity to S. pombe YPT3, and is transcriptionally active in a variety of human cell lines.	NYU,SCH MED,DEPT BIOCHEM,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University				Coutavas, Elias/0000-0003-4904-0081; D'Eustachio, Peter/0000-0002-5494-626X	NIGMS NIH HHS [GM07827] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P34; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; FUKUI Y, 1986, EMBO J, V5, P1991, DOI 10.1002/j.1460-2075.1986.tb04454.x; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MISRA R, 1989, NUCLEIC ACIDS RES, V17, P8327, DOI 10.1093/nar/17.20.8327; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; OLOFSSON B, 1988, ONCOGENE, V3, P231; PIZON V, 1988, ONCOGENE, V3, P201; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIH A, 1989, J VIROL, V63, P64, DOI 10.1128/JVI.63.1.64-75.1989; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SOMMER R, 1989, NUCLEIC ACIDS RES, V17, P6749, DOI 10.1093/nar/17.16.6749; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	37	30	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					3	9						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1704119				2022-12-17	WOS:A1991EY03900001
J	KERKHOFF, E; BISTER, K				KERKHOFF, E; BISTER, K			MYC PROTEIN-STRUCTURE - LOCALIZATION OF DNA-BINDING AND PROTEIN DIMERIZATION DOMAINS	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; NUCLEOTIDE-SEQUENCE; CARBOXY TERMINUS; GENE; MC29; TRANSFORMATION; MUTANTS; REGION; FIBROBLASTS; DELETION	Wildtype and mutant v-Myc proteins were overexpressed in Escherichia coli using the T7 RNA polymerase system, and the in vitro DNA-binding activities of partially or highly purified proteins were analysed by native DNA-cellulose chromatography. For the construction of the expression plasmids, cloned proviral DNA from wildtype MC29 or from its spontaneous deletion mutant Q10C was used, the latter lacking internal v-myc sequences. Both the wildtype (p59) and the mutant (p42) recombinant protein contain at their amino termini 12 amino acids encoded by the vector, followed by 11 gag amino acids and 9 amino acids encoded by v-myc sequences derived from noncoding c-myc sequences. In addition, p59 contains 416 amino acids encoded by v-myc sequences derived from the complete chicken c-myc coding region, whereas p42 lacks 120 amino acids from the central region of the Myc protein including the highly acidic domain. Two additional proteins were engineered which contain the first 309 (p53) or the last 107 (p16) amino acids, respectively, of the Myc protein sequence in addition to vector-encoded amino acids. The p16 protein represents the carboxyl terminus of the Myc protein sequence containing both a muscle determination gene (MyoD1) homology region, including a basic motif and an amphipathic helix-loop-helix motif, and a leucine heptad repeat. All proteins, except p53 which lacks the carboxyl-terminal Myc protein sequences, bound to native DNA-cellulose and were eluted with 200-500 mM NaCl. Based on the DNA-binding activities of recombinant or spontaneous mutant v-Myc proteins extracted from bacterial or from transformed avian cells, we conclude that the DNA-binding domain of avian Myc proteins is confined within the last 86 carboxyl-terminal amino acids. The same region is also shown to be necessary and sufficient for Myc protein dimerization. This 86-amino acid region essentially encompasses a putative basic DNA contact surface and a tandem array of two presumed protein dimerization motifs, helix-loop-helix and leucine repeat.	UNIV COLOGNE,FAK MED,INST BIOCHEM,W-5000 COLOGNE 41,GERMANY	University of Cologne			Bister, Klaus/AFA-9400-2022	Bister, Klaus/0000-0001-6545-5653				ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; ALBIGES-RIZO C, 1990, J MOL BIOL, V212, P247, DOI 10.1016/0022-2836(90)90121-2; BADER JP, 1985, J VIROL, V53, P509, DOI 10.1128/JVI.53.2.509-514.1985; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIEGALKE BJ, 1987, J VIROL, V61, P2138, DOI 10.1128/JVI.61.7.2138-2142.1987; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BISTER K, 1982, J VIROL, V41, P754, DOI 10.1128/JVI.41.3.754-766.1982; BISTER K, 1987, ONCOGENE, V1, P97; BOS TJ, 1989, ONCOGENE, V4, P123; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ENRIETTO PJ, 1983, VIROLOGY, V124, P164, DOI 10.1016/0042-6822(83)90300-8; ENRIETTO PJ, 1989, VIROLOGY, V168, P256, DOI 10.1016/0042-6822(89)90265-1; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HERMANN R, 1981, BIOCHEMISTRY-US, V20, P5195, DOI 10.1021/bi00521a015; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PATSCHINSKY T, 1986, J VIROL, V59, P341, DOI 10.1128/JVI.59.2.341-353.1986; PATSCHINSKY T, 1984, VIROLOGY, V136, P348, DOI 10.1016/0042-6822(84)90171-5; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Vogt P K, 1990, Semin Cancer Biol, V1, P27; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	39	30	32	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					93	102						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992448				2022-12-17	WOS:A1991EY03900013
J	NOTARIO, V; CASTRO, R; FLESSATE, DM; DONIGER, J; DIPAOLO, JA				NOTARIO, V; CASTRO, R; FLESSATE, DM; DONIGER, J; DIPAOLO, JA			FREQUENT ACTIVATION OF NON-RAS TRANSFORMING SEQUENCES IN NEOPLASTIC SYRIAN-HAMSTER CELLS INITIATED WITH CHEMICAL CARCINOGENS	ONCOGENE			English	Note									GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM,WASHINGTON,DC 20007; NCI,DIV CANC ETIOL,BIOL LAB,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	NOTARIO, V (corresponding author), GEORGETOWN UNIV,SCH MED,VINCENT T LOMBARDI CANC RES CTR,DEPT RADIAT MED,WASHINGTON,DC 20007, USA.		/AFP-0764-2022; /AAB-6461-2022		NCI NIH HHS [CA49858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BERWALD Y, 1965, J NATL CANCER I, V35, P641; BOREK C, 1987, P NATL ACAD SCI USA, V84, P794, DOI 10.1073/pnas.84.3.794; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CICHUTEK K, 1986, P NATL ACAD SCI USA, V83, P2340, DOI 10.1073/pnas.83.8.2340; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DIPAOLO JA, 1969, SCIENCE, V165, P917, DOI 10.1126/science.165.3896.917; DIPAOLO JA, 1973, CANCER RES, V33, P3250; DIPAOLO JA, 1971, CANCER RES, V31, P1118; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DIPAOLO JA, 1981, CANCER LETT, V12, P203, DOI 10.1016/0304-3835(81)90069-0; DIPAOLO JA, 1971, NATURE-NEW BIOL, V230, P240, DOI 10.1038/newbio230240a0; DIPAOLO JA, 1972, NATURE, V235, P278, DOI 10.1038/235278a0; DIPAOLO JA, 1978, NATL CANCER I MONOGR, V48, P245; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GILMER TM, 1988, MOL CARCINOGEN, V1, P180, DOI 10.1002/mc.2940010306; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HUBERMAN E, 1966, P NATL ACAD SCI USA, V56, P1123, DOI 10.1073/pnas.56.4.1123; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; MCCABE RP, 1983, ONCODEV BIOL MED, V4, P383; POPESCU NC, 1980, P NATL ACAD SCI-BIOL, V77, P7282, DOI 10.1073/pnas.77.12.7282; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SLOAN SR, 1990, MOL CELL BIOL, V10, P405, DOI 10.1128/MCB.10.1.405; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; WEINSTEIN IB, 1984, CANCER CELL, V1, P229; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	34	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1425	1430						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216466				2022-12-17	WOS:A1990EC24100024
J	LEIBOVITCH, SA; LENORMAND, JL; LEIBOVITCH, MP; GUILLER, M; MALLARD, L; HAREL, J				LEIBOVITCH, SA; LENORMAND, JL; LEIBOVITCH, MP; GUILLER, M; MALLARD, L; HAREL, J			RAT MYOGENIC C-MOS CDNA - CLONING SEQUENCE-ANALYSIS AND REGULATION DURING MUSCLE DEVELOPMENT	ONCOGENE			English	Article											LEIBOVITCH, SA (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 126,UA 1158,39 RUE CAMILLE DESMOULINS,F-94800 VILLEJUIF,FRANCE.		Lenormand, Jean-Luc/M-6644-2014; Lenormand, Jean-Luc/ABF-3850-2021	Lenormand, Jean-Luc/0000-0002-2766-9180				BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BARTON PJR, 1985, J BIOL CHEM, V260, P8578; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERCK AJ, 1978, P NATL ACAD SCI USA, V75, P1274; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; FRANKEL AE, 1976, P NATL ACAD SCI USA, V73, P3705, DOI 10.1073/pnas.73.10.3705; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4500; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; HILLION J, 1984, CANCER RES, V44, P2959; HUNTER T, 1986, ENZYMES, V17, P191; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KURUTA N, 1989, EMBO J, V8, P457; LEIBOVITCH MP, 1987, EXP CELL RES, V170, P80, DOI 10.1016/0014-4827(87)90118-2; LEIBOVITCH SA, 1986, CANCER RES, V46, P4097; LEIBOVITCH SA, 1986, EXP CELL RES, V166, P526, DOI 10.1016/0014-4827(86)90497-0; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; SWAN D, 1982, J VIROL, V44, P753; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1982, EMBO J, V1, P1313, DOI 10.1002/j.1460-2075.1982.tb01316.x; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	46	30	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1149	1157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	1697408				2022-12-17	WOS:A1990DX36100006
J	NICOLSON, GL; GALLICK, GE; DULSKI, KM; SPOHN, WH; LEMBO, TM; TAINSKY, MA				NICOLSON, GL; GALLICK, GE; DULSKI, KM; SPOHN, WH; LEMBO, TM; TAINSKY, MA			LACK OF CORRELATION BETWEEN INTERCELLULAR JUNCTIONAL COMMUNICATION, P21RASEJ EXPRESSION, AND SPONTANEOUS METASTATIC PROPERTIES OF RAT MAMMARY CELLS AFTER TRANSFECTION WITH C-H-RASEJ OR NEO GENES	ONCOGENE			English	Article											NICOLSON, GL (corresponding author), UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT TUMOR BIOL,BOX 108,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [R35CA044352, R01CA048210, R23CA039803] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA48210, R35-CA44352, R23-CA39803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON MM, 1986, J MEMBRANE BIOL, V91, P53, DOI 10.1007/BF01870214; AZARNIA R, 1987, MOL CELL BIOL, V7, P946, DOI 10.1128/MCB.7.2.946; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; Bennett M. V. L., 1985, GAP JUNCTIONS; BERG P, 1982, MOL APPL GENET, V1, P327; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; CARNEY WP, 1986, J CELL BIOCHEM, V32, P207, DOI 10.1002/jcb.240320307; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; DOTTO GP, 1989, ONCOGENE, V4, P637; EAGAN SE, 1987, MOL CELL BIOL, V7, P830; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; ENOMOTO T, 1985, CANCER RES, V45, P2681; ENOMOTO T, 1984, CANCER RES, V44, P5200; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIEG RG, 1985, P NATL ACAD SCI USA, V82, P3698; HAMADA J, 1988, CANCER RES, V48, P5129; HEPPNER GH, 1983, BIOCHIM BIOPHYS ACTA, V695, P215, DOI 10.1016/0304-419X(83)90012-4; HILL SA, 1988, J NATL CANCER I, V80, P484, DOI 10.1093/jnci/80.7.484; KANNO Y, 1985, JPN J PHYSIOL, V35, P693, DOI 10.2170/jjphysiol.35.693; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MACDONALD C, 1985, ESSAYS BIOCHEM, V21, P86; MAREEL MM, 1986, ANTICANCER RES, V6, P419; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NERI A, 1982, J NATL CANCER I, V68, P507; NICOLSON GL, 1988, P NATL ACAD SCI USA, V85, P473, DOI 10.1073/pnas.85.2.473; NICOLSON GL, 1984, CANCER METAST REV, V3, P25, DOI 10.1007/BF00047691; NICOLSON GL, 1988, CANCER RES, V48, P399; NICOLSON GL, 1987, CANCER RES, V47, P1473; NICOLSON GL, 1990, IN PRESS CANCER RES; NORTH SM, 1985, BRIT J CANCER, V52, P747, DOI 10.1038/bjc.1985.253; OHUCHI N, 1986, CANCER RES, V46, P2511; PITTS JD, 1986, J CELL SCI S, V4, P239; RUBIN H, 1985, CANCER RES, V45, P2935; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TROSKO JE, 1983, CANCER INVEST, V1, P511, DOI 10.3109/07357908309020276; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WELCH DR, 1983, INVAS METAST, V3, P65; WELCH DR, 1984, CLIN EXP METASTAS, V2, P333, DOI 10.1007/BF00135172	45	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					747	753						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189108				2022-12-17	WOS:A1990DG37400016
J	REED, JC; HALDAR, S; CUDDY, MP; CROCE, C; MAKOVER, D				REED, JC; HALDAR, S; CUDDY, MP; CROCE, C; MAKOVER, D			DEREGULATED BCL2 EXPRESSION ENHANCES GROWTH OF A HUMAN B-CELL LINE	ONCOGENE			English	Article									UNIV PENN,DEPT INTERNAL MED,RHEUMATOL SECT 3,PHILADELPHIA,PA 19104; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS RES INST,PHILADELPHIA,PA 19140	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	REED, JC (corresponding author), UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER; NCI NIH HHS [CA47956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1984, P NATL ACAD SCI-BIOL, V81, P593, DOI 10.1073/pnas.81.2.593; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; REED J, 1986, MOL CEL BIOL, V6, P3361; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; ROSENBERG SA, 1982, CANCER, V49, P2112; SCALA G, 1987, J IMMUNOL, V138, P2527; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHIGEKAWA K, 1988, BIOTECHNIQUES, V6, P742; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904	23	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1123	1127						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2789359				2022-12-17	WOS:A1989AM53100011
J	LI, Y; LIEBERMAN, MW				LI, Y; LIEBERMAN, MW			2 GENES ASSOCIATED WITH LIVER-CANCER ARE REGULATED BY DIFFERENT MECHANISMS IN RAST24 TRANSFORMED LIVER EPITHELIAL-CELLS	ONCOGENE			English	Article									FOX CHASE CANC CTR, DEPT PATHOL, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center					NCI NIH HHS [R37-CA39392, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R37CA039392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAMERON R, 1978, CANCER RES, V38, P823; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P211; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; FARBER E, 1984, CANCER RES, V44, P5463; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; KITAHARA A, 1984, CANCER RES, V44, P2698; KROWCZYNSKA A, 1985, J MOL BIOL, V181, P231, DOI 10.1016/0022-2836(85)90087-7; LI YC, 1988, P NATL ACAD SCI USA, V85, P344, DOI 10.1073/pnas.85.2.344; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; SATO K, 1984, GANN, V75, P199; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEYAMA T, 1988, MOL CARCINOGEN, V1, P89, DOI 10.1002/mc.2940010204; SINGER RH, 1972, NATURE, V240, P100, DOI 10.1038/240100a0; SUGIOKA Y, 1985, CANCER RES, V45, P365; TAMM I, 1978, ADV VIRUS RES, V22, P188; TSAO MS, 1985, CANCER RES, V45, P5134	21	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1989	4	6					795	798						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2567500				2022-12-17	WOS:A1989AA66000016
J	ISHIKAWA, F; SAKAI, R; OCHIAI, M; TAKAKU, F; SUGIMURA, T; NAGAO, M				ISHIKAWA, F; SAKAI, R; OCHIAI, M; TAKAKU, F; SUGIMURA, T; NAGAO, M			IDENTIFICATION OF A TRANSFORMING ACTIVITY SUPPRESSING SEQUENCE IN THE C-RAF ONCOGENE	ONCOGENE			English	Article									NATL CANC CTR,RES INST,DIV CARCINOGENESIS,CHOU KU,TOKYO 104,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo			Sakai, Ryuichi/R-7741-2017; Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305; Sakai, Ryuichi/0000-0001-6833-1103				BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; HEFFRON F, 1978, P NATL ACAD SCI USA, V75, P6012, DOI 10.1073/pnas.75.12.6012; ISHIKAWA F, 1987, ONCOGENE RES, V1, P243; ISHIKAWA F, 1986, JPN J CANCER RES, V77, P1183; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; IWAKA S, 1988, MOL CELL BIOL, V8, P2651; KING HWS, 1988, ONCOGENE, V2, P617; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; NAKATSU Y, 1986, COLD SPRING HARB SYM, V51, P1001, DOI 10.1101/SQB.1986.051.01.114; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1854; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	33	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					653	658						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577866				2022-12-17	WOS:A1988R646000005
J	LIU, E; DOLLBAUM, C; SCOTT, G; ROCHLITZ, C; BENZ, C; SMITH, HS				LIU, E; DOLLBAUM, C; SCOTT, G; ROCHLITZ, C; BENZ, C; SMITH, HS			MOLECULAR LESIONS INVOLVED IN THE PROGRESSION OF A HUMAN-BREAST CANCER	ONCOGENE			English	Article									UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA; PERALTA CANC RES INST, OAKLAND, CA USA	University of California System; University of California San Francisco	LIU, E (corresponding author), UNIV N CAROLINA, LINEBERGER CANC RES CTR, DEPT MED, CB 7297, CHAPEL HILL, NC 27599 USA.		Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [P01CA044768, R01CA012705] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA44768, CA28739, CA12705] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAPRO MS, 1987, J CLIN ONCOL, V5, P890, DOI 10.1200/JCO.1987.5.6.890; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CHANG SE, 1982, CANCER RES, V42, P2040; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; ENGEL LW, 1978, CANCER RES, V38, P4327; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH HS, 1987, JNCI-J NATL CANCER I, V78, P611; SMITH HS, 1983, BIOCHIM BIOPHYS ACTA, V738, P103, DOI 10.1016/0304-419X(84)90009-X; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THEILLET C, 1986, CANCER RES, V46, P4776; TRENT JM, 1985, BREAST CANCER RES TR, V5, P221, DOI 10.1007/BF01806017; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; 1984, NATURE, V309, P111	34	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1988	3	3					323	327						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2849743				2022-12-17	WOS:A1988Q436700011
J	GOLDMAN, DS; KIESSLING, AA; COOPER, GM				GOLDMAN, DS; KIESSLING, AA; COOPER, GM			POST-TRANSCRIPTIONAL PROCESSING SUGGESTS THAT C-MOS FUNCTIONS AS A MATERNAL MESSAGE IN MOUSE EGGS	ONCOGENE			English	Article									HARVARD UNIV,SCH MED,HUMAN REPROD & REPROD BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL & REPROD BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	GOLDMAN, DS (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016561] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028946, P01CA021082] Funding Source: NIH RePORTER; NCI NIH HHS [CA21082, CA28946] Funding Source: Medline; NICHD NIH HHS [HD16561] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BACHVAROVA R, 1985, DEV BIOL, V108, P325, DOI 10.1016/0012-1606(85)90036-3; BORNSLAEGER EA, 1986, DEV BIOL, V114, P453, DOI 10.1016/0012-1606(86)90209-5; BRAUDE P, 1979, NATURE, V282, P102, DOI 10.1038/282102a0; CASCIO SM, 1982, DEV BIOL, V89, P397, DOI 10.1016/0012-1606(82)90328-1; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CLEGG KB, 1983, DEV BIOL, V95, P331, DOI 10.1016/0012-1606(83)90034-9; COLOT HV, 1982, DEV BIOL, V94, P79, DOI 10.1016/0012-1606(82)90070-7; Davidson E. H., 1986, GENE ACTIVITY EARLY; DWORKIN MB, 1985, DEV BIOL, V112, P451, DOI 10.1016/0012-1606(85)90417-8; GIEBELHAUS DH, 1983, DEV BIOL, V98, P148, DOI 10.1016/0012-1606(83)90343-3; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HOWLETT SK, 1985, J EMBRYOL EXP MORPH, V87, P175; HOWLETT SK, 1986, CELL, V45, P387, DOI 10.1016/0092-8674(86)90324-7; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; PHILPOTT CC, 1987, DEV BIOL, V121, P568, DOI 10.1016/0012-1606(87)90192-8; PIKO L, 1982, DEV BIOL, V89, P362, DOI 10.1016/0012-1606(82)90325-6; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; POUEYMIROU WT, 1987, DEV BIOL, V121, P489, DOI 10.1016/0012-1606(87)90185-0; PRATT HPM, 1983, CIBA F SYMP, V98, P197; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROSENTHAL ET, 1987, DEV BIOL, V121, P237, DOI 10.1016/0012-1606(87)90155-2; ROSENTHAL ET, 1986, DEV BIOL, V117, P55, DOI 10.1016/0012-1606(86)90347-7; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; VANBLERKOM J, 1981, P NATL ACAD SCI-BIOL, V78, P7629; VANBLERKOM J, 1981, CELLULAR MOL ASPECTS, P155; VOURNAKIS JN, 1975, P NATL ACAD SCI USA, V72, P2959, DOI 10.1073/pnas.72.8.2959; WASSARMAN PM, 1976, NATURE, V261, P73, DOI 10.1038/261073a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7	35	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					159	162						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2457860				2022-12-17	WOS:A1988Q053400005
J	REED, JC; ALPERS, JD; SCHERLE, PA; HOOVER, RG; NOWELL, PC; PRYSTOWSKY, MB				REED, JC; ALPERS, JD; SCHERLE, PA; HOOVER, RG; NOWELL, PC; PRYSTOWSKY, MB			PROTOONCOGENE EXPRESSION IN CLONED LYMPHOCYTES-T - MITOGENS AND GROWTH-FACTORS INDUCE DIFFERENT PATTERNS OF EXPRESSION	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute	REED, JC (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA 12779, CA 36403] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM-07170] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA036403, R01CA012779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; ELY JM, 1983, J IMMUNOL, V131, P1274; FARRAR WL, 1986, PROG LEUKOCYTE BIOL, V5, P75; GLASEBROOK AL, 1980, J EXP MED, V151, P876, DOI 10.1084/jem.151.4.876; HASHIMOTO Y, 1986, IN PRESS P NATL ACAD; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; LAVU S, 1985, CANCER CELLS, P301; MAINO VC, 1975, BIOCHEM J, V146, P247, DOI 10.1042/bj1460247; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; PAN S, 1983, VIROLOGY, V125, P1, DOI 10.1016/0042-6822(83)90058-2; PERRSON H, 1984, SCIENCE, V225, P718; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RABIN H, 1981, J IMMUNOL, V127, P1852; REED JC, 1985, MOL CELL BIOL, V5, P3361, DOI 10.1128/MCB.5.12.3361; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; SCHERLE P, 1986, IN PRESS J EXP MED; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; YOKATA T, 1985, P NATL ACAD SCI US, V82, P68	29	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					223	228						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	3501855				2022-12-17	WOS:A1987J635200015
J	RADICE, P; PIEROTTI, MA; BORRELLO, MG; ILLENI, MT; ROVINI, D; DELLAPORTA, G				RADICE, P; PIEROTTI, MA; BORRELLO, MG; ILLENI, MT; ROVINI, D; DELLAPORTA, G			HRAS1 PROTO-ONCOGENE POLYMORPHISMS IN HUMAN-MALIGNANT MELANOMA - TAQI DEFINED ALLELES SIGNIFICANTLY ASSOCIATED WITH THE DISEASE	ONCOGENE			English	Article									IST NAZL TUMORI,DIV EXPTL ONCOL A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY; IST NAZL TUMORI,DIV IMMUNOHEMATOL,I-20133 MILAN,ITALY; IST NAZL TUMORI,DIV SURG ONCOL C,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan			Radice, Paolo/O-3119-2013; Borrello, Maria Grazia/C-3161-2017	Radice, Paolo/0000-0001-6298-4111; Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332				Barker D, 1983, Mol Biol Med, V1, P199; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; COOPER GM, 1984, BIOCH BIOPHYS ACTA, V783, P9; GERHARD DS, 1987, NATURE, V325, P73, DOI 10.1038/325073a0; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Greene MH, 1979, HUMAN MALIGNANT MELA, P139; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LIDEREAU R, 1986, JNCI-J NATL CANCER I, V77, P697, DOI 10.1093/jnci/77.3.697; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; PIEROTTI MA, 1986, CYTOGENET CELL GENET, V43, P174, DOI 10.1159/000132317; PULCIANI S, 1982, J CELL BIOCHEM, V20, P51, DOI 10.1002/jcb.240200106; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUKUMAR S, 1984, GENES CANCER, P353; SUTHERLAND C, 1986, BRIT J CANCER, V54, P787, DOI 10.1038/bjc.1986.241; THEIN SL, 1986, NATURE, V321, P84, DOI 10.1038/321084a0	21	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					91	95						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	2894003				2022-12-17	WOS:A1987L481300014
J	Xu, LG; Huan, L; Guo, TA; Wu, YJ; Liu, YF; Wang, QF; Huang, SL; Xu, Y; Liang, LH; He, XH				Xu, Linguo; Huan, Lin; Guo, Tianan; Wu, Yangjun; Liu, Yanfang; Wang, Qifeng; Huang, Shenglin; Xu, Ye; Liang, Linhui; He, Xianghuo			LncRNA SNHG11 facilitates tumor metastasis by interacting with and stabilizing HIF-1 alpha	ONCOGENE			English	Article							LONG NONCODING RNA; ALPHA; CANCER; LOCALIZATION; DEGRADATION; HIF-1	Epigenetic alteration is one of the hallmarks of colorectal cancer (CRC). Many driver genes are regulated by DNA methylation in CRC. However, the role of DNA methylation regulating lncRNAs remain elusive. Here, we identify that SNHG11 (small nucleolar RNA host gene 11) is upregulated by promotor hypomethylation in CRC and is associated with poor prognosis in CRC patients. SNHG11 can promote CRC cell migration and metastasis under hypoxia. Interestingly, the DNA-binding motif of SNHG11 is similar to that of HIF-1 alpha. In addition, SNHG11-associated genes are enriched with members of the HIF-1 signaling pathway in CRC. Mechanistically, SNHG11 binds to the pVHLrecognition sites on HIF-1 alpha, thus blocking the interaction of pVHL with HIF-1 alpha and preventing its ubiquitination and degradation. Moreover, SNHG11 upregulates the expression of HIF-1 alpha target genes, i.e., AK4, ENO1, HK2, and Twist1. Notably, SNHG11 can bind to the HRE sites in the promoter of these genes and increase their transcription. In summary, these results identify a SNHG11/ HIF-1 alpha axis that plays a pivotal role in tumor invasion and metastasis.	[Xu, Linguo; Huan, Lin; Wu, Yangjun; Liu, Yanfang; Huang, Shenglin; Liang, Linhui; He, Xianghuo] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Xu, Linguo; Huan, Lin; Wu, Yangjun; Liu, Yanfang; Huang, Shenglin; Liang, Linhui; He, Xianghuo] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai 200032, Peoples R China; [Xu, Linguo; Huan, Lin; Guo, Tianan; Wu, Yangjun; Liu, Yanfang; Wang, Qifeng; Huang, Shenglin; Xu, Ye; Liang, Linhui; He, Xianghuo] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Guo, Tianan; Xu, Ye] Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Wang, Qifeng] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Liang, Linhui; He, Xianghuo] Fudan Univ, Shanghai Canc Ctr, Key Lab Breast Canc Shanghai, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; Fudan University	Liang, LH; He, XH (corresponding author), Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai 200032, Peoples R China.; Liang, LH; He, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai 200032, Peoples R China.; Xu, Y; Liang, LH; He, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.	xuye021@163.com; lianglinhui@fudan.edu.cn; xhhe@fudan.edu.cn	liu, yan/HGV-1365-2022; He, Xianghuo/I-1497-2014; xu, ye/GQO-8972-2022; liu, yan/HCI-5542-2022; liang, linhui/AAW-4176-2021; Huan, Lin/W-1334-2018; Huang, Shenglin/N-9472-2018	He, Xianghuo/0000-0001-8872-668X; xu, ye/0000-0003-0455-4556; Huan, Lin/0000-0002-5791-4482; Huang, Shenglin/0000-0003-1279-0794	National Natural Science Foundation of China [81672366, 81930123, 81790252]; China Postdoctoral Science Foundation [2020M671006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from National Natural Science Foundation of China (81672366, 81930123, 81790252) and China Postdoctoral Science Foundation (2020M671006).	Athauda A, 2019, CANCER TREAT REV, V73, P31, DOI 10.1016/j.ctrv.2018.12.004; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Chu Ci, 2012, J Vis Exp, DOI 10.3791/3912; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Gao S, 2014, FASEB J, V28, P1880, DOI 10.1096/fj.12-220152; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Gudenas BL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34708-w; Han P, 2015, RNA BIOL, V12, P1094, DOI 10.1080/15476286.2015.1063770; Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1; Hou Y, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00936; Huan L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1122-z; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jan YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0698-5; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Kondo Y, 2017, CANCER SCI, V108, P1927, DOI 10.1111/cas.13342; Krishnamachary B, 2003, CANCER RES, V63, P1138; Lee ST, 2010, STROKE, V41, P1646, DOI 10.1161/STROKEAHA.110.579649; Li ZJ, 2020, J CELL BIOCHEM, V121, P2406, DOI 10.1002/jcb.29463; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Mas-Ponte D, 2017, RNA, V23, P1080, DOI 10.1261/rna.060814.117; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Moinova HR, 2002, P NATL ACAD SCI USA, V99, P4562, DOI 10.1073/pnas.062459899; Neve B, 2018, CANCERS, V10, DOI 10.3390/cancers10110440; Pefanis E, 2015, CELL, V161, P774, DOI 10.1016/j.cell.2015.04.034; Saldana-Meyer R, 2019, MOL CELL, V76, P412, DOI 10.1016/j.molcel.2019.08.015; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shi LL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1332-8; Shih JW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15874; Sigova AA, 2015, SCIENCE, V350, P978, DOI 10.1126/science.aad3346; Sun YT, 2019, CANCERS, V11, DOI 10.3390/cancers11020216; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yan SY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0853-9; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Zhan PP, 2017, MOL CARCINOGEN, V56, P1427, DOI 10.1002/mc.22603; Zhao W, 2019, J CELL PHYSIOL, V234, P14519, DOI 10.1002/jcp.28143	39	29	31	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					7005	7018		10.1038/s41388-020-01512-8	http://dx.doi.org/10.1038/s41388-020-01512-8		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33060856	hybrid, Green Published			2022-12-17	WOS:000577946300003
J	Li, CC; Zhao, W; Pan, X; Li, XY; Yan, F; Liu, SW; Feng, JF; Lu, JW				Li, Chenchen; Zhao, Wei; Pan, Xuan; Li, Xiaoyou; Yan, Fei; Liu, Siwen; Feng, Jifeng; Lu, Jianwei			LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1	ONCOGENE			English	Article							LONG NONCODING RNA; GROWTH; METASTASIS; STATISTICS; AUTOPHAGY; EVOLUTION; INVASION; GENOMICS; PATHWAY; PDK1	Non-small cell lung cancer (NSCLC) is the major cause of cancer-associated death worldwide, but its underlying mechanisms remain to be fully elucidated. Long noncoding RNAs (lncRNAs) are known to play an important role in the aberrant regulation of gene expression in many cancers, including NSCLC. Here, we investigated the involvement of the lncRNA KTN1-AS1 in NSCLC. We found that KTN1-AS1 expression was upregulated in NSCLC tissue and was positively associated with poor prognosis. KTN1-AS1 knockdown inhibited cell growth and proliferation, increased apoptosis, and modulated the expression of cell cycle- and apoptosis-related proteins (cyclin A1, cyclin-dependent kinase 2, Bcl2, and Bax) in NSCLC cell lines and tumour xenografts in nude mice. KTN1-AS1 bound to and directly regulated the expression of miR-130a-5p. Notably, miR-130a-5p overexpression suppressed NSCLC cell proliferation and increased apoptosis in vitro and in vivo, and this effect was reversed by KTN1-AS1 overexpression. Finally, we showed that KTN1-AS1 modulated the expression of 3-phosphoinositide-dependent protein kinase 1 (PDPK1), a miR-130a-5p target and key regulator of autophagy in NSCLC cells. Taken together, our results suggest that the KTN1-AS1/miR-130a-5p/PDPK1 pathway may be a potential therapeutic target for NSCLC.	[Li, Chenchen; Pan, Xuan; Li, Xiaoyou; Yan, Fei; Liu, Siwen; Feng, Jifeng; Lu, Jianwei] Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Peoples R China; [Li, Chenchen; Pan, Xuan; Li, Xiaoyou; Yan, Fei; Liu, Siwen; Feng, Jifeng; Lu, Jianwei] Jiangsu Canc Hosp, Nanjing, Peoples R China; [Li, Chenchen; Pan, Xuan; Li, Xiaoyou; Yan, Fei; Liu, Siwen; Feng, Jifeng; Lu, Jianwei] Jiangsu Inst Canc Res, Nanjing, Peoples R China; [Zhao, Wei] Chengdu Med Coll, Sch Lab Med, Sichuan Prov Engn Lab Prevent & Control Technol V, Chengdu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Chengdu Medical College	Feng, JF; Lu, JW (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Dept Med Oncol, Nanjing, Peoples R China.; Feng, JF; Lu, JW (corresponding author), Jiangsu Canc Hosp, Nanjing, Peoples R China.; Feng, JF; Lu, JW (corresponding author), Jiangsu Inst Canc Res, Nanjing, Peoples R China.	fjifvvip@126.com; lujw@medmail.com.cn	Zhao, Wei/AAC-6849-2020	Zhao, Wei/0000-0003-2421-7311; Pan, Xuan/0000-0001-9161-4267	National Natural Science Foundation of China [81602636]; General Program of Jiangsu Cancer Hospital [ZM201809]; Jiangsu Provincial Medical Youth Talent [QNRC2016645]; Young Talents Program of Jiangsu Cancer Hospital [QL201814]; Nanjing Medical Science and Technology Development Project [ZKX15049]; Key Project of Science of Sichuan Education Department [18ZA0164]; Natural Science Foundation of Chengdu Medical College [CYZ18-04]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); General Program of Jiangsu Cancer Hospital; Jiangsu Provincial Medical Youth Talent; Young Talents Program of Jiangsu Cancer Hospital; Nanjing Medical Science and Technology Development Project; Key Project of Science of Sichuan Education Department; Natural Science Foundation of Chengdu Medical College	This work was supported by the National Natural Science Foundation of China (81602636), General Program of Jiangsu Cancer Hospital (ZM201809), Jiangsu Provincial Medical Youth Talent (QNRC2016645), Young Talents Program of Jiangsu Cancer Hospital (QL201814), Nanjing Medical Science and Technology Development Project (ZKX15049), Key Project of Science of Sichuan Education Department (18ZA0164) and Natural Science Foundation of Chengdu Medical College (CYZ18-04).	Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Boolell V, 2015, CANCERS, V7, P1815, DOI 10.3390/cancers7030864; Cao W, 2017, ORAL ONCOL, V65, P94, DOI 10.1016/j.oraloncology.2016.12.017; Carrot-Zhang J, 2020, CANCER CELL, V37, P639, DOI 10.1016/j.ccell.2020.04.012; Chang CW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0250-x; Chang ZW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0724-4; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; Dan Cao, 2015, EMBO Mol Med, V7, P140, DOI 10.15252/emmm.201404797; Deng J, 2015, BIOMED PHARMACOTHER, V75, P8, DOI 10.1016/j.biopha.2015.07.003; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gong ZJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110674; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Han J, 2018, AUTOPHAGY, V14, P958, DOI 10.1080/15548627.2018.1434471; Huarte M, 2013, CELL RES, V23, P449, DOI 10.1038/cr.2012.169; Kim T, 2015, JNCI-J NATL CANCER I, V107, P1; Li Y, 2018, P NATL ACAD SCI USA, V115, pE10849, DOI 10.1073/pnas.1803377115; Li Y, 2017, CELL MOL BIOL LETT, V22, P1, DOI 10.1186/s11658-017-0033-5; Lu KH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-461; Lv JJ, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0352-9; McManus S, 2016, J BONE MINER RES, V31, P1334, DOI 10.1002/jbmr.2806; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Bautista RR, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0537-5; Shen WT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.137; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tang Q, 2019, J CELL MOL MED, V23, P7749, DOI 10.1111/jcmm.14649; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang F, 2018, INT J BIOCHEM CELL B, V99, P91, DOI 10.1016/j.biocel.2018.04.005; Wang YF, 2016, TRENDS GENET, V32, P211, DOI 10.1016/j.tig.2016.02.001; Wood SL, 2015, CANCER TREAT REV, V41, P361, DOI 10.1016/j.ctrv.2015.02.008; Xian XS, 2018, ONCOTARGETS THER, V11, P7503, DOI 10.2147/OTT.S181706; Xu CH, 2019, EUR REV MED PHARMACO, V23, P241, DOI 10.26355/eurrev_201901_16770; Yin DD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0836-7; Zhang L, 2019, BIOMED PHARMACOTHER, V109, P1140, DOI 10.1016/j.biopha.2018.10.105; Zhang L, 2018, GENES DIS, V5, P158, DOI 10.1016/j.gendis.2017.12.003; Zhao W, 2014, EUR REV MED PHARMACO, V18, P1930; Zheng NN, 2015, CELL PHYSIOL BIOCHEM, V36, P1903, DOI 10.1159/000430159; Zhou LK, 2012, HEPATOLOGY, V56, P95, DOI 10.1002/hep.25611	40	29	29	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6157	6171		10.1038/s41388-020-01427-4	http://dx.doi.org/10.1038/s41388-020-01427-4		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32820252				2022-12-17	WOS:000561253800001
J	Zhang, XM; Yang, L; Szeto, P; Abali, GK; Zhang, YF; Kulkarni, A; Amarasinghe, K; Li, JS; Vergara, IA; Molania, R; Papenfuss, AT; McLean, C; Shackleton, M; Harvey, KF				Zhang, Xiaomeng; Yang, Lie; Szeto, Pacman; Abali, Gamze Kuser; Zhang, Youfang; Kulkarni, Aishwarya; Amarasinghe, Kaushalya; Li, Jason; Vergara, Ismael A.; Molania, Ramyar; Papenfuss, Anthony T.; McLean, Catriona; Shackleton, Mark; Harvey, Kieran F.			The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis	ONCOGENE			English	Article							SIGNALING PATHWAY; VEMURAFENIB; EXPRESSION; DROSOPHILA; TAZ; DIFFERENTIATION; CLASSIFICATION; FOLLISTATIN; RESISTANCE; PHENOTYPE	Melanoma is a deadly form of skin cancer that accounts for a disproportionally large proportion of cancer-related deaths in younger people. Compared with most other skin cancers, a feature of melanoma is its high metastatic capacity, although the mechanisms that confer this are not well understood. The Hippo pathway is a key regulator of organ growth and cell fate that is deregulated in many cancers. To analyse the Hippo pathway in cutaneous melanoma, we generated a transcriptional signature of melanoma cells that overexpressed YAP, the key downstream Hippo pathway oncoprotein. YAP-mediated transcriptional activity varied in melanoma cell lines but did not cluster with known genetic drivers of melanomagenesis such asBRAFandNRASmutations. Instead, it correlated strongly with published gene expression profiles linked to melanoma cell invasiveness and varied throughout the metastatic cascade in melanoma patient tumours. Consistent with this, YAP was both necessary and sufficient for melanoma cell invasion in vitro. In vivo, YAP promoted spontaneous melanoma metastasis, whilst the growth of YAP-expressing primary tumours was impeded. Finally, we identified the YAP target genesAXL,THBS1andCYR61as key mediators of YAP-induced melanoma cell invasion. These data suggest that YAP is a critical regulator of melanoma metastasis.	[Zhang, Xiaomeng; Yang, Lie; Kulkarni, Aishwarya; Amarasinghe, Kaushalya; Li, Jason; Vergara, Ismael A.; Papenfuss, Anthony T.; Harvey, Kieran F.] Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia; [Yang, Lie] Tsinghua Univ, Sch Med, 1 Tsinghua Yuan, Beijing 100084, Peoples R China; [Szeto, Pacman; Abali, Gamze Kuser; Zhang, Youfang; McLean, Catriona; Shackleton, Mark] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [Szeto, Pacman; Abali, Gamze Kuser; Zhang, Youfang; Shackleton, Mark] Alfred Hlth, Melbourne, Vic, Australia; [Kulkarni, Aishwarya; Papenfuss, Anthony T.; Harvey, Kieran F.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3010, Australia; [Vergara, Ismael A.; Molania, Ramyar; Papenfuss, Anthony T.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic 3052, Australia; [Papenfuss, Anthony T.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia; [Harvey, Kieran F.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Harvey, Kieran F.] Monash Univ, Biomed Discovery Inst, Clayton, Vic, Australia	Peter Maccallum Cancer Center; Tsinghua University; Monash University; Peter Maccallum Cancer Center; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne; Monash University; Monash University	Harvey, KF (corresponding author), Peter MacCallum Canc Ctr, 305 Grattan St, Melbourne, Vic 3000, Australia.; Harvey, KF (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3010, Australia.; Harvey, KF (corresponding author), Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia.; Harvey, KF (corresponding author), Monash Univ, Biomed Discovery Inst, Clayton, Vic, Australia.	kieran.harvey@petermac.org	Papenfuss, Anthony T/C-6297-2008; Harvey, Kieran/AAD-5268-2022	Papenfuss, Anthony T/0000-0002-1102-8506; Yang, Lie/0000-0001-7563-3214; Vergara, Ismael/0000-0002-2960-2967; Kulkarni, Aishwarya/0000-0001-5365-214X; Amarasinghe, Kaushalya C./0000-0001-6024-657X; Kuser Abali, Gamze/0000-0002-4590-0577; Szeto, Pacman/0000-0002-6159-9913	Australian Cancer Research Foundation; National Health and Medical Research Council (NHMRC) Senior Research Fellowship [APP1078220, APP1116955]; Pfizer Australia; NHMRC [APP1145166]; veski; VCA Fellowships; Cancer Council of Victoria [APP1080255]; Peter MacCallum Cancer Foundation; Lorenzo and Pamela Galli Charitable Trust; Victorian State Government Operational Infrastructure Support; Australian Government NHMRC Independent Research Institute Infrastructure Support; China Scholarship Council; Australian Government Research Training Programme Scholarship; Rosie Lew Peter MacCallum Cancer Foundation Postgraduate Award	Australian Cancer Research Foundation; National Health and Medical Research Council (NHMRC) Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Pfizer Australia(PfizerPfizer Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); veski; VCA Fellowships; Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Peter MacCallum Cancer Foundation; Lorenzo and Pamela Galli Charitable Trust; Victorian State Government Operational Infrastructure Support; Australian Government NHMRC Independent Research Institute Infrastructure Support(National Health and Medical Research Council (NHMRC) of Australia); China Scholarship Council(China Scholarship Council); Australian Government Research Training Programme Scholarship(Australian Government); Rosie Lew Peter MacCallum Cancer Foundation Postgraduate Award	We thank the following Peter MacCallum Cancer Centre core facilities: Molecular Genomics, Bioinformatics, Flow Cytometry and the Centre for Advanced Histology and Microscopy, which were in part supported by the Australian Cancer Research Foundation. KFH was supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (APP1078220). MS was supported by Pfizer Australia, NHMRC, veski, and VCA Fellowships. This research was supported by grants from the Cancer Council of Victoria (APP1080255) and NHMRC (APP1145166), and by the Peter MacCallum Cancer Foundation. ATP was supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (APP1116955) and by the Lorenzo and Pamela Galli Charitable Trust. The research benefitted by support from the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC Independent Research Institute Infrastructure Support. LY was supported by the China Scholarship Council. AK was supported by an Australian Government Research Training Programme Scholarship and a Rosie Lew Peter MacCallum Cancer Foundation Postgraduate Award.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Brastianos PK, 2013, NAT GENET, V45, P285, DOI 10.1038/ng.2526; Bueno R, 2016, NAT GENET; Calses PC, 2019, TRENDS CANCER, V5, P297, DOI 10.1016/j.trecan.2019.04.001; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cox AG, 2016, NAT CELL BIOL, V18, P886, DOI 10.1038/ncb3389; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ege N, 2018, CELL SYST, V6, P692, DOI 10.1016/j.cels.2018.05.006; Elosegui-Artola A, 2017, CELL, V171, P1397, DOI 10.1016/j.cell.2017.10.008; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hong WJ, 2012, SEMIN CELL DEV BIOL, V23, P785, DOI 10.1016/j.semcdb.2012.05.004; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jayachandran A, 2014, ONCOTARGET, V5, P5782, DOI 10.18632/oncotarget.2164; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Larkin J, 2014, LANCET ONCOL, V15, P436, DOI 10.1016/S1470-2045(14)70051-8; Lee CK, 2019, SCIENCE, V363, P644, DOI 10.1126/science.aav0173; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Manning SA, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.179069; Manning SA, 2018, CURR BIOL, V28, P1651, DOI 10.1016/j.cub.2018.04.018; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Nallet-Staub F, 2014, J INVEST DERMATOL, V134, P123, DOI 10.1038/jid.2013.319; Ogasawara N, 2018, BIOL PHARM BULL, V41, P604, DOI 10.1248/bpb.b17-00990; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Seachrist DD, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0857-y; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Titz B, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.28; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Zabkiewicz C, 2017, CANCER GENOM PROTEOM, V14, P241, DOI 10.21873/cgp.20035; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zeng H, 2015, GROWTH FACTORS, V33, P384, DOI 10.3109/08977194.2015.1119132; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhang XM, 2019, MOL CANCER RES, V17, P1435, DOI 10.1158/1541-7786.MCR-18-0407; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111	58	29	30	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5267	5281		10.1038/s41388-020-1362-9	http://dx.doi.org/10.1038/s41388-020-1362-9		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32561850	Green Submitted			2022-12-17	WOS:000541308400001
J	Yu, SY; Yu, XT; Sun, LL; Zheng, YW; Chen, LL; Xu, H; Jin, J; Lan, Q; Chen, CC; Li, M				Yu, Shuye; Yu, Xiaoting; Sun, Lili; Zheng, Yanwen; Chen, Lili; Xu, Hui; Jin, Jing; Lan, Qing; Chen, Clark C.; Li, Ming			GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway	ONCOGENE			English	Article							BINDING PROTEIN-1; CELL-ADHESION; GENOMIC ANALYSIS; DRUG-RESISTANCE; BREAST-CANCER; FIBRONECTIN; PROLIFERATION; PROMOTES; GROWTH; LANDSCAPE	Guanylate-binding protein 2 (GBP2) is an interferon-inducible large GTPase which is crucial to the protective immunity against microorganisms. However, its biological function in cancer remains largely unknown. Glioblastoma multiforme (GBM) is the most common and deadly brain tumor in adults. Here we show that GBP2 expression is highly elevated in GBM tumor and cell lines, particularly in those of the mesenchymal subtype. High GBP2 expression is associated with poor prognosis. GBP2 overexpression significantly promotes GBM cell migration and invasion in vitro, and GBP2 silencing by RNA interference exhibits opposite effects. We further show that fibronectin (FN1) is dramatically induced by GBP2 expression at both mRNA and protein levels, and FN1 is essential for GBP2-promoted GBM invasiveness. Inhibition of Stat3 pathway prevents GBP2-promoted FN1 induction and cell invasion. Consistently, GBP2 dramatically promotes GBM tumor growth and invasion in mice and significantly reduces the survival time of the mice with tumor. Taken together, these findings establish the role of GBP2/Stat3/FN1 signaling cascade in GBM invasion and suggest GBP2 may serve as a potential therapeutic target for inhibiting GBM invasion.	[Yu, Shuye; Sun, Lili; Zheng, Yanwen; Chen, Lili; Li, Ming] Soochow Univ, Affiliated Hosp 2, Cent Lab, Suzhou, Jiangsu, Peoples R China; [Xu, Hui; Jin, Jing; Lan, Qing; Li, Ming] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China; [Yu, Xiaoting] Soochow Univ, Affiliated Hosp 2, Dept Oncol, Suzhou, Jiangsu, Peoples R China; [Chen, Clark C.; Li, Ming] Univ Minnesota, Sch Med, Dept Neurosurg, Minneapolis, MN 55455 USA; [Yu, Shuye] Songlingzhen Hlth Ctr, Suzhou, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; University of Minnesota System; University of Minnesota Twin Cities	Li, M (corresponding author), Soochow Univ, Affiliated Hosp 2, Cent Lab, Suzhou, Jiangsu, Peoples R China.; Li, M (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China.; Li, M (corresponding author), Univ Minnesota, Sch Med, Dept Neurosurg, Minneapolis, MN 55455 USA.	li001705@umn.edu	Sun, lili/GQH-2057-2022	Li, Ming/0000-0002-2540-1738	National Natural Sciences Foundation of China [81572480]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported with a grant from the National Natural Sciences Foundation of China (81572480). We thank Drs. Frank Furnari and Benjamin Purow for the gift of cell lines.	Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Britzen-Laurent N, 2013, CARCINOGENESIS, V34, P153, DOI 10.1093/carcin/bgs310; Caffo M, 2004, ACTA NEUROCHIR, V146, P1113, DOI 10.1007/s00701-004-0344-y; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Fei M, 2013, INT J HEMATOL, V98, P446, DOI 10.1007/s12185-013-1435-4; Fukumoto M, 2014, CANCER SCI, V105, P1351, DOI 10.1111/cas.12489; Godoy P, 2014, BREAST CANCER-TOKYO, V21, P491, DOI 10.1007/s12282-012-0404-8; Gong J, 2017, MOL MED REP, V16, P143, DOI 10.3892/mmr.2017.6610; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; Guimaraes DP, 2009, INT J CANCER, V124, P272, DOI 10.1002/ijc.23944; Han SW, 2006, CANCER RES, V66, P315, DOI 10.1158/0008-5472.CAN-05-2367; Hazlehurst LA, 2006, CANCER RES, V66, P2338, DOI 10.1158/0008-5472.CAN-05-3256; Iwamaru A, 2007, ONCOGENE, V26, P2435, DOI 10.1038/sj.onc.1210031; Lan Q, 2016, ONCOTARGET, V7, P9680, DOI 10.18632/oncotarget.7109; Lau J, 2015, CANCER RES, V75, P4302, DOI 10.1158/0008-5472.CAN-14-3331; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li L, 2015, DISCOV MED, V20, P369; Li M, 2011, J EXP MED, V208, P2657, DOI 10.1084/jem.20111102; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Nakagawa Y, 2014, INT J ONCOL, V44, P1376, DOI 10.3892/ijo.2014.2265; Natesh K, 2015, NEOPLASIA, V17, P225, DOI 10.1016/j.neo.2015.01.001; Olszewski MA, 2006, J INTERF CYTOK RES, V26, P328, DOI 10.1089/jir.2006.26.328; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Quintero M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3726-2; SAWAYA R, 1985, NEUROSURGERY, V16, P161, DOI 10.1227/00006123-198502000-00006; Sengupta S, 2010, NEOPLASIA, V12, P837, DOI 10.1593/neo.10662; Tipton AR, 2016, BIOCHEM BIOPH RES CO, V478, P1617, DOI 10.1016/j.bbrc.2016.08.169; Tretina K, 2019, J EXP MED, V216, P482, DOI 10.1084/jem.20182031; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vestal DJ, 2011, J INTERF CYTOK RES, V31, P89, DOI 10.1089/jir.2010.0102; Weinlander K, 2008, FASEB J, V22, P4168, DOI 10.1096/fj.08-107524; Xu H, 2018, BIOCHEM BIOPH RES CO, V495, P446, DOI 10.1016/j.bbrc.2017.11.050; Yu Q, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00130; Zhang J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.559	35	29	29	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5042	5055		10.1038/s41388-020-1348-7	http://dx.doi.org/10.1038/s41388-020-1348-7		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32518375				2022-12-17	WOS:000539201700002
J	Lai, SH; Zervoudakis, G; Chou, JS; Gurney, ME; Quesnelle, KM				Lai, Samuel Hsien; Zervoudakis, Guston; Chou, Jesse; Gurney, Mark E.; Quesnelle, Kelly M.			PDE4 subtypes in cancer	ONCOGENE			English	Review							PROTEIN-KINASE-A; PHOSPHODIESTERASE 4B; PROSTATE-CANCER; CELL-DEATH; ESOPHAGEAL ADENOCARCINOMA; INTEGRATED ANALYSIS; THERAPEUTIC TARGET; SELECTIVE PDE4B; BREAST-CANCER; IN-VITRO	Cyclic nucleotide phosphodiesterases (PDE) break down cyclic nucleotides such as cAMP and cGMP, reducing the signaling of these important intracellular second messengers. Several unique families of phosphodiesterases exist, and certain families are clinically important modulators of vasodilation. In the current work, we have summarized the body of literature that describes an emerging role for the PDE4 subfamily of phosphodiesterases in malignancy. We have systematically investigated PDE4A, PDE4B, PDE4C, and PDE4D isoforms and found evidence associating them with several cancer types including hematologic malignancies and lung cancers, among others. In this review, we compare the evidence examining the functional role of each PDE4 subtype across malignancies, looking for common signaling themes, signaling pathways, and establishing the case for PDE4 subtypes as a potential therapeutic target for cancer treatment.	[Lai, Samuel Hsien; Zervoudakis, Guston; Chou, Jesse; Quesnelle, Kelly M.] Western Michigan Univ, Homer Stryker MD Sch Med, Dept Biomed Sci, Kalamazoo, MI 49008 USA; [Gurney, Mark E.] Tetra Therapeut, Grand Rapids, MI USA	Western Michigan University	Quesnelle, KM (corresponding author), Western Michigan Univ, Homer Stryker MD Sch Med, Dept Biomed Sci, Kalamazoo, MI 49008 USA.	kelly.quesnelle@med.wmich.edu	Quesnelle, Kelly/AAJ-2580-2021	Lai, Samuel/0000-0003-0187-4255	NIMH NIH HHS [R43 MH091791, R43 MH107077] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Agostini A, 2018, INT J CANCER, V143, P1379, DOI 10.1002/ijc.31418; Araujo T, 2018, WORLD J GASTROENTERO, V24, P5338, DOI 10.3748/wjg.v24.i47.5338; Babu RV, 2013, ORG BIOMOL CHEM, V11, P6680, DOI 10.1039/c3ob41504j; Bao ZS, 2014, ONCOL REP, V32, P250, DOI 10.3892/or.2014.3176; Baty F, 2015, J BIOMED INFORM, V58, P175, DOI 10.1016/j.jbi.2015.10.002; Bodelon C, 2017, INT J CANCER, V140, P825, DOI 10.1002/ijc.30512; Bottcher R, 2016, ONCOTARGET, V7, P70669, DOI 10.18632/oncotarget.12204; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Bolger GB, 2016, ENDOCR-RELAT CANCER, V23, P419, DOI 10.1530/ERC-15-0205; Burgin AB, 2010, NAT BIOTECHNOL, V28, P63, DOI 10.1038/nbt.1598; Bye H, 2012, CARCINOGENESIS, V33, P2155, DOI 10.1093/carcin/bgs262; Cao B, 2016, ELIFE, V5, DOI 10.7554/eLife.15978; Chamseddine AN, 2016, CL LYMPH MYELOM LEUK, V16, pS67, DOI 10.1016/j.clml.2016.02.026; Chen L, 2018, AM J CANCER RES, V8, P2387; Cokic VP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135463; Cooney JD, 2018, CLIN CANCER RES, V24, P1103, DOI 10.1158/1078-0432.CCR-17-2218; Das A, 2015, PHARMACOL THERAPEUT, V147, P12, DOI 10.1016/j.pharmthera.2014.10.003; Delyon J, 2017, ONCOGENE, V36, P3252, DOI 10.1038/onc.2016.469; Dong HL, 2010, BIOCHEM PHARMACOL, V79, P321, DOI 10.1016/j.bcp.2009.09.001; Dong PX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1306-9; Fernandez-Araujo A, 2015, TOXICOL IN VITRO, V29, P1545, DOI 10.1016/j.tiv.2015.05.013; Floor SL, 2015, MOL CELL ENDOCRINOL, V411, P1, DOI 10.1016/j.mce.2015.04.001; Fox D, 2014, CELL SIGNAL, V26, P657, DOI 10.1016/j.cellsig.2013.12.003; Garritano S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.15; Ge XC, 2015, ELIFE, V4, DOI [10.7554/eLife.07068.001, 10.7554/eLife.07068]; Geybels MS, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0161-6; Goldhoff P, 2008, CLIN CANCER RES, V14, P7717, DOI 10.1158/1078-0432.CCR-08-0827; Gu JA, 2010, CANCER PREV RES, V3, P1176, DOI 10.1158/1940-6207.CAPR-09-0265; Gurney ME, 2019, J MED CHEM, V62, P4884, DOI 10.1021/acs.jmedchem.9b00193; Haddad SA, 2016, CARCINOGENESIS, V37, P870, DOI 10.1093/carcin/bgw067; Hagen TJ, 2014, BIOORG MED CHEM LETT, V24, P4031, DOI 10.1016/j.bmcl.2014.06.002; He N, 2014, MOL CANCER THER, V13, P2463, DOI 10.1158/1535-7163.MCT-14-0297; He RQ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3646-1; Henderson DJP, 2014, BRIT J CANCER, V110, P1278, DOI 10.1038/bjc.2014.22; Henderson DJP, 2019, CLIN SCI, V133, P269, DOI 10.1042/CS20180519; Holloway DT, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-24; Houslay MD, 2010, TRENDS BIOCHEM SCI, V35, P91, DOI 10.1016/j.tibs.2009.09.007; Jiang Xin, 1998, Cell Biochemistry and Biophysics, V28, P135, DOI 10.1007/BF02737809; Kang TW, 2014, SCI REP-UK, V4, DOI 10.1038/srep05546; Karachaliou N, 2015, SCI REP-UK, V5, DOI 10.1038/srep17499; Kashiwagi E, 2012, PROSTATE, V72, P741, DOI 10.1002/pros.21478; Kelly K, 2017, CLIN CANCER RES, V23, P1186, DOI 10.1158/1078-0432.CCR-16-1207; Khaled M, 2010, GENE DEV, V24, P2276, DOI 10.1101/gad.1937710; Kim DH, 1998, BLOOD, V92, P2484, DOI 10.1182/blood.V92.7.2484.2484_2484_2494; Kim DU, 2019, ONCOL LETT, V17, P3589, DOI 10.3892/ol.2019.9996; Kim DU, 2019, BIOCHEM BIOPH RES CO, V508, P825, DOI 10.1016/j.bbrc.2018.12.004; Kim J, 2015, GENE, V558, P173, DOI 10.1016/j.gene.2015.01.001; Kim SW, 2011, CLIN CANCER RES, V17, P6723, DOI 10.1158/1078-0432.CCR-11-0770; Kim SW, 2009, BLOOD, V113, P6153, DOI 10.1182/blood-2009-02-206128; Knobloch TJ, 2019, METABOLITES, V9, DOI 10.3390/metabo9070140; Kolosionek E, 2009, MOL BIOL CELL, V20, P4751, DOI 10.1091/mbc.E09-01-0019; Lapa GB, 2016, CHEM BIOL DRUG DES, V87, P575, DOI 10.1111/cbdd.12691; Li H, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01048; Liu S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1322-z; Mahmood B, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2980-z; Mareddy J, 2013, BIOORG MED CHEM LETT, V23, P6721, DOI 10.1016/j.bmcl.2013.10.035; Maurice DH, 2014, NAT REV DRUG DISCOV, V13, P290, DOI 10.1038/nrd4228; McEwan DG, 2007, CANCER RES, V67, P5248, DOI 10.1158/0008-5472.CAN-07-0097; Miklos W, 2016, ONCOTARGET, V7, P84556, DOI 10.18632/oncotarget.11821; Milinkovic V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082108; Mishra RR, 2018, CLIN CANCER RES, V24, P1987, DOI 10.1158/1078-0432.CCR-17-2776; Moon EY, 2012, LIFE SCI, V90, P373, DOI 10.1016/j.lfs.2011.12.010; Naganuma K, 2009, BIOORG MED CHEM LETT, V19, P3174, DOI 10.1016/j.bmcl.2009.04.121; Nagy ZS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057326; Nanayakkara S, 2018, AM J CARDIOL, V122, P1017, DOI 10.1016/j.amjcard.2018.06.009; Nancarrow DJ, 2008, CANCER RES, V68, P4163, DOI 10.1158/0008-5472.CAN-07-6710; Narita M, 2007, ONCOL REP, V17, P1133; Natrajan R, 2012, J PATHOL, V227, P29, DOI 10.1002/path.4003; Nishi K, 2017, ANTICANCER RES, V37, P3833, DOI 10.21873/anticanres.11762; Obernolte R, 1997, BBA-GENE STRUCT EXPR, V1353, P287, DOI 10.1016/S0167-4781(97)00080-8; Peng QP, 2018, CELL MOL BIOL, V64, P62, DOI 10.14715/cmb/2017.64.15.10; Peng YH, 2018, J CANCER, V9, P2389, DOI 10.7150/jca.24079; Persani L, 2000, J CLIN ENDOCR METAB, V85, P2872, DOI 10.1210/jc.85.8.2872; Pleiman JK, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007611; Powers GL, 2015, MOL CANCER RES, V13, P149, DOI 10.1158/1541-7786.MCR-14-0110; Praveena KSS, 2014, BIOORG CHEM, V53, P8, DOI 10.1016/j.bioorg.2013.12.002; Pullamsetti SS, 2013, ONCOGENE, V32, P1121, DOI 10.1038/onc.2012.136; Qiang Z, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0971-4; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Ramezani S, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.116880; Ramezani S, 2017, LIFE SCI, V173, P11, DOI 10.1016/j.lfs.2017.02.005; Rickles RJ, 2010, BLOOD, V116, P593, DOI 10.1182/blood-2009-11-252668; Sakkas LI, 2017, CURR MED CHEM, V24, P3054, DOI 10.2174/0929867324666170530093902; Sarfati M, 2003, BLOOD, V101, P265, DOI 10.1182/blood-2002-01-0075; Shah MS, 2011, PHYSIOL GENOMICS, V43, P640, DOI 10.1152/physiolgenomics.00213.2010; Smith PG, 2005, BLOOD, V105, P308, DOI 10.1182/blood-2004-01-0240; Suhasini AN, 2016, LEUKEMIA, V30, P617, DOI 10.1038/leu.2015.302; Tiwari S, 2005, BIOCHEM PHARMACOL, V69, P473, DOI 10.1016/j.bcp.2004.10.009; Toledo RA, 2010, CLINICS, V65, P407, DOI 10.1590/S1807-59322010000400010; Tsunoda T, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-46; van Strijp D, 2019, PROSTATE CANCER, V2019, DOI 10.1155/2019/8107807; Wang HC, 2007, BIOCHEM J, V408, P193, DOI 10.1042/BJ20070970; Wang YF, 2018, BIOCHEM BIOPH RES CO, V501, P313, DOI 10.1016/j.bbrc.2018.05.024; Warrington NM, 2010, CANCER RES, V70, P5717, DOI 10.1158/0008-5472.CAN-09-3769; Wittliff JL, 2017, HORM CANCER-US, V8, P298, DOI 10.1007/s12672-017-0309-2; Xu T, 2014, ONCOL LETT, V8, P2110, DOI 10.3892/ol.2014.2422; Yang JJ, 2012, BLOOD, V120, P4197, DOI 10.1182/blood-2012-07-440107; Zebda R, 2018, J AM ACAD DERMATOL, V78, pS43, DOI 10.1016/j.jaad.2017.11.056; Zhang C, 2017, SCI REP-UK, V7, DOI 10.1038/srep40115; Zhang LZ, 2008, P NATL ACAD SCI USA, V105, P19532, DOI 10.1073/pnas.0806152105	100	29	29	6	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3791	3802		10.1038/s41388-020-1258-8	http://dx.doi.org/10.1038/s41388-020-1258-8		MAR 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203163	Green Accepted			2022-12-17	WOS:000520614000001
J	Koch, JP; Aebersold, DM; Zimmer, Y; Medova, M				Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela			MET targeting: time for a rematch	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; RECEPTOR-TYROSINE KINASE; MODIFIED T-CELLS; DURABLE COMPLETE RESPONSE; PRIMARY COLON-CANCER; EXON 14 MUTATIONS; C-MET; SCATTER FACTOR; ONCOGENE ADDICTION	MET, the receptor tyrosine kinase (RTK) for hepatocyte growth factor, is a proto-oncogene involved in embryonic development and throughout life in homeostasis and tissue regeneration. Deregulation of MET signaling has been reported in numerous malignancies, prompting great interest in MET targeting for cancer therapy. The present review offers a summary of the biology of MET and its known functions in normal physiology and carcinogenesis, followed by an overview of the most relevant MET-targeting strategies and corresponding clinical trials, highlighting both past setbacks and promising future prospects. By placing their efforts on a more precise stratification strategy through the genetic analysis of tumors, modern trials such as the NCI-MATCH trial could revive the past enthusiasm for MET-targeted therapy.	[Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela] Bern Univ Hosp, Inselspital, Dept BioMed Res, CH-3008 Bern, Switzerland; [Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela] Univ Bern, CH-3008 Bern, Switzerland; [Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela] Bern Univ Hosp, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland; [Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medova, Michaela] Univ Bern, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University Hospital of Bern; University of Bern	Medova, M (corresponding author), Bern Univ Hosp, Inselspital, Dept BioMed Res, CH-3008 Bern, Switzerland.; Medova, M (corresponding author), Univ Bern, CH-3008 Bern, Switzerland.; Medova, M (corresponding author), Bern Univ Hosp, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland.; Medova, M (corresponding author), Univ Bern, CH-3010 Bern, Switzerland.	michaela.medova@dbmr.unibe.ch	Aebersold, Daniel Matthias/C-2946-2013	Aebersold, Daniel Matthias/0000-0002-9493-3834; Medova, Michaela/0000-0003-0649-469X	Werner und Hedy Berger-Janser Stiftung	Werner und Hedy Berger-Janser Stiftung	This work has been supported by the Werner und Hedy Berger-Janser Stiftung (grant to MM).	Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Ahmed N, 2015, J CLIN ONCOL, V33, P1688, DOI 10.1200/JCO.2014.58.0225; Ahmed N, 2009, MOL THER, V17, P1779, DOI 10.1038/mt.2009.133; Al-Saad S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181527; Androulla MN, 2018, CURR PHARM BIOTECHNO, V19, P5, DOI 10.2174/1389201019666180418095526; Ariyawutyakorn W, 2016, J CANCER, V7, P633, DOI 10.7150/jca.12663; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Awad MM, 2016, J CLIN ONCOL, V34, P721, DOI 10.1200/JCO.2015.63.4600; Bahcall M, 2016, CANCER DISCOV, V6, P1334, DOI 10.1158/2159-8290.CD-16-0686; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Basilico C, 2008, J BIOL CHEM, V283, P21267, DOI 10.1074/jbc.M800727200; Basilico C, 2013, CLIN CANCER RES, V19, P2381, DOI 10.1158/1078-0432.CCR-12-3459; Bauer TW, 2006, MOL CANCER THER, V5, P1676, DOI 10.1158/1535-7163.MCT-05-0175; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Bradley CA, 2017, NAT REV CLIN ONCOL, V14, P562, DOI 10.1038/nrclinonc.2017.40; Breindel JL, 2013, CANCER RES, V73, P5053, DOI 10.1158/0008-5472.CAN-12-3775; Burgess TL, 2010, MOL CANCER THER, V9, P400, DOI 10.1158/1535-7163.MCT-09-0824; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cabometyx, CAB; Camidge DR, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8001; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1; Catenacci DVT, 2011, CANCER DISCOV, V1, P573, DOI 10.1158/2159-8290.CD-11-0175; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Choueiri TK, 2017, ANN ONCOL, V28, pv605, DOI 10.1093/annonc/; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Comoglio PM, 2018, NAT REV CANCER, V18, P341, DOI 10.1038/s41568-018-0002-y; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; D'Arcangelo M, 2013, BIOL-TARGETS THER, V7, P61, DOI 10.2147/BTT.S28908; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Doi T, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.tps226; Du J, 2017, ONCOTARGET, V8, P26281, DOI 10.18632/oncotarget.15457; El-Deiry WS, 2015, CANCER BIOL THER, V16, P1726, DOI 10.1080/15384047.2015.1113356; Engstrom LD, 2017, CLIN CANCER RES, V23, P6661, DOI 10.1158/1078-0432.CCR-17-1192; European Medicines Agency, COM; Falchook GS, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2521; Fan QW, 2003, CANCER RES, V63, P8930; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Feng KC, 2016, SCI CHINA LIFE SCI, V59, P468, DOI 10.1007/s11427-016-5023-8; Feng Y, 2011, CANCER DISCOV, V1, P550, DOI 10.1158/2159-8290.CD-11-0289; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; de Jesus VHF, 2018, J HEPATOCELL CARCINO, V5, P87, DOI 10.2147/JHC.S171396; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; FURUKAWA T, 1995, AM J PATHOL, V147, P889; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garber K, 2014, NAT REV DRUG DISCOV, V13, P563, DOI 10.1038/nrd4406; Gherardi E, 2003, P NATL ACAD SCI USA, V100, P12039, DOI 10.1073/pnas.2034936100; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; Hara T, 1998, LAB INVEST, V78, P1143; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324; Hong DS, 2019, CLIN CANCER RES, V25, P2403, DOI 10.1158/1078-0432.CCR-18-1341; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; Huang FJ, 2016, J PATHOL CLIN RES, V2, P210, DOI 10.1002/cjp2.49; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Hui AY, 2009, J CELL BIOCHEM, V107, P1168, DOI 10.1002/jcb.22219; Ignatius SH, 2017, J THORAC ONCOL, V12, P137, DOI 10.1016/j.jtho.2016.09.119; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007; Kim K, 2007, BIOCHEM BIOPH RES CO, V354, P115, DOI 10.1016/j.bbrc.2006.12.164; Kim TY, 2016, LIVER CANCER, V5, P74; Kitajima Y, 2008, CANCER SCI, V99, P1341, DOI 10.1111/j.1349-7006.2008.00828.x; Kobayashi T, 2016, J THORAC DIS, V8, pE1381, DOI 10.21037/jtd.2016.10.62; Koeppen H, 2014, CLIN CANCER RES, V20, P4488, DOI 10.1158/1078-0432.CCR-13-1836; Koeppen H, 2014, J PATHOL, V232, P210, DOI 10.1002/path.4268; Kohno T, 2015, TRANSL LUNG CANCER R, V4, P156, DOI 10.3978/j.issn.2218-6751.2014.11.11; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Kozlov G, 2004, BIOCHEM BIOPH RES CO, V321, P234, DOI 10.1016/j.bbrc.2004.06.132; Kuba K, 2000, CANCER RES, V60, P6737; Kwak EL, 2015, CANCER DISCOV, V5, P1271, DOI 10.1158/2159-8290.CD-15-0748; Lassus P, 2006, BIOL NEONATE, V90, P28, DOI 10.1159/000091663; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Li N, 2018, TRANSL ONCOL, V11, P11, DOI 10.1016/j.tranon.2017.10.009; Lim WA, 2017, CELL, V168, P724, DOI 10.1016/j.cell.2017.01.016; Liu L, 2014, CLIN CANCER RES, V20, P6059, DOI 10.1158/1078-0432.CCR-14-0543; Liu Y, 2015, WORLD J GASTROENTERO, V21, P3706, DOI 10.3748/wjg.v21.i12.3706; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; Martens T, 2006, CLIN CANCER RES, V12, P6144, DOI 10.1158/1078-0432.CCR-05-1418; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; Matsumoto K, 2006, INT J CANCER, V119, P477, DOI 10.1002/ijc.21808; McNeil C, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv193; Medova M, 2013, MOL CANCER THER, V12, P2415, DOI 10.1158/1535-7163.MCT-13-0151; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Mignot F, 2017, RADIOTHER ONCOL, V124, P190, DOI 10.1016/j.radonc.2017.07.006; Mitchell CJ, 2016, MOL ONCOL, V10, P910, DOI 10.1016/j.molonc.2016.03.003; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Miyata Y, 2006, CLIN CANCER RES, V12, P4876, DOI 10.1158/1078-0432.CCR-06-0362; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mujtaba G, 2015, J MED GENET, V52, P548, DOI 10.1136/jmedgenet-2015-103023; Mullard A, 2015, NAT REV DRUG DISCOV, V14, P513, DOI 10.1038/nrd4694; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Nakamura Y, 2008, CANCER SCI, V99, P14, DOI 10.1111/j.1349-7006.2007.00640.x; Nakamura Y, 2007, CANCER SCI, V98, P1006, DOI 10.1111/j.1349-7006.2007.00493.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; Okamoto W, 2010, MOL CANCER THER, V9, P2785, DOI 10.1158/1535-7163.MCT-10-0481; Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674; Pacchiana G, 2010, J BIOL CHEM, V285, P36149, DOI 10.1074/jbc.M110.134031; Pagliarini R, 2015, EMBO REP, V16, P280, DOI 10.15252/embr.201439949; Paik PK, 2015, CANCER DISCOV, V5, P842, DOI 10.1158/2159-8290.CD-14-1467; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Park M, 2005, EXP MOL MED, V37, P213, DOI 10.1038/emm.2005.29; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 2000, APMIS, V108, P195, DOI 10.1034/j.1600-0463.2000.d01-44.x; Pasquini G, 2018, EXPERT OPIN INV DRUG, V27, P363, DOI 10.1080/13543784.2018.1462336; Personeni Nicola, 2018, Drugs Context, V7, P212533, DOI 10.7573/dic.212533; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Petrini I, 2015, ANN TRANSL MED, V82, P3; Pilotto S, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.33; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Qin S, 2015, EUR J CANCER, V51, pS452, DOI 10.1016/S0959-8049(16)31269-2; Qin S, 2015, LIVER CANCER, V4, P219; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosen PJ, 2010, CLIN CANCER RES, V16, P2677, DOI 10.1158/1078-0432.CCR-09-2862; Rusciano D, 1996, J BIOL CHEM, V271, P20763, DOI 10.1074/jbc.271.34.20763; Sacher AG, 2014, CANCER-AM CANCER SOC, V120, P2289, DOI 10.1002/cncr.28723; Salian-Mehta S, 2013, MOL CELL ENDOCRINOL, V374, P92, DOI 10.1016/j.mce.2013.04.018; Sangwan V, 2008, J BIOL CHEM, V283, P34374, DOI 10.1074/jbc.M805916200; Santini FC, 2017, TRANSL LUNG CANCER R, V6, P393, DOI 10.21037/tlcr.2017.04.06; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Schuler MH, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9067; Shah MA, 2017, JAMA ONCOL, V3, P620, DOI 10.1001/jamaoncol.2016.5580; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Shaw A., 2016, ANN ONCOL, DOI [10.1093/annonc/mdw383.07, DOI 10.1093/ANNONC/MDW383.07]; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Spigel DR, 2017, J CLIN ONCOL, V35, P412, DOI 10.1200/JCO.2016.69.2160; Spigel DR, 2013, J CLIN ONCOL, V31, P4105, DOI 10.1200/JCO.2012.47.4189; Srivastava AK, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.78; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; Sun YL, 2013, INT J MED SCI, V10, P548, DOI 10.7150/ijms.5191; Suryavanshi M, 2017, ONCOL RES TREAT, V40, P198, DOI 10.1159/000457801; Taher TEI, 2002, J IMMUNOL, V169, P3793, DOI 10.4049/jimmunol.169.7.3793; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Tchou J, 2017, CANCER IMMUNOL RES, V5, P1152, DOI 10.1158/2326-6066.CIR-17-0189; Thayaparan T, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1363137; Toiyama Y, 2012, INT J CANCER, V130, P2912, DOI 10.1002/ijc.26330; Tong CYK, 2004, J NEUROSURG, V100, P187, DOI 10.3171/ped.2004.100.2.0187; Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061; Tretiakova M, 2011, J ENVIRON PATHOL TOX, V30, P341, DOI 10.1615/JEnvironPatholToxicolOncol.v30.i4.70; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; van der Horst E, 2009, NEOPLASIA, V11, P355, DOI 10.1593/neo.81536; Van Schaeybroeck S, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.tps3632; Vigna E, 2015, ONCOGENE, V34, P1883, DOI 10.1038/onc.2014.142; Vigna E, 2014, J MOL MED, V92, P65, DOI 10.1007/s00109-013-1079-0; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Vosjan MJWD, 2012, MOL CANCER THER, V11, P1017, DOI 10.1158/1535-7163.MCT-11-0891; Wang JY, 2017, CLIN CANCER RES, V23, P992, DOI 10.1158/1078-0432.CCR-16-1568; Wang JY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2138-z; Wang WY, 2015, INT J CARDIOL, V181, P180, DOI 10.1016/j.ijcard.2014.10.148; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Watanabe K, 2015, J IMMUNOL, V194, P911, DOI 10.4049/jimmunol.1402346; Watermann I, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0362-5; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wu YL, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9020; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Xu YR, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.212597; Yi S, 2000, NEOPLASIA, V2, P226, DOI 10.1038/sj.neo.7900080; Zarnegar R, 1995, EXS, V74, P33; Zhang J, 2016, CARCINOGENESIS, V37, P345, DOI 10.1093/carcin/bgw015; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004; Zhao J, 2011, HISTOL HISTOPATHOL, V26, P1111, DOI 10.14670/HH-26.1111; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	210	29	29	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2845	2862		10.1038/s41388-020-1193-8	http://dx.doi.org/10.1038/s41388-020-1193-8		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034310				2022-12-17	WOS:000511752600005
J	Wang, HG; Zhang, S; Song, LY; Qu, M; Zou, ZH				Wang, Hongge; Zhang, Shan; Song, Liyan; Qu, Meng; Zou, Zhihua			Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells	ONCOGENE			English	Article							REPAIR DEFECT; HISTONE H2AX; LUNG-CANCER; INHIBITION; STABILITY; APOPTOSIS; STRESS; METABOLISM; RESISTANCE; BRCA1	PARP1 and PARP2 play critical roles in regulating DNA repair and PARP inhibitors have been approved for the treatment of BRCA1/2-mutated ovarian and breast cancers. It has long been known that PARP inhibition sensitizes cancer cells to DNA-damaging cytotoxic agents independent of BRCA status, however, clinical use of PARP inhibitors in combination with DNA-damaging chemotherapy is limited by the more-than-additive cytotoxicity. The natural compound alantolactone (ATL) inhibits the thioredoxin reductase to induce ROS accumulation and oxidative DNA damage selectively in cancer cells. Here, we showed that nontoxic doses of ATL markedly synergized with the PARP inhibitor olaparib to result in synthetic lethality irrespective of homologous recombination status. Synergistic cytotoxicity was seen in cancer but not noncancerous cells and was reduced by the ROS inhibitor NAC or knockdown of OGG1, demonstrating that the cytotoxicity resulted from the repair of ATL-induced oxidative DNA damage. PARP1 knockdown suppressed the synergistic lethality and olaparib was much more toxic than veliparib when combined with ATL, suggesting PARP-trapping as the primary inducer of cytotoxicity. Consistently, combined use of ATL and olaparib caused intense signs of replication stress and formation of double strand DNA breaks, leading to S and G(2) arrest followed by apoptosis. In vivo, the combination effectively induced regression of tumor xenografts, while either agent alone had no effect. Hence, PARP trapping combined with specific pro-oxidative agents may provide safe and effective ways to broaden the therapeutic potential of PARP inhibitors.	[Wang, Hongge; Zhang, Shan; Song, Liyan; Qu, Meng; Zou, Zhihua] Jilin Univ, Sch Life Sci, Key Lab Mol Enzymol & Engn,Minist Educ, Dept Cell Biol & Biophys,Natl Engn Lab Aids Vacci, Changchun, Peoples R China	Jilin University	Zou, ZH (corresponding author), Jilin Univ, Sch Life Sci, Key Lab Mol Enzymol & Engn,Minist Educ, Dept Cell Biol & Biophys,Natl Engn Lab Aids Vacci, Changchun, Peoples R China.	zouzh@jlu.edu.cn	wang, hg/AAE-2324-2021		Key Research and Development Program of Jilin Province [20170204025YY]; Natural Science Foundation of Jilin Province [20180101237JC]	Key Research and Development Program of Jilin Province; Natural Science Foundation of Jilin Province	This work was supported by grants from the Key Research and Development Program of Jilin Province (20170204025YY) and the Natural Science Foundation of Jilin Province (20180101237JC).	Abbotts R, 2017, FREE RADICAL BIO MED, V107, P228, DOI 10.1016/j.freeradbiomed.2016.11.039; AbdulSalam SF, 2016, BIOCHEMISTRY-US, V55, P5341, DOI 10.1021/acs.biochem.6b00703; Brown JS, 2017, CANCER DISCOV, V7, P20, DOI 10.1158/2159-8290.CD-16-0860; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53; Chou T-C., 2018, SYNERGIE, V7, P49, DOI [DOI 10.1016/J.SYNRES.2018.04.001, 10.1016/j.synres.2018.04.001]; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Davalli P, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2389523; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Deben C, 2016, CANCER LETT, V375, P313, DOI 10.1016/j.canlet.2016.03.017; Ding YS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040558; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Hanzlikova H, 2019, TRENDS GENET, V35, P412, DOI 10.1016/j.tig.2019.03.008; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; He W, 2019, FREE RADICAL RES, V53, P104, DOI 10.1080/10715762.2018.1558448; Hsu PC, 2019, ONCOGENE, V38, P1166, DOI 10.1038/s41388-018-0506-7; Huang XM, 2016, CANCER CELL, V30, P940, DOI 10.1016/j.ccell.2016.11.006; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Lee JY, 2016, BIOPHARM DRUG DISPOS, V37, P156, DOI 10.1002/bdd.2005; Liu JL, 2018, INT J MOL MED, V42, P1847, DOI 10.3892/ijmm.2018.3751; Liu Q, 2018, ONCOGENE, V37, P2793, DOI 10.1038/s41388-018-0130-6; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Marcar L, 2019, CELL REP, V27, P3422, DOI 10.1016/j.celrep.2019.05.058; Markkanen E, 2017, DNA REPAIR, V59, P82, DOI 10.1016/j.dnarep.2017.09.007; Marzo T, 2017, ACS MED CHEM LETT, V8, P997, DOI 10.1021/acsmedchemlett.7b00162; Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008-5472.CAN-12-3000; Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023; Murai J, 2014, J PHARMACOL EXP THER, V349, P408, DOI 10.1124/jpet.113.210146; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nickoloff JA, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx059; PG P, 2019, CLIN CANCER RES, V25, P3759, DOI [10.1158/1078-0432.CCR-18-0968, DOI 10.1158/1078-0432.CCR-18-0968]; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Pommier Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9246; Pulliam N, 2018, CLIN CANCER RES, V24, P3163, DOI 10.1158/1078-0432.CCR-18-0204; Reynolds P, 2015, NUCLEIC ACIDS RES, V43, P4028, DOI 10.1093/nar/gkv250; Ronson GE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03159-2; Saikolappan S, 2019, CANCER LETT, V452, P132, DOI 10.1016/j.canlet.2019.03.020; Sarkaria JN, 2008, CLIN CANCER RES, V14, P2900, DOI 10.1158/1078-0432.CCR-07-1719; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Struthers L, 1998, ANAL BIOCHEM, V255, P20, DOI 10.1006/abio.1997.2354; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Venkitaraman AR, 2014, SCIENCE, V343, P1470, DOI 10.1126/science.1252230; Wang K, 2019, TRENDS BIOCHEM SCI, V44, P401, DOI 10.1016/j.tibs.2019.01.001; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Woodhouse BC, 2008, DNA REPAIR, V7, P932, DOI 10.1016/j.dnarep.2008.03.017; Xu XG, 2019, LIFE SCI, V227, P153, DOI 10.1016/j.lfs.2019.04.034; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; Yap Timothy A, 2019, Am Soc Clin Oncol Educ Book, V39, P185, DOI 10.1200/EDBK_238473; Yin CT, 2019, J CELL MOL MED, V23, P2194, DOI 10.1111/jcmm.14139; Zhang JM, 2016, BIOCHEM PHARMACOL, V102, P34, DOI 10.1016/j.bcp.2015.12.004; Zhao P, 2015, J BIOCHEM MOL TOXIC, V29, P199, DOI 10.1002/jbt.21685; Zhou BL, 2018, J CHROMATOGR B, V1072, P370, DOI 10.1016/j.jchromb.2017.11.039	67	29	29	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2905	2920		10.1038/s41388-020-1191-x	http://dx.doi.org/10.1038/s41388-020-1191-x		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32029902	hybrid, Green Published			2022-12-17	WOS:000511540800002
J	Ying, Y; Wang, YJ; Huang, XY; Sun, YM; Zhang, JB; Li, MQ; Zeng, JH; Wang, ML; Xiao, WJ; Zhong, L; Xu, B; Li, LL; Tao, Q; Wang, XM; Shu, XS				Ying, Ying; Wang, Yejun; Huang, Xiaoyan; Sun, Yanmei; Zhang, Junbao; Li, Meiqi; Zeng, Junhui; Wang, Maolin; Xiao, Wenjun; Zhong, Lan; Xu, Bo; Li, Lili; Tao, Qian; Wang, Xiaomei; Shu, Xing-sheng			Oncogenic HOXB8 is driven by MYC-regulated super-enhancer and potentiates colorectal cancer invasiveness via BACH1	ONCOGENE			English	Article							OXIDATIVE STRESS-RESPONSE; LONG-RANGE INTERACTION; TRANSCRIPTION FACTORS; CELL DEVELOPMENT; GENES; DIFFERENTIATION; DEREGULATION; METASTASIS; INHIBITION; EXPRESSION	Aberrant activation of Homeobox genes in human cancers has long been documented, whereas the mechanisms underlying remain largely obscure. Super-enhancers (SEs) act as key regulatory elements for both cell identity genes and cancer genes. Herein, we reported that SE-associated HOXB gene cluster represented a common feature of colorectal cancer (CRC) cell lines and multiple HOXB genes within this cluster were overexpressed in CRC. Among them, we found that HOXB8 was oncogenic and its activation in CRC was driven by SE instead of genetic alteration. We further demonstrated that the master transcription factor MYC preferentially occupied SEs over TEs (typical enhancers) and regulated HOXB8 transcription by binding to the active elements of its SE. HOXB8 silencing induced reversal of transcriptional signatures associated with malignant phenotypes of CRC. Mechanistically, HOXB8 interacted with a key metastasis regulator BACH1 and instigated BACH1-mediated transcriptional cascade by directly occupying and activating BACH1 gene transcription together with BACH1 itself. Lastly, the relevance of HOXB8 activation in clinical settings was strengthened by its close association with prognostic outcomes of CRC patients.	[Ying, Ying; Wang, Yejun; Huang, Xiaoyan; Sun, Yanmei; Zhang, Junbao; Li, Meiqi; Zeng, Junhui; Wang, Maolin; Xiao, Wenjun; Wang, Xiaomei; Shu, Xing-sheng] Shenzhen Univ, Hlth Sci Ctr, Sch Med, Dept Physiol, Shenzhen 518060, Peoples R China; [Zhong, Lan] Sichuan Univ, West China Hosp 2, Dept Gynecol & Obstet, Chengdu 610041, Peoples R China; [Xu, Bo] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin 300070, Peoples R China; [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, Canc Epigenet Lab, Hong Kong 00000, Peoples R China	Shenzhen University; Sichuan University; Tianjin Medical University; Chinese University of Hong Kong	Shu, XS (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Sch Med, Dept Physiol, Shenzhen 518060, Peoples R China.	shu@szu.edu.cn	Li, Lili/Q-5750-2018	Li, Lili/0000-0002-0292-5889	Shenzhen Commission of Science and Innovation Programs [JCYJ20170817101008912, JCYJ20170818143305472, JCYJ20160331114230843]; National Key Projects of Research and Development of China [2016YFC0904600]; Natural Science Foundation of Shenzhen University for Overseas High-Caliber Personnel [827000111]; National Natural Science Foundation of China [81670760]; Guangdong Health Committee [B2019104]	Shenzhen Commission of Science and Innovation Programs; National Key Projects of Research and Development of China; Natural Science Foundation of Shenzhen University for Overseas High-Caliber Personnel; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Health Committee	This work was supported by Shenzhen Commission of Science and Innovation Programs [JCYJ20170817101008912, JCYJ20170818143305472, JCYJ20160331114230843], National Key Projects of Research and Development of China [2016YFC0904600], Natural Science Foundation of Shenzhen University for Overseas High-Caliber Personnel [827000111], National Natural Science Foundation of China [81670760] and grant from Guangdong Health Committee [B2019104]. We thank technical support from Instrumental Analysis Center of Shenzhen University (Xili Campus), and thank Mr Shikang Liu, and Ms Danhong Qiu for technical assistance.	Ahmadiyeh N, 2010, P NATL ACAD SCI USA, V107, P9742, DOI 10.1073/pnas.0910668107; Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277; Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Banerjee-Basu S, 2001, NUCLEIC ACIDS RES, V29, P3258, DOI 10.1093/nar/29.15.3258; BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Cohen AJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14400; Ding WJ, 2017, J CANCER RES CLIN, V143, P385, DOI 10.1007/s00432-016-2283-4; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Groschel S, 2014, CELL, V157, P369, DOI 10.1016/j.cell.2014.02.019; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Igarashi K, 2006, ANTIOXID REDOX SIGN, V8, P107, DOI 10.1089/ars.2006.8.107; Igarashi K, 2017, NAT REV IMMUNOL, V17, P437, DOI 10.1038/nri.2017.26; Itoh-Nakadai A, 2014, NAT IMMUNOL, V15, P1171, DOI 10.1038/ni.3024; Ke LR, 2017, P NATL ACAD SCI USA, V114, P9683, DOI 10.1073/pnas.1705236114; Knoepfler PS, 2001, ONCOGENE, V20, P5440, DOI 10.1038/sj.onc.1204710; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Liang YJ, 2012, J BIOL CHEM, V287, P33533, DOI 10.1074/jbc.M112.392332; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Mallo M, 2013, DEVELOPMENT, V140, P3951, DOI 10.1242/dev.068346; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265; McFarland JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06916-5; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Northcott PA, 2014, NATURE, V511, P428, DOI 10.1038/nature13379; Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Redecke V, 2013, NAT METHODS, V10, P795, DOI [10.1038/NMETH.2510, 10.1038/nmeth.2510]; Sengupta S, 2017, TRENDS CANCER, V3, P269, DOI 10.1016/j.trecan.2017.03.006; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Shajari N, 2018, ARTIF CELL NANOMED B, V46, P1495, DOI 10.1080/21691401.2017.1374284; Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479; Shlyueva D, 2014, NAT REV GENET, V15, P272, DOI 10.1038/nrg3682; Shu XS, 2018, J PATHOL, V244, P36, DOI 10.1002/path.4986; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sur I, 2016, NAT REV CANCER, V16, P483, DOI 10.1038/nrc.2016.62; Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364; Warnatz HJ, 2011, J BIOL CHEM, V286, P23521, DOI 10.1074/jbc.M111.220178; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Xiong X, 2017, ACS SYNTH BIOL, V6, P1034, DOI 10.1021/acssynbio.6b00358; Zhang XY, 2018, CANCER DISCOV, V8, P108, DOI 10.1158/2159-8290.CD-17-0532; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470; Zhu GD, 2018, BIOCHEM BIOPH RES CO, V499, P120, DOI 10.1016/j.bbrc.2018.02.178	45	29	29	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1004	1017		10.1038/s41388-019-1013-1	http://dx.doi.org/10.1038/s41388-019-1013-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591481				2022-12-17	WOS:000511209700004
J	Pallmann, N; Livgard, M; Tesikova, M; Nenseth, HZ; Akkus, E; Sikkeland, J; Jin, YX; Koc, D; Kuzu, OF; Pradhan, M; Danielsen, HE; Kahraman, N; Mokhlis, HM; Ozpolat, B; Banerjee, PP; Uren, A; Fazli, L; Rennie, PS; Jin, Y; Saatcioglu, F				Pallmann, Nora; Livgard, Marte; Tesikova, Martina; Nenseth, Hatice Zeynep; Akkus, Erman; Sikkeland, Jorgen; Jin, Yixin; Koc, Dogukan; Kuzu, Omer Faruk; Pradhan, Manohar; Danielsen, Havard E.; Kahraman, Nermin; Mokhlis, Hamada M.; Ozpolat, Bulent; Banerjee, Partha P.; Uren, Aykut; Fazli, Ladan; Rennie, Paul S.; Jin, Yang; Saatcioglu, Fahri			Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer Nora	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; GENE-EXPRESSION; ANDROGEN; NIBAN; PROLIFERATION; METABOLISM; REVEALS; BETA; RNA	Cancer cells exploit many of the cellular adaptive responses to support their survival needs. One such critical pathway in eukaryotic cells is the unfolded protein response (UPR) that is important in normal physiology as well as disease states, including cancer. Since UPR can serve as a lever between survival and death, regulated control of its activity is critical for tumor formation and growth although the underlying mechanisms are poorly understood. Here we show that one of the main transcriptional effectors of UPR, activating transcription factor 4 (ATF4), is essential for prostate cancer (PCa) growth and survival. Using systemic unbiased gene expression and proteomic analyses, we identified a novel direct ATF4 target gene, family with sequence similarity 129 member A (FAM129A), which is critical in mediating ATF4 effects on prostate tumorigenesis. Interestingly, FAM129A regulated both PERK and eIF2a in a feedback loop that differentially channeled the UPR output. ATF4 and FAM129A protein expression is increased in patient PCa samples compared with benign prostate. Importantly, in vivo therapeutic silencing of ATF4-FAM129A axis profoundly inhibited tumor growth in a preclinical PCa model. These data support that one of the canonical UPR branches, through ATF4 and its target gene FAM129A, is required for PCa growth and thus may serve as a novel therapeutic target.	[Pallmann, Nora; Livgard, Marte; Tesikova, Martina; Nenseth, Hatice Zeynep; Akkus, Erman; Sikkeland, Jorgen; Jin, Yixin; Koc, Dogukan; Kuzu, Omer Faruk; Jin, Yang; Saatcioglu, Fahri] Univ Oslo, Dept Biosci, Oslo, Norway; [Livgard, Marte; Sikkeland, Jorgen; Pradhan, Manohar; Danielsen, Havard E.; Jin, Yang; Saatcioglu, Fahri] Oslo Univ Hosp, Inst Canc Genet & Informat, Oslo, Norway; [Danielsen, Havard E.] Univ Oslo, Dept Informat, Oslo, Norway; [Danielsen, Havard E.] Univ Oxford, Nuffield Div Clin Lab Sci, Oxford, England; [Kahraman, Nermin; Mokhlis, Hamada M.; Ozpolat, Bulent] MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX USA; [Banerjee, Partha P.; Uren, Aykut] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA; [Fazli, Ladan; Rennie, Paul S.] Vancouver Prostate Ctr, Vancouver, BC, Canada; [Jin, Yixin] Oslo Univ Hosp, Dept Canc Immunol, Inst Canc Res, Oslo, Norway; [Koc, Dogukan] Dokuz Eylul Univ, Fac Med, Dept Child & Adolescent Psychiat, Izmir, Turkey	University of Oslo; University of Oslo; University of Oslo; University of Oxford; University of Texas System; UTMD Anderson Cancer Center; Georgetown University; University of Oslo; Dokuz Eylul University	Saatcioglu, F (corresponding author), Univ Oslo, Dept Biosci, Oslo, Norway.; Saatcioglu, F (corresponding author), Oslo Univ Hosp, Inst Canc Genet & Informat, Oslo, Norway.	fahris@ibv.uio.no	Jin, Yang/GXF-7896-2022; Koc, Dogukan/AAD-8357-2020; Danielsen, Havard/AAK-8489-2020; MOKHLIS, HAMADA/ABB-6198-2021	Jin, Yang/0000-0002-7996-048X; Koc, Dogukan/0000-0002-2309-1051; MOKHLIS, HAMADA/0000-0003-3360-6319; Ozpolat, Bulent/0000-0001-8602-7463	Norwegian Research Council grant [193337]; Norwegian Cancer Society [419204]; Health South East Norway [36024]; Faculty of Medicine at NTNU; Central Norway Regional Health Authority	Norwegian Research Council grant(Research Council of Norway); Norwegian Cancer Society(Norwegian Cancer Society); Health South East Norway; Faculty of Medicine at NTNU; Central Norway Regional Health Authority	We would like to thank Veronica F. Blihovde, Xia Sheng and Deane Stryker for experimental help and members of the FS laboratory for helpful discussions. We would like to thank Jeffrey Petro for excellent technical support and Drs Eva Corey and Colm Morrissey of University of Washington for providing LuCaP PDX lines. This work was supported by Norwegian Research Council grant 193337, Norwegian Cancer Society grant 419204, and Health South East Norway grant 36024. The microarray gene expression service was provided by the Genomics Core Facility (GCF), Norwegian University of Science and Technology (NTNU). GCF is funded by the Faculty of Medicine at NTNU and Central Norway Regional Health Authority. The LC-MS analyses were performed by the proteomics core facility at the Department of Biosciences, University of Oslo.	Adachi H, 2004, ONCOGENE, V23, P3495, DOI 10.1038/sj.onc.1207468; Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Brijwani N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01566-x; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Cohen DM, 2015, ELIFE, V4, DOI 10.7554/eLife.06821; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Evstafieva AG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191107; Halterman MW, 2008, MOL CELL NEUROSCI, V38, P125, DOI 10.1016/j.mcn.2008.01.014; Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Ito S, 2010, HEAD NECK-J SCI SPEC, V32, P96, DOI 10.1002/hed.21153; Ji HT, 2012, EMBO REP, V13, P554, DOI 10.1038/embor.2012.53; Jin Y, 2015, EMBO MOL MED, V7, P315, DOI 10.15252/emmm.201404181; Jin Y, 2013, P NATL ACAD SCI USA, V110, pE2572, DOI 10.1073/pnas.1304318110; Kannangai R, 2005, HUM PATHOL, V36, P341, DOI 10.1016/j.humpath.2005.01.002; Kilberg MS, 2012, ADV NUTR, V3, P295, DOI 10.3945/an.112.001891; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Nevedomskaya E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051359; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Quiros PM, 2017, J CELL BIOL, V216, P2027, DOI 10.1083/jcb.201702058; Shan JX, 2016, NUCLEIC ACIDS RES, V44, P9719, DOI 10.1093/nar/gkw667; Shaw GL, 2016, EUR UROL, V70, P214, DOI 10.1016/j.eururo.2015.10.042; Sheng X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08152-3; Sheng X, 2015, EMBO MOL MED, V7, P788, DOI 10.15252/emmm.201404509; Storm M, 2016, ONCOTARGET, V7, P54051, DOI 10.18632/oncotarget.9912; Sun GD, 2007, BIOCHEM BIOPH RES CO, V360, P181, DOI 10.1016/j.bbrc.2007.06.021; Thomas BC, 2016, ENDOCR-RELAT CANCER, V23, P797, DOI 10.1530/ERC-16-0287; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wortel IMN, 2017, TRENDS ENDOCRIN MET, V28, P794, DOI 10.1016/j.tem.2017.07.003; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yu KF, 2014, FEBS J, V281, P2399, DOI 10.1111/febs.12792; Yuki R, 2015, J CELL BIOCHEM, V116, P954, DOI 10.1002/jcb.25046	37	29	30	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6301	6318		10.1038/s41388-019-0879-2	http://dx.doi.org/10.1038/s41388-019-0879-2			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31312022	Green Accepted			2022-12-17	WOS:000483919400005
J	Zhu, YX; He, D; Bo, H; Liu, ZX; Xiao, MQ; Xiang, L; Zhou, JD; Liu, Y; Liu, XM; Gong, L; Ma, YN; Zhou, YH; Zhou, M; Xiong, W; Yang, F; Xing, XW; Li, RH; Li, W; Cao, K				Zhu, Yuxing; He, Dong; Bo, Hao; Liu, Zexian; Xiao, Mengqing; Xiang, Liang; Zhou, Jianda; Liu, Yan; Liu, Xiaoming; Gong, Lian; Ma, Yanni; Zhou, Yanhong; Zhou, Ming; Xiong, Wei; Yang, Fei; Xing, Xiaowei; Li, Ruhong; Li, Wei; Cao, Ke			The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway	ONCOGENE			English	Article							NONCODING RNAS; BREAST-CANCER; CARCINOMA; RADIOTHERAPY; CHEMORADIOTHERAPY; TUMORIGENICITY; PROGRESSION; MIR-27B; GROWTH; NPC	Long non-coding RNA (lncRNA) plays an important role in malignant tumor occurrence, development, and chemoresistance, but the mechanism of how they affect nasopharyngeal cancer (NPC) paclitaxel chemosensitivity is unclear. In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity. Further, MRVI1-AS1 upregulated ATF3 (activating transcription factor 3) by simultaneously inhibiting miR-513a-5p (microRNA-513a-5p) and miR-27b-3p expression levels to increase NPC paclitaxel chemosensitivity. Chromatin immunoprecipitation and quantitative real-time PCR showed that ATF3 could feed-back MRVI1-AS1 regulation positively. Furthermore, MRVI1-AS1 and ATF3 could form a positive feedback loop, which promoted the expression of RASSF1 (Ras association domain family member 1), a Hippo-TAZ (tafazzin) signaling pathway regulatory factor, thereby inhibiting TAZ expression. The MTT (3-[4,5- dimethylthiazol- 2- yl]- 2,5 diphenyltetrazolium bromide) assay and flow cytometry showed that the decreased TAZ increased NPC cell paclitaxel chemosensitivity. Overall, the results indicate that the MRVI1-AS1/ATF3 signaling pathway can increase NPC paclitaxel chemosensitivity by modulating the Hippo-TAZ signaling pathway. Therefore, targeting the loop may be a new NPC treatment strategy.	[Zhu, Yuxing; Xiao, Mengqing; Xiang, Liang; Gong, Lian; Ma, Yanni; Cao, Ke] Cent S Univ, Dept Oncol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China; [He, Dong] Hunan Univ Chinese Med, Dept Respirat, Peoples Hosp Hunan Prov 2, Changsha 410000, Hunan, Peoples R China; [Bo, Hao] Cent S Univ, Inst Reprod & Stem Cell Engn, Changsha 410083, Hunan, Peoples R China; [Liu, Zexian] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Zhou, Jianda; Liu, Yan] Cent S Univ, Xiangya Hosp 3, Dept Plast Surg, Changsha 410013, Hunan, Peoples R China; [Liu, Xiaoming] Cent S Univ, Dept Gastroenterol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China; [Zhou, Yanhong; Zhou, Ming; Xiong, Wei] Cent S Univ, Canc Res Inst, Minist Hlth, Changsha 410078, Hunan, Peoples R China; [Zhou, Yanhong; Zhou, Ming; Xiong, Wei] Cent S Univ, Key Lab Carcinogenesis, Minist Hlth, Changsha 410078, Hunan, Peoples R China; [Yang, Fei] Cent S Univ, Sch Publ Hlth, Changsha 410078, Hunan, Peoples R China; [Xing, Xiaowei] Cent S Univ, Xiangya Hosp 3, Ctr Med Expt, Changsha 410013, Hunan, Peoples R China; [Li, Ruhong] Kunming Med Univ, Yanan Affiliated Hosp, Kunming 650051, Yunnan, Peoples R China; [Li, Wei] Cent S Univ, Xiangya Hosp 3, Dept Otolaryngol Head Neck Surg, Changsha 410013, Hunan, Peoples R China	Central South University; Hunan University of Chinese Medicine; Central South University; State Key Lab Oncology South China; Sun Yat Sen University; Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Kunming Medical University; Central South University	Cao, K (corresponding author), Cent S Univ, Dept Oncol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.	csucaoke@163.com	wu, Xianrui/AAM-6540-2021; Liu, Zexian/D-1153-2011	wu, Xianrui/0000-0003-4803-5934; Liu, Zexian/0000-0001-9698-0610; Cao, Ke/0000-0001-5392-2306	National Natural Science Foundation of China [81874137]; Outstanding Youth Foundation of Hunan Province [2018JJ1047]; Huxiang Young Talent Project [2016RS3022]; Innovation-Driven Project of Central South University [2017CX012]; Fundamental Research Funds for the Central Universities of Central South University [2018zzts955]; New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University [20150201, JY201710]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Outstanding Youth Foundation of Hunan Province; Huxiang Young Talent Project; Innovation-Driven Project of Central South University; Fundamental Research Funds for the Central Universities of Central South University; New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University	This work was supported by the National Natural Science Foundation of China (81874137), the Outstanding Youth Foundation of Hunan Province (2018JJ1047), the Huxiang Young Talent Project (2016RS3022), the Innovation-Driven Project of Central South University (2017CX012), the Fundamental Research Funds for the Central Universities of Central South University, Grant/Award Number: 2018zzts955, and the New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University (20150201, JY201710).	Blanchard P, 2015, LANCET ONCOL, V16, P645, DOI 10.1016/S1470-2045(15)70126-9; Chan SW, 2011, J CELL PHYSIOL, V226, P928, DOI 10.1002/jcp.22435; Chang YS, 2017, P NATL ACAD SCI USA, V114, pE7159, DOI 10.1073/pnas.1700455114; Chueh AC, 2017, CLIN CANCER RES, V23, P5573, DOI 10.1158/1078-0432.CCR-17-0466; Giovinazzi S, 2012, ONCOGENE, V31, P13, DOI 10.1038/onc.2011.211; Guo Z, 2017, ONCOTARGET, V8, P62286, DOI 10.18632/oncotarget.19725; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Kassler Susannah, 2012, Mol Biol Int, V2012, P263267, DOI 10.1155/2012/263267; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lee JJ, 2012, ONCOGENE, V31, P3818, DOI 10.1038/onc.2011.543; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Lin JC, 2003, J CLIN ONCOL, V21, P631, DOI 10.1200/JCO.2003.06.158; Liu J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0246-6; Lo KW, 2012, SEMIN CANCER BIOL, V22, P79, DOI 10.1016/j.semcancer.2011.12.011; Matsui M, 2017, NAT REV DRUG DISCOV, V16, P167, DOI 10.1038/nrd.2016.117; Maugeri-Sacca M, 2018, PHARMACOL THERAPEUT, V186, P60, DOI 10.1016/j.pharmthera.2017.12.011; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Muti P, 2018, CARCINOGENESIS, V39, P98, DOI 10.1093/carcin/bgx126; Oh YK, 2008, MOL CANCER RES, V6, P1232, DOI 10.1158/1541-7786.MCR-07-0297; Panciera T, 2017, NAT REV MOL CELL BIO, V18, P758, DOI 10.1038/nrm.2017.87; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Ren SL, 2016, ONCOL REP, V36, P1861, DOI 10.3892/or.2016.4981; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shen SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100664; Sun YQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0113-5; Suzuki M, 2016, J CLIN INVEST, V126, P254, DOI 10.1172/JCI79775; Taniue K, 2016, P NATL ACAD SCI USA, V113, P12739, DOI 10.1073/pnas.1605938113; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556-018-0142-z; van Heesch S, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-1-r6; Wang QS, 2017, CELL CYCLE, V16, P795, DOI 10.1080/15384101.2017.1301334; Wang SY, 2017, J CLIN INVEST, V127, P4498, DOI 10.1172/JCI91553; Wang YF, 2009, J BIOL CHEM, V284, P23094, DOI 10.1074/jbc.M109.012617; Xiong H, 2017, ONCOGENE, V36, P3528, DOI 10.1038/onc.2016.521; Yang YQ, 2018, J INVEST DERMATOL, V138, P2205, DOI 10.1016/j.jid.2018.03.1510; You R, 2017, THERANOSTICS, V7, P4825, DOI 10.7150/thno.21815; Zeng PY, 2006, BIOTECHNIQUES, V41, P694, DOI 10.2144/000112297; Zeng QH, 2018, CLIN CANCER RES, V24, P445, DOI 10.1158/1078-0432.CCR-17-0419; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhu J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.361	40	29	29	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6065	6081		10.1038/s41388-019-0858-7	http://dx.doi.org/10.1038/s41388-019-0858-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31273338				2022-12-17	WOS:000480329900005
J	Yang, H; Zhu, RX; Zhao, XP; Liu, L; Zhou, ZL; Zhao, L; Liang, BB; Ma, WJ; Zhao, J; Liu, JJ; Huang, G				Yang, Hao; Zhu, Rongxuan; Zhao, Xiaoping; Liu, Liu; Zhou, Zhaoli; Zhao, Li; Liang, Beibei; Ma, Wenjing; Zhao, Jian; Liu, Jianjun; Huang, Gang			Sirtuin-mediated deacetylation of hnRNP A1 suppresses glycolysis and growth in hepatocellular carcinoma	ONCOGENE			English	Article							PYRUVATE-KINASE; PKM2 PROMOTES; M2 ISOFORM; CANCER; EXPRESSION; PROTEINS; PHOSPHORYLATION; ACETYLATION; REGULATOR; DISCOVERY	Tumor cells undergo a metabolic shift in order to adapt to the altered microenvironment, although the underlying mechanisms have not been fully explored. HnRNP A1 is involved in the alternative splicing of the pyruvate kinase (PK) mRNA, allowing tumor cells to specifically produce the PKM2 isoform. We found that the acetylation status of hnRNP A1 in hepatocellular carcinoma (HCC) cells was dependent on glucose availability, which affected the PKM2-dependent glycolytic pathway. In the glucose-starved HCC cells, SIRT1 and SIRT6, members of deacetylase sirtuin family, were highly expressed and deacetylated hnRNP A1 after direct binding. We identified four lysine residues in hnRNP A1 that were deacetylated by SIRT1 and SIRT6, resulting in significant inhibition of glycolysis in HCC cells. Deacetylated hnRNP A1 reduced PKM2 and increased PKM1 alternative splicing in HCC cells under normal glucose conditions, thereby reducing the metabolic activity of PK and the non-metabolic PKM2-beta-catenin signaling pathway. However, under glucose starvation, the low levels of acetylated hnRNP A1 reduced HCC cell metabolism to adapt to the nutrient deficiency. Taken together, sirtuin-mediated hnRNP A1 deacetylation inhibits HCC cell proliferation and tumorigenesis in a PKM2-dependent manner. These findings point to the metabolic reprogramming induced by hnRNP A1 acetylation in order to adapt to the nutritional status of the tumor microenvironment.	[Yang, Hao; Zhou, Zhaoli; Liang, Beibei; Ma, Wenjing; Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China; [Yang, Hao; Zhao, Xiaoping; Zhao, Li; Liu, Jianjun; Huang, Gang] Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Nucl Med, Sch Med, Shanghai 200127, Peoples R China; [Zhu, Rongxuan] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, Sch Med, Shanghai 200080, Peoples R China; [Liu, Liu] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China; [Zhao, Jian] Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China	Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Naval Medical University	Huang, G (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.; Liu, JJ; Huang, G (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Nucl Med, Sch Med, Shanghai 200127, Peoples R China.	nuclearj@163.com; huanggang@sumhs.edu.cn		Yang, Hao/0000-0002-3781-7271	National Natural Science Foundation of China [81530053, 81830052, 81771858, 81602415, 81670573, 81572719, 81874202, 81803581]; Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program for Medical Technology of SUMHS)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program for Medical Technology of SUMHS)	This work was supported by research grants from the National Natural Science Foundation of China (Nos. 81530053, 81830052, 81771858, 81602415, 81670573, 81572719, 81874202, and 81803581) and Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program for Medical Technology of SUMHS, 2018-2020).	Agerholm M, 2018, AM J PHYSIOL-ENDOC M, V314, pE377, DOI 10.1152/ajpendo.00213.2017; Ampferl R, 2018, RADIOTHER ONCOL, V126, P465, DOI 10.1016/j.radonc.2017.10.020; Bhardwaj A, 2016, P NATL ACAD SCI USA, V113, pE538, DOI 10.1073/pnas.1520045113; Chang CM, 2015, MOL CELL, V60, P930, DOI 10.1016/j.molcel.2015.10.037; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chen J, 2013, HEPATOLOGY, V57, P2287, DOI 10.1002/hep.26278; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Chen YH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04815-3; Chettouh H, 2013, CANCER RES, V73, P3974, DOI 10.1158/0008-5472.CAN-12-3824; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Dayton TL, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0179-2; Fang X, 2018, EXP CELL RES, V362, P279, DOI 10.1016/j.yexcr.2017.11.028; Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Iansante V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8882; Kashima T, 2007, HUM MOL GENET, V16, P3149, DOI 10.1093/hmg/ddm276; Kim YJ, 2017, INT J GYNECOL CANCER, V27, P326, DOI 10.1097/IGC.0000000000000868; Lee JY, 2014, J CELL SCI, V127, P4954, DOI 10.1242/jcs.157321; Li HL, 2012, AM J PHYSIOL-ENDOC M, V303, pE1234, DOI 10.1152/ajpendo.00198.2012; Li LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122024; Luan WK, 2015, ONCOTARGET, V6, P13006, DOI 10.18632/oncotarget.3514; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Mohagheghi F, 2016, HUM MOL GENET, V25, P534, DOI 10.1093/hmg/ddv491; Ning XL, 2017, EUR J MED CHEM, V138, P343, DOI 10.1016/j.ejmech.2017.06.064; Ong ALC, 2018, AGEING RES REV, V43, P64, DOI 10.1016/j.arr.2018.02.004; Parenti MD, 2014, J MED CHEM, V57, P4796, DOI 10.1021/jm500487d; Park SH, 2016, CANCER RES, V76, P3802, DOI 10.1158/0008-5472.CAN-15-2498; Park WC, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2387-x; Pina JM, 2018, BIOCHEMISTRY-US, V57, P3873, DOI 10.1021/acs.biochem.8b00256; PUN KK, 1988, J CLIN ENDOCR METAB, V67, P546, DOI 10.1210/jcem-67-3-546; Roda D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130543; Roy R, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1431; Sun Y, 2017, ONCOL LETT, V14, P7323, DOI 10.3892/ol.2017.7085; Williams AL, 2018, PHYSIOL GENOMICS, V50, P479, DOI 10.1152/physiolgenomics.00130.2017; Xiong Y, 2011, COLD SH Q B, V76, P285, DOI 10.1101/sqb.2011.76.010942; Xu Q, 2015, ONCOGENE, V34, P5482, DOI 10.1038/onc.2015.6; Xuan Y, 2016, MOL ONCOL, V10, P610, DOI 10.1016/j.molonc.2015.11.010; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang LF, 2015, EMBO J, V34, P2671, DOI 10.15252/embj.201591803; Zhang ZY, 2015, J HEPATOL, V62, P121, DOI 10.1016/j.jhep.2014.08.007; Zhu YM, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-15	44	29	32	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4915	4931		10.1038/s41388-019-0764-z	http://dx.doi.org/10.1038/s41388-019-0764-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30858544				2022-12-17	WOS:000472145900003
J	Lu, P; Geng, J; Zhang, L; Wang, Y; Niu, NN; Fang, Y; Liu, F; Shi, JJ; Zhang, ZG; Sun, YW; Wang, LW; Tang, YJ; Xue, J				Lu, Ping; Geng, Jing; Zhang, Lei; Wang, Yu; Niu, Ningning; Fang, Yuan; Liu, Fang; Shi, Juanjuan; Zhang, Zhi-Gang; Sun, Yong-Wei; Wang, Li-Wei; Tang, Yujie; Xue, Jing			THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer	ONCOGENE			English	Article							TARGETING TRANSCRIPTION; EXPRESSION; INHIBITION; THERAPY; GROWTH	Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with high mortality. Lack of effective treatment makes novel therapeutic discovery an urgent demand in PDAC research. By screening an epigenetic-related compound library, we identified THZ1, a covalent inhibitor of CDK7, as a promising candidate. Multiple long-established and patient-derived PDAC cell lines (PDC) were used to validate the efficacy of THZ1 in vitro. In addition, patient-derived xenograft (PDX) models and animal models of PDAC were utilized for examining THZ1 efficacy in vivo. Furthermore, RNA-Seq analyse was performed to reveal the molecular mechanism of THZ1 treatment. Finally, PDAC cell lines with primary or acquired resistance to THZ1 were investigated to explore the potential mechanism of THZ1 susceptibility. CDK7 inhibition was identified as a selective and potent therapeutic strategy for PDAC progression in multiple preclinical models. Mechanistic analyses revealed that CDK7 inhibition led to a pronounced downregulation of gene transcription, with a preferential repression of mitotic cell cycle and NF-kappa B signaling-related transcripts. MYC transcriptional was found to be involved in susceptibility of PDAC cells to CDK7 inhibition. In conclusion, Identification of CDK7-dependent transcriptional addiction in PDACs provides a potent therapeutic strategy that targets highly aggressive pancreatic cancer.	[Lu, Ping; Geng, Jing; Niu, Ningning; Shi, Juanjuan; Xue, Jing] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Stem Cell Res Ctr, Renji Hosp,Sch Med, Shanghai, Peoples R China; [Zhang, Lei; Liu, Fang; Tang, Yujie] Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Natl Minist Educ, Dept Pathophysiol,Sch Med, Shanghai, Peoples R China; [Wang, Yu; Wang, Li-Wei] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China; [Fang, Yuan] Shanghai Jiao Tong Univ, Ruijin Hosp, Res Inst Pancreat Dis, Sch Med, Shanghai, Peoples R China; [Zhang, Zhi-Gang; Wang, Li-Wei] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai, Peoples R China; [Sun, Yong-Wei] Shanghai Jiao Tong Univ, Dept Biliary Pancreat Surg, Renji Hosp, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xue, J (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Stem Cell Res Ctr, Renji Hosp,Sch Med, Shanghai, Peoples R China.; Tang, YJ (corresponding author), Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Natl Minist Educ, Dept Pathophysiol,Sch Med, Shanghai, Peoples R China.; Wang, LW (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China.; Wang, LW (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai, Peoples R China.	liweiwang@shsmu.edu.cn; yujietang@shsmu.edu.cn; jingxue@sjtu.edu.cn		Zhang, Zhi-gang/0000-0001-8965-223X; Sun, Yongwei/0000-0002-5937-634X	Program for professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [TP2015007, TP2015017]; National Natural Science Foundation of China [81702938, 81770628, 81572761, 81772655]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161312]; Recruitment Program of Global Experts of China (National 1000-Youth Talents Program); Shanghai Rising-Star Program	Program for professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Recruitment Program of Global Experts of China (National 1000-Youth Talents Program); Shanghai Rising-Star Program	This work was supported by the Program for professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning No. TP2015007 to J.X., TP2015017 to Y.T.), National Natural Science Foundation of China (81702938 and 81770628 to J.X.; 81572761 and 81772655 to Y.T.), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support No. 20161312 (J.X.), The Recruitment Program of Global Experts of China (National 1000-Youth Talents Program to Y.T.), Shanghai Rising-Star Program (Y.T.).	Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Cao KX, 2014, CANCER CELL, V26, P158, DOI 10.1016/j.ccr.2014.07.020; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Corcoran RB, 2015, CANCER RES, V71, P5020; Franco HL, 2015, CELL, V163, P28, DOI 10.1016/j.cell.2015.09.013; Gao Y, 2018, CELL CHEM BIOL, V25, P135, DOI 10.1016/j.chembiol.2017.11.007; Garcia PL, 2016, ONCOGENE, V35, P833, DOI 10.1038/onc.2015.126; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Guo JC, 2004, ONCOGENE, V23, P71, DOI 10.1038/sj.onc.1206926; Hessmann E, 2017, GUT, V66, P168, DOI 10.1136/gutjnl-2016-312539; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Jiang YY, 2017, GUT, V66, P1358, DOI 10.1136/gutjnl-2016-311818; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Loven J, 2012, CELL, V151, P476, DOI 10.1016/j.cell.2012.10.012; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Ochiai Takanori, 2008, J Med Dent Sci, V55, P49; Prabhu L, 2014, ONCOTARGET, V5, P10969, DOI 10.18632/oncotarget.2624; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang JQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11363; Wang XJ, 2016, ONCOTARGET, V7, P21441, DOI 10.18632/oncotarget.7375; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Wong MH, 2014, CLIN CANCER RES, V20, P4047, DOI 10.1158/1078-0432.CCR-13-3377; Wong RWJ, 2017, BLOOD, V130, P2326, DOI 10.1182/blood-2017-06-792184; Wu CY, 2014, GASTROENTEROLOGY, V147, P143, DOI 10.1053/j.gastro.2014.03.048; Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068; Yuan J, 2017, CANCER RES, V77, P6614, DOI 10.1158/0008-5472.CAN-17-1143; Zhang ZF, 2017, MOL CANCER THER, V16, P1739, DOI 10.1158/1535-7163.MCT-17-0078	34	29	30	4	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3932	3945		10.1038/s41388-019-0701-1	http://dx.doi.org/10.1038/s41388-019-0701-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692639				2022-12-17	WOS:000468035600012
J	Sayed, ME; Yuan, L; Robin, JD; Tedone, E; Batten, K; Dahlson, N; Wright, WE; Shay, JW; Ludlow, AT				Sayed, Mohammed E.; Yuan, Laura; Robin, Jerome D.; Tedone, Enzo; Batten, Kimberly; Dahlson, Nicole; Wright, Woodring E.; Shay, Jerry W.; Ludlow, Andrew T.			NOVA1 directs PTBP1 to hTERT pre-mRNA and promotes telomerase activity in cancer cells	ONCOGENE			English	Article							REVERSE-TRANSCRIPTASE HTERT; CATALYTIC SUBUNIT GENE; SPLICING PATTERNS; ALIGNMENT; HALLMARKS; ROLES	Alternative splicing is dysregulated in cancer cells, driving the production of isoforms that allow tumor cells to survive and continuously proliferate. Part of the reactivation of telomerase involves the splicing of hTERT transcripts to produce full-length (FL) TERT. Very few splicing factors to date have been described to interact with hTERT and promote the production of FL TERT. We recently described one such splicing factor, NOVA1, that acts as an enhancer of FL hTERT splicing, increases telomerase activity, and promotes telomere maintenance in cancer cells. NOVA1 is expressed primarily in neurons and is involved in neurogenesis. In the present studies, we describe that polypyrimidine-tract binding proteins (PTBPs), which are also typically involved in neurogenesis, are also participating in the splicing of hTERT to FL in cancer. Knockdown experiments of PTBP1 in cancer cells indicate that PTBP1 reduces hTERT FL splicing and telomerase activity. Stable knockdown of PTBP1 results in progressively shortened telomere length in H1299 and H920 lung cancer cells. RNA pulldown experiments reveal that PTBP1 interacts with hTERT pre-mRNA in a NOVA1 dependent fashion. Knockdown of PTBP1 increases the expression of PTBP2 which also interacts with NOVA1, potentially preventing the association of NOVA1 with hTERT pre-mRNA. These new data highlight that splicing in cancer cells is regulated by competition for splice sites and that combinations of splicing factors interact at cis regulatory sites on pre-mRNA transcripts. By employing hTERT as a model gene, we show the coordination of the splicing factors NOVA1 and PTBP1 in cancer by regulating telomerase that is expressed in the vast majority of cancer cell types.	[Sayed, Mohammed E.; Ludlow, Andrew T.] Univ Michigan, Sch Kinesiol, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA; [Yuan, Laura; Tedone, Enzo; Batten, Kimberly; Dahlson, Nicole; Wright, Woodring E.; Shay, Jerry W.] UT Southwestern Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Robin, Jerome D.] Aix Marseille Univ, UMR125, MMG, F-13385 Marseille, France	University of Michigan System; University of Michigan; University of Texas System; University of Texas Southwestern Medical Center Dallas; UDICE-French Research Universities; Aix-Marseille Universite	Ludlow, AT (corresponding author), Univ Michigan, Sch Kinesiol, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	atludlow@umich.edu	Robin, Jerome/AAD-4309-2019	Robin, Jerome/0000-0001-5865-8372; Ludlow, Andrew/0000-0003-0423-4800; Wright, Woodring/0000-0001-6838-6665	NIH [C06 RR30414]; National Institute on Aging [AG01228]; T32 Training Grant [CA124334]; Pathway to Independence award (National Cancer Institute (NCI)) [K99/R00 CA197672-01A1]; Harold Simmons NCI Designated Comprehensive Cancer Center Support Grant [CA142543]; NCI SPORE [CA070907]; NATIONAL CANCER INSTITUTE [K99CA197672, P30CA142543, T32CA124334, R00CA197672, P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001228] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); T32 Training Grant; Pathway to Independence award (National Cancer Institute (NCI)); Harold Simmons NCI Designated Comprehensive Cancer Center Support Grant; NCI SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Drs. John Minna and Adi Gazdar for cell lines. We acknowledge Henrietta Lacks and her family members for the important contributions "HeLa" cells have made to this work. This work was performed in laboratories constructed with support from NIH Grant C06 RR30414. This work was supported by AG01228 from the National Institute on Aging (WEW and JWS) and by a T32 Training Grant CA124334 (JWS). A Pathway to Independence award to ATL (K99/R00 CA197672-01A1, National Cancer Institute (NCI)). We also acknowledge the Harold Simmons NCI Designated Comprehensive Cancer Center Support Grant (CA142543), the NCI SPORE (CA070907), and the Southland Financial Corporation Distinguished Chair in Geriatric Research (JWS and WEW).	Avilion AA, 1996, CANCER RES, V56, P645; Aviv A, 2017, TRENDS CANCER, V3, P253, DOI 10.1016/j.trecan.2017.02.005; Gomes NMV, 2011, AGING CELL, V10, P761, DOI 10.1111/j.1474-9726.2011.00718.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He X, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.47; Holohan B, 2014, J CELL BIOL, V205, P289, DOI 10.1083/jcb.201401012; Hrdlickova R, 2012, MOL CELL BIOL, V32, P4283, DOI 10.1128/MCB.00550-12; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim W, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000016; Lai TP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01291-z; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Linares AJ, 2015, ELIFE, V4, DOI 10.7554/eLife.09268; Ludlow AT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05582-x; Ludlow AT, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku439; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Monaghan P, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2016.0435; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Polydorides AD, 2000, P NATL ACAD SCI USA, V97, P6350, DOI 10.1073/pnas.110128397; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Romanelli MG, 2013, INT J MOL SCI, V14, P22906, DOI 10.3390/ijms141122906; Saito Y, 2016, ELIFE, V5, DOI 10.7554/eLife.14371; Seluanov A, 2007, AGING CELL, V6, P45, DOI 10.1111/j.1474-9726.2006.00262.x; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Ulaner GA, 1998, CANCER RES, V58, P4168; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Withers JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048016; Wong MS, 2014, TRENDS GENET, V30, P430, DOI 10.1016/j.tig.2014.07.006; Wong MS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4306; Wong MS, 2013, CELL REP, V3, P1028, DOI 10.1016/j.celrep.2013.03.011; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wu TD, 2005, BIOINFORMATICS, V21, P1859, DOI 10.1093/bioinformatics/bti310; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yi XM, 2001, NUCLEIC ACIDS RES, V29, P4818, DOI 10.1093/nar/29.23.4818; Young AJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2016.0452; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253	37	29	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2937	2952		10.1038/s41388-018-0639-8	http://dx.doi.org/10.1038/s41388-018-0639-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30568224	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000465167600005
J	Wei, CY; Zhu, MX; Lu, NH; Peng, R; Yang, X; Zhang, PF; Wang, L; Gu, JY				Wei, Chuan-Yuan; Zhu, Meng-Xuan; Lu, Nan-Hang; Peng, Rui; Yang, Xuan; Zhang, Peng-Fei; Wang, Lu; Gu, Jian-Ying			Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma	ONCOGENE			English	Article							INTEGRATIVE ANALYSIS; AKT; IDENTIFICATION; FACILITATORS; SUPERFAMILY; PROGRESSION; PATHWAYS; PROTEINS; CANCER	Although recent therapeutic advances based on our understanding of molecular phenomena have prolonged the survival of melanoma patients, the prognosis of melanoma remains dismal and further understanding of the underlying mechanism of melanoma progression is needed. In this study, differential expression analyses revealed that many genes, including AKT1 and CDK2, play important roles in melanoma. Functional analyses of differentially expressed genes (DEGs), obtained from the GEO (Gene Expression Omnibus) database, indicated that high proliferative and metastatic abilities are the main characteristics of melanoma and that the PI3K and MAPK pathways play essential roles in melanoma progression. Among these DEGs, major facilitator superfamily domain-containing 12 (MFSD12) was found to have significantly and specifically upregulated expression in melanoma, and elevated MFSD12 level promoted cell proliferation by promoting cell cycle progression. Mechanistically, MFSD12 upregulation was found to activate PI3K signaling, and a PI3K inhibitor reversed the increase in cell proliferation endowed by MFSD12 upregulation. Clinically, high MFSD12 expression was positively associated with shorter overall survival (OS) and disease-free survival (DFS) in melanoma patients, and MFSD12 was an independent prognostic factor for OS and DFS in melanoma patients. Therapeutically, in vivo assays further confirmed that MFSD12 interference inhibited tumor growth and lung metastasis in melanoma. In conclusion, elevated MFSD12 expression promotes melanoma cell proliferation, and MFSD12 is a valuable prognostic biomarker and promising therapeutic target in melanoma.	[Wei, Chuan-Yuan; Lu, Nan-Hang; Wang, Lu; Gu, Jian-Ying] Fudan Univ, Zhongshan Hosp, Dept Plast Surg, Shanghai 200032, Peoples R China; [Wei, Chuan-Yuan; Zhu, Meng-Xuan; Peng, Rui; Yang, Xuan; Zhang, Peng-Fei] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Liver Canc Inst,Zhongshan Hosp, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Gu, JY (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Plast Surg, Shanghai 200032, Peoples R China.	zhongshanhospital@163.com			Scientific Research Fund of Zhongshan Hospital, Fudan University [2016ZSFZ62]; National Natural Science Foundation of China [G2016-023]; Science and Technology Committee of Shanghai [14DZ1940304]	Scientific Research Fund of Zhongshan Hospital, Fudan University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Committee of Shanghai(Shanghai Science & Technology Committee)	This study was funded by the Scientific Research Fund of Zhongshan Hospital, Fudan University (2016ZSFZ62), the National Natural Science Foundation of China (G2016-023), and the Science and Technology Committee of Shanghai (14DZ1940304).	Ascierto PA, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-85; Augustin R, 2010, IUBMB LIFE, V62, P315, DOI 10.1002/iub.315; Berger M, 2018, GIORN ITAL DERMAT V, V153, P349, DOI 10.23736/S0392-0488.18.05970-9; Bi DB, 2015, COMPUT BIOL CHEM, V56, P71, DOI 10.1016/j.compbiolchem.2015.04.001; Cai JB, 2015, HEPATOLOGY, V61, P1603, DOI 10.1002/hep.27682; Chen YL, 2017, INT J ONCOL, V51, P1280, DOI 10.3892/ijo.2017.4092; Crawford NG, 2017, SCIENCE, V358, P1; Cura AJ, 2012, COMPR PHYSIOL, V2, P863, DOI 10.1002/cphy.c110024; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096860; Kanda M, 2016, ONCOTARGET, V7, P13667, DOI 10.18632/oncotarget.7269; Kang Q, 2017, J CLIN PATHOL, V70, P677, DOI 10.1136/jclinpath-2016-204251; Ke AW, 2009, HEPATOLOGY, V49, P491, DOI 10.1002/hep.22639; Khunlertgit N, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1224-1; Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Namiki T, 2015, CANCER RES, V75, P2708, DOI 10.1158/0008-5472.CAN-13-3209; Park J, 2017, CANCER IMMUNOL RES, V5, P618, DOI 10.1158/2326-6066.CIR-17-0051; Peng JH, 2017, SCI REP-UK, V7, DOI 10.1038/srep46577; Peng R, 2018, CANCER MED-US, V7, P796, DOI 10.1002/cam4.1313; Rajabi Parvin, 2017, Adv Biomed Res, V6, P14, DOI 10.4103/2277-9175.200789; Rebelo TM, 2018, EXP CELL RES, V368, P1, DOI 10.1016/j.yexcr.2018.04.003; Reddy VS, 2012, FEBS J, V279, P2022, DOI 10.1111/j.1742-4658.2012.08588.x; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; Shi GM, 2008, J CANCER RES CLIN, V134, P1155, DOI 10.1007/s00432-008-0407-1; Sinnberg T, 2009, J INVEST DERMATOL, V129, P1500, DOI 10.1038/jid.2008.379; Spinola M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-62; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tazzari PL, 2004, BRIT J HAEMATOL, V126, P675, DOI 10.1111/j.1365-2141.2004.05121.x; Wang L, 2016, ONCOTARGET, V7, P3791, DOI 10.18632/oncotarget.6302; Wang SC, 2014, TRENDS PHARMACOL SCI, V35, P178, DOI 10.1016/j.tips.2014.02.004; Wei CY, 2018, ONCOL REP, V39, P2553, DOI 10.3892/or.2018.6356; Xing ZH, 2016, BBA-GEN SUBJECTS, V1860, P2725, DOI 10.1016/j.bbagen.2016.01.012; Xu ZZ, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0840-y	38	29	30	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1876	1891		10.1038/s41388-018-0531-6	http://dx.doi.org/10.1038/s41388-018-0531-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30385854	hybrid, Green Published			2022-12-17	WOS:000461164400007
J	Boudria, A; Abou Faycal, C; Jia, T; Gout, S; Keramidas, M; Didier, C; Lemaitre, N; Manet, S; Coll, JL; Toffart, AC; Moro-Sibilot, D; Albiges-Rizo, C; Josserand, V; Faurobert, E; Brambilla, C; Brambilla, E; Gazzeri, S; Eymin, B				Boudria, Asma; Abou Faycal, Cherine; Jia, Tao; Gout, Stephanie; Keramidas, Michelle; Didier, Chloe; Lemaitre, Nicolas; Manet, Sandra; Coll, Jean-Luc; Toffart, Anne-Claire; Moro-Sibilot, Denis; Albiges-Rizo, Corinne; Josserand, Veronique; Faurobert, Eva; Brambilla, Christian; Brambilla, Elisabeth; Gazzeri, Sylvie; Eymin, Beatrice			VEGF(165)b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a beta 1 integrin/VEGFR autocrine loop	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DOWN-REGULATION; CELL CARCINOMA; CANCER; EXPRESSION; ISOFORMS; APOPTOSIS; INVASION; PROTEIN; E2F1	Vascular endothelial growth factor-A (VEGF-A) is highly subjected to alternative pre-mRNA splicing that generates several splice variants. The VEGF(xxx) and VEGF(xxx)b families encode splice variants of VEGF-A that differ only at the level of six amino acids in their C-terminal part. The expression level of VEGF(xxx) splice variants and their function as pro-angiogenic factors during tumor neo-angiogenesis have been well-described. The role of VEGF(xxx)b isoforms is less well known, but they have been shown to inhibit VEGF(xxx)-mediated angiogenesis, while being partial or weak activators of VEGFR receptors in endothelial cells. On the opposite, their role on tumor cells expressing VEGFRs at their surface remains largely unknown. In this study, we find elevated levels of VEGF(165)b, the main VEGF(xxx)b isoform, in 36% of non-small cell lung carcinoma (NSCLC), mainly lung adenocarcinoma (46%), and show that a high VEGF(165)b/VEGF(165) ratio correlates with the presence of lymph node metastases. At the molecular level, we demonstrate that VEGF(165)b stimulates proliferation and invasiveness of two lung tumor cell lines through a VEGFR/beta 1 integrin loop. We further provide evidence that the isoform-specific knockdown of VEGF(165)b reduces tumor growth, demonstrating a tumor-promoting autocrine role for VEGF(165)b in lung cancer cells. Importantly, we show that bevacizumab, an anti-angiogenic compound used for the treatment of lung adenocarcinoma patients, increases the expression of VEGF(165)b and activates the invasive VEGFR/beta 1 integrin loop. Overall, these data highlight an unexpected role of the VEGF(165)b splice variant in the progression of lung tumors and their response to anti-angiogenic therapies.	[Boudria, Asma; Abou Faycal, Cherine; Jia, Tao; Gout, Stephanie; Gazzeri, Sylvie; Eymin, Beatrice] CNRS, INSERM, Team RNA Splicing Cell Signaling & Response Thera, U1209,UMR 5309, F-38042 Grenoble, France; [Boudria, Asma; Abou Faycal, Cherine; Jia, Tao; Gout, Stephanie; Keramidas, Michelle; Didier, Chloe; Lemaitre, Nicolas; Manet, Sandra; Coll, Jean-Luc; Toffart, Anne-Claire; Moro-Sibilot, Denis; Albiges-Rizo, Corinne; Josserand, Veronique; Faurobert, Eva; Brambilla, Christian; Brambilla, Elisabeth; Gazzeri, Sylvie; Eymin, Beatrice] Univ Grenoble Alpes, Inst Avancee Biosci, F-38041 Grenoble, France; [Keramidas, Michelle; Didier, Chloe; Coll, Jean-Luc; Josserand, Veronique] CNRS, INSERM, Team Canc Targets & Expt Therapeut, U1209,UMR 5309, F-38042 Grenoble, France; [Lemaitre, Nicolas; Toffart, Anne-Claire; Moro-Sibilot, Denis; Brambilla, Christian; Brambilla, Elisabeth] CNRS, INSERM, Team Tumor Mol Pathol & Biomarkers, U1209,UMR 5309, F-38042 Grenoble, France; [Manet, Sandra; Albiges-Rizo, Corinne; Faurobert, Eva] CNRS, INSERM, Team Cell Adhes Dynam & Differentiat, U1209,UMR 5309, F-38042 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm)	Eymin, B (corresponding author), CNRS, INSERM, Team RNA Splicing Cell Signaling & Response Thera, U1209,UMR 5309, F-38042 Grenoble, France.; Eymin, B (corresponding author), Univ Grenoble Alpes, Inst Avancee Biosci, F-38041 Grenoble, France.	Beatrice.Eymin@ujf-grenoble.fr	josserand, veronique/F-1773-2019; gazzeri, sylvie/U-4669-2019; Eymin, Beatrice/M-1962-2013; eymin, beatrice/U-4670-2019; Coll, Jean-Luc/G-2520-2013; JIA, Tao/AAZ-1963-2020; Albiges-Rizo, Corinne/M-2568-2013; gazzeri, sylvie/M-1961-2013; Toffart, Anne-Claire/N-6820-2013; Faurobert, Eva/M-2735-2013	josserand, veronique/0000-0001-6733-3801; gazzeri, sylvie/0000-0001-5817-1839; Eymin, Beatrice/0000-0002-7311-3810; eymin, beatrice/0000-0002-7311-3810; Coll, Jean-Luc/0000-0002-2453-3552; JIA, Tao/0000-0002-8358-6005; gazzeri, sylvie/0000-0001-5817-1839; Faurobert, Eva/0000-0002-2714-8537; MORO-SIBILOT, Denis/0000-0001-6776-8610; ALBIGES-RIZO, Corinne/0000-0002-6333-4150	Comite Departemental Isere and Comite Departemental Savoie de la Ligue Nationale contre le Cancer; INCa/DHOS (Appel d'Offre Recherche Translationnelle 2010); Fondation de France (Projet Grande Ampleur 2011); ROCHE fellowship (Bourse de Recherche Fondamentale); Fondation ARC pour la Recherche Contre le Cancer; Fonds de dotation AGIR pour les Maladies Chroniques; Ministere de l'Education et de la Recherche Algerien (program PROFAS); Fondation pour La Recherche Medicale; Ligue Nationale Contre Le Cancer; Ligue Nationale Contre Le Cancer (Equipe labellisee Ligue 2014)	Comite Departemental Isere and Comite Departemental Savoie de la Ligue Nationale contre le Cancer; INCa/DHOS (Appel d'Offre Recherche Translationnelle 2010); Fondation de France (Projet Grande Ampleur 2011); ROCHE fellowship (Bourse de Recherche Fondamentale); Fondation ARC pour la Recherche Contre le Cancer; Fonds de dotation AGIR pour les Maladies Chroniques; Ministere de l'Education et de la Recherche Algerien (program PROFAS); Fondation pour La Recherche Medicale(Fondation pour la Recherche Medicale); Ligue Nationale Contre Le Cancer(Ligue nationale contre le cancer); Ligue Nationale Contre Le Cancer (Equipe labellisee Ligue 2014)	Plasmid encoding VEGF<INF>165</INF>b was obtained from David Bates (University of Nottingham, UK). We thank Sophie Michallet, Floriane Albert, Celine Barrial, and Virginie Rouyre for technical assistance. We also thank Laurence David-Boudet and Adrien Mombrun for IHC performance. Thanks to Philippe Lorimier for tumor bank gestion and data retrieving. This work was supported by the Comite Departemental Isere and Comite Departemental Savoie de la Ligue Nationale contre le Cancer, the INCa/DHOS (Appel d'Offre Recherche Translationnelle 2010), by the Fondation de France (Projet Grande Ampleur 2011), ROCHE fellowship (Bourse de Recherche Fondamentale), the Fondation ARC pour la Recherche Contre le Cancer, and the Fonds de dotation AGIR pour les Maladies Chroniques. Stephanie Gout and Tao Jia were supported by a post-doctoral fellowship from the Fondation ARC pour la Recherche Contre le Cancer. Asma Boudria was supported by the Ministere de l'Education et de la Recherche Algerien (program PROFAS) and the Fondation pour La Recherche Medicale. Cherine Abou Faycal was supported by the Ligue Nationale Contre Le Cancer. The CAR team is supported by the Ligue Nationale Contre Le Cancer (Equipe labellisee Ligue 2014).	Bachelder RE, 2001, CANCER RES, V61, P5736; Bachelder RE, 2002, CANCER RES, V62, P7203; Bates DO, 2012, CLIN CANCER RES, V18, P6384, DOI 10.1158/1078-0432.CCR-12-2223; Bates DO, 2002, CANCER RES, V62, P4123; Beasley MB, 2005, SEMIN ROENTGENOL, V40, P90, DOI 10.1053/j.ro.2005.01.001; Carbonell WS, 2013, CANCER RES, V73, P3145, DOI 10.1158/0008-5472.CAN-13-0011; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cascone T, 2015, CLIN CANC RES; Catena R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-320; Chen TT, 2010, J CELL BIOL, V188, P595, DOI 10.1083/jcb.200906044; Diaz R, 2008, INT J CANCER, V123, P1060, DOI 10.1002/ijc.23619; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635; Franzini A, 2015, GENE EXPRESSION SIGN; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Goel HL, 2012, CANCER DISCOV, V2, P906, DOI 10.1158/2159-8290.CD-12-0085; Gout S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046539; Grepin R, 2012, ONCOGENE, V31, P1683, DOI 10.1038/onc.2011.360; Hall DMS, 2014, METHODS MOL BIOL, V1070, P1, DOI 10.1007/978-1-4614-8244-4_1; Harris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035231; Huveldt D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056505; Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Lambrechts D, 2013, J CLIN ONCOL, V31, P1219, DOI 10.1200/JCO.2012.46.2762; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Larrayoz M, 2014, EMBO MOL MED, V6, P539, DOI 10.1002/emmm.201303214; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Merdzhanova G, 2008, CELL DEATH DIFFER, V15, P1815, DOI 10.1038/cdd.2008.135; Merdzhanova G, 2010, ONCOGENE, V29, P5392, DOI 10.1038/onc.2010.281; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Pajares MJ, 2012, J CLIN ONCOL, V30, P1129, DOI 10.1200/JCO.2011.37.4231; Pritchard-Jones RO, 2007, BRIT J CANCER, V97, P223, DOI 10.1038/sj.bjc.6603839; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Rennel ES, 2008, EUR J CANCER, V44, P1883, DOI 10.1016/j.ejca.2008.05.027; Robinson CJ, 2001, J CELL SCI, V114, P853; Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006; Rugo HS, 2012, J CLIN ONCOL, V30, P898, DOI 10.1200/JCO.2011.38.5492; Salon C, 2007, ONCOGENE, V26, P6927, DOI 10.1038/sj.onc.1210499; Salon C, 2006, CELL DEATH DIFFER, V13, P260, DOI 10.1038/sj.cdd.4401739; Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9; Toffart AC, 2014, LUNG CANCER, V83, P182, DOI 10.1016/j.lungcan.2013.12.003; Toth Marta, 2012, Methods Mol Biol, V878, P121, DOI 10.1007/978-1-61779-854-2_8; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; Xin H, 2016, CELL, V167, P275, DOI 10.1016/j.cell.2016.08.054; Zhang PF, 2013, ONCOL REP, V30, P341, DOI 10.3892/or.2013.2477	49	29	30	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1050	1066		10.1038/s41388-018-0486-7	http://dx.doi.org/10.1038/s41388-018-0486-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30194450	Green Submitted			2022-12-17	WOS:000458624900009
J	Li, WL; Wong, CC; Zhang, XM; Kang, W; Nakatsu, G; Zhao, QF; Chen, HR; Go, MYY; Chiu, PWY; Wang, XH; Ji, JF; Li, XN; Cai, ZW; Ng, EKW; Yu, J				Li, Weilin; Wong, Chi Chun; Zhang, Xiaoming; Kang, Wei; Nakatsu, Geicho; Zhao, Qinfu; Chen, Huarong; Go, Minnie Yin Yin; Chiu, Philip Wai Yan; Wang, Xiaohong; Ji, Jiafu; Li, Xiaona; Cai, Zongwei; Ng, Enders Kwok Wai; Yu, Jun			CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1 alpha axis to inhibit gastric tumorigenesis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; CANCER GROWTH; AMPK; METABOLISM; REVEALS; HISTONE; METHYLATION; EPIGENETICS; REGULATOR; INTERPLAY	Metabolic dysfunction is a hallmark of gastric cancer (GC). In this study, we reported the identification of Calcium Binding Protein 39-Like (CAB39L) as a novel regulator of tumor metabolism in GC. CAB39L mRNA was frequently silenced by promoter methylation in GC cell lines and tissues. Functional studies suggested that CAB39L functions as a tumor suppressor, as overexpression of CAB39L elicited suppression of multiple cancer phenotypes both in GC cells and an orthotopic mouse model; whilst its knockdown promoted tumorigenesis. Mechanistically, CAB39L interacted with LKB1-STRAD complex and induced LKB1, leading to the phosphorylation and activation of AMPK alpha/beta. LKB1-AMPK activation in GC cell lines was tumor suppressive, as metformin (an AMPK activator) inhibited GC cell growth in the CAB39L-silenced cells. Moreover, knockdown of LKB1 reversed growth inhibitory effect of CAB39L, indicating that tumor suppression by CAB39L depended on LKB1-AMPK. RNAseq and gene set enrichment analysis revealed that CAB39L was closely correlated with oxidative phosphorylation and mitochondrial biogenesis. Consistently, CAB39L-induced p-AMPK elicited PGC1 alpha phosphorylation and increased the expression of genes involved in mitochondrial respiration complexes. Accordingly, CAB39L reversed the Warburg effect in GC, as evidenced by enhanced oxygen consumption rate and reduced extracellular acidification rate; inversely, CAB39L knockdown promoted a metabolic shift towards the Warburg phenotype. In GC patients, CAB39L promoter hypermethylation was correlated with poor prognosis. Our data demonstrate that CAB39L is a novel tumor suppressor which suppresses tumorigenesis by promoting LKB1-AMPK-PGC1 alpha axis, thereby preventing a metabolic shift that drives carcinogenesis. CAB39L methylation is a potential prognostic biomarker for GC patients.	[Li, Weilin; Wong, Chi Chun; Zhang, Xiaoming; Nakatsu, Geicho; Zhao, Qinfu; Chen, Huarong; Go, Minnie Yin Yin; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Li, Weilin; Wong, Chi Chun; Zhang, Xiaoming; Nakatsu, Geicho; Zhao, Qinfu; Chen, Huarong; Go, Minnie Yin Yin; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China; [Li, Weilin; Chiu, Philip Wai Yan; Ng, Enders Kwok Wai] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China; [Kang, Wei] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; [Wang, Xiaohong; Ji, Jiafu] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Surg, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Li, Xiaona; Cai, Zongwei] Hong Kong Baptist Univ, Dept Chem, State Key Lab Environm & Biol Anal, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University; Hong Kong Baptist University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China.; Ng, EKW (corresponding author), Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China.	endersng@surgery.cuhk.edu.hk; junyu@cuhk.edu.hk	chen, huarong/ABH-8561-2020; KANG, Wei/C-5451-2016; Cai, Zongwei/ABD-4001-2020; Li, Weilin/ABG-9032-2021; Nakatsu, Geicho/AAU-3089-2021; Chen, Huarong/ABZ-5810-2022; Chiu, Philip/ABB-1454-2020; Ng, Enders Kwok-wai/E-8276-2016	chen, huarong/0000-0003-2192-1864; KANG, Wei/0000-0002-4651-677X; Cai, Zongwei/0000-0002-8724-7684; Chiu, Philip/0000-0001-9292-112X; Ng, Enders Kwok-wai/0000-0001-7219-5810	RGC/GRF Hong Kong [14114615, 14101917, 14111216, 14106145]; National Natural Science Foundation of China (NSFC) [81772501, 81502064]; HMRF Hong Kong [03140856]; Faculty of Medicine CUHK direct grant; Shenzhen Virtual University Park Support Scheme; Vice-Chancellor's Discretionary Fund CUHK	RGC/GRF Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); HMRF Hong Kong; Faculty of Medicine CUHK direct grant; Shenzhen Virtual University Park Support Scheme; Vice-Chancellor's Discretionary Fund CUHK	This project was supported by research funds from RGC/GRF Hong Kong (14114615, 14101917, 14111216, and 14106145); National Natural Science Foundation of China (NSFC) (81772501, 81502064); HMRF Hong Kong (03140856); Faculty of Medicine CUHK direct grant; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Calcagno DQ, 2013, WORLD J GASTROENTERO, V19, P1182, DOI 10.3748/wjg.v19.i8.1182; Camacho L, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0598-8; Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Das M, 2017, LANCET ONCOL, V18, pE307, DOI 10.1016/S1470-2045(17)30321-2; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Filippi BM, 2011, EMBO J, V30, P1730, DOI 10.1038/emboj.2011.78; Garrido N, 2009, FERTIL STERIL, V91, P1307, DOI 10.1016/j.fertnstert.2008.01.078; Gupta V, 2014, CURR PHARM DESIGN, V20, P1706, DOI 10.2174/13816128113199990536; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Jacome AA, 2016, WORLD J GASTROENTERO, V22, P1160, DOI 10.3748/wjg.v22.i3.1160; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; LeBleu VS, 2014, NAT CELL BIOL, P1001, DOI DOI 10.1038/NCB3039; Li XN, 2017, ONCOTARGET, V8; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Mariotti S, 2016, ONCOTARGET, V7, P1808, DOI 10.18632/oncotarget.6577; Meng FQ, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/5063239; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Morales DR, 2015, ANNU REV MED, V66, P17, DOI 10.1146/annurev-med-062613-093128; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Nagalingam A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3128; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Rahmioglu N, 2015, HUM MOL GENET, V24, P1185, DOI 10.1093/hmg/ddu516; Richmond A, 2008, DIS MODEL MECH, V1, P78, DOI 10.1242/dmm.000976; Selaru FM, 2009, AM J GASTROENTEROL, V104, P1910, DOI 10.1038/ajg.2008.145; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wang KN, 2016, GUT, V65, P1619, DOI 10.1136/gutjnl-2015-309276; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Whitburn J, 2017, CURR UROL REP, V18, DOI 10.1007/s11934-017-0693-8; William WN, 2012, ANN ONCOL, V23, P78, DOI 10.1093/annonc/mdr036; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xing F, 2017, CELL REP, V18, P468, DOI 10.1016/j.celrep.2016.12.037; Xu LX, 2012, GUT, V61, P977, DOI 10.1136/gutjnl-2011-300411; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377	45	29	32	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6383	6398		10.1038/s41388-018-0402-1	http://dx.doi.org/10.1038/s41388-018-0402-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30054562	hybrid, Green Published			2022-12-17	WOS:000452989100001
J	Yu, M; Li, WJ; Wang, QQ; Wang, Y; Lu, F				Yu, Min; Li, Wenjing; Wang, Qianqian; Wang, Yan; Lu, Fei			Circadian regulator NR1D2 regulates glioblastoma cell proliferation and motility	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; REV-ERB-BETA; ORPHAN NUCLEAR RECEPTORS; NEWLY-DIAGNOSED GLIOBLASTOMA; RECURRENT GLIOBLASTOMA; GENE-EXPRESSION; GROWTH-ARREST; CANCER-CELLS; CROSS-TALK; PHASE-II	Nuclear receptor NR1D2 is originally characterized as the repressor of genes involved in circadian rhythm. Recently, it is documented that NR1D2 is overexpressed in various cancers. However, the pathways and biological functions that NR1D2 involved in cancers remain poorly understood. Here, we reported that NR1D2 was abundant in human glioblastoma (GBM) tissue and cell lines but not primary human astrocytes. Silencing of NR1D2 changed the morphology of GBM cells, inhibited cell proliferation and motility, whereas had no effects on apoptosis. Importantly, based on RNA-seq and ChIP assay, we identified receptor tyrosine kinase AXL as a new transcriptional target of NR1D2 in GBM cells. AXL mediated partially the regulatory effects of NR1D2 on PI3K/AKT axis and promoted proliferation, migration, and invasion of GBM cells. Besides, NR1D2 knockdown remarkably impaired the maturation of focal adhesion and assembly of F-actin, along with downregulated p-FAK, and proteins involved in actin nucleation and polymerization (p-Rac1/Cdc42, WAVE and PFN2). Moreover, NR1D2 had more targets other than AXL to regulate epithelial-to-mesenchymal transition and cell motility in GBM cells. Altogether, our findings uncover a GBM-promoting role of NR1D2 and provide the rationale for targeting NR1D2 as a potential therapeutic approach.	[Yu, Min; Li, Wenjing; Wang, Qianqian; Lu, Fei] Peking Univ, Shenzhen Grad Sch, Key Lab Chem Genom, State Key Lab Chem Oncogen, Shenzhen 518055, Peoples R China; [Wang, Yan] Qingdao Univ, Qingdao Municipal Hosp, Dept Cardiol, Qingdao 266011, Peoples R China	Peking University; University Town of Shenzhen; Qingdao Municipal Hospital; Qingdao University	Lu, F (corresponding author), Peking Univ, Shenzhen Grad Sch, Key Lab Chem Genom, State Key Lab Chem Oncogen, Shenzhen 518055, Peoples R China.	lufei@pkusz.edu.cn		Wang, Qianqian/0000-0003-4919-1998; Li, Wenjing/0000-0001-9151-9219	Natural Science Foundation of Guangdong Province [2014A030313779]; Shenzhen basic research program [JCYJ20160527100529884, JCYJ20170818085657917]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen basic research program	This work was supported by grants from Natural Science Foundation of Guangdong Province (grant no. 2014A030313779), Shenzhen basic research program (grant no. JCYJ20160527100529884 and JCYJ20170818085657917). We thank Dr. Hui Zhang for the kind gift of U-373 MG cell line.	Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119; Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Axelrod H, 2014, ONCOTARGET, V5, P1, DOI 10.18632/oncotarget.2422; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chamberlain MC, 2017, J NEURO-ONCOL, V133, P561, DOI 10.1007/s11060-017-2466-0; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048; De Mei C, 2015, ONCOGENE, V34, P2597, DOI 10.1038/onc.2014.203; Debruyne DN, 2016, ONCOGENE, V35, P3681, DOI 10.1038/onc.2015.434; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Gilbert MR, 2017, J NEURO-ONCOL, V131, P193, DOI 10.1007/s11060-016-2288-5; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Iser IC, 2017, MED RES REV, V37, P271, DOI 10.1002/med.21408; Kubelt C, 2015, INT J ONCOL, V46, P2515, DOI 10.3892/ijo.2015.2944; Lam MTY, 2013, NATURE, V498, P511, DOI 10.1038/nature12209; Li Stephen Yt, 2013, Spermatogenesis, V3, pe25385; Mahabir R, 2014, NEURO-ONCOLOGY, V16, P671, DOI 10.1093/neuonc/not239; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Meng J, 2014, ONCOTARGET, V5, P4683, DOI 10.18632/oncotarget.2088; Ott M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047663; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Qi DD, 2016, CELL CYCLE, V15, P2009, DOI 10.1080/15384101.2016.1192729; Raghuram S, 2007, NAT STRUCT MOL BIOL, V14, P1207, DOI 10.1038/nsmb1344; Ramakrishnan SN, 2009, BIOCHEM BIOPH RES CO, V388, P654, DOI 10.1016/j.bbrc.2009.08.045; Ramakrishnan SN, 2005, J BIOL CHEM, V280, P8651, DOI 10.1074/jbc.M413949200; Rankin EB, 2016, CANCERS, V8, DOI 10.3390/cancers8110103; Raspe E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200; Siripala AD, 2007, CELL, V128, P1014, DOI 10.1016/j.cell.2007.02.021; Stupp R, 2010, J CLIN ONCOL, V28, P2712, DOI 10.1200/JCO.2009.26.6650; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun ZQ, 2016, J CELL BIOL, V215, P445, DOI 10.1083/jcb.201609037; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Verma A, 2011, MOL CANCER THER, V10, P1763, DOI 10.1158/1535-7163.MCT-11-0116; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Weathers SP, 2016, J NEURO-ONCOL, V129, P487, DOI 10.1007/s11060-016-2195-9; Wick W, 2016, CLIN CANCER RES, V22, P4797, DOI 10.1158/1078-0432.CCR-15-3153; Wilson C, 2014, CANCER RES, V74, P5878, DOI 10.1158/0008-5472.CAN-14-1009; Wong GS, 2013, BRIT J CANCER, V108, P755, DOI 10.1038/bjc.2012.592; Yan YR, 2014, NEUROPATHOLOGY, V34, P128, DOI 10.1111/neup.12062; Yin F, 2014, MOL CELL BIOL, V34, P158, DOI 10.1128/MCB.00631-13; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343	47	29	30	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4838	4853		10.1038/s41388-018-0319-8	http://dx.doi.org/10.1038/s41388-018-0319-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29773903				2022-12-17	WOS:000443146000006
J	Paulitti, A; Andreuzzi, E; Bizzotto, D; Pellicani, R; Tarticchio, G; Marastoni, S; Pastrello, C; Jurisica, I; Ligresti, G; Bucciotti, F; Doliana, R; Colladel, R; Braghetta, P; Poletto, E; Di Silvestre, A; Bressan, G; Colombatti, A; Bonaldo, P; Mongiat, M				Paulitti, Alice; Andreuzzi, Eva; Bizzotto, Dario; Pellicani, Rosanna; Tarticchio, Giulia; Marastoni, Stefano; Pastrello, Chiara; Jurisica, Igor; Ligresti, Giovanni; Bucciotti, Francesco; Doliana, Roberto; Colladel, Roberta; Braghetta, Paola; Poletto, Evelina; Di Silvestre, Alessia; Bressan, Giorgio; Colombatti, Alfonso; Bonaldo, Paolo; Mongiat, Maurizio			The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; VESSEL NORMALIZATION; ANGIOGENESIS; THERAPY; METASTASIS; DEFICIENCY; PATHWAY; BREAST; CANCER; IDENTIFICATION	EMILIN2 is an extracellular matrix constituent playing an important role in angiogenesis; however, the underlying mechanism is unknown. Here we show that EMILIN2 promotes angiogenesis by directly binding epidermal growth factor receptor (EGFR), which enhances interleukin-8 (IL-8) production. In turn, IL-8 stimulates the proliferation and migration of vascular endothelial cells. Emilin2 null mice were generated and exhibited delayed retinal vascular development, which was rescued by the administration of the IL-8 murine ortholog MIP-2. Next, we assessed tumor growth and tumor-associated angiogenesis in these mice. Tumor cell growth in Emilin2 null mice was impaired as well as the expression of MIP-2. The vascular density of the tumors developed in Emilin2 null mice was prejudiced and vessels perfusion, as well as response to chemotherapy, decreased. Accordingly, human tumors expressing high levels of EMILIN2 were more responsive to chemotherapy. These results point at EMILIN2 as a key microenvironmental cue affecting vessel formation and unveil the possibility to develop new prognostic tools to predict chemotherapy efficacy.	[Paulitti, Alice; Andreuzzi, Eva; Pellicani, Rosanna; Tarticchio, Giulia; Bucciotti, Francesco; Doliana, Roberto; Colladel, Roberta; Poletto, Evelina; Di Silvestre, Alessia; Colombatti, Alfonso; Mongiat, Maurizio] CRO, Div Mol Oncol, Dept Translat Res, Aviano, Italy; [Bizzotto, Dario; Braghetta, Paola; Bressan, Giorgio; Bonaldo, Paolo] Univ Padua, Dept Mol Med, Padua, Italy; [Marastoni, Stefano; Pastrello, Chiara; Jurisica, Igor] Princess Margaret Canc Ctr, Dept Comp Sci, Toronto, ON, Canada; [Jurisica, Igor] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Ligresti, Giovanni] Mayo Clin, Dept Tissue Repair & Meccano Biol, Rochester, NY USA	IRCCS Aviano (CRO); University of Padua; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; Mayo Clinic	Mongiat, M (corresponding author), CRO, Div Mol Oncol, Dept Translat Res, Aviano, Italy.; Bonaldo, P (corresponding author), Univ Padua, Dept Mol Med, Padua, Italy.	bonaldo@bio.unipd.it; mmongiat@cro.it	Poletto, Evelina/AAW-3671-2020; Doliana, Roberto/AAA-1479-2019; Andreuzzi, Eva/AAX-5692-2020; Mongiat, Maurizio/H-8297-2018; Ligresti, Giovanni/AAB-9881-2019; Bucciotti, Francesco/AAZ-1255-2020; Pellicani, Rosanna/J-1263-2018	Poletto, Evelina/0000-0001-5675-3026; Doliana, Roberto/0000-0002-8324-7564; Andreuzzi, Eva/0000-0002-5925-5230; Mongiat, Maurizio/0000-0001-6509-0068; Bucciotti, Francesco/0000-0002-4253-855X; Pellicani, Rosanna/0000-0002-0952-0403; Bonaldo, Paolo/0000-0002-9571-8140; DI SILVESTRE, ALESSIA/0000-0003-4878-293X; BIZZOTTO, Dario/0000-0002-9036-5016	AIRC [IG-2012-12718, IG-13126 AColombatti]; Italian Ministry of Health [RF-2010-2312580]; Italian Ministry of University and Research (grant PRIN); Italian Ministry of University and Research (Progetto Strategico) [01.00858.ST97]; University of Padova [CDPA075559/07, CPDA148982/14]	AIRC(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of University and Research (grant PRIN)(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of University and Research (Progetto Strategico); University of Padova	This work was supported by AIRC (grant # IG-2012-12718 to MM, IG-13126 AColombatti), the Italian Ministry of Health (grant#RF-2010-2312580 to MM), the Italian Ministry of University and Research (grants PRIN 2007 and Progetto Strategico 01.00858.ST97 to GB), and the University of Padova (grants CDPA075559/07 to PBraghetta and CPDA148982/14 to PBonaldo).	Allegra CJ, 2013, J CLIN ONCOL, V31, P359, DOI 10.1200/JCO.2012.44.4711; Andreuzzi E, 2017, MATRIX BIOL, V64, P40, DOI 10.1016/j.matbio.2017.04.002; Aplin AC, 2008, METHOD ENZYMOL, V443, P119, DOI 10.1016/S0076-6879(08)02007-7; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bot S, 2015, MATRIX BIOL, V41, P44, DOI 10.1016/j.matbio.2014.10.001; Braghetta P, 2004, MATRIX BIOL, V22, P549, DOI 10.1016/j.matbio.2003.10.005; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Bryja V, 2006, NAT PROTOC, V1, P2082, DOI 10.1038/nprot.2006.355; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868; Colladel R, 2016, ONCOTARGET, V7, P2022, DOI 10.18632/oncotarget.6515; COLOMBATTI A, 1989, J HISTOCHEM CYTOCHEM, V37, P757, DOI 10.1177/37.5.2703709; Colombatti A, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00093; Danussi C, 2008, MOL CELL BIOL, V28, P4026, DOI 10.1128/MCB.02062-07; Doliana R, 2000, J BIOL CHEM, V275, P785, DOI 10.1074/jbc.275.2.785; Doliana R, 2008, MATRIX BIOL, V27, P96, DOI 10.1016/j.matbio.2007.09.008; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fukui A, 2013, MICROBIOL IMMUNOL, V57, P198, DOI 10.1111/1348-0421.12022; Galvagni F, 2017, MATRIX BIOL, V64, P112, DOI 10.1016/j.matbio.2017.08.003; Gharavi NM, 2007, J BIOL CHEM, V282, P31460, DOI 10.1074/jbc.M704267200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lorenzon E, 2012, ONCOGENE, V31, P3136, DOI 10.1038/onc.2011.487; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Marastoni S, 2014, J PATHOL, V232, P391, DOI 10.1002/path.4316; Massena S, 2010, BLOOD, V116, P1924, DOI 10.1182/blood-2010-01-266072; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; McIntyre A, 2015, EMBO MOL MED, V7, P368, DOI 10.15252/emmm.201404271; Mongiat M, 2007, MOL CELL BIOL, V27, P7176, DOI 10.1128/MCB.00696-07; Mongiat M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111822; Mongiat M, 2010, NEOPLASIA, V12, P294, DOI 10.1593/neo.91930; Nakatsu Martin N, 2007, J Vis Exp, P186, DOI 10.3791/186; Newman AC, 2011, MOL BIOL CELL, V22, P3791, DOI 10.1091/mbc.E11-05-0393; Nguyen-Jackson HT, 2012, J LEUKOCYTE BIOL, V92, P1215, DOI 10.1189/jlb.0312126; Ohtsu A, 2011, J CLIN ONCOL, V29, P3968, DOI 10.1200/JCO.2011.36.2236; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park JS, 2016, CANCER CELL, V30, P953, DOI 10.1016/j.ccell.2016.10.018; Rossi A, 2015, NATURE, V524, P230, DOI 10.1038/nature14580; Schiavinato A, 2016, J INVEST DERMATOL, V136, P1150, DOI 10.1016/j.jid.2016.02.021; Scott A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011863; Serini G, 2015, EMBO MOL MED, V7, P1251, DOI 10.15252/emmm.201505551; Veljkovic V, 2007, CURR MED CHEM, V14, P441, DOI 10.2174/092986707779941014; Vincenzi B, 2008, CRIT REV ONCOL HEMAT, V68, P93, DOI 10.1016/j.critrevonc.2008.07.006; Wong PP, 2015, CANCER CELL, V27, P123, DOI 10.1016/j.ccell.2014.10.015; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Zhou J, 2014, CELL SIGNAL, V26, P2896, DOI 10.1016/j.cellsig.2014.08.027	53	29	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3399	3414		10.1038/s41388-017-0107-x	http://dx.doi.org/10.1038/s41388-017-0107-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29483644	Green Published			2022-12-17	WOS:000436411300006
J	Dietrich, P; Kuphal, S; Spruss, T; Hellerbrand, C; Bosserhoff, AK				Dietrich, P.; Kuphal, S.; Spruss, T.; Hellerbrand, C.; Bosserhoff, A. K.			Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITION; MEK INHIBITION; METASTATIC MELANOMA; PATHWAY; EXPRESSION; RAF; TUMORIGENESIS; VEMURAFENIB; ACTIVATION; EVOLUTION	Malignant melanoma reveals rapidly increasing incidence and mortality rates worldwide. By now, BRAF inhibition is the standard therapy for advanced melanoma in patients carrying BRAF mutations. However, only approximately 50% of melanoma patients harbor therapeutically attackable BRAF mutations, and overall survival after treatment with BRAF inhibitors is modest. KRAS (Kirsten Rat sarcoma) proteins are acting upstream of BRAF and have a major role in human cancer. Recent approaches awaken the hope to use KRAS inhibition (KRASi) as a clinical tool. In this study, we identified wild-type KRAS as a novel therapeutic target in melanoma. KRASi functions synergistically with BRAF inhibition to reduce melanoma proliferation and to induce apoptosis independently of BRAF mutational status. Moreover, acquired resistance to BRAF inhibitors in melanoma is dependent on dynamic regulation of KRAS expression with subsequent AKT and extracellular-signal regulated kinase activation and can be overcome by KRASi. This suggests KRASi as novel approach in melanoma-alone or in combination with other therapeutic regimes.	[Dietrich, P.; Kuphal, S.; Hellerbrand, C.; Bosserhoff, A. K.] Friedrich Alexander Univ Erlangen Nuremberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany; [Spruss, T.] Univ Regensburg, Inst Pharm, Regensburg, Germany; [Hellerbrand, C.; Bosserhoff, A. K.] Comprehens Canc Ctr CCC Erlangen EMN, Erlangen, Germany	University of Erlangen Nuremberg; University of Regensburg; University of Erlangen Nuremberg	Bosserhoff, AK (corresponding author), Friedrich Alexander Univ Erlangen Nuremberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany.	anja.bosserhoff@fau.de	Bosserhoff, Anja/GNH-4801-2022; Kuphal, Silke/AAW-2702-2020	Bosserhoff, Anja/0000-0001-8147-394X	German Research Association (DFG) [RTG 1962/1]; German Cancer Aid (Deutsche Krebshilfe); Bavarian Research Network for Molecular Biosystems (BioSysNet); Interdisciplinary Center for Clinical Research (IZKF) Erlangen [J55, D24]	German Research Association (DFG)(German Research Foundation (DFG)); German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe); Bavarian Research Network for Molecular Biosystems (BioSysNet); Interdisciplinary Center for Clinical Research (IZKF) Erlangen	This work was supported by the German Research Association (DFG) (Research Training Group 'RTG 1962/1', University of Erlangen), the German Cancer Aid (Deutsche Krebshilfe), the Bavarian Research Network for Molecular Biosystems (BioSysNet) and the Interdisciplinary Center for Clinical Research (IZKF) Erlangen (J55, to PD and D24, to AB). We thank Meenhard Herlyn (The Wistar Institute, Philadelphia, USA) for providing the resistant cell lines. Furthermore, we thank Rudolf Jung, Annette Serwotka and Darleen Schonwalder for technical assistance.	[Anonymous], 2013, Cancer Discov, V3, pOF20, DOI 10.1158/2159-8290.CD-RW2013-116; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864; Carlino MS, 2015, J CLIN ONCOL, V33, pE52, DOI 10.1200/JCO.2013.51.5783; Chapuis AG, 2016, J EXP MED, V213, P1133, DOI 10.1084/jem.20152021; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Depasquale I, 2005, HISTOPATHOLOGY, V47, P186, DOI 10.1111/j.1365-2559.2005.02193.x; Dummer R, 2012, ANN ONCOL, V23, P86, DOI 10.1093/annonc/mds229; Fan XZ, 2014, J EXP MED, V211, P715, DOI 10.1084/jem.20130590; Gimotty PA, 2005, J CLIN ONCOL, V23, P8048, DOI 10.1200/JCO.2005.02.0735; Grabocka E, 2014, CANCER CELL, V25, P243, DOI 10.1016/j.ccr.2014.01.005; Gross A, 2015, TARGET ONCOL, V10, P77, DOI 10.1007/s11523-014-0318-9; Harries M, 2016, EUR J CANCER, V60, P179, DOI 10.1016/j.ejca.2016.01.011; Herrero A, 2015, CANCER CELL, V28, P170, DOI 10.1016/j.ccell.2015.07.001; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173; Johnson DB, 2015, JAMA ONCOL, V1, P380, DOI 10.1001/jamaoncol.2015.0565; Karimkhani C, 2014, AM J CLIN DERMATOL, V15, P323, DOI 10.1007/s40257-014-0083-7; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Ledford H, 2015, NATURE, V520, P278, DOI 10.1038/520278a; Leiter Ulrike, 2014, Adv Exp Med Biol, V810, P120; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Luke JJ, 2014, DRUG HEALTHC PATIENT, V6, P77, DOI 10.2147/DHPS.S39568; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Matin RN, 2013, J EXP MED, V210, P581, DOI 10.1084/jem.20121439; McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662; Milagre C, 2010, CANCER RES, V70, P5549, DOI 10.1158/0008-5472.CAN-09-4254; Milroy LG, 2014, ACS CHEM BIOL, V9, P2447, DOI 10.1021/cb500555h; Monsma DJ, 2015, AM J CANCER RES, V5, P1507; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Perna D, 2015, P NATL ACAD SCI USA, V112, pE536, DOI 10.1073/pnas.1418163112; Posch C, 2015, J INVEST DERMATOL, V135, P2475, DOI 10.1038/jid.2015.198; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Queirolo P, 2015, CANCER TREAT REV, V41, P519, DOI 10.1016/j.ctrv.2015.04.010; Richman J, 2015, EXPERT OPIN PHARMACO, V16, P1285, DOI 10.1517/14656566.2015.1044971; Ruiz C, 2015, PHYS BIOL, V12, DOI 10.1088/1478-3975/12/1/016008; Sale MJ, 2013, BRIT J PHARMACOL, V169, P1708, DOI 10.1111/bph.12220; Schmick M, 2014, CELL, V157, P459, DOI 10.1016/j.cell.2014.02.051; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Smyth T, 2014, MOL CANCER THER, V13, P2793, DOI 10.1158/1535-7163.MCT-14-0452; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sweetlove M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00135; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang JH, 2015, J INVEST DERMATOL, V135, P532, DOI 10.1038/jid.2014.418; Whittaker SR, 2015, MOL CANCER THER, V14, P2700, DOI 10.1158/1535-7163.MCT-15-0136-T; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wilson MA, 2016, CLIN CANCER RES, V22, P374, DOI 10.1158/1078-0432.CCR-15-1162; Xue W, 2014, P NATL ACAD SCI USA, V111, pE3553, DOI 10.1073/pnas.1412686111; Yang J, 2015, BIOCHEM BIOPH RES CO, V463, P900, DOI 10.1016/j.bbrc.2015.06.032; Yuan TL, 2014, CANCER DISCOV, V4, P1182, DOI 10.1158/2159-8290.CD-13-0900; Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205	55	29	30	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					897	911		10.1038/onc.2017.391	http://dx.doi.org/10.1038/onc.2017.391			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059159				2022-12-17	WOS:000425281800007
J	Chang, C; Liu, J; He, W; Qu, M; Huang, X; Deng, Y; Shen, L; Zhao, X; Guo, H; Jiang, J; Fu, XY; Huang, R; Zhang, D; Yan, J				Chang, C.; Liu, J.; He, W.; Qu, M.; Huang, X.; Deng, Y.; Shen, L.; Zhao, X.; Guo, H.; Jiang, J.; Fu, X. Y.; Huang, R.; Zhang, D.; Yan, J.			A regulatory circuit HP1 gamma/miR-451a/c-Myc promotes prostate cancer progression	ONCOGENE			English	Article							C-MYC ONCOGENE; CELL; HETEROCHROMATIN; HP1-GAMMA; OVEREXPRESSION; CARCINOMA; MICRORNAS; MIR-451A; COMPLEX; PROTEIN	Heterochromatin protein 1 gamma (HP1 gamma) has been implicated in carcinogenesis of various cancer types. However, the role of HP1 gamma in prostate cancer (PCa) progression and the underlying molecular mechanisms remain largely unknown. We found that HP1 gamma is upregulated in PCa and elevated levels of HP1 gamma in PCa predict poor outcome. In addition, depletion of HP1 gamma in PCa cells not only repressed proliferation and induced apoptosis but also impaired tumorigenicity. We also found that c-Myc was capable of upregulating HP1 gamma by directly binding to the E-box element in the first intron of HP1 gamma gene, and the upregulated HP1 gamma, in turn, repressed the expression of miR-451a by enhancing H3K9 methylation at the promoter region of miR-451a. Furthermore, reduction of miR-451a significantly reversed HP1 gamma loss-induced PCa cell apoptosis, whereas miR-451a overexpression repressed cell survival by targeting and downregulating c-Myc. The association among c-Myc, HP1 gamma and miR-451a was further confirmed in human clinical samples. Therefore, we propose that an HP1 gamma/miR-451a/c-Myc regulatory circuitry exists in PCa cells and this circuit has a crucial role in PCa progression.	[Chang, C.; Liu, J.; He, W.; Huang, X.; Shen, L.; Fu, X. Y.; Yan, J.] Nanjing Univ, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China; [Chang, C.; Liu, J.; He, W.; Huang, X.; Shen, L.; Fu, X. Y.; Yan, J.] Nanjing Univ, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing, Jiangsu, Peoples R China; [Chang, C.; Liu, J.; Huang, X.; Shen, L.; Yan, J.] Collaborat Innovat Ctr Genet & Dev, Shanghai, Peoples R China; [Qu, M.] Nanjing Univ, Jinling Coll, Sch Chem & Life Sci, Dept Biosci & Bioengn, Nanjing, Jiangsu, Peoples R China; [Deng, Y.; Zhao, X.; Guo, H.] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Urol, Med Sch,Inst Urol, Nanjing, Jiangsu, Peoples R China; [Jiang, J.] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Urol, Chongqing, Peoples R China; [Huang, R.] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China; [Zhang, D.] Philadelphia Coll Osteopath Med, Dept Biomed Sci, Philadelphia, PA USA; [Yan, J.] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China	Nanjing University; Nanjing University; Nanjing University; Nanjing University; Army Medical University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Yan, J (corresponding author), Nanjing Univ, Model Anim Res Ctr, 12 Xuefu Rd, Nanjing 210061, Jiangsu, Peoples R China.	yanjun@nju.edu.cn	Yan, Jun/Q-3031-2017	Yan, Jun/0000-0002-1303-1952	National Key Research and Development Plan of China [2016YFC0902202]; National Natural Science Foundation of China [81172009, 81672873, 81372168, 81172442]; Doctoral Fund of Ministry of Education of China [20110091120028]; Natural Science Foundation for Universities in Jiangsu Province, China [BK20151396]; Center for Chronic Disorders of Aging (CCDA) at Philadelphia College of Osteopathic Medicine; 'Personalized Medicines-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12020108]; One Hundred Talent Program of Chinese Academy of Sciences; Program sponsored for Scientific Innovation Research of College Graduate in Jiangsu province [KYZZ_ 0037]; Open Foundation of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University [KF-GN-201602]; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences [SIMM1705KF-02]	National Key Research and Development Plan of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctoral Fund of Ministry of Education of China(Ministry of Education, China); Natural Science Foundation for Universities in Jiangsu Province, China; Center for Chronic Disorders of Aging (CCDA) at Philadelphia College of Osteopathic Medicine; 'Personalized Medicines-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences; One Hundred Talent Program of Chinese Academy of Sciences(Chinese Academy of Sciences); Program sponsored for Scientific Innovation Research of College Graduate in Jiangsu province; Open Foundation of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences(Chinese Academy of Sciences)	This study was financially supported by the National Key Research and Development Plan of China (2016YFC0902202 to JY), the National Natural Science Foundation of China (81172009, 81672873 and 81372168 to JY, and 81172442 to JJ), Doctoral Fund of Ministry of Education of China (20110091120028 to JY), Natural Science Foundation for Universities in Jiangsu Province, China (BK20151396 to JY), the Center for Chronic Disorders of Aging (CCDA) at Philadelphia College of Osteopathic Medicine (to DZ), the 'Personalized Medicines-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences, Grant No. XDA12020108 (to RH), One Hundred Talent Program of Chinese Academy of Sciences (to RH), Program sponsored for Scientific Innovation Research of College Graduate in Jiangsu province (KYZZ_ 0037 to CC), the Open Foundation of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University (KF-GN-201602) and the State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM1705KF-02). We also thank Jun Qin and Min Jiang for their help in data retrieval from TCGA database.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Babapoor S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107502; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952; Bertoli G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030421; Bian HB, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-20; Black JC, 2010, MOL CELL, V40, P736, DOI 10.1016/j.molcel.2010.11.008; Borsos BN, 2017, SCI REP-UK, V7, DOI 10.1038/srep40960; Canzio D, 2014, TRENDS CELL BIOL, V24, P377, DOI 10.1016/j.tcb.2014.01.002; Chen DQ, 2014, EUR J CANCER, V50, P3050, DOI 10.1016/j.ejca.2014.09.008; Choi JD, 2012, NUCLEIC ACIDS RES, V40, P11321, DOI 10.1093/nar/gks947; Follis AV, 2008, CHEM BIOL, V15, P1149, DOI 10.1016/j.chembiol.2008.09.011; Fukumoto I, 2014, BRIT J CANCER, V111, P386, DOI 10.1038/bjc.2014.293; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Guan XW, 2016, BIOORG MED CHEM LETT, V26, P1561, DOI 10.1016/j.bmcl.2016.02.013; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hawksworth D, 2010, PROSTATE CANCER P D, V13, P311, DOI 10.1038/pcan.2010.31; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Itsumi M, 2013, J MOL ENDOCRINOL, V50, P401, DOI 10.1530/JME-13-0024; Jackstadt R, 2015, BBA-GENE REGUL MECH, V1849, P544, DOI 10.1016/j.bbagrm.2014.04.003; Jenkins RB, 1997, CANCER RES, V57, P524; Kang H, 2016, METHODS MOL BIOL, V1344, P313, DOI 10.1007/978-1-4939-2966-5_20; Khanmi K, 2015, CLIN CHIM ACTA, V451, P154, DOI 10.1016/j.cca.2015.09.022; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Laitinen VH, 2015, INT J CANCER, V136, P2316, DOI 10.1002/ijc.29276; Lee Young-Ho, 2015, J Nat Sci, V1, pe127; Li XY, 2011, J EXP MED, V208, P663, DOI 10.1084/jem.20102384; Liu M, 2015, CANCER RES, V75, P4593, DOI 10.1158/0008-5472.CAN-14-3735; Liu ZR, 2016, LIFE SCI, V149, P104, DOI 10.1016/j.lfs.2016.02.059; Liu ZR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/207684; Lu SZ, 2015, J BIOL CHEM, V290, P24178, DOI 10.1074/jbc.M115.648212; Luoto KR, 2010, CANCER RES, V70, P8748, DOI 10.1158/0008-5472.CAN-10-0944; Minna E, 2016, ONCOTARGET, V7, P12731, DOI 10.18632/oncotarget.7262; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Pazin MJ, 2010, PLOS ONE, V5; Pierorazio PM, 2012, BJU INT, V109, P988, DOI 10.1111/j.1464-410X.2011.10514.x; Rastogi S, 2006, MOL CELL BIOL, V26, P4161, DOI 10.1128/MCB.02142-05; Riquelme I, 2016, CELL ONCOL, V39, P23, DOI 10.1007/s13402-015-0247-3; Rizzardi AE, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-42; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shapiro E, 2008, J UROLOGY, V179, P2435, DOI 10.1016/j.juro.2008.01.091; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Shiota M, 2010, ENDOCR-RELAT CANCER, V17, P455, DOI 10.1677/ERC-09-0321; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Slezak J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-148; Supino R, 2007, ANN NY ACAD SCI, V1095, P175, DOI 10.1196/annals.1397.021; Takanashi M, 2009, AM J PATHOL, V174, P309, DOI 10.2353/ajpath.2009.080148; Tao JC, 2014, CELL CYCLE, V13, P191, DOI 10.4161/cc.27646; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tsai LH, 2015, ONCOGENE, V34, P1641, DOI 10.1038/onc.2014.118; Vad-Nielsen J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2059-x; Vicent GP, 2013, GENE DEV, V27, P1179, DOI 10.1101/gad.215293.113; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Yamamoto S, 2010, GENE CHROMOSOME CANC, V49, P487, DOI 10.1002/gcc.20759; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003; Zhou J, 2014, TUMOR BIOL, V35, P9777, DOI 10.1007/s13277-014-2182-8	61	29	30	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					415	426		10.1038/onc.2017.332	http://dx.doi.org/10.1038/onc.2017.332			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967902				2022-12-17	WOS:000423331600001
J	Lambrecht, C; Libbrecht, L; Sagaert, X; Pauwels, P; Hoorne, Y; Crowther, J; Louis, JV; Sents, W; Sablina, A; Janssens, V				Lambrecht, C.; Libbrecht, L.; Sagaert, X.; Pauwels, P.; Hoorne, Y.; Crowther, J.; Louis, J., V; Sents, W.; Sablina, A.; Janssens, V			Loss of protein phosphatase 2A regulatory subunit B56 delta promotes spontaneous tumorigenesis in vivo	ONCOGENE			English	Article							HUMAN CELL-TRANSFORMATION; LI-FRAUMENI-SYNDROME; C-MYC; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; PP2A COMPLEXES; RNA-SEQ; CANCER; MICE; GENE	Protein Phosphatase 2A (PP2A) enzymes counteract diverse kinase-driven oncogenic pathways and their function is frequently impaired in cancer. PP2A inhibition is indispensable for full transformation of human cells, but whether loss of PP2A is sufficient for tumorigenesis in vivo has remained elusive. Here, we describe spontaneous tumor development in knockout mice for Ppp2r5d, encoding the PP2A regulatory B56 delta subunit. Several primary tumors were observed, most commonly, hematologic malignancies and hepatocellular carcinomas (HCCs). Targeted immunoblot and immunohistochemistry analysis of the HCCs revealed heterogeneous activation of diverse oncogenic pathways known to be suppressed by PP2A-B56. RNA sequencing analysis unveiled, however, a common role for oncogenic c-Myc activation in the HCCs, independently underscored by c-Myc Ser62 hyperphosphorylation. Upstream of c-Myc, GSK-3 beta Ser9 hyperphosphorylation occurred both in the HCCs and non-cancerous B56 delta-null livers. Thus, uncontrolled c-Myc activity due to B56 delta-driven GSK-3 beta inactivation is the likely tumor predisposing factor. Our data provide the first compelling mouse genetics evidence sustaining the tumor suppressive activity of a single PP2A holoenzyme, constituting the final missing incentive for full clinical development of PP2A as cancer biomarker and therapy target.	[Lambrecht, C.; Hoorne, Y.; Louis, J., V; Sents, W.; Janssens, V] Katholieke Univ Leuven, Lab Prot Phosphorylat & Prote, Dept Cellular & Mol Med, Leuven, Belgium; [Libbrecht, L.] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium; [Sagaert, X.] Katholieke Univ Leuven, Translat Cell & Tissue Res, Dept Imaging & Pathol, Leuven, Belgium; [Pauwels, P.] Univ Hosp Antwerp, Dept Pathol, Antwerp, Belgium; [Crowther, J.; Sablina, A.] Katholieke Univ Leuven, Dept Human Genet, VIB Ctr Biol Dis, Leuven, Belgium; [Sablina, A.; Janssens, V] Leuven Canc Inst, LKI, Leuven, Belgium	KU Leuven; Ghent University; Ghent University Hospital; KU Leuven; University of Antwerp; Flanders Institute for Biotechnology (VIB); KU Leuven	Janssens, V (corresponding author), Univ Leuven, Dept Cellular & Mol Med, Lab Prot Phosphorylat & Prote, KU Leuven, Herestr 49,POB 901,Gasthuisberg O&N1, B-3000 Leuven, Belgium.	veerle.janssens@kuleuven.be	Janssens, Veerle/I-7059-2016; Sablina, Anna/B-2217-2017; Sablina, Anna/P-2818-2019	Janssens, Veerle/0000-0002-6772-8448; Sablina, Anna/0000-0001-9526-4014; Sablina, Anna/0000-0001-9526-4014	KU Leuven Research Fund [GOA/08/016, OT/13/094]; Research Foundation-Flanders [G.0582.11, G.0B01.16N]; Belgian IAP program [P7/13]; Flemish Agency for Innovation by Science and Technology; Flemish Cancer League (Emmanuel van der Schueren fellowship)	KU Leuven Research Fund(KU Leuven); Research Foundation-Flanders(FWO); Belgian IAP program; Flemish Agency for Innovation by Science and Technology; Flemish Cancer League (Emmanuel van der Schueren fellowship)	We thank Y El-Aalamat (KU Leuven, ESAT) for help with statistical analysis, and P Vermaelen (KU Leuven, MOSAIC) for PET-scan analysis. Funding was provided by KU Leuven Research Fund (GOA/08/016 to VJ; OT/13/094 to VJ and AS), Research Foundation-Flanders (G.0582.11 to VJ; G.0B01.16N to VJ), Belgian IAP program (P7/13 to VJ), Flemish Agency for Innovation by Science and Technology (to CL) and the Flemish Cancer League (Emmanuel van der Schueren fellowship to WS).	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arriazu E, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00078; Bluemn EG, 2013, MOL CANCER RES, V11, P568, DOI 10.1158/1541-7786.MCR-12-0710; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Chen LP, 2011, ONCOGENE, V30, P2943, DOI 10.1038/onc.2011.20; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Cheng YS, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005561; Cheng Y, 2011, CANCER GENET-NY, V204, P375, DOI 10.1016/j.cancergen.2011.05.002; Cristobal I, 2013, HAEMATOLOGICA, V98, pE103, DOI [10.3324/haematol.2043.084731, 10.3324/haematol.2013.084731]; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Haesen D, 2016, CANCER RES, V76, P5719, DOI 10.1158/0008-5472.CAN-15-3342; Hahn K, 2010, CELL METAB, V11, P438, DOI 10.1016/j.cmet.2010.03.015; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; He H, 2012, DIAGN MOL PATHOL, V21, P143, DOI 10.1097/PDM.0b013e318249fd8b; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HU NP, 1994, ONCOGENE, V9, P1021; Hung MH, 2016, ONCOGENE, V35, P4891, DOI 10.1038/onc.2016.21; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Jackson JB, 2012, NEOPLASIA, V14, P585, DOI 10.1593/neo.12768; Janghorban M, 2014, P NATL ACAD SCI USA, V111, P9157, DOI 10.1073/pnas.1317630111; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Khanna A, 2013, CANCER RES, V73, P6548, DOI 10.1158/0008-5472.CAN-13-1994; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; Lai TY, 2016, ONCOTARGET, V7, P4542, DOI 10.18632/oncotarget.6609; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Liu Lingfeng, 2012, Genes Cancer, V3, P23, DOI 10.1177/1947601912448067; Louis JV, 2011, P NATL ACAD SCI USA, V108, P6957, DOI 10.1073/pnas.1018777108; Low ICC, 2014, BLOOD, V124, P2223, DOI 10.1182/blood-2014-03-563296; Martens E, 2004, J MOL BIOL, V336, P971, DOI 10.1016/j.jmb.2003.12.047; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Miller JP, 2012, J BIOL CHEM, V287, P19775, DOI 10.1074/jbc.M112.361972; Nobumori Y, 2013, MOL CANCER RES, V11, P995, DOI 10.1158/1541-7786.MCR-12-0633; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2; Pinyol R, 2014, SEMIN LIVER DIS, V34, P363, DOI 10.1055/s-0034-1394137; Puustinen P, 2009, CANCER RES, V69, P2870, DOI 10.1158/0008-5472.CAN-08-2760; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ruediger R, 2011, MOL CELL BIOL, V31, P3832, DOI 10.1128/MCB.05744-11; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sangodkar J, 2016, FEBS J, V283, P1004, DOI 10.1111/febs.13573; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sents W, PP2A INACTIVATION TR; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shih IM, 2011, J PATHOL, V224, P1, DOI 10.1002/path.2884; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; Singal AG, 2015, CLIN GASTROENTEROL H, V13, P2140, DOI 10.1016/j.cgh.2015.08.014; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Varadkar P, 2014, DEV DYNAM, V243, P778, DOI 10.1002/dvdy.24111; Wandzioch E, 2014, CANCER RES, V74, P4295, DOI 10.1158/0008-5472.CAN-13-3130; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Ward JM, 2006, EXP TOXICOL PATHOL, V57, P377, DOI 10.1016/j.etp.2006.01.007; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	64	29	30	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					544	552		10.1038/onc.2017.350	http://dx.doi.org/10.1038/onc.2017.350			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967903				2022-12-17	WOS:000423331600012
J	Liu, L; Luo, C; Luo, Y; Chen, L; Liu, Y; Wang, Y; Han, J; Zhang, Y; Wei, N; Xie, Z; Wu, W; Wu, G; Feng, Y				Liu, L.; Luo, C.; Luo, Y.; Chen, L.; Liu, Y.; Wang, Y.; Han, J.; Zhang, Y.; Wei, N.; Xie, Z.; Wu, W.; Wu, G.; Feng, Y.			MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression	ONCOGENE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-K; MT-CYB; REVEALS; EVENTS; GENES; MECHANISMS; FAILURE; ROLES	MRPL33 gene encodes a large mitoribosomal subunit protein, which may be involved in mitochondrial translation. Although two splice variants of MRPL33 have been described, its splicing regulation remains elusive. Here we observed that inclusion of alternative exon 3 was greatly promoted in a panel of human cancer cells. Depletion of the exon 3-containing long isoform of MRPL33 (MRPL33-L) led to impaired proliferation and increased apoptosis in cancer cell lines and in a xenograft model. MRPL33-L knockdown could also induce mitochondrial dysfunction including increased accumulation of reactive oxygen species, decreased ATP production and 16 S rRNA levels. We further showed that alternative splicing of MRPL33-L pre-mRNA is regulated by hnRNPK and that knocking down hnRNPK could phenocopy MRPL33-L depletion. More importantly, overexpression of MRPL33-L could increase tumorigenic potential of hnRNPK-depleted cancer cells, likely indicating that hnRNPK mediates tumorigenesis through splicing regulation of MRPL33 pre-mRNA. Finally, we found that inclusion of MRPL33 exon 3 was promoted in human colorectal cancer tissues and this was correlated with hnRNPK levels. In summary, our findings underscore the biological significance of MRPL33-L and hnRNPK in the tumor formation and identifies hnRNPK as a critical splicing regulator of MRPL33 pre-mRNA in cancer cells.	[Liu, L.; Luo, C.; Luo, Y.; Chen, L.; Liu, Y.; Wang, Y.; Zhang, Y.; Wei, N.; Xie, Z.; Feng, Y.] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Food Safety Res,Inst Nutr Sci, Shanghai, Peoples R China; [Han, J.; Wu, G.] Fudan Univ, Zhongshan Hosp, Sch Med, Dept Surg, Shanghai, Peoples R China; [Wu, W.] Zhejiang Agr & Forestry Univ, Nurturing Stn, State Key Lab Subtrop Silviculture, Linan, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Fudan University; Zhejiang A&F University	Wu, G (corresponding author), Fudan Univ, Zhongshan Hosp, Sch Med, Dept Surg, Shanghai, Peoples R China.; Feng, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Food Safety Res, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	wu.guohao@zs-hospital.sh.cn; fengying@sibs.ac.cn		Wu, Guohao/0000-0001-9490-4200; Liu, Yuguo/0000-0002-1421-3854	National Natural Science Foundation [31570818, 31370786, 31601170, 31400677, 81372197]; 'Personalized Medicine-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12010100]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); 'Personalized Medicine-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences	This work was supported by grants from the National Natural Science Foundation 31570818 to Y Feng and 31370786 to Y Feng and 31601170 to N Wei and 31400677 to W Wu and 81372197 to G Wu and also from the 'Personalized Medicine-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12010100).	Barboro P, 2014, CANCER LETT, V352, P152, DOI 10.1016/j.canlet.2014.06.019; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349; Carpenter B, 2006, BBA-REV CANCER, V1765, P85, DOI 10.1016/j.bbcan.2005.10.002; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Cheng YM, 2016, MOL CELL BIOL, V36, P1628, DOI 10.1128/MCB.01071-15; Danan-Gotthold M, 2015, NUCLEIC ACIDS RES, V43, P5130, DOI 10.1093/nar/gkv210; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; El-Hattab AW, 2016, CELL CALCIUM, V60, P199, DOI 10.1016/j.ceca.2016.03.003; Gopisetty G, 2016, GENE, V589, P27, DOI 10.1016/j.gene.2016.05.008; Guha S, 2006, ANIM GENET, V37, P262, DOI 10.1111/j.1365-2052.2006.01421.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Llorian M, 2010, NAT STRUCT MOL BIOL, V17, P1114, DOI 10.1038/nsmb.1881; Menezes MJ, 2015, HUM MOL GENET, V24, P2297, DOI 10.1093/hmg/ddu747; Nazim M, 2017, NUCLEIC ACIDS RES, V45, P1455, DOI 10.1093/nar/gkw823; Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035; Pandit S, 2013, MOL CELL, V50, P223, DOI 10.1016/j.molcel.2013.03.001; Sebestyen E, 2015, NUCLEIC ACIDS RES, V43, P1345, DOI 10.1093/nar/gku1392; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Wallace L, 2016, TUMOR BIOL, V37, P12465, DOI 10.1007/s13277-016-5101-3; Wei N, 2015, CELL REP, V13, P1647, DOI 10.1016/j.celrep.2015.10.038; Xiao R, 2012, MOL CELL, V45, P656, DOI 10.1016/j.molcel.2012.01.009; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581; Zhou XX, 2014, NUCLEIC ACIDS RES, V42, P4019, DOI 10.1093/nar/gkt1387	25	29	31	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					86	94		10.1038/onc.2017.314	http://dx.doi.org/10.1038/onc.2017.314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869607				2022-12-17	WOS:000422625000009
J	Lee, JH; Han, YS; Yoon, YM; Yun, CW; Yun, SP; Kim, SM; Kwon, HY; Jeong, D; Baek, MJ; Lee, HJ; Lee, SJ; Han, HJ; Lee, SH				Lee, J. H.; Han, Y-S; Yoon, Y. M.; Yun, C. W.; Yun, S. P.; Kim, S. M.; Kwon, H. Y.; Jeong, D.; Baek, M. J.; Lee, H. J.; Lee, S-J; Han, H. J.; Lee, S. H.			Role of HSPA1L as a cellular prion protein stabilizer in tumor progression via HIF-1 alpha/GP78 axis	ONCOGENE			English	Article							PROMOTES SARCOMA METASTASIS; COLORECTAL-CANCER CELLS; HEAT-SHOCK PROTEINS; STEM-CELLS; NEUROBLASTOMA-CELLS; DEGRADATION; HYPOXIA; ACTIVATION; EXPRESSION; UBIQUITIN	The cellular prion protein (PrPC) is associated with metastasis, tumor progression and recurrence; however, the precise mechanisms underlying its action is not well understood. Our study found that PrPC degradation decreased tumor progression in colorectal cancer (CRC). In a CRC cell line and human CRC tissue exposed to hypoxia, induced heat-shock 70-kDa protein-1-like (HSPA1L) expression stabilized hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein and promoted PrPC accumulation and tumorigenicity in vivo. PrPC was degraded via the proteasome pathway mediated by the ubiquitin-protein E3 ligase glycoprotein 78 (GP78), which interacts directly with PrPC. However, hypoxia-induced HSPA1L interacted with GP78 and inhibited its functions. HSPA1L knockdown facilitated the interaction of GP78 and PrPC, thereby increasing PrPC ubiquitination. Thus, GP78 was identified as the ubiquitinase for PrPC, thereby revealing an essential mechanism that controls PrPC levels in CRC. Our results suggest that the HSPA1L/HIF-1 alpha/GP78 axis has a crucial role in PrPC accumulation during tumor progression.	[Lee, J. H.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham Sch Med, Birmingham, AL USA; [Han, Y-S; Yoon, Y. M.; Yun, C. W.; Lee, S. H.] Soonchunhyang Univ, Seoul Hosp, Med Sci Res Inst, Seoul, South Korea; [Han, Y-S; Yoon, Y. M.; Yun, C. W.; Lee, S. H.] Soonchunhyang Univ, Coll Med, Dept Biochem, Cheonan, South Korea; [Yun, S. P.; Kim, S. M.] Johns Hopkins Univ, Sch Med, Neuroregenerat & Stem Cell Programs, Inst Cell Engn,Dept Neurol, Baltimore, MD USA; [Kwon, H. Y.] Soonchunhyang Univ, Soonchunhyang Inst Medibio Sci, Cheonan, South Korea; [Jeong, D.] Soonchunhyang Univ, Coll Med, Dept Pathol, Cheonan, South Korea; [Baek, M. J.] Soonchunhyang Univ, Coll Med, Dept Surg, Cheonan, South Korea; [Lee, H. J.; Lee, S-J; Han, H. J.] Seoul Natl Univ, Coll Vet Med, Dept Vet Physiol, Seoul 151741, South Korea; [Lee, H. J.; Lee, S-J; Han, H. J.] Seoul Natl Univ, Res Inst Vet Sci, Seoul 151741, South Korea; [Lee, H. J.; Lee, S-J; Han, H. J.] Seoul Natl Univ, PLUS Creat Vet Res Ctr BK21, Seoul, South Korea	University of Alabama System; University of Alabama Birmingham; Soonchunhyang University; Soonchunhyang University; Johns Hopkins University; Soonchunhyang University; Soonchunhyang University; Soonchunhyang University; Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Han, HJ (corresponding author), Seoul Natl Univ, Coll Vet Med, Dept Vet Physiol, Seoul 151741, South Korea.; Han, HJ (corresponding author), Seoul Natl Univ, Res Inst Vet Sci, Seoul 151741, South Korea.; Lee, SH (corresponding author), Soonchunhyang Univ, Seoul Hosp, Soonchunhyang Med Sci Res Inst, Dept Biochem, 59 Daesagwan Ro,657 Hannam Dong, Seoul 140887, South Korea.	hjhan@snu.ac.kr; ykckss1114@nate.com	lee, sang hun/Q-4650-2019; Baek, Moo-Jun/W-1736-2019; Lee, Sei-Jung/V-8772-2019; Han, Ho Jae/M-1476-2016	lee, sang hun/0000-0002-9005-5966; Baek, Moo-Jun/0000-0003-3567-6687; Han, Ho Jae/0000-0002-0657-1766	Soonchunhyang University Research Fund; National Research Foundation - Korean government [NRF-2011-0009610]; NRF - Ministry of Education [2016R1D1A3B01007727, 2017M3A9B4032528]; Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI14C2253]; Next-Generation Bio-Green 21 Program, Rural Development Administration, Republic of Korea [PJ011141]	Soonchunhyang University Research Fund; National Research Foundation - Korean government(Korean Government); NRF - Ministry of Education; Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea; Next-Generation Bio-Green 21 Program, Rural Development Administration, Republic of Korea	This work was supported by the Soonchunhyang University Research Fund; a National Research Foundation grant funded by the Korean government (NRF-2011-0009610); NRF funded by the Ministry of Education (2016R1D1A3B01007727, 2017M3A9B4032528); a grant from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI14C2253); and a grant from the Next-Generation Bio-Green 21 Program (No. PJ011141), Rural Development Administration, Republic of Korea. The funders had no role in the study design, data collection or analysis, decision to publish or preparation of the manuscript.	Amelio I, 2015, P NATL ACAD SCI USA, V112, P226, DOI 10.1073/pnas.1410609111; Atarod S, 2015, TRANSPL IMMUNOL, V32, P188, DOI 10.1016/j.trim.2015.02.002; Azad AA, 2015, NAT REV UROL, V12, P26, DOI 10.1038/nrurol.2014.320; Bartolini A, 2016, CLIN CANCER RES, V22, P4923, DOI 10.1158/1078-0432.CCR-15-2664; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Chang E, 2015, CLIN CANCER RES, V21, P335, DOI 10.1158/1078-0432.CCR-14-0217; Chang YW, 2016, ONCOGENE, V35, P1517, DOI 10.1038/onc.2015.214; Cheng YY, 2014, MOL CARCINOGEN, V53, P686, DOI 10.1002/mc.22021; Chiche L, 2016, NEW ENGL J MED, V374, P2183, DOI 10.1056/NEJMc1602584; Chieng CKL, 2015, TUMOR BIOL, V36, P8107, DOI 10.1007/s13277-015-3530-z; Corsaro A, 2016, ONCOTARGET, V7, P38638, DOI 10.18632/oncotarget.9575; de Wit M, 2012, GUT, V61, P855, DOI 10.1136/gutjnl-2011-300511; Du L, 2013, CANCER RES, V73, P2682, DOI 10.1158/0008-5472.CAN-12-3759; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Gabai VL, 2012, MOL CELL BIOL, V32, P929, DOI 10.1128/MCB.05921-11; Grillari J, 2010, ADV EXP MED BIOL, V694, P172; Hu Y, 2015, CELL BIOCHEM BIOPHYS, V72, P131, DOI 10.1007/s12013-014-0420-8; Jain AK, 2010, CANCER BIOL THER, V10, P665, DOI 10.4161/cbt.10.7.13445; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jones MF, 2015, P NATL ACAD SCI USA, V112, pE1550, DOI 10.1073/pnas.1503370112; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Ledford H, 2011, NATURE, V472, P273, DOI 10.1038/472273a; Lee SH, 2012, J CELL PHYSIOL, V227, P1731, DOI 10.1002/jcp.22897; Li N, 2015, GENE DEV, V29, P157, DOI 10.1101/gad.251785.114; Li NN, 2015, ONCOTARGET, V6, P9240, DOI 10.18632/oncotarget.3284; Li QQ, 2011, CANCER SCI, V102, P400, DOI 10.1111/j.1349-7006.2010.01811.x; Lianos GD, 2015, CANCER LETT, V360, P114, DOI 10.1016/j.canlet.2015.02.026; Liu X, 2016, INT J MOL MED, V37, P825, DOI 10.3892/ijmm.2016.2482; Lopes MH, 2015, ONCOGENE, V34, P3305, DOI 10.1038/onc.2014.261; Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Mirzaei MR, 2016, CELL J, V17, P608; Mo JH, 2012, CANCER SCI, V103, P464, DOI 10.1111/j.1349-7006.2011.02181.x; Mohammadi A, 2016, INFLAMMATION, V39, P1116, DOI 10.1007/s10753-016-0343-1; Nagaraju GP, 2015, MOL CARCINOGEN, V54, P1147, DOI 10.1002/mc.22185; Natalwala A, 2008, WORLD J GASTROENTERO, V14, P3792, DOI 10.3748/wjg.14.3792; Park JY, 2015, ONCOTARGET, V6, P5342, DOI 10.18632/oncotarget.3028; Peer CJ, 2011, CANCER BIOL THER, V11, P549, DOI 10.4161/cbt.11.6.14834; Powles T, 2016, J CLIN ONCOL, V34, P1660, DOI 10.1200/JCO.2015.64.8808; Pratt WB, 2010, EXP BIOL MED, V235, P278, DOI 10.1258/ebm.2009.009250; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Shao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092290; Sherman MY, 2015, ONCOGENE, V34, P4153, DOI 10.1038/onc.2014.349; Srivastava S, 2016, GENE, V585, P154, DOI 10.1016/j.gene.2016.03.031; Tsai YC, 2007, NAT MED, V13, P1504, DOI 10.1038/nm1686; Vilches S, 2016, MOL NEUROBIOL, V53, P4438, DOI 10.1007/s12035-015-9360-6; Wang QW, 2012, ONCOL REP, V28, P2029, DOI 10.3892/or.2012.2025; Ward HA, 2016, BRIT J NUTR, V116, P316, DOI 10.1017/S0007114516001859; Watanabe T, 2012, NEUROSCI LETT, V531, P114, DOI 10.1016/j.neulet.2012.10.032; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Welch HG, 2016, NEW ENGL J MED, V374, P1605, DOI 10.1056/NEJMp1600448; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Young GP, 2005, MOL NUTR FOOD RES, V49, P571, DOI 10.1002/mnfr.200500026; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang TP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118448; Zomosa-Signoret V, 2008, VET RES, V39, DOI 10.1051/vetres:2007048	59	29	29	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6555	6567		10.1038/onc.2017.263	http://dx.doi.org/10.1038/onc.2017.263			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28759037				2022-12-17	WOS:000416049200005
J	Ko, CJ; Lan, SW; Lu, YC; Cheng, TS; Lai, PF; Tsai, CH; Hsu, TW; Lin, HY; Shyu, HY; Wu, SR; Lin, HH; Hsiao, PW; Chen, CH; Huang, HP; Lee, MS				Ko, C-J; Lan, S-W; Lu, Y-C; Cheng, T-S; Lai, P-F; Tsai, C-H; Hsu, T-W; Lin, H-Y; Shyu, H-Y; Wu, S-R; Lin, H-H; Hsiao, P-W; Chen, C-H; Huang, H-P; Lee, M-S			Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN E-2; MATRIX DEGRADATION; COX-2 INHIBITORS; DOWN-REGULATION; TUMOR-GROWTH; EXPRESSION; CELECOXIB; INFLAMMATION	Chronic inflammation plays an important role in cancer development and progression. Cyclooxygenases-2 ( COX-2) is a key enzyme in generating prostaglandins causing inflammation, is often found to be overexpressed in prostate cancer (PCa) and is correlated with PCa cell invasion and metastasis. We aim to investigate the molecular mechanism of how COX-2 promotes PCa cell invasion and metastasis and to evaluate the effect of COX-2 inhibitors in a selected model of PCa progression. Our results showed that the expression of COX-2 and Interleukin 1 beta(IL-1 beta) was upregulated in highly invasive PCa cells and was correlated with the activated levels of membrane-anchored serine protease matriptase. The expression levels of COX-2 were increased and were correlated with matriptase levels in PCa specimens. Moreover, results showed that COX-2 overexpression or a COX-2 product Prostaglandin E2 (PGE2) caused an increase in matriptase activation and PCa cell invasion, whereas COX-2 silencing antagonized matriptase activation and cell invasion. In addition, the inhibition of COX-2-mediated matriptase activation by Celebrex and sulindac sulfide suppressed the androgen-independent and COX2-overexpressing PCa PC-3 cell invasion, tumor growth and lung metastasis in an orthotopic xenograft model. Our results indicate that COX-2/matriptase signaling contributes to the invasion, tumor growth and metastasis of COX-2-overexpressing and androgen-independent PCa cells.	[Ko, C-J; Lan, S-W; Lu, Y-C; Cheng, T-S; Lai, P-F; Hsu, T-W; Lin, H-Y; Wu, S-R; Lin, H-H; Lee, M-S] Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, R817,8F,1,Sect 1,Jen Ai Rd, Taipei 100, Taiwan; [Tsai, C-H; Hsiao, P-W] Acad Sinica, Agr Biotechnol Res Ctr, Taipei, Taiwan; [Shyu, H-Y] Minist Justice, Bureau Invest, Taipei, Taiwan; [Chen, C-H] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan; [Huang, H-P] Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Lee, MS (corresponding author), Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, R817,8F,1,Sect 1,Jen Ai Rd, Taipei 100, Taiwan.; Huang, HP (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei, Taiwan.	hh691290@gmail.com; mslee2006@ntu.edu.tw	Ko, Chun-Jung/AAA-6187-2022	Ko, Chun-Jung/0000-0001-6565-7060; CHEN, CHUNG-HSIN/0000-0002-4921-5315; LEE, MING-SHYUE/0000-0002-8673-5088; HUANG, HSIANG-PO/0000-0002-3382-305X	Taiwan National Science Council [NSC 100-2628-B-002-004-MY4]; Ministry of Science and Technology [MOST 103-2321-B-002-096, MOST 104-2320-B-002-044-MY3]; National Health Research Institutes [NHRI-EX102-9909BC, NHRI-EX106-10401BI]; National Taiwan University [NTU-CESRP-104R7602C4, NTU105R89612]; National Taiwan University Hospital [NTUH106-S3387]	Taiwan National Science Council(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Health Research Institutes(National Health Research Institutes, Japan); National Taiwan University(National Taiwan University); National Taiwan University Hospital(National Taiwan University)	This study was supported by Taiwan National Science Council Grant NSC 100-2628-B-002-004-MY4, Ministry of Science and Technology Grants MOST 103-2321-B-002-096 and MOST 104-2320-B-002-044-MY3, National Health Research Institutes Grants NHRI-EX102-9909BC and NHRI-EX106-10401BI, and National Taiwan University Grants NTU-CESRP-104R7602C4 and NTU105R89612 to M.S. Lee, and National Taiwan University Hospital Grant NTUH106-S3387 to C.H. Chen and H.P. Huang. We thank Dr Ming-Fong Lin at the Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center for LNCaP cells, and Dr Chen-Yong Lin at the Georgetown University for his gifts of antibodies.	Abedinpour P, 2011, PROSTATE, V71, P813, DOI 10.1002/pros.21297; Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; [Anonymous], 2016, Clin Adv Hematol Oncol, V14, P11; Ansari KM, 2008, MOL CANCER RES, V6, P1003, DOI 10.1158/1541-7786.MCR-07-2144; Armstrong AJ, 2012, LANCET ONCOL, V13, P443, DOI 10.1016/S1470-2045(12)70111-0; Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Bieniek J, 2014, PROSTATE, V74, P999, DOI 10.1002/pros.22815; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Cai Y, 2008, INT J CANCER, V123, P195, DOI 10.1002/ijc.23481; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; Chen CJ, 2011, AM J PHYSIOL-CELL PH, V300, pC406, DOI 10.1152/ajpcell.00403.2010; Cheng TS, 2013, CANCER PREV RES, V6, P495, DOI 10.1158/1940-6207.CAPR-12-0293-T; Cheung AS, 2012, ASIAN J ANDROL, V14, P518, DOI 10.1038/aja.2012.51; Chu TH, 2014, ONCOTARGET, V5, P1475, DOI 10.18632/oncotarget.1745; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Di Lorenzo G, 2005, PROSTATE CANCER P D, V8, P54, DOI 10.1038/sj.pcan.4500768; Galkin AV, 2004, PROSTATE, V61, P228, DOI 10.1002/pros.20094; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; James ND, 2012, LANCET ONCOL, V13, P549, DOI 10.1016/S1470-2045(12)70088-8; Jeong Y, 2017, ASIA-PAC J CLIN ONCO, V13, P204, DOI 10.1111/ajco.12583; Kattan J, 2016, INVEST NEW DRUG, V34, P474, DOI 10.1007/s10637-016-0357-4; Kim SH, 2017, ASIAN J ANDROL, V19, P458, DOI 10.4103/1008-682X.180798; Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9; Kiyomiya KI, 2006, AM J PHYSIOL-CELL PH, V291, pC40, DOI 10.1152/ajpcell.00351.2005; Ko CJ, 2015, CANCER RES, V75, P2949, DOI 10.1158/0008-5472.CAN-14-3297; Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396; Lam ET, 2012, NAT REV UROL, V9, P358, DOI [10.1038/nrurol.2012.112, 10.1038/nruro1.2012.112]; Lee LM, 2001, ANTICANCER RES, V21, P1291; Lee MS, 2005, AM J PHYSIOL-CELL PH, V288, pC932, DOI 10.1152/ajpcell.00497.2004; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Li S, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-11; Li Z, 2013, ONCOGENE, V32, P1408, DOI 10.1038/onc.2012.161; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Milner JM, 2010, ARTHRITIS RHEUM-US, V62, P1955, DOI 10.1002/art.27476; Nelson William G, 2004, J Urol, V172, pS6, DOI 10.1097/01.ju.0000142058.99614.ff; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886; Ruan D, 2014, LIFE SCI, V116, P43, DOI 10.1016/j.lfs.2014.07.042; Ruder EH, 2011, AM J GASTROENTEROL, V106, P1340, DOI 10.1038/ajg.2011.38; Rundhaug JE, 2011, CANCER METAST REV, V30, P465, DOI 10.1007/s10555-011-9317-9; Saleem M, 2006, CANCER EPIDEM BIOMAR, V15, P217, DOI 10.1158/1055-9965.EPI-05-0737; SHI YE, 1993, CANCER RES, V53, P1409; Suzuki M, 2004, J BIOL CHEM, V279, P14899, DOI 10.1074/jbc.M313130200; Tsai CH, 2014, ONCOGENE, V33, P4643, DOI 10.1038/onc.2013.412; Uhland K, 2006, CELL MOL LIFE SCI, V63, P2968, DOI 10.1007/s00018-006-6298-x; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang WZ, 2005, CLIN CANCER RES, V11, P3250, DOI 10.1158/1078-0432.CCR-04-2405; Wang XY, 2007, MOL CARCINOGEN, V46, P912, DOI 10.1002/mc.20320; Wu SR, 2010, AM J PATHOL, V177, P3145, DOI 10.2353/ajpath.2010.100228; Zoratti GL, 2016, ONCOTARGET, V7, P58162, DOI 10.18632/oncotarget.11262	60	29	30	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4597	4609		10.1038/onc.2017.82	http://dx.doi.org/10.1038/onc.2017.82			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368394				2022-12-17	WOS:000407246200007
J	Marshall, AD; Bailey, CG; Champ, K; Vellozzi, M; O'Young, P; Metierre, C; Feng, Y; Thoeng, A; Richards, AM; Schmitz, U; Biro, M; Jayasinghe, R; Ding, L; Anderson, L; Mardis, ER; Rasko, JEJ				Marshall, A. D.; Bailey, C. G.; Champ, K.; Vellozzi, M.; O'Young, P.; Metierre, C.; Feng, Y.; Thoeng, A.; Richards, A. M.; Schmitz, U.; Biro, M.; Jayasinghe, R.; Ding, L.; Anderson, L.; Mardis, E. R.; Rasko, J. E. J.			CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; CELL-LINE; SOMATIC MUTATIONS; EPITHELIAL-CELLS; INTRON RETENTION; DNA METHYLATION; E-CADHERIN; BINDING; CANCER	CTCF is a haploinsufficient tumour suppressor gene with diverse normal functions in genome structure and gene regulation. However the mechanism by which CTCF haploinsufficiency contributes to cancer development is not well understood. CTCF is frequently mutated in endometrial cancer. Here we show that most CTCF mutations effectively result in CTCF haploinsufficiency through nonsense-mediated decay of mutant transcripts, or loss-of-function missense mutation. Conversely, we identified a recurrent CTCF mutation K365T, which alters a DNA binding residue, and acts as a gain-of-function mutation enhancing cell survival. CTCF genetic deletion occurs predominantly in poor prognosis serous subtype tumours, and this genetic deletion is associated with poor overall survival. In addition, we have shown that CTCF haploinsufficiency also occurs in poor prognosis endometrial clear cell carcinomas and has some association with endometrial cancer relapse and metastasis. Using shRNA targeting CTCF to recapitulate CTCF haploinsufficiency, we have identified a novel role for CTCF in the regulation of cellular polarity of endometrial glandular epithelium. Overall, we have identified two novel pro-tumorigenic roles (promoting cell survival and altering cell polarity) for genetic alterations of CTCF in endometrial cancer.	[Marshall, A. D.; Bailey, C. G.; Champ, K.; Vellozzi, M.; O'Young, P.; Metierre, C.; Feng, Y.; Thoeng, A.; Schmitz, U.; Rasko, J. E. J.] Centenary Inst, Gene & Stem Cell Therapy Program, Camperdown, NSW, Australia; [Marshall, A. D.; Bailey, C. G.; Champ, K.; Vellozzi, M.; O'Young, P.; Metierre, C.; Feng, Y.; Thoeng, A.; Schmitz, U.; Anderson, L.; Rasko, J. E. J.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Richards, A. M.] Royal Prince Alfred Hosp, Gynaecol Oncol, Camperdown, NSW, Australia; [Biro, M.] Univ New South Wales, Sch Med Sci, Cell Motil & Mech, Sydney, NSW, Australia; [Jayasinghe, R.; Ding, L.; Mardis, E. R.] Washington Univ, McDonnell Genome Inst, Canc Genom, St Louis, MO USA; [Jayasinghe, R.; Ding, L.; Mardis, E. R.] Washington Univ, Dept Med, Div Oncol, St Louis, MO USA; [Anderson, L.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia; [Rasko, J. E. J.] Royal Prince Alfred Hosp, Cell & Mol Therapies, Sydney, NSW, Australia	University of Sydney; Centenary Institute; University of Sydney; University of Sydney; University of New South Wales Sydney; Washington University (WUSTL); Washington University (WUSTL); University of Sydney; University of Sydney	Rasko, JEJ (corresponding author), RPA Hosp, Centenary Inst, Gene & Stem Cell Therapy, Bldg 93, Sydney, NSW 2050, Australia.	j.rasko@centenary.org.au	Schmitz, Ulf/B-5400-2010; Mardis, Elaine/W-2202-2019; Anderson, Lyndal/AAE-5780-2019; Biro, Mate/H-6292-2014	Schmitz, Ulf/0000-0001-5806-4662; Anderson, Lyndal/0000-0002-9405-8195; rasko, John/0000-0003-2975-807X; Biro, Mate/0000-0001-5852-3726; Marshall, Amy/0000-0001-5803-3815; Bailey, Charles/0000-0002-4725-7829	Tour de Cure (Scott Canner Research Fellowship); Cancer Council NSW [RG14-09, RG14-05]; Cure The Future Foundation; National Institute of General Medical Sciences Cell and Molecular Biology [GM 007067]; NATIONAL CANCER INSTITUTE [R01CA180006, U24CA211006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER	Tour de Cure (Scott Canner Research Fellowship); Cancer Council NSW(Cancer Council New South Wales); Cure The Future Foundation; National Institute of General Medical Sciences Cell and Molecular Biology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Financial support was provided by Tour de Cure (Scott Canner Research Fellowship) to CGB and for research grants to ADM, CGB and JEJR; Cancer Council NSW project grants (RG14-09) to JEJR and CGB; (RG14-05) to JEJR; support grants from Cure The Future Foundation and an anonymous foundation; National Institute of General Medical Sciences Cell and Molecular Biology training grant (GM 007067) to RJ. We thank the Centenary Institute Advanced Cytometry Facility for FACS and imaging. The authors acknowledge the University of Sydney HPC service at The University of Sydney for providing HPC, visualisation, database, and/or grid resources that have contributed to the research results reported within this paper. URL: http://sydney.edu.au/research_support/.	Allison KH, 2008, AM J SURG PATHOL, V32, P691, DOI 10.1097/PAS.0b013e318159a2a0; Aulmann S, 2003, BREAST CANCER RES TR, V80, P347, DOI 10.1023/A:1024930404629; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brar AK, 1996, MOL HUM REPROD, V2, P185, DOI 10.1093/molehr/2.3.185; Carico E, 2010, ANTICANCER RES, V30, P4993; Cheng YH, 2011, J MOL ENDOCRINOL, V46, P139, DOI 10.1530/JME-10-0064; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Eritja N, 2010, AM J PATHOL, V176, P2722, DOI 10.2353/ajpath.2010.090974; Filippova GN, 2002, CANCER RES, V62, P48; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gonzalez-Rodilla I, 2013, ANTICANCER RES, V33, P5091; Haidopoulos D, 2010, ACTA OBSTET GYN SCAN, V89, P1326, DOI 10.3109/00016349.2010.515666; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Hirosue A, 2012, AGING CELL, V11, P553, DOI 10.1111/j.1474-9726.2012.00809.x; Jimenez-Ayala M., 2008, MONOGRAPHS CLIN CYTO, P32, DOI [10.1159/000117494, DOI 10.1159/000117494]; Jung- H, 2015, NAT GENET, V47, P1242, DOI 10.1038/ng.3414; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kemp CJ, 2014, CELL REP, V7, P1020, DOI 10.1016/j.celrep.2014.04.004; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; KURAMOTO H, 1972, AM J OBSTET GYNECOL, V114, P1012, DOI 10.1016/0002-9378(72)90861-7; Kurman RJ, 2014, WHO CLASSIFICATION T, P128; Lacey JV, 2009, MATURITAS, V63, P39, DOI 10.1016/j.maturitas.2009.02.005; Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Li R, 2005, CANCER LETT, V219, P33, DOI 10.1016/j.canlet.2004.06.044; Li T, 2007, EXP CELL RES, V313, P3057, DOI 10.1016/j.yexcr.2007.05.018; Llaurado M, 2012, MOL CELL ENDOCRINOL, V358, P244, DOI 10.1016/j.mce.2011.10.003; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Marshall AD, 2016, INT J CANCER, V139, P2529, DOI 10.1002/ijc.30371; Marshall AD, 2014, CURR OPIN GENET DEV, V24, P8, DOI 10.1016/j.gde.2013.10.011; Moore JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034915; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Nakahashi H, 2013, CELL REP, V3, P1678, DOI 10.1016/j.celrep.2013.04.024; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Rakha EA, 2005, INT J CANCER, V114, P720, DOI 10.1002/ijc.20738; Rasko JEJ, 2001, CANCER RES, V61, P6002; Reardon SN, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.112.098871; Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989; RICHARDSON GS, 1984, GYNECOL ONCOL, V17, P213, DOI 10.1016/0090-8258(84)90080-5; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509; Tiffen JC, 2013, INT J CANCER, V133, P1603, DOI 10.1002/ijc.28184; Ukraintseva SV, 2008, ADV EXP MED BIOL, V630, P57; Walker C, 2015, JNCI-J NATL CANCER I, V107; Watanabe N, 2007, GENE CHROMOSOME CANC, V46, P929, DOI 10.1002/gcc.20481; Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001; Wong JJL, 2013, CELL, V154, P583, DOI 10.1016/j.cell.2013.06.052; Yoshida K, 2013, NAT GENET, V45, P1293, DOI 10.1038/ng.2759; Zighelboim I, 2014, HUM MUTAT, V35, P63, DOI 10.1002/humu.22463	54	29	30	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4100	4110		10.1038/onc.2017.25	http://dx.doi.org/10.1038/onc.2017.25			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319062	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000405835800002
J	Deng, L; Tang, J; Yang, H; Cheng, C; Lu, S; Jiang, R; Sun, B				Deng, L.; Tang, J.; Yang, H.; Cheng, C.; Lu, S.; Jiang, R.; Sun, B.			MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway	ONCOGENE			English	Article							METASTASIS-ASSOCIATED PROTEIN-1; DOWN-REGULATION; BREAST-CANCER; C-MYC; EXPRESSION; CELLS; BIOMARKERS; EFFECTOR; PROMOTES; GENE	MTA1 is a metastasis-associated protein, which is essential to epithelial-to-mesenchymal transition (EMT). However, information concerning its up-and downstream regulation is rare. We investigated its upstream regulation and downstream effector in human hepatocellular carcinoma ( HCC). In total, 94 paired HCC and adjacent tissue samples were involved in the study, and the results indicated that decreased miR-30e levels were associated with increased MTA1 levels in human HCC. miR-30e exerted its regulation of MTA1 transcription by binding to its 3'-untranslated region, and was negatively associated with EMT. Furthermore, significantly higher expression of MTA1 was associated with overexpression of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ErbB2) in human HCC, and MTA1 can promote transcription of ErbB2 by binding with histone deacetylase 2 (HDAC2) and acting as a promoter. The EMT promotion effect caused by MTA1 largely depended on ErbB2, and reducing the activity of ErbB2 can significantly attenuate EMT promotion by causing overexpression of MTA1 both in vitro and in vivo. In general, downregulation of miR-30e can increase levels of MTA1 in human HCC, and furthermore promote cell invasion and metastasis by promoting ErbB2.	[Deng, L.; Tang, J.; Jiang, R.; Sun, B.] Nanjing Med Univ, Dept Liver Surg, Minist Hlth, Key Lab Living Donor Liver Transplantat,Affiliate, Nanjing, Jiangsu, Peoples R China; [Yang, H.] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing, Jiangsu, Peoples R China; [Cheng, C.; Lu, S.] Nanjing Med Univ, Dept Immunol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Jiang, R; Sun, B (corresponding author), Nanjing Med Univ, Key Lab Living Donor Liver Transplantat, Minist Hlth, Dept Liver Surg,Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.; Jiang, R; Sun, B (corresponding author), Nanjing Med Univ, State Key Lab Reprod Med, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	Jiangrq@njmu.edu.cn; sunbc@njmu.edu.cn	Jiang, Runqiu/T-8844-2018	Jiang, Runqiu/0000-0003-2720-1366	National Natural Science Foundation [81201880, 81201528, 81572370, 81430062]; Six talent peaks project in Jiangsu Province [2013-wsw-20]; National Key Research and Development Program of China [2016YFC0905900]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Six talent peaks project in Jiangsu Province; National Key Research and Development Program of China	This work was supported by grants from the National Natural Science Foundation (81201880 to LD, 81201528, 81572370 to RJ and 81430062 to BS), Six talent peaks project in Jiangsu Province (2013-wsw-20 to RJ). National Key Research and Development Program of China (2016YFC0905900 to BS).	Ahmad A, 2012, MOL CANCER THER, V11, P2193, DOI 10.1158/1535-7163.MCT-12-0232-T; Bhattacharya S, 2016, AM J PATHOL, V186, P242, DOI 10.1016/j.ajpath.2015.10.003; Bruning A, 2014, CANCER METAST REV, V33, P943, DOI 10.1007/s10555-014-9520-6; Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574; Deng L, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0248-0; Gupta P, 2014, MOL ONCOL, V8, P1532, DOI 10.1016/j.molonc.2014.06.006; Hamatsu T, 2003, ONCOL REP, V10, P599; Hayes CN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030280; He Y, 2014, CANCER LETT, V344, P20, DOI 10.1016/j.canlet.2013.10.021; Jenndahl LE, 2005, INT J ONCOL, V27, P439; Levenson AS, 2014, CANCER METAST REV, V33, P929, DOI 10.1007/s10555-014-9519-z; Li D.S., 2012, INT J DISTRIB SENS N, V2012, P1, DOI DOI 10.1007/S11661-012-1269-3; Manavathi Bramanandam, 2007, Nucl Recept Signal, V5, pe010, DOI 10.1621/nrs.05010; Nair SS, 2011, HEPATOLOGY, V54, P1388, DOI 10.1002/hep.24518; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Ryu SH, 2008, HEPATOLOGY, V47, P929, DOI 10.1002/hep.22124; Sen N, 2014, CANCER METAST REV, V33, P879, DOI 10.1007/s10555-014-9515-3; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; TOH Y, 1994, J BIOL CHEM, V269, P22958; van der Burg SH, 2016, NAT REV CANCER, V16, P219, DOI 10.1038/nrc.2016.16; Wang L., 2014, DISCRETE DYN NAT SOC, V2014, P1, DOI DOI 10.1002/ASL2.454; Wang YR, 2016, HEPATOL RES, V46, P89, DOI 10.1111/hepr.12571; Xia Y, 2013, CELL PHYSIOL BIOCHEM, V32, P476, DOI 10.1159/000354452; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Zhu W, 2012, GUT, V61, P562, DOI 10.1136/gutjnl-2011-300207	26	29	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3976	3985		10.1038/onc.2016.491	http://dx.doi.org/10.1038/onc.2016.491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288133				2022-12-17	WOS:000405379900004
J	Lau, HY; Tang, J; Casey, PJ; Wang, M				Lau, H. Y.; Tang, J.; Casey, P. J.; Wang, M.			Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; CARBOXYL METHYLTRANSFERASE; CANCER-CELLS; PROTEIN PRENYLATION; EPITHELIAL-CELLS; K-RAS; DISEASE; ONCOGENESIS; APOPTOSIS; GROWTH	Despite extensive effort, there has been limited progress in the development of direct RAS inhibitors. Targeting isoprenylcysteine carboxylmethyltransferase (ICMT), a unique enzyme of RAS post-translational modification, represents a promising strategy to inhibit RAS function. However, there lacks direct genetic evidence on the role of ICMT in RAS-driven human cancer initiation and maintenance. Using CRISPR/Cas9 genome editing, we have created Icmt loss-of-function isogenic cell lines for both RAS-transformed human mammary epithelial cells (HME1) and human cancer cell lines MiaPaca-2 and MDA-MB-231 containing naturally occurring mutant KRAS. In both in vitro and in vivo tumorigenesis studies, Icmt loss-of-function abolishes the tumor initiation ability of all major isoforms of mutant RAS in HME1 cells, and the tumor maintenance capacity of MiaPaca-2 and MDA-MB-231 cells, establishing the critical role of ICMT in RAS-driven cancers.	[Lau, H. Y.; Tang, J.; Casey, P. J.; Wang, M.] Duke NUS Med Sch, Canc & Stem Cell Biol Program, 8 Coll Rd, Singapore 169857, Singapore; [Wang, M.] Natl Univ Singapore, Dept Biochem, Singapore, Singapore	National University of Singapore; National University of Singapore	Wang, M (corresponding author), Duke NUS Med Sch, Canc & Stem Cell Biol Program, 8 Coll Rd, Singapore 169857, Singapore.	mei.wang@duke-nus.edu.sg		Casey, Patrick/0000-0002-7366-9309; Wang, Mei/0000-0001-6887-6840	National Medical Research Council of Singapore	National Medical Research Council of Singapore(National Medical Research Council, Singapore)	We would like to thank Dr Shang Li and Muhammad Khairul Ramlee for their invaluable technical assistance and advice, as well as Dr Mathijs Voorhoeve and Dr Shi Yun Yeo for the gift of retroviral expression vectors. This work was supported by the National Medical Research Council of Singapore.	Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Court H, 2013, J CLIN INVEST, V123, P4681, DOI 10.1172/JCI65764; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Davies BSJ, 2009, ANNU REV GENOM HUM G, V10, P153, DOI 10.1146/annurev-genom-082908-150150; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ibrahim MX, 2013, SCIENCE, V340, P1330, DOI 10.1126/science.1238880; Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031; Lau HY, 2014, CANCER BIOL THER, V15, P1280, DOI 10.4161/cbt.29692; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002; Ramlee MK, 2015, SCI REP-UK, V5, DOI 10.1038/srep15587; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Sun WT, 2016, EXP HEMATOL, V44, P189, DOI 10.1016/j.exphem.2015.12.002; Teh JT, 2015, ONCOGENE, V34, P3296, DOI 10.1038/onc.2014.260; Tsai FD, 2015, P NATL ACAD SCI USA, V112, P779, DOI 10.1073/pnas.1412811112; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wahlstrom AM, 2008, BLOOD, V112, P1357, DOI 10.1182/blood-2007-06-094060; Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108; Wang M, 2010, ONCOGENE, V29, P4959, DOI 10.1038/onc.2010.247; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Wright LP, 2009, MOL CELL BIOL, V29, P1826, DOI 10.1128/MCB.01719-08	32	29	32	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3934	3942		10.1038/onc.2016.508	http://dx.doi.org/10.1038/onc.2016.508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28192404	hybrid, Green Published			2022-12-17	WOS:000404848200013
J	Dozier, C; Mazzolini, L; Cenac, C; Froment, C; Burlet-Schiltz, O; Besson, A; Manenti, S				Dozier, C.; Mazzolini, L.; Cenac, C.; Froment, C.; Burlet-Schiltz, O.; Besson, A.; Manenti, S.			CyclinD-CDK4/6 complexes phosphorylate CDC25A and regulate its stability	ONCOGENE			English	Article							CELL-CYCLE ARREST; BETA-TRCP; DEPENDENT KINASES; MAMMARY TUMORIGENESIS; G(1)/S TRANSITION; PHOSPHATASES; ACTIVATION; DEGRADATION; EXPRESSION; TARGETS	The phosphatase CDC25A is a key regulator of cell cycle progression by dephosphorylating and activating cyclin-CDK complexes. CDC25A is an unstable protein expressed from G1 until mitosis. CDC25A overexpression, which can be caused by stabilization of the protein, accelerates the G1/S and G2/M transitions, leading to genomic instability and promoting tumorigenesis. Thus, controlling CDC25A protein levels by regulating its stability is a critical mechanism for timing cell cycle progression and to maintain genomic integrity. Herein, we show that CDC25A is phosphorylated on Ser40 throughout the cell cycle and that this phosphorylation is established during the progression from G1 to S phase. We demonstrate that CyclinD-CDK4/CDK6 complexes mediate the phosphorylation of CDC25A on Ser40 during G1 and that these complexes directly phosphorylate this residue in vitro. Importantly, we also find that CyclinD1-CDK4 decreases CDC25A stability in a beta TrCP-dependent manner and that Ser40 and Ser88 phosphorylations contribute to this regulation. Thus our results identify cyclinD-CDK4/6 complexes as novel regulators of CDC25A stability during G1 phase, generating a negative feedback loop allowing control of the G1/S transition.	[Dozier, C.; Mazzolini, L.; Cenac, C.; Besson, A.; Manenti, S.] Univ Toulouse III Paul Sabatier, INSERM UMR1037, Canc Res Ctr Toulouse, Toulouse, France; [Dozier, C.; Mazzolini, L.; Manenti, S.] CNRS ERL5294, Equipe Labellisee Ligue Canc, Toulouse, France; [Froment, C.; Burlet-Schiltz, O.] Univ Toulouse, CNRS UMR5089, Inst Pharmacol & Biol Struct, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Dozier, C (corresponding author), Univ Toulouse III Paul Sabatier, INSERM UMR1037, Canc Res Ctr Toulouse, CNRS ERL5294, Toulouse, France.	christine.dozier@inserm.fr	manenti, stephane/P-1518-2014; Besson, Arnaud/J-6254-2014	manenti, stephane/0000-0002-4793-3196; Besson, Arnaud/0000-0002-9599-3943; CENAC, Claire/0000-0001-6641-7851; Schiltz, Odile/0000-0002-3606-2356	Region Midi-Pyrenees; Toulouse Metropole; European funds FEDER (Fonds Europeens de Developpement Regional)	Region Midi-Pyrenees(Region OccitanieRegion Provence-Alpes-Cote d'Azur); Toulouse Metropole; European funds FEDER (Fonds Europeens de Developpement Regional)	We thank H. Piwnica-Worms for providing phospho-Ser76, 82 and 88 CDC25A antibodies, V. Dulic for providing BJ-hTert cells and M. Gotanegre for technical assistance. This work was supported in part by grants to OBS from the Region Midi-Pyrenees, Toulouse Metropole and European funds FEDER (Fonds Europeens de Developpement Regional) for mass spectrometry.	Bertero T, 2013, CELL DEATH DIFFER, V20, P800, DOI 10.1038/cdd.2013.5; Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chang KH, 2012, J CELL SCI, V125, P5124, DOI 10.1242/jcs.108183; Chung JH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000863; Clucas C, 2002, EMBO J, V21, P665, DOI 10.1093/emboj/21.4.665; Ducruet AP, 2003, J BIOL CHEM, V278, P31838, DOI 10.1074/jbc.M303604200; Fernandez-Vidal A, 2006, CANCER RES, V66, P7128, DOI 10.1158/0008-5472.CAN-05-2552; Fernandez-Vidal A, 2008, ANTI-CANCER AGENT ME, V8, P825, DOI 10.2174/187152008786847684; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gubanova E, 2013, CELL CYCLE, V12, P3770, DOI 10.4161/cc.26660; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Honaker Y, 2010, ONCOGENE, V29, P3324, DOI 10.1038/onc.2010.96; Hutchins JRA, 2004, CELL CYCLE, V3, P41; Isoda M, 2009, MOL BIOL CELL, V20, P2186, DOI 10.1091/mbc.E09-01-0008; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Karagoz ID, 2010, TUMOR BIOL, V31, P597, DOI 10.1007/s13277-010-0075-z; Khaled AR, 2005, J CELL BIOL, V169, P755, DOI 10.1083/jcb.200409099; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kittipatarin C, 2006, CELL CYCLE, V5, P907, DOI 10.4161/cc.5.9.2693; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Ray D, 2007, CANCER RES, V67, P6605, DOI 10.1158/0008-5472.CAN-06-4815; Ray D, 2007, CANCER RES, V67, P984, DOI 10.1158/0008-5472.CAN-06-3927; Shen T, 2012, ANTI-CANCER AGENT ME, V12, P631, DOI 10.2174/187152012800617678; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Timofeev O, 2010, J BIOL CHEM, V285, P16978, DOI 10.1074/jbc.M109.096552; Tumurbaatar I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014711; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Yin M, 2011, CELL DIV, V6, P4	37	29	32	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3781	3788		10.1038/onc.2016.506	http://dx.doi.org/10.1038/onc.2016.506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192398				2022-12-17	WOS:000404349700013
J	Agarwal, E; Robb, CM; Smith, LM; Brattain, MG; Wang, J; Black, JD; Chowdhury, S				Agarwal, E.; Robb, C. M.; Smith, L. M.; Brattain, M. G.; Wang, J.; Black, J. D.; Chowdhury, S.			Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis	ONCOGENE			English	Article							HUMAN COLON-CARCINOMA; GROWTH-FACTOR-BETA; BREAST-CANCER; TUMOR-SUPPRESSOR; CELL-MIGRATION; UP-REGULATION; KINASE-B; ACTIN POLYMERIZATION; BLADDER-CANCER; MIM	Survival signaling is critical for the metastatic program of cancer cells. The current study investigated the role of Akt survival proteins in colorectal cancer (CRC) metastasis and explored potential mechanisms of Akt-mediated metastasis regulation. Using an orthotopic implantation model in mice, which uniquely recapitulates the entire multistep process of CRC metastasis, combined with an inducible system of short hairpin RNA-mediated Akt isoform knockdown in human CRC cells, our studies confirm a role of Akt2 in CRC cell dissemination to distant organs in vivo. Akt2 deficiency profoundly inhibited the development of liver lesions in mice, whereas Akt1 had no effect under the experimental conditions used in the study. Array analysis of human metastatic genes identified the scaffolding protein metastasis suppressor 1 (MTSS1) as a novel Akt2-regulated gene. Inducible loss of Akt2 in CRC cells robustly upregulated MTSS1 at the messenger RNA and protein level, and the accumulated protein was functionally active as shown by its ability to engage an MTSS1-Src-cortactin inhibitory axis. MTSS1 expression led to a marked reduction in levels of functional cortacin (pcortactin Y421), an actin nucleation-promoting factor that has a crucial role in cancer cell invasion and metastasis. MTSS1 was also shown to mediate suppressive effects of Akt2 deficiency on CRC cell viability, survival, migration and actin polymerization in vitro. The relevance of these findings to human CRC is supported by analysis of The Cancer Genome Atlas (TCGA) and NCBI GEO data sets, which demonstrated inverse changes in expression of Akt2 and MTSS1 during CRC progression. Taken together, the data identify MTSS1 as a new Akt2-regulated gene, and point to suppression of MTSS1 as a key step in the metastasis-promoting effects of Akt2 in CRC cells.	[Agarwal, E.; Robb, C. M.; Brattain, M. G.; Wang, J.; Black, J. D.] Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; [Agarwal, E.; Brattain, M. G.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA; [Smith, L. M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE USA; [Chowdhury, S.] Boston Univ, Med Ctr, Dept Med, Sect Gastroenterol, EBRC Room 525,650 Albany St, Boston, MA 02118 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Boston University	Black, JD (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA.; Chowdhury, S (corresponding author), Boston Univ, Med Ctr, Dept Med, Sect Gastroenterol, EBRC Room 525,650 Albany St, Boston, MA 02118 USA.	jennifer.black@unmc.edu; sanjib@bu.edu		Agarwal, Ekta/0000-0002-5992-3358	NIH R01 [CA038173, CA054807, DK60632]; UNMC Cancer Center [CA036727]; NATIONAL CANCER INSTITUTE [P30CA036727, R21CA191894, R01CA038173, R01CA054807, R37CA038173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK060632, R01DK060632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106397] Funding Source: NIH RePORTER	NIH R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNMC Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH R01 grants CA038173 and CA054807 to MGB, by DK60632 to JDB and by UNMC Cancer Center Support Grant CA036727. We thank Katie Bailey for assistance with animal surgeries; Dr Adrian Black for critical reading of the manuscript and many helpful discussions, as well as analysis of Oncomine data; Drs Babu Guda and Xiao Peng (Bioinformatics and Systems Biology Core, UNMC) for help with The Cancer Genome Atlas database, and the Confocal Imaging and Histology Cores at UNMC for assistance with tissue processing and microscopy.	Agarwal E, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-145; Agarwal E, 2013, CELL SIGNAL, V25, P1711, DOI 10.1016/j.cellsig.2013.03.025; Arboleda MJ, 2003, CANCER RES, V63, P196; Bershteyn M, 2010, DEV CELL, V19, P270, DOI 10.1016/j.devcel.2010.07.009; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Chau NM, 2004, BREAST CANCER RES, V6, P55, DOI 10.1186/bcr739; Chaudhary F, 2014, BIOCHEM J, V465, P89; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Chowdhury S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019335; Chowdhury SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068818; Du P, 2013, J EXP THER ONCOL, V10, P91; Du P, 2011, ANTICANCER RES, V31, P3205; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411; Furbert-Harris PM, 2003, CELL MOL BIOL, V49, P1009; Geng L, 2014, ONCOGENE, V33, P5332, DOI 10.1038/onc.2013.478; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Grabinski N, 2011, CELL SIGNAL, V23, P1952, DOI 10.1016/j.cellsig.2011.07.003; Guo XN, 2007, CANCER RES, V67, P5851, DOI 10.1158/0008-5472.CAN-07-0049; Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jahid S, 2012, CANCER DISCOV, V2, P540, DOI 10.1158/2159-8290.CD-11-0267; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jin KT, 2012, ONCOL LETT, V3, P11, DOI 10.3892/ol.2011.432; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Kruchten AE, 2008, AM J PHYSIOL-CELL PH, V295, pC1113, DOI 10.1152/ajpcell.00238.2008; La Rocca G, 2009, J CELL PHYSIOL, V220, P485, DOI 10.1002/jcp.21796; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Leiphrakpam PD, 2014, CELL SIGNAL, V26, P868, DOI 10.1016/j.cellsig.2014.01.014; Li J, 2016, TUMOR BIOL, V37, P8765, DOI 10.1007/s13277-015-4396-9; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Loberg RD, 2005, INT J ONCOL, V26, P1699; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martin EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049067; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Mertz KD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4465; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; National Cancer Institute, 2010, SEER STAT FACT SHEET; Navenot JM, 2009, MOL PHARMACOL, V75, P1074, DOI 10.1124/mol.108.054270; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schemionek M, 2016, LEUKEMIA, V30, P823, DOI 10.1038/leu.2015.329; Schemionek M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125783; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Valeri N, 2014, CANCER CELL, V25, P469, DOI 10.1016/j.ccr.2014.03.006; Wang DZ, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/471020; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Wang J, 2009, J BIOL CHEM, V284, P10912, DOI 10.1074/jbc.M809551200; Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Williams B, 2014, MELANOMA RES, V24, P404, DOI 10.1097/CMR.0000000000000077; WOLMARK N, 1983, CANCER, V51, P1315, DOI 10.1002/1097-0142(19830401)51:7<1315::AID-CNCR2820510723>3.0.CO;2-0; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Wu WY, 2014, MOL CELL BIOCHEM, V388, P249, DOI 10.1007/s11010-013-1916-z; Xie F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-95; Xu M, 2012, CELL MOL LIFE SCI, V69, P3601, DOI 10.1007/s00018-012-1129-8; Ye SC, 1999, CANCER RES, V59, P4725; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhou L, 2016, PATHOL ONCOL RES, V22, P7, DOI 10.1007/s12253-015-9963-2; Zhou WW, 2012, ACTA BIOCH BIOPH SIN, V44, P838, DOI 10.1093/abbs/gms071	73	29	30	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3104	3118		10.1038/onc.2016.460	http://dx.doi.org/10.1038/onc.2016.460			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068324	Green Accepted			2022-12-17	WOS:000402617900004
J	Wachter, F; Morgan, AM; Godes, M; Mourtada, R; Bird, GH; Walensky, LD				Wachter, F.; Morgan, A. M.; Godes, M.; Mourtada, R.; Bird, G. H.; Walensky, L. D.			Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting	ONCOGENE			English	Article							CANCER-THERAPY; IN-VIVO; MDM2; PROTEIN; HELIX; ACTIVATION; MUTATIONS; APOPTOSIS; AFFINITY; BIMSAHB	Hydrocarbon-stapled peptides that display key residues of the p53 transactivation domain have emerged as bona fide clinical candidates for reactivating the tumor suppression function of p53 in cancer by dual targeting of the negative regulators HDM2 and HDMX. A recent study questioned the mechanistic specificity of such stapled peptides based on interrogating their capacity to disrupt p53/HDM2 and p53/HDMX complexes in living cells using a new recombinase enhanced bimolecular luciferase complementation platform (ReBiL). Here, we directly evaluate the cellular uptake, intracellular targeting selectivity and p53-dependent cytotoxicity of the clinical prototype ATSP-7041. We find that under standard serum-containing tissue culture conditions, ATSP-7041 achieves intracellular access without membrane disruption, dose-dependently dissociates both p53/HDM2 and p53/HDMX complexes but not an unrelated protein complex in long-term ReBiL experiments, and is selectively cytotoxic to cancer cells bearing wild-type p53 by inducing a surge in p53 protein level. These studies underscore the importance of a thorough stepwise approach, including consideration of the time-dependence of cellular uptake and intracellular distribution, in evaluating and advancing stapled peptides for clinical translation.	[Wachter, F.; Morgan, A. M.; Godes, M.; Mourtada, R.; Bird, G. H.; Walensky, L. D.] Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,LC3216, Boston, MA 02215 USA; [Wachter, F.; Morgan, A. M.; Godes, M.; Mourtada, R.; Bird, G. H.; Walensky, L. D.] Dana Farber Canc Inst, Linde Program Canc Chem Biol, Boston, MA 02115 USA; [Mourtada, R.] MIT, Harvard MIT Program Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT)	Walensky, LD (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,LC3216, Boston, MA 02215 USA.	Loren_Walensky@dfci.harvard.edu	Wachter, Franziska/AAI-9671-2021	Wachter, Franziska/0000-0001-9185-3612	Alexander von Humboldt Foundation Feodor Lynen Fellowship; NIH training grant [T32GM007753]; Doctoral Foreign Studies Award from the Canadian Institutes of Health Research [DFS-134963]; William Lawrence and Blanche Hughes Foundation; Hyundai Hope on Wheels Quantum Award; Alex's Lemonade Stand Reach Grant; Todd J Schwartz Memorial Fund; Leukemia and Lymphoma SCOR and Scholar Awards; NATIONAL CANCER INSTITUTE [R50CA211399, R35CA197583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008313, T32GM007753] Funding Source: NIH RePORTER	Alexander von Humboldt Foundation Feodor Lynen Fellowship; NIH training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doctoral Foreign Studies Award from the Canadian Institutes of Health Research; William Lawrence and Blanche Hughes Foundation; Hyundai Hope on Wheels Quantum Award; Alex's Lemonade Stand Reach Grant; Todd J Schwartz Memorial Fund; Leukemia and Lymphoma SCOR and Scholar Awards; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank E Smith for graphical assistance, Lisa Cameron for assistance with confocal microscopy, and Alexandra Zoraian and Katherine Franklin for technical support. We appreciate the generosity of Drs Y Li and G Wahl for providing the ReBiL cells for this study, hosting FW in their laboratory to conduct confirmatory experiments and for helpful feedback on the manuscript. This work was supported by a Hyundai Hope on Wheels Quantum Award, Alex's Lemonade Stand Reach Grant, the Todd J Schwartz Memorial Fund, and Leukemia and Lymphoma SCOR and Scholar Awards to LDW. FW is supported by an Alexander von Humboldt Foundation Feodor Lynen Fellowship, AMM by NIH training grant T32GM007753, RM by Doctoral Foreign Studies Award DFS-134963 from the Canadian Institutes of Health Research, and AZ and KF by the William Lawrence and Blanche Hughes Foundation and a generous gift from Jim and Lisa LaTorre, respectively.	BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Bernal F, 2007, J AM CHEM SOC, V129, P2456, DOI 10.1021/ja0693587; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Bird GH, 2014, ACS CHEM BIOL, V9, P831, DOI 10.1021/cb4003305; Bird GH, 2008, METHOD ENZYMOL, V446, P369, DOI 10.1016/S0076-6879(08)01622-4; Bird Gregory H, 2011, Curr Protoc Chem Biol, V3, P99, DOI 10.1002/9780470559277.ch110042; Brown CJ, 2013, ACS CHEM BIOL, V8, P506, DOI 10.1021/cb3005148; Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110; Edwards AL, 2015, ACS CHEM BIOL, V10, P2149, DOI 10.1021/acschembio.5b00214; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LaBelle JL, 2012, J CLIN INVEST, V122, P2018, DOI 10.1172/JCI46231; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li YC, 2014, CELL REP, V9, P1946, DOI 10.1016/j.celrep.2014.10.058; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Okamoto T, 2013, ACS CHEM BIOL, V8, P297, DOI 10.1021/cb3005403; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Tan BX, 2015, SCI REP-UK, V5, DOI 10.1038/srep12116; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walensky LD, 2014, J MED CHEM, V57, P6275, DOI 10.1021/jm4011675	25	29	29	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2184	2190		10.1038/onc.2016.361	http://dx.doi.org/10.1038/onc.2016.361			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721413	Green Accepted			2022-12-17	WOS:000399782500013
J	Sewastianik, T; Szydlowski, M; Jablonska, E; Bialopiotrowicz, E; Kiliszek, P; Gorniak, P; Polak, A; Prochorec-Sobieszek, M; Szumera-Cieckiewicz, A; Kaminski, TS; Markowicz, S; Nowak, E; Grygorowicz, MA; Warzocha, K; Juszczynski, P				Sewastianik, T.; Szydlowski, M.; Jablonska, E.; Bialopiotrowicz, E.; Kiliszek, P.; Gorniak, P.; Polak, A.; Prochorec-Sobieszek, M.; Szumera-Cieckiewicz, A.; Kaminski, T. S.; Markowicz, S.; Nowak, E.; Grygorowicz, M. A.; Warzocha, K.; Juszczynski, P.			FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; THIOREDOXIN; EXPRESSION; APOPTOSIS; SURVIVAL; INHIBITOR; PATHWAYS; CANCER; GENE	Molecular profiling has led to identification of subtypes of diffuse large B-cell lymphomas (DLBCLs) differing in terms of oncogenic signaling and metabolic programs. The OxPhos-DLBCL subtype is characterized by enhanced mitochondrial oxidative phosphorylation. As increased oxidative metabolism leads to overproduction of potentially toxic reactive oxygen species (ROS), we sought to identify mechanisms responsible for adaptation of OxPhos cells to these conditions. Herein, we describe a mechanism involving the FOXO1-TXN-p300 redox-dependent circuit protecting OxPhos-DLBCL cells from ROS toxicity. We identify a BCL6-dependent transcriptional mechanism leading to relative TXN overexpression in OxPhos cells. We found that OxPhos cells lacking TXN were uniformly more sensitive to ROS and doxorubicin than control cells. Consistent with this, the overall survival of patients with high TXN mRNA expression, treated with doxorubicin-containing regimens, is significantly shorter than of those with low TXN mRNA expression. TXN overexpression curtails p300-mediated FOXO1 acetylation and its nuclear translocation in response to oxidative stress, thus attenuating FOXO1 transcriptional activity toward genes involved in apoptosis and cell cycle inhibition. We also demonstrate that FOXO1 knockdown in cells with silenced TXN expression markedly reduces ROS-induced apoptosis, indicating that FOXO1 is the major sensor and effector of oxidative stress in OxPhos-DLBCLs. These data highlight dynamic, context-dependent modulation of FOXO1 tumor-suppressor functions via acetylation and reveal potentially targetable vulnerabilities in these DLBCLs.	[Sewastianik, T.; Szydlowski, M.; Jablonska, E.; Bialopiotrowicz, E.; Kiliszek, P.; Gorniak, P.; Polak, A.; Prochorec-Sobieszek, M.; Szumera-Cieckiewicz, A.; Juszczynski, P.] Inst Hematol & Transfus Med, Dept Diagnost Hematol, Indiry Gandhi 14, PL-02776 Warsaw, Poland; [Kaminski, T. S.] Polish Acad Sci, Inst Phys Chem, Dept Soft Condensed Matter, Warsaw, Poland; [Markowicz, S.; Nowak, E.; Grygorowicz, M. A.] Maria Sklodowska Curie Mem Canc Center, Inst Oncol, Dept Immunol, Warsaw, Poland; [Warzocha, K.] Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland	Polish Academy of Sciences; Institute of Physical Chemistry of the Polish Academy of Sciences; Maria Sklodowska-Curie National Research Institute of Oncology	Juszczynski, P (corresponding author), Inst Hematol & Transfus Med, Dept Diagnost Hematol, Indiry Gandhi 14, PL-02776 Warsaw, Poland.	pjuszczynski@ihit.waw.pl	Szydlowski, Maciej/W-5014-2018; Sewastianik, Tomasz/AAC-6293-2020; Gorniak, Patryk/W-6301-2018; Prochorec-Sobieszek, Monika/AAD-5065-2020; Szumera-Ciećkiewicz, Anna/D-8391-2019; Juszczynski, Przemyslaw/W-9709-2018; Polak, Anna/W-2432-2018; Szumera-Ciećkiewicz, Anna/AAR-8502-2021; Bialopiotrowicz, Emilia/W-2322-2018; Szydlowski, Maciej/P-4329-2019; Jablonska, Ewa/W-2303-2018; Polak, Anna/AAA-7190-2020; Kaminski, Tomasz/AAD-6449-2020	Szydlowski, Maciej/0000-0002-9419-121X; Sewastianik, Tomasz/0000-0003-4603-8517; Gorniak, Patryk/0000-0002-2920-2672; Prochorec-Sobieszek, Monika/0000-0002-8109-9553; Szumera-Ciećkiewicz, Anna/0000-0001-5028-3422; Juszczynski, Przemyslaw/0000-0001-7215-0444; Polak, Anna/0000-0001-8686-3429; Szumera-Ciećkiewicz, Anna/0000-0001-5028-3422; Bialopiotrowicz, Emilia/0000-0002-9263-0928; Szydlowski, Maciej/0000-0002-9419-121X; Jablonska, Ewa/0000-0002-5445-4249; Polak, Anna/0000-0001-8686-3429; Kaminski, Tomasz/0000-0001-5124-4548; Warzocha, Krzysztof/0000-0002-2396-3905; Markowicz, Sergiusz/0000-0003-1280-6514	Foundation for Polish Science [TEAM/2011-7/4]; European Regional Development Fund and Operational Program Innovative Economy; NanoFun [POIG.02.02.00-00-025/09]	Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); European Regional Development Fund and Operational Program Innovative Economy; NanoFun	This work and T.S. PhD scholarship are supported by a Foundation for Polish Science grant TEAM/2011-7/4, co-financed by the European Regional Development Fund and Operational Program Innovative Economy 2007-2013. This work was partly performed in the laboratories founded by NanoFun POIG.02.02.00-00-025/09.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; An NF, 2014, ADV CANCER RES, V122, P245, DOI 10.1016/B978-0-12-420117-0.00007-4; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barbouti A, 2002, FREE RADICAL BIO MED, V33, P691, DOI 10.1016/S0891-5849(02)00967-X; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Brent MM, 2008, STRUCTURE, V16, P1407, DOI 10.1016/j.str.2008.06.013; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Caro P, 2012, CANCER CELL, V22, P547, DOI 10.1016/j.ccr.2012.08.014; Chen LF, 2013, CANCER CELL, V23, P826, DOI 10.1016/j.ccr.2013.05.002; Ci WM, 2009, BLOOD, V113, P5536, DOI 10.1182/blood-2008-12-193037; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dansen TB, 2009, NAT CHEM BIOL, V5, P664, DOI 10.1038/nchembio.194; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Juszczynski P, 2006, MOL CELL BIOL, V26, P5348, DOI 10.1128/MCB.02351-05; Juszczynski P, 2009, BLOOD, V114, P5315, DOI 10.1182/blood-2009-02-204362; Kiebala M, 2015, EXP HEMATOL, V43, P89, DOI 10.1016/j.exphem.2014.10.004; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li CP, 2012, ONCOTARGET, V3, P314, DOI 10.18632/oncotarget.463; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Mandal PK, 2010, CANCER RES, V70, P9505, DOI 10.1158/0008-5472.CAN-10-1509; Marinho HS, 2014, REDOX BIOL, V2, P535, DOI 10.1016/j.redox.2014.02.006; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Storz P, 2011, ANTIOXID REDOX SIGN, V14, P593, DOI 10.1089/ars.2010.3405; Szydlowski M, 2016, BLOOD, V127, P739, DOI 10.1182/blood-2015-06-654111; Szydlowski M, 2014, INT REV IMMUNOL, V33, P146, DOI 10.3109/08830185.2014.885022; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Trinh DL, 2013, BLOOD, V121, P3666, DOI 10.1182/blood-2013-01-479865; Wang SW, 2004, J BIOL CHEM, V279, P25535, DOI 10.1074/jbc.M400944200; Xie LK, 2012, BLOOD, V119, P3503, DOI 10.1182/blood-2011-09-381905; Yang Y, 2009, NEOPLASIA, V11, P313, DOI 10.1593/neo.81358; Yuan ZQ, 2009, J BIOL CHEM, V284, P11285, DOI 10.1074/jbc.M900461200	52	29	29	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5989	6000		10.1038/onc.2016.126	http://dx.doi.org/10.1038/onc.2016.126			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27132507				2022-12-17	WOS:000388509400006
J	Elabd, S; Meroni, G; Blattner, C				Elabd, S.; Meroni, G.; Blattner, C.			TRIMming p53's anticancer activity	ONCOGENE			English	Review							PROMYELOCYTIC LEUKEMIA PROTEIN; RESPONSIVE FINGER PROTEIN; TELANGIECTASIA GROUP-D; BREAST-CANCER CELLS; UBIQUITIN LIGASE; TRIPARTITE-MOTIF; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; PREMATURE SENESCENCE; E3-UBIQUITIN LIGASE	Several TRIM proteins control abundance and activity of p53. Along this route, TRIM proteins have a serious impact on carcinogenesis and prognosis for cancer patients. In the past years, a significant increase has been made in our understanding of how the TRIM protein family controls p53 activity.	[Elabd, S.; Blattner, C.] Karlsruhe Inst Technol, Inst Toxicol & Genet, Karlsruhe, Germany; [Elabd, S.] Univ Alexandria, Med Res Inst, Dept Human Physiol, Alexandria, Egypt; [Meroni, G.] Univ Trieste, Dept Life Sci, Trieste, Italy	Helmholtz Association; Karlsruhe Institute of Technology; Egyptian Knowledge Bank (EKB); Alexandria University; University of Trieste	Blattner, C (corresponding author), Karlsruhe Inst Technol, Inst Toxicol & Genet, POB 3640, CH-76021 Baden, Switzerland.	christine.blattner@kit.edu	Blattner, Christine/ABI-2152-2020; Blattner, Christine/H-2105-2013	Blattner, Christine/0000-0002-7250-5273; Blattner, Christine/0000-0002-7250-5273	FIRB-MIUR [RBAP11Z4Z9]; AFM-TELETHON [17746];  [COST-BM1307]	FIRB-MIUR(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); AFM-TELETHON(Association Francaise contre les Myopathies); 	CB and GM are supported by COST-BM1307. The work in GM's laboratory is funded by FIRB-MIUR Grant RBAP11Z4Z9 and AFM-TELETHON Grant 17746.	Addison JB, 2015, CANCER RES, V75, P344, DOI 10.1158/0008-5472.CAN-14-1561; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Alsheich-Bartok O, 2008, ONCOGENE, V27, P3653, DOI 10.1038/sj.onc.1211036; Battivelli E, 2011, J VIROL, V85, P7828, DOI 10.1128/JVI.00648-11; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Boehme KA, 2009, CRIT REV BIOCHEM MOL, V44, P367, DOI 10.3109/10409230903401507; Cambiaghi V, 2012, ADV EXP MED BIOL, V770, P77; Caratozzolo MF, 2014, ONCOTARGET, V5, P7446, DOI 10.18632/oncotarget.2081; Chen Y, 2015, ONCOTARGET, V6, P23708, DOI 10.18632/oncotarget.4291; Chu Y, 2011, ONCOGENE, V30, P1108, DOI 10.1038/onc.2010.462; Cui ZB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063887; Dahm-Daphi J, 2005, ONCOGENE, V24, P1663, DOI 10.1038/sj.onc.1208396; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Faesen AC, 2011, MOL CELL, V44, P147, DOI 10.1016/j.molcel.2011.06.034; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Ho J, 2009, J PROTEOME RES, V8, P583, DOI 10.1021/pr8007368; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Horn EJ, 2004, CARCINOGENESIS, V25, P157, DOI 10.1093/carcin/bgh003; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Jain AK, 2014, MOL CELL BIOL, V34, P2695, DOI 10.1128/MCB.01705-12; Joo HM, 2011, EUR J CELL BIOL, V90, P420, DOI 10.1016/j.ejcb.2010.12.001; Kano S, 2008, CANCER RES, V68, P5572, DOI 10.1158/0008-5472.CAN-07-6231; Kapanadze B, 1998, FEBS LETT, V426, P266, DOI 10.1016/S0014-5793(98)00357-3; KAPP LN, 1992, AM J HUM GENET, V51, P45; Kuboshima M, 2006, CANCER SCI, V97, P380, DOI 10.1111/j.1349-7006.2006.00192.x; Kung CP, 2015, MOL CANCER RES, V13, P250, DOI 10.1158/1541-7786.MCR-14-0385; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lerner M, 2007, MOL BIOL CELL, V18, P1670, DOI 10.1091/mbc.E06-03-0248; Li Q, 2011, ONCOGENE, V30, P1194, DOI 10.1038/onc.2010.499; Liu J, 2014, CELL DEATH DIFFER, V21, P1792, DOI 10.1038/cdd.2014.121; Liu L, 2013, CANCER EPIDEMIOL, V37, P71, DOI 10.1016/j.canep.2012.08.005; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Masuda Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8299; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nisole S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00125; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; Ozato K, 2008, NAT REV IMMUNOL, V8, P849, DOI 10.1038/nri2413; Qin Y., 2015, TECHNOL CANC RES TRE; Reddy BA, 2014, MOL CELL, V53, P458, DOI 10.1016/j.molcel.2013.12.017; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rokudai S, 2013, P NATL ACAD SCI USA, V110, P3895, DOI 10.1073/pnas.1300490110; Sakuma M, 2005, GYNECOL ONCOL, V99, P664, DOI 10.1016/j.ygyno.2005.07.103; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Sho T, 2011, BBA-MOL CELL RES, V1813, P1245, DOI 10.1016/j.bbamcr.2011.03.018; Short KM, 2006, J BIOL CHEM, V281, P8970, DOI 10.1074/jbc.M512755200; Sun Y, 2013, BIOCHEM BIOPH RES CO, V441, P600, DOI 10.1016/j.bbrc.2013.10.110; Suzuki T, 2005, CLIN CANCER RES, V11, P6148, DOI 10.1158/1078-0432.CCR-05-0040; Tanaka M, 2010, HISTOCHEM CELL BIOL, V133, P273, DOI 10.1007/s00418-009-0669-y; Tang ZP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063676; Tebaldi T, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1643-9; Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vaseva AV, 2009, CELL CYCLE, V8, P1711, DOI 10.4161/cc.8.11.8596; Vincent SR, 2000, BIOCHEM BIOPH RES CO, V279, P482, DOI 10.1006/bbrc.2000.3984; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Wittmann S, 2008, GENE CHROMOSOME CANC, V47, P386, DOI 10.1002/gcc.20544; Yang B, 2007, CANCER RES, V67, P9954, DOI 10.1158/0008-5472.CAN-07-1478; Yang HB, 2015, J BIOL CHEM, V290, P27146, DOI 10.1074/jbc.M115.665489; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yuan ZG, 2010, MOL CELL BIOL, V30, P3004, DOI 10.1128/MCB.01023-09; Zhang LG, 2012, P NATL ACAD SCI USA, V109, P20931, DOI 10.1073/pnas.1212047110; Zhang P, 2015, ONCOGENE, V34, P5729, DOI 10.1038/onc.2015.21; Zhou ZC, 2014, GASTROENTEROLOGY, V147, P1043, DOI 10.1053/j.gastro.2014.07.021; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200; Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200	77	29	29	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5577	5584		10.1038/onc.2016.33	http://dx.doi.org/10.1038/onc.2016.33			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	26898759	Green Submitted			2022-12-17	WOS:000386998300001
J	Cui, J; Xia, T; Xie, D; Gao, Y; Jia, Z; Wei, D; Wang, L; Huang, S; Quan, M; Xie, K				Cui, J.; Xia, T.; Xie, D.; Gao, Y.; Jia, Z.; Wei, D.; Wang, L.; Huang, S.; Quan, M.; Xie, K.			HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes	ONCOGENE			English	Article							C-MET; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PROMOTES; GROWTH; PROGRESSION; RECEPTOR; TARGET; INDUCTION; HGF/SF	Hepatocyte growth factor (HGF)/Met signaling has critical roles in pancreatic ductal adenocarcinoma (PDA) development and progression and is considered a potential therapeutic target for this disease. However, the mechanism of aberrant activation of HGF/Met signaling and resistance to Met inhibition in PDA remains unclear. The mechanistic role of cross talk between Forkhead box M1 (FOXM1) and HGF/Met signaling in promotion of PDA growth and resistance to Met inhibition was examined using cell culture, molecular biology and mouse models; and the relevance of our experimental and mechanistic findings were validated using human PDA tissues. Met was markedly overexpressed in both PDA cell lines and pancreatic tumor specimens, and the expression of Met correlated directly with that of FOXM1 in human tumor specimens. Mechanistically, FOXM1 bound to the promoter region of the Met gene and transcriptionally increased the expression of Met. Increased expression of FOXM1 enhanced the activation of HGF/Met signaling and its downstream pathways, including retrovirus-associated DNA sequences/extracellular signal-regulated kinase 1/2, phosphoinositide 3-kinase/AKT and signal transducer and activator of transcription 3. Furthermore, activation of HGF/Met signaling increased the expression and transcriptional activity of FOXM1, and the cross talk between FOXM1 and HGF/Met signaling promoted PDA growth and resistance to Met inhibition. Collectively, our findings identified a positive feedback loop formed by FOXM1 and HGF/Met and revealed that this loop is a potentially effective therapeutic target for PDA.	[Cui, J.; Jia, Z.; Wei, D.; Wang, L.; Quan, M.; Xie, K.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Xia, T.] Second Mil Med Univ, Shanghai Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Xie, D.; Gao, Y.; Quan, M.] Shanghai Tongji Univ, Dept Oncol, Affiliated East Hosp, Shanghai, Peoples R China; [Huang, S.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Naval Medical University; Tongji University; University of Texas System; UTMD Anderson Cancer Center	Quan, M (corresponding author), Shanghai Tongji Univ, Dept Oncol, Affiliated East Hosp, Shanghai, Peoples R China.; Xie, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Unit 1466, 1515 Holcombe Blvd, Houston, TX 77030 USA.	quanming2013@gmail.com; kepxie@mdanderson.org		Wang, Liang/0000-0001-5038-694X	National Cancer Institute, National Institutes of Health [R01-CA129956, R01-CA148954, R01CA152309, R01CA172233]; NATIONAL CANCER INSTITUTE [R01CA148954, R01CA198090, R01CA172233, R01CA195651, R01CA152309, R01CA129956] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Don Norwood for editorial assistance and Xuemei Wang, Associate Director of Quantitative Research at The University of Texas MD Anderson Cancer Center, for assistance with statistical analyses. This work was supported by grants R01-CA129956, R01-CA148954, R01CA152309, and R01CA172233 from the National Cancer Institute, National Institutes of Health (to K Xie).	Altomare DA, 2010, CLIN CANCER RES, V16, P486, DOI 10.1158/1078-0432.CCR-09-1026; Avan A, 2014, CURR MED CHEM, V21, P975, DOI 10.2174/09298673113209990231; Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Chiu WT, 2015, ONCOTARGET, V6, P2349, DOI 10.18632/oncotarget.2957; Christensen JG, 2003, CANCER RES, V63, P7345; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cui JJ, 2014, J MED CHEM, V57, P4427, DOI 10.1021/jm401427c; Cui JJ, 2014, CLIN CANCER RES, V20, P2595, DOI 10.1158/1078-0432.CCR-13-2407; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Huang C, 2014, BBA-REV CANCER, V1845, P104, DOI 10.1016/j.bbcan.2014.01.002; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Ketterer K, 2009, CANCER LETT, V277, P72, DOI 10.1016/j.canlet.2008.11.028; Kitajima Y, 2008, CANCER SCI, V99, P1341, DOI 10.1111/j.1349-7006.2008.00828.x; Lam AKY, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00011; Li L, 2014, GASTROENTEROLOGY, V147, P485, DOI 10.1053/j.gastro.2014.04.048; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Logan-Collins J, 2010, CANCER RES, V70, P1130, DOI 10.1158/0008-5472.CAN-09-0761; Mencalha AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048160; Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092; Otte JM, 2000, SCAND J GASTROENTERO, V35, P90; Qi J, 2011, CANCER RES, V71, P1081, DOI 10.1158/0008-5472.CAN-10-1623; Sanders DA, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0696-z; Sen N, 2012, P NATL ACAD SCI USA, V109, P600, DOI 10.1073/pnas.1114232109; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sunaga N, 2013, ONCOGENE, V32, P4034, DOI 10.1038/onc.2012.402; Wang HX, 2010, CARCINOGENESIS, V31, P1132, DOI 10.1093/carcin/bgq058; Wang ZW, 2010, CANCER TREAT REV, V36, P151, DOI 10.1016/j.ctrv.2009.11.006; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wierstra I, 2006, BIOL CHEM, V387, P963, DOI 10.1515/BC.2006.120; Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104; Yeh CY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-139; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang YJ, 2008, CANCER RES, V68, P8733, DOI 10.1158/0008-5472.CAN-08-1968; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhao S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.36; Zhu GH, 2011, DIGEST DIS SCI, V56, P1090, DOI 10.1007/s10620-010-1416-x	41	29	30	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4708	4718		10.1038/onc.2016.14	http://dx.doi.org/10.1038/onc.2016.14			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876216	Green Accepted			2022-12-17	WOS:000383324700004
J	Marjon, KD; Termini, CM; Karlen, KL; Saito-Reis, C; Soria, CE; Lidke, KA; Gillette, JM				Marjon, K. D.; Termini, C. M.; Karlen, K. L.; Saito-Reis, C.; Soria, C. E.; Lidke, K. A.; Gillette, J. M.			Tetraspanin CD82 regulates bone marrow homing of acute myeloid leukemia by modulating the molecular organization of N-cadherin	ONCOGENE			English	Article							CANCER-CELL-LINES; HEMATOPOIETIC STEM; PROGENITOR CELLS; PROTEIN; METASTASIS; MEMBRANE; ADHESION; PALMITOYLATION; EXPRESSION; INTEGRIN	Communication between acute myeloid leukemia (AML) and the bone marrow microenvironment is known to control disease progression. Therefore, regulation of AML cell trafficking and adhesion to the bone marrow is of significant interest. In this study, we demonstrate that differential expression of the membrane scaffold CD82 modulates the bone marrow homing of AML cells. By combining mutational analysis and super-resolution imaging, we identify membrane protein clustering by CD82 as a regulator of AML cell adhesion and bone marrow homing. Cluster analysis of super-resolution data indicates that N-linked glycosylation and palmitoylation of CD82 are both critical modifications that control the microdomain organization of CD82 as well as the nanoscale clustering of associated adhesion protein, N-cadherin. We demonstrate that the inhibition of CD82 glycosylation increases the molecular packing of N-cadherin and promotes the bone marrow homing of AML cells. In contrast, we find that the inhibition of CD82 palmitoylation disrupts the formation and organization of N-cadherin clusters and significantly diminishes bone marrow trafficking of AML. Taken together, these data establish a mechanism where the membrane organization of CD82, through specific posttranslational modifications, regulates N-cadherin clustering and membrane density, which impacts the in vivo trafficking of AML cells. As such, these observations provide an alternative model for targeting AML where modulation of protein organization within the membrane may be an effective treatment therapy to disrupt the bone marrow homing potential of AML cells.	[Marjon, K. D.; Termini, C. M.; Karlen, K. L.; Saito-Reis, C.; Soria, C. E.; Gillette, J. M.] Univ New Mexico, Dept Pathol, Hlth Sci Ctr, MSC 08-4640, Albuquerque, NM 87131 USA; [Lidke, K. A.] Univ New Mexico, Dept Phys & Astron, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico	Gillette, JM (corresponding author), Univ New Mexico, Dept Pathol, Hlth Sci Ctr, MSC 08-4640, Albuquerque, NM 87131 USA.	JGillette@salud.unm.edu	Termini, Christina/AAC-7667-2019	Termini, Christina/0000-0002-1831-1347; Saito Reis, Chelsea/0000-0002-6431-4602; Volcko, Karin Linnea/0000-0002-4234-0703	NIH [R01 HL122483-01A1]; New Mexico INBRE grant [NIH P20 GM103451]; University of New Mexico Cancer Center [NIH P30CA118100]; American Cancer Society Institutional Research Grant; NM Spatiotemporal Modeling Center [NIH T32 HL007736, NIH P50 GM085273, NIH F31 HL124977]; University of New Mexico Department of Pathology; NATIONAL CANCER INSTITUTE [P30CA118100] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007736, R01HL122483, F31HL124977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM085273, P20GM103451] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Mexico INBRE grant; University of New Mexico Cancer Center; American Cancer Society Institutional Research Grant(American Cancer Society); NM Spatiotemporal Modeling Center; University of New Mexico Department of Pathology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to acknowledge all of the funding sources that made this work possible. This includes funding from an NIH R01 HL122483-01A1 to JMG, a New Mexico INBRE grant subaward to JMG (NIH P20 GM103451), pilot funding from the University of New Mexico Cancer Center (NIH P30CA118100), an American Cancer Society Institutional Research Grant, a Post-Doctoral Training Fellowship to KDM (NIH T32 HL007736), Graduate Student Training Fellowships to CMT from the NM Spatiotemporal Modeling Center (NIH P50 GM085273) and (NIH F31 HL124977), and a Graduate Student Training Fellowship to CSR (NIH T32 HL007736). We also thank the NM Spatiotemporal Modeling Center for supporting the Super-Resolution Imaging Core Facility (NIH P50 GM085273) and the University of New Mexico Cancer Center (NIH P30CA118100) for use of the Keck-UNM Small Animal Models and Imaging Shared Resource. This work was also supported through faculty start-up funds to JMG from the University of New Mexico Department of Pathology. Finally, we would like to acknowledge the technical assistance of Rebecca J. Dodd and Dr I-Ming Chen, University of New Mexico Health Sciences Center. In addition, we would like to acknowledge the assistance of Dr Ravi Majeti, Division of Hematology, Institute for Stem Cell Biology and Regenerative Medicine, and Cancer Institute, Stanford University and the Stanford University Division of Hematology Tissue Bank for samples. (http://www.nature.com/onc)	Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Bassani S, 2012, INT J BIOCHEM CELL B, V44, P703, DOI 10.1016/j.biocel.2012.01.020; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Bonardi F, 2013, MOL CELL PROTEOMICS, V12, P626, DOI 10.1074/mcp.M112.021931; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; Bromberg O, 2012, BLOOD, V120, P303, DOI 10.1182/blood-2011-09-377853; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DWIVEDI C, 1988, CANCER DETECT PREV, V11, P191; Ester M., 1996, P KDD 96, P1; Gibson LF, 2002, LEUKEMIA LYMPHOMA, V43, P19, DOI 10.1080/10428190210188; GIL ML, 1992, J IMMUNOL, V148, P2826; Greenbaum AM, 2012, BLOOD, V120, P295, DOI 10.1182/blood-2011-09-377457; Guzman ML, 2014, STEM CELLS, V32, P844, DOI 10.1002/stem.1597; Heilemann M, 2008, ANGEW CHEM INT EDIT, V47, P6172, DOI 10.1002/anie.200802376; Hemler ME, 2008, NAT REV DRUG DISCOV, V7, P747, DOI 10.1038/nrd2659; Hong S, 2013, J CELL BIOL, V201, P131, DOI 10.1083/jcb.201211054; Huang F, 2011, BIOMED OPT EXPRESS, V2, P1377, DOI 10.1364/BOE.2.001377; IMAI T, 1992, J IMMUNOL, V149, P2879; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Larochelle A, 2012, BLOOD, V119, P1848, DOI 10.1182/blood-2011-08-371583; LEBELBINAY S, 1994, CELL IMMUNOL, V154, P468, DOI 10.1006/cimm.1994.1092; Machida U, 1999, NEW ENGL J MED, V340, P810; Malik FA, 2009, HISTOL HISTOPATHOL, V24, P519, DOI 10.14670/HH-24.519; Mattila PK, 2013, IMMUNITY, V38, P461, DOI 10.1016/j.immuni.2012.11.019; Mazurov D, 2007, J BIOL CHEM, V282, P3896, DOI 10.1074/jbc.M607322200; Miranti CK, 2009, CELL SIGNAL, V21, P196, DOI 10.1016/j.cellsig.2008.08.023; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nishioka C, 2013, INT J CANCER, V132, P2006, DOI 10.1002/ijc.27904; Qiu SW, 2014, LEUKEMIA RES, V38, P632, DOI 10.1016/j.leukres.2014.03.007; Swindall AF, 2013, CANCER RES, V73, P2368, DOI 10.1158/0008-5472.CAN-12-3424; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Termini CM, 2014, MOL BIOL CELL, V25, P1560, DOI 10.1091/mbc.E13-11-0660; Wang H, 2012, J PROTEOMICS, V75, P1375, DOI 10.1016/j.jprot.2011.11.013; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Xu Y, 2014, INT J CLIN EXP PATHO, V7, P5569; Yang XW, 2004, J CELL BIOL, V167, P1231, DOI 10.1083/jcb.200404100; Yoshida T, 2008, TRAFFIC, V9, P540, DOI 10.1111/j.1600-0854.2008.00700.x; Zaitseva L, 2014, ONCOTARGET, V5, P9930, DOI 10.18632/oncotarget.2479; Zhang B, 2013, BLOOD, V121, P1824, DOI 10.1182/blood-2012-02-412890; Zhang J, 2006, MICRON, V37, P14, DOI 10.1016/j.micron.2005.03.014; Zhi L, 2010, CANCER LETT, V296, P65, DOI 10.1016/j.canlet.2010.03.021; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574	48	29	30	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4132	4140		10.1038/onc.2015.449	http://dx.doi.org/10.1038/onc.2015.449			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26592446	Green Accepted, Bronze			2022-12-17	WOS:000381020900011
J	Levy, P; Bartosch, B				Levy, P.; Bartosch, B.			Metabolic reprogramming: a hallmark of viral oncogenesis	ONCOGENE			English	Review							HUMAN CYTOMEGALOVIRUS-INFECTION; SARCOMA-ASSOCIATED HERPESVIRUS; EPSTEIN-BARR-VIRUS; HPV-16 E7 ONCOPROTEIN; FATTY-ACID SYNTHESIS; ATP CITRATE LYASE; KINASE TYPE M2; HUMAN-PAPILLOMAVIRUS; PYRUVATE-KINASE; KAPOSIS-SARCOMA	More than 1 in 10 cases of cancer in the world are due to chronic viral infections. Viruses induce oncogenesis by targeting the same pathways known to be responsible for neoplasia in tumor cells, such as control of cell cycle progression, cell migration, proliferation and evasion from cell death and the host's immune defense. In addition, metabolic reprogramming has been identified over a century ago as a requirement for growth of transformed cells. Renewed interest in this topic has emerged recently with the discovery that basically all metabolic changes in tumor cells are finely orchestrated by oncogenes and tumor suppressors. Indeed, cancer cells activate biosynthetic pathways in order to provide them with sufficient levels of energy and building blocks to proliferate. Interestingly, viruses introduce into their host cells similar metabolic adaptations, and importantly, it seems that they depend on these changes for their persistence and amplification. The central carbon metabolism, for example, is not only frequently altered in tumor cells but also modulated by human papillomavirus, hepatitis B and C viruses, Epstein-Barr virus and Kaposi's Sarcoma-associated virus. Moreover, adenoviruses (Ad) and human cytomegalovirus, which are not directly oncogenic but present oncomodulatory properties, also divert cellular metabolism in a tumor cell-like mnner. Thus, metabolic reprogramming appears to be a hallmark of viral infection and provides an interesting therapeutic target, in particular, for oncogenic viruses. Therapeutic targeting of metabolic pathways may not only allow to eliminate or control the viral infection but also to prevent virus-induced carcinogenesis.	[Levy, P.; Bartosch, B.] Univ Lyon, Canc Res Ctr Lyon, Inserm U1052, 151 Cours Albert Thomas, F-69434 Lyon, France; [Bartosch, B.] DevWeCan Labs Excellence Network Labex, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Bartosch, B (corresponding author), Univ Lyon, Canc Res Ctr Lyon, Inserm U1052, 151 Cours Albert Thomas, F-69434 Lyon, France.	Birke.Bartosch@inserm.fr	Levy, Pierre/AAR-4370-2020; Bartosch, Birke/I-7255-2018	Levy, Pierre/0000-0003-3213-0080; Bartosch, Birke/0000-0001-6354-4660	French National Agency for AIDS and Viral Hepatitis Research [14370]; Comite de Savoie de la Ligue contre le cancer [RAB12023CCA]; Agence Nationale de Recherche; DevWeCan French Laboratories of Excellence Network (Labex) [ANR-10-LABX-61]; OpeRa IHU program [ANR-10-IBHU-004]; Region Rhone-Alpes	French National Agency for AIDS and Viral Hepatitis Research; Comite de Savoie de la Ligue contre le cancer; Agence Nationale de Recherche(French National Research Agency (ANR)); DevWeCan French Laboratories of Excellence Network (Labex); OpeRa IHU program; Region Rhone-Alpes(Region Auvergne-Rhone-Alpes)	This work was supported by the French National Agency for AIDS and Viral Hepatitis Research (14370), Comite de Savoie de la Ligue contre le cancer (RAB12023CCA), Agence Nationale de Recherche, the Region Rhone-Alpes, DevWeCan French Laboratories of Excellence Network (Labex, Grant ANR-10-LABX-61) and OpeRa IHU program (GRANT ANR-10-IBHU-004).	Amako Y, 2015, J VIROL, V89, P4092, DOI 10.1128/JVI.01653-14; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Bard-Chapeau EA, 2014, NAT GENET, V46, P24, DOI 10.1038/ng.2847; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019; Bhatt AP, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00401; Bhatt AP, 2012, P NATL ACAD SCI USA, V109, P11818, DOI 10.1073/pnas.1205995109; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Birungi G, 2010, J PROTEOME RES, V9, P6523, DOI 10.1021/pr100727m; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Bodily JM, 2011, CANCER RES, V71, P1187, DOI 10.1158/0008-5472.CAN-10-2626; Bugianesi E, 2012, J HEPATOL, V56, pS56, DOI 10.1016/S0168-8278(12)60007-5; Cai QL, 2006, PLOS PATHOG, V2, P1002, DOI 10.1371/journal.ppat.0020116; Cai Q, 2007, J VIROL, V81, P10413, DOI 10.1128/JVI.00611-07; Carroll PA, 2006, J VIROL, V80, P10802, DOI 10.1128/JVI.00673-06; Cavallin LE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004154; Chambers JW, 2010, J VIROL, V84, P1867, DOI 10.1128/JVI.02123-09; Cinati J, 2004, TRENDS MOL MED, V10, P19, DOI 10.1016/j.molmed.2003.11.002; Claus C, 2014, ARCH VIROL, V159, P1267, DOI 10.1007/s00705-013-1841-1; Clippinger AJ, 2011, J VIROL, V85, P9369, DOI 10.1128/JVI.05102-11; Cobbs CS, 2002, CANCER RES, V62, P3347; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; Darekar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042072; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; De Clercq E, 2004, NAT REV MICROBIOL, V2, P704, DOI 10.1038/nrmicro975; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Delgado T, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002866; Delgado T, 2010, P NATL ACAD SCI USA, V107, P10696, DOI 10.1073/pnas.1004882107; DeVita VT, 2008, CANCER RES, V68, P8643, DOI 10.1158/0008-5472.CAN-07-6611; Diamond DL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000719; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; El-Bacha T, 2013, INT J BIOCHEM CELL B, V45, P41, DOI 10.1016/j.biocel.2012.09.021; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Fajas L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00004; Fan J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.65; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Fontaine KA, 2014, J VIROL, V88, P4366, DOI 10.1128/JVI.03134-13; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Gameiro PA, 2013, CELL METAB, V17, P372, DOI 10.1016/j.cmet.2013.02.002; Gandhi MK, 2004, LANCET INFECT DIS, V4, P725, DOI 10.1016/S1473-3099(04)01202-2; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; Garcia-Cao I, 2012, CELL, V149, P49, DOI 10.1016/j.cell.2012.02.030; Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388; Graham F.L., 1984, ADENOVIRUSES, P339; Griffiths PD, 2012, LANCET INFECT DIS, V12, P790, DOI 10.1016/S1473-3099(12)70197-4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8; Henken FE, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-71; Hollenbaugh JA, 2011, VIROLOGY, V415, P153, DOI 10.1016/j.virol.2011.04.007; Jones JL, 1999, J ACQ IMMUN DEF SYND, V21, pS11; Kaarbo M, 2011, MITOCHONDRION, V11, P935, DOI 10.1016/j.mito.2011.08.008; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; Karki R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001331; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kikuchi H, 2009, CANCER RES, V69, P8499, DOI 10.1158/0008-5472.CAN-09-2213; Kim JE, 2004, DIABETES, V53, P2748, DOI 10.2337/diabetes.53.11.2748; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Kong K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004102; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; LANDINI MP, 1984, J GEN VIROL, V65, P1229, DOI 10.1099/0022-1317-65-7-1229; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Lemon SM, 2012, GASTROENTEROLOGY, V142, P1274, DOI 10.1053/j.gastro.2012.01.045; Lenaerts L, 2008, REV MED VIROL, V18, P357, DOI 10.1002/rmv.589; Li HD, 2015, SCI REP-UK, V5, DOI 10.1038/srep08421; Li QS, 2013, NAT MED, V19, P722, DOI 10.1038/nm.3190; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maehama T, 1998, INT J CANCER, V76, P639, DOI 10.1002/(SICI)1097-0215(19980529)76:5<639::AID-IJC5>3.0.CO;2-R; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Matsuoka M, 2011, ONCOGENE, V30, P1379, DOI 10.1038/onc.2010.537; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; McArdle J, 2011, J VIROL, V85, P705, DOI 10.1128/JVI.01557-10; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Mesri EA, 2014, CELL HOST MICROBE, V15, P266, DOI 10.1016/j.chom.2014.02.011; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Michaelis M, 2009, NEOPLASIA, V11, P1, DOI 10.1593/neo.81178; Miller G, 2009, SCIENCE, V323, P30, DOI 10.1126/science.323.5910.30; Molinolo AA, 2012, CLIN CANCER RES, V18, P2558, DOI 10.1158/1078-0432.CCR-11-2824; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Morrish F, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014225; Mukai R, 2014, ONCOGENE, V33, P2317, DOI 10.1038/onc.2013.181; Munger J, 2008, NAT BIOTECHNOL, V26, P1179, DOI 10.1038/nbt.1500; Munger J, 2006, PLOS PATHOG, V2, P1165, DOI 10.1371/journal.ppat.0020132; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Na TY, 2009, HEPATOLOGY, V49, P1122, DOI 10.1002/hep.22740; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; Nasimuzzaman M, 2007, J VIROL, V81, P10249, DOI 10.1128/JVI.00763-07; Negro F, 2014, J HEPATOL, V61, pS69, DOI 10.1016/j.jhep.2014.08.003; Negro F, 2010, GUT, V59, P1279, DOI 10.1136/gut.2009.192732; Nicolay BN, 2013, CURR OPIN CELL BIOL, V25, P735, DOI 10.1016/j.ceb.2013.07.012; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Pim D, 2005, ONCOGENE, V24, P7830, DOI 10.1038/sj.onc.1208935; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Price RL, 2013, CANCER RES, V73, P3441, DOI 10.1158/0008-5472.CAN-12-3846; Prins RM, 2008, NEW ENGL J MED, V359, P539, DOI 10.1056/NEJMc0804818; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; RACKER E, 1972, AM SCI, V60, P56; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Ramiere C, 2014, J VIROL, V88, P3246, DOI 10.1128/JVI.02862-13; Rickinson AB, 2014, SEMIN CANCER BIOL, V26, P99, DOI 10.1016/j.semcancer.2014.04.004; Ripoli M, 2010, J VIROL, V84, P647, DOI 10.1128/JVI.00769-09; Ritter JB, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-61; Rogers PM, 2008, DIABETES, V57, P2321, DOI 10.2337/db07-1311; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Samanta M, 2003, J UROLOGY, V170, P998, DOI 10.1097/01.ju.0000080263.46164.97; Sanchez EL, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005052; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shin YC, 2008, CANCER RES, V68, P1751, DOI 10.1158/0008-5472.CAN-07-2766; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Spangle JM, 2010, J VIROL, V84, P9398, DOI 10.1128/JVI.00974-10; Spencer CM, 2011, J VIROL, V85, P5814, DOI 10.1128/JVI.02630-10; Sripadi P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012590; Straus S.E., 1984, ADENOVIRUSES, P451, DOI [DOI 10.1007/978-1-4684-7935-5_11, 10.1007/978-1-4684-7935-5_11]; Takahashi M, 2013, ANTIVIR RES, V99, P238, DOI 10.1016/j.antiviral.2013.06.016; TANAKA S, 1975, J VIROL, V15, P297, DOI 10.1128/JVI.15.2.297-304.1975; Tang XD, 2007, CLIN CANCER RES, V13, P2568, DOI 10.1158/1078-0432.CCR-06-2704; Taylor GS, 2011, CANCER LETT, V305, P263, DOI 10.1016/j.canlet.2010.08.019; Teng CF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122373; Teng CF, 2015, J VIROL, V89, P605, DOI 10.1128/JVI.02363-14; Terry LJ, 2012, P NATL ACAD SCI USA, V109, P3071, DOI 10.1073/pnas.1200494109; Thai M, 2014, CELL METAB, V19, P694, DOI 10.1016/j.cmet.2014.03.009; Tommasino M, 2003, HUM MUTAT, V21, P307, DOI 10.1002/humu.10178; Treins C, 2006, BIOCHEM BIOPH RES CO, V342, P1197, DOI 10.1016/j.bbrc.2006.02.088; Uldrick TS, 2011, CANCER LETT, V305, P150, DOI 10.1016/j.canlet.2011.02.006; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Vastag L, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002124; Vazquez A, 2013, CANCER RES, V73, P478, DOI 10.1158/0008-5472.CAN-12-3709; Vogt PK, 2012, NAT REV CANCER, V12, P639, DOI 10.1038/nrc3320; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wang ZQ, 2010, INT J OBESITY, V34, P1355, DOI 10.1038/ijo.2010.77; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; WEINHOUSE S, 1956, SCIENCE, V124, P267, DOI 10.1126/science.124.3215.267; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wu XY, 2008, FEBS LETT, V582, P2155, DOI 10.1016/j.febslet.2008.05.033; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; You XN, 2013, CARCINOGENESIS, V34, P1644, DOI 10.1093/carcin/bgt089; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yu YJ, 2014, P NATL ACAD SCI USA, V111, P1951, DOI 10.1073/pnas.1310779111; Yu YJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003266; Yu YJ, 2012, J VIROL, V86, P2942, DOI 10.1128/JVI.06467-11; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Yurochko AD, 2008, CURR TOP MICROBIOL, V325, P205; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	177	29	33	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4155	4164		10.1038/onc.2015.479	http://dx.doi.org/10.1038/onc.2015.479			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26686092	Bronze			2022-12-17	WOS:000382149800001
J	Kotani, H; Ebi, H; Kitai, H; Nanjo, S; Kita, K; Huynh, TG; Ooi, A; Faber, AC; Mino-Kenudson, M; Yano, S				Kotani, H.; Ebi, H.; Kitai, H.; Nanjo, S.; Kita, K.; Huynh, T. G.; Ooi, A.; Faber, A. C.; Mino-Kenudson, M.; Yano, S.			Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression	ONCOGENE			English	Article							IN-SITU HYBRIDIZATION; ACQUIRED-RESISTANCE; GENE AMPLIFICATION; TARGETED THERAPIES; BREAST-CANCER; GROWTH; SENSITIVITY; ACTIVATION; GENOMICS; AZD4547	Targeted therapies are effective in subsets of lung cancers with EGFR mutations and anaplastic lymphoma kinase (ALK) translocations. Large-scale genomics have recently expanded the lung cancer landscape with FGFR1 amplification found in 10-20% of squamous cell carcinomas (SCCs). However, the response rates have been low for biomarker-directed fibroblast growth factor receptor (FGFR) inhibitor therapy in SCC, which contrasts to the relatively high rates of response seen in EGFR mutant and ALK-translocated lung cancers treated with epidermal growth factor receptor (EGFR) inhibitors and ALK inhibitors, respectively. In order to better understand the low response rates of FGFR1-amplified lung cancers to FGFR inhibitors, relationships between gene copy number, mRNA expression and protein expression of FGFR1 were assessed in cell lines, tumor specimens and data from The Cancer Genome Atlas. The importance of these factors for the sensitivity to FGFR inhibitors was determined by analyzing drug screen data and conducting in vitro and in vivo experiments. We report that there was a discrepancy between FGFR1 amplification level and FGFR1 protein expression in a number of these cell lines, and the cancers with unexpectedly low FGFR1 expression were uniformly resistant to the different FGFR inhibitors. Further interrogation of the receptor tyrosine kinase activity in these discordant cell lines revealed co-activation of HER2 and platelet-derived growth factor receptor-a (PDGFRa) caused by gene amplification or ligand overexpression maintained phosphoinositide 3-kinase (PI3K) and MEK/ERK signaling even in the presence of FGFR inhibitor. Accordingly, co-inhibition of FGFR1 and HER2 or PDGFRa led to enhanced drug responses. In contrast, FGFR1-amplified high FGFR1 protein-expressing lung cancers are sensitive to FGFR inhibitor monotherapy by downregulating ERK signaling. Addition of a PI3K inhibitor to these high FGFR1 protein-expressing cancers further sensitized them to FGFR inhibitor. These data reveal that biomarker-directed trials for FGFR1-amplified SCC require assessment of FGFR1 protein expression and uncover novel therapeutic strategies for FGFR1-amplified SCC with low FGFR1 protein expression.	[Kotani, H.; Ebi, H.; Kitai, H.; Nanjo, S.; Kita, K.; Yano, S.] Kanazawa Univ, Canc Res Inst, Div Med Oncol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan; [Huynh, T. G.; Mino-Kenudson, M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Ooi, A.] Kanazawa Univ, Grad Sch Med Sci, Dept Mol & Cellular Pathol, Kanazawa, Ishikawa, Japan; [Faber, A. C.] Virginia Commonwealth Univ, Sch Dent, VCU Philips Inst Oral Hlth Res, Richmond, VA USA; [Faber, A. C.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA	Kanazawa University; Harvard University; Massachusetts General Hospital; Kanazawa University; Virginia Commonwealth University; Virginia Commonwealth University	Ebi, H; Yano, S (corresponding author), Kanazawa Univ, Canc Res Inst, Div Med Oncol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	hebi@staff.kanazawa-u.ac.jp; syano@staff.kanazawa-u.ac.jp	Ebi, Hiromichi/AAA-7358-2019; Kitai, Hidenori/AAD-4168-2022; KITA, Kenji/D-8437-2015	Ebi, Hiromichi/0000-0003-3155-7576; KITA, Kenji/0000-0002-4622-6633; Kotani, Hiroshi/0000-0002-6001-0636; KITAI, HIDENORI/0000-0001-6372-846X	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [26830105, 22112010A01]	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Shuta Tomida at Okayama University for his assistance with the statistics. This work was supported by Grants-in-Aid for Scientific Research (H Ebi, 26830105 and S Yano, 21390256), Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' (H Ebi and S Yano, 22112010A01) and Grant-in-Aid for Project for Development of Innovative Research on Cancer Therapeutics (P-Direct) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.	Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; Dienstmann R, 2014, ANN ONCOL, V25, P552, DOI 10.1093/annonc/mdt419; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Gandara DR, 2015, CLIN CANCER RES, V21, P2236, DOI 10.1158/1078-0432.CCR-14-3039; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Heist RS, 2012, J THORAC ONCOL, V7, P1775, DOI 10.1097/JTO.0b013e31826aed28; Helsten T, 2015, CLIN CANC RES; Herbst RS, 2015, CLIN CANCER RES, V21, P1514, DOI 10.1158/1078-0432.CCR-13-3473; Kim HR, 2013, J CLIN ONCOL, V31, P731, DOI 10.1200/JCO.2012.43.8622; Kohler LH, 2012, VIRCHOWS ARCH, V461, P49, DOI 10.1007/s00428-012-1250-y; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Malchers F, 2014, CANCER DISCOV, V4, P246, DOI 10.1158/2159-8290.CD-13-0323; McDermott U, 2009, CANCER RES, V69, P3937, DOI 10.1158/0008-5472.CAN-08-4327; Meador CB, 2014, CLIN CANCER RES, V20, P2264, DOI 10.1158/1078-0432.CCR-13-1591; Montenegro MF, 2015, ONCOGENE, V34, P135, DOI 10.1038/onc.2013.605; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Nogova L, 2014, ASCO M, V32, P8034; O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016/j.ccr.2009.09.028; Ooi A, 2012, J PATHOL, V227, P8, DOI 10.1002/path.3974; Paik PK, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8035; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Pros E, 2013, INT J CANCER, V133, P898, DOI 10.1002/ijc.28090; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Schildhaus HU, 2012, MODERN PATHOL, V25, P1473, DOI 10.1038/modpathol.2012.102; Seo AN, 2014, VIRCHOWS ARCH, V465, P547, DOI 10.1007/s00428-014-1634-2; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Terai H, 2013, MOL CANCER RES, V11, P759, DOI 10.1158/1541-7786.MCR-12-0652; Tran TN, 2013, LUNG CANCER, V81, P462, DOI 10.1016/j.lungcan.2013.05.015; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wang J, 2015, ONCOGENE, V34, P2167, DOI 10.1038/onc.2014.161; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wynes MW, 2014, CLIN CANCER RES, V20, P3299, DOI 10.1158/1078-0432.CCR-13-3060; Zhang JC, 2012, CLIN CANCER RES, V18, P6658, DOI 10.1158/1078-0432.CCR-12-2694	49	29	30	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3587	3597		10.1038/onc.2015.426	http://dx.doi.org/10.1038/onc.2015.426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26549034	Green Submitted			2022-12-17	WOS:000379621500011
J	Diersch, S; Wirth, M; Schneeweis, C; Jors, S; Geisler, F; Siveke, JT; Rad, R; Schmid, RM; Saur, D; Rustgi, AK; Reichert, M; Schneider, G				Diersch, S.; Wirth, M.; Schneeweis, C.; Joers, S.; Geisler, F.; Siveke, J. T.; Rad, R.; Schmid, R. M.; Saur, D.; Rustgi, A. K.; Reichert, M.; Schneider, G.			Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells	ONCOGENE			English	Article							C-MYC; FAMILY PROTEINS; BETA-CELLS; CANCER; MOUSE; KRAS; ADENOCARCINOMA; RECEPTOR; CARCINOGENESIS; TRANSCRIPTION	Epidermal growth factor receptor (EGFR) signaling has a critical role in oncogenic Kras-driven pancreatic carcinogenesis. However, the downstream targets of this signaling network are largely unknown. We developed a novel model system utilizing murine primary pancreatic ductal epithelial cells (PDECs), genetically engineered to allow time-specific expression of oncogenic Kras(G12D) from the endogenous promoter. We show that primary PDECs are susceptible to Kras(G12D)-driven transformation and form pancreatic ductal adenocarcinomas in vivo after Cdkn2a inactivation. In addition, we demonstrate that activation of Kras(G12D) induces an EGFR signaling loop to drive proliferation. Interestingly, pharmacological inhibition of EGFR fails to decrease Kras(G12D)-activated ERK or PI3K signaling. Instead our data provide novel evidence that EGFR signaling is needed to activate the oncogenic and pro-proliferative transcription factor c-MYC. EGFR and c-MYC have been shown to be essential for pancreatic carcinogenesis. Importantly, our data link both pathways and thereby explain the crucial role of EGFR for Kras(G12D)-driven carcinogenesis in the pancreas.	[Diersch, S.; Wirth, M.; Schneeweis, C.; Joers, S.; Geisler, F.; Siveke, J. T.; Rad, R.; Schmid, R. M.; Saur, D.; Reichert, M.; Schneider, G.] Tech Univ Munich, Med Klin 2, Munich, Germany; [Siveke, J. T.] German Canc Consortium DKTK, Div Translat Solid Tumor Oncol, Partner Site Essen & German Canc Res Ctr DKFZ, Heidelberg, Germany; [Rustgi, A. K.; Reichert, M.] Univ Penn, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Rustgi, A. K.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Rustgi, A. K.] Univ Penn, Dept Genet, Perelman Sch Med, Philadelphia, PA 19104 USA; [Rustgi, A. K.; Reichert, M.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA	Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Schneider, G (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin 2, Ismaninger Str 22, D-81675 Munich, Germany.	guenter.schneider@tum.de	Siveke, Jens/AAQ-6170-2021; Saur, Dieter/O-8355-2015; Reichert, Maximilian/GOH-1246-2022; Wirth, Matthias/AEG-6333-2022	Saur, Dieter/0000-0001-5874-0210; Wirth, Matthias/0000-0002-8340-0872	Wilhelm-Sander Foundation [2012.084.1]; Deutsche Forschungsgemeinschaft (DFG) [SCHN 959/1-2, SCHN 959/2-1, GE2289/1, SI 1549/2-1, SFB824]; Deutsche Krebshilfe [110908, 111273, 109992]; NIH [NIHP30 DK050306, NIH R01DK060694]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060694, P30DK050306] Funding Source: NIH RePORTER	Wilhelm-Sander Foundation; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs S. Hingorani, I. Verma, D. Tuveson, H. Zeng, F. Costantini, T. Jacks, R. DePhino, J. Ferrer, I. de Alboran and F. Alt for generating or providing mouse lines/plasmids. This work was supported by the Wilhelm-Sander Foundation (2012.084.1 to GS), Deutsche Forschungsgemeinschaft (DFG) (SCHN 959/1-2, SCHN 959/2-1 to GS, GE2289/1 to FG, SI 1549/2-1 to JTS and SFB824 to GS and DS), Deutsche Krebshilfe (110908 to GS, 111273 (Max-Eder Program) to MR and 109992 to JTS) and NIH (NIHP30 DK050306 Center for Molecular Studies in Digestive and Liver Diseases (Molecular Pathology and Imaging, Molecular Biology/Gene Expression, Cell Culture, and Transgenic and Chimeric Mouse Cores) to MR and AKR and the NIH R01DK060694 to MR and AKR).	Appleman VA, 2012, MOL CANCER RES, V10, P1228, DOI 10.1158/1541-7786.MCR-12-0340-T; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bonal C, 2009, GASTROENTEROLOGY, V136, P309, DOI 10.1053/j.gastro.2008.10.015; Conradt L, 2011, NEOPLASIA, V13, P1026, DOI 10.1593/neo.111016; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Grippo PJ, 2012, INT J CANCER, V131, P1243, DOI 10.1002/ijc.27322; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hessmann E, 2016, ONCOGENE, V35, P1609, DOI 10.1038/onc.2015.216; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Ischenko I, 2014, P NATL ACAD SCI USA, V111, P3466, DOI 10.1073/pnas.1319911111; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Jors S, 2015, J CLIN INVEST, V125, P2445, DOI 10.1172/JCI78585; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee KE, 2010, CANCER CELL, V18, P448, DOI 10.1016/j.ccr.2010.10.020; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; Lin WC, 2013, CANCER RES, V73, P1821, DOI 10.1158/0008-5472.CAN-12-2067; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Nakhai H, 2008, DEVELOPMENT, V135, P3191, DOI 10.1242/dev.017137; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Perera RM, 2012, CANCER CELL, V22, P281, DOI 10.1016/j.ccr.2012.08.019; Pinho AV, 2011, CELL CYCLE, V10, P1312, DOI 10.4161/cc.10.8.15363; Pinho AV, 2011, GUT, V60, P958, DOI 10.1136/gut.2010.225920; Puri S, 2015, CELL STEM CELL, V16, P18, DOI 10.1016/j.stem.2014.11.001; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Reichert M, 2013, GENE DEV, V27, P288, DOI 10.1101/gad.204453.112; Reichert M, 2011, J CLIN INVEST, V121, P4572, DOI 10.1172/JCI57131; Saborowski M, 2014, GENE DEV, V28, P85, DOI 10.1101/gad.232082.113; Sancho R, 2014, CELL STEM CELL, V15, P139, DOI 10.1016/j.stem.2014.06.019; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Schild C, 2009, MOL CARCINOGEN, V48, P1149, DOI 10.1002/mc.20569; Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Skoudy Anouchka, 2011, J Gastrointest Cancer, V42, P76, DOI 10.1007/s12029-011-9258-0; Solar M, 2009, DEV CELL, V17, P849, DOI 10.1016/j.devcel.2009.11.003; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; von Burstin J, 2015, MOL CANCER RES, V13, P863, DOI 10.1158/1541-7786.MCR-14-0709; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhou Q, 2007, DEV CELL, V13, P103, DOI 10.1016/j.devcel.2007.06.001	53	29	29	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3880	3886		10.1038/onc.2015.437	http://dx.doi.org/10.1038/onc.2015.437			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26592448	Green Accepted			2022-12-17	WOS:000380753200013
J	Dai, B; Chen, AY; Corkum, CP; Peroutka, RJ; Landon, A; Houng, S; Muniandy, PA; Zhang, Y; Lehrmann, E; Mazan-Mamczarz, K; Steinhardt, J; Shlyak, M; Chen, QC; Becker, KG; Livak, F; Michalak, TI; Talwani, R; Gartenhaus, RB				Dai, B.; Chen, A. Y.; Corkum, C. P.; Peroutka, R. J.; Landon, A.; Houng, S.; Muniandy, P. A.; Zhang, Y.; Lehrmann, E.; Mazan-Mamczarz, K.; Steinhardt, J.; Shlyak, M.; Chen, Q. C.; Becker, K. G.; Livak, F.; Michalak, T. I.; Talwani, R.; Gartenhaus, R. B.			Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders	ONCOGENE			English	Article							BLOOD MONONUCLEAR-CELLS; IN-VIVO; DNA-REPAIR; IONIZING-RADIATION; OCCULT INFECTION; LOW-LEVEL; EXPRESSION; LYMPHOMA; CHK2; REPLICATION	B-cell receptor (BCR) signaling is essential for the development of B cells and has a critical role in B-cell neoplasia. Increasing evidence indicates an association between chronic hepatitis C virus (HCV) infection and B-cell lymphoma, however, the mechanisms by which HCV causes B-cell lymphoproliferative disorder are still unclear. Herein, we demonstrate the expression of HCV viral proteins in B cells of HCV-infected patients and show that HCV upregulates BCR signaling in human primary B cells. HCV nonstructural protein NS3/4A interacts with CHK2 and downregulates its activity, modulating HuR posttranscriptional regulation of a network of target mRNAs associated with B-cell lymphoproliferative disorders. Interestingly, the BCR signaling pathway was found to have the largest number of transcripts with increased association with HuR and was upregulated by NS3/4A. Our study reveals a previously unidentified role of NS3/4A in regulation of host BCR signaling during HCV infection, contributing to a better understanding of the molecular mechanisms underlying HCV-associated B-cell lymphoproliferative disorders.	[Dai, B.; Peroutka, R. J.; Landon, A.; Houng, S.; Muniandy, P. A.; Mazan-Mamczarz, K.; Steinhardt, J.; Livak, F.; Gartenhaus, R. B.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Dept Med, Baltimore, MD 21201 USA; [Chen, A. Y.; Corkum, C. P.; Michalak, T. I.] Mem Univ Newfoundland, Fac Med, Div Biomed Sci, Mol Virol & Hepatol Res Grp, St John, NF, Canada; [Zhang, Y.; Lehrmann, E.; Becker, K. G.] NIA, Gene Express & Genom Unit, Genet Lab, NIH, Baltimore, MD 21224 USA; [Shlyak, M.; Talwani, R.] Univ Maryland, Sch Med, Inst Human Virol, Dept Infect Dis, Baltimore, MD 21201 USA; [Chen, Q. C.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Gartenhaus, R. B.] Vet Adm Med Ctr, Baltimore, MD 21218 USA	University System of Maryland; University of Maryland Baltimore; Memorial University Newfoundland; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gartenhaus, RB (corresponding author), Univ Maryland, Med Ctr, Marlene & Stewart Greenebaum Canc Ctr, Dept Med, 655 West Baltimore St,BRB 9-011, Baltimore, MD 21201 USA.	rgartenhaus@som.umaryland.edu	Talwani, Rohit/B-8234-2019	Lehrmann, Elin/0000-0002-9869-9475	Department of Veterans Affairs; National Institutes of Health [R01AA017972, R01CA164311]; Canadian Institutes of Health Research [MOP-126056]; Canada Research Chair Program in Viral Hepatitis/Immunology; Intramural Research Program of the NIH, National Institute on Aging; NATIONAL CANCER INSTITUTE [R01CA164311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017972] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002990, I01BX001219] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chair Program in Viral Hepatitis/Immunology; Intramural Research Program of the NIH, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Veterans Affairs(US Department of Veterans Affairs)	We are grateful to Dr El Mustapha Bahassi for the gift of CHK2 and its truncated constructs. We thank Dr Michael MC Lai from the Institute of Molecular Biology, Academia Sinica, Taiwan for generously sharing NS3/4A constructs. We are thankful to Dr Michael Gale Jr (University of Washington, WA, USA) for generously sharing a series of FLAG epitope-tagged NS3/4A truncation and deletion mutant plasmids. We are very grateful to Dr Eric Campeau for the use of pLenti-CMVTRE3G and pLenti-CMV-rtTA3-Blast plasmids. We thank Dr Shyamasundaran Kottilil and Dr Patricia M Mulrooney-Cousins for helpful discussions. Flow cytometry analyses were performed at the University of Maryland Marlene and Stewart Greenebaum Cancer Center Flow Cytometry Shared Service. This work was supported in part by a Merit Review Award from the Department of Veterans Affairs (RBG), R01AA017972 (RBG) and R01CA164311 (RBG) from the National Institutes of Health, as well as MOP-126056 (TIM) from the Canadian Institutes of Health Research and the Canada Research Chair Program in Viral Hepatitis/Immunology (TIM). This research was also supported in part by the Intramural Research Program of the NIH, National Institute on Aging (YZ, EL and KGB).	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Beran RKF, 2008, J BIOL CHEM, V283, P29929, DOI 10.1074/jbc.M804065200; Bleesing JJH, 2003, CYTOM PART B-CLIN CY, V51B, P1, DOI 10.1002/cyto.b.10007; Dai BJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1404; Dai BJ, 2009, CANCER RES, V69, P7835, DOI 10.1158/0008-5472.CAN-09-1606; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; De Sanjose S, 2008, CLIN GASTROENTEROL H, V6, P451, DOI 10.1016/j.cgh.2008.02.011; Durand T, 2010, GUT, V59, P934, DOI 10.1136/gut.2009.192088; Hermine O, 2002, NEW ENGL J MED, V347, P89, DOI 10.1056/NEJMoa013376; Inokuchi M, 2009, J MED VIROL, V81, P619, DOI 10.1002/jmv.21388; Ito M, 2010, CLIN IMMUNOL, V135, P459, DOI 10.1016/j.clim.2010.02.002; Januszkiewicz-Lewandowska D, 2007, JPN J INFECT DIS, V60, P29; Kasama Y, 2010, BLOOD, V116, P4926, DOI 10.1182/blood-2010-05-283358; Lai CK, 2008, VIROLOGY, V370, P295, DOI 10.1016/j.virol.2007.08.037; LANFORD RE, 1995, J VIROL, V69, P8079, DOI 10.1128/JVI.69.12.8079-8083.1995; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lin L, 2002, J VIROL METHODS, V100, P97, DOI 10.1016/S0166-0934(01)00399-8; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Machida K, 2010, J IMMUNOL, V185, P6985, DOI 10.4049/jimmunol.1000618; Masuda K, 2011, EMBO J, V30, P1040, DOI 10.1038/emboj.2011.24; Mazan-Mamczarz K, 2008, ONCOGENE, V27, P6151, DOI 10.1038/onc.2008.215; Mazan-Mamczarz K, 2011, BLOOD, V117, P2441, DOI 10.1182/blood-2010-09-310987; Mellor J, 1998, J GEN VIROL, V79, P705, DOI 10.1099/0022-1317-79-4-705; Ng PP, 2014, BLOOD, V123, P1512, DOI 10.1182/blood-2013-10-532895; Okudela K, 2013, INT J CLIN EXP PATHO, V6, P1; Pal S, 2006, GASTROENTEROLOGY, V130, P1107, DOI 10.1053/j.gastro.2005.12.039; Pham TNQ, 2004, J VIROL, V78, P5867, DOI 10.1128/JVI.78.11.5867-5874.2004; Pham TNQ, 2005, J GEN VIROL, V86, P657, DOI 10.1099/vir.0.80624-0; Pham TNQ, 2008, GASTROENTEROLOGY, V134, P812, DOI 10.1053/j.gastro.2007.12.011; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Sarhan MA, 2012, J VIROL, V86, P3723, DOI 10.1128/JVI.06956-11; Sung VMH, 2003, J VIROL, V77, P2134, DOI 10.1128/JVI.77.3.2134-2146.2003; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Touma SE, 2009, BIOCHEM PHARMACOL, V78, P1127, DOI 10.1016/j.bcp.2009.06.022; Young RM, 2013, NAT REV DRUG DISCOV, V12, P229, DOI 10.1038/nrd3937	37	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2979	2990		10.1038/onc.2015.364	http://dx.doi.org/10.1038/onc.2015.364			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434584	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000377474500004
J	Yokdang, N; Hatakeyama, J; Wald, JH; Simion, C; Tellez, JD; Chang, DZ; Swamynathan, MM; Chen, M; Murphy, WJ; Carraway, KL; Sweeney, C				Yokdang, N.; Hatakeyama, J.; Wald, J. H.; Simion, C.; Tellez, J. D.; Chang, D. Z.; Swamynathan, M. M.; Chen, M.; Murphy, W. J.; Carraway, K. L., III; Sweeney, C.			LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; HUMAN-PAPILLOMAVIRUS STATUS; NEGATIVE REGULATOR LRIG1; LEUCINE-RICH REPEAT; MET RECEPTOR; C-MET; CLINICAL-IMPLICATIONS; MASTER REGULATORS; TUMOR-SUPPRESSOR; TIGHT JUNCTIONS	LRIG1 (leucine-rich repeat and immunoglobulin-like domain containing), a member of the LRIG family of transmembrane leucine-rich repeat-containing proteins, is a negative regulator of receptor tyrosine kinase signaling and a tumor suppressor. LRIG1 expression is broadly decreased in human cancer and in breast cancer and low expression of LRIG1 has been linked to decreased relapse-free survival. Recently, low expression of LRIG1 was revealed to be an independent risk factor for breast cancer metastasis and death. These findings suggest that LRIG1 may oppose breast cancer cell motility and invasion, cellular processes that are fundamental to metastasis. However, very little is known of LRIG1 function in this regard. In this study, we demonstrate that LRIG1 is downregulated during epithelial-to-mesenchymal transition (EMT) of human mammary epithelial cells, suggesting that LRIG1 expression may represent a barrier to EMT. Indeed, depletion of endogenous LRIG1 in human mammary epithelial cells expands the stem cell population, augments mammosphere formation and accelerates EMT. Conversely, expression of LRIG1 in highly invasive Basal B breast cancer cells provokes a mesenchymal-to-epithelial transition accompanied by a dramatic suppression of tumorsphere formation and a striking loss of invasive growth in three-dimensional culture. LRIG1 expression perturbs multiple signaling pathways and represses markers and effectors of the mesenchymal state. Furthermore, LRIG1 expression in MDA-MB-231 breast cancer cells significantly slows their growth as tumors, providing the first in vivo evidence that LRIG1 functions as a growth suppressor in breast cancer.	[Yokdang, N.; Hatakeyama, J.; Wald, J. H.; Simion, C.; Chang, D. Z.; Swamynathan, M. M.; Carraway, K. L., III; Sweeney, C.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Tellez, J. D.; Chen, M.] Univ Calif Davis, Dept Pathol & Lab Med, Sacramento, CA 95817 USA; [Murphy, W. J.] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Sweeney, C (corresponding author), Univ Calif, UC Davis Med Ctr, Dept Biochem & Mol Med, Res Bldg 3,4645 2nd Ave, Sacramento, CA 95817 USA.	casweeney@ucdavis.edu		Mosur Swamynathan, Manojit/0000-0003-1156-586X; Hatakeyama, Jason/0000-0001-8690-5107	T32 training grant in Oncogenic Signals and Chromosome Biology [CA108459]; Lawrence Livermore National Labs UC Davis Fitzpatrick Research Fellowship; NIH [CA118384, CA166412]; UC Davis Comprehensive Cancer Center Support Grant (CCSG) - National Cancer Institute [NCI P30CA093373]; NATIONAL CANCER INSTITUTE [T32CA108459, P30CA093373, R01CA166412, R01CA118384] Funding Source: NIH RePORTER	T32 training grant in Oncogenic Signals and Chromosome Biology; Lawrence Livermore National Labs UC Davis Fitzpatrick Research Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UC Davis Comprehensive Cancer Center Support Grant (CCSG) - National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Robert Weinberg (Whitehead Institute) for the kind gift of the HMLE and HMLE-Twist-ER cells, Dr Paola Marignani (Dalhousie University) for the kind gift of the 293GPG packaging cell line, and Dr Ashley Hodel and Mr Sina Azadi for technical support and advice. Dr Nucharee Yokdang was a trainee on the T32 training grant in Oncogenic Signals and Chromosome Biology (CA108459). Dr Joseph Tellez was supported by a Lawrence Livermore National Labs UC Davis Fitzpatrick Research Fellowship. This work was supported by NIH grants CA118384 (Sweeney) and CA166412 (Carraway). We acknowledge the UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute (NCI P30CA093373) for using the flow cytometer.	Accornero P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044982; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Bai LC, 2012, CANCER RES, V72, P1229, DOI 10.1158/0008-5472.CAN-11-2428; Chang L, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-101; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Chun J, 2013, CHEM-BIOL INTERACT, V205, P212, DOI 10.1016/j.cbi.2013.07.002; Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Gastaldi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2617; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hallett RM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00227; Hawkes SP, 2010, METHODS MOL BIOL, V622, P257, DOI 10.1007/978-1-60327-299-5_16; Hedman H, 2007, EUR J CANCER, V43, P676, DOI 10.1016/j.ejca.2006.10.021; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Ho-Yen CM, 2014, CANCER-AM CANCER SOC, V120, P163, DOI 10.1002/cncr.28386; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Jensen KB, 2006, P NATL ACAD SCI USA, V103, P11958, DOI 10.1073/pnas.0601886103; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jezequel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7; Jimenez-Salazar JE, 2014, HORM CANCER-US, V5, P161, DOI 10.1007/s12672-014-0180-3; Kim YJ, 2014, INT J CANCER, V134, P2424, DOI 10.1002/ijc.28566; Knopfova L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-15; Krig SR, 2011, MOL CANCER RES, V9, P1406, DOI 10.1158/1541-7786.MCR-11-0227; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Ledda F, 2008, J NEUROSCI, V28, P39, DOI 10.1523/JNEUROSCI.2196-07.2008; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Leidy J, 2014, ARCH PATHOL LAB MED, V138, P37, DOI 10.5858/arpa.2012-0439-RA; Lim YC, 2012, ORAL ONCOL, V48, P1114, DOI 10.1016/j.oraloncology.2012.05.013; Lindquist D, 2014, BRIT J CANCER, V110, P1793, DOI 10.1038/bjc.2014.87; Liu L, 2011, MOL CANCER THER, V10, P518, DOI 10.1158/1535-7163.MCT-10-0698; Lu L, 2013, J PATHOL, V229, P608, DOI 10.1002/path.4148; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marchini C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014131; Mehner C, 2014, ONCOTARGET, V5, P2736, DOI 10.18632/oncotarget.1932; Miller JK, 2008, CANCER RES, V68, P8286, DOI 10.1158/0008-5472.CAN-07-6316; Mueller KL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3224; Muller S, 2013, INT J ONCOL, V42, P247, DOI 10.3892/ijo.2012.1702; Munshi N, 2010, MOL CANCER THER, V9, P1544, DOI 10.1158/1535-7163.MCT-09-1173; Nakamura T, 2014, J CLIN INVEST, V124, P385, DOI 10.1172/JCI71488; Nalwoga H, 2010, BRIT J CANCER, V102, P369, DOI 10.1038/sj.bjc.6605488; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nilsson J, 2001, BIOCHEM BIOPH RES CO, V284, P1155, DOI 10.1006/bbrc.2001.5092; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ponzo MG, 2010, CELL CYCLE, V9, P1043, DOI 10.4161/cc.9.6.11033; Ponzo MG, 2009, P NATL ACAD SCI USA, V106, P12903, DOI 10.1073/pnas.0810402106; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Rafidi H, 2013, J BIOL CHEM, V288, P21593, DOI 10.1074/jbc.M113.486050; Rhodes LV, 2014, BREAST CANCER RES TR, V145, P593, DOI 10.1007/s10549-014-2979-6; Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035; Rondahl V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073635; Rouam S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-150; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Sheu JJC, 2014, ONCOGENE, V33, P1375, DOI 10.1038/onc.2013.98; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Tanemura A, 2005, DERMATOL SURG, V31, P423, DOI 10.1097/00042728-200504000-00008; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thompson PA, 2014, CANCER RES, V74, P2928, DOI 10.1158/0008-5472.CAN-13-2112; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tsai PC, 2012, TOXICON, V60, P734, DOI 10.1016/j.toxicon.2012.05.019; Valentin MD, 2012, BREAST CANCER RES TR, V134, P21, DOI 10.1007/s10549-011-1934-z; Van Itallie CM, 2014, SEMIN CELL DEV BIOL, V36, P157, DOI 10.1016/j.semcdb.2014.08.011; Wang B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041355; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Wang Y, 2013, BRIT J CANCER, V108, P1765, DOI 10.1038/bjc.2013.138; Wang YS, 2014, CANCER RES, V74, P520, DOI 10.1158/0008-5472.CAN-13-2182; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Xie RF, 2013, ONCOL REP, V29, P177, DOI 10.3892/or.2012.2102; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; YOUNG RK, 1974, IN VITRO CELL DEV B, V9, P239	80	29	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2932	2947		10.1038/onc.2015.345	http://dx.doi.org/10.1038/onc.2015.345			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387542	Green Accepted, Green Submitted			2022-12-17	WOS:000377473700013
J	Puhr, M; Hoefer, J; Eigentler, A; Dietrich, D; van Leenders, G; Uhl, B; Hoogland, M; Handle, F; Schlick, B; Neuwirt, H; Sailer, V; Kristiansen, G; Klocker, H; Culig, Z				Puhr, M.; Hoefer, J.; Eigentler, A.; Dietrich, D.; van Leenders, G.; Uhl, B.; Hoogland, M.; Handle, F.; Schlick, B.; Neuwirt, H.; Sailer, V.; Kristiansen, G.; Klocker, H.; Culig, Z.			PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer	ONCOGENE			English	Article							ANDROGEN RECEPTOR; SPLICE VARIANTS; SUMOYLATION; DOCETAXEL; ENZALUTAMIDE; ABIRATERONE; RESISTANCE; PATHWAY; PROLIFERATION; MITOXANTRONE	Novel drugs like Abiraterone or Enzalutamide, which target androgen receptor (AR) signaling to improve androgen deprivation therapy (ADT), have been developed during the past years. However, the application of these drugs is limited because of occurrence of inherent or acquired therapy resistances during the treatment. Thus, identification of new molecular targets is urgently required to improve current therapeutic prostate cancer (PCa) treatment strategies. PIAS1 (protein inhibitor of activated STAT1 (signal transducer and activator of transcription-1)) is known to be an important cell cycle regulator and PIAS1-mediated SUMOylation is essential for DNA repair. In this context, elevated PIAS1 expression has already been associated with cancer initiation. Thus, in the present study, we addressed the question of whether PIAS1 targeting can be used as a basis for an improved PCa therapy in combination with anti-androgens. We show that PIAS1 significantly correlates with AR expression in PCa tissue and in cell lines and demonstrate that high PIAS1 levels predict shorter relapse-free survival. Our patient data are complemented by mechanistic and functional in vitro experiments that identify PIAS1 as an androgen-responsive gene and a crucial factor for AR signaling via prevention of AR degradation. Furthermore, PIAS1 knockdown is sufficient to decrease cell proliferation as well as cell viability. Strikingly, Abiraterone or Enzalutamide treatment in combination with PIAS1 depletion is even more effective than singledrug treatment in multiple PCa cell models, rendering PIAS1 as a promising target protein for a combined treatment approach to improve future PCa therapies.	[Puhr, M.; Hoefer, J.; Eigentler, A.; Handle, F.; Schlick, B.; Klocker, H.; Culig, Z.] Med Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria; [Dietrich, D.; Uhl, B.; Sailer, V.; Kristiansen, G.] Univ Hosp Bonn, Inst Pathol, Bonn, Germany; [van Leenders, G.; Hoogland, M.] Erasmus MC, Inst Pathol, Rotterdam, Netherlands; [Neuwirt, H.] Med Univ Innsbruck, Dept Internal Med Nephrol & Hypertens 4, A-6020 Innsbruck, Austria	Medical University of Innsbruck; University of Bonn; Erasmus University Rotterdam; Erasmus MC; Medical University of Innsbruck	Puhr, M (corresponding author), Med Univ Innsbruck, Dept Urol, Expt Urol, Anichstr 35, A-6020 Innsbruck, Austria.	martin.puhr@i-med.ac.at	Klocker, Helmut/AAI-7130-2020; Handle, Florian/S-5447-2019; Neuwirt, Hannes/AAF-1090-2019	Handle, Florian/0000-0002-7558-5635; Hoefer, Julia/0000-0003-1138-3134; Neuwirt, Hannes/0000-0003-1064-0098	Austrian Cancer Society/Tirol; intramural funding program of the Medical University of Innsbruck for young scientists MUI-START [2010012007]; Austrian Science Fund (FWF) [P 25639-B19, W1101-B18]; Anniversary Fund Austrian National Bank (ONB) Grant [15374]; Austrian Science Fund (FWF) [P 25639] Funding Source: researchfish	Austrian Cancer Society/Tirol; intramural funding program of the Medical University of Innsbruck for young scientists MUI-START; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Anniversary Fund Austrian National Bank (ONB) Grant; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Irma Sottsas for TMA preparation, paraffin embedding and immunohistochemistry (IHC) stainings, Mag Eberhard Steiner for patient selection and statistical analysis, Dr Walter Parson for cell line authentication and Dr Yaron Galanty (University of Cambridge) for generously sharing PIAS1 constructs. This work was supported by the Austrian Cancer Society/Tirol, the intramural funding program of the Medical University of Innsbruck for young scientists MUI-START, Project 2010012007, Austrian Science Fund (FWF) Grants P 25639-B19 (to MP) and W1101-B18 (to ZC) and Anniversary Fund Austrian National Bank (ONB) Grant 15374 (to ZC).	Bu H, 2013, FEBS J, V280, P1249, DOI 10.1111/febs.12118; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Driscoll JJ, 2010, BLOOD, V115, P2827, DOI 10.1182/blood-2009-03-211045; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Geney R, 2002, CLIN CHEM LAB MED, V40, P918, DOI 10.1515/CCLM.2002.161; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Heemers HV, 2009, MOL ENDOCRINOL, V23, P572, DOI 10.1210/me.2008-0363; Heidegger I, 2014, ANTICANCER RES, V34, P307; Hobisch A, 2006, PROSTATE, V66, P413, DOI 10.1002/pros.20365; Hobisch A, 2001, CLIN CANCER RES, V7, P2941; Hoefer J, 2012, AM J PATHOL, V180, P2097, DOI 10.1016/j.ajpath.2012.01.026; Hoogland AM, 2012, MODERN PATHOL, V25, P471, DOI 10.1038/modpathol.2011.176; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089464; Mikolcevic P, 2012, MOL CELL BIOL, V32, P868, DOI 10.1128/MCB.06261-11; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Nadal R, 2014, PROSTATE, V74, P1560, DOI 10.1002/pros.22874; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Puhr M, 2014, ONCOTARGET, V5, P12043, DOI 10.18632/oncotarget.2658; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Puhr M, 2009, CANCER RES, V69, P7375, DOI 10.1158/0008-5472.CAN-09-0806; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Rytinki M, 2012, MOL CELL BIOL, V32, P4195, DOI 10.1128/MCB.00753-12; Rytinki MM, 2009, CELL MOL LIFE SCI, V66, P3029, DOI 10.1007/s00018-009-0061-z; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Sharrocks AD, 2006, GENE DEV, V20, P754, DOI 10.1101/gad.1421006; Shima H, 2013, J CELL SCI, V126, P5284, DOI 10.1242/jcs.133744; Sutinen P, 2014, NUCLEIC ACIDS RES, V42, P8310, DOI 10.1093/nar/gku543; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Toropainen S, 2015, NUCLEIC ACIDS RES, V43, P848, DOI 10.1093/nar/gku1375; van der Steen T, 2013, INT J MOL SCI, V14, P14833, DOI 10.3390/ijms140714833; van Soest RJ, 2013, EUR J CANCER, V49, P3821, DOI 10.1016/j.ejca.2013.09.026	39	29	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2322	2332		10.1038/onc.2015.292	http://dx.doi.org/10.1038/onc.2015.292			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26257066	hybrid, Green Published			2022-12-17	WOS:000376165000005
J	De Donatis, GM; Le Pape, E; Pierron, A; Cheli, Y; Hofman, V; Hofman, P; Allegra, M; Zahaf, K; Bahadoran, P; Rocchi, S; Bertolotto, C; Ballotti, R; Passeron, T				De Donatis, G. M.; Le Pape, E.; Pierron, A.; Cheli, Y.; Hofman, V.; Hofman, P.; Allegra, M.; Zahaf, K.; Bahadoran, P.; Rocchi, S.; Bertolotto, C.; Ballotti, R.; Passeron, T.			NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2	ONCOGENE			English	Article							POLYCOMB GROUP PROTEIN; KAPPA-B ACTIVITY; NEOPLASTIC TRANSFORMATION; CELLULAR SENESCENCE; SIGNALING PATHWAY; EPITHELIAL-CELLS; EXPRESSION; CANCER; GROWTH; DIFFERENTIATION	Enhancer of Zeste homologue 2 (EZH2) belongs to the polycomb repressive complex 2 and catalyzes the methylation of histone H3 lysine 27. These pivotal epigenetic marks are altered in many cancers, including melanoma, as a result of EZH2 overexpression. Here, we show that the non-canonical-NF-kB pathway accounts for most of the NF-kB activity in melanoma cells, in contrast to non-cancer cells. We identify the non-canonical-NF-kB pathway as a key regulator of EZH2 expression in melanoma. We show a striking correlation between NF-kB2 and EZH2 expression in human melanoma metastases. We demonstrate that inhibition of the non-canonical NF-kB pathway by targeting NF-kB2/p52 or the upstream kinase NIK restores the senescence program in melanoma cells through the decrease of EZH2. On the contrary, the overexpression of NF-kB2/p52 in normal human melanocytes prevents stress- and oncogene-induced senescence. Finally, we show in mouse models that the inhibition of the non-canonical NF-kB pathway restores senescence and induces a dramatic reduction in tumor growth compared with controls, thus providing potential drug targets for the re-induction of senescence in melanoma and other cancers where EZH2 is overexpressed.	[De Donatis, G. M.; Le Pape, E.; Pierron, A.; Passeron, T.] C3M, INSERM, U1065, Team 12, Nice, France; [Cheli, Y.; Allegra, M.; Bahadoran, P.; Rocchi, S.; Bertolotto, C.; Ballotti, R.] C3M, INSERM, U1065, Team 1, Nice, France; [Hofman, V.; Hofman, P.; Zahaf, K.] CHU Nice, Human Biobank, F-06202 Nice, France; [Hofman, V.; Hofman, P.; Zahaf, K.] IRCAN CNRS, Inst Res Canc & Aging, Nice, France; [Bahadoran, P.; Ballotti, R.; Passeron, T.] Univ Hosp Nice, Dept Dermatol, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Passeron, T (corresponding author), Univ Hosp Nice, Dept Dermatol, U1065, Archet Hosp 2, 150 Route Ginestiere,Batiment Archimed, F-06200 Nice, France.	passeron@unice.fr	Hofman, Paul/P-7654-2018; BALLOTTI, Robert/F-8825-2013; Bertolotto, Corine/AAF-6634-2021; Rocchi, Stephane/O-4152-2016; Cheli, Yann/O-5783-2016	Hofman, Paul/0000-0003-0431-9353; Bertolotto, Corine/0000-0001-6971-7753; Rocchi, Stephane/0000-0002-0943-1304; Cheli, Yann/0000-0001-9839-4332; veronique, HOFMAN/0000-0003-0943-1627; Bahadoran, Philippe/0000-0002-2481-0556; Passeron, Thierry/0000-0002-0797-6570; BALLOTTI, Robert/0000-0002-7322-4908	Institut National de la Sante et de la Recherche Medicale (INSERM); Fondation ARC; Societe Francaise de Recherche en Dermatologie (SRD)	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation ARC; Societe Francaise de Recherche en Dermatologie (SRD)	This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM), the Fondation ARC, and the Societe Francaise de Recherche en Dermatologie (SRD). The authors would like to thank Professor Robert Weinberg from the MIT Ludiwig Center for Molecular Biology for kindly providing the Mel-ST cells.	Arisan S, 2005, UROL INT, V75, P252, DOI 10.1159/000087804; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Boisvert M, 2008, VIROLOGY, V380, P1, DOI 10.1016/j.virol.2008.07.023; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chandra T, 2012, MOL CELL, V47, P203, DOI 10.1016/j.molcel.2012.06.010; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3; Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Dukers DF, 2004, AM J PATHOL, V164, P873, DOI 10.1016/S0002-9440(10)63175-6; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kia SK, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-16; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Li KX, 2013, BIOORG MED CHEM LETT, V23, P1238, DOI 10.1016/j.bmcl.2013.01.012; McHugh JB, 2007, J CUTAN PATHOL, V34, P597, DOI 10.1111/j.1600-0560.2006.00678.x; Razani B, 2011, IMMUNOL REV, V244, P44, DOI 10.1111/j.1600-065X.2011.01059.x; Rovillain E, 2011, ONCOGENE, V30, P2356, DOI 10.1038/onc.2010.611; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746; Su J, 2015, ONCOL REP, V34, P235, DOI 10.3892/or.2015.3944; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; Thu YM, 2012, ONCOGENE, V31, P2580, DOI 10.1038/onc.2011.427; Thu YM, 2010, CYTOKINE GROWTH F R, V21, P213, DOI 10.1016/j.cytogfr.2010.06.002; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wharry CE, 2009, CANCER BIOL THER, V8, P1567, DOI 10.4161/cbt.8.16.8961; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	45	29	29	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2735	2745		10.1038/onc.2015.331	http://dx.doi.org/10.1038/onc.2015.331			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364600				2022-12-17	WOS:000377472700007
J	Kuriyama, S; Yoshida, M; Yano, S; Aiba, N; Kohno, T; Minamiya, Y; Goto, A; Tanaka, M				Kuriyama, S.; Yoshida, M.; Yano, S.; Aiba, N.; Kohno, T.; Minamiya, Y.; Goto, A.; Tanaka, M.			LPP inhibits collective cell migration during lung cancer dissemination	ONCOGENE			English	Article							LIPOMA-PREFERRED PARTNER; N-CADHERIN EXPRESSION; MATRIX METALLOPROTEINASES; FOCAL ADHESION; VALPROIC ACID; METASTASIS; INVASION; REQUIRES; DOMAIN; ADENOCARCINOMA	Lipoma preferred partner (LPP) is a LIM domain protein, which has multiple functions as an actin-binding protein and a transcriptional coactivator, and it has been suggested that LPP has some roles in cell migration or invasion, however, its role in cancer cells remains to be elucidated. Here, we showed that LPP degraded N-cadherin in lung cancer, PC14PE6 cells via regulating the expression of matrix metalloproteinase 15 (MMP-15), and loss-of-LPP increases collective cell migration (CCM) and dissemination consequently. Knockdown of LPP and its functional partner, Etv5, markedly restores the full-length N-cadherin and increases cell-cell adhesion. We investigated the common target of LPP and Etv5, and found that MMP-15 is transcribed as their direct transcriptional target. Furthermore, MMP-15 could directly digest the N-cadherin extracellular domain. LPP knockdown in PC14PE6 cells increases N-cadherin-dependent CCM in the three-dimensional collagen gel invasion assays, and promoted the dissemination of cancer cells when they were orthotopically implanted in nude mice. Immunohistochemistry of lung adenocarcinoma specimens revealed the heterogeneity of LPP intensity and complementary expression of LPP and N-cadherin in the primary tumors. These findings suggest that loss-of-LPP, Etv5 or MMP-15 can be a prognostic marker of increasing malignancy.	[Kuriyama, S.; Aiba, N.; Tanaka, M.] Akita Univ, Grad Sch, Dept Mol Med & Biochem, Akita 0108543, Japan; [Kuriyama, S.; Yoshida, M.; Aiba, N.; Goto, A.; Tanaka, M.] Akita Univ, Fac Med, Akita 0108543, Japan; [Yoshida, M.; Goto, A.] Akita Univ, Grad Sch, Dept Cellular & Organ Pathol, Akita 0108543, Japan; [Yano, S.] Kanazawa Univ, Canc Res Inst, Canc Therapeut Dev Program, Div Med Oncol, Kanazawa, Ishikawa 920, Japan; [Kohno, T.] Natl Canc Res Ctr Inst, Div Genome Biol, Grp Dev Mol Diagnost & Individualized Therapy, Chiba, Japan; [Minamiya, Y.] Akita Univ, Dept Thoras Surg, Akita 0108543, Japan	Akita University; Akita University; Akita University; Kanazawa University; Akita University	Tanaka, M (corresponding author), Akita Univ, Dept Mol Med & Biochem, Hondo 1-1-1, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp	Kuriyama, Sei/AAV-2368-2020; Goto, Akiteru/P-5775-2014	Kuriyama, Sei/0000-0002-5502-7177; Goto, Akiteru/0000-0001-8776-9004	NICHD; JST KAKENHI [24700962, 25290042, 26640068]; MEXT KAKENHI [25111702]	NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); JST KAKENHI; MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Yuichiro Hamanaka for kindly providing the melanoma cell lines. The MNCD2 antibody developed by Takeichi and Matsunami was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of NICHD and maintained by Department of Biology, The University of Iowa, Iowa City, IA, USA. This work is supported by JST KAKENHI (grant number 24700962, SK; grant number 25290042, 26640068, MT) and MEXT KAKENHI (grant number 25111702, SK).	Asano K, 2004, J NEURO-ONCOL, V70, P3, DOI 10.1023/B:NEON.0000040811.14908.f2; Breindel JL, 2013, CANCER RES, V73, P5053, DOI 10.1158/0008-5472.CAN-12-3775; Camand E, 2012, J CELL SCI, V125, P844, DOI 10.1242/jcs.087668; Carey MF, 2009, COLD SPRING HARB PRO, V114; Colas E, 2012, ONCOGENE, V31, P4778, DOI 10.1038/onc.2011.632; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Covington MD, 2006, AM J PHYSIOL-RENAL, V290, pF43, DOI 10.1152/ajprenal.00179.2005; Cui Zheng Yun, 2006, Cancer Res Treat, V38, P234, DOI 10.4143/crt.2006.38.4.234; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; de Launoit Y, 2006, BBA-REV CANCER, V1766, P79, DOI 10.1016/j.bbcan.2006.02.002; Doki Y, 1999, BRIT J CANCER, V79, P1121, DOI 10.1038/sj.bjc.6690178; Firlej V, 2008, J CELL SCI, V121, P3393, DOI 10.1242/jcs.027201; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gorenne I, 2003, AM J PHYSIOL-CELL PH, V285, pC674, DOI 10.1152/ajpcell.00608.2002; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grunewald TGP, 2009, TRANSL ONCOL, V2, P107, DOI 10.1593/tlo.09112; Guo BQ, 2006, MOL CELL BIOL, V26, P4529, DOI 10.1128/MCB.01667-05; Haeger A, 2014, BBA-GEN SUBJECTS, V1840, P2386, DOI 10.1016/j.bbagen.2014.03.020; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hegerfeldt Y, 2002, CANCER RES, V62, P2125; Ikebe D, 2007, GENES CELLS, V12, P197, DOI 10.1111/j.1365-2443.2007.01043.x; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kobayashi K, 2004, ONCOGENE, V23, P3089, DOI 10.1038/sj.onc.1207433; Kohutek ZA, 2009, J NEUROSCI, V29, P4605, DOI 10.1523/JNEUROSCI.5126-08.2009; Kuphal S, 2006, ONCOGENE, V25, P248, DOI 10.1038/sj.onc.1209054; Kuriyama S, 2014, J CELL BIOL, V206, P113, DOI 10.1083/jcb.201402093; Lettice LA, 2012, DEV CELL, V22, P459, DOI 10.1016/j.devcel.2011.12.010; Li B, 2003, J CELL SCI, V116, P1359, DOI 10.1242/jcs.00309; Li G, 2001, CANCER RES, V61, P3819; Maret D, 2010, NEOPLASIA, V12, P1066, DOI 10.1593/neo.10954; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Petit MMR, 2008, CIRC RES, V103, P61, DOI 10.1161/CIRCRESAHA.108.177436; Petit MMR, 2003, J BIOL CHEM, V278, P2157, DOI 10.1074/jbc.M206106200; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Shih WT, 2012, J CELL SCI, V125, P3661, DOI 10.1242/jcs.103861; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Tanaka M, 2012, J CELL SCI, V125, P4343, DOI 10.1242/jcs.104083; Theveneau E, 2010, DEV CELL, V19, P39, DOI 10.1016/j.devcel.2010.06.012; Wang Y, 2003, BBA-MOL CELL RES, V1593, P115, DOI 10.1016/S0167-4889(02)00349-X; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; Yamaura T, 2000, NEOPLASIA, V2, P315, DOI 10.1038/sj.neo.7900098; Yano S, 1997, ONCOL RES, V9, P573; Zwolinska AK, 2012, ONCOGENE, V31, P3311, DOI 10.1038/onc.2011.507	52	29	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					952	964		10.1038/onc.2015.155	http://dx.doi.org/10.1038/onc.2015.155			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	26028032				2022-12-17	WOS:000370823300002
J	Zanetti, M; Rodvold, JJ; Mahadevan, NR				Zanetti, M.; Rodvold, J. J.; Mahadevan, N. R.			The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells	ONCOGENE			English	Review							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN-RESPONSE; NF-KAPPA-B; ER QUALITY-CONTROL; TUMOR-CELLS; PROSTATE-CANCER; TRANSCRIPTION FACTOR; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; CALRETICULIN EXPOSURE	The endoplasmic reticulum (ER) stress response/unfolded protein response (UPR) has been thought to influence tumorigenesis mainly through cell-intrinsic, pro-survival effects. In recent years, however, new evidence has emerged showing that the UPR is also the source of cell-extrinsic effects, particularly directed at those immune cells within the tumor microenvironment. Here we will review and discuss this new body of information with focus on the role of cell-extrinsic effects on innate and adaptive immunity, suggesting that the transmission of ER stress from cancer cells to myeloid cells in particular is an expedient used by cancer cells to control the immune microenvironment, which acquires pro-inflammatory as well as immune-suppressive characteristics. These new findings can now be seen in the broader context of similar phenomena described in Caenorhabditis elegans, and an analogy with quorum sensing and 'community effects' in prokaryotes and eukaryotes can be drawn, arguing that a cell-nonautonomous UPR-based regulation of heterologous cells may be phylogenetically conserved. Finally, we will discuss the role of aneuploidy as an inducer of proteotoxic stress and potential initiator of cell-nonautonomous UPR-based regulation. In presenting these new views, we wish to bring attention to the cell-extrinsic regulation of tumor growth, including tumor UPR-based cell-nonautonomous signaling as a mechanism of maintaining tumor heterogeneity and resistance to therapy, and suggest therapeutically targeting such mechanisms within the tumor microenvironment.	[Zanetti, M.; Rodvold, J. J.; Mahadevan, N. R.] Univ Calif San Diego, Immunol Lab, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Zanetti, M.; Rodvold, J. J.; Mahadevan, N. R.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Zanetti, M (corresponding author), Univ Calif San Diego, Immunol Lab, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mzanetti@ucsd.edu			UCSD Academic Senate; Frank H. and Eva B. Buck Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007198] Funding Source: NIH RePORTER	UCSD Academic Senate; Frank H. and Eva B. Buck Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by a grant from the UCSD Academic Senate to MZ. JJR acknowledges the support of the Frank H. and Eva B. Buck Foundation.	Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Auf G, 2010, P NATL ACAD SCI USA, V107, P15553, DOI 10.1073/pnas.0914072107; Balmain A, 2003, NAT GENET S, V33, P238; Bartoszewski R, 2011, J BIOL CHEM, V286, P41862, DOI 10.1074/jbc.M111.304956; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Boileve A, 2013, CELL CYCLE, V12, P473, DOI 10.4161/cc.23369; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Chen L, 2009, BIOCHEM PHARMACOL, V78, P70, DOI 10.1016/j.bcp.2009.03.022; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Chen YN, 2013, TRENDS CELL BIOL, V23, P547, DOI 10.1016/j.tcb.2013.06.005; Chitnis NS, 2012, MOL CELL, V48, P353, DOI 10.1016/j.molcel.2012.08.025; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Condamine T, 2014, J CLIN INVEST, V124, P2626, DOI 10.1172/JCI74056; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Cullen SJ, 2013, AM J CANCER RES, V3, P196; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; de Almeida SF, 2007, J IMMUNOL, V178, P3612, DOI 10.4049/jimmunol.178.6.3612; Delay ML, 2009, ARTHRITIS RHEUM-US, V60, P2633, DOI 10.1002/art.24763; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; DIERICK AM, 1993, HISTOPATHOLOGY, V23, P333, DOI 10.1111/j.1365-2559.1993.tb01216.x; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Drogat B, 2007, CANCER RES, V67, P6700, DOI 10.1158/0008-5472.CAN-06-3235; Duesberg P, 2007, SCI AM, V296, P52, DOI 10.1038/scientificamerican0507-52; Eletto D, 2010, SEMIN CELL DEV BIOL, V21, P479, DOI 10.1016/j.semcdb.2010.03.004; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497; Goodall JC, 2010, P NATL ACAD SCI USA, V107, P17698, DOI 10.1073/pnas.1011736107; Granados DP, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-10; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; GURDON JB, 1993, CELL, V75, P831, DOI 10.1016/0092-8674(93)90526-V; Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054; Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631; Howarth M, 2004, P NATL ACAD SCI USA, V101, P11737, DOI 10.1073/pnas.0306294101; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Hung JH, 2004, J BIOL CHEM, V279, P46384, DOI 10.1074/jbc.M403568200; Idowu MO, 2012, HUM PATHOL, V43, P364, DOI 10.1016/j.humpath.2011.05.005; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Iwakoshi NN, 2007, J EXP MED, V204, P2267, DOI 10.1084/jem.20070525; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013; Kim S, 2014, INNATE IMMUN-LONDON, V20, P799, DOI 10.1177/1753425913508593; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Krajcovic M, 2011, NAT CELL BIOL, V13, P324, DOI 10.1038/ncb2174; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Liu B, 2010, NAT COMMUN, V1, P79; Logothetis CJ, 2013, CANCER DISCOV, V3, P849, DOI 10.1158/2159-8290.CD-12-0460; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mahadevan NR, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23901; Mahadevan NR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051845; Mahadevan NR, 2011, J IMMUNOL, V187, P4403, DOI 10.4049/jimmunol.1101531; Mahadevan NR, 2010, J INFLAMM RES, V3, P99, DOI 10.2147/JIR.S11190; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; Meares GP, 2014, MOL CELL BIOL, V34, P3911, DOI 10.1128/MCB.00980-14; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200; Morales C, 2014, CANCER RES, V74, P446, DOI 10.1158/0008-5472.CAN-13-1677; Mori K, 2009, J BIOCHEM, V146, P743, DOI 10.1093/jb/mvp166; Mumm JB, 2008, ONCOGENE, V27, P5913, DOI 10.1038/onc.2008.275; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Newburger DE, 2013, GENOME RES, V23, P1097, DOI 10.1101/gr.151670.112; Norian LA, 2009, CANCER RES, V69, P3086, DOI 10.1158/0008-5472.CAN-08-2826; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Oh J, 2012, J BIOL CHEM, V287, P11629, DOI 10.1074/jbc.M111.338673; OHYAMA S, 1990, CANCER, V65, P116, DOI 10.1002/1097-0142(19900101)65:1<116::AID-CNCR2820650124>3.0.CO;2-I; Osorio F, 2014, NAT IMMUNOL, V15, P248, DOI 10.1038/ni.2808; OWAINATI AAR, 1987, BRIT J CANCER, V55, P449, DOI 10.1038/bjc.1987.88; Pellicciotta I, 2008, CANCER RES, V68, P8085, DOI 10.1158/0008-5472.CAN-08-1014; Pereira ER, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012521; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Risbridger GP, 2010, NAT REV CANCER, V10, P205, DOI 10.1038/nrc2795; Roberts HR, 2011, CARCINOGENESIS, V32, P1741, DOI 10.1093/carcin/bgr210; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Romero-Ramirez L, 2009, TRANSL ONCOL, V2, P31, DOI 10.1593/tlo.08211; Santagata S, 2013, SCIENCE, V341, P250, DOI 10.1126/science.1238303; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922; Sheltzer JM, 2012, P NATL ACAD SCI USA, V109, P12644, DOI 10.1073/pnas.1209227109; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; Siegel JJ, 2012, ANNU REV CELL DEV BI, V28, P189, DOI 10.1146/annurev-cellbio-101011-155807; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Sun JR, 2012, EMBO REP, V13, P855, DOI 10.1038/embor.2012.100; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tam AB, 2014, CELL REP, V9, P850, DOI 10.1016/j.celrep.2014.09.016; Tam AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045078; Tang YC, 2013, CELL, V152, P394, DOI 10.1016/j.cell.2012.11.043; Taylor RC, 2013, CELL, V153, P1435, DOI 10.1016/j.cell.2013.05.042; Thevenot PT, 2014, IMMUNITY, V41, P389, DOI 10.1016/j.immuni.2014.08.015; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Torres EM, 2008, GENETICS, V179, P737, DOI 10.1534/genetics.108.090878; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; Ullrich E, 2008, CELL DEATH DIFFER, V15, P21, DOI 10.1038/sj.cdd.4402266; Uramoto H, 2005, LUNG CANCER, V49, P55, DOI 10.1016/j.lungcan.2004.12.011; Vacchelli E, 2014, ONCOIMMUNOLOGY, V3, DOI [10.4161/onci.27048, 10.4161/onci.27878]; van Galen P, 2014, NATURE, V510, P268, DOI 10.1038/nature13228; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wheeler MC, 2008, J IMMUNOL, V181, P256, DOI 10.4049/jimmunol.181.1.256; Williams KW, 2014, CELL METAB, V20, P471, DOI 10.1016/j.cmet.2014.06.002; Xing XM, 2006, CLIN CHIM ACTA, V364, P308, DOI 10.1016/j.cca.2005.07.016; Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018; Yamazaki H, 2009, J IMMUNOL, V183, P1480, DOI 10.4049/jimmunol.0900017; Yang Y, 2005, MOL CELLS, V20, P173; Yang Y, 2007, IMMUNITY, V26, P215, DOI 10.1016/j.immuni.2006.12.005; Yildirim-Assaf S, 2007, J CLIN PATHOL, V60, P649, DOI 10.1136/jcp.2005.035550; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhang YL, 2015, J CLIN INVEST, V125, P859, DOI 10.1172/JCI79014	135	29	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					269	278		10.1038/onc.2015.108	http://dx.doi.org/10.1038/onc.2015.108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893303				2022-12-17	WOS:000369055300001
J	Boyle, ST; Ingman, WV; Poltavets, V; Faulkner, JW; Whitfield, RJ; McColl, SR; Kochetkova, M				Boyle, S. T.; Ingman, W. V.; Poltavets, V.; Faulkner, J. W.; Whitfield, R. J.; McColl, S. R.; Kochetkova, M.			The chemokine receptor CCR7 promotes mammary tumorigenesis through amplification of stem-like cells	ONCOGENE			English	Article							LYMPH-NODE METASTASIS; BREAST-CANCER CELLS; TUMOR-GROWTH; EXPRESSION; CXCR4; MODEL; DISEASE; ACTIVATION; INCREASES; PREDICTS	The chemokine receptor CCR7 is widely implicated in breast cancer pathobiology. Although recent reports correlated high CCR7 levels with more advanced tumor grade and poor prognosis, limited in vivo data are available regarding its specific function in mammary gland neoplasia and the underlying mechanisms involved. To address these questions we generated a bigenic mouse model of breast cancer combined with CCR7 deletion, which revealed that CCR7 ablation results in a considerable delay in tumor onset as well as significantly reduced tumor burden. Importantly, CCR7 was found to exert its function by regulating mammary cancer stem-like cells in both murine and human tumors. In vivo experiments showed that loss of CCR7 activity either through deletion or pharmacological antagonism significantly decreased functional pools of stem-like cells in mouse primary mammary tumors, providing a mechanistic explanation for the tumor-promoting role of this chemokine receptor. These data characterize the oncogenic properties of CCR7 in mammary epithelial neoplasia and point to a new route for therapeutic intervention to target evasive cancer stem cells.	[Boyle, S. T.; Poltavets, V.; Faulkner, J. W.; McColl, S. R.; Kochetkova, M.] Univ Adelaide, Sch Biol Sci, Dept Mol & Cellular Biol, Adelaide, SA 5005, Australia; [Ingman, W. V.] Univ Adelaide, Robinson Inst, Adelaide, SA 5005, Australia; [Ingman, W. V.] Univ Adelaide, Queen Elizabeth Hosp, Sch Med, Discipline Surg, Adelaide, SA 5005, Australia; [Whitfield, R. J.] Royal Adelaide Hosp, Breast Endocrine & Surg Oncol Unit, Adelaide, SA 5000, Australia; [Whitfield, R. J.] Univ Adelaide, Sch Med, Adelaide, SA 5005, Australia; [McColl, S. R.] Univ Adelaide, Ctr Mol Pathol, Adelaide, SA 5005, Australia	University of Adelaide; Robinson Research Institute; University of Adelaide; University of Adelaide; Royal Adelaide Hospital; University of Adelaide; University of Adelaide	Kochetkova, M (corresponding author), Univ Adelaide, Sch Biol Sci, Dept Mol & Cellular Biol, Adelaide, SA 5005, Australia.	marina.kochetkova@adelaide.edu.au	Kochetkova, Marina/ABE-9538-2021; Boyle, Sarah/B-3048-2019	Kochetkova, Marina/0000-0002-0599-7378; Ingman, Wendy/0000-0003-3116-2902; Poltavets, Valentina/0000-0003-1976-7765; Boyle, Sarah/0000-0001-6143-9285	NHMRC; The Hospital Research Foundation [RF2011/2] Funding Source: researchfish; National Breast Cancer Foundation [ECF-11-06] Funding Source: researchfish	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); The Hospital Research Foundation; National Breast Cancer Foundation	We are grateful to Dr Timothy Proudman and Dr Pallave Dasari from the Queen Elizabeth Hospital for supply of normal human breast tissue and Dr Deepak Dhatrak of the Department of Anatomical Pathology at SA Pathology for procurement of human breast cancer samples. We would also like to sincerely thank Professor Angel Lopez for critical reading of the manuscript, and Dr Michael Samuel and Ms Natasha Pyne for assistance with immunohistochemistry. This work was supported by an NHMRC project grant. WVI is a National Breast Cancer Foundation/The QEH Research Foundation Fellow.	Ablett MP, 2014, ONCOTARGET, V5, P599, DOI 10.18632/oncotarget.1169; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Andre F, 2006, ANN ONCOL, V17, P945, DOI 10.1093/annonc/mdl053; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Biswas S, 2014, BREAST CANCER RES TR, V143, P265, DOI 10.1007/s10549-013-2811-8; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Cabioglu N, 2005, CLIN CANCER RES, V11, P5686, DOI 10.1158/1078-0432.CCR-05-0014; Cassier PA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-213; Chin AR, 2014, MOL CELL ENDOCRINOL, V382, P598, DOI 10.1016/j.mce.2013.03.024; Cunningham HD, 2010, TRANSL ONCOL, V3, P354, DOI 10.1593/tlo.10178; Desgrosellier JS, 2014, DEV CELL, V30, P295, DOI 10.1016/j.devcel.2014.06.005; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Giordano A, 2013, ANN ONCOL, V24, P2515, DOI 10.1093/annonc/mdt223; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Iwanaga R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3219; Kochetkova M, 2009, CELL DEATH DIFFER, V16, P664, DOI 10.1038/cdd.2008.190; Lavergne E, 2004, J IMMUNOL, V173, P3755, DOI 10.4049/jimmunol.173.6.3755; Li J, 2011, DIGEST LIVER DIS, V43, P40, DOI 10.1016/j.dld.2010.05.013; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Ma J, 2012, TUMOR BIOL, V33, P1983, DOI 10.1007/s13277-012-0458-4; Ma XR, 2009, MOL CANCER THER, V8, P490, DOI 10.1158/1535-7163.MCT-08-0485; Maglione JE, 2001, CANCER RES, V61, P8298; Maxmen A, 2012, NATURE, V485, pS50, DOI 10.1038/485S50a; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Pilkington KR, 2004, J BIOL CHEM, V279, P40276, DOI 10.1074/jbc.M405808200; Schwab LP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3087; Sharma S, 2000, J IMMUNOL, V164, P4558, DOI 10.4049/jimmunol.164.9.4558; Smalley MJ, 2012, J MAMMARY GLAND BIOL, V17, P91, DOI 10.1007/s10911-012-9257-1; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Weninger W, 2003, J IMMUNOL, V170, P4638, DOI 10.4049/jimmunol.170.9.4638; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	39	29	30	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					105	115		10.1038/onc.2015.66	http://dx.doi.org/10.1038/onc.2015.66			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772241	Green Published			2022-12-17	WOS:000367812400010
J	Cheung, WKC; Nguyen, DX				Cheung, W. K. C.; Nguyen, D. X.			Lineage factors and differentiation states in lung cancer progression	ONCOGENE			English	Review							TRANSCRIPTION FACTOR-I; EPITHELIAL-MESENCHYMAL TRANSITION; GATA-6 ACTIVATES TRANSCRIPTION; BINDING-PROTEIN-ALPHA; SQUAMOUS-CELL; BETA-CATENIN; DOWN-REGULATION; C/EBP-ALPHA; STEM-CELLS; FUNCTIONAL-CHARACTERIZATION	Lung cancer encompasses a heterogeneous group of malignancies. Here we discuss how the remarkable diversity of major lung cancer subtypes is manifested in their transforming cell of origin, oncogenic dependencies, phenotypic plasticity, metastatic competence and response to therapy. More specifically, we review the increasing evidence that links this biological heterogeneity to the deregulation of cell lineage-specific pathways and the transcription factors that ultimately control them. As determinants of pulmonary epithelial differentiation, these poorly characterized transcriptional networks may underlie the etiology and biological progression of distinct lung cancers, while providing insight into innovative therapeutic strategies.	[Cheung, W. K. C.; Nguyen, D. X.] Yale Univ, Sch Med, Dept Pathol, Pathol & Canc Ctr, New Haven, CT 06520 USA; [Nguyen, D. X.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA	Yale University; Yale University	Nguyen, DX (corresponding author), Yale Univ, Sch Med, Dept Pathol, Pathol & Canc Ctr, POB 208023, New Haven, CT 06520 USA.	don.nguyen@yale.edu			Uniting Against Lung Cancer; National Cancer Institute [1R01CA166376, 1R21CA170537, 1R01CA191489]; NATIONAL CANCER INSTITUTE [R01CA191489, R01CA166376] Funding Source: NIH RePORTER	Uniting Against Lung Cancer; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all members of the Nguyen laboratory for their discussions and critical reviews of the manuscript. We apologize for omitting some examples and primary references due to space constraints. Our research is funded by grants from Uniting Against Lung Cancer (to WKCC) and the National Cancer Institute (1R01CA166376, 1R21CA170537 and 1R01CA191489 to DXN).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Alam N, 2010, CLIN LUNG CANCER, V11, pE1, DOI 10.3816/CLC.2010.n.046; Allen TD, 2011, CANCER RES, V71, P6010, DOI 10.1158/0008-5472.CAN-11-0595; Allen TD, 2011, CANCER RES, V71, P2212, DOI 10.1158/0008-5472.CAN-10-3590; Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782; Barletta JA, 2009, J CELL MOL MED, V13, P1977, DOI 10.1111/j.1582-4934.2008.00594.x; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basseres DS, 2012, LUNG CANCER, V77, P31, DOI 10.1016/j.lungcan.2012.01.011; Basseres DS, 2006, MOL CELL BIOL, V26, P1109, DOI 10.1128/MCB.26.3.1109-1123.2006; Belaguli NS, 2010, NEOPLASIA, V12, P856, DOI 10.1593/neo.10224; Berghmans T, 2006, ANN ONCOL, V17, P1673, DOI 10.1093/annonc/mdl287; Blanpain C, 2013, NAT CELL BIOL, V15, P126, DOI 10.1038/ncb2657; Bleckmann A, 2013, CLIN EXP METASTAS, V30, P471, DOI 10.1007/s10585-012-9552-7; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Bruno MD, 2000, J BIOL CHEM, V275, P1043, DOI 10.1074/jbc.275.2.1043; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Capaccione KM, 2014, ONCOTARGET, V5, P3636, DOI 10.18632/oncotarget.1970; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chang DR, 2013, P NATL ACAD SCI USA, V110, P18042, DOI 10.1073/pnas.1311760110; Chen Y, 2015, J PATHOL, V235, P397, DOI 10.1002/path.4469; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Chi XZ, 2009, CANCER RES, V69, P8111, DOI 10.1158/0008-5472.CAN-09-1057; Chia NY, 2015, GUT, V64, P707, DOI 10.1136/gutjnl-2013-306596; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Cohen J Craig, 2004, BMC Dev Biol, V4, P4; Cooke DT, 2010, ANN THORAC SURG, V90, P943, DOI 10.1016/j.athoracsur.2010.05.025; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Costa DB, 2006, LUNG CANCER, V53, P253, DOI 10.1016/j.lungcan.2006.04.011; Curtis SJ, 2010, CELL STEM CELL, V7, P127, DOI 10.1016/j.stem.2010.05.021; Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Filosso PL, 2011, LUNG CANCER, V74, P25, DOI 10.1016/j.lungcan.2011.01.030; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Gao YJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5629; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Goss AM, 2009, DEV CELL, V17, P290, DOI 10.1016/j.devcel.2009.06.005; Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Halmos B, 2002, CANCER RES, V62, P528; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hanna Jennifer M, 2013, J Carcinog, V12, P6, DOI 10.4103/1477-3163.109033; Hosono Y, 2012, EMBO J, V31, P481, DOI 10.1038/emboj.2011.416; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; Ischenko I, 2014, CELL DEATH DIFFER, V21, P1218, DOI 10.1038/cdd.2014.38; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Iwakawa R, 2013, GENE CHROMOSOME CANC, V52, P802, DOI 10.1002/gcc.22076; Iwakawa R, 2011, CLIN CANCER RES, V17, P1481, DOI 10.1158/1078-0432.CCR-10-2484; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jiang SS, 2010, CLIN CANCER RES, V16, P4363, DOI 10.1158/1078-0432.CCR-10-0138; Jimenez FR, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-70; Juan J, 2014, GENE DEV, V28, P561, DOI 10.1101/gad.233627.113; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kamnasaran D, 2007, P NATL ACAD SCI USA, V104, P8053, DOI 10.1073/pnas.0611669104; Katoh H, 2012, NEOPLASIA, V14, P559, DOI 10.1593/neo.12330; Keijzer R, 2001, DEVELOPMENT, V128, P503; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kim IJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2660; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Kwei KA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000081; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lee JM, 2011, DIFFERENTIATION, V81, P261, DOI 10.1016/j.diff.2011.02.001; Lee KS, 2010, ONCOGENE, V29, P3349, DOI 10.1038/onc.2010.79; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Liang YL, 2014, J THORAC DIS, V6, P694, DOI 10.3978/j.issn.2072-1439.2014.04.09; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lin CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053817; Lin L, 2012, P NATL ACAD SCI USA, V109, P4251, DOI 10.1073/pnas.1011989109; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Lu Y, 2010, PLOS ONE, V5; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Mainardi S, 2014, P NATL ACAD SCI USA, V111, P255, DOI 10.1073/pnas.1320383110; Martis PC, 2006, DEVELOPMENT, V133, P1155, DOI 10.1242/dev.02273; McFadden DG, 2014, CELL, V156, P1298, DOI 10.1016/j.cell.2014.02.031; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Minoo P, 1995, DEV BIOL, V172, P694, DOI 10.1006/dbio.1995.8080; Minoo P, 2007, MOL CELL BIOL, V27, P2155, DOI 10.1128/MCB.01133-06; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morrisey EE, 2010, DEV CELL, V18, P8, DOI 10.1016/j.devcel.2009.12.010; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Nakagawa K, 2003, ANN THORAC SURG, V75, P1740, DOI 10.1016/S0003-4975(03)00022-5; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Okubo T, 2005, DEVELOPMENT, V132, P1363, DOI 10.1242/dev.01678; Ooki A, 2010, ONCOGENE, V29, P3263, DOI 10.1038/onc.2010.76; Pacheco-Pinedo EC, 2011, J CLIN INVEST, V121, P1935, DOI 10.1172/JCI44871; Park KS, 2011, CELL CYCLE, V10, P2806, DOI 10.4161/cc.10.16.17012; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Popat S, 2013, LUNG CANCER, V80, P1, DOI 10.1016/j.lungcan.2012.12.019; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Que JW, 2009, DEVELOPMENT, V136, P1899, DOI 10.1242/dev.034629; Quinlan MP, 2008, MOL CELL BIOL, V28, P2659, DOI 10.1128/MCB.01661-07; Rapp UR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006029; Rawlins EL, 2012, AM J RESP CELL MOL, V46, P269, DOI 10.1165/rcmb.2011-0372PS; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Reynolds SD, 2008, STEM CELLS, V26, P1337, DOI 10.1634/stemcells.2008-0053; Rockich BE, 2013, P NATL ACAD SCI USA, V110, pE4456, DOI 10.1073/pnas.1311847110; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Saito RA, 2009, CANCER RES, V69, P2783, DOI 10.1158/0008-5472.CAN-08-3490; Sanchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906; Sato A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057013; Sato A, 2012, AM J RESP CELL MOL, V47, P454, DOI 10.1165/rcmb.2011-0239OC; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Shu WG, 2005, DEV BIOL, V283, P226, DOI 10.1016/j.ydbio.2005.04.014; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sinha S, 2008, GENOME RES, V18, P477, DOI 10.1101/gr.6828808; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Song H, 2012, P NATL ACAD SCI USA, V109, P17531, DOI 10.1073/pnas.1207238109; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019; Sutherland KD, 2010, MOL ONCOL, V4, P397, DOI 10.1016/j.molonc.2010.05.002; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tang XM, 2011, CLIN CANCER RES, V17, P2434, DOI 10.1158/1078-0432.CCR-10-1412; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Tomita T, 2008, J BIOL CHEM, V283, P25617, DOI 10.1074/jbc.M805140200; Tran PT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002125; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Tremblay AM, 2014, CANCER CELL, V26, P273, DOI 10.1016/j.ccr.2014.05.029; Treutlein B, 2014, NATURE, V509, P371, DOI 10.1038/nature13173; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Uramoto H, 2011, LUNG CANCER, V73, P361, DOI 10.1016/j.lungcan.2011.01.008; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Vaughan AE, 2015, NATURE, V517, P621, DOI 10.1038/nature14112; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Waraya M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-397; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Watanabe H, 2013, CANCER CELL, V23, P707, DOI 10.1016/j.ccr.2013.05.013; Watanabe H, 2013, GENE DEV, V27, P197, DOI 10.1101/gad.203208.112; Watanabe S, 2013, LUNG CANCER, V82, P370, DOI 10.1016/j.lungcan.2013.06.003; WATSON WL, 1962, CANCER, V15, P759, DOI 10.1002/1097-0142(196207/08)15:4<759::AID-CNCR2820150410>3.0.CO;2-6; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xiao ZX, 2013, CANCER CELL, V23, P527, DOI 10.1016/j.ccr.2013.03.009; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Xu X, 2014, GENE DEV, V28, P1929, DOI 10.1101/gad.243717.114; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yamaguchi S, 2009, INT J CANCER, V124, P2577, DOI 10.1002/ijc.24217; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Yamashita K, 2008, MOL CANCER RES, V6, P31, DOI 10.1158/1541-7786.MCR-07-0213; Yan M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4661; Yanagawa N, 2007, LUNG CANCER, V58, P131, DOI 10.1016/j.lungcan.2007.05.011; Yang HH, 2002, DEVELOPMENT, V129, P2233; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Yin Z, 2006, AM J PHYSIOL-LUNG C, V291, pL191, DOI 10.1152/ajplung.00385.2005; Zhang Y, 2008, NAT GENET, V40, P862, DOI 10.1038/ng.157; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zheng Y, 2013, INT J BIOCHEM CELL B, V45, P2369, DOI 10.1016/j.biocel.2013.07.013; Zhong Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022129; Zhou CH, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-18; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	183	29	29	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5771	5780		10.1038/onc.2015.85	http://dx.doi.org/10.1038/onc.2015.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25823023	Green Accepted			2022-12-17	WOS:000365035200001
J	Gong, C; Fujino, K; Monteiro, LJ; Gomes, AR; Drost, R; Davidson-Smith, H; Takeda, S; Khoo, US; Jonkers, J; Sproul, D; Lam, EWF				Gong, C.; Fujino, K.; Monteiro, L. J.; Gomes, A. R.; Drost, R.; Davidson-Smith, H.; Takeda, S.; Khoo, U. S.; Jonkers, J.; Sproul, D.; Lam, E. W-F			FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE EZH2; POLYCOMB TARGET GENES; DNA METHYLATION; CELL FATE; PROGNOSTIC-SIGNIFICANCE; ALPHA EXPRESSION; DIFFERENTIATION; INHIBITION; GATA-3; PROLIFERATION	FOXA1 expression correlates with the breast cancer luminal subtype and patient survival. RNA and protein analysis of a panel of breast cancer cell lines revealed that BRCA1 deficiency is associated with the downregulation of FOXA1 expression. Knockdown of BRCA1 resulted in the downregulation of FOXA1 expression and enhancement of FOXA1 promoter methylation in MCF-7 breast cancer cells, whereas the reconstitution of BRCA1 in Brca1-deficent mouse mammary epithelial cells (MMECs) promoted Foxa1 expression and methylation. These data suggest that BRCA1 suppresses FOXA1 hypermethylation and silencing. Consistently, the treatment of MMECs with the DNA methylation inhibitor 5-aza-2'-deoxycitydine induced Foxa1 mRNA expression. Furthermore, treatment with GSK126, an inhibitor of EZH2 methyltransferase activity, induced FOXA1 expression in BRCA1-deficient but not in BRCA1-reconstituted MMECs. Likewise, the depletion of EZH2 by small interfering RNA enhanced FOXA1 mRNA expression. Chromatin immunoprecipitation (ChIP) analysis demonstrated that BRCA1, EZH2, DNA methyltransferases (DNMT) 1/3a/3b and H3K27me3 are recruited to the endogenous FOXA1 promoter, further supporting the hypothesis that these proteins interact to modulate FOXA1 methylation and repression. Further co-immunoprecipitation and ChIP analysis showed that both BRCA1 and DNMT3b form complexes with EZH2 but not with each other, consistent with the notion that BRCA1 binds to EZH2 and negatively regulates its methyltransferase activity. We also found that EZH2 promotes and BRCA1 impairs the deposit of the gene silencing histone mark H3K27me3 on the FOXA1 promoter. These associations were validated in a familial breast cancer patient cohort. Integrated analysis of the global gene methylation and expression profiles of a set of 33 familial breast tumours revealed that FOXA1 promoter methylation is inversely correlated with the transcriptional expression of FOXA1 and that BRCA1 mutation breast cancer is significantly associated with FOXA1 methylation and downregulation of FOXA1 expression, providing physiological evidence to our findings that FOXA1 expression is regulated by methylation and chromatin silencing and that BRCA1 maintains FOXA1 expression through suppressing FOXA1 gene methylation in breast cancer.	[Gong, C.; Fujino, K.; Monteiro, L. J.; Gomes, A. R.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England; [Gong, C.; Khoo, U. S.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Fujino, K.; Takeda, S.] Juntendo Univ, Fac Med, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo, Japan; [Drost, R.; Jonkers, J.] Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands; [Drost, R.; Jonkers, J.] Netherlands Canc Inst, Canc Genom Ctr Netherlands, Amsterdam, Netherlands; [Davidson-Smith, H.; Sproul, D.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland	Imperial College London; University of Hong Kong; Juntendo University; Netherlands Cancer Institute; Netherlands Cancer Institute; University of Edinburgh	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, ICTEM, Hammersmith Hosp Campus,Room 134,1st Floor, London W12 0NN, England.	eric.lam@imperial.ac.uk	Jonkers, Jos/AAG-3246-2019; Lam, Eric W-F/AAW-8566-2020; Khoo, Ui Soon/K-2041-2019; Khoo, Ui Soon/C-4293-2009; Monteiro, Lara J/AAU-8518-2020; Khoo, Ui Soon/C-1345-2014	Jonkers, Jos/0000-0002-9264-9792; Lam, Eric W-F/0000-0003-1274-3576; Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Takeda, Satoru/0000-0001-9547-1435	Breast Cancer Campaign; Cancer Research UK; Joint Imperial College London and University of Hong Kong; Research and Conference Grants from the University of Hong Kong (CRCG) [201007176118]; Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Breast Cancer Campaign [2012NovPhD016, 2012MayPR070] Funding Source: researchfish	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Joint Imperial College London and University of Hong Kong; Research and Conference Grants from the University of Hong Kong (CRCG); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Breast Cancer Campaign	This work is funded by grants from the Breast Cancer Campaign and Cancer Research UK. CG is a recipient of the Joint Imperial College London and University of Hong Kong studentship. We also thank Kevin Brennan and James M Flanagan (Department of Surgery and Cancer, Imperial College London) for their help with pyrosequencing. USK is supported by Research and Conference Grants from the University of Hong Kong (CRCG)(201007176118).	Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327; Bae WK, 2014, MOL CELL ENDOCRINOL, V382, P593, DOI 10.1016/j.mce.2013.05.002; Bernardo GM, 2013, ONCOGENE, V32, P554, DOI 10.1038/onc.2012.62; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Buckley NE, 2013, NUCLEIC ACIDS RES, V41, P8601, DOI 10.1093/nar/gkt626; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ehrlich M, 2013, EPIGENOMICS-UK, V5, P553, DOI 10.2217/epi.13.43; Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008; Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933; Habashy HO, 2008, EUR J CANCER, V44, P1541, DOI 10.1016/j.ejca.2008.04.020; Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Hsu NC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056256; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li JL, 2013, NAT NEUROSCI, V16, P1745, DOI 10.1038/nn.3564; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Liu ZW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040943; Martins-Taylor K, 2012, EPIGENETICS-US, V7, P71, DOI 10.4161/epi.7.1.18750; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Mehta RJ, 2012, BREAST CANCER RES TR, V131, P881, DOI 10.1007/s10549-011-1482-6; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Myatt SS, 2014, ONCOGENE, V33, P4316, DOI 10.1038/onc.2013.546; Nakshatri H, 2007, EXPERT OPIN THER TAR, V11, P507, DOI 10.1517/14728222.11.4.507; Nakshatri H, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001008; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; Reddington JP, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r25; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Sekiya T, 2009, GENE DEV, V23, P804, DOI 10.1101/gad.1775509; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876; Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95; Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49; Wu L, 2013, BREAST CANCER RES TR, V142, P619, DOI 10.1007/s10549-013-2774-9	47	29	33	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5012	5024		10.1038/onc.2014.421	http://dx.doi.org/10.1038/onc.2014.421			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25531315	Green Published, Green Submitted, Green Accepted, hybrid			2022-12-17	WOS:000361693300002
J	Shriver, M; Stroka, KM; Vitolo, MI; Martin, S; Huso, DL; Konstantopoulos, K; Kontrogianni-Konstantopoulos, A				Shriver, M.; Stroka, K. M.; Vitolo, M. I.; Martin, S.; Huso, D. L.; Konstantopoulos, K.; Kontrogianni-Konstantopoulos, A.			Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis	ONCOGENE			English	Article							C-HA-RAS; CELL; ADHESION; INVASION; GROWTH; TRANSFORMATION; EXPRESSION; MIGRATION; LOCALIZATION; MECHANISMS	Obscurins, encoded by the single OBSCN gene, are giant cytoskeletal proteins with structural and regulatory roles. The OBSCN gene is highly mutated in different types of cancers. Loss of giant obscurins from breast epithelial cells confers them with a survival and growth advantage, following exposure to DNA-damaging agents. Here we demonstrate that the expression levels and subcellular distribution of giant obscurins are altered in human breast cancer biopsies compared with matched normal samples. Stable clones of non-tumorigenic MCF10A cells lacking giant obscurins fail to form adhesion junctions, undergo epithelial-to-mesenchymal transition and generate >100-mu m mammospheres bearing markers of cancer-initiating cells. Obscurin-knockdown MCF10A cells display markedly increased motility as a sheet in 2-dimensional (2D) substrata and individually in confined spaces and invasion in 3D matrices. In line with these observations, actin filaments redistribute to extending filopodia where they exhibit increased dynamics. MCF10A cells that stably express the K-Ras oncogene and obscurin short hairpin RNA (shRNA), but not scramble control shRNA, exhibit increased primary tumor formation and lung colonization after subcutaneous and tail vein injections, respectively. Collectively, our findings reveal that loss of giant obscurins from breast epithelium results in disruption of the cell-cell contacts and acquisition of a mesenchymal phenotype that leads to enhanced tumorigenesis, migration and invasiveness in vitro and in vivo.	[Shriver, M.; Kontrogianni-Konstantopoulos, A.] Univ Maryland Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Stroka, K. M.; Konstantopoulos, K.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA; [Stroka, K. M.; Konstantopoulos, K.] Johns Hopkins Univ, Johns Hopkins Inst NanoBioTechnol, Baltimore, MD USA; [Stroka, K. M.; Konstantopoulos, K.] Johns Hopkins Univ, Johns Hopkins Phys Sci Oncol Ctr, Baltimore, MD USA; [Vitolo, M. I.; Martin, S.; Kontrogianni-Konstantopoulos, A.] Univ Maryland Sch Med, Marlene & Stewart Greenebaum Natl Canc Inst Canc, Baltimore, MD 21201 USA; [Huso, D. L.] Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, Baltimore, MD USA; [Huso, D. L.] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Kontrogianni-Konstantopoulos, A (corresponding author), Univ Maryland Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	akons001@umaryland.edu		Vitolo, Michele/0000-0001-8055-9645; Shriver, Marey/0000-0002-1644-6408	Pilot Grant from The Johns Hopkins Physical Sciences-Oncology Center; Johns Hopkins Institute for NanoBioTechnology [U54CA143868]; National Science Foundation [NSF-1159823]; National Cancer Institute [U54-CA143868, R01-CA186286, T32-CA130840, F32-CA177756, R01-CA154624, K01-CA166576]; Kleberg Foundation; Div Of Chem, Bioeng, Env, & Transp Sys [1159823] Funding Source: National Science Foundation; NATIONAL CANCER INSTITUTE [R01CA154624, T32CA130840, P30CA134274, F32CA177756, K01CA166576, U54CA143868, R01CA186286, P30CA006973] Funding Source: NIH RePORTER	Pilot Grant from The Johns Hopkins Physical Sciences-Oncology Center; Johns Hopkins Institute for NanoBioTechnology; National Science Foundation(National Science Foundation (NSF)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Kleberg Foundation; Div Of Chem, Bioeng, Env, & Transp Sys(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Pilot Grant from The Johns Hopkins Physical Sciences-Oncology Center, The Johns Hopkins Institute for NanoBioTechnology (U54CA143868 to AK-K) and by awards from the National Science Foundation (Award NSF-1159823 to KK), the National Cancer Institute (Awards U54-CA143868 to KK; R01-CA186286 to KK; T32-CA130840 to KMS; F32-CA177756 to KMS; R01-CA154624 to SM and K01-CA166576 to MIV) and the Kleberg Foundation (to KK). Portions of this work are included in a United States patent pending, 14/221,755, filed on 21 March 2014.	Ackermann MA, 2009, MOL BIOL CELL, V20, P2963, DOI 10.1091/mbc.E08-12-1251; Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Balzer EM, 2012, FASEB J, V26, P4045, DOI 10.1096/fj.12-211441; Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; Borisov AB, 2008, J CELL BIOCHEM, V103, P1621, DOI 10.1002/jcb.21551; Brasch J, 2012, TRENDS CELL BIOL, V22, P299, DOI 10.1016/j.tcb.2012.03.004; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Chen SH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01870; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; Dallas MR, 2012, FASEB J, V26, P2648, DOI 10.1096/fj.12-203786; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Ford-Speelman DL, 2009, MOL BIOL CELL, V20, P3905, DOI 10.1091/mbc.E08-10-1029; Foroni C, 2012, CANCER TREAT REV, V38, P689, DOI 10.1016/j.ctrv.2011.11.001; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Fukuzawa A, 2005, J MUSCLE RES CELL M, V26, P427, DOI 10.1007/s10974-005-9025-6; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Hu LYR, 2013, FASEB J, V27, P2001, DOI 10.1096/fj.12-221317; Hung WC, 2013, J CELL BIOL, V202, P807, DOI 10.1083/jcb.201302132; Knights Alexander J, 2012, Trends Cancer Res, V8, P61; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; Kontrogianni-Konstantopoulos A, 2005, J MUSCLE RES CELL M, V26, P419, DOI 10.1007/s10974-005-9024-7; Kontrogianni-Konstantopoulos A, 2006, FASEB J, V20, P2102, DOI 10.1096/fj.06-5761com; Kontrogianni-Konstantopoulos A, 2009, PHYSIOL REV, V89, P1217, DOI 10.1152/physrev.00017.2009; Nanda A, 2006, P NATL ACAD SCI USA, V103, P3351, DOI 10.1073/pnas.0511306103; Perry NA, 2013, IUBMB LIFE, V65, P479, DOI 10.1002/iub.1157; Perry NA, 2012, FASEB J, V26, P2764, DOI 10.1096/fj.12-205419; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Price ND, 2007, P NATL ACAD SCI USA, V104, P3414, DOI 10.1073/pnas.0611373104; Rago C, 2007, CANCER RES, V67, P9364, DOI 10.1158/0008-5472.CAN-07-0605; Russell MW, 2002, GENE, V282, P237, DOI 10.1016/S0378-1119(01)00795-8; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tong ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029211; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang B, 1997, ANTICANCER RES, V17, P4387	46	29	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4248	4259		10.1038/onc.2014.358	http://dx.doi.org/10.1038/onc.2014.358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25381817	Green Accepted			2022-12-17	WOS:000359199800011
J	Perez, E; Das, G; Bergmann, A; Baehrecke, EH				Perez, E.; Das, G.; Bergmann, A.; Baehrecke, E. H.			Autophagy regulates tissue overgrowth in a context-dependent manner	ONCOGENE			English	Article							CELL-DEATH; GROWTH ARREST; DROSOPHILA; CANCER; RAS; EXPRESSION; TUMORS; NOTCH; PROLIFERATION; TUMORIGENESIS	Autophagy is a catabolic process that has been implicated both as a tumor suppressor and in tumor progression. Here, we investigate this dichotomy in cancer biology by studying the influence of altered autophagy in Drosophila models of tissue overgrowth. We find that the impact of altered autophagy depends on both genotype and cell type. As previously observed in mammals, decreased autophagy suppresses Ras-induced eye epithelial overgrowth. In contrast, autophagy restricts epithelial overgrowth in a Notch-dependent eye model. Even though decreased autophagy did not influence Hippo pathway-triggered overgrowth, activation of autophagy strongly suppresses this eye epithelial overgrowth. Surprisingly, activation of autophagy enhanced Hippo pathway-driven overgrowth in glia cells. These results indicate that autophagy has different influences on tissue growth in distinct contexts, and highlight the importance of understanding the influence of autophagy on growth to augment a rationale therapeutic strategy.	[Perez, E.; Das, G.; Bergmann, A.; Baehrecke, E. H.] Univ Massachusetts, Dept Canc Biol, Sch Med, Worcester, MA 01505 USA	University of Massachusetts System; University of Massachusetts Worcester	Baehrecke, EH (corresponding author), Univ Massachusetts, Dept Canc Biol, Sch Med, 364 Plantat St, Worcester, MA 01505 USA.	Andreas.Bergmann@umassmed.edu; Eric.Baehrecke@umassmed.edu		Bergmann, Andreas/0000-0002-9134-871X	NIH [GM068016, CA159314]; NATIONAL CANCER INSTITUTE [R01CA159314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068016] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank T Chang, M Dominguez, M Freeman, G Halder, G Juhasz, M Kango-Singh, TP Neufeld, the Bloomington Stock Center, the VDRC for flies and antibodies, J Lindblad, C Nelson and T Fortier for technical support, and the Bergmann and Baehrecke labs for constructive comments. This work was supported by NIH grants GM068016 to AB and CA159314 to EHB. EHB is an Ellison Medical Foundation Scholar.	Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; BOS JL, 1989, CANCER RES, V49, P4682; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Chang TK, 2013, NAT CELL BIOL, V15, P1067, DOI 10.1038/ncb2804; Chang YY, 2009, MOL BIOL CELL, V20, P2004, DOI 10.1091/mbc.E08-12-1250; Chen CL, 2012, P NATL ACAD SCI USA, V109, P484, DOI 10.1073/pnas.1113882109; Dutta S, 2008, CURR BIOL, V18, P1466, DOI 10.1016/j.cub.2008.08.052; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/BSE0530141, 10.1042/bse0530141]; Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karim FD, 1998, DEVELOPMENT, V125, P1; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; McPhee CK, 2009, BBA-MOL CELL RES, V1793, P1452, DOI 10.1016/j.bbamcr.2009.02.009; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pircs K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044214; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Reddy BVVG, 2011, DEVELOPMENT, V138, P5201, DOI 10.1242/dev.069385; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rudrapatna VA, 2012, DEV DYNAM, V241, P107, DOI 10.1002/dvdy.22771; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053; Shravage BV, 2013, DEVELOPMENT, V140, P1321, DOI 10.1242/dev.089490; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tipping M, 2014, J CELL PHYSIOL, V229, P27, DOI 10.1002/jcp.24427; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076	41	29	30	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3369	3376		10.1038/onc.2014.285	http://dx.doi.org/10.1038/onc.2014.285			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174403	Bronze, Green Accepted			2022-12-17	WOS:000356871700003
J	Moti, N; Malcolm, T; Hamoudi, R; Mian, S; Garland, G; Hook, CE; Burke, GAA; Wasik, MA; Merkel, O; Kenner, L; Laurenti, E; Dick, JE; Turner, SD				Moti, N.; Malcolm, T.; Hamoudi, R.; Mian, S.; Garland, G.; Hook, C. E.; Burke, G. A. A.; Wasik, M. A.; Merkel, O.; Kenner, L.; Laurenti, E.; Dick, J. E.; Turner, S. D.			Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; NPM-ALK; T-CELLS; KINASE; DISEASE; FUSION; IDENTIFICATION; TRANSFORMATION; MODELS; GENE	Cancer stem cells or tumour-propagating cells (TPCs) have been identified for a number of cancers, but data pertaining to their existence in lymphoma so far remain elusive. We show for the first time that a small subset of cells purified from human anaplastic lymphoma kinase (ALK)-positive and -negative, anaplastic large cell lymphoma cell lines and primary patient tumours using the side population (SP) technique have serial tumour-propagating capacity both in vitro and in vivo; they give rise to both themselves and the bulk tumour population as well as supporting growth of the latter through the production of soluble factors. In vivo serial dilution assays utilising a variety of model systems inclusive of human cell lines, primary human tumours and nucleophosmin (NPM)-ALK-induced murine tumours demonstrate the TPC frequency to vary from as many as 1/54 to 1/1336 tumour cells. In addition, the SP cells express higher levels of pluripotency-associated transcription factors and are enriched for a gene expression profile consistent with early thymic progenitors. Finally, our data show that the SP cells express higher levels of the NPM-ALK oncogene and are sensitive to an ALK inhibitor.	[Moti, N.; Malcolm, T.; Hamoudi, R.; Garland, G.; Turner, S. D.] Univ Cambridge, Div Mol Histopathol, Dept Pathol, Cambridge CB2 0QQ, England; [Mian, S.] Univ Hail, Coll Appl Med Sci, Mol Diagnost & Personalised Therapeut Unit, Hail, Saudi Arabia; [Hook, C. E.] Addenbrookes Hosp, Dept Histopathol & Cytol, Cambridge, England; [Burke, G. A. A.] Addenbrookes Hosp, Dept Paediat Oncol, Cambridge, England; [Wasik, M. A.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Merkel, O.] German Canc Res Ctr, Dept Translat Oncol, Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Merkel, O.; Kenner, L.; Turner, S. D.] Med Univ Vienna, European Res Initiat ALK Related Malignancies ERI, Vienna, Austria; [Kenner, L.] Med Univ Vienna, Clin Inst Pathol, Vienna, Austria; [Kenner, L.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Laurenti, E.; Dick, J. E.] Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Campbell Family Inst, Toronto, ON, Canada; [Laurenti, E.; Dick, J. E.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	University of Cambridge; University Ha'il; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Pennsylvania; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Medical University of Vienna; Medical University of Vienna; Ludwig Boltzmann Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Turner, SD (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Lab Block Level 3,Box 231, Cambridge CB2 0QQ, England.	sdt36@cam.ac.uk	Turner, Suzanne Dawn/K-4405-2013; Burke, Amos/AAT-1358-2021	Turner, Suzanne Dawn/0000-0002-8439-4507; Burke, Amos/0000-0003-2671-9972; Merkel, Olaf/0000-0001-5089-344X; Moti, Naushad/0000-0002-8649-9919; Hamoudi, Rifat/0000-0002-1402-0868; MIAN, SYED SHARIQ/0000-0001-7563-5121; Kenner, Lukas/0000-0003-2184-1338; Dick, John/0000-0002-9527-8317; Laurenti, Elisa/0000-0002-9917-9092	Sam Foye Fund; Leukaemia and Lymphoma Research Bennett [07006, 11051, 12065]; Cambridge Commonwealth Trust; University of Karachi, Pakistan; Elimination of Leukaemia Fund; Leukaemia and Lymphoma Research Gordon Piller Studentship [08064]	Sam Foye Fund; Leukaemia and Lymphoma Research Bennett; Cambridge Commonwealth Trust; University of Karachi, Pakistan; Elimination of Leukaemia Fund; Leukaemia and Lymphoma Research Gordon Piller Studentship	We thank past and present members of the 'Turner lab' for their helpful discussions and critical appraisal of the manuscript. We are grateful to N Miller of the Department of Pathology, University of Cambridge, FACS facility for his assistance with SP analysis and to S Johnson of the Biological Services Unit. We are also indebted to R Jarrett, L Shield and S Crae at the Leukaemia and Lymphoma Research Virus Centre, University of Glasgow, UK, for the provision of primary disaggregated, viable patient material. We also acknowledge the support of the Sam Foye Fund and dedicate this research to the memory of Sam. SDT is a Leukaemia and Lymphoma Research Bennett Fellow (grant numbers 07006, 11051, 12065). NM receives support from the Cambridge Commonwealth Trust, University of Karachi, Pakistan, and the Elimination of Leukaemia Fund. TM is supported by a Leukaemia and Lymphoma Research Gordon Piller Studentship (Grant Number 08064).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365; Cobaleda C, 2007, NATURE, V449, P473, DOI 10.1038/nature06159; Cui YX, 2009, BLOOD, V113, P5217, DOI 10.1182/blood-2008-06-160168; DELMISTRO A, 1994, LEUKEMIA, V8, P1214; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Doulatov S, 2010, NAT IMMUNOL, V11, P585, DOI 10.1038/ni.1889; Gelebart P, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.27; Georgantas RW, 2004, CANCER RES, V64, P4434, DOI 10.1158/0008-5472.CAN-03-3247; Gibbs KD, 2012, CELL STEM CELL, V10, P210, DOI 10.1016/j.stem.2012.01.004; Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007; Goodell MA, 2002, CYTOTHERAPY, V4, P507, DOI 10.1080/146532402761624638; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Goodell Margaret A, 2005, Methods Mol Biol, V290, P343; Goodell Margaret A, 2005, Curr Protoc Cytom, VChapter 9, DOI 10.1002/0471142956.cy0918s34; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jager R, 2005, ANTICANCER RES, V25, P3191; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laurent C, 2012, LEUKEMIA, V26, P188, DOI 10.1038/leu.2011.209; Le Deley MC, 2010, J CLIN ONCOL, V28, P3987, DOI 10.1200/JCO.2010.28.5999; Lutz C, 2013, LEUKEMIA, V27, P1204, DOI 10.1038/leu.2012.306; Marko NF, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-27; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mussolin L, 2005, LEUKEMIA, V19, P1643, DOI 10.1038/sj.leu.2403888; Mussolin L, 2013, LEUKEMIA, V27, P416, DOI 10.1038/leu.2012.205; Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pearson JD, 2011, INT J CLIN EXP PATHO, V4, P124; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Singh SK, 2003, CANCER RES, V63, P5821; Swerdlow SH, 2008, WHO CLASSIFICATION T, P439; Turner SD, 2006, LEUKEMIA, V20, P572, DOI 10.1038/sj.leu.2404125; Turner SD, 2005, LEUKEMIA, V19, P1128, DOI 10.1038/sj.leu.2403797; Turner SD, 2003, ONCOGENE, V22, P7750, DOI 10.1038/sj.onc.1207048; Turner SD, 2006, ANTICANCER RES, V26, P3275; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang X, 2011, J CLIN INVEST, V121, P3834, DOI 10.1172/JCI37210	41	29	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1843	1852		10.1038/onc.2014.112	http://dx.doi.org/10.1038/onc.2014.112			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24814516				2022-12-17	WOS:000352158000011
J	Castellone, MD; Laukkanen, MO; Teramoto, H; Bellelli, R; Ali, G; Fontanini, G; Santoro, M; Gutkind, JS				Castellone, M. D.; Laukkanen, M. O.; Teramoto, H.; Bellelli, R.; Ali, G.; Fontanini, G.; Santoro, M.; Gutkind, J. S.			Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma	ONCOGENE			English	Article							GASTRIN-RELEASING-PEPTIDE; NF-KAPPA-B; AUTOCRINE GROWTH; CANCER; ACTIVATION; RHO; BINDING; REQUIREMENT; INHIBITION; GTPASES	Small cell lung carcinoma (SCLC) often features the upregulation of the Sonic hedgehog (Shh) pathway leading to activation of Gli transcription factors. SCLC cells secrete bombesin (BBS)-like neuropeptides that act as autocrine growth factors. Here, we show that SCLC tumor samples feature co-expression of Shh and BBS-cognate receptor (gastrin-releasing peptide receptor (GRPR)). We also demonstrate that BBS activates Gli in SCLC cells, which is crucial for BBS-mediated SCLC proliferation, because cyclopamine, an inhibitor of the Shh pathway, hampered the BBS-mediated effects. BBS binding to GRPR stimulated Gli through its downstream G alpha(q) and G alpha(12/13) GTPases, and consistently, other G alpha(q) and G alpha(13) coupled receptors (such as muscarinic receptor, m1, and thrombin receptor, PAR-1) and constitutively active G alpha(q)QL and G alpha(12/13)QL mutants stimulated Gli. By using cells null for G alpha(q) and G alpha(12/13), we demonstrate that these G proteins are strictly necessary for Gli activation by BBS. Moreover, by using constitutively active Rho small G-protein (Rho QL) as well as its inhibitor, C3 toxin, we show that Rho mediates G-protein-coupled receptor (GPCR)-, G alpha(q)- and G alpha(12/13)-dependent Gli stimulation. At the molecular level, BBS caused a significant increase in Shh gene transcription and protein secretion that was dependent on BBS-induced GPCR/G alpha(q)-(12/13)/Rho mediated activation of nuclear factor kappa B (NF kappa B), which can stimulate a NF-kappa B response element in the Shh gene promoter. Our data identify a novel molecular network acting in SCLC linking autocrine BBS and Shh circuitries and suggest Shh inhibitors as novel therapeutic strategies against this aggressive cancer type.	[Castellone, M. D.; Teramoto, H.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Castellone, M. D.; Bellelli, R.; Santoro, M.] Univ Naples Federico II, Ist Endocrinol Oncol Sperimentale G Salvatore IEO, Dipartimento Med Mol & Biotecnol Med, I-80131 Naples, Italy; [Laukkanen, M. O.] SDN Fdn, Naples, Italy; [Teramoto, H.] Kojin Hosp, Dept Internal Med, Nagoya, Aichi, Japan; [Ali, G.; Fontanini, G.] Univ Pisa, Dept Surg, Div Anat Pathol, Pisa, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); University of Pisa	Castellone, MD (corresponding author), Univ Naples Federico II, Ist Endocrinol Oncol Sperimentale G Salvatore IEO, Dipartimento Med Mol & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.	mcastell@unina.it	Alì, Greta/J-9642-2016; Fontanini, Gabriella/O-7636-2015; Gutkind, J. Silvio/J-1201-2016; Laukkanen, Mikko/K-5868-2016	Alì, Greta/0000-0001-9258-3466; Fontanini, Gabriella/0000-0003-1957-2052; Gutkind, J. Silvio/0000-0002-5150-4482; Laukkanen, Mikko/0000-0002-1004-7131; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	Associazione Italiana per la Ricerca sul Cancro (AIRC); Intramural Research Program of NIH, National Institute of Dental and Craniofacial Research [Z01DE00551]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Intramural Research Program of NIH, National Institute of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was in part supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) and by the Intramural Research Program of NIH, National Institute of Dental and Craniofacial Research, Z01DE00551.	ALEXANDER RW, 1988, CANCER RES, V48, P1439; BRENNAN J, 1991, CANCER RES, V51, P1708; Bruzzese F, 2009, MOL CANCER THER, V8, P3075, DOI 10.1158/1535-7163.MCT-09-0254; CARNEY DN, 1987, CANCER RES, V47, P821; CARNEY DN, 1985, CANCER RES, V45, P2913; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Chinchilla P, 2010, CELL CYCLE, V9, P570, DOI 10.4161/cc.9.3.10591; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Douglas AE, 2011, J BIOL CHEM, V286, P30714, DOI 10.1074/jbc.M111.219279; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kasperczyk H, 2009, FASEB J, V23, P21, DOI 10.1096/fj.08-111096; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Kim S, 2002, ANN SURG, V235, P621, DOI 10.1097/00000658-200205000-00003; Lango MN, 2002, J NATL CANCER I, V94, P375; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Mulshine JL, 2005, NEW ENGL J MED, V352, P2714, DOI 10.1056/NEJMcp042630; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; Pacifico F, 2004, J BIOL CHEM, V279, P54610, DOI 10.1074/jbc.M403492200; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Polizio AH, 2011, J BIOL CHEM, V286, P19589, DOI 10.1074/jbc.M110.197111; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Ruiz I, 2002, NAT REV CANCER, V2, P361, DOI DOI 10.1038/NRC796; Saurin JC, 2002, CANCER RES, V62, P4829; Schally AV, 2004, CELL MOL LIFE SCI, V61, P1042, DOI 10.1007/s00018-004-3434-3; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; THOMAS F, 1992, CANCER RES, V52, P4872; ToiScott M, 1996, LUNG CANCER-J IASLC, V15, P341, DOI 10.1016/0169-5002(95)00597-8; Travis W, 2004, WHO CLASSIFICATION T; Watkins DN, 2003, CELL CYCLE, V2, P196, DOI 10.4161/cc.2.3.378; Weaver M, 2003, DEV BIOL, V258, P169, DOI 10.1016/S0012-1606(03)00117-9; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Ye RD, 2001, J LEUKOCYTE BIOL, V70, P839; Zakowski MF, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50015; Zhou JH, 2004, ANTI-CANCER DRUG, V15, P921, DOI 10.1097/00001813-200411000-00001	46	29	30	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1679	1687		10.1038/onc.2014.104	http://dx.doi.org/10.1038/onc.2014.104			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747971	Green Accepted			2022-12-17	WOS:000351848400008
J	Havel, JJ; Li, Z; Cheng, D; Peng, J; Fu, H				Havel, J. J.; Li, Z.; Cheng, D.; Peng, J.; Fu, H.			Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway	ONCOGENE			English	Article							RICH AKT SUBSTRATE; RIBOSOMAL-PROTEIN L11; LUNG-CANCER CELLS; 40 KDA PRAS40; MAMMALIAN TARGET; CELLULAR SENESCENCE; RAPAMYCIN COMPLEX-1; TUMOR SUPPRESSION; GROWTH-FACTOR; MTOR	The ribosomal protein (RP)-HDM2-p53 pathway has been shown to have key roles in oncogene-induced apoptosis and senescence, but the mechanism regulating this pathway remains elusive. The proline-rich Akt substrate of 40 kDa (PRAS40) has recently been identified as a binding partner and inhibitor of the mechanistic (formerly referred to as mammalian) target of rapamycin complex 1 (mTORC1). Although other inhibitors of mTORC1 are known tumor suppressors, PRAS40 promotes cell survival and tumorigenesis. Here we demonstrate that Akt- and mTORC1-mediated phosphorylation of PRAS40 at T246 and S221, respectively, promotes nuclear-specific association of PRAS40 with ribosomal protein L11 (RPL11). Importantly, silencing of PRAS40 induces upregulation of p53 in a manner dependent on RPL11. This effect is rescued by wild-type PRAS40, but not by the RPL11-binding-null PRAS40T246A mutant. We found that PRAS40 negatively regulates the RPL11-HDM2-p53 nucleolar stress response pathway and suppresses induction of p53-mediated cellular senescence. This work identifies nuclear PRAS40 as a dual-input signaling checkpoint that links cell growth and proliferation to inhibition of cellular senescence. These findings may help to explain the protumorigenic effect of PRAS40 and identify the PRAS40-RPL11 complex as a promising target for p53-restorative anticancer drug discovery.	[Havel, J. J.; Li, Z.; Fu, H.] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; [Havel, J. J.] Emory Univ, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA; [Cheng, D.; Peng, J.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd NE,Room 5111, Atlanta, GA 30322 USA.	hfu@emory.edu	Peng, Junmin/N-2614-2018	Peng, Junmin/0000-0003-0472-7648; Havel, Jonathan/0000-0003-0951-510X	NIH predoctoral NRSA [F31NS067844, T32GM008602]; NIH [U01CA168449]; Georgia Cancer Coalition Award; Emory University Integrated Cellular Imaging Microscopy Core of the Emory Neuroscience NINDS Core Facilities Grant [P30NS055077]; NATIONAL CANCER INSTITUTE [U01CA168449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS067844, P30NS055077] Funding Source: NIH RePORTER	NIH predoctoral NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition Award; Emory University Integrated Cellular Imaging Microscopy Core of the Emory Neuroscience NINDS Core Facilities Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This research was supported in part by NIH predoctoral NRSA F31NS067844 and training grant T32GM008602 (to JJH), NIH U01CA168449 and a Georgia Cancer Coalition Award (to HF) and the Emory University Integrated Cellular Imaging Microscopy Core of the Emory Neuroscience NINDS Core Facilities Grant P30NS055077. We thank Shannon Elf for assistance with plasmid generation, and Anita Corbett and Maureen Powers for helpful discussions.	Andersen J, 2010, DANCING TIMES, V100, P55; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Cassell A, 2012, NEOPLASIA, V14, P1005, DOI 10.1593/neo.121212; Chook YM, 2011, BBA-MOL CELL RES, V1813, P1593, DOI 10.1016/j.bbamcr.2010.10.014; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Marval PLM, 2011, ONCOTARGET, V2, P234; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fonseca BD, 2007, J BIOL CHEM, V282, P24514, DOI 10.1074/jbc.M704406200; Fregoso OI, 2013, MOL CELL, V50, P56, DOI 10.1016/j.molcel.2013.02.001; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Harthill JE, 2002, BIOCHEM J, V368, P565, DOI 10.1042/BJ20020838; Havel LS, 2011, HUM MOL GENET, V20, P1424, DOI 10.1093/hmg/ddr023; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Huang L, 2012, CANCER RES, V72, P1260, DOI 10.1158/0008-5472.CAN-11-2254; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kim W, 2013, PHARMACOL RES, V70, P90, DOI 10.1016/j.phrs.2013.01.005; Kim W, 2011, RADIAT RES, V176, P539, DOI 10.1667/RR2609.1; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 2006, NATURE, V442, P1058, DOI 10.1038/nature05020; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Madhunapantula SV, 2007, CANCER RES, V67, P3626, DOI 10.1158/0008-5472.CAN-06-4234; Makowski L, 2008, BRIT J CANCER, V99, P683, DOI 10.1038/sj.bjc.6604515; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Nascimento EBM, 2006, DIABETES, V55, P3221, DOI 10.2337/db05-1390; Nascimento Emmani B. M., 2009, Archives of Physiology and Biochemistry, V115, P163, DOI 10.1080/13813450902988580; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192; Saito A, 2006, STROKE, V37, P513, DOI 10.1161/01.STR.0000198826.56611.a2; Saito A, 2004, J NEUROSCI, V24, P1584, DOI 10.1523/JNEUROSCI.5209-03.2004; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Scott MS, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-317; Scott MS, 2010, NUCLEIC ACIDS RES, V38, P7388, DOI 10.1093/nar/gkq653; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wang L, 2008, J BIOL CHEM, V283, P15619, DOI 10.1074/jbc.M800723200; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Wei YH, 2009, EMBO J, V28, P2220, DOI 10.1038/emboj.2009.179; Wiza C, 2013, CELL SIGNAL, V25, P1762, DOI 10.1016/j.cellsig.2013.05.022; Wiza C, 2012, AM J PHYSIOL-ENDOC M, V302, pE1453, DOI 10.1152/ajpendo.00660.2011; Xu P, 2009, J PROTEOME RES, V8, P3944, DOI 10.1021/pr900251d; Yap TA, 2011, MOL CANCER THER, V10, P360, DOI 10.1158/1535-7163.MCT-10-0760; Yu FS, 2008, J CEREBR BLOOD F MET, V28, P44, DOI 10.1038/sj.jcbfm.9600501; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	68	29	32	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1487	1498		10.1038/onc.2014.91	http://dx.doi.org/10.1038/onc.2014.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704832	Green Accepted			2022-12-17	WOS:000351416800002
J	Bajpe, PK; Prahallad, A; Horlings, H; Nagtegaal, I; Beijersbergen, R; Bernards, R				Bajpe, P. K.; Prahallad, A.; Horlings, H.; Nagtegaal, I.; Beijersbergen, R.; Bernards, R.			A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity	ONCOGENE			English	Article						SIRT2; drug resistance; chromatin modifiers; genetic screen	METASTATIC COLORECTAL-CANCER; FREQUENT MUTATIONS; CELL CARCINOMA; RAS MUTATIONS; BREAST-CANCER; CETUXIMAB; RESISTANCE; RECEPTOR; PATHWAY; MARKER	Resistance to targeted therapies is a major problem in cancer treatment. The epidermal growth factor receptor (EGFR) antibody drugs are effective in a subset of colorectal cancers, but the molecular mechanisms of resistance are understood poorly. Genes involved in epigenetic regulation are frequently deregulated in cancer, raising the possibility that such genes also contribute to drug resistance. Using a focused RNA interference library for genes involved in epigenetic regulation, we identify sirtuin2 (SIRT2), an NAD(+)-dependent deacetylase, as a modulator of the response to EGFR inhibitors in colon and lung cancer. SIRT2 loss also conferred resistance to BRAF and MEK inhibitors in BRAF mutant melanoma and KRAS mutant colon cancers, respectively. These results warrant further investigation into the potential role of SIRT2 in resistance to drugs that act in the receptor tyrosine kinase-RAS-RAF-MEK-ERK signaling pathway.	[Bajpe, P. K.; Prahallad, A.; Horlings, H.; Beijersbergen, R.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands; [Horlings, H.] Acad Medisch Cent, Dept Pathol, Amsterdam, Netherlands; [Nagtegaal, I.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Canc Genom Ctr, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Nagtegaal, Iris D/A-2448-2014	Nagtegaal, Iris D/0000-0003-0887-4127; Beijersbergen, Roderick/0000-0003-0116-4130; Bernards, Rene/0000-0001-8677-3423	Dutch Cancer Society (KWF); European Union [259015]	Dutch Cancer Society (KWF)(KWF Kankerbestrijding); European Union(European Commission)	We are grateful to Kees Punt, Sabine Tejpar, Josep Tabernero, Jose Jimenez, Adriana Lopez-Doriga Guerra, Ramon Salzar and Loredana Vecchione for providing clinical specimen of cetuximab-treated colon cancers. We thank Gerrit Hooiger and Marc van de Vijver (AMC, Amsterdam) for assistance in staining tissue microarrays and Alberto Bardelli for the kind gift of the Difi cells. We thank the NKI Genomics Core Facility, especially Iris de Rink, for support. We also thank Chong Sun and Sidong Huang for helpful discussions. This work was supported by grants from the Dutch Cancer Society (KWF) and the European Union Seventh Framework Program COLTHERES project, grant agreement 259015.	Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brummelkamp TR, 2006, NAT CHEM BIOL, V2, P202, DOI 10.1038/nchembio774; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Marschalek R, 2011, BRIT J HAEMATOL, V152, P141, DOI 10.1111/j.1365-2141.2010.08459.x; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Reisman DN, 2003, CANCER RES, V63, P560; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Yeung F, ONCOGENE	27	29	32	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					531	536		10.1038/onc.2013.588	http://dx.doi.org/10.1038/onc.2013.588			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469059				2022-12-17	WOS:000348451300014
J	Bedi, U; Scheel, AH; Hennion, M; Begus-Nahrmann, Y; Ruschoff, J; Johnsen, SA				Bedi, U.; Scheel, A. H.; Hennion, M.; Begus-Nahrmann, Y.; Rueschoff, J.; Johnsen, S. A.			SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms	ONCOGENE			English	Article						estrogen receptor; breast cancer; differentiation; chromatin	HUMAN BREAST-CANCER; GENE-EXPRESSION; HISTONE H2B; TRANSCRIPTIONAL ELONGATION; CHROMATIN MODIFICATIONS; HUMAN-CELLS; P-TEFB; MONOUBIQUITINATION; SPT6; ALPHA	The estrogen receptor alpha (ER alpha) is the central transcriptional regulator of ductal mammary epithelial lineage specification and is an important prognostic marker in human breast cancer. Although antiestrogen therapies are initially highly effective at treating ER alpha-positive tumors, a large number of tumors progress to a refractory, more poorly differentiated phenotype accompanied by reduced survival. A better understanding of the molecular mechanisms involved in the progression from estrogen-dependent to hormone-resistant breast cancer may uncover new targets for treatment and the discovery of new predictive markers. Recent studies have uncovered an important role for transcriptional elongation and chromatin modifications in controlling ER alpha activity and estrogen responsiveness. The human Suppressor of Ty Homologue-6 (SUPT6H) is a histone chaperone that links transcriptional elongation to changes in chromatin structure. We show that SUPT6H is required for estrogen-regulated transcription and the maintenance of chromatin structure in breast cancer cells, possibly in part through interaction with RNF40 and regulation of histone H2B monoubiquitination (H2Bub1). Moreover, we demonstrate that SUPT6H protein levels decrease with malignancy in breast cancer. Consistently, SUPT6H, similar to H2Bub1, is required for cellular differentiation and suppression of the repressive histone mark H3K27me3 on lineage-specific genes. Together, these data identify SUPT6H as a new epigenetic regulator of ER alpha activity and cellular differentiation.	[Bedi, U.; Johnsen, S. A.] Univ Med Ctr Hamburg Eppendorf UKE, Dept Tumor Biol, Ctr Med Expt, D-20251 Hamburg, Germany; [Bedi, U.; Hennion, M.; Begus-Nahrmann, Y.; Johnsen, S. A.] Univ Med Ctr Gottingen, Inst Mol Oncol, Gottingen, Germany; [Scheel, A. H.; Rueschoff, J.] Inst Pathol Nordhessen, Kassel, Germany; [Scheel, A. H.] Univ Med Ctr Gottinngen, Dept Pathol, Ctr Pathol & Forens Med, Gottingen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen	Johnsen, SA (corresponding author), Univ Med Ctr Hamburg Eppendorf UKE, Dept Tumor Biol, Ctr Med Expt, D-20251 Hamburg, Germany.	sjohnsen@alumni.mayo.edu	Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805; Hennion, Magali/0000-0002-0352-2790	Erasmus Mundus External Cooperation Window EURINDIA; Gottingen Graduate School for Neurosciences, Biophysics and Molecular Biosciences; Deutsche Krebshilfe [109088]; Deutsche Forschungsgemeinschaft [JO 815/3]	Erasmus Mundus External Cooperation Window EURINDIA; Gottingen Graduate School for Neurosciences, Biophysics and Molecular Biosciences; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank L Schreiber, J Schiller and CR Schlegel for initial efforts in establishing SUPT6H knockdown. UB was supported by doctoral fellowships from the Erasmus Mundus External Cooperation Window EURINDIA and the Gottingen Graduate School for Neurosciences, Biophysics and Molecular Biosciences. This work was supported by grants from the Deutsche Krebshilfe (109088) and the Deutsche Forschungsgemeinschaft (JO 815/3) to SAJ.	Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen SZ, 2012, GENE DEV, V26, P1364, DOI 10.1101/gad.186056.111; Chen S, 2012, CELL RES, V22, P1402, DOI 10.1038/cr.2012.114; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Diebold ML, 2010, J BIOL CHEM, V285, P38389, DOI 10.1074/jbc.M110.146696; Egloff S, 2008, TRENDS GENET, V24, P280, DOI 10.1016/j.tig.2008.03.008; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fuchs G, 2012, MOL CELL, V46, P662, DOI 10.1016/j.molcel.2012.05.023; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Johnsen S A, 2006, Ernst Schering Found Symp Proc, P1; Johnsen SA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002860; Johnsen SA, 2012, FEBS LETT, V586, P1592, DOI 10.1016/j.febslet.2012.04.002; Kari V, 2011, CELL CYCLE, V10, P3495, DOI 10.4161/cc.10.20.17769; Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022; Ketchart W, 2011, ONCOGENE, V30, P3563, DOI 10.1038/onc.2011.76; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kininis M, 2009, MOL CELL BIOL, V29, P1123, DOI 10.1128/MCB.00841-08; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Metivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626; Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712; Ogba N, 2008, CANCER RES, V68, P7015, DOI 10.1158/0008-5472.CAN-08-0814; Pirngruber J, 2010, ONCOGENE, V29, P2853, DOI 10.1038/onc.2010.42; Pirngruber J, 2009, CELL CYCLE, V8, P3636, DOI 10.4161/cc.8.22.9890; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5; Reijm EA, 2011, BREAST CANCER RES TR, V125, P387, DOI 10.1007/s10549-010-0836-9; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Wang AHJ, 2013, EMBO J, V32, P1075, DOI 10.1038/emboj.2013.54; Wittmann BM, 2005, ONCOGENE, V24, P5576, DOI 10.1038/sj.onc.1208728; Yoh SM, 2007, GENE DEV, V21, P160, DOI 10.1101/gad.1503107; Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024	46	29	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					465	473		10.1038/onc.2013.558	http://dx.doi.org/10.1038/onc.2013.558			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24441044				2022-12-17	WOS:000348451300007
J	Elias, HK; Schinke, C; Bhattacharyya, S; Will, B; Verma, A; Steidl, U				Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.			Stem cell origin of myelodysplastic syndromes	ONCOGENE			English	Review						MDS; myelodysplastic syndrome; stem cell; HSC; progenitor cell; cell-of-origin	ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION PROFILES; IN-SITU HYBRIDIZATION; BONE-MARROW-CELLS; HEMATOPOIETIC STEM; CD34(+) CELLS; SELF-RENEWAL; LINEAGE INVOLVEMENT; INITIATING CELLS; PROGENITOR CELLS	Myelodysplastic syndromes (MDS) are common hematologic disorders that are characterized by decreased blood counts due to ineffective hematopoiesis. MDS is considered a 'preleukemic' disorder linked to a significantly elevated risk of developing an overt acute leukemia. Cytopenias can be observed in all three myeloid lineages suggesting the involvement of multipotent, immature hematopoietic cells in the pathophysiology of this disease. Recent studies using murine models of MDS as well as primary patient-derived bone marrow samples have provided direct evidence that the most immature, self-renewing hematopoietic stem cells (HSC), as well as lineage-committed progenitor cells, are critically altered in patients with MDS. Besides significant changes in the number and distribution of stem as well as immature progenitor cells, genetic and epigenetic aberrations have been identified, which confer functional changes to these aberrant stem cells, impairing their ability to proliferate and differentiate. Most importantly, aberrant stem cells can persist and further expand after treatment, even upon transient achievement of clinical complete remission, pointing to a critical role of these cells in disease relapse. Ongoing preclinical and clinical studies are particularly focusing on the precise molecular and functional characterization of aberrant MDS stem cells in response to therapy, with the goal to develop stem cell-targeted strategies for therapy and disease monitoring that will allow for achievement of longer-lasting remissions in MDS.	[Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] Albert Einstein Coll Med, Albert Einstein Canc Ctr, New York, NY 10461 USA; [Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] NYU, Dept Cell Biol, New York, NY 10016 USA; [Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] Dept Dev & Mol Biol, New York, NY USA; [Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] Dept Med Oncol, Div Hematol Malignancies, New York, NY USA; [Elias, H. K.; Schinke, C.; Bhattacharyya, S.; Will, B.; Verma, A.; Steidl, U.] Chanin Inst Canc Res, Ruth L & David S Gottesman Inst Stem Cell & Regen, New York, NY USA	Yeshiva University; New York University	Will, B (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, New York, NY 10461 USA.	britta.will@einstein.yu.edu; amit.verma@einstein.yu.edu; ulrich.steidl@einstein.yu.edu	Elias, Harold/F-6457-2015	Elias, Harold/0000-0002-6189-4752; Will, Britta/0000-0002-9534-6690				Abdel-Wahab O, 2013, J EXP MED, V210, P2641, DOI 10.1084/jem.20131141; Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032; ABRAHAMSON G, 1991, BRIT J HAEMATOL, V79, P550, DOI 10.1111/j.1365-2141.1991.tb08080.x; Abramovich C, 2005, ANN NY ACAD SCI, V1044, P109, DOI 10.1196/annals.1349.014; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bacher U, 2007, HAEMATOLOGICA, V92, P744, DOI 10.3324/haematol.10869; Bains A, 2011, AM J CLIN PATHOL, V135, P62, DOI 10.1309/AJCPEI9XU8PYBCIO; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Barreyro L, 2012, BLOOD, V120, P1290, DOI 10.1182/blood-2012-01-404699; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Benito AI, 2003, LEUKEMIA RES, V27, P425, DOI 10.1016/S0145-2126(02)00221-7; Bereshchenko O, 2009, CANCER CELL, V16, P390, DOI 10.1016/j.ccr.2009.09.036; Bernell P, 1996, LEUKEMIA, V10, P662; Boultwood J, 2010, LEUKEMIA, V24, P1062, DOI 10.1038/leu.2010.20; Boultwood J, 2001, INT J HEMATOL, V73, P411, DOI 10.1007/BF02994002; Broske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Challen GA, 2012, NAT GENET, V44, P23, DOI 10.1038/ng.1009; Chaturvedi A, 2013, BLOOD, V122, P2877, DOI 10.1182/blood-2013-03-491571; Chen GB, 2004, BLOOD, V104, P4210, DOI 10.1182/blood-2004-01-0103; Chen W, 2008, CANCER CELL, V13, P432, DOI 10.1016/j.ccr.2008.03.005; Choi CW, 2008, HAEMATOL-HEMATOL J, V93, P1394, DOI 10.3324/haematol.13042; Chung SS, 2012, BLOOD, V120, P210; Craddock C, 2013, LEUKEMIA, V27, P1028, DOI 10.1038/leu.2012.312; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Giassi LJ, 2008, EXP BIOL MED, V233, P997, DOI 10.3181/0802-RM-70; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Graf L, 2002, BLOOD, V100, P1509, DOI 10.1182/blood-2002-03-0844; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Haase D, 1997, LEUKEMIA, V11, P674, DOI 10.1038/sj.leu.2400638; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Iriuchishima H, 2011, BLOOD, V117, P2373, DOI 10.1182/blood-2010-07-294801; Ishikawa F, 2008, CURR TOP MICROBIOL, V324, P87; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jaju RJ, 2000, GENE CHROMOSOME CANC, V29, P276, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1035>3.0.CO;2-L; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jan M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004315; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kawahara M, 2012, CANCER CELL, V22, P194, DOI 10.1016/j.ccr.2012.06.027; Kerbauy DMB, 2004, BLOOD, V104, P2202, DOI 10.1182/blood-2004-04-1518; Khandanpour C, 2011, STEM CELLS, V29, P376, DOI 10.1002/stem.575; Kirstetter P, 2008, CANCER CELL, V13, P299, DOI 10.1016/j.ccr.2008.02.008; Kitagawa M, 1997, LEUKEMIA, V11, P2049, DOI 10.1038/sj.leu.2400844; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Kosmider O, 2010, LEUKEMIA, V24, P1094, DOI 10.1038/leu.2010.52; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kroef MJPL, 1997, LEUKEMIA, V11, P519, DOI 10.1038/sj.leu.2400597; KROEF MJPL, 1993, BLOOD, V81, P1849; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kuo YH, 2006, CANCER CELL, V9, P57, DOI 10.1016/j.ccr.2005.12.014; Lam DH, 2001, LEUKEMIA, V15, P1689, DOI 10.1038/sj.leu.2402269; Laricchia-Robbio L, 2006, MOL CELL BIOL, V26, P7658, DOI 10.1128/MCB.00363-06; Laurenti E, 2008, CELL STEM CELL, V3, P611, DOI 10.1016/j.stem.2008.09.005; Li X, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.11; Lin YW, 2005, BLOOD, V106, P287, DOI 10.1182/blood-2004-12-4794; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Louz D, 2000, LEUKEMIA, V14, P1876, DOI 10.1038/sj.leu.2401887; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; Misaghian N, 2009, LEUKEMIA, V23, P25, DOI 10.1038/leu.2008.246; Miura I, 2000, INT J HEMATOL, V72, P310; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Muguruma Y, 2011, HAEMATOL-HEMATOL J, V96, P543, DOI 10.3324/haematol.2010.027557; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; Nilsson L, 2002, BLOOD, V100, P259, DOI 10.1182/blood-2001-12-0188; Nilsson L, 2007, BLOOD, V110, P3005, DOI 10.1182/blood-2007-03-079368; Oda M, 2009, NUCLEIC ACIDS RES, V37, P3829, DOI 10.1093/nar/gkp260; Pang WW, 2013, P NATL ACAD SCI USA, V110, P3011, DOI 10.1073/pnas.1222861110; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Pardanani A, 2010, LEUKEMIA, V24, P1370, DOI 10.1038/leu.2010.98; Parkin B, 2013, BLOOD, V121, P369, DOI 10.1182/blood-2012-04-427039; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Patnaik MM, 2012, LEUKEMIA, V26, P101, DOI 10.1038/leu.2011.298; Pellagatti A, 2010, LEUKEMIA, V24, P756, DOI 10.1038/leu.2010.31; Pellagatti A, 2006, BLOOD, V108, P337, DOI 10.1182/blood-2005-12-4769; Petzer AL, 1996, P NATL ACAD SCI USA, V93, P1470, DOI 10.1073/pnas.93.4.1470; Prall WC, 2009, INT J HEMATOL, V89, P173, DOI 10.1007/s12185-008-0242-9; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; Rhyasen GW, 2013, CANCER CELL, V24, P90, DOI 10.1016/j.ccr.2013.05.006; Rodrigues NP, 2012, INT J BIOCHEM CELL B, V44, P457, DOI 10.1016/j.biocel.2011.12.004; ROECKLEIN BA, 1995, BLOOD, V85, P997, DOI 10.1182/blood.V85.4.997.bloodjournal854997; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Ruiz-Herguido C, 2012, J EXP MED, V209, P1457, DOI 10.1084/jem.20120225; Santaguida M, 2009, CANCER CELL, V15, P341, DOI 10.1016/j.ccr.2009.02.016; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Shimizu R, 2004, MOL CELL BIOL, V24, P10814, DOI 10.1128/MCB.24.24.10814-10825.2004; Smith LL, 2011, CELL STEM CELL, V8, P649, DOI 10.1016/j.stem.2011.05.004; SOENEN V, 1995, BRIT J HAEMATOL, V90, P701, DOI 10.1111/j.1365-2141.1995.tb05604.x; Sportoletti P, 2008, BLOOD, V111, P3859, DOI 10.1182/blood-2007-06-098251; Starczynowski DT, 2010, NAT MED, V16, P49, DOI 10.1038/nm.2054; Steidl U, 2006, NAT GENET, V38, P1269, DOI 10.1038/ng1898; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Taketani T, 2002, CANCER RES, V62, P33; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Tanaka S, 2012, BLOOD, V120, P1107, DOI 10.1182/blood-2011-11-394932; Tehranchi R, 2010, NEW ENGL J MED, V363, P1025, DOI 10.1056/NEJMoa0912228; Thanopoulou E, 2004, BLOOD, V103, P4285, DOI 10.1182/blood-2003-09-3192; Thol F, 2012, BLOOD, V119, P3578, DOI 10.1182/blood-2011-12-399337; Thol F, 2010, HAEMATOL-HEMATOL J, V95, P1668, DOI 10.3324/haematol.2010.025494; Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016; vanLom K, 1996, BRIT J HAEMATOL, V93, P594, DOI 10.1046/j.1365-2141.1996.d01-1692.x; Venner CP, 2013, HAEMATOLOGICA, V98, P409, DOI 10.3324/haematol.2012.066068; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; Verma Amit, 2005, Curr Hematol Rep, V4, P429; Walter MJ, 2011, LEUKEMIA, V25, P1153, DOI 10.1038/leu.2011.44; Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Will B, 2012, BLOOD, V120, P2076, DOI 10.1182/blood-2011-12-399683; Will B, 2009, BLOOD, V114, P3899, DOI 10.1182/blood-2009-04-219493; Yang LP, 2005, J IMMUNOL, V174, P752, DOI 10.4049/jimmunol.174.2.752; Zeng WH, 2004, BLOOD, V103, P325, DOI 10.1182/blood-2003-02-0490; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	129	29	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5139	5150		10.1038/onc.2013.520	http://dx.doi.org/10.1038/onc.2013.520			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24336326				2022-12-17	WOS:000343914900001
J	Hrdinka, M; Horejsi, V				Hrdinka, M.; Horejsi, V.			PAG - a multipurpose transmembrane adaptor protein	ONCOGENE			English	Review						PAG1; Cbp; Csk; Src family kinases; receptor signaling; membrane microdomains	CSK-BINDING PROTEIN; TERMINAL SRC KINASE; T-CELL-ACTIVATION; GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS; FAMILY TYROSINE KINASES; LIPID RAFT; NEGATIVE REGULATION; SIGNAL-TRANSDUCTION; DOWN-REGULATION; C-SRC	Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), also known as Csk-binding protein (Cbp), is a ubiquitously expressed transmembrane adaptor protein present in lipid rafts and involved in a number of signaling pathways. It helps recruit cytoplasmic C-terminal Src kinase (Csk) to lipid raft-associated Src kinases, mediates a link to actin cytoskeleton and interacts with several other important cytoplasmic and plasma membrane-associated proteins. In recent years, PAG has been implicated in various aspects of cancer cell biology. Our review covers all so far published data on this interesting protein.	[Hrdinka, M.; Horejsi, V.] Acad Sci Czech Republ, Inst Mol Genet, Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Horejsi, V (corresponding author), IMG AS CR, Dept Mol Immunol, Videnska 1083, CZ-14220 Prague, Czech Republic.	vaclav.horejsi@img.cas.cz	Hrdinka, Matous/B-9187-2011	Hrdinka, Matous/0000-0002-2981-2825	Czech Science Foundation [P302-12-G101]; Institute of Molecular Genetics ASCR [RVO 68378050]	Czech Science Foundation(Grant Agency of the Czech Republic); Institute of Molecular Genetics ASCR	This work was supported by Grant No. P302-12-G101 from the Czech Science Foundation and by the Institute of Molecular Genetics ASCR (RVO 68378050).	Abram Clare L, 2007, Sci STKE, V2007, pre2, DOI 10.1126/stke.3772007re2; Awasthi-Kalia M, 2001, BIOCHEM BIOPH RES CO, V287, P77, DOI 10.1006/bbrc.2001.5536; Bamberger M, 2011, J BIOL CHEM, V286, P30324, DOI 10.1074/jbc.M111.230102; Baniyash M, 2004, NAT REV IMMUNOL, V4, P675, DOI 10.1038/nri1434; Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Boyd RS, 2009, MOL CELL PROTEOMICS, V8, P1501, DOI 10.1074/mcp.M800515-MCP200; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdickova N, 2003, J EXP MED, V198, P1453, DOI 10.1084/jem.20031484; Brdickova N, 2001, FEBS LETT, V507, P133, DOI 10.1016/S0014-5793(01)02955-6; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Cao LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046725; Capitani N, 2010, FEBS LETT, V584, P4915, DOI 10.1016/j.febslet.2010.08.046; Chen Y, 2009, J CELL SCI, V122, P3966, DOI 10.1242/jcs.049346; CINEK T, 1992, J IMMUNOL, V149, P2262; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cohen S, 1999, BLOOD, V93, P2013, DOI 10.1182/blood.V93.6.2013.406k25_2013_2024; Cornez I, 2010, FEBS LETT, V584, P2681, DOI 10.1016/j.febslet.2010.04.056; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Davidson D, 2007, MOL CELL BIOL, V27, P1960, DOI 10.1128/MCB.01983-06; Dobenecker MW, 2005, MOL CELL BIOL, V25, P10533, DOI 10.1128/MCB.25.23.10533-10542.2005; Draber P, 2011, MOL CELL BIOL, V31, P4550, DOI 10.1128/MCB.05817-11; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Durrheim GA, 2001, CELL BIOL INT, V25, P33, DOI 10.1006/cbir.2000.0675; Feng X, 2009, ONCOGENE, V28, P3320, DOI 10.1038/onc.2009.185; Fuller DM, 2011, IMMUNOL RES, V49, P97, DOI 10.1007/s12026-010-8197-3; Fuller DM, 2009, IMMUNOL REV, V232, P72, DOI 10.1111/j.1600-065X.2009.00828.x; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; Georgakopoulos A, 2011, FASEB J, V25, P3594, DOI 10.1096/fj.11-187856; Gupta N, 2006, NAT IMMUNOL, V7, P625, DOI 10.1038/ni1337; Hamerman JA, 2009, IMMUNOL REV, V232, P42, DOI 10.1111/j.1600-065X.2009.00841.x; Hermiston ML, 2009, IMMUNOL REV, V228, P288, DOI 10.1111/j.1600-065X.2008.00752.x; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Hong H, 2007, BLOOD, V110, P2511, DOI 10.1182/blood-2007-01-066092; Horejsi V, 2004, NAT REV IMMUNOL, V4, P603, DOI 10.1038/nri1414; Horejsi V, 1998, IMMUNOL LETT, V63, P63, DOI 10.1016/S0165-2478(98)00054-6; Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105-2896.2005.00325.x; Hur EM, 2003, J EXP MED, V198, P1463, DOI 10.1084/jem.20030232; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Inomata M, 2007, FEBS LETT, V581, P3039, DOI 10.1016/j.febslet.2007.05.063; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Iwaki S, 2007, INT J BIOCHEM CELL B, V39, P868, DOI 10.1016/j.biocel.2006.10.018; Jiang LQ, 2006, ONCOGENE, V25, P5495, DOI 10.1038/sj.onc.1209554; Kalland ME, 2012, EXP CELL RES, V318, P1611, DOI 10.1016/j.yexcr.2012.05.014; Kanou T, 2011, MOL CANCER RES, V9, P103, DOI 10.1158/1541-7786.MCR-10-0340; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Ke Q, 2012, CANCER BIOTHER RADIO, V27, P678, DOI 10.1089/cbr.2012.1191; Kitaura J, 2007, J IMMUNOL, V178, P455, DOI 10.4049/jimmunol.178.1.455; Kusumi A, 2012, ANNU REV CELL DEV BI, V28, P215, DOI 10.1146/annurev-cellbio-100809-151736; Lanier LL, 2009, IMMUNOL REV, V227, P150, DOI 10.1111/j.1600-065X.2008.00720.x; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lindquist S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023978; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Maksumova L, 2005, J IMMUNOL, V175, P7947, DOI 10.4049/jimmunol.175.12.7947; Marie-Cardine A, 1999, EUR J IMMUNOL, V29, P1175, DOI 10.1002/(SICI)1521-4141(199904)29:04<1175::AID-IMMU1175>3.0.CO;2-Z; Marie-Cardine A, 1999, J EXP MED, V189, P1181, DOI 10.1084/jem.189.8.1181; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Marinari B, 2003, EUR J IMMUNOL, V33, P2609, DOI 10.1002/eji.200324064; Matsubara T, 2010, J BONE MINER RES, V25, P1068, DOI 10.1359/jbmr.091039; Matsuoka H, 2004, J BIOL CHEM, V279, P5975, DOI 10.1074/jbc.M311278200; Mosenden R, 2011, CELL SIGNAL, V23, P1009, DOI 10.1016/j.cellsig.2010.11.018; Mutch CM, 2007, INT IMMUNOL, V19, P19, DOI 10.1093/intimm/dxl118; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NEET K, 1995, MOL CELL BIOL, V15, P4908; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; Ohtake H, 2002, J IMMUNOL, V168, P2087, DOI 10.4049/jimmunol.168.5.2087; Okada M, 2012, INT J BIOL SCI, V8, P1385, DOI 10.7150/ijbs.5141; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Oneyama C, 2009, MOL CELL BIOL, V29, P6462, DOI 10.1128/MCB.00941-09; Owen DM, 2012, BIOESSAYS, V34, P739, DOI 10.1002/bies.201200044; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Park Inyoung, 2009, Immune Netw, V9, P53, DOI 10.4110/in.2009.9.2.53; Place AT, 2011, MOL PHARMACOL, V80, P665, DOI 10.1124/mol.111.073957; Posevitz-Fejfar A, 2008, EUR J IMMUNOL, V38, P250, DOI 10.1002/eji.200636664; Rahmouni S, 2005, MOL CELL BIOL, V25, P2227, DOI 10.1128/MCB.25.6.2227-2241.2005; Relucio J, 2009, J NEUROSCI, V29, P11794, DOI 10.1523/JNEUROSCI.0888-09.2009; Resh MD, 2008, CANCER CELL, V13, P469, DOI 10.1016/j.ccr.2008.05.011; Rey-Barroso J, 2013, CELL SIGNAL, V25, P848, DOI 10.1016/j.cellsig.2013.01.010; Rivera J, 2005, TRENDS IMMUNOL, V26, P119, DOI 10.1016/j.it.2005.01.001; Ruppelt A, 2007, J IMMUNOL, V179, P5159, DOI 10.4049/jimmunol.179.8.5159; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Saito K, 2008, BIOCHEM BIOPH RES CO, V366, P969, DOI 10.1016/j.bbrc.2007.12.055; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; Sekino-Suzuki N, 2013, J NEUROCHEM, V124, P514, DOI 10.1111/jnc.12040; Semac I, 2003, CANCER RES, V63, P534; Shima T, 2003, P NATL ACAD SCI USA, V100, P14897, DOI 10.1073/pnas.2432139100; Shimada Y, 2005, FEBS J, V272, P5454, DOI 10.1111/j.1742-4658.2005.04938.x; Simeoni L, 2005, SEMIN IMMUNOL, V17, P35, DOI 10.1016/j.smim.2004.09.002; Sirvent A, 2010, ONCOGENE, V29, P1303, DOI 10.1038/onc.2009.450; Smida M, 2007, BLOOD, V110, P596, DOI 10.1182/blood-2006-07-038752; Solheim SA, 2008, FEBS J, V275, P4863, DOI 10.1111/j.1742-4658.2008.06626.x; Solheim SA, 2008, J BIOL CHEM, V283, P2773, DOI 10.1074/jbc.M705215200; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Stepanek O, 2013, J IMMUNOL, V190, P1807, DOI 10.4049/jimmunol.1202401; Stokka AJ, 2010, BIOCHEM J, V425, P381, DOI 10.1042/BJ20091136; Suzuki K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.195362; Svec A, 2005, IMMUNOL LETT, V100, P94, DOI 10.1016/j.imlet.2005.05.002; Svec A, 2008, PATHOL RES PRACT, V204, P785, DOI 10.1016/j.prp.2008.06.006; Svojgr K, 2009, IMMUNOL LETT, V122, P185, DOI 10.1016/j.imlet.2008.12.008; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Takeuchi S, 2006, PROTEIN J, V25, P295, DOI 10.1007/s10930-006-9015-6; Tanaka H, 2013, J BIOL CHEM, V288, P15240, DOI 10.1074/jbc.M112.439075; Tauzin S, 2008, BLOOD, V111, P2310, DOI 10.1182/blood-2007-05-090985; Tauzin S, 2011, EXP CELL RES, V317, P151, DOI 10.1016/j.yexcr.2010.09.011; Tedoldi S, 2006, BLOOD, V107, P213, DOI 10.1182/blood-2005-06-2273; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Turnbull IR, 2007, NAT REV IMMUNOL, V7, P155, DOI 10.1038/nri2014; Vacaresse N, 2008, J BIOL CHEM, V283, P35815, DOI 10.1074/jbc.M807964200; Vang T, 2003, J BIOL CHEM, V278, P17597, DOI 10.1074/jbc.C300077200; Vang T, 2012, NAT CHEM BIOL, V8, P437, DOI [10.1038/NCHEMBIO.916, 10.1038/nchembio.916]; Veracini L, 2008, J CELL BIOL, V182, P603, DOI 10.1083/jcb.200705102; Whiting RJ, 2012, BIOCHEM J, V442, P611, DOI 10.1042/BJ20111485; Wong L, 2005, J MOL BIOL, V351, P131, DOI 10.1016/j.jmb.2005.05.042; Xu SL, 2005, MOL CELL BIOL, V25, P8486, DOI 10.1128/MCB.25.19.8486-8495.2005; Xu YK, 2012, IMMUNOL CELL BIOL, V90, P903, DOI 10.1038/icb.2012.31; Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813; Yerly S, 2010, EUR J HAEMATOL, V85, P93, DOI 10.1111/j.1600-0609.2010.01492.x; Yu LX, 2013, CELL SIGNAL, V25, P581, DOI 10.1016/j.cellsig.2012.11.017; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhao MM, 2006, MOL CELL BIOL, V26, P2479, DOI 10.1128/MCB.26.7.2479-2489.2006; Zheng Y, 2008, EMBO REP, V9, P50, DOI 10.1038/sj.embor.7401138; Zhou Dong, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P1781	126	29	33	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4881	4892		10.1038/onc.2013.485	http://dx.doi.org/10.1038/onc.2013.485			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24213579				2022-12-17	WOS:000343767900001
J	Wilson, IM; Vucic, EA; Enfield, KSS; Thu, KL; Zhang, YA; Chari, R; Lockwood, WW; Radulovich, N; Starczynowski, DT; Banath, JP; Zhang, M; Pusic, A; Fuller, M; Lonergan, KM; Rowbotham, D; Yee, J; English, JC; Buys, TPH; Selamat, SA; Laird-Offringa, IA; Liu, P; Anderson, M; You, M; Tsao, MS; Brown, CJ; Bennewith, KL; MacAulay, CE; Karsan, A; Gazdar, AF; Lam, S; Lam, WL				Wilson, I. M.; Vucic, E. A.; Enfield, K. S. S.; Thu, K. L.; Zhang, Y. A.; Chari, R.; Lockwood, W. W.; Radulovich, N.; Starczynowski, D. T.; Banath, J. P.; Zhang, M.; Pusic, A.; Fuller, M.; Lonergan, K. M.; Rowbotham, D.; Yee, J.; English, J. C.; Buys, T. P. H.; Selamat, S. A.; Laird-Offringa, I. A.; Liu, P.; Anderson, M.; You, M.; Tsao, M. S.; Brown, C. J.; Bennewith, K. L.; MacAulay, C. E.; Karsan, A.; Gazdar, A. F.; Lam, S.; Lam, W. L.			EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk	ONCOGENE			English	Article						EYA4; two hit; hypermethylation; tumor suppressor; TSG; non-small-cell lung cancer	GENE-EXPRESSION SIGNATURE; SUSCEPTIBILITY LOCUS; DNA METHYLATION; HISTONE H2AX; GENOME; SMOKING; ADENOCARCINOMA; DELETION; BRCA1	In an effort to identify novel biallelically inactivated tumor suppressor genes (TSGs) in sporadic invasive and preinvasive non-small-cell lung cancer (NSCLC) genomes, we applied a comprehensive integrated multiple 'omics' approach to investigate patient-matched, paired NSCLC tumor and non-malignant parenchymal tissues. By surveying lung tumor genomes for genes concomitantly inactivated within individual tumors by multiple mechanisms, and by the frequency of disruption in tumors across multiple cohorts, we have identified a putative lung cancer TSG, Eyes Absent 4 (EYA4). EYA4 is frequently and concomitantly deleted, hypermethylated and underexpressed in multiple independent lung tumor data sets, in both major NSCLC subtypes and in the earliest stages of lung cancer. We found that decreased EYA4 expression is not only associated with poor survival in sporadic lung cancers but also that EYA4 single-nucleotide polymorphisms are associated with increased familial cancer risk, consistent with EYA4s proximity to the previously reported lung cancer susceptibility locus on 6q. Functionally, we found that EYA4 displays TSG-like properties with a role in modulating apoptosis and DNA repair. Cross-examination of EYA4 expression across multiple tumor types suggests a cell-type-specific tumorigenic role for EYA4, consistent with a tumor suppressor function in cancers of epithelial origin. This work shows a clear role for EYA4 as a putative TSG in NSCLC.	[Wilson, I. M.; Vucic, E. A.; Enfield, K. S. S.; Thu, K. L.; Chari, R.; Lockwood, W. W.; Banath, J. P.; Zhang, M.; Pusic, A.; Fuller, M.; Lonergan, K. M.; Rowbotham, D.; Buys, T. P. H.; Bennewith, K. L.; MacAulay, C. E.; Karsan, A.; Lam, S.; Lam, W. L.] British Columbia Canc Res Ctr, Integrat Oncol Genet Unit, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada; [Zhang, Y. A.; Gazdar, A. F.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Chari, R.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Lockwood, W. W.] NHGRI, Canc Genet Branch, Bethesda, MD 20892 USA; [Radulovich, N.; Tsao, M. S.] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; [Starczynowski, D. T.] Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH USA; [Yee, J.] Vancouver Gen Hosp, Dept Surg, Vancouver, BC, Canada; [English, J. C.] Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada; [Selamat, S. A.; Laird-Offringa, I. A.] Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Liu, P.; Anderson, M.; You, M.] Med Coll Wisconsin, Ctr Canc, Milwaukee, WI 53226 USA; [Brown, C. J.] Univ British Columbia, Life Sci Ctr, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of British Columbia; University of British Columbia; University of Southern California; Medical College of Wisconsin; University of British Columbia	Wilson, IM (corresponding author), British Columbia Canc Res Ctr, Integrat Oncol Genet Unit, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	iwilson@bccrc.ca	Brown, Carolyn J/A-5159-2014; Chari, Raj/G-3285-2019; Karsan, Aly/K-2067-2015; Tsao, Ming Sound/AFQ-7332-2022; Offringa, Ite/R-4101-2019; Tsao, Ming-Sound/M-3503-2017; MacAulay, Calum/K-1795-2016	Brown, Carolyn J/0000-0002-8959-0101; Tsao, Ming Sound/0000-0002-9160-5405; Thu, Kelsie/0000-0001-9262-7238; Selamat, Suhaida/0000-0002-7185-6995; Vucic, Emily/0000-0002-2728-8708; MacAulay, Calum/0000-0003-4440-2792; Fuller, Megan/0000-0002-8752-8312	Canadian Institutes of Health Research (CIHR) [MOP86731, MOP77903, MOP94867]; Canadian Cancer Society [CCS017076, CCS20485]; Terry Fox Foundation [20395]; NCI Early Detection Research Network [5U01 CA84971-10]; Canary Foundation; NIH Genetic Epidemiology of Lung Cancer Consortium [U01CA76293]; CIHR, Canada; Vanier Canada; NATIONAL CANCER INSTITUTE [U01CA084971, U01CA076293, P50CA070907] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Terry Fox Foundation; NCI Early Detection Research Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canary Foundation; NIH Genetic Epidemiology of Lung Cancer Consortium; CIHR, Canada(Canadian Institutes of Health Research (CIHR)); Vanier Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Miwa Suzuki, Denise McDougal, Chad Malloff and Bradley Coe for assistance. Grant supports were from Canadian Institutes of Health Research (CIHR MOP86731, MOP77903, MOP94867), Canadian Cancer Society (CCS017076, CCS20485); Terry Fox Foundation (20395); NCI Early Detection Research Network (5U01 CA84971-10), Canary Foundation, NIH Genetic Epidemiology of Lung Cancer Consortium (U01CA76293); and scholarships from CIHR (IMW, EAV, KSSE and WWL) and Vanier Canada (RC, KLT and NR).	Amos CI, 2010, CANCER RES, V70, P2359, DOI 10.1158/0008-5472.CAN-09-3096; Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857; Barrett T, 2009, NUCLEIC ACIDS RES, V37, pD885, DOI 10.1093/nar/gkn764; Bell DW, 2002, CANCER RES, V62, P2741; Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14; Bijron JG, 2012, ENDOCR-RELAT CANCER, V19, P69, DOI 10.1530/ERC-11-0338; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522; Boelens MC, 2009, J PATHOL, V218, P182, DOI 10.1002/path.2520; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chitale D, 2009, ONCOGENE, V28, P2773, DOI 10.1038/onc.2009.135; Clark SW, 2002, J BIOL CHEM, V277, P3560, DOI 10.1074/jbc.M108410200; Coe BP, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq548; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kim YH, 2011, ANN SURG ONCOL, V18, P2338, DOI 10.1245/s10434-011-1573-y; Kisiel JB, 2013, ALIMENT PHARM THER, V37, P546, DOI 10.1111/apt.12218; Kisiel JB, 2012, CANCER-AM CANCER SOC, V118, P2623, DOI 10.1002/cncr.26558; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Liu PY, 2008, JNCI-J NATL CANCER I, V100, P1326, DOI 10.1093/jnci/djn268; Liu X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042725; Lockwood WW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037775; Lonergan KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009162; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; MacPhail SH, 2003, INT J RADIAT BIOL, V79, P351, DOI 10.1080/0955300032000093128; Miller SJ, 2010, ONCOGENE, V29, P368, DOI 10.1038/onc.2009.360; Nagayama K, 2007, GENE CHROMOSOME CANC, V46, P1000, DOI 10.1002/gcc.20485; Okabe Y, 2009, NATURE, V460, P520, DOI 10.1038/nature08138; Olive PL, 2004, INT J RADIAT ONCOL, V58, P331, DOI 10.1016/j.ijrobp.2003.09.028; Osborn NK, 2006, CLIN GASTROENTEROL H, V4, P212, DOI 10.1016/j.cgh.2005.11.009; Oster B, 2011, INT J CANCER, V129, P2855, DOI 10.1002/ijc.25951; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Sadatomi D, 2013, INT J MOL SCI, V14, P4596, DOI 10.3390/ijms14034596; Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111; Selamat SA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021443; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SELLERS TA, 1992, CANCER RES, V52, pS2694; Tessema M, 2008, CANCER RES, V68, P1707, DOI 10.1158/0008-5472.CAN-07-6325; Thu KL, 2014, ONCOGENE, V33, P279, DOI 10.1038/onc.2012.595; Thu KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033003; Thu KL, 2011, J THORAC ONCOL, V6, P1521, DOI 10.1097/JTO.0b013e3182289479; Thusberg J, 2011, HUM MUTAT, V32, P358, DOI 10.1002/humu.21445; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; You M, 2009, CLIN CANCER RES, V15, P2666, DOI 10.1158/1078-0432.CCR-08-2335; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zou HZ, 2005, CANCER EPIDEM BIOMAR, V14, P830, DOI 10.1158/1055-9965.EPI-04-0506	53	29	30	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4464	4473		10.1038/onc.2013.396	http://dx.doi.org/10.1038/onc.2013.396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24096489	Green Accepted, Green Submitted			2022-12-17	WOS:000341158800002
J	Kumar, S; Pan, CC; Bloodworth, JC; Nixon, AB; Theuer, C; Hoyt, DG; Lee, NY				Kumar, S.; Pan, C. C.; Bloodworth, J. C.; Nixon, A. B.; Theuer, C.; Hoyt, D. G.; Lee, N. Y.			Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-beta signaling	ONCOGENE			English	Article						endoglin; soluble endoglin; TRC105; angiogenesis; TGF-beta	ENDOTHELIAL-CELL PROLIFERATION; TUMOR VASCULATURE; SOLUBLE ENDOGLIN; CORECEPTOR ENDOGLIN; RECEPTOR COMPLEXES; GROWTH; ANGIOGENESIS; CANCER; MICE; EXPRESSION	Endoglin is a transforming growth factor beta (TGF-beta) coreceptor that serves as a prognostic, diagnostic and therapeutic vascular target in human cancer. A number of endoglin ectodomain-targeting antibodies (Abs) can effectively suppress both normal and tumor-associated angiogenesis, but their molecular actions remain poorly characterized. Here we define a key mechanism for TRACON105 (TRC105), a humanized monoclonal Ab in clinical trials for treatment of advanced or metastatic tumors. TRC105, along with several other endoglin Abs tested, enhance endoglin shedding through direct coupling of endoglin and the membrane-type 1 matrix metalloproteinase (MMP)-14 at the cell surface to release the antiangiogenic factor, soluble endoglin (sEng). In addition to this coupling process, endoglin shedding is further amplified by increased MMP-14 expression that requires TRC105 concentration-dependent c-Jun N-terminal kinase (JNK) activation. There were also notable counterbalancing effects on canonical Smad signaling in which TRC105 abrogated both the steady-state and TGF-beta-induced Smad1/5/8 activation while augmenting Smad2/3 activation. Interestingly, TRC105-induced sEng and aberrant Smad signaling resulted in an excessive migratory response through enhanced stress fiber formation and disruption of endothelial cell-cell junctions. Collectively, our study defines endoglin shedding and deregulated TGF-beta signaling during migration as major mechanisms by which TRC105 inhibits angiogenesis.	[Kumar, S.; Pan, C. C.; Bloodworth, J. C.; Hoyt, D. G.; Lee, N. Y.] Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA; [Nixon, A. B.] Duke Canc Inst, Durham, NC USA; [Theuer, C.] TRACON Pharmaceut, San Diego, CA USA; [Lee, N. Y.] Davis Heart & Lung Res Inst, Columbus, OH USA	University System of Ohio; Ohio State University; Duke University; University System of Ohio; Ohio State University	Lee, NY (corresponding author), Ohio State Univ, Coll Pharm, Div Pharmacol, 500 West 12th Ave, Columbus, OH 43210 USA.	lee.5064@osu.edu	Nixon, Andrew/AAJ-4712-2020; Lee, Nam/H-3073-2016	Nixon, Andrew/0000-0003-3971-2964; 	National Institute of Health [R00 HL103791]; College of Pharmacy, Division of Pharmacology; Davis Heart and Lung Research Institute, at The Ohio State University; NATIONAL CANCER INSTITUTE [R01CA178443, P30CA014236] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL103791] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); College of Pharmacy, Division of Pharmacology; Davis Heart and Lung Research Institute, at The Ohio State University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the National Institute of Health (R00 HL103791 to NYL) and internal funds from the College of Pharmacy, Division of Pharmacology, and Davis Heart and Lung Research Institute, at The Ohio State University. We thank Dr Jian Cao for the MMP-14 construct (Stony Brook University) and Dr Charles Theuer for the TRC105 antibody (TRACON Pharmaceuticals).	Anderberg C, 2013, J EXP MED, V210, P563, DOI 10.1084/jem.20120662; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Blazquez-Medela AM, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-86; Castonguay R, 2011, J BIOL CHEM, V286, P30034, DOI 10.1074/jbc.M111.260133; Cherney RJ, 2006, BIOORG MED CHEM LETT, V16, P1028, DOI 10.1016/j.bmcl.2005.10.078; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Covington MD, 2006, AM J PHYSIOL-RENAL, V290, pF43, DOI 10.1152/ajprenal.00179.2005; Dallas NA, 2008, CLIN CANCER RES, V14, P1931, DOI 10.1158/1078-0432.CCR-07-4478; Daly AC, 2008, MOL CELL BIOL, V28, P6889, DOI 10.1128/MCB.01192-08; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Duwel A, 2007, TUMOR BIOL, V28, P1, DOI 10.1159/000097040; Ehrlich M, 2011, CELL SIGNAL, V23, P1424, DOI 10.1016/j.cellsig.2011.04.004; Fonsatti E, 2010, CARDIOVASC RES, V86, P12, DOI 10.1093/cvr/cvp332; Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466; Landt S, 2011, ANTICANCER RES, V31, P2651; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Lee BH, 2007, J BIOL CHEM, V282, P17985, DOI 10.1074/jbc.M702664200; Lee NY, 2008, J BIOL CHEM, V283, P32527, DOI 10.1074/jbc.M803059200; Lee NY, 2007, J BIOL CHEM, V282, P21507, DOI 10.1074/jbc.M700176200; Lee NY, 2012, MOL BIOL CELL, V23, P2412, DOI 10.1091/mbc.E11-12-0993; Lee NY, 2009, FASEB J, V23, P3712, DOI 10.1096/fj.09-131607; Levine RJ, 2006, NEW ENGL J MED, V355, P992, DOI 10.1056/NEJMoa055352; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Novoa JM, 2010, AM J PHYSIOL-HEART C, V299, pH959, DOI 10.1152/ajpheart.01251.2009; Lowrey GE, 2008, RESP MED, V102, P845, DOI 10.1016/j.rmed.2008.01.006; Marom B, 2011, J BIOL CHEM, V286, P19287, DOI 10.1074/jbc.M110.210377; Meng QJ, 2006, J BIOL CHEM, V281, P37069, DOI 10.1074/jbc.M608614200; Nasser MW, 2012, CANCER RES, V72, P604, DOI 10.1158/0008-5472.CAN-11-0669; Nolan-Stevaux O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050920; Pan CC, 2012, BIOCHEM BIOPH RES CO, V424, P620, DOI 10.1016/j.bbrc.2012.06.163; Park S, 2013, J CELL SCI, V126, P1392, DOI 10.1242/jcs.117275; Pece-Barbara N, 2005, J BIOL CHEM, V280, P27800, DOI 10.1074/jbc.M503471200; Perez-Gomez E, 2010, THESCIENTIFICWORLDJO, V10, P2367, DOI 10.1100/tsw.2010.230; Rosen LS, 2012, CLIN CANCER RES, V18, P4820, DOI 10.1158/1078-0432.CCR-12-0098; Santibanez JF, 2010, CARCINOGENESIS, V31, P2145, DOI 10.1093/carcin/bgq199; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Shields MA, 2011, J BIOL CHEM, V286, P10495, DOI 10.1074/jbc.M110.195628; Tsirakis G, 2012, EUR J INTERN MED, V23, P368, DOI 10.1016/j.ejim.2012.01.012; Tsujie M, 2008, INT J CANCER, V122, P2266, DOI 10.1002/ijc.23314; Tsujie M, 2006, INT J ONCOL, V29, P1087; Uneda S, 2009, INT J CANCER, V125, P1446, DOI 10.1002/ijc.24482; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007	45	29	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3970	3979		10.1038/onc.2013.386	http://dx.doi.org/10.1038/onc.2013.386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24077288	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000339394700009
J	Ren, G; Liu, Y; Zhao, X; Zhang, J; Zheng, B; Yuan, ZR; Zhang, L; Qu, X; Tischfield, JA; Shao, C; Shi, Y				Ren, G.; Liu, Y.; Zhao, X.; Zhang, J.; Zheng, B.; Yuan, Z-R; Zhang, L.; Qu, X.; Tischfield, J. A.; Shao, C.; Shi, Y.			Tumor resident mesenchymal stromal cells endow naive stromal cells with tumor-promoting properties	ONCOGENE			English	Article						mesenchymal stem/stromal cells; lymphoma; tumor promotion; tumor microenvironment; chemokines; macrophages	STEM-CELLS; RECRUITMENT; FIBROBLASTS; TRANSITION; NICHE	Bone marrow mesenchymal stem/stromal cells (BM-MSCs) can infiltrate into tumors and subsequently evolve into tumor resident MSCs in tumor microenvironment. In this study, using a mouse lymphoma model, we showed that the lymphoma resident MSCs (L-MSCs) are able to confer tumor-promoting property to the naive cocultured BM-MSCs. Examination of cytokines and chemokines showed that post exposure to L-MSCs, BM-MSCs acquired an expression profile that is similar to that in L-MSCs. In vivo, BM-MSCs educated by L-MSCs (BM-L-MSCs) possess a greatly enhanced ability in promoting lymphoma growth. Consistent with an elevated CCL-2 expression in BM-L-MSCs, the tumor-promoting effect of BM-L-MSCs largely depends on CCR2-mediated macrophage recruitment to tumor sites. We further showed that the transmission of tumor-promoting effect is partially mediated by soluble factors. Our findings thus revealed a novel reinforcing mechanism in the maintenance of tumor microenvironment.	[Ren, G.; Zhang, J.; Yuan, Z-R; Zhang, L.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Rutgers Biomed & Hlth Sci, Child Hlth Inst New Jersey, New Brunswick, NJ 08901 USA; [Ren, G.; Shi, Y.] Chinese Acad Sci, Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Biol Sci,Inst Hlth Sci, Shanghai, Peoples R China; [Liu, Y.; Qu, X.] Shandong Univ, Qilu Hosp, Inst Basic Med Sci, Dept Med Oncol, Jinan 250100, Shandong, Peoples R China; [Liu, Y.; Zhao, X.; Zheng, B.; Tischfield, J. A.; Shao, C.] Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; [Liu, Y.; Zhao, X.; Zheng, B.; Tischfield, J. A.; Shao, C.] Rutgers State Univ, Human Genet Inst New Jersey, Piscataway, NJ 08854 USA; [Shao, C.] Shandong Univ, Sch Med, Inst Mol Med & Genet, Minist Educ Key Lab Expt Teratol, Jinan 250100, Shandong, Peoples R China	Rutgers State University New Brunswick; Rutgers State University Medical Center; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shandong University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Shandong University	Shao, C (corresponding author), Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA.	shao@biology.rutgers.edu; shiyu@rwjms.rutgers.edu	Shao, Changshun/AAD-8977-2022; Shi, Yufang/AAE-4431-2020	Shao, Changshun/0000-0003-2618-9342; Shi, Yufang/0000-0001-8964-319X; Ren, Guangwen/0000-0003-2436-9593; Qu, Xun/0000-0002-2521-3761; Tischfield, Jay/0000-0003-3217-8287	National Institutes of Health of the United States of America [GM866889, DE014913, DE019932, ES005022]; Ministry of Science and Technology of China [2010CB945600, 2011DFA30630]; Human Genetics Institute of New Jersey; Robert Wood Johnson Foundation of the Child Health Institute of New Jersey [67038]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM866889] Funding Source: NIH RePORTER	National Institutes of Health of the United States of America(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Human Genetics Institute of New Jersey; Robert Wood Johnson Foundation of the Child Health Institute of New Jersey; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from National Institutes of Health of the United States of America (GM866889, DE014913, DE019932 and ES005022), Ministry of Science and Technology of China (2010CB945600 and 2011DFA30630) and a grant from the Human Genetics Institute of New Jersey. We would also like to thank the Robert Wood Johnson Foundation (Grant 67038) for their support of the Child Health Institute of New Jersey.	Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood-2003-04-1193; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Goldstein RH, 2010, CANCER RES, V70, P10044, DOI 10.1158/0008-5472.CAN-10-1254; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guilloton F, 2012, BLOOD, V119, P2556, DOI 10.1182/blood-2011-08-370908; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Kabashima-Niibe A, 2013, CANCER SCI, V104, P157, DOI 10.1111/cas.12059; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Li HJ, 2012, CANCER DISCOV, V2, P840, DOI 10.1158/2159-8290.CD-12-0101; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Studeny M, 2004, JNCI-J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299; Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008-5472.CAN-12-0122	18	29	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					4016	4020		10.1038/onc.2013.387	http://dx.doi.org/10.1038/onc.2013.387			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24077286				2022-12-17	WOS:000339394700013
J	Tsai, LH; Chen, PM; Cheng, YW; Chen, CY; Sheu, GT; Wu, TC; Lee, H				Tsai, L-H; Chen, P-M; Cheng, Y-W; Chen, C-Y; Sheu, G-T; Wu, T-C; Lee, H.			LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas	ONCOGENE			English	Article						LKB1; NKX2-1; p53; lung adenocarcinoma	GENE-EXPRESSION; CANCER; MUTATIONS; P53; TRANSCRIPTION; SUPPRESSOR; LKB1/STK11; GENOME	LKB1 loss is a frequent homozygous deletion and/or gene mutation found in lung adenocarcinomas. However, few cases of LKB1 loss by either deletion or mutation are seen in Asian patients. Our preliminary data showed that LKB1 loss was associated with p53 mutation in lung tumors from Taiwanese adenocarcinoma patients and p53 transcription is directly regulated by NKX2-1. Therefore, we hypothesized that LKB1 loss could occur due to aberration of p53 regulation mediated by NKX2-1. In the present study, 16 lung adenocarcinoma cell lines were investigated to determine if LKB1 transcription could be deregulated by NKX2-1-mediated p53 aberration. Mechanistic studies indicated that LKB1 was directly upregulated by p53 and that NKX2-1-mediated p53 expression may positively regulate LKB1 expression in p53 wild-type cells. However, in p53-mutated cells, LKB1 transcription was deregulated by NKX2-1 via suppression of SP1 binding onto the LKB1 promoter. Therefore, the action of the NKX2-1/p53 pathway on LKB1 loss differed in p53 wild-type versus p53-mutated cells. As expected, soft-agar growth and invasion capability was significantly reduced by ectopic expression of NKX2-1 in p53 wild-type cells, but it was markedly elevated by silencing NKX2-1 in p53-mutated cells. Similar reciprocal observations were also seen in lung tumors from lung adenocarcinoma patients with either wild-type or mutated p53 tumors. Cox regression analysis showed that patients with low-LKB1 tumors had poorer overall survival (OS) and relapse-free survival (RFS) when compared with patients with high-LKB1 tumors. In p53 wild-type patients, shorter OS and RFS periods were predicted for low-NKX2-1/low-LKB1 tumors than for high-NKX2-1/high-LKB1 tumors. In patients with p53-mutated tumors, poorer OS and RFS were predicted for high-NKX2-1/low-LKB1 tumors than for low-NKX2-1/high-LKB1 tumors. In summary, losses of LKB1 at the transcriptional level by altered activity of the NKX2-1/p53 pathway may promote tumor malignancy and poor patient outcome.	[Tsai, L-H; Chen, P-M; Lee, H.] Inst Med & Mol Toxicol, Taichung, Taiwan; [Tsai, L-H; Chen, P-M; Sheu, G-T; Lee, H.] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Cheng, Y-W; Lee, H.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Wu, T-C] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan	Chung Shan Medical University; Taipei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, 250 Wu Hsing St, Taipei 110, Taiwan.	hl@tmu.edu.tw	Sheu, Gwo-Tarng/H-8855-2019	Sheu, Gwo-Tarng/0000-0002-1299-3375	National Science Council of Taiwan, ROC [NSC99-2628-B-038-016-MY3, NSC1-100-2314-B-038-043-MY3]	National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by Grants from the National Science Council (NSC99-2628-B-038-016-MY3 and NSC1-100-2314-B-038-043-MY3) of Taiwan, ROC.	Au NHC, 2004, J PATHOL, V204, P101, DOI 10.1002/path.1612; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Charloux A, 1997, INT J EPIDEMIOL, V26, P14, DOI 10.1093/ije/26.1.14; Chen F, 2007, CANCER EPIDEM BIOMAR, V16, P2724, DOI 10.1158/1055-9965.EPI-07-0455; Chen JJW, 2001, CANCER RES, V61, P5223; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Fernandez P, 2004, ONCOGENE, V23, P5084, DOI 10.1038/sj.onc.1207665; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Gong FR, 2011, NUCLEIC ACIDS RES, V39, P4640, DOI 10.1093/nar/gkr023; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kim MJ, 2010, CANCER GENET CYTOGEN, V196, P204, DOI 10.1016/j.cancergencyto.2009.09.020; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Makowski L, 2008, BRIT J CANCER, V99, P683, DOI 10.1038/sj.bjc.6604515; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Onozato R, 2007, CANCER SCI, V98, P1747, DOI 10.1111/j.1349-7006.2007.00585.x; Saad RS, 2004, HUM PATHOL, V35, P3, DOI 10.1016/j.humpath.2003.08.011; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Scott KD, 2007, CANCER RES, V67, P5622, DOI 10.1158/0008-5472.CAN-07-0762; Shiraishi K, 2012, NAT GENET, V44, P900, DOI 10.1038/ng.2353; Steger DJ, 2008, MOL CELL BIOL, V28, P2825, DOI 10.1128/MCB.02076-07; Sun YH, 2010, J CLIN ONCOL, V28, P4616, DOI 10.1200/JCO.2010.29.6038; Sung WW, 2011, CLIN CANCER RES, V17, P5991, DOI 10.1158/1078-0432.CCR-11-0227; Takeda H, 2006, ONCOGENE, V25, P1816, DOI 10.1038/sj.onc.1209207; Tang XM, 2011, CLIN CANCER RES, V17, P2434, DOI 10.1158/1078-0432.CCR-10-1412; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Wei CJ, 2005, CANCER RES, V65, P11297, DOI 10.1158/0008-5472.CAN-05-0716; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu HH, 2010, ONCOGENE, V29, P4330, DOI 10.1038/onc.2010.178; Wu YH, 2010, CANCER RES, V70, P10422, DOI 10.1158/0008-5472.CAN-10-2615; Zeng PY, 2006, CANCER RES, V66, P10701, DOI 10.1158/0008-5472.CAN-06-0999	38	29	30	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3851	3860		10.1038/onc.2013.353	http://dx.doi.org/10.1038/onc.2013.353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995788				2022-12-17	WOS:000339394100011
J	Tsuchida, R; Osawa, T; Wang, F; Nishii, R; Das, B; Tsuchida, S; Muramatsu, M; Takahashi, T; Inoue, T; Wada, Y; Minami, T; Yuasa, Y; Shibuya, M				Tsuchida, R.; Osawa, T.; Wang, F.; Nishii, R.; Das, B.; Tsuchida, S.; Muramatsu, M.; Takahashi, T.; Inoue, T.; Wada, Y.; Minami, T.; Yuasa, Y.; Shibuya, M.			BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors	ONCOGENE			English	Article						Bone Morphogenetic Protein 4 (BMP4); Thrombospondin-1 (TSP1); angiogenesis; tumor microenvironment; tumor endothelial cells; vascular endothelial growth factor (VEGF)	BONE MORPHOGENETIC PROTEIN-4; SIDE-POPULATION FRACTION; EMBRYONIC STEM-CELLS; ENDOTHELIAL-CELLS; CANCER-CELLS; SIGNALING PATHWAY; DOWN-REGULATION; BMP4; APOPTOSIS; EXPRESSION	Bone morphogenetic protein 4 (BMP4) has potential as an anticancer agent. Recent studies have suggested that BMP4 inhibits the survival of cancer stem cells (CSCs) of neural and colon cancers. Here, we showed that BMP4 paracrinically inhibited tumor angiogenesis via the induction of Thrombospondin-1 (TSP1), and consequently suppressed tumor growth in vivo. Although HeLa (human cervical cancer), HCl-H460-LNM35 (highly metastatic human lung cancer) and B16 (murine melanoma) cells did not respond to the BMP4 treatment in vitro, the growth of xeno- and allografts of these cells was suppressed via reductions in tumor angiogenesis after intraperitoneal treatment with BMP4. When we assessed the mRNA expression of major angiogenesis-related factors in grafted tumors, we found that the expression of TSP1 was significantly upregulated by BMP4 administration. We then confirmed that BMP4 was less effective in suppressing the tumor growth of TSP1-knockdown cancer cells. Furthermore, we found that BMP4 reduced vascular endothelial growth factor (VEGF) expression in vivo in a TSP1-dependent manner, which indicates that BMP4 interfered with the stabilization of tumor angiogenesis. In conclusion, the BMP4/TSP1 loop paracrinically suppressed tumor angiogenesis in the tumor microenvironment, which subsequently reduced the growth of tumors. BMP4 may become an antitumor agent and open a new field of antiangiogenic therapy.	[Tsuchida, R.; Osawa, T.; Wang, F.; Nishii, R.; Tsuchida, S.; Muramatsu, M.; Yuasa, Y.; Shibuya, M.] Tokyo Med & Dent Univ, Dept Mol Oncol, Tokyo, Japan; [Tsuchida, R.; Nishii, R.] Tokyo Med & Dent Univ, Dept Pediat, Tokyo, Japan; [Osawa, T.; Inoue, T.; Wada, Y.; Minami, T.] Univ Tokyo, RCAST, Lab Syst Biol & Med, Tokyo, Japan; [Wang, F.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; [Das, B.] Stanford Univ, Sch Med, Dept Pathol & Med, Div Oncol, Stanford, CA 94305 USA; [Tsuchida, S.] Tokyo Univ Hosp, Dept Pediat, Tokyo 113, Japan; [Muramatsu, M.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; [Takahashi, T.] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi 4648601, Japan; [Shibuya, M.] Jobu Univ, Inst Physiol & Med, Takasaki, Gunma, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Tokyo; Memorial Sloan Kettering Cancer Center; Stanford University; University of Tokyo; Roswell Park Cancer Institute; Nagoya University	Tsuchida, R (corresponding author), Tokyo Med & Dent Univ, Dept Pediat, Bunkyo Ku, 1-5-45 Yushima, Tokyo, Japan.	rtsuped@tmd.ac.jp; shibuya@ims.u-tokyo.ac.jp	Takahashi, Takashi/I-7262-2014; Das, Bikul/ABF-9292-2020; Wang, Feng/Q-7386-2017; Nishii, Rina/AAC-4177-2022	Takahashi, Takashi/0000-0003-0615-7001; 	Japan Society for the Promotion of Science [22-400024]; Takeda Science Foundation; Ministry of Education, Culture, Sports, Science, and Technology of Japan [17014020];  [23701047];  [24116509]; Grants-in-Aid for Scientific Research [23701047, 24116509] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF)); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); ; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Takashi Koda and Ms Kiyomi Kaneki for assisting in analysis of microarray data, Mr Daichi Yamanaka for operating of FACS sorting and Ms Shigeko Shimizu for preparing of immunohistochemistry. RT is a Research Fellow of the Japan Society of the Promotion of Science. This work was supported by the Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists (22-400024), Grant-in-Aid for Young Scientist (23701047), Grant-in-Aid for Scientific Research on Innovative Areas (24116509), the Takeda Science Foundation and a Grant-in-Aid Special Project Research on Cancer-Bioscience (17014020) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Bakrania P, 2008, AM J HUM GENET, V82, P304, DOI 10.1016/j.ajhg.2007.09.023; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; Chiu CY, 2012, MOL CANCER RES, V10, P415, DOI 10.1158/1541-7786.MCR-11-0293; Das B, 2008, STEM CELLS, V26, P1818, DOI 10.1634/stemcells.2007-0724; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; Farnsworth RH, 2011, CANCER RES, V71, P6547, DOI 10.1158/0008-5472.CAN-11-0200; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Gee MFW, 2005, ONCOGENE, V24, P8025, DOI 10.1038/sj.onc.1208939; Giuriato S, 2006, P NATL ACAD SCI USA, V103, P16266, DOI 10.1073/pnas.0608017103; Guo NH, 1997, CANCER RES, V57, P1735; Guo W, 1999, CLIN ORTHOP RELAT R, P175; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Haubold M, 2010, INT J BIOL SCI, V6, P700; Hayashi S, 2008, AM J MED GENET A, V146A, P2905, DOI 10.1002/ajmg.a.32519; Heinke J, 2007, CARDIOVASC RES, V76, P390, DOI 10.1016/j.cardiores.2007.08.003; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kim IY, 2004, CANCER RES, V64, P7355, DOI 10.1158/0008-5472.CAN-04-0154; Kiyono M, 2006, ONCOGENE, V25, P7131, DOI 10.1038/sj.onc.1209700; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; Komuro A, 2009, JNCI-J NATL CANCER I, V101, P592, DOI 10.1093/jnci/djp058; Kozaki K, 2000, CANCER RES, V60, P2535; Li ZW, 2012, CELL STEM CELL, V10, P171, DOI 10.1016/j.stem.2011.12.016; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Moreno-Miralles I, 2011, ARTERIOSCL THROM VAS, V31, P2216, DOI 10.1161/ATVBAHA.111.230235; Muramatsu M, 2010, CANCER RES, V70, P8211, DOI 10.1158/0008-5472.CAN-10-0202; Nishanian TG, 2004, CANCER BIOL THER, V3, P667; Nor JE, 2000, J VASC RES, V37, P209, DOI 10.1159/000025733; Osawa T, 2011, P NATL ACAD SCI USA, V108, P20725, DOI 10.1073/pnas.1108462109; Osawa T, 2009, CANCER SCI, V100, P844, DOI 10.1111/j.1349-7006.2009.01105.x; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Sarnat HB, 2005, J CHILD NEUROL, V20, P637, DOI 10.1177/08830738050200080101; Shepherd TG, 2008, GENE, V414, P95, DOI 10.1016/j.gene.2008.02.015; Shibuya M, 2008, BMB REP, V41, P278, DOI 10.5483/BMBRep.2008.41.4.278; Su DM, 2009, J BIOL CHEM, V284, P12153, DOI 10.1074/jbc.M807930200; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Tsuchida R, 2008, ONCOGENE, V27, P3923, DOI 10.1038/onc.2008.38; Wang F, 2011, CANCER SCI, V102, P2007, DOI 10.1111/j.1349-7006.2011.02065.x; Wang F, 2011, J BIOL CHEM, V286, P9097, DOI 10.1074/jbc.M110.165605; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Yamauchi M, 2007, CANCER SCI, V98, P1491, DOI 10.1111/j.1349-7006.2007.00534.x; Zaslavsky A, 2010, MOL CANCER RES, V8, P1198, DOI 10.1158/1541-7786.MCR-10-0047; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408; Zhou ZM, 2011, CANCER BIOTHER RADIO, V26, P77, DOI 10.1089/cbr.2010.0857	50	29	31	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3803	3811		10.1038/onc.2013.358	http://dx.doi.org/10.1038/onc.2013.358			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	24013228	Bronze			2022-12-17	WOS:000339394100006
J	Maynard, MA; Ferretti, R; Hilgendorf, KI; Perret, C; Whyte, P; Lees, JA				Maynard, M. A.; Ferretti, R.; Hilgendorf, K. I.; Perret, C.; Whyte, P.; Lees, J. A.			Bmi1 is required for tumorigenesis in a mouse model of intestinal cancer	ONCOGENE			English	Article						Bmi1; Apc; colorectal cancer; intestine; apoptosis; Arf	STEM-CELLS; EXPRESSION; PROGRESSION; MICE	The epigenetic regulator BMI1 is upregulated progressively in a wide variety of human tumors including colorectal cancer. In this study, we assessed the requirement for Bmi1 in intestinal tumorigenesis using an autochthonous mouse model in which Apc was conditionally ablated in the intestinal epithelium. Germline mutation of Bmi1 significantly reduced both the number and size of small intestinal adenomas arising in this model, and it acted in a dose-dependent manner. Moreover, in contrast to wild-type controls, Bmi1(-/-) mice showed no increase in median tumor size, and a dramatic decrease in tumor number, between 3 and 4 months of age. Thus, Bmi1 is required for both progression and maintenance of small intestinal adenomas. Importantly, Bmi1 deficiency did not disrupt oncogenic events arising from Apc inactivation. Instead, the Arf tumor suppressor, a known target of Bmi1 epigenetic silencing, was upregulated in Bmi1 mutant tumors. This was accompanied by significant upregulation of p53, which was confirmed by sequencing to be wild-type, and also elevated apoptosis within the smallest Bmi1(-/-) adenomas. By crossing Arf into this cancer model, we showed that Arf is required for the induction of both p53 and apoptosis, and it is a key determinant of the ability of Bmi1 deficiency to suppress intestinal tumorigenesis. Finally, a conditional Bmi1 mutant strain was generated and used to determine the consequences of deleting Bmi1 specifically within the intestinal epithelium. Strikingly, intestinal-specific Bmi1 deletion suppressed small intestinal adenomas in a manner that was indistinguishable from germline Bmi1 deletion. Thus, we conclude that Bmi1 deficiency impairs the progression and maintenance of small intestinal tumors in a cell autonomous and highly Arf-dependent manner.	[Maynard, M. A.; Ferretti, R.; Hilgendorf, K. I.; Lees, J. A.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Hilgendorf, K. I.; Lees, J. A.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Perret, C.] Univ Paris 05, INSERM, Inst Cochin, Paris, France; [Whyte, P.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; McMaster University	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts ave, Cambridge, MA 02139 USA.	jalees@mit.edu	Perret-Mayeux, Christine/L-3297-2017	perret, christine/0000-0003-4710-7051	NCI/NIH grant; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NCI/NIH grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We dedicate this paper to the memory of Officer Sean Collier, for his caring service to the MIT community and for his sacrifice. This work was supported by an NCI/NIH grant to JAL who is a Ludwig Scholar at MIT, and fellowships to MAM (CIHR), RF (Ludwig) and KIH (NSF). We thank the Koch Institute Swanson Biotechnology Center for key technical support, particularly personnel in the ES Cell & Transgenic, Histology and Microscopy facilities. We also thank Sylvie Robine (Institut Curie) for the Vil-cre mouse and members of the Lees and Jacks labs for thoughtful comments.	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gibson SL, 2003, CANCER RES, V63, P742; Gieni RS, 2009, BIOCHEM CELL BIOL, V87, P711, DOI 10.1139/O09-057; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Grinstein E, 2007, CELL SIGNAL, V19, P2428, DOI 10.1016/j.cellsig.2007.06.021; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sherr CJ, 2005, COLD SH Q B, V70, P129, DOI 10.1101/sqb.2005.70.004; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Subkhankulova T, 2010, MOL CELL NEUROSCI, V45, P151, DOI 10.1016/j.mcn.2010.06.006; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2; Tateishi K, 2006, CLIN CANCER RES, V12, P6960, DOI 10.1158/1078-0432.CCR-06-0449; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Yu TX, 2012, J BIOL CHEM, V287, P3760, DOI 10.1074/jbc.M111.316349	25	29	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3742	3747		10.1038/onc.2013.333	http://dx.doi.org/10.1038/onc.2013.333			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23955081	Green Submitted, Green Accepted, Bronze			2022-12-17	WOS:000338942900013
J	Ray, KC; Moss, ME; Franklin, JL; Weaver, CJ; Higginbotham, J; Song, Y; Revetta, FL; Blaine, SA; Bridges, LR; Guess, KE; Coffey, RJ; Crawford, HC; Washington, MK; Means, AL				Ray, K. C.; Moss, M. E.; Franklin, J. L.; Weaver, C. J.; Higginbotham, J.; Song, Y.; Revetta, F. L.; Blaine, S. A.; Bridges, L. R.; Guess, K. E.; Coffey, R. J.; Crawford, H. C.; Washington, M. K.; Means, A. L.			Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia	ONCOGENE			English	Article						pancreatic ductal adenocarcinoma; inflammation; transdifferentiation; EGFR	DUCTAL ADENOCARCINOMA; FACTOR RECEPTOR; K-RAS; EPITHELIAL-CELLS; ACINAR-CELLS; EGF RECEPTOR; CANCER; MICE; EXPRESSION; CARCINOMA	Pancreatic cancer remains as one of the most deadly cancers with few treatment options at late stages and little information about how it develops through earlier stages. Activating mutation of the Kras gene has been implicated in, but is not sufficient for, tumorigenesis. In mouse models of pancreatic cancer, loss of tumor suppressor genes in conjunction with Kras mutation leads to gradual stochastic acquisition of neoplastic precursors and carcinomas, whereas many cells remain phenotypically unaltered in younger mice. Here, we demonstrate that two oncogenic events, mutation of Kras and production of the growth factor heparin-binding epidermal growth factor-like growth factor (HB-EGF), are sufficient for rapid and complete neoplastic transformation of the exocrine pancreas. We found that macrophages are the major source of HB-EGF production in pancreatic cancer tissue samples, and that macrophages are present in high density and in close association with human pancreatic cancer lesions. In a mouse model, high macrophage density was observed at the earliest stages of neoplastic transformation. The consequence of elevated HB-EGF signaling was investigated without the confounding effects of other macrophage-produced factors via transgenic overexpression of the active form of HB-EGF. In this model, HB-EGF was sufficient to promote Kras-initiated tumorigenesis, inducing rapid and complete neoplastic transformation of the entire exocrine pancreas shortly after birth. HB-EGF overexpression and Kras(G12D) together, but neither alone, increased proliferation with increased cyclinD1 and decreased Cdkn2a/2d (p16/p19(Ink4A/Arf)). These findings establish the importance of oncogenic synergy in cancer initiation and promotion, and establish a molecular link between inflammation and the earliest stages of tumor induction.	[Ray, K. C.; Moss, M. E.; Weaver, C. J.; Blaine, S. A.; Bridges, L. R.; Guess, K. E.; Means, A. L.] Vanderbilt Univ, Med Ctr, Div Surg Oncol, Nashville, TN 37232 USA; [Franklin, J. L.; Higginbotham, J.; Coffey, R. J.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Franklin, J. L.; Coffey, R. J.; Means, A. L.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; [Song, Y.; Crawford, H. C.] SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; [Revetta, F. L.; Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Crawford, H. C.] Vet Affairs Med Ctr, Dept Res, Northport, NY USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Means, AL (corresponding author), Vanderbilt Univ, Med Ctr, Div Surg Oncol, D2300 Med Ctr North,1161 21st Ave S, Nashville, TN 37232 USA.	anna.means@vanderbilt.edu		Moss, M Elizabeth/0000-0002-9761-7263	NIH [CA123061, P30DK058404, P50CA095103, CA136754]; VA Merit; Knapp Chair in Pancreatic Cancer Research; NATIONAL CANCER INSTITUTE [R01CA159222, R01CA136754, P50CA095103, R21CA123061, R01CA046413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit(US Department of Veterans Affairs); Knapp Chair in Pancreatic Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank R Daniel Beauchamp for support and helpful discussions, Steven D Leach, Barbara Fingleton and Harold L Moses for critically reading the manuscript, and Heidi Moreno and Christian Kis for technical assistance. This work was supported by NIH grants CA123061 (ALM), P30DK058404 and P50CA095103 (MKW), CA136754, VA Merit, and the Knapp Chair in Pancreatic Cancer Research (HCC).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Blaine SA, 2010, DEVELOPMENT, V137, P2289, DOI 10.1242/dev.048421; Blaine SA, 2009, AM J PHYSIOL-GASTR L, V297, pG434, DOI 10.1152/ajpgi.00152.2009; Brand RE, 2007, GUT, V56, P1460, DOI 10.1136/gut.2006.108456; Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; DOYLE CM, 1978, DEV BIOL, V65, P11, DOI 10.1016/0012-1606(78)90175-6; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008-5472.CAN-09-4645; Hansel DE, 2003, ANNU REV GENOM HUM G, V4, P237, DOI 10.1146/annurev.genom.4.070802.110341; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Ito Y, 2001, INT J PANCREATOL, V29, P47, DOI 10.1385/IJGC:29:1:47; Ji BA, 2009, GASTROENTEROLOGY, V137, P1072, DOI 10.1053/j.gastro.2009.05.052; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOBRIN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1705, DOI 10.1006/bbrc.1994.2131; Kojima K, 2007, CANCER RES, V67, P8121, DOI 10.1158/0008-5472.CAN-06-4167; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Luttges J, 1999, VIRCHOWS ARCH, V435, P461, DOI 10.1007/s004280050428; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Mohammed A, 2010, CANCER PREV RES, V3, P1417, DOI 10.1158/1940-6207.CAPR-10-0038; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Odegaard JI, 2011, ANNU REV PATHOL-MECH, V6, P275, DOI 10.1146/annurev-pathol-011110-130138; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Ray KC, 2009, GASTROENTEROLOGY, V137, P1785, DOI 10.1053/j.gastro.2009.07.067; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Siveke JT, 2007, CANCER CELL, V12, P266, DOI 10.1016/j.ccr.2007.08.002; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Wang XM, 2011, J MOL CELL BIOL, V3, P206, DOI 10.1093/jmcb/mjq038; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Zhu ZW, 2000, BIOCHEM BIOPH RES CO, V273, P1019, DOI 10.1006/bbrc.2000.3033	46	29	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					823	831		10.1038/onc.2013.3	http://dx.doi.org/10.1038/onc.2013.3			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23376846	Green Accepted			2022-12-17	WOS:000331626900003
J	Burkitt, MD; Williams, JM; Duckworth, CA; O'Hara, A; Hanedi, A; Varro, A; Caamano, JH; Pritchard, DM				Burkitt, M. D.; Williams, J. M.; Duckworth, C. A.; O'Hara, A.; Hanedi, A.; Varro, A.; Caamano, J. H.; Pritchard, D. M.			Signaling mediated by the NF-kappa B sub-units NF-kappa B1, NF-kappa B2 and c-Rel differentially regulate Helicobacter felis-induced gastric carcinogenesis in C57BL/6 mice	ONCOGENE			English	Article						Helicobacter felis infection; NF-kappa B; MALT lymphoma; gastric cancer	MOUSE MODEL; CELL PROLIFERATION; INFECTION; PYLORI; INFLAMMATION; LACKING; CANCER; APOPTOSIS; DEFECTS; FAMILY	The classical nuclear factor-kappaB (NF-kappa B) signaling pathway has been shown to be important in a number of models of inflammation-associated cancer. In a mouse model of Helicobacter-induced gastric cancer, impairment of classical NF-kappa B signaling in the gastric epithelium led to the development of increased preneoplastic pathology, however the role of specific NF-kappa B proteins in Helicobacter-associated gastric cancer development remains poorly understood. To investigate this C57BL/6, Nfkb1(-/-), Nfkb2(-/-) and c-Rel(-/-) mice were infected with Helicobacter felis for 6 weeks or 12 months. Bacterial colonization, gastric atrophy and preneoplastic changes were assessed histologically and cytokine expression was assessed by qPCR. Nfkb1(-/-) mice developed spontaneous gastric atrophy when maintained for 12 months in conventional animal house conditions. They also developed more pronounced gastric atrophy after short-term H. felis colonization with a similar extent of preneoplasia to wild-type (WT) mice after 12 months. c-Rel(-/-) mice developed a similar degree of gastric atrophy to WT mice; 3 of 6 of these animals also developed lymphoproliferative lesions after 12 months of infection. Nfkb2(-/-) mice developed minimal gastric epithelial pathology even 12 months after H. felis infection. These findings demonstrate that NF-kappa B1- and NF-kappa B2-mediated signaling pathways differentially regulate the epithelial consequences of H. felis infection in the stomach, while c-Rel-mediated signaling also appears to modulate the risk of lymphomagenesis in gastric mucosa-associated lymphoid tissue.	[Burkitt, M. D.; Williams, J. M.; Duckworth, C. A.; O'Hara, A.; Hanedi, A.; Pritchard, D. M.] Univ Liverpool, Dept Gastroenterol, Henry Wellcome Labs, Inst Translat Med, Liverpool L69 3GE, Merseyside, England; [Varro, A.] Univ Liverpool, Inst Translat Med, Dept Cellular & Mol Physiol, Liverpool L69 3GE, Merseyside, England; [Caamano, J. H.] Univ Birmingham, Coll Med & Dent Sci, IBR Sch Immun & Infect, Birmingham, W Midlands, England	University of Liverpool; University of Liverpool; University of Birmingham	Pritchard, DM (corresponding author), Univ Liverpool, Dept Gastroenterol, Henry Wellcome Labs, Inst Translat Med, 1st Floor,Nuffield Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	mark.pritchard@liverpool.ac.uk	Caamano, Jorge/I-6778-2012; Duckworth, Carrie A/K-7302-2014; Varro, Andras/M-2647-2016; Duckworth, Carrie/AAC-8361-2020; Caamano, Jorge/O-7530-2019; O'Hara, Adrian/ABE-7987-2020; Burkitt, Michael/AAU-9506-2021	Caamano, Jorge/0000-0003-3530-7056; Duckworth, Carrie A/0000-0001-9992-7540; Duckworth, Carrie/0000-0001-9992-7540; Caamano, Jorge/0000-0003-3530-7056; O'Hara, Adrian/0000-0003-1837-680X; Burkitt, Michael/0000-0002-5055-6408; Williams, Jonathan/0000-0002-6617-0323; Pritchard, David Mark/0000-0001-7971-3561	Wellcome Trust Research Training Fellowship; North West Cancer Research project grant; EU FP7 integrated project INFLACARE; College of Medical and Dental Sciences-University of Birmingham; BBSRC [BB/K009400/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/K009400/1] Funding Source: researchfish; National Institute for Health Research [CL-2011-07-501] Funding Source: researchfish; North West Cancer Research [CR930] Funding Source: researchfish	Wellcome Trust Research Training Fellowship(Wellcome Trust); North West Cancer Research project grant; EU FP7 integrated project INFLACARE; College of Medical and Dental Sciences-University of Birmingham; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); North West Cancer Research	This work was supported by a Wellcome Trust Research Training Fellowship awarded to MDB, and a North West Cancer Research project grant. JC was supported by the EU FP7 integrated project INFLACARE and the College of Medical and Dental Sciences-University of Birmingham.	Artis D, 2002, J IMMUNOL, V169, P4481, DOI 10.4049/jimmunol.169.8.4481; Burkitt MD, 2009, WORLD J GASTROENTERO, V15, P1, DOI 10.3748/wjg.15.1; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Court M, 2003, J PATHOL, V201, P303, DOI 10.1002/path.1422; Curry Choladda V, 2009, J Hematop, V2, P20, DOI 10.1007/s12308-009-0021-4; Duckworth CA, 2012, AM J PHYSIOL-GASTR L, V303, pG915, DOI 10.1152/ajpgi.00068.2012; ENNO A, 1995, AM J PATHOL, V147, P217; Erdman SE, 2001, J IMMUNOL, V166, P1443, DOI 10.4049/jimmunol.166.3.1443; Ferreira BI, 2008, HAEMATOLOGICA, V93, P670, DOI 10.3324/haematol.12221; Ferrero RL, 2000, J PATHOL, V191, P333; Fox JG, CANC RES, V62, P696; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Mantovani A, 2009, NATURE, V457, P36, DOI 10.1038/457036b; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Ohmae T, 2005, J IMMUNOL, V175, P7162, DOI 10.4049/jimmunol.175.11.7162; Persson C, 2011, AM J EPIDEMIOL, V173, P259, DOI 10.1093/aje/kwq370; Pritchard DM, 2004, ALIMENT PHARM THER, V19, P841, DOI 10.1111/j.1365-2036.2004.01911.x; Rogers AB, 2005, CANCER RES, V65, P10709, DOI 10.1158/0008-5472.CAN-05-1846; Rogers Arlin B, 2012, Methods Mol Biol, V921, P189; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shibata W, 2010, GASTROENTEROLOGY, V138, P1022, DOI 10.1053/j.gastro.2009.11.054; Smale ST, 2012, IMMUNOL REV, V246, P193, DOI 10.1111/j.1600-065X.2011.01091.x; Starczynowski DT, 2007, ONCOGENE, V26, P2685, DOI 10.1038/sj.onc.1210089; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Tu SP, 2011, CANCER RES, V71, P4247, DOI 10.1158/0008-5472.CAN-10-4009; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	34	29	30	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5563	5573		10.1038/onc.2013.334	http://dx.doi.org/10.1038/onc.2013.334			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23975431	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000328461400001
J	Dvorakova, M; Karafiat, V; Pajer, P; Kluzakova, E; Jarkovska, K; Pekova, S; Krutilkova, L; Dvorak, M				Dvorakova, M.; Karafiat, V.; Pajer, P.; Kluzakova, E.; Jarkovska, K.; Pekova, S.; Krutilkova, L.; Dvorak, M.			DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment	ONCOGENE			English	Article						acute leukemia; tumor microenvironment; extracellular nucleosomes; extracellular DNA; DNA damage response; cell death	LEUCINE-ZIPPER; MYB; ONCOGENE; DAMAGE; PHOSPHORYLATION; TRANSFORMATION; PROLIFERATION	Reciprocal interactions between a tumor and its microenvironment control expansion of tumor cells. Here we show a specific type of interaction in which blasts of experimental leukemia destroy the bone marrow ( BM) structures and kill stromal cells. The in vitro experiments showed that the cytotoxic agent released by leukemic cells is the fragmented DNA derived from their genome and occurring in nucleosome-like complexes. This DNA entered nuclei of BM or other cells and induced H2A.X phosphorylation at serine 139, similar to double-strand break-inducing agents. There was a correlation between large amounts of acquired DNA and death of recipient cells. Moreover, the DNA integrated into chromosomal DNA of recipient cells. Primary human acute myeloid leukemia cells also released fragmented DNA that penetrated the nuclei of other cells both in vitro and in vivo. We suggest that DNA fragments released from leukemic and also perhaps other types of tumor cells can activate DNA repair mechanisms or death in recipient cells of a tumor microenvironment, depending on the amount of the acquired DNA. This can impair DNA stability and viability of tumor stromal cells, undermine homeostatic capacity of tumor microenvironment and facilitate tumor progression.	[Dvorakova, M.; Karafiat, V.; Pajer, P.; Dvorak, M.] AS CR, Inst Mol Genet, Prague 14220, Czech Republic; [Kluzakova, E.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic; [Jarkovska, K.] AS CR, Inst Anim Physiol & Genet, Libechov, Czech Republic; [Pekova, S.; Krutilkova, L.] Chambon Lab Mol Diagnost, Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Charles University Prague; Czech Academy of Sciences; Institute of Animal Physiology & Genetics of the Czech Academy of Sciences	Dvorak, M (corresponding author), AS CR, Inst Mol Genet, Vvi, Videnska 1083, Prague 14220, Czech Republic.	mdvorak@img.cas.cz	Dvořák, Michal/I-9939-2014; Jarkovska, Karla/G-7137-2014; Pajer, Petr/G-5869-2014; Dvorak, Michal/G-5861-2014	Kluzakova, Eva/0000-0001-8714-2519	Academy of Sciences of the Czech Republic [AV0Z50520514, KAN200520801]; Ministry of Education, Youth and Sports [LC06061]; Grant Agency of the Czech Republic [204/06/1728, 301/09/1727]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NR 9651-4]	Academy of Sciences of the Czech Republic(Czech Academy of Sciences); Ministry of Education, Youth and Sports(Ministry of Education, Youth & Sports - Czech Republic); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Internal Grant Agency of the Ministry of Health of the Czech Republic	We thank Professor Milos Grim and Drs Vladimir Pecenka, Vladimir Cermak and Jan Kosla for critical comments on manuscript. We are indebted to Drs Petr Novak, Vladimir Havlicek and Petr Pompach for identification of proteins by mass spectrometry, to Drs A Ekefjard and D Enetoft from Ludesi for providing Viper software, and to Dr David W Hardekopf for his help in manuscript preparation. This work was supported by Grants AV0Z50520514 and KAN200520801 from the Academy of Sciences of the Czech Republic and LC06061 from the Ministry of Education, Youth and Sports and 204/06/1728 and 301/09/1727 from the Grant Agency of the Czech Republic to MD and from the Internal Grant Agency of the Ministry of Health of the Czech Republic, Grant no. NR 9651-4 to SP. We are also indebted to Tomas Hlavnicka, Roman Minarik, Miroslav Navratil, Leos Navratil, Vladimir Pecenka, Karel Rybacek, Miroslav Sobotka, Josef Soukal and Petr Streitberg for financial support.	Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8; Braakhuis BJM, 2003, CANCER RES, V63, P1727; Burger-Kentischer A, 2010, J IMMUNOL METHODS, V358, P93, DOI 10.1016/j.jim.2010.03.020; Cramer K, 2008, CANCER RES, V68, P6884, DOI 10.1158/0008-5472.CAN-08-1101; Dvorakova M, 2001, BLOOD CELL MOL DIS, V27, P437, DOI 10.1006/bcmd.2001.0402; ECKERT EA, 1951, J NATL CANCER I, V12, P447; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fleischhacker M, 2010, CANCER BIOMARK, V6, P211, DOI 10.3233/CBM-2009-0131; Gahan PB, 2010, CELL BIOCHEM FUNCT, V28, P529, DOI 10.1002/cbf.1690; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HLOZANEK I, 1968, Veterinarni Medicina (Prague), V13, P561; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; Jarkovska K, 2010, J PROTEOME RES, V9, P1289, DOI 10.1021/pr900802u; Jin CY, 2007, GENE DEV, V21, P1519, DOI 10.1101/gad.1547707; Karafiat V, 2005, CELL MOL LIFE SCI, V62, P2516, DOI 10.1007/s00018-005-5297-7; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; Labit H, 2008, BIOTECHNIQUES, V45, P649, DOI 10.2144/000113002; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; MacCallum DE, 1996, ONCOGENE, V13, P2575; Mani RS, 2010, NAT REV GENET, V11, P819, DOI 10.1038/nrg2883; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; Peters DL, 2011, CLIN CHIM ACTA, V412, P806, DOI 10.1016/j.cca.2011.01.026; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Sallmyr A, 2008, CANCER LETT, V270, P1, DOI 10.1016/j.canlet.2008.03.036; Savic V, 2009, CELL CYCLE, V8, P3285, DOI 10.4161/cc.8.20.9719; Shimura T, 2010, ONCOGENE, V29, P4826, DOI 10.1038/onc.2010.238; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vichalkovski A, 2010, ONCOGENE, V29, P3554, DOI 10.1038/onc.2010.115; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	37	29	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5201	5209		10.1038/onc.2012.553	http://dx.doi.org/10.1038/onc.2012.553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23222712				2022-12-17	WOS:000326497100003
J	Leisner, TM; Moran, C; Holly, SP; Parise, LV				Leisner, T. M.; Moran, C.; Holly, S. P.; Parise, L. V.			CIB1 prevents nuclear GAPDH accumulation and non-apoptotic tumor cell death via AKT and ERK signaling	ONCOGENE			English	Article						cell death; CIB1; GAPDH; AKT; ERK	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; BAD PHOSPHORYLATION; BINDING PROTEIN; DNA-REPAIR; PATHWAYS; TRANSLOCATION; ACTIVATION; IDENTIFICATION; TRANSFORMATION; LOCALIZATION	CIB1 is a 22-kDa regulatory protein previously implicated in cell survival and proliferation. However, the mechanism by which CIB1 regulates these processes is poorly defined. Here, we report that CIB1 depletion in SK-N-SH neuroblastoma and MDA-MB-468 breast cancer cells promotes non-apoptotic, caspase-independent cell death that is not initiated by increased outer mitochondrial membrane permeability or translocation of apoptosis-inducing factor to the nucleus. Instead, cell death requires nuclear GAPDH accumulation. Furthermore, CIB1 depletion disrupts two commonly dysregulated, oncogenic pathways-PI3K/AKT and Ras/MEK/ERK, resulting in a synergistic mechanism of cell death, which was mimicked by simultaneous pharmacological inhibition of both pathways, but not either pathway alone. In defining each pathway's contributions, we found that AKT inhibition alone maximally induced GAPDH nuclear accumulation, whereas MEK/ERK inhibition alone had no effect on GAPDH localization. Concurrent GAPDH nuclear accumulation and ERK inhibition were required, however, to induce a significant DNA damage response, which was critical to subsequent cell death. Collectively, our results indicate that CIB1 is uniquely positioned to regulate PI3K/AKT and MEK/ERK signaling and that simultaneous disruption of these pathways synergistically induces a nuclear GAPDH-dependent cell death. The mechanistic insights into cell death induced by CIB1 interference suggest novel molecular targets for cancer therapy.	[Leisner, T. M.; Moran, C.; Holly, S. P.; Parise, L. V.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Moran, C.] PRA Int, Raleigh, NC USA; [Parise, L. V.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Leisner, TM (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 120 Mason Farm Rd Suite 3010, Chapel Hill, NC 27599 USA.	tml13@med.unc.edu			NIH [HL07149T32, 5R01HL092544]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092544, T32HL007149] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank members of the Parise, Cook and A Sancar laboratories, Drs Yue Xiong, Matthew Torres, and Howard Fried for critical review and suggestions. We also thank Dr Akira Sawa for generously providing GAPDH plasmids. Special thanks to Dr H Fried and Andrew McFadden for lentiviral plasmid construction. This work was funded by the postdoctoral fellowship grant HL07149T32 (CM) and 5R01HL092544 (LVP) from the NIH.	Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Azam S, 2008, J BIOL CHEM, V283, P30632, DOI 10.1074/jbc.M801401200; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Broniowska KA, 2010, AM J PHYSIOL-HEART C, V299, pH1212, DOI 10.1152/ajpheart.00472.2010; Carujo S, 2006, ONCOGENE, V25, P4033, DOI 10.1038/sj.onc.1209433; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Colell A, 2009, CELL DEATH DIFFER, V16, P1573, DOI 10.1038/cdd.2009.137; Dai Y, 2008, BLOOD, V112, P2439, DOI 10.1182/blood-2008-05-159392; Dastoor Z, 2001, J CELL SCI, V114, P1643; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dent P, 2009, DRUG RESIST UPDATE, V12, P65, DOI 10.1016/j.drup.2009.03.001; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gentry HR, 2005, J BIOL CHEM, V280, P8407, DOI 10.1074/jbc.M411515200; Golding SE, 2007, CANCER RES, V67, P1046, DOI 10.1158/0008-5472.CAN-06-2371; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Hara MR, 2006, CELL MOL NEUROBIOL, V26, P527, DOI 10.1007/s10571-006-9011-6; Hara MR, 2006, P NATL ACAD SCI USA, V103, P3887, DOI 10.1073/pnas.0511321103; Huynh N, 2010, BBA-MOL CELL RES, V1803, P1106, DOI 10.1016/j.bbamcr.2010.05.007; Kodama R, 2005, GENES CELLS, V10, P1211, DOI 10.1111/j.1365-2443.2005.00911.x; Kornberg MD, 2010, NAT CELL BIOL, V12, P1094, DOI 10.1038/ncb2114; Kragten E, 1998, J BIOL CHEM, V273, P5821, DOI 10.1074/jbc.273.10.5821; Kwon HJ, 2010, EXP MOL MED, V42, P254, DOI 10.3858/emm.2010.42.4.025; Lartigue L, 2009, MOL BIOL CELL, V20, P4871, DOI 10.1091/mbc.E09-07-0649; Leisner TM, 2005, J CELL BIOL, V170, P465, DOI 10.1083/jcb.200502090; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Mikami I, 2010, ONCOL REP, V24, P1677, DOI 10.3892/or_00001033; Mills JR, 2012, CELL CYCLE, V11, P88, DOI 10.4161/cc.11.1.18408; Milosevic J, 2009, PROTEOMICS, V9, P1230, DOI 10.1002/pmic.200700604; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nakajima H, 2009, J BIOL CHEM, V284, P34331, DOI 10.1074/jbc.M109.027698; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Phadke MS, 2009, J PHARMACOL EXP THER, V331, P77, DOI 10.1124/jpet.109.155671; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sastry KSR, 2006, J BIOL CHEM, V281, P27367, DOI 10.1074/jbc.M511485200; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Schmitz HD, 2001, EUR J CELL BIOL, V80, P419, DOI 10.1078/0171-9335-00174; Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Tristan C, 2011, CELL SIGNAL, V23, P317, DOI 10.1016/j.cellsig.2010.08.003; Xing CG, 2004, P NATL ACAD SCI USA, V101, P5862, DOI 10.1073/pnas.0307476101; Xu Y, 2008, ONCOGENE, V27, P3501, DOI 10.1038/sj.onc.1211023; Yoon KB, 2009, TOP CATAL, V52, P1, DOI 10.1007/s11244-008-9132-x; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan W, 2006, MOL CELL BIOL, V26, P8507, DOI 10.1128/MCB.01488-06; Zayed MA, 2007, CIRC RES, V101, P1185, DOI 10.1161/CIRCRESAHA.107.157586; Zayed MA, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-17	53	29	33	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4017	4027		10.1038/onc.2012.408	http://dx.doi.org/10.1038/onc.2012.408			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22964641	Green Accepted			2022-12-17	WOS:000323748100010
J	Scherf, DB; Sarkisyan, N; Jacobsson, H; Claus, R; Bermejo, JL; Peil, B; Gu, L; Muley, T; Meister, M; Dienemann, H; Plass, C; Risch, A				Scherf, D. B.; Sarkisyan, N.; Jacobsson, H.; Claus, R.; Bermejo, J. L.; Peil, B.; Gu, L.; Muley, T.; Meister, M.; Dienemann, H.; Plass, C.; Risch, A.			Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4	ONCOGENE			English	Article						DNA methylation; risk factors; non-small cell lung cancer (NSCLC); CHRNB4; TERT	CANCER SUSCEPTIBILITY LOCUS; LUNG-CANCER; MASS-SPECTROMETRY; NICOTINE; GENES; SEQUENCE; BINDING; RISK; POLYMORPHISMS; TRANSCRIPTION	Genome-wide association studies have highlighted three major lung cancer susceptibility regions at 15q25.1, 5p15.33 and 6p21.33. To gain insight into the possible mechanistic relevance of the genes in these regions, we investigated the regulation of candidate susceptibility gene expression by epigenetic alterations in healthy and lung tumor tissues. For genes up or downregulated in lung tumors, the influence of genetic variants on DNA methylation was investigated and in vitro studies were performed. We analyzed 394 CpG units within 19 CpG islands in the susceptibility regions in a screening set of 34 patients. Significant findings were validated in an independent patient set (n = 50) with available DNA and RNA. The most consistent overall DNA methylation difference between tumor and adjacent normal tissue on 15q25 was tumor hypomethylation in the promoter region of CHRNB4 with a median difference of 8% (P<0.001), which resulted in overexpression of the transcript in tumors (P<0.001). Confirming previous studies, we also found hypermethylation in CHRNA3 and telomerase reverse transcriptase (TERT) with significant expression changes. Decitabine treatment of H1299 cells resulted in reduced methylation levels in gene promoters, elevated transcript levels of CHRNB4 and CHRNA3, and a slight downregulation of TERT demonstrating epigenetic regulation of lung cancer cells. Single-nucleotide polymorphisms rs421629 on 5p15.33 and rs1948, rs660652, rs8040868 and rs2036527 on 15q25.1, previously identified as lung cancer risk or nicotine-addiction modifiers, were associated with tumor DNA methylation levels in the promoters of TERT and CHRNB4 (P < 0.001), respectively, in two independent sample sets (n = 82; n = 150). In addition, CHRNB4 knockdown in two different cell lines (A549 and H1299) resulted in reduced proliferation (P-A549 < 0.05; P-H1299 < 0.001) and propensity to form colonies in H1299 cells. These results suggest epigenetic deregulation of nicotinic acetylcholine receptor subunit (nAChR) genes which in the case of CHRNB4 is strongly associated with genetic lung cancer susceptibility variants and a functional impact on tumorigenic potential.	[Scherf, D. B.; Sarkisyan, N.; Jacobsson, H.; Claus, R.; Gu, L.; Plass, C.; Risch, A.] German Canc Res Ctr, Div Epigen & Canc Risk Factors C010, D-69120 Heidelberg, Germany; [Bermejo, J. L.; Peil, B.] Univ Heidelberg Hosp, German Canc Res Ctr, Div Mol Genet Epidemiol, Inst Med Biometry & Informat, Heidelberg, Germany; [Muley, T.; Meister, M.] Heidelberg Univ, Thoraxklin Heidelberg gGmbH, Translat Res Unit, D-69115 Heidelberg, Germany; [Dienemann, H.] Heidelberg Univ, Thoraxklin Heidelberg gGmbH, Dept Thorac Surg, D-69115 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Risch, A (corresponding author), German Canc Res Ctr, Div Epigen & Canc Risk Factors C010, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	a.risch@dkfz.de	Plass, Christoph/H-7192-2014; Claus, Rainer/AAZ-5606-2020; Risch, Angela/H-2669-2013	Claus, Rainer/0000-0003-2617-8766; Risch, Angela/0000-0002-8026-5505	Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative; National Institute of Health (USA) [CA148127]; Deutsche Krebshilfe [70-2387]; Deutsche Forschungsgemeinschaft (DFG) [SFB/TRR77]; NATIONAL CANCER INSTITUTE [U19CA148127] Funding Source: NIH RePORTER	Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative; National Institute of Health (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Frau Heinzmann-Groth, Birgit Jager and all other members of the clinical and laboratory teams for help with sample and/or data collection and archiving for the Heidelberg lung study. We are grateful to all patients at the Thoraxklinik Heidelberg, who participated in the study. We thank Ruprecht Kuner for the cell lines, Oliver Mucke for competent technical assistance, Chris Amos for helpful comments on the manuscript and the members of the Plass Laboratory for thoughtful discussions. The scientific development and funding of this project were in part supported by the Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative. This work was in part supported by the National Institute of Health (USA; grant number CA148127) and earlier sample collection by the Deutsche Krebshilfe (grant number 70-2387). JLB was in part supported by a grant of the Deutsche Forschungsgemeinschaft (DFG, SFB/TRR77, project Z2).	Allemand E, 2008, CURR OPIN GENET DEV, V18, P145, DOI 10.1016/j.gde.2008.01.006; Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109; Amos CI, 2010, J NATL CANCER I, V102, P1199, DOI 10.1093/jnci/djq232; Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Brena RM, 2007, PLOS MED, V4, P572, DOI 10.1371/journal.pmed.0040108; Brena RM, 2007, HUM MOL GENET, V16, pR96, DOI 10.1093/hmg/ddm073; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Erlich PM, 2010, HUM GENET, V128, P491, DOI 10.1007/s00439-010-0876-6; Esteller M, 1997, CARCINOGENESIS, V18, P2307, DOI 10.1093/carcin/18.12.2307; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Gebhard C, 2010, CANCER RES, V70, P1398, DOI 10.1158/0008-5472.CAN-09-3406; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Herceg Zdenko, 2009, Eur J Cancer, V45 Suppl 1, P442, DOI 10.1016/S0959-8049(09)70082-6; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hitchins MP, 2011, CANCER CELL, V20, P200, DOI 10.1016/j.ccr.2011.07.003; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Improgo MR, MOL CANC RES, V8, P194; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Joseph J, 2002, CANCER RES, V62, P6467; Kawai H, 2001, J NEUROCHEM, V78, P1367, DOI 10.1046/j.1471-4159.2001.00526.x; Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Liu Y, 2009, CANCER RES, V69, P7844, DOI 10.1158/0008-5472.CAN-09-1833; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; McCabe MT, 2009, CANCER RES, V69, P282, DOI 10.1158/0008-5472.CAN-08-3274; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Oeth P, 2009, METHODS MOL BIOL, V578, P307, DOI 10.1007/978-1-60327-411-1_20; Paliwal A, 2010, CANCER RES, V70, P2779, DOI 10.1158/0008-5472.CAN-09-4550; Park JC, 2008, BIOCHEM BIOPH RES CO, V365, P221, DOI 10.1016/j.bbrc.2007.10.144; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125; Schalkwyk LC, 2010, AM J HUM GENET, V86, P196, DOI 10.1016/j.ajhg.2010.01.014; Schlaelpfer IR, 2008, BIOL PSYCHIAT, V63, P1039, DOI 10.1016/j.biopsych.2007.10.024; Schuller HM, 2009, NAT REV CANCER, V9, P195, DOI 10.1038/nrc2590; Schuller HM, 1999, CANCER RES, V59, P4510; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shiraishi K, 2009, CARCINOGENESIS, V30, P65, DOI 10.1093/carcin/bgn257; Shivapurkar N, 2008, CANCER EPIDEM BIOMAR, V17, P995, DOI 10.1158/1055-9965.EPI-07-2808; Stephens SH, 2012, BEHAV GENET, V42, P402, DOI 10.1007/s10519-011-9514-x; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Van den Berg RM, 2010, INT J ONCOL, V37, P455, DOI 10.3892/ijo_00000694; Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273; Zhang YY, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-12-r138	49	29	31	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2013	32	28					3329	3338		10.1038/onc.2012.344	http://dx.doi.org/10.1038/onc.2012.344			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22945651	Green Accepted			2022-12-17	WOS:000321620200003
J	Das, CM; Taylor, P; Gireud, M; Singh, A; Lee, D; Fuller, G; Ji, L; Fangusaro, J; Rajaram, V; Goldman, S; Eberhart, C; Gopalakrishnan, V				Das, C. M.; Taylor, P.; Gireud, M.; Singh, A.; Lee, D.; Fuller, G.; Ji, L.; Fangusaro, J.; Rajaram, V.; Goldman, S.; Eberhart, C.; Gopalakrishnan, V.			The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation	ONCOGENE			English	Article						REST; proliferation; p27; USP37; deubiquitylase	CDK INHIBITOR P27; RESTRICTIVE SILENCER FACTOR; SCF-BETA-TRCP; NEURONAL DIFFERENTIATION; N-MYC; ONCOGENIC TRANSFORMATION; REGULATES PROTEOLYSIS; SUBTYPE SPECIFICATION; NEURAL DEVELOPMENT; TUMOR SUPPRESSORS	The RE1 silencing transcription factor (REST) is a repressor of neuronal differentiation and its elevated expression in neural cells blocks neuronal differentiation. In this study, we demonstrate a role for REST in the control of proliferation of medulloblastoma cells. REST expression decreased the levels of cyclin-dependent kinase (CDK)NIB/p27, a CDK inhibitor and a brake of cell proliferation in these cells. The reciprocal relationship between REST and p27 was validated in human tumor samples. REST knockdown in medulloblastoma cells derepessed a novel REST target gene encoding the deubiquitylase ubiquitin (Ub)-specific peptidase 37 (USP37). Ectopically expressed wild-type USP37 formed a complex with p27, promoted its deubiquitination and stabilization and blocked cell proliferation. Knockdown of REST and USP37 prevented p27 stabilization and blocked the diminution in proliferative potential that normally accompanied REST loss. Unexpectedly, wild-type USP37 expression also induced the expression of REST-target neuronal differentiation genes even though REST levels were unaffected. In contrast, a mutant of USP37 carrying a site-directed change in a conserved cysteine failed to rescue REST-mediated p27 destabilization, maintenance of cell proliferation and blockade to neuronal differentiation. Consistent with these findings, a significant correlation between USP37 and p27 was observed in patient tumors. Collectively, these findings provide a novel connection between REST and the proteasomal machinery in the control of p27 and cell proliferation in medulloblastoma cells. Oncogene (2013) 32, 1691-1701; doi:10.1038/onc.2012.182; published online 4 June 2012	[Das, C. M.; Taylor, P.; Gireud, M.; Singh, A.; Lee, D.; Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Dept Pediat & Mol & Cellular Oncol, Houston, TX 77030 USA; [Fuller, G.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Ji, L.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Fangusaro, J.; Goldman, S.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Rajaram, V.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Eberhart, C.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; [Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Houston, TX 77030 USA; [Gopalakrishnan, V.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Gopalakrishnan, V.] Univ Texas Houston, Grad Sch Biomed Sci, Program Neurosci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Gopalakrishnan, V (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pediat & Mol & Cellular Oncol, Unit 853, 1515 Holcombe Blvd, Houston, TX 77030 USA.	vgopalak@mdanderson.org	Lee, Dean Anthony/AAK-8443-2021	Lee, Dean Anthony/0000-0001-6693-5392; Gireud-Goss, Monica/0000-0001-5172-2351; Fuller, Gregory/0000-0001-9447-2647	American Cancer Center [RSG-09-273-01-DDC]; National Institutes of Neurological Disorders and Stroke [1R03NS077021]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS079715, R03NS077021] Funding Source: NIH RePORTER	American Cancer Center; National Institutes of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the American Cancer Center (RSG-09-273-01-DDC) and the National Institutes of Neurological Disorders and Stroke (1R03NS077021) to VG.	Abrajano JJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007936; Abrajano JJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007665; Aguilera DG, 2009, J NEURO-ONCOL, V93, P303, DOI 10.1007/s11060-008-9788-x; Ayrault O, 2009, MOL CANCER RES, V7, P33, DOI 10.1158/1541-7786.MCR-08-0369; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Ballas N, 2005, CURR OPIN NEUROBIOL, V15, P500, DOI 10.1016/j.conb.2005.08.015; Bhatia B, 2010, CELL CYCLE, V9, P4307, DOI 10.4161/cc.9.21.13441; Bhatia B, 2010, CELL CYCLE, V9, P456, DOI 10.4161/cc.9.3.10532; Bhatia B, 2009, CANCER RES, V69, P7224, DOI 10.1158/0008-5472.CAN-09-1299; Blain SW, 2008, CELL CYCLE, V7, P892, DOI 10.4161/cc.7.7.5637; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chang L, 2011, MOL CANC RES; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coulson JM, 2005, CURR BIOL, V15, pR665, DOI 10.1016/j.cub.2005.08.032; Das CM, 2010, EUR J CANCER, V46, P2771, DOI 10.1016/j.ejca.2010.05.010; Eletr ZM, 2011, CELL BIOCHEM BIOPHYS, V60, P3, DOI 10.1007/s12013-011-9184-6; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fuller GN, 2005, MOL CANCER THER, V4, P343; Gao ZL, 2011, J NEUROSCI, V31, P9772, DOI 10.1523/JNEUROSCI.1604-11.2011; Gopalakrishnan V, 2009, FUTUR NEUROL, V4, P317, DOI 10.2217/FNL.09.1; Goto T, 2004, DEV NEUROSCI-BASEL, V26, P208, DOI 10.1159/000082138; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Hara T, 2005, MOL CELL BIOL, V25, P9292, DOI 10.1128/MCB.25.21.9292-9303.2005; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; Hayes SD, 2010, NAT CELL BIOL, V12, P311, DOI 10.1038/ncb2043; Hsieh J, 2005, CURR OPIN CELL BIOL, V17, P664, DOI 10.1016/j.ceb.2005.09.002; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Juliandi B, 2010, CURR OPIN NEUROBIOL, V20, P408, DOI 10.1016/j.conb.2010.04.001; Kagalwala MN, 2008, COLD SH Q B, V73, P227, DOI 10.1101/sqb.2008.73.042; Kaldis P, 2007, CELL, V128, P241, DOI 10.1016/j.cell.2007.01.006; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Keller UB, 2007, EMBO J, V26, P2562, DOI 10.1038/sj.emboj.7601691; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koff A, 2006, CANCER CELL, V9, P75, DOI 10.1016/j.ccr.2006.01.020; Kohyama J, 2010, J CELL BIOL, V189, P159, DOI 10.1083/jcb.200908048; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kotoshiba S, 2005, J BIOL CHEM, V280, P17694, DOI 10.1074/jbc.M500866200; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; Lu Z, 2010, CELL CYCLE, V9, P2400; Malumbres M, 2009, NAT CELL BIOL, V11, P1275, DOI 10.1038/ncb1109-1275; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Masuda K, 2010, ONCOGENE, V29, P1798, DOI 10.1038/onc.2009.469; McFarlane C, 2010, CANCER RES, V70, P3329, DOI 10.1158/0008-5472.CAN-09-4152; Miyazawa K, 2000, J NEUROSCI, V20, P5756, DOI 10.1523/JNEUROSCI.20-15-05756.2000; Ooi L, 2007, NAT REV GENET, V8, P544, DOI 10.1038/nrg2100; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; Peschiaroli A, 2010, ONCOGENE, V29, P1384, DOI 10.1038/onc.2009.430; Ravanpay AC, 2010, MOL CELL NEUROSCI, V44, P178, DOI 10.1016/j.mcn.2010.03.006; Reed SI, 2002, CELL CYCLE, V1, P389, DOI 10.4161/cc.1.6.261; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Singh A, 2011, CANCER-AM CANCER SOC, V117, P5189, DOI 10.1002/cncr.26145; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Spencer EM, 2006, NEUROBIOL DIS, V24, P41, DOI 10.1016/j.nbd.2006.04.020; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; Sun YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003656; Todi S.V., 2011, TRENDS NEUROSCI; Tomasoni R, 2011, J CELL SCI, V124, P3174, DOI 10.1242/jcs.087551; Ungermannova D, 2005, J BIOL CHEM, V280, P30301, DOI 10.1074/jbc.M411103200; van Leuken RJ, 2008, CELL CYCLE, V7, P2710, DOI 10.4161/cc.7.17.6553; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Westbrook TF, 2008, NATURE, V452, P370, DOI 10.1038/nature06780; Wilkinson KD, 2009, J CELL SCI, V122, P2325, DOI 10.1242/jcs.041046; Zindy F, 2006, P NATL ACAD SCI USA, V103, P11579, DOI 10.1073/pnas.0604727103	72	29	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 28	2013	32	13					1691	1701		10.1038/onc.2012.182	http://dx.doi.org/10.1038/onc.2012.182			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22665064	Green Accepted			2022-12-17	WOS:000316855800009
J	Li, Z; Zhang, Y; Kim, WJ; Daaka, Y				Li, Z.; Zhang, Y.; Kim, W. J.; Daaka, Y.			PGE2 promotes renal carcinoma cell invasion through activated RalA	ONCOGENE			English	Article						renal cell carcinoma; cell invasion; inflammation; PGE2; Ral	PROTEIN-COUPLED RECEPTORS; PROSTAGLANDIN-E-RECEPTORS; CANCER; GROWTH; E-2; PATHWAY; GTPASE; PHARMACOLOGY; INFLAMMATION; PROGRESSION	Incidence of kidney cancer is on the rise, and a better understanding of molecular mechanisms involved in the cancer invasion and metastasis is required for the development of curative therapeutics. In this study, we report that the proinflammatory cytokine prostaglandin E2 (PGE2) induces the malignant SN12C, but not benign HK2 kidney cell invasion. The PGE2 increases SN12C cell invasion through a signal pathway that encompasses EP2 and EP4, Akt, small GTPase RalA and Ral . GTP inactivator RGC2. The results support the idea that targeted interference of EP2/EP4 signal to RalA . GTP may provide benefit to patients diagnosed with advanced kidney cancer. Oncogene (2013) 32, 1408-1415; doi:10.1038/onc.2012.161; published online 14 May 2012	[Li, Z.; Zhang, Y.; Kim, W. J.; Daaka, Y.] Univ Florida, Coll Med, Dept Urol, Gainesville, FL 32610 USA; [Li, Z.; Zhang, Y.; Kim, W. J.; Daaka, Y.] Univ Florida, Coll Med, Prostate Dis Ctr, Gainesville, FL 32610 USA; [Daaka, Y.] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Daaka, Y (corresponding author), Univ Florida, Coll Med, Dept Urol, CGRC Rm 462,2033 Mowry Rd, Gainesville, FL 32610 USA.	ydaaka@ufl.edu			US National Institutes of Health [R01 CA129155]; NATIONAL CANCER INSTITUTE [R01CA129155] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr A Saltiel for providing anti-RGC2 and anti-phospho-RGC2 antibodies and the NCI for providing the SN12C cancer cells. We also thank Ms E Grigson and Ms K Durst for editorial assistance, and Dr Z Nie for reading and commenting on the manuscript. This work was supported, in part, by US National Institutes of Health grant R01 CA129155 (to YD).	Asano T, 2002, CLIN CANCER RES, V8, P1157; Balkwill F, 2010, CLIN PHARMACOL THER, V87, P401, DOI 10.1038/clpt.2009.312; Biswas S, 2009, NAT REV CLIN ONCOL, V6, P478, DOI 10.1038/nrclinonc.2009.91; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Bukowski RM, 2009, CANCER-AM CANCER SOC, V115, P2273, DOI 10.1002/cncr.24226; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen XW, 2011, MOL BIOL CELL, V22, P141, DOI 10.1091/mbc.E10-08-0665; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DeWire SM, 2011, CIRC RES, V109, P205, DOI 10.1161/CIRCRESAHA.110.231308; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Eruslanov E, 2011, INT IMMUNOPHARMACOL, V11, P848, DOI 10.1016/j.intimp.2011.01.033; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; HALBRUGGE M, 1990, J CHROMATOGR, V521, P335, DOI 10.1016/0021-9673(90)85057-3; Hao CM, 2008, ANNU REV PHYSIOL, V70, P357, DOI 10.1146/annurev.physiol.70.113006.100614; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Kim WJ, 2012, CANC LETT, V1820, P743; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Murai M, 2004, CURR OPIN UROL, V14, P229, DOI 10.1097/01.mou.0000135078.04721.f5; PUGH S, 1994, GUT, V35, P675, DOI 10.1136/gut.35.5.675; Salcedo R, 2003, BLOOD, V102, P1966, DOI 10.1182/blood-2002-11-3400; Schlesinger-Raab A, 2008, EUR J CANCER, V44, P2485, DOI 10.1016/j.ejca.2008.07.039; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Smith SC, 2009, UROL ONCOL-SEMIN ORI, V27, P42, DOI 10.1016/j.urolonc.2008.04.012; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Sun M, 2010, NAT REV UROL, V7, P327, DOI 10.1038/nrurol.2010.57; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wu JJ, 2011, J BIOL CHEM, V286, P33954, DOI 10.1074/jbc.M110.187344; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Young AN, 2006, UROLOGY, V67, P873, DOI 10.1016/j.urology.2005.11.042	36	29	32	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1408	1415		10.1038/onc.2012.161	http://dx.doi.org/10.1038/onc.2012.161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22580611	Green Accepted			2022-12-17	WOS:000316455600007
J	Bompard, G; Rabeharivelo, G; Cau, J; Abrieu, A; Delsert, C; Morin, N				Bompard, G.; Rabeharivelo, G.; Cau, J.; Abrieu, A.; Delsert, C.; Morin, N.			P21-activated kinase 4 (PAK4) is required for metaphase spindle positioning and anchoring	ONCOGENE			English	Article						p21-activated kinase 4; metaphase; spindle orientation; spindle assembly checkpoint	REGULATORY LIGHT-CHAIN; IMPORTIN-BETA; CYTOPLASMIC DYNEIN; CELL-MIGRATION; INDEPENDENT GROWTH; MAMMALIAN-CELLS; MITOTIC SPINDLE; ADHERENT CELLS; MITOSIS; PHOSPHORYLATION	The oncogenic kinase PAK4 was recently found to be involved in the regulation of the G1 phase and the G2/M transition of the cell cycle. We have also identified that PAK4 regulates Ran GTPase activity during mitosis. Here, we show that after entering mitosis, PAK4-depleted cells maintain a prolonged metaphase-like state. In these cells, chromosome congression to the metaphase plate occurs with normal kinetics but is followed by an extended period during which membrane blebbing and spindle rotation are observed. These bipolar PAK4-depleted metaphase-like spindles have a defective astral microtubule MT network and are not centered in the cell but are in close contact with the cell cortex. As the metaphase-like state persists, centrosome fragmentation occurs, chromosomes scatter from the metaphase plate and move toward the spindle poles with an active spindle assembly checkpoint, a phenotype that is reminiscent of cohesion fatigue. PAK4 also regulates the acto-myosin cytoskeleton and we report that PAK4 depletion results in the induction of cortical membrane blebbing during prometaphase arrest. However, we show that membrane blebs, which are strongly enriched in phospho-cofilin, are not responsible for the poor anchoring of the spindle. As PAK4 depletion interferes with the localization of components of the dynein/dynactin complexes at the kinetochores and on the astral MTs, we propose that loss of PAK4 could induce a change in the activities of motor proteins., Oncogene (2013) 32, 910-919; doi:10.1038/onc.2012.98; published online 26 March 2012	[Bompard, G.; Rabeharivelo, G.; Cau, J.; Abrieu, A.; Delsert, C.; Morin, N.] Univ Montpellier 2, Montpellier, France; [Bompard, G.; Rabeharivelo, G.; Cau, J.; Abrieu, A.; Delsert, C.; Morin, N.] Univ Montpellier I, Montpellier, France; [Bompard, G.; Rabeharivelo, G.; Abrieu, A.; Delsert, C.; Morin, N.] CNRS, CRBM, UMR 5237, F-34293 Montpellier, Herault, France; [Cau, J.] CNRS UPR1142, IGH, MRI, Montpellier, France; [Delsert, C.] IFREMER, LGP, La Tremblade, France	Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Ifremer	Morin, N (corresponding author), CNRS, CRBM, UMR 5237, 1919 Route Mende, F-34293 Montpellier, Herault, France.	nathalie.morin@crbm.cnrs.fr	Abrieu, Ariane/G-6336-2013; Abrieu, Ariane/P-3307-2019	Abrieu, Ariane/0000-0002-0942-8877; Morin, Nathalie/0000-0001-8677-1401; cau, Julien/0000-0001-6045-6737; Bompard, Guillaume/0000-0001-6729-4507	Fondation de la Recherche Medicale; MEGAPAK from the ANR (Agence Nationale pour la Recherche) GENOPAT	Fondation de la Recherche Medicale(Fondation pour la Recherche Medicale); MEGAPAK from the ANR (Agence Nationale pour la Recherche) GENOPAT(French National Research Agency (ANR))	We thank Drs Lorca, Castro, Merdes for the gift of reagents. We are indebted to Dr A Desai, Dr K Vaughan and Dr A Musacchio for the kind gifts of reagents. We want to especially thank Dr Dan Fisher (IGMM, UMR5535 CNRS, Montpellier, France) for critical reading and editing of the manuscript, We thank the Montpellier RIO imaging facility. GB is supported by a grant from 'Fondation de la Recherche Medicale'. This work was supported by a grant MEGAPAK to NM from the ANR (Agence Nationale pour la Recherche) GENOPAT.	Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; Bompard G, 2010, J CELL BIOL, V190, P807, DOI 10.1083/jcb.200912056; Bright MD, 2011, INT J BIOCHEM CELL B, V43, P1776, DOI 10.1016/j.biocel.2011.08.015; Brzeska H, 2004, CELL MOTIL CYTOSKEL, V58, P186, DOI 10.1002/cm.20009; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Cau J, 2001, J CELL BIOL, V155, P1029, DOI 10.1083/jcb.200104123; Charras G, 2008, NAT REV MOL CELL BIO, V9, P730, DOI 10.1038/nrm2453; Charras GT, 2006, J CELL BIOL, V175, P477, DOI 10.1083/jcb.200602085; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Ciciarello M, 2004, J CELL SCI, V117, P6511, DOI 10.1242/jcs.01569; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Dasso M, 2006, BIOCHEM SOC T, V34, P711, DOI 10.1042/BST0340711; Daum JR, 2011, CURR BIOL, V21, P1018, DOI 10.1016/j.cub.2011.05.032; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Famulski JK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016494; Fan SL, 2007, J CELL BIOL, V178, P387, DOI 10.1083/jcb.200609096; Gassmann R, 2010, GENE DEV, V24, P957, DOI 10.1101/gad.1886810; Gehmlich K, 2004, EMBO REP, V5, P97, DOI 10.1038/sj.embor.7400046; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; Goshima G, 2005, J CELL BIOL, V171, P229, DOI 10.1083/jcb.200505107; Gundersen GG, 2004, CURR OPIN CELL BIOL, V16, P106, DOI 10.1016/j.ceb.2003.11.010; Kaji N, 2008, J BIOL CHEM, V283, P4983, DOI 10.1074/jbc.M708644200; Kalab P, 2006, NATURE, V440, P697, DOI 10.1038/nature04589; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kobayashi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007827; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li ZL, 2010, MOL BIOL CELL, V21, P3317, DOI 10.1091/mbc.E10-03-0245; Li ZL, 2010, J BIOL CHEM, V285, P23699, DOI 10.1074/jbc.M110.123497; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Mannherz HG, 2005, EUR J CELL BIOL, V84, P503, DOI 10.1016/j.ejcb.2004.11.008; Maroto B, 2008, ONCOGENE, V27, P4900, DOI 10.1038/onc.2008.131; Menzel N, 2007, MECH DEVELOP, V124, P78, DOI 10.1016/j.mod.2006.09.007; Mitsushima M, 2009, MOL CELL BIOL, V29, P2816, DOI 10.1128/MCB.01713-08; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Nekrasova T, 2011, J CELL BIOCHEM, V112, P1795, DOI 10.1002/jcb.23092; Norman L, 2011, EUR J CELL BIOL, V90, P37, DOI 10.1016/j.ejcb.2010.09.013; O'Connell CB, 2000, MOL BIOL CELL, V11, P1765, DOI 10.1091/mbc.11.5.1765; Ozaki Y, 2011, J BIOL CHEM, V286, P5589, DOI 10.1074/jbc.M110.167742; Pearson CG, 2004, NAT REV MOL CELL BIO, V5, P481, DOI 10.1038/nrm1402; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Stevens D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022969; Toyoshima F, 2007, DEV CELL, V13, P796, DOI 10.1016/j.devcel.2007.10.014; Vigneron S, 2009, EMBO J, V28, P2786, DOI 10.1038/emboj.2009.228; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Whale A, 2011, FRONT BIOSCI-LANDMRK, V16, P849, DOI 10.2741/3724; Whyte J, 2008, J CELL BIOL, V183, P819, DOI 10.1083/jcb.200804114; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Wong LE, 2010, J CELL BIOCHEM, V110, P1244, DOI 10.1002/jcb.22639; Yanase Y, 2010, BIOCHEM J, V425, P179, DOI 10.1042/BJ20091122; Yang ZY, 2007, CURR BIOL, V17, P973, DOI 10.1016/j.cub.2007.04.056; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhou TH, 2006, P NATL ACAD SCI USA, V103, P9039, DOI 10.1073/pnas.0602916103; Zimmerman W, 2000, TRAFFIC, V1, P927, DOI 10.1034/j.1600-0854.2000.011202.x	62	29	29	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					910	919		10.1038/onc.2012.98	http://dx.doi.org/10.1038/onc.2012.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22450748	Green Published			2022-12-17	WOS:000316581100011
J	Cavallari, C; Fonsato, V; Herrera, MB; Bruno, S; Tetta, C; Camussi, G				Cavallari, C.; Fonsato, V.; Herrera, M. B.; Bruno, S.; Tetta, C.; Camussi, G.			Role of Lefty in the anti tumor activity of human adult liver stem cells	ONCOGENE			English	Article						lefty; tumor growth; adult stem cells; liver; hepatoma	MELANOMA-CELLS; PHENOTYPE; PATHWAYS; ABSENCE	Recent studies demonstrated that factors derived from embryonic stem cells inhibit the tumorigenicity of a variety of cancer cell lines. Embryonic stem cell-secreted Lefty, an inhibitor of Nodal-signalling pathway, was implicated in reprogramming cancer cells. Whether adult stem cells exhibited similar properties has not been explored. The aim of the present study was to investigate whether the conditioned medium (CM) derived from adult stem cells influence in vitro and in vivo tumor growth by a Nodal-dependent pathway. In particular we compared the anti-tumor effect of CM from human liver stem cells (HLSC) with that of bone marrow-derived mesenchymal stem cells (MSC). We found that HLSC-CM inhibited the in vitro growth and promoted apoptosis in HepG2 cells that expressed a deregulated Nodal pathway. The effect of HLSC-CM was related to the presence of Lefty A in the CM of HLSC. Silencing Lefty A in HLSC or Lefty A blockade with a blocking peptide abrogated the anti-proliferative and pro-apoptotic effect of HLSC-CM. Moreover, the administration of human recombinant Lefty A protein mimicked the effect of HLSC-CM indicating that Nodal pathway is critical for the growth of HepG2. At variance of HLSC, bone marrow-derived MSC did not express and release Lefty A and the MSC-CM did not exhibited an anti-tumor activity in vitro, but rather stimulated proliferation of HepG2. In addition, the intra-tumor administration of HLSC-CM was able to inhibit the in vivo growth of HepG2 hepatoma cells implanted subcutaneously in SCID mice. At variance, HLSC-CM derived from Lefty A silenced HLSC was unable to inhibit tumor growth. In conclusion, the results of present study suggest that Lefty A may account for the tumor suppressive activity of HLSC as a result of an inhibition of the Nodal-signalling pathway by a mechanism similar to that described for embryonic stem cells. Oncogene (2013) 32, 819-826; doi:10.1038/onc.2012.114; published online 2 April 2012	[Cavallari, C.; Fonsato, V.; Herrera, M. B.; Camussi, G.] Univ Turin, Dept Internal Med, Res Ctr Expt Med CeRMS, Turin, Italy; [Cavallari, C.; Fonsato, V.; Herrera, M. B.; Camussi, G.] Univ Turin, Ctr Mol Biotechnol, Turin, Italy; [Bruno, S.; Tetta, C.] SisTER, Palazzo Pignano, Italy; [Bruno, S.; Tetta, C.] Fresenius Med Care, Bad Homburg, Germany	University of Turin; University of Turin	Camussi, G (corresponding author), Osped Maggiore S Giovanni Battista Molinette, Cattedra Nefrol, Dipartimento Med Interna, Corso Dogliotti 14, I-10126 Turin, Italy.	giovanni.camussi@unito.it	Camussi, Giovanni/J-7624-2016	Camussi, Giovanni/0000-0003-2795-232X; BRUNO, Stefania/0000-0002-8879-9536	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG8912]; Fresenius Medical Care; Italian Ministry of University and Research (MIUR); Regione Piemonte, Project Oncoprot and Piattaforme Biotecnologiche, Pi-Stem project	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fresenius Medical Care; Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); Regione Piemonte, Project Oncoprot and Piattaforme Biotecnologiche, Pi-Stem project	We thank Federica Antico for technical help. This study was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), project IG8912, by Fresenius Medical Care, by Italian Ministry of University and Research (MIUR) Prin08 and by Regione Piemonte, Project Oncoprot and Piattaforme Biotecnologiche, Pi-Stem project.	Abbott DE, 2008, CANCER MICROENVIRON, V1, P13, DOI 10.1007/s12307-008-0004-5; Barroso-delJesus A, 2011, FASEB J, V25, P1497, DOI 10.1096/fj.10-172221; Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798; Costa FF, 2009, EPIGENOMICS-UK, V1, P387, DOI 10.2217/EPI.09.25; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Diez-Torre A, 2009, INT J DEV BIOL, V53, P1563, DOI 10.1387/ijdb.093021ad; Dvash T, 2007, STEM CELLS, V25, P465, DOI 10.1634/stemcells.2006-0179; Giuffrida D, 2009, CELL PROLIFERAT, V42, P788, DOI 10.1111/j.1365-2184.2009.00640.x; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Herrera MB, 2010, J CELL MOL MED, V14, P1605, DOI 10.1111/j.1582-4934.2009.00860.x; Herrera MB, 2006, STEM CELLS, V24, P2840, DOI 10.1634/stemcells.2006-0114; Kulesa PM, 2006, P NATL ACAD SCI USA, V103, P3752, DOI 10.1073/pnas.0506977103; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Meno C, 2001, DEV CELL, V1, P127, DOI 10.1016/S1534-5807(01)00006-5; PIERCE GB, 1982, CANCER RES, V42, P1082; PODESTA AH, 1984, P NATL ACAD SCI-BIOL, V81, P7608, DOI 10.1073/pnas.81.23.7608; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Postovit LM, 2006, STEM CELLS, V24, P501, DOI 10.1634/stemcells.2005-0459; Sakuma R, 2002, GENES CELLS, V7, P401, DOI 10.1046/j.1365-2443.2002.00528.x; Tabibzadeh S, 2006, STEM CELLS, V24, P1998, DOI 10.1634/stemcells.2006-0075; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448	23	29	30	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					819	826		10.1038/onc.2012.114	http://dx.doi.org/10.1038/onc.2012.114			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22469982	Green Published, hybrid			2022-12-17	WOS:000316581100002
J	Chaudhry, SI; Hooper, S; Nye, E; Williamson, P; Harrington, K; Sahai, E				Chaudhry, S. I.; Hooper, S.; Nye, E.; Williamson, P.; Harrington, K.; Sahai, E.			Autocrine IL-1 beta-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine INF alpha, signalling to carcinoma-associated fibroblasts	ONCOGENE			English	Article						Traf6; Interleukin-1; TNR alpha; invasion; carcinoma-associated fibroblast	NECROSIS-FACTOR-ALPHA; KAPPA-B; CYTOSKELETAL CHANGES; ACTIN CYTOSKELETON; CANCER CELLS; TNF-ALPHA; TGF-BETA; ACTIVATION; TRAF6; TUMORS	The invasion of squamous cell carcinoma (SCC) is a significant cause of morbidity and mortality. Here, we identify an E3 ligase, Traf6 and a de-ubiquitinating enzyme, Cezanne/ZA20D1, as important regulators of this process in organotypic models. Traf6 can promote the formation of Cdc42-dependent F-actin microspikes. Furthermore, Traf6 has a key role in autocrine interleukin-1 beta signalling in SCC cells, which in turn is required to drive the expression of tumour necrosis factor alpha (TNF alpha). TNF alpha acts in a paracrine manner to increase the invasion-promoting potential of carcinoma-associated fibroblasts (CAFs). Exogenous TNF alpha signalling can restore invasion in cells depleted of Traf6. In conclusion, Traf6 has two important roles in SCC invasion: it promotes cell intrinsic Cdc42-dependent regulation of the actin cytoskeleton and enables production of the paracrine signal, TNF alpha, that enhances the activity of CAFs. Oncogene (2013) 32, 747-758; doi:10.1038/onc.2012.91; published online 26 March 2012	[Chaudhry, S. I.; Hooper, S.; Sahai, E.] Canc Res UK London Res Inst, Tumour Cell Biol Lab, London WC2A 3LY, England; [Chaudhry, S. I.] UCL Eastman Dent Inst, London, England; [Chaudhry, S. I.] UCLHT Eastman Dent Hosp, London, England; [Nye, E.] Canc Res UK London Res Inst, Expt Histopathol Lab, London WC2A 3LY, England; [Williamson, P.] St George Hosp, Thomas Tatum Head & Neck Unit, London, England; [Harrington, K.] Inst Canc Res, London SW3 6JB, England	Cancer Research UK; University of London; University College London; University of London; University College London; Cancer Research UK; St Georges University London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Sahai, E (corresponding author), Canc Res UK London Res Inst, Tumour Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	erik.sahai@cancer.org.uk		Harrington, Kevin/0000-0002-6014-348X; Sahai, Erik/0000-0002-3932-5086	Cancer Research UK; Cancer Research UK [15154] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank the Cancer Research UK for funding. We thank St George's Thomas Tatum Head and the Neck Unit staff involved in tissue collection, Martin Gore for providing reagents, and lab members for their advice and discussions.	Ahn KS, 2007, CURR MOL MED, V7, P619, DOI 10.2174/156652407782564363; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bremm A, 2010, NAT STRUCT MOL BIOL, V17, P939, DOI 10.1038/nsmb.1873; Castillo-Lluva S, 2010, NAT CELL BIOL, V12, P1078, DOI 10.1038/ncb2112; Chen YZ, 2009, MOL CELL, V35, P841, DOI 10.1016/j.molcel.2009.09.004; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Elmets CA, 2010, JNCI-J NATL CANCER I, V102, P1835, DOI 10.1093/jnci/djq442; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264-6021:3570617; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gil Z, 2009, ISR MED ASSOC J, V11, P296; GRONOWICZ G, 1992, J PERIODONTAL RES, V27, P562, DOI 10.1111/j.1600-0765.1992.tb01737.x; Hanna AN, 2001, MOL BIOL CELL, V12, P3618, DOI 10.1091/mbc.12.11.3618; Heyninck K, 1999, FEBS LETT, V442, P147, DOI 10.1016/S0014-5793(98)01645-7; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; HOOPER S, BR J CANC, V102, P392; Jeong JG, 2004, BIOCHEM BIOPH RES CO, V324, P3, DOI 10.1016/j.bbrc.2004.09.011; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Krelin Y, 2007, CANCER RES, V67, P1062, DOI 10.1158/0008-5472.CAN-06-2956; Kurihara Y, 2009, CLIN EXP METASTAS, V26, P425, DOI 10.1007/s10585-009-9241-3; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pritchard S, 2006, ARTHRITIS RHEUM-US, V54, P2164, DOI 10.1002/art.21941; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Rosenblum H, 2011, AUTOIMMUN REV, V10, P563, DOI 10.1016/j.autrev.2011.04.010; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; Scott KA, 2003, MOL CANCER THER, V2, P445; Shah JP, 2009, ORAL ONCOL, V45, P394, DOI 10.1016/j.oraloncology.2008.05.017; Smith PC, 2009, J PERIODONTAL RES, V44, P73, DOI 10.1111/j.1600-0765.2007.01081.x; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Tse WKF, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-637; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang KZQ, 2006, J CELL SCI, V119, P1579, DOI 10.1242/jcs.02889; Windheim M, 2008, MOL CELL BIOL, V28, P1783, DOI 10.1128/MCB.02380-06; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yao M, 2007, ORAL ONCOL, V43, P213, DOI 10.1016/j.oraloncology.2006.04.013; Yin Q, 2009, NAT STRUCT MOL BIOL, V16, P658, DOI 10.1038/nsmb.1605	44	29	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					747	758		10.1038/onc.2012.91	http://dx.doi.org/10.1038/onc.2012.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22450746	Green Accepted			2022-12-17	WOS:000315746700008
J	Neeb, A; Wallbaum, S; Novac, N; Dukovic-Schulze, S; Scholl, I; Schreiber, C; Schlag, P; Moll, J; Stein, U; Sleeman, JP				Neeb, A.; Wallbaum, S.; Novac, N.; Dukovic-Schulze, S.; Scholl, I.; Schreiber, C.; Schlag, P.; Moll, J.; Stein, U.; Sleeman, J. P.			The immediate early gene Ier2 promotes tumor cell motility and metastasis, and predicts poor survival of colorectal cancer patients	ONCOGENE			English	Article						Ier2; Pip92; ETR101; metastasis; motility; invasion	SIGNALING PATHWAYS; T-LYMPHOCYTE; PC12 CELLS; EXPRESSION; GROWTH; PIP92; PROTEIN; IDENTIFICATION; TRANSCRIPTION; DIFFERENTIATION	Here, we report unbiased screens for genes expressed in metastatic tumor cells that are associated with cell motility. These screens identified Ier2, an immediate early gene of unknown function, as potentially having a role in tumor cell motility and metastasis. Knockdown of Ier2 in 3T3 fibroblasts inhibited their motility upon relief of contact inhibition in monolayer wounding assays. Furthermore, ectopic Ier2 expression promoted the motility and invasiveness of poorly metastatic 1AS pancreatic tumor cells in vitro. Relief of contact inhibition was associated with translocation of the Ier2 protein from the cytoplasm to the nucleus in both 3T3 fibroblasts and 1AS tumor cells. Importantly, ectopic Ier2 expression in 1AS cells stimulated metastasis formation when cells were implanted into experimental animals. Furthermore, we found elevated Ier2 expression in a wide variety of human tumor types. This correlated with poor metastasis-free and overall survival in patients with colorectal adenocarcinomas. Together, these data reveal Ier2 as a new player in the regulation of tumor progression and metastasis, and suggest that Ier2 may be useful prognostically and therapeutically in the management of cancer. Oncogene (2012) 31, 3796-3806; doi: 10.1038/onc.2011.535; published online 28 November 2011	[Sleeman, J. P.] Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, D-68167 Mannheim, Germany; [Neeb, A.; Wallbaum, S.; Novac, N.; Dukovic-Schulze, S.; Scholl, I.; Schreiber, C.; Moll, J.; Sleeman, J. P.] Karlsruhe Inst Technol, Inst Genet & Toxikol, Karlsruhe, Germany; [Schlag, P.] Charite Comprehens Canc Ctr, Berlin, Germany; [Stein, U.] Charite, Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr, D-13353 Berlin, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sleeman, JP (corresponding author), Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, TRIDOMUS Gebaude Haus C,Ludolf Krehl Str 13-17, D-68167 Mannheim, Germany.	sleeman@medma.uni-heidelberg.de	Dukowic-Schulze, Stefanie/AAC-8685-2019; Sleeman, Jonathan P/H-2515-2013	Dukowic-Schulze, Stefanie/0000-0003-2675-1075; Sleeman, Jonathan P/0000-0003-1718-7687; Neeb, Antje/0000-0002-6516-2938; Stein, Ulrike/0000-0001-7006-282X	BMBF NGFN2 CancerNet Programme; European Union [LSHC-CT-2004-503224, HEALTH-F2-2008-201662]	BMBF NGFN2 CancerNet Programme(Federal Ministry of Education & Research (BMBF)); European Union(European Commission)	We are very grateful to Norma Howells, Selma Huber and Manuela Sauer for their assistance with the animal experiments, to Anja Steffen for expert technical support and to Wilko Thiele for critical reading of this manuscript. The contribution of Franziska Arlt and Markus Niederstrasser is also gratefully acknowledged. This work was supported by grants to JPS and US from the BMBF NGFN2 CancerNet Programme and to JPS from the European Union (FP6 STREP project BRECOSM, contract no. LSHC-CT-2004-503224 and FP7 Collaborative Project TuMIC, contract no. HEALTH-F2-2008-201662).	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Bradley LM, 2003, CURR OPIN IMMUNOL, V15, P343, DOI 10.1016/S0952-7915(03)00043-8; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; Chen L, 2003, J GEN VIROL, V84, P3203, DOI 10.1099/vir.0.19283-0; Chiou CC, 2001, GUT, V48, P598, DOI 10.1136/gut.48.5.598; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Chung KC, 2000, J NEUROCHEM, V75, P9, DOI 10.1046/j.1471-4159.2000.0750009.x; COLECLOUGH C, 1990, P NATL ACAD SCI USA, V87, P1753, DOI 10.1073/pnas.87.5.1753; Eschelbach A, 1998, ANN NY ACAD SCI, V865, P181, DOI 10.1111/j.1749-6632.1998.tb11177.x; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; French PJ, 2005, CANCER RES, V65, P11335, DOI 10.1158/0008-5472.CAN-05-1886; Gutmann DH, 2002, CANCER RES, V62, P2085; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; Hippo Y, 2002, CANCER RES, V62, P233; Hofmann M, 1998, J CELL SCI, V111, P1673; Hong SK, 2009, P NATL ACAD SCI USA, V106, P2230, DOI 10.1073/pnas.0812880106; Keeton AB, 2002, J BIOL CHEM, V277, P48565, DOI 10.1074/jbc.M207837200; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Li W, 2004, MOL BIOL CELL, V15, P294, DOI 10.1091/mbc.e03-05-0352; Mengwasser J, 2004, ONCOGENE, V23, P7430, DOI 10.1038/sj.onc.1207987; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Nestl A, 2001, CANCER RES, V61, P1569; Niebuhr K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P398; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Schneider A, 2004, J CEREBR BLOOD F MET, V24, P224, DOI 10.1097/01.WCB.0000104960.26014.7A; SCOTT JL, 1994, J CELL BIOCHEM, V54, P135, DOI 10.1002/jcb.240540202; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; Skotheim RI, 2005, CANCER RES, V65, P5588, DOI 10.1158/0008-5472.CAN-05-0153; Sleeman JP, 2011, INT J CANCER, V128, P2511, DOI 10.1002/ijc.26027; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stein U, 2002, J CLIN ONCOL, V20, P3282, DOI 10.1200/JCO.2002.01.003; Takaya T, 2009, BIOSCI BIOTECH BIOCH, V73, P1653, DOI 10.1271/bbb.90162; Wallbaum S, 2009, BIOTECHNIQUES, V46, P433, DOI 10.2144/000113121; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	37	29	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3796	3806		10.1038/onc.2011.535	http://dx.doi.org/10.1038/onc.2011.535			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120713				2022-12-17	WOS:000307924900006
J	Gillibert-Duplantier, J; Duthey, B; Sisirak, V; Salaun, D; Gargi, T; Tredan, O; Finetti, P; Bertucci, F; Birnbaum, D; Bendriss-Vermare, N; Badache, A				Gillibert-Duplantier, J.; Duthey, B.; Sisirak, V.; Salaun, D.; Gargi, T.; Tredan, O.; Finetti, P.; Bertucci, F.; Birnbaum, D.; Bendriss-Vermare, N.; Badache, A.			Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis	ONCOGENE			English	Article						ErbB2/Her2; cell migration; transcriptome; ST2/IL1RL1; metastasis	SOLUBLE ST2 PROTEIN; ERBB SIGNALING NETWORK; ACTIVATED RECEPTOR-2; ACUTE EXACERBATION; RESPONSIVE GENE; IL-1 RECEPTOR; CANCER CELLS; INVASION; INDUCTION; MIGRATION	Overexpression of the ErbB2 receptor tyrosine kinase in breast cancer contributes to tumor development and is associated with poor prognosis. However, the mechanism by which ErbB2 might contribute to metastasis is not well defined. To identify genes that mediate ErbB2-driven cell motility, we performed differential gene expression analysis of ErbB2-expressing migrating breast cancer cells vs mutant ErbB2-expressing non-migrating cells. Among the genes that were specifically induced in migrating cells were known transcriptional targets of ErbB2, such as matrix metalloproteinases, and novel ErbB2 targets. Contribution of selected candidate genes to ErbB2-driven cell motility was tested by small interfering RNA targeting. Knockdown of the soluble form of ST2 (sST2), also called interleukin-1 receptor-like 1, one of the most robustly induced genes, decreased ErbB2-induced cell motility in two different cell lines. In response to ErbB2 activation, sST2 protein expression and secretion were increased. Moreover, recombinant sST2 associated with the plasma membrane and sST2-blocking antibodies reduced ErbB2-induced motility. Interestingly, cells from metastatic breast tumors secreted higher levels of sST2 than primary tumor cells. Finally, sST2 was found at high levels in the serum of metastatic breast cancer patients. Our data suggest that sST2 contributes to breast cancer cell motility and that sST2 secretion is associated with metastasis. Oncogene (2012) 31, 3516-3524; doi:10.1038/onc.2011.525; published online 21 November 2011	[Gillibert-Duplantier, J.; Duthey, B.; Salaun, D.; Finetti, P.; Bertucci, F.; Birnbaum, D.; Badache, A.] Ctr Rech Cancerol Marseille, Inserm U891, Marseille, France; [Gillibert-Duplantier, J.; Duthey, B.; Salaun, D.; Finetti, P.; Bertucci, F.; Birnbaum, D.; Badache, A.] Inst J Paoli I Calmettes, F-13009 Marseille, France; [Gillibert-Duplantier, J.; Duthey, B.; Salaun, D.; Bertucci, F.; Birnbaum, D.; Badache, A.] Aix Marseille Univ, Marseille, France; [Sisirak, V.; Bendriss-Vermare, N.] Ctr Rech Cancerol Lyon, Inserm UMR1052, CNRS UMR5286, Lyon, France; [Sisirak, V.; Tredan, O.; Bendriss-Vermare, N.] Ctr Leon Berard, F-69373 Lyon, France; [Sisirak, V.; Bendriss-Vermare, N.] Univ Lyon 1, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Badache, A (corresponding author), Ctr Rech Cancerol Marseille, Inserm U891, Marseille, France.	ali.badache@inserm.fr	Bendriss-Vermare, Nathalie/M-9197-2018; Sisirak, Vanja/O-9393-2016; Tredan, Olivier/N-9794-2017; Sisirak, Vanja/GRJ-7805-2022; Badache, Ali/Q-6098-2017; Sisirak, Vanja/L-7304-2019; Finetti, Pascal/O-8669-2017	Bendriss-Vermare, Nathalie/0000-0002-8771-3585; Sisirak, Vanja/0000-0003-3070-6533; Tredan, Olivier/0000-0001-5881-9383; Badache, Ali/0000-0001-7710-2505; Sisirak, Vanja/0000-0003-3070-6533; Finetti, Pascal/0000-0002-2674-3123	Fondation de France; Association pour la Recherche contre le Cancer; Inserm Avenir Program; Ligue Nationale Contre le Cancer-Label Ligue; INCa [PL-969-017]; Association pour la Recherche sur le Cancer	Fondation de France(Fondation de France); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Inserm Avenir Program(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue Nationale Contre le Cancer-Label Ligue; INCa(Institut National du Cancer (INCA) France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We thank R Marone and N Hynes for support in the preliminary phase of the project, M Lopez and A Goncalves for helpful discussions, and E Tabone and G Clapisson for providing clinical data. This work was supported by Fondation de France, Association pour la Recherche contre le Cancer and Inserm Avenir Program (AB), Ligue Nationale Contre le Cancer-Label Ligue (DB), INCa grant PL-969-017 "Met-Escape" (NB-V) and fellowships from Fondation de France (JG-D and BD) and Association pour la Recherche sur le Cancer (VS).	Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Brunner M, 2004, INTENS CARE MED, V30, P1468, DOI 10.1007/s00134-004-2184-x; Caruso R, 2006, AM J PATHOL, V169, P268, DOI 10.2353/ajpath.2006.050841; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dufour A, 2008, J CELL PHYSIOL, V217, P643, DOI 10.1002/jcp.21535; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fabre S, 2002, J BIOL CHEM, V277, P27006, DOI 10.1074/jbc.M203228200; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; Grossmann KS, 2009, P NATL ACAD SCI USA, V106, P16704, DOI 10.1073/pnas.0904336106; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200; Hijazi MM, 2000, INT J ONCOL, V17, P629; Ho IAW, 2009, STEM CELLS, V27, P1366, DOI 10.1002/stem.50; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jarry A, 2007, BIOCHEM BIOPH RES CO, V364, P689, DOI 10.1016/j.bbrc.2007.10.073; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660; Kedrin D, 2009, CLIN CANCER RES, V15, P3733, DOI 10.1158/1078-0432.CCR-08-2163; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Mazumdar A, 2001, CANCER RES, V61, P400; Meisel C, 2001, J IMMUNOL, V166, P3143, DOI 10.4049/jimmunol.166.5.3143; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; ROSSLER U, 1995, DEV BIOL, V168, P86, DOI 10.1006/dbio.1995.1063; Sanada S, 2007, J CLIN INVEST, V117, P1538, DOI 10.1172/JCI30634; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Su S, 2009, ONCOGENE, V28, P3047, DOI 10.1038/onc.2009.163; Tajima S, 2003, CHEST, V124, P1206, DOI 10.1378/chest.124.4.1206; Tominaga S, 1999, BIOCHEM BIOPH RES CO, V264, P14, DOI 10.1006/bbrc.1999.1469; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zaoui K, 2008, J CELL BIOL, V183, P401, DOI 10.1083/jcb.200805107	47	29	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	30					3516	3524		10.1038/onc.2011.525	http://dx.doi.org/10.1038/onc.2011.525			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105364	Bronze			2022-12-17	WOS:000306844100004
J	Pelletier, J; Dayan, F; Durivault, J; Ilc, K; Pecou, E; Pouyssegur, J; Mazure, NM				Pelletier, J.; Dayan, F.; Durivault, J.; Ilc, K.; Pecou, E.; Pouyssegur, J.; Mazure, N. M.			The asparaginyl hydroxylase factor-inhibiting HIF is essential for tumor growth through suppression of the p53-p21 axis	ONCOGENE			English	Article						FIH; HIF-1; hypoxia; p53; tumor growth	HYPOXIA-INDUCIBLE FACTOR; PAS DOMAIN PROTEIN-1; RENAL-CELL CARCINOMA; TRANSCRIPTIONAL ACTIVITY; FACTOR-I; TRANSACTIVATION DOMAIN; FIH; EXPRESSION; HIF-1-ALPHA; PATHWAY	We showed previously that factor-inhibiting hypoxia-inducible factor HIF (FIH) monitors the expression of a spectrum of genes that are dictated by the cell's partial oxygen pressure. This action is mediated by the C-TAD, one of two transactivation domains (TADs) of the hypoxia-inducible factor. Here, we questioned: (1) the function of FIH as a HIF-1 modulator of gene expression in the context of a physiological oxygen gradient occurring in three-dimensional cultures and in tumors and (2) the role of FIH as a modulator of the growth of human tumor cells. We first showed that the expression pattern of HIF target genes that depend on the C-TAD, such as carbonic anhydrase IX, was spacially displaced to more oxygenated areas when FIH was silenced, whereas overexpression of FIH restricted this pattern to more hypoxic areas. Second, we showed that silencing fih severely reduced in vitro cell proliferation and in vivo tumor growth of LS174 colon adenocarcinoma and A375 melanoma cells. Finally, silencing of fih significantly increased both the total and phosphorylated forms of the tumor suppressor p53, leading to an increase in its direct target, the cell cycle inhibitor p21. Moreover, p53-deficient or mutant cells were totally insensitive to FIH expression. Thus, FIH activity is essential for tumor growth through the suppression of the p53-p21 axis, the major barrier that prevents cancer progression.	[Mazure, N. M.] Univ Nice Sophia Antipolis, CNRS, Inst Dev Biol & Canc Res, Ctr Antoine Lacassagne,UMR 6543, F-06189 Nice, France; [Dayan, F.; Pecou, E.] Univ Nice Sophia Antipolis, CNRS, Lab JA Dieudonne, UMR 6632, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Mazure, NM (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Dev Biol & Canc Res, Ctr Antoine Lacassagne,UMR 6543, 33 Ave Valombrose, F-06189 Nice, France.	Nathalie.Mazure@unice.fr	pelletier, joffrey/K-8930-2014	pelletier, joffrey/0000-0001-9174-044X; Durivault, Jerome/0000-0002-8228-2915; Pecou Gambaudo, Elisabeth/0000-0002-1108-7282	Ligue Nationale Contre le Cancer (equipe labellisee); Association pour la Recherche contre le Cancer; Institut National du Cancer; Agence Nationale pour la Recherche; METOXIA (EU); Centre A Lacassagne; Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; University of Nice	Ligue Nationale Contre le Cancer (equipe labellisee)(Ligue nationale contre le cancer); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Agence Nationale pour la Recherche(French National Research Agency (ANR)); METOXIA (EU)(European Commission); Centre A Lacassagne; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Nice	The laboratory is funded by the Ligue Nationale Contre le Cancer (equipe labellisee), the Association pour la Recherche contre le Cancer, the Institut National du Cancer, the Agence Nationale pour la Recherche, METOXIA (EU program FP7), the Centre A Lacassagne, the Centre National de la Recherche Scientifique, the Institut National de la Sante et de la Recherche Medicale and the University of Nice (http://www.unice.fr/isdbc/). We thank Dr Corinne Bertolotto and Dr Frederic Bost for their helpful advices. We also thank Dr M Christiane Brahimi-Horn for critical reading and editorial correction.	Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Cockman ME, 2006, P NATL ACAD SCI USA, V103, P14767, DOI 10.1073/pnas.0606877103; Cockman ME, 2009, ANN NY ACAD SCI, V1177, P9, DOI 10.1111/j.1749-6632.2009.05042.x; Dayan F, 2006, CANCER RES, V66, P3688, DOI 10.1158/0008-5472.CAN-05-4564; Dayan F, 2008, CANCER MICROENVIRON, V1, P53, DOI 10.1007/s12307-008-0006-3; Dayan F, 2009, J THEOR BIOL, V259, P304, DOI 10.1016/j.jtbi.2009.03.009; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fels DR, 2005, TRENDS BIOCHEM SCI, V30, P426, DOI 10.1016/j.tibs.2005.06.009; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaluz S, 2008, BLOOD, V111, P5258, DOI 10.1182/blood-2008-02-140079; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Kroeze SGC, 2010, EUR J CANCER, V46, P3375, DOI 10.1016/j.ejca.2010.07.018; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200; Lisy K, 2008, CELL DEATH DIFFER, V15, P642, DOI 10.1038/sj.cdd.4402315; Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Morris MR, 2004, J CLIN PATHOL, V57, P706, DOI 10.1136/jcp.2003.011767; Newbold RF, 2002, MUTAGENESIS, V17, P539, DOI 10.1093/mutage/17.6.539; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Sakamoto T, 2009, J BIOL CHEM, V284, P30350, DOI 10.1074/jbc.M109.019216; Schodel J, 2010, KIDNEY INT, V78, P857, DOI 10.1038/ki.2010.284; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shin DH, 2008, BLOOD, V111, P3131, DOI 10.1182/blood-2007-11-120576; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian YM, 2011, J BIOL CHEM, V286, P13041, DOI 10.1074/jbc.M110.211110; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yan JL, 2007, P NATL ACAD SCI USA, V104, P1841, DOI 10.1073/pnas.0605562104; Zhang N, 2010, CELL METAB, V11, P364, DOI 10.1016/j.cmet.2010.03.001	40	29	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2989	3001		10.1038/onc.2011.471	http://dx.doi.org/10.1038/onc.2011.471			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22002313				2022-12-17	WOS:000305388400008
J	Berezov, A; Cai, Z; Freudenberg, JA; Zhang, H; Cheng, X; Thompson, T; Murali, R; Greene, MI; Wang, Q				Berezov, A.; Cai, Z.; Freudenberg, J. A.; Zhang, H.; Cheng, X.; Thompson, T.; Murali, R.; Greene, M. I.; Wang, Q.			Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin	ONCOGENE			English	Article						mitosis; cancer; therapeutic; survivin	KINETOCHORE FIBERS CONTRIBUTES; THERAPEUTIC TARGET; SIGNALING PATHWAY; INNER CENTROMERE; MOTOR PROTEINS; CELL-DIVISION; BINDING-SITE; AURORA B; APOPTOSIS; MITOSIS	Survivin is a member of the inhibitor of apoptosis protein family and has an essential role in mitosis. Survivin is overexpressed in a large variety of human cancers and represents an attractive target for cancer therapy. Epidermal growth factor receptor and Her/neu-transformed human tumors in particular exhibit high levels of survivin. The survivin protein forms dimers through a conserved region that is critical for subcellular localization and biological functions of the protein. We identified small molecules that target a specific cavity adjacent to the survivin dimerization surfaces. S12, a lead compound identified in the screen, can bind to the survivin protein at the intended target site. Moreover, S12 alters spindle formation, causing mitotic arrest and cell death, and inhibits tumor growth in vitro and in vivo. Cell death occurs in premetaphase stage following mitotic arrest and is not a consequence of general toxicity. Thus, the study validates a novel therapeutic target site in the survivin protein and provides a promising strategy to develop a new class of therapeutic small molecules for the treatment of human cancers. Oncogene (2012) 31, 1938-1948; doi:10.1038/onc.2011.377; published online 5 September 2011	[Berezov, A.; Cai, Z.; Freudenberg, J. A.; Zhang, H.; Cheng, X.; Thompson, T.; Murali, R.; Greene, M. I.; Wang, Q.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu; Qiang.Wang@cshs.org	Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Neely, Jaclyn/0000-0001-7137-3953; Murali, Ramachandran/0000-0002-8384-2793; Zhang, Hongtao/0000-0001-9173-0049	Abramson Family Cancer Research Institute of the University of Pennsylvania; The National Cancer Institute; Breast Cancer Research Foundation; Nidus Laboratories, Inc.; NATIONAL CANCER INSTITUTE [R01CA089481, R01CA055306] Funding Source: NIH RePORTER	Abramson Family Cancer Research Institute of the University of Pennsylvania; The National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; Nidus Laboratories, Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Robert L Margolis (the Sanford-Burnham Medical Research Institute, La Jolla, CA, USA) for providing the pGEX-survivin plasmid. This work was supported by grants from the Abramson Family Cancer Research Institute of the University of Pennsylvania, The National Cancer Institute, the Breast Cancer Research Foundation and the Nidus Laboratories, Inc.	Ainsztein AM, 1998, J CELL BIOL, V143, P1763, DOI 10.1083/jcb.143.7.1763; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; Giodini A, 2002, CANCER RES, V62, P2462; Goshima G, 2005, J CELL BIOL, V171, P229, DOI 10.1083/jcb.200505107; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Kappler M, 2004, CANCER GENE THER, V11, P186, DOI 10.1038/sj.cgt.7700677; Kelly AE, 2010, SCIENCE, V330, P235, DOI 10.1126/science.1189505; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Maiato H, 2004, J CELL BIOL, V167, P831, DOI 10.1083/jcb.200407090; Maiato H, 2004, CHROMOSOME RES, V12, P585, DOI 10.1023/B:CHRO.0000036587.26566.81; Murali R, 2005, P NATL ACAD SCI USA, V102, P10970, DOI 10.1073/pnas.0504301102; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Noton EA, 2006, J BIOL CHEM, V281, P1286, DOI 10.1074/jbc.M508773200; Rieder CL, 2005, CHROMOSOMA, V114, P310, DOI 10.1007/s00412-005-0028-2; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Sun CH, 2005, BIOCHEMISTRY-US, V44, P11, DOI 10.1021/bi0485171; Tamm I, 1998, CANCER RES, V58, P5315; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Wang Q, 2005, EXP MOL PATHOL, V79, P100, DOI 10.1016/j.yexmp.2005.05.002; Wendt MD, 2007, BIOORG MED CHEM LETT, V17, P3122, DOI 10.1016/j.bmcl.2007.03.042; Xia WL, 2006, CANCER RES, V66, P1640, DOI 10.1158/0008-5472.CAN-05-2000; Yamagishi Y, 2010, SCIENCE, V330, P239, DOI 10.1126/science.1194498	38	29	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	15					1938	1948		10.1038/onc.2011.377	http://dx.doi.org/10.1038/onc.2011.377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21892210	Green Accepted			2022-12-17	WOS:000302809900006
J	Kawamata, N; Pennella, MA; Woo, JL; Berk, AJ; Koeffler, HP				Kawamata, N.; Pennella, M. A.; Woo, J. L.; Berk, A. J.; Koeffler, H. P.			Dominant-negative mechanism of leukemogenic PAX5 fusions	ONCOGENE			English	Article						PAX5 fusions; DNA binding; multimerization	ACUTE PROMYELOCYTIC LEUKEMIA; UNBALANCED TRANSLOCATIONS; INTRANUCLEAR MOBILITY; HISTONE DEACETYLASE; DECREASED MOBILITY; PAIRED DOMAIN; PROTEINS; BINDING; RAR; CHROMATIN	PAX5 encodes a master regulator of B-cell development. It fuses to other genes associated with acute lymphoblastoid leukemia (ALL). These fusion products are potent dominant-negative (DN) inhibitors of wild-type PAX5, resulting in a blockade of B-cell differentiation. Here, we show that multimerization of PAX5 DNA-binding domain (DBD) is necessary and sufficient to cause extremely stable chromatin binding and DN activity. ALL-associated PAX5-C20S results from fusion of the N-terminal region of PAX5, including its paired DBD, to the C-terminus of C20orf112, a protein of unknown function. We report that PAX5-C20S is a tetramer, which interacts extraordinarily stably with chromatin as determined by Fluorescence Recovery After Photobleaching in living cells. Tetramerization, stable chromatin binding and DN activity all require a putative five-turn amphipathic a-helix at the C-terminus of C20orf112, and does not require potential corepressor binding peptides elsewhere in the sequence. In vitro, the monomeric PAX5 DBD and PAX5-C20S binds a PAX5-binding site with equal affinity when it is at the center of an oligonucleotide too short to bind to more than one PAX5 DBD. But, PAX5-C20S binds the same sequence with 10-fold higher affinity than the monomeric PAX5 DBD when it is in a long DNA molecule. We suggest that the increased affinity results from interactions of one or more of the additional DBDs with neighboring non-specific sites in a long DNA molecule, and that this can account for the increased stability of PAX5-C20S chromatin binding compared with wild-type PAX5, resulting in DN activity by competition for binding to PAX5-target sites. Consistent with this model, the ALL-associated PAX5 fused to ETV6 or the multimerization domain of ETV6 SAM results in stable chromatin binding and DN activity. In addition, PAX5 DBD fused to artificial dimerization, trimerization and tetramerization domains results in parallel increases in the stability of chromatin binding and DN activity. Our studies suggest that oncogenic fusion proteins that retain the DBD of the transcription factor (TF) and the multimerization sequence of the partner protein can act in a DN manner by multimerizing and binding avidly to gene targets, preventing the normal TF from binding and inducing expression of its target genes. Inhibition of this multimeriztion may provide a novel therapeutic approach for cancers with this or similar fusion proteins. Oncogene (2012) 31, 966-977; doi:10.1038/onc.2011.291; published online 18 July 2011	[Kawamata, N.] Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA; [Pennella, M. A.; Woo, J. L.; Berk, A. J.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, Los Angeles, CA 90048 USA; [Woo, J. L.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; [Koeffler, H. P.] Natl Univ Singapore, Natl Canc Inst, Singapore 117548, Singapore; [Koeffler, H. P.] Natl Univ Singapore, Canc Inst Singapore, Singapore 117548, Singapore	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Regeneron; National University of Singapore; National University of Singapore	Kawamata, N (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Inst Med Genet, 8700 Beverly Blvd,Room D5068, Los Angeles, CA 90048 USA.	Norihiko.Kawamata@cshs.org; berk@mbi.ucla.edu	BERK, ARNOLD/AAF-7052-2020		NIH [R01CA026038-32, U54CA143930, GM008243]; A*STAR [R37CA25235]; Tower Cancer Foundation; ACS [PF0804801GMC]; NATIONAL CANCER INSTITUTE [U54CA143930, R01CA026038, R37CA025235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008243] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); A*STAR(Agency for Science Technology & Research (A*STAR)); Tower Cancer Foundation; ACS(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants R01CA026038-32, U54CA143930, and A*STAR Investigator Grant to HPK and R37CA25235 to AJB, the Tower Cancer Foundation grant and NIH grant GM008243 to NK, and ACS postdoctoral fellowship PF0804801GMC to MAP. We thank Kolja A Wawrowsky in the Confocal Microscopy Unit, and BK Bernstein for Core Unit, Patricia Lin in the FACS Core Unit for their technical assistance. FRAP experiments were performed at the California Nano Systems Institute Advanced Light Microscopy/Spectroscopy (CNSI-ALMS) at UCLA.	An Q, 2008, P NATL ACAD SCI USA, V105, P17050, DOI 10.1073/pnas.0803494105; Antolini F, 2003, PROTEIN EXPRES PURIF, V29, P94, DOI 10.1016/S1046-5928(03)00004-4; Bousquet M, 2007, BLOOD, V109, P3417, DOI 10.1182/blood-2006-05-025221; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Davison TS, 2001, J MOL BIOL, V307, P605, DOI 10.1006/jmbi.2001.4450; Delorenzi M, 2002, BIOINFORMATICS, V18, P617, DOI 10.1093/bioinformatics/18.4.617; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Edwards PAW, 2010, J PATHOL, V220, P244, DOI 10.1002/path.2632; Elvenes J, 2010, CELL MOL LIFE SCI, V67, P4079, DOI 10.1007/s00018-010-0429-0; Fazio G, 2008, CANCER RES, V68, P181, DOI 10.1158/0008-5472.CAN-07-2778; Gasparini P, 2007, J CELL BIOCHEM, V102, P320, DOI 10.1002/jcb.21481; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gruber M, 2005, NUCLEIC ACIDS RES, V33, pW239, DOI 10.1093/nar/gki405; Huang Y, 2008, BIOCHEM BIOPH RES CO, V365, P258, DOI 10.1016/j.bbrc.2007.10.184; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kawamata N, 2008, P NATL ACAD SCI USA, V105, P11921, DOI 10.1073/pnas.0711039105; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Letarov AV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P817; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Martens JHA, 2010, CANCER CELL, V17, P173, DOI 10.1016/j.ccr.2009.12.042; McDonnell AV, 2006, BIOINFORMATICS, V22, P356, DOI 10.1093/bioinformatics/bti797; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; O'Neil J, 2007, ONCOGENE, V26, P6838, DOI 10.1038/sj.onc.1210766; Pabst T, 2007, ONCOGENE, V26, P6829, DOI 10.1038/sj.onc.1210765; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Qiu J, 2006, ONCOGENE, V25, P3982, DOI 10.1038/sj.onc.1209431; Qiu JJ, 2011, ONCOGENE, V30, P967, DOI 10.1038/onc.2010.473; Schebesta A, 2007, IMMUNITY, V27, P49, DOI 10.1016/j.immuni.2007.05.019; Siegel R M, 2000, Sci STKE, V2000, ppl1, DOI 10.1126/stke.2000.38.pl1; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Sprague BL, 2005, TRENDS CELL BIOL, V15, P84, DOI 10.1016/j.tcb.2004.12.001; Strefford JC, 2009, CELL CYCLE, V8, P2175, DOI 10.4161/cc.8.14.9103; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Wichmann C, 2007, CANCER RES, V67, P2280, DOI 10.1158/0008-5472.CAN-06-3360; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Zhou J, 2006, P NATL ACAD SCI USA, V103, P9238, DOI 10.1073/pnas.0603324103	44	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					966	977		10.1038/onc.2011.291	http://dx.doi.org/10.1038/onc.2011.291			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765475	Green Accepted, Green Submitted			2022-12-17	WOS:000300709700003
J	Wang, Y; Lazo, JS				Wang, Y.; Lazo, J. S.			Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion	ONCOGENE			English	Article						PRL-2; lung cancer; cell invasion; ERK	PROTEIN-TYROSINE-PHOSPHATASE; PANCREATIC-CANCER CELLS; REGENERATING LIVER-3; COLORECTAL-CANCER; BREAST-CANCER; LUNG-CANCER; EXPRESSION; PROMOTES; MOTILITY; PROGNOSIS	The phosphatase of regenerating liver (PRL) family, comprising PRL-1, PRL-2 and PRL-3, is a group of prenylated phosphatases that are candidate cancer biomarkers and therapeutic targets. Although several studies have documented that altered expression of PRL-1 or PRL-3 can influence cell proliferation, migration and invasion, there is a dearth of knowledge about the biological functions of PRL-2. Thus, in the current study we have evaluated the role of PRL-2 in cell migration and invasion in human cancer cells. We found that four human lung cancer cells, including A549 cells, overexpress PRL-2 when compared with normal lung cells. PRL-2 knockdown by RNA interference markedly inhibited cell migration and invasion, and this inhibition can be restored by overexpressing the short interference RNA (siRNA)resistant vector HA-PRL-2m. PRL-2 suppression by siRNA decreased p130Cas and vinculin expression, and decreased extracellular signal-regulated kinase (ERK) phosphorylation, while increasing the phosphorylation of ezrin on tyrosine 146. We found no significant changes in total p53, Akt and c-Src expression levels or their phosphorylation status, suggesting that PRL-2 knockdown could inhibit tumor cell migration and invasion through a Src-independent p130Cas signaling pathway. Ectopic expression of wild-type PRL-2, a catalytic inactive C101S mutant and a C-terminal CAAX deletion revealed a requirement for both the PRL-2 catalytic functionality and prenylation site. Expression of wild-type but not mutant forms of PRL-2 caused ERK phosphorylation and nuclear translocation. These results support a model in which PRL-2 promotes cell migration and invasion through an ERK-dependent signaling pathway. Oncogene (2012) 31, 818-827; doi: 10.1038/onc.2011.281; published online 18 July 2011	[Wang, Y.; Lazo, J. S.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Virginia, Dept Pharmacol, POB 800793, Charlottesville, VA 22908 USA.	lazo@virginia.edu			National Institutes of Health National Cancer Institute [CA78039]; Fiske Drug Discovery Fund; NATIONAL CANCER INSTITUTE [P01CA078039] Funding Source: NIH RePORTER	National Institutes of Health National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fiske Drug Discovery Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from the National Institutes of Health National Cancer Institute (CA78039) and the Fiske Drug Discovery Fund.	Achiwa H, 2007, CANCER RES, V67, P643, DOI 10.1158/0008-5472.CAN-06-2436; Basak S, 2008, MOL CELL, V30, P303, DOI 10.1016/j.molcel.2008.04.002; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; Forte E, 2008, BBA-MOL CELL RES, V1783, P334, DOI 10.1016/j.bbamcr.2007.11.004; Guo K, 2004, CANCER BIOL THER, V3, P945, DOI 10.4161/cbt.3.10.1111; Han HY, 2002, CANCER RES, V62, P2890; Hardy S, 2010, CANCER RES, V70, P8959, DOI 10.1158/0008-5472.CAN-10-2041; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Kim W, 2004, J BIOL CHEM, V279, P8333, DOI 10.1074/jbc.M312026200; Li ZR, 2007, SURG TODAY, V37, P646, DOI 10.1007/s00595-006-3437-9; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; Luo Y, 2009, BIOCHEMISTRY-US, V48, P1838, DOI 10.1021/bi8020789; Min SH, 2009, ONCOGENE, V28, P545, DOI 10.1038/onc.2008.409; Ming J, 2009, PATHOLOGY, V41, P118, DOI 10.1080/00313020802579268; Miskad UA, 2004, PATHOBIOLOGY, V71, P176, DOI 10.1159/000078671; Peng LR, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-110; Peng LR, 2004, J CANCER RES CLIN, V130, P521, DOI 10.1007/s00432-004-0563-x; Radke I, 2006, BRIT J CANCER, V95, P347, DOI 10.1038/sj.bjc.6603261; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Stephens BJ, 2005, MOL CANCER THER, V4, P1653, DOI 10.1158/1535-7163.MCT-05-0248; Stephens B, 2008, MOL CANCER THER, V7, P202, DOI 10.1158/1535-7163.MCT-07-0542; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang J, 2002, J BIOL CHEM, V277, P46659, DOI 10.1074/jbc.M206407200; Wang L, 2006, ANN ONCOL, V17, P1517, DOI 10.1093/annonc/mdl159; Wang Q, 2002, CANCER LETT, V175, P63, DOI 10.1016/S0304-3835(01)00703-0; Wang Y, 2007, INT J COLORECTAL DIS, V22, P1179, DOI 10.1007/s00384-007-0303-1; Wu XP, 2004, AM J PATHOL, V164, P2039, DOI 10.1016/S0002-9440(10)63763-7; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Zamir E, 2001, J CELL SCI, V114, P3583; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 2003, CANCER RES, V63, P2716	34	29	31	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	7					818	827		10.1038/onc.2011.281	http://dx.doi.org/10.1038/onc.2011.281			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21765462	Green Accepted			2022-12-17	WOS:000300615800002
J	Haberkorn, U; Markert, A; Mier, W; Askoxylakis, V; Altmann, A				Haberkorn, U.; Markert, A.; Mier, W.; Askoxylakis, V.; Altmann, A.			Molecular imaging of tumor metabolism and apoptosis	ONCOGENE			English	Review						glucose metabolism; amino-acid transport; PET; imaging; tumor; apoptosis	AMINO-ACID-TRANSPORT; MAGNETIC-RESONANCE-SPECTROSCOPY; CHOLINE PHOSPHOLIPID-METABOLISM; POSITRON-EMISSION-TOMOGRAPHY; ALPHA-AMINOISOBUTYRIC-ACID; MAMMARY EPITHELIAL-CELLS; HSV THYMIDINE KINASE; BREAST-CANCER CELLS; GLUCOSE-TRANSPORTER; PROTEIN-SYNTHESIS	Increased metabolism in a number of cellular pathways is a common feature of malignant tumors. This metabolic hallmark of neoplastic tissue led to the development of radiopharmaceuticals for the assessment of transport and enzymatic activity for tumor diagnosis and staging. The malignant transformation causes the activation of oncogenic proteins and signaling pathways that stimulate glycolysis. The resulting high-glucose metabolism of cancer cells allows PET imaging using FDG. Other molecules frequently applied in preclinical and clinical studies are C-11-methionine, tyrosine analogs and choline-based tracers. Using quantitative procedures they enable therapy monitoring by assessment of changes in transport and metabolization. As apoptosis is an important mechanism of cell death in tumors responding to treatment, non-invasive assessment of apoptosis using tracers for detection of phosphatidyl-serine presentation and/or caspase activation could be used as a surrogate marker for therapeutic efficacy. Oncogene (2011) 30, 4141-4151; doi:10.1038/onc.2011.169; published online 16 May 2011	[Haberkorn, U.; Markert, A.; Mier, W.; Askoxylakis, V.; Altmann, A.] Univ Heidelberg Hosp, Dept Nucl Med, D-69120 Heidelberg, Germany; [Haberkorn, U.; Markert, A.; Altmann, A.] DKFZ, Clin Cooperat Unit Nucl Med, D-69120 Heidelberg, Germany; [Askoxylakis, V.] Heidelberg Univ, Dept Radiat Therapy, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Haberkorn, U (corresponding author), Univ Heidelberg Hosp, Dept Nucl Med, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Uwe.Haberkorn@med.uni-heidelberg.de						Aboagye EO, 1999, CANCER RES, V59, P80; Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Bassa P, 1996, J NUCL MED, V37, P931; Bauer C, 2005, J NUCL MED, V46, P1066; BERGSTROM M, 1987, J COMPUT ASSIST TOMO, V11, P815, DOI 10.1097/00004728-198709000-00014; Blankenberg FG, 1999, J NUCL MED, V40, P184; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Bogin L, 1998, BBA-LIPID LIPID MET, V1392, P217, DOI 10.1016/S0005-2760(98)00035-6; Brown RS, 1999, J NUCL MED, V40, P556; BUSCH H, 1959, CANCER RES, V19, P1030; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CUADRADO A, 1993, ONCOGENE, V8, P2959; CUADRADO A, 1994, J CELL PHYSIOL, V159, P434, DOI 10.1002/jcp.1041590307; DAEMEN BJG, 1991, J NUCL MED, V32, P1587; de Domenech E. E. Machado, 1980, FEBS LETT, V119, P174, DOI DOI 10.1016/0014-5793(80)81024-6; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; DECERTAINES JD, 1993, NMR BIOMED, V6, P345, DOI 10.1002/nbm.1940060602; DeGrado TR, 2001, CANCER RES, V61, P110; DeGrado TR, 2001, J NUCL MED, V42, P1805; DUNZENDORFER U, 1981, EUR J NUCL MED, V6, P535; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; GALLAGHER BM, 1977, J NUCL MED, V18, P990; GALONS JP, 1995, MAGN RESON MED, V33, P422, DOI 10.1002/mrm.1910330317; Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005; Gribbestad IS, 1999, ANTICANCER RES, V19, P1737; GUTHRIDGE CJ, 1994, CANCER LETT, V86, P11, DOI 10.1016/0304-3835(94)90175-9; HABERKORN U, 1994, NUCL MED BIOL, V21, P827, DOI 10.1016/0969-8051(94)90162-7; Haberkorn U, 1997, J NUCL MED, V38, P1048; Haberkorn U, 2005, CURR MED CHEM, V12, P779, DOI 10.2174/0929867053507351; HABERKORN U, 1993, J NUCL MED, V34, P12; HABERKORN U, 1992, J NUCL MED, V33, P1981; HABERKORN U, 1991, J NUCL MED, V32, P1485; Haberkorn U, 2001, EUR J NUCL MED, V28, P1690, DOI 10.1007/s002590100644; Haberkorn U, 2001, NUCL MED BIOL, V28, P793, DOI 10.1016/S0969-8051(01)00247-5; Haberkorn U, 2001, EUR J NUCL MED, V28, P418, DOI 10.1007/s002590100489; Haberkorn U, 1997, J NUCL MED, V38, P1215; Haberkorn U, 1998, GENE THER, V5, P880, DOI 10.1038/sj.gt.3300679; HAEFFNER EW, 1975, EUR J BIOCHEM, V51, P219, DOI 10.1111/j.1432-1033.1975.tb03922.x; Hara T, 2002, J NUCL MED, V43, P187; Hara T, 1998, J NUCL MED, V39, P990; HAYES N, 1993, BIOCHEM BIOPH RES CO, V190, P881, DOI 10.1006/bbrc.1993.1131; Heiss P, 1999, J NUCL MED, V40, P1367; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HIGASHI K, 1993, J NUCL MED, V34, P773; HUGHES CS, 1989, CANCER RES, V49, P4452; Ishiwata K, 1996, J NUCL MED, V37, P279; ISSELBACHER KJ, 1972, NEW ENGL J MED, V286, P929; Jager PL, 2001, J NUCL MED, V42, P432; JANSSON T, 1995, J CLIN ONCOL, V13, P1470, DOI 10.1200/JCO.1995.13.6.1470; Katz-Brull R, 1996, ANTICANCER RES, V16, P1375; KISS Z, 1993, FEBS LETT, V336, P115, DOI 10.1016/0014-5793(93)81622-7; Kobori D, 1999, CANCER-AM CANCER SOC, V86, P1638, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1638::AID-CNCR4>3.0.CO;2-U; Kurhanewicz J, 2000, NEOPLASIA, V2, P166, DOI 10.1038/sj.neo.7900081; Kuwert T, 1997, J NUCL MED, V38, P1551; Kwee SA, 2006, J NUCL MED, V47, P262; Kwee SA, 2004, J NEUROIMAGING, V14, P285, DOI 10.1177/1051228404264957; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Langen KJ, 1997, J NUCL MED, V38, P517; Leach MO, 1998, NMR BIOMED, V11, P314, DOI 10.1002/(SICI)1099-1492(1998110)11:7<314::AID-NBM522>3.0.CO;2-Z; Li XJ, 2002, J MAGN RESON IMAGING, V16, P229, DOI 10.1002/jmri.10147; Lindholm P, 1998, J NUCL MED, V39, P1393; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McConathy J, 2002, J MED CHEM, V45, P2240, DOI 10.1021/jm010241x; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NEGENDANK W, 1992, NMR BIOMED, V5, P303, DOI 10.1002/nbm.1940050518; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; OGAWA T, 1991, ACTA RADIOL, V32, P197; Pauleit D, 2005, BRAIN, V128, P678, DOI 10.1093/brain/awh399; Popperl G, 2004, EUR J NUCL MED MOL I, V31, P1464, DOI 10.1007/s00259-004-1590-1; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Rau FC, 2002, EUR J NUCL MED MOL I, V29, P1039, DOI 10.1007/s00259-002-0821-6; Ronen SM, 2001, BRIT J CANCER, V84, P691, DOI 10.1054/bjoc.2000.1663; ROZENTAL JM, 1989, ARCH NEUROL-CHICAGO, V46, P1302, DOI 10.1001/archneur.1989.00520480044018; SAIER MH, 1988, J MEMBRANE BIOL, V104, P1, DOI 10.1007/BF01871898; Salber D, 2007, J NUCL MED, V48, P2056, DOI 10.2967/jnumed.107.046615; SCANLON KJ, 1987, CANCER CHEMOTH PHARM, V19, P21, DOI 10.1007/BF00296249; SCANLON KJ, 1983, CANCER RES, V43, P4211; Schaider H, 1996, EUR J NUCL MED, V23, P55, DOI 10.1007/BF01736990; SHAWVER LK, 1987, MOL CELL BIOL, V7, P2112, DOI 10.1128/MCB.7.6.2112; Shoup TM, 1999, J NUCL MED, V40, P331; Sieger S, 2004, CANCER GENE THER, V11, P41, DOI 10.1038/sj.cgt.7700654; Sieger S, 2003, EUR J NUCL MED MOL I, V30, P748, DOI 10.1007/s00259-002-1099-4; Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z; SOLS A, 1954, J BIOL CHEM, V210, P581; Uehara H, 1997, J CEREBR BLOOD F MET, V17, P1239, DOI 10.1097/00004647-199711000-00013; VAALBURG W, 1992, NUCL MED BIOL, V19, P227, DOI 10.1016/0883-2897(92)90011-M; Vansteenkiste JF, 1999, J CLIN ONCOL, V17, P3201, DOI 10.1200/JCO.1999.17.10.3201; Vees H, 2009, EUR J NUCL MED MOL I, V36, P182, DOI 10.1007/s00259-008-0943-6; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525; Wester HJ, 1999, J NUCL MED, V40, P205; WIDNELL CC, 1990, FASEB J, V4, P1634, DOI 10.1096/fasebj.4.6.2156742; WIENHARD K, 1991, J NUCL MED, V32, P1338; WILLEMSEN ATM, 1995, J NUCL MED, V36, P411; Wurker M, 1996, EUR J NUCL MED, V23, P583; Zhou D, 2009, ORG BIOMOL CHEM, V7, P1337, DOI 10.1039/b819024k; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	99	29	32	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	40					4141	4151		10.1038/onc.2011.169	http://dx.doi.org/10.1038/onc.2011.169			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21577202				2022-12-17	WOS:000295924600001
J	Trinh, BQ; Barengo, N; Naora, H				Trinh, B. Q.; Barengo, N.; Naora, H.			Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF-beta cytostatic program and blocks the antiproliferative effect of TGF-beta	ONCOGENE			English	Article						cell growth; homeobox genes; Smad; Sp1; TGF-beta	GROWTH-FACTOR-BETA; HOMEOBOX GENE-EXPRESSION; MICROSATELLITE INSTABILITY; BREAST-CANCER; C-MYC; EPITHELIAL-CELLS; LUNG CANCERS; COLON-CANCER; II RECEPTOR; DNA-BINDING	The antiproliferative activity of transforming growth factor-beta (TGF-beta) is essential for maintaining normal tissue homeostasis and is lost in many types of tumors. Gene responses that are central to the TGF-beta cytostatic program include activation of the cyclin-dependent kinase inhibitors, p15(Ink4B) and p21(WAF1/Cip1), and repression of c-myc. These gene responses are tightly regulated by a repertoire of transcription factors that include Smad proteins and Sp1. The DLX4 homeobox patterning gene encodes a transcription factor that is absent from most normal adult tissues, but is expressed in a wide variety of malignancies, including lung, breast, prostate and ovarian cancers. In this study, we demonstrate that DLX4 blocks the antiproliferative effect of TGF-b. DLX4 inhibited TGF-beta-mediated induction of p15(Ink4B) and p21(WAF1/Cip1) expression. DLX4 bound and prevented Smad4 from forming complexes with Smad2 and Smad3, but not with Sp1. However, DLX4 also bound and inhibited DNA-binding activity of Sp1. In addition, DLX4 induced expression of c-myc independently of TGF-beta/Smad signaling. The ability of DLX4 to counteract key transcriptional control mechanisms of the TGF-beta cytostatic program could explain, in part, the resistance of tumors to the antiproliferative effect of TGF-beta Oncogene (2011) 30, 2718-2729; doi: 10.1038/onc.2011.4; published online 7 February 2011	[Trinh, B. Q.; Barengo, N.; Naora, H.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77054 USA; [Trinh, B. Q.; Naora, H.] Univ Texas Hlth Sci Ctr, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Naora, H (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 7435 Fannin St,Unit 950, Houston, TX 77054 USA.	hnaora@mdanderson.org	Trinh, Bon/K-7132-2014	Trinh, Bon/0000-0002-0956-8941	Schissler Foundation; Vietnam Education Foundation; US Department of Defense [W81XWH-06-1-0259]; National Institutes of Health [R01 CA141078]; NATIONAL CANCER INSTITUTE [R01CA141078] Funding Source: NIH RePORTER	Schissler Foundation; Vietnam Education Foundation; US Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Schissler Foundation Fellowship (B Trinh), the Vietnam Education Foundation (B Trinh), the US Department of Defense grant W81XWH-06-1-0259 (H Naora) and the National Institutes of Health grant R01 CA141078 (H Naora). We thank Sabine Thonard for technical assistance, and Song Yi Ko, Gary Gallick, Michelle Barton, Janet Price, Peng Huang and Miles Wilkinson	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Bello-DeOcampo D, 2003, CURR DRUG TARGETS, V4, P197, DOI 10.2174/1389450033491118; Berghorn KA, 2006, J BIOL CHEM, V281, P20357, DOI 10.1074/jbc.M603049200; Boogerd KJ, 2008, CARDIOVASC RES, V78, P485, DOI 10.1093/cvr/cvn049; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chiba S, 2003, P NATL ACAD SCI USA, V100, P15577, DOI 10.1073/pnas.2536757100; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Francis-Thickpenny KM, 2001, BRIT J CANCER, V85, P687, DOI 10.1054/bjoc.2001.1950; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2; Haga SB, 2000, LEUKEMIA, V14, P1867, DOI 10.1038/sj.leu.2401912; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hara F, 2007, AM J PATHOL, V170, P1594, DOI 10.2353/ajpath.2007.061025; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hyman E, 2002, CANCER RES, V62, P6240; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Man YG, 2005, BREAST CANCER RES TR, V90, P241, DOI 10.1007/s10549-004-4492-9; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Nagatake M, 1996, CANCER RES, V56, P2718; Naora H, 2001, P NATL ACAD SCI USA, V98, P4060, DOI 10.1073/pnas.071594398; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Park GT, 2002, NUCLEIC ACIDS RES, V30, P515, DOI 10.1093/nar/30.2.515; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014; Schutte M, 1996, CANCER RES, V56, P2527; Schwartz AM, 2009, MODERN PATHOL, V22, P1, DOI 10.1038/modpathol.2008.168; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Takenoshita S, 1998, ONCOL REP, V5, P367; Takenoshita S, 1997, CARCINOGENESIS, V18, P1427, DOI 10.1093/carcin/18.7.1427; Tokunaga H, 1999, CLIN CANCER RES, V5, P2520; Tomida S, 2007, ONCOGENE, V26, P4600, DOI 10.1038/sj.onc.1210242; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Wang D, 2000, CANCER RES, V60, P4507; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Williams TM, 2005, NUCLEIC ACIDS RES, V33, P4475, DOI 10.1093/nar/gki761; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Yamada SD, 1999, GYNECOL ONCOL, V75, P72, DOI 10.1006/gyno.1999.5535; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	53	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2718	2729		10.1038/onc.2011.4	http://dx.doi.org/10.1038/onc.2011.4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21297662	Green Accepted			2022-12-17	WOS:000291678500003
J	Mochmann, LH; Bock, J; Ortiz-Tanchez, J; Schlee, C; Bohne, A; Neumann, K; Hofmann, WK; Thiel, E; Baldus, CD				Mochmann, L. H.; Bock, J.; Ortiz-Tanchez, J.; Schlee, C.; Bohne, A.; Neumann, K.; Hofmann, W. K.; Thiel, E.; Baldus, C. D.			Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG	ONCOGENE			English	Article						ETS-related gene (ERG); WNT11; acute leukemia; ERG target genes; 6-bromoindirubin-3-oxime (BIO); morphological transformation	ACUTE MYELOID-LEUKEMIA; EMBRYONIC STEM-CELLS; T-LYMPHOBLASTIC LEUKEMIA; PROSTATE-CANCER; FAMILY; EXPRESSION; DIFFERENTIATION; TUMORIGENESIS; OVEREXPRESSION; TRANSFORMATION	E26 transforming sequence-related gene (ERG) is a transcription factor involved in normal hematopoiesis and is dysregulated in leukemia. ERG mRNA overexpression was associated with poor prognosis in a subset of patients with T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Herein, a genome-wide screen of ERG target genes was conducted by chromatin immunoprecipitation-on-chip (ChIP-chip) in Jurkat cells. In this screen, 342 significant annotated genes were derived from this global approach. Notably, ERG-enriched targets included WNT signaling genes: WNT11, WNT2, WNT9A, CCND1 and FZD7. Furthermore, chromatin immunoprecipitation (ChIP) of normal and primary leukemia bone marrow material also confirmed WNT11 as a target of ERG in six of seven patient samples. A larger sampling of patient diagnostic material revealed that ERG and WNT11 mRNA were co-expressed in 80% of AML (n = 30) and 40% in T-ALL (n = 30) bone marrow samples. Small interfering RNA (siRNA)-mediated knockdown of ERG confirmed down-regulation of WNT11 transcripts. Conversely, in a tet-on ERG-inducible assay, WNT11 transcripts were co-stimulated. A WNT pathway agonist, 6-bromoindirubin-3-oxime (BIO), was used to determine the effect of cell growth on the ERG-inducible cells. The addition of BIO resulted in an ERG-dependent proliferative growth advantage over ERG-uninduced cells. Finally, ERG induction prompted morphological transformation whereby round unpolarized K562 cells developed elongated protrusions and became polarized. This morphological transformation could effectively be inhibited with BIO and with siRNA knockdown of WNT11. In conclusion, ERG transcriptional networks in leukemia converge on WNT signaling targets. Specifically, WNT11 emerged as a direct target of ERG. Potent ERG induction promoted morphological transformation through WNT11 signals. The findings in this study unravel new ERG-directed molecular signals that may contribute to the resistance of current therapies in acute leukemia patients with poor prognosis characterized by high ERG mRNA expression. Oncogene (2011) 30, 2044-2056; doi:10.1038/onc.2010.582; published online 17 January 2011	[Mochmann, L. H.; Bock, J.; Ortiz-Tanchez, J.; Schlee, C.; Bohne, A.; Thiel, E.; Baldus, C. D.] Charite, Dept Hematol & Oncol, D-12203 Berlin, Germany; [Neumann, K.] Charite, Inst Biometr & Clin Epidemiol, Berlin, Germany; [Hofmann, W. K.] Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg	Baldus, CD (corresponding author), Charite, Dept Hematol & Oncol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany.	claudia.baldus@charite.de			Deutsche Krebshilfe (Max Eder Nachwuchsforderung)	Deutsche Krebshilfe (Max Eder Nachwuchsforderung)(Deutsche Krebshilfe)	This study was supported by a grant from the Deutsche Krebshilfe (Max Eder Nachwuchsforderung) to CDB. We thank Dr Martin Neumann (Department of Hematology and Oncology, Charite, Berlin, Germany) for his critical reading of the manuscript. We also thank Dr Anja Kuhl (Research Center ImmunoSciences, Charite, Berlin, Germany) for helpful advice and fluorescence microscopy assistance.	Anderson MK, 1999, DEVELOPMENT, V126, P3131; Anton R, 2007, FEBS LETT, V581, P5247, DOI 10.1016/j.febslet.2007.10.012; Baldus CD, 2004, P NATL ACAD SCI USA, V101, P3915, DOI 10.1073/pnas.0400272101; Baldus CD, 2007, BRIT J HAEMATOL, V137, P387, DOI 10.1111/j.1365-2141.2007.06566.x; Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854; Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood-2007-08-105346; Bohne A, 2009, LEUKEMIA RES, V33, P817, DOI 10.1016/j.leukres.2008.11.012; Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141; CHIANG J, 2009, P NATL ACAD SCI USA, V106, P3396; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Eisenberg CA, 1997, DEVELOPMENT, V124, P525; Ellett F, 2009, MECH DEVELOP, V126, P220, DOI 10.1016/j.mod.2008.11.001; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Flaherty MP, 2008, TRENDS CARDIOVAS MED, V18, P260, DOI 10.1016/j.tcm.2008.12.001; GOMEZ JR, 2007, BLOOD, V109, P3462; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Holmes T, 2008, STEM CELLS, V26, P1288, DOI 10.1634/stemcells.2007-0600; Hu D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006640; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iwamoto M, 2007, DEV BIOL, V305, P40, DOI 10.1016/j.ydbio.2007.01.037; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Kong XT, 1997, BLOOD, V90, P1192; Lai SL, 2009, CELL RES, V19, P532, DOI 10.1038/cr.2009.41; LELINEK J, 2008, LEUKEMIA, V22, P1529; Lin ZH, 2007, CANCER RES, V67, P5017, DOI 10.1158/0008-5472.CAN-06-3696; Loughran SJ, 2008, NAT IMMUNOL, V9, P810, DOI 10.1038/ni.1617; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Marcucci G, 2005, J CLIN ONCOL, V23, P9234, DOI 10.1200/JCO.2005.03.6137; MARTIN V, 2009, CANCER SCI, V3, P1; Narod SA, 2008, BRIT J CANCER, V99, P847, DOI 10.1038/sj.bjc.6604558; O'Neil J, 2007, ONCOGENE, V26, P6838, DOI 10.1038/sj.onc.1210766; Rainis L, 2005, CANCER RES, V65, P7596, DOI 10.1158/0008-5472.CAN-05-0147; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shu JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008-5472.CAN-05-2629; Singla DK, 2006, BIOCHEM BIOPH RES CO, V345, P789, DOI 10.1016/j.bbrc.2006.04.125; Soda M, 2008, CELL SIGNAL, V20, P2317, DOI 10.1016/j.cellsig.2008.09.001; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Stankiewicz MJ, 2009, BLOOD, V113, P3337, DOI 10.1182/blood-2008-08-174813; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Uysal-Onganer P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-55; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; WU D, 2009, TREND BIOCH SCI, V722, P1; Zhou WL, 2007, NAT GENET, V39, P1225, DOI 10.1038/ng2112; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	50	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2044	2056		10.1038/onc.2010.582	http://dx.doi.org/10.1038/onc.2010.582			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21242973	Green Submitted			2022-12-17	WOS:000289977400008
J	Wu, SM; Huang, YH; Yeh, CT; Tsai, MM; Liao, CH; Cheng, WL; Chen, WJ; Lin, KH				Wu, S-M; Huang, Y-H; Yeh, C-T; Tsai, M-M; Liao, C-H; Cheng, W-L; Chen, W-J; Lin, K-H			Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells	ONCOGENE			English	Article						cysteine proteases; receptors; migration; hepatocellular carcinoma	LYSOSOMAL CYSTEINE PROTEASES; GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; EPITHELIAL-CELLS; PITUITARY-TUMOR; MOUSE MODEL; B ACTIVITY; V-ERBA; CANCER; EXPRESSION	Thyroid hormone, 3, 3', 5-triiodo-L-thyronine (T-3), mediates cell growth, development and differentiation by binding to its nuclear receptors (TRs). The role of TRs in cancer is still undefined. Notably, hyperthyroxinemia has been reported to influence the rate of colon cancer in an experimental model of carcinogenesis in rats. Previous microarray analysis revealed that cathepsin H (CTSH) is upregulated by T-3 in HepG2-TR cells. We verified that mRNA and protein expression of CTSH are induced by T3 in HepG2-TR cells and in thyroidectomized rats following administration of T-3. The possible thyroid hormone-responsive elements of the CTSH promoter localized to the nucleotides -2038 to -1966 and -1565 to -1501 regions. An in vitro functional assay showed that CTSH can increase metastasis. J7 cells overexpressing CTSH were inoculated into severe combined immune-deficient mice and these J7-CTSH mice displayed a greater metastatic potential than did J7-control mice. The clinicopathologic significance of CTSH expression in hepatocellular carcinoma (HCC) was also investigated. The CTSH overexpressing in HCC was associated with the presence of microvascular invasion (P = 0.037). The microvascular invasion characteristic is closely related to our in vitro characterization of CTSH function. Our results show that T-3-mediated upregulation of CTSH led to matrix metallopeptidase or extracellular signal-regulated kinase activation and increased cell migration. This study demonstrated that CTSH overexpression in a subset hepatoma may be TR dependent and suggests that this overexpression has an important role in hepatoma progression. Oncogene (2011) 30, 2057-2069; doi:10.1038/onc.2010.585; published online 10 January 2011	[Wu, S-M; Tsai, M-M; Liao, C-H; Cheng, W-L; Lin, K-H] Chang Gung Univ, Sch Med, Dept Biochem, Tao Yuan 333, Taiwan; [Huang, Y-H] Chang Gung Mem Hosp, Med Res Ctr, Tao Yuan, Taiwan; [Yeh, C-T] Chang Gung Med Ctr, Liver Res Unit, Taipei, Taiwan; [Tsai, M-M] Chang Gung Inst Technol, Dept Nursing, Tao Yuan, Taiwan; [Chen, W-J] Chang Gung Mem Hosp, Cardiovasc Div 1, Tao Yuan, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology; Chang Gung Memorial Hospital	Lin, KH (corresponding author), Chang Gung Univ, Sch Med, Dept Biochem, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	khlin@mail.cgu.edu.tw		Liao, Hsiang-Ruei/0000-0003-0843-4375	Chang-Gung University, Taoyuan, Taiwan [CMRPD 34013, NMRP 140511]; National Science Council of the Republic of China [NSC 94-2320-B-182-052]	Chang-Gung University, Taoyuan, Taiwan; National Science Council of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang-Gung University, Taoyuan, Taiwan (CMRPD 34013, NMRP 140511) and from the National Science Council of the Republic of China (NSC 94-2320-B-182-052).	Ando S, 2001, MOL ENDOCRINOL, V15, P1529, DOI 10.1210/me.15.9.1529; Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; Berdowska I, 2004, CLIN CHIM ACTA, V342, P41, DOI 10.1016/j.cccn.2003.12.016; Chamba A, 1996, J CLIN ENDOCR METAB, V81, P360, DOI 10.1210/jc.81.1.360; Chen RN, 2008, ENDOCRINOLOGY, V149, P3817, DOI 10.1210/en.2007-0989; Chen RN, 2008, CANCER RES, V68, P1697, DOI 10.1158/0008-5472.CAN-07-5492; Chiloeches A, 2008, MOL ENDOCRINOL, V22, P2466, DOI 10.1210/me.2008-0107; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; del Re EC, 2000, BRIT J CANCER, V82, P1317; Dickinson DP, 2002, CRIT REV ORAL BIOL M, V13, P238, DOI 10.1177/154411130201300304; GABRIJELCIC D, 1992, EUR J CLIN CHEM CLIN, V30, P69; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Hall LC, 2008, J STEROID BIOCHEM, V109, P57, DOI 10.1016/j.jsbmb.2007.12.008; Hassan MM, 2009, HEPATOLOGY, V49, P1563, DOI 10.1002/hep.22793; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang YH, 2010, J CELL PHYSIOL, V222, P347, DOI 10.1002/jcp.21959; Huang Ya-Hui, 2008, Chang Gung Med J, V31, P325; Huang YH, 2006, ENDOCRINOLOGY, V147, P2481, DOI 10.1210/en.2005-1166; Joyce JA, 2004, CELL CYCLE, V3, P1516, DOI 10.4161/cc.3.12.1289; Kos J, 1997, CLIN CANCER RES, V3, P1815; Kress E, 2010, GASTROENTEROLOGY, V138, P1863, DOI 10.1053/j.gastro.2010.01.041; Kress E, 2009, J BIOL CHEM, V284, P1234, DOI 10.1074/jbc.M806548200; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liao CS, 2009, MOL CELL ENDOCRINOL, V307, P109, DOI 10.1016/j.mce.2009.04.013; Lin KH, 2000, ENDOCRINOLOGY, V141, P2540, DOI 10.1210/en.141.7.2540; Lin KH, 2001, ENDOCRINOLOGY, V142, P653, DOI 10.1210/en.142.2.653; Martinez-Iglesias O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006428; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nelson D, 2006, J LEUKOCYTE BIOL, V80, P685, DOI 10.1189/jlb.1105646; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Plateroti M, 2006, MOL CELL BIOL, V26, P3204, DOI 10.1128/MCB.26.8.3204-3214.2006; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Rosen MD, 2009, MOL ENDOCRINOL, V23, P1183, DOI 10.1210/me.2009-0126; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Schraufstatter IU, 2003, J IMMUNOL, V171, P6714, DOI 10.4049/jimmunol.171.12.6714; Shih CH, 2004, ENDOCRINOLOGY, V145, P2804, DOI 10.1210/en.2003-1372; Sivaparvathi M, 1996, CANCER LETT, V104, P121, DOI 10.1016/0304-3835(96)04242-5; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Teranishi S, 2009, INVEST OPHTH VIS SCI, V50, P5646, DOI 10.1167/iovs.08-2534; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tsui KH, 2008, PROSTATE, V68, P610, DOI 10.1002/pros.20725; TSUSHIMA H, 1991, INT J CANCER, V48, P726, DOI 10.1002/ijc.2910480516; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Wilson TJ, 2008, BBA-REV CANCER, V1785, P85, DOI 10.1016/j.bbcan.2007.11.001; Wu SM, 2010, CELL MOL LIFE SCI, V67, P1831, DOI 10.1007/s00018-010-0281-2; Yang H, 1999, ENDOCRINOLOGY, V140, P43, DOI 10.1210/en.140.1.43; Yang L, 2008, CANCER RES, V68, P9107, DOI 10.1158/0008-5472.CAN-08-2556; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; YEN PM, 1994, J BIOL CHEM, V269, P903; Zhu XG, 2010, ONCOGENE, V29, P1909, DOI 10.1038/onc.2009.476	52	29	30	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2057	2069		10.1038/onc.2010.585	http://dx.doi.org/10.1038/onc.2010.585			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21217776				2022-12-17	WOS:000289977400009
J	Cheng, JC; Auersperg, N; Leung, PCK				Cheng, J-C; Auersperg, N.; Leung, P. C. K.			Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin	ONCOGENE			English	Article						serous borderline ovarian tumors; p53; ovarian cancer; invasion; E-cadherin	EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN CANCERS; PIK3CA GENE; LOW-GRADE; EXPRESSION; MUTATIONS; TRANSCRIPTION; INVASIVENESS; CARCINOMAS; KINASE	Serous borderline ovarian tumors (SBOTs) are slow-growing, non-invasive ovarian epithelial neoplasms. SBOTs are considered to be distinct entities that give rise to invasive low-grade serous carcinomas (LGCs), which have a relatively poor prognosis and are unrelated to high-grade serous carcinomas (HGCs). The mechanisms underlying the progression of non-invasive SBOTs to invasive epithelial ovarian carcinomas are not understood. We recently established short-term cultures of SBOT cells from tumor biopsies and showed that inactivation of p53, retinoblastoma (Rb) and/or PP2A by the simian virus 40 (SV40) large (LT) and small T antigens extends the life span of the cells and endows them with the ability to invade Matrigel-coated transwells. In this study, we show that concurrent inhibition of p53 and Rb by the SV40 LT produces cells (referred to as SBOT4-LT) with increased life span and cell invasion. To distinguish the roles of p53 and Rb in the progression from SBOTs to invasive ovarian carcinomas, we performed small interfering RNA-mediated knockdown of endogenous p53 in a spontaneously immortalized SBOT cell line, SBOT3.1, which increased cell invasion. This increased invasive activity was associated with the transcriptional downregulation of E-cadherin, correlated with an increase in PIK3CA levels and the increased activation of Akt. Conversely, in invasive LGC-derived MPSC1 cells, enhancing the levels of p53 decreased cell invasion and diminished the phosphatidylinositol 3-kinase (PI3K)/Akt-mediated downregulation of E-cadherin. Inhibition of Rb also enhanced invasiveness, but did not affect the levels of PIK3CA and E-cadherin in SBOT3.1 cells, suggesting that it functions by a different pathway. To our knowledge, this study is the first to show that p53 has an important role in the progression from SBOTs to invasive carcinomas. In addition, our findings suggest that downregulation of E-cadherin by the PI3K/Akt pathway contributes to this progression. Oncogene (2011) 30, 1020-1031; doi:10.1038/onc.2010.486; published online 25 October 2010	[Cheng, J-C; Auersperg, N.; Leung, P. C. K.] Univ British Columbia, Dept Obstet & Gynecol, Child & Family Res Inst, Vancouver, BC V6H 3V5, Canada	Child & Family Research Institute; University of British Columbia	Leung, PCK (corresponding author), Univ British Columbia, Dept Obstet & Gynaecol, Room 2H-30,4490 Oak St, Vancouver, BC V6H 3V5, Canada.	peleung@interchange.ubc.ca	Cheng, Jung-Chien/T-4258-2019	Cheng, Jung-Chien/0000-0002-5399-9327; Leung, Peter/0000-0003-3152-3800	National Cancer Institute of Canada; Canadian Cancer Society; Canadian Institutes of Health Research	National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by grants from the National Cancer Institute of Canada, with funds from the Canadian Cancer Society to NA and Canadian Institutes of Health Research to PCKL. We thank Dr David Huntsman and Winnie Yang (Centre for Translational and Applied Genomics, BC Cancer Agency) for providing the sequence data. We thank Dr Ie-Ming Shih (Department of Pathology, Johns Hopkins Medical Institutions) for providing the MPSC1 cells. We greatly appreciate the advice and help of Drs Christian Klausen and Michelle Woo.	Arima Y, 2008, CANCER RES, V68, P5104, DOI 10.1158/0008-5472.CAN-07-5680; Astanehe A, 2008, J CELL SCI, V121, P664, DOI 10.1242/jcs.013029; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bonome T, 2005, CANCER RES, V65, P10602, DOI 10.1158/0008-5472.CAN-05-2240; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Gershenson DM, 1998, CANCER, V83, P2157, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D; Grille SJ, 2003, CANCER RES, V63, P2172; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Parker RL, 2004, INT J GYNECOL PATHOL, V23, P265, DOI 10.1097/01.pgp.0000130049.19643.f6; Pohl G, 2005, CANCER RES, V65, P1994, DOI 10.1158/0008-5472.CAN-04-3625; Roger L, 2010, J CELL SCI, V123, P1295, DOI 10.1242/jcs.061002; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shih IM, 2005, CLIN CANCER RES, V11, P7273, DOI 10.1158/1078-0432.CCR-05-0755; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Woo MMM, 2008, INT J GYNECOL CANCER, V18, P1234, DOI 10.1111/j.1525-1438.2007.01171.x; Woo MM, 2008, GYNECOL ONCOL, V111, P125, DOI 10.1016/j.ygyno.2008.06.021; Woo MMM, 2007, IN VITRO CELL DEV-AN, V43, P7, DOI 10.1007/s11626-006-9002-4; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhao RB, 2000, GENE DEV, V14, P981	35	29	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1020	1031		10.1038/onc.2010.486	http://dx.doi.org/10.1038/onc.2010.486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	20972462				2022-12-17	WOS:000287964100002
J	Jang, MS; Lee, SJ; Kim, CJ; Lee, CW; Kim, E				Jang, M-S; Lee, S-J; Kim, C-J; Lee, C-W; Kim, E.			Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADD	ONCOGENE			English	Article						FADD; Plk1; phosphorylation; tumor suppressor; negative feedback	FAS-ASSOCIATED PROTEIN; NECROTIC CELL-DEATH; INDUCED APOPTOSIS; CANCER-CELLS; SIGNALING PATHWAY; FACTOR-I; DOMAIN; PLK1; INHIBITOR; EXPRESSION	Phosphorylation of the Fas-associated death domain (FADD) protein sensitizes cancer cells to various chemotherapeutics. However, the molecular mechanism underlying chemosensitization by phosphorylated FADD (P-FADD) is poorly understood. In this study, we describe the physical interactions and functional interplay between Polo-like kinase 1 (Plk1) and FADD. Plk1 phosphorylates FADD at Ser-194 in response to treatment with taxol. Overexpression of a phosphorylation-mimicking mutant, FADD S194D, caused degradation of Plk1 in an ubiquitin-independent manner, and delayed cytokinesis, consistent with the expected cellular phenotype of Plk1 deficiency. This demonstrates that Plk1 is regulated via a negative feedback loop by its substrate, FADD. Overexpression of FADD S194D sensitized HeLa cells to a low dose of taxol independently of caspase activation, whereas overexpression of FADD S194D resulted in caspase activation in response to a high dose of taxol. Therefore, we examined whether the death potential of P-FADD affected Plk1-mediated tumorigenesis. Transfection of FADD S194D inhibited colony formation by Plk1-overexpressing HeLa cells (HeLa-Plk1). Moreover, overexpression of FADD S194D suppressed tumorigenesis in nude mice xenografted with HeLa-Plk1. Therefore, this study reports the first in vivo validation of tumor-suppressing activity of P-FADD. Collectively, our data demonstrate that in response to taxol, Plk1 endows death-promoting and tumor-suppressor functions to its substrate, FADD. Oncogene (2011) 30, 471-481; doi: 10.1038/onc.2010.423; published online 4 October 2010	[Jang, M-S; Lee, S-J; Kim, E.] Chungnam Natl Univ, Coll Biol Sci & Biotechnol, Taejon 305764, South Korea; [Kim, C-J] Chungnam Natl Univ, Coll Vet Med, Taejon 305764, South Korea; [Lee, C-W] Sungkyunkwan Univ, Dept Mol Cell Biol, Sch Med, Suwon, South Korea; [Kim, E.] Chungnam Natl Univ, Daedeok R&D Innopolis Bio Brain Ctr BK21, Taejon 305764, South Korea	Chungnam National University; Chungnam National University; Sungkyunkwan University (SKKU); Chungnam National University	Kim, E (corresponding author), Chungnam Natl Univ, Coll Biol Sci & Biotechnol, 220 Gung Dong, Taejon 305764, South Korea.	eunhee@cnu.ac.kr	ê, ìí/F-5894-2013	Kim, Chul-Joong/0000-0001-8827-6332	21C Frontier Functional Human Genome Project [FG09-21-02]; Center for Biological Modulators [CMB34-A2300-01-00-00]; National Research foundation at the Ministry of Education, Science and Technology in Korea [2009-0093957]	21C Frontier Functional Human Genome Project(Ministry of Education, Science & Technology (MEST), Republic of Korea); Center for Biological Modulators(Ministry of Education, Science & Technology (MEST), Republic of Korea); National Research foundation at the Ministry of Education, Science and Technology in Korea	This work was supported by a grant (FG09-21-02) from the 21C Frontier Functional Human Genome Project, by a grant (CMB34-A2300-01-00-00) from the Center for Biological Modulators of the 21st Century Frontier R&D Program and by the National Research foundation (2009-0093957) at the Ministry of Education, Science and Technology in Korea. We thank Dr Soojin Lee (Department of Microbiology, Chungnam National University, Daejeon, Korea) for assistance with the colony formation studies, and Byung-Jung Choi (Medical Genomics Research Center, KRIBB, Daejeon, Korea) for assistance with the FPLC.	Alappat EC, 2005, MOL CELL, V19, P321, DOI 10.1016/j.molcel.2005.06.024; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Eckerdt F, 2006, CANCER RES, V66, P6895, DOI 10.1158/0008-5472.CAN-06-0358; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Gilmartin AG, 2009, CANCER RES, V69, P6969, DOI 10.1158/0008-5472.CAN-09-0945; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Jang MS, 2008, J BIOL CHEM, V283, P32344, DOI 10.1074/jbc.M804199200; Jariel-Encontre I, 2008, BBA-REV CANCER, V1786, P153, DOI 10.1016/j.bbcan.2008.05.004; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Krelin Y, 2008, CELL DEATH DIFFER, V15, P1350, DOI 10.1038/cdd.2008.88; Lahav G, 2008, ADV EXP MED BIOL, V641, P28; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Lu LY, 2008, MOL CELL BIOL, V28, P6870, DOI 10.1128/MCB.00392-08; Luschen S, 2005, EXP CELL RES, V310, P33, DOI 10.1016/j.yexcr.2005.07.022; Matsuyoshi S, 2006, BRIT J CANCER, V94, P532, DOI 10.1038/sj.bjc.6602955; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Park MY, 2005, INT J CANCER, V115, P412, DOI 10.1002/ijc.20857; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Preisinger C, 2005, EMBO J, V24, P753, DOI 10.1038/sj.emboj.7600569; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Shimada K, 2005, J PATHOL, V206, P423, DOI 10.1002/path.1791; Shimada K, 2004, CARCINOGENESIS, V25, P1089, DOI 10.1093/carcin/bgh130; Shimada K, 2002, JPN J CANCER RES, V93, P1164, DOI 10.1111/j.1349-7006.2002.tb01219.x; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Xu H, 2009, CANCER INVEST, V27, P836, DOI 10.1080/07357900902849681; Yamaguchi H, 2006, MOL CELL BIOL, V26, P569, DOI 10.1128/MCB.26.2.569-579.2006; Yamaguchi T, 2005, J CELL BIOL, V171, P431, DOI 10.1083/jcb.200504091; Yang Qin, 2005, Ai Zheng, V24, P321; Yoo NJ, 2007, PATHOL RES PRACT, V203, P73, DOI 10.1016/j.prp.2006.11.002; Zhande R, 2007, MOL CELL BIOL, V27, P7394, DOI 10.1128/MCB.00600-07; Zhang J, 2009, CANCER BIOL THER, V8, P2374, DOI 10.4161/cbt.8.24.10182; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	50	29	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					471	481		10.1038/onc.2010.423	http://dx.doi.org/10.1038/onc.2010.423			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20890306				2022-12-17	WOS:000286621600009
J	Fu, J; Yan, P; Li, S; Qu, Z; Xiao, G				Fu, J.; Yan, P.; Li, S.; Qu, Z.; Xiao, G.			Molecular determinants of PDLIM2 in suppressing HTLV-I Tax-mediated tumorigenesis	ONCOGENE			English	Article						HTLV-I; Tax; PDLIM2; protein shuttling; protein degradation; tumorigenesis	T-CELL LEUKEMIA; VIRUS TYPE-I; NF-KAPPA-B; DOMAIN-CONTAINING PROTEIN-2; 1ST HUMAN RETROVIRUS; TRANSGENIC MICE; DNA METHYLATION; TYPE-1; GENE; TRANSFORMATION	Human T-cell leukemia virus type I (HTLV-I) encodes a Tax oncoprotein that has crucial roles in both virus replication and cell transformation. Our recent studies suggest that the counterbalance between HTLV-I/Tax and PDZ-LIM domain-containing protein PDLIM2 may determine the outcome of HTLV-I infection. Although HTLV-I represses PDLIM2 epigenetically and specifically in transformed cells, PDLIM2 shuttles Tax into the nuclear matrix for ubiquitination-mediated proteasomal degradation, thereby suppressing the transforming ability of HTLV-I. Here, we have further shown that PDLIM2 binds to Tax directly, which was mediated by a putative a-helix motif of PDLIM2 at amino acids 236-254. Consistently, selective disruption of this short-helix crippled PDLIM2 in shutting Tax to the nuclear matrix for ubiquitination-mediated degradation, therefore, PDLIM2 lost the ability in tumor suppression. Although the C-terminal LIM domain of PDLIM2 was not required for Tax binding, it was important for PDLIM2 to interact with the nuclear matrix. Accordingly, the LIM domain was essential for PDLIM2-mediated Tax repression. On the contrary, the N-terminal PDZ domain of PDLIM2 was dispensable for all these events, although the PDZ domain was involved in PDLIM2 binding to cytoskeleton. These studies dissect functional sequences within PDLIM2 and their distinct roles in Tax regulation. Oncogene (2010) 29, 6499-6507; doi:10.1038/onc.2010.374; published online 13 September 2010	[Xiao, G.] Univ Pittsburgh, Inst Canc, Dept Microbiol & Mol Genet, Hillman Canc Ctr Res Pavil,Sch Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xiao, G (corresponding author), Univ Pittsburgh, Inst Canc, Dept Microbiol & Mol Genet, Hillman Canc Ctr Res Pavil,Sch Med, 5117 Ctr Ave, Pittsburgh, PA 15213 USA.	xiaog2@upmc.edu	Fu, Jing/C-7921-2016; Yan, Pengrong/H-1150-2012; fu, jing/G-6084-2012	Fu, Jing/0000-0002-3894-722X; Yan, Pengrong/0000-0003-0021-6461	NIH/NCI [R01 CA116616]; ACS [RSG-06-066-01-MGO]; NATIONAL CANCER INSTITUTE [R01CA116616] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank N Raab-Traub for Rat-1 cells, OJ Semmes for Tax-GFP mutants, and NIH AIDS Research & Reference Reagent Program for various reagents. This study was supported by NIH/NCI Grant R01 CA116616 and ACS Grant RSG-06-066-01-MGO to G Xiao.	AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Fryrear KA, 2009, J VIROL, V83, P5339, DOI 10.1128/JVI.00232-09; Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Kwon H, 2005, J BIOL CHEM, V280, P35713, DOI 10.1074/jbc.M504848200; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OKA T, 1992, J VIROL, V66, P6686, DOI 10.1128/JVI.66.11.6686-6694.1992; PEEBLES RS, 1995, ONCOGENE, V10, P1045; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Qing GL, 2005, J BIOL CHEM, V280, P18, DOI 10.1074/jbc.M406619200; Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104; Qu ZX, 2010, CANCER RES, V70, P1766, DOI 10.1158/0008-5472.CAN-09-3263; Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561; Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200; Radivojac P, 2007, BIOPHYS J, V92, P1439, DOI 10.1529/biophysj.106.094045; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tanaka T, 2005, IMMUNITY, V22, P729, DOI 10.1016/j.immuni.2005.04.008; Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464; Torrado M, 2004, INVEST OPHTH VIS SCI, V45, P3955, DOI 10.1167/iovs.04-0721; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xiao GT, 2006, CYTOKINE GROWTH F R, V17, P281, DOI 10.1016/j.cytogfr.2006.04.005; YAMAOKA S, 1992, ONCOGENE, V7, P43; Yan PR, 2009, NEOPLASIA, V11, P1036, DOI 10.1593/neo.09752; Yan PR, 2009, BLOOD, V113, P4370, DOI 10.1182/blood-2008-10-185660; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981	35	29	29	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	49					6499	6507		10.1038/onc.2010.374	http://dx.doi.org/10.1038/onc.2010.374			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20838382	Green Accepted			2022-12-17	WOS:000285138900009
J	Suraneni, MV; Schneider-Broussard, R; Moore, JR; Davis, TC; Maldonado, CJ; Li, H; Newman, RA; Kusewitt, D; Hu, J; Yang, P; Tang, DG				Suraneni, M. V.; Schneider-Broussard, R.; Moore, J. R.; Davis, T. C.; Maldonado, C. J.; Li, H.; Newman, R. A.; Kusewitt, D.; Hu, J.; Yang, P.; Tang, D. G.			Transgenic expression of 15-lipoxygenase 2 (15-LOX2) in mouse prostate leads to hyperplasia and cell senescence	ONCOGENE			English	Article						15-lipoxygenase 2; prostate; hyperplasia; senescence; tumor suppression; stem cells	FUNCTIONAL TUMOR-SUPPRESSOR; ACTIVATED RECEPTOR-GAMMA; HUMAN BREAST-CANCER; INTRAEPITHELIAL NEOPLASIA; STEM-CELL; ELEVATED EXPRESSION; EPITHELIAL-CELLS; PROGENITOR CELLS; GENE-EXPRESSION; IN-VITRO	15-Lipoxygenase 2 (15-LOX2), a lipid-peroxidizing enzyme, is mainly expressed in the luminal compartment of the normal human prostate, and is often decreased or lost in prostate cancer. Previous studies from our lab implicate 15-LOX2 as a functional tumor suppressor. To better understand the biological role of 15-LOX2 in vivo, we generated prostate-specific 15-LOX2 transgenic mice using the ARR2PB promoter. Unexpectedly, transgenic expression of 15-LOX2 or 15-LOX2sv-b, a splice variant that lacks arachidonic acid-metabolizing activity, resulted in age-dependent prostatic hyperplasia and enlargement of the prostate. Prostatic hyperplasia induced by both 15-LOX2 and 15-LOX2sv-b was associated with an increase in luminal and Ki-67(+) cells; however, 15-LOX2-transgenic prostates also showed a prominent increase in basal cells. Microarray analysis revealed distinct gene expression profiles that could help explain the prostate phenotypes. Strikingly, 15-LOX2, but not 15-LOX2sv-b, transgenic prostate showed upregulation of several well-known stem or progenitor cell molecules including Sca-1, Trop2, p63, Nkx3.1 and Psca. Prostatic hyperplasia caused by both 15-LOX2 and 15-LOX2sv-b did not progress to prostatic intraprostate neoplasia or carcinoma and, mechanistically, prostate lobes (especially those of 15-LOX2 mice) showed a dramatic increase in senescent cells as revealed by increased SA-beta gal, p27(Kip1) and heterochromatin protein 1 gamma staining. Collectively, our results suggest that 15-LOX2 expression in mouse prostate leads to hyperplasia and also induces cell senescence, which may, in turn, function as a barrier to tumor development. Oncogene (2010) 29, 4261-4275; doi: 10.1038/onc.2010.197; published online 31 May 2010	[Suraneni, M. V.; Schneider-Broussard, R.; Moore, J. R.; Davis, T. C.; Maldonado, C. J.; Li, H.; Kusewitt, D.; Tang, D. G.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; [Newman, R. A.; Yang, P.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Hu, J.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Tang, D. G.] Univ Texas Grad Sch Biomed Sci, Program Mol Carcinogenesis, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tang, DG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, 1808 Pk Rd,1C, Smithville, TX 78957 USA.	dtang@mdanderson.org	Tang, Dean/AAI-3457-2020; Kusewitt, Donna F/E-8107-2011	Tang, Dean/0000-0001-5029-1174; 	NIH [R01-AG023374, R01-ES015888, R21-ES015893-01A1]; American Cancer Society [RSG MGO-105961]; Department of Defense [W81XWH-07-1-0616, W81XWH-08-1-0472]; Elsa Pardee Foundation; Center Grants [CCSG-5 P30 CA016672, ES07784]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES015893, P30ES007784, R01ES015888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023374] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Department of Defense(United States Department of Defense); Elsa Pardee Foundation; Center Grants; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr R Matusik (Vanderbilt University) for providing the ARR2PB promoter, D Holowell for transgenic studies, Dr H Thames and K Lin for assistance in statistics, the Histology Core for help in IHC, Animal Facility Core for animal-related experiments, Molecular Biology Core, especially J Repass, for assistance in qPCR analysis, C Perez for assistance in LCM, S Gaddis, L Shen and S Tsavachidis for assistance in microarray analysis, Drs S Fischer and C Jeter for critically reading the paper and other members of the Tang lab for support and helpful discussions. This work was supported in part by grants from NIH (R01-AG023374, R01-ES015888 and R21-ES015893-01A1), American Cancer Society (RSG MGO-105961), Department of Defense (W81XWH-07-1-0616 and W81XWH-08-1-0472) and Elsa Pardee Foundation (DGT) and by two Center Grants (CCSG-5 P30 CA016672 and ES07784).	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Allred DC, 1998, MODERN PATHOL, V11, P155; Bhatia B, 2005, ONCOGENE, V24, P3583, DOI 10.1038/sj.onc.1208406; Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Bhatia B, 2008, J BIOL CHEM, V283, P27957, DOI 10.1074/jbc.M803467200; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Chano T, 2002, ONCOGENE, V21, P1295, DOI 10.1038/sj.onc.1205178; Chen GG, 2003, INT J CANCER, V107, P837, DOI 10.1002/ijc.11447; Chen X, 2009, DIFFERENTIATION, V77, P324, DOI 10.1016/j.diff.2008.10.011; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Dillner K, 2003, ENDOCRINOLOGY, V144, P4955, DOI 10.1210/en.2003-0415; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fang H, 2009, METHODS MOL BIOL, V563, P379, DOI 10.1007/978-1-60761-175-2_20; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; Gonzalez AL, 2004, HUM PATHOL, V35, P840, DOI 10.1016/j.humpath.2004.04.001; Ibaragi S, 2009, MOL CANCER RES, V7, P415, DOI 10.1158/1541-7786.MCR-08-0137; Ikebuchi K, 2009, INT J CANCER, V125, P861, DOI 10.1002/ijc.24466; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P235, DOI 10.1016/j.plefa.2006.01.009; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287; Kasper S, 1998, LAB INVEST, V78, pI; Katona TM, 2005, CLIN CANCER RES, V11, P8358, DOI 10.1158/1078-0432.CCR-05-0962; Kelavkar UP, 2006, NEOPLASIA, V8, P510, DOI 10.1593/neo.06202; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Kim E, 2005, ONCOGENE, V24, P1174, DOI 10.1038/sj.onc.1208269; Kindblom J, 2003, ENDOCRINOLOGY, V144, P2269, DOI 10.1210/en.2002-0187; Lawson DA, 2007, J CLIN INVEST, V117, P2044, DOI 10.1172/JCI32810; Mahipal SVK, 2007, BIOCHEM PHARMACOL, V74, P202, DOI 10.1016/j.bcp.2007.04.005; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Masumori N, 2001, CANCER RES, V61, P2239; Melkoumian ZK, 2005, CANCER RES, V65, P6676, DOI 10.1158/0008-5472.CAN-04-4142; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Schweiger D, 2007, J LIPID RES, V48, P553, DOI 10.1194/jlr.M600311-JLR200; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shappell SB, 2003, CANCER RES, V63, P2256; Shappell SB, 2001, J INVEST DERMATOL, V117, P36, DOI 10.1046/j.1523-1747.2001.01378.x; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Spindler SA, 1997, BIOCHEM BIOPH RES CO, V239, P775, DOI 10.1006/bbrc.1997.7471; Subbarayan V, 2006, ONCOGENE, V25, P6015, DOI 10.1038/sj.onc.1209617; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; Tang DG, 2007, PROSTAG OTH LIPID M, V82, P135, DOI 10.1016/j.prostaglandins.2006.05.022; Tang DG, 2007, MOL CARCINOGEN, V46, P1, DOI 10.1002/mc.20255; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Tang Y, 2009, INT J CANCER, V124, P1545, DOI 10.1002/ijc.24118; Tran CP, 2002, MOL CANCER RES, V1, P113; Wang D, 2006, TUMOR BIOL, V27, P261, DOI 10.1159/000094761; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Xu XC, 2003, NEOPLASIA, V5, P121, DOI 10.1016/S1476-5586(03)80003-9; Yoshioka N, 2006, P NATL ACAD SCI USA, V103, P14519, DOI 10.1073/pnas.0606708103; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698	54	29	30	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4261	4275		10.1038/onc.2010.197	http://dx.doi.org/10.1038/onc.2010.197			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20514017	Green Accepted			2022-12-17	WOS:000280547900003
J	Jeffery, JM; Urquhart, AJ; Subramaniam, VN; Parton, RG; Khanna, KK				Jeffery, J. M.; Urquhart, A. J.; Subramaniam, V. N.; Parton, R. G.; Khanna, K. K.			Centrobin regulates the assembly of functional mitotic spindles	ONCOGENE			English	Article						Centrobin; mitosis; mitotic spindle; spindle assembly checkpoint	CENTROSOME INTEGRITY; CG-NAP; CHECKPOINT; PROTEIN; PHOSPHORYLATION; ANAPHASE; NEK2; NIP2/CENTROBIN; ORGANIZATION; SUBSTRATE	The proper function of the spindle is crucial to the high fidelity of chromosome segregation and is indispensable for tumor suppression in humans. Centrobin is a recently identified centrosomal protein that has a role in stabilizing the microtubule structure. Here we functionally characterize the defects in centrosome integrity and spindle assembly in Centrobin-depleted cells. Centrobin-depleted cells show a range of spindle abnormalities including unfocused poles that are not associated with centrosomes, S-shaped spindles and mini spindles. These cells undergo mitotic arrest and subsequently often die by apoptosis, as determined by live cell imaging. Co-depletion of Mad2 relieves the mitotic arrest, indicating that cells arrest due to a failure to silence the spindle checkpoint in metaphase. Consistent with this, Centrobin-depleted metaphase cells stained positive for BubR1 and BubR1 S676. Staining with a panel of centrosome markers showed a loss of centrosome anchoring to the mitotic spindle. Furthermore, these cells show less cold-stable microtubules and a shorter distance between kinetochore pairs. These results show a requirement of Centrobin in maintaining centrosome integrity, which in turn promotes anchoring of mitotic spindle to the centrosomes. Furthermore, this anchoring is required for the stability of microtubule-kinetochore attachments and biogenesis of tension-ridden and properly functioning mitotic spindle. Oncogene (2010) 29, 2649-2658; doi:10.1038/onc.2010.37; published online 1 March 2010	[Jeffery, J. M.; Urquhart, A. J.; Khanna, K. K.] Queensland Inst Med Res, Signal Transduct Lab, Canc & Cell Biol Div, Brisbane, Qld 4006, Australia; [Subramaniam, V. N.] Queensland Inst Med Res, Membrane Transport Lab, Canc & Cell Biol Div, Brisbane, Qld 4006, Australia; [Parton, R. G.] Univ Queensland, Mol Cell Biol Div, Inst Mol Biosci, Brisbane, Qld, Australia; [Parton, R. G.] Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland	Khanna, KK (corresponding author), Queensland Inst Med Res, Signal Transduct Lab, Canc & Cell Biol Div, 300 Herston Rd, Brisbane, Qld 4006, Australia.	kumkum.khanna@qimr.edu.au	Parton, Robert G/C-5673-2009; Khanna, Kum Kum/I-1747-2013; Subramaniam, V. Nathan/A-1901-2010	Parton, Robert G/0000-0002-7494-5248; Subramaniam, V. Nathan/0000-0002-4583-7790; Khanna, Kum Kum/0000-0001-8650-5381	National Health and Research Council of Australia	National Health and Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Sabine Elowe for the BubR1 S676 antibody, Duane Compton for the NuMA antibody, Andreas Merdes for the PCM1 antibody, Yoshitaka Ono for CG-NAP nd Kendrin antibodies, and Kunsoo Rhee for the myc-Centrobin constructs. We also thank Randy Poon and Uttam Surana for critical reading of the article and helpful suggestions. This work is supported in part by Program grant from the National Health and Research Council of Australia (K Khanna).	Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Casenghi M, 2005, J CELL SCI, V118, P5101, DOI 10.1242/jcs.02622; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; Emdad L, 2005, FRONT BIOSCI-LANDMRK, V10, P728; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Jeong Y, 2007, J CELL SCI, V120, P2106, DOI 10.1242/jcs.03458; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Lampson MA, 2005, NAT CELL BIOL, V7, P93, DOI 10.1038/ncb1208; Lawo S, 2009, CURR BIOL, V19, P816, DOI 10.1016/j.cub.2009.04.033; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Morrison EE, 2001, EUR J CELL BIOL, V80, P749, DOI 10.1078/0171-9335-00221; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Oshimori N, 2006, NAT CELL BIOL, V8, P1095, DOI 10.1038/ncb1474; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Roh M, 2003, CANCER RES, V63, P8079; Shimizu H, 2009, J CELL SCI, V122, P3145, DOI 10.1242/jcs.052795; Sonn S, 2009, MOL REPROD DEV, V76, P587, DOI 10.1002/mrd.20990; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tang CJC, 2009, NAT CELL BIOL, V11, P825, DOI 10.1038/ncb1889; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Zou CZ, 2005, J CELL BIOL, V171, P437, DOI 10.1083/jcb.200506185	32	29	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2649	2658		10.1038/onc.2010.37	http://dx.doi.org/10.1038/onc.2010.37			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190801				2022-12-17	WOS:000277354600005
J	Kim, YM; Geiger, TR; Egan, DI; Sharma, N; Nyborg, JK				Kim, Y-M; Geiger, T. R.; Egan, D. I.; Sharma, N.; Nyborg, J. K.			The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription	ONCOGENE			English	Article						CRE; cell cycle; transducer of regulated CREB; CREB-regulated transcription co-activator; CRTC	LEUKEMIA-VIRUS TYPE-1; NF-KAPPA-B; ELEMENT-BINDING PROTEIN; CAMP-RESPONSIVE ELEMENT; I TAX; COACTIVATOR CBP; GENE-EXPRESSION; T-CELLS; MOLECULAR CHARACTERIZATION; TRANSACTIVATOR TAX	Adult T-cell leukemia/lymphoma is a fatal malignancy etiologically linked to infection with the human T-cell leukemia virus (HTLV-1). The virally encoded oncoprotein Tax activates the transcription of HTLV-1 and cellular genes by cooperating with cellular transcription factors. Cyclin D1 is a pivotal regulator of cell cycle progression, and increased expression strongly correlates with malignant transformation. Here, we characterize the mechanism of Tax transactivation of cyclin D1. We find that cyclin D1 transcript levels are elevated in HTLV-1 infected cells and that Tax physically associates with the cyclin D1 gene in vivo. Tax binds the cyclin D1 promoter-proximal cyclic AMP response element (CRE) in the presence of phosphorylated CREB (pCREB) in vitro, and together the Tax-pCREB complex recruits the cellular co-activator p300 to the promoter through this unconventional Tax-responsive element. We further show that the transducer of regulated CREB 2 (TORC2) cooperates with Tax to further enhance p300 recruitment to the cyclin D1 promoter in vitro. Tax and TORC2 in combination stimulate cyclin D1 expression in vivo, demonstrating the functional outcome of the binding interactions. Together, our findings support a model in which Tax-induced accumulation of cyclin D1 shortens the G1 phase of the cell cycle, promotes mitotic replication of the virus, and drives selection and expansion of malignant T-cells. Oncogene (2010) 29, 2142-2152; doi: 10.1038/onc.2009.498; published online 25 January 2010	[Kim, Y-M; Geiger, T. R.; Egan, D. I.; Sharma, N.; Nyborg, J. K.] Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Campus Box 1870, Ft Collins, CO 80523 USA.	Jennifer.Nyborg@ColoState.Edu			National Institutes of Health [CA055035]; NATIONAL CANCER INSTITUTE [R55CA055035, R01CA055035] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs R Pestell (Thomas Jefferson University, Philadelphia, PA, USA) and A Baldwin (University of North Carolina, Chapel Hill, NC, USA) for the cyclin D1 luciferase constructs, and DY Jin (University of Hong Kong, Pokfulam, Hong Kong) for the TORC expression plasmids. We also thank Sarah Horstmann for helping with TORC2 cloning and expression and Holli Giebler for critical reading of the manuscript. This work was supported by a grant from the National Institutes of Health (CA055035).	Afonso PV, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-27; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; de la Fuente C, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-43; Fox KE, 2008, J BIOL CHEM, V283, P35096, DOI 10.1074/jbc.M806423200; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Geiger TR, 2008, MOL CELL BIOL, V28, P1383, DOI 10.1128/MCB.01657-07; Georges SA, 2003, MOL CELL BIOL, V23, P3392, DOI 10.1128/MCB.23.10.3392-3404.2003; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hiraiwa N, 2003, BLOOD, V101, P3615, DOI 10.1182/blood-2002-07-2301; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kim YM, 2007, J BIOL CHEM, V282, P18750, DOI 10.1074/jbc.M700391200; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; Koga H, 2004, J BIOL CHEM, V279, P52978, DOI 10.1074/jbc.M409021200; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lemasson I, 2006, J BIOL CHEM, V281, P13075, DOI 10.1074/jbc.M512193200; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Lopez DI, 2007, PROTEIN EXPRES PURIF, V55, P406, DOI 10.1016/j.pep.2007.06.011; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Ramirez JA, 2007, J MOL BIOL, V372, P958, DOI 10.1016/j.jmb.2007.06.062; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Sharma N, 2008, P NATL ACAD SCI USA, V105, P7959, DOI 10.1073/pnas.0800534105; Siu YT, 2006, J VIROL, V80, P7052, DOI 10.1128/JVI.00103-06; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SUZUKI T, 1994, ONCOGENE, V9, P3099; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; Terme JM, 2008, J VIROL, V82, P7913, DOI 10.1128/JVI.02414-07; Trevisan R, 2006, EXP CELL RES, V312, P1390, DOI 10.1016/j.yexcr.2006.01.009; Trevisan R, 2004, EXP CELL RES, V299, P57, DOI 10.1016/j.yexcr.2004.05.024; Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730; Wang D, 2008, J BIOL CHEM, V283, P16299, DOI 10.1074/jbc.M706426200; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	56	29	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2142	2152		10.1038/onc.2009.498	http://dx.doi.org/10.1038/onc.2009.498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101207	Green Accepted			2022-12-17	WOS:000276402800012
J	Dalton, WB; Yu, B; Yang, VW				Dalton, W. B.; Yu, B.; Yang, V. W.			p53 suppresses structural chromosome instability after mitotic arrest in human cells	ONCOGENE			English	Article						p53; cell cycle arrest; chromosomal instability; DNA damage; mitotic checkpoint; polypoidization	SPINDLE-ASSEMBLY CHECKPOINT; WILD-TYPE P53; DNA-DAMAGE; CYTOKINESIS FAILURE; CYCLE PROGRESSION; MAMMALIAN-CELLS; TP53 MUTATIONS; CANCER-CELLS; POSTMITOTIC CHECKPOINT; TELOMERE DYSFUNCTION	The p53 tumor suppressor inhibits the proliferation of cells that undergo prolonged activation of the mitotic checkpoint. However, the function of this antiproliferative response is not well defined. Here, we report that p53 suppresses structural chromosome instability after mitotic arrest in human cells. In both HCT116 colon cancer cells and normal human fibroblasts, DNA breaks occurred during mitotic arrest in a p53-independent manner, but p53 was required to suppress the proliferation and structural chromosome instability of the resulting polyploid cells. In contrast, cells made polyploid without mitotic arrest exhibited neither significant structural chromosome instability nor p53-dependent cell cycle arrest. We also observed that p53 suppressed both the frequency and structural chromosome instability of spontaneous polyploids in HCT116 cells. Furthermore, time-lapse videomicroscopy revealed that polyploidization of p53(-/-) HCT116 cells is frequently accompanied by mitotic arrest. These data suggest that a function of the p53-dependent postmitotic response is the prevention of structural chromosome instability after prolonged activation of the mitotic checkpoint. Accordingly, our study suggests a novel mechanism of tumor suppression for p53, as well as a potential function for p53 in the outcome of antimitotic chemotherapy. Oncogene (2010) 29, 1929-1940; doi:10.1038/onc.2009.477; published online 11 January 2010	[Dalton, W. B.; Yu, B.; Yang, V. W.] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; [Dalton, W. B.; Yu, B.; Yang, V. W.] Emory Univ, Sch Med, Biochem Cell & Dev Biol Grad Program, Atlanta, GA 30322 USA; [Yang, V. W.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu	yu, bing/B-3078-2009; Yu, Bing/AAF-9459-2019; Dalton, William/M-7944-2017	yu, bing/0000-0002-7259-8190; Yu, Bing/0000-0002-7259-8190; Dalton, William/0000-0002-1314-0534	National Institutes of Health [DK52230, DK64399, CA84197, 5T32GM008367-18, 5T32GM008367]; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK052230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169, T32GM008367] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D Pallas, P Doetsch, D Jones, A Corbett, G Davis, and M Wiltenburg for discussion and support, and B Vogelstein for providing cell lines. This work was supported in part by grants from the National Institutes of Health to VWY (DK52230, DK64399, and CA84197) and to WBD (5T32GM008367-18). This work was supported in part by grants from the National Institutes of Health to VWY (DK52230, DK64399, and CA84197) and to WBD (5T32GM008367).	Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chan YW, 2008, J BIOL CHEM, V283, P15716, DOI 10.1074/jbc.M800629200; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Curtis LJ, 2000, J PATHOL, V192, P440; Dalton WB, 2007, CANCER RES, V67, P11487, DOI 10.1158/0008-5472.CAN-07-5162; Dalton WB, 2009, FUTURE ONCOL, V5, P1363, DOI 10.2217/FON.09.118; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Di Leonardo A, 1997, CANCER RES, V57, P1013; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Galmarini CM, 2001, BRIT J CANCER, V85, P902, DOI 10.1054/bjoc.2001.2017; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Hastak K, 2008, P NATL ACAD SCI USA, V105, P6314, DOI 10.1073/pnas.0802080105; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; IKEUCHI T, 1972, J CELL BIOL, V52, P97, DOI 10.1083/jcb.52.1.97; Jong YJ, 2004, CANCER GENET CYTOGEN, V148, P55, DOI 10.1016/S0165-4608(03)00205-X; KATO H, 1967, J CELL BIOL, V34, P35, DOI 10.1083/jcb.34.1.35; Kienitz A, 2005, ONCOGENE, V24, P4301, DOI 10.1038/sj.onc.1208589; Kim KT, 2004, J BIOL CHEM, V279, P38597, DOI 10.1074/jbc.M400781200; Kleivi K, 2005, J PATHOL, V207, P14, DOI 10.1002/path.1812; Koller E, 2006, CANCER RES, V66, P2059, DOI 10.1158/0008-5472.CAN-05-1531; LALLE P, 1995, ONCOGENE, V10, P2447; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Pantic M, 2006, ONCOGENE, V25, P4413, DOI 10.1038/sj.onc.1209486; Pfleghaar K, 2005, PLOS BIOL, V3, P2127, DOI 10.1371/journal.pbio.0030416; Quignon F, 2007, ONCOGENE, V26, P165, DOI 10.1038/sj.onc.1209787; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; SAVAGE JRK, 1976, J MED GENET, V13, P103, DOI 10.1136/jmg.13.2.103; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Stevens JB, 2007, CANCER RES, V67, P7686, DOI 10.1158/0008-5472.CAN-07-0472; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Stukenberg PT, 2004, J CELL BIOL, V165, P607, DOI 10.1083/jcb.200405089; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Tao WK, 2007, MOL CELL BIOL, V27, P689, DOI 10.1128/MCB.01505-06; THIBODEAU A, 1991, EXP CELL RES, V195, P145, DOI 10.1016/0014-4827(91)90510-2; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2007, CURR BIOL, V17, P2081, DOI 10.1016/j.cub.2007.10.065; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang ZZ, 2007, MUTAT RES-FUND MOL M, V617, P98, DOI 10.1016/j.mrfmmm.2007.01.003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Westra JL, 2005, GENE CHROMOSOME CANC, V43, P194, DOI 10.1002/gcc.20148; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yamaguchi H, 2004, J BIOL CHEM, V279, P39431, DOI 10.1074/jbc.M401530200; Yang Z, 2008, NAT CELL BIOL, V10, P748, DOI 10.1038/ncb1738; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Zhang H, 2002, J BIOL CHEM, V277, P43648, DOI 10.1074/jbc.M203214200	76	29	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1929	1940		10.1038/onc.2009.477	http://dx.doi.org/10.1038/onc.2009.477			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062083	Green Accepted			2022-12-17	WOS:000276199600006
J	Chen, G; Wang, Y; Garate, M; Zhou, J; Li, G				Chen, G.; Wang, Y.; Garate, M.; Zhou, J.; Li, G.			The tumor suppressor ING3 is degraded by SCFSkp2-mediated ubiquitin-proteasome system	ONCOGENE			English	Article						ING3; protein degradation; Skp2; cell cycle; apoptosis	MEDIATED PROTEIN-DEGRADATION; CELL-CYCLE CONTROL; MELANOMA-CELLS; EXPRESSION; CANCER; SKP2; NUCLEAR; P33(ING1B); OVEREXPRESSION; PATHWAY	The inhibitor of growth family member 3 (ING3) has been shown to modulate transcription, cell cycle control and apoptosis. We previously reported that nuclear ING3 expression was remarkably reduced in melanomas, which correlated with a poorer patient survival, suggesting that decreased ING3 expression may be associated with melanoma progression. However, the mechanism of diminished ING3 expression in melanoma is not clear. Here we show that ING3 level was decreased in metastatic melanoma cells because of a rapid degradation. Furthermore, we showed that ING3 undergoes degradation through the ubiquitin proteasome pathway. ING3 physically interacts with subunits of E3 ligase Skp1-Cullin-F-box protein complex (SCF complex). Knockdown of F-box protein S-phase kinase-associated protein 2 (Skp2) reduces the ubiquitination of ING3 and significantly stabilizes ING3 in melanoma cells. In addition, lysine 96 residue is essential for ING3 ubiquitination as its mutation to arginine dramatically abrogated ING3 degradation. Disruption of ING3 degradation stimulated ING3-induced G1 cell-cycle arrest and enhanced ultraviolet-induced apoptosis. Taken together, our data show that ING3 is degraded by the ubiquitin-proteasome pathway through the SCFSkp2 complex and interruption of ING3 degradation enhances the tumor-suppressive function of ING3, which provides a potential cancer therapeutic approach by interfering ING3 degradation. Oncogene (2010) 29, 1498-1508; doi:10.1038/onc.2009.424; published online 23 November 2009	[Chen, G.; Wang, Y.; Garate, M.; Li, G.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver, BC V6H 3Z6, Canada; [Zhou, J.] Nanjing Med Univ, Sch Publ Hlth, Dept Mol Cell Biol & Toxicol, Nanjing, Peoples R China	University of British Columbia; Vancouver Coastal Health Research Institute; Nanjing Medical University	Li, G (corresponding author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011		Cancer Research Society; Canadian Institutes of Health Research [MOP-93810]; Canadian Dermatology Foundation; Michael Smith Foundation for Health Research; University of British Columbia; National Cancer Institute of Canada	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Dermatology Foundation; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); University of British Columbia; National Cancer Institute of Canada(Canadian Cancer Society (CCS))	We gratefully thank Drs HR Byers, AP Albino, H Silver, R Zhang, M Pagano, S Sun and J Hsieh for kindly providing the materials. This study was supported by Cancer Research Society, the Canadian Institutes of Health Research (MOP-93810) and the Canadian Dermatology Foundation (GL). GC is a recipient of Postdoctoral Trainee Award from Michael Smith Foundation for Health Research. YW is a recipient of Roman M Babicki Fellowship from the University of British Columbia and a research fellow of the Terry Fox Foundation through an award from the National Cancer Institute of Canada.	Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Ben-Shahar S, 1999, J BIOL CHEM, V274, P21963, DOI 10.1074/jbc.274.31.21963; Burger AM, 2004, EUR J CANCER, V40, P2217, DOI 10.1016/j.ejca.2004.07.006; Chiappetta G, 2007, ENDOCR-RELAT CANCER, V14, P405, DOI 10.1677/ERC-06-0030; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Fadlelmola FM, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-2; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Garate M, 2008, EMBO REP, V9, P576, DOI 10.1038/embor.2008.48; Garate M, 2007, FASEB J, V21, P3705, DOI 10.1096/fj.07-8069com; Goldberg AL, 2007, BIOCHEM SOC T, V35, P12, DOI 10.1042/BST0350012; Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; Gunduz M, 2008, CANCER SCI, V99, P531, DOI 10.1111/j.1349-7006.2007.00708.x; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Katagiri Y, 2006, J DERMATOL SCI, V42, P215, DOI 10.1016/j.jdermsci.2005.12.016; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Li J, 2008, CARCINOGENESIS, V29, P1373, DOI 10.1093/carcin/bgn086; Li Q, 2004, J CUTAN PATHOL, V31, P633, DOI 10.1111/j.0303-6987.2004.00243.x; Lu F, 2006, BRIT J CANCER, V95, P80, DOI 10.1038/sj.bjc.6603205; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Masuda T, 2002, CANCER RES, V62, P3819; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056; Nandi D, 2006, J BIOSCIENCES, V31, P137, DOI 10.1007/BF02705243; Newton K, 2007, CANCER INVEST, V25, P502, DOI 10.1080/07357900701508041; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Nouman GS, 2002, HISTOPATHOLOGY, V40, P360, DOI 10.1046/j.1365-2559.2002.01369.x; Schwelchheimer C, 2004, CURR OPIN PLANT BIOL, V7, P677, DOI 10.1016/j.pbi.2004.09.009; Shah Imtiaz M., 2007, Cardiovascular & Hematological Disorders - Drug Targets, V7, P250, DOI 10.2174/187152907782793572; Sonoda H, 2006, CLIN CANCER RES, V12, P1215, DOI 10.1158/1078-0432.CCR-05-1709; Sumimoto H, 2006, INT J CANCER, V118, P472, DOI 10.1002/ijc.21286; Tsai KW, 2008, EXP CELL RES, V314, P3130, DOI 10.1016/j.yexcr.2008.08.002; von Mikecz A, 2006, J CELL SCI, V119, P1977, DOI 10.1242/jcs.03008; Wang YM, 2007, CLIN CANCER RES, V13, P4111, DOI 10.1158/1078-0432.CCR-07-0408; Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200; Woenckhaus C, 2005, HISTOL HISTOPATHOL, V20, P501, DOI 10.14670/HH-20.501; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; Zetter Bruce R, 2005, Future Oncol, V1, P567, DOI 10.2217/14796694.1.5.567	43	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2010	29	10					1498	1508		10.1038/onc.2009.424	http://dx.doi.org/10.1038/onc.2009.424			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19935701				2022-12-17	WOS:000275392400008
J	Hassan, S; Biswas, MHU; Zhang, C; Du, C; Balaji, KC				Hassan, S.; Biswas, M. H. U.; Zhang, C.; Du, C.; Balaji, K. C.			Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells	ONCOGENE			English	Article						PKD1; Hsp27; AR; p38; prostate cancer	BETA-CATENIN; MAPKAP KINASE-2; SERINE-82 PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; E-CADHERIN; C-MU; HSP27; NEUROTENSIN; ACTIVATION; GROWTH	We have previously shown that protein kinase D1 (PKD1), charter member of PKD protein family, is downregulated in advanced prostate cancer ( PC) and influences androgen receptor (AR) function in PC cells. Other independent studies showed that serine 82 residue in heat shock protein 27 (Hsp27) undergoes substrate phosphorylation by PKD1 and is associated with nuclear transport of AR resulting in increased AR transcriptional activity. In this study, we show that PKD1 interacts and phosphorylates Hsp27 at Ser82 in PC cells, which is mediated by p38-dependent mitogen-activated protein kinase pathway and is necessary for PKD1 repression of AR transcriptional activity and androgen-dependent proliferation of PC cells. The study provides first in vivo evidence that Hsp27 is a mediator of repression of AR function by PKD1 in PC cells, thereby linking the data in the published literature. Oncogene (2009) 28, 4386-4396; doi: 10.1038/onc.2009.291; published online 21 September 2009	[Hassan, S.; Biswas, M. H. U.; Zhang, C.; Du, C.; Balaji, K. C.] Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Balaji, KC (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Div Urol, 55 Lake Ave N,Room S4-868, Worcester, MA 01655 USA.	Balajik@ummhc.org	Du, Cheng/F-1569-2013	Du, Cheng/0000-0002-8882-2513	Department of Surgery, University of Massachusetts Medical School	Department of Surgery, University of Massachusetts Medical School	We thank Dr FJ Johannes, Fraunhofer Institute for Interfacial Engineering, Stuttgart, Germany for providing the PKD1 expression vector. This study was supported by an institutional grant from the Department of Surgery, University of Massachusetts Medical School.	BELKA C, 1995, LEUKEMIA, V9, P288; CARRAWAY R, 1976, J BIOL CHEM, V251, P7045; Carraway RE, 2007, REGUL PEPTIDES, V141, P140, DOI 10.1016/j.regpep.2006.12.027; Cornford PA, 2000, CANCER RES, V60, P7099; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Du C, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-28; Du C, 2009, CANCER RES, V69, P1117, DOI 10.1158/0008-5472.CAN-07-6270; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Edwards J, 2005, BJU INT, V95, P1327, DOI 10.1111/j.1464-410X.2005.05527.x; Evans IM, 2008, CELL SIGNAL, V20, P1375, DOI 10.1016/j.cellsig.2008.03.002; Fanelli MA, 2008, CELL STRESS CHAPERON, V13, P207, DOI 10.1007/s12192-007-0007-z; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; Gomase VS, 2008, CURR DRUG METAB, V9, P255, DOI 10.2174/138920008783884803; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; Jaggi M, 2005, CANCER RES, V65, P483; Jaggi M, 2003, BIOCHEM BIOPH RES CO, V307, P254, DOI 10.1016/S0006-291X(03)01161-6; Jaggi M, 2008, MOL CANCER THER, V7, P2703, DOI 10.1158/1535-7163.MCT-08-0119; Jaggi M, 2007, FRONT BIOSCI-LANDMRK, V12, P3757, DOI 10.2741/2349; Ku GY, 2008, CANCER CHEMOTH PHARM, V62, P875, DOI 10.1007/s00280-008-0677-y; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Li J, 2008, J BIOL CHEM, V283, P2614, DOI 10.1074/jbc.M707513200; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Mak P, 2008, BIOCHEM BIOPH RES CO, V373, P618, DOI 10.1016/j.bbrc.2008.06.097; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Martinez V, 2000, PEPTIDES, V21, P1617, DOI 10.1016/S0196-9781(00)00293-X; Moody TW, 2003, CURR PHARM DESIGN, V9, P495, DOI 10.2174/1381612033391621; Mosca A, 2005, J Endocrinol Invest, V28, P141; Neckers L, 2003, CURR MED CHEM, V10, P733, DOI 10.2174/0929867033457818; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Roberts JD, 2006, CLIN CANCER RES, V12, P5809, DOI 10.1158/1078-0432.CCR-05-2730; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rybin VO, 2009, J BIOL CHEM, V284, P2332, DOI 10.1074/jbc.M806381200; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; So A, 2007, CURR GENOMICS, V8, P252; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Syed V, 2008, J CELL BIOCHEM, V104, P82, DOI 10.1002/jcb.21603; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008-5472.CAN-08-1718; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yuan J, 2008, J CELL BIOCHEM, V103, P648, DOI 10.1002/jcb.21439; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	46	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4386	4396		10.1038/onc.2009.291	http://dx.doi.org/10.1038/onc.2009.291			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19767773				2022-12-17	WOS:000272876400007
J	Baum, N; Schiene-Fischer, C; Frost, M; Schumann, M; Sabapathy, K; Ohlenschlager, O; Grosse, F; Schlott, B				Baum, N.; Schiene-Fischer, C.; Frost, M.; Schumann, M.; Sabapathy, K.; Ohlenschlaeger, O.; Grosse, F.; Schlott, B.			The prolyl cis/trans isomerase cyclophilin 18 interacts with the tumor suppressor p53 and modifies its functions in cell cycle regulation and apoptosis	ONCOGENE			English	Article						apoptosis; cell cycle; cyclosporin; genetic polymorphism; peptidyl-prolyl cis/trans isomerization	CIS-TRANS ISOMERASE; DEPENDENT PROLINE ISOMERIZATION; CYCLOSPORINE-A; LUNG-CANCER; POLYMORPHIC VARIANTS; DNA-DAMAGE; WILD-TYPE; PIN1; PROTEIN; CATALYSIS	The functional diversity of the tumor suppressor protein p53 is mainly regulated by protein interactions. In this study, we describe a new interaction with the peptidylprolyl cis/trans isomerase cyclophilin 18 (Cyp18). The interaction reduced the sequence-specific DNA binding of p53 in vitro, whereas the inhibition of the interaction increased p53-reporter gene activity in vivo. The active site of the folding helper enzyme Cyp18 was directly involved in binding. The proline-rich region (amino acids 64-91) of p53 was most likely responsible for the observed binding because a synthetic peptide comprising amino acids 68-81 of p53 inhibited this interaction, and a p53 variant containing a proline residue at position 72 (p53(P72)) interacted with Cyp18 more effectively than the corresponding p53(R72) variant. Impairment of the Cyp18-p53 interaction induced an accumulation of cells in the G2/M phase of the cell cycle, which was more pronounced when p53(P72) was expressed compared with p53(R72) in an otherwise isogenic cellular background. Moreover, p53-dependent apoptosis was elevated in Cyp18 knockout cells, suggesting an antiapoptotic potential of Cyp18-p53 complexes. Functional in vivo data hint to a possible clinical relevance of the p53-Cyp18 interaction observed. Oncogene (2009) 28, 3915-3925; doi:10.1038/onc.2009.248; published online 31 August 2009	[Schlott, B.] Leibniz Inst Age Res, Fritz Lipmann Inst, Biochem Grp, Dept Biochem, D-07745 Jena, Thuringia, Germany; [Schiene-Fischer, C.; Frost, M.; Schumann, M.] Max Planck Res Unit Prot Folding, Halle, Saale, Germany; [Sabapathy, K.] Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, Singapore, Singapore; [Ohlenschlaeger, O.] Leibniz Inst Age Res, Dept NMR, D-07745 Jena, Thuringia, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Max Planck Society; National Cancer Centre Singapore (NCCS); Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Schlott, B (corresponding author), Leibniz Inst Age Res, Fritz Lipmann Inst, Biochem Grp, Dept Biochem, Beutenbergstr 11, D-07745 Jena, Thuringia, Germany.	bschlott@fli-leibniz.de		Ohlenschlaeger, Oliver/0000-0002-6428-4423	Deutsche Forschungsgemeinschaft [GK1026, SFB604]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft grant GK1026 (to CS-F) and SFB604 (to Gunter Fischer, Halle, and FG). The technical assistance of Mrs Anita Willitzer is acknowledged. Jurkat cells were kindly provided by J Luban (Columbia University, New York).	Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Bauerschmidt C, 2007, GENES CELLS, V12, P745, DOI 10.1111/j.1365-2443.2007.01090.x; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Choi KJ, 2007, CANCER RES, V67, P3654, DOI 10.1158/0008-5472.CAN-06-1759; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Fanghanel J, 2003, ANGEW CHEM INT EDIT, V42, P490, DOI 10.1002/anie.200390149; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; Herman M, 2001, J LAB CLIN MED, V137, P14, DOI 10.1067/mlc.2001.111469; Howard BA, 2005, CANCER RES, V65, P8853, DOI 10.1158/0008-5472.CAN-05-1219; Howard BA, 2004, LUNG CANCER, V46, P313, DOI 10.1016/j.lungcan.2004.05.013; Hsu T, 2001, NAT CELL BIOL, V3, P538, DOI 10.1038/35078508; Jensen P, 1999, J AM ACAD DERMATOL, V40, P177, DOI 10.1016/S0190-9622(99)70185-4; Johnson MD, 1999, J NEUROSCI, V19, P2996; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; LARSSON R, 1991, ANTICANCER RES, V11, P455; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Liu WF, 2001, FEBS LETT, V496, P105, DOI 10.1016/S0014-5793(01)02411-5; Ma L, 2005, P NATL ACAD SCI USA, V102, P14266, DOI 10.1073/pnas.0501352102; MARKS WH, 1991, TRANSPLANTATION, V52, P340, DOI 10.1097/00007890-199108000-00030; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Pinton P, 2007, SCIENCE, V315, P659, DOI 10.1126/science.1135380; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; Pyrzynska B, 2002, J BIOL CHEM, V277, P14102, DOI 10.1074/jbc.M104443200; Rey O, 1999, ONCOGENE, V18, P827, DOI 10.1038/sj.onc.1202328; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Ross HJ, 1997, LUNG CANCER-J IASLC, V18, P189, DOI 10.1016/S0169-5002(97)00061-5; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Siddique M, 2006, ONCOGENE, V25, P3489, DOI 10.1038/sj.onc.1209405; Soe K, 2002, ONCOGENE, V21, P6614, DOI 10.1038/sj.onc.1205912; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	52	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3915	3925		10.1038/onc.2009.248	http://dx.doi.org/10.1038/onc.2009.248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19718045				2022-12-17	WOS:000271471900006
J	Fazi, B; Melino, S; De Rubeis, S; Bagni, C; Paci, M; Piacentini, M; Di Sano, F				Fazi, B.; Melino, S.; De Rubeis, S.; Bagni, C.; Paci, M.; Piacentini, M.; Di Sano, F.			Acetylation of RTN-1C regulates the induction of ER stress by the inhibition of HDAC activity in neuroectodermal tumors	ONCOGENE			English	Article						acetylation; ER; RTN-1C; apoptosis	ENDOPLASMIC-RETICULUM; CALRETICULIN EXPOSURE; HISTONE DEACETYLASE; INDUCED APOPTOSIS; CELL-DEATH; PROTEIN; BINDING; FAMILY; CANCER; RNA	Reticulons are a family of highly conserved proteins, localized in the endoplasmic reticulum (ER) and involved in different cellular functions, such as intracellular membrane trafficking, apoptosis and nuclear envelope formation. The reticulon protein family consists of four members, but their specific functions are presently poorly understood. RTN-1C overexpression triggers apoptosis, regulating ER stress versus DNA damage-induced cell death in a mutually exclusive way. The different RTN isoforms share a C-terminal reticulon homology domain containing two hydrophobic segments and a 66-amino acid hydrophilic loop. In the C-terminal region of RTN-1C, a unique consensus sequence (GAKRH) has recently been identified, showing 100% identity with the DNA-binding domain of histone H4. In this study, we show that this sequence is essential for RTN-1C-mediated apoptosis. It is noteworthy that the lysine 204 present in this region is post-translationally modified by acetylation and that this event is associated with a significant decrease in histone deacetylase activity and contributes to RTN-1C binding to DNA. These data demonstrate a molecular mechanism by which RTN-1C controls apoptosis and indicate this protein to be a novel potential target for cancer therapy. Oncogene (2009) 28, 3814-3824; doi:10.1038/onc.2009.233; published online 10 August 2009	[Fazi, B.; De Rubeis, S.; Piacentini, M.; Di Sano, F.] Univ Roma Tor Vergata, Dept Biol, I-133 Rome, Italy; [Melino, S.; Paci, M.] Univ Roma Tor Vergata, Dept Sci & Chem Technol, I-133 Rome, Italy; [De Rubeis, S.; Bagni, C.] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; [De Rubeis, S.; Bagni, C.] Flanders Inst Biotechnol VIB, Dept Mol & Dev Genet, Louvain, Belgium; [Bagni, C.] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-133 Rome, Italy; [Piacentini, M.] Natl Inst Infect Dis IRCCS L Spallanzani, Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; KU Leuven; Flanders Institute for Biotechnology (VIB); University of Rome Tor Vergata; IRCCS Lazzaro Spallanzani	Piacentini, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Viale Ric Sci 1, I-133 Rome, Italy.	mauro.piacentini@uniroma2.it	De Rubeis, Silvia/E-9852-2013; Piacentini, Mauro/I-2411-2016	De Rubeis, Silvia/0000-0001-9383-6883; Piacentini, Mauro/0000-0003-2919-1296; Di Sano, Federica/0000-0002-5048-3966; Bagni, Claudia/0000-0002-4419-210X; MELINO, SONIA/0000-0001-7694-5279	Ricerca Corrente; Ministero della Salute; AIRC; Telethon Foundation; EU; Cofin; FIRB	Ricerca Corrente(Ministry of Health, ItalyMinistry of Health Italy - Ricerca Corrente (MOH-RC)); Ministero della Salute(Ministry of Health, Italy); AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon Foundation(Fondazione Telethon); EU(European Commission); Cofin; FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB))	This work was partially supported by grants from Ricerca Corrente and Finalizzata from Ministero della Salute, AIRC, Telethon Foundation, EU integrated project 'Apo-sys' and Cofin 2006 to MP, and from COFIN and FIRB to CB.	Anderson DJ, 2007, NAT CELL BIOL, V9, P1160, DOI 10.1038/ncb1636; Babic I, 2004, ONCOGENE, V23, P3781, DOI 10.1038/sj.onc.1207484; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Di Sano F, 2007, J NEUROCHEM, V102, P345, DOI 10.1111/j.1471-4159.2007.04479.x; Eliseeva ED, 2007, MOL CANCER THER, V6, P2391, DOI 10.1158/1535-7163.MCT-07-0159; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gonzenbach RR, 2008, CELL MOL LIFE SCI, V65, P161, DOI 10.1007/s00018-007-7170-3; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gupta S, 2005, NUCLEIC ACIDS RES, V33, P6972, DOI 10.1093/nar/gki990; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Huber AB, 2002, J NEUROSCI, V22, P3553; Iwahashi J, 2003, Cell Mol Biol (Noisy-le-grand), V49 Online Pub, pOL467; Iwahashi J, 2007, BIOCHEM BIOPH RES CO, V355, P508, DOI 10.1016/j.bbrc.2007.02.001; Kawaguchi Y, 2006, J BIOL CHEM, V281, P1394, DOI 10.1074/jbc.M505772200; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kuang E, 2005, J CELL PHYSIOL, V204, P549, DOI 10.1002/jcp.20340; Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Melino S, 2009, BIOCHEMISTRY-US, V48, P242, DOI 10.1021/bi801407w; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; PUIG OM, 1988, BIOCHIM BIOPHYS ACTA, V1397, P79; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Steiner P, 2004, J NEUROCHEM, V89, P569, DOI 10.1111/j.1471-4159.2004.02345.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; Tufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275; Ulbert S, 2006, J CELL BIOL, V173, P469, DOI 10.1083/jcb.200512078; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000	39	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3814	3824		10.1038/onc.2009.233	http://dx.doi.org/10.1038/onc.2009.233			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19668229				2022-12-17	WOS:000271248400005
J	Haan, S; Wuller, S; Kaczor, J; Rolvering, C; Nocker, T; Behrmann, I; Haan, C				Haan, S.; Wueller, S.; Kaczor, J.; Rolvering, C.; Noecker, T.; Behrmann, I.; Haan, C.			SOCS-mediated downregulation of mutant Jak2 ( V617F, T875N and K539L) counteracts cytokine-independent signaling	ONCOGENE			English	Article						SOCS; Janus kinases; proteasomal degradation; myeloproliferative disorders	CHRONIC MYELOPROLIFERATIVE DISORDERS; ACUTE MYELOID-LEUKEMIA; JANUS TYROSINE KINASE; POLYCYTHEMIA-VERA; WILD-TYPE; ESSENTIAL THROMBOCYTHEMIA; CONSTITUTIVE ACTIVATION; HEMATOPOIETIC-CELLS; NEGATIVE REGULATOR; LYMPHOMA LINE	Recently, mutations in the gene of Janus kinase 2 (Jak2) were discovered in patients suffering from chronic myeloproliferative disorders (MPD) and leukemia. As suppressors of cytokine signaling (SOCS) proteins are potent feedback inhibitors of Jak-mediated signaling, we investigated their role in signal transduction through constitutively active Jak2 mutants. We selected two mutants, Jak2-V617F and Jak2-K539L, found in patients with MPDs and Jak2-T875N identified in acute mega-karyoblastic leukemia. We found SOCS family members to be induced through Jak2-V617F in human leukemia cell lines expressing the mutant allele and in stable HEK transfectants inducibly expressing constitutively active Jak2 mutants. SOCS proteins were recruited to the membrane and bound to the constitutively active Jaks. In contrast to wild-type Jak2, the mutant proteins were constitutively ubiquitinated and degraded through the proteasome. Taken together, we show a SOCS-mediated downregulation of the constitutively active, disease-associated mutant Jak2 proteins. Furthermore, a threshold level of mutant Jak expression has to be overcome to allow full cytokine-independent constitutive activation of signaling proteins, which may explain progression to homozygocity in MPDs as well as gene amplification in severe phenotypes and leukemia. Oncogene (2009) 28, 3069-3080; doi:10.1038/onc.2009.155; published online 22 June 2009	[Haan, S.; Kaczor, J.; Rolvering, C.; Behrmann, I.; Haan, C.] Univ Luxembourg, Life Sci Res Unit, L-1511 Luxembourg, Luxembourg; [Wueller, S.; Noecker, T.] Rhein Westfal TH Aachen, Dept Biochem, Aachen, Germany; [Wueller, S.] Rhein Westfal TH Aachen, Dept Pediat, Aachen, Germany	University of Luxembourg; RWTH Aachen University; RWTH Aachen University	Haan, S (corresponding author), Univ Luxembourg, Life Sci Res Unit, Campus Limpertsberg,162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	serge.haan@uni.lu; claude.haan@uni.lu		Behrmann, Iris/0000-0003-3688-3645	UL [R1F105L01, R1F107L01]; Marie Curie Research Training Network ReceptEUR; Serono GmbH (Unterschleissheim, Germany)	UL; Marie Curie Research Training Network ReceptEUR(European Commission); Serono GmbH (Unterschleissheim, Germany)	This work was supported by the UL Grant nos. R1F105L01 and R1F107L01, the Marie Curie Research Training Network ReceptEUR, and by Serono GmbH (Unterschleissheim, Germany).	Andrieux Joris Loup, 2005, Curr Hematol Rep, V4, P224; Bacher U, 2005, CANCER GENET CYTOGEN, V160, P179, DOI 10.1016/j.cancergencyto.2004.12.015; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Bock O, 2006, J MOL DIAGN, V8, P170, DOI 10.2353/jmoldx.2006.050064; Bock O, 2007, LEUKEMIA RES, V31, P799, DOI 10.1016/j.leukres.2006.08.022; Bumm TGP, 2006, CANCER RES, V66, P11156, DOI 10.1158/0008-5472.CAN-06-2210; Capello D, 2008, BRIT J HAEMATOL, V141, P504, DOI 10.1111/j.1365-2141.2008.07072.x; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Ekmekci CG, 2004, AM J HEMATOL, V77, P233, DOI 10.1002/ajh.20186; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Garcon L, 2006, BLOOD, V108, P1551, DOI 10.1182/blood-2005-10-009514; Grandage VL, 2006, BRIT J HAEMATOL, V135, P303, DOI 10.1111/j.1365-2141.2006.06291.x; Hookham MB, 2007, BLOOD, V109, P4924, DOI 10.1182/blood-2006-08-039735; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kralovics R, 2005, BLOOD, V106, P3374, DOI 10.1182/blood-2005-05-1889; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kratz CP, 2006, LEUKEMIA, V20, P381, DOI 10.1038/sj.leu.2404060; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Lu XH, 2008, J BIOL CHEM, V283, P5258, DOI 10.1074/jbc.M707125200; Melzner I, 2006, INT J CANCER, V118, P1941, DOI 10.1002/ijc.21485; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Mercher T, 2006, BLOOD, V108, P2770, DOI 10.1182/blood-2006-04-014712; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Quentmeier H, 2006, LEUKEMIA, V20, P471, DOI 10.1038/sj.leu.2404081; Reilly JT, 2005, SEMIN ONCOL, V32, P359, DOI 10.1053/j.seminoncol.2005.04.007; Roder S, 2001, EXP HEMATOL, V29, P694, DOI 10.1016/S0301-472X(01)00637-3; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tefferi A, 2006, CANCER-AM CANCER SOC, V106, P631, DOI 10.1002/cncr.21645; Teofili L, 2008, INT J CANCER, V123, P1586, DOI 10.1002/ijc.23694; Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Vannucchi AM, 2007, BLOOD, V110, P840, DOI 10.1182/blood-2006-12-064287; Vuong BQ, 2004, MOL CELL BIOL, V24, P9092, DOI 10.1128/MCB.24.20.9092-9101.2004; Walz C, 2006, J BIOL CHEM, V281, P18177, DOI 10.1074/jbc.M600064200; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zaleskas VM, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000018; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	51	29	32	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	2009	28	34					3069	3080		10.1038/onc.2009.155	http://dx.doi.org/10.1038/onc.2009.155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543316				2022-12-17	WOS:000269319000006
J	Roovers, K; Wagner, S; Storbeck, CJ; O'Reilly, P; Lo, V; Northey, JJ; Chmielecki, J; Muller, WJ; Siegel, PM; Sabourin, LA				Roovers, K.; Wagner, S.; Storbeck, C. J.; O'Reilly, P.; Lo, V.; Northey, J. J.; Chmielecki, J.; Muller, W. J.; Siegel, P. M.; Sabourin, L. A.			The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility	ONCOGENE			English	Article						cell migration; focal adhesion; Ste20-like kinase; ErbB2; HER2	GROWTH-FACTOR; ERBB RECEPTORS; MAMMARY TUMORIGENESIS; STE20-RELATED KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ADHESION; FAK; TRANSFORMATION; MIGRATION	The Ste20-like kinase, SLK, is involved in the control of cell motility through its effects on actin reorganization and focal adhesion turnover. Here we investigated the role of SLK in chemotaxis downstream of the tyrosine kinase receptor, HER2/ErbB2/Neu, which is frequently over-expressed in human breast cancers. Our results show that SLK is required for the efficient cell migration of human and mouse mammary epithelial cell lines in the presence of the Neu activator, heregulin, as a chemoattractant. SLK activity is stimulated by heregulin treatment or by overexpression of activated Neu. Phosphorylation of tyrosine 1201 or tyrosines 1226/7 on Neu is a key event for SLK activation and cell migration, and cancer cell invasion mediated by these tyrosines is inhibited by kinase-inactive SLK. Signaling pathway inhibitors show that Neu-mediated SLK activation is dependent on MEK, PI3K, PLC gamma and Shc signaling. Furthermore, heregulin-stimulated SLK activity requires signals from the focal adhesion proteins, FAK and src. Finally, phospho-FAK analysis shows that SLK is required for Neu-dependent focal adhesion turnover. Together, these studies de. ne an interaction between Neu and SLK signaling in the regulation of cancer cell motility. Oncogene (2009) 28, 2839-2848; doi:10.1038/onc.2009.146; published online 15 June 2009	[Roovers, K.; Storbeck, C. J.; O'Reilly, P.; Sabourin, L. A.] Ottawa Hlth Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada; [Wagner, S.; Lo, V.; Sabourin, L. A.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Northey, J. J.; Muller, W. J.; Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Chmielecki, J.; Muller, W. J.] McGill Univ, Dept Med, Montreal, PQ, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; McGill University; McGill University	Sabourin, LA (corresponding author), Ottawa Reg Canc Ctr, 501 Smyth Rd,Box 926, Ottawa, ON K1H 8L6, Canada.	lsabourin@ohri.ca	Northey, Jason/AAX-6365-2021	Northey, Jason/0000-0003-3115-2560	Canadian Breast Cancer Foundation; Canadian Institute for Health Research; Premier's Research for Excellence Award; OGSST; NSERC; Canadian Heart and Stroke Foundation Fellowship; National Cancer Institute of Canada; CIHR scholar award	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Premier's Research for Excellence Award; OGSST; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Heart and Stroke Foundation Fellowship(Heart & Stroke Foundation of Canada); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); CIHR scholar award(Canadian Institutes of Health Research (CIHR))	This work was supported by the Canadian Breast Cancer Foundation, the Canadian Institute for Health Research and a Premier's Research for Excellence Award. KR is supported by the Canadian Breast Cancer Foundation, SW is supported by OGSST and NSERC studentships and CJS is the recipient of a Canadian Heart and Stroke Foundation Fellowship. PMS is a research scientist of the National Cancer Institute of Canada and LAS is the recipient of a CIHR scholar award.	BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Broussard JA, 2008, CURR OPIN CELL BIOL, V20, P85, DOI 10.1016/j.ceb.2007.10.009; Burakov AV, 2008, MOL BIOL CELL, V19, P1952, DOI 10.1091/mbc.E06-12-1156; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort D L, 1996, Cancer Treat Res, V83, P71; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Hauck CR, 2001, CANCER RES, V61, P7079; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Itoh S, 1997, ARCH BIOCHEM BIOPHYS, V340, P201, DOI 10.1006/abbi.1997.9893; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; MANSOUR EG, 1994, CANCER, V74, P381, DOI 10.1002/cncr.2820741326; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; O'Reilly PG, 2005, J BIOL CHEM, V280, P42383, DOI 10.1074/jbc.M510763200; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo Alexander F, 2002, Sci STKE, V2002, ppe31, DOI 10.1126/stke.2002.139.pe31; Pytowski B, 1998, ARCH BIOCHEM BIOPHYS, V359, P310, DOI 10.1006/abbi.1998.0907; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Siegel PM, 2000, ADV EXP MED BIOL, V480, P185; Siesser PMF, 2008, CELL MOTIL CYTOSKEL, V65, P25, DOI 10.1002/cm.20241; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Wagner S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001868; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yamada E, 2000, BBA-MOL CELL RES, V1495, P250, DOI 10.1016/S0167-4889(99)00164-0; Zhang YH, 2002, DEV BRAIN RES, V139, P205, DOI 10.1016/S0165-3806(02)00551-5	42	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2839	2848		10.1038/onc.2009.146	http://dx.doi.org/10.1038/onc.2009.146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19525980				2022-12-17	WOS:000268684400007
J	Woo, HH; Zhou, Y; Yi, X; David, CL; Zheng, W; Gilmore-Hebert, M; Kluger, HM; Ulukus, EC; Baker, T; Stoffer, JB; Chambers, SK				Woo, H-H; Zhou, Y.; Yi, X.; David, C. L.; Zheng, W.; Gilmore-Hebert, M.; Kluger, H. M.; Ulukus, E. C.; Baker, T.; Stoffer, J. B.; Chambers, S. K.			Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer	ONCOGENE			English	Article						breast cancer; c-fms proto-oncogene; post-transcriptional regulation; HuR	MESSENGER-RNA STABILITY; STIMULATING FACTOR-1 RECEPTOR; CSF-1 RECEPTOR; BINDING PROTEIN; POSTTRANSCRIPTIONAL REGULATION; CYCLOOXYGENASE-2 EXPRESSION; MONOCYTIC DIFFERENTIATION; QUANTITATIVE-ANALYSIS; CROSS-LINKING; CARCINOMA	The role of RNA-binding proteins in cancer biology is recognized increasingly. The nucleocytoplasmic shuttling and AU-rich RNA-binding protein HuR stabilizes several cancer-related target mRNAs. The proto-oncogene c-fms, whose 3'untranslated region (3'UTR) is not AU-rich, is associated with poor prognosis in breast cancer. Using a large breast-cancer tissue array (N=670), we found nuclear HuR expression to be associated with nodal metastasis and independently with poor survival (P=0.03, RR 1.45), as well as to be co-expressed with c-fms in the breast tumors (P=0.0007). We described c-fms mRNA as a direct target of HuR in vivo, and that HuR bound specifically to a 69-nt region containing 'CUU' motifs in 3'UTR c-fms RNA. Overexpressing or silencing HuR significantly up-or down-regulated c-fms RNA expression, respectively. We also found that known glucocorticoid stimulation of c-fms RNA and protein is largely dependent on the presence of HuR. HuR, by binding to the 69-nt wild type, but not mutant, c-fms sequence can regulate reporter gene expression post-transcriptionally. We are the first to describe that HuR can regulate gene expression by binding non-AU-rich sequences in 3'UTR c-fms RNA. Collectively, our findings suggest that HuR plays a supportive role for c-fms in breast cancer progression by binding a 69-nt element in its 3'UTR, thus regulating its expression.	[Woo, H-H; Zhou, Y.; Yi, X.; David, C. L.; Zheng, W.; Baker, T.; Stoffer, J. B.; Chambers, S. K.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; [Gilmore-Hebert, M.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Ulukus, E. C.] Dokuz Eylul Univ, Izmir, Turkey	Arizona Center Cancer Care; University of Arizona; Yale University; Dokuz Eylul University	Chambers, SK (corresponding author), Univ Arizona, Arizona Canc Ctr, POB 245024, Tucson, AZ 85724 USA.	schambers@azcc.arizona.edu			Department of Defense [DAMD 17-02-1-0633]; Susan G Komen Breast Cancer Foundation; Breast Cancer Alliance	Department of Defense(United States Department of Defense); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Alliance	This work was supported by Department of Defense Grant DAMD 17-02-1-0633 ( to SKC), and in part by the Susan G Komen Breast Cancer Foundation and by the Breast Cancer Alliance ( to HMK). We thank Joan A Steitz for providing the GST plasmids, and Ite A Laird-Offringa for providing purified HuR protein.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; ALLEGRA JC, 1979, CANCER RES, V39, P1447; Apponi LH, 2007, MOL CELL BIOL, V27, P6569, DOI 10.1128/MCB.00881-07; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Camp RL, 2003, CANCER RES, V63, P1445; Camp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204; Chambers SK, 1997, CLIN CANCER RES, V3, P999; Chambers SK, 2004, AM J OBSTET GYNECOL, V190, P974, DOI 10.1016/j.ajog.2004.01.021; CHAMBERS SK, 1993, EXP HEMATOL, V21, P1328; CHAMBERS SK, 1994, STEROIDS, V59, P514, DOI 10.1016/0039-128X(94)90069-8; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; De Boer P, 2006, RNA, V12, P263, DOI 10.1261/rna.2257606; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099; Kacinski BM, 2001, J SOC GYNECOL INVEST, V8, P114, DOI 10.1016/S1071-5576(01)00092-2; KACINSKI BM, 1991, ONCOGENE, V6, P941; Kluger HM, 2004, CLIN CANCER RES, V10, P173, DOI 10.1158/1078-0432.CCR-0699-3; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Maher MG, 1998, CLIN CANCER RES, V4, P1851; Meisner NC, 2004, CHEMBIOCHEM, V5, P1432, DOI 10.1002/cbic.200400219; Moore MJ, 2002, CELL, V108, P431, DOI 10.1016/S0092-8674(02)00645-1; Nabors LB, 2001, CANCER RES, V61, P2154; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Peritz T, 2006, NAT PROTOC, V1, P577, DOI 10.1038/nprot.2006.82; SAPI E, 1995, ONCOGENE, V10, P529; Sapi E, 1996, CANCER RES, V56, P5704; STOLOW DT, 1990, MOL CELL BIOL, V10, P5937, DOI 10.1128/MCB.10.11.5937; Sureban SM, 2007, GASTROENTEROLOGY, V132, P1055, DOI 10.1053/j.gastro.2006.12.031; Toy EP, 2005, CLIN EXP METASTAS, V22, P1, DOI 10.1007/s10585-005-0718-4; Urlaub H, 2000, J BIOL CHEM, V275, P41458, DOI 10.1074/jbc.M007434200; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; Wein G, 2003, EUR J BIOCHEM, V270, P350, DOI 10.1046/j.1432-1033.2003.03396.x; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200	42	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1176	1186		10.1038/onc.2008.469	http://dx.doi.org/10.1038/onc.2008.469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151756				2022-12-17	WOS:000263906200002
J	Duan, H; Xiang, H; Ma, L; Boxer, LM				Duan, H.; Xiang, H.; Ma, L.; Boxer, L. M.			Functional long-range interactions of the IgH 3 ' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells	ONCOGENE			English	Article						t(14;18) lymphoma; bcl-2; IgH enhancer; spatial interactions	CHROMOSOME CONFORMATION; CREB PROTEINS; IN-VIVO; EXPRESSION; GENE; APOPTOSIS; CHEMORESISTANCE; LOCUS	To better understand the mechanisms underlying the role of the immunoglobulin heavy-chain gene (IgH) 3' enhancers on bcl-2 transcriptional deregulation in t(14; 18) lymphoma, we characterized the physical interactions of the IgH 3' enhancer region with the bcl-2 promoters. Using the chromosome conformation capture technique, we found that the IgH 3' enhancers physically interact with the bcl-2 promoter region over a 350 kb genomic region in t( 14; 18) lymphoma cells. No interactions of the bcl-2 promoter region with sequences distant to the IgH enhancers were observed. The physical interactions of the IgH enhancers with the bcl-2 5' region are functionally involved in the transcriptional control of bcl-2. The histone deacetylase inhibitor, trichostatin A, repressed bcl-2 transcription and decreased the IgH enhancer-bcl-2 promoter region interactions. We showed by chromatin immunoprecipitation assay and small interference RNA transfection studies that the POU2 family transcription factor Oct-2 and its cofactor Bob-1 have an important function in mediating the IgH enhancer-bcl-2 promoter region interactions. This study reveals a new aspect of the regulatory role of the IgH 3' enhancers on bcl-2 transcription in t(14; 18) lymphomas.	[Duan, H.; Xiang, H.; Ma, L.; Boxer, L. M.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Duan, H.; Xiang, H.; Ma, L.; Boxer, L. M.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Palo Alto, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR 1155,269 Campus Dr, Stanford, CA 94305 USA.	lboxer@stanford.edu			National Institutes of Health [CA56764]; NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by National Institutes of Health Grant CA56764. We are grateful to Dr Job Dekker (U Mass) for advice and for providing the 3C protocol, and to Drs Tao Li, Jianqun Lin and Xinwen Qiu in Dr Andrew Hoffman's laboratory at Stanford University for expert assistance with the 3C analysis.	Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Duan H, 2007, ONCOGENE, V26, P2635, DOI 10.1038/sj.onc.1210061; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; Heckman CA, 2006, ONCOGENE, V25, P888, DOI 10.1038/sj.onc.1209127; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2003, CANCER RES, V63, P6666; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Ju ZL, 2007, J BIOL CHEM, V282, P35169, DOI 10.1074/jbc.M705719200; Khamlichi AA, 2000, ADV IMMUNOL, V75, P317, DOI 10.1016/S0065-2776(00)75008-5; Liu Z, 2005, MOL CELL BIOL, V25, P3220, DOI 10.1128/MCB.25.8.3220-3231.2005; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MIELE A, 2006, CURRENT PROTOCOLS MO; Mills FC, 1997, J EXP MED, V186, P845, DOI 10.1084/jem.186.6.845; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Wilson BE, 1996, MOL CELL BIOL, V16, P5546	26	29	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2008	27	53					6720	6728		10.1038/onc.2008.286	http://dx.doi.org/10.1038/onc.2008.286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18695675	Green Accepted			2022-12-17	WOS:000260866200002
J	Araki, K; Kawauchi, K; Tanaka, N				Araki, K.; Kawauchi, K.; Tanaka, N.			IKK/NF-kappa B signaling pathway inhibits cell-cycle progression by a novel Rb-independent suppression system for E2F transcription factors	ONCOGENE			English	Article						E2F; Rb; IKK; NF-kappa B; cell cycle; HAT	TUMOR-NECROSIS-FACTOR; FAMILY-MEMBERS; GROWTH; ALPHA; PHOSPHORYLATION; ACETYLATION; ACTIVATION; DISTINCT; TRANSFORMATION; PROLIFERATION	E2Fs are key regulators of cell-cycle progression, and their transcriptional activities are regulated by histone acetyltransferases (HATs). Retinoblastoma (Rb) family proteins (pRb, p107 and p130) bind to E2Fs and inhibit their transcriptional activities by disrupting HAT binding and recruitment of histone deacetylases. In this study, we show that I kappa B kinases (IKK alpha or IKK beta) activation inhibits cell growth and E2F-dependent transcription in normal human fibroblasts. The inhibition of E2F by IKKs was not observed in cells lacking nuclear factor (NF)-kappa B/p65; however, it was observed in cells lacking three Rb family genes. p65 disrupted the physical interaction between activator E2Fs (F2F1, E2F2 and E2F3) and the HAT cofactor transactivation/transformation-domain associated protein, resulting in a reduction in E2F-responsive gene expression. Furthermore, IKK alpha and IKK beta directly phosphorylated E2F4, resulting in nuclear accumulation and enhanced DNA binding of the E2F4/p130 repressor complex. Our study describes a novel growth inhibitory system that functions by Rb-independent suppression of E2Fs by the IKK/NF-kappa B signaling pathway.	[Araki, K.; Kawauchi, K.; Tanaka, N.] Nippon Med Sch, Dept Mol Oncol, Inst Gerontol, Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Nippon Medical School	Tanaka, N (corresponding author), Nippon Med Sch, Dept Mol Oncol, Inst Gerontol, Nakahara Ku, Kosugicho 1-396, Kawasaki, Kanagawa 2118533, Japan.	nobuta@nms.ac.jp	Kawauchi, Keiko/G-4198-2010	Tanaka, Nobuyuki/0000-0002-6373-2220	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank M Ikeda, K Ohtani, S Sugano, T Doi, MD Cole, G Leone, DV Goeddel, J Sage and T Jacks for providing the materials; K Tobiume, E Oda-Sato, Y Abe, I Uehara, W Nakajima and M Ando for the useful discussion, and Y Asano, H Hiroike and M Kawagoe for technical assistance. This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; AGGARWAL BB, 1995, FEBS LETT, V357, P1, DOI 10.1016/0014-5793(94)01299-G; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Banno T, 2004, J BIOL CHEM, V279, P32633, DOI 10.1074/jbc.M400642200; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; DeGregori J, 2006, CURR MOL MED, V6, P739; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Ferreira R, 2001, ONCOGENE, V20, P3128, DOI 10.1038/sj.onc.1204337; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 2005, TRENDS IMMUNOL, V26, P318, DOI 10.1016/j.it.2005.04.003; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Rowland BD, 2006, CELL, V127, P871, DOI 10.1016/j.cell.2006.11.019; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Spyridopoulos I, 1998, CIRCULATION, V98, P2883, DOI 10.1161/01.CIR.98.25.2883; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Tu Z, 2006, J BIOL CHEM, V281, P6699, DOI 10.1074/jbc.M512439200; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	32	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5696	5705		10.1038/onc.2008.184	http://dx.doi.org/10.1038/onc.2008.184			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542057				2022-12-17	WOS:000259487100005
J	Britschgi, A; Trinh, E; Rizzi, M; Jenal, M; Ress, A; Tobler, A; Fey, MF; Helin, K; Tschan, MP				Britschgi, A.; Trinh, E.; Rizzi, M.; Jenal, M.; Ress, A.; Tobler, A.; Fey, M. F.; Helin, K.; Tschan, M. P.			DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function	ONCOGENE			English	Article						DAPK2; E2F1; KLF6; Sp1; transcription; cell death	KRUPPEL-LIKE FACTOR-6; TRANSCRIPTION FACTORS; PROSTATE-CANCER; CPG ISLAND; APOPTOSIS; KLF6; PROMOTER; PROTEIN; FAMILY; E2F1	Death-associated protein kinase 2 (DAPK2) belongs to a family of proapoptotic Ca(2+)/calmodulin-regulated serine/threonine kinases. We recently identified DAPK2 as an enhancing factor during granulocytic differentiation. To identify transcriptional DAPK2 regulators, we cloned 2.7 kb ofthe 5'-flanking region ofthe DAPK2 gene. We found that E2F1 and Kruppel-like factor 6 (KLF6) strongly activate the DAPK2 promoter. We mapped the E2F1 and KLF6 responsive elements to a GC-rich region 50 of exon 1 containing several binding sites for KLF6 and Sp1 but not for E2F. Moreover, we showed that transcriptional activation of DAPK2 by E2F1 and KLF6 is dependent on Sp1 using Sp1/KLF6-deficient insect cells, mithramycin A treatment to block Sp1-binding or Sp1 knockdown cells. Chromatin immunoprecipitation revealed recruitment of Sp1 and to lesser extent that of E2F1 and KLF6 to the DAPK2 promoter. Activation of E2F1 in osteosarcoma cells led to an increase of endogenous DAPK2 paralleled by cell death. Inhibition of DAPK2 expression resulted in significantly reduced cell death upon E2F1 activation. Similarly, KLF6 expression in H1299 cells increased DAPK2 levels accompanied by cell death that is markedly decreased upon DAPK2 knockdown. Moreover, E2F1 and KLF6 show cooperation in activating the DAPK2 promoter. In summary, our findings establish DAPK2 as a novel Sp1-dependent target gene for E2F1 and KLF6 in cell death response.	[Britschgi, A.; Rizzi, M.; Jenal, M.; Ress, A.; Tobler, A.; Fey, M. F.; Tschan, M. P.] Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; [Trinh, E.; Helin, K.] Univ Copenhagen, Ctr Epigenet, Biotech Res & Innovat Ctr, Copenhagen, Denmark; [Tobler, A.] Univ Hosp Bern, Inselspital, Dept Hematol, CH-3010 Bern, Switzerland; [Fey, M. F.] Univ Hosp Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland	University of Bern; University of Copenhagen; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Tschan, MP (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35, CH-3010 Bern, Switzerland.	mtschan@dkf.unibe.ch	Helin, Kristian/HDM-8306-2022; Rizzi, Mattia/AHE-4168-2022; Helin, Kristian/K-2526-2019; Rizzi, Mattia/ABE-3996-2021	Helin, Kristian/0000-0003-1975-6097; Tschan, Mario P./0000-0001-5897-3647; Rizzi, Mattia/0000-0001-6987-0678	Swiss National Foundation [3100-067213]; Marlies-Schwegler Foundation; Bernese Foundation of Cancer Research; Werner and Hedy Berger-Janser Foundation of Cancer Research; Bern University Research Foundation; Danish Cancer Society	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Marlies-Schwegler Foundation; Bernese Foundation of Cancer Research; Werner and Hedy Berger-Janser Foundation of Cancer Research; Bern University Research Foundation; Danish Cancer Society(Danish Cancer Society)	Expert technical assistance by D Shan and G Arvidsson is appreciated. We are grateful to Drs SL Friedmann, G Thiel and JJ Rossi for providing the KLF6, CBP/p300 and Sp1 expression plasmids as well as an U6 promoter constructs. We also thank Dr D Kojic for providing the Schneider SL2 cells. This work was supported by grants from the Swiss National Foundation 3100-067213 (to AT and MFF); the Marlies-Schwegler Foundation and the Bernese Foundation of Cancer Research (to MFF and AT); the Werner and Hedy Berger-Janser Foundation of Cancer Research (to MFF and MPT); the Bern University Research Foundation (to MPT); and the Danish Cancer Society (to KH).	ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Christoph F, 2006, BRIT J CANCER, V95, P1701, DOI 10.1038/sj.bjc.6603482; DeGregori J, 2006, CURR MOL MED, V6, P739; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Difeo A, 2006, CLIN CANCER RES, V12, P3730, DOI 10.1158/1078-0432.CCR-06-0054; Esteller M, 2001, CANCER RES, V61, P3225; Geng Y, 1996, ONCOGENE, V12, P1173; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; Koutsodontis G, 2004, ONCOGENE, V23, P9190, DOI 10.1038/sj.onc.1208141; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; Li D, 2005, CANCER RES, V65, P9216, DOI 10.1158/0008-5472.CAN-05-1040; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Maruyama R, 2001, CANCER RES, V61, P8659; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Narla G, 2003, AM J PATHOL, V162, P1047, DOI 10.1016/S0002-9440(10)63901-6; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Park KK, 2003, BIOCHEM BIOPH RES CO, V306, P239, DOI 10.1016/S0006-291X(03)00941-0; Putzer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582-4934.2007.00030.x; Radziwill G, 2003, MOL CELL BIOL, V23, P4663, DOI 10.1128/MCB.23.13.4663-4672.2003; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Rizzi M, 2007, J LEUKOCYTE BIOL, V81, P1599, DOI 10.1189/jlb.0606400; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Shohat G, 2002, BBA-PROTEINS PROTEOM, V1600, P45, DOI 10.1016/S1570-9639(02)00443-0; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Stanelle J, 2005, CELL DEATH DIFFER, V12, P347, DOI 10.1038/sj.cdd.4401532; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2005, ARTERIOSCL THROM VAS, V25, P1135, DOI 10.1161/01.ATV.0000165656.65359.23; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Voso MT, 2004, BLOOD, V103, P698, DOI 10.1182/blood-2003-07-2249; Xie W, 2006, NUCLEIC ACIDS RES, V34, P2046, DOI 10.1093/nar/gkl150; Yin D, 2007, INT J ONCOL, V30, P65	50	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	43					5706	5716		10.1038/onc.2008.179	http://dx.doi.org/10.1038/onc.2008.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18521079				2022-12-17	WOS:000259487100006
J	Matsui, Y; Watanabe, J; Ikegawa, M; Kamoto, T; Ogawa, O; Nishiyama, H				Matsui, Y.; Watanabe, J.; Ikegawa, M.; Kamoto, T.; Ogawa, O.; Nishiyama, H.			Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3 beta with p53	ONCOGENE			English	Article						urothelial cancer; cisplatin; triptolide; p53; p21; GSK3 beta	TUMOR-NECROSIS-FACTOR; KINASE-C-ALPHA; TRIPTERYGIUM-WILFORDII; INDUCED APOPTOSIS; BLADDER-CANCER; CELL-DEATH; SUSTAINED ACTIVATION; CARCINOMA-CELLS; DNA-DAMAGE; PROLIFERATION	To improve conventional chemotherapeutic efficacy, a combination use of traditional medicines is effective but detailed mechanisms have been rarely elucidated. In the this study, we attempted to clarify how triptolide (PG490), an oxygenated diterpene derived from a Chinese herb, enhances the cisplatin (CDDP)-induced cytotoxicity in urothelial cancer cells. Our results showed that a combined CDDP/triptolide therapy induced apoptosis in urothelial cancer cell lines with wild-type p53, but not in those with mutant-type p53 or normal human urothelium. As the mechanism, triptolide suppressed CDDP-induced p53 transcriptional activity, leading to p21 attenuation, which promoted apoptosis via the activation of c-Jun N-terminal kinase (JNK) and Bax. We further demonstrated that the functional regulation of p53 by triptolide was mediated by an intranuclear association of p53 with glycogen synthase kinase-3 beta (GSK3 beta), which was inactivated by protein kinase C (PKC). This modulation of the PKC-GSK3 beta axis by triptolide was observed in a cancer-specific manner. A mouse xenograft model also showed that a combined CDDP/triptolide therapy completely suppressed tumor growth without any side effects. We expect that cancer-specific enhancement of CDDP-induced cytotoxicity with triptolide may effectively overcome the resistance to a CDDP-based conventional chemotherapy as a treatment for urothelial cancer.	[Matsui, Y.; Watanabe, J.; Kamoto, T.; Ogawa, O.; Nishiyama, H.] Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 6608507, Japan; [Ikegawa, M.] Kyoto Prefectural Univ, Grad Sch Med Sci, Dept Genom Med Sci, Kyoto 606, Japan	Kyoto University; Kyoto Prefectural University	Ogawa, O (corresponding author), Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6608507, Japan.	ogawao@kuhp.kyoto-u.ac.jp	MATSUI, Yoshiyuki/I-2323-2019; Ikegawa, Masaya/AAG-5327-2020					Aaltonen V, 2006, J HISTOCHEM CYTOCHEM, V54, P795, DOI 10.1369/jhc.5A6839.2006; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Camacho-Carvajal MM, 2004, MOL CELL PROTEOMICS, V3, P176, DOI 10.1074/mcp.T300010-MCP200; Carter BZ, 2006, BLOOD, V108, P630, DOI 10.1182/blood-2005-09-3898; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Chen BJ, 2000, TRANSPLANTATION, V70, P1442, DOI 10.1097/00007890-200011270-00008; Cibere J, 2003, J RHEUMATOL, V30, P465; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fidler JM, 2003, MOL CANCER THER, V2, P855; Gartel AL, 2002, MOL CANCER THER, V1, P639; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Jiang XH, 2004, CANCER RES, V64, P5787, DOI 10.1158/0008-5472.CAN-03-1172; Jiang XH, 2001, ONCOGENE, V20, P8009, DOI 10.1038/sj.onc.1204981; Koivunen J, 2004, CANCER RES, V64, P5693, DOI 10.1158/0008-5472.CAN-03-3511; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; Lam KS, 2003, ACCOUNTS CHEM RES, V36, P370, DOI 10.1021/ar0201299; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lou YJ, 2005, LEUKEMIA RES, V29, P99, DOI 10.1016/j.leukres.2004.05.014; Mandil R, 2001, CANCER RES, V61, P4612; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Matsui Y, 2007, CANCER RES, V67, P1212, DOI 10.1158/0008-5472.CAN-06-3283; Miyata Y, 2005, BIOCHEM BIOPH RES CO, V336, P1081, DOI 10.1016/j.bbrc.2005.08.247; Nishiyama H, 2004, EUR UROL, V45, P176, DOI 10.1016/j.eururo.2003.09.011; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nogawa M, 2005, CANCER LETT, V217, P243, DOI 10.1016/j.canlet.2004.07.010; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; SARKIS AS, 1995, J CLIN ONCOL, V13, P1384, DOI 10.1200/JCO.1995.13.6.1384; Shamon LA, 1997, CANCER LETT, V112, P113, DOI 10.1016/S0304-3835(96)04554-5; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Tan J, 2005, CANCER RES, V65, P9012, DOI 10.1158/0008-5472.CAN-05-1226; Wan CK, 2006, CANCER LETT, V241, P31, DOI 10.1016/j.canlet.2005.10.001; Watanabe J, 2006, ONCOGENE, V25, P2500, DOI 10.1038/sj.onc.1209162; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Weiss RH, 2003, CANCER LETT, V189, P39, DOI 10.1016/S0304-3835(02)00495-0; Yang SM, 2003, MOL CANCER THER, V2, P65	42	29	33	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4603	4614		10.1038/onc.2008.89	http://dx.doi.org/10.1038/onc.2008.89			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18391982				2022-12-17	WOS:000258077300009
J	Nakamura, K; Ichise, H; Nakao, K; Hatta, T; Otani, H; Sakagami, H; Kondo, H; Katsuki, M				Nakamura, K.; Ichise, H.; Nakao, K.; Hatta, T.; Otani, H.; Sakagami, H.; Kondo, H.; Katsuki, M.			Partial functional overlap of the three ras genes in mouse embryonic development	ONCOGENE			English	Article						H-Ras; N-Ras; K-Ras; gene targeting; knockout mice; transgenic mice	H-RAS; K-RAS; PLASMA-MEMBRANE; N-RAS; EXPRESSION; LOCALIZATION; PROTEIN; GROWTH; CELLS; MICE	In mammals, three ras genes, H-ras, N-ras and K-ras, encode homologous but distinct 21-kDa Ras proteins. We examined the in vivo functional relationship of the three ras genes in mouse embryonic development by investigating the phenotypes of mice deficient in one or multiple ras genes. H-ras(-/-) mice and N-ras(-/-) mice as well as a substantial proportion of H-ras(-/-)/N-ras(-/-) mice expressing only the K-ras gene were viable, while K-ras(-/-) mice were embryonically lethal, as have been reported previously. N-ras(-/-)/K-ras(+/-) mice died neonatally, while H-ras(-/-)/K-ras(-/-) embryos died much earlier than K-ras homozygous mutant fetuses. To further investigate the functional relationship of the ras genes in embryonic development, we introduced a human H-ras transgene into single or multiple ras mutant mice and found that the transgene rescued mice, including triple ras mutants, from embryonic lethality in association with correction of thin ventricular walls of the heart in null K-ras mutant mice. In situ hybridization revealed that the expression of the H-ras transgene on embryonic day E13.5 and E15.5 was more intense in major organs, including the heart, than those of endogenous ras genes. We therefore conclude that the functions of the ras genes are partially overlapping in mouse embryonic development.	[Nakamura, K.] Mitsubishi kagaku Inst Life Sci, Mouse Genome Technol Lab, Tokyo, Japan; [Ichise, H.] Univ Tokyo, Lab Gene Express & Regulat, Ctr Med Expt, Inst Med Sci,Minato Ku, Tokyo, Japan; [Nakao, K.] Ctr Dev Biol, Lab Anim Resources & Genet Engn, Chuo Ku, Kobe, Hyogo, Japan; [Hatta, T.; Otani, H.] Shimane Univ, Fac Med, Dept Anat, Izumo, Shimane, Japan; [Sakagami, H.; Kondo, H.] Tohoku Univ, Div Histol, Dept Cell Biol, Grad Sch Med Sci, Sendai, Miyagi 980, Japan; [Katsuki, M.] Natl Inst Basic Biol, Okazaki, Aichi 444, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); University of Tokyo; Shimane University; Tohoku University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Katsuki, M (corresponding author), Natl Inst Nat Sci, Minato Ku, Toranomon 4-3-13, Tokyo 1050001, Japan.	katsuki@nibb.ac.jp	Ichise, Hirotake/V-3536-2019	Ichise, Hirotake/0000-0002-3424-6637; zhong wei, he gui/0000-0002-3066-3564				Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Hancock JF, 2005, BIOCHEM J, V389, P1, DOI 10.1042/BJ20050231; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHER J, 1995, ONCOGENE, V11, P1639; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Manabe T, 2000, J NEUROSCI, V20, P2504; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Perez de Castro I, 2003, CANCER RES, V63, P1615; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; SAITOH A, 1990, ONCOGENE, V5, P1195; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yamaguchi H, 1996, GENES CELLS, V1, P253, DOI 10.1046/j.1365-2443.1996.d01-238.x	30	29	30	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2961	2968		10.1038/sj.onc.1210956	http://dx.doi.org/10.1038/sj.onc.1210956			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059342				2022-12-17	WOS:000255681700003
J	Wiesner, C; Winsauer, G; Resch, U; Hoeth, M; Schmid, JA; Van Hengel, J; Van Roy, F; Binder, BR; De Martin, R				Wiesner, C.; Winsauer, G.; Resch, U.; Hoeth, M.; Schmid, J. A.; Van Hengel, J.; Van Roy, F.; Binder, B. R.; De Martin, R.			alpha-Catulin, a Rho signalling component, can regulate NF-kappa B through binding to IKK-beta, and confers resistance to apoptosis	ONCOGENE			English	Article						Rho; alpha-catulin; IKK-beta; NF-kappa B	SERUM RESPONSE FACTOR; ENDOTHELIAL-CELLS; TRANSCRIPTION FACTORS; ADHESION COMPLEX; EPITHELIAL-CELLS; PROTEIN-RHO; CATENIN; ACTIVATION; ACTIN; IDENTIFICATION	Rho GTPases regulate diverse cellular functions including adhesion, cytokinesis and motility, as well as the activity of the transcription factors NF-kappa B, serum response factor and C/EBP. alpha-Catulin, an alpha-catenin-related protein that shares structural similarities with cytoskeletal linker proteins, facilitates Rho signalling by serving as a scaffold for the Rho-specific guanine nucleotide exchange factor Lbc. We report here that alpha-catulin also interacts with a key component of the NF-kappa B signalling pathway, namely the I kappa B kinase (IKK)-beta. In co-immunoprecipitations, alpha-catulin can bind IKK-beta and Lbc. Ectopic expression of alpha-catulin augmented NF-kappa B activity, promoted cell migration and increased resistance to apoptosis, whereas knockdown experiments showed the opposite effects. Together, these features suggest that alpha-catulin has tumorigenic potential.	[Wiesner, C.; Winsauer, G.; Resch, U.; Hoeth, M.; Schmid, J. A.; Binder, B. R.; De Martin, R.] Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria; [Van Hengel, J.; Van Roy, F.] Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; [Van Hengel, J.; Van Roy, F.] Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Medical University of Vienna; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	De Martin, R (corresponding author), Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, Lazarettg 19, A-1090 Vienna, Austria.	rainer.demartin@meduniwien.ac.at	van Roy, Frans M/C-6123-2009; Schmid, Johannes A./C-7659-2009	van Roy, Frans M/0000-0003-4358-1039; Schmid, Johannes A./0000-0002-6586-3507; Resch, Ulrike/0000-0002-8380-9555; Wiesner, Christoph/0000-0002-3281-0695				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; BEG AA, 1996, SCIENCE, V274, P784; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brock A. L., 2005, Molecular & Cellular Biomechanics, V2, P135; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Dutt P, 2004, CELL SIGNAL, V16, P201, DOI 10.1016/S0898-6568(03)00132-3; Ebner K, 2003, BLOOD, V102, P192, DOI 10.1182/blood-2002-12-3753; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Hippenstiel S, 2002, BIOCHEM PHARMACOL, V64, P971, DOI 10.1016/S0006-2952(02)01162-0; Hofer-Warbinek R, 2004, CELL DEATH DIFFER, V11, P1317, DOI 10.1038/sj.cdd.4401502; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Janssens B, 1999, BBA-GENE STRUCT EXPR, V1447, P341, DOI 10.1016/S0167-4781(99)00170-0; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Merdek KD, 2004, MOL CELL BIOL, V24, P2410, DOI 10.1128/MCB.24.6.2410-2422.2004; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park B, 2002, J BIOL CHEM, V277, P45361, DOI 10.1074/jbc.M202447200; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Surpili MJ, 2003, BIOCHEMISTRY-US, V42, P15369, DOI 10.1021/bi034575v; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHANG JC, 1995, J THORAC CARDIOV SUR, V109, P1059, DOI 10.1016/S0022-5223(95)70188-5; Zhang JS, 1998, GENOMICS, V54, P149, DOI 10.1006/geno.1998.5458; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	43	29	31	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2159	2169		10.1038/sj.onc.1210863	http://dx.doi.org/10.1038/sj.onc.1210863			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952117				2022-12-17	WOS:000254621300006
J	Camacho-Leal, P; Stanners, CP				Camacho-Leal, P.; Stanners, C. P.			The human carcinoembryonic antigen (CEA) GPI anchor mediates anoikis inhibition by inactivation of the intrinsic death pathway	ONCOGENE			English	Article						CEA; anoikis; molecular mechanism; caspases	HUMAN-TUMOR-MARKER; INTERCELLULAR-ADHESION MOLECULE; CYTOCHROME-C RELEASE; SIGNALING PATHWAY; CASPASE ACTIVATION; CELL-SURVIVAL; GENE FAMILY; INTEGRIN; DIFFERENTIATION; EXPRESSION	Human carcinoembryonic antigen (CEA) is a cell surface adhesion molecule member of the Immunoglobulin Superfamily (IgSF). Aberrant upregulation of CEA is a common feature found in a wide variety of human cancers such as colon, breast and lung. Previous in vitro and in vivo results have demonstrated that CEA can have tumorigenic effects including the inhibition of cell differentiation and anoikis, a specific type of apoptosis triggered by the absence of extracellular matrix-cell contacts. In the present work, we investigate the involvement of the caspase cascade in CEA-mediated inhibition of anoikis and the structural requirements for this signal. Expression of CEA and/or a chimeric protein consisting of the NCAM extracellular domain attached to the CEA-GPI anchor correlates with an early inactivation of caspase-9 and activation of the PI3-K/Akt survival pathway, and at later times, inactivation of caspase-8. The CEA-mediated caspase inactivation as well as activation of Akt was not observed by expression of a CEA molecule incapable of self-binding (DNCEA). These results suggest that the intrinsic caspase pathway is involved in the inhibitory effects of anoikis by CEA and this signal is dependent on the presence of self-adhesive extracellular domains and a CEA-GPI anchor.	[Camacho-Leal, P.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Stanners, CP (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	cliff.stanners@mcgill.ca						BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Camacho-Leal P, 2007, J CELL PHYSIOL, V211, P791, DOI 10.1002/jcp.20989; CHA YJ, 2001, EXP MOL MED, V33, P28492; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Nollau P, 1997, CANCER RES, V57, P2354; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; Ordonez C, 2000, CANCER RES, V60, P3419; Ordonez C, 2007, J CELL PHYSIOL, V210, P757, DOI 10.1002/jcp.20887; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Rennebeck G, 2005, CANCER RES, V65, P11230, DOI 10.1158/0008-5472.CAN-05-2763; Rojas M, 1996, CELL GROWTH DIFFER, V7, P655; ROSENBERG M, 1993, CANCER RES, V53, P4938; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; Soeth E, 2001, CLIN CANCER RES, V7, P2022; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P57; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Taheri M, 2003, J BIOL CHEM, V278, P14632, DOI 10.1074/jbc.M212500200; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Tiberio R, 2002, FEBS LETT, V524, P139, DOI 10.1016/S0014-5793(02)03040-5; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	39	29	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1545	1553		10.1038/sj.onc.1210789	http://dx.doi.org/10.1038/sj.onc.1210789			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17891182				2022-12-17	WOS:000253815800006
J	Neise, D; Graupner, V; Gillissen, BF; Daniel, PT; Schulze-Osthoff, K; Janicke, RU; Essmann, F				Neise, D.; Graupner, V.; Gillissen, B. F.; Daniel, P. T.; Schulze-Osthoff, K.; Jaenicke, R. U.; Essmann, F.			Activation of the mitochondrial death pathway is commonly mediated by a preferential engagement of Bak	ONCOGENE			English	Article						apoptosis; Bak; Bax; Bcl-2; caspase; cytochrome c	BCL-2 FAMILY-MEMBERS; BH3 MIMETIC ABT-737; INDUCED APOPTOSIS; CELL-DEATH; BH3-ONLY PROTEINS; INTERCHAIN PROTEOLYSIS; CANCER CELLS; X-L; CASPASE-3; MCL-1	Among the members of the Bcl-2 family, the multidomain proteins Bax and Bak are crucial for the activation of mitochondria. However, it is still unclear whether they act in a unique and distinct manner or whether they exhibit redundant functions. To systematically investigate their activation on a single-cell level, we established MCF-7 cell lines stably expressing GFP-fusion variants of these proteins. We found that MCF-7/GFP-Bak cells showed an increased sensitivity to apoptosis induction by staurosporine, actinomycin D, TRAIL and overexpression of Puma compared to GFP-Bax-expressing cells. Independently of the death stimulus used, oligomerization of endogenous and exogenous Bak was mostly detected prior to an activation of Bax, whereas cells displaying oligomerized Bax in the absence of Bak clusters were not observed. In addition, activation of Bax but not Bak was attenuated by a caspase inhibitor. Consistent with this, caspase-3-deficient MCF-7 cells displayed a significantly reduced activation of endogenous Bax than caspase-3-proficient MCF-7 cells. Thus, our data strongly suggest that diverse apoptotic stimuli preferentially engage the Bak pathway, whereas the triggering of Bax occurs, at least partially, downstream of mitochondrial caspase activation, most likely constituting a positive feedback loop for the amplication of the death signal.	[Neise, D.; Graupner, V.; Schulze-Osthoff, K.; Jaenicke, R. U.; Essmann, F.] Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, NRW, Germany; [Gillissen, B. F.; Daniel, P. T.] Univ Med Ctr, Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Heinrich Heine University Dusseldorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Essmann, F (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, NRW, Germany.	essmann@uni-duesseldorf.de	Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adams KW, 2007, J BIOL CHEM, V282, P6192, DOI 10.1074/jbc.M610643200; Blanc C, 2000, CANCER RES, V60, P4386; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Han J, 2004, LEUKEMIA, V18, P1671, DOI 10.1038/sj.leu.2403496; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Letai A, 2005, J CLIN INVEST, V115, P2648, DOI 10.1172/JCI26250; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lindenboim L, 2005, CELL DEATH DIFFER, V12, P713, DOI 10.1038/sj.cdd.4401638; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; Lucken-Ardjomande S, 2005, J CELL SCI, V118, P473, DOI 10.1242/jcs.01654; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Murphy BM, 2004, J BIOL CHEM, V279, P36916, DOI 10.1074/jbc.M402039200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Pardo J, 2006, J CELL BIOL, V174, P509, DOI 10.1083/jcb.200604044; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Pop C, 2006, MOL CELL, V22, P269, DOI 10.1016/j.molcel.2006.03.009; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Shimazu T, 2007, GENE DEV, V21, P929, DOI 10.1101/gad.1522007; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	51	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1387	1396		10.1038/sj.onc.1210773	http://dx.doi.org/10.1038/sj.onc.1210773			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724463				2022-12-17	WOS:000253548200005
J	Downs, JA				Downs, J. A.			Chromatin structure and DNA double-strand break responses in cancer progression and therapy	ONCOGENE			English	Review						chromatin; DNA repair; genome stability; linker histone; H2A; H2AX; HMGB	HISTONE DEACETYLASE INHIBITOR; TELOMERE MAINTENANCE; H2AX PHOSPHORYLATION; GENOMIC INSTABILITY; IONIZING-RADIATION; DAMAGE RESPONSE; REPAIR PROTEINS; HUMAN TUMOR; RECOMBINATION; CELLS	Defects in the detection and repair of DNA double-strand breaks (DSBs) have been causatively linked to tumourigenesis. Moreover, inhibition of DNA damage responses (DDR) can increase the efficacy of cancer therapies that rely on generation of damaged DNA. DDR must occur within the context of chromatin, and there have been significant advances in recent years in understanding how the modulation and manipulation of chromatin contribute to this activity. One particular covalent modification of a histone variant-the phosphorylation of H2AX-has been investigated in great detail and has been shown to have important roles in DNA DSB responses and in preventing tumourigenesis. These studies are reviewed here in the context of their relevance to cancer therapy and diagnostics. In addition, there is emerging evidence for contributions by proteins involved in mediating higher order structure to DNA DSB responses. The contributions of a subset of these proteins-linker histones and high-mobility group box (HMGB) proteins-to DDR and their potential significance in tumourigenesis are discussed.	Univ Sussex, MRC Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Sussex	Downs, JA (corresponding author), Univ Sussex, MRC Genome Damage & Stabil Ctr, Sci Pk Rd, Brighton BN1 9RQ, E Sussex, England.	j.a.downs@sussex.ac.uk		Downs, Jessica/0000-0002-6600-849X				Alami R, 2003, P NATL ACAD SCI USA, V100, P5920, DOI 10.1073/pnas.0736105100; Ausio J, 2000, BIOESSAYS, V22, P873, DOI 10.1002/1521-1878(200010)22:10<873::AID-BIES1>3.3.CO;2-I; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bergeron S, 2005, J BIOL CHEM, V280, P31314, DOI 10.1074/jbc.M503063200; Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Costelloe T, 2006, EXP CELL RES, V312, P2677, DOI 10.1016/j.yexcr.2006.06.031; Cowell IG, 2005, BIOCHEM PHARMACOL, V71, P13, DOI 10.1016/j.bcp.2005.09.029; Dai Y, 2005, MOL CELL BIOL, V25, P4413, DOI 10.1128/MCB.25.11.4413-4425.2005; Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532; Downs JA, 2003, MOL CELL, V11, P1685, DOI 10.1016/S1097-2765(03)00197-7; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Funayama R, 2006, J CELL BIOL, V175, P869, DOI 10.1083/jcb.200604005; Gallmeier E, 2005, CARCINOGENESIS, V26, P1811, DOI 10.1093/carcin/bgi132; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harvey AC, 2004, MOL MICROBIOL, V53, P771, DOI 10.1111/j.1365-2958.2004.04195.x; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; HASHIMOTO H, 2007, IN PRESS DNA REPAIR; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Kao J, 2006, CURR CANCER DRUG TAR, V6, P197, DOI 10.2174/156800906776842957; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Lavin MF, 2006, EMBO REP, V7, P154, DOI 10.1038/sj.embor.7400629; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madhusudan S, 2005, CANCER TREAT REV, V31, P603, DOI 10.1016/j.ctrv.2005.09.006; Mahrhofer H, 2006, INT J RADIAT ONCOL, V64, P573, DOI 10.1016/j.ijrobp.2005.09.037; Meng LH, 2005, CANCER RES, V65, P5337, DOI 10.1158/0008-5472.CAN-05-0003; Michor F, 2005, PHILOS T R SOC B, V360, P631, DOI 10.1098/rstb.2004.1617; Morrison AJ, 2005, CELL CYCLE, V4, P568; Munshi A, 2006, MOL CANCER THER, V5, P1967, DOI 10.1158/1535-7163.MCT-06-0022; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nagaki S, 1998, BIOCHEM BIOPH RES CO, V246, P137, DOI 10.1006/bbrc.1998.8589; Neumann AA, 2002, NAT REV CANCER, V2, P879, DOI 10.1038/nrc929; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Qian XZ, 2006, MOL CANCER THER, V5, P2086, DOI 10.1158/1535-7163.MCT-06-0111; Qvarnstrom OF, 2004, RADIOTHER ONCOL, V72, P311, DOI 10.1016/j.radonc.2004.07.009; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Raucci A, 2007, AUTOIMMUNITY, V40, P285, DOI 10.1080/08916930701356978; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Reeves R, 2005, DNA REPAIR, V4, P926, DOI 10.1016/j.dnarep.2005.04.010; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Stros M, 2000, EUR J BIOCHEM, V267, P4088, DOI 10.1046/j.1432-1327.2000.01450.x; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741; Ueda T, 2002, BBA-MOL CELL RES, V1593, P77, DOI 10.1016/S0167-4889(02)00332-4; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Williams RS, 2007, BIOCHEM CELL BIOL, V85, P509, DOI 10.1139/O07-069; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yamakov V, 2002, NAT MATER, V1, P45, DOI 10.1038/nmat700; Yoshida K, 2004, CANCER RES, V64, P4131, DOI 10.1158/0008-5472.CAN-03-2566; Yu T, 2006, DNA REPAIR, V5, P935, DOI 10.1016/j.dnarep.2006.05.040	67	29	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7765	7772		10.1038/sj.onc.1210874	http://dx.doi.org/10.1038/sj.onc.1210874			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066089				2022-12-17	WOS:000251537900007
J	Christensen, KL; Brennan, JDG; Aldridge, CS; Ford, HL				Christensen, K. L.; Brennan, J. D. G.; Aldridge, C. S.; Ford, H. L.			Cell cycle regulation of the human Six1 homeoprotein is mediated by APC(Cdh1)	ONCOGENE			English	Article						Six1; anaphase-promoting complex; Cdh1; proteasome; homeoprotein; cell cycle	ANAPHASE-PROMOTING COMPLEX; DESTRUCTION BOX; DNA-DAMAGE; AURORA-A; PROTEIN; DEGRADATION; RECOGNITION; EXPRESSION; MECHANISM; SYSTEM	The Six1 homeoprotein is an important mediator of normal development, where it is critical for the proliferation of precursor cell populations that ultimately constitute the muscle, kidney and inner ear, among other organs. Interestingly, its overexpression has been observed in numerous cancers, where it contributes to the proliferative and metastatic ability of the cancer cells. Here we show that Six1 not only regulates the cell cycle, but is itself regulated throughout the cell cycle via ubiquitin-mediated proteolysis. The protein is present from the G(1)/S boundary until mitosis, when it is degraded via the anaphase-promoting complex (APC) with its activating subunit Cdh1. However, unlike most identified APC(Cdh1) targets, Six1 does not contain functional destruction or KEN box motifs that are necessary for its degradation. Instead, the Six1 protein contains multiple, as yet undefined, sequences within its N- and C-termini responsible for its degradation, including an N-terminal region that binds to Cdh1. Cell cycle regulation of Six1 occurs both transcriptionally and post-translationally via phosphorylation; therefore, this study demonstrates a third and novel mechanism of cell cycle-specific regulation of Six1, underscoring the importance of confining its activity to a defined cell cycle window from the G(1)/S boundary to early mitosis.	Univ Colorado, Dept Obstet & Gynecol, Aurora, CO 80045 USA; Hlth Sci Ctr, Aurora, CO USA; Univ Colorado, Program Mol Biol, Denver, CO 80202 USA; Univ Colorado, Dept Biochem & Mol Genet, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Boulder	Ford, HL (corresponding author), Univ Colorado, Dept Obstet & Gynecol, Mailstop 8309,12800 E 19th Ave,POB 6511, Aurora, CO 80045 USA.	heide.ford@uchsc.edu			NCI NIH HHS [R01 CA095277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Araki M, 2005, GENE DEV, V19, P2458, DOI 10.1101/gad.1361905; Brodbeck S, 2004, MECH DEVELOP, V121, P1211, DOI 10.1016/j.mod.2004.05.019; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; Castro A, 2005, ONCOGENE, V24, P314, DOI 10.1038/sj.onc.1207973; Castro A, 2003, MOL CELL BIOL, V23, P4126, DOI 10.1128/MCB.23.12.4126-4138.2003; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Eytan E, 2006, P NATL ACAD SCI USA, V103, P2081, DOI 10.1073/pnas.0510695103; Fang CH, 1998, INT J MOL MED, V1, P163; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; FORD HL, 1995, ONCOGENE, V10, P1597; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Gabellini D, 2003, EMBO J, V22, P3715, DOI 10.1093/emboj/cdg340; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JAMIESON C, 1991, J IMMUNOL, V147, P416; Kawakami K, 2000, BIOESSAYS, V22, P616, DOI 10.1002/1521-1878(200007)22:7<616::AID-BIES4>3.3.CO;2-I; Kenyon KL, 2005, DEV BIOL, V286, P158, DOI 10.1016/j.ydbio.2005.07.017; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; Ozaki H, 2004, DEVELOPMENT, V131, P551, DOI 10.1242/dev.00943; Park KH, 2005, BREAST CANCER RES, V7, pR238, DOI 10.1186/bcr978; Passmore LA, 2005, EMBO REP, V6, P873, DOI 10.1038/sj.embor.7400482; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Zheng WM, 2003, DEVELOPMENT, V130, P3989, DOI 10.1242/dev.00628	36	29	32	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3406	3414		10.1038/sj.onc.1210122	http://dx.doi.org/10.1038/sj.onc.1210122			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130831				2022-12-17	WOS:000246579600010
J	Nakazawa, Y; Suzuki, M; Manabe, N; Yamada, T; Kihara-Negishi, F; Sakurai, T; Tenen, DG; Iwama, A; Mochizuki, M; Oikawa, T				Nakazawa, Y.; Suzuki, M.; Manabe, N.; Yamada, T.; Kihara-Negishi, F.; Sakurai, T.; Tenen, D. G.; Iwama, A.; Mochizuki, M.; Oikawa, T.			Cooperative interaction between ETS1 and GFI1 transcription factors in the repression of Bax gene expression	ONCOGENE			English	Article						ETS1; GFI1; Bax; transcription; cross-talk	ZINC-FINGER PROTEIN; T-CELL DEATH; TERNARY COMPLEX; DIFFERENTIATION; ACTIVATION; PU.1; FAMILY; DNA; HEMATOPOIESIS; LEUKEMIA	The proto-oncoproteins ETS1 and growth factor independent-1 (GFI1) are implicated in cell growth and differentiation in various types of cells, and their deregulated expression is involved in malignant transformation. Here, we report that ETS1 and GFI1 interact and affect gene expression through their cross-talk. Co-immunoprecipitation analyses and glutathione-S-transferase pull-down assays revealed that ETS1 bound directly to GFI1 via its Ets domain, and GFI1 bound to ETS1 via its zinc-finger domain. Luciferase (Luc) assays using artificial reporters showed that GFI1 repressed ETS1-mediated transcriptional activation and ETS1 repressed GFI1-mediated transcriptional activation, in a dose-dependent manner. However, in the Bax promoter where the Ets- and Gfi-binding sites (EBS and GBS) are adjacent, ETS1 and GFI1 cooperatively reduced activation. Site-directed mutagenesis on the EBS and GBS of the Bax promoter showed that both binding sites were necessary for full repression. Chromatin immunoprecipitation analyses con. rmed that an ETS1-GFI1 complex formed on the Bax promoter even when either EBS or GBS was mutated. Introduction of small interfering RNA against ETS1 and/ or GFI1 enhanced endogenous Bax gene expression. Our results suggest that the interaction between ETS1 and GFI1 facilitates their binding to speci. c sites on the Bax promoter and represses Bax expression in vivo.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan; Kyoritsu Coll Pharmaceut Sci, Div Organ & Bioorgan Chem, Minato Ku, Tokyo, Japan; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan	Harvard University; Harvard Medical School; Chiba University	Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	oikawat@hoku-iryo-u.dc.jp		Tenen, Daniel/0000-0002-6423-3888				BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Davidson B, 2003, CANCER METAST REV, V22, P103, DOI 10.1023/A:1022272204045; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Duan Zhijun, 2003, Hematology, V8, P339, DOI 10.1080/10245330310001612116; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; Escalante CR, 2002, MOL CELL, V10, P1097, DOI 10.1016/S1097-2765(02)00703-7; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; HELLE JP, 1997, MOL CELL BIOL, V17, P4220; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kazanjian A, 2004, CANCER RES, V64, P6874, DOI 10.1158/0008-5472.CAN-04-0633; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; OIKAWA T, 2005, MOL GENETICS CANC, P119; Osawa M, 2002, BLOOD, V100, P2769, DOI 10.1182/blood-2002-01-0182; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sledz CA, 2005, BLOOD, V106, P787, DOI 10.1182/blood-2004-12-4643; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yucel R, 2003, J EXP MED, V197, P831, DOI 10.1084/jem.20021417; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	40	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3541	3550		10.1038/sj.onc.1210140	http://dx.doi.org/10.1038/sj.onc.1210140			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17213822				2022-12-17	WOS:000246799200010
J	Ma, C; Zhang, J; Durrin, LK; Lv, J; Zhu, D; Han, X; Sun, Y				Ma, C.; Zhang, J.; Durrin, L. K.; Lv, J.; Zhu, D.; Han, X.; Sun, Y.			The BCL2 major breakpoint region (mbr) regulates gene expression	ONCOGENE			English	Article						BCL2; mbr; t(14;18); homologous recombination; gene regulation	T(14/18) LYMPHOMA-CELLS; MAR-BINDING PROTEIN; AU-RICH ELEMENT; HEMATOPOIETIC-CELLS; CODING SEQUENCE; DOWN-REGULATION; MESSENGER-RNA; APOPTOSIS; SATB1; SITE	BCL2 expression is finely tuned by a variety of environmental and endogenous stimuli and regulated at both transcriptional and post-transcriptional levels. Our previous investigations demonstrated that the BCL2 major breakpoint region (mbr) in the 30-UTR upregulates reporter gene expression, which implies that this region possessed intrinsic regulatory function. However, the effect of the mbr on BCL2 expression, and the underlying regulatory mechanisms, remain to be elucidated. To assess the direct effect of the mbr on the transcriptional activity of the BCL2 gene, we employed targeted homologous recombination to establish a mbr(+) / mbr(-) heterozygous Nalm-6 cell line and then compared the transcriptional activity and apoptotic effect on transcription between the wild type and targeted alleles. We found that deletion of the mbr significantly decreased the transcriptional activity of the corresponding allele in the mbr(+)/mbr(-) cell. The BCL2 allele deleted of the mbr had a slower response to apoptotic stimuli than did the wild type allele. The regulatory function of the mbr was mediated through SATB1. Overexpression of SATB1 increased BCL2 expression, while knockdown of SATB1 with RNAi decreased BCL2 expression. Our results clearly indicated that the mbr could positively regulate BCL2 gene expression and this regulatory function was closely related to SATB1.	Nanjing Med Univ, Coll Basic Med, Key Lab Human Funct Genom & Jiangsu Province, Nanjing 210029, Peoples R China; Nanjing Med Univ, Dept Cell Biol & Med Genet, Nanjing 210029, Peoples R China; Nanjing Med Univ, Sch Pharm, Nanjing 210029, Peoples R China; City Hope Natl Med Ctr, Dept Mol Med, Duarte, CA 91010 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; City of Hope	Sun, Y (corresponding author), Nanjing Med Univ, Coll Basic Med, Key Lab Human Funct Genom & Jiangsu Province, Hangzhong Rd 140, Nanjing 210029, Peoples R China.	hanxiao@njmu.edu.cn; yujiesun@njmu.edu.cn						Adams JM, 1999, COLD SPRING HARB SYM, V64, P351, DOI 10.1101/sqb.1999.64.351; Alvarez JD, 2000, GENE DEV, V14, P521; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHEN M, 1995, CANCER RES, V55, P991; DELIC J, 1991, BIOCHEM BIOPH RES CO, V181, P818, DOI 10.1016/0006-291X(91)91263-C; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DICROCE PA, 1995, P NATL ACAD SCI USA, V92, P10137, DOI 10.1073/pnas.92.22.10137; Donnini M, 2004, J BIOL CHEM, V279, P20154, DOI 10.1074/jbc.M314071200; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KATO M, 1992, J BIOCHEM-TOKYO, V112, P492, DOI 10.1093/oxfordjournals.jbchem.a123927; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; Lang G, 2005, IMMUNOLOGY, V114, P25, DOI 10.1111/j.1365-2567.2004.02073.x; MIYASHITA T, 1994, CANCER RES, V54, P3131; Narla RK, 2001, LEUKEMIA LYMPHOMA, V41, P625, DOI 10.3109/10428190109060353; Patrone G, 2000, BIOTECHNIQUES, V29, P1012, DOI 10.2144/00295st02; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Raghavan SC, 2005, J BIOL CHEM, V280, P22749, DOI 10.1074/jbc.M502952200; Ramakrishnan M, 2000, MOL CELL BIOL, V20, P868, DOI 10.1128/MCB.20.3.868-877.2000; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Sun YJ, 2006, CELL BIOL INT, V30, P244, DOI 10.1016/j.cellbi.2005.10.025; Suzuki A, 1996, ONCOGENE, V13, P31; Tong X, 2005, J BIOL CHEM, V280, P15503, DOI 10.1074/jbc.M411978200; Tsurusawa M, 1997, INT J HEMATOL, V66, P79; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang JJ, 2006, GENE, V379, P127, DOI 10.1016/j.gene.2006.05.002; Zhang MX, 2005, P NATL ACAD SCI USA, V102, P16967, DOI 10.1073/pnas.0503853102	36	29	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2649	2657		10.1038/sj.onc.1210069	http://dx.doi.org/10.1038/sj.onc.1210069			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17057736				2022-12-17	WOS:000245831200012
J	Kuninaka, S; Iida, SI; Hara, T; Nomura, M; Naoe, H; Morisaki, T; Nitta, M; Arima, Y; Mimori, T; Yonehara, S; Saya, H				Kuninaka, S.; Iida, S-I; Hara, T.; Nomura, M.; Naoe, H.; Morisaki, T.; Nitta, M.; Arima, Y.; Mimori, T.; Yonehara, S.; Saya, H.			Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferation	ONCOGENE			English	Article						apoptosis; serine protease; mitotic kinase; staurosporine; cell cycle; PDZ domain	ANTI-APOPTOTIC PROTEIN; TUMOR-SUPPRESSOR; CHECKPOINT FUNCTION; PROMOTES APOPTOSIS; MITOTIC APPARATUS; GENOMIC INTEGRITY; CASPASE ACTIVITY; HUMAN HOMOLOG; DROSOPHILA; INHIBITOR	The serine protease Omi/HtrA2 was initially regarded as a proapoptotic molecule that proteolyses several proteins to induce cell death. Recent studies, however, indicate that loss of Omi protease activity increases susceptibility to stress-induced cell death. These complicated findings suggest that the protease activity of Omi is involved not only in apoptosis but also in cellular homeostasis. However, the targets which Omi uses to mediate this novel process are unknown. Previously, we showed that WARTS (WTS)/large tumor-suppressor 1 mitotic kinase interacts with the protein/discs-large protein/zonula (PDZ) domain of Omi and promotes its protease activity. We nowreport that WTS is a substrate for Omi protease activity, thus it is not only a regulator but also a downstream target of this protease. Interaction with Omi PDZ domain is required for WTS to be proteolysed. When caspase-9-deficient mouse embryonic. broblasts (MEFs) were treated with staurosporine, WTS was proteolysed by activated endogenous Omi without induction of cell death. Therefore, protease activity of Omi and proteolysis of WTS are not necessarily required for cell death. We found that depletion of Omi from HeLa cells results in accelerated cell proliferation despite no significant change in the duration of mitosis. The depletion of WTS showed the same effect on S phase progression. Therefore, WTS proteolytic fragment(s) generated by Omi may act as an inhibitor of G1/S progression. Our data reveal a role for Omi-mediated processing of WTS in negative regulation of cell cycle progression at interphase, suggesting a novel function of Omi other than apoptosis.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kyoto Univ, Inst Virus Res, Mol & Cellular Biol Lab, Kyoto 606, Japan	Kumamoto University; Kyoto University	Kuninaka, S (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Kuninaka, Shinji/J-7158-2013; Arima, Yoshimi/J-8057-2013	Naoe, Hideaki/0000-0003-4274-8220				Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hockley D, 1998, JAVA REP, V3, P6; Iida S, 2004, ONCOGENE, V23, P5266, DOI 10.1038/sj.onc.1207623; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuninaka S, 2005, ONCOGENE, V24, P5287, DOI 10.1038/sj.onc.1208682; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; McPherson JP, 2004, EMBO J, V23, P3677, DOI 10.1038/sj.emboj.7600371; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140	35	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2395	2406		10.1038/sj.onc.1210042	http://dx.doi.org/10.1038/sj.onc.1210042			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17130845				2022-12-17	WOS:000245831000001
J	Brauweiler, A; Lorick, KL; Lee, JP; Tsai, YC; Chan, D; Weissman, AM; Drabkin, HA; Gemmill, RM				Brauweiler, A.; Lorick, K. L.; Lee, J. P.; Tsai, Y. C.; Chan, D.; Weissman, A. M.; Drabkin, H. A.; Gemmill, R. M.			RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene	ONCOGENE			English	Article						ubiquitin ligase; SREBP; clear-cell renal carcinoma; RING-H2	RENAL-CELL CARCINOMA; ELEMENT-BINDING PROTEIN; CHOLESTEROL; EXPRESSION; GROWTH; TRANSLOCATION; ACTIVATION; MECHANISMS; COMPLEX; DOMAIN	TRC8/RNF139 and von Hippel-Lindau (VHL) both encode E3 ubiquitin (Ub) ligases mutated in clear-cell renal carcinomas (ccRCC). VHL, inactivated in nearly 70% of ccRCCs, is a tumor suppressor encoding the targeting subunit for a Ub ligase complex that down-regulates hypoxia-inducible factor-alpha. TRC8/RNF139 is a putative tumor suppressor containing a sterol-sensing domain and a RING-H2 motif essential for Ub ligase activity. Here we report that human kidney cells are growth inhibited by TRC8. Inhibition is manifested by G2/M arrest, decreased DNA synthesis and increased apoptosis and is dependent upon the Ub ligase activity of the RING domain. Tumor formation in a nude mouse model is inhibited by TRC8 in a RING-dependent manner. Expression of TRC8 represses genes involved in cholesterol and fatty acid biosynthesis that are transcriptionally regulated by the sterol response element binding proteins (SREBPs). Expression of activated SREBP-1a partially restores the growth of TRC8-inhibited cells. These data suggest that TRC8 modulation of SREBP activity comprises a novel regulatory link between growth control and the cholesterol/lipid homeostasis pathway.	Univ Colorado Denver & Hlth Sci Ctr, Div Med Oncol, Dept Med, Aurora, CO 80045 USA; Univ Colorado, Ctr Canc, Aurora, CO 80045 USA; NCI, Lab Prot Dynam & Signaling, Frederick, MD 21701 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gemmill, RM (corresponding author), Univ Colorado Denver & Hlth Sci Ctr, Div Med Oncol, Dept Med, 12801 E 17th Ave,Mail Stop 8117,POB 6511, Aurora, CO 80045 USA.	robert.gemmill@uchsc.edu		Tsai, Yien Che/0000-0001-9624-1092	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA076035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076035, Z01BC009392] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ciechanover A, 2006, NEUROLOGY, V66, pS7, DOI 10.1212/01.wnl.0000192261.02023.b8; CLAYMAN RV, 1986, CANCER RES, V46, P2958; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; GEBHARD RL, 1987, J LIPID RES, V28, P1177; Gemmill RM, 2002, ONCOGENE, V21, P3507, DOI 10.1038/sj.onc.1205437; Gemmill RM, 2005, ONCOGENE, V24, P3503, DOI 10.1038/sj.onc.1208509; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kaelin WG, 2004, CLIN CANCER RES, V10, p6290S, DOI 10.1158/1078-0432.CCR-sup-040025; Katoh S, 2003, J BIOL CHEM, V278, P15341, DOI 10.1074/jbc.M210531200; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ma DQ, 2005, CANCER RES, V65, P5523, DOI 10.1158/0008-5472.CAN-04-2582; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	28	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2263	2271		10.1038/sj.onc.1210017	http://dx.doi.org/10.1038/sj.onc.1210017			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016439	Bronze			2022-12-17	WOS:000245466000002
J	Rose, PP; Carroll, JM; Carroll, PA; DeFilippis, VR; Lagunoff, M; Moses, AV; Roberts, CT; Fruh, K				Rose, P. P.; Carroll, J. M.; Carroll, P. A.; DeFilippis, V. R.; Lagunoff, M.; Moses, A. V.; Roberts, C. T., Jr.; Fruh, K.			The insulin receptor is essential for virus-induced tumorigenesis of Kaposi's sarcoma	ONCOGENE			English	Article						Kaposi's sarcoma; endothelial cell; tumorigenesis; insulin; insulin-like growth factor	GENE-EXPRESSION; ENDOTHELIAL-CELLS; IGF-II; HERPESVIRUS; GROWTH; TRANSFORMATION; INFECTION; ISOFORM; ESTABLISHMENT; DISEASES	Kaposi sarcoma (KS), a multifocal neoplasm of the skin that can spread to visceral organs, is the most prevalent malignant tumor in acquired immuno deficiency syndrome (AIDS) patients. KS-associated herpesvirus (KSHV or HHV8) is considered the primary etiological factor of this malignancy, as well as of primary effusion lymphoma and multicentric Castleman's disease. KS lesions are characterized by proliferating spindle cells of endothelial cell (EC) origin. The action of the insulin-like growth factor (IGF) system has been implicated in many malignancies, and recent data have demonstrated that the IGF-I receptor (IGF-IR) is required for in vitro growth of the KS-derived KSIMM cell line. To examine whether the IGF pathway is also involved in KSHV-mediated transformation of ECs, we examined the expression and function of the IGF system in KSHV-infected, immortalized dermal microvascular EC (E-DMVEC). The expression of the insulin receptor (IR) was strongly induced in latently infected E-DMVEC, whereas the expression levels of the IGF-IR remained unchanged. Gene knockdown of IR, but not IGF-IR, prevented the characteristic focus formation seen in KSHV-infected E-DMVEC. Similarly, treatment with the IR-specific small-molecule inhibitor HNMPA-(AM(3)) inhibited post-confluent growth. These data suggest a role for the IR, but not the IGF-IR, in KSHV-induced transformation of vascular ECs.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA	Oregon Health & Science University; University of Washington; University of Washington Seattle	Fruh, K (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW 185th ave, Beaverton, OR 97006 USA.	fruehk@ohsu.edu	Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772; Frueh, Klaus/0000-0001-8014-3877; Carroll, Patrick/0000-0001-8147-5750	NATIONAL CANCER INSTITUTE [R01CA099906] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007781] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA099906, R01 CA097934] Funding Source: Medline; NHLBI NIH HHS [T32 HL007781-13] Funding Source: Medline; NCHHSTP CDC HHS [PS1-RR00163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCHHSTP CDC HHS		Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Denley A, 2004, MOL ENDOCRINOL, V18, P2502, DOI 10.1210/me.2004-0183; Denley A, 2003, HORM METAB RES, V35, P778; Flamand L, 1996, J ACQ IMMUN DEF SYND, V13, P194, DOI 10.1097/00042560-199610010-00011; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Hailey J, 2002, MOL CANCER THER, V1, P1349; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Lagunoff M, 2002, J VIROL, V76, P2440, DOI 10.1128/JVI.76.5.2440-2448.2002; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; McAllister SC, 2004, BLOOD, V103, P3465, DOI 10.1182/blood-2003-08-2781; Moses AV, 2002, J VIROL, V76, P8383, DOI 10.1128/JVI.76.16.8383-8399.2002; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Orem J, 2004, CURR OPIN ONCOL, V16, P468, DOI 10.1097/00001622-200409000-00010; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; SAPERSTEIN R, 1989, BIOCHEMISTRY-US, V28, P5694, DOI 10.1021/bi00439a053; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; Sharma-Walia N, 2005, J VIROL, V79, P10308, DOI 10.1128/JVI.79.16.10308-10329.2005; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384	31	29	30	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					1995	2005		10.1038/sj.onc.1210006	http://dx.doi.org/10.1038/sj.onc.1210006			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001305				2022-12-17	WOS:000245313400002
J	Zapatka, M; Zboralski, D; Radacz, Y; Bockmann, M; Arnold, C; Schoneck, A; Hoppe, S; Tannapfel, A; Schmiegel, W; Simon-Assmann, P; Schwarte-Waldhoff, I				Zapatka, M.; Zboralski, D.; Radacz, Y.; Boeckmann, M.; Arnold, C.; Schoeneck, A.; Hoppe, S.; Tannapfel, A.; Schmiegel, W.; Simon-Assmann, P.; Schwarte-Waldhoff, I.			Basement membrane component laminin-5 is a target of the tumor suppressor Smad4	ONCOGENE			English	Article						tumor suppressor Smad4; TGF-beta; laminin-5; invasion; basement membrane	STABLE RNA INTERFERENCE; GAMMA-2 CHAIN; COLORECTAL-CANCER; CARCINOMA CELLS; EXPRESSION; INVASION; DPC4; METASTASIS; LAMC2; LINES	The tumor suppressor Smad4 is involved in carcinogenesis mainly of the pancreas and colon. Functional inactivation of Smad4 is a genetically late event that occurs upon transition from premalignant stages to invasive and metastatic growth. Smad4 encodes an intracellular messenger common to all signalling cascades induced by members of the transforming growth factor-beta (TGF-beta) superfamily of cytokines. Despite extensive knowledge about the mechanisms of TGF-beta/Smadsignal transduction, little is known about Smad4 targets involved in the transition to malignancy. The hallmark of invasive growth is a breakdown of the basement membrane ( BM), a specialized sheet of extracellular matrix produced through of epithelial and stromal cells. Laminin-5, a heterotrimeric epithelial-derived BM component, is commonly lost in carcinomas but not in premalignant tumors. Herein, we report that in human colon and pancreatic tumor cells, Smad4 functions as a positive transcriptional regulator of all three genes encoding laminin-5. Coordinate re-expression of the three laminin-5 chains induced by reconstitution of Smad4 leads to secretion and deposition of the heterotrimeric molecule in BM-like structures. These data de. ne the expression control of an essential BM component as a novel function for the tumor suppressor Smad4.	Ruhr Univ Bochum, Dept Internal Med, Knappschaftskrankenhaus, IMBL, D-44892 Bochum, Germany; Univ Strasbourg, INSERM, U682, Strasbourg, France; Ruhr Univ Bochum, Inst Pathol, BG Kliniken Bergmannsheil, D-4630 Bochum, Germany; Ruhr Univ Bochum, Dept Gastroenterol & Hepatol, Kliniken Bergmannsheil, D-4630 Bochum, Germany	Ruhr University Bochum; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Ruhr University Bochum; Ruhr University Bochum	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Dept Internal Med, Knappschaftskrankenhaus, IMBL, Schornau 23-25, D-44892 Bochum, Germany.	Irmgard.Schwarte-Waldhoff@ruhr-uni-bochum.de	Zapatka, Marc/G-9896-2013	Zapatka, Marc/0000-0001-8287-5967; Zboralski, Dirk/0000-0002-2224-2452				Aberdam D, 2000, MICROSC RES TECHNIQ, V51, P228, DOI 10.1002/1097-0029(20001101)51:3<228::AID-JEMT3>3.0.CO;2-9; BOUZIGES F, 1991, INT J CANCER, V48, P101; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Giannelli G, 2001, CLIN EXP METASTAS, V18, P439; Givant-Horwitz V, 2005, CANCER LETT, V223, P1, DOI 10.1016/j.canlet.2004.08.030; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hlubek F, 2001, CANCER RES, V61, P8089; Imamura T, 2004, BIOCHEM BIOPH RES CO, V318, P289, DOI 10.1016/j.bbrc.2004.04.029; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Jonson T, 2003, GENE CHROMOSOME CANC, V36, P340, DOI 10.1002/gcc.10179; Katayama M, 2004, J MOL HISTOL, V35, P277; KORANG K, 1995, FEBS LETT, V368, P556, DOI 10.1016/0014-5793(95)00740-Z; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Lu W, 2001, HISTOCHEM J, V33, P629, DOI 10.1023/A:1016350316926; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Mizushima H, 1998, HORM RES, V50, P7, DOI 10.1159/000053118; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; Olsen J, 2003, BIOCHEM J, V371, P211, DOI 10.1042/BJ20021454; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1994, AM J PATHOL, V145, P782; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Simon-Assmann P, 1998, ANN NY ACAD SCI, V859, P46, DOI 10.1111/j.1749-6632.1998.tb11110.x; Sordat I, 2000, INT J CANCER, V88, P708, DOI 10.1002/1097-0215(20001201)88:5<708::AID-IJC5>3.0.CO;2-J; Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A; Takahashi H, 2004, CLIN CANCER RES, V10, P3772, DOI 10.1158/1078-0432.CCR-03-0120; Takahashi S, 2002, CANCER, V94, P1894, DOI 10.1002/cncr.10395; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TELLER IC, 2001, EXPERT REV MOL MED, P1; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Volmer MW, 2004, PROTEOMICS, V4, P1324, DOI 10.1002/pmic.200300703; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; Wilentz RE, 2000, CANCER RES, V60, P2002; Yuen HW, 2005, EXP CELL RES, V309, P198, DOI 10.1016/j.yexcr.2005.05.013	41	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1417	1427		10.1038/sj.onc.1209918	http://dx.doi.org/10.1038/sj.onc.1209918			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953227				2022-12-17	WOS:000244558800006
J	Mancini, A; El Bounkari, O; Norrenbrock, AF; Scherr, M; Schaefer, D; Eder, M; Banham, AH; Pulford, K; Lyne, L; Whetton, AD; Tamura, T				Mancini, A.; El Bounkari, O.; Norrenbrock, A-F; Scherr, M.; Schaefer, D.; Eder, M.; Banham, A. H.; Pulford, K.; Lyne, L.; Whetton, A. D.; Tamura, T.			FMIP controls the adipocyte lineage commitment of C2C12 cells by downmodulation of C/EBPalpha	ONCOGENE			English	Article						adipocyte/muscle differentiation; insulin signaling; C/EBP; mesenchymal stem cells; mRNA export complex	BINDING-PROTEIN-ALPHA; MITOTIC CLONAL EXPANSION; TRANSCRIPTIONAL REGULATION; REGULATED EXPRESSION; INTERACTING PROTEIN; ECTOPIC EXPRESSION; GENE-EXPRESSION; DIFFERENTIATION; GRANULOCYTE; BETA	Fms interacting protein ( FMIP) is a substrate for Fms tyrosine kinase, and a nuclear/cytoplasm shuttling protein with a leucine zipper. As the phosphorylation of FMIP is observed in insulin-stimulated preadipocytes, we examined the role of FMIP in adipocyte differentiation, using the mesenchymal multipotent stem cells, C2C12 cells, that can differentiate into adipocytes, muscle cells and osteoblasts. Ectopic expression of FMIP in C2C12 impairs the adipocyte differentiation induced by treatment with insulin, dexamethasone and 3-isobutyl-1-methylxanthine. These cells exhibit muscle phenotype with multinuclear morphology. Furthermore, knockdown of endogenous FMIP expression by small interfering RNA improves adipocytic lineage commitment of C2C12 cells, while impairing muscle differentiation. Upon stimulation with insulin, CCAAT/enhancer binding protein ( C/EBP)beta, but not C/EBPalpha, is upregulated in cells expressing ectopic FMIP, whereas in FMIP knockdown cells, C/EBPalpha is constitutively expressed. Ectopic expression of C/EBPalpha counteracts the effects of FMIP, whereas C/EBPalpha knockdown partially mimics the effects of FMIP in this system. Northern blot analysis and reverse transcriptase-polymerase chain reaction study reveal that ectopic FMIP-expressing cells do not contain the polyadenylated C/EBPalpha mRNA, but contain the C/EBPalpha pre-mRNA, suggesting that FMIP plays a role in RNA processing and/or export. Indeed, a member of the THO complex that plays a role in mRNA export, THOC1, is co-precipitated with FMIP. The data we have acquired on FMIP suggest that it is a target for tyrosine kinase receptors that potentiate mRNA export.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England; Univ Manchester, Christie Hosp, Fac Med & Human Sci, Canc Studies Div, Manchester M13 9PL, Lancs, England	Hannover Medical School; University of Oxford; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@mh-hannover.de	Banham, Alison H/B-2966-2009; Pulford, Karen/B-3609-2009	Pulford, Karen/0000-0002-2989-789X; WHETTON, ANTHONY D/0000-0002-1098-3878; Banham, Alison/0000-0002-3197-273X				CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Fux C, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh001; Gridley S, 2005, CELL SIGNAL, V17, P59, DOI 10.1016/j.cellsig.2004.05.013; Helftenbein G, 1996, ONCOGENE, V12, P931; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Koch A, 2005, ONCOGENE, V24, P3436, DOI 10.1038/sj.onc.1208558; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; MASON DY, 1983, TECHNIQUES IMMUNOCYT, P175; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Popernack PM, 2001, J HEMATOTH STEM CELL, V10, P631, DOI 10.1089/152581601753193841; Rehwinkel J, 2004, NAT STRUCT MOL BIOL, V11, P558, DOI 10.1038/nsmb759; Scherr M, 2002, BLOOD, V99, P709, DOI 10.1182/blood.V99.2.709; Scherr M, 2003, CELL CYCLE, V2, P251, DOI 10.4161/cc.2.3.376; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101	32	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1020	1027		10.1038/sj.onc.1209853	http://dx.doi.org/10.1038/sj.onc.1209853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909111				2022-12-17	WOS:000244245400008
J	Takeuchi, T; Adachi, Y; Sonobe, H; Furihata, M; Ohtsuki, Y				Takeuchi, T.; Adachi, Y.; Sonobe, H.; Furihata, M.; Ohtsuki, Y.			A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion	ONCOGENE			English	Article						melanoma; invasion; ubiquitin; skeletrophin; Notch	METHYLATION-SPECIFIC PCR; T-CADHERIN CDH13; MALIGNANT-MELANOMA; TUMOR PROGRESSION; DYSPLASTIC NEVUS; NOTCH LIGAND; H-CADHERIN; STEM-CELL; MIND BOMB; EXPRESSION	Skeletrophin (mindbomb homolog 2 (MIB2)) is a RING (Really Interesting New Gene) finger-dependent ubiquitin ligase, which targets the intracellular region of Notch ligands. A previous immunohistochemical study demonstrated that skeletrophin was downregulated in many melanomas. In the present study, we have identified a promoter region of skeletrophin on a CpG island and detected aberrant methylation of this region in six of 31 invasive melanomas, but in none of 25 benign nevi or five non-invasive superficial spreading melanomas. Subsequently, we found that a zinc-finger transcriptional factor Snail, which is overexpressed in many melanoma cells, repressed the skeletrophin promoter activity via an E-box-related element and was involved in downregulation of skeletrophin. An activator protein-2, which has a tumor suppressor-like role in melanoma, increased skeletrophin expression. Interestingly, exogenously expressed skeletrophin reduced melanoma cell invasion in vitro and in vivo. Colony formation in soft agar was also reduced in a RING motif-dependent manner, without affecting cell growth. We also found that skeletrophin downregulated transcription of the Met oncogene, which encodes the hepatocyte growth factor receptor and plays a role in the determination of the invasive phenotype of many malignant tumors. Finally, exogenously expressed skeletrophin, but not its RING mutant, increased transcription of Hes1 gene, a downstream effector of Notch pathway in melanoma cells. The present findings indicate that skeletrophin might be a novel suppressor factor for melanoma invasion.	Kochi Med Sch, Dept Pathol, Nankoku, Kochi 7838505, Japan; Natl Hosp Org, Fukuyama Med Ctr, Dept Lab Med & Pathol, Hiroshima, Japan	Kochi University	Takeuchi, T (corresponding author), Kochi Med Sch, Dept Pathol, Nankoku, Kochi 7838505, Japan.	takeutit@med.kochi-ms.ac.jp						BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fan X, 2002, ONCOL REP, V9, P181; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; Grichnik JM, 2006, J INVEST DERMATOL, V126, P142, DOI 10.1038/sj.jid.5700017; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hewett PW, 1998, BIOCHEM BIOPH RES CO, V252, P546, DOI 10.1006/bbrc.1998.9690; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; ISHIHARA T, IN PRESS VIRCHOW ARC; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Koo BK, 2005, DEVELOPMENT, V132, P3459, DOI 10.1242/dev.01922; Koo BK, 2005, J BIOL CHEM, V280, P22335, DOI 10.1074/jbc.M501631200; LEONGKG, 2006, BLOOD, V107, P2223; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nijjar SS, 2002, AM J PATHOL, V160, P1695, DOI 10.1016/S0002-9440(10)61116-9; Parr C, 2004, INT J MOL MED, V14, P779; Pitsouli C, 2005, DEVELOPMENT, V132, P4041, DOI 10.1242/dev.01979; Poetsch M, 2003, MELANOMA RES, V13, P29, DOI 10.1097/00008390-200302000-00006; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; Takeuchi T, 2005, AM J PATHOL, V166, P1817, DOI 10.1016/S0002-9440(10)62491-1; Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471-4159.2000.0741489.x; Takeuchi T, 2003, AM J PATHOL, V163, P1395, DOI 10.1016/S0002-9440(10)63497-9; Takeuchi T, 2002, LAB INVEST, V82, P1023, DOI 10.1097/01.LAB.0000025391.35798.F1; Takeuchi T, 1997, J IMMUNOL, V159, P726; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Wang WD, 2005, DEVELOPMENT, V132, P2883, DOI 10.1242/dev.01860; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355	35	29	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7059	7069		10.1038/sj.onc.1209688	http://dx.doi.org/10.1038/sj.onc.1209688			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715130				2022-12-17	WOS:000241910500005
J	Wang, X; Wang, TT; White, JH; Studzinski, GP				Wang, X.; Wang, T-T; White, J. H.; Studzinski, G. P.			Induction of kinase suppressor of RAS-1( KSR-1) gene by 1, alpha 25-dihydroxyvitamin D-3 in human leukemia HL60 cells through a vitamin D response element in the 5 '-flanking region	ONCOGENE			English	Article						KSR; differentiation; vitamin D; vitamin D receptor; VDRE; RXRalfa; MAPK	ACTIVATED PROTEIN-KINASE; 1,25-DIHYDROXYVITAMIN D-3; MONOCYTIC DIFFERENTIATION; SIGNAL-TRANSDUCTION; HL-60 CELLS; D-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; TRANSCRIPTIONAL ACTIVATION; MYELOID-LEUKEMIA; BINDING PROTEINS	Differentiation therapy is being developed as an additional therapeutic option for the treatment of several forms of cancer, including myeloid leukemia. In model systems, the physiologically active form of vitamin D, 1, alpha 25-dihydroxyvitamin D-3 (1,25D), induces monocytic differentiation of human myeloid cells, but the mechanism is not clear. We report here, the first direct connection between the signal provided by 1,25D and the molecular circuitry known to be involved in monocytic differentiation. Specifically, we show that 1,25D selectively increases the expression of the gene encoding kinase suppressor of Ras-1 (KSR-1) in HL60 cells, while other differentiation-inducing agents such as 12-O-tetradecanoylphorbol-13-acetate, retinoic acid or dimethyl sulfoxide do not significantly increase KSR-1 expression. Further, the upregulation of KSR-1 gene by 1,25D is competed by ZK159222, an antagonist of vitamin D receptor (VDR) action, and can occur in the presence of protein synthesis inhibitor cycloheximide, showing that the effect is direct. Most importantly, we have identified a vitamin D responsive element (VDRE) in the promoter region of the human KSR-1 gene, to which VDR binds in a 1,25D-dependent manner, in vitro and in vivo. This binding is paralleled by increased association of RNA polymerase II with the transcription start site of KSR-1 gene, and the VDRE is functional in reporter assays. Our findings offer a potential mechanism for a signaling pathway that contributes to 1,25D-induced monocytic differentiation of human myeloid leukemia cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA; McGill Univ, Dept Physiol, Montreal, PQ, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; McGill University	Studzinski, GP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, 185 S Orange Ave,C543, Newark, NJ 07103 USA.	studzins@umdnj.edu	white, john h/N-9782-2013	white, john h/0000-0002-4785-2687	NCI NIH HHS [R01 CA044722-16, R01 CA044722, R01-CA44722-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044722] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BUNCE CM, 1983, EXP HEMATOL, V11, P828; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; CHOMIENNE C, 1990, BLOOD, V76, P1710; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Dhawan P, 2005, MOL CELL BIOL, V25, P472, DOI 10.1128/MCB.25.1.472-487.2005; FERRARA J, 1994, J BIOL CHEM, V269, P2971; FRETZ JA, 2006, MOL ENDOCRINOL; Herdick M, 2000, J BIOL CHEM, V275, P16506, DOI 10.1074/jbc.M910000199; Ikezoe T, 2005, CANCER RES, V65, P4762, DOI 10.1158/0008-5472.CAN-03-3619; Ji Y, 2004, CANCER RES, V64, P370, DOI 10.1158/0008-5472.CAN-03-3029; Kolesnick R, 2004, J CLIN INVEST, V114, P1233, DOI 10.1172/JCI200423441; KOLLA SS, 1994, CANCER RES, V54, P1418; Lamkin TJ, 2006, J CELL BIOCHEM, V97, P1328, DOI 10.1002/jcb.20745; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Marcinkowska E, 2001, ANTICANCER RES, V21, P499; Ory S, 2004, CURR BIOL, V14, pR277, DOI 10.1016/j.cub.2004.03.023; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Roy F, 2002, CURR BIOL, V12, pR325, DOI 10.1016/S0960-9822(02)00831-X; SIEGEL MR, 1963, NATURE, V200, P675, DOI 10.1038/200675a0; Song XD, 1998, ENDOCRINOLOGY, V139, P457, DOI 10.1210/en.139.2.457; Studzinski GP, 2005, J STEROID BIOCHEM, V97, P47, DOI 10.1016/j.jsbmb.2005.06.010; STUDZINSKI GP, 1985, P SOC EXP BIOL MED, V179, P288; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Wang Q, 2005, J CELL PHYSIOL, V204, P962, DOI 10.1002/jcp.20355; Wang Q, 2003, J CELL BIOCHEM, V89, P1087, DOI 10.1002/jcb.10595; Wang QM, 1996, CANCER RES, V56, P264; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wang XN, 2004, J CELL PHYSIOL, V198, P333, DOI 10.1002/jcp.10443; Wang XN, 2001, J CELL BIOCHEM, V80, P471, DOI 10.1002/1097-4644(20010315)80:4<471::AID-JCB1001>3.0.CO;2-J; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	37	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7078	7085		10.1038/sj.onc.1209697	http://dx.doi.org/10.1038/sj.onc.1209697			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732322	Green Accepted			2022-12-17	WOS:000241910500007
J	Takada, H; Imoto, I; Tsuda, H; Nakanishi, Y; Sakakura, C; Mitsufuji, S; Hirohashi, S; Inazawa, J				Takada, H.; Imoto, I.; Tsuda, H.; Nakanishi, Y.; Sakakura, C.; Mitsufuji, S.; Hirohashi, S.; Inazawa, J.			Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis	ONCOGENE			English	Article						array-CGH; gastric cancer; VLDLR; homozygous deletion; methylation	CANCER CELL-LINES; LUNG-CANCER; HOMOZYGOUS DELETIONS; PANCREATIC-CARCINOMA; DNA METHYLATION; VLDL RECEPTOR; BREAST-CANCER; LDL RECEPTOR; SHORT ARM; GENE	Homozygous loss in the genomic sequence, a mechanism for inactivating tumor-suppressor genes (TSGs) in cancer, has been used as a tag for the identification of novel TSGs, and array-based comparative genomic hybridization (array-CGH) has a great potential for high-throughput identification of this change. We identified a homozygous loss of the very-low-density lipoprotein receptor (VLDLR) gene (9p24.2) from genome-wide screening for copy-number alterations in 32 gastric cancer ( GC) cell lines using array-CGH. Although previous reports demonstrated mRNA or protein expression of VLDLR in various cancers including GC, the association between genomic losses or epigenetic silencing of this gene and carcinogenesis has never been reported before. Homozygous deletion of VLDLR was also seen in primary GCs, albeit infrequently, and about half of GC cell lines showed lost or reduced VLDLR expression. The VLDLR expression was restored in gene-silenced GC cells after treatment with 5-aza 2'-deoxycytidine. According to methylation analyses, hypermethylation of the VLDLR promoter region, which all of GC lines without its expression showed, occurred in some primary GCs. Restoration of VLDLR type I expression in GC cells reduced colony formation. These results suggest that not only the expression of VLDLR but also genetic or epigenetic silencing of this gene may contribute to tumor formation and be involved in gastric carcinogenesis.	Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; Grad Sch Biomed Sci, Tokyo, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Gastroenterol & Hepatol, Kyoto, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Tokyo, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Digest Surg, Kyoto, Japan; Tokyo Med & Dent Univ, COE Program Frontier Res Mol Destruct & Reconstit, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Kyoto Prefectural University of Medicine; National Cancer Center - Japan; Kyoto Prefectural University of Medicine; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Imoto, Issei/AAD-5799-2020; imoto, Issei/D-8065-2012					An HX, 1999, CANCER RES, V59, P3941; Baylin SB, 1998, ADV CANCER RES, V72, P141; Chen T, 2005, WORLD J GASTROENTERO, V11, P2817, DOI 10.3748/wjg.v11.i18.2817; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Heidenblad M, 2004, CANCER RES, V64, P3052, DOI 10.1158/0008-5472.CAN-03-3159; Hembrough TA, 2001, J BIOL CHEM, V276, P12241, DOI 10.1074/jbc.M010395200; Hiltunen TP, 1998, CIRCULATION, V97, P1079, DOI 10.1161/01.CIR.97.11.1079; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Kim SK, 1997, CANCER RES, V57, P400; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; Nakamura Y, 2000, ARCH PATHOL LAB MED, V124, P119; Near SE, 2001, J HUM GENET, V46, P490, DOI 10.1007/s100380170051; Noguchi M, 1997, PATHOL INT, V47, P685, DOI 10.1111/j.1440-1827.1997.tb04442.x; Reisman DN, 2003, CANCER RES, V63, P560; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAKATA K, 1995, JPN J CANCER RES, V86, P333, DOI 10.1111/j.1349-7006.1995.tb03060.x; Sarkar S, 2002, J BIOL CHEM, V277, P36585, DOI 10.1074/jbc.M204244200; Sato M, 2005, GENE CHROMOSOME CANC, V44, P405, DOI 10.1002/gcc.20253; Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008; Shim YH, 2000, LAB INVEST, V80, P689, DOI 10.1038/labinvest.3780072; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Tanabe C, 2003, GENE CHROMOSOME CANC, V38, P168, DOI 10.1002/gcc.10269; Tanami H, 2005, LAB INVEST, V85, P1118, DOI 10.1038/labinvest.3700312; Vo QN, 2002, HUM PATHOL, V33, P1200, DOI 10.1053/hupa.2002.130108; Wada Y, 2000, HEART VESSELS, V15, P74, DOI 10.1007/s003800070035; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamano M, 2000, AM J PATHOL, V156, P2123, DOI 10.1016/S0002-9440(10)65083-3; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x	38	29	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6554	6562		10.1038/sj.onc.1209657	http://dx.doi.org/10.1038/sj.onc.1209657			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16715143				2022-12-17	WOS:000241395100012
J	Doig, J; Anderson, C; Lawrence, NJ; Selfridge, J; Brownstein, DG; Melton, DW				Doig, J.; Anderson, C.; Lawrence, N. J.; Selfridge, J.; Brownstein, D. G.; Melton, D. W.			Mice with skin-specific DNA repair gene (Ercc1) inactivation are hypersensitive to ultraviolet irradiation-induced skin cancer and show more rapid actinic progression	ONCOGENE			English	Article						Ercc1; nucleotide; excision repair; skin cancer; ultraviolet irradiation	TRANSCRIPTION-COUPLED REPAIR; STEM-CELLS; HPRT GENE; DEFICIENCY; EXPRESSION; LACKING; TUMORS; CARCINOGENESIS; SUSCEPTIBILITY; DISRUPTION	Ercc1 has an essential role in the nucleotide excision repair (NER) pathway that protects against ultraviolet (UV)-induced DNA damage and is also involved in additional repair pathways. The premature death of simple Ercc1 mouse knockouts meant that we were unable to study the role of Ercc1 in the skin. To do this, we have used the Cre-lox system to generate a skin-specific Ercc1 knockout. With a Cre transgene under control of the bovine keratin 5 promoter we achieved 100% recombination of the Ercc1 gene in the epidermis. Hairless mice with Ercc1-deficient skin were hypersensitive to the short-term effects of UV irradiation, showing a very low minimal erythemal dose and a dramatic hyperproliferative response. Ultraviolet-irradiated mice with Ercc1-deficient skin developed epidermal skin tumours much more rapidly than controls. These tumours appeared to arise earlier in actinic progression and grew more rapidly than tumours on control mice. These responses are more pronounced than have been reported for other NER-deficient mice, demonstrating that Ercc1 has a keyrole in protecting against UV-induced skin cancer.	Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Royal Infirm Edinburgh NHS Trust, Dept Pathol, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Queens Med Res Inst, Res Anim Pathol Core Lab, Edinburgh, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	David.Melton@ed.ac.uk		SELFRIDGE, JIM/0000-0003-2473-4386				Berg RJW, 2000, CANCER RES, V60, P2858; Berg RJW, 1997, CANCER RES, V57, P581; CANFIELD PJ, 1988, PATHOLOGY, V20, P109, DOI 10.3109/00313028809066620; Chipchase MD, 2002, DNA REPAIR, V1, P335, DOI 10.1016/S1568-7864(02)00010-1; de Boer J, 1999, CANCER RES, V59, P3489; de Vries A, 1998, ONCOGENE, V16, P2205, DOI 10.1038/sj.onc.1201744; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; GALLAGHER CH, 1984, J INVEST DERMATOL, V83, P169, DOI 10.1111/1523-1747.ep12263512; Hsia KT, 2003, DEVELOPMENT, V130, P369, DOI 10.1242/dev.00221; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Kuhn Ralf, 2002, Methods Mol Biol, V180, P175; MAGIN TM, 1992, GENE, V122, P289, DOI 10.1016/0378-1119(92)90217-D; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MOORE RC, 1995, BIO-TECHNOL, V13, P999, DOI 10.1038/nbt0995-999; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nunez F, 2000, FASEB J, V14, P1073, DOI 10.1096/fasebj.14.9.1073; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Remenyik E, 2003, ONCOGENE, V22, P6369, DOI 10.1038/sj.onc.1206657; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Selfridge J, 2001, NUCLEIC ACIDS RES, V29, P4541, DOI 10.1093/nar/29.22.4541; STACEY A, 1994, MOL CELL BIOL, V14, P1009, DOI 10.1128/MCB.14.2.1009; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; van Schanke A, 2005, J INVEST DERMATOL, V124, P241, DOI 10.1111/j.0022-202X.2004.23551.x; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8	29	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6229	6238		10.1038/sj.onc.1209642	http://dx.doi.org/10.1038/sj.onc.1209642			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16682947				2022-12-17	WOS:000241218200001
J	Shimura, T; Toyoshima, M; Adiga, SK; Kunoh, T; Nagai, H; Shimizu, N; Inoue, M; Niwa, O				Shimura, T.; Toyoshima, M.; Adiga, S. K.; Kunoh, T.; Nagai, H.; Shimizu, N.; Inoue, M.; Niwa, O.			Suppression of replication fork progression in low-dose-specic p53-dependent S-phase DNA damage checkpoint	ONCOGENE			English	Article						p53; PCNA; ATM; S-phase DNA damage checkpoint; replication fork progression	CELL NUCLEAR ANTIGEN; ATM GENE-PRODUCT; REPLICON INITIATION; IONIZING-RADIATION; BLM HELICASE; P53; PROTEIN; REPAIR; ACTIVATION; DYNAMICS	The S-phase DNA damage checkpoint is activated by DNA damage to delay DNA synthesis allowing time to resolve the replication block. We previously discovered the p53-dependent S-phase DNA damage checkpoint in mouse zygotes fertilized with irradiated sperm. Here, we report that the same p53 dependency holds in mouse embryonic fibroblasts (MEFs) at low doses of irradiation. DNA synthesis in p53 wild-type (WT) MEFs was suppressed in a biphasic manner in which a sharp decrease below 2.5 Gy was followed by a more moderate decrease up to 10 Gy. In contrast, p53-/- MEFs exhibited radioresistant DNA synthesis below 2.5 Gy whereas the cells retained the moderate suppression above 5 Gy. DNA fiber analysis revealed that 1 Gy irradiation suppressed replication fork progression in p53 WT MEFs, but not in p53-/- MEFs. Proliferating cell nuclear antigen (PCNA), clamp loader of DNA polymerase, was phosphorylated in WT MEFs after 1 Gy irradiation and redistributed to form foci in the nuclei. In contrast, PCNA was not phosphorylated and dissociated from chromatin in 1 Gy-irradiated p53-/- MEFs. These results demonstrate that the novel low-dosespecific p53-dependent S-phase DNA damage checkpoint is likely to regulate the replication fork movement through phosphorylation of PCNA.	Kyoto Univ, Dept Late Effect Studies, Radiat Biol Ctr, Sakyo Ku, Kyoto, Japan; Kyoto Univ, Dept Radiat Syst Biol, Radiat Biol Ctr, Sakyo Ku, Kyoto, Japan; Hiroshima Univ, Grad Sch Biosphere Sci, Hiroshima, Japan; Kanazawa Med Univ, Med Res Inst, Uchinada, Ishikawa 92002, Japan	Kyoto University; Kyoto University; Hiroshima University; Kanazawa Medical University	Shimura, T (corresponding author), NCI, Mol Pharmacol Lab, Canc Res Ctr, NIH Bldg 37,Rm 5056 37 Convent Dr, Bethesda, MD 20892 USA.	shimurat@mail.nih.gov	Kunoh, Tatsuki/AAQ-7881-2021; Kunoh, Tatsuki/K-7824-2019; Adiga, Satish Kumar/AAU-4386-2020	Kunoh, Tatsuki/0000-0002-8423-2903; Adiga, Satish Kumar/0000-0002-2897-4697				Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Bohnke A, 2004, INT J RADIAT BIOL, V80, P53, DOI 10.1080/09553000310001642902; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; ELKIND MM, 1959, NATURE, V184, P1293, DOI 10.1038/1841293a0; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Karmakar P, 2001, MUTAGENESIS, V16, P225, DOI 10.1093/mutage/16.3.225; KEARSEY JM, 1995, SCIENCE, V270, P1004; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Laderoute MP, 1996, ANTICANCER RES, V16, P2825; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ma H, 1998, J CELL BIOL, V143, P1415, DOI 10.1083/jcb.143.6.1415; MAKINO F, 1975, RADIAT RES, V62, P37, DOI 10.2307/3574182; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Miura M, 1996, RADIAT RES, V145, P75, DOI 10.2307/3579198; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1975, RADIAT RES, V64, P648, DOI 10.2307/3574254; PAINTER RB, 1976, BIOCHIM BIOPHYS ACTA, V418, P146, DOI 10.1016/0005-2787(76)90063-0; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; Rowley R, 1999, INT J RADIAT BIOL, V75, P267, DOI 10.1080/095530099140456; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Savio M, 1998, CARCINOGENESIS, V19, P591, DOI 10.1093/carcin/19.4.591; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shimura T, 2002, RADIAT RES, V158, P735, DOI 10.1667/0033-7587(2002)158[0735:TNSMOT]2.0.CO;2; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Solomon DA, 2004, J CELL BIOL, V166, P455, DOI 10.1083/jcb.200312048; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Storer RD, 1997, MUTAT RES-FUND MOL M, V373, P157, DOI 10.1016/S0027-5107(96)00227-8; Toyoshima M, 2005, ONCOGENE, V24, P3229, DOI 10.1038/sj.onc.1208514; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABE I, 1974, RADIAT RES, V58, P541, DOI 10.2307/3573922; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793	57	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5921	5932		10.1038/sj.onc.1209624	http://dx.doi.org/10.1038/sj.onc.1209624			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682953				2022-12-17	WOS:000240826300001
J	Skapek, SX; Pan, YR; Lee, EYHP				Skapek, S. X.; Pan, Y-R; Lee, E. Y-H P.			Regulation of cell lineage specification by the retinoblastoma tumor suppressor	ONCOGENE			English	Review						tumor suppressor gene; retinoblastoma susceptibility gene; cellular differentiation	SKELETAL-MUSCLE CELLS; C-ELEGANS; CAENORHABDITIS-ELEGANS; RNA INTERFERENCE; GENE FAMILY; TRANSCRIPTIONAL COACTIVATOR; ADIPOCYTE DIFFERENTIATION; DEFINITIVE ERYTHROPOIESIS; SOMATIC INACTIVATION; VULVAL DEVELOPMENT	Early studies of the retinoblastoma gene (RB) have uncovered its critical role as a regulator of the G(1)/S cell cycle phase progression. Surprisingly, genetic approaches in mammals and nematodes have also shown RB controls cell lineage specification and aspects of differentiation. The RB gene product accomplishes this by diverse mechanisms such as by interacting with tissue-specific transcription factors, enhancing RNA interference, and modifying chromatin structure. We review recent studies uncovering novel mechanisms by which RB works in several cell lineages and we provide perspectives on how these new findings might relate to RB tumor suppression.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA	St Jude Children's Research Hospital; University of California System; University of California Irvine; University of California System; University of California Irvine	Skapek, SX (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	steve.skapek@stjude.org						Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Ashe M, 2004, J BIOL CHEM, V279, P664, DOI 10.1074/jbc.M308810200; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; Camarda G, 2004, J CELL BIOL, V167, P417, DOI 10.1083/jcb.200408164; Cardoso C, 2005, DEV BIOL, V278, P49, DOI 10.1016/j.ydbio.2004.10.014; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen G, 1996, J BIOL CHEM, V271, P9567, DOI 10.1074/jbc.271.16.9567; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; Couteau F, 2002, EMBO REP, V3, P235, DOI 10.1093/embo-reports/kvf051; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ebel C, 2004, NATURE, V429, P776, DOI 10.1038/nature02637; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fay DS, 2003, DEVELOPMENT, V130, P3319, DOI 10.1242/dev.00561; FERGUSON EL, 1989, GENETICS, V123, P109; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GODBOUT R, 1983, NATURE, V304, P451, DOI 10.1038/304451a0; Grishok A, 2005, P NATL ACAD SCI USA, V102, P17360, DOI 10.1073/pnas.0508989102; Grishok A, 2005, GENE DEV, V19, P683, DOI 10.1101/gad.1247705; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hu NP, 1997, CANCER RES, V57, P4123; HU NP, 1994, ONCOGENE, V9, P1021; Hub MS, 2004, J CELL BIOL, V166, P865, DOI 10.1083/jcb.200403004; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kelly WG, 2002, DEVELOPMENT, V129, P479; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee KY, 1999, MOL CELL BIOL, V19, P7724; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Mantela J, 2005, DEVELOPMENT, V132, P2377, DOI 10.1242/dev.01834; MAYOL X, 1993, ONCOGENE, V8, P2561; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Miccadei S, 2005, ONCOGENE, V24, P6993, DOI 10.1038/sj.onc.1208861; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Myers TR, 2005, DEV CELL, V8, P117, DOI 10.1016/j.devcel.2004.11.015; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Papadimou E, 2005, EMBO J, V24, P1750, DOI 10.1038/sj.emboj.7600652; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puigserver P, 1998, EUR J CELL BIOL, V77, P117, DOI 10.1016/S0171-9335(98)80079-4; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Qiu XH, 2006, DEV BIOL, V291, P239, DOI 10.1016/j.ydbio.2005.11.045; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Skapek SX, 2001, ONCOGENE, V20, P6742, DOI 10.1038/sj.onc.1204876; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Takahashi C, 2003, MOL CELL BIOL, V23, P5256, DOI 10.1128/MCB.23.15.5256-5268.2003; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wang D, 2005, NATURE, V436, P593, DOI 10.1038/nature04010; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; WIKENHEISERBROK.KA, 2006, CELL MOL LIFE SCI; Wildwater M, 2005, CELL, V123, P1337, DOI 10.1016/j.cell.2005.09.042; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wylie C, 1999, CELL, V96, P165, DOI 10.1016/S0092-8674(00)80557-7; Yuan SSF, 2002, BIOCHEM BIOPH RES CO, V296, P1019, DOI 10.1016/S0006-291X(02)02032-6; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang JK, 2004, CELL CYCLE, V3, P952; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	99	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5268	5276		10.1038/sj.onc.1209710	http://dx.doi.org/10.1038/sj.onc.1209710			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936747				2022-12-17	WOS:000240064100012
J	Hirohashi, Y; Wang, Q; Liu, Q; Du, X; Zhang, H; Sato, N; Greene, MI				Hirohashi, Y.; Wang, Q.; Liu, Q.; Du, X.; Zhang, H.; Sato, N.; Greene, M. I.			p78/MCRS1 forms a complex with centrosomal protein Nde1 and is essential for cell viability	ONCOGENE			English	Article						centrosome; cancer; mitosis; spindle; microtubule	GAMMA-TUBULIN; CYTOPLASMIC DYNEIN; TRANSFORMING ACTIVITY; CANCER PROGRESSION; MITOTIC SPINDLE; LIVING CELLS; RING COMPLEX; FHA DOMAIN; DYNAMICS; DEFECTS	The centrosome, an organelle that functions as the major microtubule-organizing center, plays an essential role in the formation of the mitotic spindle and guiding accurate chromosome segregation. Centrosome aberrations are frequently associated with various forms of human cancers and it is thought that defects in this organelle contribute to genomic instability and malignant transformation. We recently identified and characterized a centrosome-localized protein complex that is comprised of Su48 and Nde1. Disruption of the normal function of these proteins leads to abnormal cell division. To extend our understanding of how this protein complex operates, we sought to identify Nde1-interacting molecules by the yeast two-hybrid screening method. Here, we demonstrate that both Nde1 and Su48 can associate with p78/MCRS1, a protein implicated in cancer development. We found that, whereas the majority of p78 localizes to the nucleus as reported in earlier studies, a fraction of the p78 protein can be detected in the centrosome. Moreover, we determined that a region containing the forkhead-associated domain of p78 is involved in association with Nde1 and Su48, as well as in centrosomal localization. We also provide evidence that the association between p78 and Nde1 is regulated by phosphorylation on Nde1. Furthermore, abrogation of the endogenous p78 function by small interfering RNA knockdown causes cell death and a modest delay in mitosis. These results indicate that a subset of the p78 proteins comprises a component of the centrosome and that p78 is essential for cell viability.	Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA; Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido, Japan	University of Pennsylvania; Sapporo Medical University	Greene, MI (corresponding author), Univ Penn, Dept Pathol & Lab Med, Sch Med, 252 John Morgan Bldg,36th Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu	Wang, Qiang/N-7310-2015; Hirohashi, Yoshihiko/AFQ-4227-2022	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049				Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bruni R, 1998, J VIROL, V72, P8525, DOI 10.1128/JVI.72.11.8525-8531.1998; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; ENGEL E, 1969, NATURE, V223, P152, DOI 10.1038/223152a0; ENGEL E, 1969, J CELL SCI, V5, P93; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2004, NEURON, V44, P279, DOI 10.1016/j.neuron.2004.09.023; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Paluh JL, 2000, MOL BIOL CELL, V11, P1225, DOI 10.1091/mbc.11.4.1225; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 1998, CANCER RES, V58, P3974; Prigozhina NL, 2004, MOL BIOL CELL, V15, P1374, DOI 10.1091/mbc.E03-06-0405; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sato N, 1999, CLIN CANCER RES, V5, P963; Schnackenberg BJ, 1998, P NATL ACAD SCI USA, V95, P9295, DOI 10.1073/pnas.95.16.9295; Shono M, 2001, LAB INVEST, V81, P945, DOI 10.1038/labinvest.3780306; Song H, 2004, BIOCHEM BIOPH RES CO, V316, P1116, DOI 10.1016/j.bbrc.2004.02.166; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Strome S, 2001, MOL BIOL CELL, V12, P1751, DOI 10.1091/mbc.12.6.1751; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	39	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4937	4946		10.1038/sj.onc.1209500	http://dx.doi.org/10.1038/sj.onc.1209500			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547491				2022-12-17	WOS:000239687100011
J	Fukuda, N; Saitoh, M; Kobayashi, N; Miyazono, K				Fukuda, N.; Saitoh, M.; Kobayashi, N.; Miyazono, K.			Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells	ONCOGENE			English	Article						bMP; apoptosis; p53; ER stress; signal transduction	ENDOPLASMIC-RETICULUM STRESS; BONE MORPHOGENETIC PROTEIN-2; MULTIPLE-MYELOMA; CARCINOMA-CELLS; ACTIVIN-A; ACTIVATION; GROWTH; P53; IDENTIFICATION; INVOLVEMENT	Bone morphogenic protein (BMP)-4 inhibits proliferation and induces the apoptosis of myeloma cells. However, little is known about the molecular mechanisms of how BMP-4 executes this apoptosis. In this report, we investigated the roles of p53 and the endoplasmic reticulum (ER) in BMP-4-induced apoptosis of mouse hybridoma HS-72 cells. We found that 3ng/ml of BMP-4 is sufficient to induce the expression of proapoptotic proteins, puma and bax, in a p53-dependent mechanism, and facilitate Ca2+ release from the ER to the cytosol, resulting in the activation of caspase-12 and ER dysfunction. Similarly to HS-72 cells, multiple myeloma cells with wild-type p53 genes show much higher sensitivity to BMP-4-induced apoptosis than cells without wild-type p53 genes, suggesting that wild-type p53 status is required for dysfunction of the ER during BMP-4-induced apoptosis in ER-enriched cells, such as hybridoma and myeloma cells. These. findings demonstrate that the presence of wild-type p53 genes and enrichment of the ER determines the sensitivity to effective apoptosis by BMP-4, and suggest that ER stress-inducing agents would be valuable in the treatment of multiple myeloma.	Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp		Fukuda, Noboru/0000-0003-0098-054X				BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; Bruno B, 2004, LANCET ONCOL, V5, P430, DOI 10.1016/S1470-2045(04)01511-6; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; CHO HJ, 2005, IN PRESS CANC LETT; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Glozak MA, 2001, EXP CELL RES, V268, P128, DOI 10.1006/excr.2001.5281; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; Huang GC, 2002, BRIT J CANCER, V86, P1104, DOI 10.1038/sj/bjc/6600219; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kawamura C, 2002, LEUKEMIA LYMPHOMA, V43, P635, DOI 10.1080/10428190290012182; Kiyono M, 2003, MOL CELL BIOL, V23, P4627, DOI 10.1128/MCB.23.13.4627-4636.2003; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oh SJ, 2000, MOL CELLS, V10, P275; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Phillips DJ, 1999, J ENDOCRINOL, V162, P111, DOI 10.1677/joe.0.1620111; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386; Shapiro-Shelef M, 2004, CURR OPIN IMMUNOL, V16, P226, DOI 10.1016/j.coi.2004.02.001; Sun YP, 2005, J BIOL CHEM, V280, P15561, DOI 10.1074/jbc.m412630200; Takebayashi-Suzuki K, 2003, DEVELOPMENT, V130, P3929, DOI 10.1242/dev.00615; Takuma K, 2005, J PHARMACOL SCI, V97, P312, DOI 10.1254/jphs.CPJ04006X; Wach S, 2001, ONCOGENE, V20, P7761, DOI 10.1038/sj.onc.1204962; Yamato K, 2000, EXP CELL RES, V257, P198, DOI 10.1006/excr.2000.4876; Yamato K, 2001, ONCOGENE, V20, P4383, DOI 10.1038/sj.onc.1204572; Zipori D, 2001, J LEUKOCYTE BIOL, V69, P867	31	29	30	3	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3509	3517		10.1038/sj.onc.1209393	http://dx.doi.org/10.1038/sj.onc.1209393			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449972				2022-12-17	WOS:000238448200003
J	To, MD; Gokgoz, N; Doyle, TG; Donoviel, DB; Knight, JA; Hyslop, PS; Bernstein, A; Andrulis, IL				To, M. D.; Gokgoz, N.; Doyle, T. G.; Donoviel, D. B.; Knight, J. A.; Hyslop, P. S.; Bernstein, A.; Andrulis, I. L.			Functional characterization of novel presenilin-2 variants identified in human breast cancers	ONCOGENE			English	Article						presenilins; PS-2; breast cancer; Alzheimer's disease; susceptibility	FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; BETA-CATENIN; SUBCELLULAR-LOCALIZATION; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; CELL-CYCLE; IN-VIVO; GENE; MUTANT	We identified in breast cancer cases two germline alterations, R62H and R71W, in presenilin-2 (PS-2), a gene involved in familial Alzheimer's disease (FAD). The role of these alleles in FAD is unclear, but neither allele affected A beta(42)/A beta(40) ratio. However, both R62H and R71W alterations compromised PS-2 function in Notch signaling in Caenorhabditis elegans and cell growth inhibition in mouse embryonic fibroblasts, and these effects were dependent on gene dosage. We found that both alterations enhanced the degradation of the PS-2 full-length protein, indicating that they may have a loss-of function effect. The effect of the R71W alteration was noticeably stronger, and we observed an almost threefold higher frequency of this allele in breast cancer cases versus controls, but this difference did not reach statistical significance. Nonetheless, these results collectively suggest that the novel PS-2 alleles described here, especially R71W, affect PS-2 function and may potentially confer a moderate risk of susceptibility to breast cancer.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Fred A Litwin Ctr Canc Genet, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Prosserman Ctr Hlth Res, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Ctr Res Neurodegenerat, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Canadian Inst Hth Res, Ottawa, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Columbia University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto	Andrulis, IL (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Fred A Litwin Ctr Canc Genet, 600 Univ Ave,Room 984, Toronto, ON M5G 1X5, Canada.	andrulis@mshri.on.ca	Knight, Julia/R-5617-2019; Knight, Julia/A-6843-2012; Andrulis, Irene L./E-7267-2013	Knight, Julia/0000-0002-7610-7635; St George-Hyslop, Peter/0000-0003-0796-7209	NATIONAL CANCER INSTITUTE [U01CA069467] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA69467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Baumeister R, 1997, Genes Funct, V1, P149; Bird TD, 1996, ANN NEUROL, V40, P932, DOI 10.1002/ana.410400619; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Gokgoz N, 2001, CANCER, V92, P2181, DOI 10.1002/1097-0142(20011015)92:8<2181::AID-CNCR1561>3.0.CO;2-3; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639; Jacobsen H, 1999, J BIOL CHEM, V274, P35233, DOI 10.1074/jbc.274.49.35233; Janicki SM, 1999, AM J PATHOL, V155, P135, DOI 10.1016/S0002-9440(10)65108-5; Janicki SM, 2000, NEUROBIOL AGING, V21, P829, DOI 10.1016/S0197-4580(00)00222-0; Jeong SJ, 2000, FASEB J, V14, P2171, DOI 10.1096/fj.99-1068com; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Knight JA, 2002, ANN EPIDEMIOL, V12, P27, DOI 10.1016/S1047-2797(01)00253-8; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takano T, 1997, NEUROSCI LETT, V221, P205, DOI 10.1016/S0304-3940(96)13290-0; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walker ES, 2005, J NEUROCHEM, V92, P294, DOI 10.1111/j.1471-4159.2004.02858.x; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	43	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 15	2006	25	25					3557	3564		10.1038/sj.onc.1209397	http://dx.doi.org/10.1038/sj.onc.1209397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16474849				2022-12-17	WOS:000238448200008
J	Heckman, CA; Duan, H; Garcia, PB; Boxer, LM				Heckman, CA; Duan, H; Garcia, PB; Boxer, LM			Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; Oct; Bob-1	NF-KAPPA-B; IMMUNOGLOBULIN GENE-TRANSCRIPTION; T-CELLS; SOMATIC MUTATION; CREB PROTEINS; BINDING-SITE; MYB; ACTIVATION; INDUCTION; APOPTOSIS	Oct-1 and Oct-2 are members of the POU homeodomain family of transcriptional regulators and are critical for normal embryonic development. Gene-targeting studies showed that Oct-1 and Oct-2 are largely dispensable for B-cell development and immunoglobulin production, although both Oct-2 and Bob-1 are required for a proper immune response and germinal center formation. In these studies, we investigated the role of Oct factors in B-cell lymphomas. Recent investigations have shown increased expression of Oct-2 and Bob-1 in lymphomas, and we observed greatly increased levels of Oct-2 in lymphoma cells with the t(14; 18) translocation. Decreased expression of Oct-1, Oct-2, or Bob-1 by RNA interference resulted in apoptosis and down-regulation of bcl-2 expression. Furthermore, Oct-2 induced bcl-2 promoter activity and mediated this effect through three regions in the bcl-2 P2 promoter. Although these regions did not contain canonical octamer motifs, we observed the direct interaction of Oct-2 with all three sites both in vitro by EMSA and in vivo by chromatin immunoprecipitation assay. Moreover, by mutation analysis we found that the ability of Oct-2 to activate bcl-2 required C/EBP, Cdx, and TATA-binding sites. Oct-2, therefore, acts as a cell survival factor in t(14; 18) lymphoma cells by directly activating the antiapoptotic gene bcl-2.	VAHCS, Ctr Mol Biol Med, Palo Alto, CA USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA USA	Stanford University	Boxer, LM (corresponding author), Stanford Univ, Dept Hematol, Sch Med, 269 Campus Dr,CCSR 1155, Stanford, CA 94305 USA.	lboxer@stanford.edu		Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA 56764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; Bendall HH, 1997, J BIOL CHEM, V272, P28826, DOI 10.1074/jbc.272.46.28826; Bertolino E, 2002, MOL CELL, V10, P397, DOI 10.1016/S1097-2765(02)00597-X; Brunner C, 2003, J EXP MED, V197, P1205, DOI 10.1084/jem.20022014; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; Dunn TL, 1996, BLOOD, V88, P4072, DOI 10.1182/blood.V88.10.4072a.bloodjournal88104072a; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Grassilli E, 1999, CANCER RES, V59, P2451; Greiner A, 2000, AM J PATHOL, V156, P501, DOI 10.1016/S0002-9440(10)64754-2; Grenfell SJ, 1996, BIOCHEM J, V315, P889, DOI 10.1042/bj3150889; Hatada EN, 2000, EUR J IMMUNOL, V30, P174, DOI 10.1002/1521-4141(200001)30:1<174::AID-IMMU174>3.0.CO;2-T; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2003, CANCER RES, V63, P6666; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Hoefnagel JJ, 2005, BLOOD, V105, P3671, DOI 10.1182/blood-2004-04-1594; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Jin TR, 2001, J BIOL CHEM, V276, P14752, DOI 10.1074/jbc.M008277200; KANG SM, 1992, MOL CELL BIOL, V12, P3149, DOI 10.1128/MCB.12.7.3149; Kim U, 2003, P NATL ACAD SCI USA, V100, P8868, DOI 10.1073/pnas.1033108100; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; Lossos IS, 2000, BLOOD, V96, P635; Marafioti T, 2003, AM J PATHOL, V162, P861, DOI 10.1016/S0002-9440(10)63882-5; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; MILLER CL, 1991, MOL CELL BIOL, V11, P4885, DOI 10.1128/MCB.11.10.4885; Nagy M, 2002, BRIT J HAEMATOL, V116, P429, DOI 10.1046/j.1365-2141.2002.03271.x; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Pileri SA, 2003, LEUKEMIA LYMPHOMA, V44, pS21, DOI 10.1080/10428190310001623810; Pileri SA, 2003, AM J PATHOL, V162, P243, DOI 10.1016/S0002-9440(10)63815-1; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; Robetorye RS, 2002, J MOL DIAGN, V4, P123, DOI 10.1016/S1525-1578(10)60693-9; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Sauter P, 1997, IMMUNOBIOLOGY, V198, P207, DOI 10.1016/S0171-2985(97)80041-1; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; Sepulveda MA, 2004, J IMMUNOL, V172, P1054, DOI 10.4049/jimmunol.172.2.1054; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wang VEH, 2004, MOL CELL BIOL, V24, P1022, DOI 10.1128/MCB.24.3.1022-1032.2004; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	53	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					888	898		10.1038/sj.onc.1209127	http://dx.doi.org/10.1038/sj.onc.1209127			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16186795				2022-12-17	WOS:000235212700008
J	Park, HU; Jeong, SJ; Jeong, JH; Chung, JH; Brady, JN				Park, HU; Jeong, SJ; Jeong, JH; Chung, JH; Brady, JN			Human T-cell leukemia virus type 1 Tax attenuates gamma-irradiation-induced apoptosis through physical interaction with Chk2	ONCOGENE			English	Article						HTLV-1 Tax; Chk2; interaction; attenuation; apoptosis	NF-KAPPA-B; DNA-DAMAGE; CHECKPOINT KINASE; P53-MEDIATED TRANSACTIVATION; PHASE PROGRESSION; TUMOR-SUPPRESSOR; P53 INACTIVATION; GENE-EXPRESSION; PROTEIN; LYMPHOCYTES	Checkpoint kinase 2 (Chk2) is known to mediate diverse cellular responses to genotoxic stress. The fundamental role of Chk2 is to regulate the network of genomesurveillance pathways that coordinate cell-cycle progression withDN A repair and cell survival or death. Defects in Chk2 contribute to the development of both hereditary and sporadic human cancers. We now present evidence that the human T-cell leukemia virus type-1 (HTLV-1) Tax protein directly interacts with Chk2 and the kinase activity of Chk2 is inhibited by Tax. The physical interaction of Chk2 and Tax was observed by co-immunoprecipitation assays in HTLV-1-infected T cells (C81) as well as GST pull-down assays using purified proteins. Binding and kinase activity inhibition studies with Tax deletion mutants indicated that at least two domains of Tax mediate the interaction with Chk2. We have analysed the functional consequence of de novo expression of Tax upon the cellular DNA-damage-induced apoptosis, which is mediated by Chk2. Using transient transfection and TUNEL assay, we found that cirradiation-induced apoptosis was decreased in 293T and HCT-116 (p53 (-/-)) cells expressing HTLV-1 Tax. Our studies demonstrate an important potential target of Tax in cellular transformation.	NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Brady, JN (corresponding author), NCI, Virus Tumor Biol Sect, Cellular Oncol Lab, Ctr Canc Res,NIH, Bldg 41-B201,41 Medlars Dr,9000 Rockville Pike, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005691, ZIABC005691] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002243, ZIAHL002243] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Anderson CW, 1998, J PROTEIN CHEM, V17, P527; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2003, ONCOGENE, V22, P1611, DOI 10.1038/sj.onc.1206244; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; COOGAN TP, 1992, TOXICOL APPL PHARM, V113, P227, DOI 10.1016/0041-008X(92)90118-C; COOGAN TP, 1994, J TOXICOL ENV HEALTH, V41, P233, DOI 10.1080/15287399409531839; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Matsuda T, 2005, J VIROL, V79, P1367, DOI 10.1128/JVI.79.3.1367-1378.2005; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185-2193.2001; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; SEGAWA K, 1993, ONCOGENE, V8, P543; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; Sieburg M, 2004, J VIROL, V78, P10399, DOI 10.1128/JVI.78.19.10399-10409.2004; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	59	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					438	447		10.1038/sj.onc.1209059	http://dx.doi.org/10.1038/sj.onc.1209059			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158050				2022-12-17	WOS:000234714100012
J	Carvalho, R; Milne, ANA; Polak, M; Corver, WE; Offerhaus, GJA; Weterman, MAJ				Carvalho, R; Milne, ANA; Polak, M; Corver, WE; Offerhaus, GJA; Weterman, MAJ			Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas	ONCOGENE			English	Article						RUNX3; gastric carcinoma; EOGC; TSG	TRANSCRIPTION FACTOR; CLEIDOCRANIAL DYSPLASIA; REGULATED EXPRESSION; CANCER; CELLS; HYBRIDIZATION; SURVIVAL; NEURONS; PROTEIN; REGION	Recent studies claim a critical role for RUNX3 in gastric epithelial homeostasis. However, conflicting results exist regarding RUNX3 expression in the stomach and its potential role as a tumour-suppressor gene (TSG) in gastric carcinogenesis. Our aim was to evaluate the role of RUNX3 in early-onset gastric carcinomas (EOGCs). We analysed 41 EOGCs for RUNX3 aberrations using loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) analyses. LOH of markers flanking RUNX3 was relatively common, indicating that loss of the gene may play a role in gastric carcinogenesis. However, FISH analysis of selected cases and a panel of 14 gastric carcinoma-derived cell lines showed widespread presence of multiple copies of centromere 1. While RUNX3 copy numbers were generally equal to or fewer than those of centromere 1, at least two copies were present in almost all cells analysed. Accordingly, a subpopulation of tumour cells in 12/37 cases showed RUNX3 protein expression. However, expression was not detected in the adjacent nontumorous mucosa of any case. Together, these observations indicate that chromosome 1 aberrations occur frequently in EOGCs and are rejected in the LOH and IHC patterns found. Our findings refute a role for RUNX3 as a TSG in EOGCs.	Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Carvalho, R (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9,Room L2-114, NL-1105 AZ Amsterdam, Netherlands.	r.p.carvalho@amc.uva.nl	Corver, Willem/T-6576-2018	Corver, Willem/0000-0001-8313-3658				Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Carvalho R, 2004, J PATHOL, V204, P75, DOI 10.1002/path.1602; Corver WE, 2005, J PATHOL, V206, P233, DOI 10.1002/path.1765; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Ehlers M, 2003, J IMMUNOL, V171, P3594, DOI 10.4049/jimmunol.171.7.3594; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Haralambieva E, 2002, J PATHOL, V198, P163, DOI 10.1002/path.1197; Igarashi J, 2000, JPN J CANCER RES, V91, P797, DOI 10.1111/j.1349-7006.2000.tb01016.x; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288; Kokkola A, 1998, CANCER GENET CYTOGEN, V107, P32, DOI 10.1016/S0165-4608(98)00092-2; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Miki R, 2004, J VET MED SCI, V66, P797, DOI 10.1292/jvms.66.797; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osaki M, 2004, EUR J CLIN INVEST, V34, P605, DOI 10.1111/j.1365-2362.2004.01401.x; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; SANO T, 1991, CANCER RES, V51, P2926; TANAKA K, 1993, ONCOGENE, V8, P2253; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Varis A, 2003, BRIT J CANCER, V88, P1914, DOI 10.1038/sj.bjc.6600969; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wu CW, 2002, GENE CHROMOSOME CANC, V35, P219, DOI 10.1002/gcc.10106	38	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 15	2005	24	56					8252	8258		10.1038/sj.onc.1208963	http://dx.doi.org/10.1038/sj.onc.1208963			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091737				2022-12-17	WOS:000233956500004
J	Morales, C; Ribas, M; Aiza, G; Peinado, MA				Morales, C; Ribas, M; Aiza, G; Peinado, MA			Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells	ONCOGENE			English	Article						drug resistance; colorectal cancer; genetic instability; tumor classification	COMPARATIVE GENOMIC HYBRIDIZATION; DIHYDROFOLATE-REDUCTASE; FRAGILE SITES; CHROMOSOME; AMPLIFICATION; PATHWAYS; TUMOR; INSTABILITY; EXPRESSION; HYDROLASE	Alternative genetic pathways characterized by specific genetic profiles and exhibiting distinctive biological and clinical features have been proposed in colorectal carcinogenesis. Methotrexate (MTX) is a potent inhibitor of the dihydrofolate reductase (DHFR) enzyme, which is essential for DNA synthesis and cell growth. We have evaluated the association between different genetic features and the capacity to develop MTX resistance in colon cancer cell lines representative of alternative genetic pathways. Three aneuploid cell lines (HT-29, SW480, and SK-CO-1) showed pre-existing amplifications, but only one (HT-29) developed MTX resistance, showing amplification of the DHFR gene at 5q12-14 (> 20-fold amplification and presence of extrachromosomal double minutes). Failure to develop resistance was attributed to the absence of two complete chromosomes 5 in SW480 and SK-CO-1 cells. Four near-diploid cell lines (LoVo, HCT116, DLD-1 and KM12C) and two aneuploid KM12C-derived metastases (KM12SM and KM12L4A) developed MTX resistance but none exhibited DHFR amplification. All resistant cells without DHFR gene amplification showed microsatellite instability. We conclude that chemoresistance capacity and the mechanism of chemoresistance are related with the genetic pathway and the karyotypic features of colon cancer cells.	Inst Recerca Oncol, IDIBELL, Barcelona 08907, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Peinado, MA (corresponding author), Inst Recerca Oncol, IDIBELL, Granvia Km 2-7,Hosp, Barcelona 08907, Spain.	mpeinado@iro.es	Peinado, Miguel A./A-5591-2008	Peinado, Miguel A./0000-0002-4090-793X				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Blakley RL, 1998, HUM MUTAT, V11, P259, DOI 10.1002/(SICI)1098-1004(1998)11:4<259::AID-HUMU1>3.3.CO;2-N; Bosson G, 2003, BRIT J BIOMED SCI, V60, P117, DOI 10.1080/09674845.2003.11783687; Camps J, 2004, INT J CANCER, V110, P869, DOI 10.1002/ijc.20195; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; Chu E, 1996, STEM CELLS, V14, P41, DOI 10.1002/stem.140041; Cole PD, 2001, CANCER RES, V61, P4599; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DICKER AP, 1993, P NATL ACAD SCI USA, V90, P11797, DOI 10.1073/pnas.90.24.11797; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Goel A, 2003, CANCER RES, V63, P1608; Gorlick R, 1996, NEW ENGL J MED, V335, P1041, DOI 10.1056/NEJM199610033351408; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Heppner GH, 1998, INT REV CYTOL, V177, P1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 2001, CANCER RES, V61, P3230; Masramon L, 2000, CANCER GENET CYTOGEN, V121, P17, DOI 10.1016/S0165-4608(00)00219-3; Masramon L, 1998, BRIT J CANCER, V77, P2349, DOI 10.1038/bjc.1998.390; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; MORIKAWA K, 1988, CANCER RES, V48, P1943; MORIKAWA K, 1988, CANCER RES, V48, P6863; NUNBERG JH, 1978, P NATL ACAD SCI USA, V75, P5553, DOI 10.1073/pnas.75.11.5553; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ribas M, 2002, FASEB J, V16, P289, DOI 10.1096/fj.02-0425fje; Risques RA, 2003, CANCER RES, V63, P7206; Rots MG, 2000, BRIT J HAEMATOL, V110, P791, DOI 10.1046/j.1365-2141.2000.02070.x; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; Ruggiero T, 2003, NUCLEIC ACIDS RES, V31, P6561, DOI 10.1093/nar/gkg858; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Tanaka H, 2002, P NATL ACAD SCI USA, V99, P8772, DOI 10.1073/pnas.132275999; Tsushimi T, 2001, CANCER GENET CYTOGEN, V126, P34, DOI 10.1016/S0165-4608(00)00391-5; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; [No title captured]	45	29	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6842	6847		10.1038/sj.onc.1208834	http://dx.doi.org/10.1038/sj.onc.1208834			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007155				2022-12-17	WOS:000232527800012
J	Keller, U; Nilsson, JA; Maclean, KH; Old, JB; Cleveland, JL				Keller, U; Nilsson, JA; Maclean, KH; Old, JB; Cleveland, JL			Nfkb1 is dispensable for Myc-induced lymphomagenesis	ONCOGENE			English	Article						NF-kappa B1; c-Myc; lymphomagenesis	NF-KAPPA-B; C-MYC; CELL-CYCLE; MEDIATED APOPTOSIS; INDUCTION; TRANSCRIPTION; SUPPRESSOR; GENE; REL; PROLIFERATION	Rel/NF-kappa B transcription factors are critical arbiters of immune responses, cell survival, and transformation, and are frequently deregulated in cancer. The p50 NF-kappa B1 component of Rel/NF-kappa B DNA-binding dimers regulates genes involved in both cell cycle traverse and apoptosis. Nfkb1 loss accelerates B cell growth and leads to increased B cell turnover in vivo, phenotypes akin to those manifested in B cells of E mu-Myc transgenic mice, a model of human Burkitt lymphoma. Interestingly, E mu-Myc B cells express reduced levels of cytoplasmic and nuclear NF-kappa B1 and have reduced Rel/NF-kappa B DNA-binding activity, suggesting that Myc-mediated repression of NF-kappa B1 might mediate its proliferative and apoptotic effects on B cells. Furthermore, Nfkb1 expression was reduced in the majority of E mu-Myc lymphomas and was also suppressed in human Burkitt lymphoma. Nonetheless, loss of Nfkb1 did not appreciably affect Myc's proliferative or apoptotic responses in B cells and had no effect on lymphoma development in E mu-Myc mice. Therefore, Nfkb1 is dispensable for Myc-induced lymphomagenesis.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Cleveland, JL (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale, Memphis, TN 38105 USA.	john.cleveland@stjude.org	Nilsson, Jonas/E-5346-2013	Nilsson, Jonas/0000-0003-0346-6837	NATIONAL CANCER INSTITUTE [F32CA099478, P30CA021765, R01CA076379] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA76379, F32 CA099478] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; ASKEW DS, 1991, ONCOGENE, V6, P1915; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kanda K, 2000, J BIOL CHEM, V275, P32338, DOI 10.1074/jbc.M004148200; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Zelazowski P, 1997, J IMMUNOL, V159, P3133; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	47	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6231	6240		10.1038/sj.onc.1208779	http://dx.doi.org/10.1038/sj.onc.1208779			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940251				2022-12-17	WOS:000231877100004
J	Tosi, GM; Trimarchi, C; Macaluso, M; La Sala, D; Ciccodicola, A; Lazzi, S; Massaro-Giordano, M; Caporossi, A; Giordano, A; Cinti, C				Tosi, GM; Trimarchi, C; Macaluso, M; La Sala, D; Ciccodicola, A; Lazzi, S; Massaro-Giordano, M; Caporossi, A; Giordano, A; Cinti, C			Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: implications for pathogenesis and therapeutic approach	ONCOGENE			English	Article						sporadic retinoblastoma; Rb2/p130 mutation; methylation; demethylating agent; 5-Aza-dC	DNA METHYLATION; P53; APOPTOSIS; RB; EXPRESSION; PROTEIN; P73; ACCUMULATION; PROMOTER; MUTATION	Human retinoblastoma occurs in two forms (familial and sporadic) both due to biallelic mutation of the RB1/p105 gene even if its loss is insufficient for malignancy. We have recently reported that loss of expression of the retinoblastoma-related protein pRb2/p130 correlates with low apoptotic index, suggesting that RB2/p130 gene could be involved in retinoblastoma. Mutational analysis of RB2/p130 in primary tumors showed a tight correlation between Exon 1 mutations and pRb2/p130 expression level in sporadic retinoblastoma. These mutations are located within a CpG-enriched region prone to de novo methylation. Analysis of RB2/p130 methylation status revealed that epigenetic events, most probably consequent to the Exon 1 mutations, determined the observed phenotype. Treatment of Weri-Rb1 cell line by 5-Aza-dC induced an increase in expression level of pRb2/p130, E2F1, p73 and p53. Overall, our results highlight a crucial role of epigenetic events in sporadic retinoblastoma, which opens a perspective for new therapeutic approaches.	Univ Siena, CNR, IFC,Pathol Anat Unit, Inst Clin Physiol,Dept Human Pathol & Oncol, I-53100 Siena, Italy; CNR, Inst Clin Physiol, Siena, Italy; CNR, Inst Genet & Biophys, Naples, Italy; Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA; Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; CNR, Inst Neurosci, I-56100 Pisa, Italy; Univ Siena, Dept Ophthalmol & Neurosurg, I-53100 Siena, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Siena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR); University of Siena	Cinti, C (corresponding author), Univ Siena, CNR, IFC,Pathol Anat Unit, Inst Clin Physiol,Dept Human Pathol & Oncol, Via Scotte 6, I-53100 Siena, Italy.	cinti@area.bo.cnr.it	Lazzi, Stefano/P-8265-2018; Giordano, Antonio/F-1927-2010	Lazzi, Stefano/0000-0002-2218-3771; Giordano, Antonio/0000-0002-5959-016X; Cinti, Caterina/0000-0001-8049-0369; Ciccodicola, Alfredo/0000-0002-9924-1482; CAPOROSSI, Aldo/0000-0002-8680-3773				Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Bender CM, 1998, CANCER RES, V58, P95; Brown R, 2002, TRENDS MOL MED, V8, pS43, DOI 10.1016/S1471-4914(02)02314-6; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Choy KW, 2004, INVEST OPHTH VIS SCI, V45, P3404, DOI 10.1167/iovs.03-1273; CINTI C, 2003, REGULATION G1 PHASE, P200; CINTI C, 2000, EMERGING THER TARGET, V4, P765; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Douc-Rasy S, 2004, M S-MED SCI, V20, P317, DOI 10.1051/medsci/2004203317; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Gallie BL, 1999, CANCER RES, V59, p1731S; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KALIBIC T, 2003, ANN NY ACAD SCI, V983, P278; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; Knudson AG, 2002, AM J MED GENET, V111, P96, DOI 10.1002/ajmg.10320; Kondo Y, 1997, EXP CELL RES, V236, P51, DOI 10.1006/excr.1997.3693; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kusek JC, 2001, BRAIN RES BULL, V54, P187, DOI 10.1016/S0361-9230(00)00447-0; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Lai H, 2003, J CELL BIOCHEM, V88, P121, DOI 10.1002/jcb.10283; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; MAYOL X, 1993, ONCOGENE, V8, P2561; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stirzaker C, 1997, CANCER RES, V57, P2229; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Zheng L, 2002, ADV CANCER RES, V85, P13, DOI 10.1016/S0065-230X(02)85002-3	39	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5827	5836		10.1038/sj.onc.1208630	http://dx.doi.org/10.1038/sj.onc.1208630			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007224				2022-12-17	WOS:000231590400005
J	Rugo, RE; Almeida, KH; Hendricks, CA; Jonnalagadda, VS; Engelward, BP				Rugo, RE; Almeida, KH; Hendricks, CA; Jonnalagadda, VS; Engelward, BP			A single acute exposure to a chemotherapeutic agent induces hyper-recombination in distantly descendant cells and in their neighbors	ONCOGENE			English	Article						genetic instability; homologous recombination; persistent; bystander; DNA damage	INDUCED GENOMIC INSTABILITY; SISTER-CHROMATID EXCHANGES; MITOTIC HOMOLOGOUS RECOMBINATION; EMBRYONIC STEM-CELLS; DOUBLE-STRAND BREAKS; VERY-LOW FLUENCES; ALPHA-PARTICLES; IONIZING-RADIATION; MAMMALIAN-CELLS; MITOMYCIN-C	Homologous recombination can induce tumorigenic sequence rearrangements. Here, we show that persistent hyper-recombination can be induced following exposure to a bifunctional alkylating agent, mitomycin C (MMC), and that the progeny of exposed cells induce a hyperrecombination phenotype in unexposed neighboring cells. Residual damage cannot be the cause of delayed recombination events, since recombination is observed after drug and template damage are diluted over a millionfold. Furthermore, not only do progeny of MMC-exposed cells induce recombination in unexposed cells ( bystanders), but these bystanders can in turn induce recombination in their unexposed neighbors. Thus, a signal to induce homologous recombination can be passed from cell to cell. Although the underlying molecular mechanism is not yet known, these studies reveal that cells suffer consequences of damage long after exposure, and that can signal unexposed neighboring cells to respond similarly. Thus, a single acute exposure to a chemotherapeutic agent can cause long-term changes in genomic stability. If the results of these studies of mouse embryonic stem (ES) cells are generally applicable to many cell types, these results suggest that a relatively small number of cells could potentially induce a tissue-wide increase in the risk of de novo homologous recombination events.	MIT, Biol Engn Div, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Engelward, BP (corresponding author), MIT, Biol Engn Div, 77 Mass Ave,56-631, Cambridge, MA 02139 USA.	bevin@mit.edu			NCI NIH HHS [R01 CA079827, CA84740, R21 CA084740] Funding Source: Medline; NIEHS NIH HHS [P30 ES002109, P30-ES02109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA084740, R01CA079827, R33CA084740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUBRECHT J, 1995, CARCINOGENESIS, V16, P2841, DOI 10.1093/carcin/16.11.2841; Auerbach Charlotte, 1946, PROC ROY SOC EDINBURGH, V62B, P211; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Bishop AJR, 2000, HUM MOL GENET, V9, P2427, DOI 10.1093/hmg/9.16.2427; Bishop AJR, 2003, EXP MOL PATHOL, V74, P94, DOI 10.1016/S0014-4800(03)00010-8; Brennan RJ, 2001, RADIAT RES, V155, P768, DOI 10.1667/0033-7587(2001)155[0768:PGIITY]2.0.CO;2; Camenisch G, 1996, NUCLEIC ACIDS RES, V24, P3707, DOI 10.1093/nar/24.19.3707; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Gupta PK, 1997, CANCER RES, V57, P1188; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hendricks CA, 2003, P NATL ACAD SCI USA, V100, P6325, DOI 10.1073/pnas.1232231100; Huang L, 2004, MOL CELL BIOL, V24, P5060, DOI 10.1128/MCB.24.11.5060-5068.2004; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Iyer R, 2000, CANCER RES, V60, P1290; JONNALAGADDA V, 2005, IN PRESS DNA REPAIR; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Lehnert BE, 1997, CANCER RES, V57, P2164; Limoli CL, 1998, CANCER RES, V58, P3712; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; LITTLE JB, 1990, INT J RADIAT ONCOL, V19, P1425, DOI 10.1016/0360-3016(90)90354-M; LIULEE VW, 1984, MUTAT RES, V127, P139, DOI 10.1016/0027-5107(84)90015-0; LOEB LA, 1991, CANCER RES, V51, P3075; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Morgan WF, 2003, ONCOGENE, V22, P7094, DOI 10.1038/sj.onc.1206992; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; MORLEY AA, 1990, CANCER RES, V50, P4584; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988; NAGASAWA H, 1991, RADIAT RES, V126, P280, DOI 10.2307/3577917; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Nagasawa H, 2002, CANCER RES, V62, P2531; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; OHTSURU M, 1980, CANCER RES, V40, P477; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Sasaki MS, 2004, CYTOGENET GENOME RES, V104, P28, DOI 10.1159/000077463; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Sobol RW, 2003, J BIOL CHEM, V278, P39951, DOI 10.1074/jbc.M306592200; STETKA DG, 1978, MUTAT RES, V51, P383, DOI 10.1016/0027-5107(78)90126-4; Suzuki K, 2003, CANCER RES, V63, P936; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; TOMASZ M, 1987, SCIENCE, V235, P1204, DOI 10.1126/science.3103215; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; WILSON VL, 1983, CELL, V32, P239, DOI 10.1016/0092-8674(83)90514-7; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; ZHU X, 1992, CYTOGENET CELL GENET, V59, P248, DOI 10.1159/000133261	57	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5016	5025		10.1038/sj.onc.1208690	http://dx.doi.org/10.1038/sj.onc.1208690			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856014				2022-12-17	WOS:000230816900002
J	Lewandowski, SA; Thiery, J; Jalil, A; Leclercq, G; Szczylik, C; Chouaib, S				Lewandowski, SA; Thiery, J; Jalil, A; Leclercq, G; Szczylik, C; Chouaib, S			Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity	ONCOGENE			English	Article						estrogen receptor; p53; cell death	TUMOR-SUPPRESSOR P53; BREAST-CANCER CELLS; ER-BETA; INDUCED APOPTOSIS; SIGNALING PATHWAYS; RESPONSE ELEMENTS; GENE-EXPRESSION; MAMMARY-GLAND; BAX GENE; BCL-2	We have investigated the effect of estrogen on p53 cellular location and its influence on tumor cell susceptibility to tumor necrosis factor (TNF)-mediated cytotoxic action. For this purpose, we have used the TNF- sensitive human breast adenocarcinoma MCF-7 and its derivative, the TNF- resistant 1001 clone. Our data indicate that although estrogen receptor (ER) a is present in both cell lines, estrogen treatment (1 x 10(-8) M) has an influence only on the MCF- 7 cells and protects these cells from the TNF cytotoxicity. This protective effect is associated with translocation of p53 from the nucleus to the cytoplasm in p53 wild-type MCF-7 and not in p53-mutated 1001 cells. The translocation of p53 in MCF- 7 cells results in a decrease in its transcriptional activity, as revealed by diminished p21(WAF1/CIP1) induction and an altered ratio of Bax and Bcl-2 proteins. The estrogen-induced effects are reversed by the selective estrogen inhibitor 182, 780 (1 x 10(-6) M). Interestingly, transient transfection of MCF-7 cells with ER beta but not ER alpha cDNA encoding plasmid results in retention of p53 in the nucleus, a subsequent potentiation of its transcriptional activity, and in an increased MCF-7 sensitivity to TNF. The estrogen effects on p53 location and transcriptional activity may involve the mdm2 protein since both events were reversed following MCF-7 transfection with plasmid encoding the ARF cDNA. These studies suggest that estrogen-induced MCF-7 cell survival in the presence of TNF requires a transcriptionally active p53 and, more importantly, indicate that introduction of ERb can attenuate the estrogen effects on the p53 protein location, its transcriptional activity and also results in a potentiation of cell sensitivity to TNF-mediated cell death.	Inst Gustave Roussy, INSERM, U487, Cytokines & Immunol Tumeurs Humaines, F-94805 Villejuif, France; Military Inst Med, Dept Oncol, PL-00909 Warsaw, Poland; Univ Libre Bruxelles, Inst Jules Bordet, Serv Med Interne, Lab JC Heuson Cancerol Mammaire, B-1000 Brussels, Belgium; Postgrad Sch Mol Med, PL-02093 Warsaw, Poland	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut Jules Bordet; Universite Libre de Bruxelles	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U487, Cytokines & Immunol Tumeurs Humaines, Rue Camille Desmoulins, F-94805 Villejuif, France.	chouaib@igr.fr	Chouaib, Salem/F-7939-2016; THIERY, Jerome/N-2469-2018; Lewandowski, Sebastian A./K-2492-2019	THIERY, Jerome/0000-0002-0998-3627; Lewandowski, Sebastian A./0000-0002-5935-0211; JALIL, Abdelali/0000-0003-2710-8735; Guy, LECLERCQ/0000-0001-7231-6563				Ameyar M, 1998, J BIOL CHEM, V273, P29002, DOI 10.1074/jbc.273.44.29002; Berns EMJJ, 2000, CANCER RES, V60, P2155; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brown JM, 1999, CANCER RES, V59, P1391; Burow ME, 2001, J STEROID BIOCHEM, V78, P409, DOI 10.1016/S0960-0760(01)00117-0; Burow ME, 2000, INT J ONCOL, V16, P1179; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Driggers PH, 2002, TRENDS ENDOCRIN MET, V13, P422, DOI 10.1016/S1043-2760(02)00634-3; Geisler S, 2001, CANCER RES, V61, P2505; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Hyder SM, 1999, BIOCHEM PHARMACOL, V57, P597, DOI 10.1016/S0006-2952(98)00355-4; Kanda N, 2003, J INVEST DERMATOL, V121, P1500, DOI 10.1111/j.1523-1747.2003.12617.x; Kato K, 2002, J BIOL CHEM, V277, P11217, DOI 10.1074/jbc.M107391200; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706; Lilling G, 2000, CANCER LETT, V161, P27, DOI 10.1016/S0304-3835(00)00579-6; Liu G, 1999, BIOCHEM BIOPH RES CO, V264, P359, DOI 10.1006/bbrc.1999.1525; Liu GZ, 2000, CANCER RES, V60, P1810; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Molinari AM, 2000, CANCER RES, V60, P2594; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; OLTVAI ZN, 1993, CELL, V74, P619; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Phelps M, 2003, CANCER RES, V63, P2616; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Sudoh N, 2001, CIRCULATION, V103, P724; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Thiery J, 2003, J IMMUNOL, V170, P5919, DOI 10.4049/jimmunol.170.12.5919; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade CB, 2001, ENDOCRINOLOGY, V142, P2336, DOI 10.1210/en.142.6.2336; Weatherman RV, 2001, J BIOL CHEM, V276, P3827, DOI 10.1074/jbc.M005414200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522	61	29	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4789	4798		10.1038/sj.onc.1208595	http://dx.doi.org/10.1038/sj.onc.1208595			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870704				2022-12-17	WOS:000230477900005
J	Radhika, V; Ha, JH; Jayaraman, M; Tsim, ST; Dhanasekaran, N				Radhika, V; Ha, JH; Jayaraman, M; Tsim, ST; Dhanasekaran, N			Mitogenic signaling by lysophosphatidic acid (LPA) involves G alpha(12)	ONCOGENE			English	Article						G protein; LPA; G alpha(13); cell-proliferation; oncogene; transformation	INDUCED CELL-PROLIFERATION; PROTEIN-COUPLED RECEPTORS; OVARIAN-CANCER CELLS; N-TERMINAL KINASE; NEURITE RETRACTION; G(12) FAMILY; 3T3 CELLS; ACTIVATION; IDENTIFICATION; TRANSFORMATION	Lysophosphatidic acid (LPA), a major G protein coupled receptor(GPCR)-activating ligand present in serum, elicits growth factor like responses by stimulating specific GPCRs coupled to heterotrimeric G proteins such as G(i), G(q), and G(12/13). Previous studies have shown that the overexpression of wild-type G alpha(12) (G alpha 12WT) results in the oncogenic transformation of NIH3T3 cells (G alpha 12WT-NIH3T3) in a serum-dependent manner. Based on the potent growth-stimulating activity of LPA and the presence of LPA and LPA-like molecules in the serum, we hypothesized that the serum-dependent neoplastic transformation of G alpha 12WT-NIH3T3 cells was mediated by the stimulation of LPA-receptors (LPARs) by LPA in the serum. In the present study, using guanine nucleotide exchange assay and GST-TPR binding assay, we show that the treatment of G alpha 12WT-NIH3T3 with 2 mu M LPA leads to the activation of G alpha(12). Stimulation of these cells with LPA promotes JNK-activation, a critical component of G alpha(12)-response and cell proliferation. We also show that LPA can substitute for serum in stimulating JNK-activity, DNA synthesis, and proliferation of G alpha 12WT-NIH3T3 cells. LPA-mediated proliferative response in NIH3T3 cells involves G alpha(12), but not the closely related G alpha(13). Pretreatment of G alpha 12WT-NIH3T3 cells with suramin (100 mu M), a receptor-uncoupling agent, inhibited LPA-stimulated proliferation of these cells by 55% demonstrating the signal coupling between cell surface LPAR and Ga-12 in the neoplastic proliferation of NIH3T3 cells. As LPA and LPAR mediated mitogenic pathways have been shown to play a major role in tumor genesis and progression, a mechanistic understanding of the signal coupling between LPAR, Ga-12, and the downstream effectors is likely to unravel additional targets for novel cancer chemotherapies.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.	danny001@temple.edu	Jayaraman, Muralidharan/H-8563-2019	Jayaraman, Muralidharan/0000-0003-3274-877X; HA, Ji Hee/0000-0002-6281-1904	NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Barr AJ, 1997, J BIOL CHEM, V272, P2223; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Dermott JM, 2004, ONCOGENE, V23, P226, DOI 10.1038/sj.onc.1207009; Dermott JM, 2002, METHOD ENZYMOL, V344, P298; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Furui T, 1999, CLIN CANCER RES, V5, P4308; Goetzl EJ, 1999, CANCER RES, V59, P5370; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P70, DOI 10.1016/S1388-1981(02)00138-5; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Windh RT, 2002, METHOD ENZYMOL, V344, P3; WONG YH, 1995, ONCOGENE, V10, P1927; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200	42	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4597	4603		10.1038/sj.onc.1208665	http://dx.doi.org/10.1038/sj.onc.1208665			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856019				2022-12-17	WOS:000230157100014
J	Daboussi, F; Thacker, J; Lopez, BS				Daboussi, F; Thacker, J; Lopez, BS			Genetic interactions between RAD51 and its paralogues for centrosome fragmentation and ploidy control, independently of the sensitivity to genotoxic stresses	ONCOGENE			English	Article						RAD51; paralogues; centrosome; genotoxic stress; homologous recombination	HOMOLOGY-DIRECTED REPAIR; DOUBLE-STRAND BREAKS; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; REPLICATION INHIBITION; RADIOSENSITIZING AGENT; RECOMBINATION; XRCC3; CAFFEINE; COMPLEXES	We evaluate here whether RAD51 and its paralogues XRCC2 and XRCC3 act via a common pathway for sensitivity to genotoxic stress, centrosome fragmentation and chromosome stability. We expressed the RAD51 dominant-negative SMRAD51 in irs1 and irs1SF cells, defective for XRCC2 and XRCC3, respectively, and in their corresponding wild-type cells (V79 and AA8, respectively). V79-SMRAD51 cells are sensitive to mitomycin C(MMC), but SMRAD51 did not further sensitize irs1 cells to MMC, showing that SMRAD51 and XRCC2 act on the same pathway for resistance to MMC. However, in contrast to irs1 and irs1SF cells, SMRAD51-V79 and SMRAD51-AA8 cells are not sensitive to c-rays or UV-C. Despite these differences in sensitivity, SMRAD51-expressing cells and xrcc2- or xrcc3-defective cells show similar increased levels of centrosome fragmentation. This spontaneous centrosome fragmentation is resistant to caffeine, suggesting that ATM and ATR are not involved. Consistent with centrosome fragmentation, increased aneuploidy was measured in irs1 and SMRAD51-expressing cells. Expression of SMRAD51 in irs1 or irs1SF cells did not increase further the frequency of multipolar cells. Thus, RAD51, XRCC2 and XRCC3 act in the same pathway for centrosome fragmentation, independently of the sensitivity to exogenous genotoxic stresses and of the ATM/ATR pathway.	CEA, CNRS, UMR 217, Direct Sci Vivant,Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, CNRS, UMR 217, Direct Sci Vivant,Dept Radiobiol & Radiopathol, 18 Route Panorama,POB 06,Bat 05, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Lopez, Bernard S/O-7308-2017	Lopez, Bernard S/0000-0001-5088-0155; Daboussi, Fayza/0000-0001-7689-7975				Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Block WD, 2004, NUCLEIC ACIDS RES, V32, P1967, DOI 10.1093/nar/gkh508; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; Lambert S, 2001, ONCOGENE, V20, P6627, DOI 10.1038/sj.onc.1204813; Linke SP, 2003, CANCER RES, V63, P2596; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Liu YL, 2004, SCIENCE, V303, P243, DOI 10.1126/science.1093037; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Wang HC, 2004, ONCOGENE, V23, P824, DOI 10.1038/sj.onc.1207168	36	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3691	3696		10.1038/sj.onc.1208438	http://dx.doi.org/10.1038/sj.onc.1208438			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782136				2022-12-17	WOS:000229221800017
J	Ego, T; Tanaka, Y; Shimotohno, K				Ego, T; Tanaka, Y; Shimotohno, K			Interaction of HTLV-1 Tax and methyl-CpG-binding domain 2 positively regulates the gene expression from the hypermethylated LTR	ONCOGENE			English	Article						Tax; methyl-CpG-binding domain 2; epigenetic regulation	T-CELL LEUKEMIA; VIRUS TYPE-I; MONOCLONAL-ANTIBODIES; DEMETHYLASE ACTIVITY; LENTIVIRUS VECTOR; DNA METHYLATION; TERMINAL REPEAT; C-MYB; PROTEIN; TRANSCRIPTION	Epigenetic regulation of gene expression is critical in the maintenance of cellular homeostasis. Dysregulation of normal epigenetic transcription occurs in abnormal physiological conditions, such as those seen in cancer cells and cells infected with parasites, making the mechanism underlying abnormal epigenetic transcription of great interest. Gene expression of human T-cell leukemia virus type 1 (HTLV-1) is regulated by a viral transcriptional stimulator, Tax. We herein report a novel mechanism of transcription from the HTLV-1 long terminal repeat (LTR) that is regulated by Tax. In this study, we determined that Tax is able to activate transcription from the LTR, even when it was heavily methylated. In addition, the methyl-CpG-binding domain 2 (MBD2) protein played an important role in Tax-mediated transcriptional activation. We demonstrated the importance of a physical interaction between Tax and MBD2 in enhancing the transcriptional activity of Tax against the methylated LTR. Furthermore, we identified the formation of a protein complex composed of MBD2 and Tax bound to the methylated LTR. We propose a new model of epigenetic regulation by MBD2 acting in concert with a virally encoded transactivator, Tax. Our observation provides insight into the epigenetic regulation of gene expression and the diverse mechanisms of transcriptional regulation using methylated promoters.	Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Univ Ryukyus, Fac Med, Nishihara, Okinawa 9030215, Japan	Kyoto University; University of the Ryukyus	Shimotohno, K (corresponding author), Kyoto Univ, Dept Viral Oncol, Inst Virus Res, Sakyo Ku, 53 Kawara Cho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp						Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Fujita H, 2003, MOL CELL BIOL, V23, P2645, DOI 10.1128/MCB.23.8.2645-2657.2003; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nicot C, 2000, MOL CELL BIOL, V20, P8580, DOI 10.1128/MCB.20.22.8580-8589.2000; Nicot C, 2001, MOL CELL BIOL, V21, P7391, DOI 10.1128/MCB.21.21.7391-7402.2001; NOSAKA T, 1993, NUCLEIC ACIDS RES, V21, P5124, DOI 10.1093/nar/21.22.5124; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; TANAKA Y, 1991, INT J CANCER, V48, P623, DOI 10.1002/ijc.2910480423; TANAKA Y, 1986, INT J CANCER, V37, P35, DOI 10.1002/ijc.2910370107; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshida M, 2004, BLOOD, V103, P2753, DOI 10.1182/blood-2003-07-2482	42	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1914	1923		10.1038/sj.onc.1208394	http://dx.doi.org/10.1038/sj.onc.1208394			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674330				2022-12-17	WOS:000227542000010
J	Robb, VA; Gerber, MA; Hart-Mahon, EK; Gutmann, DH				Robb, VA; Gerber, MA; Hart-Mahon, EK; Gutmann, DH			Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression	ONCOGENE			English	Article						meningioma; brain tumor; Protein 4.1B; DAL-1; tumor suppressor	TUMOR-SUPPRESSOR; NF2 GENE; FUNCTIONAL-CHARACTERIZATION; MERLIN EXPRESSION; CELL-SURVIVAL; DAL-1; IDENTIFICATION; ASSOCIATION; ACTIVATION; EZRIN	Meningiomas are common central nervous system tumors; however, the molecular mechanisms underlying their pathogenesis are largely undefined. Previous work has implicated Protein 4.1B as an important tumor suppressor involved in the development of these neoplasms. In this report, we demonstrate that the U2 domain is necessary and sufficient for the ability of Protein 4.1B to function as a meningioma growth suppressor. Using a series of truncation and deletion constructs of DAL-1 (a fragment of Protein 4.1B that retains all the growth suppressive properties), we narrowed the domain required for 4.1B growth suppression to a fragment containing a portion of the FERM domain and the U2 domain using clonogenic assays on meningioma cells. Deletion of the U2 domain in the context of the full-length DAL-1 molecule eliminated growth suppressor function, as measured by thymidine incorporation and caspase-3 activation. Moreover, targeting the U2 domain to the plasma membrane using a membrane localization signal (MLS) reduced cell proliferation, similar to wild-type DAL-1. Collectively, the data suggest that the U2 domain, when properly targeted to the plasma membrane, contains all the residues necessary for mediating Protein 4.1B growth suppression.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NCI NIH HHS [1-F32-CA-097816-01] Funding Source: Medline; NINDS NIH HHS [NS41520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA097816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bostrom J, 2001, AM J PATHOL, V159, P661, DOI 10.1016/S0002-9440(10)61737-3; Brault E, 2001, J CELL SCI, V114, P1901; Cai DX, 2001, AM J CLIN PATHOL, V115, P213; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Dard N, 2004, DEV BIOL, V271, P87, DOI 10.1016/j.ydbio.2004.03.024; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Denisenko-Nehrbass N, 2003, EUR J NEUROSCI, V17, P411, DOI 10.1046/j.1460-9568.2003.02441.x; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Huang S, 2001, EUR J CLIN INVEST, V31, P907, DOI 10.1046/j.1365-2362.2001.00892.x; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Lozupone F, 2004, J BIOL CHEM, V279, P9199, DOI 10.1074/jbc.M305561200; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Perry A, 1996, CANCER, V77, P2567, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2567::AID-CNCR21>3.0.CO;2-P; Perry A, 2001, J NEUROPATH EXP NEUR, V60, P994, DOI 10.1093/jnen/60.10.994; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Peters LL, 1998, GENOMICS, V54, P348, DOI 10.1006/geno.1998.5537; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; SIMON M, 1995, CANCER RES, V55, P4696; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Sun YQ, 2004, MOL CELL BIOL, V24, P1531, DOI 10.1128/MCB.24.4.1531-1539.2004; Surace EI, 2004, ANN NEUROL, V56, P295, DOI 10.1002/ana.20201; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; Toby G, 1998, BIOTECHNIQUES, V24, P637, DOI 10.2144/98244st05; Tran YK, 1999, CANCER RES, V59, P35; Tse JYM, 1998, HUM PATHOL, V29, P1200, DOI 10.1016/S0046-8177(98)90246-5; Ueki K, 1999, CANCER RES, V59, P5995; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Yageta M, 2002, CANCER RES, V62, P5129; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu TX, 2002, BIOCHEM J, V365, P783, DOI 10.1042/BJ20020060; Zhang SP, 2003, J BIOL CHEM, V278, P52810, DOI 10.1074/jbc.M308244200	53	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1946	1957		10.1038/sj.onc.1208335	http://dx.doi.org/10.1038/sj.onc.1208335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688033				2022-12-17	WOS:000227542000013
J	Morris, C; Jalinot, P				Morris, C; Jalinot, P			Silencing of human Int-6 impairs mitosis progression and inhibits cyclin B-Cdk1 activation	ONCOGENE			English	Article						Int-6; mitosis; chromosome segregation; Cdk1; Wee1	MAMMARY-TUMOR VIRUS; FISSION YEAST HOMOLOG; TRANSLATION INITIATION; CELL-DIVISION; SUBUNIT; KINASES; PROTEIN; GENE; SITE; PHOSPHORYLATION	The Int-6 protein has been originally identified as the product of a mouse gene being a frequent integration site of the mouse mammary tumour virus. Here, we show that reducing Int-6 expression by RNA interference in HeLa cells markedly alters mitosis progression. Defects in spindle formation, chromosome segregation and cytokinesis were observed. These abnormalities of mitosis completion are correlated with an inhibition of cyclin B Cdk1 kinase activity, due to a prolonged inhibitory phosphorylated state of Cdk1. In line with this observation, the Wee1 tyrosine kinase that negatively controls Cdk1 was less efficiently inactivated during G2 in Int-6-depleted cells. These findings support the notion that the oncogenic properties associated with alteration of Int-6 originate from chromosomal instability.	Ecole Normale Super Lyon, CNRS, UMR5161, Lab Biol Mol Cellule,IFR 128, F-69364 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, CNRS, UMR5161, Lab Biol Mol Cellule,IFR 128, 46 Allee Italie, F-69364 Lyon, France.	pjalinot@ens-lyon.fr	Morris, Christelle/M-8168-2014	Morris, Christelle/0000-0003-1575-4609				Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; ALVES K, 2004, THESIS ECOLE NORMALE; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; DANIELS MJ, 2004, SCIENCE, V16, P16; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; HOAREAU AK, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Kawasaki H, 2003, ONCOGENE, V22, P6839, DOI 10.1038/sj.onc.1206903; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Mizunuma M, 2001, EMBO J, V20, P1074, DOI 10.1093/emboj/20.5.1074; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1999, NATL CELL BIOL, V1, P73; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Qin XL, 2004, J BIOL CHEM, V279, P13721, DOI 10.1074/jbc.M312854200; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Secchiero P, 1998, BLOOD, V92, P1685, DOI 10.1182/blood.V92.5.1685.417k30_1685_1696; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Stock RP, 2003, NAT BIOTECHNOL, V21, P13, DOI 10.1038/nbt0103-13; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watkins SJ, 2004, CELL PROLIFERAT, V37, P149, DOI 10.1111/j.1365-2184.2004.00305.x; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370	39	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1203	1211		10.1038/sj.onc.1208268	http://dx.doi.org/10.1038/sj.onc.1208268			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558017				2022-12-17	WOS:000226898700007
J	Cuevas, BD; Uhlik, MT; Garrington, TP; Johnson, GL				Cuevas, BD; Uhlik, MT; Garrington, TP; Johnson, GL			MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability	ONCOGENE			English	Article						MEKK1; AP-1; dimer	NEGATIVE C-JUN; CELL-PROLIFERATION; MOUSE DEVELOPMENT; GENE DISRUPTION; DEFICIENT MICE; PHOSPHORYLATION; PLASMINOGEN; ACTIVATION; KINASE; FOS	Activator protein 1 (AP-1) transcription factor dimers are composed of Jun, Fos, and ATF member proteins, but the mechanisms that determine AP-1 composition are not clearly de. ned and the function of specific dimers is not well understood. MEKK1 is a mitogen-activated protein kinase ( MAPK) kinase kinase and an ubiquitin ligase that regulates both the extracellular signal-regulated kinase 1/2 and the c-Jun amino-terminal kinase. Herein, we demonstrate that MEKK1 regulates the AP-1 protein repertoire. Both FGF-2 and phorbol ester-inducible urokinase-type plasminogen activator (uPA) expression requires AP-1 binding to an enhancer element in the uPA promoter, and we have previously shown that FGF-2 or PMA induction of uPA expression is strongly dependent on MEKK1. JunB mRNA is significantly increased in MEKK1-/- cells, demonstrating that MEKK1 suppresses JunB mRNA expression. Upregulation of JunB expression in MEKK1-/- cells forms an inhibitory AP-1 complex that binds to the uPA promoter and inhibits uPA transcription. MEKK1 also regulates Fra-2 protein stability by inducing Fra-2 ubiquitination and degradation. MEKK1 regulates AP-1-dependent gene expression by regulating the expression, activity and degradation of component members of the AP-1 complex. Controlling the repertoire of a transcription factor complex is a newly defined function for an MAPK kinase kinase.	Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pediat, Denver, CO 80262 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cuevas, BD (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, 1108 Mary Ellen Jones Bldg,Campus Box 7365,102 Ma, Chapel Hill, NC 27599 USA.	bruce_cuevas@med.unc.edu; glj@med.unc.edu						Acquaviva C, 2002, ANN NY ACAD SCI, V973, P426, DOI 10.1111/j.1749-6632.2002.tb04677.x; Acquaviva C, 2001, BIOCHIMIE, V83, P357, DOI 10.1016/S0300-9084(01)01243-3; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Cohen D, 2001, AM SOC HEMATOL ED PR, P1; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DECESARE D, 1995, ONCOGENE, V11, P365; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Legrand C, 2001, EXP CELL RES, V264, P326, DOI 10.1006/excr.2000.5125; Lund LR, 2000, DEVELOPMENT, V127, P4481; McHenry JZ, 1998, ONCOGENE, V17, P1131, DOI 10.1038/sj.onc.1202044; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OHagan RC, 1996, ONCOGENE, V13, P1323; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Roselli HT, 1998, AM J PHYSIOL-GASTR L, V275, pG1472, DOI 10.1152/ajpgi.1998.275.6.G1472; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Thompson EJ, 2002, CANCER RES, V62, P3044; Witowsky J, 2003, J BIOL CHEM, V278, P5941, DOI 10.1074/jbc.M212363200; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Young MR, 2002, MOL CARCINOGEN, V34, P72, DOI 10.1002/mc.10050; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	46	29	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					801	809		10.1038/sj.onc.1208239	http://dx.doi.org/10.1038/sj.onc.1208239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558021				2022-12-17	WOS:000226577100006
J	Worch, J; Tickenbrock, L; Schwable, J; Steffen, B; Cauvet, T; Mlody, B; Buerger, H; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C				Worch, J; Tickenbrock, L; Schwable, J; Steffen, B; Cauvet, T; Mlody, B; Buerger, H; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C			The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RAR alpha and regulates differentiation of hematopoietic cells	ONCOGENE			English	Article						AML; balanced translocation; myeloid differentiation; MNK1; eIF4E; c-myc	ACUTE MYELOID-LEUKEMIA; INITIATION-FACTOR 4E; CAP-BINDING PROTEIN; ACUTE PROMYELOCYTIC LEUKEMIA; MESSENGER-RNA TRANSPORT; P14(ARF) TUMOR-SUPPRESSOR; TRANSLATION INITIATION; CYCLIN D1; MALIGNANT TRANSFORMATION; HISTONE DEACETYLASE	Microarray analyses were performed to identify target genes that are shared by the acute myeloid leukemia (AML) translocation products PML-RARalpha, PLZF-RARalpha and AML1-ETO in inducibly transfected U937 cell lines. The cytoplasmic serine and threonine kinase MNK1 was identified as one of the target genes. At the protein level, MNK1 was significantly induced by each of the three fusion proteins. Protein half-life analyses showed that PML-RARalpha enhanced MNK1 protein stability in U937 cells and ATRA exposure decreased MNK1 half-life in NB4 cells. EIF4E, the main MNK1 substrate, plays a role in the pathogenesis of a variety of cancers. Upon MNK1 overexpression, eIF4E phosphorylation increased as a sign of functional activation. Interestingly, MNK1 protein expression decreased during myeloid differentiation. Inhibition of MNK1 activity by a specific inhibitor (CGP57380) enhanced differentiation of HL60 and 32D cells, further suggesting a role for MNK1 in the myeloid differentiation. In addition, kinase dead mutants of MNK1 significantly impaired proliferation of 32D cells. Immunohistochemistry of primary AML bone marrow biopsies showed strong cytoplasmic MNK1 expression in 25 of 99 AML specimens (25%). MNK1 expression was associated with high levels of c-myc expression. Taken together, we identified MNK1 as a target gene of several leukemogenic fusion proteins in AML. MNK1 plays a role in myeloid differentiation. These data suggest a role for MNK1 in the AML fusion protein-associated differentiation block.	Univ Munster, Dept Med Hematol & Oncol, D-48129 Munster, Germany; Univ Munster, Gerhard Domagk Inst Pathol, D-4400 Munster, Germany; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA	University of Munster; University of Munster; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Serve, H (corresponding author), Univ Munster, Dept Med Hematol & Oncol, Domagkstr 3, D-48129 Munster, Germany.	muellerc@uni-muenster.de	Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018	Müller-Tidow, Carsten/0000-0002-7166-5232; Mlody, Barbara/0000-0001-5184-1772				Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Ferrara FF, 2001, CANCER RES, V61, P2; Flynn A, 1996, CANCER SURV, V27, P293; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Kalantry S, 1997, J CELL PHYSIOL, V173, P288, DOI 10.1002/(SICI)1097-4652(199711)173:2<288::AID-JCP38>3.3.CO;2-Q; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Muller-Tidow C, 2004, LEUKEMIA, V18, P720, DOI 10.1038/sj.leu.2403296; Muller-Tidow C, 2004, CLIN CANCER RES, V10, P1241, DOI 10.1158/1078-0432.CCR-0954-03; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nathan CAO, 2000, CANCER RES, V60, P3599; Nikolcheva T, 2002, J CLIN INVEST, V110, P119, DOI 10.1172/JCI200215336; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sorrells DL, 1999, J ORAL MAXIL SURG, V57, P294, DOI 10.1016/S0278-2391(99)90676-6; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Topisirovic I, 2002, MOL CELL BIOL, V22, P6183, DOI 10.1128/MCB.22.17.6183-6198.2002; Tschopp C., 2000, Molecular Cell Biology Research Communications, V3, P205, DOI 10.1006/mcbr.2000.0217; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	44	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9162	9172		10.1038/sj.onc.1208164	http://dx.doi.org/10.1038/sj.onc.1208164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516979				2022-12-17	WOS:000225638000001
J	Sisci, D; Aquila, S; Middea, E; Gentile, M; Maggiolini, M; Mastroianni, F; Montanaro, D; Ando, S				Sisci, D; Aquila, S; Middea, E; Gentile, M; Maggiolini, M; Mastroianni, F; Montanaro, D; Ando, S			Fibronectin and type IV collagen activate ER alpha AF-1 by c-Src pathway: effect on breast cancer cell motility	ONCOGENE			English	Article						estrogen receptor alpha; extracellular matrix; fibronectin; type IV collagen; c-Src	FOCAL ADHESION KINASE; MEDIATED SIGNAL-TRANSDUCTION; STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; GROWTH-FACTOR; MAP KINASE; PROTEIN-KINASE; TYROSINE KINASES; FAMILY KINASES; MAMMARY-TUMORS	The expression of estrogen receptor alpha (ERalpha) is generally associated with a less invasive and aggressive phenotype in breast carcinoma. In an attempt to understand the role of ERalpha in regulating breast cancer cells invasiveness, we have demonstrated that cell adhesion on fibronectin (Fn) and type IV Collagen (Col) induces ERalpha-mediated transcription and reduces cell migration in MCF-7 and in MDA-MB-231 cell lines expressing ERalpha. Analysis of deleted mutants of ERalpha indicates that the transcriptional activation function (AF)-1 is required for ERalpha-mediated transcription as well as for the inhibition of cell migration induced by cell adhesion on extracellular matrix(ECM) proteins. In addition, the nuclear localization signal region and some serine residues in the AF-1 of the ERalpha are both required for the regulation of cell invasiveness as we have observed in HeLa cells. It is worth noting that c-Src activation is coincident with adhesion of cells to ECM proteins and that the inhibition of c-Src activity by PP2 or the expression of a dominant-negative c-Src abolishes ERalpha-mediated transcription and partially reverts the inhibition of cell invasiveness in ERalpha-positive cancer cells. These findings address the integrated role of ECM proteins and ERalpha in influencing breast cancer cell motility through a mechanism that involves c-Src and seems not to be related to a specific cell type.	Univ Calabria, Ctr Sanitario, Dipartimento Biol Cellulare, I-87030 Cosenza, Italy; Univ Calabria, Dipartimento Farmacobiol, Arcavacata Di Rende, Italy	University of Calabria; University of Calabria	Ando, S (corresponding author), Univ Calabria, Ctr Sanitario, Dipartimento Biol Cellulare, I-87030 Cosenza, Italy.	sebastiano.ando@unical.it	Maggiolini, Marcello/Z-4729-2019; /AAD-9701-2019	/0000-0001-6577-1541; Maggiolini, Marcello/0000-0002-7485-854X; AQUILA, Saveria/0000-0003-4738-6927				Abidi SMA, 1997, CLIN EXP METASTAS, V15, P432, DOI 10.1023/A:1018458406797; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Aplin AE, 1999, J CELL SCI, V112, P695; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; CHEN Q, 1994, J BIOL CHEM, V6, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Couse JF, 1995, BIOCHEM SOC T, V23, P929, DOI 10.1042/bst0230929; Crowe David L., 1999, Neoplasia (New York), V1, P368, DOI 10.1038/sj.neo.7900041; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Feng WJ, 2001, MOL ENDOCRINOL, V15, P32, DOI 10.1210/me.15.1.32; FRAKER LD, 1984, CANCER RES, V44, P5757; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Hynes RO, 1990, FIBRONECTINS; IGNARTROWBRIDGE DM, 1995, ENVIRON HEALTH PERSP, V103, P35, DOI 10.2307/3432505; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; LEHRER S, 1989, MT SINAI J MED, V56, P83; Lin TH, 1997, J BIOL CHEM, V272, P8849; Liotta L A, 1991, Semin Cancer Biol, V2, P111; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MCGUIRE WL, 1986, CANCER SURV, V5, P527; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OSBORNE CK, 1985, CANCER RES, V45, P584; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PRICE JE, 1990, CANCER RES, V50, P717; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Suen PW, 1999, J CELL SCI, V112, P4067; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	54	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8920	8930		10.1038/sj.onc.1208098	http://dx.doi.org/10.1038/sj.onc.1208098			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467744				2022-12-17	WOS:000225354600007
J	Kappler, R; Bauer, R; Calzada-Wack, J; Rosemann, M; Hemmerlein, B; Hahn, H				Kappler, R; Bauer, R; Calzada-Wack, J; Rosemann, M; Hemmerlein, B; Hahn, H			Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; patched; p53; microarrays; mouse	ALVEOLAR RHABDOMYOSARCOMA; MYOGENIC DIFFERENTIATION; P53 MUTATIONS; MOUSE MODEL; STEM-CELLS; MICE; EXPRESSION; SARCOMAS; TUMORS; MUSCLE	Rhabdomyosarcoma (RMS) is a highly malignant tumor that is histologically related to skeletal muscle, yet genetic and molecular lesions underlying its genesis and progression remain largely unknown. In this study we have compared the molecular profiles of two different mouse models of RMS, each associated with a defined primary genetic defect known to play a role in rhabdomyosarco-magenesis in man. We report that RMS of heterozygous Patched1 (Ptch1) mice show less aggressive growth and a greater degree of differentiation than RMS of heterozygous p53 mice. By means of cDNA microarray analysis we demonstrate that RMS in Ptch1 mutants predominantly express a number of myogenic markers, including myogenic differentiation 1, myosin heavy chain, actin, troponin and tropomyosin, as well as genes associated with Hedgehog/Patched signaling like insulin-like growth factor 2, forkhead box gene Foxf1 and the growth arrest and DNA-damage-inducible gene Gadd45a. In sharp contrast, RMS in p53 mutants display higher expression levels of cell cycle-associated genes like cyclin B1, cyclin-dependent kinase 4 and the proliferation marker Ki-67. These results demonstrate that different causative mutations lead to distinct gene expression profiles in RMS, which appear to reflect their different biological characteristics. Our results provide a first step towards a molecular classification of different forms of RMS. If the described differences can be confirmed in human RMS our results will contribute to a new molecular taxonomy of this cancer, which will be critical for gene mutation- and expression-specific therapy.	Univ Gottingen, Inst Human Genet, Gottingen, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Pathol, Neuherberg, Germany; Univ Gottingen, Dept Pathol, D-3400 Gottingen, Germany	University of Gottingen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Gottingen	Hahn, H (corresponding author), Univ Gottingen, Inst Human Genet, Heinrich Duker Weg 12, Gottingen, Germany.	hhahn@gwdg.de	Rosemann, Michael/AAX-8082-2020; Rosemann, Michael/O-2449-2015	Rosemann, Michael/0000-0002-5855-065X; Rosemann, Michael/0000-0002-5855-065X; Calzada, Julia/0000-0003-0816-9305; Kappler, Roland/0000-0002-8581-2803				Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Amthor H, 2002, DEV BIOL, V243, P115, DOI 10.1006/dbio.2001.0555; Armand AS, 2003, DEV DYNAM, V227, P256, DOI 10.1002/dvdy.10306; Astolfi A, 2001, GENE, V274, P139, DOI 10.1016/S0378-1119(01)00619-9; Boman F, 1997, PEDIATR PATHOL LAB M, V17, P233, DOI 10.1080/107710497174886; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; Coindre JM, 2003, HISTOPATHOLOGY, V43, P1, DOI 10.1046/j.1365-2559.2003.01639.x; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Dagher R, 1999, Oncologist, V4, P34; DAVIS RJ, 1994, CANCER RES, V54, P2869; Doyle DD, 2003, BIOCHEM BIOPH RES CO, V304, P22, DOI 10.1016/S0006-291X(03)00528-X; FELIX CA, 1992, CANCER RES, V52, P2243; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HORN RC, 1958, CANCER, V11, P181, DOI 10.1002/1097-0142(195801/02)11:1<181::AID-CNCR2820110130>3.0.CO;2-I; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kablar B, 2003, DEV BIOL, V258, P307, DOI 10.1016/S0012-1606(03)00139-8; Kappler R, 2004, INT J ONCOL, V25, P113; Kappler R, 2003, J PATHOL, V200, P348, DOI 10.1002/path.1361; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; Kherif S, 1999, DEV BIOL, V205, P158, DOI 10.1006/dbio.1998.9107; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Moretti A, 2002, EUR J CANCER, V38, P2290, DOI 10.1016/S0959-8049(02)00454-9; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Ragazzini P, 2004, HISTOL HISTOPATHOL, V19, P401, DOI 10.14670/HH-19.401; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; STRATTON MR, 1990, ONCOGENE, V5, P1297; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wada MR, 2002, DEVELOPMENT, V129, P2987; Wetmore C, 2001, CANCER RES, V61, P513; WEXLER LH, 1997, RHABDOMYOSARCOMA UND; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	46	29	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8785	8795		10.1038/sj.onc.1208133	http://dx.doi.org/10.1038/sj.onc.1208133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480423				2022-12-17	WOS:000225165100008
J	Semont, A; Nowak, EB; Lages, CS; Mathieu, C; Mouthon, MA; May, E; Allemand, I; Millet, P; Boussin, FD				Semont, A; Nowak, EB; Lages, CS; Mathieu, C; Mouthon, MA; May, E; Allemand, I; Millet, P; Boussin, FD			Involvement of p53 and Fas/CD95 in murine neural progenitor cell response to ionizing irradiation	ONCOGENE			English	Article						p53; Fas/CD95; neural progenitor; apoptosis; radiation	RADIATION-INDUCED APOPTOSIS; CENTRAL-NERVOUS-SYSTEM; CD95 APO-1/FAS; DNA-DAMAGE; WILD-TYPE; IN-VIVO; TUMOR-SUPPRESSOR; DEATH RECEPTOR; DENTATE GYRUS; STEM-CELLS	We investigated the role of tumor suppressor p53 and Fas (CD95/APO-1), a member of the tumor necrosis factor receptor family, in neural progenitors response to gamma-irradiation exposure. Telencephalic cells were obtained from wild-type C57Bl/6, or p53 -/- or fas -/-, 15-day-old mouse embryos. They were cultured in conditions allowing neural progenitors to form proliferating clusters ( neurospheres). A 2 Gy gamma-irradiation induced a G1 cell cycle arrest and triggered apoptosis in wild-type neural progenitor cultures in correlation with an enhanced expression of p53 and of its downstream target p21(WAF1), both of them acquiring a nuclear localization. These effects did not occur in p53 -/- neural progenitors demonstrating the central role played by p53 in their response to ionizing radiation. Furthermore, the monoclonal antibody Jo2 directed against Fas induced apoptosis of wild type but not of fas -/- neural progenitors, indicating the existence of a functional Fas signaling pathway in neural progenitors. Ionizing radiation induced an increase of Fas membrane expression related to a p53-dependent increase of fas mRNA expression in wild-type neural progenitors. Moreover, fas -/- neural progenitors exhibited delayed radiation-induced apoptosis compared to wild-type cells. Therefore, these findings establish a role for Fas/CD95 related to p53 in the response of neural progenitors to gamma-radiation exposure. Similar mechanisms could be triggered in neural progenitors in case of different stresses during brain development or in the course of various diseases affecting the adult brain.	CEA, IPSC, DRR DSV, Lab Radiopathol, Fontenay Aux Roses, France; CEA, CNRS,UMR 217, DRR DSV, Lab Cancerol Mol, Fontenay Aux Roses, France; CEA, IPSC, SEGG DRR DSV, Lab Radiosensibil Cellules Germinales, Fontenay Aux Roses, France	CEA; CEA; Centre National de la Recherche Scientifique (CNRS); CEA	Boussin, FD (corresponding author), CEA, IPSC, DRR DSV, Lab Radiopathol, Fontenay Aux Roses, France.	boussin@cea.fr		Boussin, francois/0000-0003-3778-4403; Mouthon, Marc-Andre/0000-0003-2633-9179; allemand, isabelle/0000-0002-8861-7632; MILLET, Pascal/0000-0001-8877-8455				ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Becher B, 1998, NEUROSCIENCE, V84, P627, DOI 10.1016/S0306-4522(97)00455-7; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Blaschke AJ, 1998, J COMP NEUROL, V396, P39, DOI 10.1002/(SICI)1096-9861(19980622)396:1<39::AID-CNE4>3.0.CO;2-J; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Chow BM, 2000, CELL DEATH DIFFER, V7, P712, DOI 10.1038/sj.cdd.4400704; Craig CG, 1996, J NEUROSCI, V16, P2649; D'Sa-Eipper C, 2001, DEVELOPMENT, V128, P137; DANIEL PT, 1994, J IMMUNOL, V152, P5624; del Arroyo AG, 2000, ONCOGENE, V19, P3647, DOI 10.1038/sj.onc.1203662; DHEIN J, 1992, J IMMUNOL, V149, P3166; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Embree-Ku M, 2002, BIOL REPROD, V66, P1456, DOI 10.1095/biolreprod66.5.1456; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Fuchs EJ, 1997, CANCER RES, V57, P2550; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Haik S, 2000, ONCOGENE, V19, P2957, DOI 10.1038/sj.onc.1203596; HARPER JW, 1993, CELL, V75, P805; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Johnson MD, 1999, J NEUROSCI, V19, P2996; Jordan J, 1997, J NEUROSCI, V17, P1397; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kovac AD, 2002, EUR J NEUROSCI, V16, P159, DOI 10.1046/j.1460-9568.2002.02060.x; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu X, 1999, NEUROREPORT, V10, P3087, DOI 10.1097/00001756-199909290-00039; Maecker HL, 2000, CANCER RES, V60, P4638; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsui Y, 2001, AM J CLIN ONCOL-CANC, V24, P486, DOI 10.1097/00000421-200110000-00014; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Monje ML, 2003, CURR OPIN NEUROL, V16, P129, DOI 10.1097/00019052-200304000-00002; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nat R, 2001, J CELL MOL MED, V5, P417, DOI 10.1111/j.1582-4934.2001.tb00177.x; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nishimura Y, 1997, INT IMMUNOL, V9, P307, DOI 10.1093/intimm/9.2.307; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; O'Connor L, 2000, CANCER RES, V60, P1217; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; Rakic S, 2000, EUR J NEUROSCI, V12, P2721, DOI 10.1046/j.1460-9568.2000.00153.x; Rao MS, 1999, ANAT RECORD, V257, P137; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Roos W, 2004, ONCOGENE, V23, P359, DOI 10.1038/sj.onc.1207080; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sheard MA, 2001, INT J CANCER, V96, P213, DOI 10.1002/ijc.1020; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; Strasser-Wozak EMC, 1998, CELL DEATH DIFFER, V5, P687, DOI 10.1038/sj.cdd.4400402; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; Uberti D, 2001, MOL BRAIN RES, V93, P81, DOI 10.1016/S0169-328X(01)00180-2; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Unger C, 1998, CELL DEATH DIFFER, V5, P87, DOI 10.1038/sj.cdd.4400321; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; WALDMAN T, 1995, CANCER RES, V55, P5187; Xiang H, 1998, J NEUROSCI, V18, P1363	81	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8497	8508		10.1038/sj.onc.1207821	http://dx.doi.org/10.1038/sj.onc.1207821			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361846				2022-12-17	WOS:000224870700010
J	Treff, NR; Dement, GA; Adair, JE; Britt, RL; Nie, R; Shima, JE; Taylor, WE; Reeves, R				Treff, NR; Dement, GA; Adair, JE; Britt, RL; Nie, R; Shima, JE; Taylor, WE; Reeves, R			Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells	ONCOGENE			English	Article						high mobility group A1; stem cell factor; malignant transformation; chromatin; MCF-7; OCC1	C-KIT; IN-VIVO; EXPRESSION; PROTEIN; COEXPRESSION; RECEPTOR; GENE; ACTIVATION; APOPTOSIS; SEQUENCE	KIT ligand (KL) and its receptor, c-kit, are coexpressed in many types of cancer cells and have been implicated in tumor growth and angiogenesis. While Sertoli cell-specific regulation of the KL promoter has been well characterized, regulation in cancer cells remains to be elucidated. We recently reported microarray results demonstrating that increased high-mobility group (HMG) A1a protein expression correlates with increased KL transcription in MCF-7 human breast cancer cells. Sequence analysis indicates a potential for multiple HMGA1 binding sites within the human KL promoter. In order to better de. ne the underlying molecular mechanisms that HMGA1 uses to facilitate malignant transformation of cancer cells, we have used a variety of methods to determine whether HMGA1a directly regulates the human KL promoter in breast and ovarian cancer cells. Our results indicate that: (i) KL promoter activity is significantly higher in MCF-7 cells overexpressing HMGA1a; (ii) HMGA1a protein binds to AT-rich regions of the KL promoter DNA both in vitro and in vivo; (iii) mutation of the AT-rich regions inhibits HMGA1a binding in vitro; and (iv) HMGA1a-specific inhibition significantly decreases transcription of KL in OCC1 human ovarian cancer cells. In addition, MCF-7 cells with transgenic HMGA1 overexpression stained positive for the KL protein by immunocytochemistry and immunohistochemistry, and were growth-inhibited by KL neutralization. The cumulative evidence indicates that HMGA1 positively regulates the human KL promoter in breast and ovarian cancer cells and implicates serum KL as a diagnostic marker for HMGA1-positive carcinomas.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Charles R Drew Univ Med & Sci, Div Endocrinol Metab & Mol Med, Los Angeles, CA 90059 USA	Washington State University; Charles R. Drew University of Medicine & Science	Reeves, R (corresponding author), Washington State Univ, Sch Mol Biosci, POB 644660, Pullman, WA 99164 USA.	reevesr@mail.wsu.edu		Adair, Jennifer/0000-0003-4599-016X	NIGMS NIH HHS [GM-46352, T-32 GM008336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352, T32GM008336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Bellone G, 2001, CANCER RES, V61, P2200; Bokemeyer C, 1996, J CANCER RES CLIN, V122, P301, DOI 10.1007/BF01261407; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Caceres-Cortes JR, 2001, CANCER RES, V61, P6281; ELTON T, 1987, P NATL ACAD SCI USA, V84, P6531; Flohr AM, 2003, HISTOL HISTOPATHOL, V18, P999, DOI 10.14670/HH-18.999; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Grimaldi P, 2003, BIOL REPROD, V69, P1979, DOI 10.1095/biolreprod.103.019471; Hassan S, 1998, DIGEST DIS SCI, V43, P8, DOI 10.1023/A:1018851415704; HIBI K, 1991, ONCOGENE, V6, P2291; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hines SJ, 1999, BREAST CANCER RES TR, V58, P1, DOI 10.1023/A:1006272527435; Huss R, 1996, ANN HEMATOL, V72, P253, DOI 10.1007/s002770050168; INOUE M, 1994, CANCER RES, V54, P3049; Jiang CY, 1997, GENE, V185, P285, DOI 10.1016/S0378-1119(96)00668-3; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Langelotz C, 2003, BRIT J CANCER, V88, P1406, DOI 10.1038/sj.bjc.6600935; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Liu J, 2003, MOL REPROD DEV, V66, P81, DOI 10.1002/mrd.10323; Parrott JA, 2000, BIOL REPROD, V62, P1600, DOI 10.1095/biolreprod62.6.1600; Pedulla ML, 2001, GENE, V271, P51, DOI 10.1016/S0378-1119(01)00500-5; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; RYAN JJ, 1994, J NEUROSCI RES, V37, P415, DOI 10.1002/jnr.490370314; Simak R, 2000, HISTOL HISTOPATHOL, V15, P365, DOI 10.14670/HH-15.365; Taylor WE, 1996, ENDOCRINOLOGY, V137, P5407, DOI 10.1210/en.137.12.5407; Timeus F, 1997, EXP HEMATOL, V25, P1253; TOYOTA M, 1993, TUMOR BIOL, V14, P295, DOI 10.1159/000217842; Treff NR, 2004, ONCOGENE, V23, P777, DOI 10.1038/sj.onc.1207167; Zhang W, 2000, CANCER RES, V60, P6757	34	29	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8557	8562		10.1038/sj.onc.1207926	http://dx.doi.org/10.1038/sj.onc.1207926			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378028				2022-12-17	WOS:000224870700017
J	Martin-Caballero, J; Flores, JM; Garcia-Palencia, P; Collado, M; Serrano, M				Martin-Caballero, J; Flores, JM; Garcia-Palencia, P; Collado, M; Serrano, M			Different cooperating effect of p21 or p27 deficiency in combination with INK4a/ARF deletion in mice	ONCOGENE			English	Article						INK4a; ARF; p21Cip1; p27Kip1; tumorigenesis	DEPENDENT KINASE INHIBITOR; TUMOR SUPPRESSION; SUBCELLULAR-LOCALIZATION; PROGNOSTIC-SIGNIFICANCE; CELL LYMPHOMAS; CYCLIN-E; P27(KIP1); EXPRESSION; RB; TUMORIGENESIS	The control exerted by the INK4a/ARF locus on cellular proliferation is crucial to restrict tumor development. In agreement with this, mice with defects in this locus are highly tumor prone. However, the potential contribution of other pathways in modulating tumorigenesis in the absence of INK4a/ARF is largely unexplored. In the present study, we investigated the consequences of the combined loss of either of two cyclin-dependent kinase inhibitors, p21 and p27, in cooperation with deletion of the INK4a/ARF locus. Our results show a clear differential effect in tumorigenesis depending on the CKI that is absent. The absence of p21 produced no overt alteration of the lifespan of the INK4a/ARF-null mice, although it modified their tumor spectrum, causing a significant increase in the incidence of fibrosarcomas and the appearance of a small number of rhabdomyosarcomas. In contrast, deficiency of p27 resulted in a significant increase in lethality due to accelerated tumor development, especially in the case of T-cell lymphomas. Finally, combined deficiency of INK4a/ARF and p27 resulted in a significant increase in the number of metastatic tumors. These results demonstrate genetically the oncogenic cooperation between defects on INK4a/ARF and p27, which are common alterations in human cancer.	Spanish Natl Canc Ctr, Mol Oncol Program, E-28029 Madrid, Spain; Univ Complutense Madrid, Fac Vet, Anim Surg & Med Dept, E-28040 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Serrano, M (corresponding author), Spanish Natl Canc Ctr, Mol Oncol Program, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	mserrano@cnio.es	Serrano, Manuel/H-2634-2015; Collado, Manuel/K-8140-2014	Serrano, Manuel/0000-0001-7177-9312; Collado, Manuel/0000-0002-0330-0880; Garcia Palencia, Pilar/0000-0002-4077-3732				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bearss DJ, 2002, CANCER RES, V62, P2077; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Carneiro C, 2003, ONCOGENE, V22, P361, DOI 10.1038/sj.onc.1206163; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Ciaparrone M, 1998, CANCER RES, V58, P114; Cipriano SC, 2001, MOL ENDOCRINOL, V15, P985, DOI 10.1210/me.15.6.985; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Erlanson M, 1998, BLOOD, V92, P770; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; Hurteau JA, 2001, GYNECOL ONCOL, V83, P292, DOI 10.1006/gyno.2001.6376; Jackson RJ, 2003, CANCER RES, V63, P3021; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lebel M, 2001, CANCER RES, V61, P1816; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Myung N, 2000, CANCER LETT, V153, P129, DOI 10.1016/S0304-3835(00)00359-1; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Quintanilla-Martinez L, 1998, AM J PATHOL, V153, P175, DOI 10.1016/S0002-9440(10)65558-7; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Sanchez-Beato M, 2001, AM J PATHOL, V159, P205, DOI 10.1016/S0002-9440(10)61686-0; SanchezBeato M, 1997, AM J PATHOL, V151, P151; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Singh SP, 1998, CANCER RES, V58, P1730; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tsihlias J, 1999, ANNU REV MED, V50, P401; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1999, CANCER RES, V59, P2050; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Yang WC, 2001, CANCER RES, V61, P565; Zhang W, 2002, RARE METALS, V21, P48; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L	57	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8231	8237		10.1038/sj.onc.1207863	http://dx.doi.org/10.1038/sj.onc.1207863			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378017	Bronze			2022-12-17	WOS:000224749500005
J	Shinohara, S; Rothstein, JL				Shinohara, S; Rothstein, JL			Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells	ONCOGENE			English	Article						inflammation; interleukin 24; Mda7; RET/PTC; thyroid	DIFFERENTIATION-ASSOCIATED GENE; PAPILLARY THYROID-CARCINOMA; HUMAN-MELANOMA DIFFERENTIATION; LYMPHOCYTIC THYROIDITIS; TYROSINE KINASE; SUPPRESSOR GENE; BRAF MUTATIONS; IN-VITRO; CANCER; EXPRESSION	Thyroid cancers, like hematological malignancies, are commonly associated with chromosomal translocations leading to the formation of fusion proteins. Through altered signaling by fusion proteins, cell death and survival pathways are disrupted and the physiological balance of cell - cell communication may be lost. A consequence of this disruption is the release of factors by stressed cells that alert the host. One type of host response is leukocytic infiltration that may develop into chronic inflammation or autoimmune disease. Although inflammation can be associated with neoplastic tissue, the mechanism driving this process is largely unknown. Therefore, to address the mechanism of cancer inflammation we investigated the effects of an oncogene in a murine model system. A comprehensive genetic analysis revealed several soluble factors that were induced by RET/papillary thyroid carcinoma (PTC) 3 gene expression including several proinflammatory cytokines, chemokines and immunologically relevant costimulatory molecules. Following a large genetic screen using RP3-expressing thyroid cells, we identified a highly abundant transcript and later identified it as interleukin 24 (Il24), a cytokine with diverse tumor suppressor and inflammatory activities. We show that RET/PTC3 induces Il24 expression in rat thyrocytes and that this expression is dependent on the signaling properties of its tyrosine kinase. Likewise, RET/PTC3 induces large amounts of Il24 following expression in murine thyrocytes, but its expression is dramatically reduced in poorly differentiated carcinomas, a finding that parallels the loss of RET/PTC3 expression. Consistent with its behavior as a tumor suppressor, the loss of Il24 coincided with the loss of RET/PTC3 in poorly differentiated mouse tumors. A functional role of Il24 in the autocrine growth/survival of RET/PTC3-expressing thyroid cells was identified helping to support its role in cellular transformation. These data suggest that the induction of Il24 by oncogenes may support tumor growth at the early stages of cancer.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, 233 S 10th St,BLSB 909, Philadelphia, PA 19107 USA.	jay.rothstein@jefferson.edu	Shinohara, Shogo/H-8976-2019	Shinohara, Shogo/0000-0002-1794-2091	NCI NIH HHS [CA-76259, T32-CA09678] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA076259, T32CA009678] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aust G, 1996, EXP CLIN ENDOCR DIAB, V104, P64, DOI 10.1055/s-0029-1211705; Basolo F, 1998, CLIN CANCER RES, V4, P381; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; DAILEY ME, 1955, AMA ARCH SURG, V70, P271; Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; ENOMOTO T, 1990, CANCER, V65, P1971, DOI 10.1002/1097-0142(19900501)65:9<1971::AID-CNCR2820650916>3.0.CO;2-V; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUSCO A, 1995, J ENDOCRINOL INVEST, V18, P127, DOI 10.1007/BF03349720; JHIANG SM, 1992, ONCOGENE, V7, P1331; Jiang HP, 1995, ONCOGENE, V11, P2477; KAYSER L, 1995, AUTOIMMUNITY, V20, P75, DOI 10.3109/08916939509001930; Kimura ET, 2003, CANCER RES, V63, P1454; Kurebayashi J, 2000, J CLIN ENDOCR METAB, V85, P2889, DOI 10.1210/jc.85.8.2889; Lebedeva IV, 2003, SEMIN CANCER BIOL, V13, P169, DOI 10.1016/S1044-579X(02)00134-7; Loh KC, 1999, J CLIN ENDOCR METAB, V84, P458, DOI 10.1210/jc.84.2.458; MATSUBAYASHI S, 1995, J CLIN ENDOCR METAB, V80, P3421, DOI 10.1210/jc.80.12.3421; Mechler C, 2001, BRIT J CANCER, V85, P1831, DOI 10.1054/bjoc.2001.2187; Nakada T, 1996, INTERNAL MED, V35, P815, DOI 10.2169/internalmedicine.35.815; OTT RA, 1987, AM SURGEON, V53, P442; PASQUALE D, 2001, HUM PATHOL, V32, P24; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Powell DJ, 1998, CANCER RES, V58, P5523; Powell DJ, 2003, J IMMUNOL, V170, P861, DOI 10.4049/jimmunol.170.2.861; Powell DJ, 2001, ONCOGENE, V20, P3235, DOI 10.1038/sj.onc.1204425; Ramesh R, 2003, CANCER RES, V63, P5105; Rasmussen AK, 2000, DAN MED BULL, V47, P94; Russell JP, 2000, ONCOGENE, V19, P5729, DOI 10.1038/sj.onc.1203922; Russell JP, 2004, J IMMUNOL, V172, P4059, DOI 10.4049/jimmunol.172.7.4059; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Sarkar D, 2002, BIOTECHNIQUES, P30; Scarpino S, 2000, AM J PATHOL, V156, P831, DOI 10.1016/S0002-9440(10)64951-6; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; Soo C, 1999, J CELL BIOCHEM, V74, P1; Stassi G, 2003, CANCER RES, V63, P6784; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; TAKAHASHI K, 1995, PATHOL INT, V45, P366, DOI 10.1111/j.1440-1827.1995.tb03470.x; Tamimi DM, 2002, INT J SURG PATHOL, V10, P141, DOI 10.1177/106689690201000207; TOHYAMA K, 1992, JPN J CANCER RES, V83, P153, DOI 10.1111/j.1349-7006.1992.tb00080.x; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Winterrowd GE, 1999, J IMMUNOL METHODS, V226, P105, DOI 10.1016/S0022-1759(99)00049-6; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623; YOSHIDA M, 1992, CANCER RES, V52, P464; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	52	29	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7571	7579		10.1038/sj.onc.1207964	http://dx.doi.org/10.1038/sj.onc.1207964			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326486				2022-12-17	WOS:000224176500014
J	Maiorana, A; Tu, XA; Cheng, GJ; Baserga, R				Maiorana, A; Tu, XA; Cheng, GJ; Baserga, R			Role of pescadillo in the transformation and immortalization of mammalian cells	ONCOGENE			English	Article						pescadillo; transformation; immortalization	INSULIN-RECEPTOR SUBSTRATE-1; RNA-POLYMERASE-I; GROWTH-FACTOR-I; LARGE T-ANTIGEN; RIBOSOMAL GENE-TRANSCRIPTION; LARGE TUMOR-ANTIGEN; HUMAN-FIBROBLASTS; SIMIAN VIRUS-40; NUCLEAR TRANSLOCATION; IGF-I	The murine and human homologs of the zebrafish pescadillo protein (Pes1 and PES1, respectively) play important roles in ribosome biogenesis and DNA replication. We investigated the effect of Pes1 on the growth of mouse embryo (3T3-like) fibroblasts and conditionally immortalized human fibroblasts expressing the SV40 T antigen (AR5 cells). Increased expression of Pes1 causes transformation of mouse and human fibroblasts in culture ( colony formation in soft agar). Although Pes1 can replace the SV40 T antigen in inducing colony formation in soft agar, it cannot substitute the T antigen in the immortalization of human fibroblasts, indicating that it distinguishes between the two functions. As the biological effects of Pes1 are similar to those of the insulin receptor substrate- 1 (IRS-1), we investigated the interactions of Pes1 with IRS-1 itself and with the SV40 T antigen. The Pes1 protein ( which localizes to the nuclei and nucleoli of cells) interacts with both IRS-1 and the SV40 T antigen, and markedly decreases the interaction of T antigen with p53. Taken together, these results suggest mechanisms for the ability of Pes1 to transform cells, and its failure to immortalize them.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	r_baserga@mail.jci.tju.edu	Maiorana, Arianna/AAA-6517-2020	Maiorana, Arianna/0000-0001-9986-1385	NCI NIH HHS [CA89640] Funding Source: Medline; NIA NIH HHS [AG16291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; BASERGA R, 1984, EXP CELL RES, V151, P1, DOI 10.1016/0014-4827(84)90349-5; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; CHANG LS, 1985, VIROLOGY, V146, P246, DOI 10.1016/0042-6822(85)90008-X; Chang Q, 2002, CANCER RES, V62, P6035; Comai L, 2000, CELL GROWTH DIFFER, V11, P63; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; FRASER RSS, 1978, NATURE, V271, P726, DOI 10.1038/271726a0; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Haque J, 2000, GENOMICS, V70, P201, DOI 10.1006/geno.2000.6375; HARTWELL LH, 1978, J CELL BIOL, V77, P627, DOI 10.1083/jcb.77.3.627; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pete G, 1999, ENDOCRINOLOGY, V140, P5478, DOI 10.1210/en.140.12.5478; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; SOPRANO KJ, 1979, P NATL ACAD SCI USA, V76, P3885, DOI 10.1073/pnas.76.8.3885; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WHITE JA, 1992, EXP CELL RES, V203, P157, DOI 10.1016/0014-4827(92)90051-9; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	57	29	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7116	7124		10.1038/sj.onc.1207916	http://dx.doi.org/10.1038/sj.onc.1207916			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273728				2022-12-17	WOS:000223885100012
J	Dang-Tan, T; Mahmud, SM; Puntoni, R; Franco, EL				Dang-Tan, T; Mahmud, SM; Puntoni, R; Franco, EL			Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association	ONCOGENE			English	Article						Simian Virus 40; poliovirus vaccines; causality; mesothelioma; ependymoma; neoplasms	MALIGNANT MESOTHELIOMA; HUMAN TUMORS; SV40; VIRUS; POLIOMYELITIS; CONTAMINATION; EXPOSURE; RISK; CELL	In 1960, it was discovered that Simian Virus 40 (SV40) contaminated up to 30% of the poliovirus vaccines in the US. This contamination arose because the vaccines were produced in monkey kidney cell cultures harboring SV40 between 1955 and 1963. During this period, approximately 90% of children and 60% of adults in the USA were inoculated for polio and possibly exposed to SV40. Many epidemiologic and molecular pathogenesis studies have been conducted in order to identify potential cancer risks since this `natural' experiment began. Productive SV40 infection has the potential to initiate malignancy in a variety of target tissues. Epidemiological studies that investigated the relationship between SV40 infection and cancer risks have yielded mixed results. Studies can be grouped into three categories based on their exposure definition of SV40 infection: (1) use of vaccination or birth cohorts as proxy variables for infection, (2) follow-up of children of pregnant women who received polio vaccines, and (3) direct molecular detection of the virus or serologic detection of anti-SV40 antibody responses. A meta-analysis of five published studies did not support the hypothesis that SV40 exposure increases the overall risk of cancer incidence or cancer mortality. The analysis of specific cancer sites is largely inconclusive because of substantial problems that most studies have had in reliably de. ning exposure, de. ning latency effects, or dealing with confounding and other biases. A new generation of molecular epidemiologic	McGill Univ, Dept Oncol, Montreal, PQ H2W 1S6, Canada; McGill Univ, Dept Epidemiol, Montreal, PQ H2W 1S6, Canada; Natl Inst Canc Res, Dept Environm Epidemiol & Biostat, Genoa, Italy	McGill University; McGill University; University of Genoa; IRCCS AOU San Martino IST	Franco, EL (corresponding author), McGill Univ, Dept Oncol, 546 Pine Ave W, Montreal, PQ H2W 1S6, Canada.	eduardo.franco@mcgill.ca	Franco, Eduardo/C-6445-2014	Franco, Eduardo/0000-0002-4409-8084; Mahmud, Salaheddin/0000-0002-6574-0574				[Anonymous], 2002, IMMUNIZATION SAFETY; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Carbone M, 2000, ANTICANCER RES, V20, P875; Carbone M, 2003, ONCOGENE, V22, P5173, DOI 10.1038/sj.onc.1206552; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Carroll-Pankhurst C, 2001, BRIT J CANCER, V85, P1295, DOI 10.1054/bjoc.2001.2065; Carter JJ, 2003, JNCI-J NATL CANCER I, V95, P1522, DOI 10.1093/jnci/djg074; Cerrano PG, 2003, INT J ONCOL, V22, P187; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; Engels EA, 2003, JNCI-J NATL CANCER I, V95, P532, DOI 10.1093/jnci/95.7.532; Engels EA, 2003, INT J CANCER, V106, P283, DOI 10.1002/ijc.11211; Farwell J R, 1979, Trans Am Neurol Assoc, V104, P261; Fisher SG, 1999, ANTICANCER RES, V19, P2173; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; JENSEN F, 1964, J NATL CANCER I, V32, P917; KIRSCHSTEIN RL, 1962, NATURE, V195, P299, DOI 10.1038/195299b0; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; Procopio A, 2000, GENE CHROMOSOME CANC, V29, P173, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1019>3.0.CO;2-B; Puntoni R, 2003, MUTAT RES-REV MUTAT, V544, P385, DOI 10.1016/j.mrrev.2003.06.012; Rollison DEM, 2003, CANCER EPIDEM BIOMAR, V12, P460; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Strickler HD, 1999, MED PEDIATR ONCOL, V32, P77, DOI 10.1002/(SICI)1096-911X(199901)32:1<77::AID-MPO21>3.3.CO;2-6; SWEET BH, 1960, P SOC EXP BIOL MED, V105, P420, DOI 10.3181/00379727-105-26128; Testa JR, 1998, CANCER RES, V58, P4505	28	29	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6535	6540		10.1038/sj.onc.1207877	http://dx.doi.org/10.1038/sj.onc.1207877			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322523				2022-12-17	WOS:000223468800017
J	Tsuei, DJ; Hsu, HC; Lee, PH; Jeng, YM; Pu, YS; Chen, CN; Lee, YC; Chou, WC; Chang, CJ; Ni, YH; Chang, MH				Tsuei, DJ; Hsu, HC; Lee, PH; Jeng, YM; Pu, YS; Chen, CN; Lee, YC; Chou, WC; Chang, CJ; Ni, YH; Chang, MH			RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts	ONCOGENE			English	Article						RBMY; hepatocellular carcinoma; hepatoblastoma; RNA-binding motif; SRGY box	HEPATITIS-B-VIRUS; HUMAN Y-CHROMOSOME; HEPATOCELLULAR-CARCINOMA; GENE FAMILY; SPERMATOGENESIS; AZOOSPERMIA; TUMORS; OVEREXPRESSION; AMPLIFICATION; ORGANIZATION	The RNA-binding motif (RRM) gene on Y chromosome (RBMY), encoding a male germ cell-specific RNA-binding protein associated with spermatogenesis, was found inserted by hepatitis B virus (HBV) DNA in one childhood hepatocellular carcinoma (HCC). This study is aimed to explore the oncogenic potential of the RBMY protein. The RBMY transcripts, expressed exclusively in the testis of normal people, were detected by reverse transcription-polymerase chain reaction in 36% of HCCs from 90 males and in 67% of hepatoblastoma from six boys. The nontumor liver counter parts, cirrhotic liver tissues from children with biliary atresia, and other types of cancers, such as bile duct, colon, stomach, lung, prostate, and kidney, were all negative for RBMY expression. One to four types of RBMY transcripts, including wild type and variants with N-terminal RRM deletion, C-terminal SRGY (serine-arginine-glycine-tyrosine) boxes deletion, or deletion of both domains, were found in the testis and liver cancer tissues. The wild-type RBMY protein was expressed in the nucleus and demonstrated its tumorigenicity by transformation of mouse fibroblast NIH3T3 cells and in vivo tumor formation. The RBMY variant protein with deletion of C-terminal exons 9-12 was trapped in the cytoplasm and showed decreased tumorigenicity. Our results suggest that RBMY is a new candidate oncogene specific for male liver cancer.	Natl Taiwan Univ, Dept Pediat, Coll Med, Natl Taiwan Univ Hosp, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Surg, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Urol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Chang, MH (corresponding author), Natl Taiwan Univ, Dept Pediat, Coll Med, Natl Taiwan Univ Hosp, 7 Chung Shan S Rd, Taipei 10016, Taiwan.	mhchang@ha.mc.ntu.edu.tw		PU, YEONG-SHIAU/0000-0002-2859-3966; Chang, Mei Hwei/0000-0002-3648-9261; Ni, Yen-Hsuan/0000-0002-1158-5249; CHEN, CHIUNG-NIEN/0000-0003-1192-5220; LEE, PO-HUANG/0000-0001-5831-035X; JENG, YUNG-MING/0000-0002-3878-4491				Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BYRNE JA, 1993, GENE CHROMOSOME CANC, V8, P104, DOI 10.1002/gcc.2870080207; Chai NN, 1997, GENOMICS, V45, P355, DOI 10.1006/geno.1997.4944; Chai NN, 1998, GENOMICS, V49, P283, DOI 10.1006/geno.1998.5255; CHANG MH, 1989, CANCER-AM CANCER SOC, V64, P2377, DOI 10.1002/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8; CHEN JY, 1986, BRIT J EXP PATHOL, V67, P279; CHEN WJ, 1988, J PEDIATR SURG, V23, P457, DOI 10.1016/S0022-3468(88)80448-2; DING SF, 1994, J HEPATOL, V20, P672, DOI 10.1016/S0168-8278(05)80359-9; Elliott DJ, 2000, P NATL ACAD SCI USA, V97, P5717, DOI 10.1073/pnas.97.11.5717; Elliott DJ, 1998, J CELL SCI, V111, P1255; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; EXELBY PR, 1975, J PEDIATR SURG, V10, P329; Flickinger JC, 1997, CANC PRINCIPLES PRAC, P1087; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Idilman R, 1998, J VIRAL HEPATITIS, V5, P285, DOI 10.1046/j.1365-2893.1998.00116.x; IWAMA T, 1994, CANCER, V73, P2065, DOI 10.1002/1097-0142(19940415)73:8<2065::AID-CNCR2820730809>3.0.CO;2-O; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kume T, 1999, HISTOPATHOLOGY, V34, P502, DOI 10.1111/j.1365-2559.1999.00686.x; Lee CL, 1998, EUR J CANCER, V34, P2064, DOI 10.1016/S0959-8049(98)00281-0; Lin T M, 1977, Taiwan Yi Xue Hui Za Zhi, V76, P656; Lin Y., 1996, Annals Academy of Medicine Singapore, V25, P22; Lingenfelter PA, 2001, MAMM GENOME, V12, P538, DOI 10.1007/s00335001-0003-z; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Mercatante D, 2000, PHARMACOL THERAPEUT, V85, P237, DOI 10.1016/S0163-7258(99)00067-4; Miyoshi Y, 1998, CANCER RES, V58, P2524; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Najmabadi H, 1996, J CLIN ENDOCR METAB, V81, P1347, DOI 10.1210/jc.81.4.1347; Nakahori Y, 1996, HORM RES, V46, P20, DOI 10.1159/000185175; NI YH, 1991, CANCER, V8, P1731; NISHIDA N, 1994, CANCER RES, V54, P3107; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Tsuei DJ, 2002, J MED VIROL, V68, P513, DOI 10.1002/jmv.10240; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Venables JP, 2000, HUM MOL GENET, V9, P685, DOI 10.1093/hmg/9.5.685; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Venables JP, 1999, CURR OPIN GENET DEV, V9, P346, DOI 10.1016/S0959-437X(99)80052-5; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933	40	29	31	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5815	5822		10.1038/sj.onc.1207773	http://dx.doi.org/10.1038/sj.onc.1207773			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184870				2022-12-17	WOS:000222629800011
J	Koma, Y; Ito, A; Wakayama, T; Watabe, K; Okada, M; Tsubota, N; Iseki, S; Kitamura, Y				Koma, Y; Ito, A; Wakayama, T; Watabe, K; Okada, M; Tsubota, N; Iseki, S; Kitamura, Y			Cloning of a soluble isoform of the SgIGSF adhesion molecule that binds the extracellular domain of the membrane-bound isoform	ONCOGENE			English	Article						IGSF4; TSLC1; homophilic binding; splicing	IMMUNOGLOBULIN SUPERFAMILY; TSLC1 GENE; EXPRESSION; IDENTIFICATION; VCAM-1; LIGAND	SgIGSF (spermatogenic immunoglobulin superfamily) is a recently identified intercellular adhesion molecule of the immunoglobulin superfamily. In a mast-cell cDNA library, we found a clone that resulted from the retention of intron 7 within the mature SgIGSF message. This clone was predicted to encode a soluble isoform of SgIGSF (sSgIGSF) with 336 amino-acid residues because its open reading frame ended just before the transmembrane domain. We constructed a plasmid expressing sSgIGSF fused to the human IgG Fc fragment at its C-terminus (sSgIGSF-Fc), and transfected it into COS-7 cells. The fusion protein was readily detectable in the culture supernatant. Solid-phase binding assay showed that sSgIGSF interacted directly the extracellular domain of membrane-bound SgIGSF (mSgIGSF). We next examined whether this interaction inhibited homophilic binding of mSgIGSF by aggregation assays using L cells that did not express mSgIGSF. A stable L-cell clone that overexpressed mSgIGSF aggregated with each other but not with mock-transfected L cells, indicating that a homophilic interaction of mSgIGSF mediated the aggregation. Addition of sSgIGSF-Fc inhibited the aggregation of L cells overexpressing mSgIGSF in a dose-dependent manner. Moreover, FACScan analyses revealed the specific binding of sSgIGSF-Fc to mSgIGSF expressed in L cells. Binding of sSgIGSF-Fc to mSgIGSF appeared to inhibit homophilic interactions of mSgIGSF.	Osaka Univ, Sch Med, Dept Pathol, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Histol & Embryol, Kanazawa, Ishikawa 9208640, Japan; Hyogo Med Ctr Adults, Dept Thorac Surg, Akashi, Hyogo 6738558, Japan	Osaka University; Kanazawa University	Ito, A (corresponding author), Kobe Univ, Grad Sch Med, Div Surg Pathol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650, Japan.	akito@med.kobe-u.ac.jp						Budt M, 2002, BIOCHEM BIOPH RES CO, V292, P749, DOI 10.1006/bbrc.2002.6704; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukami T, 2002, GENE, V295, P7, DOI 10.1016/S0378-1119(02)00835-1; HAHNE M, 1994, EUR J IMMUNOL, V24, P421, DOI 10.1002/eji.1830240223; Ito A, 2003, LAB INVEST, V83, P1175, DOI 10.1097/01.LAB.0000081391.28136.80; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; KAPLAN AJ, 1993, J IMMUNOL, V151, P4022; Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074-7613(00)00062-5; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lee G, 2003, BLOOD, V101, P1790, DOI 10.1182/blood-2002-08-2529; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; MEYER DM, 1995, J IMMUNOL, V155, P3578; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Nakamoto K, 2001, AM J PATHOL, V159, P1363, DOI 10.1016/S0002-9440(10)62523-0; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; Pletcher MT, 2001, GENE, V273, P181, DOI 10.1016/S0378-1119(01)00592-3; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Wakayama T, 2003, BIOL REPROD, V68, P1755, DOI 10.1095/biolreprod.102.012344; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; Yageta M, 2002, CANCER RES, V62, P5129	21	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5687	5692		10.1038/sj.onc.1207761	http://dx.doi.org/10.1038/sj.onc.1207761			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184876				2022-12-17	WOS:000222629500014
J	Al-Fageeh, M; Li, QJ; Dashwood, WM; Myzak, MC; Dashwood, RH				Al-Fageeh, M; Li, QJ; Dashwood, WM; Myzak, MC; Dashwood, RH			Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32	ONCOGENE			English	Article						beta-catenin; TCF/LEF; APC; Wnt signaling; colorectal cancer; CTNNB1; human beta-catenin gene; Ctnnb1; rat beta-catenin gene	WNT SIGNALING PATHWAY; RAT COLON TUMORS; MUTATIONAL ANALYSIS; ADHESION SYSTEM; LIVER-TUMORS; GENE CTNNB1; CELL-LINES; CANCER; CADHERIN; DEGRADATION	beta-Catenin, a member of the Wnt signaling pathway, is downregulated by glycogen synthase kinase-3beta (GSK-3beta)-dependent phosphorylation of Ser/Thr residues in the N-terminus of the protein, followed by ubiquitination and proteosomal degradation. In human and rodent cancers, mutations that substitute one of the critical Ser/Thr residues in the GSK-3beta region of beta-catenin stabilize the protein and activate beta-catenin/TCF/LEF target genes. This study examined three oncogenic beta-catenin mutants from rat colon tumors containing substitutions adjacent to amino-acid residue Ser33, a key target for phosphorylation by GSK-3beta. Compared with wild-type beta-catenin (WT), the beta-catenin mutants D32G, D32N, and D32Y strongly activated TCF-4-dependent transcription in HEK293 cells, and there was accumulation of beta-catenin in the cell lysates. Immunoblotting with phosphospecific antibodies indicated that there was little if any effect on the phosphorylation of Ser37, Thr41 or Ser45; however, the phosphorylation of Ser33 appeared to be affected in the beta-catenin mutants. Specifically, antiphospho-beta-catenin 33/37/41 antibody identified high, intermediate and low expression levels of phosphorylated beta-catenin in cells transfected with D32G, D32N and D32Y, respectively. Experiments with the proteosome inhibitor N-acetyl-Leu-Leu-norleucinal ( ALLN) revealed ubiquitinated bands on all three mutant beta-catenins, as well as on WT beta-catenin. The relative order of ubiquitination was WT>D32G>D32N>D32Y, in parallel with findings from the phosphorylation studies. These results are discussed in the context of previous studies, which indicated that amino-acid residue D32 lies within the ubiquitination recognition motif of beta-catenin.	Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Dashwood, RH (corresponding author), Oregon State Univ, Linus Pauling Inst Sci & Med, 571 Weniger Hall, Corvallis, OR 97331 USA.	rod.dashwood@oregonstate.edu	Dashwood, Roderick H/E-9090-2011; Dashwood, Roderick/AAF-2025-2020	Li, Qingjie/0000-0003-1405-7000	NCI NIH HHS [R01 CA065525-07, CA65525, R01 CA080176-05, R01 CA065525-09, R01 CA080176-02, R01 CA065525-08, R01 CA080176-04, R01 CA065525-06A1, P01 CA090890-01A29001, R01 CA065525, P01 CA090890-05, R29 CA065525, CA80176, P01 CA090890-05S1, CA90890, R01 CA080176, P01 CA090890-01A20003, P01 CA090890, R01 CA080176-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065525, P01CA090890, R29CA065525, R01CA080176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Blum CA, 2003, MOL CARCINOGEN, V36, P195, DOI 10.1002/mc.10112; Blum CA, 2001, CARCINOGENESIS, V22, P315, DOI 10.1093/carcin/22.2.315; Clements WM, 2002, CANCER RES, V62, P3503; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Dashwood RH, 1998, CANCER RES, V58, P1127; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Hagen T, 2002, BIOCHEM BIOPH RES CO, V294, P324, DOI 10.1016/S0006-291X(02)00485-0; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Li QJ, 2002, GENE, V283, P255, DOI 10.1016/S0378-1119(01)00839-3; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Polakis P, 2000, GENE DEV, V14, P1837; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; Suzui M, 1999, MOL CARCINOGEN, V24, P232, DOI 10.1002/(SICI)1098-2744(199903)24:3<232::AID-MC10>3.0.CO;2-M; Takahashi M, 1998, CANCER RES, V58, P42; Van Gassen G, 2000, MOL MED, V6, P570, DOI 10.1007/BF03401795; Wang ZH, 2003, CANCER RES, V63, P5234	32	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2004	23	28					4839	4846		10.1038/sj.onc.1207634	http://dx.doi.org/10.1038/sj.onc.1207634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064718	Green Accepted			2022-12-17	WOS:000222104200004
J	Leung, SW; Wloga, EH; Castro, AF; Nguyen, T; Bronson, RT; Yamasaki, L				Leung, SW; Wloga, EH; Castro, AF; Nguyen, T; Bronson, RT; Yamasaki, L			A dynamic switch in Rb+/- mediated neuroendocrine tumorigenesis	ONCOGENE			English	Article						Rb; tumorigenesis; pituitary	RETINOBLASTOMA GENE; PITUITARY-TUMORS; MICE LACKING; DNA-REPLICATION; TARGETED DISRUPTION; MICROARRAY ANALYSIS; DEFICIENT CELLS; CHIMERIC MICE; G(1) CONTROL; LUNG-CANCER	Rb+/- mice develop a complex spectrum of neuroendocrine tumors on a mixed genetic (129Sv x C57BL/6) background. To understand how the 129Sv and C57BL/6 contributions affect Rb+/- tumorigenesis, we serially backcrossed Rb+/- animals to the 129Sv or C57BL/6 strain, and analysed their pathological profiles. Strikingly, the length of survival and the penetrance, severity and multiplicity of neuroendocrine tumors switch dramatically between Rb+/- animals from the two genetic backgrounds. In fact, the 129Sv background significantly enhances both the initiation and progression of tumorigenesis in the intermediate lobe of the pituitary (ILP) in Rb+/- animals. This is due to the surprising fact that ILPs from wild-type 129Sv animals are inherently abnormal, and thus greatly predisposed to neoplasia. This is likely to explain the high incidence of ILP tumors, an otherwise rare tumor type in wild-type mice, in numerous knockout studies performed on the 129Sv strain, and raises the intriguing possibility that the classic Rb+/- neuroendocrine tumors may fade away in another as of yet unidentified inbred strain. Finally, we have increased the utility of the Rb+/- tumor model, since Rb+/- animals on the C57BL/6 background develop high-penetrance tumors of the anterior lobe of the pituitary, a class of tumors estimated to occur in 20-25% of humans.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA	Columbia University; Tufts University	Yamasaki, L (corresponding author), Columbia Univ, Dept Biol Sci, 1102 Fairchild Bldg,Mail Code 2428, New York, NY 10027 USA.	ly63@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA079646] Funding Source: NIH RePORTER; NCI NIH HHS [5-R01-CA79646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GARY KA, 1992, INT J DEV NEUROSCI, V10, P131, DOI 10.1016/0736-5748(92)90041-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HU NP, 1994, ONCOGENE, V9, P1021; Humbert PO, 2000, GENE DEV, V14, P690; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudson AG, 1997, ANN NY ACAD SCI, V833, P58, DOI 10.1111/j.1749-6632.1997.tb48593.x; Kratzke RA, 1996, CANCER RES, V56, P3415; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OKAMOTO A, 1995, CANCER RES, V55, P1448; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Simpson DJ, 2000, CANCER RES, V60, P1211; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; YAMASAKI L, 2003, SIGNAL TRANSDUCTION, P209; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	59	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3296	3307		10.1038/sj.onc.1207457	http://dx.doi.org/10.1038/sj.onc.1207457			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021915				2022-12-17	WOS:000220975000004
J	Andre, F; Janssens, B; Bruyneel, E; van Roy, F; Gespach, C; Mareel, M; Bracke, M				Andre, F; Janssens, B; Bruyneel, E; van Roy, F; Gespach, C; Mareel, M; Bracke, M			Alpha-catenin is required for IGF-I-induced cellular migration but not invasion in human colonic cancer cells	ONCOGENE			English	Article						colorectal cancer; E-cadherin/catenin complex; IGF-IR; type-I collagen; woundhealing	COLLAGEN TYPE-I; E-CADHERIN; EPITHELIAL-CELLS; CARCINOMA-CELLS; GROWTH-FACTORS; INSULIN; EXPRESSION; ADHESION; RECEPTOR; BREAST	The mechanisms by which growth factors cooperate with cell adhesion molecules to modulate epithelial cell motility remain poorly understood. Here, we investigated the role of the E-cadherin/catenin complex in insulin-like growth factor (IGF-I)-dependent cell migration and invasion. We used variants of the HCT-8 colon cancer family that differ in their expression of alphaE-catenin, an intracellular molecule that links the E-cadherin/catenin complex to the actin cytoskeleton. Migration was determined using a monolayer wound model and cell invasion by the penetration of the cells into type-I collagen gels. We showed that alpha-catenin-deficient cells were not able to migrate in cohort upon IGF-I stimulation. Transfection of these cells with alpha-catenin isoforms (alphaN- or alphaT-catenin) restored migratory response IGF-I. These results suggest that alpha-catenins are involved in the signal issued from the E-cadherin/catenin complex to regulate IGF-I-stimulated migration. In contrast, IGF-I promoted invasion of both alpha-catenin-deficient and alpha-catenin-expressing cells, indicating that alpha-catenin did not participate in the regulation of IGF-I-induced invasion. Inhibition of E-cadherin function by treatment with MB-2 monoclonal antibodies inhibited both IGF-I-dependent cell migration and invasion. Taken together, our results indicate that functional alpha-catenin is essential for migration but not for invasion, while E-cadherin is involved in both phenomena.	Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; State Univ Ghent VIB, Dept Mol Biol, Mol Cell Biol Unit, Ghent, Belgium; Hop St Antoine, INSERM, U482, F-75571 Paris, France	Ghent University; Ghent University Hospital; Flanders Institute for Biotechnology (VIB); Ghent University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bracke, M (corresponding author), Ghent Univ Hosp, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	brackemarc@hotmail.com	van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Angst BD, 2001, J CELL SCI, V114, P629; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Debruyne PR, 2002, ONCOGENE, V21, P6740, DOI 10.1038/sj.onc.1205729; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; GLUKHOVA M, 1995, AM J PATHOL, V146, P706; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Janssens B, 2001, J CELL SCI, V114, P3177; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Matsubara S, 2001, J CELL BIOL, V154, P573, DOI 10.1083/jcb.200103097; Mauro L, 2001, J BIOL CHEM, V276, P39892, DOI 10.1074/jbc.M106673200; Menke A, 2001, CANCER RES, V61, P3508; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Nabeshima K, 1999, HISTOL HISTOPATHOL, V14, P1183, DOI 10.14670/HH-14.1183; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Steelant WFA, 2001, INT J CANCER, V92, P527, DOI 10.1002/ijc.1216; Van Hoorde L, 2000, Prog Mol Subcell Biol, V25, P105; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	32	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1177	1186		10.1038/sj.onc.1207238	http://dx.doi.org/10.1038/sj.onc.1207238			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961074				2022-12-17	WOS:000188892200001
J	Hu, N; Wang, CY; Han, XY; He, LJ; Tang, ZZ; Giffen, C; Emmert-Buck, MR; Goldstein, AM; Taylor, PR				Hu, N; Wang, CY; Han, XY; He, LJ; Tang, ZZ; Giffen, C; Emmert-Buck, MR; Goldstein, AM; Taylor, PR			Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer	ONCOGENE			English	Article						familial; mutation; LOH; high risk; DNA sequencing	SQUAMOUS-CELL CARCINOMA; ALLELIC LOSS; SHANXI-PROVINCE; BREAST	Previous studies of esophageal squamous cell carcinoma (ESCC) have shown a high frequency of allelic loss on chromosome 13q, infrequent somatic mutations in BRCA2, and a suggested association between a positive family history (FH+) of upper gastrointestinal cancer and germline BRCA2 mutations. In all, 70 ESCC patients ( 44 FH+ and 26 FH-) were examined by direct full sequencing of germline DNA for BRCA2 mutations. In addition, 28 family members of three of these patients and 232 unrelated healthy blood bank donor controls were examined for the mutations identified in the 70 ESCC patients. Five BRCA2 germline mutations, including three not previously reported (N1600del, A2054P, and V2109I), were identified in six of 44 FH+ patients, but none of 26 FH- patients ( 14 vs 0%, P = 0.078), consistent with our previous findings (3/34 or 9% FH+ vs 0/22 or 0% FH-, P = 0.27). The cumulative frequency of BRCA2 germline mutations in ESCC patients in this and our previous study combined is 12%, with all mutations found in FH+ as opposed to FH- cases (9/78 or 12% FH+ vs 0/48 or 0% FH-, P = 0.013). We conclude that germline mutations in BRCA2 in ESCC patients from this high-risk area of China are more frequent in FH+ than FH- cases, suggesting that BRCA2 may play a role in genetic susceptibility to familial ESCC.	NCI, Canc Prevent Studies Branch, Bethesda, MD 20892 USA; Shanxi Canc Hosp, Taiyuan 030013, Shanxi, Peoples R China; Yangcheng Canc Hosp, Yangcheng 048100, Shanxi, Peoples R China; Informat Management Serv Inc, Silver Spring, MD 20904 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Information Management Services, Inc.	Taylor, PR (corresponding author), NCI, Canc Prevent Studies Branch, 6116 Execut Plaza,Suite 705, Bethesda, MD 20892 USA.	ptaylor@mail.nih.gov			DIVISION OF CANCER PREVENTION AND CONTROL [Z01CN000150] Funding Source: NIH RePORTER	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; CARTER CL, 1992, J NATL CANCER I, V84, P771, DOI 10.1093/jnci/84.10.771; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Harada H, 1999, CANCER RES, V59, P3724; Hu N, 2002, CLIN CANCER RES, V8, P1121; Hu N, 2001, CLIN CANCER RES, V7, P883; HU N, 1992, INT J EPIDEMIOL, V21, P877, DOI 10.1093/ije/21.5.877; HU N, 1991, EUR J CANCER, V27, P1336, DOI 10.1016/0277-5379(91)90116-U; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Li G, 2001, GENE CHROMOSOME CANC, V31, P390, DOI 10.1002/gcc.1158; LI G, 1986, P 1 SIN AM HUM GEN W, P43; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; Li M H, 1980, Adv Cancer Res, V33, P173; Liede A, 2002, HUM MUTAT, V20, P413, DOI 10.1002/humu.10154; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; *NAT CANC CONTR OF, 1980, INV CANC MORT CHIN; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Pyne MT, 2000, J HUM GENET, V45, P351, DOI 10.1007/s100380070007; WANG YP, 1992, CANCER CAUSE CONTROL, V3, P107, DOI 10.1007/BF00051650; WU M, 1989, FAM CANC 1 INT RES C, P187; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Zhi XC, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9083	22	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					852	858		10.1038/sj.onc.1207150	http://dx.doi.org/10.1038/sj.onc.1207150			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647438	Bronze			2022-12-17	WOS:000188304900025
J	Whiteside, MA; Chen, DT; Desmond, RA; Abdulkadir, SA; Johanning, GL				Whiteside, MA; Chen, DT; Desmond, RA; Abdulkadir, SA; Johanning, GL			A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance	ONCOGENE			English	Article						lung cancer; drug resistance; gene expression profiling; mechanisms of drug action	CANCER CELL-LINES; PLASMINOGEN-ACTIVATOR; EXPRESSION PROFILES; LUNG-CANCER; DNA-REPAIR; STROMELYSIN-3; CHEMOSENSITIVITY; RADIATION; BRCA1; OVEREXPRESSION	In recent years, most cDNA microarray studies of chemotherapeutic drug resistance have not considered the temporal pattern of gene expression. The objective of this study was to examine systematically changes in gene expression of NCI-H226 and NCI-H2170 lung cancer cells treated weekly with IC10 doses of cisplatin. NCI-H226 lung cancer cells were treated weekly with an IC10 dose of cisplatin. Candidate genes with a fold change of 2.0 or more were identified from this study. A second experiment was conducted by exposing NCI-H2170 cells to cisplatin doses that were increased in week 4 and decreased in week 5. Overall, 44 genes were differentially expressed in both the NCI-H226 and NCI-H2170 cell lines. In the NCI-H2170 cell line, 24 genes had a twofold gene expression change from weeks 3 to 4. Real-time PCR found a significant correlation of the gene expression changes for seven genes of interest. This small time-ordered series identified novel genes associated with cisplatin resistance. This kind of analysis should be viewed as a first step towards building gene-regulatory networks.	Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA; NCI, Canc Prevent Fellowship Program, Bethesda, MD 20892 USA; Univ Alabama Birmingham, Biostat & Bioinformat Unit, Birmingham, AL USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Johanning, GL (corresponding author), Univ Alabama Birmingham, Dept Nutr Sci, Rm 404 Webb Bldg,1675 Univ Blvd, Birmingham, AL 35294 USA.	garyj@uab.edu						Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Amundson SA, 2000, CANCER RES, V60, P6101; ANDERSON IC, 1995, CANCER RES, V55, P4120; Anderson KM, 2002, ANTICANCER RES, V22, P75; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bolon I, 1997, AM J PATHOL, V150, P1619; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Boulay A, 2001, CANCER RES, V61, P2189; Brognard J, 2001, CANCER RES, V61, P3986; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Clave E, 1997, LEUKEMIA, V11, P114, DOI 10.1038/sj.leu.2400528; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; Dan S, 2002, CANCER RES, V62, P1139; De Larco JE, 2001, CANCER RES, V61, P2857; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Dunkern TR, 2001, MUTAT RES-DNA REPAIR, V486, P249, DOI 10.1016/S0921-8777(01)00095-7; Henderson YC, 1997, BRIT J HAEMATOL, V96, P566, DOI 10.1046/j.1365-2141.1997.d01-2057.x; Kudoh K, 2000, CANCER RES, V60, P4161; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Lamendola DE, 2003, CANCER RES, V63, P2200; Lee DH, 2003, CANCER RES, V63, P4648; Li QD, 2000, ANTICANCER RES, V20, P645; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Munster PN, 2002, CANCER RES, V62, P3132; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; Phelps RM, 1996, J CELL BIOCHEM, P32; PLUMB JA, 1989, CANCER RES, V49, P4435; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Wang Y, 2000, GENE DEV, V14, P927; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Zhang JL, 1999, BIOCHEM J, V337, P231, DOI 10.1042/0264-6021:3370231	34	29	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					744	752		10.1038/sj.onc.1207164	http://dx.doi.org/10.1038/sj.onc.1207164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737109				2022-12-17	WOS:000188304900013
J	Steinman, HA; Sluss, HK; Sands, AT; Pihan, G; Jones, SN				Steinman, HA; Sluss, HK; Sands, AT; Pihan, G; Jones, SN			Absence of p21 partially rescues Mdm4 loss and uncovers an antiproliferative effect of Mdm4 on cell growth	ONCOGENE			English	Article						Mdm4; p21; Mdm2; p53; mice	EMBRYONIC LETHALITY; TRANSCRIPTION FACTOR; MDM2-DEFICIENT MICE; P53; PROTEIN; DELETION	Mdm4 (MdmX) is a p53-binding protein that shares structural similarities with Mdm2 and has been proposed to be a negative regulator of p53 function. Like Mdm2, the absence of Mdm4 has recently been found to induce embryonic lethality in mice that is rescued by p53 deletion. Mdm4-null embryos are reduced in size and die at mid-gestation, and Mdm4-deficient embryos and embryonic fibroblasts displayed reduced rates of cell proliferation. The p53-induced, cyclin-dependent kinase inhibitor p21 is strongly upregulated in Mdm4-null embryos and cells. Here, we report that deletion of p21 delays the mid-gestation lethality observed in Mdm4-null mice, suggesting that Mdm4 downregulates p53-mediated suppression of cell growth. Surprisingly, the absence of p21 also uncovers an antiproliferative effect of Mdm4 on cell growth in vitro and in Mdm4-heterozygous mice. These results indicate that p21 is a downstream modifier of Mdm4, and provides genetic evidence that Mdm4 can function to regulate cell growth both positively and negatively.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Lexicon Genet, The Woodlands, TX 77381 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; Lexicon Pharmaceuticals; University of Massachusetts System; University of Massachusetts Worcester	Jones, SN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.	stephen.jones@umassmed.edu			NCI NIH HHS [CA77735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077735, R56CA077735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Finch RA, 2002, CANCER RES, V62, P3221; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; LUNA RMD, 1995, NATURE, V378, P203; Luna RMD, 1997, NAT GENET, V16, P336; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Strachan GD, 2003, J CELL BIOCHEM, V88, P557, DOI 10.1002/jcb.10318; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	17	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					303	306		10.1038/sj.onc.1206925	http://dx.doi.org/10.1038/sj.onc.1206925			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712235				2022-12-17	WOS:000187895300032
J	Rassool, FV; North, PS; Mufti, GJ; Hickson, ID				Rassool, FV; North, PS; Mufti, GJ; Hickson, ID			Constitutive DNA damage is linked to DNA replication abnormalities in Bloom's syndrome cells	ONCOGENE			English	Article						Bloom's syndrome; DNA damage; double-strand break repair; timing of replication	SYNDROME GENE-PRODUCT; DEFENDING GENOME INTEGRITY; SISTER-CHROMATID EXCHANGES; WERNERS-SYNDROME GENES; RECQ FAMILY HELICASES; STRAND BREAK REPAIR; COMMON FRAGILE SITE; SYNDROME PROTEIN; S-PHASE; TOPOISOMERASE-III	Bloom's syndrome (BS) is an autosomal recessive disorder associated with an elevated incidence of cancers. The gene mutated in BS, BLM, encodes a RecQ helicase family member. BS cells exhibit genomic instability, including excessive homologous recombination and chromosomal aberrations. W e reported previously that BS cells also demonstrate increased error-prone nonhomologous end-joining, which could contribute to genomic instability in these cells. Here, we show that BS cells display an abnormality in the timing of replication of both early-replicating genes and late-replicating loci such as chromosomal fragile sites. This delayed replication is associated with a constitutively increased frequency of sites of DNA damage and repair, as determined by the presence of DNA repair factors such as RAD51 and Ku86. In addition, another RecQ family helicase, WRN, also localizes to these repair sites. The presence of these repair sites correlates with the temporal appearance of cyclin B1 expression, indicative of the cells having progressed beyond mid-S phase in the cell division cycle. Critically, these defects in BS cells are the direct result of loss of BLM function, because BS cells phenotypically 'reverted' following transfection with the BLM cDNA no longer show such defects. Thus, our data indicate that constitutive DNA damage is coupled to delayed DNA replication in BS cells.	Guys Kings & Thomas Sch Med, Rayne Inst, Leukaemia Sci Labs, Dept Haematol Med, London SE5 9NU, England; Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Labs, Oxford OX3 9DS, England	University of London; King's College London; Cancer Research UK; University of Oxford	Rassool, FV (corresponding author), Guys Kings & Thomas Sch Med, Rayne Inst, Leukaemia Sci Labs, Dept Haematol Med, 123 Coldharbour Lane, London SE5 9NU, England.	feyruz.rassool@kcl.ac.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; Cooper MP, 2000, GENE DEV, V14, P907; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, J CELL SCI, V113, P2641; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; Glover TW, 1998, RECENT RES CANCER, V154, P185; GLOVER TW, 1987, AM J HUM GENET, V41, P882; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Langland G, 2002, CANCER RES, V62, P2766; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Li BM, 2000, J BIOL CHEM, V275, P39800; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; LONN U, 1990, CANCER RES, V50, P3141; Moens PB, 2000, J CELL SCI, V113, P663; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Oakley TJ, 2002, DNA REPAIR, V1, P175, DOI 10.1016/S1568-7864(02)00002-2; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Wang Y, 2000, GENE DEV, V14, P927; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2001, CELL MOL LIFE SCI, V58, P894, DOI 10.1007/PL00000909; Wu L, 2000, COLD SPRING HARB SYM, V65, P573, DOI 10.1101/sqb.2000.65.573; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; YUNIS JJ, 1987, ONCOGENE, V1, P59	45	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8749	8757		10.1038/sj.onc.1206970	http://dx.doi.org/10.1038/sj.onc.1206970			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647470	Bronze			2022-12-17	WOS:000186844900013
J	Goldberg, Z				Goldberg, Z			Clinical implications of radiation-induced genomic instability	ONCOGENE			English	Article						radiation; genomic instability; clinical implications	INDUCED CHROMOSOMAL INSTABILITY; BONE-MARROW CELLS; BREAST-CANCER; HODGKINS-DISEASE; NO EVIDENCE; RADIOTHERAPY; THERAPY; LUNG; RADIOSENSITIVITY; SUSCEPTIBILITY	Radiation-induced genomic instability encompasses a range of measurable end points such as chromosome destabilization, sister chromatid exchanges, gene mutation and amplification, late cell death and aneuploidy, all of which may be causative factors in the development of clinical disease, including carcinoma. Clinical implications of genomic instability can be broadly grouped into two main areas: as a marker for increased cancer risk/early detection, and as a consequence of radiation therapy (IR) that may be causative of, or a strong marker for, the induction of a therapy-induced second malignancy. Research in human populations has been limited, but broadly encompasses three populations: those exposed to alpha-particle irradiation, those with a cancer diagnosis who were examined for lymphocyte sensitivity to IR as a biomarker for risk of cancer induction, and those who successfully completed radiation therapy for an index cancer and who were examined for the induction of a second malignancy. This review examines each of those populations in turn and offers some potential future research directions to better elucidate the role of radiation-induced genomic instability in clinical disease.	Univ Calif Davis, Ctr Canc, Dept Radiat Oncol, Sacramento, CA 95817 USA	University of California System; University of California Davis	Goldberg, Z (corresponding author), Univ Calif Davis, Ctr Canc, Dept Radiat Oncol, 4501 X St,Ste G-126, Sacramento, CA 95817 USA.							Al-Maghrabi J, 2001, MODERN PATHOL, V14, P1252, DOI 10.1038/modpathol.3880471; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; Buchholz TA, 2001, INT J RADIAT ONCOL, V49, P533, DOI 10.1016/S0360-3016(00)01502-9; Chronowski GM, 2003, INT J RADIAT ONCOL, V55, P36, DOI 10.1016/S0360-3016(02)03915-9; Colleu-Durel S, 2001, ONCOL REP, V8, P1001; Dann EJ, 2001, BEST PRACT RES CL HA, V14, P119, DOI 10.1053/beha.2000.0119; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; Dorr Wolfgang, 2002, J Radiol Prot, V22, pA117, DOI 10.1088/0952-4746/22/3A/321; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Finette BA, 2000, SCIENCE, V288, P514, DOI 10.1126/science.288.5465.514; Hande MP, 2003, AM J HUM GENET, V72, P1162, DOI 10.1086/375041; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; HSU TC, 1991, CANCER EPIDEM BIOMAR, V1, P83; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; KADHIM MA, 1994, LANCET, V344, P987, DOI 10.1016/S0140-6736(94)91643-8; Kryscio A, 2001, INT J RADIAT BIOL, V77, P1087, DOI 10.1080/09443000110070289; Leith CP, 1999, BLOOD, V94, P1086; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Liu D, 2002, INT J CANCER, V102, P366, DOI 10.1002/ijc.10726; Matheson JB, 2002, RADIOTHER ONCOL, V65, P159, DOI 10.1016/S0167-8140(02)00135-4; Pickles T, 2002, RADIOTHER ONCOL, V65, P145, DOI 10.1016/S0167-8140(02)00307-9; Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544; Schmidberger H, 2001, INT J RADIAT ONCOL, V50, P857, DOI 10.1016/S0360-3016(01)01521-8; Scott D, 1999, INT J RADIAT BIOL, V75, P1, DOI 10.1080/095530099140744; Siantar CLH, 2001, MED PHYS, V28, P1322, DOI 10.1118/1.1381551; Tawn EJ, 2000, MUTAT RES-GEN TOX EN, V465, P45, DOI 10.1016/S1383-5718(99)00210-7; Watson GE, 1996, INT J RADIAT BIOL, V69, P175, DOI 10.1080/095530096146002; Whitehouse CA, 2001, RADIAT RES, V156, P467, DOI 10.1667/0033-7587(2001)156[0467:NEFCII]2.0.CO;2; WHITEHOUSE CA, 2001, RAD RES 1, V156, P7587; Zablotska LB, 2003, CANCER, V97, P1404, DOI 10.1002/cncr.11214; Zhang HF, 2000, INT J ONCOL, V17, P399	32	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7011	7017		10.1038/sj.onc.1206990	http://dx.doi.org/10.1038/sj.onc.1206990			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557805				2022-12-17	WOS:000185903900005
J	Zhang, ZQ; Wang, Y; Lantry, LE; Kastens, E; Liu, GJ; Hamilton, AD; Sebti, SM; Lubet, RA; You, M				Zhang, ZQ; Wang, Y; Lantry, LE; Kastens, E; Liu, GJ; Hamilton, AD; Sebti, SM; Lubet, RA; You, M			Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf	ONCOGENE			English	Article						farnesyltransferase inhibitor; lung cancer; chemoprevention; A/J mice; transgenic mice; P53; Ink4a/Arf	GERANYLGERANYLTRANSFERASE-I INHIBITORS; PROTEIN TRANSFERASE INHIBITOR; TRANSGENIC MICE; TUMOR-GROWTH; RAS; MOUSE; CARCINOMAS; MUTATION; PATHWAY; MAMMARY	Mutations in the Kras2 gene are seen in both human and mouse lung adenocarcinomas. The protein product (p21(ras)) encoded by the Kras2 gene must be post-translationally modified at a terminal CAAX motif in order to be biologically active. In this study, we systematically investigated the chemopreventive efficacy of two different farnesyltransferase inhibitors (FTIs): one is a peptidomimetic (FTI-276) and the other is an imidazole (L778 - 123). Both FTIs are designed to inhibit the posttranslational modi. cation of p21ras proteins with a terminal CAAX motif. In a complete chemoprevention study, where the inhibitor was administered before carcinogen was given, and throughout the study, FTI-276 treatment significantly reduced both the tumor multiplicity by 41.7% (P<0.005), and the total tumor volume by 79.4% (P<0.0001). In the late treatment study, where mice were treated with an inhibitor 12 to 20 weeks after carcinogen administration, FTI-276 treatment resulted in a 60% reduction in tumor multiplicity and 58% reduction in tumor volume. Next, we examined the chemopreventive efficacy of a new FTI, L-778,123, on lung tumor development in A/J mice and transgenic mice with a dominant-negative p53 mutation and/or heterozygous deletion of Ink4a/Arf. Treatment of mice with L-778,123 for a period of 10 weeks from 20 weeks to 30 weeks post carcinogen initiation resulted in an similar to50% decrease in tumor multiplicity in wild-type mice and mice with a dominant-negative p53 mutation and/or heterozygous deletion of the Ink4a/Arf tumor suppressor genes. Interestingly, tumor volume was decreased similar to50% in wildtype mice and in mice with an Ink4a/Arf heterozygous deletion, while tumor volume was decreased similar to75% in animals with a dominant-negative p53 and in mice with both a p53 mutation and heterozygous deletion of Ink4a/ Arf. This result suggests that FTI exhibited a significantly (P<0.05) more efficacious chemopreventive effect in animals with alterations of p53 and Ink4a/ Arf as contrasted with wild-type mice. Thus, FTIs are potent lung chemopreventive agents in both A/J mice and transgenic mice harboring a dominant-negative p53 and heterozygous deletion of Ink4a/Arf. In fact, L-778,123 is more effective in inhibiting primary lung progression in mice with a p53 mutation and/or an Ink4a/Arf deletion than in wild-type animals.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; Med Coll Ohio, Dept Pathol, Toledo, OH 43614 USA; Yale Univ, Dept Chem, New Haven, CT USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Drug Discovery Program, Tampa, FL USA; NCI, Chemoprevent Agent Dev Res Grp, Bethesda, MD 20892 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Yale University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA078797, R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554, R01CA78797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BOS JL, 1989, CANCER RES, V49, P4682; Brassard DL, 2002, EXP CELL RES, V273, P138, DOI 10.1006/excr.2001.5440; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIBA I, 1990, ONCOGENE, V5, P1603; Crespo NC, 2002, CELL DEATH DIFFER, V9, P702, DOI 10.1038/sj.cdd.4401023; Du W, 1999, MOL CELL BIOL, V19, P1831; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; Gu WZ, 1999, EUR J CANCER, V35, P1394, DOI 10.1016/S0959-8049(99)00132-X; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Herzog CR, 1996, ONCOGENE, V13, P1885; Herzog CR, 1997, J CELL BIOCHEM, P49; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lantry LE, 2000, CARCINOGENESIS, V21, P113, DOI 10.1093/carcin/21.1.113; Lantry LE, 2000, EXP LUNG RES, V26, P773, DOI 10.1080/01902140150216819; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Lubet RA, 2000, EXP LUNG RES, V26, P581, DOI 10.1080/01902140150216684; Mangues R, 1998, CANCER RES, V58, P1253; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; McDoniels-Silvers AL, 2001, EXP LUNG RES, V27, P297, DOI 10.1080/019021401300054064; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Minna JD, 1989, CANCER PRINCIPLES PR, P591; NAGASU T, 1995, CANCER RES, V55, P5310; Omer CA, 2000, CANCER RES, V60, P2680; Prendergast GC, 2000, SEMIN CANCER BIOL, V10, P443, DOI 10.1006/scbi.2000.0335; Reuter CWM, 2000, BLOOD, V96, P1655, DOI 10.1182/blood.V96.5.1655.h8001655_1655_1669; RODENHUIS S, 1992, CANCER RES, V52, pS2665; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; SELLERS TA, 1992, CANCER RES, V52, pS2694; SUN JZ, 1995, CANCER RES, V55, P4243; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; XU HJ, 1991, CANCER RES, V51, P2735; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, CANCER RES, V62, P3024; Zhang ZQ, 2002, ONCOGENE, V21, P5960, DOI 10.1038/sj.onc.1205725	42	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6257	6265		10.1038/sj.onc.1206630	http://dx.doi.org/10.1038/sj.onc.1206630			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679864				2022-12-17	WOS:000185506200015
J	Berton, TR; Matsumoto, T; Page, A; Conti, CJ; Deng, CX; Jorcano, JL; Johnson, DG				Berton, TR; Matsumoto, T; Page, A; Conti, CJ; Deng, CX; Jorcano, JL; Johnson, DG			Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues	ONCOGENE			English	Article						BRCA1; Cre-lox; epithelium; E2F1	SUPPRESSOR GENE BRCA1; DNA-DAMAGE RESPONSE; INTERACT IN-VIVO; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; CENTROSOME AMPLIFICATION; MESSENGER-RNA; BREAST; EXPRESSION; P53	The BRCA1 tumor-suppressor protein has been implicated in the regulation of transcription, DNA repair, proliferation, and apoptosis. BRCA1 is expressed in many proliferative tissues and this is at least in part due to E2F-dependent transcriptional control. In this study, inactivation of a conditional murine Brca1 allele was achieved in a variety of epithelial tissues via expression of the Cre recombinase under the control of a keratin 5 (K5) promoter. The K5 Cre:Brca1 conditional knockout mice exhibited modest epidermal hyperproliferation, increased apoptosis, and were predisposed to developing tumors in the skin, the inner ear canal, and the oral epithelium after 1 year of age. Overexpression of the E2F1 transcription factor in K5 Cre:Brca1 conditional knockout mice dramatically accelerated tumor development. In addition, Brca1 heterozygous female mice that had elevated E2F1 expression developed tumors of the reproductive tract at high incidence. These findings demonstrate that in mice Brca1 functions as a tumor suppressor in other epithelial tissues in addition to the mammary gland. Moreover, inactivation of Brca1 is shown to cooperate with deregulation of the Rb-E2F1 pathway to promote tumorigenesis.	Univ Texas, Dept Carcinogenesis, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA; CIEMAT, E-28040 Madrid, Spain; NIDDKD, Biochem & Metab Lab, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Johnson, DG (corresponding author), Univ Texas, Dept Carcinogenesis, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.	djohnson@sprd1.mdacc.tmc.edu	deng, chuxia/N-6713-2016	Page, Angustias/0000-0002-0231-8536; Johnson, David/0000-0002-6223-1790	NATIONAL CANCER INSTITUTE [T32CA009480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011047] Funding Source: NIH RePORTER; NCI NIH HHS [T-32 CA9480] Funding Source: Medline; NIEHS NIH HHS [U01 ES11047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baldwin RL, 2000, CANCER RES, V60, P5329; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Eisinger F, 1997, LANCET, V350, P1101, DOI 10.1016/S0140-6736(05)70461-X; Esteller M, 2001, CANCER RES, V61, P3225; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hill ADK, 1997, BRIT J SURG, V84, P1334; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Johannsson O, 1999, EUR J CANCER, V35, P1248, DOI 10.1016/S0959-8049(99)00135-5; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Randrianarison V, 2001, CANCER GENE THER, V8, P759, DOI 10.1038/sj.cgt.7700366; Rao VN, 1996, ONCOGENE, V12, P523; Rhei E, 1998, CANCER RES, V58, P3193; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMEDTS F, 1992, AM J PATHOL, V140, P601; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tong D, 2000, INT J CANCER, V88, P319, DOI 10.1002/1097-0215(20001015)88:2<319::AID-IJC27>3.0.CO;2-X; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	74	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5415	5426		10.1038/sj.onc.1206825	http://dx.doi.org/10.1038/sj.onc.1206825			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934101				2022-12-17	WOS:000184735000006
J	Jansson, AK; Emterling, AM; Arbman, G; Sun, XF				Jansson, AK; Emterling, AM; Arbman, G; Sun, XF			Noxa in colorectal cancer: a study on DNA, mRNA and protein expression	ONCOGENE			English	Article						Noxa; colorectal cancer; DNA sequencing; real-time PCR; immunohistochemistry	P53-DEPENDENT APOPTOSIS; BAX; P53; TRANSFORMATION; MUTATIONS; MEDIATOR; DEATH; CELLS; TUMOR; PUMA	Noxa is a BH3-only member of the Bcl-2 family, upregulated by p53 as a response to DNA damage. Mutations in the BH3-only region of other BH3-only members lead to an inactive protein. We have investigated the mRNA expression of Noxa with real-time PCR in 94 unselected colorectal adenocarcinomas and the corresponding normal mucosa. Among them, Noxa protein expression was investigated with immunohistochemistry in 16 tumors and six corresponding normal mucosa samples. Further, we searched for Noxa mutations in all the cases using single-stranded conformation polymorphism and DNA sequencing. The mRNA expression of Noxa was weak in 9% and strong in 2% of the tumors, and decreased in 9% and increased in 16% of the tumors compared with the normal mucosa; however, these changes did not have any clinical or pathological significance. The protein level in most of the cases investigated was correlated with the mRNA level. We did not find any mutations in the Noxa gene. Thus, we suggest that Noxa may not be of importance in the development of colorectal cancer.	Linkoping Univ, Dept Biomed & Surg, Div Oncol, S-58185 Linkoping, Sweden; Vrinnevi Hosp, Dept Surg, Norrkoping, Sweden	Linkoping University	Jansson, AK (corresponding author), Linkoping Univ, Dept Biomed & Surg, Div Oncol, S-58185 Linkoping, Sweden.	agnja@ibk.liu.se						Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jansson A, 2002, J CLIN ONCOL, V20, P811, DOI 10.1200/JCO.20.3.811; Jansson A, 2001, INT J CANCER, V92, P338, DOI 10.1002/ijc.1189; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Wei MC, 2000, GENE DEV, V14, P2060; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	18	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4675	4678		10.1038/sj.onc.1206655	http://dx.doi.org/10.1038/sj.onc.1206655			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879012				2022-12-17	WOS:000184157000008
J	Nozell, S; Wu, YJ; McNaughton, K; Liu, G; Willis, A; Paik, JC; Chen, XB				Nozell, S; Wu, YJ; McNaughton, K; Liu, G; Willis, A; Paik, JC; Chen, XB			Characterization of p73 functional domains necessary for transactivation and growth suppression	ONCOGENE			English	Article						p73; p53 family; apoptosis; cell cycle	KINASE C-ABL; DNA-DAMAGE; P53 FAMILY; APOPTOTIC RESPONSE; TRANSCRIPTIONAL ACTIVITY; P53-RELATED PROTEIN; INDUCE APOPTOSIS; TERMINAL DOMAIN; TARGET GENES; TUMOR-CELLS	p73, a p53 family member, is highly similar to p53 in both structure and function. Like p53, the p73 protein contains an N-terminal activation domain, a DNA-binding domain, a tetramerization domain, and several PXXP motifs. Previously, we and others have shown that some functional domains in p53, such as the DNA-binding and tetramerization domains, are required for inducing both cell cycle arrest and apoptosis whereas others, such as the second activation domain, the proline-rich domain, and the C-terminal basic domain, are only required for inducing apoptosis. To determine the activity of p73 functional domains, we have generated stable inducible cell lines that express p73beta and various mutants deficient in one or more functional domains. We found that in addition to the DNA-binding domain, p73-mediated growth suppression requires the N-terminal activation domain and the tetramerization domain. However, unlike p53, p73-mediated apoptosis does not require the region adjacent to the activation domain or the entire C-terminal region. Interestingly, while the N- or the C-terminal PXXP motifs are dispensable for p73 function, deletion of both the Nand the C-terminal PXXP motifs renders p73 inactive in transactivation. In addition, we found that substitution of two conserved tandem hydrophobic residues with two hydrophilic ones, which can abrogate the activity of the first activation domain in p53, has no effect on p73 transcriptional activity. Together, we showed that the p73 protein has its own unique determinants for transactivation and growth suppression.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu		, Gang/0000-0002-6999-7633; Paik, Jason/0000-0002-9075-4679; Liu, Gang/0000-0003-2615-131X; Amara, Amy/0000-0003-0762-9656	NCI NIH HHS [CA 81237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gong JG, 1999, NATURE, V399, P806; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LIN JY, 1995, ONCOGENE, V10, P2387; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Schultz J, 1997, PROTEIN SCI, V6, P249; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CANCER RES, V62, P3598; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Takada N, 1999, CANCER RES, V59, P2810; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	52	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4333	4347		10.1038/sj.onc.1206470	http://dx.doi.org/10.1038/sj.onc.1206470			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853970				2022-12-17	WOS:000183978900003
J	Boehden, GS; Akyuz, N; Roemer, K; Wiesmuller, L				Boehden, GS; Akyuz, N; Roemer, K; Wiesmuller, L			p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair	ONCOGENE			English	Article						genome stability; homologous recombination; p53; transcriptional transactivation; tumor suppression	BASE EXCISION-REPAIR; DNA-POLYMERASE BETA; MUTANT P53; REPLICATION FIDELITY; GENOMIC INTEGRITY; PROMOTER REGION; MISMATCH REPAIR; RECOMBINATION; PROTEIN; GENE	The tumor suppressor p53 transcriptionally transactivates cellular target genes that are implicated in growth control, apoptosis, and DNA repair. However, several studies involving p53 core domain mutants suggested that regulatory functions in recombinative repair do not require transcriptional transactivation and are separable from growth-regulation and apoptosis. Leu22 and Trp23 within the transactivation domain of human p53 play a critical role in binding basal components of the transcription machinery and, therefore, in the transactivation activity of p53. To further delineate whether p53 target genes are involved in recombination regulation, we ectopically expressed p53(22Q,23S) in p53-negative cell lines, which carry reporter systems for different homology-directed double-strand break (DSB) repair events. Like wild-type p53, p53(22Q,23S) efficiently downregulated homologous recombination on two chromosomally integrated substrates without affecting exchange on a substrate for the compound pathway of gene conversion and nonhomologous end joining. Only upon lowering the p53 protein to DNA substrate ratio by several orders of magnitude, we noticed a weak defect of a p53 transactivation domain mutant in DSB repair assays. In conclusion, molecular interactions of p53 within the N-terminal domain are not required to restrain DNA recombination, but might contribute to this genome stabilizing function.	Univ Ulm, Frauenklin, D-89075 Ulm, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Saarland, Dept Virol, D-66421 Homburg, Germany	Ulm University; Heinrich Pette Institute; University of Hamburg; Saarland University	Wiesmuller, L (corresponding author), Univ Ulm, Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.	Lisa.Wiesmueller@medizin.uni-ulm.de						Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Bogliolo M, 2000, ONCOGENE, V19, P5781, DOI 10.1038/sj.onc.1203951; Botuyan MVE, 1997, FOLD DES, V2, P331, DOI 10.1016/S1359-0278(97)00047-3; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doetsch PW, 2001, PROG NUCLEIC ACID RE, V68, P29; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Mahdi T, 1998, BIOL CHEM, V90, P15; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; Melle C, 2002, NUCLEIC ACIDS RES, V30, P1493, DOI 10.1093/nar/30.7.1493; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Morris SM, 2002, MUTAT RES-REV MUTAT, V511, P45, DOI 10.1016/S1383-5742(01)00075-8; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Reichenberger S, 1998, EUR J BIOCHEM, V251, P81, DOI 10.1046/j.1432-1327.1998.2510081.x; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Schaffner DL, 1996, LAB INVEST, V74, P1005; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SOUSSI T, 1993, NOUV REV FR HEMATOL, V35, P33; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Theis S, 1997, INT J CANCER, V71, P858; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Warnick CT, 2001, J BIOL CHEM, V276, P27363, DOI 10.1074/jbc.M103088200; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Willers H, 2001, CARCINOGENESIS, V22, P1757, DOI 10.1093/carcin/22.11.1757; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	56	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4111	4117		10.1038/sj.onc.1206632	http://dx.doi.org/10.1038/sj.onc.1206632			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821945				2022-12-17	WOS:000183707600014
J	Dowen, SE; Neutze, DM; Pett, MR; Cottage, A; Stern, P; Coleman, N; Stanley, MA				Dowen, SE; Neutze, DM; Pett, MR; Cottage, A; Stern, P; Coleman, N; Stanley, MA			Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes	ONCOGENE			English	Article						5p; HPV; SKP2; p27	HUMAN-PAPILLOMAVIRUS TYPE-16; F-BOX PROTEIN; CARCINOMA CELL-LINES; CYTOGENETIC ANALYSIS; RECURRENT PATTERN; GENOMIC CHANGES; CERVIX UTERI; HELA-CELL; IN-SITU; S-PHASE	The oncogenic HPVs immortalize primary genital keratinocytes in vitro and there is evidence that such lines represent suitable models to examine HPV-induced carcinogenesis. Early in vivo studies and more recent CGH analyses have revealed amplification of chromosome 5p in advanced stage carcinoma of the uterine cervix (CaCx). In the present study, a panel of established CaCx-derived cell tines were analysed by M-FISH to identify recurrent karyotypic abnormalities. Amplification of 5p was observed in I I of 13 CaCx cell lines harbouring HR (high-risk) HPV. The region of 5p undergoing amplification was confirmed using human band-specific paints. The F-box protein Skp2 is present at 5p13 and its protein is present at increased levels in many cancers of an advanced stage. The HPV16-harbouring cell line W12 shows progressive morphological abnormality with in vitro passage, culminating in an invasive phenotype. The expression of Skp2 at different stages of this progression was investigated utilizing Western blot and TaqMan quantitative PCR. At medium to late passage, gain of 5p as an isochromosome was observed. Increased expression of Skp2 and a reduction in the expression of its target p27 correlated with increasing passage in this line.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; MRC, Res Ctr, Cambridge CB2 2QH, England; Christie Hosp NHS Trust, Canc Res UK, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England	University of Cambridge; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester	Dowen, SE (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	sally-dowen@hotmail.com						ATKIN NB, 1982, CANCER GENET CYTOGEN, V7, P209, DOI 10.1016/0165-4608(82)90068-1; ATKIN NB, 1984, CANCER GENET CYTOGEN, V13, P189, DOI 10.1016/0165-4608(84)90043-8; Aubele M, 1998, CANCER CYTOPATHOL, V84, P375, DOI 10.1002/(SICI)1097-0142(19981225)84:6<375::AID-CNCR10>3.0.CO;2-1; AUERSPERG N, 1964, J NATL CANCER I, V32, P135; Brady CS, 2000, TISSUE ANTIGENS, V55, P401, DOI 10.1034/j.1399-0039.2000.550502.x; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Ciaparrone M, 1998, CANCER RES, V58, P114; Cottage A, 2001, GENE CHROMOSOME CANC, V30, P72, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1060>3.0.CO;2-X; Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; DURST M, 1987, ONCOGENE, V1, P251; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; HERZ F, 1977, CANCER RES, V37, P3209; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; *INT AG RES CANC, 1995, IARC MONOGRAPHS EVAL, V74; JAMES GK, 1989, CANCER GENET CYTOGEN, V38, P53, DOI 10.1016/0165-4608(89)90165-9; Jee KJ, 2001, MODERN PATHOL, V14, P377, DOI 10.1038/modpathol.3880321; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; JONES HW, 1971, OBSTET GYNECOL, V38, P945; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V24, P144, DOI 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9; Kudo Y, 2001, CANCER RES, V61, P7044; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAEVILLE M, 1999, CANCER RES, V59, P141; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; MILLER OJ, 1971, CYTOGENETICS, V10, P338, DOI 10.1159/000130152; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Roberts I, 1999, GENE CHROMOSOME CANC, V25, P241, DOI 10.1002/(SICI)1098-2264(199907)25:3<241::AID-GCC6>3.0.CO;2-7; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SMITH PP, 1989, INT J CANCER, V44, P1124, DOI 10.1002/ijc.2910440631; STANLEY M, 1994, PAPILLOMAVIRUS REV, P131; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STANLEY MA, 1991, CULTURE EPITHELIAL C, P135; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071	49	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2531	2540		10.1038/sj.onc.1206296	http://dx.doi.org/10.1038/sj.onc.1206296			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717429				2022-12-17	WOS:000182383500015
J	Lee, GH; Nishimori, H; Sasaki, Y; Matsushita, H; Kitagawa, T; Tokino, T				Lee, GH; Nishimori, H; Sasaki, Y; Matsushita, H; Kitagawa, T; Tokino, T			Analysis of lung tumorigenesis in chimeric mice indicates the Pulmonary adenoma resistance 2 (Par2) locus to operate in the tumor-initiation stage in a cell-autonomous manner: detection of polymorphisms in the Poh gene as a candidate for Par2	ONCOGENE			English	Article						chimeric mouse; lung tumor; resistance locus; cell-autonomy; candidate gene	HUMAN DNA-POLYMERASE; URETHANE-INDUCTION; BALB/CBYJ MICE; RAS GENE; IOTA; SUSCEPTIBILITY; CARCINOGENESIS; IDENTIFICATION; HOMOLOG; LESIONS	The Pulmonary adenoma resistance 2 (Par2) locus of the BALB/cByJ mouse, located within 0.5 cM of chromosome 18, is responsible for reducing the mean multiplicity of urethane-induced lung tumors relative to those in C57BL/6J, A/J and C3H/HeJ mice. Thus, BALB/B6-Par2 congenic strain genetically identical to BALB/cByJ except carrying C57BL/6J Par2 alleles develops seven times more tumors than BALB/cByJ. To gain clues for identification of Par2 candidate genes, we analysed lung tumorigenesis in BALB/cByJ <----> BALB.B6-Par2 chimeric animals. Of 100 tumors induced by urethane in 16 chimeras, 82 originated from BALB.B6-Par2 cells, indicating the Par2 phenotype to be cell-autonomous. In addition, the BALB.B6-Par2- and BALB/cByJ-derived tumors were similar in mean size, implying that the phenotype is primarily expressed during initiation rather than in the promotion stage of carcinogenesis. Given these results, we surveyed a comprehensive mouse genome database and physically mapped Par2 within a 2.3 Mbp segment containing three known genes, Poh, Mbd2 and Dcc. Among those, the Poh seemed to be the most reasonable Par2 candidate, since it encodes an extremely error-prone DNA polymerase preferentially incorporating G or T opposite template T in vitro, reminiscent of the Kras2 activation because of an A to G or T point mutation within codon 61 with which most urethane-induced lung tumors are initiated. Indeed, our sequencing of Poh cDNAs from BALB/cByJ, C57BL/6J, A/J and C3H/HeJ lungs revealed 21 BALB/cByJ-specific single-nucleotide polymorphisms in the coding region accompanied by seven amino-acid substitutions and an elevated frequency of alternative splicing, while no polymorphisms associated with tumor susceptibility were found for either Mbd2 or Dcc. Notably, we obtained evidence that BALB/cByJ Par2 alleles may selectively decrease the frequency of Kras2-mutated tumors compared with C57BL/6J alleles. Consequently, the Poh is an intriguing Par2 candidate clearly deserving further evaluation.	Toranomon Gen Hosp, Dept Pathol, Minato Ku, Tokyo 1058470, Japan; Okinaka Mem Inst Med Res, Minato Ku, Tokyo 1058470, Japan; Sapporo Med Univ, Inst Canc Res, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo 1708455, Japan	Toranomon Hospital; Sapporo Medical University; Japanese Foundation for Cancer Research	Lee, GH (corresponding author), Toranomon Gen Hosp, Dept Pathol, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.	lee@toranomon.gr.jp	Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019	Sasaki, Yasushi/0000-0002-3500-8059				Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; Cooper HM, 1995, ONCOGENE, V11, P2243; Devereux TR, 1997, CARCINOGENESIS, V18, P1751, DOI 10.1093/carcin/18.9.1751; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Karasaki H, 1997, ONCOGENE, V15, P1833, DOI 10.1038/sj.onc.1201357; LEE GH, 1991, CANCER RES, V51, P3257; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; Lee GH, 2001, ONCOGENE, V20, P3979, DOI 10.1038/sj.onc.1204562; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; MANAM S, 1992, MOL CARCINOGEN, V6, P68, DOI 10.1002/mc.2940060111; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Obata M, 1996, ONCOGENE, V13, P1599; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928; Zhang ZQ, 2000, EXP LUNG RES, V26, P627, DOI 10.1080/01902140150216710	25	29	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2374	2382		10.1038/sj.onc.1206387	http://dx.doi.org/10.1038/sj.onc.1206387			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700672				2022-12-17	WOS:000182231500015
J	Falahatpisheh, MH; Ramos, KS				Falahatpisheh, MH; Ramos, KS			Ligand-activated Ahr signaling leads to disruption of nephrogenesis and altered Wilms' tumor suppressor mRNA splicing	ONCOGENE			English	Article						Ahr; WT1 splicing; nephrogenesis	ARYL-HYDROCARBON RECEPTOR; GENE-EXPRESSION; EMBRYONAL CARCINOMA; KIDNEY DEVELOPMENT; DEFICIENT MICE; WT1 GENE; GROWTH; CELLS; TRANSCRIPTION; INVOLVEMENT	The aryl hydrocarbon receptor (Ahr), a member of the large basic helix-loop-helix (bHLH) and PAS homology domain superfamily, is a highly conserved transcriptional regulator involved in mammalian development. In the present study, a murine metanephros organ culture system was employed to evaluate the role of the Ahr signaling in nephrogenesis in vitro. Ahr and Wilms' tumor suppressor (wt1) mRNAs were detected by in situ hybridization and RT-PCR during the course of renal development. Treatment with 3 pm BaP, a hydrocarbon ligand of Ahr, inhibited glomerulogenesis and branching morphogenesis of metanephric kidneys. Deficits in the epithelialization of mesenchymal cells were evidenced by inhibition of the formation of podocyte foot processes and glomerular basement membranes. Hydrocarbon treatment markedly induced -KTS wt1 splice variants, although total wt1 mRNA levels remained unchanged. A significant decrease in total WT1 protein was observed by both immunocytochemistry and Western analysis in cultures challenged with BaP compared to controls. Comparison of metanephric cultures from Ahr+/+ and Ahr-/- mice showed that Ahr is involved in kidney development, and required for BaP-induced deficits in nephrogenesis. These results indicate that ligand activation of Ahr signaling disrupts nephrogenesis in vitro, and that this response involves modulation of wt1 alternative splicing and post-transcriptional control.	Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Ramos, KS (corresponding author), Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA.				NIEHS NIH HHS [ES09106, ES04917] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106, P42ES004917] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott BD, 1995, TOXICOLOGY, V105, P365, DOI 10.1016/0300-483X(95)03234-7; ASWIN M, 1998, KIDNEY INT, V53, P1512; AVNER ED, 1990, PEDIATR NEPHROL, V4, P372, DOI 10.1007/BF00862522; AVNER ED, 1993, SEMIN NEPHROL, V13, P427; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bowes RC, 1996, BIOCHEM PHARMACOL, V52, P587, DOI 10.1016/0006-2952(96)00310-3; BOWES RC, 1994, TOXICOL IN VITRO, V8, P1151, DOI 10.1016/0887-2333(94)90104-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; Cantrell SM, 1998, TOXICOL APPL PHARM, V148, P24, DOI 10.1006/taap.1997.8309; Carver LA, 1997, J BIOL CHEM, V272, P11452; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Dressler G R, 1997, Adv Nephrol Necker Hosp, V26, P1; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; Gutierrez A, 1997, MOL BRAIN RES, V45, P59, DOI 10.1016/S0169-328X(96)00237-9; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HABIB R, 1985, CLIN NEPHROL, V24, P269; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hewitt SM, 1996, ANTICANCER RES, V16, P621; Hida M, 2002, KIDNEY INT, V61, P1252, DOI 10.1046/j.1523-1755.2002.00273.x; Hundeiker C, 1999, INT J IMMUNOPHARMACO, V21, P841, DOI 10.1016/S0192-0561(99)00053-3; Hushka LJ, 1998, TOXICOL APPL PHARM, V152, P200, DOI 10.1006/taap.1998.8508; KAFAFI SA, 1993, CHEM RES TOXICOL, V6, P328, DOI 10.1021/tx00033a012; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kudoh T, 1996, ONCOGENE, V13, P1431; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Laity JH, 2000, BIOCHEMISTRY-US, V39, P5341, DOI 10.1021/bi9926678; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Renshaw J, 1997, GENE CHROMOSOME CANC, V19, P256, DOI 10.1002/(SICI)1098-2264(199708)19:4<256::AID-GCC8>3.0.CO;2-W; RYAN G, 1995, DEVELOPMENT, V121, P867; SAXON L, 1987, ORGANOGENESIS KIDNEY; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Toth T, 1996, NEPHRON, V74, P64, DOI 10.1159/000189283; WALKER C, 1994, CANCER RES, V54, P3101; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; Yeger H, 1996, IN VITRO CELL DEV-AN, V32, P496; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	47	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 10	2003	22	14					2160	2171		10.1038/sj.onc.1206238	http://dx.doi.org/10.1038/sj.onc.1206238			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687018	Bronze			2022-12-17	WOS:000182066900010
J	Konishi, H; Sugiyama, M; Mizuno, K; Saito, H; Yatabe, Y; Takahashi, T; Osada, H; Takahashi, T				Konishi, H; Sugiyama, M; Mizuno, K; Saito, H; Yatabe, Y; Takahashi, T; Osada, H; Takahashi, T			Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer	ONCOGENE			English	Article						homozygous deletion; 17p13.3; tumor suppressor gene; lung cancer; LOST1	HUMAN-CHROMOSOME 3P21.3; HEPATOCELLULAR-CARCINOMA; EPIGENETIC INACTIVATION; MITOTIC CHECKPOINT; BREAST-CANCER; CELL-LINES; IN-VIVO; GENE; IDENTIFICATION; P53	17p13.3 is one of the chromosomal regions most frequently affected by allelic loss in a variety of human neoplasms including lung cancer. A number of loss of heterozygosity (LOH) analyses have suggested the existence of a tumor suppressor gene at 17p13.3, distal to the p53 locus at 17p13.1. In the present study, we characterized a homozygous deletion at 17p13.3 in a small cell lung cancer cell line by constructing a bacterial artificial chromosome (BAC) contig and a restriction map surrounding the region, as well as by utilizing publicly available draft sequences. We defined the breakpoint, assigned and analysed two known genes, 14-3-3epsilon. and CRK, and a novel gene LOST1 within or at the end of the homozygous deletion of about 170 kb in size. Marked reduction of LOST1 expression was detected in 69% (11/16) of lung cancer specimens by quantitative real-time RT-PCR, while significant DNA hypermethylation was observed at the 5' end of the LOST1 gene in four of six lung cancer cell lines with negligible LOST1 expression. We also show here that a polymorphic marker D17S1174, which resides within the homozygous deletion, was apparently located in the middle of the minimum LOH region, providing further supportive evidence for the presence of a tumor suppressor gene(s) in this region.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Anat & Mol Diagnost Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Immunol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; Konishi, Hiroyuki/0000-0003-1131-4905				BIEGEL JA, 1992, CANCER RES, V52, P3391; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CAIRNS P, 1994, CANCER RES, V54, P1422; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; COGEN PH, 1992, AM J HUM GENET, V50, P584; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FUJIMORI M, 1991, CANCER RES, V51, P89; Haataja L, 1997, CANCER RES, V57, P32; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Ji L, 2002, CANCER RES, V62, P2715; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Konishi H, 1998, ONCOGENE, V17, P2095, DOI 10.1038/sj.onc.1202128; Konishi H, 2002, CANCER RES, V62, P271; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Lerman MI, 2000, CANCER RES, V60, P6116; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; McHale JC, 2000, CYTOGENET CELL GENET, V88, P225, DOI 10.1159/000015556; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Oh JJ, 2002, CANCER RES, V62, P3207; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Osada H, 2001, CANCER RES, V61, P8331; Phillips NJ, 1996, CANCER RES, V56, P606; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; SAXENA A, 1992, CANCER RES, V52, P6716; Schultz DC, 1996, CANCER RES, V56, P1997; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TADOKORO K, 1992, ONCOGENE, V7, P1215; TAKAHASHI T, 1992, CANCER RES, V52, P2340; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tamura K, 2002, J HUM GENET, V47, P348, DOI 10.1007/s100380200048; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; Zhao XT, 2001, CANCER RES, V61, P7383	53	29	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2003	22	12					1892	1905		10.1038/sj.onc.1206304	http://dx.doi.org/10.1038/sj.onc.1206304			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660825				2022-12-17	WOS:000181678200016
J	Vernon, EG; Malik, K; Reynolds, P; Powlesland, R; Dallosso, AR; Jackson, S; Henthorn, K; Green, ED; Brown, KW				Vernon, EG; Malik, K; Reynolds, P; Powlesland, R; Dallosso, AR; Jackson, S; Henthorn, K; Green, ED; Brown, KW			The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour	ONCOGENE			English	Article						Wilms' tumour; chromosome 7; PTH-B1 gene	SHORT ARM; HETEROZYGOSITY; TRANSLOCATION; CHROMOSOME-7; CELLS; LOCUS; IDENTIFICATION; ABNORMALITIES; MUTATIONS; ALLELES	Wilms' tumour (WT) has a diverse and complex molecular aetiology, with several different loci identified by cytogenetic and molecular analyses. One such locus is on chromosome 7p, where cytogenetic abnormalities and loss of heterozygosity (LOH) indicate the presence of a Wilms' tumour suppressor gene. In order to isolate a candidate gene for this locus, we have characterized the breakpoint regions at a novel constitutional chromosome translocation (t(1;7)(q42;p15)), found in a child with WT and skeletal abnormalities. We identified two genes that were interrupted by the translocation: the parathyroid hormone-responsive B1 gene (PTH-B1) at 7p and obscurin at 1q. With no evidence for LOH at 1q42, we focused on the characterization of PTH-B1. We detected novel alternately spliced isoforms of PTH-B1, which were expressed in a wide range of adult and foetal tissues. Importantly, expression of two isoforms were disrupted in the WT of the t(1;7) patient. We also identified an additional splice isoform expressed only in 7p LOH tumours. The disruption of PTH-B1 by the t(1;7), together with aberrant splicing in sporadic WTs, suggests that PTH-B1 is a candidate for the 7p Wilms' tumour suppressor gene.	Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, CLIC Res Unit, Bristol BS8 1TD, Avon, England; MGH Canc Ctr, Boston, MA USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA	University of Bristol; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Brown, KW (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, CLIC Res Unit, Bristol BS8 1TD, Avon, England.		dallosso, anthony/A-8335-2008; Brown, Keith/C-3355-2009	Brown, Keith/0000-0002-4258-5129; Vernon, Ellen/0000-0002-8344-1025; Dallosso, Anthony/0000-0002-1460-2550; Malik, Karim/0000-0002-8965-200X				Adams AE, 1999, BONE, V24, P305, DOI 10.1016/S8756-3282(98)00188-4; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Baudry D, 2000, CLIN CANCER RES, V6, P3957; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BROWN KW, 1993, GENE CHROMOSOME CANC, V8, P74, DOI 10.1002/gcc.2870080203; BROWN KW, 1989, BRIT J CANCER, V60, P25, DOI 10.1038/bjc.1989.213; BROWN KW, 2001, EXP REV MOL MED, V14; DEKRAKER J, 1979, HELV PAEDIATR ACTA, V34, P459; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY PE, 1994, CANCER RES, V54, P2331; Grundy RG, 1998, ONCOGENE, V17, P395, DOI 10.1038/sj.onc.1201927; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HEWITT M, 1991, J MED GENET, V28, P411, DOI 10.1136/jmg.28.6.411; KOUFOS A, 1989, AM J HUM GENET, V44, P711; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Lobbert RW, 1998, GENE CHROMOSOME CANC, V21, P347, DOI 10.1002/(SICI)1098-2264(199804)21:4<347::AID-GCC9>3.0.CO;2-Z; Miozzo M, 1996, GENOMICS, V37, P310, DOI 10.1006/geno.1996.0565; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Perotti D, 2001, GENE CHROMOSOME CANC, V31, P42, DOI 10.1002/gcc.1116; PING AJ, 1989, AM J HUM GENET, V44, P720; Powlesland RM, 2000, BRIT J CANCER, V82, P323, DOI 10.1054/bjoc.1999.0922; RADICE P, 1995, GENOMICS, V27, P497, DOI 10.1006/geno.1995.1082; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reynolds PA, 1996, GENE CHROMOSOME CANC, V17, P151, DOI 10.1002/(SICI)1098-2264(199611)17:3<151::AID-GCC2>3.0.CO;2-3; RIVERA H, 1995, CANCER GENET CYTOGEN, V81, P97, DOI 10.1016/S0165-4608(94)00199-5; Sambrook J, 1989, MOL CLONING LAB MANU; SAWYER JR, 1993, CANCER GENET CYTOGEN, V69, P57, DOI 10.1016/0165-4608(93)90114-2; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; WILMORE HP, 1994, CANCER GENET CYTOGEN, V77, P93, DOI 10.1016/0165-4608(94)90221-6; WILSON K, 1986, BIOL GUIDE PRINCIPLE; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110	31	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1371	1380		10.1038/sj.onc.1206332	http://dx.doi.org/10.1038/sj.onc.1206332			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618763				2022-12-17	WOS:000181360900012
J	Kim, Y; Park, H; Lim, Y; Han, I; Kwon, HJ; Woods, A; Oh, ES				Kim, Y; Park, H; Lim, Y; Han, I; Kwon, HJ; Woods, A; Oh, ES			Decreased syndecan-2 expression correlates with trichostatin-A induced-morphological changes and reduced tumorigenic activity in colon carcinoma cells	ONCOGENE			English	Article						colon carcinoma; historic deacetylase syndecan-2; tumorigenesis	HISTONE DEACETYLASES; INHIBITION; MODULATION; REVERSION; GROWTH	The inhibition of histone deacetylase activity is known to induce morphological changes of transformed cells. In this study, we investigated the effect of the specific HDAC inhibitor, trichostatin A (TSA), on colon carcinoma cell lines. Treatment of human colorectal carcinoma cells, KM1214 and KM12SM, with TSA induced distinct morphological changes. Both cell lines, which normally piled up in layers without clear boundary, became more flattened, and formed monolayers with evident boundaries between cells, with concomitant increased actin filament organization. Cell-cell interaction was not affected much, based on expression level, membrane localization, and interaction of E-cadherin with P-catenin. In contrast, syndecan-2 expression was dramatically reduced and it was correlated with the morphological changes of colon carcinoma cells. Consistently, downregulation of syndecan-2 expression by antisense cDNA clearly mimicked the morphological changes in KM12SM and reduced anchorage-independent growth of colon cancer cells. All these results indicate that reduced syndecan-2 expression correlates with TSA-induced morphological changes and reduced tumorigenic activity in colon carcinoma cells.	Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Natl Caner Canc, Div Radiat & Nucl Med Radiat, Med Branch, Gyeonggi 411764, South Korea; Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, Seoul 143747, South Korea; Univ Alabama Birmingham, Dept Cell Biol & Cell Adhes, Matrix Res Ctr, Birmingham, AL 35294 USA	Ewha Womans University; Ewha Womans University; National Cancer Center - Korea (NCC); Sejong University; University of Alabama System; University of Alabama Birmingham	Oh, ES (corresponding author), Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea.	OhES@mm.ewha.ac.kr	권, 호정/AAS-3642-2021					BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Couchman JR, 1999, J CELL SCI, V112, P3415; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; Kusano Y, 2000, EXP CELL RES, V256, P434, DOI 10.1006/excr.2000.4802; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; RACHEL BH, 2000, J CELL BIOL, V148, P779; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUGITA K, 1992, CANCER RES, V52, P168; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zimmermann P, 1999, FASEB J, V13, pS91	19	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					826	830		10.1038/sj.onc.1206068	http://dx.doi.org/10.1038/sj.onc.1206068			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584561				2022-12-17	WOS:000180864300004
J	Antlsperger, DSM; Dirsch, VM; Ferreira, D; Su, JL; Kuo, ML; Vollmar, AM				Antlsperger, DSM; Dirsch, VM; Ferreira, D; Su, JL; Kuo, ML; Vollmar, AM			Ajoene-induced cell death in human promyeloleukemic cells does not require JNK but is amplified by the inhibition of ERK	ONCOGENE			English	Article						ajoene; apoptosis; mitogen-activated protein kinase; c-Jun NH2-terminal kinase; extracellular signal-regulated kinases	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; JUN NH2-TERMINAL KINASE; INDUCED APOPTOSIS; SIGNALING PATHWAYS; CANCER CELLS; CYTOCHROME-C; HL-60 CELLS; KAPPA-B; T-CELLS	Treatment of human promyeloleukemic HL-60 cells with the experimental antileukemic drug ajoene induces the activation of the mitogen-activated protein kinases (MAPKs) c-Jun NH2-terminal kinase (JNK), p38 and extracellular signal-regulated kinases (ERK) 1/2 as well as the survival kinase Akt. JNK activation occurred in HL-60/neo, HL-60/bcl-x(L), and in HL-60 cells pretreated with the pan-caspase inhibitor zVAD-fmk, indicating that JNK activation is not dependent on ajoene-induced mitochondria perturbation and subsequent caspase activation. Cells overexpressing a dominant-negative JNK showed no altered sensitivity towards ajoene suggesting that the activation of JNK is not necessary for ajoene-induced cell death. Inhibition of p38 MAPK by SB 203580 had no influence on ajoene-mediated apoptosis. In contrast, inhibition of ERK1/2 vastly enhanced ajoene-induced cell death. The survival kinase Akt, in contrast, did not participate in ajoene-induced death signaling as shown by the use of the phosphatidylinositol-3-kinase inhibitor wortmannin. Thus in contrast to the previous findings regarding stress-induced cell death, ajoene-mediated activation of JNK and p38 has no impact on ajoene-induced apoptosis in HL-60 cells. Blockade of ERK1/2 but not Akt pathways leads to sensitization of cells against ajoene-mediated apoptosis supporting the view that inhibition of ERK1/2 is a valuable strategy to increase the sensitivity of promyeloleukemic cells towards ajoene.	Univ Munich, Ctr Drug Res, Dept Pharm, D-81377 Munich, Germany; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan	University of Munich; National Taiwan University	Dirsch, VM (corresponding author), Univ Munich, Ctr Drug Res, Dept Pharm, Butenandtstr 5-13, D-81377 Munich, Germany.		Kuo, Min-Liang/C-4872-2009	Dirsch, Verena/0000-0002-9261-5293				Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; Bamford M, 2000, EXP CELL RES, V256, P1, DOI 10.1006/excr.2000.4837; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dirsch VM, 2001, CANCER RES, V61, P5817; Dirsch VM, 1998, MOL PHARMACOL, V53, P402, DOI 10.1124/mol.53.3.402; Dirsch VM, 2002, LEUKEMIA, V16, P74, DOI 10.1038/sj.leu.2402337; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hancock JT, 2001, BIOCHEM SOC T, V29, P345, DOI 10.1042/0300-5127:0290345; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Ibrado AM, 1996, CANCER RES, V56, P4743; Jarvis WD, 1999, J PHARMACOL EXP THER, V290, P1384; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Mandlekar S, 2000, CANCER RES, V60, P5995; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Shiah SG, 2001, MOL PHARMACOL, V59, P254, DOI 10.1124/mol.59.2.254; Shiah SG, 1999, CANCER RES, V59, P391; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen A, 1998, CANCER RES, V58, P3163; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	44	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					582	589		10.1038/sj.onc.1206161	http://dx.doi.org/10.1038/sj.onc.1206161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555071				2022-12-17	WOS:000180538200011
J	Heinrichs, S; Deppert, W				Heinrichs, S; Deppert, W			Apoptosis or growth arrest: modulation of the cellular response to p53 by proliferative signals	ONCOGENE			English	Article						p53; p21; apoptosis; growth arrest; lymphoid tumors	NF-KAPPA-B; WILD-TYPE P53; MITOCHONDRIAL PERMEABILITY TRANSITION; KINASE C-THETA; P53-MEDIATED APOPTOSIS; BCL-X; P53-DEPENDENT APOPTOSIS; CALCIUM IONOPHORES; PHORBOL ESTER; CYCLE ARREST	Activation of the tumor suppressor p53 after genotoxic insults may result in two different responses: growth arrest or apoptosis. In this study, we analysed how mitogenic stimulation of primary mouse lymphocytes influences p53 signaling upon gamma-irradiation. We found that Go lymphocytes rapidly went into p53-dependent apoptosis, whereas stimulated lymphocytes went into a p53-dependent, p21-mediated growth arrest. The switch in p53 response upon stimulation did neither result from a switch in transcriptional activation of major p53 target genes, nor from the high level of p21 expressed in stimulated, irradiated cells. Growth stimulation, however, led to the upregulation of the antiapoptotic factors Bcl-x(L) and Bfl-1. In resting cells, p53 induced apoptosis after gamma-irradiation was accompanied by a breakdown of the mitochondrial membrane potential (Psi(m)) that was counteracted by growth stimulation. We propose that growth stimulation intercepted p53 proapoptotic signaling at the level of mitochondrial integrity, most likely by upregulating the antiapoptotic factors Bcl-x(L) and Bfl-1. Upregulation of Bcl-x(L) and of Bfl-1 upon growth stimulation was mediated by the PKC-dependent activation of NF-kappaB. Consequently, blocking PKC activity restored apoptosis in stimulated, irradiated splenocytes. The inherent coupling of growth stimulation with antiapoptotic signaling in primary lymphocytes might provide hints as to how precancerous lymphocytes bypass the need for mutational inactivation of p53. Thus, our findings might explain the relatively low frequency of p53 mutations in lymphomas in comparison to other tumor entities.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BROOME HE, 1995, J IMMUNOL, V155, P2311; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Castedo M, 1996, J IMMUNOL, V157, P512; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; DOSCH HM, 1980, J IMMUNOL, V125, P827; Drexler HG, 2000, LEUKEMIA, V14, P198, DOI 10.1038/sj.leu.2401604; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAWRYLOWICZ CM, 1984, IMMUNOLOGY, V53, P703; Henry H, 2002, ONCOGENE, V21, P748, DOI 10.1038/sj.onc.1205125; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KASTAN MB, 1991, CANCER RES, V51, P6304; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; LI YS, 1989, EUR J IMMUNOL, V19, P1721, DOI 10.1002/eji.1830190929; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NOVOGRODSKY A, 1971, BIOCHIM BIOPHYS ACTA, V228, P579, DOI 10.1016/0005-2787(71)90064-5; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OPPENHEIM JJ, 1976, PROG ALLERGY, V20, P65; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; Tian H, 2000, CANCER RES, V60, P679; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; Tymms M J, 1995, Methods Mol Biol, V37, P31; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WEDNER HJ, 1976, PROG ALLERGY, V20, P195; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	73	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					555	571		10.1038/sj.onc.1206138	http://dx.doi.org/10.1038/sj.onc.1206138			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555069				2022-12-17	WOS:000180538200009
J	Nimmanapalli, R; Bhalla, K				Nimmanapalli, R; Bhalla, K			Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571	ONCOGENE			English	Article						Bcr-Abl protein; tyrosine kinase; imatinib; CML	TYROSINE KINASE INHIBITOR; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; RIBOZYME-MEDIATED CLEAVAGE; DNA-BINDING ACTIVITY; ARSENIC TRIOXIDE; CELL-LINES; IN-VITRO; C-ABL; SELECTIVE-INHIBITION	In the pathophysiology of CML, the constitutive activity of the Ber-Abl tyrosine kinase (TK) is, most likely, the sole molecular abnormality of the chronic phase. It also remains a critical molecular determinant of malignant behavior of the leukemic progenitors in the accelerated and blastic phase of CML. Therefore, downregulation of the levels and activity of Bcr-Abl is clearly the lynchpin of a rational therapeutic strategy against all phases of CML. Support for this has only been strengthened by the observations that resistance to imatinib mesylate (imatinib) commonly involves a breakthrough and the persistent activity of Bcr-Abl TK. This is due to either mutations that inhibit imatinib action on Bcr-Abl TK or amplification of the bcr-abl gene. Recent studies have demonstrated that other small molecule tyrosine kinase inhibitors that also inhibit Bcr-Abl TK may be highly active in inducing differentiation and apoptosis of CML progenitors, regardless of their sensitivity to imatinib. Small molecule inhibitors that downregulate the levels of Bcr - Abl by inhibiting its translation, e.g., arsenic trioxide, or promoting its proteasomal degradation, e.g., geldanamycin analogues, have also been identified. Finally the identification of other potent survival and antiapoptotic signaling pathways in imatinib-resistant CML progenitors indicates that inhibitors of these pathways will eventually be treatment strategies for advanced phases of CML.	Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33620 USA; H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute	Bhalla, K (corresponding author), Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33620 USA.	bhallakn@moffitt.usf.edu		Bhalla, Kapil/0000-0001-5209-5126				AFAR DEH, 1994, COLD SPRING HARB SYM, V59, P589, DOI 10.1101/SQB.1994.059.01.067; An WG, 2000, CELL GROWTH DIFFER, V11, P355; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barthe C, 2001, SCIENCE, V293; Bayever E, 1993, Antisense Res Dev, V3, P383; BEDI A, 1994, BLOOD, V83, P2038; Beran M, 1998, CLIN CANCER RES, V4, P1661; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Blagosklonny MV, 2001, LEUKEMIA, V15, P1537, DOI 10.1038/sj.leu.2402257; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; de Fabritiis P, 1998, BLOOD, V91, P3156, DOI 10.1182/blood.V91.9.3156; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, CANCER RES, V60, P2049; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DeLong RK, 1997, ANTISENSE NUCLEIC A, V7, P71, DOI 10.1089/oli.1.1997.7.71; DHUT S, 1990, LEUKEMIA, V4, P745; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DONATO NJ, 2001, ASH; Dorsey JF, 2000, CANCER RES, V60, P3127; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; EVANS CA, 1993, CANCER RES, V53, P1735; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Gong JG, 1999, NATURE, V399, P806; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; Hochhaus A, 2001, SCIENCE, V293, P2163; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; James HA, 1998, BLOOD, V91, P371, DOI 10.1182/blood.V91.2.371.371_371_382; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; KANO Y, 2001, LEUKEMIA, V15, P772; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; LANGE W, 1994, FEBS LETT, V338, P175, DOI 10.1016/0014-5793(94)80359-5; LANGE W, 1993, LEUKEMIA, V7, P1786; LAROSEE P, 2001, ASH; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Mills K. I., 1996, Blood, V88, p577A; NAKAJIMA A, 2002, P AM ASSOC CANC RES, V43, P4235; Nimmanapalli R, 2001, BLOOD, V98, p618A; Nimmanapalli R, 2001, CLIN CANCER RES, V7, P350; Nimmanapalli R, 2001, CANCER RES, V61, P1799; NIMMANAPALLI R, 2001, P AM ASSOC CANC RES, V42, P4293; Nishii K, 1996, ONCOGENE, V13, P2225; NOWELL PC, 1960, SCIENCE, V132, P1497; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Porosnicu M, 2001, LEUKEMIA, V15, P772, DOI 10.1038/sj.leu.2402104; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, CANCER J SCI AM, V5, P63; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Sawyers CL, 2001, J CLIN ONCOL, V19, p13S; SAWYERS CL, 1991, NEW ENGL J MED, V340, P1330; SHORE SK, 1993, ONCOGENE, V8, P3183; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SKORSKI T, 1991, FOLIA HISTOCHEM CYTO, V29, P85; Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WRIGHT L, 1993, EXP HEMATOL, V21, P1714; Wu YP, 1999, HUM GENE THER, V10, P2847, DOI 10.1089/10430349950016573; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Yu CR, 2002, CANCER RES, V62, P188; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZHANG RW, 1995, CLIN PHARMACOL THER, V58, P44, DOI 10.1016/0009-9236(95)90071-3; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	95	29	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8584	8590		10.1038/sj.onc.1206086	http://dx.doi.org/10.1038/sj.onc.1206086			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476305				2022-12-17	WOS:000179734300008
J	Shore, SK; Tantravahi, RV; Reddy, EP				Shore, SK; Tantravahi, RV; Reddy, EP			Transforming pathways activated by the v-Abl tyrosine kinase	ONCOGENE			English	Article						A-MuLV; tyrosine kinase; transformation; cytokines; apoptosis; signal transduction	MURINE LEUKEMIA-VIRUS; NF-KAPPA-B; C-MYC TRANSCRIPTION; ABELSON-VIRUS; PROTEIN-KINASE; INTERLEUKIN-3 DEPENDENCE; LYMPHOID-CELLS; IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC TRANSFORMATION	The Abelson Murine Leukemia Virus (A-MuLV) is the acute transforming retrovirus encoding the v-abl oncogene. Two isolates of the virus encoding proteins of p120 Kd and 160 Kd have been extensively studied. These viral isolates have been found to transform both hematopoietic and fibroblastic cells in vitro, while inducing predominantly pre-B cell leukemias in vivo. Both p120(v-Abl) and p160(v-Abl) are plasma membrane-associated non-receptor tyrosine kinases and the transforming activity of these proteins requires their tyrosine kinase activity. A-MuLV infection of hematopoietic cells has often been found to result in the abrogation of their cytokine-dependence for growth. In addition, v-Abl expressing hematopoietic cells often lose their ability to differentiate in response to appropriate cytokines. This review discusses some of the early transformation studies of A-MuLV, as well as some of the findings concerning the structure and biochemical activity of the v-Abl protein. Finally, we discuss the mechanisms associated with v-Abl mediated transformation through examination of the various signal transduction pathways activated by this oncogene.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@unix.temple.edu	Reddy, E. Premkumar/F-6233-2011					ABELSON HT, 1970, CANCER RES, V30, P2208; ABELSON HT, 1970, CANCER RES, V30, P2213; Banerjee A, 1998, J IMMUNOL, V161, P4611; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Chen CF, 1999, J COMPUT ACOUST, V7, P15, DOI 10.1142/S0218396X99000035; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Cong F, 1999, MOL CELL BIOL, V19, P8314; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; Coutts M, 2000, ONCOGENE, V19, P801, DOI 10.1038/sj.onc.1203398; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; EVANS CA, 1995, J CELL SCI, V108, P2591; Foo SY, 1999, TRENDS GENET, V15, P229; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREEN PL, 1989, J VIROL, V63, P1989, DOI 10.1128/JVI.63.5.1989-1994.1989; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HORI Y, 1990, ONCOGENE, V5, P1201; Huang TS, 1996, ONCOGENE, V13, P625; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; Jahn T, 2001, J BIOL CHEM, V276, P43419, DOI 10.1074/jbc.M107030200; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KELLER JR, 1990, ONCOGENE, V5, P549; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; LATT SA, 1983, J VIROL, V45, P1195, DOI 10.1128/JVI.45.3.1195-1199.1983; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MOLONEY JB, 1960, J NATL CANCER I, V24, P933; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PREMKUMAR E, 1975, CELL, V6, P149, DOI 10.1016/0092-8674(75)90005-7; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; RABSTEIN LS, 1971, J NATL CANCER I, V46, P481; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RASCHKE WC, 1975, J NATL CANCER I, V54, P1249, DOI 10.1093/jnci/54.5.1249; REDDY E P, 1980, Cell, V19, P663, DOI 10.1016/S0092-8674(80)80043-2; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG N, 1980, COLD SPRING HARB SYM, V44, P859, DOI 10.1101/SQB.1980.044.01.092; ROSENBERG N, 1980, J VIROL, V33, P340, DOI 10.1128/JVI.33.1.340-348.1980; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; ROVERA G, 1987, ONCOGENE, V1, P29; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SAEZ E, 1995, CANCER RES, V55, P6196; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHULTZ A, 1984, VIROLOGY, V133, P431, DOI 10.1016/0042-6822(84)90409-4; SIEGLER R, 1972, J NATL CANCER I, V48, P189; SKLAR MD, 1974, P NATL ACAD SCI USA, V71, P4077, DOI 10.1073/pnas.71.10.4077; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SRINIVASAN A, 1982, P NATL ACAD SCI-BIOL, V79, P5508, DOI 10.1073/pnas.79.18.5508; STACEY DW, 1991, ONCOGENE, V6, P2297; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Thome KC, 1997, J VIROL, V71, P8149, DOI 10.1128/JVI.71.11.8149-8156.1997; Unnikrishnan I, 1999, MOL CELL BIOL, V19, P4825, DOI 10.1128/mcb.19.7.4825; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG JYJ, 1984, CELL, V36, P349; WANG N, 1993, FOCUS, V3, P3; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WITTE ON, 1980, COLD SPRING HARB SYM, V44, P855, DOI 10.1101/SQB.1980.044.01.091; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654; Zou XM, 2000, MOL CELL BIOL, V20, P628, DOI 10.1128/MCB.20.2.628-633.2000	98	29	30	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8568	8576		10.1038/sj.onc.1206084	http://dx.doi.org/10.1038/sj.onc.1206084			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476303	Bronze			2022-12-17	WOS:000179734300006
J	Liu, LT; Chang, HC; Chiang, LC; Hung, WC				Liu, LT; Chang, HC; Chiang, LC; Hung, WC			Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells	ONCOGENE			English	Article						RECK; NSAIDs; lung cancer	MATRIX METALLOPROTEINASES; GENE-EXPRESSION; INHIBITORS; INVASION; ASPIRIN; METASTASIS; TISSUE; COLON	Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to exert anti-angiogenic and anti-metastatic activity both in vitro and in vivo. Block of angiogenesis and metastasis by NSAlDs has been found to be mediated partly via suppression of matrix metalloproteinase (MMP) activity. However, the molecular mechanism of this inhibitory action has not been well defined. Recent works demonstrated that a membrane-anchored MMP inhibitor RECK may potently suppress MMP-2 and -9 activity to inhibit angiogenesis and metastasis in vitro and in vivo. In this study, we test the possibility that NSAlDs may up-regutate RECK to inhibit MMP activity. RT-PCR analyses showed that NS398 and aspirin up-regulated RECK mRNA level in CL-1 human lung cancer cells. Additionally, NSAIDs increased RECK protein level as detected by immuno-blotting. Since RECK is a membrane-anchored glycoprotein, we also performed immunofluorescent staining to assess the expression of RECK on cell surface. Our results showed that fluorescent intensity of RECK was obviously increased after NSAID treatment. Moreover, induction of RECK by NSAlDs was associated with reduction of MMP-2 activity. We also found that NSAID-activated RECK expression might not be mediated via inhibition of cyclo-oxygenases (COXs) because addition of prostaglandin E-2 (PGE(2)) could not counteract the effect of NSAIDs and overexpression of COX-2 could not down-regulate RECK. Taken together, our results suggest that induction of RECK expression may be one of the mechanisms by which NSAlDs suppress MMP activity to block angiogenesis and metastasis.	Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Physiol, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Microbiol, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.		Chiang, Lien-Chai/A-1327-2010	Liu, Li-Teh/0000-0002-7993-7263				Akhmedkhanov A, 2002, BRIT J CANCER, V87, P49, DOI 10.1038/sj.bjc.6600370; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chen JJW, 2001, CANCER RES, V61, P5223; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048; FUTAKI N, 1993, J PHARM PHARMACOL, V45, P753, DOI 10.1111/j.2042-7158.1993.tb07103.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Masferrer JL, 2000, CANCER RES, V60, P1306; MEREDITH TJ, 1992, THERAPEUTIC APPL NSA, P67; NELSON C, 1995, J NATL CANCER I, V87, P567, DOI 10.1093/jnci/87.8.567; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Pan MR, 2001, FEBS LETT, V508, P365, DOI 10.1016/S0014-5793(01)03118-0; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400	23	29	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8347	8350		10.1038/sj.onc.1206017	http://dx.doi.org/10.1038/sj.onc.1206017			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447698				2022-12-17	WOS:000179323900013
J	Yatabe, Y; Osada, H; Tatematsu, Y; Mitsudomi, T; Takahashi, T				Yatabe, Y; Osada, H; Tatematsu, Y; Mitsudomi, T; Takahashi, T			Decreased expression of 14-3-3 sigma in neuroendocrine tumors is independent of origin and malignant potential	ONCOGENE			English	Article						14-3-3 sigma; stratifin; small cell lung cancer; carcinoid; stem cell	CELL LUNG-CANCER; BREAST-CANCER; CARCINOID-TUMORS; P53 MUTATIONS; PROGNOSTIC-SIGNIFICANCE; TRANSGENIC MICE; GENE-MUTATIONS; DNA-DAMAGE; STEM-CELLS; P73 GENE	We recently reported that 14-3-3sigma is frequently inactivated in small cell lung cancer (SCLC) and a part of large cell carcinomas. Subsequent studies revealed that the large cell carcinomas could be morphologically categorized as large cell neuroendocrine carcinomas (LCNEC). The present study therefore examines 14-3-3sigma expression in a spectrum of neuroendocrine lung tumors, which had varied p53 status, proliferative activity and clinical aggressiveness. The expression of 14-3-3sigma was decreased in all four categories of the spectrum, (5 out of 5 typical carcinoids, 2 out of 2 atypical carcinoids, 5 out of 7 LCNECs and 15 out of 18 SCLCs). In sharp contrast, the level of 14-3-3sigma expression in 75 non-small cell lung cancers (NSCLCs) was the same as that in normal lung tissue, with only one exception. The expression status of neuroendocrine tumors and NSCLCs was not affected by p53 status, but dense promoter hypermethylation of the 14-3-3sigma gene was specifically observed in neuroendocrine tumors, suggesting that methylation plays a regulatory role in 14-3-3sigma expression in vivo as well as in vitro. Furthermore, the expression was not only down-regulated in pulmonary neuroendocrine tumors, but also in neuroendocrine tumors arising from various other organs, through examination of 123 non-pulmonary tumors. Since various carcinogenic machineries are involved in the neuroendocrine tumors, a reduced expression of 14-3-3sigma might be required for the development of neuroendocrine tumors. Constitutive 14-3-3sigma expression was distributed exclusively in putative stem cells of the normal lung, namely the basal cells of the bronchus, and type 11 pneumocytes. Notably, 14-3-3sigma expression was up-regulated during the regeneration of type 11 pneumocytes, suggesting that 14-3-3sigma plays a biological role when a regenerative and/or differentiating drive is activated, facilitating exit from stem cells.	Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Yatabe, Y (corresponding author), Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Anbazhagan R, 1999, CANCER RES, V59, P5119; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Boers JE, 1998, AM J RESP CRIT CARE, V157, P2000, DOI 10.1164/ajrccm.157.6.9707011; Brambilla E, 1996, AM J PATHOL, V149, P1941; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; COLBY TV, 1995, TUMORS LOWER RESP TR; Corn PG, 1999, CANCER RES, V59, P3352; Debelenko LV, 2000, GENE CHROMOSOME CANC, V28, P58, DOI 10.1002/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2; Debelenko LV, 1997, GASTROENTEROLOGY, V113, P773, DOI 10.1016/S0016-5085(97)70171-9; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; DELLAMBRA E, 1995, J CELL SCI, V108, P3569; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Dosaka-Akita H, 2000, CANCER, V88, P550, DOI 10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D; Endl E, 2001, J PATHOL, V195, P457, DOI 10.1002/path.978; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Galanis E, 1997, CANCER-AM CANCER SOC, V79, P1729, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1729::AID-CNCR14>3.0.CO;2-#; GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Gruvberger S, 2001, CANCER RES, V61, P5979; Haruki N, 2000, JPN J CANCER RES, V91, P317, DOI 10.1111/j.1349-7006.2000.tb00947.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hida T, 1998, CANCER RES, V58, P3761; Hoos A, 2001, LAB INVEST, V81, P1331, DOI 10.1038/labinvest.3780347; HORIO Y, 1993, CANCER RES, V53, P1; IBRAHIM NBN, 1984, CANCER-AM CANCER SOC, V54, P1645, DOI 10.1002/1097-0142(19841015)54:8<1645::AID-CNCR2820540828>3.0.CO;2-Q; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Konishi H, 2002, CANCER RES, V62, P271; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; LOHMANN DR, 1993, CANCER RES, V53, P5797; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MILLER CW, 1992, CANCER RES, V52, P1695; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURREN J, 2001, CANC PRINCIPLES PRAC, P1010; Nishio M, 1997, CLIN CANCER RES, V3, P1051; Nomoto S, 1998, CANCER RES, V58, P1380; Onuki N, 1999, CANCER, V85, P600, DOI 10.1002/(SICI)1097-0142(19990201)85:3<600::AID-CNCR10>3.0.CO;2-W; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Ostergaard M, 1997, CANCER RES, V57, P4111; Padberg BC, 1996, AM J SURG PATHOL, V20, P815, DOI 10.1097/00000478-199607000-00004; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Przygodzki RM, 1996, AM J PATHOL, V148, P1531; Ramnani DM, 1999, MODERN PATHOL, V12, P443; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sampietro G, 2000, APPL IMMUNOHISTO M M, V8, P49, DOI 10.1097/00022744-200003000-00008; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sturm N, 2002, HUM PATHOL, V33, P175, DOI 10.1053/hupa.2002.31299; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; Travis W, 1999, HISTOLOGICAL TYPING, P7; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; VERHAGEN APM, 1992, CANCER RES, V52, P6182; WILLIAMS ED, 1963, LANCET, V1, P238; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998; Yatabe Y, 1998, CANCER RES, V58, P1042; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	70	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8310	8319		10.1038/sj.onc.1206014	http://dx.doi.org/10.1038/sj.onc.1206014			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447694				2022-12-17	WOS:000179323900009
J	Cummings, KM				Cummings, KM			Programs and policies to discourage the use of tobacco products	ONCOGENE			English	Review						tobacco control; smoking cessation; prevention; nicotine dependence	SMOKING-CESSATION; HEALTH WARNINGS; MEDIA COVERAGE; LOW TAR; CIGARETTE; ADOLESCENTS; MORTALITY; NICOTINE; SMOKERS; CAMPAIGN	The past 50 years has witnessed a dramatic change in attitudes toward and use of tobacco by Americans that has resulted in recent declines in the incidence of lung cancer. Most public health scholars believe that this change has been accelerated by public policy interventions to reduce tobacco use. The research literature suggests that the most potent demand reducing influences on tobacco use have been efforts to increase the financial cost of using tobacco products primarily through taxation, smoke-free policies, comprehensive advertising bans, and paid counter-advertising campaigns. New therapies for treating nicotine dependence and measures to liberalize access to medicinal forms of nicotine have the potential to revolutionize the way societies address the problem of tobacco use in the future. Unfortunately, the economic reality of the tobacco business has hindered public health efforts to curb the use of tobacco products. While government regulation of tobacco products is a worthy goal, capitalism, and not government regulation, most likely holds the greatest potential to rapidly alter the worldwide epidemic of tobacco caused disease. It is up to the public health community to harness the powers of capitalism to speed the development of less dangerous alternatives to the conventional cigarette.	Roswell Pk Canc Inst, Dept Canc Prevent Epidemiol & Biostat, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Cummings, KM (corresponding author), Roswell Pk Canc Inst, Dept Canc Prevent Epidemiol & Biostat, Elm & Carlton St, Buffalo, NY 14263 USA.	Michael.Cummings@Roswellpark.org			NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056-26] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1981, FED TRAD COMM STAFF; Ayanian JZ, 1999, JAMA-J AM MED ASSOC, V281, P1019, DOI 10.1001/jama.281.11.1019; Bates C, 1999, TOB CONTROL, V8, P225, DOI 10.1136/tc.8.2.225; BLUM A, 1993, TOBACCO USE AM CRISI, P63; Bondurant, 2001, CLEARING SMOKE ASSES; Borland R, 1997, ADDICTION, V92, P1427; Borland R, 1997, Tob Control, V6, P317; BRANDT AM, 1990, DAEDALUS-US, V119, P155; *BROWN WILL TOB CO, 2000, NEW YORK SEN BILL FI; Cecil H, 1996, J APPL SOC PSYCHOL, V26, P502, DOI 10.1111/j.1559-1816.1996.tb02728.x; CHALOUPKA FJ, 2001, TABACCO CONTROL DEV, P237; CHALOUPKA FJ, 2002, TOBACCO CONTROL S1, V11, P62; CONNOLLY GN, 1992, MONOGR NCI, V12, P29; CUMMINGS K, 2002, IN PRESS NICOTINE TO; Cummings KM, 2002, TOB CONTROL, V11, pI110, DOI 10.1136/tc.11.suppl_1.i110; CUMMINGS KM, 2002, IN PRESS ADDICTION; CUMMINGS KM, 2002, TOBACCO CONTROL S1, V11, P5; CUNNINGHAM R, 2002, EVALUATION NEW WARNI; Curry SJ, 1998, NEW ENGL J MED, V339, P673, DOI 10.1056/NEJM199809033391006; DAVIS RM, 1989, JAMA-J AM MED ASSOC, V261, P90, DOI 10.1001/jama.261.1.90; Daynard R., 1994, TOB CONTROL, V3, P59; Daynard RA, 2001, AM J PUBLIC HEALTH, V91, P1967, DOI 10.2105/AJPH.91.12.1967; Dunn W.L., 1972, MOTIVES INCENTIVES C; *EC CONS FIRM ORZ, 2000, TAX BURD TAB HIST CO, V35; Emont SL., 1993, TOB CONTROL, V2, P13, DOI [10.1136/tc.2.1.13, DOI 10.1136/TC.2.1.13]; Evans WN, 1999, AM ECON REV, V89, P728, DOI 10.1257/aer.89.4.728; *FED COMM COMM, 1987, FED COMM COMM REC, V2, P5272; *FED TRAD COMM, 1981, REP TAR NIC CARB MON; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; FIORE MC, 2000, TREATING TOBACCO USE; FISCHER PM, 1989, JAMA-J AM MED ASSOC, V261, P84, DOI 10.1001/jama.261.1.84; Fischer PM, 1993, TOB CONTROL, V2, P279, DOI DOI 10.1136/TC.2.4.279; GAJALAKSHMI GK, 2000, TOBACCO CONTROL DEV, P11; HAMILTON JL, 1972, REV ECON STAT, V54, P401, DOI 10.2307/1924567; HARRIS JE, 1997, MMWR-MORBID MORTAL W, V45, P960; Healton C, 2001, AM J PUBLIC HEALTH, V91, P554, DOI 10.2105/AJPH.91.4.554; HEATH AC, 1993, ADDICT BEHAV, V18, P19, DOI 10.1016/0306-4603(93)90005-T; Henningfield J. E., 1993, NICOTINE ADDICTION P, P24; Hieda Y, 1999, PSYCHOPHARMACOLOGY, V143, P150, DOI 10.1007/s002130050930; HO R, 1992, AUST PSYCHOL, V27, P109, DOI 10.1080/00050069208257590; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; Hughes JR, 1999, TOB CONTROL, V8, P323, DOI 10.1136/tc.8.3.323; *I MED, 1994, GROW TOB FREE; JHA P, 2000, TOBACCO CONTROL DEV, P449; Kennedy GE, 1999, TOB CONTROL, V8, P254, DOI 10.1136/tc.8.3.254; Kessler DA, 1996, NEW ENGL J MED, V335, P988, DOI 10.1056/NEJM199609263351321; Kessler David A., 1994, TOB CONTROL, V3, P150, DOI DOI 10.1136/TC.3.2.148; King C, 2001, NEW ENGL J MED, V345, P504, DOI 10.1056/NEJMsa003149; Kluger R, 1996, ASHES ASHES AM 100 Y; KOPSTEIN A, 2001, DHHS PUBLICATION; Kozlowski LT, 2001, TOB CONTROL, V10, P201, DOI 10.1136/tc.10.3.201; Leavell NR, 1999, TOB CONTROL, V8, P433, DOI 10.1136/tc.8.4.433; LINTHWAITE P, 1985, HLTH ED J, V44, P218, DOI DOI 10.1177/001789698504400419; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; Mahood G, 1999, TOB CONTROL, V8, P356, DOI 10.1136/tc.8.4.356; MALOUFF J, 1992, J PSYCHOL, V126, P371, DOI 10.1080/00223980.1992.10543370; MITCHELL B, 1999, REV DOCUMENTS TOBACC; *NAT CANC I, 1996, MONOGRAPH US DHHS NA, V7; *NAT CANC I, 1993, NIH PUBLICATION US D; Niu SR, 1998, BRIT MED J, V317, P1423, DOI 10.1136/bmj.317.7170.1423; NOVOTNY TE, 2001, TOBACCO CONTROL DEV, P287; OKEEFE MT, 1971, PUBLIC OPIN QUART, V35, P242, DOI 10.1086/267896; PARKINSON MD, 1992, TOBACCO CONTROL S, V1, pS52; Pierce JP, 2001, TOB CONTROL, V10, P145, DOI 10.1136/tc.10.2.145; PIERCE JP, 1998, JAMA-J AM MED ASSOC, V80, P893; Pollay R, 1994, TOB CONTROL, V3, P130; Pollay R. W., 1994, TOB CONTROL, V3, P134; Pollay RW, 2000, TOB CONTROL, V9, P136, DOI 10.1136/tc.9.2.136; Pollay RW, 2002, TOB CONTROL, V11, pI18, DOI 10.1136/tc.11.suppl_1.i18; POLLAY RW, 1997, PUBLIC RELAT REV, V16, P27; Proctor R., 1999, NAZI WAR CANC, p[173, 226]; RABIN RL, 1993, SMOKING POLICY LAW P; Rigotti NA, 1997, NEW ENGL J MED, V337, P1044, DOI 10.1056/NEJM199710093371505; Robinson TN, 1997, ARCH PEDIAT ADOL MED, V151, P267, DOI 10.1001/archpedi.1997.02170400053010; Saffer H., 2000, TOBACCO CONTROL POLI, P215; Schauffler HH, 2001, TOB CONTROL, V10, P175, DOI 10.1136/tc.10.2.175; SCHAUFFLER HH, 1993, SMOKING POLICY LAW P, P184; Shiffman S, 1997, Tob Control, V6, P306; Shiffman S, 2001, TOB CONTROL, V10, pI17; Siegel M, 2000, AM J PUBLIC HEALTH, V90, P380, DOI 10.2105/AJPH.90.3.380; Simonich WL, 1991, GOVT ANTISMOKING POL; SLADE J, 1993, NICOTINE ADDICTION P; Slovic P., 2001, SMOKING RISK PERCEPT, DOI 10.4135/9781452232652; Strahan EJ, 1999, ENHANCING EFFECTIVEN; SWAIN PA, 1996, Patent No. 5876727; Sweanor D, 2000, ADDICTION, V95, pS25; THOMPSON S, 2002, STOP MAGAZINE, V9, P26; U.S. Department of Health and Human Services, 2000, RED TOB US REP SURG; *US DHHS, 1989, DHHS PUBL CDC CTR CH; *US DHHS, 1986, DHHS PUBL CDC CTR HL; *US DHHS, 1994, PREV TOB US AM YOUNG; *US EPS, 1992, 600690006F EPA OFF H; WAGNER S, 1971, FED TRAD COMM; WAKEFIELD MA, 2002, IN PRESS AM J PUB HL; Warner KE, 1997, JAMA-J AM MED ASSOC, V278, P1087, DOI 10.1001/jama.278.13.1087; WARNER KE, 1992, AM J PUBLIC HEALTH, V82, P17, DOI 10.2105/AJPH.82.1.17; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144; WARNER KE, 1986, SELLING SMOKING CIGA; WASSERMAN J, 1991, J HEALTH ECON, V10, P43, DOI 10.1016/0167-6296(91)90016-G; Wayne GF, 2002, TOB CONTROL, V11, pI32, DOI 10.1136/tc.11.suppl_1.i32; Westman E C, 2001, Nicotine Tob Res, V3, P391, DOI 10.1080/14622200126973; Wilkenfeld J, 2000, JNCI-J NATL CANCER I, V92, P90, DOI 10.1093/jnci/92.2.90; Wilson C, 2001, NEW SCI, V172, P28; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; [No title captured]; 1967, FED REG, V29, P530; 1969, FED REG, V34, P7917	107	29	29	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7349	7364		10.1038/sj.onc.1205810	http://dx.doi.org/10.1038/sj.onc.1205810			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379878				2022-12-17	WOS:000178618000008
J	Archey, WB; McEachern, KA; Robson, M; Offit, K; Vaziri, SAJ; Casey, G; Borg, A; Arrick, BA				Archey, WB; McEachern, KA; Robson, M; Offit, K; Vaziri, SAJ; Casey, G; Borg, A; Arrick, BA			Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers	ONCOGENE			English	Article						BRCA1; estrogen receptor; methylation; breast cancer	SPORADIC BREAST; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; DNA METHYLATION; BRCA1; CARCINOMAS; EXPRESSION; TUMORS; PROMOTER; MUTATIONS	A distinctive feature of BRCA1-linked breast cancers is that they typically do not express estrogen receptor-alpha (ERalpha). Previous investigation suggests that methylation of CpGs within the ERa promoter mediates repression of gene expression in some ERalpha-negative breast cancers. To determine if methylation of CpGs within the ERalpha promoter is associated with BRCA1-linked breast cancers, we evaluated methylation in exon 1 of the ERalpha gene in 40 ERalpha-negative breast cancers, 20 of which were non BRCA1-linked and 20 BRCA1-linked. CpG methylation was evaluated by either methylation-sensitive restriction digest (HpaII), methylation-sensitive PCR (MSP), or direct sequencing of bisulfite-treated genomic DNA. Results from HpaII digests and MSP documented a high degree of methylation, the MSP data showing slightly higher methylation in the BRCA1-linked group. CpGs analysed by direct sequencing showed an overall average methylation of 25% among non BRCA1-linked cancers and 40% among BRCA1-linked cancers (P=0.0031). The most notable difference was found at five particular CpGs, each of which exhibited a greater than twofold increase in methylation in the BRCA1-linked group compared to the non BRCA1-linked group (P < 0.03 for each CpG). Methylation of certain critical CpGs may represent an important factor in transcriptional repression of the ERa gene in BRCA1-linked breast cancers.	Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden	Dartmouth College; Dartmouth College; Dartmouth College; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cleveland Clinic Foundation; Lund University; Skane University Hospital	Arrick, BA (corresponding author), Dartmouth Coll Sch Med, Dept Med, Kellogg Box 0128, Hanover, NH 03755 USA.			Robson, Mark/0000-0002-3109-1692	NATIONAL CANCER INSTITUTE [R01CA077772] Funding Source: NIH RePORTER; NCI NIH HHS [CA77772] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Archey WB, 1999, CANCER RES, V59, P2292; BARRETTLEE PJ, 1987, CANCER RES, V47, P6653; Berns EMJJ, 2001, BRIT J CANCER, V85, P538, DOI 10.1054/bjoc.2001.1937; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; FERGUSON AT, 1995, CANCER RES, V55, P2279; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y; Lapidus RG, 1998, CANCER RES, V58, P2515; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Loman N, 1998, CANCER, V83, P310, DOI 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Penolazzi L, 2000, BBA-GENE STRUCT EXPR, V1492, P560, DOI 10.1016/S0167-4781(00)00145-7; PIVA R, 1990, BRIT J CANCER, V61, P270, DOI 10.1038/bjc.1990.50; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; Tomlinson GE, 1998, CANCER RES, V58, P3237; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vaziri SAJ, 2001, CLIN CANCER RES, V7, P1937; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; YAICH L, 1992, CANCER RES, V52, P77; Yang XW, 2000, CANCER RES, V60, P6890; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	34	29	32	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7034	7041		10.1038/sj.onc.1205844	http://dx.doi.org/10.1038/sj.onc.1205844			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370825				2022-12-17	WOS:000178424900006
J	Hoogeveen, AT; Rossetti, S; Stoyanova, V; Schonkeren, J; Fenaroli, A; Schiaffonati, L; van Unen, L; Sacchi, N				Hoogeveen, AT; Rossetti, S; Stoyanova, V; Schonkeren, J; Fenaroli, A; Schiaffonati, L; van Unen, L; Sacchi, N			The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16;21)-positive myeloid malignancies	ONCOGENE			English	Article						MTG16; t (16;21)-positive myeloid malignancies; chromosome translocation; nucleolus; transcriptional co-repressor; histone deacetylases	HIV-1 REGULATORY PROTEINS; T(8-21) FUSION PROTEIN; SUBCELLULAR-LOCALIZATION; REPRESSES TRANSCRIPTION; ACUTE-LEUKEMIA; GENE; ETO; FAMILY; NUCLEAR; MEMBER	The MTG (Myeloid Translocation Gene) proteins are a family of novel transcriptional corepressors. We report that MTG16a, a protein isoform encoded by the MTG16 gene deranged by the t (16; 21) in myeloid malignancies, is targeted to the nucleolus. The amino acid sequence necessary for nucleolar localization was mapped to the MTG16a N-terminal region. MTG16a, like MTG8, the nuclear corepressor deranged by the t (8; 21), is capable to interact with specific histone deacetylases (HDACs) suggesting that the protein may mediate silencing of nucleolar gene transcription. In addition, MTG16a is capable to form oligomers with other MTG proteins. As a consequence of the t (16; 21) the AML1 DNA-binding domain replaces the MTG16a N-terminal region. The AML1-MTG16 fusion protein is targeted to the nucleoplasm where it is capable to oligomerize with MTG16a and interact with HDAC1 and HDAC3. The deficiency of HDAC-containing complexes at nucleolar sites and the accumulation of HDAC-containing complexes at AML1-sites may be critical in the pathogenesis of t (16; 21) myeloid malignancies.	Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Brescia, Dept Biomed Sci & Biotechnol, Brescia, Italy; Univ Milan, San Paolo Univ Hosp, Milan, Italy; Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Erasmus University Rotterdam; University of Brescia; University of Milan; Johns Hopkins University; Johns Hopkins Medicine	Hoogeveen, AT (corresponding author), Erasmus Univ, Dept Clin Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.							Akhmanova A, 2000, J CELL SCI, V113, P4463; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; ANASTASSOVAKRISTEVA M, 1977, J CELL SCI, V25, P103; ASOU H, 1991, BLOOD, V77, P2031; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERICKSON P, 1992, BLOOD, V80, P1825; Evert BO, 1999, HUM MOL GENET, V8, P1169, DOI 10.1093/hmg/8.7.1169; FEINSTEIN PG, 1995, GENETICS, V140, P573; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; McCLINTOCK BARBARA, 1934, ZEITSCHR ZELLJORSCH U MIKROSK ANAT, V21, P294, DOI 10.1007/BF00374060; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Pikaard CS, 2000, TRENDS GENET, V16, P495, DOI 10.1016/S0168-9525(00)02113-2; Sacchi N, 1996, ONCOGENE, V12, P437; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Shimada H, 2000, BLOOD, V96, P655; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Sullivan GJ, 2001, EMBO J, V20, P2867, DOI 10.1093/emboj/20.11.2867; Tamanini F, 2000, HUM MOL GENET, V9, P1487, DOI 10.1093/hmg/9.10.1487; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	38	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6703	6712		10.1038/sj.onc.1205882	http://dx.doi.org/10.1038/sj.onc.1205882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242670				2022-12-17	WOS:000178202300018
J	Takino, T; Yoshioka, K; Miyamori, H; Yamada, KM; Sato, H				Takino, T; Yoshioka, K; Miyamori, H; Yamada, KM; Sato, H			A scaffold protein in the c-Jun N-terminal kinase signaling pathway is associated with focal adhesion kinase and tyrosine-phosphorylated	ONCOGENE			English	Article						FAK; JSAP1; Src; tyrosine phosphorylation	PROMOTED CELL-MIGRATION; SRC FAMILY KINASES; NH2-TERMINAL KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; V-SRC; P130(CAS); FIBRONECTIN; ACTIVATION; AUTOPHOSPHORYLATION; INVOLVEMENT	Focal adhesion kinase (FAK) becomes activated and tyrosine-phosphorylated in response to cell adhesion to extracellular matrix proteins in a variety of cell types, and associates with a number of signaling molecules, structural proteins, and beta integrin cytoplasmic domains. Here we demonstrated that c-Jun N-terminal kinase (JNK)/stress activated protein kinase-associated protein 1 (JSAP1), a scaffold factor in the mitogen-activated protein kinase (MAPK) cascades, forms a complex with the N-terminus of FAK. The complex formation was further stimulated by c-Src, in which JSAP1 was tyrosine-phosphorylated and other FAK/Src signaling molecules were recruited. Fibronectin (FN) stimulation of cells expressing JSAP1 induced its tyrosine phosphorylation concomitant with association with FAK. Expression of JSAP1 in Hela cells facilitated formation of well-organized focal contacts and actin stress fibers, and promoted cell spreading onto FN. Taken together, these results suggest that JSAP1 is involved an integrin-mediated signaling pathway through FAK/Src by recruiting other signaling molecules, resulting in promotion of cell spreading onto FN.	Kanazawa Univ, Canc Res Inst, Div Mol Virol & Oncol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Kanazawa University; Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Takino, T (corresponding author), Kanazawa Univ, Canc Res Inst, Div Mol Virol & Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		SATO, Hiroshi/D-8454-2015; TAKINO, Takahisa/D-8460-2015	Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000524, ZIADE000525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Ito M, 1999, MOL CELL BIOL, V19, P7539; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	28	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6488	6497		10.1038/sj.onc.1205840	http://dx.doi.org/10.1038/sj.onc.1205840			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226752	Green Submitted			2022-12-17	WOS:000177925300009
J	Aldaz, CM; Hu, YH; Daniel, R; Gaddis, S; Kittrell, F; Medina, D				Aldaz, CM; Hu, YH; Daniel, R; Gaddis, S; Kittrell, F; Medina, D			Serial analysis of gene expression in normal p53 null mammary epithelium	ONCOGENE			English	Article						SAGE; p53; mammary gland; breast cancer; gene expression; preneoplasia	TUMOR-SUPPRESSOR GENE; BREAST-CANCER; C-MYC; CELLS; GELSOLIN; MODEL; ADRENOMEDULLIN; INSTABILITY; APOPTOSIS; MECHANISM	Much evidence has accumulated implicating the p53 gene as of importance in breast carcinogenesis. However, much still remains to be uncovered on the specific downstream pathways influenced by this important activator/repressor of transcription. This study investigated the effects of a p53 null genotype on the transcriptome of 'normal' mouse mammary epithelium using a unique in vivo model of preneoplastic transformation. We used SAGE for the comparative analysis of p53 wild type (wt) and null mammary epithelium unexposed and exposed to hormonal stimulation. Analysis of the hormone exposed samples provided a comprehensive view of the dramatic changes in gene expression as consequence of the functional differentiation of the mammary epithelium in an in vivo system. We detected the dysregulation in p53(null) epithelium of <1% of the transcriptome. Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes. The dysregulation of specific genes and their potential use as preneoplastic markers was further validated using an independent model of premalignant mammary outgrowth lines. This is the first study to examine the transcriptome of very early stages of preneoplastic progression in an in vivo model that mimics human breast cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Aldaz, CM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, POB 389,PK Rd 1-C, Smithville, TX 78957 USA.		Aldaz, C. Marcelo/E-7868-2011	Aldaz, C. Marcelo/0000-0002-2453-2939	NCI NIH HHS [CA84243] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asch HL, 1996, CANCER RES, V56, P4841; Charpentier AH, 2000, CANCER RES, V60, P5977; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; DEAR TN, 1988, CANCER RES, V48, P5203; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Griffioen M, 1998, MOL IMMUNOL, V35, P829, DOI 10.1016/S0161-5890(98)00074-1; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; KLEIN B, 1991, CANCER, V67, P2295, DOI 10.1002/1097-0142(19910501)67:9<2295::AID-CNCR2820670915>3.0.CO;2-T; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Lal A, 1999, CANCER RES, V59, P5403; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MORRISON BW, 1994, ONCOGENE, V9, P3417; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Williams JA, 2000, CANCER RES, V60, P4667; Winston JS, 2001, BREAST CANCER RES TR, V65, P11, DOI 10.1023/A:1006446108411; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhao RB, 2000, GENE DEV, V14, P981; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	28	29	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6366	6376		10.1038/sj.onc.1205816	http://dx.doi.org/10.1038/sj.onc.1205816			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214277				2022-12-17	WOS:000177829000013
J	Claes, K; Vandesompele, J; Poppe, B; Dahan, K; Coene, I; De Paepe, A; Messiaen, L				Claes, K; Vandesompele, J; Poppe, B; Dahan, K; Coene, I; De Paepe, A; Messiaen, L			Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5 ' end of the BRCA1 gene	ONCOGENE			English	Article						BRCA1; splice mutation; real time RT-PCR; breast cancer	OVARIAN-CANCER; MESSENGER-RNA; BREAST; IDENTIFICATION; EXPRESSION	We report two novel mutations in the splice sites of BRCA1 exon 5: IVS5+3A>G, a Belgian founder mutation, and IVS3-6T>G, identified in one family with a strong family history of breast cancer. Real-time RT-PCR showed that IVS3-6T>G leads to a fivefold increase of the BRCA1-Deltaex5 (isoform with an in frame skip of exon 5) ratio to the total BRCA1 expression level. lVS5+3A>G results in a 10-fold increase of the BRCA1-Delta22ntex5 ratio (isoform with an out of frame skip of the last 22 nucleotides of exon 5) and a twofold increase of the BRCA1-Deltaex5 ratio. These altered ratios are most likely to result from increased expression of the alternative transcripts, although we cannot completely rule out a small decrease of the total BRCA1 expression level due to highly variable BRCA1 levels in cultured cell lines. In order to explore the functional significance of the isoforms, we evaluated their prevalence in normal tissues and cancer cell lines. The BRCA1-Delta22ntex5 ratio was significantly higher in an ovarian cancer cell line compared to normal ovarian tissue. Our findings suggest that revealing the defects caused by some splice mutations requires accurate quantitative methods. We hypothesize that disruption of alternative transcript ratios of BRCA1 may be a dominant mechanism affecting predisposition to hereditary breast and/or ovarian cancer.	Ghent Univ Hosp, Dept Med Genet, Ctr Genet Med, B-9000 Ghent, Belgium; Clin Univ St Luc, Ctr Genet Humaine, B-1200 Brussels, Belgium	Ghent University; Ghent University Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Messiaen, L (corresponding author), Ghent Univ Hosp, Dept Med Genet, Ctr Genet Med, OK5,Pintelaan 185, B-9000 Ghent, Belgium.	Ludwine.Messiaen@rug.ac.bc	Vandesompele, Jo/W-3411-2018; Claes, Kathleen/AFR-6830-2022	Vandesompele, Jo/0000-0001-6274-0184; Claes, Kathleen/0000-0003-0841-7372				ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Claes K, 1999, DIS MARKERS, V15, P69, DOI 10.1155/1999/241046; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ohno K, 1999, AM J HUM GENET, V65, P635, DOI 10.1086/302551; Pummi K, 2000, ARCH DERMATOL RES, V292, P422, DOI 10.1007/s004030000155; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vandenbroucke I I, 2001, Nucleic Acids Res, V29, pE68, DOI 10.1093/nar/29.13.e68; VANDESOMPELE, 2002, IN PRESS; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	23	29	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4171	4175		10.1038/sj.onc.1205520	http://dx.doi.org/10.1038/sj.onc.1205520			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037674				2022-12-17	WOS:000176186000012
J	Wu, WS; Xu, ZX; Ran, RX; Meng, F; Chang, KS				Wu, WS; Xu, ZX; Ran, RX; Meng, F; Chang, KS			Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions	ONCOGENE			English	Article						PML; Nur77; transcriptional regulation; apoptosis	CREB BINDING-PROTEIN; RAR-ALPHA; ORPHAN RECEPTOR; GROWTH-FACTORS; NGFI-B; NUCLEAR; GENE; APOPTOSIS; NUR77; TRANSFORMATION	The promyelocytic leukemia protein PML is a tumor and growth suppressor and plays an important role in a multiple pathways of apoptosis and regulation of cell cycle progression. Our previous studies and others also documented a role of PML in transcriptional regulation through its association with transcription coactivator CBP and transcription corepressor HDAC. Here, we showed that PML is a potent transcriptional repressor of Nur77, an orphan receptor and a member of the steroid receptor superfamily of proteins. We found that PML represses Nur77-mediated transactivation through a physical and functional interaction between the two proteins. PML interacts with Nur-77 in vitro in a GST-pull down assay and in vivo by coimmunoprecipitation assay. PML/Nur77 colocalized in vivo in a double immunofluorescent staining and confocal microscopic analysis. Our study further showed that the coiled-coil domain of PML interacts with the DNA-binding domain of Nur77 (amino acids 267-332). Electrophoretic mobility shift assay demonstrated that PML interferes with Nur77 DNA binding in a dose-dependent manner. This study indicates that PML interacts with the DNA-binding domain of Nur77 and represses transcription by preventing it from binding to the target promoter. This study supports a role of PML/Nur77 interaction in regulating cell growth and apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Chang, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	kchang@mail.mdanderson.org	Wu, Wen-Shu/I-1258-2014	Wu, Wen-Shu/0000-0002-0225-2522	NCI NIH HHS [CA-11627, CA-55577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055577, R01CA011627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amsen D, 1999, P NATL ACAD SCI USA, V96, P622, DOI 10.1073/pnas.96.2.622; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; CALNAN BJ, 1995, IMMUNITY, V3, P273; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Duprez E, 1999, J CELL SCI, V112, P381; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VALLIAN S, 1998, ONCOGENE, V90, P3265; Wang ZG, 1998, SCIENCE, V279, P1547; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	48	29	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3925	3933		10.1038/sj.onc.1205491	http://dx.doi.org/10.1038/sj.onc.1205491			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032831				2022-12-17	WOS:000175847200012
J	Dell'Era, P; Coco, L; Ronca, R; Sennino, B; Presta, M				Dell'Era, P; Coco, L; Ronca, R; Sennino, B; Presta, M			Gene expression profile in fibroblast growth factor 2-transformed endothelial cells	ONCOGENE			English	Article						angiogenesis; endothelium; FGF; gene expression; vascular tumor	INHIBITORY FACTOR MIF; AUTOCRINE MECHANISM; PROTEIN; ANGIOGENESIS; IDENTIFICATION; HYPOXIA; ID3; TRANSCRIPTION; INDUCTION; RECEPTOR	Fibroblast growth factor-2 (FGF2) exerts paracrine and autocrine functions on endothelial cells. FGF2-overexpressing murine aortic endothelial cells (FGF2-T-MAE cells) induce opportunistic hemangioendothelioma-like tumors when inoculated in immunodeficient mice. To evaluate the impact of FGF2-mediated activation on gene expression profile in transformed endothelial cells, we performed subtractive suppression hybridization analysis between FGF2-T-MAE cells and parental MAE cells. The two cell populations were compared for differential gene expression also by gene macroarray hybridization with P-32-labeled cDNAs. The two approaches allowed the identification of 27 transcripts whose expression was upregulated by FGF2 in endothelial cells. With the exception of one unknown gene, the differentially expressed transcripts encoded for proteins involved in the modulation of cell cycle, differentiation, and cell adhesion. Among them, the stress-inducible genes A170, GADD45 and GADD153 are upregulated by FGF2 transfection or recombinant growth factor treatment. Their expression was also induced in vascular tumors originated by parental or FGF2-transfected MAE cells in nude mice. This study extends the number of genes involved in tumor angiogenesis and/or endothelial cell transformation, a finding with possible implications for the discovery of novel targets for angiostatic therapy.	Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy	University of Brescia	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy.	presta@med.unibs.it	Dell'Era, Patrizia/G-5294-2010; Presta, Marco/B-4345-2010; Dell'Era, Patrizia/ABD-5848-2020; Dell'Era, Patrizia/N-6964-2019	Dell'Era, Patrizia/0000-0001-6682-6321; PRESTA, Marco/0000-0002-4398-8376; RONCA, Roberto/0000-0001-8979-7068				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; CAREY I, 1995, CELL GROWTH DIFFER, V6, P899; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; Chen BB, 1997, NUCLEIC ACIDS RES, V25, P423, DOI 10.1093/nar/25.2.423; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P579; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432-1327.2000.01325.x; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hong NA, 2000, DEV BIOL, V220, P76, DOI 10.1006/dbio.2000.9615; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kroon ME, 2001, THROMB HAEMOSTASIS, V85, P296, DOI 10.1055/s-0037-1615683; KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Liekens S, 2001, CANCER RES, V61, P5057; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Nishihira J, 2000, J INTERF CYTOK RES, V20, P751, DOI 10.1089/10799900050151012; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; Orre RS, 2001, J BIOL CHEM, V276, P1794, DOI 10.1074/jbc.M008560200; Ribatti D, 1999, J PATHOL, V189, P590; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Roland I, 2000, EUR J BIOCHEM, V267, P3567, DOI 10.1046/j.1432-1327.2000.01385.x; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; St Croix B, 2000, SCIENCE, V289, P1197; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vasile E, 2001, FASEB J, V15, P458, DOI 10.1096/fj.00-0051com; Wang JL, 2000, MICROVASC RES, V59, P394, DOI 10.1006/mvre.2000.2242; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; Yanagawa T, 1997, BIOCHEM BIOPH RES CO, V241, P157, DOI 10.1006/bbrc.1997.7783; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	47	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2433	2440		10.1038/sj.onc.1205301	http://dx.doi.org/10.1038/sj.onc.1205301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948428				2022-12-17	WOS:000174635600017
J	Theodosiou, A; Ashworth, A				Theodosiou, A; Ashworth, A			Differential effects of stress stimuli on a JNK-inactivating phosphatase	ONCOGENE			English	Article						JNK; phosphatase; tumour promotion; degradation	DUAL-SPECIFICITY PHOSPHATASES; MAP KINASE PHOSPHATASE; N-TERMINAL KINASE; C-JUN; SIGNAL-TRANSDUCTION; CATALYTIC ACTIVATION; GENE FAMILY; DELTA; INHIBITOR; PATHWAY	Stress signals elicit a wide variety of cellular responses, many of which converge on the phosphorylation of JNK and p38 kinases, the activation of which has been well-characterized. How these kinases are switched off by dephosphorylation is not well understood. Here we describe how diverse cellular stresses affect differently the stability and activity of a JNK-inactivating dual-specificity threonine-tyrosine phosphatase M3/6. Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase. However, while anisomycin treatment of cells leads to M3/6 protein degradation, arsenite appears to inactivate M3/6 directly. These results might have implications for the mechanism of tumour promotion by arsenic.	Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, CRC, Gene Funct & Regulat Grp, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, CRC, Gene Funct & Regulat Grp, Fulham Rd, London SW3 6JB, England.	alana@icr.ac.uk						ADLER V, 1994, J BIOL CHEM, V269, P11186; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen YR, 2000, INT J ONCOL, V16, P651; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907	48	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2387	2397		10.1038/sj.onc.1205309	http://dx.doi.org/10.1038/sj.onc.1205309			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948422				2022-12-17	WOS:000174635600011
J	Takata, M; Tachiiri, S; Fujimori, A; Thompson, LH; Miki, Y; Hiraoka, M; Takeda, S; Yamazaoe, M				Takata, M; Tachiiri, S; Fujimori, A; Thompson, LH; Miki, Y; Hiraoka, M; Takeda, S; Yamazaoe, M			Conserved domains in the chicken homologue of BRCA2	ONCOGENE			English	Article						BRCA2; homologous recombination; Rad51; BRC repeat	DNA RECOMBINATION; RADIATION HYPERSENSITIVITY; GENE; RAD51; REPAIR; MICE; EXPRESSION; REPEATS; IDENTIFICATION; CHECKPOINT	Germline mutation of the BRCA2 gene causes a high risk of developing breast and ovarian cancer. Although the BRCA2 protein has been implicated in homologous recombination (HR) of DNA and in transcription, it is still unclear how mutation leads to tumorigenesis. We have identified a nonmammalian homologue of BRCA2 from chicken, which encodes a protein with 3397 amino acids (aa) and shows only 40% identity to human BRCA2. However, comparison of the mammalian and chicken sequences revealed remarkably high homology in several segments. These include a N-terminal region (similar to100 aa), which was previously shown to possess intrinsic transcriptional activity, and a C-terminal region (aa residue similar to2480-similar to3180 in human BRCA2), which has not been clearly assigned any function. In contrast, although the eight BRC repeats of mammalian BRCA2 are believed to play an important role in HR by interacting with Rad51, the BRC3, BRC5, and BRC6 repeats exhibit virtually no similarity to their mammalian counterparts. Among 311 missense mutations listed as unclassified variants in the NIH Breast Cancer Information Core database, only 83 of these sites are identical in chicken BRCA2. Thus, chicken BRCA2 may provide a means to identify domains and residues associated with cancer predisposition.	Kawasaki Med Sch, Dept Immunol & Mol Genet, Kurashiki, Okayama 7010192, Japan; Kyoto Univ, Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Sch Med, Dept Therapeut Radiol & Oncol, Sakyo Ku, Kyoto 6068507, Japan; Lawrence Livermore Natl Lab, BBR Program, Livermore, CA 94551 USA; Japanese Fdn Canc Res, Toshima Ku, Tokyo 1708640, Japan	Kawasaki Medical School; Kyoto University; Kyoto University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Japanese Foundation for Cancer Research	Takata, M (corresponding author), Kawasaki Med Sch, Dept Immunol & Mol Genet, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.	mtakata@med.kawasaki-m.ac.jp		Takata, Minoru/0000-0002-4926-3675; Takeda, Shunichi/0000-0002-7924-7991				Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen CH, 1998, HUM MUTAT, V11, P328; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Friedman LS, 1998, CANCER RES, V58, P1338; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Futamura M, 2000, CANCER RES, V60, P1531; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; McAllister KA, 1997, CANCER RES, V57, P3121; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Morimatsu M, 1998, CANCER RES, V58, P3441; Morrison C, 2000, INT J BIOCHEM CELL B, V32, P817, DOI 10.1016/S1357-2725(00)00033-9; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Orelli BJ, 2001, ONCOGENE, V20, P4433, DOI 10.1038/sj.onc.1204485; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 2001, PHILOS T ROY SOC B, V356, P111, DOI 10.1098/rstb.2000.0755; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Wagner TMU, 1999, HUM MOL GENET, V8, P413, DOI 10.1093/hmg/8.3.413; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	37	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1130	1134		10.1038/sj.onc.1205168	http://dx.doi.org/10.1038/sj.onc.1205168			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850831				2022-12-17	WOS:000173580100017
J	Kuschak, TI; Kuschak, BC; Taylor, CL; Wright, JA; Wiener, F; Mai, S				Kuschak, TI; Kuschak, BC; Taylor, CL; Wright, JA; Wiener, F; Mai, S			c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene	ONCOGENE			English	Article						c-Myc; genomic instability; amplification; DNA replication; ribonucleotide reductase R2	SYRIAN-HAMSTER CELLS; DIHYDROFOLATE-REDUCTASE; GENOMIC INSTABILITY; METHOTREXATE RESISTANCE; DNA-REPLICATION; CAD GENES; AMPLIFICATION; MOUSE; OVEREXPRESSION; TUMORIGENESIS	The mechanisms through which the oncoprotein c-Myc initiates locus-specific gene amplification are not understood. When analysing the initiation mechanism of c-Myc-dependent amplification of the mouse ribonucleotide reductase R2 (R2) gene, we observe c-Myc-dependent initiation of illegitimate DNA replication of the R2 gene. We demonstrate multiple simultaneous c-Myc-induced R2 replication forks, whereas R2 normally replicates with a single fork. In contrast, cyclin C replicates with only a single replication fork irrespective of c-Myc deregulation. In addition to de novo replication forks, c-Myc also initiates bi-allelic replication of R2, abrogating its normal mono-allelic replication pattern, Moreover, several chromosomal regions also display c-Myc-induced illegitimate replication profiles. Thus, c-Myc can act as an illegitimate replication-licensing factor that promotes de novo replication initiation and illegitimate replication timing that adversely impacts upon genomic stability.	Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag & CancerCare Manitoba, Dept Microbiol, Winnipeg, MB R3E 0V9, Canada; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	CancerCare Manitoba Foundation; University of Manitoba; Karolinska Institutet	Mai, S (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag & CancerCare Manitoba, Dept Microbiol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; Butler DK, 1996, CELL, V87, P1115, DOI 10.1016/S0092-8674(00)81805-X; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DENIS N, 1991, ONCOGENE, V6, P1453; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; HAMLIN JL, 1991, PROG NUCLEIC ACID RE, V41, P203; HAMLIN JL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P107, DOI 10.1016/0167-4781(90)90195-8; HENRIKSSON M, 1988, CURR TOP MICROBIOL, V141, P202; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; KHAN F, 1994, GENOMICS, V21, P128, DOI 10.1006/geno.1994.1234; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li HM, 1996, GENOMICS, V32, P253, DOI 10.1006/geno.1996.0112; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MAI S, 1994, CYCLIN D2 TARGET C M, P53; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; MEINKOTH J, 1987, MOL CELL BIOL, V7, P1415, DOI 10.1128/MCB.7.4.1415; MORRIS T, 1993, P NATL ACAD SCI USA, V90, P1392, DOI 10.1073/pnas.90.4.1392; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; Simon I, 1999, NATURE, V401, P929, DOI 10.1038/44866; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; SPRADLING AC, 1981, CELL, V27, P193, DOI 10.1016/0092-8674(81)90373-1; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; WAHL GM, 1979, J BIOL CHEM, V254, P8679; Wang ST, 1998, MOL CELL BIOL, V18, P39, DOI 10.1128/MCB.18.1.39; Wells J, 1996, MOL CELL BIOL, V16, P634; WIENER F, 2000, TECHNICAL TIPS ONLIN; STATSOFT ELECT STAT	49	29	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					909	920		10.1038/sj.onc.1205145	http://dx.doi.org/10.1038/sj.onc.1205145			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840336				2022-12-17	WOS:000173427100006
J	Adachi, Y; Chandrasekar, N; Kin, Y; Lakka, SS; Mohanam, S; Yanamandra, N; Mohan, PM; Fuller, GN; Fang, BL; Fueyo, J; Dinh, DH; Olivero, WC; Tamiya, T; Ohmoto, T; Kyritsis, AP; Rao, JS				Adachi, Y; Chandrasekar, N; Kin, Y; Lakka, SS; Mohanam, S; Yanamandra, N; Mohan, PM; Fuller, GN; Fang, BL; Fueyo, J; Dinh, DH; Olivero, WC; Tamiya, T; Ohmoto, T; Kyritsis, AP; Rao, JS			Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences	ONCOGENE			English	Article						glioblastoma; invasion; adenovirus; antisense; urokinase plasminogen receptor	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN GLIOBLASTOMA CELLS; UROKINASE RECEPTOR; IN-VITRO; TUMOR SUPPRESSION; MALIGNANT-CELLS; CYCLE ARREST; EXPRESSION; INTEGRIN; LOCALIZATION	Our previous studies showed that the urokinase-type plasminogen activator receptor (uPAR) and the p16 tumor suppressor gene play a significant role in glioma invasion. We expected that downregulation of uPAR and overexpression of p16 using a bicistronic vector might cause a additive and cooperative effect in the suppression of glioma invasion and growth. The bicistronic construct (Ad-uPAR/p16)-infected glioblastoma cell lines had significantly lower levels of uPAR and higher levels of p16 than controls. Cell cycle analysis showed the bicistronic vector caused G0/G1 arrest of the cell cycle. In vitro glioblastoma cell growth and invasiveness were inhibited in Ad-uPAR/p16-infected cells compared with controls. Ad-uPAR/p16 suppressed the tumor growth of glioblastoma cell lines in an ex vivo intracerebral tumor model and an in vivo subcutaneous tumor model. Our results support the therapeutic potential of simultaneously targeting uPAR and p16 in the treatment of gliomas.	Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 7008558, Japan; Osmania Univ, Dept Biochem, Hyderabad 500007, Andhra Pradesh, India; Univ Texas, MD Anderson Canc Ctr, Dept Neuropathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Okayama University; Osmania University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rao, JS (corresponding author), Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Fueyo, Juan/0000-0001-6941-2335; Fuller, Gregory/0000-0001-9447-2647	NCI NIH HHS [CA 76350, CA 75557, CA80748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076350, R01CA075557, R01CA080748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ARAP W, 1995, CANCER RES, V55, P1351; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; Costello JF, 1996, CANCER RES, V56, P2405; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Frizelle SP, 1998, ONCOGENE, V16, P3087, DOI 10.1038/sj.onc.1201870; Fueyo J, 1996, ONCOGENE, V12, P103; Fueyo J, 1996, ONCOGENE, V13, P1615; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; GLADSON CL, 1995, AM J PATHOL, V146, P1150; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Go Y, 1996, CANCER LETT, V110, P225, DOI 10.1016/S0304-3835(96)04515-6; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Harada H, 1999, CANCER RES, V59, P3783; Ichimura K, 1996, ONCOGENE, V13, P1065; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kyritsis AP, 1996, ONCOGENE, V12, P63; KYRITSIS AP, 1997, PRACTICE GUIDELINES, P473; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mohan PM, 1999, CANCER RES, V59, P3369; Mohanam S, 1998, INT J ONCOL, V13, P1285; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; Naruse I, 1998, ANTICANCER RES, V18, P4275; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; POLLANEN J, 1991, ADV CANCER RES, V57, P273; REED JA, 1995, CANCER RES, V55, P2713; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; Wang J, 1997, CANCER RES, V57, P351; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	48	29	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					87	95		10.1038/sj.onc.1204999	http://dx.doi.org/10.1038/sj.onc.1204999			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791179				2022-12-17	WOS:000172887800009
J	Robinson, GW; Wagner, KU; Hennighausen, L				Robinson, GW; Wagner, KU; Hennighausen, L			Functional mammary gland development and oncogene-induced tumor formation are not affected by the absence of the retinoblastoma gene	ONCOGENE			English	Article						mammary gland; tumor suppressor gene; oncogenes; pocket proteins; breast cancer	G(1) CONTROL; EXPRESSION; MICE; DIFFERENTIATION; EPITHELIUM; PROTEIN; IMMORTALIZATION; TGF-BETA-1; MUTATION; PROSTATE	results in impaired mammary gland development and neoplasia. We investigated the consequences of the absence of pRb in mammary epithelial cells during normal development and in mice that express an oncogene in the mammary epithelium. Since pRb-deficiency results in embryonic lethality, we transplanted pRb-null mammary anlagen into wild hosts. pRb-deficient mammary epithelia were capable of functional differentiation in term animals and they regenerated a differentiated gland even after multiple pregnancies. In serial transplantations no significant differences were found in outgrowth of pRb-deficient and wild type epithelia indicating that the absence of pRb does not lead to transformation. Likewise the effect of a TGF beta1 transgene was not altered in the absence of pRb. The susceptibility of mammary epithelium to form tumors was assessed in three different models. No differences in tumor incidence were found between wild type and Rb +/- WAP-int3, MMTV-PyMT transgenic and Brcal(-/-) epithelia. These results demonstrate that the absence of pRb does not affect normal mammary gland development and tumorigenesis in three different mouse models investigated and suggest that loss of more than one member of the pRb pathway is required to induce mammary tumors.	NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Robinson, GW (corresponding author), NIDDK, LGP, NIH, 8 Ctr Dr,Bldg 8,Rm 101, Bethesda, MD 20892 USA.		Wagner, Kay-Uwe/B-6044-2009; Robinson, Gertraud/I-2136-2012	Wagner, Kay-Uwe/0000-0002-5081-0226; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DEOME KB, 1959, CANCER RES, V19, P515; Dublin EA, 1998, INT J CANCER, V79, P71, DOI 10.1002/(SICI)1097-0215(19980220)79:1<71::AID-IJC14>3.0.CO;2-K; Gallahan D, 1996, CANCER RES, V56, P1775; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HU NP, 1994, ONCOGENE, V9, P1021; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Marsh KL, 1998, BRIT J CANCER, V77, P1460, DOI 10.1038/bjc.1998.240; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P307; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SERRA R, 1995, DEVELOPMENT, V121, P3057; TZENG YJ, 1993, ONCOGENE, V8, P1965; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang YH, 2000, CANCER RES, V60, P6008; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	30	29	29	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7115	7119		10.1038/sj.onc.1204888	http://dx.doi.org/10.1038/sj.onc.1204888			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704837				2022-12-17	WOS:000171739300016
J	Seidel, MG; Look, AT				Seidel, MG; Look, AT			E2A-HLF usurps control of evolutionarily conserved survival pathways	ONCOGENE			English	Article						apoptosis; acute leukemia; chromosomal translocation; circadian rhythm; hepatic leukemia factor; developmental cell fate	ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEINS; ZINC-FINGER PROTEIN; CHIMERIC TRANSCRIPTION FACTOR; LEUCINE-ZIPPER PROTEINS; PROGRAMMED CELL-DEATH; DNA-BINDING PROTEINS; FUSION MESSENGER-RNA; PRO-B LYMPHOCYTES; C-ELEGANS	E2A-HLF, the chimeric fusion protein resulting from the leukemogenic translocation t(17;19), appears to employ evolutionarily conserved signaling cascades for its transforming and antiapoptotic functions. These arise from both impairment of normal E2A function and activation of a survival pathway triggered through the HLF bZip DNA binding and dimerization domain. Recent reports identify wild-type E2A as a tumor suppressor in T lymphocytes. Moreover, E2A-HLF has been shown to activate SLUG, a mammalian homologue of the cell death specification protein CES-1 in Caenorhabditis elegans, which appears to regulate an evolutionarily conserved cell survival program. Recently, several key mouse models have been generated, enabling further elucidation of these pathways on a molecular genetic level in vivo. In this review, we discuss the characteristics of both components of the fusion protein with regard to their contribution to the regulation of cell fate and the oncogenic potential of E2A-HLF.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Look, AT (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St,M-630, Boston, MA 02115 USA.	thomas_look@dfci.harvard.edu	Seidel, Markus G/N-9951-2017	Seidel, Markus G/0000-0003-0981-8661				BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bayly R, 2000, MOL CELL BIOL, V20, P5789, DOI 10.1128/MCB.20.16.5789-5796.2000; Begbie M, 1999, DNA CELL BIOL, V18, P165, DOI 10.1089/104454999315556; Begley CG, 1999, BLOOD, V93, P2760; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; Brambillasca F, 1999, LEUKEMIA, V13, P369, DOI 10.1038/sj.leu.2401338; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chu C, 2001, J BIOL CHEM, V276, P8524, DOI 10.1074/jbc.M008371200; COWELL IG, 1994, NUCLEIC ACIDS RES, V22, P59, DOI 10.1093/nar/22.1.59; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Duncan DD, 1996, IMMUNITY, V4, P301, DOI 10.1016/S1074-7613(00)80438-0; ELLIS RE, 1991, DEVELOPMENT, V112, P591; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Ferrando AA, 2000, SEMIN HEMATOL, V37, P381, DOI 10.1053/shem.2000.16447; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hitzler JK, 1999, BRAIN RES, V820, P1, DOI 10.1016/S0006-8993(98)00999-8; Honda H, 1999, BLOOD, V93, P2780; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inoue A, 1999, BLOOD, V94, p687A; Inukai T, 1998, MOL CELL BIOL, V18, P6035, DOI 10.1128/MCB.18.10.6035; Inukai T, 1997, MOL CELL BIOL, V17, P1417, DOI 10.1128/MCB.17.3.1417; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; IZRAELI S, 1992, BLOOD, V80, P1413; Jia YW, 1997, DEVELOPMENT, V124, P2063; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Kurosawa H, 1999, BLOOD, V93, P321, DOI 10.1182/blood.V93.1.321.401k05_321_332; Lan Y, 1998, DEV BIOL, V198, P207; LAVERY DJ, 1996, PAR TRANSCRIPTION RA, P135; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Look AT, 1997, CURR TOP MICROBIOL, V220, P45; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Maloney KW, 1998, LEUKEMIA, V12, P1417, DOI 10.1038/sj.leu.2401124; McDonald JM, 1998, CANCER RES, V58, P1387; Mehenni H, 1997, AM J HUM GENET, V61, P1327, DOI 10.1086/301644; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUMATA SI, 1993, LEUKEMIA, V7, P1441; Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; Ripperger JA, 2000, GENE DEV, V14, P679; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Smith KS, 1999, MOL CELL BIOL, V19, P4443; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; TAKEDA J, 1990, MOL CELL BIOL, V10, P5027, DOI 10.1128/MCB.10.10.5027; TAKEUCHI S, 1995, CANCER RES, V55, P5377; Wang JJ, 2000, P NATL ACAD SCI USA, V97, P3497, DOI 10.1073/pnas.97.7.3497; WUARIN J, 1992, J CELL SCI, P123; Yamaguchi S, 2000, MOL CELL BIOL, V20, P4773, DOI 10.1128/MCB.20.13.4773-4781.2000; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; ZHANG W, 1995, MOL CELL BIOL, V15, P6055; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	97	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5718	5725		10.1038/sj.onc.1204591	http://dx.doi.org/10.1038/sj.onc.1204591			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607821				2022-12-17	WOS:000170887500012
J	DeSalle, LM; Latres, E; Lin, D; Graner, E; Montagnoli, A; Baker, RT; Pagano, M; Loda, M				DeSalle, LM; Latres, E; Lin, D; Graner, E; Montagnoli, A; Baker, RT; Pagano, M; Loda, M			The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein	ONCOGENE			English	Article						Unp; retinoblastoma; isopeptidase; ubiquitin	FAT FACETS GENE; DEUBIQUITINATING ENZYME; MOUSE GENE; DEGRADATION; EXPRESSION; ENCODES; PROTOONCOGENE; ISOPEPTIDASE; PROTEASOME; SEQUENCES	The ubiquitin pathway is involved in the proteolytic turnover of many short-lived cellular regulatory proteins. Since selective degradation of substrates of this system requires the covalent attachment of a polyubiquitin chain to the substrates, degradation could be counteracted by de-ubiquitinating enzymes (or isopeptidases) which selectively remove the polyubiquitin chain. Unp is a human isopeptidase with still poorly understood biological functions. Here, we show that cellular Unp specifically interacts with the retinoblastoma gene product (pRb).	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Caplan Comprehens Canc Ctr, New York, NY 10016 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Harvard University; Dana-Farber Cancer Institute; New York University; New York University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Australian National University; John Curtin School of Medical Research	Pagano, M (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.		Graner, Edgard/K-4411-2012; Graner, Edgard/P-4651-2019	Graner, Edgard/0000-0002-4737-7935; pagano, michele/0000-0003-3210-2442; Lin, Douglas/0000-0003-0105-9760	NATIONAL CANCER INSTITUTE [R01CA076584, R01CA081755, P30CA016087, R21CA066229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1-CA81755, R21-CA66229, P30-CA16087, R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Gilchrist CA, 1997, J BIOL CHEM, V272, P32280, DOI 10.1074/jbc.272.51.32280; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Isaksson A, 1997, MECH DEVELOP, V68, P59, DOI 10.1016/S0925-4773(97)00126-3; KANAIAZUMA M, 2000, MECH DEVELOP, V68, P59; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; PAGANO M, 1992, EMBO J, V11, P761; PAGANO M, 1995, CELL CYCLE MAT METHO, P271; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wood SA, 1997, MECH DEVELOP, V63, P29, DOI 10.1016/S0925-4773(97)00672-2; Wu ZR, 1999, DEV GENET, V25, P312, DOI 10.1002/(SICI)1520-6408(1999)25:4<312::AID-DVG5>3.0.CO;2-Z	29	29	34	1	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5538	5542		10.1038/sj.onc.1204824	http://dx.doi.org/10.1038/sj.onc.1204824			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571652				2022-12-17	WOS:000170781100015
J	Yin, XY; Landay, MF; Han, WP; Levitan, ES; Watkins, SC; Levenson, RM; Farkas, DL; Prochownik, EV				Yin, XY; Landay, MF; Han, WP; Levitan, ES; Watkins, SC; Levenson, RM; Farkas, DL; Prochownik, EV			Dynamic in vivo interactions among Myc network members	ONCOGENE			English	Article						Max; Mad Mxi1; green fluorescent protein (GFP); SC-35; transcription	RNA-POLYMERASE-II; C-MYC; DNA-BINDING; TRANSCRIPTIONAL REPRESSORS; HISTONE DEACETYLASE; LEUCINE-ZIPPER; LARGE SUBUNIT; CELL-GROWTH; MAD FAMILY; N-COR	Members of the Myc oncoprotein network (c-Myc, Max, and Mad) play important roles in proliferation, differentiation, and apoptosis. We expressed chimeric green fluorescent protein (GF-P) fusions of c-Myc,. Max, and three Mad proteins in fibroblasts.. Individually, c-Myc and Mad proteins localized in subnuclear speckles, whereas Max assumed a homogeneous nuclear pattern. These distributions were co-dominant and dynamic, however, as each protein assumed the pattern of its heterodimeric partner when the latter was co-expressed at a higher level. Deletion mapping of two Mad members, Mad1 and Mxi1, demonstrated that the domains responsible for nuclear localization and speckling are separable. A non-speckling Mxi1 mutant was also less effective as a transcriptional repressor than wild-type Mxi1. c-Myc nuclear speckles were distinct from SC-35 domains involved in mRNA processing. However, in the presence of co-expressed Max, c-Myc, but not Mad, co-localized to a subset of SC-35 loci. These results show that Myc network proteins comprise dynamic subnuclear structures and behave co-dominantly when co-expressed with their normal heterodimerization partners. In addition, c-Myc-Max heterodimers, but not Max-Mad heterodimers, localize to foci actively engaged in pre-mRNA transcription/processing. These findings suggest novel means by which Myc network members promote transcriptional activation or repression.	Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Ctr Light Microscope Imaging & Biotechnol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, 3705 5th Ave, Pittsburgh, PA 15213 USA.	edward_prochownik@poplar.chp.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL CANCER INSTITUTE [R01CA078259] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78259] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; Cardoso MC, 1998, J CELL BIOCHEM, V70, P222, DOI 10.1002/(SICI)1097-4644(19980801)70:2<222::AID-JCB8>3.0.CO;2-Q; Chen YM, 1996, CANCER RES, V56, P3168; Clemson CM, 1996, J CELL BIOCHEM, V62, P181, DOI 10.1002/(SICI)1097-4644(199608)62:2<181::AID-JCB6>3.3.CO;2-V; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; LARSSON LG, 1994, ONCOGENE, V9, P1247; Leonhardt H, 1995, INT REV CYTOL, V162B, P303; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MOEN PT, 1995, HUM MOL GENET, V4, P1779, DOI 10.1093/hmg/4.suppl_1.1779; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RABBITS PH, 1985, NATURE, V314, P363; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHULMAN IG, 1977, LEUKEMIA S, V3, P376; Smith KP, 1999, J CELL BIOL, V144, P617, DOI 10.1083/jcb.144.4.617; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1987, ONCOGENE, V1, P5; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	67	29	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4650	4664		10.1038/sj.onc.1204606	http://dx.doi.org/10.1038/sj.onc.1204606			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498788				2022-12-17	WOS:000170208600006
J	MacGrogan, D; Alvarez, S; DeBlasio, T; Jhanwar, SC; Nimer, SD				MacGrogan, D; Alvarez, S; DeBlasio, T; Jhanwar, SC; Nimer, SD			Identification of candidate genes on chromosome band 20q12 by physical mapping of translocation breakpoints found in myeloid leukemia cell lines	ONCOGENE			English	Article						myeloid leukemia; 20q deletion; loss of heterozygosity	COMMONLY DELETED SEGMENT; MYELOPROLIFERATIVE DISORDERS; MYELODYSPLASTIC SYNDROMES; HEMATOLOGIC DISORDERS; DELETIONS; MAP; REGION; NEUROFIBROMATOSIS; REFINEMENT; ABNORMALITIES	Deletions of the long arm of chromosome 20 have been reported in a wide range of myeloid disorders and may reflect loss of critical tumor suppressor gene(s), To identify such candidate genes, 65 human myeloid cell line DNAs were screened by polymerase chain reaction (PCR) tor evidence of allelic loss at 39 highly polymorphic loci on the long arm of chromosome 20, A mono-allelic pattern was present in eight cell lines at multiple adjacent loci spanning the common deleted regions (CDRs) previously defined in primary hematological samples, suggesting loss of heterozygosity (LOH) at 20q, Fluorescence in situ hybridization (FISH) was then performed using a series of yeast artificial chromosomes (YACs) ordered in the CDR, and in five of eight cell lines, the deletions resulted from cytogenetically detectable whole chromosomal loss or large interstitial deletion, whereas in another cell line deletion was associated with an unbalanced translocation, LOH in the CMK megakaryocytic cell line, which has a hypotetraploid karyotype, was associated with a der(20)t(1;20)(q32;q12)x2 leading to complete deletion of the CDR, Three additional unbalanced translocations were found within the CDR and all three breakpoints mapped to a single YAC, We then used a series of P1 artificial chromosomes (PACs) spanning this YAC clone, and two PACs produced 'split' signals suggesting that they each span one of these breakpoints, Exon trapping using PACs that overlap the breakpoint regions yielded portions of six genes and evaluation of these genes as candidate tumor suppressor genes is underway. The limited information available about these genes suggests that the h-1(3)mbt gene is the most attractive candidate.	Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, Cytogenet Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	MacGrogan, D (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.		MacGrogan, Donal/AAR-7392-2021; MacGrogan, Donal/E-8604-2016	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422	NIDDK NIH HHS [R01DK43025] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AATOLA M, 1992, CANCER GENET CYTOGEN, V62, P75, DOI 10.1016/0165-4608(92)90043-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asimakopoulos FA, 1996, BRIT J HAEMATOL, V95, P219; ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; Asimakopoulos FA, 1996, BLOOD, V88, P2690, DOI 10.1182/blood.V88.7.2690.bloodjournal8872690; Bench AJ, 2000, ONCOGENE, V19, P3902, DOI 10.1038/sj.onc.1203728; Bench AJ, 1998, GENOMICS, V49, P351, DOI 10.1006/geno.1998.5231; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DEWALD GW, 1995, SEMIN ONCOL, V22, P341; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; HIRAMA T, 1995, BLOOD, V86, P841; HOLLINGS PE, 1994, BLOOD, V83, P305; HOLLINGS PE, 1995, CANCER GENET CYTOGEN, V79, P32, DOI 10.1016/0165-4608(94)00068-M; KNUUTILA S, 1994, GENE CHROMOSOME CANC, V10, P95, DOI 10.1002/gcc.2870100204; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; Kurtin PJ, 1996, AM J CLIN PATHOL, V106, P680; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; MERTENS F, 1991, LEUKEMIA, V5, P214; MITELMAN F, 1995, CATALOG CHROMOSOME A; Mori N, 1997, BLOOD, V90, P2010, DOI 10.1182/blood.V90.5.2010; NACHEVA E, 1995, CANCER GENET CYTOGEN, V80, P87, DOI 10.1016/0165-4608(94)00150-A; NobenTrauth K, 1996, GENOMICS, V35, P610, DOI 10.1006/geno.1996.0408; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Paige AJW, 2000, CANCER RES, V60, P1690; ROULSTON D, 1993, BLOOD, V82, P3424; Sambrook J, 1989, MOL CLONING LAB MANU; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; Stoffel M, 1996, P NATL ACAD SCI USA, V93, P3937, DOI 10.1073/pnas.93.9.3937; STRACHAN T, 1996, HUM MOL GENET, P151; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wang PW, 2000, GENOMICS, V67, P28, DOI 10.1006/geno.2000.6215; Wang PW, 1998, GENE CHROMOSOME CANC, V21, P75, DOI 10.1002/(SICI)1098-2264(199802)21:2<75::AID-GCC1>3.0.CO;2-4; WHITE NJ, 1994, BLOOD, V83, P2809, DOI 10.1182/blood.V83.10.2809.2809	38	29	31	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4150	4160		10.1038/sj.onc.1204540	http://dx.doi.org/10.1038/sj.onc.1204540			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464281				2022-12-17	WOS:000169857200005
J	Miyoshi-Akiyama, T; Aleman, LM; Smith, JM; Adler, CE; Mayer, BJ				Miyoshi-Akiyama, T; Aleman, LM; Smith, JM; Adler, CE; Mayer, BJ			Regulation of Cbl phosphorylation by the Abl tyrosine kinase and the Nck SH2/SH3 adaptor	ONCOGENE			English	Article						signal transduction; protein binding modules	GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-3 DOMAINS; PROTOONCOGENE C-CBL; SH3 DOMAINS; IN-VIVO; V-ABL; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR	The Cbl proto-oncogene product is tyrosine phosphorylated in response to a wide variety of stimuli. Cbl and the Abl nonreceptor tyrosine kinase both bind to SH3 domains from the SH2/SH3 adaptor Nck, and are candidate effecters for Nck function. Numerous additional SH2- and SH3-domain-mediated interactions are also possible between Cbl, Abl, and Nck, We find that these three signaling proteins associate when overexpressed in mammalian cells and can regulate each other's activity. Go-expression of mt Cbl together with c-Abl, the activity of which is normally repressed in vivo, led to extensive Abl-dependent phosphorylation of Cbl, The major proline-rich region of Cbl was required for ifs phosphorylation by c-Abl, but not by a constitutively activated Abl mutant, suggesting Cbl activates c-Abl by engaging its SH3 domain. Efficient phosphorylation of Cbl and its stable association with Abl required the SH2 domain of Abl, suggesting that SH2-phosphotyrosine interactions prevent dissociation of active Abl from Cbl, We also show that overexpression of Nck could repress the phosphorylation of Cbl by Abl in vivo. Studies with Nck mutants suggested that the Nck SH2 domain is responsible for inhibiting the activity of Abl toward both Cbl and Nck itself, most likely by competing with the Abl SH2 for tyrosine-phosphorylated binding sites.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	University of Connecticut; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.				NCI NIH HHS [CA82258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler CE, 2000, J BIOL CHEM, V275, P36472, DOI 10.1074/jbc.M005424200; Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; BLAKE TJ, 1991, ONCOGENE, V6, P653; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Majidi M, 1998, J BIOL CHEM, V273, P16608, DOI 10.1074/jbc.273.26.16608; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Parrini MC, 1999, CHEM BIOL, V6, P679, DOI 10.1016/S1074-5521(00)80015-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; Raffel GD, 1996, J BIOL CHEM, V271, P4640; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sattler M, 1996, ONCOGENE, V12, P839; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1995, ONCOGENE, V10, P1977; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	73	29	29	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4058	4069		10.1038/sj.onc.1204528	http://dx.doi.org/10.1038/sj.onc.1204528			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494134				2022-12-17	WOS:000169681500014
J	Brooks, DG; James, RM; Patek, CE; Williamson, J; Arends, MJ				Brooks, DG; James, RM; Patek, CE; Williamson, J; Arends, MJ			Mutant K-ras enhances apoptosis in embryonic stem cells in combination with DNA damage and is associated with increased levels of p19(ARF)	ONCOGENE			English	Article						K-ras; DNA damage; ES cells; apoptosis	ONCOGENIC RAS; N-RAS; TUMOR SUPPRESSION; MATRIX ADHESION; PLASMA-MEMBRANE; C-MYC; P53; ACTIVATION; TRANSFORMATION; KINASE	The roles of K-ras in neoplasia are not entirely understood, although there is evidence that K-ras affects susceptibility to apoptosis, modulating survival of DNA damaged cells which would otherwise be eliminated. In this study, we investigated the effects of mutant K-ras on apoptosis in vitro following DNA damage. To avoid complications resulting from mutations in other cancer-related genes and from the presence of endogenous K-ras, we derived K-ras null embryonic stem cells. Expression of either wild-type or mutant K-vas was reconstructed by stable plasmid transfection, The cell lines were treated with etoposide, cisplatin and UV radiation and apoptosis measured flow cytometrically. Mutant K-ras potentiated the effect of etoposide-derived DNA damage by increasing apoptosis, whereas absence of K-ras had the opposite effect. This pattern was similar but less marked with cisplatin, whereas UV yielded no difference in apoptosis with regard to K-ras status, suggesting that the effect of K-ras on apoptosis is dependent on the nature of the DNA damage, To investigate possible mechanisms, we examined the expression of p19(ARF) mRNA by RT-PCR, Cells expressing mutant K-ras produced elevated levels of p19(ARF) mRNA, which could link K-ras status with p53 expression and hence susceptibility to DNA damage-induced apoptosis.	Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England; Univ Edinburgh, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh	Arends, MJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Hills Rd, Cambridge CB2 2QQ, England.							Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BREIVIK J, 1994, BRIT J CANCER, V69, P367, DOI 10.1038/bjc.1994.67; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; CHEN F, 1994, PROCESS BIOCHEM, V29, P245, DOI 10.1016/0032-9592(94)80064-2; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Koo HM, 1999, JNCI-J NATL CANCER I, V91, P236, DOI 10.1093/jnci/91.3.236; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Orecchia R, 2000, J PATHOL, V190, P423; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; REIHSAUS E, 1990, ONCOGENE, V5, P137; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Vater CA, 1996, ONCOGENE, V13, P739; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2144	2152		10.1038/sj.onc.1204309	http://dx.doi.org/10.1038/sj.onc.1204309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360198				2022-12-17	WOS:000168116700009
J	Maulon, L; Mari, B; Bertolotto, C; Ricci, JE; Luciano, F; Belhacene, N; Deckert, M; Baier, G; Auberger, P				Maulon, L; Mari, B; Bertolotto, C; Ricci, JE; Luciano, F; Belhacene, N; Deckert, M; Baier, G; Auberger, P			Differential requirements for ERK1/2 and p38 MAPK activation by thrombin in T cells. Role of P59Fyn and PKC epsilon	ONCOGENE			English	Article						T lymphocytes; thrombin; Src kinases; PKCs; MAP kinases	PROTEIN-KINASE-C; RECEPTOR AGONIST PEPTIDE; EPIDERMAL-GROWTH-FACTOR; SRC FAMILY KINASES; TYROSINE KINASE; COUPLED RECEPTORS; IL-2 PROMOTER; CROSS-LINKING; RAS; PHOSPHORYLATION	Activation of the mitogen-activated protein kinase (MAPK) cascade is a well documented mechanism for the G-protein-coupled receptors, Here, we have analysed the requirements for ERKs and p38 MAPK activation by thrombin in Jurkat T cells. We show that thrombin-mediated ERKs activation requires both PTK and PKC activities, whereas p38 MAPK activation is dependent only on PTKs, Thrombin-induced ERK and p38 MAPK activation was more pronounced in p56Lck deficient cells indicating that this PTK exerts a negative control on MAPK activity. Accordingly, overexpression of p50 Csk a kinase that inactivates p56Lck induced constitutive activation of ERKs, Requirement for a Src kinase was evidenced by expression of a constitutively active form of p59Fyn in Jurkat cells. Besides its effect on tyrosine phosphorylation events, thrombin also triggered a rapid and robust redistribution of PKC epsilon and delta from the cytosol to the membrane. Expression of constitutively active and dominant negative PKC epsilon demonstrates the pivotal role of this PKC isoform in ERKs activation by thrombin, These data are consistent with a model where thrombin induces ERK activation via both PKC-dependent and independent pathways, whereas p38 MAPK activation requires only PTKs, The PKC-independent pathway requires Src kinases other than p56Lck more likely p59Fyn, while the PKC-dependent mechanism depends on PKC epsilon.	INSERM, U526, F-06107 Nice 2, France; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Hop Archet, INSERM U343, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Innsbruck; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm)	Auberger, P (corresponding author), INSERM, U526, 28 Ave Valombrose, F-06107 Nice 2, France.		Mari, Bernard P/GVS-3100-2022; Bertolotto, Corine/AAF-6634-2021; Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019; RICCI, Jean Ehrland/AAS-4379-2020; Ricci, Jean Ehrland/I-7117-2016; Mari, Bernard/Q-5832-2019; Baier, Gottfried/E-8755-2012; luciano, frederic/P-6264-2016; Bertolotto-Ballotti, Corine/O-2155-2016; Mari, Bernard P/D-7445-2015; Mari, Bernard P/F-8960-2013; AUBERGER, Patrick/G-1491-2013	Mari, Bernard P/0000-0002-0422-9182; Bertolotto, Corine/0000-0001-6971-7753; Deckert, Marcel/0000-0003-2094-559X; RICCI, Jean Ehrland/0000-0003-1585-8117; Ricci, Jean Ehrland/0000-0003-1585-8117; Mari, Bernard/0000-0002-0422-9182; luciano, frederic/0000-0001-9253-4998; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Baier, Gottfried/0000-0002-2085-8325				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AUTERO M, 1996, MOL CELL BIOL, V16, P1842; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BRANCH DR, 1995, J IMMUNOL, V154, P3678; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CONWAY AM, 1999, BIOCHEM J, P171; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; DERY O, 1998, AM J PHYSIOL, P1429; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DIKIC I, 1998, J BIOL CHEM, V269, P31706; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; GOLDSCHMITH MA, 1998, P NATL ACAD SCI USA, V84, P6879; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Joyce DE, 1997, BLOOD, V90, P1893, DOI 10.1182/blood.V90.5.1893; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; MARI B, 1994, J BIOL CHEM, V269, P8517; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Maulon L, 1998, BLOOD, V91, P4232, DOI 10.1182/blood.V91.11.4232.411k32_4232_4241; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Satoh K, 1996, BIOCHEM BIOPH RES CO, V225, P1084, DOI 10.1006/bbrc.1996.1299; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	43	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1964	1972		10.1038/sj.onc.1204266	http://dx.doi.org/10.1038/sj.onc.1204266			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360180				2022-12-17	WOS:000168043800004
J	Strathdee, G; Sansom, OJ; Sim, A; Clarke, AR; Brown, R				Strathdee, G; Sansom, OJ; Sim, A; Clarke, AR; Brown, R			A role for mismatch repair in control of DNA ploidy following DNA damage	ONCOGENE			English	Article						mismatch repair; cell cycle; polyploidy; p53; DNA damage	CELL-CYCLE CHECKPOINT; MICROSATELLITE INSTABILITY; TUMOR-CELLS; SPINDLE CHECKPOINT; DRUG-RESISTANCE; P53 PROTEIN; APOPTOSIS; MUTATION; CISPLATIN; MICE	Many reports have shown a link between mismatch repair (MMR) deficiency and loss of normal cell cycle control, particularly loss of G2 arrest. However almost all of these studies utilized transformed cell lines, and thus the involvement of other genes in this phenotype cannot be excluded. We have examined the effects of cisplatin treatment on primary embryo fibroblasts (MEFs) derived from mice in which the MMR gene Msh2 had been inactivated (Msh2(-/-)). This analysis determined that both primary Msh2(-/-) and wild type (WT) fibroblasts exhibited an essentially identical G2 arrest following cisplatin treatment. Similarly, we observed a cisplatin-induced G2 arrest in immortalized MMR deficient (Mlh1 (/) and Pms2(-/-)) and WT MEFs, p53 deficient primary MEFs (p53(-/-)) exhibited both a clear G2 arrest and an increase in cells with a DNA content of 8N in response to cisplatin, When the Msh2 and p53 defects were combined (p53(-/-)/Msh2(-/-)) the G2 arrest was essentially identical to the p53(-/-) fibroblasts. However, the p53(-/-)/Msh2(-/-) fibroblasts demonstrated a further increase in cells with an 8N DNA content, above that seen in the p53 (/) fibroblasts, These results suggest that loss of MMR on its own is not enough to overcome G2 arrest following exposure to cisplatin but does play a role in preventing polyploidization, or aberrant DNA reduplication, in the absence of functional p53.	Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Wales Coll Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Beatson Institute; University of Glasgow; University of Edinburgh; Cardiff University	Brown, R (corresponding author), Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Brown, Robert/0000-0001-7960-5755; Sansom, Owen J./0000-0001-9540-3010; Strathdee, Gordon/0000-0001-9681-8429; Clarke, Alan/0000-0002-4281-426X				Anthoney DA, 1996, CANCER RES, V56, P1374; Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davis TW, 1998, CANCER RES, V58, P767; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fink D, 1998, CLIN CANCER RES, V4, P1; Gong JG, 1999, NATURE, V399, P806; HAWN MT, 1995, CANCER RES, V55, P3721; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KOI M, 1994, CANCER RES, V54, P4308; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Nehme A, 1997, CANCER RES, V57, P3253; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687	28	29	29	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1923	1927		10.1038/sj.onc.1204276	http://dx.doi.org/10.1038/sj.onc.1204276			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313940				2022-12-17	WOS:000167908400013
J	Ehrhardt, GRA; Korherr, C; Wieler, JS; Knaus, M; Schrader, JW				Ehrhardt, GRA; Korherr, C; Wieler, JS; Knaus, M; Schrader, JW			A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth	ONCOGENE			English	Article						Ras; exchange factor; negative regulation; Elk-1	NUCLEOTIDE DISSOCIATION STIMULATOR; GTPASE-ACTIVATING PROTEIN; C-FOS PROMOTER; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; KINASE; IDENTIFICATION; PATHWAY; FAMILY; PHOSPHORYLATION	Here, we report the identification and characterization of a new member of the RaIGDS-family, which is widely expressed and interacts strongly and selectively with the GTP-bound forms of M-Ras and p21 Ras, This Ras pathway modulator (RPM), also termed RGL3, exhibited Ras-binding and catalytic domains typical of the RalGDS-family of guanine nucleotide exchange factors, and nas most similar to Rlf (RalGDS-like factor), but ras distinguished by a unique proline-rich region with multiple candidate SH3-domain binding sites. RPM/ RGL3 resembled AF-6 and Nore1 in interacting strongly with constitutively active M-Ras and p21 Ras. In contrast to Rlf, transiently expressed RPM/RGL3 did not activate an Elk-1-indueible reporter gene alone or in combination with activated p21 Ras, but strongly inhibited induction of this reporter gene by co-expression of activated H-Ras or MEKK-1. This inhibitory effect was independent of the Ras binding domain and required a second signal provided by p21 Ras or MEKK-1, but not Raf-1 or M-Ras. Expression of RPM/RGL3 also strongly inhibited cell growth of fibroblasts transformed by an activated Src Y527F. Thus, RPM/RGL3 is a novel potential effector of both p21 Ras and M-Ras with the novel function of negatively regulating Elk-1-dependent gene induction downstream of p21 Ras or MEKK-1.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Orchansky PL, 1999, J BIOL CHEM, V274, P20818, DOI 10.1074/jbc.274.30.20818; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shaw MK, 1997, J EXP MED, V185, P1711, DOI 10.1084/jem.185.9.1711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353	41	29	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					188	197		10.1038/sj.onc.1204053	http://dx.doi.org/10.1038/sj.onc.1204053			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313946				2022-12-17	WOS:000166410900006
J	Maa, MC; Hsieh, CY; Leu, TH				Maa, MC; Hsieh, CY; Leu, TH			Overexpression of p97(Eps8) leads to cellular transformation: implication of pleckstrin homology domain in p97(Eps8)-mediated ERK activation	ONCOGENE			English	Article						p97(Eps8); pleckstrin homology domain; transformation; ERK	TYROSINE KINASE SUBSTRATE; BETA-GAMMA-SUBUNITS; PROTEIN-KINASE; HIGH-AFFINITY; PH DOMAIN; SH3 DOMAIN; EPS8; BINDING; PHOSPHORYLATION; GENE	Two isoforms of Eps8, p(97Eps8) and p68(Eps8), have been identified as the substrates for receptor tyrosine kinases, Our previous studies indicated that both tyrosyl phosphorylation and protein expression of Eps8 were elevated in v-Src transformed cells, In an attempt to examine the role played by p97(Eps8) in tumorigenesis, we have first obtained cells overexpressing p97(Eps8) and its pleckstrin homology (PH)-truncated variant. We then demonstrated that cells overexpressing p97(Eps8) not only exhibited the ability of focus formation in cell culture but also promoted the tumor formation in mice as compared to controls, Furthermore, elevated serum-induced extracellular responsive kinase (ERK) activation was observed in p97(Eps8) overexpressors, This enhanced ERK activation was sensitive to a MEK1 specific inhibitor PD98059 and was important for p97(Eps8)-mediated transformation, since transfection of vectors expressing dominant negative MEK1 and p97(Eps8) abrogated focus formation by p97(Eps8) In contrast, PH-truncated p97(Eps8) failed to localize at the plasma membrane and that the truncated variant also did not elevate ERK activation and cellular transformation in response to serum stimulation, Our results thus indicated that: (1) the gene encoding p97(Eps8) was an oncogene; (ii) p97(Eps8)-induced oncogenesis was partly mediated by ERK activation; and (iii) the PH domain of p97(Eps8) was critical for its cellular localization, ERK activation and its ability to transform cells.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; Chung shan Med & Dent Coll, Inst Biochem, Taichung 402, Taiwan	National Cheng Kung University; Chung Shan Medical University	Leu, TH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.				Animal center at NCKU; National Science Council Grant (NSC) [89-2320-B-006-007]; NHRI [DOH-87-HR-625, NHRIGT-EX89S932L]	Animal center at NCKU; National Science Council Grant (NSC); NHRI(National Health Research Institutes - Taiwan)	We thank Dr Sally Parsons and Dr Michael Weber for the pBabe (puro) expression vector and polyclonal ERK antibody (TR2) respectively, Dr Garry P Norlan and Dr Sue Lin-Chao for the virus-packaging cell line fNX-Eco and Dr Ching-Hsine Huang and Dr Hsin-Fang Yang-Yen for their critical comments on this manuscript. We appreciate the technical help provided by Ya-Chun Chuang, Hsaio-Hwai Chen and Hong-Ming Lin. We are also grateful to the animal center at NCKU for the care of animals. This work was supported by National Science Council Grant to M-C Maa (NSC 89-2320-B-006-007) and grants of NHRI to T-H Leu (DOH-87-HR-625, NHRIGT-EX89S932L).	Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; KARLSSON T, 1995, ONCOGENE, V10, P1475; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; MAA MC, 1992, ONCOGENE, V7, P2429; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Provenzano C, 1998, EXP CELL RES, V242, P186, DOI 10.1006/excr.1998.4095; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WONG WT, 1994, ONCOGENE, V9, P3057	31	29	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					106	112		10.1038/sj.onc.1204069	http://dx.doi.org/10.1038/sj.onc.1204069			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244499				2022-12-17	WOS:000166361400012
J	Roh, H; Pippin, JA; Green, DW; Boswell, CB; Hirose, CT; Mokadam, N; Drebin, JA				Roh, H; Pippin, JA; Green, DW; Boswell, CB; Hirose, CT; Mokadam, N; Drebin, JA			HER2/neu antisense targeting of human breast carcinoma	ONCOGENE			English	Article						HER2/neu; breast cancer; antisense oligonucleotides; oncogenes; apoptosis; cell cycle	HER2/NEU-OVEREXPRESSING METASTATIC BREAST; MONOCLONAL-ANTIBODIES; CANCER CELLS; OVARIAN-CANCER; TUMOR-GROWTH; NEU ONCOGENE; PHASE-II; IN-VIVO; RECEPTOR; OVEREXPRESSION	Overexpression of the HER2/neu oncogene is observed in approximately 30% of human breast carcinoma specimens. HER2/neu overexpression is a negative prognostic factor in breast cancer patients. Cancer cells that overexpress HER2/neu may also be less sensitive to chemotherapy. In order to further define mechanisms by which HER2/neu overexpression drives neoplastic cell growth and chemoresistance, antisense oligonucleotides (ODNs) have been utilized to selectively down-regulate HER2/neu expression in human breast cancer cells. Such antisense ODNs suppress HER2/neu mRNA and protein levels in a dose-dependent, sequence-specific manner. Down-regulation of HER2/neu expression in HER2/neu overexpressing breast cancer cells inhibits cell cycle progression in G(0)/G(1) and results in apoptotic cell death. In tissue culture studies, combined treatment of HER2/neu overexpressing breast cancer cells with HER2/neu antisense ODNs and conventional chemotherapeutic agents results in synergistic inhibition of cancer cell growth and activation of apoptotic cell death mechanisms. These studies have been extended to demonstrate synergistic antitumor effects following systemic treatment with antisense ODNs plus doxorubicin in nude mice bearing human breast carcinoma xenografts. Collectively these findings demonstrate that HER2/neu overexpression stimulates anti-apoptotic cell survival mechanisms and suggest that HER2/neu antisense ODNs may be of use in cancer therapeutics.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA	Washington University (WUSTL)	Drebin, JA (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109, St Louis, MO 63110 USA.				NCI NIH HHS [T32-CA09621, CA09141] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009141, T32CA009621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1997, Oncology (Williston Park), V11, P43; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BERCHUCK A, 1990, CANCER RES, V50, P4087; Brodowicz T, 1997, INT J CANCER, V73, P875, DOI 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO;2-3; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1985, CELL, V41, P95; Ghetie MA, 1997, P NATL ACAD SCI USA, V94, P7509, DOI 10.1073/pnas.94.14.7509; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Green DW, 2000, J AM COLL SURGEONS, V191, P93, DOI 10.1016/S1072-7515(00)00305-7; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KERN JA, 1990, CANCER RES, V50, P5184; Kita Y, 1996, BIOCHEM BIOPH RES CO, V226, P59, DOI 10.1006/bbrc.1996.1311; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; Roh H, 1999, SURGERY, V126, P413, DOI 10.1016/S0039-6060(99)70186-8; Roh H, 1998, J SURG RES, V77, P85, DOI 10.1006/jsre.1998.5353; Roh H, 2000, CANCER RES, V60, P560; Shen K, 1997, BIOCHEM BIOPH RES CO, V230, P89, DOI 10.1006/bbrc.1996.5896; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; WEBB SJ, 1997, ADV PHARMACOL, V40, P1; You XL, 1998, ONCOGENE, V17, P3177, DOI 10.1038/sj.onc.1202246	34	29	42	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6138	6143		10.1038/sj.onc.1204001	http://dx.doi.org/10.1038/sj.onc.1204001			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156527				2022-12-17	WOS:000166121400007
J	Kim, JS; Pirnia, F; Choi, YH; Nguyen, P; Knepper, B; Tsokos, M; Schulte, TW; Birrer, MJ; Blagosklonny, MV; Schaefer, O; Mushinski, JF; Trepel, JB				Kim, JS; Pirnia, F; Choi, YH; Nguyen, P; Knepper, B; Tsokos, M; Schulte, TW; Birrer, MJ; Blagosklonny, MV; Schaefer, O; Mushinski, JF; Trepel, JB			Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G-1 checkpoint	ONCOGENE			English	Article						lovastatin; differentiation; apoptosis; ESFT	PROSTATE CARCINOMA-CELLS; CYCLIN-DEPENDENT KINASES; EWINGS-SARCOMA; THYMOCYTE APOPTOSIS; DNA-BINDING; PHASE-I; CANCER; E2F-1; INHIBITION; INDUCTION	To develop a new approach to the treatment of primitive neuroectodermal tumors we evaluated the effect of the HMG-CoA reductase inhibitor lovastatin on the Ewing's sarcoma cell line CHP-100, Lovastatin induced neural morphology and markers including neuron-specific enolase and neurofilament protein. The acquisition of neural morphology required nem mRNA synthesis, and cDNA microarray analysis confirmed that lovastatin altered the program of gene expression. After morphologic differentiation the cells underwent rapidly progressive apoptosis. In normal development of neuronal progenitors, differentiation signals trigger p21(WAF1) accumulation, RB hypophosphorylation, enhanced RB-E2F-1 association, and G1 arrest, and these events have been shown to protect from apoptosis. In contrast, in the Ewing's sarcoma cells lovastatin triggered differentiation without causing cell cycle arrest: p21(WAF1) was not induced, RE remained hyperphosphorylated, and RE protein expression and RE-E2F-1 association were markedly downregulated, suggesting that loss of an RE-regulated G1 checkpoint promoted apoptosis. Consistent with this hypothesis, adenoviral p21(WAF1) decreased DNA synthesis and partially protected from lovastatin-induced cytotoxicity. The data demonstrate a new model for examining the genetic regulation of cell fate in a neural progenitor tumor and suggest a new approach to the treatment of this neoplasm.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, Div Clin Sci, NIH, Bethesda, MD 20892 USA; NCI, Genet Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Trepel, JB (corresponding author), NCI, Med Branch, NIH, Bldg 10,Room 12N230, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC008727, ZIABC008727] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; BERNAL S, 1983, CANCER RES, V43, P1256; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 1997, INT J ONCOL, V11, P1165; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denny CT, 1996, CANCER INVEST, V14, P83, DOI 10.3109/07357909609018438; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fontaine C, 1997, ANN ONCOL, V8, P691, DOI 10.1023/A:1008271903643; GrayBablin J, 1997, CANCER RES, V57, P604; GUDAS JM, 1993, CELL GROWTH DIFFER, V4, P421; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hense HW, 1999, ANN ONCOL, V10, P1073, DOI 10.1023/A:1008357018737; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; ISHIZAWA M, 1991, NUCLEIC ACIDS RES, V19, P5792, DOI 10.1093/nar/19.20.5792; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; Jang JS, 1999, ONCOGENE, V18, P1789, DOI 10.1038/sj.onc.1202497; Jurgens H F, 1994, Curr Opin Oncol, V6, P391; Kaelin WG, 1999, J CLIN INVEST, V104, P1503, DOI 10.1172/JCI8888; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kogan SC, 1999, ONCOGENE, V18, P5261, DOI 10.1038/sj.onc.1202996; Kovar H, 1998, Sarcoma, V2, P3, DOI 10.1080/13577149878109; LADENSTEIN R, 1995, BONE MARROW TRANSPL, V15, P697; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lees JA, 1999, P NATL ACAD SCI USA, V96, P4221, DOI 10.1073/pnas.96.8.4221; LIPINSKI M, 1987, CANCER RES, V47, P183; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Macaulay RJB, 1999, J NEURO-ONCOL, V42, P1, DOI 10.1023/A:1006164406202; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Muller C, 1999, INT J MOL MED, V3, P63; MUNRO E, 1994, EUR J CLIN INVEST, V24, P766, DOI 10.1111/j.1365-2362.1994.tb01074.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PACHTER JS, 1984, DEV BIOL, V103, P200, DOI 10.1016/0012-1606(84)90021-6; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Ross SD, 1999, ARCH INTERN MED, V159, P1793, DOI 10.1001/archinte.159.15.1793; SCHLESINGER HR, 1976, CANCER RES, V36, P3094; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Stewart ZA, 1999, CANCER RES, V59, P3831; Thibault A, 1996, CLIN CANCER RES, V2, P483; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Tsokos M, 1992, Perspect Pediatr Pathol, V16, P27; WHITESELL L, 1991, MOL CELL BIOL, V11, P1360, DOI 10.1128/MCB.11.3.1360; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	58	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6082	6090		10.1038/sj.onc.1204008	http://dx.doi.org/10.1038/sj.onc.1204008			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146561				2022-12-17	WOS:000165827900016
J	Pierce, A; Spooncer, E; Wooley, S; Dive, C; Francis, JM; Miyan, J; Owen-Lynch, PJ; Dexter, TM; Whetton, AD				Pierce, A; Spooncer, E; Wooley, S; Dive, C; Francis, JM; Miyan, J; Owen-Lynch, PJ; Dexter, TM; Whetton, AD			Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation	ONCOGENE			English	Article						Bcr-Abl; p53; CML; differentiation; haemopoietic	CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC-CELL LINE; CHRONIC MYELOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; WILD-TYPE P53; BLAST CRISIS; HOMOLOGOUS RECOMBINATION; RETROVIRAL TRANSDUCTION; CLONAL EVOLUTION; PROGENITOR CELLS	Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which is the expression of the Bcr-Abl Protein Tyrosine Kinase (PTK), We have previously reported that activation of a temperature sensitive Bcr-Abl PTK in the multipotent haemopoietic cell line FDCP-Mix for short periods resulted in subtle changes including, a transient suppression of apoptosis and no inhibition of differentiation. In contrast, activation of the Bcr-Abl PTK for 12 weeks results in cells that display a delay in differentiation at the early granulocyte stage. Plow cytometric analysis also indicates that the expression of cell surface differentiation markers and nuclear morphology are uncoupled. Furthermore, a significant number of the mature neutrophils display abnormal morphological features. Prolonged exposure to Bcr-Abl PTK results in interleukin-3 independent growth and decreased p53 protein levels. FDCP-Mix cells expressing a dominant negative p53 and p53(null) FDCP-Mix cells demonstrate that the reduction in p53 is causally related to the delay in development. Returning the cells to the restrictive temperature restores the p53 protein levels, the growth factor dependence and largely relieves the effects on development. We conclude that prolonged Bcr-Abl PTK activity within multipotent cells results in a reduction of p53 that drives a delayed and abnormal differentiation.	Christie Hosp NHS Trust, Canc Res Campaign, Dept Expt Haematol, Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England; UMIST, Leukaemia Res Fund Cellular Dev Unit, Manchester M60 1QD, Lancs, England; UMIST, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Sch Biol Sci, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester; University of Manchester; University of Manchester	Spooncer, E (corresponding author), Christie Hosp NHS Trust, Canc Res Campaign, Dept Expt Haematol, Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England.		Miyan, Jaleel/AAB-1910-2021	Miyan, Jaleel/0000-0002-1835-0143; Owen-Lynch, Penelope Jane/0000-0002-5928-2327; WHETTON, ANTHONY D/0000-0002-1098-3878; Dive, Caroline/0000-0002-1726-8850; Pierce, Andrew/0000-0001-5995-2469				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; CARLESSO N, 1994, ONCOGENE, V9, P149; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FLEMING TJ, 1993, J IMMUNOL, V151, P2399; FOTI A, 1991, BLOOD, V77, P2441; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gotoh A, 1997, Curr Opin Hematol, V4, P3; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; LANEUVILLE P, 1992, BLOOD, V80, P1788; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lub M, 1996, J LEUKOCYTE BIOL, V59, P648, DOI 10.1002/jlb.59.5.648; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Maguer-Satta V, 1998, ONCOGENE, V16, P237, DOI 10.1038/sj.onc.1201533; MASHAL R, 1990, BLOOD, V75, P180; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; METCALF D, 1974, BLOOD, V43, P847, DOI 10.1182/blood.V43.6.847.847; NAKAI H, 1995, BRIT J HAEMATOL, V90, P147, DOI 10.1111/j.1365-2141.1995.tb03393.x; NAKAI H, 1995, LEUKEMIA LYMPHOMA, V19, P213, DOI 10.3109/10428199509107891; NAKAI H, 1992, CANCER RES, V52, P6588; PEDERSEN B, 1982, BRIT J HAEMATOL, V51, P339, DOI 10.1111/j.1365-2141.1982.tb02789.x; Pierce A, 1998, J CELL SCI, V111, P815; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROVIRA A, 1995, ANN HEMATOL, V70, P129; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sambrook J., MOL CLONING LAB MANU; Seliger B, 1996, EUR J HAEMATOL, V57, P230; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shounan Y, 1996, LEUKEMIA, V10, P1619; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; STRIFE A, 1988, SEMIN HEMATOL, V25, P1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Verfaillie CM, 1998, HEMATOL ONCOL CLIN N, V12, P1, DOI 10.1016/S0889-8588(05)70495-0; WILLIAMS J, 1995, WILLIAMS HEMATOLOGY	59	29	29	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5487	5497		10.1038/sj.onc.1203940	http://dx.doi.org/10.1038/sj.onc.1203940			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114726				2022-12-17	WOS:000165396100009
J	Wu, R; Connolly, D; Ngelangel, C; Bosch, FX; Munoz, N; Cho, KR				Wu, R; Connolly, D; Ngelangel, C; Bosch, FX; Munoz, N; Cho, KR			Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix	ONCOGENE			English	Article						cervical cancer; FGFR; oncogene	MULTIPLE-MYELOMA; CHROMOSOMAL TRANSLOCATION; ACTIVATING MUTATIONS; HUMAN-PAPILLOMAVIRUS; RAS GENE; ACHONDROPLASIA; ONCOGENE; CANCER; T(4/14)(P16.3,Q32); OVEREXPRESSION	Germline mutations of the gene encoding human fibroblast growth factor receptor 3 (FGFR3) have been shown to be responsible for several related autosomal dominant forms of syndromic craniosynostosis and short limb dwarfism. Somatic activating mutations of FGFR3 were recently reported to occur in three of 12 (25%) uterine cervical carcinomas and nine of 26 (35%) bladder carcinomas, suggesting that constitutive activation of FGFR3 may be an important mechanism underlying the development and/or progression of these common epithelial malignancies. In order to investigate further a possible role for FGFR3 mutations in cervical carcinogenesis, we performed sequence-based mutational analysis of FGFR3 in 51 primary cervical carcinomas and seven cervical carcinoma-derived cell lines. The regions analysed (exons 7, 10, 13, 15, and 19) encompassed all previously described FGFR3 mutations. A single nucleotide substitution at codon 249, predicting a serine to cysteine amino acid substitution (S249C) in the FGFR3 extracellular domain, was identified in one primary tumor. Only wild type FGFR3 alleles were identified in the remaining tumors and cell lines. The S249C mutation is the only FGFR3 mutation described to date in cervical carcinomas. These findings suggest that while activating mutations of FGFR3 occur in cervical cancer, they may not be as common as initially reported.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Philippines, Philippine Gen Hosp, Dept Med, Clin Epidemiol Unit, Manila, Philippines; Hosp Llobregat, Inst Catala Oncol, Serv Epidemiol & Registre Canc, E-08907 Barcelona, Spain; Int Agcy Res Canc, F-69372 Lyon 08, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of the Philippines System; University of the Philippines Manila; Catalan Institute of Oncology; University of Barcelona; World Health Organization; International Agency for Research on Cancer (IARC)	Cho, KR (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 4301 MSRBIII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		; BOSCH JOSE, FRANCESC XAVIER/J-6339-2012	Cho, Kathleen/0000-0003-0500-9998; BOSCH JOSE, FRANCESC XAVIER/0000-0002-7172-3412	NATIONAL CANCER INSTITUTE [R29CA064466] Funding Source: NIH RePORTER; NCI NIH HHS [CA64466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER VV, 1988, J SURG ONCOL, V39, P225, DOI 10.1002/jso.2930390403; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Finelli P, 1999, BLOOD, V94, P724, DOI 10.1182/blood.V94.2.724.414k05_724_732; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; Grendys EC, 1997, GYNECOL ONCOL, V65, P343, DOI 10.1006/gyno.1997.4649; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; IKEGAWA S, 1995, HUM GENET, V96, P309; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Katsumata N, 1998, ENDOCR J, V45, pS171, DOI 10.1507/endocrj.45.Suppl_S171; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; MITRA AB, 1994, CANCER RES, V54, P637; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; RIOU G, 1988, ONCOGENE, V3, P329; RIOU GF, 1990, ANTICANCER RES, V10, P1225; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WONG YF, 1995, CANCER LETT, V95, P29, DOI 10.1016/0304-3835(95)03857-S; Wuchner C, 1997, HUM GENET, V100, P215, DOI 10.1007/s004390050493	31	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5543	5546		10.1038/sj.onc.1203934	http://dx.doi.org/10.1038/sj.onc.1203934			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114733				2022-12-17	WOS:000165396100016
J	Panigone, S; Debernardi, S; Taya, Y; Fontanella, E; Airoldi, R; Delia, D				Panigone, S; Debernardi, S; Taya, Y; Fontanella, E; Airoldi, R; Delia, D			pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide	ONCOGENE			English	Article						HPR; pRb; cell cycle	CANCER CELL-LINES; DEPENDENT KINASE-ACTIVITY; BREAST-CARCINOMA CELLS; RETINOIC ACID RECEPTOR; RETINOBLASTOMA PROTEIN; GROWTH-INHIBITION; CYCLE PROGRESSION; APOPTOSIS; PHOSPHORYLATION; RETINAMIDE	The cancer chemopreventive synthetic retinoid N-(4-hydroxyphenyl)retinamide (HPR) can inhibit the growth and induce apoptosis of tumor cells. In this study we analysed the growth suppressive effect of HPR on human breast cancer cell lines in vitro and the role of the retinoblastoma protein (pRb) in this response. Treatment of MCF7, T47D and SKBR3 for 24-48 h with 3 mu M HPR, a concentration attainable in vivo, resulted in growth inhibition and marked dephosphorylation of pRb involving Ser(612), Thr(821), Ser(795) and Ser(780), target residues for cyclin-dependent kinase 2 (Cdk2) the former two, and Cdk4 the latter two. Interestingly, this dephosphorylation of pRb occurred in S-G2-M phase cells, as revealed by experiments on cells fractionated by FACS according to the cell cycle phase, hence suggesting that the retinoid interferes with the regulation of pRb phosphorylation, The in vitro phosphorylation of a GST-pRb recombinant substrate by Cdk2 immunocomplexes from MCF7, T47D and SKBR3 was markedly suppressed after HPR treatment, whereas that by Cdk4 complexes was suppressed in T47D and SKBR3 but not in MCF7, The steady-state levels of Cdk2, Cdk4 and Cyclin A proteins were unaffected by HPR, while those of Cyclin D1 were significantly reduced in all three cell lines. Interestingly, Cyclin D1 downregulation by HPR correlated with transcriptional repression, but not with enhanced proteolysis of Cyclin D1 typically elicited by other retinoids, Collectively, our data suggest that the antiproliferative activity of HPR arises from its capacity to maintain pRb in a de-phosphorylated growth-suppressive status in S-G2/M, possibly through Cyclin D1 downregulation and inhibition of pRb-targeting Cdks.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Natl Canc Ctr, Res Inst, Div Biol, Mol Biol Lab,Chuo Ku, Tokyo 1040045, Japan	Fondazione IRCCS Istituto Nazionale Tumori Milan; National Cancer Center - Japan	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.							Adams PD, 1999, MOL CELL BIOL, V19, P1068; Angoli D, 1996, BIOCHEM BIOPH RES CO, V229, P681, DOI 10.1006/bbrc.1996.1863; BHATNAGAR R, 1991, BIOCHEM PHARMACOL, V41, P1471, DOI 10.1016/0006-2952(91)90563-K; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Brooks SC, 1996, BLOOD, V87, P227; Chen XM, 1999, ONCOGENE, V18, P5691, DOI 10.1038/sj.onc.1202948; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DELIA D, 1995, BLOOD, V85, P3659; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; Kazmi SMI, 1996, CANCER RES, V56, P1056; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; Louvet C, 1996, BRIT J CANCER, V74, P394, DOI 10.1038/bjc.1996.371; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARIOTTI A, 1994, J NATL CANCER I, V86, P1245, DOI 10.1093/jnci/86.16.1245; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; McCormick DL, 1996, CARCINOGENESIS, V17, P2513, DOI 10.1093/carcin/17.11.2513; Moon Richard C., 1994, P573; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; PIENTA KJ, 1993, CANCER RES, V53, P224; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLLARD M, 1991, CANCER RES, V51, P3610; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	44	29	33	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4035	4041		10.1038/sj.onc.1203743	http://dx.doi.org/10.1038/sj.onc.1203743			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962560				2022-12-17	WOS:000088825300009
J	Yamamoto, H; Ochiya, T; Takahama, Y; Ishii, Y; Osumi, N; Sakamoto, H; Terada, M				Yamamoto, H; Ochiya, T; Takahama, Y; Ishii, Y; Osumi, N; Sakamoto, H; Terada, M			Detection of spatial localization of Hst-1/Fgf-4 gene expression in brain and testis from adult mice	ONCOGENE			English	Article						Hst-1/Fgf-4; brain; testis; in situ; RT-PCR; adult	FACTOR-LIKE IMMUNOREACTIVITY; FIBROBLAST GROWTH-FACTORS; RAT SERTOLI CELLS; MESSENGER-RNA; SKELETAL-MUSCLE; NERVOUS-SYSTEM; FGF-4; RECEPTOR; MOUSE; HST-1	HST-1, a member of the fibroblast grow th factor (FGF) family (FGF-4), has been shown to be a signaling molecule whose expression is essential for embryonic development. However, HST-1/FGF-4 expression has not been detected or reported in adult tissues so far analysed. To investigate whether there is a possible role of HST-1/FGF-4 in adult stage, we have carried out a highly sensitive RT-PCR analysis of Hst-1/Fgf-4 gene expression in adult mice tissues. Results show Hst-1/Fgf-4 gene expression in the nervous system, intestines, and testis of normal adult mice. In situ hybridization technique was used to localize Hst-1/Fgf-4 gene expression in the cerebellum and testis from 10-week-old mice. Cell type-specific gene expression was detected: Purkinje cells in the cerebellum and Sertoli cells in testis, These findings suggest that the Hst-1/Fgf-4 gene also plays an important role in adult tissues, and may offer insights into the biological significance of HST-1/FGF-4 in cerebellar and testicular functions.	Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Nara Med Univ, Dept Surg 1, Nara 6348522, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Biochem & Cell Biol, Kodaira, Tokyo 1878502, Japan	National Cancer Center - Japan; Nara Medical University; National Center for Neurology & Psychiatry - Japan	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 1-1 Tsukiji 5-chome, Tokyo 1040045, Japan.		Osumi, Noriko/T-2823-2019; Ochiya, Takahiro/AAH-7585-2019	Osumi, Noriko/0000-0003-0548-6452; 				BEAN AJ, 1991, P NATL ACAD SCI USA, V88, P10237, DOI 10.1073/pnas.88.22.10237; Cancilla B, 1998, BIOL REPROD, V58, P1138, DOI 10.1095/biolreprod58.5.1138; Collignon J, 1996, DEVELOPMENT, V122, P509; Dahmane N, 1999, DEVELOPMENT, V126, P3089; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; ELHUSSEINI AE, 1994, MOL CELL ENDOCRINOL, V104, P191, DOI 10.1016/0303-7207(94)90122-8; FUJINO I, 1995, CELL TISSUE RES, V280, P201, DOI 10.1007/BF00307790; GOMEZPINILLA F, 1993, BRAIN RES, V606, P79, DOI 10.1016/0006-8993(93)91572-A; GRISWOLD MD, 1988, OXFORD REV REPROD B, V10, P124; GUILLOU F, 1990, CELL TISSUE RES, V260, P395, DOI 10.1007/BF00318642; Hannon K, 1996, J CELL BIOL, V132, P1151, DOI 10.1083/jcb.132.6.1151; HEIKINHEIMO O, 1995, MOL REPROD DEV, V42, P397, DOI 10.1002/mrd.1080420405; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; Khodakhah K, 1997, P NATL ACAD SCI USA, V94, P14009, DOI 10.1073/pnas.94.25.14009; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; LEMAGUERESSEBATTISTONI B, 1994, ENDOCRINOLOGY, V135, P2404, DOI 10.1210/en.135.6.2404; MATSUDA S, 1992, NEUROSCIENCE, V50, P99, DOI 10.1016/0306-4522(92)90384-E; MATSUDA S, 1994, NEUROSCIENCE, V59, P651, DOI 10.1016/0306-4522(94)90184-8; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Nakamua S, 1999, GLIA, V28, P53, DOI 10.1002/(SICI)1098-1136(199910)28:1<53::AID-GLIA7>3.0.CO;2-V; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; ORTH JM, 1990, ANAT REC, V226, P320, DOI 10.1002/ar.1092260308; Ozawa K, 1996, MOL BRAIN RES, V41, P279, DOI 10.1016/0169-328X(96)00108-8; PARANKO J, 1986, DEV BIOL, V117, P35, DOI 10.1016/0012-1606(86)90345-3; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Shamim H, 1999, DEVELOPMENT, V126, P945; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; THEILLET C, 1989, ONCOGENE, V4, P915; Todo T, 1998, BRAIN RES, V783, P179, DOI 10.1016/S0006-8993(97)01340-1; TSUDA H, 1989, CANCER RES, V49, P3104; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; vanDisselEmiliani FMF, 1996, ENDOCRINOLOGY, V137, P647, DOI 10.1210/en.137.2.647; WILCOX BJ, 1991, NEURON, V6, P397, DOI 10.1016/0896-6273(91)90248-X; Wilkinson DG, 1992, SITU HYBRIDIZATION P; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; YOSHIDA T, 1991, METHOD ENZYMOL, V198, P124; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	45	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3805	3810		10.1038/sj.onc.1203752	http://dx.doi.org/10.1038/sj.onc.1203752			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949936				2022-12-17	WOS:000088568400014
J	Kaul, SC; Sugihara, T; Yoshida, A; Nomura, H; Wadhwa, R				Kaul, SC; Sugihara, T; Yoshida, A; Nomura, H; Wadhwa, R			Gros1, a potential growth suppressor on chromosome 1: its identity to basement membrane-associated proteoglycan, leprecan	ONCOGENE			English	Article						Gros1/leprecan; proteoglycan; tumor suppressor; chomosome 1	IN-SITU HYBRIDIZATION; ALLELIC LOSS; MULTIFUNCTIONAL REGULATOR; MEDIATED SUPPRESSION; BREAST-CANCER; REGION; CARCINOMA; DELETION; DECORIN; HETEROZYGOSITY	By immunoscreening with an antibody raised against a plasma membrane protein, we have cloned a growth suppressor gene, Gros1 and assigned it to short arm of human chromosome 1. Two alternatively spliced forms of the gene encoding 84- and 41-kDa (carboxy-terminus truncated) proteins were cloned. The two transcripts, 4.4 and 2.7 kb, were expressed weakly in most of the human tissues, with a high expression of the smaller transcript in placenta, ovary and testis. Normal human fibroblasts in culture shelved two transcripts, with a higher level of expression of the 4.4 kb transcript. Transformed cells on the other hand showed predominant expression of the 2.7 kb transcript. Two Gros1 transcripts were also detected in most of the mouse tissues. Stable transfection of the mouse cDNA encoding the 85-kDa protein into NIH3T3 cells resulted in their slow growth and reduced colony-forming efficiency. Stable clones expressing antisense RNA on the other hand exhibited higher colony forming efficiency. Wlile our data implied that Gros1 is a novel growth suppressor gene on human chromosome 1, an independent study has recently characterized its rat-homolog as a <(le)under bar>ucine <(pr)under bar>oline-(e) under bar nriched novel basement membrane-associated proteogly<(can)under bar> leprecan. We describe here cloning, expression and biological activity analysis implying that this novel proteoglycan is a potential growth suppressor on chromosome 1p31, frequently altered in many malignancies.	Chugai Res Inst Mol Med, Ibaraki, Osaka 30041, Japan; AIST, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Wadhwa, R (corresponding author), Chugai Res Inst Mol Med, 153-2 Nagai, Ibaraki, Osaka 30041, Japan.		Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916				Anttonen A, 1999, BRIT J CANCER, V79, P558, DOI 10.1038/sj.bjc.6690088; ARIYAMA T, 1995, GENOMICS, V25, P114, DOI 10.1016/0888-7543(95)80116-4; Arlt MF, 1996, HUM MOL GENET, V5, P1017, DOI 10.1093/hmg/5.7.1017; Bomme L, 1998, GENE CHROMOSOME CANC, V21, P185, DOI 10.1002/(SICI)1098-2264(199803)21:3<185::AID-GCC2>3.0.CO;2-W; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; Caput D, 1997, B CANCER, V84, P1081; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Carrino DA, 2000, ARCH BIOCHEM BIOPHYS, V373, P91, DOI 10.1006/abbi.1999.1545; Chen HL, 1996, CANCER GENET CYTOGEN, V86, P102, DOI 10.1016/0165-4608(95)00186-7; CHENG NC, 1995, ONCOGENE, V10, P291; Dhodapkar MV, 1998, BLOOD, V91, P2679, DOI 10.1182/blood.V91.8.2679.2679_2679_2688; Dhodapkar MV, 1999, LEUKEMIA LYMPHOMA, V34, P35, DOI 10.3109/10428199909083378; Di Vinci A, 1998, CANCER-AM CANCER SOC, V83, P415; Fujimoto Y, 1998, Rinsho Byori, V46, P9; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iolascon A, 1997, LEUKEMIA, V11, P359, DOI 10.1038/sj.leu.2400596; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Ishino S, 1998, CANCER, V83, P360, DOI 10.1002/(SICI)1097-0142(19980715)83:2<360::AID-CNCR21>3.0.CO;2-Q; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kolettas E, 1998, EUR J BIOCHEM, V254, P266, DOI 10.1046/j.1432-1327.1998.2540266.x; Lee WC, 1996, CANCER RES, V56, P4297; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; Merle B, 1999, J CELL BIOCHEM, V75, P538; MOLEY JF, 1992, CANCER RES, V52, P770; MUNN KE, 1995, ONCOGENE, V10, P1653; NAGAI H, 1995, CANCER RES, V55, P1752; Nakanishi K, 1999, INT J CANCER, V80, P527, DOI 10.1002/(SICI)1097-0215(19990209)80:4<527::AID-IJC8>3.3.CO;2-P; Nash MA, 1999, CANCER RES, V59, P6192; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Perlman EJ, 1996, GENE CHROMOSOME CANC, V16, P15, DOI 10.1002/(SICI)1098-2264(199605)16:1<15::AID-GCC2>3.0.CO;2-6; PRAML C, 1995, ONCOGENE, V11, P1357; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Stander M, 1998, GENE THER, V5, P1187, DOI 10.1038/sj.gt.3300709; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.3.CO;2-P; Verbeek MM, 1999, AM J PATHOL, V155, P2115, DOI 10.1016/S0002-9440(10)65529-0; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1993, J BIOL CHEM, V268, P6615; Wassnehove-McCarthy DJ, 1999, J BIOL CHEM, V274, P25004, DOI 10.1074/jbc.274.35.25004; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0	41	29	33	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3576	3583		10.1038/sj.onc.1203696	http://dx.doi.org/10.1038/sj.onc.1203696			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951563				2022-12-17	WOS:000088568300003
J	Bruckheimer, EM; Cho, S; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ				Bruckheimer, EM; Cho, S; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ			The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo	ONCOGENE			English	Article						prostate; bcl-2; bax; apoptosis; androgen	PROGRAMMED CELL-DEATH; TRANSGENIC MICE; IN-VIVO; IMMUNOHISTOCHEMICAL ANALYSIS; REGULATED EXPRESSION; ANDROGEN-ABLATION; CANCER; APOPTOSIS; ANTIGEN; GENE	Prostatic glandular epithelial cells undergo apoptosis in response to androgen-deprivation. The molecular determinants of androgen-responsiveness in these cells are incompletely understood. Recent evidence suggests that bcl-2 gene family members mag be important in this context, We used the probasin promoter to target a human bcl-2 transgene specifically to the prostate in order to assess its impart on conferring resistance to androgen withdrawal in, otherwise sensitive, prostatic glandular epithelial cells in vivo, We examined the contribution of bax to mediating androgen-responsiveness in prostatic glandular epithelial cells using hair knockout mice, The histologic appearance of the prostates from probasin-bcl-2 transgenic mice or bax(-/-) mice did not differ from those of control littermates. There was no evidence of hyperplastic or neoplastic growth, There was no difference between probasin bcl-2 transgenic mice, bax(-/-) mice, and control littermates in steady-state levels of apoptosis, Following castration our findings suggest that both bax and bcl-2 may each contribute to the androgen-responsiveness of prostatic glandular epithelial cells. It is apparent from these results, however, that bax is not required to mediate cell death in prostatic glandular epithelial cells following castration. A comparison between the apoptotic indices in the ventral prostate from the probasin-hcl-2 and bax(-/-) mice following castration suggests that the presence of bcl-2 may be a more important indicator of androgen-sensitivity than a deficiency of bax.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.			Gingrich, Jeffrey/0000-0002-4516-2893	NCI NIH HHS [T32CA67759-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANERJEE PP, 1995, ENDOCRINOLOGY, V136, P4368, DOI 10.1210/en.136.10.4368; Beham AW, 1998, INT J MOL MED, V1, P953; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Bruckheimer EM, 1999, SEMIN ONCOL, V26, P382; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; COLOMBEL M, 1993, AM J PATHOL, V143, P390; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pang S, 1997, CANCER RES, V57, P495; Perlman H, 1999, CELL DEATH DIFFER, V6, P48, DOI 10.1038/sj.cdd.4400453; RAFFO AJ, 1995, CANCER RES, V55, P4438; Schorr K, 1999, CANCER RES, V59, P2541; TUNN S, 1989, PROSTATE, V15, P263, DOI 10.1002/pros.2990150307; Westin P, 1997, INT J ONCOL, V10, P113; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	31	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2404	2412		10.1038/sj.onc.1203571	http://dx.doi.org/10.1038/sj.onc.1203571			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828882				2022-12-17	WOS:000087018400005
J	Roth, J; Koch, P; Contente, A; Dobbelstein, M				Roth, J; Koch, P; Contente, A; Dobbelstein, M			Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain	ONCOGENE			English	Article						p53; apoptosis; transcriptional activation; protein-DNA-interaction; p73	FUNCTIONAL DOMAINS; GROWTH SUPPRESSION; CRYSTAL-STRUCTURE; CERVICAL-CANCER; WILD-TYPE; APOPTOSIS; PROTEIN; GENE; POLYMORPHISM; REGION	The p53 tumor suppressor protein induces apoptosis through a mechanism that may involve the transcriptional activation of cellular genes, including the PIG3 gene. A p53 protein lacking the proline-rich region (p53 Delta 62-91) induces many p53-responsive genes but not PIG3, In parallel, this mutant induces growth arrest but not apoptosis, We show here that the replacement of the N-terminal (amino acids 1-80) or C-terminal (amino acids 344-393) domains of p53 with heterologous domains does not interfere with transcription from the PIG3 promoter, but these chimeras still require the proline-rich region for PIG3 activation. The p53-homolog p73 beta also activated the PIG3 promoter, but in contrast to p53, the proline-rich domain of p73 beta (residues 81-113) was dispensable to induce the PIG3 promoter, Some tumor-derived p53-mutants, especially M246I, retained the ability to activate transcription of mdm2 but specifically failed to induce the PIG3 promoter, thus resembling p53 Delta 62-91. Further, p53 Delta 62-91 and p53M246I were defective for induction of apoptosis, Finally, p53 Delta 62-91 and p53M246I both showed reduced binding to the DNA of the PIG3 promoter and also to the DNA of the mdm2 and p21 promoters in vitro. Correspondingly, at low expression levels, p53 Delta 62-91 and p53M246I poorly activated the mdm2 promoter when compared to wild type p53. Our results suggest that the proline-rich domain of p53 affects the ability of the central domain to bind DNA, Moreover, some tumor-derived mutations within the central DNA binding domain of p53 mimic the loss of the proline-rich domain.	Univ Marburg, Inst Virol, Zentrum Mikrobiol & Hyge, D-35037 Marburg, Germany; Univ Marburg, Zentrum Innere Med, Abt Gastroenterol & Stoffwechsel, Fachbereich Med, D-35043 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Zentrum Mikrobiol & Hyge, Robert Koch Str 17, D-35037 Marburg, Germany.		Koch, Philipp/AAZ-3751-2020	Dobbelstein, Matthias/0000-0001-5052-3967; Koch, Philipp/0000-0003-3713-8786				Agami R, 1999, NATURE, V399, P809; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Dobbelstein M, 1996, J VIROL, V70, P6479, DOI 10.1128/JVI.70.9.6479-6485.1996; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; Gong JG, 1999, NATURE, V399, P806; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON P, 1993, ONCOGENE, V8, P589; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Konig C, 1999, J VIROL, V73, P2253; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Minaguchi T, 1998, CANCER RES, V58, P4585; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rosenthal AN, 1998, LANCET, V352, P871, DOI 10.1016/S0140-6736(98)07357-7; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Sun XF, 1996, ONCOGENE, V13, P407; Taylor JA, 1996, CANCER RES, V56, P294; Thomas M, 1999, MOL CELL BIOL, V19, P1092; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	44	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1834	1842		10.1038/sj.onc.1203500	http://dx.doi.org/10.1038/sj.onc.1203500			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777217				2022-12-17	WOS:000086292500011
J	Mazars, A; Tournigand, C; Mollat, P; Prunier, C; Ferrand, N; Bourgeade, MF; Gespach, C; Atfi, A				Mazars, A; Tournigand, C; Mollat, P; Prunier, C; Ferrand, N; Bourgeade, MF; Gespach, C; Atfi, A			Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-beta	ONCOGENE			English	Article						apoptosis; c-Myc; JNK; Smad2; TGF-beta	TRANSFORMING-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; SELECTIVE ACTIVATION; CYCLE PROGRESSION; INDUCED APOPTOSIS; GENE-EXPRESSION; RAC; RECEPTOR; INDUCTION; SAPK/JNK	The transforming growth factor beta (TGF-beta) plays an important role in constraining cellular proliferation, but it is also a potent inducer of programmed cell death or apoptosis. Here, we demonstrate that TGF-beta can have an opposite effect, acting as a survival factor to prevent c-Myc-induced cell death in Rat-1 fibroblasts, However, in marked contrast to TCF-beta, Smad2, which is a critical intracellular mediator of the TGF-beta signaling pathway, functions as an antagonist to induce increased cell death. The protective activity of TGF-beta was associated with the activation of c-Jun N-terminal Kinase (JNK) and was not linked to the ability of TGF-beta to promote cell cycle progression. Expression of dominant-interfering forms of various components of the JNK signaling pathway, including Rac1, Cdc42, mitogen-activated protein kinase kinase 4 (MKK4), and c-Jun, abolished TGF-beta-mediated cell survival. Furthermore, overexpression of the constitutively activated mutant RacL61F37A, which selectively stimulates JNK cascade but not G1 cell cycle progression or actin polymerization, was sufficient to prevent apoptosis induced by c-Myc. These findings describe a differential effect of two separated signaling pathways of TGF-beta and indicate for the first time that Smad2 can act as antagonist to suppress TGF-beta-dependent cell survival.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Hop St Antoine, INSERM, U417, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Atfi, A (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Frottier, Celine Prunier/G-8259-2017; Tournigand, Christophe/Q-2831-2018	Frottier, Celine Prunier/0000-0002-7784-0273; 				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ASKEW DS, 1991, ONCOGENE, V6, P1915; Atfi A, 1999, ONCOGENE, V18, P3878, DOI 10.1038/sj.onc.1202734; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Frey RS, 1997, CANCER RES, V57, P628; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAPP UR, 1994, ONCOGENE, V9, P3493; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SACHINIDIS A, 1993, FEBS LETT, V319, P221, DOI 10.1016/0014-5793(93)80550-E; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	55	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2000	19	10					1277	1287		10.1038/sj.onc.1203420	http://dx.doi.org/10.1038/sj.onc.1203420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713669				2022-12-17	WOS:000085743800004
J	Tsuneoka, M; Mekada, E				Tsuneoka, M; Mekada, E			Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras	ONCOGENE			English	Article						apoptosis; MEK; Myc; Ras; transformation	CYCLIN-E; INDUCTION; ONCOGENES; PROTEIN; KINASE; PROLIFERATION; ONCOPROTEIN; FIBROBLASTS; REQUIRES; CANCER	Cooperation of myc and activated ras has been suggested to cause malignant cell transformation but the mechanism is still unknown. Here we isolated a transformed cell line in which activation of c-Mye and Ras are independently controllable, and show that after establishment of the transformed state by c-myc and activated ras, removal of activated Ras initiates apoptosis that is dependent on c-Myc activity. Apoptosis is also initiated by an inhibitor of MEK (MAPK/ERK kinase), a kinase downstream of Ras, and apoptosis is blocked by activated Mek1. These results suggest that one of the conditions required for establishment of the transformed state is a block of apoptosis involving MEK activity. We tested the effect of MEK inhibition on cells transformed by various oncogenes, Suppression of apoptosis by MEK; is not critical in general, but in cells transformed by c-myc plus a gene that activates the MAPK cascade it is necessary to avoid cell death, Activated Ras/MEK did not suppress c-myc-dependent apoptosis due to serum-limitation. Overexpression of chicken bcl-xL suppressed apoptosis under serum-limiting conditions, but not apoptosis initiated by Ras/MEK inhibition in cells transformed by myc and activated ras. Altogether, these results suggest the existence of a novel el regulatory mechanism for myc-dependent apoptosis in certain transformed cells.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Kurume University	Tsuneoka, M (corresponding author), Kurume Univ, Inst Life Sci, 2432-3 Aikawa Machi, Kurume, Fukuoka 8390861, Japan.			Mekada, Eisuke/0000-0001-8858-4781				BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BOS JL, 1989, CANCER RES, V49, P4682; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PFEIFER AMA, 1989, P NATL ACAD SCI USA, V86, P10075, DOI 10.1073/pnas.86.24.10075; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; Tsuneoka M, 1998, J BIOCHEM-TOKYO, V124, P1013, DOI 10.1093/oxfordjournals.jbchem.a022193; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; YAMASHITA T, 1980, INT J CANCER, V26, P435, DOI 10.1002/ijc.2910260408	29	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					115	123		10.1038/sj.onc.1203232	http://dx.doi.org/10.1038/sj.onc.1203232			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644986				2022-12-17	WOS:000084844300013
J	Liu, JF; Chevet, E; Kebache, S; Lemaitre, G; Barritault, D; Larose, L; Crepin, M				Liu, JF; Chevet, E; Kebache, S; Lemaitre, G; Barritault, D; Larose, L; Crepin, M			Functional Rac-1 and Nck signaling networks are required for FGF-2-induced DNA synthesis in MCF-7 cells	ONCOGENE			English	Article						FGF-2; MCF-7; DNA synthesis	FIBROBLAST-GROWTH-FACTOR; BREAST-CANCER CELLS; PROTEIN-KINASE PATHWAY; TYROSINE PHOSPHATASE; RECEPTOR ACTIVATION; STIMULATED CELLS; FACTOR FAMILY; MAP KINASE; RAS; SHC	The effects of Fibroblast Growth Factor-2 (FGF-2) on breast cancer cell DNA synthesis are controversial. To elucidate the mechanisms by which FGF-2 stimulates or inhibits DNA synthesis, we analysed FGF-2 signaling pathways in breast cancer MCF-7 and MCF-7 cells overexpressing Ha-Ras (MCF-7ras), We found that FGF-2-induction of DNA synthesis correlates with Ras transient activation, FRS-2 tyrosine phosphorylation and low level of expression of p66(She). In addition, Nck-associated proteins are highly tyrosine phosphorylated and JNK reaches a higher level of activation when FGF-2 triggers DNA synthesis. Interestingly upon FGF-2 treatment, JNK activation and DNA synthesis are dependent on Rac-1 activity. These results confirm that in MCF-7 cells, induction of DNA synthesis by FGF-2 requires a transient activation of the Ras/MAPK cascade and demonstrates for the first time that intact Rac-1 and Nck signaling networks are required.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B2, Canada; Univ Paris 13, UFR Leonard de Vinci, Lab Rech Oncol Mol Humaine, EA 445, F-93012 Bobigny, France; Univ Paris 13, Lab CRRET, F-94010 Creteil, France	McGill University; McGill University; Universite Paris 13; Universite Paris 13; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Chevet, E (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.		Liu, Jianfeng/E-2786-2012; chevet, eric/E-4992-2016; Lemaître, Gilles/AAL-5889-2021	chevet, eric/0000-0001-5855-4522; Lemaitre, Gilles/0000-0002-0898-1582				Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Cantrell D, 1998, TRENDS CELL BIOL, V8, P180, DOI 10.1016/S0962-8924(98)01264-1; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Fenig E, 1997, CLIN CANCER RES, V3, P135; GELMANN EP, 1992, INT J CANCER, V50, P665, DOI 10.1002/ijc.2910500431; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GOMM JJ, 1991, CANCER RES, V51, P4685; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KAREY KP, 1988, CANCER RES, V48, P4083; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JF, 1998, EUR J BIOCHEM, V258, P271, DOI 10.1046/j.1432-1327.1998.2580271.x; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCLESKEY SW, 1994, CANCER RES, V54, P523; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Rockow S, 1996, ONCOGENE, V12, P2351; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; SOMMERS CL, 1990, CANCER RES, V50, P67; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Wang HS, 1997, CANCER RES, V57, P1750; Wang JK, 1996, ONCOGENE, V13, P721; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	47	29	31	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6425	6433		10.1038/sj.onc.1203027	http://dx.doi.org/10.1038/sj.onc.1203027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597244				2022-12-17	WOS:000083709200004
J	Verheijen, MHG; Wolthuis, RMF; Defize, LHK; den Hertog, J; Bos, JL				Verheijen, MHG; Wolthuis, RMF; Defize, LHK; den Hertog, J; Bos, JL			Interdependent action of RalGEF and Erk in Ras-induced primitive endoderm differentiation of F9 embryonal carcinoma cells	ONCOGENE			English	Article						Ras; RalGEF; Erk; F9 embryonal carcinoma; primitive endoderm	PROTEIN-KINASE ACTIVATION; DISSOCIATION STIMULATOR; C-JUN; TRANSFORMATION; PHOSPHORYLATION; INDUCTION; CASCADE; PATHWAY	Previous work by us and others has implicated a role for Ral guanine exchange factors (RalGEFs) in Ras-induced cell growth and oncogenic transformation. Here we show for the first time that RalGEFs are involved in Ras-induced differentiation as well. Expression of oncogenic Ras in F9 embryonal carcinoma (EC) cells is known to induce differentiation to a primitive endoderm (PrE)-like phenotype, but the downstream signal transduction mechanisms involved are unclear. We found that PrE differentiation is induced by the Ras effector domain mutants, RasV12G37 and RasV12E38, but not by RasV12C40. Accordingly, expression of constitutively active forms of RalGEF (Rlf-CAAX) or Raf1 (Raf-CAAX) is sufficient to induce differentiation. Inhibition of RalGEF activity by expression of dominant negative Ral completely abolishes Rlf-CAAX- and RasV12G37-induced differentiation, while it reduces differentiation by RasV12 and Raf-CAAX. Finally, while Rlf-CAAX does not increase Erk activity, inhibition of MEK blocks both Ras- as web as Rlf-CAAX-induced differentiation, suggesting that RalGEFs induce PrE differentiation in a manner depending on basal MEK or Erk activity. Based on these results we conclude that Ras induces PrE differentiation of F9 EC cells via an interplay of Erk- and RalGEF-mediated pathways.	Univ Utrecht, Physiol Chem Lab, NL-3508 TC Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3508 TC Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Utrecht University; Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Bos, JL (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3508 TC Utrecht, Netherlands.		Verheijen, Mark/AAD-8112-2019; Verheijen, Mark/GQY-5157-2022	Verheijen, Mark/0000-0002-3739-3755; Wolthuis, Rob/0000-0002-3109-1588				BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; RODRIGUEZ VP, 1997, CELL, V89, P457; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	21	29	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4435	4439		10.1038/sj.onc.1202834	http://dx.doi.org/10.1038/sj.onc.1202834			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442634				2022-12-17	WOS:000081813500005
J	Heger, P; Rosorius, O; Hauber, J; Stauber, RH				Heger, P; Rosorius, O; Hauber, J; Stauber, RH			Titration of cellular export factors, but not heteromultimerization, is the molecular mechanism of trans-dominant HTLV-1 Rex mutants	ONCOGENE			English	Article						HTLV-1 Rex; nucleo-cytoplasmic trafficking; trans-dominance; GFP	VIRUS TYPE-I; VIRAL MESSENGER-RNA; LEUKEMIA-VIRUS; NUCLEAR EXPORT; GENE-EXPRESSION; NEGATIVE MUTANTS; TRANSCRIPTIONAL ACTIVATOR; NUCLEOLAR LOCALIZATION; SEQUENCE REQUIREMENTS; REGULATORY PROTEINS	The HTLV-1 Rex protein is an essential shuttle protein required for nuclear export of unspliced and incompletely-spliced viral RNAs. Several trans-dominant (TD) mutant Rex proteins have been reported, however, the mechanism of trans-dominance is not known. We compared TD Rex mutants and found that a natural occurring Rex mutant, Rexp21, lacking the RNA. binding domain, was highly TD and inhibited also HIV-1 Rev function. Using fusions to the green fluorescent protein (GFP) we observed that Rexp21-GFP displayed a cytoplasmic localization but was actively shuttling between the nucleus and the cytoplasm in live human cells. The presence of Rexp21-GFP inhibited the nuclear export of Res and HIV-1 Rev as assayed by cotransfection and microinjection experiments, However, Rex-GFP or Rexp21-GFP did not form heteromultimers with nuclear Res mutants in Fire. In contrast, shuttling was essential for tr ans-dominance. Thus, we propose that TD Res mutants do not function by retaining WT Res in the nucleus by protein-protein interactions, as demonstrated for Rev, but to titrate factors essential for Rex/Rev export, Our findings demonstrate differences between the regulatory proteins Res and Rev and implicate a novel strategy to generate highly TD Res mutants also applicable to other proteins.	Univ Erlangen Nurnberg, Inst Med & Clin Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Stauber, RH (corresponding author), Univ Erlangen Nurnberg, Inst Med & Clin Virol, Schlossgarten 4, D-91054 Erlangen, Germany.			Heger, Peter/0000-0003-2583-2981; Stauber, Roland/0000-0002-1341-4523				ADACHI Y, 1992, J BIOL CHEM, V267, P21977; Bakker A, 1996, J VIROL, V70, P5511, DOI 10.1128/JVI.70.8.5511-5518.1996; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BHAT NK, 1993, VIROLOGY, V196, P15, DOI 10.1006/viro.1993.1450; BLACK AC, 1991, VIROLOGY, V181, P433, DOI 10.1016/0042-6822(91)90875-C; BLACK AC, 1994, VIROLOGY, V200, P29, DOI 10.1006/viro.1994.1159; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BOHNLEIN E, 1991, J VIROL, V65, P7051; BOHNLEIN S, 1991, J VIROL, V65, P81; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Ciminale V, 1997, J VIROL, V71, P2810, DOI 10.1128/JVI.71.4.2810-2818.1997; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381; ESSEX M, 1995, LEUKEMIA, V9, pS71; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FELBER BK, 1997, MRNA METABOLISM POST, P323; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; FURUTA RA, 1995, J VIROL, V69, P1591, DOI 10.1128/JVI.69.3.1591-1599.1995; GESSAIN A, 1985, LANCET, V2, P407; GITLIN SD, 1993, MOL BIOL HUMAN T CEL; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; Grone M, 1996, VIROLOGY, V218, P316, DOI 10.1006/viro.1996.0200; Hakata Y, 1998, J VIROL, V72, P6602, DOI 10.1128/JVI.72.8.6602-6607.1998; Hammarskjold ML, 1997, SEMIN CELL DEV BIOL, V8, P83, DOI 10.1006/scdb.1996.0127; HAMMES SR, 1993, VIROLOGY, V193, P41, DOI 10.1006/viro.1993.1101; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOFER L, 1991, J VIROL, V65, P3379, DOI 10.1128/JVI.65.6.3379-3383.1991; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; KANAMORI H, 1990, EMBO J, V9, P4161, DOI 10.1002/j.1460-2075.1990.tb07639.x; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; King JA, 1998, ONCOGENE, V16, P3309, DOI 10.1038/sj.onc.1201884; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KUBOTA S, 1992, J VIROL, V66, P2510, DOI 10.1128/JVI.66.4.2510-2513.1992; Kubota S, 1996, VIROLOGY, V220, P502, DOI 10.1006/viro.1996.0339; KUBOTA S, 1991, J VIROL, V65, P2452, DOI 10.1128/JVI.65.5.2452-2456.1991; LAGRENADE L, 1990, LANCET, V336, P1345; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MORGAN OS, 1989, LANCET, V2, P1184; MURAI K, 1990, J ACQ IMMUN DEF SYND, V3, P1006; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; ORITA S, 1991, FEBS LETT, V295, P127, DOI 10.1016/0014-5793(91)81402-T; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POLLARD VW, 1998, IN PRESS ANN REV MIC; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; ROSORIUS O, 1998, UNPUB; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295; SZILVAY AM, 1995, J VIROL, V69, P3315, DOI 10.1128/JVI.69.6.3315-3323.1995; Thomas SL, 1998, J VIROL, V72, P2935, DOI 10.1128/JVI.72.4.2935-2944.1998; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; WEICHSELBRAUN I, 1992, J VIROL, V66, P4540, DOI 10.1128/JVI.66.7.4540-4545.1992; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1996, J ACQ IMMUN DEF SYND, V13, P63; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	83	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4080	4090		10.1038/sj.onc.1202762	http://dx.doi.org/10.1038/sj.onc.1202762			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435589				2022-12-17	WOS:000081431000005
J	Ricci, JE; Maulon, L; Luciano, F; Guerin, S; Livolsi, A; Mari, B; Breittmayer, JP; Peyron, JF; Auberger, P				Ricci, JE; Maulon, L; Luciano, F; Guerin, S; Livolsi, A; Mari, B; Breittmayer, JP; Peyron, JF; Auberger, P			Cleavage and relocation of the tyrosine kinase P59FYN during Fas-mediated apoptosis in T lymphocytes	ONCOGENE			English	Article						Fas; apoptosis; caspases; p59Fyn	PROGRAMMED CELL-DEATH; NF-KAPPA-B; ICE/CED-3 PROTEASE; ICE-LIKE; POLY(ADP-RIBOSE) POLYMERASE; CAENORHABDITIS-ELEGANS; CYSTEINE PROTEASE; ACTIVATION; SRC; PHOSPHORYLATION	Ligation of Fas with its natural ligand or with anti-Fas antibodies induces an apoptotic program in Fas sensitive cells. We report here the identification of the tyrosine kinase p59Fyn as a substrate for CPP32-like proteinases and more particularly caspase 3 during Fas-mediated apoptosis in Jurkat T cells. Inhibition of CPP32-like proteinases by Ac-Asp-Glu-Val-Asp-aldehyde but not by Ac-Tyr-Val-Ala-Asp-aldehyde prevents CPP32, PARP and p59Fyn cleavage indicating that CPP32 or CPP32-like proteinases are responsible for the cleavage of p59Fyn, Cleavage occurs in the N-terminal domain of p59Fyn between Asp19 and Gly20 and is accompanied by relocation of an active p57Fyn kinase to cytoplasm of Fas-stimulated Jurkat cells as judged by both biochemical and confocal microscopy experiments. Thus, p59Fyn relocation and activity may play an important role during Fas-mediated cell death in human T lymphocytes.	Fac Med Nice, CJF Activat Cellules Hematopoiet 96 05, F-06107 Nice 02, France; Hop de lArchet, INSERM, U343, Nice, France	UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Auberger, P (corresponding author), Fac Med Nice, CJF Activat Cellules Hematopoiet 96 05, Ave de Valombrose, F-06107 Nice 02, France.		Ricci, Jean Ehrland/I-7117-2016; AUBERGER, Patrick/G-1491-2013; luciano, frederic/P-6264-2016; RICCI, Jean Ehrland/AAS-4379-2020; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022; Mari, Bernard P/F-8960-2013; Mari, Bernard/Q-5832-2019; Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016	Ricci, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275; luciano, frederic/0000-0001-9253-4998; RICCI, Jean Ehrland/0000-0003-1585-8117; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Campbell KS, 1998, J IMMUNOL, V161, P1728; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; Mari B, 1996, FASEB J, V10, P309, DOI 10.1096/fasebj.10.2.8641564; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Simon HU, 1998, BLOOD, V92, P547, DOI 10.1182/blood.V92.2.547.414k02_547_557; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	38	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					3963	3969		10.1038/sj.onc.1202782	http://dx.doi.org/10.1038/sj.onc.1202782			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435619				2022-12-17	WOS:000081327800006
J	Uemura, N; Salgia, R; Ewaniuk, DS; Little, MT; Griffin, JD				Uemura, N; Salgia, R; Ewaniuk, DS; Little, MT; Griffin, JD			Involvement of the adapter protein CRKL in integrin-mediated adhesion	ONCOGENE			English	Article						adhesion; integrins; BCR ABL; signal transduction; adapter proteins; CRKL	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; V-CRK; C-ABL; SIGNAL-TRANSDUCTION; CELLULAR PROTEINS; BCR/ABL ONCOGENE; SH3 DOMAIN; IN-VIVO	CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell Lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3-5 individual sublines which stably overexpressed each transgene were obtained [Bal F-CRKL, Ba/F-CRKL Delta SH2, and Ba/F-CRKL Delta SH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not Delta SH2- or Delta SH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti-beta 1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of beta 1 integrins, nor did it spontaneously induce expression of the beta 1 integrin 'activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA036167, R37CA036167] Funding Source: NIH RePORTER; NCI NIH HHS [CA36167] Funding Source: Medline; NIDDK NIH HHS [DK560654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Andoniou CE, 1996, ONCOGENE, V12, P1981; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; BELLIS SL, 1997, BIOCHEM J, V15, P375; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Jacobsen K, 1996, BLOOD, V87, P73; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NICHOLS GL, 1994, BLOOD, V84, P2912; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; ONODA JM, 1992, RADIAT RES, V130, P281, DOI 10.2307/3578372; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, EXP HEMATOL, V24, P310; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; WHITE GC, 1993, ADV EXP MED BIOL, V344, P187; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3343	3353		10.1038/sj.onc.1202689	http://dx.doi.org/10.1038/sj.onc.1202689			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362355				2022-12-17	WOS:000080589300005
J	Skourides, PA; Perera, SA; Ren, RB				Skourides, PA; Perera, SA; Ren, RB			Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins	ONCOGENE			English	Article						chronic myelogenous leukemia; Bcr-Abl; phosphorylation; Grb2; Shc; Cbl	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; TRANSGENIC MICE; SIGNAL-TRANSDUCTION; INTEGRIN FUNCTION; ADAPTER PROTEIN; LYMPHOID-CELLS; V-ABL; ONCOGENE	Bcr-Abl plays a critical role in the pathogenesis of Philadelphia chromosome-positive leukemia. Although a large number of substrates and interacting proteins of Bcr-Abl have been identified, it remains unclear whether Bcr-Abl assembles multi-protein complexes and if it does where these complexes are within cells. We have investigated the localization of Bcr-Abl in 32D myeloid cells attached to the extracellular matrix. We have found that Bcr-Abl displays a polarized distribution, colocalizing with a subset of filamentous actin at trailing portions of migrating 32D cells, and localizes on the cortical F-actin and on vesicle-like structures in resting 32D cells. Deletion of the actin binding domain of Bcr-Abl (Bcr-Abl-AD) dramatically enhances the localization of Bcr-Abl on the vesicle-like structures. These distinct localization patterns of Bcr-Abl and Bcr-Abl-AD enabled us to examine the localization of Bcr-Abl substrate and interacting proteins in relation to Bcr-Abl. We found that a subset of biochemically defined target proteins of Bcr-Abl redistributed and co-localized with Bcr-Abl on F-actin and on vesicle-like structures. The co-localization of signaling proteins with Bcr-Abl at its sites of localization supports the idea that Bcr-Abl forms a multi-protein signaling complex, while the polarized distribution and vesicle-like localization of Bcr-Abl may play a role in leukemogenesis.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, MS 029, Waltham, MA 02254 USA.			Skourides, Paris/0000-0003-3502-5729	NCI NIH HHS [CA68008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Cortes JE, 1996, AM J MED, V100, P555, DOI 10.1016/S0002-9343(96)00061-7; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Enright H, 1996, Curr Opin Hematol, V3, P303; Goldman J M, 1997, Curr Opin Hematol, V4, P277; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Hariharan I K, 1988, Oncogene Res, V3, P387; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HAWLEY RG, 1994, GENE THER, V1, P136; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PULL L, 1994, EMBO J, V13, P764; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; ZHANG X, 1998, IN PRESS BLOOD	60	29	30	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1165	1176		10.1038/sj.onc.1202407	http://dx.doi.org/10.1038/sj.onc.1202407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022122				2022-12-17	WOS:000078510700005
J	Chughtai, SA; Crundwell, MC; Cruickshank, NRJ; Affie, E; Armstrong, S; Knowles, MA; Takle, LA; Kuo, M; Khan, N; Phillips, SMA; Neoptolemos, JP; Morton, DG				Chughtai, SA; Crundwell, MC; Cruickshank, NRJ; Affie, E; Armstrong, S; Knowles, MA; Takle, LA; Kuo, M; Khan, N; Phillips, SMA; Neoptolemos, JP; Morton, DG			Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer	ONCOGENE			English	Article						colorectal cancer; human; chromosome 8p; loss of heterozygosity; tumour behaviour; putative TSGs	TUMOR-SUPPRESSOR GENE; HUMAN PROSTATE-CANCER; BETA-GENE; BREAST-CARCINOMA; COPY NUMBER; DNA; CLONING; HETEROZYGOSITY; MUTATION; LOCI	We have investigated interstitial deletions of chromosome 8 in 70 colorectal carcinomas and 11 colonic adenomas using 11 microsatellite markers, including eight spanning the centromeric region of chromosome 8p (p11.2-p12). Allelic loss or imbalance was observed in 38 (54%) cancers and four (36%) adenomas, Twenty-eight (40%) of the cancers had deletions of 8p11.2-p12. Two distinct and independent regions of interstitial loss were found within this region. Fluorescent in situ hybridization, using an alpha! satellite repeat probe to the centromere of 8p and two probes to the P1 region, was performed in four tumours that demonstrated allelic imbalance. Localized heterozygous deletions were confirmed in all four tumours, Eleven (16%) cancers had localized deletion in the region ANK-1 to D8S255 (P1) and a further eleven (16%) cancers had a less well localized deletion in the region defined by the markers D8S87 to D8S259 (P2), Loss of both centromeric loci was identified in a further six (9%) tumours, A functional significance for these two deletion regions was sought by correlation with primary and secondary tumour characteristics. Isolated P2 deletion was associated with 'early' T1 cancers (2p = 0.0002), and were also identified in 3/11 adenomas, Conversely, interstitial deletions of the P1 locus were more frequently seen in 'locally invasive' T3/4 cancers (2p = 0.015), and isolated P1 deletions were also associated with the presence of liver metastases (2p = 0.016). Our data provide evidence of at least two genes within the 8p11.2-p12 region, mutations in which may confer different and independent roles in the pathogenesis of colorectal cancer.	Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Urol, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Pathol, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Biol, Birmingham B15 2TT, W Midlands, England; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Marie Curie Res Inst, Surrey RH8 0TL, England; Royal Liverpool Univ Hosp, Dept Surg, Liverpool L69 3GA, Merseyside, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Saint James's University Hospital; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Morton, DG (corresponding author), Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England.		Neoptolemos, John/HGU-7742-2022; Neoptolemos, John P/G-4488-2010	Knowles, Margaret/0000-0002-9363-8657; Neoptolemos, John/0000-0002-6201-7399				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; *ACS, 1990, CANC FACTS FIG, P4; Afify A, 1997, CANCER GENET CYTOGEN, V97, P101, DOI 10.1016/S0165-4608(96)00361-5; Afify A, 1996, BREAST CANCER RES TR, V38, P201, DOI 10.1007/BF01806674; BERKNER KL, 1977, J BIOL CHEM, V252, P3176; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CANNIZZARO LA, 1987, CYTOGENET CELL GENET, V46, P589; CHYAN YJ, 1994, NUCLEIC ACIDS RES, V22, P2719, DOI 10.1093/nar/22.14.2719; Crundwell MC, 1996, INT J CANCER, V69, P295, DOI 10.1002/(SICI)1097-0215(19960822)69:4<295::AID-IJC10>3.3.CO;2-#; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; CUNNINGHAM C, 1994, BRIT J CANCER, V70, P18, DOI 10.1038/bjc.1994.243; DIB A, 1995, ONCOGENE, V10, P995; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOBASHI Y, 1994, CANCER RES, V54, P2827; EMI M, 1992, CANCER RES, V52, P5368; Eydmann ME, 1997, CANCER GENET CYTOGEN, V93, P167, DOI 10.1016/S0165-4608(96)00200-2; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Gustafson CE, 1996, CANCER RES, V56, P5238; Hermanek P, 1987, UICC TNM CLASSIFICAT; Ichikawa K, 1997, GENE, V189, P277, DOI 10.1016/S0378-1119(96)00863-3; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; JONES TA, 1993, CYTOGENET CELL GENET, V63, P35, DOI 10.1159/000133497; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LIPPINCOTT JB, 1992, AM JOINT COMMITTEE C; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MACOSKA JA, 1995, CANCER RES, V55, P5390; ROHEN C, 1995, CANCER GENET CYTOGEN, V80, P33, DOI 10.1016/0165-4608(94)00164-7; SHIKE M, 1990, B WORLD HEALTH ORGAN, V68, P377; Shimamoto A, 1996, P NATL ACAD SCI USA, V93, P10913, DOI 10.1073/pnas.93.20.10913; Visscher DW, 1997, GENE CHROMOSOME CANC, V18, P1; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WANG LM, 1992, CANCER RES, V52, P4824; WASYLYSHYN ML, 1991, SURGERY, V110, P265; Yamabe Y, 1997, GENOMICS, V39, P198, DOI 10.1006/geno.1996.4480; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; [No title captured]	43	29	30	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					657	665		10.1038/sj.onc.1202340	http://dx.doi.org/10.1038/sj.onc.1202340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989816				2022-12-17	WOS:000078394400011
J	Stahler, F; Roemer, K				Stahler, F; Roemer, K			Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53	ONCOGENE			English	Article						cell death; p53; c-Myc; serine protease	KAPPA-B ACTIVATION; DNA-DAMAGE; INDUCE APOPTOSIS; HEPATOMA-CELLS; GROWTH ARREST; DOMAIN; CHECKPOINT; PROMOTERS; PROTEIN; DEATH	Wild-type (wt) p53 frequently induces apoptosis when expressed in tumor cells whereas mutant p53 acts as an oncoprotein and consequently, stimulates cell proliferation. We report here exceptions to that rule, p53 conformational mutant 175H and DNA contact mutant 273H provoke apoptosis in human p53-deficient Hep3B hepatoma cells with delayed kinetics relative to wt p53. Similarly, c-Myc strongly stimulates apoptosis in these cells. In contrast,, viral oncoproteins EIA and E7, and the cellular oncoprotein MDM-2, fail to elicit cytocidal responses. Efficient apoptotic cell death by mutant p53 requires oligomerization as 175H and 273H with deletions between amino acid residues 326 and 347 of the oligomerization domain are nontoxic. Apoptosis by mutant or wt p53 was significantly inhibited by the serine protease inhibitor AEBSF but not by the inactive analog AEBSA, Together, these results suggest that a nit p53-independent control mechanism is operational in Hep3B cells that eliminates cells upon sensing illegitimate proliferation signals originating from certain oncoproteins, including mutant p53 and Myc. We suggest that some tumor cell types lack p53 altogether because they tolerate neither wild-type nor mutant forms of the protein.	Univ Saarlandes, Sch Med, Dept Virol, D-66421 Homburg, Germany	Saarland University	Roemer, K (corresponding author), Univ Saarlandes, Sch Med, Dept Virol, D-66421 Homburg, Germany.							ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Friedman SL, 1997, ONCOGENE, V15, P63, DOI 10.1038/sj.onc.1201149; Fuchs EJ, 1997, CANCER RES, V57, P2550; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roemer K, 1996, ONCOGENE, V12, P2069; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Theis S, 1997, INT J CANCER, V71, P858; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; YEE JK, 1994, METHOD CELL BIOL, V43, P99; YonishRouach E, 1995, ONCOGENE, V11, P2197	29	29	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3507	3512		10.1038/sj.onc.1202245	http://dx.doi.org/10.1038/sj.onc.1202245			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030675				2022-12-17	WOS:000078086200012
J	Hengstermann, A; Whitaker, NJ; Zimmer, D; Zentgraf, H; Scheffner, M				Hengstermann, A; Whitaker, NJ; Zimmer, D; Zentgraf, H; Scheffner, M			Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation	ONCOGENE			English	Article						degradation; E6-AP; p53; phosphorylation; UV	HUMAN PAPILLOMAVIRUS TYPE-16; DNA-DAMAGE; TUMOR-SUPPRESSOR; E6 ONCOPROTEIN; WILD-TYPE; IN-VIVO; RAPID DEGRADATION; TRANSFORMED-CELLS; PROTEIN; PHOSPHORYLATION	The growth suppressive properties of the tumor suppressor protein p53 are activated upon DNA damage. The activation of p53 is reflected in increased p53 levels which are, at least in part, the result of an extended half-life of the protein. Although this suggests that stabilization of p53 is an intrinsic feature of p53 activation, the mechanisms involved in p53 degradation and stabilization are poorly understood. Here we report on the identification of an internal deletion mutant of wild-type p53, termed Delta 62-96, which can be stably expressed in various cell lines. This deletion mutant has a turnover rate similar to wild-type p53 and its stability is upregulated by treatment with UV light. In cell lines that express endogenous mutant or no p53, however, Delta 62-96 appears to be stable, strongly indicating that these cell lines have lost the ability to degrade p53. Further characterization of Delta 62-96 by mutational analyses defines sequence and structural requirements for p53 degradation and indicates that none of the known p53 phosphorylation sites is essential with respect to p53 stability regulation upon UV-irradiation.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Scheffner, M (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.		Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; FISCELLA M, 1993, ONCOGENE, V8, P1519; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; Momand J, 1997, J CELL BIOCHEM, V64, P343; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	55	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2933	2941		10.1038/sj.onc.1202282	http://dx.doi.org/10.1038/sj.onc.1202282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879999				2022-12-17	WOS:000077286400013
J	Kondo, S; Shinomura, Y; Kanayama, S; Higashimoto, Y; Kiyohara, T; Zushi, S; Kitamura, S; Ueyama, H; Matsuzawa, Y				Kondo, S; Shinomura, Y; Kanayama, S; Higashimoto, Y; Kiyohara, T; Zushi, S; Kitamura, S; Ueyama, H; Matsuzawa, Y			Modulation of apoptosis by endogenous Bcl-x(L) expression in MKN-45 human gastric cancer cells	ONCOGENE			English	Article						bcl-x(L); antisense oligonucleotides; bak; apoptosis; fas; chemotherapy	CHEMOTHERAPY-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; BCL-2 HOMOLOG BAK; IN-VIVO PATTERNS; IMMUNOHISTOCHEMICAL ANALYSIS; SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; ANTICANCER AGENTS; FAS ANTIGEN; DEATH	This study was designed to clarify the role of endogenous Bcl-x(L) expression in modulating apoptosis of malignant cells. Administration of bcl-x-antisense oligonucleotides decreased Bcl-x(L) protein levels in the MKN-45 human gastric cancer cell line. The decrease in Bcl-x(L) protein content resulted in increased cell death induced by serum deprivation or Fas-antibody administration. Flow cytometric analysis revealed that the increased apoptotic cell death was more prominent in bcl-x-antisense-treated cells as compared to control cells, bcl-x-sense-treated cells, or bcl-x-nonsense-treated cells. To inhibit the effect of intrinsic Bcl-x(L) protein, we overexpressed Bak, which binds Bcl-x(L) and inhibits the anti-apoptotic effect of Bcl-x(L), by transfection into MKN-45 cells. Bak-overexpressing cells showed increased apoptotic cell death induced by Fas-antibody when compared to parent cells and MKN-neo-transfected cells. Bak-overexpressing cells also showed greater sensitization to 5-fluorouracil and cisplatin than parent cells and MKN-neo-transfected cells. In conclusion, we demonstrated that administration of bcl-x-antisense oligonucleotides or overexpression of Bak protein induces sensitization to apoptosis in MKN-45 gastric cancer cells, suggesting that endogenous Bcl-x, expression in cancer cells is an important modulator of apoptosis.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 5650871, Japan	Osaka University	Kondo, S (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yanadaoka, Suita, Osaka 5650871, Japan.							Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHERBONNELASSER.C, 1997, ONCOGENE, V13, P1489; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Decaudin D, 1997, CANCER RES, V57, P62; DOLE M, 1994, CANCER RES, V54, P3253; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Hayashi H, 1997, JPN J CANCER RES, V88, P49, DOI 10.1111/j.1349-7006.1997.tb00301.x; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAMESAKI S, 1993, CANCER RES, V53, P4251; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V149, P1449; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROUQUET N, 1995, ONCOGENE, V11, P1061; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZORNIG M, 1995, ONCOGENE, V10, P2397	32	29	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2585	2591		10.1038/sj.onc.1202194	http://dx.doi.org/10.1038/sj.onc.1202194			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840921				2022-12-17	WOS:000077058900005
J	Yasuda, M; D'Sa-Eipper, C; Gong, XL; Chinnadurai, G				Yasuda, M; D'Sa-Eipper, C; Gong, XL; Chinnadurai, G			Regulation of apoptosis by a Caenorhabditis elegans BNIP3 homolog	ONCOGENE			English	Article						apoptosis; ceBNIP3; mitochondria; CED-9; CED-3	CELL-DEATH; BCL-2 FAMILY; CYTOCHROME-C; CED-4; PROTEINS; ENCODES; ACTIVATION; DISTINCT; PROTEASE	We have identified a C. elegans protein, ceBNIP3, homologous to the human BCL-2/EIB-19K interacting BCL-2 family pro-apoptotic protein BNIP3. In transiently transfected mammalian cells, ceBNIP3 complexes with CED-9, the worm homolog of BCL-2, CeBNIP3 also efficiently heterodimerizes with the cell death protease proCED-3 by direct binding via the prodomain, Transfection of ceBNIP3 and CED-3 results in enhanced proteolytic processing of the CED-3 zymogen and in cooperative induction of apoptosis. Coexpression of CED-9 suppresses the cooperative cell death induced by ceBNIP3 and CED-3, In cells coexpressing CED-9, ceBNIP3 and CED-3, all three proteins exist as a ternary complex suggesting that CED-9 may suppress cooperative apoptosis induced by CED-3 and ceBNIP3 by simultaneous complex formation with CED-3 and ceBNIP3, Our results suggest that ceBNIP3 may be a novel component of the C, elegans apoptosis paradigm and may initiate apoptosis by recruiting CED-3 to mitochondria and other cytoplasmic membranes.	St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Med Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NCI NIH HHS [CA-73803, CA-33616, R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Theodorakis P, 1996, ONCOGENE, V12, P1707; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	25	29	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2525	2530		10.1038/sj.onc.1202467	http://dx.doi.org/10.1038/sj.onc.1202467			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824163	Bronze			2022-12-17	WOS:000076927300012
J	Ma, L; Broomfield, S; Lavery, C; Lin, SL; Xiao, W; Bacchetti, S				Ma, L; Broomfield, S; Lavery, C; Lin, SL; Xiao, W; Bacchetti, S			Up-regulation of CIR1/CROC1 expression upon cell immortalization and in tumor-derived human cell lines	ONCOGENE			English	Article						CIR1; CROC1; UEV-1; immortalization; tumorigenesis differential display	COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER; HUMAN TELOMERASE; SV40-MEDIATED IMMORTALIZATION; REPLICATIVE SENESCENCE; DIFFERENTIAL DISPLAY; HUMAN FIBROBLASTS; GENE-EXPRESSION; T-ANTIGEN; AMPLIFICATION	Acquisition of the immortal phenotype by tumor cells represents an essential and potentially rate-limiting step in tumorigenesis, To identify changes in gene expression that are associated with the early stages of cell immortalization, we compared genetically matched pairs of pre-immortal and immortal human cell clones by mRNA differential display. Two transcripts, denoted CIR1 and CIR2, were identified which were up-regulated in immortal cells. Sequence analysis revealed CIR1 to be identical to the recently cloned CROC1/UEV-1 gene, whereas CIR2 corresponds to an as yet uncharacterized 1.2 kb mRNA, A 5-6-fold elevation in CIR1/CROC1 expression and a 2-3-fold elevation in CIR2 expression were observed in SV40-transformed human enbryonic kidney cells immediately following proliferative crisis, suggesting a potential role for these genes in immortalization, Expression of CIR1/CROC1 was found to be elevated also in a variety of immortal human tumor-derived cell lines, as compared to their normal tissue counterparts. These results are compatible with induction of CIR1/CROC1 being an early event in the acquisition of immortality and with a role for this gene in the immortal phenotype of tumor cells.	McMaster Univ, Dept Pathol, Canc Res Grp, Hamilton, ON L8N 3Z5, Canada; Univ Saskatchewan, Dept Microbiol, Saskatoon, SK S7N 5E5, Canada; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA	McMaster University; University of Saskatchewan; Rutgers State University New Brunswick; Rutgers State University Medical Center	Broomfield, S (corresponding author), McMaster Univ, Dept Pathol, Canc Res Grp, HSC-4H30,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Xiao, Wei/0000-0001-7568-0782				Avilion AA, 1996, CANCER RES, V56, P645; Bacchetti S, 1996, CANCER SURV, V28, P197; Brinkmann U, 1996, GENOME RES, V6, P187, DOI 10.1101/gr.6.3.187; BROOMFIELD S, 1998, IN PRESS P NATL ACAD; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; EDWARDS PAW, 1993, CANCER SURV, V16, P79; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Harley CB, 1997, CANCER SURV, V29, P263; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; IMAI S, 1992, BIOCHEM BIOPH RES CO, V189, P148, DOI 10.1016/0006-291X(92)91537-Z; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pardinas J, 1997, J CELL PHYSIOL, V171, P325, DOI 10.1002/(SICI)1097-4652(199706)171:3<325::AID-JCP11>3.0.CO;2-9; Rothofsky ML, 1997, GENE, V195, P141, DOI 10.1016/S0378-1119(97)00097-8; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SASAKI M, 1994, CANCER RES, V54, P6090; SATOH Y, 1994, MUTAT RES, V316, P25, DOI 10.1016/0921-8734(94)90005-1; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	34	29	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1321	1326		10.1038/sj.onc.1202058	http://dx.doi.org/10.1038/sj.onc.1202058			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771976				2022-12-17	WOS:000075803300015
J	Cmarik, JL; Li, Y; Ogram, SA; Min, HZ; Reeves, R; Colburn, NH				Cmarik, JL; Li, Y; Ogram, SA; Min, HZ; Reeves, R; Colburn, NH			Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not -resistant cells	ONCOGENE			English	Article						HMG-I(Y); tumor promotion; gene expression; neoplastic transformation; 12-O-tetradecanoylphorbol acetate	MOUSE EPIDERMAL-CELLS; JB6 CELLS; GENE-EXPRESSION; NEOPLASTIC TRANSFORMATION; NUCLEAR PROTEINS; THYROID-CELLS; E-SELECTIN; C PROTEIN; BETA GENE; HMG-I(Y)	Elevated levels of high mobility group (HMG) nonhistone chromosomal proteins I and Y, alternatively spliced members of the HMG-I(Y) family of architectural transcription factors? have been linked with human cancer and with neo-plastic and metastatic phenotypes in model systems, To investigate whether HMG-I(Y) proteins may influence susceptibility to neoplastic transformation, HMG-I(Y) mRNA and protein levels mere compared in the JB6 murine model of neoplastic progression, HMG-I(Y) mRNAs were expressed at very low levels in preneoplastic, transformation-resistant (P-) cell lines and were constitutively expressed at much higher levels in both transformation-sensitive (P+) and transformed (Tx) tumorigenic cell lines. HMG-I(Y) mRNAs mere induced to higher levels by the tumor promoter 12-O-tetradecanoylphorbol acetate (TPA) and were sustained longer in P+ than in P- cells. Nevertheless, in both P- and P+ cells, primer extension analysis revealed that the same four major HMG-I(Y) gene transcription start sites were utilized with or without TPA treatment. RT-PCR revealed that there nas always slightly more Y than I form mRNA present in all of the variant JB6 cell lines. Immunoblotting indicated that both HMG-I and -Y proteins increased in P+ cells in response to TPA treatment. Remarkably, in P- cells treated with TPA, only HMG-I (and not HMG-Y) protein levels increased. This unique differential TPA-induction of the HMG-Y protein in JB6 variants suggests a role for HMG-Y in mediating tumor promoter-induced neoplastic transformation, Furthermore, these results demonstrate that HMG-I and Y protein translation and/or stability is differently regulated in JB6 P- cells and provide the first indication that I and Y proteins may have different functions.	NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Sci Applicat Int Corp, Frederick, MD 21702 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA; Washington State Univ, Dept Genet & Cell Biol, Pullman, WA 99164 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Washington State University; Washington State University	Cmarik, JL (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM46352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CMARIK JL, 1994, MOL CARCINOGEN, V11, P115, DOI 10.1002/mc.2940110209; COLBURN N H, 1980, Teratogenesis Carcinogenesis and Mutagenesis, V1, P87; COLBURN NH, 1978, CANCER RES, V38, P624; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; DONG Z, 1997, IN PRESS MOL CARCINO; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; Fedele M, 1996, CANCER RES, V56, P1896; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GOODWIN GH, 1985, EUR J BIOCHEM, V149, P47, DOI 10.1111/j.1432-1033.1985.tb08891.x; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HIRANO K, 1992, ONCOL RES, V4, P17; Holth LT, 1997, DNA CELL BIOL, V16, P1299, DOI 10.1089/dna.1997.16.1299; Huang ZQ, 1996, BIOTECHNIQUES, V20, P1012; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1990, EXP CELL RES, V187, P69, DOI 10.1016/0014-4827(90)90118-T; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KIM J, 1995, EUR J IMMUNOL, V25, P798, DOI 10.1002/eji.1830250326; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LI J, 1997, IN PRESS CANC RES; Li JJ, 1996, CANCER RES, V56, P483; MARGIS W, 1995, BIOCHEM BIOPH RES CO, V214, P927; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OGRAM SA, 1995, J BIOL CHEM, V270, P14235, DOI 10.1074/jbc.270.23.14235; RAM TG, 1993, CANCER RES, V53, P2655; SKALNIK DG, 1992, BIOCHEM BIOPH RES CO, V187, P563, DOI 10.1016/0006-291X(92)91231-E; SUN Y, 1994, CANCER RES, V54, P1139; TAMIMI Y, 1993, CANCER RES, V53, P5512; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; Williams AJ, 1997, AM J PATHOL, V150, P911; Wunderlich V, 1997, J CANCER RES CLIN, V123, P133, DOI 10.1007/BF01214665; Xiao S, 1997, AM J PATHOL, V150, P901; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	53	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3387	3396		10.1038/sj.onc.1201888	http://dx.doi.org/10.1038/sj.onc.1201888			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692546				2022-12-17	WOS:000074544100005
J	Tzeng, YJ; Zimmermann, C; Guhl, E; Berg, B; Avantaggiati, ML; Graessmann, A				Tzeng, YJ; Zimmermann, C; Guhl, E; Berg, B; Avantaggiati, ML; Graessmann, A			SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors	ONCOGENE			English	Article						SV40 T-antigen; transgenic animals; apoptosis; immortalization; breast cancer; p53 missense mutation	LARGE T-ANTIGEN; EPITHELIAL-CELLS; TRANSGENIC MICE; BREAST-CANCER; C-MYC; GENE; PROTEIN; IMMORTALIZATION; SUPPRESSION; INDUCTION	We recently established transgenic animals (WAP-SV-T/t) carrying the early coding region of Simian Virus 40 (SV40) under the transcriptional control of the whey acidic milk protein promoter (WAP), which restricts the expression of the transgene to mammary gland epithelial cells (ME-cells). SV40 T/t-antigen synthesis causes premature mammary gland involution during late pregnancy by inducing apoptosis and leads to development of mammary tumors after the first lactation period in both p53 positive (WAP-SV-T/t) and p53 negative double transgenic animals (WAP-SV-T/t.p53 -/-), The high apoptotic rate persists in all of the T/t-antigen positive breast tumor cells, as well as in established ME-tissue culture cell lines. ME-cells which spontaneously switch off the expression of the WAP-SV-T/t transgene do not undergo apoptosis, However, these cells again exhibit an extensive DNA fragmentation when SV40 T/t-antigen synthesis is reintroduced, which indicates that it is the expression of T/t antigen which is the critical factor for induction of apoptosis, In addition, we isolated several ME-cell lines from different breast tumors which hale spontaneously lost the T/t-antigen yet remain maximally transformed. Strikingly, these cells contain a missense mutation of the p53 gene at codon 242 (p53(242)), which substitutes alanine for glycine, This mutation increases p53 stability and it reduces the transactivating function of p53, albeit without affecting the ability of the protein to interact with the DNA. This indicates that p53 missense mutations are selected for in breast tumors initially expressing T/t-antigen. Therefore, the p53(242) mutation is sufficient to maintain the transformed state after the ME-cells have switched off the WAP-SV-T/t transgene, Interestingly, the p53 minus state per se is not sufficient to induce ME-cell transformation since homozygous null mice for the p53 gene (p53-/-) fail to develop breast cancer.	Free Univ Berlin, Inst Biochem & Mol Biol, D-14195 Berlin, Germany; SUNY Buffalo, Sch Med, Dept Microbiol, Buffalo, NY 14214 USA	Free University of Berlin; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Graessmann, A (corresponding author), Free Univ Berlin, Inst Biochem & Mol Biol, Arnimallee 22, D-14195 Berlin, Germany.							Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Celis JE, 1994, CELL BIOL, P305; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GRAESSMANN M, 1976, P NATL ACAD SCI USA, V73, P366, DOI 10.1073/pnas.73.2.366; GUENAL I, 1995, FEBS LETT, V374, P384, DOI 10.1016/0014-5793(95)01157-A; HARTMANN A, 1997, TIG, V3, P27; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; HERMEKING H, 1995, ONCOGENE, V11, P1409; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenahan MK, 1996, ONCOGENE, V12, P1847; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTI A, 1994, ONCOGENE, V9, P1213; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Merlo GR, 1997, CELL GROWTH DIFFER, V8, P251; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; Muraoka M, 1996, ONCOGENE, V12, P1565; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sambrook J, 1989, MOL CLONING LAB MANU; Santarelli R, 1996, ONCOGENE, V12, P495; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Shibata MA, 1996, CANCER RES, V56, P2998; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Tzeng YJ, 1996, FEBS LETT, V380, P215, DOI 10.1016/0014-5793(96)00021-X; TZENG YJ, 1993, ONCOGENE, V8, P1965; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; ZHENG DQ, 1994, ONCOGENE, V9, P3345	40	29	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2103	2114		10.1038/sj.onc.1201733	http://dx.doi.org/10.1038/sj.onc.1201733			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572491				2022-12-17	WOS:000073177200008
J	Burger, A; Li, H; Zhang, XK; Pienkowska, M; Venanzoni, M; Vournakis, J; Papas, T; Seth, A				Burger, A; Li, H; Zhang, XK; Pienkowska, M; Venanzoni, M; Vournakis, J; Papas, T; Seth, A			Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12	ONCOGENE			English	Article						gene anatomy; breast cancer; molecular oncology; subtractive cloning; differential display; immunohistochemistry	DIFFERENTIAL DISPLAY; IDENTIFICATION; PROTEINS; BINDING	To determine which genes may be activated or inactivated during breast cancer development, we employed two cloning strategies (subtractive hybridization and differential display) using RNA samples from a human breast tumor and its matching normal breast cell line. Of 950 clones isolated, 102 cDNA inserts were analysed by DNA sequencing and database searching. We found 30 clones that were obviously unidentified, with no significant homology to any listed human gene. We focused upon one of the novel genes, Di12, that is differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell-lines. and in several normal tissues. A full length cDNA of this gene was cloned, and its DIVA sequence revealed an open reading frame of 339 amino acids. Antibodies to the ten N-terminal amino acids were developed to investigate the expression of Di12 in breast cancer cell-lines and tumors. The Di12 protein was found in tissue sections of infiltrating ductal carcinomas (IDCs), but not in benign or normal breast specimens. RT-PCR analysis confirmed expression of Di12 in 80% of infiltrating ductal carcinomas (IDCs). As IDC constitutes similar to 70% of breast cancers seen clinically, the level of Di12 expression may be predictive of disease progression.	Univ Toronto, Womens Coll Hosp, Dept Pathol, Toronto, ON M5S 1B3, Canada; Univ Toronto, Womens Coll Hosp, Lab Lab Med & Pathobiol, Toronto, ON M5S 1B3, Canada; Univ Bradford, Clin Oncol Unit, Bradford BD7 1DP, W Yorkshire, England; Mem Sloan Kettering Canc Inst, New York, NY 10021 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; INRCA, Ancona, Italy	University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Bradford; Memorial Sloan Kettering Cancer Center; Medical University of South Carolina; IRCCS INRCA	Seth, A (corresponding author), Univ Toronto, Womens Coll Hosp, Dept Pathol, 76 Grenville St, Toronto, ON M5S 1B3, Canada.							ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; ALLRED D, 1990, P ASCO, V9, P23; BERNS EMJJ, 1992, CANCER RES, V52, P1107; Burger AM, 1996, INT J ONCOL, V8, P395; EASTON D, 1993, CANCER SURV, V18, P95; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; IWASE H, 1994, BREAST CANC RES TREA, V33, P83; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAINSBURY JRC, 1987, LANCET, V1, P1398; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; Sambrook J, 1989, MOL CLONING LAB MANU; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SOUBEYRAN I, 1995, BREAST CANCER RES TR, V34, P119, DOI 10.1007/BF00665784; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333	20	29	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					327	333		10.1038/sj.onc.1201517	http://dx.doi.org/10.1038/sj.onc.1201517			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467958				2022-12-17	WOS:000071582100005
J	Johnston, D; Hatzis, D; Sunday, ME				Johnston, D; Hatzis, D; Sunday, ME			Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma	ONCOGENE			English	Article						C-cells; RT-PCR; immunohistochemistry; thyroglobulin; cell lineage; dense-core granules	ONCOGENE INDUCES DIFFERENTIATION; CELL LUNG-CANCER; THYROGLOBULIN IMMUNOREACTIVITY; C-CELLS; MICE; PROTEIN; PHEOCHROMOCYTOMAS; TUMORS; ORIGIN; ENTITY	v-Ha-ras has been demonstrated previously to induce neuroendocrine differentiation of medullary thyroid carcinoma (MTC, malignant C cell tumor) cell lines. The potential role of ras mediated signaling in neuroendocrine cells in vivo has been investigated by expressing v-Ha-ras under control of the neural/neuroendocrine specific calcitonin/calcitonin gene-related peptide (CGRP) promoter. Five independent mouse lineages were derived following germ line insertion of the transgene. Four of the five lineages consistently express the transgene; neuroendocrine expression is found in three of the five lineages as both spliced and full length messages. Phenotypically, the mice expressing rascal have shortened lifespans primarily due to the high incidence of MTCs between 6 months to a year of age. C-cell hyperplasia is demonstrated in several mice in the absence of gross evidence of tumor formation. Histopathological and ultrastructural analyses demonstrate typical features of MTCs including prominent immunohistochemical staining for calcitonin and dense-core neurosecretory-type granules. In addition, four of 22 tumors co-express thyroglobulin (a non-neuroendocrine follicular epithelial cell marker) and calcitonin (a neuroendocrine marker) in a subset of the tumor cells. The rascal transgenic mouse provides a unique model for investigating the sequential pathogenesis of MTC and possibly also for elucidating the relationship between MTC and mixed medullary-follicular carcinomas.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Sunday, ME (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.			Sunday, Mary E./0000-0002-6788-1469	NHLBI NIH HHS [R01-HL44984, R01-HL50045] Funding Source: Medline; NICHD NIH HHS [N01-HD02911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044984, R01HL050045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BAETSCHER M, 1991, ONCOGENE, V6, P1133; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENNETT MM, 1992, ANN NY ACAD SCI, V657, P36, DOI 10.1111/j.1749-6632.1992.tb22755.x; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BOS JL, 1989, CANCER RES, V49, P4682; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; CUTHBERTSON RA, 1988, LAB INVEST, V58, P484; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; DeLellis RA, 1994, PATHOBIOLOGY AGING R, P285; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; GLASSER SW, 1994, AM J PHYSIOL-LUNG C, V267, pL489, DOI 10.1152/ajplung.1994.267.5.L489; HARVEY M, 1995, CANCER RES, V55, P1146; HOLM R, 1987, LAB INVEST, V57, P258; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOSTROUCH Z, 1991, ENDOCRINOLOGY, V129, P2202, DOI 10.1210/endo-129-4-2202; KOVACS CS, 1994, CANCER-AM CANCER SOC, V74, P928, DOI 10.1002/1097-0142(19940801)74:3<928::AID-CNCR2820740321>3.0.CO;2-E; LEBLANC B, 1990, VET PATHOL, V27, P445, DOI 10.1177/030098589902700610; LJUNGBERG O, 1985, VET PATHOL, V22, P95, DOI 10.1177/030098588502200201; LJUNGBERG O, 1983, CANCER, V52, P1053, DOI 10.1002/1097-0142(19830915)52:6<1053::AID-CNCR2820520621>3.0.CO;2-Q; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MABRY M, 1989, J CLIN INVEST, V84, P194, DOI 10.1172/JCI114140; MANENTI G, 1994, EUR J CANCER, V30A, P987, DOI 10.1016/0959-8049(94)90130-9; MANGUES R, 1990, ONCOGENE, V5, P1491; MOLEY JF, 1991, CANCER RES, V51, P1596; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; POLAK JM, 1974, HISTOCHEMISTRY, V40, P209, DOI 10.1007/BF00501955; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; SANTELLI G, 1993, CANCER RES, V53, P5523; SCHULZ N, 1992, CANCER RES, V52, P450; SOBRINHOSIMOES M, 1985, ULTRASTRUCT PATHOL, V8, pR3; SUNDAY ME, 1988, ENDOCRINOLOGY, V122, P1551, DOI 10.1210/endo-122-4-1551; SUNDAY ME, 1994, LAB INVEST, V70, P875; SUNDAY ME, 1991, METHODS NEUROSCI, V5, P123; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILLIAMS ED, 1989, J PATHOL, V159, P135, DOI 10.1002/path.1711590208	39	29	29	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	1998	16	2					167	177		10.1038/sj.onc.1201478	http://dx.doi.org/10.1038/sj.onc.1201478			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464534				2022-12-17	WOS:000071427100003
J	Zimmermann, S; Rommel, C; Ziogas, A; Lovric, J; Moelling, K; Radziwill, G				Zimmermann, S; Rommel, C; Ziogas, A; Lovric, J; Moelling, K; Radziwill, G			MEK1 mediates a positive feedback an Raf-1 activity independently of Ras and Src	ONCOGENE			English	Article						feedback loop; mitogen-activated protein kinase cascade; MEK1; Raf-1 activation	PROTEIN-TYROSINE-PHOSPHATASE; MAP KINASE-KINASE; PLASMA-MEMBRANE; PHOSPHORYLATION; ACTIVATION; C-RAF-1; INSULIN; IDENTIFICATION; MUTANTS; BINDING	Growth factor stimulated receptor tyrosine kinases activate a protein kinase cascade via the serine/threonine protein kinase Raf-1, Direct upstream activators of Raf-1 are Ras and Src, This study shows that MEK1, the direct downstream effector of Raf-1, can also stimulate Raf-1 kinase activity by a positive feedback loop, Activated MEK1 mediates hyperphosphorylation of the amino terminal regulatory as well as of the carboxy terminal catalytic domain of Raf-1. The hyperphosphorylation of Raf-1 correlates with a change in the tryptic phosphopeptide pattern only at terminus of Raf-1 and an increase in activity, MEK1-mediated Raf-1 activation is inhibited by co-expression of the MAPK specific phosphatase MKP-1 indicating that the MEK1 effect is exerted through a MAPK dependent pathway. Stimulation of Raf-1 activity by MEK1 is independent of Ras, Src and tyrosine phosphorylation of Raf-1, MEK1 can however synergize with Ras and leads to further increase of the Raf-1 kinase activity, Thus, MEK1 can mediate activation of Raf-1 by a novel positive feedback mechanism which allows fast signal amplification and could prolong activation of Raf-1.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND	University of Zurich				Lovric, Josip/0000-0002-0338-6581				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Alessandrini A, 1996, J BIOL CHEM, V271, P31612, DOI 10.1074/jbc.271.49.31612; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENT P, 1995, MOL CELL BIOL, V15, P4125; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Holt KH, 1996, MOL CELL BIOL, V16, P577; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; JOHN J, 1988, J BIOL CHEM, V263, P11792; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Lovric J, 1996, ONCOGENE, V12, P1109; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEBREDA AR, 1994, TRENDS BIOCHEM SCI, V19, P1, DOI 10.1016/0968-0004(94)90163-5; NIEHOF M, 1995, BIOCHEM BIOPH RES CO, V206, P46, DOI 10.1006/bbrc.1995.1007; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; Radziwill G, 1996, BIOCHEM BIOPH RES CO, V227, P20, DOI 10.1006/bbrc.1996.1461; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUEN KL, 1995, SCIENCE, V264, P1463; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; UEKI K, 1994, J BIOL CHEM, V269, P15756; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	50	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1503	1511		10.1038/sj.onc.1201322	http://dx.doi.org/10.1038/sj.onc.1201322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380402				2022-12-17	WOS:A1997XX36900001
J	Guo, WT; Baluda, MA; Park, NH				Guo, WT; Baluda, MA; Park, NH			Ethanol upregulates the expression of p21(WAF1/CIP1) and prolongs G(1) transition via a p53-independent pathway in human epithelial cells	ONCOGENE			English	Article						ethanol; p53; p21(WAF1/CIP1); cell cycle	HUMAN ORAL KERATINOCYTES; WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; ALCOHOL-CONSUMPTION; HUMAN PAPILLOMAVIRUS; SIGNAL-TRANSDUCTION; HUMAN-LYMPHOCYTES; LEUKEMIC-CELLS; DNA-DAMAGE; APOPTOSIS	The control of cell cycle progression is necessary for accuracy in the replication of DNA and the distribution of genetic information to daughter cells, Disturbances in progression of the cell cycle may result in the loss of genomic integrity, a 'hallmark' of cancer cells, Extensive consumption of alcoholic beverages is a risk with the development of various associated epidermoid cancer including oral and pharyngeal squamous cell carcinomas, However, effects of ethanol on cell cycle progression and on the expression of genes associated with the cell cycle have not been studied. We report here that exposure of human epithelial cells to ethanol, at concentrations (100-200 mM) that do not cause cell death, (a) does not affect or only reduces slightly the cellular level of p53 protein, (b) upregulates the transcription of the WAF1/CIP1 gene, (c) inhibits the Cdk2 activity, and (d) reduces the rate of cellular proliferation by inducing a delay in G(1) phase transition, The results also indicate that, at these non-cytotoxic concentrations, ethanol exhibits its effects through a p53-independent mechanism.	UNIV CALIF LOS ANGELES, DENT RES INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH DENT, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P20DE010598, P50DE010598] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10598] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHLUWALIA BS, 1995, ALCOHOL, V12, P589, DOI 10.1016/0741-8329(95)02008-X; ANDERSON LM, 1995, ALCOHOL, V12, P97, DOI 10.1016/0741-8329(94)00089-1; BAEK JH, 1994, INT J ONCOL, V5, P1023; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BLOT WJ, 1994, CANCER SURV, V20, P23; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Deleyiannis FWB, 1996, JNCI-J NATL CANCER I, V88, P542, DOI 10.1093/jnci/88.8.542; DEPETRILLO PB, 1993, ALCOHOL CLIN EXP RES, V17, P351, DOI 10.1111/j.1530-0277.1993.tb00774.x; DIAMOND I, 1994, EXS, V71, P175; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELMORE JG, 1995, OTOLARYNG HEAD NECK, V113, P253, DOI 10.1016/S0194-5998(95)70114-1; EWALD SJ, 1993, ALCOHOL CLIN EXP RES, V17, P359, DOI 10.1111/j.1530-0277.1993.tb00776.x; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARPER JW, 1993, CELL, V75, P805; Hsieh KP, 1996, J BIOL CHEM, V271, P2709, DOI 10.1074/jbc.271.5.2709; KASTAN MB, 1991, CANCER RES, V51, P6304; KO YC, 1995, J ORAL PATHOL MED, V24, P450, DOI 10.1111/j.1600-0714.1995.tb01132.x; Kobayashi T, 1995, ONCOGENE, V11, P2311; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LONGNECKER MP, 1995, ALCOHOL, V12, P87, DOI 10.1016/0741-8329(94)00088-3; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAIER H, 1994, ALCOHOL CLIN EXP RES, V18, P387, DOI 10.1111/j.1530-0277.1994.tb00030.x; MILES MF, 1991, J BIOL CHEM, V266, P2409; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUFTI SI, 1992, CANCER DETECT PREV, V16, P157; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; RABIN RA, 1983, J PHARMACOL EXP THER, V227, P551; Seitz H K, 1992, Eur J Cancer Prev, V1 Suppl 3, P5, DOI 10.1097/00008469-199210003-00002; SHAO H, 1995, CELL IMMUNOL, V164, P11, DOI 10.1006/cimm.1995.1137; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SPINOZZI F, 1993, GASTROENTEROLOGY, V105, P1490, DOI 10.1016/0016-5085(93)90156-7; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILKE N, 1994, EXS, V71, P49; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1995, CANCER RES, V55, P668	43	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1143	1149		10.1038/sj.onc.1201287	http://dx.doi.org/10.1038/sj.onc.1201287			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294607				2022-12-17	WOS:A1997XU99100003
J	Lutz, W; Schwab, M				Lutz, W; Schwab, M			In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; N-myc; amplification; gene regulation; E2F; Spl	HUMAN NEURO-BLASTOMA; GROWTH-FACTOR RECEPTOR; LIGATION-MEDIATED PCR; ZINC-FINGER PROTEIN; C-MYC; TRANSCRIPTION FACTOR; IN-VIVO; GENE AMPLIFICATION; BINDING-PROTEIN; NUCLEAR FACTOR	Amplification with subsequent overexpression of N-myc is a recurrent genomic alteration of neuroblastoma cells, DMS-in-vivo-footprinting of the basal promoter of the human N-myc gene (positions -221 to +21) revealed three changes in promoter architecture that are clustered in a 50 bp region and included (1) protein binding to two overlapping E2F-sites, (2) extreme hypersensitivity of guanine -159, and (3) a short stretch of single stranded DNA with a single protected guanine. While in transient assays the basal promoter activated gene expression in all cell lines analysed, the changes at the endogenous promoter were restricted to neuroblastoma cells with strong N-myc expression. The hypersensitivity of guanine -159 could result from protein binding to a flanking, evolutionary conserved 5'-CCTCCC-3'-element, referred to as CT-box, that was bound in vitro in a Zn2+-requiring manner by a protein from nuclear extracts of neuroblastoma cells. Four copies of the CT-box in front of an N-myc minimal promoter (-60 to +18) activated expression of a reporter gene in transient transfections whereas four copies of the mutant element did not. Our data add N-myc to a growing list of mammalian genes with CT-boxes that bind proteins in a Zn2+-dependent manner. Moreover, the data suggest that a common mechanism controls N-myc expression in neuroblastomas irrespective of N-myc copy number, and that in cell lines with amplification all gene copies contribute to N-myc expression.			Lutz, W (corresponding author), GERMAN CANC RES CTR, DEPT CYTOGENET 0825, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							AMBER LC, 1989, MOL CELL BIOL, V9, P4903; AMBER LC, 1990, GENE CHROMOSOME CANC, V1, P181; Arts J, 1997, NUCLEIC ACIDS RES, V25, P311, DOI 10.1093/nar/25.2.311; ASSELIN C, 1989, ONCOGENE, V4, P549; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Bennett JD, 1996, ONCOGENE, V13, P1073; Bosher JM, 1996, ONCOGENE, V13, P1701; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Botz J, 1996, MOL CELL BIOL, V16, P3401; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; Brodeur G M, 1985, Prog Clin Biol Res, V175, P105; BUONO P, 1993, FEBS LETT, V328, P243, DOI 10.1016/0014-5793(93)80936-O; CHEN CJ, 1995, CANCER RES, V55, P3873; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; ELDER GA, 1992, MOL BRAIN RES, V15, P99, DOI 10.1016/0169-328X(92)90156-6; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HALL DJ, 1990, ONCOGENE, V5, P47; HARA E, 1993, ONCOGENE, V8, P1023; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILLER S, 1991, ONCOGENE, V6, P969; HIYAMA E, 1991, J PEDIATR SURG, V26, P838, DOI 10.1016/0022-3468(91)90151-I; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; IBSON JM, 1988, ONCOGENE, V2, P399; IMAMURA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P177, DOI 10.1016/0167-4781(92)90009-O; Ince TA, 1996, CANCER RES, V56, P2021; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI RS, 1994, J BIOL CHEM, V269, P7941; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Lutz W, 1996, ONCOGENE, V13, P803; MAJELLO B, 1995, ONCOGENE, V10, P1841; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Minucci S, 1996, EMBO J, V15, P888, DOI 10.1002/j.1460-2075.1996.tb00423.x; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PLET A, 1992, ONCOGENE, V7, P1847; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; QUIVY JP, 1993, NUCLEIC ACIDS RES, V21, P2779, DOI 10.1093/nar/21.11.2779; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SADEE W, 1987, CANCER RES, V47, P5207; SAWAI S, 1990, MOL CELL BIOL, V10, P2017, DOI 10.1128/MCB.10.5.2017; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; Shi YG, 1996, BIOCHEMISTRY-US, V35, P3845, DOI 10.1021/bi952384p; SLAVC I, 1990, CANCER RES, V50, P1459; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; WADA RK, 1992, ONCOGENE, V7, P711; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; XU L, 1995, ONCOGENE, V11, P1865; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	93	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					303	315		10.1038/sj.onc.1201195	http://dx.doi.org/10.1038/sj.onc.1201195			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233765	Bronze			2022-12-17	WOS:A1997XK99900007
J	Zhang, YW; Bae, SC; Takahashi, E; Ito, Y				Zhang, YW; Bae, SC; Takahashi, E; Ito, Y			The cDNA cloning of the transcripts of human PEBP2 alpha A/CBFA1 mapped to 6p12.3-p21.1, the locus for cleidocranial dysplasia	ONCOGENE			English	Article						PEBP2 alpha A/CBFAl; 6p21; cleidocranial dysplasia	ACUTE MYELOID-LEUKEMIA; FLUORESCENCE INSITU HYBRIDIZATION; RUNT DOMAIN; AML1 GENE; FAMILY; EXPRESSION; PROTEIN; LOCALIZATION	PEBP2/CBF is a heterodimeric transcription factor composed of alpha and beta subunits. There are at least three closely related genes, PEBP2 alpha A/Cbfa1, AML1/PEBP2 alpha B/Cbfa2 and PEBP2 alpha C/Cbfa3, encoding the alpha subunit and one beta subunit encoding gene. Structural alterations of AML1 and the beta subunit gene by chromosome translocations are frequently associated with several types of human leukemia. Structural changes of any of these gene products would have potential to affect the function of others. In this study, we isolated the human PEBP2 alpha A cDNA by which we mapped the gene to 6p12.3-p21.1. Human chromosome 6p21 is the locus for cleidocranial dysplasia, an autosomal dominant bone disease. Recent gene disruption study revealed that PEBP2 alpha A/Cbfa1 plays an essential role in osteogenesis (Komori et al., Cell, 1997, in press). Therefore, a close relationship between human PEBP2 alpha A/CBFA1 and this bone disease is strongly implicated.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; CHUNGBUK NATL UNIV,COLL MED,CHONJU 360763,SOUTH KOREA; NATL INST RADIOL SCI,DIV GENET,INAGE KU,CHIBA 263,JAPAN	Kyoto University; Chungbuk National University; National Institutes for Quantum Science & Technology								Ahn MY, 1996, GENE, V168, P279, DOI 10.1016/0378-1119(95)00751-2; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; COLLING G, 1996, MOL CELL BIOL, V16, P932; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; ITO Y, IN PRESS ONCOGENES T; JARVIS JL, 1974, AM J ROENTGENOL, V121, P5, DOI 10.2214/ajr.121.1.5; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KOMORI T, 1997, IN PRESS CELL; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1996, ANN NY ACAD SCI, V785, P301, DOI 10.1111/j.1749-6632.1996.tb56290.x; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; NIKIK M, 1997, IN PRESS P NATL ACAD; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Sambrook J, 1989, MOL CLONING LAB MANU; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WIJIMENGA C, 1995, GENOMICS, V26, P611; ZHANG YW, 1997, IN PRESS MOL CELL BI, V17	38	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					367	371		10.1038/sj.onc.1201352	http://dx.doi.org/10.1038/sj.onc.1201352			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233771				2022-12-17	WOS:A1997XK99900013
J	Osada, S; Izawa, M; Saito, R; Mizuno, K; Suzuki, A; Hirai, S; Ohno, S				Osada, S; Izawa, M; Saito, R; Mizuno, K; Suzuki, A; Hirai, S; Ohno, S			YSK1, a novel mammalian protein kinase structurally related to Ste20 and SPS1, but is not involved in the known MAPK pathways	ONCOGENE			English	Article						MAP kinase; protein kinase; stress; signal transduction	SIGNAL-TRANSDUCTION PATHWAYS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CDC42 GTPASES; ACTIVATION; IDENTIFICATION; YEAST; RAC; HOMOLOG; CASCADE	To clarify the upstream regulatory mechanism of mitogen-activated protein kinase (MAPK), we performed the reverse transcriptase-based polymerase chain reaction (RT-PCR) with degenerate primers synthesized based on sequences conserved among the kinase domains of yeast MAPK kinase kinases (MAPKKKs), Stell, Bck1, and Byr2. We isolated several mammalian cDNA fragments that encode kinase subdomains sharing significant sequence homology with yeast MAPKKKs. Subsequent screening of a HeLa cell cDNA library using one of these cDNA fragments as a probe resulted in the isolation of a full-length cDNA that encodes a novel protein kinase. The catalytic domain sequence of this gene product is closely related to those of budding yeast Sps1 and Ste20 protein kinases, Thus, we call this protein YSK1 (Yeast Sps1/Ste20-related Kinase 1), The transcript of YSK1 was detected in a wide range of tissues and cells, Immunoprecipitated YSK1 shows protein kinase activity, Although YSK1 is significantly similar in its kinase domain to kinases of the yeast and mammalian MAPK pathways, the overexpression of YSK1 did not lead to the activation of the ERK (extracellular signal-regulated kinase) pathway, JNK (c-Jun NH2-terminal kinase)/SAPK (stress-activated protein kinase) pathway, or p38/Mpk2 pathway, These results suggest that YSK1 may be involved in the regulation of a novel intracellular signaling pathway.	YOKOHAMA CITY UNIV, SCH MED, DEPT BIOL MOL, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN	Yokohama City University			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAYHOFF MO, 1978, ATLAS PROTEIN SEQ S3, V5, P353; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FISHER SM, 1994, NATURE, V372, P739; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; Goudet J., 2001, CLADISTICS; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirai S, 1996, ONCOGENE, V12, P641; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	50	29	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	1997	14	17					2047	2057		10.1038/sj.onc.1201043	http://dx.doi.org/10.1038/sj.onc.1201043			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160885				2022-12-17	WOS:A1997WW80900007
J	Doherty, J; Freund, R				Doherty, J; Freund, R			Polyomavirus large T antigen overcomes p53 dependent growth arrest	ONCOGENE			English	Article						polyomavirus; large T antigen; p53; cell cycle arrest	RETINOBLASTOMA GENE-PRODUCT; WILD-TYPE P53; P53-DEPENDENT G(1) ARREST; TUMOR SUPPRESSOR GENE; CELL-CYCLE CONTROL; MIDDLE-T; SUSCEPTIBILITY GENE; DNA-DAMAGE; C-MYC; TRANSCRIPTIONAL ACTIVATION	Polyomavirus transforms cells in culture and induces tumors in mice without apparent interaction with or inactivation of the p53 tumor suppressor protein. In this report we investigate the ability of polyomavirus T antigens to overcome the growth suppression function of p53. A temperature sensitive p53 gene was introduced into mouse embryo fibroblasts derived from a p53 null mouse, resulting in expression of a protein with a mutant conformation at 37 degrees C and a functionally wild-type conformation at 32 degrees C. We found that expression of p53 at 32 degrees C induced the cyclin-dependent kinase inhibitor p21/WAF1 and arrested cell growth in the G(1)/G(0) phase of the cell cycle. Only the under-phosphorylated form of the retinoblastoma tumor suppressor protein (pRB) was detected in these growth arrested cells. We introduced both polyomavirus large T (LT) and middle T (MT) antigens into this cell line and showed that LT overcame p53-dependent growth arrest, while MT did not. In cells grown at 32 degrees C, LT expession led to cell proliferation and phosphorylation of pRB in the presence of p21. A mutant LT containing a defective pRB binding domain failed to overcome the growth arrest, indicating that interaction of LT with RE proteins is required to override p53 function. Although the polyomavirus T antigens do not interact with p53 directly, our results indicate that the virus, through LT, is able to interfere with the growth suppressive activity of p53.	UNIV MARYLAND,CELL & MOL BIOL PROGRAM,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Doherty, Joanne/AAU-3288-2020	Doherty, Joanne/0000-0003-2705-5194	NCI NIH HHS [CA63111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BENJAMIN T, 1990, VIROLOGY, P347; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Flint S. J, 1981, DNA TUMOR VIRUSES; FRANCKE B, 1973, VIROLOGY, V55, P127, DOI 10.1016/S0042-6822(73)81014-1; FREUND R, 1994, J VIROL, V68, P7227, DOI 10.1128/JVI.68.11.7227-7234.1994; FREUND R, 1992, ONCOGENE, V7, P1979; GJORUP OV, 1994, P NATL ACAD SCI USA, V91, P12125, DOI 10.1073/pnas.91.25.12125; Gray J W, 1979, Methods Enzymol, V58, P233; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLSTEIN M, 1991, SCIENCE, V75, P839; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1983, P NATL ACAD SCI USA, V80, P4345; Sambrook J, 1989, MOL CLONING LAB MANU; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHLEGEL R, 1978, CELL, V14, P587, DOI 10.1016/0092-8674(78)90244-1; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	96	29	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1923	1931		10.1038/sj.onc.1201025	http://dx.doi.org/10.1038/sj.onc.1201025			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150359				2022-12-17	WOS:A1997WV80400005
J	Kamano, H; Klempnauer, KH				Kamano, H; Klempnauer, KH			B-Myb and cyclin D1 mediate heat shock element dependent activation of the human HSP70 promoter	ONCOGENE			English	Article						B-Myb; heat shock element; HSP70 promoter; cyclin D1	DNA-BINDING ACTIVITY; A-MYB; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATOR; RETINOBLASTOMA PROTEIN; V-MYB; C-MYB; HEMATOPOIETIC-CELLS; GENE-TRANSCRIPTION; REGULATORY DOMAINS	Previous studies have shown that B-Myb, a conserved member of the Myb transcription factor family, is a potent activator of the promoter of the human HSP70 gene but does not activate promoters containing Myb binding sites. We have now investigated the transactivation properties of B-Myb in more detail. We here report that B-Myb activates the HSP70 promoter by a novel mechanism which involves the heat shock element (HSE). Deletion analysis of B-Myb shows that a specific domain in the center of B-Myb, but not the DNA-binding domain is required for HSE-dependent transactivation. We also show that deletion of the C-terminal domain of B-Myb does not affect HSE-dependent transactivation but allows the protein to activate a promoter containing Myb binding sites. This suggests that the ability to activate Myb binding site containing promoters is repressed in the context of full length B-Myb and that HSE dependent and Myb binding site dependent transactivation are distinct functions of B-Myb. Finally, we report that cyclin D1 like B-Myb strongly activates the HSP70 promoter via the HSE. HSE-dependent transactivation is a novel activity of cyclin D1 and appears to be independent of the phosphorylation of the Rb protein. Our results reveal an interesting and unexpected connection between HSE-dependent gene activation and proteins expressed during the G1/S-transition of the cell cycle.	MAX PLANCK INST IMMUNOBIOL, HANS SPEMANN LAB, D-79108 FREIBURG, GERMANY	Max Planck Society								AMIN J, 1985, MOL CELL BIOL, V5, P197, DOI 10.1128/MCB.5.1.197; ARSURA M, 1992, BLOOD, V79, P2708; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Kamano H, 1995, ONCOGENE, V11, P2575; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KAO HT, 1985, MOL CELL BIOL, V5, P628, DOI 10.1128/MCB.5.4.628; KATO J, 1993, GENE DEV, V7, P331; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NEVINS JR, 1992, SCIENCE, V258, P424; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Sitzmann J, 1996, ONCOGENE, V12, P1889; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TASHIRO S, 1995, ONCOGENE, V10, P1699; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	52	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1223	1229		10.1038/sj.onc.1200945	http://dx.doi.org/10.1038/sj.onc.1200945			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121772				2022-12-17	WOS:A1997WM78200012
J	Lutterbach, B; Hann, SR				Lutterbach, B; Hann, SR			Overexpression of c-Myc and cell immortalization alters c-Myc phosphorylation	ONCOGENE			English	Article						c-Myc; phosphorylation; immortalization; transactivation	CASEIN KINASE-II; TRANSFORMING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; NEOPLASTIC-CELLS; POINT MUTATIONS; GENE-EXPRESSION; PROTEIN; SITE; VIRUS	Using an extensive series of deletion and site-specific mutation constructs, we have identified five new phosphorylation sites in c-Myc in the N-terminal transactivation domain and near the C-terminal DNA binding/heterodimerization domain. We have also found that Thr-58 phosphorylation is regulated by specific cellular events. When c-Myc is overexpressed in cells Thr-58 phosphorylation was greatly enhanced in the overexpressed, exogenous c-Myc as compared with the endogenous protein. In contrast, an inhibition of Thr-58 phosphorylation and an enhancement of Serine 62 phosphorylation was observed in c-Myc from immortalized cells compared with primary cells. No significant changes in c-Myc phosphorylation were found when transformed and nontransformed cells were compared. Finally, mutations at these phosphorylation sites, either individually or in combination with previously described sites, did not affect the ability of c-Myc to transactivate through the CACGTG Myc/Max DNA binding sites. These results further suggest that either the molecular role for c-Myc phosphorylation does not involve modulating transcriptional activity of c-Myc or that the CACGTG site does not represent a physiological promoter element.	VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University					NCI NIH HHS [CA-47399, CA-48799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047399, P01CA048799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FILARDO EJ, 1991, J VIROL, V65, P6621, DOI 10.1128/JVI.65.12.6621-6629.1991; FRYKBERG L, 1987, ONCOGENE, V1, P415; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEEK DW, 1992, BIOCHEM J, V287, P1; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PULVERER BJ, 1994, ONCOGENE, V9, P59; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SYMONDS G, 1989, ONCOGENE, V4, P285; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	46	29	29	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					967	975		10.1038/sj.onc.1200920	http://dx.doi.org/10.1038/sj.onc.1200920			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050996				2022-12-17	WOS:A1997WK34400010
J	Ghosh, AK; Datta, PK; Jacob, ST				Ghosh, AK; Datta, PK; Jacob, ST			The dual role of helix-loop-helix-zipper protein USF in ribosomal RNA gene transcription in vivo	ONCOGENE			English	Article						ribosomal RNA gene; upstream stimulatory factor; repressor; activator; pol I transcription	POLYMERASE-I TRANSCRIPTION; UPSTREAM STIMULATORY FACTOR; KU-RELATED PROTEIN; WILD-TYPE P53; BINDING-FACTOR; MAMMALIAN-CELLS; CORE PROMOTER; FACTOR CPBF; FACTOR E1BF; E-BOX	We have previously demonstrated that the core promoter of rat ribosomal RNA gene (rDNA) contains an E-box-Like sequence to which the core promoter binding factor CPBF binds and that the 44 kDa subunit of this protein is immunologically related to USF1, the helix-loop-helix-zipper DNA binding protein. Further, we showed that RNA polymerase I (pol I) transcription in vitro is competed by oligonucleotides containing USF-binding site, which suggested a key role for USF in rDNA transcription. To prove the potential role of USF in pol I transcription in vivo, USF1 and USF2 homodimers and USF1/USF2 heterodimer were overexpressed in CHO cells by transfection of the respective cDNAs, Co-transfection of a plasmid containing rDNA followed by primer extension analysis showed that overexpression of USF1 and USF2 as homodimers resulted in inhibition of rDNA transcription by as much as 85-90% whereas overexpression of USF1/USF2 in the heterodimeric form activated transcription approximately 3.5-fold. Transfection of mutant USF2 cDNA that is devoid of the basic DNA-binding domain produced only minimal inhibition of rDNA transcription. These data show that USF can modulate transcription of rRNA gene in vivo by functioning as a repressor (homodimer) or activator (heterodimer) of pol I transcription in vivo and suggest that inhibition of rDNA transcription may be responsible for the antiproliferative action of USF homodimers.	FINCH UNIV HLTH SCI CHICAGO MED SCH, DEPT PHARMACOL & MOL BIOL, CHICAGO, IL 60064 USA	Chicago Medical School			Jacob, Samson/H-3135-2011	Datta, Prasun/0000-0001-5133-253X	NATIONAL CANCER INSTITUTE [R01CA031894] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DATTA PK, 1995, J BIOL CHEM, V270, P8637, DOI 10.1074/jbc.270.15.8637; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; Ghosh AK, 1996, BIOCHEM BIOPH RES CO, V225, P890, DOI 10.1006/bbrc.1996.1268; GHOSH AK, 1993, GENE, V125, P217, DOI 10.1016/0378-1119(93)90332-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HOFF CM, 1993, BIOCHEM BIOPH RES CO, V190, P747, DOI 10.1006/bbrc.1993.1112; ISHIKAWA Y, 1991, J MOL BIOL, V218, P55, DOI 10.1016/0022-2836(91)90873-5; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; JI Z, 1990, MOL CELL BIOL, V10, P5177, DOI 10.1128/MCB.10.10.5177; JOOST CBM, 1994, SCIENCE, V266, P2015; JUVEN T, 1993, ONCOGENE, V8, P3411; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LI JM, 1994, MOL CELL BIOL, V14, P2191, DOI 10.1128/MCB.14.3.2191; LIN Q, 1994, J BIOL CHEM, V269, P23894; LIU ZJ, 1994, J BIOL CHEM, V269, P16618; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; NIU H, 1994, P NATL ACAD SCI USA, V91, P9101, DOI 10.1073/pnas.91.19.9101; Niu Huifeng, 1995, Gene Expression, V4, P111; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; Paule Marvin R., 1993, Gene Expression, V3, P1; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; XIE WQ, 1991, BIOTECHNIQUES, V11, P324	44	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					589	594		10.1038/sj.onc.1200866	http://dx.doi.org/10.1038/sj.onc.1200866			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053857				2022-12-17	WOS:A1997WF52400010
J	McGuire, TF; Sebti, SM				McGuire, TF; Sebti, SM			Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity	ONCOGENE			English	Article						Ras inhibition; lovastatin; geranylgeraniol	CELL-CYCLE PROGRESSION; POSTTRANSLATIONAL MODIFICATIONS; PROTEIN FARNESYLTRANSFERASE; CDC42 GTPASES; GROWTH; BIOSYNTHESIS; MEVALONATE; SUBUNIT; RHO; ISOPRENYLATION	Oncogenic H-Ras requires farnesylation for its transforming activity. Lovastatin inhibits both protein farnesylation and geranylgeranylation by decreasing cellular pools of farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), respectively. Use of lovastatin as a chemotherapeutic agent has been precluded by its significant cytotoxic effects. In this report, we describe a novel approach utilizing a combination of lovastatin and geranylgeraniol (GGOH) to potentiate the ability of lovastatin to block oncogenic H-Ras signaling and concomitantly rescue lovastatin toxicity. GGOH co-treatment with lovastatin enhances inhibition of oncogenic H-Ras processing and constitutive activation of mitogen-activated protein kinase (MAPK), and preserves the processing of geranylgeranyltransferase (GGTase) I and GGTase II protein substrates. Moreover, co-treatment with GGOH significantly (15-fold) attenuates the cytotoxic effects of lovastatin as well as prevents lovastatin-induced cell rounding. These results demonstrate that GGOH potentiates the anti-oncogenic/anti-signaling activity of lovastatin while antagonizing its cytotoxicity. These opposing effects are due to a GGOH metabolite that serves simultaneously as a potent inhibitor for farneslyltransferase as web as a substrate for GGTases I and II.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055823] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BROWN MS, 1980, J LIPID RES, V21, P505; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; CRICK DC, 1994, BIOCHEM BIOPH RES CO, V205, P955, DOI 10.1006/bbrc.1994.2758; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; EPSTEIN WW, 1990, P NATL ACAD SCI USA, V87, P7352, DOI 10.1073/pnas.87.19.7352; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HORI Y, 1991, ONCOGENE, V6, P515; ILLINGWORTH DR, 1989, ARTERIOSCLEROSIS, V9, pI121; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REISS Y, 1992, J BIOL CHEM, V267, P6403; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SUN JZ, 1995, CANCER RES, V55, P4243; VIGANO T, 1995, EUR J PHARM-MOLEC PH, V291, P201, DOI 10.1016/0922-4106(95)90143-4	37	29	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					305	312		10.1038/sj.onc.1200819	http://dx.doi.org/10.1038/sj.onc.1200819			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018116				2022-12-17	WOS:A1997WD51600006
J	Tomida, A; Suzuki, H; Kim, HD; Tsuruo, T				Tomida, A; Suzuki, H; Kim, HD; Tsuruo, T			Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells	ONCOGENE			English	Article						glucose-regulated response; growth arrest; retinoblastoma protein; cyclin D1; p21(WAF1)	MAMMALIAN-CELLS; DEPENDENT KINASES; TUMOR-SUPPRESSOR; P53 PROTEIN; G1 PHASE; GROWTH; INDUCTION; ARREST; P21; ACCUMULATION	Glucose-regulated stress response of cancer cells occurs during the growth of solid tumors and is induced in culture by treatments with various agents, including 2-deoxyglucose, glucosamine, and calcium ionophore A23187. We previously reported that the three stressors commonly induced cell-cycle arrest in the G(1) phase and resistance to antitumor drugs in human cancer A2780 and HT-29 cells. In this study, we investigated the mechanisms of stress-induced G(1) arrest by determining the expression of cell-cycle-regulating proteins. Among G(1) cyclins and cyclin-dependent kinases (cdk) examined, the expression levels of cyclin D1 preferentially decreased in the stressed cells. A time-course study showed that the decrease in cyclin D1 coincided with the appearance of hypophosphorylated retinoblastoma protein (pRb), which is the growth suppressive form. These findings suggest that the stress-induced G(1) arrest is mediated through the down-regulation of cyclin D1-associated kinases (cdk4/6), pRb kinases during G(1) phase. This was also supported by decreased cdk4 expression in stressed HT-29 cells, In addition, p21(WAF1), a cdk inhibitor, was induced in the stressed cells, particularly A23187-treated cells. A23187, compared with the other stressors, caused extreme pRb hypophosphorylation, suggesting that p21(WAf1) is involved in the regulation of pRb phosphorylation in the stressed cells. Our present findings could explain a molecular-based mechanism of a growth-arrested quiescent state and also resistance to chemotherapy of solid tumor cells.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BIOMED RES LAB,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CAI JW, 1993, J CELL PHYSIOL, V154, P229, DOI 10.1002/jcp.1041540204; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1992, SCIENCE, V258, P424; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; SHEN JW, 1989, MOL CELL BIOL, V9, P3284, DOI 10.1128/MCB.9.8.3284; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TOMIDA A, 1996, IN PRESS INT J CANC; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yun J, 1995, ONCOL RES, V7, P583	40	29	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2699	2705						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000144				2022-12-17	WOS:A1996VZ65400020
J	Itakura, O; Yamada, S; Narita, M; Kikuta, H				Itakura, O; Yamada, S; Narita, M; Kikuta, H			High prevalence of a 30-base pair deletion and single-base mutations within the carboxy terminal end of the LMP-1 oncogene of Epstein-Barr virus in the Japanese population	ONCOGENE			English	Article						EBV; LMP-1; 30-bp deletion; six point mutations; Japanese population	T-CELL LYMPHOMAS; MEMBRANE-PROTEIN LMP-1; NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; HODGKINS-DISEASE; BNLF-1 GENE; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; HEMOPHAGOCYTIC SYNDROME; HIGH-FREQUENCY; EBV INFECTION	The presence of 30-base pair (bp) deletion mutants within the carboxy terminal end of the LMP-1 oncogene (BNLF-1 gene) of Epstein-Barr virus (EBV) has been reported in EBV-associated neoplasms. We analysed the 30-bp deletion and the single-base mutations of the LMP-1 gene in 13 spontaneously established lymphoblastoid cell lines (LCLs) from peripheral blood mononuclear cells of three healthy children, four patients with EBV-unrelated acute febrile illnesses, three patients with infectious mononucleosis (IM), and three patients with chronic active EBV infection (CEBV), and six frozen samples from four patients with CEBV and two patients with EBV-associated hemophagocytic syndrome (EBV-AHS). For molecular analysis of the carboxy terminal end of the LMP-1 gene, PCR was performed using primers spanning the carboxy terminal region of the LMP-1 gene. Direct sequence analysis of the PCR products revealed identical 30-bp deletion in 14 of 19 samples (74%). Six point mutations at nucleotide positions 168357, 168355, 168320, 168308, 168295, and 168225 were frequently identified regardless of disease status. Our findings revealed the carboxy terminal end of the LMP-1 gene was mutational hot spots. The 30-bp deletion mutant is widely spread in the Japanese population and is not implicated in EBV-associated lymphoproliferative diseases.	HOKKAIDO UNIV,SCH MED,DEPT PEDIAT,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University								ANAGNOSTOPOULOS I, 1992, BLOOD, V80, P1804; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; CHEN CL, 1993, J VIROL, V67, P6303, DOI 10.1128/JVI.67.10.6303-6308.1993; Chen WG, 1996, AM J PATHOL, V148, P17; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; HUEN DS, 1995, ONCOGENE, V10, P549; KIKUTA H, 1988, NATURE, V333, P455, DOI 10.1038/333455a0; KIKUTA H, 1993, BLOOD, V82, P3259; KIKUTA H, 1989, J INFECT DIS, V160, P546; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1995, LEUKEMIA, V9, P458; Liebowitz David, 1993, P107; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MOORTHY R, 1990, J VIROL, V64, P829, DOI 10.1128/JVI.64.2.829-837.1990; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; Palefsky JM, 1996, J INFECT DIS, V173, P710, DOI 10.1093/infdis/173.3.710; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; SANDVEJ K, 1994, BLOOD, V84, P4053, DOI 10.1182/blood.V84.12.4053.bloodjournal84124053; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TOBI M, 1982, LANCET, V1, P61; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WEISS LM, 1987, AM J PATHOL, V129, P86; WILSON ER, 1981, J PEDIATR-US, V98, P260, DOI 10.1016/S0022-3476(81)80654-3; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZHOU XG, 1994, HISTOPATHOLOGY, V24, P115, DOI 10.1111/j.1365-2559.1994.tb01289.x; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	42	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1549	1553						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875994				2022-12-17	WOS:A1996VL38400021
J	Hansen, RS; Braithwaite, AW				Hansen, RS; Braithwaite, AW			The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras	ONCOGENE			English	Review						p53 cell growth; apoptosis; transformation; transcriptional regulation	WILD-TYPE P53; PROGRAMMED CELL-DEATH; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; TEMPERATURE-SENSITIVE MUTANT; RETINOBLASTOMA GENE-PRODUCT; BREAST-CANCER CELLS; S-PHASE ENTRY; P53-DEPENDENT APOPTOSIS; TUMOR-SUPPRESSOR; ADENOVIRUS E1A	p53 is known to suppress oncogenic cell transformation, inhibit cell growth, induce apoptosis and activate and repress gene transcription, To investigate the relationships between these functions, we have examined various mutant forms of p53 for their abilities to perform each activity, This study has shown that growth inhibition is not a prerequisite for apoptotic cell death as these two functions are separate and alternative activities of p53, Additionally, we have demonstrated that the ability of p53 to suppress transformation (by adenovirus E1a and activated Ras) correlates with its ability to induce apoptosis and not with its ability to inhibit cell growth, Although p53 is thought to inhibit growth through the transactivation of p21(WAF1), Our study has demonstrated that transcriptional activation and repression are neither sufficient nor necessary for growth inhibition, This indicates that p53 has more than ne mechanism for inhibiting cell growth and that anorther type of biochemical function must be involved, Furthermore, we have shown that transcriptional activation and repression may each be necessary, and the combination of these activities may even be sufficient, for p53-dependent apoptosis, In summary, our results have provided new information about the cellular and biochemical mechanisms through which p53 acts as a tumour suppressor.			Hansen, RS (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL & IMMUNOL,CANBERRA,ACT 0200,AUSTRALIA.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CASEY G, 1991, ONCOGENE, V6, P1791; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EGAN C, 1989, ONCOGENE, V4, P383; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HALDAR S, 1994, CANCER RES, V54, P2095; Hansen R, 1995, ONCOGENE, V11, P2535; HANSEN RS, 1995, THESIS ANU; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIRANO Y, 1995, ONCOGENE, V10, P1879; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKSON P, 1993, ONCOGENE, V8, P589; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NEVINS JR, 1992, SCIENCE, V258, P424; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; OROURKE RW, 1990, ONCOGENE, V5, P1829; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PERREM K, 1995, ONCOGENE, V11, P1299; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SANG BC, 1994, ONCOGENE, V9, P853; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEWART N, 1995, ONCOGENE, V10, P109; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHANG W, 1994, CELL GROWTH DIFFER, V5, P705	112	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					995	1007						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806689				2022-12-17	WOS:A1996VG76600013
J	Mangues, R; Symmans, WF; Lu, SY; Schwartz, S; Pellicer, A				Mangues, R; Symmans, WF; Lu, SY; Schwartz, S; Pellicer, A			Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis	ONCOGENE			English	Article						transgenic mice; ras pathway; lymphomas; mammary tumors	MURINE SARCOMA-VIRUS; TRANSGENIC MICE; NEU PROTOONCOGENE; MOUSE EMBRYOS; 3T3 CELLS; HA-RAS; TRANSFORMATION; EXPRESSION; GENE; TUMORS	We compared the tumorigenic effects of the N-ras oncogene and the N-ras proto-oncogene in lymphoid and mammary tissues in an in vivo model, For this purpose, we generated transgenic mice with high levels of N-ras oncogene or N-ras proto-oncogene expression, driven by the complete mouse mammary tumor virus LTR (MMTV-LTR) (MMTV/N-ras(T) and MMTV/N-ras(N) constructs) and transgenic mice with low levels of N-ras oncogene or N-ras proto-oncogene expression, driven by a truncated MMTV-LTR (TMTV/N-ras(T) and TMTV/N-ras(N) constructs), We show that both, the N-ras proto-oncogene and the N-ras oncogene with a C:G-->A:T mutation at codon 61, lead to identical tumor types: lymphoblastic T-cell lymphomas, cleaved B-cell lymphomas and poorly differentiated mammary carcinomas, Nevertheless, there were quantitative differences in tumor incidence and latency and in transgene expression among N-ras oncogene and N-ras proto-oncogene transgenics, Despite these differences in tumor kinetics, the predisposition to identical tumor types is in agreement with the idea that the N-ras oncogene and the N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis in B-cells, T-cells or mammary epithelial cells.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			MARTINEZ, ANTONIO PELLICER/C-4832-2015; Mangues, Ramon/J-6396-2014; Schwartz, Simo/H-7776-2012	Mangues, Ramon/0000-0003-2661-9525; Schwartz, Simo/0000-0001-8297-7971; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R37CA036327, T32CA009161, R01CA050434, R01CA036327] Funding Source: NIH RePORTER; NCI NIH HHS [CA50434, 5T32 CA09161, CA36327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOS JL, 1989, CANCER RES, V49, P4682; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CICHUTEK K, 1989, J VIROL, V63, P1377, DOI 10.1128/JVI.63.3.1377-1383.1989; Coffman R L, 1982, Immunol Rev, V69, P5; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUERRERO I, 1984, SCIENCE, V225, P1041, DOI 10.1126/science.6089339; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HANCOCK JF, 1988, ONCOGENE, V3, P187; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LUO W, 1992, J IMMUNOL, V148, P1630; MANGUES R, 1994, CANCER RES, V54, P6395; MANGUES R, 1992, ONCOGENE, V7, P2073; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORRIS JDH, 1989, ONCOGENE, V4, P27; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REDMOND SMS, 1988, ONCOGENE, V2, P259; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUYRI M, 1989, J VIROL, V63, P3944, DOI 10.1128/JVI.63.9.3944-3953.1989; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	36	29	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1053	1063						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806695				2022-12-17	WOS:A1996VG76600019
J	Lebel, M; Bertrand, R; MesMasson, AM				Lebel, M; Bertrand, R; MesMasson, AM			Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice	ONCOGENE			English	Article						transgenic mice; polyomavirus large T-antigen; Fas antigen receptor; testicular cells	VIRUS EARLY PROTEINS; DIFFERENTIAL DISPLAY; MOLECULAR-CLONING; SURFACE ANTIGEN; MESSENGER-RNAS; FIBROBLASTS; ONCOGENE; MEMBER; GENE; CDNA	MT-PVLT-10 transgenic mice express large T-antigen of polyomavirus under the control of the mouse metallothionein-1 promoter and males of this transgenic line develop testicular tumors at advanced ages. The differential display technique was employed to compare mRNA expression from immortalized cell lines derived from normal or adenomatous testis from MT-PVLT-10 transgenic males. Using this technique, a complementary DNA fragment corresponding to the mouse Fas antigen receptor was recovered from normal testicular cells but not from tumor cells. RNAse protection assays with the Fas antigen specific fragment confirmed its differential expression. Normal testicular cells from the transgenic animals responded to treatment of interferon-gamma by increasing the expression of Fas antigen specific mRNA and were sensitive to the proliferative inhibitory effect of anti-Fas antibody in vitro. This proliferative inhibition was characterized by an accumulation of cells in S phase of the cell cycle. In contrast, the testicular tumor cells did not respond to either interferon-gamma or to anti-Fas antibody in vitro. These results suggest that the loss of proliferative inhibitory effect mediated by the Fas antigen pathway in tumor cells may be an important step in testicular tumor progression in the MT-PVLT-10 transgenic mice.	UNIV MONTREAL,INST CANC MONTREAL,CTR RECH LOUIS CHARLES SIMARD,MONTREAL,PQ H2L 4M1,CANADA	Universite de Montreal				Mes-Masson, Anne-Marie/0000-0002-6498-266X				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; ASSELIN C, 1983, MOL CELL BIOL, V3, P1451, DOI 10.1128/MCB.3.8.1451; BAUTCH VL, 1989, MOL BIOL MED, V6, P309; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BONAVIDA B, 1995, OVARIAN CANC, V3, P295; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHALIFOUR LE, 1990, ONCOGENE, V5, P1719; CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V13, P2633; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENSEN NA, 1989, MOL BIOL MED, V6, P493; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; LEBEL M, 1994, EXP CELL RES, V213, P12, DOI 10.1006/excr.1994.1167; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MERCILLE S, 1994, BIOTECHNOL BIOENG, V44, P1140, DOI 10.1002/bit.260440916; MURAKAMI T, 1995, CANCER RES, V55, P3093; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PERRAS JP, 1993, CYTOMETRY, V14, P441, DOI 10.1002/cyto.990140414; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RIMOLDI D, 1990, EXP CELL RES, V191, P76, DOI 10.1016/0014-4827(90)90038-C; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sambrook J, 1989, MOL CLONING LAB MANU; SMERDELY P, 1993, ENDOCRINOLOGY, V133, P2403, DOI 10.1210/en.133.5.2403; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; ZHENG DQ, 1994, ONCOGENE, V9, P3345	37	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1127	1135						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649805				2022-12-17	WOS:A1996UA88400022
J	Shin, KH; Tannyhill, RJ; Liu, X; Park, NH				Shin, KH; Tannyhill, RJ; Liu, X; Park, NH			Oncogenic transformation of HPV-immortalized human oral keratinocytes is associated with the genetic instability of cells	ONCOGENE			English	Article						genetic stability; oral cancer; p53; HPV; carcinogenesis	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; SIMPLEX VIRUS TYPE-1; DNA-DAMAGING AGENTS; SHUTTLE VECTOR; GROWTH ARREST; MUTAGENESIS; MUTATIONS; IRRADIATION; INDUCTION	HPV-immortalized human oral keratinocytes can convert to tumorigenic cells when exposed to N-methyl-N-nitro-N-nitrosoguanidine (MNNG), but normal human oral keratinocytes cannot transform with a similar exposure. The different responses of these cells could be due to different genetic stability of cells. In as much as genetic stability is determined by cell cycle control and of repair of damaged DNA, we studied the effect of MNNG exposure upon cell cycle progression, expression of p53, WAF1/CIP1 and gadd45, and the mutation frequency of a shuttle vector pS189 in normal human oral keratinocytes, in HPV-immortalized oral keratinocytes, and in an oral cancer cell line expressing mutant p53. Normal cells demonstrated transient cell cycle arrest after exposure to MNNG, but the other tested cells did not. While MNNG exposure significantly increased the levels of intranuclear wt p53 protein and the expression of WAF1/CIP1 and gadd45 genes in normal cells, it did not alter them in the immortalized and cancer cells. The mutation frequency of pS189 plasmid was significantly lower in normal cells than in the other tested cells. These data indicate that malignant conversion of HPV-immortalized oral keratinocytes may, in part, be associated with the cells' genetic instability. The genetic instability may be due to cells' (1) inability to accumulate intranuclear wt p53 to a threshold level at which p53 upregulates the transcription of WAF1/CIP1 and gadd45, resulting in the loss of cell cycle control and (2) inefficient repair of DNA damage caused by genotoxic agents.	UNIV CALIF LOS ANGELES, SCH DENT, DENT RES INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles			Tannyhill, R. John/AAE-7432-2019	Tannyhill, R. John/0000-0003-3172-0345	NIDCR NIH HHS [K15 DE00371, R01 DE 10049, DE11229] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010049, R01DE011229, K15DE000371] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAEK JH, 1994, INT J ONCOL, V5, P1023; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BURNS PA, 1987, J MOL BIOL, V194, P385, DOI 10.1016/0022-2836(87)90668-1; CANMAN CE, 1994, CANCER RES, V54, P5054; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUKUSHIMA A, 1994, GENOMICS, V22, P127, DOI 10.1006/geno.1994.1353; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HWANG CBC, 1991, VIROLOGY, V181, P620, DOI 10.1016/0042-6822(91)90895-I; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, MOL CELL BIOL, V13, P4242; KIM MS, 1993, ANTICANCER RES, V13, P1405; KIM S, 1986, MUTAT RES, V173, P141, DOI 10.1016/0165-7992(86)90092-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEIDMAN M, 1989, MUTAT RES, V220, P55, DOI 10.1016/0165-1110(89)90010-9; SEIDMAN MM, 1987, P NATL ACAD SCI USA, V84, P4944, DOI 10.1073/pnas.84.14.4944; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHILLITOE EJ, 1993, VIRUS RES, V27, P239, DOI 10.1016/0168-1702(93)90036-M; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; SUN XG, 1995, MOL CELL BIOL, V15, P4489; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YEUNG MC, 1993, BIOTECHNIQUES, V15, P381; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	43	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1089	1096						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649801				2022-12-17	WOS:A1996UA88400018
J	LopezBarahona, M; Bustelo, XR; Barbacid, M				LopezBarahona, M; Bustelo, XR; Barbacid, M			The TC21 oncoprotein interacts with the rat guanosine nucleotide dissociation factor	ONCOGENE			English	Article						TC21; RalGDS; effector domain	COMPLEX-FORMATION; ESCHERICHIA-COLI; GENES; PROTEIN; GTPASE	TC21 is a highly oncogenic member of the Ras superfamily of small GTP binding proteins. We have used the yeast two hybrid system to identify proteins that interact with an oncogenic form of the TC21 protein. cDNA clones encoding the carboxy-terminal region of the RalGDS protein were isolated from human B-cell and HeLa cDNA libraries. RalGDS is an exchange factor that stimulates GDP dissociation from Ral, another member of the Ras superfamily of proteins. The interaction between RalGDS to TC21 is direct and appears to be mediated by the effector domain of TC21 and the carboxy-terminal region of RalGDS. Moreover, RalGDS only binds to TC21 in its active, GTP-loaded configuration. These results suggest that RalGDS might be an effector molecule for TC21 and may participate in cross-talking between Ral and TC21 signalling pathways.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072				ALAN J, 1990, ANAL BIOCHEM, V188, P245; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CARBONI JM, 1995, ONCOGENE, V10, P1905; CAUDRADO A, 1990, CELL GROWTH DIFFER, V1, P9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FEIG LA, 1993, RAS SUPERFAMILY GTPA, P247; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERONA R, 1993, ONCOGENE, V8, P1285; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	37	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					463	470						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637701				2022-12-17	WOS:A1996TV59700001
J	Hadman, M; Gabos, L; Loo, M; Sehgal, A; Bos, TJ				Hadman, M; Gabos, L; Loo, M; Sehgal, A; Bos, TJ			Isolation and cloning of JTAP-1: A cathepsin like gene upregulated in response to V-Jun induced cell transformation	ONCOGENE			English	Article						Jun; targets; cysteine protease; transformation; cathepsin O	CHICKEN-EMBRYO FIBROBLASTS; C-JUN; GLUCOCORTICOID RECEPTOR; DNA-BINDING; FUNCTIONAL ANTAGONISM; COLLAGENASE GENE; FOS; EXPRESSION; AP-1; INHIBITION	The oncogenic potential of Jun in chicken embryo fibroblasts (CEF) varies depending on its structure. V-Jun, which has a number of structural differences from c-Jun is highly transforming and tumorigenic. C-Jun however, is only weakly transforming and is not tumorigenic. We have used this difference in oncogenic potential between v-Jun and c-Jun to screen for downstream target genes associated with the v-Jun induced transformed phenotype. We describe here the identification, cloning and characterization of one of these genes, JTAP-1. JTAP-1 is consistently overexpressed 7 to 10-fold in CEF transformed by v-Jun compared with c-Jun overexpressing or normal CEF. This pattern of expression suggests that JTAP-1 is associated with the transformed phenotype. DNA and amino acid homology search analysis revealed that JTAP-1 shares a high degree of similarity with over 100 cysteine proteases from a variety of species and is likely the chicken homolog of cathepsin O. Analysis of expression of JTAP-1 in CEF overexpressing other oncogenes including v-Ha-ras, v-Src, c-Fos, and Myc revealed that it's overexpression is unique to v-Jun transformed cells. Thus, JTAP-1 is likely a specific target of v-Jun overexpression and not simply a consequence of cell transformation.	EASTERN VIRGINIA MED SCH,DEPT MICROBIOL & IMMUNOL,NORFOLK,VA 23501	Eastern Virginia Medical School					NCI NIH HHS [R29 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ATKINS KB, 1995, CELL GROWTH DIFFER, V6, P713; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GINSBERG D, 1991, ONCOGENE, V6, P669; GIZANGGINSBERG E, 1990, GENE DEV, V4, P447; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HADMAN M, 1993, ONCOGENE, V8, P1895; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; KASAI M, 1993, CELL IMMUNOL, V150, P124, DOI 10.1006/cimm.1993.1184; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kozyreva E. A., 1994, Voprosy Meditsinskoi Khimii, V40, P25; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LETO G, 1994, IN VIVO, V2, P231; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SLOANE BF, 1994, J CELL SCI, V107, P373; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOLOVYEVA NI, 1995, INT J CANCER, V8; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TOURAY M, 1991, ONCOGENE, V6, P1227; VALASCO G, 1994, J BIOL CHEM, V269, P27136; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1990, CANCER BIOL, V1, P27; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	48	29	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					135	142						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552384				2022-12-17	WOS:A1996TQ01400017
J	Torres, M; Bogenmann, E				Torres, M; Bogenmann, E			Nerve growth factor induces a multimeric TrkA receptor complex in neuronal cells that includes Crk, SHC and PLC-gamma 1 but excludes P130(CAS)	ONCOGENE			English	Article						c-Crk; TrkA; NGF; signal transduction	GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; TRANSFORMING PROTEIN; RAS; PROTOONCOGENE; BINDING; PRODUCT; ASSOCIATION	Binding of nerve growth factor (NGF) to the TrkA receptor results in homodimerization, and activation of the intrinsic tyrosine kinase activity of the receptor, leading to multiple phosphorylations. We investigated the in vivo formation and composition of the receptor complex induced by NGF in a central nervous system-derived cell line (B104-neo), transfected with the human cDNA for TrkA. Using receptor-activated immunoprecipitation followed by analysis of the immune complexes by SDS-PAGE and immunoblotting, we show that NGF induces the association of TrkA with c-Crk-II in a multimeric complex that also includes SHC and PLC-gamma 1. While the tyrosine phosphorylation of TrkA, SHC and PLC-gamma gamma 1 increased with time in the presence of NGF and was inhibited by the tyrosine kinase inhibitor K252a, the state of tyrosine phosphorylation of c-Crk-II did not appear to change with NGF treatment. Immunodepletion studies demonstrated that the interaction of c-Crk-II with TrkA not only occurs indirectly through the SHC proteins, but may also involve another mode of binding. Furthermore, we show that c-Crk-II is associated with tyrosine phosphorylated p130(CAS) is unstimulated cells and that NGF treatment results in the de-association of p130(CAS)/c-Crk-II complex in the absence of an apparent change in the tyrosine phosphorylation of p130(CAS). These results clearly implicate c-Crk-II in the NGF signaling pathway and support the concept that more than one signaling molecule known to participate in the activation of Ras associates with TrkA upon NGF treatment.	UNIV SO CALIF, SCH MED, DEPT PEDIAT, PASADENA, CA 91125 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL & TOXICOL, PASADENA, CA 91125 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Southern California; University of Southern California; California Institute of Technology	Torres, M (corresponding author), CHILDRENS HOSP LOS ANGELES, RES INST, 4650 SUNSET BLVD MS57, LOS ANGELES, CA 90027 USA.				NINDS NIH HHS [NS25795] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025795] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altin JG, 1991, GROWTH FACTORS, V4, P145, DOI 10.3109/08977199109000265; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERG MM, 1992, J BIOL CHEM, V267, P13; BOGENMANN E, 1995, ONCOGENE, V10, P1915; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARONEY AC, 1995, J NEUROCHEM, V64, P540; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MUROYA K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P353, DOI 10.1016/0167-4889(92)90243-5; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OGAWA S, 1994, ONCOGENE, V9, P1669; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORRES M, 1993, J IMMUNOL, V150, P1563; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					77	86						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552402				2022-12-17	WOS:A1996TQ01400010
J	LABRECQUE, S; MATLASHEWSKI, GJ				LABRECQUE, S; MATLASHEWSKI, GJ			VIABILITY OF WILD-TYPE P53-CONTAINING AND P53-DEFICIENT TUMOR-CELLS FOLLOWING ANTICANCER TREATMENT - THE USE OF HUMAN PAPILLOMAVIRUS E6 TO TARGET P53	ONCOGENE			English	Note						P53; CELL VIABILITY; ANTICANCER TREATMENT	TRANSFORMED-CELLS; ACTIVATED RAS; EARLY GENES; CANCER; IDENTIFICATION; TRANSCRIPTION; PROTEINS	One of the mechanisms in which anticancer therapies function is to induce cell death by apoptosis. In this regard, the biological activity of p53 may be critical since the presence of p53 appears to play a role in apoptosis following genotoxic stress. In experimental systems using in vitro transformed primary cells, there is a direct correlation between the presence of p53 and apoptosis. For example, E1A/ras-transformed primary mouse fibroblasts are less viable and undergo apoptosis following genotoxic stress if these cells contain a wild type p53. In comparison, similarly transformed cells which are p53-deficient are more viable and will not undergo apoptosis under these conditions. Although these are important observations, it remains to be established whether there exists a similar relationship between the presence of wild type p53 and loss of cell viability following therapy in human tumour cells. One way to address this question is to target wild type p53 in human tumour cells using human papillomavirus E6 which mediates the degradation of wild type p53 through the ubiquitin pathway. In this manner, E6 engineered p53-deficient and parental p53-containing human tumour cells provides an appropriate experimental system in which to determine whether wild type p53 in tumour cells has influence on cell viability following genotoxic anticancer treatments, In the present study, the wild type p53 protein in human fibrosarcoma HT1080 cells were targeted with HPV-18 E6 and the viability of these cells in response to treatment with adriamycin, u.v.-irradiation and gamma-irradiation was examined. Data is presented which shows that p53-containing and p53-deficient cells were equally sensitive to these treatments, These data argue that the wild type p53 in these tumour cells does not cause these cells to be less viable when treated with anticancer agents or u.v.-irradiation, Therefore, the status of p53 alone in tumour cells may not be an indicator of response to anticancer treatments.	MCGILL UNIV, INST PARASITOL, ST ANNE DE BELLEVUE, PQ H9X 3V9, CANADA; MCGILL CANC CTR, MONTREAL, PQ, CANADA	McGill University; McGill University								CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GU ZM, 1994, ONCOGENE, V9, P629; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARX J, 1993, SCIENCE, V262, P1645, DOI 10.1126/science.8259507; MATLASHEWSKI G, 1989, ANTICANCER RES, V9, P1447; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIYASHITA T, 1995, CELL, V80, P293; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; RON D, 1994, P NATL ACAD SCI USA, V91, P1985, DOI 10.1073/pnas.91.6.1985; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SHARMA S, 1993, CELL GROWTH DIFFER, V4, P861; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STOREY A, 1994, KERATINOCYTE HDB, P439; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	30	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					387	392						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624152				2022-12-17	WOS:A1995RK95700019
J	SPITKOVSKY, D; STEINER, P; GOPALKRISHNAN, RV; EILERS, M; JANSENDURR, P				SPITKOVSKY, D; STEINER, P; GOPALKRISHNAN, RV; EILERS, M; JANSENDURR, P			THE ROLE OF P53 IN COORDINATED REGULATION OF CYCLIN D1 AND P21 GENE-EXPRESSION BY THE ADENOVIRUS E1A AND E1B ONCOGENES	ONCOGENE			English	Note						ADENOVIRUS E1A; ADENOVIRUS EIB; CYCLIN D1; P53; P2L(WAF-1); CIP-1	CELL-CYCLE; PROTEIN; TRANSFORMATION; MUTANT; PHOSPHORYLATION; LOCALIZATION; FIBROBLASTS; INHIBITION; PRODUCTS; G(1)	Expression of the cyclin D1 gene is induced when quiescent fibroblasts are stimulated to reenter the cell cycle by addition of growth factors. Moderate ectopic expression of cyclin D1 in early G1 facilitates progression through G1, When transiently overexpressed at the G1/S boundary, cyclin D1 prevents S phase entry, suggesting a dual role for this protein in cellular growth control. It was shown that the retinoblastoma protein (pRB) can activate cyclin D1 gene expression; furthermore, there is evidence that expression of the cyclin D1 gene is down-regulated by the SV40 large T and adenovirus E1A genes, both of which were shown to target pRB, We now report that in diploid human fibroblasts functional inactivation of pRB by adenovirus E1A is not sufficient for efficient repression Of cyclin D1 gene expression, since the E1B gene product, in addition to E1A, is required for repression of the cyclin D1 gene. Since E1B was shown to target p53, we investigated the role of p53 for expression of the cyclin D1 gene. In a cell line with temperature-sensitive p53, cyclin D1 is moderately expressed at the restrictive temperature. Induction of p53 function by temperature shift leads to an increase of cyclin D1 mRNA and protein, parallel to the activation of p21(WAF-1/CIP1) gene expression in this system, When the capability of adenovirus gene products to affect expression of either gene was analysed, we found that infection of Ad5 drastically reduced cyclin D1 and p21(WAF-1/CIP1) gene expression in cells where p53 function is limiting. Under these conditions E1A and E1B cooperate to reduce the cyclin D1 level, while p21(WAF-1)/(CIP1) expression was found insensitive to E1A expression. In cells containing elevated p53 function, modulation of gene expression by E1B was severely compromised; under these conditions, expression of E1A reduced expression of cyclin D1 without affecting p21(WAF-1/CIP1). The data suggest that E1A and E1B cooperate to inhibit expression of cyclin D1 and identify the cyclin D1 gene as a new downstream target for p53.	DEUTSCH KREBSFORSCHUNGSZENTRUM,ABT 620,D-69120 HEIDELBERG,GERMANY; ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY; INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Institut National de la Sante et de la Recherche Medicale (Inserm)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Eilers, Martin/0000-0002-0376-6533				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUPPI K, 1994, ONCOGENE, V9, P3017; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P2547; KATO J, 1993, GENE DEV, V7, P331; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHULZE A, 1994, ONCOGENE, V9, P3475; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; TAM SW, 1994, ONCOGENE, V9, P2663; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	30	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2421	2425						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784093				2022-12-17	WOS:A1995RE54300020
J	TONG, Q; LI, YS; SMANIK, PA; FITHIAN, LJ; XING, SH; MAZZAFERRI, EL; JHIANG, SM				TONG, Q; LI, YS; SMANIK, PA; FITHIAN, LJ; XING, SH; MAZZAFERRI, EL; JHIANG, SM			CHARACTERIZATION OF THE PROMOTER REGION AND OLIGOMERIZATION DOMAIN OF H4 (D10S170), A GENE FREQUENTLY REARRANGED WITH THE RET PROTOONCOGENE	ONCOGENE			English	Article						H4 (D10S170); VET; PROMOTER; OLIGOMERIZATION	THYROID PAPILLARY CARCINOMAS; TYROSINE KINASE; TRANSGENIC MICE; CELL-LINE; PROTOONCOGENE; ACTIVATION; SEQUENCE; CLONING; FUSION; EXPRESSION	PTC-1, the predominant form of PTC oncogene in human papillary thyroid carcinoma, encodes a fusion protein containing the N-terminus of H4 (D10S170) fused 5' to the ret tyrosine kinase domain. Accordingly, the PTC-1 expression is driven by the H4 gene promoter. Our study showed that H4 is expressed in various human tissues, including thyroid. Furthermore, we have localized the transcriptional start sites of H4 to a region 100 to 190 bp upstream of the translation initiation site (ATG) by primer extension assay, and the 114 promoter to a region within 259 bp upstream of the ATG site by luciferase assay. Interestingly, protein sequence analysis indicated a potential coiled-coil domain in the N-terminal region of H4. Indeed, oligomerization was demonstrated by an in vitro assay with recombinant proteins containing this region. As dimerization is considered to be a crucial step for receptor tyrosine kinase activation, we hypothesize that both unscheduled expression of ret tyrosine kinase and constitutive oligomerization of PTC-1 proteins are responsible for PTC-1 transforming activity in thyroid.	OHIO STATE UNIV,DEPT PHYSIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NCI NIH HHS [R29 CA60074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V4, P1519; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; IWAMOTO T, 1991, EUR J IMMUNOL, V21, P1809, DOI 10.1002/eji.1830210805; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RENOLDS GA, 1984, CELL, V38, P275; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; WEINER DB, 1989, NATURE, V239, P230	41	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1781	1787						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753554				2022-12-17	WOS:A1995QX46900011
J	JONES, TL; KARAVANOVA, I; MAENO, M; ONG, RC; KUNG, HF; DAAR, IO				JONES, TL; KARAVANOVA, I; MAENO, M; ONG, RC; KUNG, HF; DAAR, IO			EXPRESSION OF AN AMPHIBIAN HOMOLOG OF THE EPH FAMILY OF RECEPTOR TYROSINE KINASES IS DEVELOPMENTALLY-REGULATED	ONCOGENE			English	Article						EPH; TYROSINE KINASE; XENOPUS LAEVIS	XENOPUS-EMBRYOS; PROTEIN-KINASES; CDNA CLONING; W-LOCUS; GENE; MOUSE; DROSOPHILA; IDENTIFICATION; ENCODES; CHICKEN	In order to study the function of tyrosine kinase receptors during Xenopus development, we have isolated Xek (Xenopus Elk-like kinase), a tyrosine kinase receptor, which shows significant homology to rat Elk and chicken cek5, members of the Eph family. Xek exists as a maternally expressed mRNA which decreases in expression at the mid blastula transition and reappears at late neurulation in Xenopus, Xek mRNA is expressed at higher levels in the anterior and dorsal regions of embryonic stages 16, 24 and 37. In adult Xenopus tissues, Xek appears to be ubiquitously expressed with higher expression observed in brain and ovary, In situ hybridization analysis demonstrates localized mRNA expression in the brain, brachial arches, trigeminal facial ganglion, and the retina of the swimming tadpole stage of development. The similarities in sequence and expression pattern suggest that Xek is an amphibian member of the Eph family and may play a role in the development or function of the central nervous system.	NCI,FREDERICK CANC RES & DEV CTR,LEUKOCYTE BIOL LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOCHEM PHYSIOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Daar, Ira/0000-0003-2657-526X				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; BECKMANN M, 1994, ONCOGENE, V9, P3757; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BOHME B, 1993, ONCOGENE, V8, P2857; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FLETCHER FA, 1994, ONCOGENE, V9, P3241; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GANJU P, 1994, ONCOGENE, V9, P1613; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAMPS MP, 1988, ONCOGENE, V2, P305; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEWTIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP PD, 1967, DAUDIN; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; XU QL, 1994, DEVELOPMENT, V120, P287; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	48	29	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1111	1117						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700636				2022-12-17	WOS:A1995QN35300011
J	KRAUTWALD, S; BUSCHER, D; DENT, P; RUTHENBERG, K; BACCARINI, M				KRAUTWALD, S; BUSCHER, D; DENT, P; RUTHENBERG, K; BACCARINI, M			SUPPRESSION OF GROWTH FACTOR-MEDIATED MAP KINASE ACTIVATION BY V-RAF IN MACROPHAGES - A PUTATIVE ROLE FOR THE MKP-1 PHOSPHATASE	ONCOGENE			English	Article						V-RAF; MAP KINASES; PHOSPHATASES; MKP-1	IMMEDIATE-EARLY GENE; SIGNAL-REGULATED KINASE; MAMMALIAN SOMATIC-CELLS; PROTEIN-KINASE; IN-VITRO; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; XENOPUS-OOCYTES; FACTOR P62TCF; C-MYC	Many tyrosine kinase growth factor receptors activate the MAP Kinase (MAPK) pathway by stimulating the activity of the RAF kinase. In some, but not all cell types, the expression of activated RAF is sufficient to induce constitutive MAPK activation. In BAC-1.2F5 macrophages the expression of virally activated RAF does not correlate with constitutive MAPK activation; on the contrary, growth factor-mediated stimulation of MAPK activity is suppressed in these cells. Suppression correlates with v-RAF expression, as MAPK activation is normal in a revertant cell Line that stopped expressing v-RAF. Inhibition of MAPK activation is associated,vith lack of ERK-2 tyrosine phosphorylation, and is not due to the suppression of CSF-l-mediated MEK activation. Pretreatment with vanadate restores growth factor-stimulated activation and tyrosine phosphorylation of MAPK in v-RAF-expressing macrophages, indicating the involvement of a tyrosine phosphatase. Interestingly, v-RAF-expressing macrophages contain low constitutive levels of MKP-1 mRNA, an immediate early gene that encodes a MAPK-specific phosphatase and is induced in the parental cell line by CSF-1 treatment. The restoration of MAPK activation by vanadate pretreatment and the presence of MKP-1 mRNA in V-RAF-expressing macrophages raise the intriguing possibility that in macrophages RAF may be feeding back on the MAPK pathway by participating in the control of MKP-1 expression.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,DEPT IMMUNOBIOL,D-30625 HANNOVER,GERMANY; UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	Fraunhofer Gesellschaft; University of Virginia; University of Virginia			Baccarini, Manuela/B-6481-2014; Krautwald, Stefan/J-9984-2016	Baccarini, Manuela/0000-0002-3033-391X; Krautwald, Stefan/0000-0001-7768-2132				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Baccarini M, 1991, Receptor, V1, P243; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUSCHER D, 1993, ONCOGENE, V8, P3323; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KEYSE SM, 1992, NATURE, V59, P644; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KRAUTWALD S, 1993, BIOCHEM BIOPH RES CO, V192, P720, DOI 10.1006/bbrc.1993.1474; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; PORRAS A, 1994, J BIOL CHEM, V269, P12741; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SETH A, 1991, J BIOL CHEM, V266, P23521; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; STANLEY ER, 1985, METHOD ENZYMOL, V116, P565; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P56; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	59	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1187	1192						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700643				2022-12-17	WOS:A1995QN35300020
J	LIN, PH; SHENOY, S; GALITSKI, T; SHALLOWAY, D				LIN, PH; SHENOY, S; GALITSKI, T; SHALLOWAY, D			TRANSFORMATION OF MOUSE CELLS BY WILD-TYPE MOUSE C-SRC	ONCOGENE			English	Note						SRC; SPECIES-SPECIFIC; TRANSFORMATION	NIH 3T3 CELLS; PROTEIN-KINASE; V-SRC; NUCLEOTIDE-SEQUENCE; TYROSINE KINASE; TERMINAL REGION; PP60C-SRC; ACTIVATION; P60C-SRC; GENE	Previous studies in which chicken and human c-Src were overexpressed in chicken and rodent cells have indicated that overexpression of wild-type c-Src can not induce complete neoplastic transformation. However, studies with v-Src mutants have demonstrated that species-specific differences can play a significant role in transforming activity. Here we show that, in contrast to chicken c-Src, overexpressed mouse c-Src can induce significant anchorage-independent growth and tumori- genicity when transfected into NIH3T3 mouse cells. The biochemical cause for this difference is unknown. In particular, the protein-tyrosine kinase activities of chicken and mouse c-Src appear to be similar. This result is consistent with the hypothesis that v-Src-induced transformation results from perturbation of signalling pathways modulated by c-Src and highlights the need for caution in controlling for potential species-specific differences in studies of c-Src function.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University			Lin, Pei-Hui/I-3011-2015	Lin, Pei-Hui/0000-0002-3894-5099	NATIONAL CANCER INSTITUTE [R01CA008964, R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA08964, CA32317] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVY BT, 1984, DEV BIOL, V104, P9, DOI 10.1016/0012-1606(84)90031-9; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Potts W. M., 1989, ONCOGENE RES, V3, P343; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SHALLOWAY D, 1991, ADV CANCER RES, V57, P185; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VERDERAME MF, 1994, ONCOGENE, V9, P175; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453	35	29	29	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					401	405						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530829				2022-12-17	WOS:A1995QC62400020
J	FLETCHER, FA; CARPENTER, MK; SHILLING, H; BAUM, P; ZIEGLER, SF; GIMPEL, S; HOLLINGSWORTH, T; BOS, TV; JAMES, L; HJERRILD, K; DAVISON, BL; LYMAN, SD; BECKMANN, MP				FLETCHER, FA; CARPENTER, MK; SHILLING, H; BAUM, P; ZIEGLER, SF; GIMPEL, S; HOLLINGSWORTH, T; BOS, TV; JAMES, L; HJERRILD, K; DAVISON, BL; LYMAN, SD; BECKMANN, MP			LERK-2, A BINDING-PROTEIN FOR THE RECEPTOR-TYROSINE KINASE ELK, IS EVOLUTIONARILY CONSERVED AND EXPRESSED IN A DEVELOPMENTALLY-REGULATED PATTERN	ONCOGENE			English	Article							GROWTH-FACTOR; FAMILY; GENE; PHOSPHORYLATION; MEMBERS; CLONING; CELLS; SITES	We have isolated and characterized cDNA clones that encode the rat homologue of a binding protein, LERK-2, for the receptor tyrosine kinase, elk. The cDNAs contain an open reading frame of 1527 nucleotides capable of encoding a protein 345 amino acid residues in length. The nucleotide sequence of the present clones is >90% identical to the previously identified human LERK-2 cDNA, and the predicted proteins encoded by the rat and human clones are identical at 95% of amino acid residues. Recombinant proteins expressed from the rat cDNAs bind to elk with high affinity, similar to recombinant human LERK-2 and an endogenously-expressed rat elk-binding protein. Expression of the rat LERK-2 mRNA was detected in embryonic brain, kidney, lung, skeletal muscle, thymus, liver, and heart, and diminished in the early post-natal period. Significant LERK-2 mRNA expression in the young adult rat was restricted to the lung, kidney, heart and testes.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101									BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, IN PRESS EMBO J; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAN J, 1991, ONCOGENE, V6, P1057; COOPER JA, 1984, J BIOL CHEM, V259, P7835; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sambrook J., 1989, MOL CLONING LAB MANU; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	29	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3241	3247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936648				2022-12-17	WOS:A1994PM65800017
J	SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; THOMSON, CT; SACCHETTINI, JC; DEPINHO, RA				SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; THOMSON, CT; SACCHETTINI, JC; DEPINHO, RA			EVOLUTIONARY RELATIONSHIPS AND FUNCTIONAL CONSERVATION AMONG VERTEBRATE MAX-ASSOCIATED PROTEINS - THE ZEBRA FISH HOMOLOG OF MXI1	ONCOGENE			English	Article							C-MYC ONCOGENE; INDUCED TERMINAL DIFFERENTIATION; DNA-BINDING; LEUCINE ZIPPER; N-MYC; RAS COTRANSFORMATION; MUTATIONAL ANALYSIS; MESSENGER-RNAS; CELL-CYCLE; EXPRESSION	In mammals, current evidence supports the view that Myc-responsive activities are regulated in part through an intracellular balance between levels of transcriptionally-active Myc/Max heterodimers and those of transcriptionally-inert Max/Max, Mad/Max-and Mxil/Max complexes. To gain insight into the roles of Mad and Mxi1 in cellular growth and differentiation and to fortify key structure-function relationships from an evolutionary standpoint, low stringency hybridization screens were used to identify potential homologs of these Max-associated proteins in the zebra fish genome. A single class of cDNA clones that cross-hybridized both to human mad and mxi1 probes was shown to encode a putative protein with significantly greater homology to mammalian Mxi1 than to Mad, particularly in the basic and helix-loop-helix (bHLH) regions. The high degree of structural relatedness between vertebrate Mxi1 proteins apparent in molecular;modelling studies was consistent with the findings that the HLH/leucine zipper (LZ) region of zMxi1 exhibited the same profile of. dimerization specificities as its mammalian counterpart in the two-hybrid system and that zmxi1 could, like human mxi1 (Lahoz et al., 1994), suppress the oncogenic potential of mouse c-myc in a mammalian cell. Finally, a comparison of steady-state zc-myc and zmxi1 mRNA levels during zebra fish embryogenesis demonstrated (i) high levels of zc-myc relative to zmxi1 mRNA during initiation of organogenesis, a period characterized by intense growth and active differentiation and (ii) rising levels of zmxi1 mRNA during progression towards the terminally differentiated state. These contrasting patterns of developmental expression together with the capacity of zmxi1 to repress myc-induced transformation support a model for the regulation, by Max-associated proteins, of Myc functions in the control of normal cell development and neoplastic growth.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA09173-14] Funding Source: Medline; NIGMS NIH HHS [T32 GM07128, GM45859] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128, R01GM045859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHISHOLM O, 1992, ONCOGENE, V7, P1827; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HISAOKA K. KENNETH, 1960, JOUR MORPHOL, V107, P205, DOI 10.1002/jmor.1051070206; HISAOKA KENICHI KENNETH, 1958, J MORPH, V102, P311, DOI 10.1002/jmor.1051020205; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARUYAMA K, 1987, ONCOGENE, V1, P361; Maxam A M, 1980, Methods Enzymol, V65, P499; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Nei M., 1987, MOL EVOLUT GENET, P293; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; REDDY CD, 1992, ONCOGENE, V7, P2085; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	69	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3167	3177						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936639				2022-12-17	WOS:A1994PM65800008
J	CHEN, HC; WANG, LM; BANERJEE, S				CHEN, HC; WANG, LM; BANERJEE, S			ISOLATION AND CHARACTERIZATION OF THE PROMOTER REGION OF HUMAN NM23-H1, A METASTASIS SUPPRESSOR GENE	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; HUMAN BREAST-CARCINOMA; MESSENGER-RNA; GOOD PROGNOSIS; EXPRESSION; CANCER; OVEREXPRESSION; AMPLIFICATION; ASSOCIATION; PRODUCT	Allelic deletions in the nm23, a metastasis suppressor gene, are known to occur in neuroblastomas, breast and colorectal carcinomas. Down-regulation of nm23 expression has been reported in various rodent and human tumor cells with high metastasis phenotype. Colorectal tumors showed overexpression of nm23. To elucidate the regulatory mechanisms of nm23, we isolated, cloned and sequenced the presumptive regulatory DNA fragment spanning the 5' region of the human nm23-H1 gene. The region's nucleotide sequence shows the presence of motifs typical for transcriptional elements such as TFIID, AP-1 and CTF/NF1. A common transcription initiation site is located at - 136 upstream from the first ATG codon in placenta tissue, in breast, colorectal, prostate tumor cell lines and in primary colorectal tumor. Multiple transcription start sites were identified in tumor cell lines and colorectal tumor. When the promoter element was linked to a reporter gene, chloramphenicol acetyltransferase (CAT) and transfected in human 2fTGH cells, strong CAT activity was detected, which also showed that the presence of AP-1 and CTF/NF1 elements are essential for promoter activity. A detailed study of the structure and function of the promoter element of the nm23-H1 gene will help in understanding the regulatory mechanisms of nm23 expression and its role in tumor progression, especially in metastasis.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation								Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; BACKER JM, 1993, ONCOGENE, V8, P497; BEVILACQUA G, 1989, CANCER RES, V49, P5185; CLARK GM, 1991, CANCER RES, V51, P944; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FLORENES VA, 1992, CANCER RES, V52, P6088; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HONOKI K, 1993, CANCER RES, V53, P5038; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LASKO M, 1992, CELL GROWTH DIFFER, V3, P876; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; LEONE A, 1991, CANCER RES, V51, P2490; Maniatis T, 1989, DECONTAMINATION DILU; MCALPINE PJ, 1991, CYTOGENET CELL GENET, V58, P5, DOI 10.1159/000133160; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; RADINSKY R, 1992, CANCER RES, V52, P5808; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKINNER A, 1993, ONCOGENE, V8, P3393; STAHL JA, 1991, CANCER RES, V51, P445; VARESCO L, 1992, GENE CHROMOSOME CANC, V4, P84, DOI 10.1002/gcc.2870040113; WANG LM, 1993, CANCER RES, V53, P717	36	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2905	2912						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084595				2022-12-17	WOS:A1994PG82200016
J	WONG, WT; CARLOMAGNO, F; DRUCK, T; BARLETTA, C; CROCE, CM; HUEBNER, K; KRAUS, MH; DIFIORE, PP				WONG, WT; CARLOMAGNO, F; DRUCK, T; BARLETTA, C; CROCE, CM; HUEBNER, K; KRAUS, MH; DIFIORE, PP			EVOLUTIONARY CONSERVATION OF THE EPS8 GENE AND ITS MAPPING TO HUMAN-CHROMOSOME 12Q23-Q24	ONCOGENE			English	Note							RECEPTOR TYROSINE KINASES; SIGNALING PROTEINS; SH3 DOMAINS; IDENTIFICATION; PURIFICATION; SUBSTRATE; BINDS; CELLS	We have previously isolated the coding sequence for a novel substrate for tyrosine kinases, eps8, from NIH3T3 fibroblasts. Eps8 was phosphorylated in vivo by several receptor tyrosine kinases (RTKs) and, upon overexpression, was able to enhance EGFR-mediated mitogenic signaling in NIH3T3 cells. To gain understanding of eps8 function as well as its role in normal and neoplastic proliferation, we cloned the human eps8 coding sequence and studied expression of the human RNA and protein, evolutionary conservation, and chromosomal location. In addition to a previously identified SH3 domain, the predicted amino acid sequence of human eps8 revealed a non-random distribution of prolines, clustered in a way to suggest SH3-binding sites and a putative PH domain. Eps8 was expressed in all epithelial and fibroblastic lines examined and in some, but not all, hematopoietic cells. An essential function of eps8 in cell growth regulation was underscored by its conservation during evolution, where eps8-related sequences were detected as early as in Saccaromyces cerevisiae. Finally, the human EPS8 locus was mapped to chromosome 12q23-q24.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; ATENEO FEDERICIANO, FAC MED & CHIRURG, DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL, NAPLES, ITALY; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA; REGINA ELENA INST CANC RES, MOLEC PATHOL & IMMUNOL LAB, ROME, ITALY; FAC MED & CHIRURG BARI, IST MICROBIOL, BARI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro			Young, Richard A/F-6495-2012; Di Fiore, Pier Paolo/K-2130-2012	Young, Richard A/0000-0001-8855-8647; Di Fiore, Pier Paolo/0000-0002-2252-0950	NCI NIH HHS [CA51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CRAIG IW, 1993, 1992 CHROM COORD M, P402; CUTICCHIA AJ, 1993, GENOME PRIORITY REPO, V1; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1991, METHOD ENZYMOL, V196, P65; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUEBNER K, 1991, AM J HUM GENET, V48, P726; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3228; Katz Wendy S., 1992, Current Opinion in Cell Biology, V4, P939, DOI 10.1016/0955-0674(92)90122-S; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MITELMAN F, 1993, 1992 CHROM COORD M, P700; MURANO I, 1989, HUM GENET, V83, P45, DOI 10.1007/BF00274145; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OZISIK YY, 1993, CANCER GENET CYTOGEN, V69, P35, DOI 10.1016/0165-4608(93)90109-Y; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHOUTEN HC, 1989, BLOOD, V73, P2149; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STREHL S, 1993, CANCER GENET CYTOGEN, V71, P94, DOI 10.1016/0165-4608(93)90207-3; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	35	29	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					3057	3061						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084614				2022-12-17	WOS:A1994PG82200037
J	ARCINAS, M; BOXER, LM				ARCINAS, M; BOXER, LM			DIFFERENTIAL PROTEIN-BINDING TO THE C-MYC PROMOTER DURING DIFFERENTIATION OF HEMATOPOIETIC-CELL LINES	ONCOGENE			English	Article							LIGATION-MEDIATED PCR; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ZINC-FINGER PROTEIN; BURKITT-LYMPHOMA; CHROMATIN STRUCTURE; INDUCIBLE PROTEIN; DNA INTERACTIONS; HEAT-SHOCK; 1ST EXON	In vivo footprinting has been used to examine protein binding sites in the c-myc promoter during differentiation cell lines. The c-myc gene is proliferating cells, but c-myc levels decrease dramatically during differentiation. A number of potential protein binding sites have been identified from in vitro studies of the c-myc promoter, but very little is known about occupancy of these sites in vivo. We have identified in vivo footprints at DNase hypersensitive sites II2 and III1 which disappear during differentiation, while a footprint at site IV is present only in differentiated cells. Footprints at DNase hypersensitive sites I and II1 do not change with differentiation. A protected region near DNase hypersensitive site III2 is present in both undifferentiated and differentiated cells, but it extends further 5' in undifferentiated cells. From the protected sequences we have been able to identify candidate transcription factors likely to be involved in the control of c-myc expression. By electrophoretic mobility shift assay we have demonstrated that a protein binds to the sequence at site IV. We have also examined the 3' end of the first exon and the 5' end of intron I and do not find any evidence for protein binding sites in this region that was thought to be important for the block to transcription elongation during differentiation.	VET ADM MED CTR, CTR MOLEC BIOL MED, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER; NCI NIH HHS [CA34233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BORNKAMM GW, 1988, C MYC DEGREGULATION; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; CONKLIN KF, 1984, DNA METHYLATION; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FIBACH E, 1983, CANCER RES, V43, P4136; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LANG JC, 1991, ONCOGENE, V6, P2067; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MOBERG KH, 1992, ONCOGENE, V7, P411; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PLET A, 1992, ONCOGENE, V7, P1847; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SALUZ HP, 1987, LABORATORY GUIDE GEN; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WANG ZY, 1992, BIOCHEM BIOPH RES CO, V188, P433, DOI 10.1016/0006-291X(92)92403-K; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	62	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2699	2706						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058334				2022-12-17	WOS:A1994PC05400031
J	VELASCO, JA; CASTRO, R; AVILA, MA; LABORDA, J; DIPAOLO, JA; CANSADO, J; NOTARIO, V				VELASCO, JA; CASTRO, R; AVILA, MA; LABORDA, J; DIPAOLO, JA; CANSADO, J; NOTARIO, V			CPH, A NOVEL ONCOGENE WHICH COOPERATES WITH H-RAS IN THE TRANSFORMATION OF NIH3T3 FIBROBLASTS	ONCOGENE			English	Note							BLADDER-CARCINOMA ONCOGENE; POINT MUTATION; PROTO-ONCOGENE; NEU ONCOGENE; ACTIVATION; CELLS; GENE; SEQUENCES; CANCER; ACQUISITION	We have performed the molecular cloning of the non-ras transforming sequences previously detected in neoplastic Syrian hamster embryo fibroblasts initiated in vitro with 3-methylcholanthrene (MCA) (Notario et at, 1990). These sequences were isolated using cosmid-rescue techniques from a third-cycle NIH3T3 transformant obtained by sequential transfections of genomic DNA from MCA-initiated hamster fetal cells. Rescued (C-5) clones encompassed about 42.5 kbp of Syrian hamster genomic DNA containing hamster-specific repetitive elements (HRS). An internal 19 kbp BamHI fragment (B-1) was the only C-5 fragment which recognized specific transcripts in poly(A)(+) RNA from hamster embryo cells, The same mRNA species were present in both normal and MCA-initiated neoplastic cells: a major transcript of about 2.5 kb, and other less abundant ones, ranging from approximately 2.0 kb to 5.0 kb. These mRNA species were detected consistently by each of several B-1 DNA subfragments located at positions spanning almost the entire B-1 length. The nucleotide sequence of some transcript-positive (S5P2 and S-6) genomic B-1 fragments was determined. No significant homology exists between the nucleotide sequences of these B-1 subfragments and established DNA databases. Therefore, the C-5 cosmid clone contains novel genomic sequences. Transfection of C-5 DNA into mouse NIH3T3 cells resulted in the appearance of transformed foci (about five foci per mu g of DNA) within 25 days post-transfection, thus demonstrating the transforming activity of the C-5 clone, which was consequently renamed as the cph oncogene. Co-transfection of the cph oncogene with the human H-ras oncogene (T24), demonstrated a synergistic action between the two oncogenes in the transformation of murine fibroblasts.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,DIV EXPTL CARCINOGENESIS,WASHINGTON,DC 20007; NCI,BIOL LAB,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			/AFP-0764-2022; /AAB-6461-2022; Cansado, Jose/ABC-6872-2020; Cansado, Jose/K-5212-2014; Avila, Matias A/Y-6342-2019; Laborda, Jorge/L-5726-2014	Cansado, Jose/0000-0002-2342-8152; Avila, Matias A/0000-0001-6570-3557; Laborda, Jorge/0000-0002-9210-838X	NATIONAL CANCER INSTITUTE [R29CA049858] Funding Source: NIH RePORTER; NCI NIH HHS [CA49858] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BERWALD Y, 1965, J NATL CANCER I, V35, P641; BOREK C, 1987, P NATL ACAD SCI USA, V84, P794, DOI 10.1073/pnas.84.3.794; BOS JL, 1989, CANCER RES, V49, P4682; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASTRO R, 1990, CELL MOL NEUROBIOL, V10, P281, DOI 10.1007/BF00734581; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CICHUTEK K, 1986, P NATL ACAD SCI USA, V83, P2340, DOI 10.1073/pnas.83.8.2340; CUADRADO A, 1993, ONCOGENE, V8, P2443; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GILMER TM, 1988, MOL CARCINOGEN, V1, P180, DOI 10.1002/mc.2940010306; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NOTARIO V, 1990, ONCOGENE, V5, P1425; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	34	29	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2065	2069						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208552				2022-12-17	WOS:A1994NR68500032
J	LALLE, P; DELATOUR, M; RIO, P; BIGNON, YJ				LALLE, P; DELATOUR, M; RIO, P; BIGNON, YJ			DETECTION OF ALLELIC LOSSES ON 17Q12-Q21 CHROMOSOMAL REGION IN BENIGN LESIONS AND MALIGNANT-TUMORS OCCURRING IN A FAMILIAL CONTEXT	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; DINUCLEOTIDE REPEAT POLYMORPHISM; HUMAN OVARIAN CARCINOMAS; ADENOMATOUS POLYPOSIS; ESTROGEN-RECEPTOR; HETEROZYGOSITY; GENE; ALLELOTYPE; DISEASE; MUTATIONS	A predisposing gene (BRCA-1) for breast and ovarian cancer has been located on chromosomal region 17q12-21. According to Knudson's hypothesis if this gene is a tumor suppressor gene, allelic losses would be found in tumors occurring in families with cancer aggregations. We studied 25 samples of both benign lesions and malignant tumors, from breast cancer site-specific families and other familial cancer aggregations. Allelic losses seem to be more frequent in tumors from breast site-specific families but also include the predisposing locus in other syndromes, suggesting a role of BRCA-1 in such families. Finding of allele losses near this locus in benign lesions suggests that such alterations may represent a first step in breast carcinogenesis. It is noteworthy that allele losses involve larger chromosome fragments in malignant tumors than in benign lesions where BRCA-1 is not lost, suggesting a similar mechanism for genomic deletion in the tumorigenesis of the colon and of the breast.	CTR JEAN PERRIN,ONCOL MOLEC LAB,F-63011 CLERMONT 1,FRANCE; CTR JEAN PERRIN,SERV ANAT PATHOL,F-63011 CLERMONT 1,FRANCE; INSERM,U71,F-63005 CLERMONT FERRAND,FRANCE	UNICANCER; Centre Jean Perrin; UNICANCER; Centre Jean Perrin; Institut National de la Sante et de la Recherche Medicale (Inserm)			LALLE, Philippe/G-7734-2018; , bignon/Y-3243-2019; Rio, Pascale/N-5237-2018					ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BOWCOCK AM, 1993, AM J HUM GENET, V52, P730; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EASTON DF, 1993, AM J HUM GENET, V52, P679; ECCLES DM, 1992, ONCOGENE, V7, P2069; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; FOULKES W, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91065-3; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTREAL PA, 1992, HUM MOL GENET, V1, P66, DOI 10.1093/hmg/1.1.66-a; GARCIA T, 1989, NUCLEIC ACIDS RES, V17, P8364; GENUARDI M, 1989, AM J HUM GENET, V45, P73; HALL JM, 1992, AM J HUM GENET, V50, P1235; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE JH, 1990, CANCER RES, V50, P2724; LEONE A, 1991, CANCER RES, V51, P2490; LINDBLOM A, 1993, HUM GENET, V91, P6; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MAZOYER S, 1993, AM J HUM GENET, V52, P754; MIYAKI M, 1990, CANCER RES, V50, P7166; NAROD SA, 1991, LANCET, V338, P82; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SKOLNICK MH, 1990, SCIENCE, V250, P1715, DOI 10.1126/science.2270486; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STEPHENSON CF, 1992, CANCER GENET CYTOGEN, V63, P32, DOI 10.1016/0165-4608(92)90060-L; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; ZIEGLER M, 1992, GENETICS MOL BIOL BR, P83; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	48	29	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					437	442						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290255				2022-12-17	WOS:A1994MW24800010
J	LIEBL, EC; MARTIN, GS				LIEBL, EC; MARTIN, GS			INTRACELLULAR TARGETING OF PP60SRC EXPRESSION - LOCALIZATION OF V-SRC TO ADHESION PLAQUES IS SUFFICIENT TO TRANSFORM CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; INSOLUBLE CELLULAR MATRIX; GENE-PRODUCT; PROTEIN-PHOSPHORYLATION; MORPHOLOGICAL TRANSFORMATION; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; PLATELET PROTEIN; PLASMA-MEMBRANE; FOREIGN DNA	To define the effects of pp60v-src activity at different intracellular sites, we have constructed chimeric molecules which target the pp60v-src kinase to specific intracellular locations. pp60v-src was targeted to the nucleus by insertion of the SV40 large T antigen nuclear localization signal. Nuclear pp60v-src was active as a tyrosine kinase and phosphorylated nuclear proteins at tyrosine. However, cells expressing the nuclear pp60v-src were phenotypically normal by a number of criteria, and nuclear src kinase did not induce the expression of an mRNA (CEF-4) whose induction is characteristic of transformation by wild-type v-src. pp60v-src was targeted to perinuclear membranes by fusion to rat growth hormone and vesicular stomatis G protein sequences. Cells expressing this chimeric molecule were phenotypically normal by most criteria. However the perinuclear src protein did induce elevated levels of CEF-4 mRNA, indicating that the v-src kinase expressed at this site induces partial transformation. The v-src and activated c-src kinases were targeted to adhesion plaques by fusion to the talin-binding sequence of vinculin. Cells expressing these fusion proteins were transformed by morphological, physiological and biochemical criteria, although the foci induced by these viruses were distinct from those induced by wild-type v-src. A chimeric protein which targeted c-src to adhesion plaques was not transforming. Thus targeting pp60src to adhesion plaques, although not sufficient to activate the transforming capacity of c-src, is sufficient to allow transformation by v-src.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R37CA017542, R01CA017542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232] Funding Source: NIH RePORTER; NCI NIH HHS [CA09041, CA-17542] Funding Source: Medline; NIGMS NIH HHS [GM07232] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRICK BA, 1990, CANCER RES, V50, P299; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL JC, 1987, NATURE, V325, P552, DOI 10.1038/325552a0; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BRYAN WR, 1958, ACTA UNION INT CONTR, V15, P764; BRZESKI H, 1980, CELL, V22, P513, DOI 10.1016/0092-8674(80)90361-X; BURR JG, 1980, P NATL ACAD SCI USA, V77, P3483; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; CARTER VC, 1986, J CELL BIOL, V103, P2017, DOI 10.1083/jcb.103.5.2017; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hunter E, 1979, Methods Enzymol, V58, P379; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P1005; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; KRUEGER JG, 1984, MOL CELL BIOL, V4, P454, DOI 10.1128/MCB.4.3.454; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARTINSGREEN M, 1990, J CELL BIOL, V101, P581; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROHRSCHNEIDER L, 1985, MOL CELL BIOL, V5, P3097, DOI 10.1128/MCB.5.11.3097; ROHRSCHNEIDER L, 1983, MOL CELL BIOL, V3, P731, DOI 10.1128/MCB.3.4.731; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROYCHOUDHURY R, 1983, GENE, V25, P161, DOI 10.1016/0378-1119(83)90179-8; Sambrook J., 1989, MOL CLONING LAB MANU; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SHAWVER LK, 1987, MOL CELL BIOL, V7, P2112, DOI 10.1128/MCB.7.6.2112; SHILO BZ, 1987, TRENDS GENET, V3, P69, DOI 10.1016/0168-9525(87)90178-8; SUDOL M, 1986, NUCLEIC ACIDS RES, V14, P2391, DOI 10.1093/nar/14.5.2391; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1	74	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2417	2428						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334249				2022-12-17	WOS:A1992KA85600006
J	WU, WS; LIN, JK; WU, FYH				WU, WS; LIN, JK; WU, FYH			DIFFERENTIAL INDUCTION OF C-FOS AND C-JUN PROTOONCOGENES AND AP-1 ACTIVITY BY TUMOR PROMOTER 12-O-TETRADECANOYL PHORBOL 13-ACETATE IN CELLS AT DIFFERENT STAGES OF TUMOR PROMOTION INVITRO	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; INDUCIBLE ENHANCER ELEMENTS; IMMEDIATE EARLY GENES; EPIDERMAL JB6 CELLS; KINASE-C; CHEMICAL CARCINOGENESIS; 67-BASE-PAIR SEQUENCE; COORDINATE REGULATION; TRANSFORMING GENE; NONCODING REGION	A two-stage (initiation and promotion) model of chemical transformation of mouse embryonic fibroblasts was used to elucidate the molecular mechanisms of tumor promotion in vitro. C3H10T1/2 cells which had been initiated with a subcarcinogenic dose (0.5 mug ml-1) of benzo[a]pyrene (B[a]P) were isolated after 12-O-tetradecanoyl phorbol 13-acetate (TPA) treatment lasting 12, 24 or 36 days. These series of partially promoted cells were designated T-12, T-24 and T-36 cells. T-12 and T-24 cells exhibited higher anchorage-independent growth on soft agar in the presence of TPA than did the initiated or T-36 cells. Cytosolic protein kinase C (PKC) in the resting state was slightly depleted in T-24 and T-36 cells. Proteolytic down-regulation of membrane-bound PKC was enhanced in T-12 cells compared with the initiated cells after 3h of TPA treatment. Induction of c-fos and c-jun proto-oncogene expression increased two- to threefold in T-12 cells. Moreover, the basal level of c-fos mRNA progressively increased in T-12, T-24 and T-36 cells. As compared with other cell types, T-12 cells had the highest AP-1 DNA-binding activity at both the basal level and at 30 min after TPA treatment. These results indicate that deregulation of the TPA-induced cellular responses occurs in the cells at various stages of tumor promotion, and might be associated with transforming processes.	ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN	Academia Sinica - Taiwan								ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CARTER TH, 1987, MECH ENV CARCINOGENE, P47; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIDA K, 1986, CANCER RES, V46, P1055; CHIDA K, 1986, J BIOL CHEM, V261, P3013; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; GREENBERG ME, 1985, CANCER CELL, V3, P307; HANSEN LA, 1990, CANCER RES, V50, P5740; ITO M, 1988, BIOCHEM BIOPH RES CO, V153, P648, DOI 10.1016/S0006-291X(88)81144-6; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KISCHEL T, 1989, BIOCHEM BIOPH RES CO, V165, P981, DOI 10.1016/0006-291X(89)92699-5; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LERMAN MI, 1988, TUMOR PROMOTION BIOL, P357; Maniatis T., 1982, MOL CLONING; MANIATIS T, 1982, MOL CLONING, V2; MARC C, 1990, ONCOGENE, V5, P1541; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER EC, 1978, CANCER RES, V38, P1479; MONDAL S, 1976, CANCER RES, V36, P2254; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J., 1989, MOL CLONING LAB MANU; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WEINSTEIN IB, 1984, CANCER CELL, V1, P229; WEYMAN CM, 1988, CANCER RES, V48, P5740	43	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2287	2294						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437150				2022-12-17	WOS:A1992JW66500022
J	LARSEN, J; BEUG, H; HAYMAN, MJ				LARSEN, J; BEUG, H; HAYMAN, MJ			THE V-SKI ONCOGENE COOPERATES WITH THE V-SEA ONCOGENE IN ERYTHROID TRANSFORMATION BY BLOCKING ERYTHROID-DIFFERENTIATION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; MYELOID CELLS; HISTONE H-5; EXPRESSION; TRANSCRIPTION; GROWTH; LEUKEMIA; PROTEIN; MUSCLE; GENES	The avian retrovirus oncogene v-ski was analysed for its ability to alter the differentiation program of erythroid cells and to cooperate with tyrosine kinase oncogenes in leukemogenesis. For this, a retrovirus combining v-ski with a temperature-sensitive version of the v-sea oncogene was constructed. In transformed erythroblasts, v-ski disturbed the concerted expression of several erythrocyte genes, leading to an abnormal erythroblast phenotype. Expression levels of hemoglobin and erythrocyte anion transporter (band 3) were elevated, while expression of the erythroid-specific histone H5 was strongly suppressed. v-ski could also be shown to repress or severely retard the temperature-induced erythroid differentiation of v-ski/ts-v-sea-transformed cells. The undifferentiated celts had an abnormal erythroblast or early reticulocyte phenotype characterized by unusually low levels of histone H5. In chicks, the v-ski/ts-v-sea virus displayed enhanced leukemogenicity compared with viruses containing just the single oncogenes. Thus, v-ski cooperates with tyrosine kinase oncogenes in a similar fashion to the v-erbA oncogene, however the pattern of genes affected by these two oncogenes is different.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NCI NIH HHS [CA28146, CA42573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BERGMAN MG, 1988, J CELL SCI, V91, P201; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAYMAN MJ, 1992, IN PRESS CANCER SURV; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1986, 12 S COMP RES LEUK R, P41; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOWENZ E, 1987, MODERN TRENDS HUMAN, V7, P199; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; METZ T, 1992, ONCOGENE, V7, P597; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PAIN B, 1990, New Biologist, V2, P284; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SCHROEDER C, 1990, ONCOGENE, V5, P1445; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; STRIFE A, 1988, CANCER RES, V48, P1035; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	42	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1903	1911						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408132				2022-12-17	WOS:A1992JP42400002
J	WALKER, CW; BOOM, JDG; MARSH, AG				WALKER, CW; BOOM, JDG; MARSH, AG			1ST NONVERTEBRATE MEMBER OF THE MYC GENE FAMILY IS SEASONALLY EXPRESSED IN AN INVERTEBRATE TESTIS	ONCOGENE			English	Article							HUMAN C-MYC; STAR PISASTER-OCHRACEUS; DNA-BINDING; SEA STAR; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; ASTERIAS-VULGARIS; GERMINAL CELLS; PROTEIN; ONCOGENES	We have cloned and characterized the first non-vertebrate member of the myc gene family, pAv-myc, from testes of the Northern sea star, Asterias vulgaris (Echinodermata). We have used an oligonucleotide that is complementary to the virtually 100% conserved vertebrate c-myc box A in the second exon and a cDNA library constructed from spermatogenically active testes. Relatives of this echinoderm existed approximately 100 million years prior to the origin of the earliest known organism for which c-myc sequence is currently available (the trout). Nonetheless, our cDNA encodes a protein with approximately 30% amino acid identity and 46% overall conservation to human c-myc. Regions of substantially higher conservation (63-95%) correspond in order to the transcriptional activation (boxes A, B and C), casein kinase II phosphorylation, nuclear-targeting, basic DNA-binding and oligomerization domains in the second and third exons of human c-myc. Sea star c-myc cDNA detects a 2.7-kb transcript on Northern blots of monthly samples of testicular tissue from field-collected individuals (n = 6-8), indicating peak expression during active spermatogenesis. This is also the first example of seasonal variation in expression of c-myc during spermatogenesis in laboratory or natural populations of any animal. It is intriguing to speculate about the potential oncogenic character of c-myc in this invertebrate, in which tumors have not yet been observed, and about the possibility that c-myc is more widely present in eucaryotes than has been anticipated.	UNIV MARYLAND,COMB,BALTIMORE,MD 21203; SIMON FRASER UNIV,INST MOLEC BIOL & BIOCHEM,BURNABY V5A 1S6,BC,CANADA	University System of Maryland; University of Maryland Baltimore; Simon Fraser University	WALKER, CW (corresponding author), UNIV NEW HAMPSHIRE,DEPT ZOOL,DURHAM,NH 03824, USA.							ARGUAT C, 1991, GENE, V97, P231; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEPINHO RA, 1987, GENE DEV, V1, P1131; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; HOWELL AM, 1987, J MOL EVOL, V25, P29, DOI 10.1007/BF02100038; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOVESDI I, 1985, MOL CELL BIOL, V5, P3001, DOI 10.1128/MCB.5.11.3001; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1991, THESIS HELSINKI FINL; MIFFLIN D, 1988, BIOSCIENCE REP, V8, P415, DOI 10.1007/BF01121638; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PETERS EC, 1988, AM FISH SOC SPECIAL, V18, P74; PRENDERGAST GC, 1990, NATURE, V342, P392; Sambrook J., 1989, MOL CLONING LAB MANU; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SARID J, 1988, NUCLEIC ACIDS RES, V16, P4725, DOI 10.1093/nar/16.10.4725; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SPARKS AK, 1972, INVERTEBRATE PATHOLO, P271; STEWART MA, 1986, VIROLOGY, V154, P121, DOI 10.1016/0042-6822(86)90435-6; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WALKER CW, 1980, J MORPHOL, V166, P81, DOI 10.1002/jmor.1051660107; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATTS SA, 1990, TISSUE CELL, V22, P435, DOI 10.1016/0040-8166(90)90073-I; WATTS SA, 1990, BIOL BULL, V179, P159, DOI 10.2307/1541750; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907	50	29	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2007	2012						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408141				2022-12-17	WOS:A1992JP42400014
J	MIN, SY; TAPAROWSKY, EJ				MIN, SY; TAPAROWSKY, EJ			V-MYC, BUT NOT MAX, POSSESSES DOMAINS THAT FUNCTION IN BOTH TRANSCRIPTION ACTIVATION AND CELLULAR-TRANSFORMATION	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; DNA-BINDING PROTEINS; HUMAN C-MYC; RETINOBLASTOMA GENE-PRODUCT; LEUCINE ZIPPER; ADENOVIRUS E1A; MULTISTEP TRANSFORMATION; NUCLEAR-LOCALIZATION; NEGATIVE REGULATOR; LARGE-T	Deregulated expression of myc gene family members is associated with the development of malignant neoplasms in several species. Despite the evidence linking expression of this family of nuclear proteins with the proper control of cellular growth and development, the function of the myc protein remains unknown. Intrigued by the observed structural similarity between the myc protein and several eukaryotic transcription factors, we have investigated the ability of the MC29 viral myc protein to activate transcription of a heterologous promoter in C3H10T1/2 cells. Overlapping portions of v-myc coding sequences were inserted 3' to the yeast GAL4 DNA-binding domain and tested for their ability to activate transcription of a chloramphenicol acetyl transferase reporter gene containing GAL4 binding sites. Two transcription activation domains were identified within the amino terminus of v-Myc. The importance of these regions for cellular transformation was examined using ras/myc co-transformation assays. Our results demonstrate that deletion of either of the transcription activation domains, or the DNA-binding and protein oligomerization domains, abolishes the ability of v-Myc to cooperate with Ras to transform C3H10T1/2 cells. Similarly, we investigated whether Max, the protein-binding partner of Myc, also possesses the potential to activate transcription. Interestingly, chimeric GAL4/Max proteins were not functional in our assays, suggesting that the potential of the Myc-Max complex to influence gene expression and function in cellular transformation relies primarily on sequences found within the amino terminus of Myc.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Min, Soyoung/0000-0001-7511-1520	NATIONAL CANCER INSTITUTE [R23CA042835, R01CA042835] Funding Source: NIH RePORTER; NCI NIH HHS [CA42835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVENPORT EA, 1990, MOL CARCINOGEN, V3, P83, DOI 10.1002/mc.2940030206; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DEAN M, 1986, J BIOL CHEM, V261, P9161; DENIS N, 1987, EXP CELL RES, V172, P212, DOI 10.1016/0014-4827(87)90107-8; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IGVARSSO S, 1990, SEM CANCER BIOL, V1, P359; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KITCHENER G, 1980, P NATL ACAD SCI-BIOL, V77, P1637, DOI 10.1073/pnas.77.3.1637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	63	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1531	1540						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630816				2022-12-17	WOS:A1992JE81300009
J	OUELLETTE, MM; CHEN, J; WRIGHT, WE; SHAY, JW				OUELLETTE, MM; CHEN, J; WRIGHT, WE; SHAY, JW			COMPLEXES CONTAINING THE RETINOBLASTOMA GENE-PRODUCT RECOGNIZE DIFFERENT DNA MOTIFS RELATED TO THE E2F-BINDING SITE	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; CELL-CYCLE; SUSCEPTIBILITY GENE; BINDING ACTIVITY; RB GENE; PHOSPHORYLATION; ACTIVATION; PROMOTER; SUPPRESSION	The retinoblastoma tumor-suppressor gene encodes a 105-kDa nuclear phosphoprotein (RB) that can associate with DRTF-1 and E2F. These two transcription factors can recognize the same DNA motif in the adenovirus E2A promoter and can bind to it by themselves or in association with RB. In the present report, we describe the use of CASTing (cyclic amplification and selection of targets) to determine the consensus binding site of RB-containing complexes. An anti-human RB antibody was used to isolate RB-containing complexes formed after mixing nuclear extracts obtained from human diploid fibroblasts with a pool of random oligonucleotides flanked with polymerase chain reaction (PCR) primers. After the immunoselection, the DNA was isolated, amplified, mixed with fresh nuclear extract and reselected. After six CASTing cycles, the DNA was cloned and sequenced. We found that the highest affinity motifs recognized by RB-containing complexes are related to the E2F/DRTF-I binding site and fall into three classes: TTTTCCCGCCAAAA, TTTTCCCGCCTTTTTT or TTTTCCCGCGCTTTTTT. Competition experiments revealed that these three classes are functionally equivalent to each other and to the E2F/DRTF-1 binding site in the adenovirus E2A promoter. Screening these sequences against a DNA database identified their presence in non-coding regions of many oncogenes, growth factor genes and in the RB gene itself.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA50195] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1990, CANCER SURV, V9, P529; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LASANTHA AB, 1991, CELL, V352, P249; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	31	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1075	1081						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1534398				2022-12-17	WOS:A1992HU64200004
J	MAIONE, R; FIMIA, GM; AMATI, P				MAIONE, R; FIMIA, GM; AMATI, P			INHIBITION OF INVITRO MYOGENIC DIFFERENTIATION BY A POLYOMAVIRUS EARLY FUNCTION	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; FIBROBLAST GROWTH-FACTOR; MUSCLE-SPECIFIC GENES; MYOSIN HEAVY-CHAIN; LARGE T-ANTIGENS; DNA-BINDING; EMBRYO FIBROBLASTS; TRANS-ACTIVATION; EARLY PROTEINS; CELL-CYCLE	In the present work we report on the role of a polyomavirus (Py) early function in interfering with both morphological and biochemical differentiation of the myogenic C2 cell line. The analysis of cell clones stably transfected with a plasmid carrying an ORI- Py genome showed that in the presence of the whole viral early region myogenesis is blocked and a transformed phenotype is evident. By using a plasmid that only encodes large-T function, the involvement of this individual early viral gene product was determined. Inhibition of myogenic differentiation by Py large T is proportional to the level of its expression. This inhibition does not appear to require alteration of cell growth properties. The analysis of muscle-specific functions expressed at different steps in the myogenic pathway showed that Py large T blocks the expression of terminal differentiation markers without altering the expression of the regulatory gene MyoD.	UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOPATOL UMANA,SEZ BIOL CELLULARE,VIALE REGINA ELENA 326,I-00161 ROME,ITALY	Sapienza University Rome			Fimia, Gian Maria/K-3232-2016	Fimia, Gian Maria/0000-0003-4438-3325				ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ASSELIN C, 1984, MOL CELL BIOL, V4, P755, DOI 10.1128/MCB.4.4.755; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1990, ONCOGENE, V5, P1731; COWIE A, 1984, J VIROL, V52, P750, DOI 10.1128/JVI.52.3.750-760.1984; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; Endo T., 1989, CELLULAR MOL BIOL MU, P95; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FELSANI A, 1985, COLD SPRING HARB SYM, V50, P753, DOI 10.1101/SQB.1985.050.01.093; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; FRANCKE B, 1973, VIROLOGY, V55, P127, DOI 10.1016/S0042-6822(73)81014-1; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; IUJVIDIN S, 1990, DIFFERENTIATION, V43, P192; JAINES JB, 1986, MOL CELL BIOL, V6, P2855; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KERN FG, 1986, CANCER CELL, V4, P115; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LATHROP B, 1985, J CELL BIOL, V101, P2194, DOI 10.1083/jcb.101.6.2194; LINCKHART TA, 1981, DEV BIOL, V86, P19; MAIONE R, 1989, J VIROL, V63, P4890, DOI 10.1128/JVI.63.11.4890-4897.1989; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NODA T, 1986, J VIROL, V60, P105, DOI 10.1128/JVI.60.1.105-113.1986; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Sambrook J., 1989, MOL CLONING LAB MANU; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STRAUSS M, 1990, ONCOGENE, V5, P1223; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	60	29	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					85	93						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311065				2022-12-17	WOS:A1992HC22700012
J	NEUBERG, M; SCHUERMANN, M; MULLER, R				NEUBERG, M; SCHUERMANN, M; MULLER, R			MUTAGENESIS OF THE DNA CONTACT SITE IN FOS PROTEIN - COMPATIBILITY WITH THE SCISSORS GRIP MODEL AND REQUIREMENT FOR TRANSFORMATION	ONCOGENE			English	Article							HYPOTHETICAL STRUCTURE COMMON; TRANSCRIPTION FACTOR AP-1; LEUCINE ZIPPER MOTIF; ONCOGENE V-JUN; C-FOS; BINDING PROTEINS; GENE-EXPRESSION; AUTO-REGULATION; CELLULAR GENES; NUCLEAR FACTOR	To elucidate the mechanisms involved in the transformation by fos we have initiated a study pertaining to the identification of molecular functions of Fos protein that are crucial for transformation. We have previously reported that the presence of an intact leucine zipper in Fos is an absolute requirement for the induction of transformation, but that the autorepression function of Fos is dispensable. We now show that Fos protein also needs an intact DNA (TRE)-binding site to be able to transform. Amino acid substitutions in this domain of Fos which impair DNA binding also destroy the transforming potential of Fos, suggesting that the interaction of Fos-Jun complexes with TREs may be a crucial part of Fos-induced transformation. This hypothesis is further strengthened by our observation that Fos and Jun can cooperate in the induction of transformation. We show that a Fos protein which contains a Jun leucine zipper and is thus capable of dimerization is still dependent on the presence of exogenous Jun to induce transformation. The critical positions in the Fos DNA-binding site include those which the 'scissors grip' model predicts to be crucial, although the DNA-binding site in Fos seems to extend beyond the basic region into an adjacent cluster of acidic amino acids.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FU TH, 1989, MOL CELL BIOL, V9, P1120; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALAZONETIS TD, 1988, CELL, V55, P916; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATSUI M, 1990, ONCOGENE, V5, P249; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MULLER R, 1984, EMBO J, V3, P1121, DOI 10.1002/j.1460-2075.1984.tb01939.x; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NEUBERG M, 1989, NATURE, V341, P2243; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHEURMANN M, 1989, CELL, V56, P507; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	60	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1325	1333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1909428				2022-12-17	WOS:A1991GX27200005
J	VANDERHOORN, FA; SPIEGEL, JE; MAYLIEPFENNINGER, MF; NORDEEN, SK				VANDERHOORN, FA; SPIEGEL, JE; MAYLIEPFENNINGER, MF; NORDEEN, SK			A 43 KD C-MOS PROTEIN IS ONLY EXPRESSED BEFORE MEIOSIS DURING RAT SPERMATOGENESIS	ONCOGENE			English	Article							DISTINCT DEVELOPMENTAL PATTERNS; MOUSE GERM-CELLS; ONCOGENE PRODUCT; PROTOONCOGENE EXPRESSION; MEIOTIC MATURATION; XENOPUS OOCYTES; SEQUENCE; RNA; FEMALE; TRANSCRIPTS	We have investigated the RNA and protein expression pattern of the rat c-mos proto-oncogene during spermatogenesis. In mouse testis a 43 kD c-mos protein is expressed throughout spermatogenesis, which is in agreement with one report detecting a 1.7 kb c-mos RNA in pachytene spermatocytes and in early spermatids. However, several other reports show that the mouse 1.7 kb c-mos RNA is exclusively expressed in postmeiotic male germ cells. We report that in rat male germ cells three c-mos RNA species of 5, 3.6 and 1.7 kb are detectable by Northern blotting analysis both before and after meiosis, with highest levels in early spermatids. However, western immuno-blot analysis reveals the presence of a 43 kD c-mos protein in total testis and pachytene spermatocytes, but not in post-meiotic cells. These findings combined with those made in the mouse system strongly suggest that c-mos protein may be a regulator of meiosis during spermatogenesis.	UNIV COLORADO,DEPT PATHOL,BOULDER,CO 80309; UNIV COLORADO,DEPT CELLULAR & STRUCT BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	VANDERHOORN, FA (corresponding author), UNIV CALGARY,DEPT MED BIOCHEM,3330 HOSP DR NW,CALGARY T2N 4N1,ALBERTA,CANADA.							BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GROOTEGOED JA, 1977, BIOCHEM J, V168, P23, DOI 10.1042/bj1680023; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; KESHET E, 1988, ONCOGENE, V2, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; VANDERHOORN F, 1986, NUCLEIC ACIDS RES, V14, P8771, DOI 10.1093/nar/14.22.8771; VANDERHOORN FA, 1985, MOL CELL BIOL, V5, P2204, DOI 10.1128/MCB.5.9.2204; VANDERHOORN FA, 1987, J MOL BIOL, V193, P255, DOI 10.1016/0022-2836(87)90217-8; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; VANDERHOORN FA, 1989, BIOCHEM BIOPH RES CO, V161, P8, DOI 10.1016/0006-291X(89)91552-0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0	28	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					929	932						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1712445				2022-12-17	WOS:A1991GU62200006
J	MAKOVER, D; CUDDY, M; YUM, S; BRADLEY, K; ALPERS, J; SUKHATME, V; REED, JC				MAKOVER, D; CUDDY, M; YUM, S; BRADLEY, K; ALPERS, J; SUKHATME, V; REED, JC			PHORBOL ESTER-MEDIATED INHIBITION OF GROWTH AND REGULATION OF PROTOONCOGENE EXPRESSION IN THE HUMAN T-CELL LEUKEMIA LINE JURKAT	ONCOGENE			English	Article							C-MYC; FOLLICULAR LYMPHOMA; MOLECULAR-CLONING; SARCOMA VIRUS; CDNA CLONE; GENE; DIFFERENTIATION; ENCODES; FOS; SEQUENCE	The expression and function of several proto-oncogenes were examined in a human acute T cell leukemia line, JURKAT, during phorbol ester-induced terminal differentiation. Treating JURKAT cells with the phorbol ester tetradecanoyl phorbol acetate (TPA) inhibited their proliferation and induced expression of the gene for the interleukin 2 receptor alpha chain (IL2R-alpha), consistent with previous reports. In unstimulated proliferating JURKAT cells, high levels of C-MYC, N-RAS, and BCL2 mRNAs were found that diminished rapidly following TPA-induced cessation of growth. In contrast, accumulation of mRNAs for the C-FOS, C-JUN, and EGR-1 genes increased markedly in TPA-treated cells and preceded the induction of IL2R-alpha mRNA. Expression of the C-MYB, C-RAF-1, C-LCK, C-FYN, and C-FGR proto-oncogenes was relatively unchanged. To explore directly the function of two of these proto-oncogenes in regulating the growth of JURKAT T cells, we stably transferred C-MYC and BCL2 expression plasmids into these cells. Despite sustained expression of C-MYC, BCL2, or the combination of these proto-oncogenes, TPA continued to inhibit JURKAT cell growth and to induce IL2R expression. Thus, although C-MYC and BCL2 proto-oncogene expression correlated with proliferation in TPA-treated JURKAT cells, continuous over-expression of even the combination of these oncogenes was insufficient for abrogating the effects of TPA in these leukemic T cells. Because human lymphoid malignancies frequently contain chromosomal translocations that deregulate the expression of C-MYC and BCL2, our findings could have relevance for attempts to induce terminal differentiation of leukemic cells by in vitro exposure of patients' bone marrow cells to phorbol esters.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Pennsylvania; University of Pennsylvania; University of Chicago			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [CA47956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHM JL, 1986, CANCER RES, V46, P3711; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BOHNMANN D, 1987, SCIENCE, V238, P1386; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P155; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCHINI G, 1983, P  NATL ACAD SCI US, V80, P7380; GAUWERKY CE, 1988, ONCOGENE, V2, P431; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GREENE WC, 1984, J IMMUNOL, V133, P1042; GROSSO LE, 1985, CANCER RES, V45, P847; INOUE K, 1987, ONCOGENE, V1, P301; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LEE WMF, 1989, ONCOGENES, P37; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEONARD WJ, 1984, NATURE, V311, P636; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PEGORARO L, 1980, BLOOD, V55, P859; PERLMUTTER RM, 1989, SCIENCE, V245, P344, DOI 10.1126/science.2787933; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RAPP UR, 1988, HDB ONCOGENES, P213; REED J, 1990, IN PRESS P INT S CHI; REED J, 1988, INTERLEUKIN, V2, P367; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REED JC, 1985, MOL CELL BIOL, V5, P3361, DOI 10.1128/MCB.5.12.3361; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REED JC, 1987, DEV RECOGNITION TRAN, P39; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	52	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					455	460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011401				2022-12-17	WOS:A1991FT34400016
J	CHALIFOUR, LE; GOMES, ML; WANG, NS; MESMASSON, AM				CHALIFOUR, LE; GOMES, ML; WANG, NS; MESMASSON, AM			POLYOMAVIRUS LARGE T-ANTIGEN EXPRESSION IN HEART OF TRANSGENIC MICE CAUSES CARDIOMYOPATHY	ONCOGENE			English	Article									SIR MORTIMER B DAVIS JEWISH HOSP, LADY DAVIS INST MED RES, BLOOMFIELD CTR RES AGING, MONTREAL H3T 1E2, QUEBEC, CANADA; MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, MONTREAL H3A 2T5, QUEBEC, CANADA; MCGILL UNIV, DEPT PATHOL, MONTREAL H3A 2T5, QUEBEC, CANADA; INST CANC MONTREAL, MONTREAL H2L 4M1, QUEBEC, CANADA	Lady Davis Institute; McGill University; McGill University; McGill University; Universite de Montreal	CHALIFOUR, LE (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, 6100 ROYALMOUNT AVE, MONTREAL, QUEBEC, CANADA.			Mes-Masson, Anne-Marie/0000-0002-6498-266X				ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; ASSELIN C, 1983, MOL CELL BIOL, V3, P1451, DOI 10.1128/MCB.3.8.1451; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V13, P2633; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; DAWE CJ, 1987, AM J PATHOL, V127, P243; DEPAMPHILIS ML, 1988, BIOTECHNIQUES, V6, P662; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EDDY BE, 1982, MOUSE BIOMEDICAL RES, V2, P293; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; Flint S. J, 1981, DNA TUMOR VIRUSES; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; GLAICHENHAUS N, 1985, ADV CANCER RES, V45, P291, DOI 10.1016/S0065-230X(08)60271-7; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; GROSS L, 1970, ONCOGENIC VIRUSES, P651; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HULLAND TJ, 1978, TUMORS DOMESTIC ANIM; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEOPOLD P, 1986, BIOCHEM BIOPH RES CO, V141, P1162, DOI 10.1016/S0006-291X(86)80166-8; Maniatis T., 1982, MOL CLONING; MCALLISTER HA, 1987, PATHOLOGY HEART GREA, P343; MONK M, 1988, GENE DEV, V2, P921, DOI 10.1101/gad.2.8.921; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MUELLER CR, 1984, MOL CELL BIOL, V4, P2594, DOI 10.1128/MCB.4.12.2594; MULLER WJ, 1983, J VIROL, V47, P586, DOI 10.1128/JVI.47.3.586-599.1983; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PIPER HM, 1987, HEART CELL CULTURE, V1, P49; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1986, CELL, V46, P513, DOI 10.1016/0092-8674(86)90876-7; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RASSOULZADEGAN M, 1987, ONCOGENE RES, V1, P1; ROCHFORD R, 1990, J VIROL, V64, P476, DOI 10.1128/JVI.64.2.476-485.1990; RUGH R, 1968, MOUSE ITS REPRODUCTI; SOLTER D, 1988, ANNU REV GENET, V22, P127; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TRASK RV, 1988, J BIOL CHEM, V263, P17142; WEISS R, 1984, MOL BIOL TUMOR VIRUS; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WIRAK DO, 1985, MOL CELL BIOL, V5, P2924, DOI 10.1128/MCB.5.11.2924; YEE SP, 1989, P NATL ACAD SCI USA, V86, P5873, DOI 10.1073/pnas.86.15.5873; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	55	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1990	5	11					1719	1726						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2176284				2022-12-17	WOS:A1990EL40100016
J	RASSOULZADEGAN, M; COURTNEIDGE, SA; LOUBIERE, R; ELBAZE, P; CUZIN, F				RASSOULZADEGAN, M; COURTNEIDGE, SA; LOUBIERE, R; ELBAZE, P; CUZIN, F			A VARIETY OF TUMORS INDUCED BY THE MIDDLE T-ANTIGEN OF POLYOMA-VIRUS IN A TRANSGENIC MOUSE FAMILY	ONCOGENE			English	Article									EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY; UNIV NICE,FAC MED,F-06034 NICE,FRANCE	European Molecular Biology Laboratory (EMBL); UDICE-French Research Universities; Universite Cote d'Azur	RASSOULZADEGAN, M (corresponding author), UNIV NICE,CTR BIOCHIM,INSERM,U273,F-06034 NICE,FRANCE.		Rassoulzadegan, Minoo/O-7939-2016					ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AGUZZI A, 1990, IN PRESS NEW BIOL; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; DAWE CJ, 1987, AM J PATHOL, V127, P243; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; GERLINGER P, 1986, NUCLEIC ACIDS RES, V14, P6565, DOI 10.1093/nar/14.16.6565; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; Hogan B., 1986, MANIPULATING MOUSE E; JENSEN NA, 1989, IN PRESS MOL BIOL ME; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Maniatis T., 1982, MOL CLONING; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; STEWART SARAH E., 1960, ADVANCES IN VIRUS RES, V7, P61; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WILLIAMS RL, 1988, CELL, V52, P121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	28	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1507	1510						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2123530				2022-12-17	WOS:A1990EK50200009
J	DAVIS, JN; BARGMANN, W; BOSE, HR				DAVIS, JN; BARGMANN, W; BOSE, HR			IDENTIFICATION OF PROTEIN COMPLEXES CONTAINING THE C-REL PROTOONCOGENE PRODUCT IN AVIAN HEMATOPOIETIC-CELLS	ONCOGENE			English	Article									UNIV TEXAS,CELL RES INST,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	DAVIS, JN (corresponding author), UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712, USA.				NCI NIH HHS [CA 33192, CA 26169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026169, R01CA033192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P616; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LIM MT, 1990, IN PRESS VIROLOGY; MOORE BE, 1989, ONCOGENE, V4, P845; MORRISON LE, 1989, ONCOGENE, V4, P677; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; TUNG HYL, 1988, BIOCHEM BIOPH RES CO, V152, P441; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WONG TC, 1981, VIROLOGY, V111, P289, DOI 10.1016/0042-6822(81)90674-7; ZHANG J, 1989, MOL CELL BIOL, V9, P4970, DOI 10.1128/MCB.9.11.4970; ZHANG J, 1990, UNPUB MOL CELL BIOL; ZHANG JY, 1989, J VIROL, V63, P1107, DOI 10.1128/JVI.63.3.1107-1115.1989	28	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1109	1115						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2202947				2022-12-17	WOS:A1990DX36100001
J	GRANT, ML; BRUTON, RK; BYRD, PJ; GALLIMORE, PH; STEELE, JC; TAYLOR, AMR; GRAND, RJA				GRANT, ML; BRUTON, RK; BYRD, PJ; GALLIMORE, PH; STEELE, JC; TAYLOR, AMR; GRAND, RJA			SENSITIVITY TO IONIZING-RADIATION OF TRANSFORMED HUMAN-CELLS CONTAINING MUTANT RAS GENES	ONCOGENE			English	Article									UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,POB 363,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham								ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P394, DOI 10.1016/0968-0004(89)90281-8; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; BYRD PJ, 1988, ONCOGENE, V2, P477; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COX R, 1980, INT J RADIAT BIOL, V38, P575, DOI 10.1080/09553008014551391; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FITZGERALD TJ, 1985, AM J CLIN ONCOL-CANC, V8, P517, DOI 10.1097/00000421-198512000-00012; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLUZMAN Y, 1980, P NATL ACAD SCI-BIOL, V77, P3898, DOI 10.1073/pnas.77.7.3898; GRAND RJA, 1989, ONCOGENE, V4, P355; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GRAND RJA, 1987, ONCOGENE, V1, P305; GRAND RJA, 1986, EMBO J, V5, P1253, DOI 10.1002/j.1460-2075.1986.tb04354.x; GUTIERREZ L, 1989, EMBO J, V8, P1098; HANCOCK JF, 1989, CELL, V57, P1166; HAND PH, 1987, BIOCHIM BIOPHYS ACTA, V908, P131, DOI 10.1016/0167-4781(87)90052-2; KASID UN, 1989, CANCER RES, V49, P3396; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MCCKENNA WG, 1990, CANCER RES, V50, P97; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; MURNANE JP, 1985, EXP CELL RES, V158, P119, DOI 10.1016/0014-4827(85)90437-9; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SIGNAL IS, 1986, P NATL ACAD SCI USA, V83, P4725; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SMITH KJ, 1989, ONCOGENE, V4, P489; STACEY M, 1989, INT J RADIAT BIOL, V56, P45, DOI 10.1080/09553008914551171; TAYLOR AMR, 1987, J MED GENET, V24, P669, DOI 10.1136/jmg.24.11.669; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	39	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1159	1164						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2168028				2022-12-17	WOS:A1990DX36100007
J	YANAGIHARA, K; CIARDIELLO, F; TALBOT, N; MCGEADY, ML; COOPER, H; BENADE, L; SALOMON, DS; BASSIN, RH				YANAGIHARA, K; CIARDIELLO, F; TALBOT, N; MCGEADY, ML; COOPER, H; BENADE, L; SALOMON, DS; BASSIN, RH			ISOLATION OF A NEW CLASS OF FLAT REVERTANTS FROM RAS-TRANSFORMED NIH3T3 CELLS USING CIS-4-HYDROXY-L-PROLINE	ONCOGENE			English	Article									NCI,DIV CANC BIOL & DIAG,TUMOR IMMUNOL & BIOL LAB,BLDG 10,RM 8B05,BETHESDA,MD 20892; AMER RED CROSS,TRANSMISSIBLE DIS LAB,ROCKVILLE,MD 20855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American Red Cross			Cutler, Mary L/G-5735-2017	Cutler, Mary L/0000-0001-9727-4320; Ciardiello, Fortunato/0000-0002-3369-4841				BASSIN RH, 1971, NATURE, V229, P564, DOI 10.1038/229564b0; BASSIN RH, 1987, ADV VIRAL ONCOL, V6, P103; BASSIN RH, 1984, CANCER CELLS ONCOGEN, V2, P462; BERNSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P1726, DOI 10.1073/pnas.82.6.1726; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CIARDIELLO F, 1988, CANCER RES, V48, P2483; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Maniatis T., 1982, MOL CLONING; MATHEYPREVOT B, 1984, J VIROL, V50, P325, DOI 10.1128/JVI.50.2.325-334.1984; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OZANNE B, 1974, J VIROL, V14, P239, DOI 10.1128/JVI.14.2.239-248.1974; PIZON V, 1988, ONCOGENE, V3, P201; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHIH TY, 1979, VIROLOGY, V96, P64, DOI 10.1016/0042-6822(79)90173-9; SIRCAR S, 1988, ONCOGENE, V3, P725; TAGLIAFERRI P, 1987, INT J CANCER, V4, P653; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; YANAGIHARA K, 1985, JPN J CANCER RES, V76, P331; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	29	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1179	1186						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2202950				2022-12-17	WOS:A1990DX36100010
J	BAUER, SR; PIECHACZYK, M; NORDAN, RP; OWENS, JD; NEPVEU, A; MARCU, KB; MUSHINSKI, JF				BAUER, SR; PIECHACZYK, M; NORDAN, RP; OWENS, JD; NEPVEU, A; MARCU, KB; MUSHINSKI, JF			ALTERED MYC-GENE TRANSCRIPTION AND INTRON-INDUCED STABILIZATION OF MYC RNAS IN 2 MOUSE PLASMACYTOMAS	ONCOGENE			English	Article									NCI,GENET LAB,BETHESDA,MD 20892; UNIV MARYLAND,DEPT BIOCHEM,COLLEGE PK,MD 20742; UNIV MONTPELLIER 2,BIOL MOLEC LAB,F-34060 MONTPELLIER,FRANCE; CTR PAUL LAMARQUE,BIOCHEM LAB,F-34033 MONTPELLIER,FRANCE; SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland College Park; Universite de Montpellier; Universite de Montpellier; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Bauer, Steven/G-5559-2012; /AAB-8315-2020; PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597; Bauer, Steven/0000-0003-2831-846X	NCI NIH HHS [CA 36246] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036246] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ALT FW, 1982, MOL CELL BIOL, V2, P386, DOI 10.1128/MCB.2.4.386; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BONNIEU A, 1988, ONCOGENE RES, V3, P155; CECH TR, 1983, CELL, V34, P713, DOI 10.1016/0092-8674(83)90527-5; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HU NT, 1982, GENE, V17, P271; Jacob S T, 1973, Prog Nucleic Acid Res Mol Biol, V13, P93, DOI 10.1016/S0079-6603(08)60101-4; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LANG RB, 1982, NUCLEIC ACIDS RES, V10, P611, DOI 10.1093/nar/10.2.611; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LOENEN WAM, 1980, GENE, V10, P249, DOI 10.1016/0378-1119(80)90054-2; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MUSHINSKI JF, 1983, P NATL ACAD SCI-BIOL, V80, P1073, DOI 10.1073/pnas.80.4.1073; MUSHINSKI JF, 1988, CELLULAR ONCOGENE AC, P181; MUSHINSKI JF, 1985, MECHANISMS B CELL NE, P237; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PERRY RP, 1983, CELL, V33, P647, DOI 10.1016/0092-8674(83)90006-5; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1986, CURR TOP MICROBIOL, V132, P331; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; POTTER M, 1984, SURV SYN PATHOL RES, V3, P499; POTTER M, 1984, ADV VIRAL ONCOL, V4, P139; PREHN J, 1984, NUCLEIC ACIDS RES, V12, P8987, DOI 10.1093/nar/12.23.8987; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SWARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052, DOI 10.1128/MCB.7.6.2052; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1982, P NATL ACAD SCI USA, V79, P7839; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WIRSCHUBSKY Z, 1984, INT J CANCER, V33, P477, DOI 10.1002/ijc.2910330410; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	63	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					615	623						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657576				2022-12-17	WOS:A1989U768800012
J	MOROY, T; ETIEMBLE, J; BOUGUELERET, L; HADCHOUEL, M; TIOLLAIS, P; BUENDIA, MA				MOROY, T; ETIEMBLE, J; BOUGUELERET, L; HADCHOUEL, M; TIOLLAIS, P; BUENDIA, MA			STRUCTURE AND EXPRESSION OF HCR, A LOCUS REARRANGED WITH C-MYC IN A WOODCHUCK HEPATOCELLULAR-CARCINOMA	ONCOGENE			English	Article									INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,CNRS,UA 271,INSERM,U163,F-75724 PARIS 15,FRANCE; HOP BICETRE,INSERM,U56,F-94275 KREMLIN BICETRE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Moroy, Tarik/D-9923-2011					BIRCHMEIER C, 1984, P NATL ACAD SCI-BIOL, V81, P1057, DOI 10.1073/pnas.81.4.1057; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CALZONE FJ, 1988, GENE DEV, V2, P305, DOI 10.1101/gad.2.3.305; CLAVERIE JM, 1986, NUCLEIC ACIDS RES, V14, P179, DOI 10.1093/nar/14.1.179; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GOODMAN RH, 1979, BIOCHEM BIOPH RES CO, V91, P932, DOI 10.1016/0006-291X(79)91969-7; GUBLER U, 1983, P NATL ACAD SCI-BIOL, V80, P4311, DOI 10.1073/pnas.80.14.4311; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HERBERT E, 1983, TRENDS BIOCHEM SCI, V6, P184; JAISWAL AK, 1987, NUCLEIC ACIDS RES, V15, P6755, DOI 10.1093/nar/15.16.6755; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOROY T, 1985, EMBO J, V4, P1507, DOI 10.1002/j.1460-2075.1985.tb03810.x; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NISHIKURA K, 1984, SCIENCE, V224, P399, DOI 10.1126/science.6424234; PATEY G, 1986, ANN ENDOCRINOL-PARIS, V47, P71; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; RUPPERT S, 1984, NATURE, V308, P554, DOI 10.1038/308554a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAUL Y, 1987, EMBO J, V6, P1913, DOI 10.1002/j.1460-2075.1987.tb02451.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SNYDER RL, 1980, COLD SPRING HARBOR C, V7, P447; SONIGO P, 1987, P NATL ACAD SCI USA, V84, P3768, DOI 10.1073/pnas.84.11.3768; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UYEDA A, 1987, NUCLEIC ACIDS RES, V15, P6738, DOI 10.1093/nar/15.16.6738; VARMUS HE, 1984, ANNU REV GENET, V18, P553; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	43	29	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					59	65						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2536918				2022-12-17	WOS:A1989U567400009
J	BOEHM, T; LAVENIR, I; FORSTER, A; WADEY, RB; COWELL, JK; HARBOTT, J; LAMPERT, F; WATERS, J; SHERRINGTON, P; COUILLIN, P; AZOULAY, M; JUNIEN, C; VANHEYNINGEN, V; PORTEOUS, DJ; HASTIE, ND; RABBITTS, TH				BOEHM, T; LAVENIR, I; FORSTER, A; WADEY, RB; COWELL, JK; HARBOTT, J; LAMPERT, F; WATERS, J; SHERRINGTON, P; COUILLIN, P; AZOULAY, M; JUNIEN, C; VANHEYNINGEN, V; PORTEOUS, DJ; HASTIE, ND; RABBITTS, TH			THE T-ALL SPECIFIC T(11-14)(P13-Q11) TRANSLOCATION BREAKPOINT CLUSTER REGION IS LOCATED NEAR TO THE WILMS TUMOR PREDISPOSITION LOCUS	ONCOGENE			English	Article									INST CHILD HLTH,DEPT HAEMATOL & ONCOL,ICRF,MOLEC GENET LAB,LONDON WC1N 1EH,ENGLAND; UNIV GIESSEN KLINIKUM,ZENTRUM KINDERHEILKUNDE,D-6300 GIESSEN,FED REP GER; ADDENBROOKES HOSP,DEPT CYTOGENET,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV CAMBRIDGE,DEPT HAEMATOL MED,CAMBRIDGE CB2 2QH,ENGLAND; INSERM,U73,GENET & PATHOL FOETALE,F-75005 PARIS,FRANCE; WESTERN GEN HOSP,MRC,CLIN & POPULAT CYTOGENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of London; University College London; University Hospital of Giessen & Marburg; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Edinburgh	BOEHM, T (corresponding author), MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND.		Porteous, David/AAA-3446-2021; van Heyningen, Veronica/B-8039-2008; VAN HEYNINGEN, Veronica/GYE-0531-2022; Porteous, David J/C-7289-2013	Porteous, David/0000-0003-1249-6106; van Heyningen, Veronica/0000-0003-0359-0141; Porteous, David J/0000-0003-1249-6106; Cowell, John/0000-0002-2079-5950				BARKER PE, 1986, AM J HUM GENET, V39, P661; BICKMORE W, 1988, NUCLEIC ACIDS RES, V16, P51, DOI 10.1093/nar/16.1.51; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; COUILLIN P, 1988, UNPUB; COWELL JK, 1988, UNPUB; DAVIS LM, 1988, SCIENCE, V241, P840, DOI 10.1126/science.2841760; GLASER T, 1986, NATURE, V321, P882, DOI 10.1038/321882a0; KORNELUK RG, 1984, J BIOL CHEM, V259, P3819; LAMPERT F, 1988, BLUT, V56, P117, DOI 10.1007/BF00320016; LEWIS WH, 1985, NATURE, V317, P544, DOI 10.1038/317544a0; PORTEOUS DJ, 1987, P NATL ACAD SCI USA, V84, P5355, DOI 10.1073/pnas.84.15.5355; RABBITTS TH, 1985, EMBO J, V4, P1461, DOI 10.1002/j.1460-2075.1985.tb03803.x; RICCARDI VM, 1978, PEDIATRICS, V61, P604; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUNNACLIFFE A, 1987, EMBO J, V6, P2953, DOI 10.1002/j.1460-2075.1987.tb02600.x; TURLEAU C, 1984, HUM GENET, V67, P455, DOI 10.1007/BF00291410; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; WATKINS PC, 1987, DNA-J MOLEC CELL BIO, V6, P205, DOI 10.1089/dna.1987.6.205	19	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					691	695						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577871				2022-12-17	WOS:A1988R646000011
J	KLEMPNAUER, KH				KLEMPNAUER, KH			INTERACTION OF MYB PROTEINS WITH NUCLEAR MATRIX INVITRO	ONCOGENE			English	Article											KLEMPNAUER, KH (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEC BIOL,IM NEUENHEIMER FELD 282,D-6900 HEIDELBERG,FED REP GER.							BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; CIEJEK EM, 1982, BIOCHEMISTRY-US, V21, P4945, DOI 10.1021/bi00263a018; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COOK PR, 1982, EMBO J, V1, P447, DOI 10.1002/j.1460-2075.1982.tb01189.x; CRAIG RW, 1984, CANCER RES, V44, P442; DIJKWEL PA, 1986, NUCLEIC ACIDS RES, V14, P3241, DOI 10.1093/nar/14.8.3241; DIJKWEL PA, 1979, NUCLEIC ACIDS RES, V6, P218; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1984, MOL CELL BIOL, V4, P591; GONDA TJ, 1981, CELL, V23, P279, DOI 10.1016/0092-8674(81)90292-0; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; ROBINSON SI, 1982, CELL, V28, P99, DOI 10.1016/0092-8674(82)90379-8; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	34	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					545	551						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290804				2022-12-17	WOS:A1988N841500003
J	HIGUCHI, Y; SETOGUCHI, M; YOSHIDA, S; AKIZUKI, S; YAMAMOTO, S				HIGUCHI, Y; SETOGUCHI, M; YOSHIDA, S; AKIZUKI, S; YAMAMOTO, S			ENHANCEMENT OF C-FOS EXPRESSION IS ASSOCIATED WITH ACTIVATED MACROPHAGES	ONCOGENE			English	Article											HIGUCHI, Y (corresponding author), MED COLL OITA,DEPT PATHOL,OITA 87956,JAPAN.							AKAGAWA KS, 1981, MICROBIOL IMMUNOL, V25, P1215, DOI 10.1111/j.1348-0421.1981.tb00130.x; AKAGAWA KS, 1982, MICROBIOL IMMUNOL, V26, P831, DOI 10.1111/j.1348-0421.1982.tb00229.x; ANDREW PW, 1984, EUR J IMMUNOL, V14, P962, DOI 10.1002/eji.1830141018; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; GEMSA D, 1983, J IMMUNOL, V131, P833; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HIGUCHI Y, 1984, IMMUNOGENETICS, V20, P95, DOI 10.1007/BF00364481; HOMMA Y, 1982, J IMMUNOL, V129, P1619; INTRONA M, 1986, J IMMUNOL, V137, P2711; JONES CM, 1986, J IMMUNOL, V137, P571; KLEINSCHMIDT WJ, 1982, J INTERFERON RES, V2, P291, DOI 10.1089/jir.1982.2.291; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LE JM, 1983, J IMMUNOL, V131, P2821; LEE JC, 1986, J IMMUNOL, V136, P1322; MANIATIS T, 1982, MOL CLONING LABORATO; MECHAM JO, 1985, J IMMUNOL, V134, P3516; MELTZER MS, 1982, J IMMUNOL, V129, P2802; MELTZER MS, 1981, J IMMUNOL, V127, P197; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; ONOZAKI K, 1983, CELL IMMUNOL, V75, P242, DOI 10.1016/0008-8749(83)90323-4; PACE JL, 1983, P NATL ACAD SCI-BIOL, V80, P3782, DOI 10.1073/pnas.80.12.3782; ROBERTS WK, 1982, J INTERFERON RES, V2, P519, DOI 10.1089/jir.1982.2.519; Schiffmann E, 1979, Curr Top Cell Regul, V15, P203; SCHREIBER RD, 1983, J IMMUNOL, V131, P826; STEARNE PA, 1985, J IMMUNOL, V134, P443; TAKAHASHI T, 1970, J EXP MED, V131, P1325, DOI 10.1084/jem.131.6.1325; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WEIEL JE, 1985, J IMMUNOL, V134, P293; YAMAMOTO S, 1984, BIOMED RES-TOKYO, V5, P91, DOI 10.2220/biomedres.5.91; YAMAMOTO S, 1984, IMMUNOGENETICS, V19, P519, DOI 10.1007/BF00403443; YAMAMOTO S, 1971, IMMUNOLOGY, V20, P803	43	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					515	521						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3131720				2022-12-17	WOS:A1988N434800014
J	IBSON, JM; RABBITTS, PH				IBSON, JM; RABBITTS, PH			SEQUENCE OF A GERM-LINE N-MYC GENE AND AMPLIFICATION AS A MECHANISM OF ACTIVATION	ONCOGENE			English	Article											IBSON, JM (corresponding author), LUDWIG INST CANC RES, CAMBRIDGE CB2 2QH, ENGLAND.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; IBSON JM, 1987, J CELL BIOCHEM, V33, P267, DOI 10.1002/jcb.240330405; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIBUYA M, 1985, MOL CELL BIOL, V5, P414, DOI 10.1128/MCB.5.2.414; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1722; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019	25	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					399	402						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	2834684				2022-12-17	WOS:A1988M947200013
J	GRAND, RJA; SMITH, KJ; GALLIMORE, PH				GRAND, RJA; SMITH, KJ; GALLIMORE, PH			PURIFICATION AND CHARACTERIZATION OF THE PROTEIN ENCODED BY THE ACTIVATED HUMAN N-RAS GENE AND ITS MEMBRANE LOCALIZATION	ONCOGENE			English	Article											GRAND, RJA (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.							BERGER M, 1984, EMBO J, V3, P713, DOI 10.1002/j.1460-2075.1984.tb01874.x; BOURNE HR, 1986, CANCER SURV, V5, P257; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; FEIG LA, 1984, SCIENCE, V223, P698, DOI 10.1126/science.6695178; GALLIMORE PH, 1986, CANCER CELL, V4, P339; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRAND RJA, 1985, FEBS LETT, V181, P229, DOI 10.1016/0014-5793(85)80265-9; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HALL A, 1986, J BIOL CHEM, V261, P963; Helenius A, 1979, Methods Enzymol, V56, P734; HJELMELAND LM, 1984, METHOD ENZYMOL, V104, P305; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LOWY DR, 1986, CANCER SURV, V5, P275; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MCILHINNEY RAJ, 1985, EMBO J, V4, P1145, DOI 10.1002/j.1460-2075.1985.tb03752.x; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PARASKEVA C, 1982, J GEN VIROL, V58, P73, DOI 10.1099/0022-1317-58-1-73; PRYDE JG, 1986, TRENDS BIOCHEM SCI, V11, P160, DOI 10.1016/0968-0004(86)90132-5; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHLESINGER MJ, 1980, J BIOL CHEM, V255, P21; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIH TY, 1984, CANCER INVEST, V2, P109, DOI 10.3109/07357908409020294; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	46	29	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					305	314						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	3133625				2022-12-17	WOS:A1987J970500012
J	Ruan, DY; Li, T; Wang, YN; Meng, Q; Li, Y; Yu, K; Wang, M; Lin, JF; Luo, LZ; Wang, DS; Lin, JZ; Bai, L; Liu, ZX; Zhao, Q; Wu, XY; Ju, HQ; Xu, RH				Ruan, Dan-Yun; Li, Ting; Wang, Ying-Nan; Meng, Qi; Li, Yang; Yu, Kai; Wang, Min; Lin, Jin-Fei; Luo, Li-Zhi; Wang, De-Shen; Lin, Jun-Zhong; Bai, Long; Liu, Ze-Xian; Zhao, Qi; Wu, Xiang-Yuan; Ju, Huai-Qiang; Xu, Rui-Hua			FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis	ONCOGENE			English	Article							CELL-PROLIFERATION; SELF-RENEWAL; RNA; DEMETHYLASE; MTA1; DEGRADATION; EXPRESSION; STABILITY; PROTEIN	Fat mass and obesity-associated protein (FTO), an N6-methyladenosine (m(6)A) demethylase, participates in tumor progression and metastasis in many malignancies, but its role in colorectal cancer (CRC) is still unclear. Here, we found that FTO protein levels, but not RNA levels, were downregulated in CRC tissues. Reduced FTO protein expression was correlated with a high recurrence rate and poor prognosis in resectable CRC patients. Moreover, we demonstrated that hypoxia restrained FTO protein expression, mainly due to an increase in ubiquitin-mediated protein degradation. The serine/threonine kinase receptor associated protein (STRAP) might served as the E3 ligase and K216 was the major ubiquitination site responsible for hypoxia-induced FTO degradation. FTO inhibited CRC metastasis both in vitro and in vivo. Mechanistically, FTO exerted a tumor suppressive role by inhibiting metastasis-associated protein 1 (MTA1) expression in an m(6)A-dependent manner. Methylated MTA1 transcripts were recognized by an m(6)A "reader", insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), which then stabilized its mRNA. Together, our findings highlight the critical role of FTO in CRC metastasis and reveal a novel epigenetic mechanism by which the hypoxic tumor microenvironment promotes CRC metastasis.	[Ruan, Dan-Yun; Li, Ting; Wang, Ying-Nan; Meng, Qi; Yu, Kai; Wang, Min; Lin, Jin-Fei; Luo, Li-Zhi; Wang, De-Shen; Bai, Long; Liu, Ze-Xian; Zhao, Qi; Ju, Huai-Qiang; Xu, Rui-Hua] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Ruan, Dan-Yun; Li, Yang; Wu, Xiang-Yuan] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Guangdong Key Lab Liver Dis, Guangzhou, Peoples R China; [Wang, Ying-Nan] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China; [Lin, Jun-Zhong] Sun Yat Sen Univ, Canc Ctr, Dept Colorectal Surg, Guangzhou, Peoples R China; [Ju, Huai-Qiang; Xu, Rui-Hua] Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College	Ju, HQ; Xu, RH (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China.; Ju, HQ; Xu, RH (corresponding author), Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou, Peoples R China.	juhq@sysucc.org.cn; xurh@sysucc.org.cn	Xu, Rui-Hua/AAW-4766-2021; xu, rui/GRX-5734-2022	Xu, Rui-Hua/0000-0001-9771-8534; Yu, Kai/0000-0003-3343-2902	National Natural Science Foundation of China [81930065, 81871951, 82022052, 81903163]; Science and Technology Program of Guangdong [2019B020227002]; Science and Technology Program of Guangzhou [201904020046]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-5-036]; Open Funds of State Key Laboratory of Oncology in South China [KY013712]; Medical Scientific Research Foundation of Guangdong Province [A2021115]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangdong; Science and Technology Program of Guangzhou; CAMS Innovation Fund for Medical Sciences (CIFMS); Open Funds of State Key Laboratory of Oncology in South China; Medical Scientific Research Foundation of Guangdong Province	This research was supported by the National Natural Science Foundation of China (81930065, 81871951, 82022052, 81903163), Science and Technology Program of Guangdong (2019B020227002), Science and Technology Program of Guangzhou (201904020046), CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-036), Open Funds of State Key Laboratory of Oncology in South China (KY013712) and Medical Scientific Research Foundation of Guangdong Province (A2021115).	Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen GF, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00265-z; Chen X, 2013, BIOINFORMATICS, V29, P1614, DOI 10.1093/bioinformatics/btt196; Chen ZH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1178-z; Christensen J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-274; Cong L, 2011, J BIOL CHEM, V286, P43793, DOI 10.1074/jbc.M111.267237; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; Fedeles BI, 2015, J BIOL CHEM, V290, P20734, DOI 10.1074/jbc.R115.656462; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Huang H, 2020, CANCER RES, V80, P3200, DOI 10.1158/0008-5472.CAN-19-4044; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Huff S, 2021, ACS CHEM BIOL, V16, P324, DOI 10.1021/acschembio.0c00841; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Ju HQ, 2019, JNCI-J NATL CANCER I, V111, P584, DOI 10.1093/jnci/djy160; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liu XM, 2020, HEPATOLOGY, V72, P2029, DOI 10.1002/hep.31222; Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1004-4; Ohshiro K, 2010, EMBO REP, V11, P691, DOI 10.1038/embor.2010.99; Peng W, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1408-4; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Rong ZX, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00369; Roundtree IA, 2017, ELIFE, V6, DOI 10.7554/eLife.31311; Toh Y, 2014, CANCER METAST REV, V33, P891, DOI 10.1007/s10555-014-9516-2; Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030; Wang RA, 2014, CANCER METAST REV, V33, P1001, DOI 10.1007/s10555-014-9525-1; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang YJ, 2021, RNA BIOL, V18, P131, DOI 10.1080/15476286.2020.1804697; Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0; Weber CE, 2012, SURG ONCOL, V21, P172, DOI 10.1016/j.suronc.2011.09.001; Wu XY, 2013, NUCLEIC ACIDS RES, V41, P2644, DOI 10.1093/nar/gks1453; Xu KW, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320916024; Xu RH, 2018, LANCET ONCOL, V19, P660, DOI 10.1016/S1470-2045(18)30140-2; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Ye S, 2016, FEBS LETT, V590, P1641, DOI 10.1002/1873-3468.12205; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhu TY, 2018, J MOL BIOL, V430, P363, DOI 10.1016/j.jmb.2017.12.003; Zhu W, 2020, J CELL MOL MED, V24, P3521, DOI 10.1111/jcmm.15042; Zhu W, 2012, GUT, V61, P562, DOI 10.1136/gutjnl-2011-300207; Zhuang CS, 2019, J CELL MOL MED, V23, P2163, DOI 10.1111/jcmm.14128; Zou DL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1045-1	48	28	29	5	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5168	5181		10.1038/s41388-021-01916-0	http://dx.doi.org/10.1038/s41388-021-01916-0		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34218271	Green Published, hybrid			2022-12-17	WOS:000669300400001
J	Eniafe, J; Jiang, S				Eniafe, Joseph; Jiang, Shuai			The functional roles of TCA cycle metabolites in cancer	ONCOGENE			English	Review							ONCOMETABOLITE 2-HYDROXYGLUTARATE; REDUCTIVE CARBOXYLATION; GLUTAMINE-METABOLISM; FUMARATE HYDRATASE; SUPPORTS GROWTH; DEFICIENT CELLS; IDH MUTATIONS; SDH MUTATIONS; CITRATE; HISTONE	The tricarboxylic acid cycle (TCA cycle) has been known for decades as a hub for generating cellular energy and precursors for biosynthetic pathways. Several cancers harbor mutations that affect the integrity of this cycle, mostly at the levels of isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), and fumarate hydratase (FH). This results in dysregulation in the production of TCA cycle metabolites and is probably implicated in cancer initiation. By modulating cellular activities, including metabolism and signaling, TCA cycle intermediates are able to impact the processes of cancer development and progression. In this review, we discuss the functional roles of the TCA cycle intermediates in suppressing or promoting the progression of cancers. A further understanding of TCA metabolites' roles and molecular mechanisms in oncogenesis would prompt developing novel metabolite-based cancer therapy in the future.	[Eniafe, Joseph; Jiang, Shuai] Louisiana State Univ, Dept Microbiol & Immunol, Hlth Sci Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Jiang, S (corresponding author), Louisiana State Univ, Dept Microbiol & Immunol, Hlth Sci Ctr, Shreveport, LA 71130 USA.	sjiang@lsuhsc.edu		Jiang, Shuai/0000-0002-0572-4660; Eniafe, Joseph/0000-0003-4616-4273	Louisiana State University (LSU) Feist-Weiller Cancer Center (FWCC) Legacy Funds [149741373A]; Intramural Research Council [110251225A]; Micro Seed Funds	Louisiana State University (LSU) Feist-Weiller Cancer Center (FWCC) Legacy Funds; Intramural Research Council; Micro Seed Funds	The authors apologize to the researchers whose work was not cited because of space limitation. The authors are supported by Louisiana State University (LSU) Feist-Weiller Cancer Center (FWCC) Legacy Funds (149741373A), Intramural Research Council Support (110251225A), and the Micro Seed Funds. Figures are created with BioRender.com. We thank Patrick Simon for his contributions during the editing stage of the paper.	Abla H, 2020, SEMIN CELL DEV BIOL, V98, P26, DOI 10.1016/j.semcdb.2019.05.031; Alderson NL, 2006, ARCH BIOCHEM BIOPHYS, V450, P1, DOI 10.1016/j.abb.2006.03.005; Bardella C, 2011, BBA-BIOENERGETICS, V1807, P1432, DOI 10.1016/j.bbabio.2011.07.003; Bennett Saidu Nathaniel Edward, 2018, Oncotarget, V9, P9088, DOI 10.18632/oncotarget.24144; Bottcher M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1445454; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Brahimi-Horn MC, 2011, CURR OPIN GENET DEV, V21, P67, DOI 10.1016/j.gde.2010.10.006; Bunse L, 2018, NAT MED, V24, P1192, DOI 10.1038/s41591-018-0095-6; Caiazza C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112613; Chatterjee N, 2017, ENVIRON MOL MUTAGEN, V58, P235, DOI 10.1002/em.22087; Chen JY, 2016, SCI REP-UK, V6, DOI 10.1038/srep32428; Chen LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115708; Chen QY, 2018, CELL METAB, V27, P1007, DOI 10.1016/j.cmet.2018.03.002; Chesney J, 2006, CURR OPIN CLIN NUTR, V9, P535, DOI 10.1097/01.mco.0000241661.15514.fb; Chinopoulos C, 2018, ASN NEURO, V10, DOI 10.1177/1759091418818261; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Dang L, 2016, ANN ONCOL, V27, P599, DOI 10.1093/annonc/mdw013; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; El Sayed SM, 2012, J BIOENERG BIOMEMBR, V44, P513, DOI 10.1007/s10863-012-9455-y; Fan J, 2013, J BIOL CHEM, V288, P31363, DOI 10.1074/jbc.M113.502740; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Fernandez HR, 2018, CELL DEATH DIFFER, V25, P1239, DOI 10.1038/s41418-018-0101-z; Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P375, DOI 10.1111/j.1755-148X.2012.00989.x; Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56; Gameiro PA, 2013, CELL METAB, V17, P372, DOI 10.1016/j.cmet.2013.02.002; Gao CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154576; Han GC, 2016, IN VITRO CELL DEV-AN, V52, P1034, DOI 10.1007/s11626-016-0069-2; Han YB, 2017, J BIOL CHEM, V292, P4789, DOI 10.1074/jbc.M116.763821; Hanai J, 2012, J CELL PHYSIOL, V227, P1709, DOI 10.1002/jcp.22895; Hanse EA, 2017, ONCOGENE, V36, P3915, DOI 10.1038/onc.2017.36; Hui S, 2017, NATURE, V551, P115, DOI 10.1038/nature24057; Icard P, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0676-y; Icard P, 2012, BBA-REV CANCER, V1825, P111, DOI 10.1016/j.bbcan.2011.10.007; Intlekofer AM, 2017, NAT CHEM BIOL, V13, P494, DOI [10.1038/NCHEMBIO.2307, 10.1038/nchembio.2307]; Jeong SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep30767; Jiang YH, 2015, NAT CELL BIOL, V17, P1158, DOI 10.1038/ncb3209; Johnson TI, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0912-3; Kaluzki I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111329; Kiwerska K, 2019, J APPL GENET, V60, P329, DOI 10.1007/s13353-019-00516-9; Kuang Y, 2018, CANCER MED-US, V7, P1416, DOI 10.1002/cam4.1410; Kuiper C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00359; Laukka T, 2016, J BIOL CHEM, V291, P4256, DOI 10.1074/jbc.M115.688762; Letouze E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018; Li L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12235; Lim JKM., 2019, CELL DEATH DIS, V10, P1; Lin CC, 2012, SCI REP-UK, V2, DOI 10.1038/srep00785; Lincet H, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-72; Liu H, 2019, AM J TRANSL RES, V11, P4713; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Marino G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016; Martinez S, 2015, J BIOL CHEM, V290, P20702, DOI 10.1074/jbc.R115.648691; McBrayer SK, 2018, CELL, V175, P101, DOI 10.1016/j.cell.2018.08.038; McGuirk S, 2020, TRENDS CANCER, V6, P49, DOI 10.1016/j.trecan.2019.11.009; MELENDEZRODRIGU.AA, 2019, CELL REP, V26, DOI DOI 10.1016/J.CELREP.2019.01.106; Morris JP, 2019, NATURE, V573, P595, DOI 10.1038/s41586-019-1577-5; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; O'Flaherty L, 2010, HUM MOL GENET, V19, P3844, DOI 10.1093/hmg/ddq305; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Peng MX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1475-7; Philippe I, 2016, DRUG RESIST UPDATE, V29, P47, DOI 10.1016/j.drup.2016.09.003; Raffel S, 2017, NATURE, V551, P384, DOI 10.1038/nature24294; Ren JG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04626-4; Rzeski W, 2012, SCAND J GASTROENTERO, V47, P565, DOI 10.3109/00365521.2012.660539; Saidu NEB, 2017, MOL CANCER THER, V16, P529, DOI 10.1158/1535-7163.MCT-16-0405; Schmidt C, 2020, SEMIN CELL DEV BIOL, V98, P15, DOI 10.1016/j.semcdb.2019.05.002; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shafer Danielle, 2020, Neurooncol Adv, V2, pvdz052, DOI 10.1093/noajnl/vdz052; Smestad J, 2018, ISCIENCE, V2, P63, DOI 10.1016/j.isci.2018.03.012; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sulkowski PL, 2018, NAT GENET, V50, P1086, DOI 10.1038/s41588-018-0170-4; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Sullivan LB, 2013, MOL CELL, V51, P236, DOI 10.1016/j.molcel.2013.05.003; Tardito S, 2015, NAT CELL BIOL, V17, P1556, DOI 10.1038/ncb3272; Tennant DA, 2009, ONCOGENE, V28, P4009, DOI 10.1038/onc.2009.250; Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070; Trefely S, 2020, MOL METAB, V38, DOI 10.1016/j.molmet.2020.01.005; Tseng PL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21361-6; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Valesky EM, 2016, EXP DERMATOL, V25, P200, DOI 10.1111/exd.12907; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wang TA, 2016, ONCOL REP, V35, P1287, DOI 10.3892/or.2015.4511; Wang YG, 2017, NATURE, V552, P273, DOI 10.1038/nature25003; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Williams NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00141; Wu JY, 2020, MOL CELL, V77, P213, DOI 10.1016/j.molcel.2019.10.023; Xia Y, 2018, ONCOL LETT, V15, P6622, DOI 10.3892/ol.2018.8111; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xie X, 2015, BRIT J PHARMACOL, V172, P3929, DOI 10.1111/bph.13184; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang ZK, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-017-0664-4; Ye D, 2013, CANCER CELL, V23, P274, DOI 10.1016/j.ccr.2013.03.005; Yi CH, 2011, CELL, V146, P607, DOI 10.1016/j.cell.2011.06.050; Yogev O, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000328; Zaslona Z, 2020, MOL CELL, V78, P814, DOI 10.1016/j.molcel.2020.04.002; Zhang BX, 2017, J CANCER, V8, P2088, DOI 10.7150/jca.19373; Zhang ZH, 2011, NAT CHEM BIOL, V7, P58, DOI 10.1038/NCHEMBIO.495; Zhao YQ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55718-2; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	108	28	28	8	39	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3351	3363		10.1038/s41388-020-01639-8	http://dx.doi.org/10.1038/s41388-020-01639-8		APR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33864000				2022-12-17	WOS:000640748600002
J	Attalla, S; Taifour, T; Bui, T; Muller, W				Attalla, Sherif; Taifour, Tarek; Bui, Tung; Muller, William			Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo	ONCOGENE			English	Review							EPITHELIAL-SPECIFIC DISRUPTION; MAMMARY-GLAND DEVELOPMENT; ENDOTHELIAL GROWTH-FACTOR; MIDDLE TUMOR-ANTIGEN; T-ANTIGEN; GENE-EXPRESSION; PROMOTES PROGRESSION; TYROSINE KINASE; RECEPTOR GENE; METASTASIS	Breast cancer is associated with the second highest cancer-associated deaths worldwide. Therefore, understanding the key events that determine breast cancer progression, modulation of the tumor-microenvironment and metastasis, which is the main cause of cancer-associated death, are of great importance. The mammary specific polyomavirus middle T antigen overexpression mouse model (MMTV-PyMT), first published in 1992, is the most commonly used genetically engineered mouse model (GEMM) for cancer research. Mammary lesions arising in MMTV-PyMT mice follow similar molecular and histological progression as human breast tumors, making it an invaluable tool for cancer researchers and instrumental in understanding tumor biology. In this review, we will highlight key studies that demonstrate the utility of PyMT derived GEMMs in understanding the molecular basis of breast cancer progression, metastasis and highlight its use as a pre-clinical tool for therapeutic discovery.	[Attalla, Sherif; Muller, William] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; [Attalla, Sherif; Taifour, Tarek; Bui, Tung; Muller, William] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Taifour, Tarek; Muller, William] McGill Univ, Fac Med, Montreal, PQ H3A 1A3, Canada	McGill University; McGill University; McGill University	Muller, W (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada.; Muller, W (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; Muller, W (corresponding author), McGill Univ, Fac Med, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca		Taifour, Tarek/0000-0002-1390-3597; Attalla, sattalla/0000-0003-4193-6393	McGill faculty of medicine Gosselin Graduate Studentship; McGill faculty of medicine; Canada Research Chair of Molecular Oncology; Terry Fox Research Institute Program Group Grant; National Institute of Health Research; Canadian Institute of Health Research the Canadian Cancer Society Impact Grant; Cancer Research Society	McGill faculty of medicine Gosselin Graduate Studentship; McGill faculty of medicine; Canada Research Chair of Molecular Oncology; Terry Fox Research Institute Program Group Grant; National Institute of Health Research(National Institute for Health Research (NIHR)); Canadian Institute of Health Research the Canadian Cancer Society Impact Grant(Canadian Institutes of Health Research (CIHR)); Cancer Research Society	SA is supported by the McGill faculty of medicine Gosselin Graduate Studentship. TT is supported by the MD/PhD stipend awarded by McGill faculty of medicine. WJM is supported by the Canada Research Chair of Molecular Oncology. This work was also supported by Terry Fox Research Institute Program Group Grant, National Institute of Health Research, Canadian Institute of Health Research the Canadian Cancer Society Impact Grant and Cancer Research Society.	Ahn R, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14638; Allen E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aak9679; Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047; Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115; Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11; Ben-David U, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12160; Boyd NF, 1998, CANCER EPIDEM BIOMAR, V7, P1133; Boyle ST, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0394-1; Brenner DR, 2020, CAN MED ASSOC J, V192, pE199, DOI 10.1503/cmaj.191292; Butt SA, 2015, MAGN RESON MED, V73, P51, DOI 10.1002/mrm.25095; Cai Y, 2017, TRANSCRIPTOMIC DYNAM, V18, P1; Cai Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24005-x; Cai Y, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3563-3; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Cook RS, 2011, CANCER RES, V71, P3941, DOI 10.1158/0008-5472.CAN-10-3775; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dabrosin C, 2003, BREAST CANCER RES TR, V78, P1, DOI 10.1023/A:1022133219353; Dadi S, 2016, CELL, V164, P365, DOI 10.1016/j.cell.2016.01.002; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; Decock J, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0545-8; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; Ekiz HA, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1480286; Esbona K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0695-3; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Eyob H, 2013, CANCER DISCOV, V3, P751, DOI 10.1158/2159-8290.CD-12-0480; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Gill JK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1507; Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x; Gross ETE, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1268310; GROSS L, 1953, P SOC EXP BIOL MED, V83, P414; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halaoui R, 2017, GENE DEV, V31, P1573, DOI 10.1101/gad.300566.117; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hirukawa A, 2019, CELL REP, V29, P249, DOI 10.1016/j.celrep.2019.08.105; Hirukawa A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04864-8; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hodgson JG, 2005, CANCER RES, V65, P9695, DOI 10.1158/0008-5472.CAN-05-0755; Hunter KW, 2001, CANCER RES, V61, P8866; HUNTER T, 1984, EMBO J, V3, P73, DOI 10.1002/j.1460-2075.1984.tb01763.x; Jang I, 2019, CANCERS, V11, DOI 10.3390/cancers11050721; Jin MS, 2016, VIRCHOWS ARCH, V469, P183, DOI 10.1007/s00428-016-1953-6; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; Kesavan R, 2020, P NATL ACAD SCI USA, V117, P5923, DOI 10.1073/pnas.1921381117; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Li JR, 2011, J CLIN INVEST, V121, P4655, DOI 10.1172/JCI46134; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; Lin EY, 2007, MOL ONCOL, V1, P288, DOI 10.1016/j.molonc.2007.10.003; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0760-3; Lopez-Tarruella S, 2007, CLIN CANCER RES, V13, P6921, DOI 10.1158/1078-0432.CCR-07-1399; Lukes L, 2009, CANCER RES, V69, P310, DOI 10.1158/0008-5472.CAN-08-3520; Ma J, 2012, TUMOR BIOL, V33, P1983, DOI 10.1007/s13277-012-0458-4; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Maglione JE, 2001, CANCER RES, V61, P8298; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; Martin LJ, 2010, CANCER EPIDEM BIOMAR, V19, P456, DOI 10.1158/1055-9965.EPI-09-0881; Mazzieri R, 2011, CANCER CELL, V19, P512, DOI 10.1016/j.ccr.2011.02.005; Montagna C, 2003, CANCER RES, V63, P2179; Movahedi K, 2012, CANCER RES, V72, P4165, DOI 10.1158/0008-5472.CAN-11-2994; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Ni T, 2016, NAT CELL BIOL, V18, P1221, DOI 10.1038/ncb3425; Ohs I, 2017, CANCER RES, V77, P7059, DOI 10.1158/0008-5472.CAN-17-1032; Ojalvo LS, 2009, AM J PATHOL, V174, P1048, DOI 10.2353/ajpath.2009.080676; Ong SH, 2001, EMBO J, V20, P6327, DOI 10.1093/emboj/20.22.6327; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Ostuni R, 2015, TRENDS IMMUNOL, V36, P229, DOI 10.1016/j.it.2015.02.004; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Park YG, 2005, NAT GENET, V37, P1055, DOI 10.1038/ng1635; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Putzer BM, 1997, P NATL ACAD SCI USA, V94, P10889, DOI 10.1073/pnas.94.20.10889; Qin JJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1206-z; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Rao T, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3603; Rennhack J, 2017, J MAMMARY GLAND BIOL, V22, P71, DOI 10.1007/s10911-017-9374-y; Rennhack JP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11236-3; Ross C, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008743; Schwab LP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3087; Shiao SL, 2015, CANCER IMMUNOL RES, V3, P518, DOI 10.1158/2326-6066.CIR-14-0232; Simond AM, 2020, GENE DEV, V34, P1304, DOI 10.1101/gad.339424.120; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Swiatnicki MR, 2020, J THORAC ONCOL, V15, pS20; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Wagner KU, 2004, BREAST CANCER RES, V6, P31, DOI 10.1186/bcr723; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Weichand B, 2017, J EXP MED, V214, P2695, DOI 10.1084/jem.20160392; Welford AF, 2011, J CLIN INVEST, V121, P1969, DOI 10.1172/JCI44562; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xiao B, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107571	113	28	30	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					475	491		10.1038/s41388-020-01560-0	http://dx.doi.org/10.1038/s41388-020-01560-0		NOV 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33235291	hybrid, Green Published			2022-12-17	WOS:000592588400001
J	Yuan, JP; Song, YM; Pan, WT; Li, YK; Xu, YY; Xie, MY; Shen, Y; Zhang, NS; Liu, JD; Hua, H; Wang, BW; An, CM; Yang, M				Yuan, Jupeng; Song, Yemei; Pan, Wenting; Li, Yankang; Xu, Yeyang; Xie, Mengyu; Shen, Yue; Zhang, Nasha; Liu, Jiandong; Hua, Hui; Wang, Bowen; An, Changming; Yang, Ming			LncRNA SLC26A4-AS1 suppresses the MRN complex-mediated DNA repair signaling and thyroid cancer metastasis by destabilizing DDX5	ONCOGENE			English	Article							PENDRED-SYNDROME; COMMON VARIANTS; GENE; PAPILLARY; CARCINOMA; RISK; ASSOCIATION; ACTIVATION; E2F-1; FOXE1	Lymph node metastasis is the major adverse feature for recurrence and death of thyroid cancer patients. To identify lncRNAs involved in thyroid cancer metastasis, we systemically screened differentially expressed lncRNAs in lymph node metastasis, thyroid cancer, and normal tissues via RNAseq. We found that lncRNA SLC26A4-AS1 was continuously, significantly down-regulated in normal tissues, thyroid cancer, and lymph node metastasis specimens. Low SLC26A4-AS1 levels in tissues were significantly associated with poor prognosis of thyroid cancer patients. LncRNA SLC26A4-AS1 markedly inhibited migration, invasion, and metastasis capability of cancer cells in vitro and in vivo. Intriguingly, SLC26A4-AS1 could simultaneously interact with DDX5 and the E3 ligase TRIM25, which promoting DDX5 degradation through the ubiquitin-proteasome pathway. In particular, SLC26A4-AS1 inhibited expression of multiple DNA double-strand breaks (DSBs) repair genes, especially genes coding proteins in the MRE11/RAS50/NBS1 (MRN) complex. Enhanced interaction between DDX5 and transcriptional factor E2F1 due to silencing of SLC26A4-AS1 promoted binding of the DDX5-E2F1 complex at promoters of the MRN genes and, thus, stimulate the MRN/ATM dependent DSB signaling and thyroid cancer metastasis. Our study uncovered new insights into the biology driving thyroid cancer metastasis and highlights potentials of lncRNAs as future therapeutic targets again cancer metastasis.	[Yuan, Jupeng; Song, Yemei; Pan, Wenting; Li, Yankang; Xu, Yeyang; Xie, Mengyu; Shen, Yue; Zhang, Nasha; Liu, Jiandong; Hua, Hui; Wang, Bowen; Yang, Ming] Shandong First Med Univ, Shandong Canc Hosp & Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China; [Yuan, Jupeng; Song, Yemei; Pan, Wenting; Li, Yankang; Xu, Yeyang; Xie, Mengyu; Shen, Yue; Zhang, Nasha; Liu, Jiandong; Hua, Hui; Wang, Bowen; Yang, Ming] Shandong Acad Med Sci, Jinan, Shandong, Peoples R China; [Li, Yankang; Xu, Yeyang; Xie, Mengyu; Shen, Yue; Wang, Bowen] Shandong Univ, Cheeloo Coll Med, Jinan, Shandong, Peoples R China; [An, Changming] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Head & Neck Surg, Beijing, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Yang, M (corresponding author), Shandong First Med Univ, Shandong Canc Hosp & Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China.; Yang, M (corresponding author), Shandong Acad Med Sci, Jinan, Shandong, Peoples R China.; An, CM (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Head & Neck Surg, Beijing, Peoples R China.	anchangming@cicams.ac.cn; aaryoung@yeah.net	Yang, Ming/G-4705-2012	Yang, Ming/0000-0002-7722-7487; Yuan, Jupeng/0000-0003-1817-7771	National Natural Science Foundation of China [31671300, 31871306, 81702276]; Taishan Scholars Program of Shandong Province [tsqn20161060]; Program of Science and Technology for the youth innovation team in universities of Shandong Province [2020KJL001]; Natural Science Foundation of Shandong Province [ZR2016HQ48, ZR2019LZL011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province; Program of Science and Technology for the youth innovation team in universities of Shandong Province; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This work was supported by National Natural Science Foundation of China (31671300, 31871306, 81702276); Taishan Scholars Program of Shandong Province (tsqn20161060); Program of Science and Technology for the youth innovation team in universities of Shandong Province (2020KJL001); Natural Science Foundation of Shandong Province (ZR2016HQ48, ZR2019LZL011). The authors would like to thank many individuals who participated in the study.	Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Bian L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1100-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Figlioli G, 2014, J CLIN ENDOCR METAB, V99, pE2084, DOI 10.1210/jc.2014-1734; Gao P, 2018, CELL, V174, P576, DOI 10.1016/j.cell.2018.06.003; Gudmundsson J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14517; Gudmundsson J, 2012, NAT GENET, V44, P319, DOI 10.1038/ng.1046; Gudmundsson J, 2009, NAT GENET, V41, P460, DOI 10.1038/ng.339; Gugnoni M, 2021, THYROID, V31, P247, DOI 10.1089/thy.2020.0001; He HL, 2015, P NATL ACAD SCI USA, V112, P6128, DOI 10.1073/pnas.1506255112; He HL, 2015, J CLIN ENDOCR METAB, V100, pE164, DOI 10.1210/jc.2014-2147; Hua JT, 2018, CELL, V174, P564, DOI 10.1016/j.cell.2018.06.014; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Hwangbo Y, 2018, J CLIN ENDOCR METAB, V103, P4384, DOI 10.1210/jc.2017-02439; Jendrzejewski J, 2019, INT J CANCER, V144, P503, DOI 10.1002/ijc.31933; Jendrzejewski J, 2012, P NATL ACAD SCI USA, V109, P8646, DOI 10.1073/pnas.1205654109; Kim SY, 2018, WORLD J SURG, V42, P123, DOI 10.1007/s00268-017-4158-5; Knoll M, 2015, NAT REV ENDOCRINOL, V11, P151, DOI 10.1038/nrendo.2014.229; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Li HJ, 2021, FEBS J, V288, P212, DOI 10.1111/febs.15325; Liang WW, 2019, PEERJ, V7, DOI 10.7717/peerj.7441; Liyanarachchi S, 2020, P NATL ACAD SCI USA, V117, P5997, DOI 10.1073/pnas.1919976117; Mao JX, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00265; Mazurek A, 2012, CANCER DISCOV, V2, P812, DOI 10.1158/2159-8290.CD-12-0116; Muhanhali D, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00360; Nyamao RM, 2019, BBA-REV CANCER, V1871, P85, DOI 10.1016/j.bbcan.2018.11.003; Onda M, 2004, J HUM GENET, V49, P312, DOI 10.1007/s10038-004-0146-3; Pan WT, 2018, J BIOL CHEM, V293, P17154, DOI 10.1074/jbc.RA118.003055; Rao YS, 2020, COMPUT MATH METHOD M, V2020, DOI 10.1155/2020/3651051; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Reginato G, 2020, DNA REPAIR, V91-92, DOI 10.1016/j.dnarep.2020.102869; Ren YL, 2017, J BIOL CHEM, V292, P17939, DOI 10.1074/jbc.M116.773978; Saiz AD, 2002, J PATHOL, V198, P157, DOI 10.1002/path.1185; Son HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15966; Swierniak M, 2016, CLIN CANCER RES, V22, P1111, DOI 10.1158/1078-0432.CCR-15-1746; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wang DP, 2020, J CELL PHYSIOL, V235, P2403, DOI 10.1002/jcp.29145; Wang YQ, 2017, P NATL ACAD SCI USA, V114, P474, DOI 10.1073/pnas.1619917114; Xing MZ, 2003, CANCER RES, V63, P2312; Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yuan JP, 2015, J PATHOL, V235, P784, DOI 10.1002/path.4492; Zhu H, 2016, SCI REP-UK, V6, DOI 10.1038/srep31969	46	28	28	3	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6664	6676		10.1038/s41388-020-01460-3	http://dx.doi.org/10.1038/s41388-020-01460-3		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32939012				2022-12-17	WOS:000570051900001
J	Brummer, T; McInnes, C				Brummer, Tilman; McInnes, Campbell			RAF kinase dimerization: implications for drug discovery and clinical outcomes	ONCOGENE			English	Review							ALLOSTERIC ACTIVATION; INHIBITOR RESISTANCE; GENE FUSIONS; BRAF MUTANTS; PHOSPHORYLATION; PROTEIN; MECHANISM; MUTATION; PATHWAY; DIMERS	The RAF kinases activated by RAS GTPases regulate cell growth and division by signal transduction through the ERK cascade and mutations leading to constitutive activity are key drivers of human tumors, as are upstream activators including RAS and receptor tyrosine kinases. The development of first-generation RAF inhibitors, including vemurafenib (VEM) and dabrafenib led to initial excitement due to high response rates and profound regression of malignant melanomas carrying BRAF(V600E) mutations. The excitement about these unprecedented response rates, however, was tempered by tumor unresponsiveness through both intrinsic and acquired drug-resistance mechanisms. In recent years much insight into the complexity of the RAS-RAF axis has been obtained and inactivation and signal transduction mechanisms indicate that RAF dimerization is a critical step in multiple cellular contexts and plays a key role in resistance. Both homo- and hetero-dimerization of BRAF and CRAF can modulate therapeutic response and disease progression in patients treated with ATP-competitive inhibitors and are therefore highly clinically significant. Ten years after the definition of the RAF dimer interface (DIF) by crystallography, this review focuses on the implications of RAF kinase dimerization in signal transduction and for drug development, both from a classical ATP-competitive standpoint and from the perspective of new therapeutic strategies including inhibiting dimer formation. A structural perspective of the DIF, how dimerization impacts inhibitor activation and the structure-based design of next-generation RAF kinase inhibitors with unique mechanisms of action is presented. We also discuss potential fields of application for DIF inhibitors, ranging from non-V600E oncoproteins and BRAF fusions to tumors driven by aberrant receptor tyrosine kinase or RAS signaling.	[Brummer, Tilman] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany; [Brummer, Tilman] German Canc Res Ctr, Partner Site Freiburg, German Canc Consortium DKTK, Heidelberg, Germany; [Brummer, Tilman] Univ Freiburg, Comprehens Canc Ctr Freiburg, Freiburg, Germany; [McInnes, Campbell] Univ South Carolina, Drug Discovery & Biomed Sci, Columbia, SC 29208 USA	University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of South Carolina System; University of South Carolina Columbia	McInnes, C (corresponding author), Univ South Carolina, Drug Discovery & Biomed Sci, Columbia, SC 29208 USA.	mcinnes@cop.sc.edu	Brummer, Tilman/AAA-9428-2020; Brummer, Tilman/B-6218-2016	Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905				Agianian B, 2018, J MED CHEM, V61, P5775, DOI 10.1021/acs.jmedchem.7b01306; Baljuls A, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.194167; Beneker CM, 2019, J MED CHEM, V62, P3886, DOI 10.1021/acs.jmedchem.8b01288; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Botton T, 2019, CELL REP, V29, P573, DOI 10.1016/j.celrep.2019.09.009; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Cope NJ, 2020, J BIOL CHEM, V295, P2407, DOI 10.1074/jbc.RA119.011536; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; Diamond EL, 2016, CANCER DISCOV, V6, P154, DOI [10.1158/2159-8290.CD-15-0913, 10.1158/2159-8290.CD-NB2016-001]; Diedrich B, 2017, EMBO J, V36, P646, DOI 10.15252/embj.201694732; Dietrich S, 2016, BLOOD, V127, P2847, DOI 10.1182/blood-2015-11-680074; Dorard C, 2017, BIOCHEM SOC T, V45, P27, DOI 10.1042/BST20160135; Douziech M, 2006, GENE DEV, V20, P807, DOI 10.1101/gad.1390406; Eide CA, 2019, CANCER CELL, V36, P431, DOI 10.1016/j.ccell.2019.08.004; Eisenhardt AE, 2016, ONCOTARGET, V7, P26628, DOI 10.18632/oncotarget.8427; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gunderwala AY, 2019, ACS CHEM BIOL, V14, P1471, DOI 10.1021/acschembio.9b00191; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hernandez MA, 2016, CELL SIGNAL, V28, P561, DOI 10.1016/j.cellsig.2016.02.009; Herr R, 2018, ONCOGENE, V37, P1576, DOI 10.1038/s41388-017-0063-5; Hu J, 2015, MOL CELL BIOL, V35, P264, DOI 10.1128/MCB.00943-14; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Jain P, 2017, ONCOGENE, V36, P6348, DOI 10.1038/onc.2017.276; Jambrina PG, 2016, ANGEW CHEM INT EDIT, V55, P983, DOI 10.1002/anie.201509272; Jambrina PG, 2014, BIOCHEM SOC T, V42, P784, DOI 10.1042/BST20140025; Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; Karoulia Z, 2016, CANCER CELL, V30, P485, DOI 10.1016/j.ccell.2016.06.024; Kholodenko BN, 2015, CELL REP, V12, P1939, DOI 10.1016/j.celrep.2015.08.014; Kohler M, 2016, EMBO J, V35, P143, DOI 10.15252/embj.201592097; Kondo Y, 2019, SCIENCE, V366, P109, DOI 10.1126/science.aay0543; Kordes M, 2016, LEUKEMIA, V30, P937, DOI 10.1038/leu.2015.319; Lavoie H, 2018, NATURE, V554, P549, DOI 10.1038/nature25478; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Li D, 2019, NAT MED, V25, P1116, DOI 10.1038/s41591-019-0479-2; Lin LP, 2014, P NATL ACAD SCI USA, V111, pE748, DOI 10.1073/pnas.1320956111; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Mai TT, 2018, NAT MED, V24, P902, DOI 10.1038/s41591-018-0111-x; Marino KA, 2015, J AM CHEM SOC, V137, P5280, DOI 10.1021/jacs.5b01421; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323; Mooz J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005484; Nielsen DS, 2017, CHEM REV, V117, P8094, DOI 10.1021/acs.chemrev.6b00838; Park E, 2019, NATURE, V575, P545, DOI 10.1038/s41586-019-1660-y; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rauen KA, 2018, AM J MED GENET A, V176, P2924, DOI 10.1002/ajmg.a.40632; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Rukhlenko OS, 2018, CELL SYST, V7, P161, DOI 10.1016/j.cels.2018.06.002; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110; Sun Y, 2017, NEURO-ONCOLOGY, V19, P774, DOI 10.1093/neuonc/now261; Takahashi M, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00132-17; Terrell EM, 2019, MOL CELL, V76, P872, DOI 10.1016/j.molcel.2019.09.004; Terrell Elizabeth M., 2018, COLD SPRING HARB PER, V9, pa033746; Thevakumaran N, 2015, NAT STRUCT MOL BIOL, V22, P37, DOI 10.1038/nsmb.2924; Tsai CJ, 2018, CURR OPIN STRUC BIOL, V53, P100, DOI 10.1016/j.sbi.2018.07.007; Unal EB, 2017, FEBS LETT, V591, P2607, DOI 10.1002/1873-3468.12740; Weber CK, 2001, CANCER RES, V61, P3595; Weinberg F, 2020, ONCOGENE, V39, P814, DOI 10.1038/s41388-019-1021-1; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wu X, 2012, MOL CELL BIOL, V32, P3872, DOI 10.1128/MCB.00751-12; Yao Z, 2019, NAT MED, V25, P284, DOI 10.1038/s41591-018-0274-5; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Yuan JM, 2018, ONCOGENE, V37, P5719, DOI 10.1038/s41388-018-0365-2; Zang MW, 2008, J BIOL CHEM, V283, P31429, DOI 10.1074/jbc.M802855200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	77	28	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4155	4169		10.1038/s41388-020-1263-y	http://dx.doi.org/10.1038/s41388-020-1263-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32269299				2022-12-17	WOS:000534819000001
J	Cui, KS; Liu, C; Li, X; Zhang, Q; Li, YJ				Cui, Kaisa; Liu, Cheng; Li, Xu; Zhang, Qiang; Li, Youjun			Comprehensive characterization of the rRNA metabolism-related genes in human cancer	ONCOGENE			English	Article							COLON-CANCER; END-POINTS; EXOSOME; BOP1; TUMORIGENESIS; DEFINITIONS; EXPRESSION; SIGNATURES; DATABASE; ONTOLOGY	Although rRNA metabolism-related genes have been reported to be associated with human cancer, a systematic assessment of rRNA metabolism-related genes across human cancers is lacking. Thus, we performed a Pan-cancer analysis of rRNA metabolism-related genes across 20 human cancers. Here, we examined mRNA expression, mutation, DNA methylation, copy number variation (CNV) and clinical landscape of rRNA metabolism-related genes in more than 8600 patients across 20 human cancers from The Cancer Genome Atlas (TCGA) dataset. Besides, ten independent Gene Expression Omnibus (GEO) datasets, Cancer Cell Line Encyclopedia (CCLE) dataset and Project Achilles dataset were used to verify our study. A landscape of rRNA metabolism-related genes was established across 20 human cancers. The results suggest that rRNA metabolism-related genes are upregulated in multiple cancers, particularly in digestive and respiratory system cancers. Most of the upregulated genes were driven by CNV gain rather than mutation or DNA hypomethylation. We systematically identified CNV-driven rRNA metabolism-related genes with clinical relevance, including EXOSC8. Finally, functional experiments confirmed the oncogenic roles of EXOSC8 in colorectal carcinoma. Our study highlights the important roles of rRNA metabolism-related genes in tumorigenesis as prognostic biomarkers.	[Cui, Kaisa; Liu, Cheng; Li, Xu; Zhang, Qiang; Li, Youjun] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China; [Cui, Kaisa; Liu, Cheng; Li, Xu; Zhang, Qiang; Li, Youjun] Wuhan Univ, Sch Med, Med Res Inst, Wuhan 430071, Peoples R China	Wuhan University; Wuhan University	Li, YJ (corresponding author), Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China.; Li, YJ (corresponding author), Wuhan Univ, Sch Med, Med Res Inst, Wuhan 430071, Peoples R China.	liy7@whu.edu.cn	Cui, Kaisa/AAM-6601-2020	Cui, Kaisa/0000-0001-7255-2689	National Key R&D Program of China [2016YFC1302300]; National Nature Science Foundation of China [81772609]; Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University [TFJC2018005]	National Key R&D Program of China; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University	We thank the TCGA, GEO, CCLE and Project Achilles teams. We thank Professor Jinxiang Zhang (Wuhan Union Hospital, Wuhan) for providing the CRC patient samples. This work was supported by grants from the National Key R&D Program of China (2016YFC1302300), National Nature Science Foundation of China (81772609) and Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University (TFJC2018005).	Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhattacharya C, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-82; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Calo E, 2018, NATURE, V554, P112, DOI 10.1038/nature25449; Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108; Chestkov IV, 2018, SCHIZOPHR RES, V197, P305, DOI 10.1016/j.schres.2018.01.001; Choudhury P, 2019, RNA BIOL, V16, P54, DOI 10.1080/15476286.2018.1556149; Chung KY, 2011, HEPATOLOGY, V54, P307, DOI 10.1002/hep.24372; Cowling VH, 2014, ONCOGENE, V33, P3519, DOI 10.1038/onc.2013.338; Dolezal JM, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4178-z; Driscoll JJ, 2009, CANCER J, V15, P401, DOI 10.1097/PPO.0b013e3181bdc2e0; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; Foroutan M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2435-4; Gamazon ER, 2015, BRIEF FUNCT GENOMICS, V14, P352, DOI 10.1093/bfgp/elv017; Gantenbein N, 2018, EUR J CANCER, V101, P165, DOI 10.1016/j.ejca.2018.07.001; Ge ZQ, 2018, CELL REP, V23, P213, DOI 10.1016/j.celrep.2018.03.047; Gong J, 2017, CELL REP, V21, P1968, DOI 10.1016/j.celrep.2017.10.070; Haag S, 2015, RNA, V21, P180, DOI 10.1261/rna.047910.114; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Henrichsen CN, 2009, HUM MOL GENET, V18, pR1, DOI 10.1093/hmg/ddp011; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Killian A, 2006, GENE CHROMOSOME CANC, V45, P874, DOI 10.1002/gcc.20351; Kulkarni S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182705; Li WJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0523-z; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lin TC, 2016, ELIFE, V5, DOI 10.7554/eLife.11288; Liu TZ, 2016, CANCER RES, V76, P572, DOI 10.1158/0008-5472.CAN-15-0671; Maruvka YE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083100; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; McIver SC, 2014, BLOOD, V124, P2285, DOI 10.1182/blood-2014-04-571083; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Miluzio A, 2011, CANCER CELL, V19, P765, DOI 10.1016/j.ccr.2011.04.018; Pan Y, 2018, MOL CARCINOGEN, V57, P1780, DOI 10.1002/mc.22896; Prieto JL, 2007, GENE DEV, V21, P2041, DOI 10.1101/gad.436707; Punt CJA, 2007, JNCI-J NATL CANCER I, V99, P998, DOI 10.1093/jnci/djm024; Rohrmoser M, 2007, MOL CELL BIOL, V27, P3682, DOI 10.1128/MCB.00172-07; Ruggero D, 2014, BLOOD, V124, P2784, DOI 10.1182/blood-2014-04-526301; Schaub FX, 2018, CELL SYST, V6, P282, DOI 10.1016/j.cels.2018.03.003; Shen HX, 2017, CELL DEATH DIFFER, V24, P1253, DOI 10.1038/cdd.2017.63; Sloan KE, 2014, RNA, V20, P540, DOI 10.1261/rna.043471.113; Song JL, 2018, J CELL MOL MED, V22, P6304, DOI 10.1111/jcmm.13922; Srivastava L, 2010, MOL CELL BIOL, V30, P2947, DOI 10.1128/MCB.00226-10; Stransky N, 2015, NATURE, V528, P84, DOI 10.1038/nature15736; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tai P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-48; Tang XL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00396-9; Tsoi H, 2017, ONCOGENE, V36, P6109, DOI 10.1038/onc.2017.86; Van Dijk EL, 2007, RNA, V13, P1027, DOI 10.1261/rna.575107; Wang YM, 2018, CELL REP, V25, P1304, DOI 10.1016/j.celrep.2018.10.001; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Yan DM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15749-z; Ye YQ, 2019, NAT METAB, V1, P431, DOI 10.1038/s42255-019-0045-8; Zhu YH, 2017, CELL DEATH DIFFER, V24, P2199, DOI 10.1038/cdd.2017.151	57	28	28	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					786	800		10.1038/s41388-019-1026-9	http://dx.doi.org/10.1038/s41388-019-1026-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31548613				2022-12-17	WOS:000509197200004
J	Deng, L; Qian, GQ; Zhang, S; Zheng, HM; Fan, SQ; Lesinski, GB; Owonikoko, TK; Ramalingam, SS; Sun, SY				Deng, Liang; Qian, Guoqing; Zhang, Shuo; Zheng, Hongmei; Fan, Sonqing; Lesinski, Gregory B.; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Sun, Shi-Yong			Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced beta-TrCP degradation	ONCOGENE			English	Article							MAMMALIAN TARGET; PREDICTIVE BIOMARKERS; ACTIVATION; EXPRESSION; EVEROLIMUS; EFFICACY; BLOCKADE; PATHWAY; AKT; AMPLIFICATION	The involvement of mammalian target of rapamycin (mTOR) in the positive regulation of oncogenesis has been well documented and thus mTOR has emerged as an attractive cancer therapeutic target. Although rapamycin and its analogues (rapalogs) are FDA-approved for the treatment of certain cancers, major success in targeting mTOR, particularly with new generation mTOR kinase inhibitors, for the effective treatment of cancers has not been achieved. Hence, a thorough understanding of the biology of the mTOR axis in cancer is still needed. It is now recognized that programmed death-ligand 1 (PD-L1) expression on cancer cells is a critical mechanism contributing to immunosuppression and immune escape via interacting with program death-1 (PD-1) on immune cells. This study has revealed a previously undiscovered role of the mTOR complex 1 (mTORC1)/p70 S6 kinase (p70S6K) in the negative regulation of PD-L1 on cancer cells and tissues. We demonstrate that disruption of this signaling pathway with mTOR inhibitors, raptor knockdown or p70S6K inhibitors elevated PD-L1 levels in some lung and other cancer cell lines. Elevation of PD-L1 by inhibition of mTORC1/p70S6K signaling is likely due to suppression of 13-TrCP-mediated proteasomal degradation of PD-L1, because inhibition of either mTORC1 or p70S6K facilitated beta-TrCP degradation accompanied with enhanced PD-L1 protein stabilization. Our current findings indicate the complexity of the mTOR axis in cancer, which should be considered when targeting this axis for effective cancer treatment. Our findings also suggest a strong scientific rationale for enhancing PD-1/PD-L1-targeted cancer immunotherapy through co-targeting mTORC1/p70S6K signaling.	[Deng, Liang] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China; [Deng, Liang; Qian, Guoqing; Zhang, Shuo; Lesinski, Gregory B.; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Sun, Shi-Yong] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Deng, Liang; Qian, Guoqing; Zhang, Shuo; Lesinski, Gregory B.; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Sun, Shi-Yong] Winship Canc Inst, Atlanta, GA 30322 USA; [Zhang, Shuo] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [Zheng, Hongmei; Fan, Sonqing] Cent S Univ, Dept Pathol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China	Central South University; Emory University; Xi'an Jiaotong University; Central South University	Sun, SY (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.; Sun, SY (corresponding author), Winship Canc Inst, Atlanta, GA 30322 USA.	ssun@emory.edu	Ramalingam, Suresh/AAV-7478-2020; Qian, Guoqing/ABH-1307-2021	Qian, Guoqing/0000-0003-1804-7993	Winship Cancer Institute lung cancer pilot award of Emory University	Winship Cancer Institute lung cancer pilot award of Emory University	We are grateful to Dr. Wenyi Wei for providing beta-TrCP shRNAs and expression plasmids. We also thank Dr. Anthea Hammond in our department for editing the paper. This work was supported by Winship Cancer Institute lung cancer pilot award of Emory University (S-YS). S-YS, TKO and SSR are Georgia Research Alliance Distinguished Cancer Scientists. S-YS is a Halpern Research Scholar. LD was a visiting medical student participating in the Xiangya-Emory Visiting Medical Student Program.	Abraham RT, 2007, CLIN CANCER RES, V13, P3109, DOI 10.1158/1078-0432.CCR-06-2798; Amato RJ, 2009, CANCER-AM CANCER SOC, V115, P2438, DOI 10.1002/cncr.24280; Amiel E, 2012, J IMMUNOL, V189, P2151, DOI 10.4049/jimmunol.1103741; Araki K, 2010, IMMUNOL REV, V235, P234, DOI 10.1111/j.0105-2896.2010.00898.x; Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Ben-Sahra I, 2017, CURR OPIN CELL BIOL, V45, P72, DOI 10.1016/j.ceb.2017.02.012; Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood-2010-02-271874; Beziaud L, 2016, CANCER RES, V76, P4100, DOI 10.1158/0008-5472.CAN-15-2452; Chapman NM, 2014, IMMUNOTHERAPY-UK, V6, P1295, DOI 10.2217/imt.14.84; Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198; Diken M, 2013, CANCER IMMUNOL RES, V1, P386, DOI 10.1158/2326-6066.CIR-13-0046; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Fan SQ, 2006, HUM PATHOL, V37, P593, DOI 10.1016/j.humpath.2006.01.010; Fantus D, 2015, AM J TRANSPLANT, V15, P891, DOI 10.1111/ajt.13151; Fu L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-315; Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Guan J, 2017, ARCH PATHOL LAB MED, V141, P851, DOI 10.5858/arpa.2016-0361-RA; Hirayama Y, 2016, CANCER SCI, V107, P1736, DOI 10.1111/cas.13099; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Ilagan E, 2016, TRENDS CANCER, V2, P241, DOI 10.1016/j.trecan.2016.03.008; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; Koo JH, 2015, MOL CELL BIOL, V35, P2344, DOI 10.1128/MCB.01525-14; Koo J, 2015, ONCOTARGET, V6, P8974, DOI 10.18632/oncotarget.3291; Koo J, 2014, CANCER RES, V74, P2555, DOI 10.1158/0008-5472.CAN-13-2946; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Li CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12632; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892; Mineharu Y, 2014, MOL CANCER THER, V13, P3024, DOI 10.1158/1535-7163.MCT-14-0400; Moore EC, 2016, CANCER IMMUNOL RES, V4, P611, DOI 10.1158/2326-6066.CIR-15-0252; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Ott PA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0218-5; Ou JN, 2012, SCI REP-UK, V2, DOI 10.1038/srep00295; Remon J, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0819-3; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Shi PY, 2016, CANCER LETT, V380, P494, DOI 10.1016/j.canlet.2016.07.021; Shien K, 2016, LUNG CANCER, V99, P79, DOI 10.1016/j.lungcan.2016.06.016; Shimizu K, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4117; Somasundaram A, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0456-5; Song Y, 2019, IMMUNOTHERAPY-UK, V11, P515, DOI 10.2217/imt-2018-0173; Sparks CA, 2010, ONCOGENE, V29, P3733, DOI 10.1038/onc.2010.139; Stambrook PJ, 2017, MOL CANCER RES, V15, P635, DOI 10.1158/1541-7786.MCR-16-0427; Sun SY, 2013, CANCER LETT, V340, P1, DOI 10.1016/j.canlet.2013.06.017; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Thomas DL, 2011, CANCER IMMUNOL IMMUN, V60, P1461, DOI 10.1007/s00262-011-1045-z; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522; Wen QY, 2016, ONCOTARGET, V7, P27787, DOI 10.18632/oncotarget.8497; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yao WL, 2015, CANCER LETT, V364, P70, DOI 10.1016/j.canlet.2015.04.028; Zhang YJ, 2011, DRUG DISCOV TODAY, V16, P325, DOI 10.1016/j.drudis.2011.02.008; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029	56	28	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6270	6282		10.1038/s41388-019-0877-4	http://dx.doi.org/10.1038/s41388-019-0877-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31316145				2022-12-17	WOS:000483919400003
J	Sun, QY; Ding, LW; Johnson, K; Zhou, SQ; Tyner, JW; Yang, H; Doan, NB; Said, JW; Xiao, JF; Loh, XY; Ran, XB; Venkatachalam, N; Lao, ZT; Chen, Y; Xu, L; Fan, LF; Chien, WW; Lin, DC; Koeffler, HP				Sun, Qiao-Yang; Ding, Ling-Wen; Johnson, Kara; Zhou, Siqin; Tyner, Jeffrey W.; Yang, Henry; Doan, Ngan B.; Said, Jonathan W.; Xiao, Jin-Fen; Loh, Xin-Yi; Ran, Xue-Bin; Venkatachalam, Nachiyappan; Lao, Zhentang; Chen, Ye; Xu, Liang; Fan, Li-Fei; Chien, Wenwen; Lin, De-Chen; Koeffler, H. Phillip			SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; LUNG-CANCER; GLUCOCORTICOID RESISTANCE; DRUG-RESISTANCE; EXPRESSION; ACTIVATION; PROMOTES; SURVIVAL; PATHWAY; GENES	Apoptosis of cancer cells occurs by a complex gene regulatory network. Here we showed that SOX7 was significantly downregulated in different cancer types, especially in lung and breast cancers. Low expression of SOX7 was associated with advantage stage of cancer with shorter overall survival. Cancer cells with loss of SOX7 promoted cell survival and colony formation, suppressed cellular apoptosis and produced a drug resistant phenotype against a variety of chemo/targeting therapeutic agents. Mechanistically, SOX7 induced cellular apoptosis through upregulation of genes associated with both P38 and apoptotic signaling pathway, as well as preventing the proteasome mediated degradation of pro-apoptotic protein BIM. Treatment of either a proteasome inhibitor MG132 or bortezomib, or with a p-ERK/MEK inhibitor U0126 attenuate the SOX7 promoted BIM degradation. We identified Panobinostat, an FDA approved pan-HDAC inhibitor, could elevate and restore SOX7 expression in SOX7 silenced lung cancer cells. Taken together, these data revealed an unappreciated role of SOX7 in regulation of cellular apoptosis through control of MAPK/ERK-BIM signaling.	[Sun, Qiao-Yang; Ding, Ling-Wen; Zhou, Siqin; Yang, Henry; Xiao, Jin-Fen; Loh, Xin-Yi; Ran, Xue-Bin; Venkatachalam, Nachiyappan; Lao, Zhentang; Chen, Ye; Xu, Liang; Fan, Li-Fei; Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Johnson, Kara; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA; [Doan, Ngan B.; Said, Jonathan W.] Ronald Reagan UCLA Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Fan, Li-Fei] Inner Mongolia Univ, Sch Life Sci, Hohhot 010021, Inner Mongolia, Peoples R China; [Chien, Wenwen; Lin, De-Chen; Koeffler, H. Phillip] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA	National University of Singapore; Oregon Health & Science University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Ronald Reagan UCLA Medical Center; Inner Mongolia University; Cedars Sinai Medical Center	Ding, LW (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.	lingwen.dlw@gmail.com	Xu, Liang/I-9877-2014; Sun, Qiao-Yang/ABA-6813-2020; Ding, Ling-Wen/H-6916-2019	Xu, Liang/0000-0002-2700-4840; Ding, Ling-Wen/0000-0003-0022-1551; Said, Jonathan/0000-0001-9474-2563; Johnson, Kara/0000-0002-0993-4470; Sun, Qiao-Yang/0000-0002-9855-5586; Nachi, Nachiyappan/0000-0003-4293-8278	National Research Foundation Singapore under the Singapore Translational Research (STaR) Investigator Award [NMRC/STaR/0021/2014]; NMRC Centre Grant; RNA Biology Center at the Cancer Science Institute of Singapore (NUS, as part of Singapore Ministry of Education) [MOE2014-T3-1-006]; Tower Cancer Research Foundation; Department of Defense USAMRMC [W81XWH-17-1-0093, BM160010]	National Research Foundation Singapore under the Singapore Translational Research (STaR) Investigator Award(National Research Foundation, Singapore); NMRC Centre Grant(National Medical Research Council, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore (NUS, as part of Singapore Ministry of Education)(Ministry of Education, SingaporeNational University of Singapore); Tower Cancer Research Foundation; Department of Defense USAMRMC(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC))	Research was supported by the National Research Foundation Singapore under the Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/0021/2014) and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC), the NMRC Centre Grant awarded to National University Cancer Institute of Singapore, the National Research Foundation Singapore, the Singapore Ministry of Education under its Research Centers of Excellence initiatives and RNA Biology Center at the Cancer Science Institute of Singapore (NUS, as part of funding under the Singapore Ministry of Education's Tier 3 grants, grant number MOE2014-T3-1-006). This research was also supported by the Tower Cancer Research Foundation Michele and Ted Kaplan Family Senior Investigator Grant and Department of Defense USAMRMC (Proposal Number BM160010, Award Number W81XWH-17-1-0093).	Afouda BA, 2018, DATA BRIEF, V17, P559, DOI 10.1016/j.dib.2018.01.005; Barton K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12731; Brown JA, 2018, CANCER CELL, V34, P869, DOI 10.1016/j.ccell.2018.11.011; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chakraborty AR, 2013, BLOOD, V121, P4115, DOI 10.1182/blood-2012-08-449140; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Ding LW, 2015, ONCOGENE, V34, P1463, DOI 10.1038/onc.2014.34; Dong C, 2004, CYTOGENET GENOME RES, V105, P442, DOI 10.1159/000078217; Einolf HJ, 2017, DRUG METAB DISPOS, V45, P1304, DOI 10.1124/dmd.117.076851; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Fan R, 2018, DNA CELL BIOL, V37, P126, DOI 10.1089/dna.2017.3866; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gettinger S, 2016, J CLIN ONCOL, V34, P2980, DOI 10.1200/JCO.2016.66.9929; Guo LH, 2008, MOL CANCER RES, V6, P1421, DOI 10.1158/1541-7786.MCR-07-2175; Gurtner A, 2010, J BIOL CHEM, V285, P14160, DOI 10.1074/jbc.M109.094813; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han LC, 2017, J CELL MOL MED, V21, P2000, DOI 10.1111/jcmm.13120; Hayano T, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-17; Hishida T, 2012, STEM CELLS, V30, P1634, DOI 10.1002/stem.1147; Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769; Jiang Q, 2013, FEBS LETT, V587, P2420, DOI 10.1016/j.febslet.2013.06.011; Jing DH, 2018, CANCER CELL, V34, P906, DOI 10.1016/j.ccell.2018.11.002; Kanki Y, 2017, NUCLEIC ACIDS RES, V45, P4344, DOI 10.1093/nar/gkx159; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kim IK, 2018, J EXP MED, V215, P963, DOI 10.1084/jem.20170123; Kohno T, 2015, TRANSL LUNG CANCER R, V4, P156, DOI 10.3978/j.issn.2218-6751.2014.11.11; Lenassi M, 2006, RADIOL ONCOL, V40, P51; Lilly AJ, 2017, MECH DEVELOP, V146, P31, DOI 10.1016/j.mod.2017.05.004; Liu HD, 2016, SCI REP-UK, V6, DOI 10.1038/srep26136; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mah V, 2011, LUNG CANCER, V74, P318, DOI 10.1016/j.lungcan.2011.03.009; Man CH, 2015, BLOOD, V125, P3928, DOI 10.1182/blood-2014-06-580993; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meunier I, 2016, HUM MOL GENET, V25, P916, DOI 10.1093/hmg/ddv624; Montero J, 2015, CELL, V160, P977, DOI 10.1016/j.cell.2015.01.042; Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713; Oh KY, 2017, J ORAL PATHOL MED, V46, P752, DOI 10.1111/jop.12566; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Rajgara RF, 2017, STEM CELL REP, V9, P1139, DOI 10.1016/j.stemcr.2017.08.014; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Rueff J, 2016, METHODS MOL BIOL, V1395, P1, DOI 10.1007/978-1-4939-3347-1_1; Sahay B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000687; Scuto A, 2008, BLOOD, V111, P5093, DOI 10.1182/blood-2007-10-117762; Shojaee Samira, 2017, F1000Res, V6, P2110, DOI 10.12688/f1000research.11471.1; Stovall DB, 2014, HISTOL HISTOPATHOL, V29, P439, DOI 10.14670/HH-29.10.439; Stovall DB, 2013, AM J PATHOL, V183, P1645, DOI 10.1016/j.ajpath.2013.07.025; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun QY, 2015, J PATHOL, V235, P559, DOI 10.1002/path.4482; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Wang DP, 2017, ONCOL REP, V38, P2078, DOI 10.3892/or.2017.5854; Yan L, 2018, J CELL BIOCHEM, V119, P3989, DOI 10.1002/jcb.26553; Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010; Zhang Y, 2009, CANCER LETT, V277, P29, DOI 10.1016/j.canlet.2008.11.014; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020; Zhou YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116095	58	28	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6196	6210		10.1038/s41388-019-0865-8	http://dx.doi.org/10.1038/s41388-019-0865-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31332289				2022-12-17	WOS:000482210100004
J	Wang, YC; Li, X; Liu, W; Li, BJ; Chen, DQ; Hu, FP; Wang, LZ; Liu, XGM; Cui, RJ; Liu, RH				Wang, Yicun; Li, Xin; Liu, Wei; Li, Bingjin; Chen, Dongquan; Hu, Fengping; Wang, Lizhong; Liu, Xiaoguang M.; Cui, Ranji; Liu, Runhua			MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; LONG-RANGE INTERACTION; IN-SITU HYBRIDIZATION; PROLYL HYDROXYLASE; NEURONAL APOPTOSIS; C-MYC; PROMOTES; BREAST; EXPRESSION; GENES	The chromosome 8q24.21 locus, which contains the proto-oncogene c-MYC, long non-coding RNA PVT1, and microRNAs (miRs), is the most commonly amplified region in human prostate cancer. A long-range interaction of genetic variants with c-MYC or long non-coding PVT1 at this locus contributes to the genetic risk of prostate cancer. At this locus is a cluster of genes for six miRs (miR-1204, -1205, -1206, -1207-3p, -1207-5p, and -1208), but their functional role remains elusive. Here the copy numbers and expression levels of miRs-1204-1208 were investigated using quantitative PCR for prostate cancer cell lines and primary tumors. The data revealed that copy numbers and expression of miR-1205 were increased in both castration-resistant prostate cancer cell lines and in primary tumors. In castration-resistant prostate cancer specimens, the copy number at the miR-1205 locus correlated with the expression of miR-1205. Furthermore, functional analysis with an miR-1205 mimic, an miR-1205 inhibitor, and CRISPR/Cas9 knockout revealed that, in human prostate cancer cells, miR-1205 promoted cell proliferation and cell cycle progression and inhibited hydrogen peroxide-induced apoptosis. In these cells, miR-1205 downregulated the expression of the Egl-9 family hypoxia inducible factor 3(EGLN3) gene and targeted a site in its 3'-untranslated region to downregulate its transcriptional activity. Thus, by targeting EGLN3, miR-1205 has an oncogenic role and may contribute to the genetic risk of castration-resistant prostate cancer.	[Wang, Yicun; Li, Xin; Liu, Wei; Li, Bingjin; Cui, Ranji] Jilin Univ, Prov Key Lab Mol & Chem Genet, Hosp 2, Changchun, Jilin, Peoples R China; [Wang, Yicun; Li, Xin; Liu, Wei; Hu, Fengping; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; [Chen, Dongquan] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA; [Chen, Dongquan; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Liu, Xiaoguang M.] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL USA	Jilin University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cui, RJ (corresponding author), Jilin Univ, Prov Key Lab Mol & Chem Genet, Hosp 2, Changchun, Jilin, Peoples R China.; Liu, RH (corresponding author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.; Liu, RH (corresponding author), Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA.	cuiranji@jlu.edu.cn; runhua@uab.edu	cui, ranji/AAV-6234-2021	Wang, Yicun/0000-0001-6497-3387; Liu, Xiaoguang (Margaret)/0000-0002-4617-9750	National Institutes of Health/National Cancer Institute [CA118948, CA179282, CA013148]; Department of Defense [BC160808, PC130594, PC140308]; Mike Slive Foundation for Prostate Cancer Research; Natural Science Foundation of China [31571126, 31571342, 81772757]; NATIONAL CANCER INSTITUTE [P30CA013148, U54CA118638, U54CA118948] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Mike Slive Foundation for Prostate Cancer Research; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Donald L Hill for editorial assistance in preparing this manuscript. This work was supported by grants from the National Institutes of Health/National Cancer Institute (CA118948, CA179282, and CA013148 to LW and RL), the Department of Defense (BC160808, PC130594, and PC140308 to LW and RL), the Mike Slive Foundation for Prostate Cancer Research (to LW), and the Natural Science Foundation of China (Nos. 31571126, 31571342, and 81772757 to XL, BL, and RC). Results are based, in part, on data generated by the TCGA Research Network: http://ca ncergenome. nih. gov/.	Ahmadiyeh N, 2010, P NATL ACAD SCI USA, V107, P9742, DOI 10.1073/pnas.0910668107; [Anonymous], 2018, CANCER DISCOV, V8, pOF15; Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048; Barsotti AM, 2012, J BIOL CHEM, V287, P2509, DOI 10.1074/jbc.M111.322875; Bawa P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122143; Beck-Engeser GB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-4; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; Cho SW, 2018, CELL, V173, P1398, DOI 10.1016/j.cell.2018.03.068; Das DK, 2016, EXP CELL RES, V348, P190, DOI 10.1016/j.yexcr.2016.09.021; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Fu J, 2013, MOL CELL BIOL, V33, P3050, DOI 10.1128/MCB.00273-13; Gao S, 2017, ONCOTARGET, V8, P41451, DOI 10.18632/oncotarget.17816; Garvalov BK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6577; Gerber SA, 2009, ARTERIOSCL THROM VAS, V29, P1363, DOI 10.1161/ATVBAHA.109.192542; Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999; Henze AT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6582; Hogel H, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0410-5; Hogel H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027112; Huppi K, 2008, MOL CANCER RES, V6, P212, DOI 10.1158/1541-7786.MCR-07-0105; Huppi Konrad, 2012, Frontiers in Genetics, V3, P69, DOI 10.3389/fgene.2012.00069; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim T, 2014, P NATL ACAD SCI USA, V111, P4173, DOI 10.1073/pnas.1400350111; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Liu RH, 2015, CANCER RES, V75, P1714, DOI 10.1158/0008-5472.CAN-14-2109; Liu RH, 2015, CANCER RES, V75, P1703, DOI 10.1158/0008-5472.CAN-14-2108; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Liu XY, 2018, ONCOGENE, V37, P3426, DOI 10.1038/s41388-018-0215-2; Luo WB, 2014, MOL BIOL CELL, V25, P2788, DOI 10.1091/mbc.E14-02-0775; Luo YZ, 2018, J CANCER, V9, P1096, DOI 10.7150/jca.23909; Ma Lijiang, 2014, Curr Protoc Hum Genet, V80, DOI 10.1002/0471142905.hg0721s80; Madden SL, 1996, CANCER RES, V56, P5384; Meyer KB, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002165; Min H, 2010, EXP MOL MED, V42, P233, DOI 10.3858/emm.2010.42.4.032; Peng XW, 2015, CANCER BIOL THER, V16, P261, DOI 10.1080/15384047.2014.1001287; Place TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014617; Riquelme E, 2014, J THORAC ONCOL, V9, P998, DOI 10.1097/JTO.0000000000000202; Rodriguez J, 2018, CELL REP, V24, P1316, DOI 10.1016/j.celrep.2018.06.108; Sato H, 2006, INT J UROL, V13, P761, DOI 10.1111/j.1442-2042.2006.01399.x; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Schlisio S, 2009, J CELL MOL MED, V13, P4104, DOI 10.1111/j.1582-4934.2009.00881.x; Shi HL, 2015, ONCOL REP, V33, P1185, DOI 10.3892/or.2014.3695; Shi YX, 2017, MED SCI MONITOR, V23, P2042, DOI 10.12659/MSM.901191; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sotelo J, 2010, P NATL ACAD SCI USA, V107, P3001, DOI 10.1073/pnas.0906067107; Tang JM, 2018, ONCOGENE, V37, P4723, DOI 10.1038/s41388-018-0310-4; Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; VANDENBERG C, 1995, CLIN CANCER RES, V1, P11; Vergara R, 2012, J EXP BOT, V63, P4123, DOI 10.1093/jxb/ers094; VISAKORPI T, 1995, CANCER RES, V55, P342; Wang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6909; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wasserman NF, 2010, GENOME RES, V20, P1191, DOI 10.1101/gr.105361.110; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Wu GY, 2015, ONCOTARGET, V6, P28882, DOI 10.18632/oncotarget.4921; Yan C, 2017, CANCER SCI, V108, P868, DOI 10.1111/cas.13212; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022; Zhang GX, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0858-x; Zhang W, 2016, CLIN CANCER RES, V22, P2545, DOI 10.1158/1078-0432.CCR-15-1927; Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z	64	28	29	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4820	4834		10.1038/s41388-019-0760-3	http://dx.doi.org/10.1038/s41388-019-0760-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30808975	Green Accepted			2022-12-17	WOS:000471160500012
J	Hald, OH; Olsen, L; Gallo-Oller, G; Elfman, LHM; Lokke, C; Kogner, P; Sveinbjornsson, B; Flaegstad, T; Johnsen, JI; Einvik, C				Hald, Oyvind H.; Olsen, Lotte; Gallo-Oller, Gabriel; Elfman, Lotta Helena Maria; Lokke, Cecilie; Kogner, Per; Sveinbjornsson, Baldur; Flaegstad, Trond; Johnsen, John Inge; Einvik, Christer			Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma	ONCOGENE			English	Article							RNA-POLYMERASE I; N-MYC; THERAPEUTIC STRATEGY; G-QUADRUPLEXES; EXPRESSION; CANCER; P53; CX-5461; TARGET; PATHWAYS	Abnormal increases in nucleolar size and number caused by dysregulation of ribosome biogenesis has emerged as a hallmark in the majority of spontaneous cancers. The observed ribosome hyperactivity can be directly induced by the MYC transcription factors controlling the expression of RNA and protein components of the ribosome. Neuroblastoma, a highly malignant childhood tumor of the sympathetic nervous system, is frequently characterized by MYCN gene amplification and high expression of MYCN and c-MYC signature genes. Here, we show a strong correlation between high-risk disease, MYCN expression, poor survival, and ribosome biogenesis in neuroblastoma patients. Treatment of neuroblastoma cells with quarfloxin or CX-5461, two small molecule inhibitors of RNA polymerase I, suppressed MycN expression, induced DNA damage, and activated p53 followed by cell cycle arrest or apoptosis. CX-5461 repressed the growth of established MYCN-amplified neuroblastoma xenograft tumors in nude mice. These findings suggest that inhibition of ribosome biogenesis represent new therapeutic opportunities for children with high-risk neuroblastomas expressing high levels of Myc.	[Hald, Oyvind H.; Flaegstad, Trond; Einvik, Christer] UNN Univ Hosp North Norway, Dept Pediat, Div Child & Adolescent Hlth, NO-9038 Tromso, Norway; [Olsen, Lotte; Lokke, Cecilie; Flaegstad, Trond; Einvik, Christer] Arctic Univ Norway UiT, Pediat Res Grp, Dept Clin Med, Fac Hlth Sci, NO-9037 Tromso, Norway; [Gallo-Oller, Gabriel; Elfman, Lotta Helena Maria; Kogner, Per; Sveinbjornsson, Baldur; Johnsen, John Inge] Karolinska Inst, Childhood Canc Res Unit, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden; [Sveinbjornsson, Baldur] Arctic Univ Norway UiT, Mol Inflammat Res Grp, Dept Med Biol, Fac Hlth Sci, NO-9037 Tromso, Norway	UiT The Arctic University of Tromso; University Hospital of North Norway; UiT The Arctic University of Tromso; Karolinska Institutet; UiT The Arctic University of Tromso	Einvik, C (corresponding author), UNN Univ Hosp North Norway, Dept Pediat, Div Child & Adolescent Hlth, NO-9038 Tromso, Norway.; Einvik, C (corresponding author), Arctic Univ Norway UiT, Pediat Res Grp, Dept Clin Med, Fac Hlth Sci, NO-9037 Tromso, Norway.	christer.einvik@uit.no	Gallo-Oller, Gabriel/D-6825-2019	Gallo-Oller, Gabriel/0000-0002-3864-1941; Johnsen, John Inge/0000-0003-1277-812X	Norwegian Childhood Cancer Society (Barnekreftforeningen); Northern-Norwegian Health Authorities (Helse Nord); Simon Fougner Hartmanns Familiefond; Swedish Childhood Cancer Foundation; Swedish Cancer Foundation; Swedish Foundation for Strategic Research; Cancer Research Foundations of Radiumhemmet	Norwegian Childhood Cancer Society (Barnekreftforeningen); Northern-Norwegian Health Authorities (Helse Nord); Simon Fougner Hartmanns Familiefond; Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Foundation; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Cancer Research Foundations of Radiumhemmet	This work was supported by the Norwegian Childhood Cancer Society (Barnekreftforeningen), The Northern-Norwegian Health Authorities (Helse Nord), the Simon Fougner Hartmanns Familiefond, the Swedish Childhood Cancer Foundation, the Swedish Cancer Foundation, the Swedish Foundation for Strategic Research (www.nnbcr.se) and The Cancer Research Foundations of Radiumhemmet. We wish to thank Dr. Emma Bell for kindly providing the siMYCN IMR-32 microarray data.	Bell E, 2007, CELL CYCLE, V6, P1249, DOI 10.4161/cc.6.10.4222; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bykov VJN, 2018, NAT REV CANCER, V18, P89, DOI 10.1038/nrc.2017.109; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Cole KA, 2012, CLIN CANCER RES, V18, P2423, DOI 10.1158/1078-0432.CCR-11-1409; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2009, CANCER RES, V69, P7653, DOI 10.1158/0008-5472.CAN-09-1304; EGAN M, 1988, J CLIN PATHOL, V41, P527, DOI 10.1136/jcp.41.5.527; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Goldschneider D, 2006, NUCLEIC ACIDS RES, V34, P5603, DOI 10.1093/nar/gkl619; Gonin-Laurent N, 2006, CARCINOGENESIS, V27, P1266, DOI 10.1093/carcin/bgi356; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Henriksen JR, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-1; Johnsen JI, 2018, PHARMACOL RES, V131, P164, DOI 10.1016/j.phrs.2018.02.023; Karahan G, 2015, ONCOL REP, V33, P3131, DOI 10.3892/or.2015.3940; Keshelava N, 2001, CANCER RES, V61, P6185; Kitade S, 2016, CANCER SCI, V107, P1399, DOI 10.1111/cas.13026; Kobayashi C, 2005, CANCER-AM CANCER SOC, V103, P174, DOI 10.1002/cncr.20717; Lee HC, 2017, BRIT J HAEMATOL, V177, P80, DOI 10.1111/bjh.14525; Li LM, 2016, ONCOTARGETS THER, V9, P5985, DOI 10.2147/OTT.S104513; Lutz W, 1996, ONCOGENE, V13, P803; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Negi SS, 2015, ONCOTARGET, V6, P18094, DOI 10.18632/oncotarget.4093; Niemas-Teshiba Risa, 2018, Oncotarget, V9, P6416, DOI 10.18632/oncotarget.23740; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104; Popov A, 2013, NUCLEUS-AUSTIN, V4, P134, DOI 10.4161/nucl.23985; Quin J, 2016, ONCOTARGET, V7, P49800, DOI 10.18632/oncotarget.10452; Rhodes D, 2015, NUCLEIC ACIDS RES, V43, P8627, DOI 10.1093/nar/gkv862; Roth Sarah Andrea, 2018, Oncotarget, V9, P18160, DOI 10.18632/oncotarget.24793; Ruiz-Perez MV, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040113; Scaife JE, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.7_suppl.94; Schroeder U, 2003, BLOOD, V102, P246, DOI 10.1182/blood-2002-07-2268; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Singhal J, 2011, CANCER PREV RES, V4, P879, DOI 10.1158/1940-6207.CAPR-11-0025; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; Suenaga Y, 2009, BIOCHEM BIOPH RES CO, V390, P21, DOI 10.1016/j.bbrc.2009.09.044; Trajkovski M, 2012, J AM CHEM SOC, V134, P4132, DOI 10.1021/ja208483v; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Wang LL, 2013, CANCER-AM CANCER SOC, V119, P3718, DOI 10.1002/cncr.28251; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Xu H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14432; Xue C, 2007, CANCER RES, V67, P10351, DOI 10.1158/0008-5472.CAN-06-4345; Yokobori T, 2009, CANCER RES, V69, P3788, DOI 10.1158/0008-5472.CAN-08-2846	44	28	30	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2800	2813		10.1038/s41388-018-0611-7	http://dx.doi.org/10.1038/s41388-018-0611-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542116	Green Published, hybrid			2022-12-17	WOS:000464121600010
J	Di Leo, L; Vegliante, R; Ciccarone, F; Salvatori, I; Scimeca, M; Bonanno, E; Sagnotta, A; Grazi, GL; Aquilano, K; Ciriolo, MR				Di Leo, Luca; Vegliante, Rolando; Ciccarone, Fabio; Salvatori, Illari; Scimeca, Manuel; Bonanno, Elena; Sagnotta, Andrea; Grazi, Gian Luca; Aquilano, Katia; Ciriolo, Maria Rosa			Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-alpha/p300-mediated acetylation of p53	ONCOGENE			English	Article							ADIPOSE TRIGLYCERIDE LIPASE; HEPATOCELLULAR-CARCINOMA; TRIACYLGLYCEROL HYDROLYSIS; ENERGY-METABOLISM; LIPID-METABOLISM; FATTY-ACIDS; CANCER; LIPOLYSIS; OMEGA-3-FATTY-ACIDS; PHOSPHORYLATION	Metabolic reprogramming is a typical feature of cancer cells aimed at sustaining high-energetic demand and proliferation rate. Here, we report clear-cut evidence for decreased expression of the adipose triglyceride lipase (ATGL), the first and rate-limiting enzyme of triglyceride hydrolysis, in both human and mouse-induced hepatocellular carcinoma (HCC). We identified metabolic rewiring as major outcome of ATGL overexpression in HCC-derived cell lines. Indeed, ATGL slackened both glucose uptake/utilization and cell proliferation in parallel with increased oxidative metabolism of fatty acids and enhanced mitochondria capacity. We ascribed these ATGL-downstream events to the activity of the tumor-suppressor p53, whose protein levels-but not transcript-were upregulated upon ATGL overexpression. The role of p53 was further assessed by abrogation of the ATGL-mediated effects upon p53 silencing or in p53-null hepatocarcinoma Hep3B cells. Furthermore, we provided insights on the molecular mechanisms governed by ATGL in HCC cells, identifying a new PPAR-alpha/p300 axis responsible for p53 acetylation/accumulation. Finally, we highlighted that ATGL levels confer different susceptibility of HCC cells to common therapeutic drugs, with ATGL overexpressing cells being more resistant to glycolysis inhibitors (e.g., 2-deoxyglucose and 3-bromopyruvate), compared to genotoxic compounds. Collectively, our data provide evidence for a previously uncovered tumor-suppressor function of ATGL in HCC, with the outlined molecular mechanisms shedding light on new potential targets for anticancer therapy.	[Di Leo, Luca; Vegliante, Rolando; Ciccarone, Fabio; Aquilano, Katia; Ciriolo, Maria Rosa] Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy; [Salvatori, Illari] IRCCS Fdn Santa Lucia, Santa Lucia Fdn, I-00143 Rome, Italy; [Scimeca, Manuel; Bonanno, Elena] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Scimeca, Manuel; Ciriolo, Maria Rosa] IRCCS San Raffaele Pisana, Via Pisana 235, I-00163 Rome, Italy; [Sagnotta, Andrea] Santa Maria di Terni Hosp, Digest Surg & Liver Unit, I-05100 Terni, Italy; [Sagnotta, Andrea] Sapienza Univ Rome, Fac Med & Psychol, St Andrea Hosp, Surg & Med Dept Translat Med, Via Grottarossa 1035-39, I-00189 Rome, Italy; [Grazi, Gian Luca] IRCCS, Regina Elena Natl Canc Inst, Dept Clin & Expt Oncol, Hepatopancreatobiliary Surg Unit, Via Elio Chianesi 53, I-00144 Rome, Italy; [Vegliante, Rolando] Inst Hematol & Immunol 1, INSERM U1109HOP CIVIL, Microenvironm Niche Tumorigenesis & Targeted Ther, Pl Hop, F-67091 Strasbourg, France	University of Rome Tor Vergata; IRCCS Santa Lucia; University of Rome Tor Vergata; IRCCS San Raffaele Pisana; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea	Ciriolo, MR (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy.; Ciriolo, MR (corresponding author), IRCCS San Raffaele Pisana, Via Pisana 235, I-00163 Rome, Italy.	ciriolo@bio.uniroma2.it	Ciccarone, Fabio/AAR-9128-2021; Salvatori, Illari/AAB-6129-2022; CICCARONE, FABIO/K-4225-2016; AQUILANO, KATIA/K-8888-2016	Ciccarone, Fabio/0000-0002-2425-2240; Salvatori, Illari/0000-0001-9700-1269; AQUILANO, KATIA/0000-0002-5905-9870; Di Leo, Luca/0000-0002-2419-2196; Sagnotta, Andrea/0000-0002-0606-0317	Italian Association for Cancer Research (AIRC) [IG 15403]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Italian Association for Cancer Research (AIRC, IG 15403). The authors would like to thank Dr. Serena Castelli for her valid help during the revision process. This manuscript is dedicated to Prof. Maria Teresa Carri.	Agustsson T, 2007, CANCER RES, V67, P5531, DOI 10.1158/0008-5472.CAN-06-4585; Al-Zoughbi W, 2016, ONCOTARGET, V7, P33832, DOI 10.18632/oncotarget.9418; Allen MA, 2014, ELIFE, V3, DOI 10.7554/eLife.02200; Aquilano K, 2016, ONCOTARGET, V7, P23019, DOI 10.18632/oncotarget.8552; Barascu A, 2006, INT J BIOCHEM CELL B, V38, P196, DOI 10.1016/j.biocel.2005.08.015; Barbato DL, 2014, BBA-REV CANCER, V1845, P317, DOI 10.1016/j.bbcan.2014.02.003; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Bruix J, 2017, J HEPATOL; Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808; Cardaci S, 2012, CANCER RES, V72, P4526, DOI 10.1158/0008-5472.CAN-12-1741; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Ciccarone F, 2017, SEMIN CANCER BIOL, V47, P50, DOI 10.1016/j.semcancer.2017.06.008; Cui W, 2010, AM J TRANSL RES, V2, P95; Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973; DeWaal D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02733-4; Doherty JR, 2014, CANCER RES, V74, P908, DOI 10.1158/0008-5472.CAN-13-2034; Duncan RE, 2010, J LIPID RES, V51, P309, DOI 10.1194/jlr.M000729; Gerber M, 2012, BRIT J NUTR, V107, pS228, DOI 10.1017/S0007114512001614; Grace SA, 2017, ANTICANCER RES, V37, P699, DOI 10.21873/anticanres.11366; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670; Jha P, 2014, HEPATOLOGY, V59, P858, DOI 10.1002/hep.26732; Khan SA, 2015, DIABETES, V64, P418, DOI 10.2337/db14-0325; Kitamura K, 2011, J HEPATOL, V55, P846, DOI 10.1016/j.jhep.2011.01.038; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kurahara H, 2018, ANN SURG ONCOL, V25, P1432, DOI 10.1245/s10434-018-6357-1; Labuschagne CF, 2018, BIOCH BIOPHYS ACTA; Lee James T, 2013, Genes Cancer, V4, P112, DOI 10.1177/1947601913484496; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu Y, 2012, J BIOL CHEM, V287, P41469, DOI 10.1074/jbc.M112.367847; Mashek DG, 2015, HEPATOLOGY, V62, P964, DOI 10.1002/hep.27839; McDonnell E, 2016, CELL REP, V17, P1463, DOI 10.1016/j.celrep.2016.10.012; Meex RCR, 2015, AM J PHYSIOL-ENDOC M, V308, pE960, DOI 10.1152/ajpendo.00598.2014; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Ong KT, 2011, HEPATOLOGY, V53, P116, DOI 10.1002/hep.24006; Ou JJ, 2014, CELL REP, V9, P1798, DOI 10.1016/j.celrep.2014.11.016; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Puzio-Kuter Anna M, 2011, Genes Cancer, V2, P385, DOI 10.1177/1947601911409738; Reed SM, 2015, CANCERS, V7, P30, DOI 10.3390/cancers7010030; Reid BN, 2008, J BIOL CHEM, V283, P13087, DOI 10.1074/jbc.M800533200; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sapiro JM, 2009, J LIPID RES, V50, P1621, DOI 10.1194/jlr.M800614-JLR200; Sathyanarayan A, 2017, CELL REP, V19, P1, DOI 10.1016/j.celrep.2017.03.026; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Sharma Arishya, 2012, Methods Mol Biol, V920, P613, DOI 10.1007/978-1-61779-998-3_40; So WW, 2015, NUTRIENTS, V7, P6956, DOI 10.3390/nu7085319; Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172; Tomin T, 2018, J PROTEOME RES, V17, P1415, DOI 10.1021/acs.jproteome.7b00782; Vegliante R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0345-z; Vegliante R, 2016, CARCINOGENESIS, V37, P233, DOI 10.1093/carcin/bgw003; Waller LP, 2015, WORLD J HEPATOL, V7, P2648, DOI 10.4254/wjh.v7.i26.2648; Won KY, 2012, HUM PATHOL, V43, P221, DOI 10.1016/j.humpath.2011.04.021; Wu JW, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006716; Wu JW, 2011, HEPATOLOGY, V54, P122, DOI 10.1002/hep.24338; Xu SB, 2013, CELL RES, V23, P423, DOI 10.1038/cr.2012.162; Zagani R, 2015, ONCOTARGET, V6, P28282, DOI 10.18632/oncotarget.5061; Zechner R, 2012, CELL METAB, V15, P279, DOI 10.1016/j.cmet.2011.12.018; Zhang X, 2017, ELIFE, V6; Zheng SS, 2017, CANCER RES, V77, P4342, DOI 10.1158/0008-5472.CAN-17-0424; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	64	28	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1860	1875		10.1038/s41388-018-0545-0	http://dx.doi.org/10.1038/s41388-018-0545-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30367149	Green Published, hybrid			2022-12-17	WOS:000461164400006
